# NATIONAL CLEARINGHOUSE FOR MENTAL HEALTH INFORMATION
# PSYCHOPHARMACOLOGY ABSTRACTS

**Volume 10**

**Cumulative Index**

**December 1971**

*Page*


Author Index . . . . . A1

Subject Index . . . . . S1



Carrie Lee Rothgeb, *Editor*
Bette L. Shannon, *Managing Editor*



U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE
Public Health Service

Alcohol, Drug Abuse and Mental Health Administration
5600 Fishers Lane
Rockville, Maryland 20852

Publication No. (ADM) 74-1
Printed 1974

U.S. GOVERNMENT PRINTING OFFICE

For sale by the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402. Subscription price per year in the United States, Canada, and Mexico: $23.50; other countries, $29.50. Single copy $2.00. The Clearinghouse does not sell copies of *Psychopharmacology Abstracts*. Persons wishing to subscribe by the year or to purchase single copies should send their orders, accompanied by check or money order, directly to the Superintendent of Documents.

# AUTHOR INDEX

(The 6-digit number is the abstract accession number. The next two digits are the issue number; digits after the hyphen are the category number.)


A

AAGAARD GN 066921 05-11
AAKER H 088600 10-03
AARONSON B 060280 03-14, 111933 12-17
ABBS ET 055323 02-05, 055323 02-05
ABEL EL 059032 03-04
ABER RC 045543 01-05, 045543 01-05
ABLAD B 066506 05-03
ABLES MF 057480 02-14, 057480 02-14
ABRAMS R 066440 05-10
ABRAMSON AU 070024 07-14
ABRAMSON HA 064609 04-06
ABREU BE 071292 07-07
ABT K 066954 05-14
ABUZZAHAB FS 075879 09-08, 097621 11-17
ADAMS PM 103267 12-04
ADAMSON JD 061562 03-14
ADLER MW 070977 07-04
AGALLIANOS D 064286 04-08
AGARWAL AK 134937 12-11, 134940 12-09
AGERSBORG HPK 046640 01-05, 046640 01-05
AGHAJANIAN GK 040418 01-03, 040418 01-03
AGOLA P 058373 02-07, 058373 02-07
AGRANOFF BW 083170 10-03
AHAD A 067022 05-10
AHMAD R 077404 09-16
AHMAD SS 075559 08-04
AHMED SH 138145 12-17
AIELLO E 067253 06-04
AILION J 069062 06-03
AIRAKSINEN MM 065494 05-03
AKAI K 069312 06-05
AKHTAR SN 075372 08-15
AKHVLEDIANI KS 087303 10-01
AKINDELE MO 067924 06-14
ALAPIN B 098069 11-16
ALBANUS L 072524 08-04
ALBERT J 089159 10-08
ALBUS K 074936 08-03
ALDERTON HR 071946 07-11
ALEXANDER CS 088600 10-03
ALEXANDER DF 070024 07-14
ALEXANDER GJ 064422 04-05
ALEXANDER RB 064422 04-05
ALINO JJL 086923 10-09
ALINO JML 086923 10-09
ALIVISATOS SGA 046189 01-03, 046189 01-03, 055584 02-03, 055584 02-03
ALLAIN P 089003 10-05
ALLEN AH 046201 01-03, 046201 01-03
ALLEN C 066235 05-14
ALLEN JN 058966 03-11
ALLEN VL 070352 07-14
ALLERS G 086235 10-10
ALLEWIJN FTN 079968 09-03
ALLIKMETS LK 064333 04-04, 098024 11-04
ALLISON T 066468 05-03
ALLTOP LB 063588 03-09
ALLUISI EA 043270 01-17, 043270 01-17
ALPERS HS 051128 02-17, 051128 02-17
ALPERT M 063568 03-17, 064386 04-14, 121083 12-14
ALTAFFER FB 058357 02-06, 058357 02-06
ALTMAN H 045508 01-07, 045508 01-07
ALTSCHULE MD 068975 06-13, 075105 08-01
AMABILE G 093133 11-09
AMATI A 114880 12-09
AMBROSINI G 080142 09-11
AMBROZI L 098039 11-13
AMDISEN A 100082 11-09
AMIT Z 065070 05-04, 075316 08-04
AMMON HPT 058800 02-03, 058800 02-03, 079954 09-03
AMRUMOVA A 126632 12-09
AN R 038488 01-04, 038488 01-04, 041907 01-02, 041907 01-02, 046196 01-03, 046196 01-03, 065494 05-03
ANAGNOSTE B 068457 06-04
ANAN I 130427 12-03
ANANTH JV 072142 07-08, 075423 08-08, 086445 10-15
ANCILL RJ 066713 05-03
ANDEN N-E 081151 09-03
ANDERSON HW 067488 06-08
ANDERSON K 062521 03-04
ANDO H 129273 12-08
ANDREOLA ML 079972 09-03
ANDREWS JC 071987 07-13
ANGLADE P 089111 10-07
ANGRIST B 075426 08-10, 079888 09-04, 121083 12-14
ANGST J 060264 03-17, 060266 03-09, 060267 03-09, 079986 09-07, 128390 12-15
ANGUS JWS 063773 04-16, 063775 04-14, 063778 04-15
ANNIS H 082410 10-14
ANSEL RD 092974 11-11
ANSLINGER HJ 046113 01-13, 046113 01-13
ANTHONY EJ 080634 09-03
ANTUNES JL 070856 07-09
AOKI K 114836 12-02
APPEL JB 078402 09-04, 082545 10-04, 086029 10-12, 097965 11-04
APPLEGATE CW 067687 06-03
APPLETON WS 058212 02-15, 058212 02-15, 100526 12-15, 100529 12-15
APPLEWHITE PB 066813 05-04
APRISON MH 079998 09-04
ARATA A 080142 09-11
ARBITMAN R 058968 03-08
ARCE L 059692 03-07
ARCHER S 046195 01-13, 046195 01-13
ARMITAGE P 058240 02-11, 058240 02-11
ARNOLD OH 089107 10-17
ARONOFF MS 043277 01-03, 043277 01-03, 062352 03-09, 075410 08-09
ARONSON H 075968 09-13
ARRAS MJ 056852 02-11, 056852 02-11
ARTEMENKO GN 058605 02-03, 058605 02-03
ASBERG M 082104 10-15
ASH ASF 041564 01-03, 041564 01-03
ASHCROFT G 077404 09-16
ASHTON A 060871 03-03
ASPINWALL R 100959 12-07, 105486 12-07
ASSAEL M 064101 04-03
ASTAKHOVA AV 058604 02-03, 058604 02-03
ASTON R 046144 01-03, 046144 01-03
ATKINS C 064282 04-03
AUBRY M 063993 04-03
AVAKUMOV VM 067301 06-17, 072579 08-03
AVERY DD 075234 08-04
AVIADO DM 041539 01-03, 041539 01-03
AVIVI A 097964 11-06
AXELROD J 062327 03-03, 075714 08-03, 075715 08-03, 080352 09-03, 088376 10-03
AXELROD JK 069051 06-13
AYRES JJ 066831 05-04
AZBEKYAN SG 098058 11-03
AZMITIA EC 064146 04-03, 067324 06-03
AZZARO AJ 040753 01-03, 040753 01-03

B

BAASTRUP P 060264 03-17, 060266 03-09, 060267 03-09, 100076 11-09, 100082 11-09, 106766 12-09
BABA A 067243 06-03
BABIKOW PW 058448 02-12, 058448 02-12, 072147 07-14
BACK KC 070732 07-04
BACK KW 058638 02-14, 058638 02-14
BACKSTROM T 066854 05-03
BACON VA 066738 05-06, 097582 11-01
BADALIK L 067597 06-09
BAER L 047828 01-09, 047828 01-09, 075410 08-09, 090419 11-03
BAGADIA VN 138362 12-08
BAGLEY SK 065127 05-14
BAHR F 093540 11-11
BAILEY J 068414 06-13, 106768 12-09
BAINBRIDGE JG 069080 06-04
BAKALAR E 070954 07-12
BAKAY B 040027 01-05, 040027 01-05
BAKER AA 072149 07-15
BAKER BR 051115 01-17, 051115 01-17
BAKER M 058455 02-15, 058455 02-15
BAKER SBDC 057607 02-05, 057607 02-05
BAKKER SJ 070880 07-08
BALAGURA S 067892 06-06, 070821 07-05
BALASUBRAMANIAM K 063800 04-13
BALAZS T 045545 01-06, 045545 01-06
BALDESSARINI R 063825 04-03
BALDESSARINI RJ 047831 01-09, 047831 01-09
BALDINI JT 067569 06-11
BALDRIDGE BJ 069034 06-08
BALMELLE J 072157 07-07
BALSTER RL 041907 01-02, 041907 01-02, 046210 01-04, 046210 01-04, 110682 12-04
BALZANO E 090157 11-04
BAN TA 056500 02-08, 056500 02-08, 058968 03-08, 062643 03-08, 068450 06-08, 069060 06-11, 069580 07-15, 070412 07-15, 072140 07-10, 072142 07-08, 072146 07-11, 075422 08-08, 075423 08-08, 081043 09-14, 082055 10-04, 085289 10-11, 086444 10-15, 086445 10-15, 097985 11-11, 097997 11-07, 126180 12-14
BANERJEE U 046404 01-03, 046404 01-03
BANKS WL 088599 10-03
BANNA NR 081063 09-03
BAPNA JS 064392 04-04
BARAHONA-FERNANDES HJ 059039 03-17
BARANOV VF 087312 10-16
BARBEAU A 058243 02-11, 058243 02-11, 064582 04-07, 081392 09-17, 086351 10-13, 122098 12-17
BARBEE T 063062 03-03
BARBER MA 090425 11-06
BARBIERI NF 128509 12-17
BARBORAKOVA E 070929 07-08
BARCAI A 058375 02-09, 058375 02-09
BARCHAS J 056934 02-04, 056934 02-04, 060633 03-01, 062853 03-03, 063015 03-03, 072463 08-04
BARDONE MC 074685 08-02
BARFKNECHT CF 089440 11-04, 095700 11-01
BARJAKTAROVIC-NIKOLIC K 069085 06-13
BARNES DT 087470 10-12
BARNES KR 081631 10-14
BARO F 064284 04-09
BARR AN 079974 09-11, 081150 09-15
BARRATT E 095014 11-03, 097971 11-07
BARRON SP 076254 09-12
BARROS-FEREIRA M 087498 10-11
BARRY H 064424 04-04, 070443 07-03
BARTH R 094789 11-06
BARTHOLINI G 042726 01-03, 042726 01-03
BARTONICEK VJ 063989 04-06, 066805 05-03
BARTOSEK I 064255 04-03
BARU AM 073716 08-03
BASAGIC E 040578 01-04, 040578 01-04
BASTIE Y 079858 09-11
BATCHELDER E 075412 08-13
BATENCHUK C 075399 08-04
BATTEGAY R 066954 05-14
BATTIG K 069078 06-04, 069079 06-04
BATTISTA AF 068457 06-04
BATTISTELLA GF 092077 11-09
BATTISTI A 087661 10-11
BATULIN YM 072579 08-03
BAU D 067962 06-03
BAUDIS P 070932 07-08, 070937 07-09, 086202 10-17, 101034 12-07
BAUEN A 088616 10-06
BAUER A 079990 09-15, 079994 09-11
BAUER G 044134 01-15, 044134 01-15
BAUER R 065876 05-04
BAUM M 063275 03-04, 065070 05-04
BAUMEL I 064480 04-03, 069052 06-03
BAUMGARTEN HG 058327 02-13, 058327 02-13
BAUST W 133916 12-14
BAXTER RCH 058241 02-11, 058241 02-11
BAXTER RM 064262 04-06, 064264 04-01
BAZILIAN SE 075868 09-10
BEACH FA 072463 08-04, 080606 09-03
BEARD JD 063591 03-03, 065193 05-13
BEATTIE IA 041537 01-06, 041537 01-06
BEATTY PA 075890 09-04
BEATTY WW 075890 09-04
BEAUBIEN J 072146 07-11
BECH P 100014 11-14

BECHTEREVA NP 073770 08-13
BECK CH 076213 09-04
BECK EC 056925 02-14, 056925 02-14
BECKER RE 101681 12-08
BEDARD P 040124 01-05, 040124 01-05, 086349 10-03
BEERING SC 086025 10-10
BEHROOZI K 064101 04-03
BEIN HJ 074861 08-03
BEJEROT N 064272 04-17, 079254 09-15, 079255 09-15, 079256 09-15, 079257 09-15
BELANGER D 083317 10-14
BELAYA I 111031 12-08
BELFER ML 100515 12-15, 100525 12-15, 100534 12-15
BELL DS 064610 04-11
BELYY B 111031 12-08
BENADY DR 078931 09-07
BENES V 070953 07-03
BENESOVA O 070953 07-03
BENKERT O 066322 05-09, 079965 09-13
BENNETT IF 069579 07-14
BENNETT J 056500 02-08, 056500 02-08, 075423 08-08, 097997 11-07
BENSON D 101801 12-11
BENSON H 089999 11-04
BENTE D 098022 11-15
BERGAMINI L 093091 11-10
BERGENER M 089785 11-15
BERGER BD 069311 06-04
BERGMANN F 088463 10-03
BERGOUIGNAN M 079863 09-07
BERKOWITZ BA 066411 05-03
BERKOWITZ PT 046188 01-03, 046188 01-03
BERMAN SA 064356 04-09
BERNARD J 089174 10-11
BERNARD P 058989 03-03, 079179 09-03
BERNARDINI AT 069367 06-03
BERNAREGGI V 072586 08-03
BERNSTEIN A 070897 07-17
BERRY H 069056 06-04
BERRY PA 041537 01-06, 041537 01-06
BERTHOLET G 058282 02-11, 058282 02-11
BERTOLETTI P 094305 11-11
BERTOLOTTI P 124311 12-15
BERTUZZI F 080143 09-08
BERZEWSKI H 079969 09-07
BESSER GM 067602 06-13
BESSON MJ 042742 01-03, 042742 01-03
BEUTHIN PK 040671 01-03, 040671 01-03
BEVILACQUA P 080142 09-11
BHAGAT B 041552 01-03, 041552 01-03, 097958 11-03
BIALOS DS 069613 07-15
BIANCHETTI A 068600 06-03
BIANCHINE JR 063822 04-13, 088615 10-05
BICK MD 079982 09-04
BICKEL MH 067260 06-03
BIEDER J 091076 11-11
BIEDERMAN GB 060858 03-04, 061540 03-04
BIEMOND A 078733 09-13
BIENIEK D 064417 04-04
BIGNAMI G 064365 04-04, 090418 11-04
BILLIET M 079179 09-03
BILY J 070952 07-09
BIRKMAYER W 098039 11-13
BIRLEY JLT 075304 08-08
BISHOP MP 069059 06-07, 072033 07-04, 082053 10-08
BLACK AH 075399 08-04
BLACK IB 062327 03-03
BLACK P 082055 10-04
BLACK WC 069065 06-04, 076133 09-04
BLACKWELL B 082017 10-15
BLAKEMORE CB 061654 03-13
BLANC M 089158 10-11
BLEIWEISS H 071968 07-15
BLINDER MG 065183 05-13, 078422 09-17
BLISS EL 069062 06-03
BLOCH HS 075860 09-14
BLOCK ML 081227 09-04
BLOOM FE 093132 11-03
BLOOM JB 075839 08-15
BLUM A 097999 11-15
BLUM K 047326 01-04, 047326 01-04, 064390 04-04
BLUMBERG AG 070576 07-13, 075227 08-08, 075426 08-10
BLUMENFIELD M 086025 10-10
BLUMER D 081135 09-15
BLUSTEIN J 072397 07-07
BOADLE-BIBER MC 073063 08-06
BOAKES AJ 067657 06-15
BOAKES RJ 041973 01-02, 041973 01-02
BOBON DP 075115 08-14, 089104 10-09
BOBON J 069070 06-07, 089104 10-09
BODOG J 089106 10-15
BOERNER D 089040 10-17
BOETTGER F 079951 09-03
BOGAN J 066853 05-03
BOGDANSKI DF 043277 01-03, 043277 01-03
BOGDONOFF MD 058638 02-14, 058638 02-14
BOGOCH S 111961 12-13
BOHARD F 079288 09-11, 087498 10-11
BOHDANECKY Z 078509 09-14
BOHM M 089099 10-08
BOISSENIN JM 062406 03-08
BOLES J 075438 08-03
BONASEGLA F 094467 11-14
BONATO RS 060862 03-16
BONDAREFF W 072471 08-03
BONITZ G 059015 03-09
BOOIJ J 078732 09-09
BOOK MH 062737 03-15
BOOTH DA 061572 03-03
BOOTS UJ 076276 09-14
BORBELY AA 074939 08-03
BORDELEAU J 075884 09-14, 089054 10-17
BORENSTEIN P 085347 10-08, 089158 10-11
BORGA O 066278 05-03
BORGE GF 067585 06-09
BORGEN LA 060857 03-03
BORN GS 090427 11-13
BORNSTEIN S 079859 09-11
BORTIN AW 065416 05-08
BORTS M 110105 12-17
BORUD O 060272 03-13
BOSZORMENYI Z 089103 10-15
BOTTEGHELLI R 092481 11-14
BOULTER P 092004 11-11
BOULTON AA 092211 11-15
BOURASSA G 098018 11-09
BOURGEOIS M 062347 03-09
BOUSQUET WF 040584 01-03, 040584 01-03, 040671 01-03, 040671 01-03
BOUTILLIER H 079864 09-11
BOWEN DAL 067212 06-06
BOWEN WT 052476 02-11, 052476 02-11
BOWERS MB 047506 01-03, 047506 01-03, 059020 03-11, 066509 05-03, 070824 07-13, 074938 08-14
BOZHKO GK 073716 08-03
BRADLEY PB 041973 01-02, 041973 01-02, 071997 07-04
BRADLEY RJ 121087 12-14
BRADSHAW JL 075161 08-13
BRAET WW 095507 11-06
BRAHAM J 081104 09-14
BRAHMA RK 060659 03-08
BRANCHEY M 075891 09-04
BRANDSMA M 075878 09-07
BRANZEI P 062866 03-11
BRAUDE MC 088412 10-05
BRAUN JJ 076316 09-04
BRAUZER B 040127 01-08, 040127 01-08
BRAZELTON TB 075607 08-05
BREESE GR 040126 01-03, 040126 01-03
BREETVELD J 075881 09-08
BREHM ML 058638 02-14, 058638 02-14
BREMNER FJ 090424 11-04
BRENOT M 086237 10-07
BREZINOVA V 070933 07-14, 070934 07-14
BRIDGES PK 069081 06-13
BRIGGS I 041973 01-02, 041973 01-02
BRILL H 055628 02-14, 055628 02-14
BRILL NQ 071027 07-17
BRIMIJOIN S 080336 09-03, 088376 10-03
BRINK JJ 067120 06-02, 083170 10-03
BRION S 089158 10-11
BROCK N 055397 02-03, 055397 02-03
BRODER LE 040755 01-03, 040755 01-03
BRODIE BB 058985 03-04
BRODIE HKH 067591 06-09, 081038 09-09, 090188 11-11, 092975 11-09
BRODSKY CM 075420 08-17
BROERMANN I 088587 10-03
BROHULT J 097974 11-11
BROOKE G 060659 03-08
BROOKES LG 066738 05-06, 094789 11-06, 097582 11-01
BROOTEN P 058213 02-15, 058213 02-15
BROPHY PD 085144 10-03
BROSER F 051140 02-15, 051140 02-15
BROSNAN CF 066380 05-03
BROUSEK J 086161 10-16
BROUSSEAU ER 064074 04-14
BROWN FD 058966 03-11
BROWN GM 075665 08-03
BROWN GW 075304 08-08
BROWN HD 070906 07-05
BROWN P 067919 06-04
BROWN RG 064258 04-01
BROWN T 067962 06-03
BROWN WT 067862 06-14
BROWNE L 075288 08-04
BRUGMANS J 064284 04-09, 067176 06-11
BRUMMIT H 059275 03-11
BRUN O 089109 10-17
BRUNAUD M 055581 02-03, 055581 02-03
BRUS M 089046 10-03
BRUSCHI WC 065346 05-17
BRUYN HB 082063 10-17
BUCCI L 065475 05-08, 076347 09-10
BUCK R 070352 07-14
BUCKLEY JP 064259 04-04
BUENO JR 080506 09-08
BUGADA G 072586 08-03
BUISSON J 089158 10-11
BUNGE MB 066380 05-03
BUNNEY WE 047828 01-09, 047828 01-09, 062366 03-13, 065165 05-09, 066493 05-13, 067585 06-09, 067591 06-09, 081038 09-09, 092688 11-09, 092975 11-09
BUNO W 098171 11-03
BUONDONNO E 124320 12-17
BURDOCK EI 058374 02-07, 058374 02-07
BUREAU D 079859 09-11
BURGEN ASV 051113 01-17, 051113 01-17
BURKE DH 089436 11-03
BURKMAN AM 075922 09-04, 089437 11-06
BURKS TF 046404 01-03, 046404 01-03
BURLEY DM 066873 05-15
BURN JH 067833 06-03
BURNETT LS 058998 03-05
BURNHEIM RB 076276 09-14
BURNIDGE GK 067703 06-04, 067704 06-04
BUSHART W 058327 02-13, 058327 02-13
BUSSE EW 068955 06-11
BUSTAMANTE JA 058561 02-14, 058561 02-14
BUTCHER L 059033 03-03
BUTCHER R 069056 06-04
BUTLER PWP 067602 06-13

## C

CABANA BE 066364 05-03, 066365 05-03
CADDEN JJ 052574 02-10, 052574 02-10
CAFFEY EM 063607 04-09, 094978 11-11
CAKULS P 106771 12-09
CALDWELL DF 045526 01-04, 045526 01-04
CALDWELL RW 040311 01-03, 040311 01-03
CALHOUN HD 060649 03-13
CALHOUN WH 065876 05-04
CALLAWAY E 074625 08-08
CALNE DB 066419 05-13, 119840 12-17
CALVER DM 043697 01-11, 043697 01-11
CAMARDESE M 114880 12-09
CAMERON DC 071747 07-16
CAMPBELL BA 063688 04-04
CAMPBELL IC 040573 01-13, 040573 01-13
CAMPBELL RJ 061597 03-04
CAMPOS HA 067461 06-03
CANCRINI L 094305 11-11
CANCRO R 062351 03-15
CANDEBAT L 084978 10-08
CANN HM 066838 05-14
CANNARSA DN 065418 05-13
CANNIZZARO G 098049 11-04
CANTLON B 100959 12-07, 105486 12-07
CAPAKOVA L 070946 07-10
CAPSTICK N 065472 05-17
CARAFFA T 087661 10-11
CARBONE JJ 046402 01-03, 046402 01-03
CARCHMAN RA 069593 07-04
CARDON PV 047828 01-09, 047828 01-09, 064420 04-15, 090371 11-13
CAREY JJH 064623 04-15

CAREY RJ 067695 06-04
CARIGLIA N 067120 06-02
CARINO MA 064277 04-05
CARL JL 072119 07-03
CARLEY JL 075917 09-04
CARLINI EA 064417 04-04, 072531 08-04
CARLSON LA 093689 11-11
CARLSSON C 099957 11-11
CARR D 082153 10-15
CARROLL BJ 058404 02-10, 058404 02-10, 059053 03-09, 067012 05-14
CARTER CH 061704 03-15, 061706 03-15
CARTER VL 070732 07-04
CASE W 058969 03-10, 062321 03-10
CASSELL WA 072032 07-14
CASSIUS J 069016 06-11
CASTLEMAN B 042655 01-15, 042655 01-15
CATALANO A 124308 12-10
CATALFOMO P 074074 08-01
CATTANEO ML 098033 11-17
CAUSSINUS H 042676 01-07, 042676 01-07
CAVALCA GG 094467 11-14
CAVANAGH RJ 081516 09-09
CAVANAUGH JH 090373 11-03
CAVINESS VS 081298 09-11
CAZZULLO C 105623 12-08
CEDROLA G 114880 12-09
CELESIA GG 079974 09-11, 081150 09-15
CELIKOVSKA G 055398 02-05, 055398 02-05
CERONE G 087658 10-14
CERVANTES-LEON G 085456 10-14, 086780 10-14
CERVEN J 079139 09-13
CHAMBERS WW 076213 09-04
CHAMOVE AS 060490 03-04
CHANAS PJ 060729 03-17
CHANG FH 058382 02-04, 058382 02-04
CHANLEY JD 064144 04-03
CHAPPA HJ 089798 11-08
CHARI-BITRON A 097964 11-06
CHARLAND P 075884 09-14
CHASE TN 064097 04-13, 068290 06-03, 069852 07-13, 070247 07-13, 072031 07-03, 090371 11-13, 093445 11-15
CHATTERJEE AK 074855 08-03
CHATTOPADHYAY SK 070906 07-05
CHAUDHARY B 065477 05-08
CHAUDHRY MR 138526 12-10
CHEN CH 082056 10-07
CHERAMY A 042742 01-03, 042742 01-03
CHERIPKO JA 046402 01-03, 046402 01-03
CHERKES A 110632 12-03
CHERKIN A 070978 07-04
CHERNOV HI 058989 03-03
CHESROW EJ 059359 03-10
CHEYMOL G 058991 03-05
CHIBA S 089788 11-13
CHIEN C 067513 06-11
CHINN C 104737 12-03
CHISHOLM DC 065451 05-04, 075235 08-04
CHISTONI G 112282 12-16
CHOLET R 086005 10-11
CHOSY JJ 054890 02-11, 054890 02-11
CHOTLOS JW 052476 02-11, 052476 02-11
CHOU C 064161 04-03
CHOULIS NH 068970 06-03
CHOUZA C 098172 11-07
CHRISSTOFFELS J 075980 09-15
CHRISTIAN JE 090427 11-13
CHRISTIANSEN J 100014 11-14, 100026 11-13
CHRISTMAS AJ 040581 01-04, 040581 01-04
CHRISTONI GC 086984 10-16
CHRISTRUP H 100014 11-14
CHRUSCIEL T 105266 12-17, 110225 12-17, 110226 12-17
CHUNG H 058969 03-10, 062321 03-10
CIANCIARA J 116482 12-08
CIUMAGEANU D 078730 09-14
CLAGHORN J 063567 03-10, 067175 06-08
CLAGHORN JL 064285 04-10
CLANCY DD 058589 02-15, 058589 02-15
CLANCY J 045526 01-04, 045526 01-04, 088707 10-15
CLARIDGE G 110896 12-14
CLARK CVH 067980 06-03, 074830 08-04, 075848 09-04
CLARK EL 065247 05-10, 066276 05-10
CLARK LD 066871 05-04
CLARK ML 067719 06-08, 080631 09-06, 088221 10-13
CLARK R 066315 05-03
CLARK WG 070063 07-06
CLAUDER O 055740 02-03, 055740 02-03
CLAUSSEN U 064417 04-04
CLEARY P 060862 03-16
CLEGHORN JM 060880 03-13, 075321 08-08
CLEMENT WR 063753 04-15
CLOETENS WJH 058282 02-11, 058282 02-11
CNOCKAERT P 088618 10-15
COBB HW 090424 11-04
COBY WF 069067 06-04
COCCHI A 079972 09-03, 098033 11-17, 105623 12-08
COCHIN J 056238 02-03, 056238 02-03
COCITO E 080142 09-11
COHEN H 056934 02-04, 056934 02-04
COHEN S 046725 01-12, 046725 01-12, 046727 01-12, 046727 01-12, 046728 01-12, 046728 01-12, 046729 01-14, 046729 01-14, 046730 01-12, 046730 01-12, 046731 01-12, 046731 01-12, 046732 01-12, 046732 01-12, 046733 01-11, 046733 01-11, 046734 01-15, 046734 01-15, 046735 01-15, 046735 01-15, 046736 01-17, 046736 01-17, 067343 06-12
COLBURN RW 062366 03-13
COLDWELL BB 064160 04-05, 090032 11-05
COLE HF 064260 04-04
COLE JO 060861 03-15, 063143 03-11, 075421 08-08, 076327 09-17, 089433 10-08
COLE RE 076016 09-13
COLE SO 064968 05-04, 066821 05-04, 068288 06-04
COLLARD J 089160 10-11
COLLINGS L 115037 12-08
COLLINS J 066903 05-15
COLLINS L 075332 08-11
COLONNA L 085129 10-15
COLUCCI D'AMATO F 114885 12-08
COMLY H 088707 10-15
COMTOIS RJ 103636 12-14
CONNER RL 062853 03-03, 063015 03-03
CONNERS CK 070971 07-17
CONNEY AH 064282 04-03
CONROY RF 059624 03-14
CONSOLO S 042756 01-13, 042756 01-13
CONTRERAS E 075846 09-03
CONWAY MW 080631 09-06
COOK L 065493 05-04, 075720 08-04
COOKSON B 092211 11-15
COONS EE 090473 11-04
COONS WH 082410 10-14
COOPER BR 069065 06-04, 076133 09-04
COOPER IS 071985 07-07, 081392 09-17
COOPER RM 081149 09-04
COOPER T 106783 12-03
COOPWOOD WE 063209 03-09
COPER H 088587 10-03
COPPEN A 067676 06-10, 068414 06-13, 075470 08-13, 106768 12-09
CORBALLIS MC 075771 08-14
CORDEIRO MAP 113137 12-15
CORDERO FUNES J 100959 12-07, 105486 12-07
CORDLE M 078378 09-03
COREY MJ 071987 07-13
CORNETTE M 088568 10-15
CORNU F 079986 09-07
CORRODI H 081151 09-03
CORSICO R 089798 11-08
CORSON JA 060756 03-04
COSTA E 088392 10-03, 107549 12-13
COTT A 068976 06-08
COTTEREAU M 085129 10-15
COTZIAS GC 056574 02-11, 056574 02-11
COUADAU A 091502 11-08
COUDIERE G 072159 07-07
COUDRAY P 085043 10-15
COULL DC 070854 07-15
COURT JH 085327 10-09
COURTNEY RJ 075553 08-04
COUTINHO CB 046402 01-03, 046402 01-03
COVI L 066741 05-16, 076292 09-10, 087386 10-10
COWAN G 076351 09-17
COWIE AL 041974 01-03, 041974 01-03
COX B 040572 01-03, 040572 01-03
COX BM 041570 01-03, 041570 01-03
COX CE 067716 06-04
COX RH 040241 01-03, 040241 01-03, 074937 08-04, 103710 12-04
COYLE JT 075869 09-04
CRAMER H 059054 03-09
CRAMMER JL 064409 04-03
CRANE GE 042699 01-15, 042699 01-15, 068603 06-15
CRAVES F 066413 05-03
CRAWFORD JM 040580 01-03, 040580 01-03
CREAVEN PJ 046197 01-03, 046197 01-03, 063062 03-03
CRESON D 095014 11-03, 097971 11-07
CRETALLAZ JC 058282 02-11, 058282 02-11
CREVELING CR 062783 03-13
CRIM M 063927 04-13
CRIPPS DJ 066318 05-15
CROME A 079995 09-14
CROMWELL RL 075413 08-08
CRONHOLM B 082104 10-15
CROOKS J 070854 07-15
CROW TJ 058397 02-13, 058397 02-13
CRUMPTON E 071027 07-17
CUANALO GF 085454 10-14
CUJO P 085347 10-08
CULLEN JW 061094 03-04
CUNNINGHAM W 071984 07-07
CURRAN J 063854 04-15, 072144 07-08
CURRY AS 046395 01-01, 046395 01-01
CURRY SH 041559 01-13, 041559 01-13, 046138 01-13, 046138 01-13, 047913 01-13, 047913 01-13, 047951 01-09, 047951 01-09, 066937 05-03
CURTIN ME 057480 02-14, 057480 02-14
CURZON G 069081 06-13
CUTTING WC 051111 01-17, 051111 01-17
CWIERTNIA T 072896 08-08
CZERWENKA-W H 042693 01-11, 042693 01-11

D

D'AMELIO V 109255 12-11
D'ENCARNACAO P 058357 02-06, 058357 02-06
D'ENCARNACAO PS 062521 03-04
DAHLBERG CC 051530 02-13, 051530 02-13
DAHLSTROM A 066499 05-03
DAIRMAN W 045545 01-06, 045545 01-06
DALLAPICCOLA B 068181 06-15
DALLY P 063144 03-11, 066950 05-17
DALY J 062783 03-13
DAM M 066189 05-05
DAMASIO AR 070856 07-09
DANA L 075429 08-08
DANDIYA PC 064392 04-04
DANIEL R 090428 11-17
DANIELS JC 066890 05-15
DARRAH G 070415 07-12
DASHER CE 071467 07-04
DAVE KP 138362 12-08
DAVENPORT JW 070839 07-02
DAVEY DG 057607 02-05, 057607 02-05
DAVIDSON AB 065493 05-04, 075720 08-04
DAVIES B 058404 02-10, 058404 02-10, 059053 03-09, 066826 05-07, 067012 05-14, 075472 08-15
DAVIES DS 051593 02-17, 051593 02-17
DAVIS D 085237 10-08
DAVIS HN 063014 03-04
DAVIS JM 047913 01-13, 047913 01-13, 047951 01-09, 047951 01-09, 062366 03-13, 064170 04-03, 087632 10-09
DAVIS LE 066368 05-03
DAVIS N 075839 08-15
DAVIS RB 134902 12-09
DAVIS WM 060857 03-03
DAVISON K 067864 06-14
DAVISON MC 075579 08-04
DAWSON AA 063874 04-13
DAWSON-BUTTERWORTH K 059380 03-11
DAYNE D 079863 09-07
DE BALBIAN VERSTER F 058357 02-06, 058357 02-06
DE CARO E 128509 12-17
DE FAZIO F 124320 12-17
DE GROAT WC 040752 01-03, 040752 01-03
DE GROOT MH 088951 10-08
DE JONGHE FERER 078213 09-13
DE LA ROCHA M 064286 04-08
DE LA TORRE JC 074084 08-03
DE MORI V 091502 11-08
DE MOURA RS 046399 01-03, 046399 01-03
DE PERROT E 112282 12-16

DE PIETRI L 124311 12-15
DE RIVIERES HS 079859 09-11
DE ROPP RS 094553 11-03
DE SCHAEPDRYVER A 079179 09-03
DE SMEDT R 067176 06-11
DE SOUZA MARTINS SA 046399 01-03, 046399 01-03
DEBANDT R 067176 06-11
DEBOLD RG 092209 11-01
DEBRAY H 085343 10-11, 089158 10-11
DECHERD JF 059623 03-13
DEDE G 095719 11-14
DEFEO JJ 064480 04-03, 069052 06-03
DEGROSS J 066395 05-15
DEL VECCHIO M 114880 12-09
DELAUNOIS A 079179 09-03
DELAY J 091500 11-07
DELBARRE B 081261 09-06
DELGADO JN 064258 04-01
DELINI-STULA A 082409 10-03
DELONG SL 060861 03-15
DEMARET A 070267 07-13
DEMBICKI EL 095410 11-15, 096196 11-16
DEMENT W 056934 02-04, 056934 02-04, 062853 03-03, 072463 08-04
DEMERS R 066747 05-13, 067900 06-15
DEMIRGIAN E 074217 08-17
DEN BESTEN W 070779 07-01
DENBER HCB 089443 11-15
DENBER MJA 069309 06-02
DENIKER P 085129 10-15, 085130 10-15, 100276 11-07
DENSON R 063873 04-12
DENT MJW 068175 06-15
DEPAEPE A 058282 02-11, 058282 02-11
DEPOORTERE H 089045 10-12
DEROGATIS LR 066741 05-16
DERR JE 041559 01-13, 041559 01-13, 066937 05-03
DERR RF 088600 10-03
DESCHAMBAULT M 072406 07-15
DESI I 065441 05-04
DESILVERIO RV 065247 05-10
DESPOPOULOS A 074862 08-03
DESSAIGNE S 055580 02-03, 055580 02-03
DESTOUNIS N 072147 07-14
DETTBARN W 060856 03-03, 069515 06-13
DEUTSCH M 069060 06-11
DEVENPORT L 067892 06-06
DEVENYI P 065187 05-13
DEVOINO LV 040579 01-03, 040579 01-03
DEWEY WL 058994 03-03, 069594 07-04
DEWS PB 075793 08-14
DEWSBURY DA 063014 03-04
DEYOUNG DV 090365 11-17
DHAWAN BN 064414 04-04
DHAWAN KN 064413 04-03
DI GIACOMO S 055394 02-03, 055394 02-03
DI MEZZA F 055394 02-03, 055394 02-03
DIAMOND AL 076016 09-13
DIAMOND B 064638 05-08, 065314 05-10
DIAMOND F 121083 12-14
DIASSI PA 051123 02-17, 051123 02-17
DIAZ PM 067613 06-03
DICARLO FJ 071942 07-03
DICKEL HA 063594 03-10
DIM BH 065473 05-07
DIMASCIO A 052502 02-14, 052502 02-14, 058212 02-15, 058212 02-15, 065477 05-08, 074217 08-17, 076003 09-08, 080350 09-17, 100512 11-15, 100515 12-15, 100516 12-15, 100517 12-15, 100523 12-15, 100524 12-15, 100526 12-15, 100527 12-15, 100528 12-15, 100529 12-15, 100531 12-15, 100532 12-13, 100534 12-15, 105560 12-15
DINGELL JV 066374 05-03, 066955 05-03
DINGWALL-FORDYCE I 070854 07-15
DISTEFANO V 040417 01-03, 040417 01-03, 064167 04-03
DITZION BR 043276 01-03, 043276 01-03, 071972 07-13
DLABAC A 070949 07-04, 081110 09-17
DOBRZANSKI T 116482 12-08
DOGGETT NS 068165 06-03
DOGLIANI P 080143 09-08
DOLE VP 070021 07-13
DOLLERY CT 051593 02-17, 051593 02-17
DOLMIERSKI R 085102 10-15
DOM R 064284 04-09
DOMINO EF 074782 08-12
DONY JGH 079968 09-03
DOOHER L 076233 09-11
DOONGAJI DR 134932 12-13
DORFMAN W 060728 03-17
DORR M 067599 06-06, 067606 06-04
DOSTAL T 106771 12-09, 106776 12-14
DOTTI A 094305 11-11
DOWLING J 076233 09-11
DOWNES H 066372 05-03, 116471 12-03
DOWNING RW 063207 03-10, 064287 04-15, 074130 08-10, 092102 11-16
DRASKOCZY PR 066363 05-03
DRAY A 041973 01-02, 041973 01-02
DREISBACH RH 051111 01-17, 051111 01-17
DREYFUS J 111961 12-13
DRISCOLL P 069079 06-04
DROMMER W 056060 02-15, 056060 02-15
DRONKERT A 066399 05-13
DROPPLEMAN LF 047836 01-10, 047836 01-10, 075873 09-14
DRUCKER H 088438 10-14
DUBIEL GC 067513 06-11
DUBOIS B 072157 07-07
DUCHE DJ 086451 10-11
DUCROT R 074685 08-02
DUFFIELD AM 097582 11-01
DUFFY JP 067864 06-14
DUFRASNE M 069070 06-07, 093537 11-14
DUHAZE P 086005 10-11
DUJOVNE CA 088615 10-05
DUKE CR 076164 09-04
DULL TA 075388 08-10
DUMAINE A 085347 10-08
DUMAS G 081261 09-06
DUNCAN C 070303 07-14
DUNDEE JW 067607 06-03
DUNLOP D 083128 10-15
DUNLOP E 063600 04-13
DUNN M 067138 06-15
DUPUIS R 063993 04-03
DURELL J 047828 01-09, 047828 01-09, 075410 08-09
DUSTMAN RE 056925 02-14, 056925 02-14
DUTTA SN 046190 01-04, 046190 01-04, 071786 07-04
DVORAKOVA M 070932 07-08, 070937 07-09
DYNE LJ 076066 09-04
DYNES JB 083339 10-15
DYRUD J 047919 01-09, 047919 01-09
DYSON WL 058375 02-09, 058375 02-09

E

EADE NR 064421 04-03
EADES CG 090422 11-03
EAGLE CT 075191 08-12
EARLE A 062108 03-08
EARLE BV 075428 08-09
EARNSHAW BA 056350 02-15, 056350 02-15
EBADI MS 046397 01-02, 046397 01-02
EBERT MH 100514 12-15, 100521 12-15, 100522 12-15
EBERT WR 090427 11-13
EBNER E 076254 09-12
ECHOLS CL 072508 08-15
ECKERT H 073709 08-03
ECKMANN F 067597 06-09
EDDY TP 079912 09-11
EDGE ND 041538 01-03, 041538 01-03
EDGELL PG 071970 07-15
EDGLEY R 058422 02-15, 058422 02-15
EDWARDS D 062510 03-13, 075274 08-13
EDWARDS DA 081233 09-04
EDWARDS H 075416 08-15
EGOROV BB 082954 10-14
EGOZCUE J 067342 06-15
EIDELBERG E 090149 11-03
EIDUSON S 060865 03-03
EINSTEIN S 083415 10-17
EISDORFER C 071336 07-14
EK L 066506 05-03
EL-TOUMI A 045508 01-07, 045508 01-07
ELIASSON M 058531 02-04, 058531 02-04
ELLINWOOD EH 064143 04-05, 071993 07-05
ELLIOTT HW 051111 01-17, 051111 01-17, 063927 04-13
ELLIOTT RC 072034 07-03
EMERY L 075819 08-11
ENG EW 057480 02-14, 057480 02-14
ENGEL J 059033 03-03
ENGLEMAN K 070247 07-13
ENGLERT LF 038488 01-04, 038488 01-04
EPPE H 084978 10-08
EPSTEIN LJ 070897 07-17
EPSTEIN RS 062352 03-09
EPSTEIN SE 064420 04-15
ERDOSSOVA R 065434 05-03
EREMINA OF 040579 01-03, 040579 01-03
ERIKSOO E 089786 11-01
ERWIN CW 068955 06-11
ESCALANTE O 064143 04-05, 071993 07-05
ESCANDE M 089173 10-07
ESHCHANOV T 105720 12-03
ESSIG C 046205 01-15, 046205 01-15, 097548 11-03
ESSMAN WB 070976 07-17
ESTEVEZ V 089439 11-03
ESTLER C 058800 02-03, 058800 02-03, 079954 09-03
ESTRADA T 067510 06-15
ETEZADY MH 066276 05-10
ETTINGER M 063854 04-15
EUGSTER CH 074074 08-01
EVANGELISTA AM 046186 01-04, 046186 01-04
EVANS HL 071790 07-03
EVANS JI 067924 06-14, 072216 07-14
EVANS WH 058877 02-01, 058877 02-01
EVDOKIMOVA N 105721 12-03
EVETTS KD 074053 08-04
EY H 079288 09-11, 087498 10-11

F

FABER J 089037 10-14
FAHN S 059021 03-11
FAHY T 097562 11-09
FAILLACE LA 052457 02-12, 052457 02-12, 075290 08-12, 075859 09-12
FAKROT MI 096512 11-09
FALENI RA 063589 03-08
FALK JL 067703 06-04, 067704 06-04
FANALI A 112131 12-09
FANELLI R 064000 04-03, 081106 09-03, 090134 11-03
FANN WE 075413 08-08
FARAGALLA FF 063939 04-13, 075837 08-11
FARETRA G 076233 09-11
FARKAS I 065441 05-04
FARNEBO L 040245 01-03, 040245 01-03
FAROUX C 072155 07-14
FARRER DN 070732 07-04
FASTIER FN 085613 10-17
FAURBYE A 067107 06-13, 100016 11-15
FAYERS PM 066419 05-13
FAZIO C 075111 08-14
FEHERVARY E 078730 09-14
FEHLING C 056574 02-11, 056574 02-11, 066940 05-14
FEJERMAN N 100959 12-07, 105486 12-07
FEKETE M 069074 06-04
FELDBERG W 041569 01-03, 041569 01-03, 046404 01-03, 046404 01-03
FELDMAN HS 066832 05-10, 070784 07-13, 075868 09-10
FELDSTEIN A 058382 02-04, 058382 02-04
FELINE A 091500 11-07
FELPEL LP 064100 04-03
FERGUSON J 056934 02-04, 056934 02-04
FERHOLT JB 067221 06-08
FERRARI G 094423 11-11, 094472 11-13
FERRIERE G 093537 11-14
FERRO-DIAZ P 064639 05-07
FIBIGER HC 063688 04-04, 110922 12-04
FIEGENSCHUE B 064263 04-03
FIEVE R 047952 01-09, 047952 01-09, 063138 03-09, 063142 03-09, 090419 11-03, 106767 12-13
FINE EW 061654 03-13
FINE J 058371 02-14, 058371 02-14
FINER MJ 074732 08-11
FINESTONE SC 058371 02-14, 058371 02-14
FINK M 041568 01-09, 041568 01-09, 065475 05-08, 072141 07-10, 075313 08-08, 075427 08-16
FINLAYSON P 076276 09-14
FINN R 063923 04-17, 088707 10-15
FINNERTY FA 076346 09-17

FINNERTY RJ 075421 08-08
FIORENTINO D 075332 08-11
FIRSHEIN W 092209 11-01
FIRTH H 063978 04-14
FISCHBACH R 081143 09-13
FISCHER CM 067218 06-15
FISCHER E 079970 09-04
FISCHER R 058454 02-12, 058454 02-12, 064323 04-12, 065433 05-12, 121086 12-12
FISHER AE 081227 09-04
FISHER G 062808 03-12, 080609 09-08, 087530 10-12
FISHER RG 072465 08-11
FISHER S 047836 01-10, 047836 01-10, 065488 05-10, 075873 09-14
FISHER WJ 075372 08-15
FLACH FF 052574 02-10, 052574 02-10, 063939 04-13
FLEISHER JH 046188 01-03, 046188 01-03
FLEISHMAN P 089444 11-10
FLEMING P 074874 08-08
FLEMING RM 070063 07-06
FLEMING WW 040243 01-03, 040243 01-03, 040753 01-03, 040753 01-03
FLETCHER EA 074148 08-03
FLICHMAN JC 063590 03-17
FLOCK EV 066938 05-03
FLORIO V 085337 10-03
FLOYD A 059040 03-07
FLYNN PD 064623 04-15
FOG R 063019 03-04, 091127 11-04
FOKSTUEN T 059037 03-11, 105734 12-17
FOLDI M 126051 12-04, 126053 12-04, 126054 12-04, 126055 12-04, 126056 12-04
FOLEY CW 069610 07-04
FOLLENFANT MJ 055322 02-03, 055322 02-03
FOMOCHKIN I 110633 12-03
FONDA P 105623 12-08
FONTAINE G 072157 07-07
FONTANI F 064159 04-01
FOOTE WE 040418 01-03, 040418 01-03
FORD GD 040753 01-03, 040753 01-03
FORJAZ NJ 086977 10-07
FORNEY RB 069579 07-14
FORREST FM 071989 07-13
FORREST I 045543 01-05, 045543 01-05, 060222 03-05, 066738 05-06, 094789 11-06, 097582 11-01
FORREST IS 071989 07-13
FOUKS L 088999 10-15
FOURNIE H 086859 10-11
FOWLES DC 067719 06-08
FOX KA 081098 09-04
FOXWELL MH 046139 01-04, 046139 01-04
FRACCHIA J 115037 12-08
FRAIPONT J 093537 11-14
FRANCK G 088568 10-15
FRANK ET 075413 08-08
FRANK GB 066382 05-03, 090139 11-03, 090189 11-03
FRANK I 070778 07-14, 071027 07-17
FRANKENHEIM JM 042719 01-04, 042719 01-04
FRANTSUZOVA S 110632 12-03
FRANZEN G 075212 08-08
FREE SM 069025 06-10
FREEDMAN AM 041568 01-09, 041568 01-09, 075427 08-16
FREEDMAN DX 082545 10-04, 086029 10-12, 097965 11-04
FREEDMAN LS 066854 05-03
FREEMAN JJ 066955 05-03
FREEMAN RD 079144 09-17
FREEMON F 078933 09-14
FREGLY MJ 067716 06-04
FREIMARK SJ 059616 03-04
FREOUR P 085043 10-15
FREUND G 058492 02-04, 058492 02-04
FREUND J 068987 06-17
FREYHAN F 106773 12-09, 106782 12-17
FREYRE AV 063590 03-17
FRICK B 124312 12-17
FRIEDHOFF AJ 064053 04-03, 064386 04-14
FRIEDMAN MJ 075842 08-03
FRIEDMAN PH 070352 07-14
FRIEDMAN R 089438 11-13
FRIES H 058405 02-15, 058405 02-15
FRIESEN H 058243 02-11, 058243 02-11
FRITCHIE GE 046198 01-03, 046198 01-03, 067081 05-03
FROMMER E 063934 04-10
FROSCH WA 075300 08-13
FUCHS M 065475 05-08, 076347 09-10
FUJIMORI M 064331 04-08
FUJIMOTO JM 040754 01-03, 040754 01-03, 057473 02-16, 057473 02-16
FUKUSHIMA DK 047954 01-09, 047954 01-09
FULGINITI S 064178 04-04
FULLER GC 076186 09-03
FULLER JL 066828 05-04
FULLER RW 058942 02-03, 058942 02-03, 066507 05-03
FUNCKE ABH 070779 07-01
FUNDERBURK WH 046139 01-04, 046139 01-04, 082051 10-03
FUNFGELD EW 087336 10-11
FURLONG FW 075425 08-10
FURON D 072155 07-14
FURST A 063606 04-05
FUSE Y 088611 10-13
FUXE K 059033 03-03, 081065 09-03, 081151 09-03
FYRO B 095440 11-03

G

GAASTERLAND D 058534 02-15, 058534 02-15
GABAY S 060223 03-03
GABRIYELYAN E 111767 12-03
GAGNON A 072406 07-15
GAIND R 079914 09-15
GALIPEAU LA 067120 06-02
GALLAGHER TF 047954 01-09, 047954 01-09
GALLANT DM 069059 06-07, 072033 07-04, 082053 10-08
GALUSZKO P 072895 08-11
GALVAN RV 085453 10-14
GALZIGNA L 072705 08-01
GANDELMAN RJ 060871 03-03
GANNON P 063597 04-08, 080031 09-07
GANSMAN DH 066709 05-10
GANTT WH 071705 07-13
GARATTINI S 064000 04-03, 064255 04-03, 081106 09-03, 090134 11-03, 107549 12-13
GARBER RS 076508 09-17
GARCIA MONGE MT 058974 03-05
GARCIA PR 086793 10-09
GARCIA-AUSTT E 098171 11-03
GARDNER FT 066813 05-04, 092209 11-01
GARDNER LI 063880 04-15
GARDOS G 075421 08-08
GARG M 065452 05-04
GAROUX R 088438 10-14
GARRET C 074685 08-02
GARSIDE RF 097562 11-09
GARSKE G 066829 05-04
GARTSIDE IB 067600 06-06
GASTON A 086877 10-17
GASTON ET 075191 08-12
GATTONI RC 046186 01-04, 046186 01-04
GAURON EF 060090 03-04
GAYRAL L 042676 01-07, 042676 01-07, 084978 10-08, 086859 10-11, 089001 10-11
GEARING FR 071314 07-17
GEHRING A 079966 09-13
GEISLER L 079971 09-07
GELLER A 066830 05-04, 097953 11-04
GELLER E 042840 01-03, 042840 01-03
GELLER I 047326 01-04, 047326 01-04
GENDREAU P 059567 03-04
GENEVIEVE J 089055 10-11
GENTILI E 087661 10-11, 091138 11-14, 112130 12-11
GEORGE DJ 074146 08-05
GEORGE HR 067692 06-09
GERAUD J 089173 10-07
GERBER GJ 063725 04-06
GERSHON ES 052456 02-10, 052456 02-10
GERSHON S 058374 02-07, 058374 02-07, 058914 02-12, 058914 02-12, 059040 03-07, 060859 03-09, 064253 04-04, 066413 05-03, 073734 08-17, 075426 08-10, 079888 09-04, 088614 10-03, 095013 11-09, 106769 12-15, 121083 12-14
GERSON IM 089438 11-13
GERSTEIN AR 067926 06-15
GERSTENBRAND F 089784 11-14
GERWIRTZ GP 092383 11-03
GESSNER PK 066364 05-03, 066365 05-03
GETTNER HH 064609 04-06
GEWIRTZ GP 080337 09-01
GEYER HM 064259 04-04
GHITTONI NE 090148 11-03
GHOSE A 074855 08-03
GIACOBINI E 040756 01-03, 040756 01-03
GIANGUZZA M 098049 11-04
GIARDINA WJ 055583 02-03, 055583 02-03, 055584 02-03, 055584 02-03
GIBBINS RJ 057866 02-01, 057866 02-01
GIDLEY JT 047325 01-03, 047325 01-03
GILBERT JC 058991 03-05
GILDER SSB 074858 08-12
GILL EW 086405 10-01
GILLER DR 100523 12-15, 100532 12-13
GILLESPIE HK 040128 01-14, 040128 01-14, 066231 05-14, 066232 05-14, 071998 07-14, 073886 08-14
GILLINGHAM FJ 077404 09-16
GINSBERG MD 064236 04-15
GINTHER R 080506 09-08
GIRARD J 062407 03-11
GITLOW SE 081072 09-17
GITTELMAN-KLEIN R 075227 08-08
GJESSING LR 060272 03-13
GLASSMAN E 078378 09-03
GLATZEL J 087066 10-17
GLESER GC 075321 08-08
GLICK ID 068215 06-09
GLICK SD 065420 05-04, 065747 05-04, 075238 08-04, 075917 09-04, 095351 11-03
GLINER J 069645 07-03
GLOVER AB 064254 04-03
GLOWINSKI J 042742 01-03, 042742 01-03, 120465 12-03
GODSE DD 075425 08-10
GOGAN MP 064268 04-15
GOL'DOVSKAYA IL 073788 08-15
GOLD AP 066838 05-14
GOLD GM 064422 04-05
GOLD HK 064420 04-15
GOLDBERG GJ 060659 03-08
GOLDBERG HL 065477 05-08, 076003 09-08
GOLDBERG JB 062175 03-14, 069071 06-11
GOLDBERG LI 040311 01-03, 040311 01-03
GOLDBERG ME 058993 03-04, 064056 04-03, 082398 10-04
GOLDBERG SC 115463 12-17, 134057 12-17
GOLDBERG SG 085237 10-08
GOLDBERG SR 046208 01-03, 046208 01-03, 061632 03-04
GOLDEN RL 070288 07-10
GOLDFARB A 058403 02-15, 058403 02-15
GOLDFOOT DA 065332 05-03
GOLDSTEIN A 075844 09-04, 101316 12-03
GOLDSTEIN BJ 040127 01-08, 040127 01-08, 063599 04-08
GOLDSTEIN F 063879 04-14
GOLDSTEIN L 063879 04-14
GOLDSTEIN M 066854 05-03, 068457 06-04, 103255 12-08
GOLDWURM G 098033 11-17, 105623 12-08
GOMENSORO JB 098172 11-07
GONIER T 066398 05-08, 066817 05-08
GONNE L 081065 09-03
GONZALEZ A 058561 02-14, 058561 02-14
GONZALEZ-GONZALEZ J 085456 10-14, 086780 10-14
GOODMAN MM 080032 09-02
GOODRICH CA 046404 01-03, 046404 01-03
GOODWIN DW 078933 09-14
GOODWIN FK 059054 03-09, 066493 05-13, 067585 06-09, 067591 06-09, 081038 09-09, 090188 11-11, 092688 11-09, 092975 11-09
GORCEIX A 091503 11-11
GORDON EK 064097 04-13, 075410 08-09
GORDON NB 062817 03-11
GORDON PE 062321 03-10, 065453 05-10, 066709 05-10, 075415 08-10, 075868 09-10
GORMAN D 074830 08-04
GOTFREDSEN C 106778 12-05
GOTTFRIES C 089108 10-11, 100017 11-08
GOTTSCHALK LA 075321 08-08
GOUDA MW 046136 01-17, 046136 01-17
GOY RW 065332 05-03
GOZ B 051120 02-17, 051120 02-17
GRABNER F 090126 11-15
GRABOWSKA M 067384 06-03
GRAEDON J 063879 04-14

GRAEFF FG 069738 07-04
GRAHAM DT 054890 02-11, 054890 02-11
GRAJALES A 081121 09-10
GRAM L 100019 11-09, 100026 11-13
GRANDMONTAGNE O 084978 10-08
GRANT RHE 080635 09-11
GRAY B 065453 05-10, 066832 05-10
GRAY C 075430 08-09
GRAY JA 063333 04-03, 064375 04-04
GREEN JP 067199 06-06
GREEN PC 069645 07-03
GREEN R 067696 06-04, 076086 09-04
GREENBAU GHC 060240 03-08
GREENBLATT DJ 100518 12-15, 100527 12-15
GREENE EG 067522 06-04
GREENSPAN K 043277 01-03, 043277 01-03, 047828 01-09, 047828 01-09, 075410 08-09
GREER M 064188 04-11
GREINER AC 062935 03-08
GRELAK RP 066315 05-03
GRIFFITH JD 090373 11-03
GRIFFITHS NR 066496 05-10
GRINBERG K 102119 12-16
GROF P 060264 03-17, 060266 03-09, 060267 03-09, 106771 12-09
GROF S 067339 06-12, 097286 11-12
GROH J 070952 07-09
GROH RH 066490 05-15, 082155 10-09, 091919 11-11
GROMSKA J 085102 10-15
GROSCHEL D 067926 06-15
GROSS H 089100 10-09, 101020 12-15, 105730 12-07
GROSS MM 065188 05-13
GROSSER HH 063186 03-08
GROSSMAN HJ 065175 05-11
GROTA LJ 063605 04-04, 075665 08-03
GROUNDS D 075472 08-15
GRUNBERGER J 089784 11-14
GRUNDEN LR 072030 07-03
GRUZELIER JH 075771 08-14
GUARALDI GP 094467 11-14
GUENSBERGER E 059038 03-17, 070957 07-15
GUERRERO-FIGUEROA R 069059 06-07, 072033 07-04
GUEST ADL 070303 07-14
GUILLAN R 076364 09-15, 090359 11-15
GUIONNIERE M 081261 09-06
GUIRGUIS W 063934 04-10
GUMULKA W 066500 05-03, 080338 09-01
GUPTA BS 078786 09-14
GUPTA GP 064413 04-03
GUPTA SC 134937 12-11
GUROVICH IY 081539 10-15
GURR DM 067212 06-06
GUSEL' VA 110631 12-03
GUTH E 080041 09-11
GUTH S 103354 12-04
GUTMAN Y 088463 10-03
GUTMANN L 072421 08-07
GUTRECHT JA 072421 08-07
GUTTMAN H 070412 07-15
GUY W 060862 03-16
GYLYS JA 064181 04-04

H

HABER B 058192 02-03, 058192 02-03
HABER S 064282 04-03
HABERLER H 105730 12-07
HACKMAN C 067961 06-03
HADLIK J 070935 07-08, 070938 07-08, 070940 07-09
HAERTZEN CA 097961 11-14
HAGGENDAL J 066499 05-03
HAHN WC 090424 11-04
HAIDER I 082027 10-15
HAIN JD 047825 01-11, 047825 01-11
HAINE SE 069579 07-14
HAJOS P 065441 05-04
HAKALA MW 046139 01-04, 046139 01-04
HAKOLA P 105732 12-14
HALEY B 082172 10-11
HALEY TJ 047325 01-03, 047325 01-03
HALL GH 041567 01-03, 041567 01-03
HALL JL 068952 06-03
HALL RD 074939 08-03
HALL S 058357 02-06, 058357 02-06
HALLSTEN EA 103301 12-14
HALPERN B 066738 05-06
HALPERN LM 066329 05-15
HAMBERGER B 040245 01-03, 040245 01-03, 066278 05-03
HAMETOVA M 070952 07-09
HAMILTON AE 058879 02-03, 058879 02-03
HAMILTON HE 071467 07-04
HAMILTON LW 095697 11-03
HAMILTON M 075113 08-11
HAN T 063597 04-08
HANA K 131623 12-03
HANDRICK GR 093550 11-01
HANIEH A 077404 09-16
HANIG JP 067253 06-04
HANLEY T 057606 02-05, 057606 02-05
HANLON TE 058451 02-15, 058451 02-15
HANSBROUGH ET 058442 02-15, 058442 02-15
HANSING R 067884 06-04
HANSON HM 064426 04-04
HANUS H 070952 07-09
HAPKE HJ 089044 10-17
HAQ M 041540 01-03, 041540 01-03
HARBANS L 064480 04-03
HARDEMAN WJ 070880 07-08
HARDY DF 081228 09-04
HARDY RW 066187 05-03
HARIRATNAJOTHI N 046187 01-13, 046187 01-13
HARLOW HF 060490 03-04
HARMATZ JS 100520 12-15, 105560 12-15
HAROON-AHMED S 138144 12-11
HARPER MA 056350 02-15, 056350 02-15
HARPER P 068153 06-15
HARRELL WB 055324 02-01, 055324 02-01
HARRER G 079960 09-14, 133147 12-09
HARRER H 079960 09-14
HARRIMAN AE 068287 06-04
HARRIS LS 058994 03-03, 069594 07-04
HARRIS LW 046188 01-03, 046188 01-03
HARRIS RT 041907 01-02, 041907 01-02, 046194 01-17, 046194 01-17, 046200 01-14, 046200 01-14, 046210 01-04, 046210 01-04, 065494 05-03
HARRIS WC 075645 08-04
HARRISON-READ PE 067600 06-06
HARSH J 075196 08-04
HARSTON SJ 066713 05-03
HARTLEY LW 058942 02-03, 058942 02-03
HARTMANN A 072067 07-03
HASEGAWA K 055585 02-03, 055585 02-03, 114838 12-02, 129367 12-07
HASKOVEC L 064331 04-08
HATAGOSHI H 129273 12-08
HAUPTMAN B 068215 06-09
HAWARD LRC 070973 07-14
HAWKINS DR 065416 05-08
HAYASHIDA K 066510 05-03
HAYNES JR 069530 07-04
HEALY JM 071960 07-15
HEATON AM 070576 07-13
HEBERT A 062347 03-09
HECHT K 112003 12-04
HECKER SE 040572 01-03, 040572 01-03
HEERMANS HW 092209 11-01
HEGEDUS ZL 068975 06-13
HEIKEL TAJ 040125 01-05, 040125 01-05
HEILBRONN E 069515 06-13
HEIMANN H 079986 09-07
HEIN PL 068955 06-11
HEINDEL ND 062322 03-02
HEINE E 086958 10-11
HEINEMANN H 072067 07-03
HEINEMANN L 063597 04-08, 073710 08-13
HEINRICH K 085993 10-11, 100997 12-15
HEISE GA 062942 03-04, 064410 04-04, 088471 10-04
HEISTAD GT 075645 08-04
HEITZMAN M 063208 03-16
HEKIMIAN LJ 058374 02-07, 058374 02-07, 059040 03-07
HELD JM 075413 08-08
HELFER H 046400 01-03, 046400 01-03
HELLER B 064331 04-08
HELLMAN L 047954 01-09, 047954 01-09
HELMCHEN H 106772 12-13
HEMINGWAY P 072032 07-14
HENDERSON A 078378 09-03
HENDERSON JG 063874 04-13
HENINGER G 059020 03-11, 066747 05-13
HENNING M 055587 02-03, 055587 02-03, 063888 04-03
HENRIKSEN S 056934 02-04, 056934 02-04
HENRY P 079863 09-07
HENSCHLER D 051140 02-15, 051140 02-15
HERD JA 089999 11-04
HERKERT EE 121084 12-13
HERMAN ZS 062941 03-04, 090421 11-04
HERRMANN J 072145 07-08
HERSON RN 081082 09-15
HERTZMAN M 064236 04-15
HERZ A 074936 08-03, 089042 10-01
HERZBERG B 075470 08-13
HERZKA HS 071241 07-15
HES J 074566 08-15
HESBACHER P 063207 03-10, 065446 05-10, 065453 05-10, 066709 05-10, 066832 05-10
HESS EH 091173 11-04
HESS P 064146 04-03, 067324 06-03
HESS R 089042 10-01
HESSOV I 071971 07-15
HEUSGHEM C 089104 10-09
HEYKANTS JJP 072589 08-03, 079968 09-03
HIEBERT JM 091208 11-17
HIGGINS ES 088599 10-03
HILL GB 060659 03-08
HILLEL JM 089159 10-08
HILLYARD IW 064181 04-04
HIMWICH HE 051128 02-17, 051128 02-17, 064331 04-08, 080506 09-08
HINDLE W 067836 06-15
HINE CH 063927 04-13
HINES CW 066507 05-03
HINES G 075870 09-04
HINGTGEN JN 079998 09-04
HIPPIUS H 079950 09-15, 079969 09-07, 079996 09-15
HIRAI T 118585 12-09
HIROSE A 107190 12-03
HIROSE K 114836 12-02
HIROTA Y 088610 10-11
HIRTZEL MS 110906 12-04
HITZEMANN RJ 066413 05-03
HO AKS 066413 05-03, 088614 10-03
HO BT 038488 01-04, 038488 01-04, 041907 01-02, 041907 01-02, 046196 01-03, 046196 01-03, 046200 01-14, 046200 01-14, 065494 05-03, 067081 05-03, 089439 11-03, 090426 11-01
HO O 094164 11-05
HOATS DL 075206 08-04, 076131 09-04
HOCHMAN JS 071027 07-17
HOEBEL BG 058227 02-04, 058227 02-04
HOFER R 106774 12-09
HOFFER A 075909 09-15, 075944 09-08
HOFFER BJ 093132 11-03
HOFFMAN TW 094623 11-01
HOFFMANN I 079988 09-02
HOFLING CK 068964 06-10
HOFMANN G 089105 10-09, 106774 12-09
HOFMANN KW 055738 02-09, 055738 02-09
HOFMANN WW 071974 07-07
HOHNBAUM M 079967 09-10
HOKFELT B 081151 09-03
HOKFELT T 081151 09-03
HOLCENBERG JS 066329 05-15
HOLDEN JMC 067510 06-15, 074218 08-08, 120899 12-13
HOLDEN UP 074218 08-08
HOLLISTER LE 040128 01-14, 040128 01-14, 041559 01-13, 041559 01-13, 046202 01-13, 046202 01-13, 046558 01-16, 046558 01-16, 063147 03-11, 066231 05-14, 066232 05-14, 066399 05-13, 071998 07-14, 073886 08-14, 075841 08-12, 075872 09-08, 094978 11-11
HOLM E 079951 09-03
HOLMES D 064423 04-03, 085860 10-11
HOLMES MA 097582 11-01
HOLSCHER E 081135 09-15
HOLT NF 052483 02-09, 052483 02-09
HOLTERMANN W 055396 02-03, 055396 02-03
HONG SS 064180 04-03
HOPF A 073709 08-03
HOPF HC 051140 02-15, 051140 02-15
HORITA A 058879 02-03, 058879 02-03, 064277 04-05
HORLINGTON M 058349 02-04, 058349 02-04
HORN B 069309 06-02

HORN H 105733 12-11
HORNER B 063897 04-15
HORODESKY S 086445 10-15
HORODNICKI J 123373 12-08
HOROVITZ ZP 051123 02-17, 051123 02-17
HORT V 070933 07-14, 070934 07-14
HORVATH KB 055740 02-03, 055740 02-03
HORWITZ M 075430 08-09
HOSHI A 088612 10-03
HOSOYA E 066366 05-03
HOUCK JE 064312 04-10
HOUSER NW 051784 02-13, 051784 02-13
HOUSER VP 076132 09-03
HOWARD JC 059728 03-16
HOWARD K 075843 09-17, 076292 09-10
HOWES JF 058994 03-03, 069594 07-04
HOYLAND VJ 081264 09-04
HOZAKI H 129237 12-17
HRUBECKA J 070952 07-09
HSU B 080031 09-07
HSU SY 058571 02-03, 058571 02-03
HSU W 063597 04-08
HUANG CL 058571 02-03, 058571 02-03, 064094 04-03, 064261 04-03
HUBBARD B 069515 06-13
HUBER H 075375 08-04
HUBER WK 067719 06-08
HUCKER HB 051118 02-17, 051118 02-17
HUDAKOVA G 079139 09-13
HUDSON RD 076576 09-02, 079997 09-03
HUEBNER CF 058989 03-03
HUESSY HR 080095 09-14
HUFFER V 075968 09-13
HUFFINE J 080631 09-06
HUGHES RE 063061 03-03, 067716 06-04
HUGHES RN 076066 09-04
HUGHES SWM 066873 05-15
HUISMAN JW 066190 05-13
HUITRIC AC 062435 03-01
HUMBERTSON AO 068952 06-03
HUNDER KR 067657 06-15
HUNT E 092145 11-04
HUNTER KR 058240 02-11, 058240 02-11, 074874 08-08
HURST CM 069333 06-04
HURST PM 065127 05-14
HUSEMANN F 070778 07-14
HUSSAIN MZ 066907 05-14, 067022 05-10
HUSSAIN Z 067013 05-09
HUSTMYER FE 052455 02-11, 052455 02-11
HUTCHINS DA 067608 06-03
HUTCHISON J 062321 03-10, 065247 05-10, 065446 05-10

I

IANZITO BM 063277 03-15, 078933 09-14
IDANPAAN-HEIKKILA JE 045544 01-03, 045544 01-03, 046198 01-03, 046198 01-03, 046201 01-03, 046201 01-03, 067081 05-03
IDESTROM C 064389 04-14
IGIC R 040578 01-04, 040578 01-04
IIVANAINEN M 105732 12-14
IIZUKA R 129451 12-08
ILYIN EA 082954 10-14
ILYUTCHENOK RY 040579 01-03, 040579 01-03
IMAMURA H 131059 12-02
IMLAH NW 065474 05-07, 080007 09-17
IMPERATORE A 055394 02-03, 055394 02-03
INNISS CN 058527 02-15, 058527 02-15
INSUA A 058561 02-14, 058561 02-14
INUI M 105731 12-14
INVERNIZZI G 098002 11-08
IRESON JD 064290 04-03
IRWIN S 067342 06-15
ISAAC M 067607 06-03
ISAACSON EI 064258 04-01
ISAACSON RL 075197 08-04, 075280 08-04
ISBELL H 105266 12-17, 110225 12-17, 110226 12-17
ISGRIG FA 066831 05-04
ISHAM AC 082172 10-11
ISHAQ M 138526 12-10
ISHIHARA I 106270 12-03
ISMAIL AA 046136 01-17, 046136 01-17
ISRAEL L 087489 10-10
ITIL T 041568 01-09, 041568 01-09, 063597 04-08, 064431 04-08, 065476 05-08, 073710 08-13, 075313 08-08, 080031 09-07, 120899 12-13
ITO K 070334 07-03, 088611 10-13, 118583 12-08
IVERSEN LL 064002 04-06, 066501 05-03, 072120 07-03, 074053 08-04
IVERSEN SD 074053 08-04
IVRIANI I 064101 04-03
IWAHARA S 070083 07-04, 092692 11-04
IWATA H 067243 06-03
IZAKSON K 109788 12-08
IZQUIERDO I 046142 01-04, 046142 01-04, 046186 01-04, 046186 01-04

J

JABBUR SJ 081063 09-03
JACKSON DE 075314 08-04
JACOBSON AE 038489 01-01, 038489 01-01
JACQUEMIN C 091503 11-11
JAFFEE JH 046113 01-13, 046113 01-13
JAHNCHEN E 089043 10-03
JAJU BP 064413 04-03
JAKOUBEK B 065434 05-03
JANATKA J 070954 07-12
JANOWSKY DS 047913 01-13, 047913 01-13, 047951 01-09, 047951 01-09, 071972 07-13
JANSSEN PAJ 064476 04-04, 069076 06-04, 072589 08-03, 079968 09-03, 095507 11-06
JANZ D 093919 11-11
JAQUES R 046400 01-03, 046400 01-03
JARMUZEK Z 085106 10-15
JARNIOU AP 086236 10-07
JARROLD L 058968 03-08, 072140 07-10, 072146 07-11
JARROTT B 064002 04-06
JARVIK LF 064315 04-05
JARVIK M 065420 05-04, 065747 05-04, 066277 05-13, 066830 05-04, 075917 09-04, 095351 11-03, 097953 11-04, 121085 12-12
JAVOY F 120465 12-03
JELIC V 074575 08-15
JENKINS BW 075415 08-10
JENKINS RB 066490 05-15, 091919 11-11
JENNER FA 086453 10-17
JENSEN ON 042700 01-11, 042700 01-11
JENSEN P 100019 11-09
JERI FR 093524 11-08
JETER RD 069333 06-04
JHAMANDAS K 090139 11-03, 090189 11-03
JIN SK 138967 12-08
JOFFE MH 046199 01-14, 046199 01-14
JOHANSON T 099957 11-11
JOHANSSON B 066506 05-03
JOHNSON AW 057483 02-07, 057483 02-07
JOHNSON DN 082051 10-03
JOHNSON FG 062934 03-11
JOHNSON FN 064407 04-04, 097959 11-04
JOHNSON G 060859 03-09, 064386 04-14, 106769 12-15
JOHNSON MH 070982 07-17
JOHNSTON GS 063208 03-16
JOHNSTON VS 121087 12-14
JOLI I 106774 12-09
JONASON KR 065419 05-04
JONES BJ 069077 06-04
JONES H 065235 05-10
JONES PR 063061 03-03
JONES RT 064416 04-12
JONSSON J 081065 09-03
JORDAN A 058561 02-14, 058561 02-14
JORI A 068600 06-03
JOSEPH H 070021 07-13
JOVANOVIC UJ 072585 08-14, 089040 10-17
JOYCE CRB 068005 06-14, 087863 10-06, 087866 10-11
JOYCE D 067599 06-06, 067606 06-04, 091997 11-04, 129564 12-17
JUDGE F 075288 08-04
JULOU L 074685 08-02
JUNKER E 058235 02-11, 058235 02-11
JURUPE H 067461 06-03

K

KAESER HE 073900 08-15
KAGAN I 111032 12-08
KAHN RJ 047836 01-10, 047836 01-10, 075873 09-14
KAIM SC 078429 09-17, 094978 11-11
KALANT H 064052 04-03
KALBUT M 090135 11-04
KALENSKY J 071241 07-15
KALES A 066233 05-14, 066234 05-14, 066235 05-14, 092974 11-11
KALES JD 066234 05-14, 066235 05-14
KALOUSEK M 074575 08-15
KALTENBACK E 101020 12-15
KAMBAROVA DK 073770 08-13
KAMIOKA T 114769 12-02, 114835 12-07
KANE FJ 065118 05-13, 065691 05-09, 075471 08-13
KANEKO J 129082 12-08
KANEKO Z 105731 12-14
KANG S 067199 06-06
KANIG K 094962 11-13
KANNAS S 079859 09-11
KANOWSKI S 106772 12-13
KANTER S 041559 01-13, 041559 01-13, 066399 05-13, 075841 08-12
KANTOR HI 078223 09-14
KANZLER AW 103350 12-04
KAPADIA AJ 090425 11-06
KAPLITZ SE 059359 03-10
KAPP BS 064412 04-04
KAPPELER T 058454 02-12, 058454 02-12, 064323 04-12
KARIYA T 129452 12-09
KARJALAINEN K 040756 01-03, 040756 01-03
KARKALAS Y 064429 04-10
KARLER R 116471 12-03
KARNICK CR 046185 01-17, 046185 01-17
KARP SA 052455 02-11, 052455 02-11
KASE Y 055586 02-03, 055586 02-03
KASPER-PANDI P 067884 06-04, 075288 08-04
KASSIR S 090419 11-03
KASTL L 094553 11-03
KASTRITSIS CD 060637 03-03
KATO I 118583 12-08
KATO R 063982 04-03, 066366 05-03
KATO T 064315 04-05
KATO Y 131057 12-02, 131059 12-02
KATSCHNIG H 089105 10-09, 106774 12-09
KATZ DM 067599 06-06
KATZ J 058371 02-14, 058371 02-14
KATZ MH 046143 01-04, 046143 01-04
KATZ MM 047832 01-12, 047832 01-12
KATZ RI 072031 07-03
KAUL PN 080631 09-06
KAWAI N 064369 04-03
KAY DWK 097562 11-09
KEIM KL 097962 11-03
KEIPER RR 063634 04-03
KELLEHER RT 040758 01-04, 040758 01-04, 089999 11-04
KELLER C 062942 03-04
KELLETT G 071984 07-07
KELLNER R 058364 02-16, 058364 02-16, 064285 04-10, 075942 09-11
KELLY D 063934 04-10
KEMALI D 114880 12-09
KENNY FM 066838 05-14
KERKUT GA 084758 10-04
KERN R 128389 12-15
KERPEL-FRONIUS S 040756 01-03, 040756 01-03
KERR MM 071123 07-11
KERRY RJ 047953 01-09, 047953 01-09
KERTAI P 065441 05-04
KESKINER A 063597 04-08, 064431 04-08, 065476 05-08, 080031 09-07
KESSELL A 052483 02-09, 052483 02-09
KESSLER JT 067666 06-07
KESSLER WV 058572 02-05, 058572 02-05
KETCHAM RG 105332 12-01
KEUP W 115027 12-01, 121084 12-13
KEY BJ 064367 04-04
KEYL AC 066497 05-03
KHALSA JH 060857 03-03
KHAN I 041540 01-03, 041540 01-03
KHANNA JM 064052 04-03
KHANNA KL 069804 07-01
KHAUNINA R 098064 11-03, 105620 12-03
KHAZAN N 067919 06-04, 069069 06-04
KHRISTOLYUBOVA N 101006 12-03
KHRULEVA LN 067299 06-04
KIBRICK E 093085 11-17
KIER LB 090068 11-13
KIKUCHI K 055586 02-03, 055586 02-03

KIM CH 069822 07-08
KIM SS 058374 02-07, 058374 02-07
KIM Y 066510 05-03
KIMURA K 114837 12-05
KING LJ 072119 07-03
KING MB 058227 02-04, 058227 02-04
KING S 063880 04-15
KING WT 060857 03-03
KINGSTONE E 072143 07-10, 098048 11-08
KIPLINGER GF 069579 07-14
KIRCHER KA 076316 09-04
KIRK L 100016 11-15, 100019 11-09
KIRPEKAR SM 040244 01-03, 040244 01-03
KISELEVA IP 097989 11-04
KISHORE B 134906 12-08
KISSEN B 065188 05-13
KISSIN B 052455 02-11, 052455 02-11, 075891 09-04
KITO G 055586 02-03, 055586 02-03
KITS TP 078212 09-10
KLAVIS G 056060 02-15, 056060 02-15
KLEIN DF 068215 06-09, 075227 08-08, 087632 10-09
KLEIN DR 070970 07-17
KLEINROK Z 062937 03-04
KLEMM LH 066815 05-01, 074844 08-01
KLERMAN G 052456 02-10, 052456 02-10, 074926 08-09, 085237 10-08, 106765 12-09
KLETT CJ 094978 11-11
KLINE ES 088599 10-03
KLINE N 063139 03-09, 065458 05-07, 106783 12-03
KLING JW 064842 05-02
KLINGER W 058987 03-05
KLOSINSKA B 072893 08-15
KLOTI R 128389 12-15
KLYGUL' TA 058604 02-03, 058604 02-03
KNAAPE HH 080563 09-11
KNIGHT AH 058333 02-15, 058333 02-15
KNILL-JONES RP 043697 01-11, 043697 01-11, 058241 02-11, 058241 02-11
KNOBEL M 080096 09-17
KNOPP W 058966 03-11, 092917 11-10, 119884 12-17
KNOTT DH 065193 05-13
KNOWLES M 067288 06-15
KNOX A 063595 04-10, 075871 09-10
KNOX C 059567 03-04
KOBAYASHI K 060865 03-03
KOBAYASHI S 055585 02-03, 055585 02-03, 114769 12-02, 114835 12-07, 114838 12-02
KOBAYASHI T 129452 12-09
KOCHMAN J 082706 10-06
KOCHSIEK K 071258 07-15
KOEPKE HH 058969 03-10
KOFOD B 100026 11-13
KOGAN S 110105 12-17
KOHL M 058403 02-15, 058403 02-15, 059057 03-15, 067073 05-15, 081090 09-15
KOHLER W 059001 03-11
KOHNO T 088358 10-01
KOIKE H 114838 12-02
KOJIMA M 066415 05-06
KOLIVAKIS T 072143 07-10, 098048 11-08
KOLUCH J 070939 07-09
KOMATSU K 129273 12-08
KOMISSAROV IV 073715 08-03
KOMOVA Y 111028 12-11
KONDAKIS X 060208 03-08
KONIG JW 079951 09-03
KONIG-BERSIN P 064408 04-03
KOONCE JM 095188 11-04
KOPELL BS 062510 03-13, 075274 08-13
KOPIN IJ 040126 01-03, 040126 01-03, 040309 01-03, 040309 01-03, 064170 04-03, 068290 06-03, 072031 07-03, 080337 09-01, 088356 10-09, 092383 11-03, 092889 11-13
KOPPANYI T 058985 03-04
KOREIN J 060859 03-09
KORF J 070857 07-09, 097963 11-13
KORN M 105551 12-11
KORNETSKY C 058531 02-04, 058531 02-04, 064474 04-13
KOROLKOVAS A 115114 12-17
KORTE F 064417 04-04
KORTY PR 069344 06-03
KOSE W 058966 03-11
KOSEK JC 045543 01-05, 045543 01-05
KOSSATZ I 072143 07-10, 098048 11-08
KOSTERLITZ HW 041974 01-03, 041974 01-03
KOTOKU S 131625 12-06
KOVACH AGB 055740 02-03, 055740 02-03
KOVACS J 063841 04-04
KOVALCIK V 070948 07-04
KOZAK I 089036 10-03
KOZUKA H 051207 02-01, 051207 02-01
KOZYREV V 111031 12-08
KOZYREVA S 111031 12-08
KRAKOV L 063774 04-14, 063776 04-08
KRALIK PM 065494 05-03, 090426 11-01
KRALL AR 065118 05-13
KRAMER M 069034 06-08
KRAUS M 065434 05-03
KRAUSS KR 040309 01-03, 040309 01-03
KREAM J 047954 01-09, 047954 01-09
KREMSER M 089105 10-09, 106774 12-09
KRIEGLSTEIN J 089043 10-03
KRIPPNER S 067340 06-12
KRISTT DA 059616 03-04
KRIVANEK JA 069066 06-04
KROP S 046143 01-04, 046143 01-04
KRSIAK M 090423 11-06
KRULIK R 081111 09-03, 089787 11-09
KRUMHOLZ WV 066852 05-08, 067570 06-15
KRYLOV SS 073717 08-03
KSENOFONTOVA TA 072580 08-03
KUBENA RK 064424 04-04
KUCH H 079988 09-02
KUCHARSKI JM 058382 02-04, 058382 02-04
KUEHN A 063841 04-04
KUGLER J 070778 07-14
KUHN P 089046 10-03
KULKARNI AS 058430 02-04, 058430 02-04
KUMAGAI H 051112 01-17, 051112 01-17
KUMAKURA S 114835 12-07
KUMANO A 126778 12-17
KUMAR R 059072 03-17, 064475 04-04
KUMAR S 134902 12-09
KUNTZMAN R 074866 08-03
KUNUGI H 139090 12-08
KURIYAMA K 058192 02-03, 058192 02-03, 070521 07-01
KURLAND AA 058365 02-15, 058365 02-15, 058448 02-12, 058448 02-12, 058451 02-15, 058451 02-15, 062175 03-14, 064286 04-08, 064356 04-09, 064639 05-07, 065473 05-07, 069071 06-11, 072147 07-14, 073852 08-12, 089099 10-08, 097286 11-12
KURTI M 069074 06-04
KURTI V 055398 02-05, 055398 02-05
KURUMA I 042726 01-03, 042726 01-03
KUTTER E 089042 10-01
KUZNIECKI N 064415 04-04
KVETNANSKY R 092383 11-03
KVITKO IY 072580 08-03
KWIEK J 067384 06-03
KYRIAKOPOULOS A 088221 10-13

L

LA BARRE J 089242 10-17
LADER MH 064406 04-07, 074135 08-14
LADISICH W 064364 04-03, 070951 07-03
LAFONT H 058312 02-11, 058312 02-11
LAL H 064429 04-10, 068978 06-03, 069052 06-03, 076186 09-03
LAMBERT GA 047323 01-04, 047323 01-04
LAMBERT PA 065480 05-09, 089000 10-17
LAMPE WT 067174 06-15
LANDON M 065433 05-12
LANDSBERG L 058213 02-15, 058213 02-15
LANG WJ 041569 01-03, 041569 01-03, 047323 01-04, 047323 01-04, 066386 05-03
LANG WR 069072 06-07
LANGE E 059015 03-09
LANGE J 079996 09-15
LANGEMANN H 064408 04-03
LANGNER E 089100 10-09
LANGSLET A 072525 08-03
LANGWINSKI R 074086 08-04
LAPIN I 072580 08-03, 098003 11-03, 098055 11-03, 105621 12-04, 118730 12-09, 122378 12-17
LAPOLLA A 065235 05-10
LARBIG D 071258 07-15
LARGE WA 041913 01-03, 041913 01-03
LAROCHELLE L 040124 01-05, 040124 01-05, 086349 10-03
LARRIEU A 072156 07-15
LARSON MD 064621 04-03
LASAGNA L 051133 02-17, 051133 02-17, 088615 10-05
LASHINKER N 111028 12-11
LATHE GH 040125 01-05, 040125 01-05
LAUBER SM 065419 05-04
LAUGHLIN N 062942 03-04
LAURELL B 065850 05-11, 065851 05-09, 065852 05-14, 065853 05-14, 065854 05-15, 065855 05-11, 065856 05-11
LAURENCE DR 058240 02-11, 058240 02-11, 067657 06-15
LAUTER H 090358 11-16
LAVELLE G 088615 10-05
LAWLER HC 069312 06-05
LAWLOR RB 058996 03-05
LAWRENCE CW 069530 07-04
LAWTHER PJ 070303 07-14
LAYDEN TA 064481 04-04
LEAF RC 070979 07-04
LEATON RN 067882 06-04
LEBEDEVA MN 073681 08-03
LECHAT P 089003 10-05
LEDER A 067739 06-14
LEE AE 075870 09-04
LEE JE 042521 01-15, 042521 01-15, 067666 06-07
LEE N 064180 04-03, 067130 06-11
LEE WC 040242 01-03, 040242 01-03
LEGER J 088438 10-14
LEHMAN HE 072146 07-11
LEHMANN HE 056500 02-08, 056500 02-08, 058968 03-08, 062643 03-08, 065459 05-17, 068450 06-08, 069060 06-11, 069580 07-15, 070412 07-15, 072140 07-10, 072142 07-08, 075422 08-08, 075423 08-08, 081043 09-14, 082055 10-04, 085289 10-11, 086444 10-15, 086445 10-15, 097985 11-11, 097997 11-07, 126180 12-14
LEHRNBECHER W 058908 02-15, 058908 02-15
LEIBOWITZ SF 092166 11-03
LEIGHTON WP 064144 04-03
LEIST N 063515 03-13
LEITZ FH 064427 04-03
LEMBERGER L 064170 04-03, 069051 06-13, 074866 08-03
LEMPERIERE T 091500 11-07
LENKE D 055397 02-03, 055397 02-03
LENNARD HL 070897 07-17
LEON M 069063 06-04
LEONARD BE 065436 05-12, 074149 08-04
LEREBOULLET J 089161 10-11
LESENEY JL 089440 11-04
LESSER LI 080097 09-17
LETOURNEAU J 083317 10-14
LEUNG ASH 064088 04-11
LEVANN LJ 097655 11-14
LEVENSTEIN S 075227 08-08
LEVI G 072586 08-03
LEVI L 093689 11-11, 097974 11-11
LEVIN B 065420 05-04, 075917 09-04
LEVIN L 075968 09-13
LEVINE J 060861 03-15, 060862 03-16, 089433 10-08
LEVINE RJ 075276 08-03
LEVINE S 062853 03-03, 063015 03-03
LEVINTHAL CF 071792 07-04
LEVITAN SJ 075426 08-10
LEVITT LP 046189 01-03, 046189 01-03
LEVITT RA 076081 09-04
LEVY BS 047828 01-09, 047828 01-09
LEVY L 072159 07-07
LEWI PJ 072589 08-03, 079968 09-03, 095507 11-06
LEWIS D 061654 03-13
LEWIS EG 056925 02-14, 056925 02-14
LEWIS SA 063978 04-14, 067924 06-14
LEWIS WC 054890 02-11, 054890 02-11
LEWIS WH 070287 07-09
LEY KF 060756 03-04
LI K 090426 11-01
LICHTENSTEIGER W 064408 04-03
LIDDLE GW 051122 02-17, 051122 02-17
LIEBALDT GP 072585 08-14, 079992 09-15
LIEBERMAN AN 081298 09-11
LIENERT GA 079956 09-12
LIESIENE VA 095655 11-14
LILIE NL 064410 04-04

LILJEBERG JA 058995 03-03
LIM R 083170 10-03
LINDEMANN M 071703 07-03
LINGJAERDE O 071791 07-03
LIPKIN KM 047919 01-09, 047919 01-09
LIPMAN RS 065488 05-10, 066741 05-16, 076292 09-10, 087386 10-10
LIPPMANN W 058878 02-02, 058878 02-02, 090136 11-03
LIPTON MA 042654 01-09, 042654 01-09, 061682 03-09, 063595 04-10, 065118 05-13, 075471 08-13, 075871 09-10
LISONKOVA D 070946 07-10
LISTER RE 041537 01-06, 041537 01-06
LITINSCHI G 078730 09-14
LIU CY 108212 12-17
LIU J 069312 06-05
LLOYD D 054715 02-12, 054715 02-12
LOBB H 075315 08-14
LOCHAYA E 081694 10-17
LOCHNER W 055396 02-03, 055396 02-03
LOEB M 043270 01-17, 043270 01-17
LOEV B 080032 09-02
LOEW DM 089045 10-12
LOGEMANN G 079950 09-15
LOH HH 066413 05-03, 069595 07-03
LOMAX P 067522 06-04, 071027 07-17
LOMOURI ID 087303 10-01
LON J 100959 12-07, 105486 12-07
LONG CJ 058357 02-06, 058357 02-06
LONGO N 075375 08-04
LONGO VG 085337 10-03
LOO H 085129 10-15
LOPEZ IBOR ALINO JJ 106770 12-17
LOPEZ IBOR ALINO JM 106770 12-17
LOPEZ-GOMEZ MR 085456 10-14
LORENZ AA 064074 04-14
LORENZ D 079961 09-03
LOTT D 064479 04-04
LOTT IT 070024 07-14
LOTTI VJ 040750 01-03, 040750 01-03
LOURIE CH 063515 03-13
LOVE KE 082039 10-15
LOVELL RA 083168 10-03, 097965 11-04
LOVETT D 061572 03-03
LOWENSTEIN LM 092004 11-11
LOWINGER P 076254 09-12
LU L 067513 06-11
LUBIN M 069063 06-04
LUBRAN M 070821 07-05
LUCAS GJ 058908 02-15, 058908 02-15
LUCAS SB 063800 04-13
LUKE D 064479 04-04
LUKESH R 067900 06-15
LUNDE D 062510 03-13, 075274 08-13
LUPARELLO TJ 063515 03-13
LUTHE R 105733 12-11
LUTHER IG 060274 03-04
LUTTGE WG 067696 06-04, 076086 09-04
LUTZENKIRCHEN H 079962 09-17, 079963 09-11
LYDON RJ 041974 01-03, 041974 01-03
LYNCH WJ 135186 12-14
LYNN F 062108 03-08
LYTLE LD 063688 04-04

M

MACCARIO M 060859 03-09
MACEDO C 070856 07-09
MACGREGOR JM 068007 06-15
MACHADO R 064639 05-07
MACIAS G 085454 10-14
MACKAY DN 079215 09-11
MACKENZIE DH 078932 09-08
MACKO E 080032 09-02
MACLEAN JR 071987 07-13
MACPHERSON CFC 072516 08-04
MADALENA JC 094453 11-09
MADAN B 114978 12-03
MADAN V 114978 12-03
MAEDA T 129879 12-07
MAGISTRETTI MJ 055519 02-03, 055519 02-03
MAGOS L 070823 07-03
MAHENDRU RK 134937 12-11
MAHER JF 064168 04-15, 064623 04-15
MAI FMM 085327 10-09
MAICKEL RP 040241 01-03, 040241 01-03, 074937 08-04
MAILLET-JURQUET A 089157 10-09
MAISONDIEU J 062347 03-09
MAITRE L 074861 08-03
MAJ J 067384 06-03
MAJOR MA 064621 04-03
MAKAR H 074874 08-08
MALACARNE P 068181 06-15
MALAGUTI P 072003 07-07
MALICK JB 058993 03-04, 088617 10-04
MALING HM 058985 03-04, 066937 05-03
MALM U 058372 02-08, 058372 02-08, 100020 11-11
MALMFORS T 066278 05-03
MALPAS A 068005 06-14
MALPICA JF 067461 06-03
MALY J 042693 01-11, 042693 01-11
MANACH J 055738 02-09, 055738 02-09
MANASER J 062108 03-08
MANDEL HG 064045 04-03, 064046 04-03
MANDELL S 071985 07-07
MANDREKAR SS 075845 09-03
MANEZ J 055580 02-03, 055580 02-03
MANIAN AA 088358 10-01, 094623 11-01
MANN DE 089436 11-03
MANNIRONI G 092077 11-09
MANNO JE 069579 07-14
MANSEL-JONES D 057608 02-07, 057608 02-07
MANTEL K 082202 10-15
MANZ F 067743 06-15
MARCHAND C 046191 01-03, 046191 01-03
MARCHITELLO J 064386 04-14
MARCJAN K 072896 08-08
MARCOTTE DB 075471 08-13
MARCOU G 065480 05-09, 089000 10-17
MARCUCCI F 064000 04-03, 081106 09-03, 090134 11-03
MARCUS R 066186 05-03
MARECEK P 070954 07-12
MAREN TH 040755 01-03, 040755 01-03
MARESCA A 080098 09-07
MARGOLINA E 109723 12-09
MARGOLIS RU 063526 03-01
MARGULES DL 060801 03-04
MARIN A 086237 10-07
MARIN C 098172 11-07
MARISHCHUK VL 086039 10-14
MARKHAM CH 092974 11-11
MARKLEY H 075859 09-12
MARKOVIC V 069082 06-13
MARKS N 073327 08-03
MARLEY E 068166 06-03, 072030 07-03
MARMO E 055394 02-03, 055394 02-03
MARR MJ 075906 09-04
MARRAZZI AS 121080 12-17
MARSDEN P 058241 02-11, 058241 02-11
MARSHALL HL 047913 01-13, 047913 01-13
MARSHALL I 067599 06-06
MARSHALL JHL 047951 01-09, 047951 01-09
MARSHALL MH 058431 02-09, 058431 02-09, 063601 04-09
MARSHMAN JA 057866 02-01, 057866 02-01
MARTIN A 072154 07-16, 090425 11-06
MARTIN J 072421 08-07, 087530 10-12
MARTIN NH 092888 11-01
MARTIN WE 066940 05-14, 081039 09-11, 091715 11-07
MARTIN WR 056113 02-13, 056113 02-13, 069053 06-13, 090422 11-03, 093000 11-13
MARTY J 085043 10-15
MASCARENHAS M 086977 10-07
MASCIOCCHI A 063200 03-13
MASE G 063200 03-13
MASELLA C 091139 11-09
MASHETER HC 078932 09-08
MASHKOVSKYY MD 073787 08-17
MASSARANI E 055519 02-03, 055519 02-03
MASSENGILL R 090170 11-15
MASSON JM 072154 07-16
MASUDA H 114837 12-05
MASUR J 069069 06-04, 072531 08-04
MATHEWS AM 074135 08-14
MATIN SB 137993 12-01
MATLINA ES 090355 11-03
MATSUHIRO B 063606 04-05, 094553 11-03
MATSUI E 131059 12-02
MATSUMIYA Y 064842 05-02
MATSUNUMA H 114837 12-05
MATTHYSSE S 063825 04-03
MATTKE D 063776 04-08
MATUSSEK N 064364 04-03, 066322 05-09, 070951 07-03, 079964 09-14, 079965 09-13
MATVEYEV YK 073770 08-13
MATVEYEVA Y 111034 12-08
MAULDING HV 046137 01-03, 046137 01-03
MAUREL H 084978 10-08
MAURER M 126055 12-04
MAURUSCHAT W 097999 11-15
MAWDSLEY C 042483 01-07, 042483 01-07
MAWER GE 063800 04-13
MAWSON AB 067074 05-16, 067673 06-11
MAWSON C 067603 06-03
MAXWELL DR 040581 01-04, 040581 01-04
MAXWELL S 090170 11-15
MAY DG 040754 01-03, 040754 01-03
MAY JS 103152 12-14
MAY P 115463 12-17
MAY PRA 071322 07-08, 134057 12-17
MAYER SR 040639 01-03, 040639 01-03
MAYET J 072156 07-15
MAYNARD RC 051373 02-15, 051373 02-15
MAYO J 106762 12-14, 106773 12-09
MAZURKIEWICZ-KWILECKI IM 055579 02-03, 055579 02-03
MCBRIDE A 067604 06-03
MCCABE MS 062350 03-09
MCCARTHY M 138597 12-08
MCCARTHY ME 085893 10-12
MCCLAE TK 063595 04-10
MCCLANE TK 042654 01-09, 042654 01-09, 075871 09-10
MCCLEARN GE 075957 09-02
MCCLELLAN TA 076351 09-17
MCCLELLAND HA 066496 05-10, 067288 06-15
MCCULLOCH MW 064254 04-03
MCDONALD C 082732 10-11
MCDOWELL F 042521 01-15, 042521 01-15, 067666 06-07, 122098 12-17
MCEWEN BS 090135 11-04
MCFARLAND H 040105 01-13, 040105 01-13
MCGAUGH JL 069066 06-04, 097952 11-04
MCGLOTHLIN MS 067343 06-12
MCGLOTHLIN W 067343 06-12, 071027 07-17
MCGRATH WR 064481 04-04
MCISAAC WM 038488 01-04, 038488 01-04, 041907 01-02, 041907 01-02, 045544 01-03, 045544 01-03, 046194 01-17, 046194 01-17, 046196 01-03, 046196 01-03, 046197 01-03, 046197 01-03, 046198 01-03, 046198 01-03, 046200 01-14, 046200 01-14, 065494 05-03, 067081 05-03, 089439 11-03, 090426 11-01
MCKEARNEY JW 064749 05-04
MCKEGNEY FP 058951 02-15, 058951 02-15
MCKIM WA 063587 03-04
MCKNELLY WV 067138 06-15
MCLAUGHLIN JL 070751 07-01
MCLEAN AEM 046187 01-13, 046187 01-13
MCLEOD MJ 071987 07-13
MCLEOD WR 066826 05-07, 067012 05-14
MCLONE DG 072471 08-03
MCMILLAN DE 042719 01-04, 042719 01-04, 061597 03-04, 069593 07-04
MCNAIR DM 047836 01-10, 047836 01-10, 075873 09-14
MCNAMARA DG 082039 10-15
MCNEELY BU 042655 01-15, 042655 01-15
MEADOW SR 071949 07-15
MEAGHER RB 075559 08-04
MECKELNBURG R 065453 05-10
MEDOFF J 063022 03-07
MEEK J 058799 02-03, 058799 02-03
MEGRABYAN AA 090264 11-08
MEIER MJ 066940 05-14, 081039 09-11
MEIER-RUGE W 085338 10-15
MEIERS RL 067364 06-08
MEIKLE S 075779 08-13
MELDRUM BS 068163 06-03, 090157 11-04
MELGES FT 066232 05-14, 071998 07-14, 073886 08-14
MELIA PI 060263 03-09, 081152 09-09
MELIK-PASHAYAN MA 090264 11-08
MELLERIO F 075112 08-13
MELLERUP E 066822 05-03, 106780 12-03
MELO RG 085453 10-14
MELON J 069070 06-07
MENDEZ H 046143 01-04, 046143 01-04, 086793 10-09
MENNEAR JH 058984 03-05

MERCIER J 055580 02-03, 055580 02-03, 072158 07-11
MERLINO N 058840 02-04, 058840 02-04
MERLIS S 058373 02-07, 058373 02-07, 064638 05-08, 065314 05-10, 067570 06-15, 075332 08-11, 075429 08-08, 089444 11-10, 115037 12-08
MERLO AB 064415 04-04
MERTENS HG 079962 09-17, 079963 09-11
MESLEY RJ 058877 02-01, 058877 02-01
MESSELOFF C 058403 02-15, 058403 02-15, 059057 03-15
METYS J 070926 07-02, 074936 08-03
METYSOVA J 070926 07-02
MEYER DR 065419 05-04, 076316 09-04
MEYER GG 047919 01-09, 047919 01-09
MEYER PM 065419 05-04, 076316 09-04
MEYER RE 052502 02-14, 052502 02-14
MEYERHOFF JL 075869 09-04
MEYERS F 064287 04-15
MICHAEL CM 078223 09-14
MICHAEL RP 075829 08-04, 076554 09-03
MICHALAKEAS A 060208 03-08
MICHEL D 087489 10-10
MIEDZYRZECKI J 067375 06-07
MIHOVILOVIC M 106775 12-09
MIKHALENKO I 109724 12-14
MIKUS P 072588 08-14
MILBERG J 040582 01-03, 040582 01-03
MILES BE 064422 04-05
MILES JM 089440 11-04
MILLAN S 086793 10-09
MILLER AA 067601 06-04
MILLER EK 074422 08-04
MILLER ER 082173 10-14
MILLER FP 040241 01-03, 040241 01-03, 074937 08-04
MILLER KW 066955 05-03
MILLER NE 069637 07-04
MILLER RC 074422 08-04
MILLER RR 090365 11-17
MILLER WT 075870 09-04
MILTON AS 041913 01-03, 041913 01-03
MIN KS 064180 04-03
MINDE KK 072825 08-14
MINDER R 067260 06-03
MIR GM 064261 04-03
MIRKIN BL 051125 02-17, 051125 02-17
MISSALA K 086350 10-13
MISUREC J 070935 07-08, 070940 07-09
MITCHELL G 056934 02-04, 056934 02-04
MITCHELL-HEGGS N 063934 04-10
MITOMA C 058990 03-03, 071783 07-03
MITSUNOBU K 100852 12-03
MITSUYAMA Y 129753 12-15
MITTELSTAEDT A 089785 11-15
MIYA TS 040584 01-03, 040584 01-03, 058984 03-05, 066369 05-03
MIYAGISHI T 070334 07-03
MIZUNO S 139090 12-08
MOCK JE 087386 10-10
MODESTIN J 079987 09-17
MOFFATT WR 079215 09-11
MOHLER G 082054 10-08
MOKOTOFF M 038489 01-01, 038489 01-01
MOLCAN J 073707 08-10
MOLDENHAUER B 080040 09-16
MOLINA GB 064637 05-09
MOLINENGO L 068291 06-04, 071787 07-04
MOLINOFF PB 088376 10-03
MOLTZ H 069063 06-04
MOMIC-MUIC Z 074575 08-15
MONEY J 080178 09-14
MONRO P 090366 11-15
MONSEU G 088618 10-15
MONTGOMERY RB 058961 03-04
MOON HM 078378 09-03
MOORE F 075841 08-12
MOORE GE 040751 01-03, 040751 01-03
MOORE JW 065451 05-04, 075235 08-04
MOORE KE 058986 03-03, 064590 04-04
MOORE MT 062737 03-15
MOORHEAD DT 058840 02-04, 058840 02-04
MORALISHVILI E 064315 04-05
MORAN G 075559 08-04
MORANDINI F 064159 04-01
MORAVEC DF 064335 04-17
MOREAU S 067375 06-07
MORGAN H 087863 10-06
MORGAN LL 075236 08-04
MORGANDO E 093091 11-10
MORI M 055585 02-03, 055585 02-03, 088358 10-01
MORIC-PETROVIC S 069082 06-13
MORK DPS 058572 02-05, 058572 02-05
MORMONT C 069070 06-07
MOROSAWA S 094623 11-01
MORPURGO C 082409 10-03
MORRIS PA 078932 09-08
MORRIS RW 090427 11-13
MORRISON CF 051651 02-06, 051651 02-06, 065440 05-04
MORSE DL 075851 09-03, 076133 09-04
MORSE WH 089999 11-04
MORSELLI PL 042756 01-13, 042756 01-13
MOSKOWITZ M 089444 11-10
MOSLER A 079994 09-11
MOTAWI MM 046136 01-17, 046136 01-17
MOTYLOVA A 073707 08-10
MOUREN P 072156 07-15
MOWBRAY R 058404 02-10, 058404 02-10, 059053 03-09, 066826 05-07, 075472 08-15, 082732 10-11
MRNA B 070939 07-09
MUCHA H 059015 03-09
MUELLER FO 070823 07-03
MUELLER RA 075714 08-03, 075715 08-03, 080352 09-03, 088374 10-03
MULAS A 067605 06-04
MULDER D 070779 07-01
MULE SJ 046401 01-03, 046401 01-03
MULINOS MM 070784 07-13
MULLAN S 074084 08-03
MULLER PJ 040028 01-05, 040028 01-05
MUNCNEROVA L 079139 09-13
MURATA T 129097 12-10
MURATORIO A 087658 10-14
MURPHY DL 047828 01-09, 047828 01-09, 062366 03-13, 066493 05-13, 067585 06-09, 067591 06-09, 078542 09-09, 081038 09-09, 092688 11-09, 092975 11-09
MURRAY MR 066380 05-03
MURRI L 087658 10-14
MURTY BSR 064262 04-06, 064264 04-01
MUSKO Z 065441 05-04
MUSSINI E 064000 04-03, 064255 04-03, 081106 09-03, 090134 11-03
MUTSUDA K 089789 11-02

N

NADLER RD 058358 02-06, 058358 02-06
NADORFI MI 095443 11-15
NAGAI H 088611 10-13
NAGANO M 129097 12-10
NAGASAWA HT 088600 10-03
NAHUM JP 100531 12-15
NAHUNEK K 070927 07-09, 070931 07-08, 070935 07-08, 070936 07-08, 070938 07-08, 070940 07-09, 070941 07-09, 070942 07-09, 070943 07-09, 070950 07-08, 070956 07-09, 086205 10-15, 106777 12-09
NAIMZADA MK 088392 10-03
NAIR KCR 082056 10-07
NAIR V 067962 06-03
NAKAMURA RK 066277 05-13, 095351 11-03
NAKANISHI M 131057 12-02, 131058 12-02
NAKATANI S 068457 06-04
NAKAYAMA K 114835 12-07, 114838 12-02
NAKAZATO Y 074854 08-03
NAKAZAWA Y 129447 12-13
NANCE DM 075234 08-04
NANIKAWA R 131625 12-06
NAQUET R 068163 06-03, 090157 11-04
NARANG RL 134903 12-09
NARASIMHACHARI N 064331 04-08
NARDI D 055519 02-03, 055519 02-03
NARDINI M 112131 12-09
NAROTZKY R 072471 08-03
NARUMI S 131623 12-03
NASHOLD B 090170 11-15
NATHAN P 056779 02-11, 056779 02-11, 092004 11-11
NATIN J 087498 10-11
NAUTA WT 070779 07-01
NAVARRO J 055581 02-03, 055581 02-03
NAVRATIL K 086209 10-17
NAYAK U 075105 08-01
NEAL CD 065474 05-07
NEAL JM 070751 07-01
NEARY ER 067569 06-11
NEDUVA S 126632 12-09
NEFEDYEVA MI 096512 11-09
NEGRIN P 093443 11-09
NEHUNEK K 070928 07-09
NESTARCOVA K 069795 07-08
NESTLINGEROVA E 069795 07-08
NEU RL 063880 04-15
NEUBAUER H 066713 05-03
NEUMANN CP 063601 04-09
NEVSIMALOVA S 089037 10-14
NEWBOLD HL 065232 05-15, 070284 07-17
NEWELL DJ 066496 05-10
NG KY 068290 06-03
NIBRA JP 086780 10-14
NICHOLAS P 063061 03-03
NICHOLS D 075957 09-02
NICHOLS RE 058988 03-03
NIEDERBERGER W 086984 10-16, 112282 12-16
NIEDERMEYER E 081135 09-15
NIEMEGEERS CJE 064476 04-04, 069076 06-04, 095507 11-06
NIES A 086987 10-13
NIESCHULZ O 067595 06-04
NIGRO A 091110 11-10
NIKOLIC B 069085 06-13
NIKOLIC J 069082 06-13
NIKOLOVSKI O 072141 07-10, 076347 09-10, 082052 10-10
NIR I 064101 04-03
NISHIE K 066497 05-03
NISHIKAWA T 067243 06-03
NISHIO S 114838 12-02
NISHIURA N 088610 10-11
NISHIYAMA T 114837 12-05
NISHIZONO M 129097 12-10
NISTICO G 067072 05-03
NIX CR 103004 12-05
NOBLE E 075841 08-12
NODIFF EA 088358 10-01, 094623 11-01
NOEL MB 038488 01-04, 038488 01-04
NOGUERA R 067676 06-10
NOMA T 129579 12-09
NOMOF N 063927 04-13
NORA AH 082039 10-15
NORA JJ 082039 10-15
NORDGREN RA 079982 09-04
NORRIS AS 088707 10-15
NOSE T 066415 05-06
NOVOTNA D 070950 07-08
NOWLIN J 058638 02-14, 058638 02-14, 071336 07-14
NOYER J 084978 10-08
NUITE JA 069594 07-04
NUMAN M 069063 06-04
NYBACK H 042727 01-03, 042727 01-03, 042755 01-03, 042755 01-03, 058798 02-03, 058798 02-03, 066502 05-03, 095440 11-03
NYBOE J 100014 11-14
NYHAN WL 040027 01-05, 040027 01-05, 075236 08-04

O

O'CONNELL R 073711 08-15, 106773 12-09
O'CONNOR M 110897 12-17
O'DONNELL SR 040751 01-03, 040751 01-03
O'HARA M 072145 07-08
O'KEEFFE R 041566 01-03, 041566 01-03
O'REGAN JB 064233 04-10, 067023 05-10
OATES JA 090373 11-03
OBERLEAS D 045526 01-04, 045526 01-04
OBRIST P 065118 05-13, 075471 08-13
OELFKE SR 058638 02-14, 058638 02-14
OGNJANOV V 045508 01-07, 045508 01-07
OGSBURY JS 067666 06-07
OGUNREMI O 063978 04-14, 072216 07-14
OHGA A 074854 08-03
OHLSSON WG 090148 11-03
OHSHIMA T 066366 05-03
OHTSUKI S 129579 12-09
OJEDA PA 082090 10-14
OKADA T 131057 12-02, 131058 12-02, 131059 12-02
OKONOGI T 114837 12-05
OKSENKRUG GF 098042 11-03, 098058 11-03
OLATUNDE IA 067462 06-03

OLDS ME 074935 08-04
OLESEN OV 042700 01-11, 042700 01-11
OLIVER AP 093132 11-03
OLIVER G 084758 10-04
OLIVEROS RT 097985 11-11
OLNEY JW 094164 11-05
OLSSON JE 047832 01-12, 047832 01-12, 065473 05-07
ONODA K 063982 04-03
ONODERA I 089029 10-13
OPITZ K 080144 09-03
OPPENHEIM GB 067212 06-06
ORAVEC M 086350 10-13
ORENSTEIN S 069309 06-02
ORNSTEIN PH 069034 06-08
ORSINGHER OA 064178 04-04
OSHIMA T 114835 12-07, 114838 12-02
OSIPOVA MS 090355 11-03
OSIPOVA SV 098042 11-03
OSMAN OH 041570 01-03, 041570 01-03
OSMOND H 111933 12-17
OSSELTON J 067864 06-14
OSTAPTZEFF G 091501 11-08
OSTAPTZEFF-LAVOINE M 091501 11-08
OSTLUND RE 116471 12-03
OSTROVSKAYA RU 058605 02-03, 058605 02-03
OSWALD I 063978 04-14, 067924 06-14, 082027 10-15
OTA K 058451 02-15, 058451 02-15, 064286 04-08, 064356 04-09, 064639 05-07, 089099 10-08
OTHMER E 078933 09-14
OTSUKI S 100852 12-03
OTTEN H 066322 05-09, 079965 09-13
OTTOSSON J 063140 03-09
OWEN CA 066938 05-03
OWEN G 046640 01-05, 046640 01-05, 047953 01-09, 047953 01-09
OWENS ML 066374 05-03
OXENKRUG GF 097988 11-03
OZOLA MY 067547 06-08

P

PACELTOVA L 070945 07-15
PACHA W 041967 01-03, 041967 01-03
PADILLA-NIBRA J 085456 10-14
PADJEN A 067598 06-03
PAHNKE WN 067355 06-12, 097286 11-12
PAKHTER A 111031 12-08
PAKKENBERG H 091127 11-04
PALMER EC 060856 03-03
PAN L 087866 10-11
PANGBORN RM 066710 05-14
PANOV PA 067147 06-13
PAPANASTASSIOU A 060208 03-08
PAPAVASILIOU PS 056574 02-11, 056574 02-11
PAPINI M 055393 02-11, 055393 02-11
PAPPAS MT 058371 02-14, 058371 02-14
PAPSDORF JD 071792 07-04
PARK LC 065488 05-10, 076292 09-10, 087386 10-10
PARKER CW 063848 04-06
PARKER KD 063927 04-13
PARKER WJ 068412 06-13
PARKES JD 043697 01-11, 043697 01-11, 058241 02-11, 058241 02-11
PARTYKA DA 058989 03-03
PASSERON JP 058312 02-11, 058312 02-11
PATON WDM 086405 10-01
PATTEE CJ 060880 03-13
PATTERSON CS 058988 03-03
PATTERSON DA 046395 01-01, 046395 01-01, 058880 02-06, 058880 02-06
PATTON RA 071790 07-03
PAUK GL 043276 01-03, 043276 01-03
PAUL AG 069804 07-01
PAUL MI 043276 01-03, 043276 01-03, 059054 03-09, 071972 07-13
PAULSON G 058966 03-11
PAULTON R 092211 11-15
PAXINOS J 090365 11-17
PAYKEL E 106765 12-09
PEACH MJ 040753 01-03, 040753 01-03
PEARCE TAA 052483 02-09, 052483 02-09
PEARLMAN M 100511 11-15
PEARSON L 066386 05-03
PEARSON RE 068203 06-13
PEASTON MJT 063822 04-13
PELICIER Y 086452 10-17
PEN A 075881 09-08
PENNEY DP 075665 08-03
PENNINGTON SN 070906 07-05
PEPEU G 067605 06-04
PEREIRA-OGAN JA 058969 03-10, 066709 05-10
PEREZ VJ 095188 11-04
PERLOFF M 075415 08-10
PERLSTEIN MA 069822 07-08
PERNHAUPT G 092306 11-11
PERRIS C 065850 05-11
PERROT ED 086984 10-16
PERRY RS 116471 12-03
PERSSON T 074818 08-03
PERTWEE RG 086405 10-01
PESCOR FT 062940 03-04
PETERFY G 060880 03-13, 071970 07-15
PETEROVA E 070932 07-08, 070937 07-09, 101034 12-07
PETERS HA 066318 05-15
PETERS UH 079991 09-15
PETERSON E 047681 01-17, 047681 01-17
PETRI H 079969 09-07
PETRILOWITSCH N 058281 02-07, 058281 02-07
PETURSSON ES 068601 06-17
PHARD GS 063776 04-08
PHILLIPS FJ 065446 05-10
PHILLIPS MI 071997 07-04
PICHOT P 085343 10-11
PICKENS R 046206 01-04, 046206 01-04, 056237 02-04, 056237 02-04
PICKETT RD 068167 06-05
PIERSON RN 047952 01-09, 047952 01-09
PIETTE LH 064423 04-03
PILIERO SJ 051121 02-17, 051121 02-17
PINCKNEY L 088614 10-03
PINELLI P 078555 09-13
PINEYRO A 064637 05-09
PINTER EJ 060880 03-13, 071970 07-15
PINTO A 058448 02-12, 058448 02-12, 072147 07-14
PINTO F 087659 10-09, 087660 10-11
PIOTROWSKI A 072897 08-08
PIROZYNSKI T 062866 03-11
PISANI D 091110 11-10
PISHKIN V 076164 09-04
PITT CG 092888 11-01
PITTS FN 058455 02-15, 058455 02-15
PLATMAN S 047952 01-09, 047952 01-09, 062349 03-09, 064317 04-09, 106764 12-09
PLENAT M 091502 11-08
PLENGE P 066822 05-03, 106780 12-03
PLETSCHER A 042726 01-03, 042726 01-03
PLOMTEUX G 089104 10-09
PLOTNIKOFF N 058992 03-04
PLUCHINO S 080336 09-03
PLZAK M 086207 10-17
PODVALOVA J 070949 07-04
POGADY J 079139 09-13
POHLMEIER H 066322 05-09, 079964 09-14, 079965 09-13
POIRE R 062406 03-08
POIRIER LJ 040124 01-05, 040124 01-05, 086349 10-03
POLACKOVA J 070952 07-09
POLAK L 073707 08-10
POLDINGER W 079966 09-13, 079986 09-07
POLIEVTSEV N 105721 12-03
POLLACK M 070968 07-14
POLVAN N 065478 05-08
POLYAK AI 090349 11-11
PONCE D 075313 08-08
PONTI G 104836 12-17
POOL W 063838 04-04
POPKOWSKA N 072891 08-08
POPOVA NK 133861 12-13
PORAY-KOSHITS BA 072580 08-03
POROT M 062407 03-11, 091502 11-08
PORSOLT RD 091997 11-04
PORTER AMW 072055 07-09
PORTER CC 040750 01-03, 040750 01-03
PORTER R 110897 12-17
PORTNOVA I 111254 12-17
PORTOGHESE PS 051116 01-17, 051116 01-17
PORZAK JP 074782 08-12
POSNER E 067836 06-15
POSSANZA GJ 088616 10-06
POSTEL J 079859 09-11
POTTS WJ 076133 09-04
POULSEN J 100082 11-09
POWELL BJ 075882 09-04
POWERS HO 063880 04-15
PRABHU GG 134940 12-09
PRADHAN RJ 075845 09-03
PRADHAN SN 046190 01-04, 046190 01-04, 071786 07-04
PRAKHYE IB 098040 11-03
PRANGE AJ 042654 01-09, 042654 01-09, 063595 04-10, 075871 09-10
PRASAD AS 045526 01-04, 045526 01-04
PRAT JC 040244 01-03, 040244 01-03
PREBLE E 068601 06-17
PREECE JM 068414 06-13
PREININGEROVA O 070952 07-09
PRESCOTT RGW 085204 10-04
PRESTINI PE 068600 06-03
PRESTON TA 066233 05-14
PREZIOSI P 067072 05-03
PRICHARD J 067900 06-15
PRIEN RF 060861 03-15, 063607 04-09, 089433 10-08
PRIEST WC 055582 02-03, 055582 02-03
PRINCE LN 040105 01-13, 040105 01-13
PRINDLE KH 064420 04-15
PROVENZANO PM 098049 11-04
PRUSOFF WH 051120 02-17, 051120 02-17
PRZEGALINSKI E 062937 03-04
PRZYBYLSKI A 082706 10-06
PUCA FM 128509 12-17
PULLAR IA 077404 09-16
PURI SK 076186 09-03
PUSTISEK B 081147 09-17
PUYELO R 067375 06-07

Q

QUADRI E 067254 06-04
QUANDT J 105619 12-05
QUARTERMAIN D 090473 11-04
QUATEMBER R 042693 01-11, 042693 01-11, 092306 11-11
QUEROL M 098174 11-10
QURESHI Z 041540 01-03, 041540 01-03

R

RAAB E 065446 05-10
RABON AM 042654 01-09, 042654 01-09, 063595 04-10
RACZEK S 087143 10-11
RADLOW R 065127 05-14
RADMAYR E 094307 11-09
RADOUCO-THOMAS S 086348 10-03
RAFAELSEN L 100014 11-14
RAFAELSEN O 066822 05-03, 100014 11-14, 100026 11-13, 106778 12-05, 106780 12-03
RAFFAELE R 130414 12-09
RAGLAND RE 088221 10-13
RAINAUT J 085992 10-11
RALSTON JD 071292 07-07
RAMSAY A 076068 09-03, 097997 11-07
RAMSAY RA 056500 02-08, 056500 02-08
RANCE A 089157 10-09
RANCE AM 089157 10-09
RANCK JB 066474 05-03
RANDALL LO 063838 04-04
RANDIC M 067598 06-03
RANDRUP A 091127 11-04
RANSOM DC 070897 07-17
RAO NS 067623 06-13
RAPISARDA V 130414 12-09
RAPOPORT JL 070024 07-14
RASMUSSEN EA 076164 09-04
RASMUSSEN K 100016 11-15
RASMUSSEN OS 070476 07-11
RASSIDAKIS NC 060208 03-08
RASTOPCHIN IP 067148 06-10
RATCLIFFE JG 067602 06-13
RATHEY U 059020 03-11
RAUTAKORPI J 064152 04-14
RAVN J 042671 01-09, 042671 01-09
RAYEVSKIY KS 058605 02-03, 058605 02-03
RAZDAN RK 093550 11-01
RECH RH 058998 03-05, 064096 04-03
RECHTSCHAFFEN JS 064113 04-14
REDA GC 094305 11-11
REDFERN PH 066713 05-03, 074148 08-03
REES L 067602 06-13

REES RM 046195 01-13, 046195 01-13
REICH T 062350 03-09
REICHARD H 097974 11-11
REICHLIN S 075665 08-03
REID L 075553 08-04, 085144 10-03
REILLY MA 083169 10-03
REIMER F 067744 06-07
REIMOLD WV 071258 07-15
REINERT RE 090359 11-15
REINHARD JF 066498 05-03
REINIS S 065933 05-04, 067713 06-04, 068677 06-04
REIS D 058840 02-04, 058840 02-04, 064146 04-03, 067324 06-03
REITANO S 063200 03-13
REITH H-J 079951 09-03
REMMER H 057033 02-03, 057033 02-03
RENAULT F 058313 02-11, 058313 02-11
RENTON KW 064421 04-03
RESNICK RB 075427 08-16
REVILLA GS 086923 10-09
REVUELTA A 088392 10-03
REYNIER M 089547 11-03, 089548 11-03
REYNOLDS EH 068414 06-13
RHEAUME S 072397 07-07
RICCI-GAMALERO S 071787 07-04
RICE M 103273 12-08
RICHARDS WA 067355 06-12
RICHARDSON JS 083413 10-04
RICHMOND JB 051784 02-13, 051784 02-13
RICHMOND LH 086025 10-10
RICHTER JA 075844 09-04, 101316 12-03
RICK JT 084758 10-04
RICKELS K 058969 03-10, 062321 03-10, 063145 03-11, 063207 03-10, 064287 04-15, 065247 05-10, 065446 05-10, 065453 05-10, 065488 05-10, 066276 05-10, 066709 05-10, 066741 05-16, 066832 05-10, 074130 08-10, 075415 08-10, 075843 09-17, 075868 09-10, 076292 09-10, 087386 10-10, 092102 11-16
RIDGES AP 068153 06-15
RIDOLO P 124309 12-08
RIES JJ 092999 11-06
RIGOTTI S 093443 11-09
RIIS M 064046 04-03
RIKOVSKY S 070929 07-08, 070939 07-09
RILEY HD 066838 05-14
RILEY L 063588 03-09
RIMOIN DL 056611 02-15, 056611 02-15
RIOBO F 075847 09-04
RITSON EB 064268 04-15
RITTER G 090126 11-15
RITZEN M 040756 01-03, 040756 01-03
RIVERS N 063897 04-15
RIZZO PA 093133 11-09
ROACH MK 063062 03-03
ROBBINS MJ 065419 05-04
ROBERGE A 086350 10-13
ROBERT G 072158 07-11
ROBERTS DJ 069077 06-04
ROBERTS E 058192 02-03, 058192 02-03
ROBERTSON MI 055323 02-05, 055323 02-05
ROBICHAUD RC 064181 04-04
ROBIE TR 058456 02-07, 058456 02-07
ROBINSON DS 064622 04-15
ROBINSON M 063601 04-09
ROBINSON SM 040582 01-03, 040582 01-03
ROBISON GA 060856 03-03
ROBSON JM 057605 02-05, 057605 02-05
ROBSON RD 055322 02-03, 055322 02-03
ROBUSTELLI F 066830 05-04
ROCK NL 066806 05-11
RODIN EA 060649 03-13, 074782 08-12
RODOVA A 070927 07-09, 070931 07-08, 070935 07-08, 070938 07-08, 070940 07-09, 070942 07-09, 070943 07-09, 070950 07-08, 106777 12-09
RODRIGUS E 067176 06-11
ROGER J 089157 10-09
ROGERS KJ 067608 06-03
ROHTE O 065442 05-04, 089786 11-01
ROIZIN L 064315 04-05, 069312 06-05
ROLFE B 064409 04-03
ROLL SK 063849 04-04
ROLL WD 089435 11-02
ROLO A 064609 04-06
ROLOVIC Z 069082 06-13
ROMAGNOLI A 055579 02-03, 055579 02-03
ROMASZEWSKA K 072897 08-08
ROMERO S 098172 11-07
ROPERT M 072159 07-07
ROPERT R 072159 07-07, 089162 10-17
ROSE C 063825 04-03, 064161 04-03
ROSE LI 086025 10-10
ROSE SD 066738 05-06
ROSECRANS JA 047324 01-04, 047324 01-04, 081231 09-04
ROSEN AJ 060275 03-04, 069075 06-04
ROSENBAUM JM 067926 06-15
ROSENBERG H 069804 07-01
ROSENBERG P 090147 11-03
ROSENBLATT S 064144 04-03
ROSENBLUM JA 067512 06-11
ROSENKRANTZ H 088412 10-05
ROSIC N 064365 04-04, 090418 11-04
ROSS EJ 082153 10-15
ROSSI R 075111 08-14
ROSSMAN M 089444 11-10
ROSSMANN H 056059 02-15, 056059 02-15
ROST H-D 079971 09-07
ROTH B 089037 10-14
ROTH M 051572 02-17, 051572 02-17
ROTH RH 074864 08-01, 074865 08-04
ROTHSCHILD B 088995 10-14
ROTHSTEIN E 058589 02-15, 058589 02-15
ROUKEMA RW 075819 08-11
ROULEAU Y 086443 10-15
ROUTTENBERG A 072471 08-03
ROUX C 063993 04-03
ROWAN AJ 068005 06-14
ROWLAND CR 042837 01-04, 042837 01-04
ROWLES SG 090427 11-13
ROWLEY VN 060090 03-04
ROXBURGH PA 064089 04-09, 075417 08-15
ROYDS RB 058333 02-15, 058333 02-15
ROZHIN V 111031 12-08
ROZITIS A 066509 05-03
ROZMAN RS 058365 02-15, 058365 02-15
RUBBO SD 075412 08-13
RUBENSON A 055587 02-03, 055587 02-03, 063888 04-03
RUDNICK A 069025 06-10
RUIKKA I 064152 04-14
RUMYANTSEVA G 096512 11-09, 109723 12-09, 111034 12-08
RUNYON RP 065416 05-08
RUSH ML 066386 05-03
RUSSELL G 095014 11-03
RUSSELL HT 090427 11-13
RUSSELL RW 075438 08-03, 085757 10-13
RUVIDIC R 069082 06-13
RYAN RL 071974 07-07
RYD E 093689 11-11
RYDIN C 081151 09-03
RYDZYNSKI Z 070930 07-08, 070944 07-09
RYE MM 072033 07-04
RYLE AE 082016 10-15

S

SAARMA J 062664 03-08, 075103 08-14
SAARMA M 075103 08-14
SAAVEDRA JM 079970 09-04
SABELLI HC 055582 02-03, 055582 02-03, 055583 02-03, 055583 02-03, 055584 02-03, 055584 02-03
SABLOSKY L 065446 05-10
SACHAR EJ 047954 01-09, 047954 01-09
SACHS FL 058213 02-15, 058213 02-15
SACHS T 066276 05-10, 075415 08-10
SACKS OW 058403 02-15, 058403 02-15, 059057 03-15, 067073 05-15, 081090 09-15
SADAVONGVIVAD C 041539 01-03, 041539 01-03, 041565 01-03, 041565 01-03
SAEKI M 139090 12-08
SAENZ RV 064258 04-01
SAFER DJ 041562 01-14, 041562 01-14, 064387 04-13, 064388 04-12
SAFRATOVA V 062800 03-14, 070933 07-14, 070955 07-14
SAGGERS VH 046187 01-13, 046187 01-13
SAH M 067513 06-11
SAITO C 139090 12-08
SAJI Y 089788 11-13
SAKALIS G 064406 04-07
SAKATA K 067719 06-08
SAKURAI S 139090 12-08
SALAMA AI 058383 02-03, 058383 02-03, 064056 04-03
SALIM AP 067695 06-04
SALLE J 055581 02-03, 055581 02-03
SALTER FJ 068203 06-13
SALVADOR RA 064282 04-03
SALZMAN C 047832 01-12, 047832 01-12, 100528 12-15
SAMACH M 079888 09-04
SAMANIN R 066500 05-03, 080338 09-01
SAMSONOVA ML 098009 11-03
SANARELLI L 093133 11-09
SANDER DM 076081 09-04
SANDERS-BUSH E 062805 03-03, 069596 07-03
SANDOR P 055740 02-03, 055740 02-03
SANGER MD 063593 03-11
SANGHVI I 064253 04-04
SANNOMIYA T 100852 12-03
SANO A 129273 12-08
SANSEIGNE A 065470 05-03
SANTOS M 064417 04-04
SAPIRA JD 075867 09-09
SAPRA RK 066276 05-10
SARAN B 079914 09-15, 106781 12-09
SARGANT W 063934 04-10
SARONIO C 064255 04-03
SASAJIMA M 063982 04-03, 130422 12-03
SATO H 074854 08-03
SATTES H 079967 09-10
SAUL W 058985 03-04
SAUNDERS M 067288 06-15
SAUNDERS RN 040584 01-03, 040584 01-03
SAVAGE C 058448 02-12, 058448 02-12, 097286 11-12
SAXENA BM 056500 02-08, 056500 02-08, 062643 03-08, 069060 06-11, 075422 08-08, 086444 10-15, 097985 11-11, 097997 11-07
SAXENA MD 046185 01-17, 046185 01-17
SAYLER A 081159 09-04
SCALA A 130417 12-17
SCAPICCHIO PL 094305 11-11
SCHAEFFER LA 062322 03-02
SCHAEPPI UH 088412 10-05
SCHAFER IS 066838 05-14
SCHAFER H 055689 02-10, 055689 02-10
SCHAFFER RJ 058942 02-03, 058942 02-03
SCHALLEK W 063841 04-04
SCHALLING D 064389 04-14
SCHAPIRA K 051572 02-17, 051572 02-17, 066496 05-10
SCHARF MB 066234 05-14, 066235 05-14, 092974 11-11
SCHARTZ W 058403 02-15, 058403 02-15
SCHAUMBURG C 055689 02-10, 055689 02-10, 128568 12-14
SCHAYER RW 083169 10-03
SCHECKEL CL 063838 04-04
SCHECKTMAN Y 042676 01-07, 042676 01-07
SCHEIBER V 089105 10-09, 106774 12-09
SCHELKUNOV E 105622 12-06
SCHERGNA E 093443 11-09
SCHEXNAYDRE C 064263 04-03
SCHIELE BC 066398 05-08, 066817 05-08, 072144 07-08
SCHIEREN AG 059275 03-11
SCHIFFTER R 079969 09-07
SCHILDKRAUT JJ 052484 02-03, 052484 02-03, 061683 03-09, 067687 06-03, 075410 08-09
SCHILTER R 071703 07-03
SCHLAG J 066186 05-03
SCHMID E 072587 08-13
SCHMIDT H 069067 06-04
SCHMIDT MJ 060856 03-03
SCHMIDT-NOWARA WW 064236 04-15
SCHMITT H 058991 03-05
SCHMITT K 079988 09-02
SCHMITT RC 097971 11-07
SCHNEE J 065409 05-15
SCHNEIDER AM 064412 04-04
SCHNEIDER K 066322 05-09, 079965 09-13
SCHNEIDER-JONIETZ B 105733 12-11
SCHNEIDERMAN N 075236 08-04
SCHNELL RC 066369 05-03
SCHNIEDEN H 081066 09-04
SCHNIERLE F 088358 10-01, 094623 11-01
SCHNUR JA 064097 04-13
SCHOBER JG 082202 10-15
SCHOENFELD RI 069738 07-04

SCHON I 079964 09-14
SCHOOLAR JC 046201 01-03, 046201 01-03, 067175 06-08
SCHOU M 060264 03-17, 060266 03-09, 060267 03-09, 062326 03-13, 082017 10-15, 100082 11-09, 106766 12-09
SCHREIBER EC 051117 02-17, 051117 02-17
SCHREINER GE 064623 04-15
SCHREURS-DIJKSTRA M 080098 09-07
SCHROLD J 090420 11-04
SCHUBERT J 042755 01-03, 042755 01-03, 058798 02-03, 058798 02-03, 066502 05-03, 095440 11-03
SCHUBERT P 074936 08-03
SCHUFFEL W 055689 02-10, 055689 02-10, 128568 12-14
SCHUGURENSKY E 105486 12-07
SCHULTES RE 058973 03-17
SCHUMAN M 075197 08-04
SCHUPPEL R 057032 02-04, 057032 02-04, 057033 02-03, 057033 02-03
SCHUSTER CR 046194 01-17, 046194 01-17, 046207 01-04, 046207 01-04, 056240 02-04, 056240 02-04, 061632 03-04
SCHUT T 075881 09-08
SCHUTZ E 072381 07-09
SCHWARTZ AS 090149 11-03
SCHWARTZ W 059057 03-15
SCHWARZ GA 059021 03-11
SCHWEID D 075430 08-09
SCHWEITZER JW 064053 04-03
SCHWINGENHEUER J 073708 08-09
SCOBIE SR 066829 05-04
SCOLLO-LAVIZZARI G 073900 08-15
SCOTT AM 070854 07-15
SCOTT DF 068005 06-14, 087863 10-06
SCOTT GD 064091 04-17
SCOTT J 070247 07-13
SEAL E 087470 10-12
SEAL RE 080002 09-17
SEARS DR 082173 10-14
SEDIVEC V 070932 07-08, 070945 07-15
SEDVALL G 042727 01-03, 042727 01-03, 042755 01-03, 042755 01-03, 066502 05-03, 095440 11-03
SEDWALL G 058798 02-03, 058798 02-03
SEEBANDT G 081144 09-11
SEGAL DS 066825 05-04
SEGAWA T 056610 02-03, 056610 02-03, 114975 12-03
SEIDEL M 079991 09-15
SEIDL G 079988 09-02
SEIFTER J 067253 06-04
SELBY M 062108 03-08
SELLER TJ 068166 06-03
SELLINGER OZ 090148 11-03
SEMIGINOVSKY B 065434 05-03
SENAY EC 075276 08-03
SENDBUEHLER JM 072397 07-07
SENINI G 080143 09-08
SERAFETINIDES EA 067719 06-08
SERISE M 085043 10-15
SERNATINGER E 074866 08-03
SERRA MT 045543 01-05, 045543 01-05, 071989 07-13
SERRY D 072219 07-17
SERRY M 072219 07-17
SETH PK 046189 01-03, 046189 01-03
SETHI BB 134937 12-11
SETHNA DM 067601 06-04
SETHY VH 075845 09-03
SHADER RI 058212 02-15, 058212 02-15, 075362 08-14, 100511 11-15, 100512 11-15, 100513 11-15, 100514 12-15, 100515 12-15, 100516 12-15, 100517 12-15, 100518 12-15, 100519 12-15, 100520 12-15, 100521 12-15, 100522 12-15, 100523 12-15, 100524 12-15, 100525 12-15, 100526 12-15, 100527 12-15, 100528 12-15, 100529 12-15, 100530 12-15, 100531 12-15, 100532 12-13, 100533 12-15, 100534 12-15, 105560 12-15
SHAFER N 067512 06-11
SHAFFER JW 064478 04-10
SHAH HC 068978 06-03
SHAH LP 138362 12-08
SHAPIRO AK 067264 06-14, 067265 06-14
SHAPIRO I 102119 12-16
SHARKAWI M 064288 04-03
SHARMA HL 088358 10-01
SHARMA VN 063981 04-03
SHARMAN DF 041566 01-03, 041566 01-03
SHASKAN DA 082173 10-14
SHATTUCK CL 081298 09-11
SHAW DM 067675 06-10
SHAW SM 058572 02-05, 058572 02-05
SHCHELKUNOV EL 098035 11-03
SHEARD MH 040418 01-03, 040418 01-03, 062777 03-04, 081112 09-03, 082545 10-04, 086029 10-12, 095671 11-04
SHEK RPN 072516 08-04
SHELLENBERGER MK 068949 06-03
SHEMBERG K 069645 07-03
SHEN F 069595 07-03
SHEPHERD M 063141 03-09
SHEPPARD C 067570 06-15, 075332 08-11, 089444 11-10, 115037 12-08
SHERMAN WM 064412 04-04
SHETH UK 075845 09-03
SHICK JFE 067341 06-15
SHIDEMAN FE 063044 03-03
SHILLITO EE 041541 01-04, 041541 01-04, 064289 04-04, 081264 09-04
SHIMADA K 114836 12-02
SHIMAZONO Y 129452 12-09
SHIRKEY HC 066838 05-14
SHMILOVICH LA 090349 11-11
SHOENBERG E 087866 10-11
SHOPSIN B 064316 04-15, 106769 12-15
SHORE H 078223 09-14
SHORT CA 059100 03-10, 059102 03-08
SHORT CR 066368 05-03
SHTERNBERG E 111018 12-09
SHULL WK 075867 09-09
SIDDIQUI AR 079215 09-11
SIDOROWICZ S 123373 12-08
SIEGEL RK 064499 04-04
SIEGEL S 067962 06-03
SIGG EB 097962 11-03
SIGGINS GR 093132 11-03
SIKES JC 075584 08-11
SIKES SC 075584 08-11
SILBERG IA 066738 05-06
SILBERSTEIN SD 069051 06-13
SILVA MT 090135 11-04
SILVESTRINI B 067254 06-04
SIMEON J 041568 01-09, 041568 01-09, 065475 05-08, 072141 07-10, 075313 08-08, 076347 09-10, 082052 10-10
SIMICH S 109786 12-13
SIMKO A 133935 12-14
SIMMONDS MA 073069 08-03
SIMMONS AV 082153 10-15
SIMON EJ 090147 11-03
SIMON JP 089111 10-07
SIMONE R 092004 11-11
SIMONS PJ 063800 04-13
SIMOPOULOS AM 058448 02-12, 058448 02-12
SIMPSON GM 063146 03-11, 063773 04-16, 063774 04-14, 063775 04-14, 063776 04-08, 063777 04-14, 063778 04-15, 065458 05-07, 065471 05-15, 086987 10-13
SINCLAIR JG 064100 04-03
SINGER G 058961 03-04
SINGER K 079915 09-15
SINGH JM 058995 03-03, 064263 04-03
SINGH KP 063981 04-03
SINKWITZ K 071703 07-03
SIOU G 055581 02-03, 055581 02-03
SIZARET P 089111 10-07
SJOQVIST F 066278 05-03, 082104 10-15
SKALNYY VV 096513 11-08
SKARBEK A 095020 11-15
SKODA C 069795 07-08
SKORUPSKI A 082706 10-06
SKORUPSKI JD 075915 09-04
SLAZMANN R 041967 01-03, 041967 01-03
SLEDGE KL 064181 04-04
SLETTEN IW 045508 01-07, 045508 01-07
SLIZEWSKI M 087537 10-15
SLOAN JW 069053 06-13
SLOTKIN T 040417 01-03, 040417 01-03, 064167 04-03
SLY WS 056611 02-15, 056611 02-15
SMALLEY RL 090359 11-15
SMART RG 093085 11-17
SMELTZER D 058966 03-11
SMITH A 066510 05-03
SMITH AA 065876 05-04
SMITH BM 047825 01-11, 047825 01-11
SMITH CB 064419 04-03
SMITH DE 058227 02-04, 058227 02-04, 067218 06-15, 067341 06-15, 067354 06-12
SMITH DF 070821 07-05
SMITH FD 064481 04-04
SMITH RR 063879 04-14
SMITH THF 046640 01-05, 046640 01-05
SMITS SE 063798 04-03, 090451 11-03
SNEGIREV YEA 073717 08-03
SNODGRASS WR 040241 01-03, 040241 01-03
SNYDER F 070247 07-13
SNYDER SH 052457 02-12, 052457 02-12, 070921 07-04, 075859 09-12, 075869 09-04, 081680 10-17
SOARES FN 086977 10-07
SOEHRING K 057032 02-04, 057032 02-04
SOFIA RD 058383 02-03, 058383 02-03, 070443 07-03
SOGTROP HH 055738 02-09, 055738 02-09
SOKOLOVA Y 111022 12-08
SOLIS HG 064637 05-09
SOLLERO L 046399 01-03, 046399 01-03
SOLOMON GF 075412 08-13
SOLOMON MD 097582 11-01
SOLOMON PR 075851 09-03
SOLTYS JJ 100517 12-15
SOLURSH LP 063753 04-15
SOLZMAN C 100511 11-15
SOMMER H 105619 12-05
SONKODI S 126052 12-04
SORGONA F 112131 12-09
SOSKIN RA 052476 02-11, 052476 02-11
SOUKUPOVA B 062800 03-14, 070933 07-14, 070955 07-14
SOURANDER L 064152 04-14
SOUREK K 089036 10-03
SOURKES TL 040124 01-05, 040124 01-05, 070218 07-02, 086350 10-13
SOUTHGATE PJ 040639 01-03, 040639 01-03
SPAIDE J 064331 04-08, 080506 09-08
SPARBER SB 060274 03-04, 063044 03-03
SPECTOR E 066498 05-03
SPECTOR S 063848 04-06, 066411 05-03
SPEISER P 128389 12-15
SPENCER PSJ 066935 05-05, 068165 06-03
SPERO M 072141 07-10, 082052 10-10
SPIEGEL EA 071984 07-07
SPIEGEL R 066954 05-14
SPIEGELBERG U 058281 02-07, 058281 02-07
SPIERS ASD 066419 05-13
SPIGEL IM 076068 09-03
SPINDLER JS 058974 03-05
SPRAGUE RL 081631 10-14
SPRING G 075430 08-09
SQUIRE LR 075237 08-04, 097953 11-04
SRIMAL RC 064414 04-04
STABENAU JR 062783 03-13
STAEHELIN M 074861 08-03
STAEL P 062406 03-08
STAMENOVIC BA 074133 08-03
STANCER HC 075425 08-10
STANISLAWSKA J 108694 12-03
STARK P 058942 02-03, 058942 02-03
STASTNA J 055398 02-05, 055398 02-05
STEIDINGER J 072587 08-13
STEIN DG 067120 06-02
STEIN L 069311 06-04
STEINBERG H 059072 03-17, 067606 06-04, 090423 11-06
STEINBERG I 067599 06-06
STEINBERG J 075430 08-09
STEINBERG MI 064419 04-03
STEINER H 079986 09-07
STELLAR S 071985 07-07
STEPANSKY W 075415 08-10
STEPHENS JH 047831 01-09, 047831 01-09, 064478 04-10
STEPHENSON J 063825 04-03
STEPHENSON JA 065440 05-04
STERLIN C 058968 03-08, 062643 03-08, 072140 07-10, 075422 08-08, 097985 11-11
STERN FH 063598 04-09
STERN GM 058240 02-11, 058240 02-11, 067657 06-15
STERN JJ 081226 09-04
STERN MH 075316 08-04
STERN P 040578 01-04, 040578 01-04
STERN WC 088471 10-04

STERNALSKI M 064173 04-07
STEVENS HM 058880 02-06, 058880 02-06
STEVENSON I 047825 01-11, 047825 01-11, 063980 04-03
STIFLER L 052502 02-14, 052502 02-14
STITZEL RE 040243 01-03, 040243 01-03
STOCK G 072067 07-03
STOLERMAN IP 059072 03-17, 064475 04-04, 067599 06-06, 079999 09-04, 090423 11-06
STOLK JM 058998 03-05, 062853 03-03, 063015 03-03, 064096 04-03
STOLMAN S 046144 01-03, 046144 01-03
STONE CA 064426 04-04
STONE EA 075275 08-03
STONE GC 064416 04-12
STONE WE 064177 04-03
STONE WN 067221 06-08, 068964 06-10, 075321 08-08
STORES OPR 080635 09-11
STOUPEL N 088618 10-15
STRADA SJ 062805 03-03, 066374 05-03, 102415 12-06
STRAKER M 075424 08-08
STRAUSS S 088587 10-03
STRETCH R 063725 04-06
STROMBERG U 064411 04-03, 066508 05-03, 074145 08-04
STRUBELT O 055739 02-03, 055739 02-03
STUMP JM 066315 05-03
STURM V 072067 07-03
SUEMITSU S 105790 12-14
SUGERMAN AA 072145 07-08
SUGIMURA T 070083 07-04
SUHR Y 074865 08-04
SUITS E 075280 08-04
SULEMAN M 138526 12-10
SULSER F 062805 03-03, 066374 05-03, 066955 05-03, 069596 07-03
SULTANOV M 105721 12-03
SUMIDA Y 131625 12-06
SUMME JP 069067 06-04
SUMMERFIELD A 067606 06-04, 091997 11-04
SUPPRIAN U 079973 09-06
SURIS OR 070287 07-09
SUSSMAN C 075873 09-14
SUTTER W 079966 09-13
SUWA N 118583 12-08
SUZUKI Y 114769 12-02, 114836 12-02, 114837 12-05, 131623 12-03
SVENSSON T 066508 05-03, 067259 06-04, 074145 08-04, 081151 09-03, 097960 11-04
SVESTKA A 070936 07-08, 070950 07-08
SVESTKA J 070927 07-09, 070928 07-09, 070931 07-08, 070938 07-08, 070940 07-09, 070941 07-09, 070942 07-09, 070943 07-09, 106777 12-09
SWEET P 063515 03-13
SWEET RD 067666 06-07
SWEETNAM MT 067836 06-15
SWENSON JE 065458 05-07
SWIFT T 067666 06-07
SYDIAHA E 063873 04-12
SYLVESTER J 069802 07-13, 087679 10-14
SYLWESTER D 064622 04-15
SYMINGTON A 072787 08-11
SZABO KT 089398 10-05
SZAPARY D 064045 04-03
SZARA S 075290 08-12
SZCZEPKA K 086958 10-11
SZE PY 058192 02-03, 058192 02-03, 083168 10-03
SZENTPETERY GB 055740 02-03, 055740 02-03
SZEWCZUK J 087143 10-11

T

TABUSHI K 064331 04-08
TACHIKAWA R 114769 12-02
TACKER MM 046197 01-03, 046197 01-03
TAKADA K 094623 11-01
TAKAGI H 055585 02-03, 055585 02-03, 114769 12-02, 114835 12-07, 114838 12-02, 114975 12-03
TAKAHASHI A 066366 05-03
TAKAHASHI S 118583 12-08
TAKAHATA N 070334 07-03
TAKAMISAWA M 129452 12-09
TAKATSUKA K 114975 12-03
TAKEMORI AE 063798 04-03, 090451 11-03
TAKEO Y 089788 11-13
TAKIDO M 069804 07-01
TALALAYENKO AN 073715 08-03
TALBOTT JA 059035 03-15
TAMAI Y 139090 12-08
TAMAYO L 075846 09-03
TAN RSH 067836 06-15
TAN T 066233 05-14, 066234 05-14, 092974 11-11
TANABE K 094623 11-01
TANASE H 114836 12-02
TANDOU P 130714 12-10
TANIMUKAI H 080506 09-08, 105731 12-14, 129082 12-08
TANSELLA M 064406 04-07
TANSEY LW 038488 01-04, 038488 01-04, 041907 01-02, 041907 01-02, 046196 01-03, 046196 01-03, 067081 05-03, 090426 11-01
TAPIA HL 079746 09-11, 081121 09-10
TARGOWLA J 086005 10-11
TART CT 045515 01-17, 045515 01-17
TARVER JH 066411 05-03
TAUBERGER G 089046 10-03
TAVERNA P 094423 11-11
TAYLOR HL 082959 10-05
TAYLOR KM 070921 07-04, 075869 09-04
TAYLOR W 066938 05-03, 126639 12-15
TEEHAN BP 064623 04-15
TEICHMANN H 080563 09-11
TEITELBAUM DT 082004 10-15
TEJA JS 134903 12-09, 134940 12-09
TEJERINA W 098171 11-03
TELLER DN 069309 06-02
TEMPLE TE 051122 02-17, 051122 02-17
TERMAN DS 082004 10-15
TESAROVA O 059038 03-17, 070957 07-15
TESCHEMACHER H 074936 08-03, 089042 10-01
TESCHEMACHER HJ 089047 10-03
TESEI R 094305 11-11
TESSEL RE 060275 03-04
TETREAULT L 075884 09-14, 089054 10-17, 089159 10-08
THATCHER K 058454 02-12, 058454 02-12, 064323 04-12
THIEL JH 075980 09-15
THOENEN H 075714 08-03, 075715 08-03, 080352 09-03, 088374 10-03
THOMAS DLC 082018 10-15
THOMAS J 063841 04-04
THOMPSON GR 088412 10-05
THOMPSON RA 072508 08-15
THOMPSON T 046206 01-04, 046206 01-04, 056237 02-04, 056237 02-04, 064479 04-04
THOMSEN HG 066822 05-03
THOMSEN K 100082 11-09, 100083 11-15, 106766 12-09, 106779 12-05
THOR CJ 075206 08-04
THOR DH 068765 06-04, 075206 08-04, 076131 09-04, 082511 10-04
THOUVENOT J 072154 07-16
TIEN HC 063596 04-08
TILL E 089102 10-17
TINKLENBERG JR 066232 05-14, 071998 07-14, 073886 08-14
TOBIN JM 064074 04-14
TODD JJ 085144 10-03
TODRICK A 040573 01-13, 040573 01-13
TODT N 064431 04-08
TOH HT 041564 01-03, 041564 01-03
TOLLE R 079995 09-14, 094963 11-09
TOLLINCHI G 089157 10-09
TOLMAN BD 069077 06-04
TOMKIEWICZ M 067606 06-04
TOMPKINS WF 046113 01-13, 046113 01-13
TOMPSETT SL 067924 06-14
TONGE SR 065436 05-12, 070542 07-03
TOPHAM JC 064001 04-03
TORBA V 102119 12-16
TORD I 093689 11-11
TORNYA PT 090078 11-07
TORTORA E 080142 09-11
TORU M 129452 12-09
TOSOVSKY J 089037 10-14
TOWNSEND HRA 060659 03-08
TRABER DL 097971 11-07
TRAFTON CL 060636 03-03
TRAHAN P 058995 03-03
TRAPET P 086237 10-07
TRAVNICEK V 089036 10-03
TRENDELENBURG U 066363 05-03, 080336 09-03
TRENHOLM HL 064160 04-05, 090032 11-05
TREPTOW K 112003 12-04
TREUTING JJ 059622 03-03
TRICE J 071043 07-09
TRICOIRE J 058312 02-11, 058312 02-11
TRIDENTI A 124309 12-08
TRIESTER SR 064045 04-03
TRIPI E 109258 12-11
TROMBLEY J 064479 04-04
TROST JG 046209 01-04, 046209 01-04
TROWILL JA 060871 03-03
TRUITT EB 090068 11-13
TRUSLOVE GM 081066 09-04
TSAI LS 095188 11-04
TSCHABITSCHER H 042693 01-11, 042693 01-11
TSUCHIYA K 129452 12-09
TSUMAGARI T 131058 12-02
TUCK D 082104 10-15
TUCKOSH JR 081098 09-04
TUMA AH 071322 07-08
TUPIN J 067138 06-15, 095014 11-03, 106763 12-09
TUREK I 064286 04-08, 064356 04-09, 064639 05-07, 089099 10-08
TURK JA 058942 02-03, 058942 02-03
TURNBULL MJ 063980 04-03, 067604 06-03
TURNER M 100959 12-07, 105486 12-07
TURNER TAR 068165 06-03
TURNER WJ 070972 07-14
TUZEL IH 075388 08-10
TYCE GM 066938 05-03
TYSON V 058335 02-10, 058335 02-10

U

UCKO FA 068298 06-09
UDALL V 057606 02-05, 057606 02-05
UEMATSU S 088611 10-13
UHLENHUTH EH 065488 05-10, 066741 05-16, 076292 09-10, 087386 10-10
ULLMAN KC 082155 10-09
UNGAR F 046189 01-03, 046189 01-03
UNGER S 097286 11-12
UNTERBERGER H 089438 11-13
URETSKY NJ 072120 07-03, 073069 08-03, 074053 08-04
URQUILLA PR 040243 01-03, 040243 01-03
USHER DR 067884 06-04
USHIJIMA S 129447 12-13
USKOVA NV 098042 11-03
UTELL MJ 067882 06-04
UYENO ET 058997 03-04, 075282 08-04, 075788 08-04

V

VACAFLOR L 069580 07-15
VACCARI A 064050 04-03
VACHON M 046191 01-03, 046191 01-03
VAKHING VA 064333 04-04, 098024 11-04
VAL'DMAN AV 073681 08-03
VALENOVA Z 070945 07-15
VALLADE L 088998 10-17
VALZELLI L 066500 05-03, 080338 09-01
VAN AST W 063753 04-15
VAN DER HELM HJ 078213 09-13
VAN DER VELDE CD 062348 03-09
VAN HEYCOP TEN HAM MW 066190 05-13
VAN HOUTEN PL 071960 07-15
VAN KREVELEN DA 080098 09-07
VAN LOMMEL R 064284 04-09
VAN MESDAG-ETTY H 075881 09-08
VAN PRAAG HM 070857 07-09, 070881 07-13, 075881 09-08, 078212 09-10, 097963 11-13
VAN RIEL DG 095507 11-06
VAN TWYVER H 066468 05-03
VAN TYLE WK 089437 11-06
VAN WINKLE E 064053 04-03
VAN WOERT MH 058534 02-15, 058534 02-15, 059020 03-11, 063845 04-15, 070824 07-13, 089998 11-05
VAN WOUDENBERG F 097963 11-13
VAN ZIJL CHW 066190 05-13
VANDERVORT WJ 065453 05-10
VANYSEK J 070935 07-08
VARAGIC VM 074133 08-03
VARGO TA 082039 10-15
VARSAMIS J 080355 09-08

VASQUEZ BJ 046142 01-04, 046142 01-04
VEDERNIKOV YP 055756 02-03, 055756 02-03, 075840 08-05
VEITZMAN V 121795 12-15
VENALAINEN E 105732 12-14
VENCOVSKY E 070932 07-08, 070937 07-09, 079146 09-07, 101034 12-07
VENTURINI E 087659 10-09, 087660 10-11
VERBRUGGEN FJ 064476 04-04, 069076 06-04, 095507 11-06
VERNADAKIS A 067980 06-03, 070825 07-03, 074131 08-03, 074830 08-04
VERNIER VG 066315 05-03
VERNIKOS-DANELLIS J 040028 01-05, 040028 01-05
VERTUA R 064050 04-03
VESTRE ND 066398 05-08, 066817 05-08, 072144 07-08
VIALA A 088997 10-03
VIAU J 071942 07-03
VIGOURET JM 089045 10-12
VIKHLYAYEV YI 058604 02-03, 058604 02-03, 067301 06-17
VILA M 058561 02-14, 058561 02-14
VILLA-LANDA I 061654 03-13
VILLABLANCA J 066186 05-03, 075847 09-04
VILLANI M 092481 11-14
VILLAR JI 098171 11-03
VILLARREAL JE 046203 01-13, 046203 01-13
VILLENEUVE A 064090 04-01, 072406 07-15, 098018 11-09
VILLENEUVE C 072142 07-08
VINAR O 070924 07-17, 080394 09-17, 086208 10-17
VIRABYAN T 111767 12-03
VITALI A 098002 11-08
VIUKARI NMA 059055 03-15
VOGEL WH 040105 01-13, 040105 01-13
VOGELBERG W 055739 02-03, 055739 02-03
VOGT M 041566 01-03, 041566 01-03, 081264 09-04
VOJTECHOVSKY M 062800 03-14, 070925 07-17, 070933 07-14, 070934 07-14, 070955 07-14, 079993 09-08, 086208 10-17
VOLBEHR H 064364 04-03, 070951 07-03
VOLDENG AN 073265 08-01
VOLKOVA R 126631 12-11
VOLMAT R 086235 10-10
VOLTOLINA EJ 067213 06-15
VON VOIGTLANDER PF 058986 03-03
VORHEES C 069056 06-04
VOTAVA Z 062800 03-14, 086206 10-17
VOURLEKIS A 075290 08-12
VOVINA E 110105 12-17
VUCKOVIC S 089102 10-17
VURCHIO AM 093091 11-10

W

WADE GN 076080 09-04, 076239 09-03
WAGNER B 106783 12-03
WAISMAN HA 060490 03-04
WAISS AC 066497 05-03
WAITE R 066935 05-05
WAJSZCZUK-RELIGA A 108694 12-03
WAKITA Y 055586 02-03, 055586 02-03
WALASZEK E 058988 03-03, 068949 06-03
WALCHER W 073706 08-09
WALDECK B 066506 05-03, 074145 08-04, 074818 08-03, 097960 11-04
WALKER BA 081135 09-15
WALKER KE 038488 01-04, 038488 01-04, 046196 01-03, 046196 01-03, 065494 05-03, 090426 11-01
WALKER RJ 084758 10-04
WALL ME 092888 11-01
WALLACE J 088951 10-08
WALLACH MB 079888 09-04
WALTERS GC 059032 03-04
WALTZ JM 071985 07-07
WANG RIH 057473 02-16, 057473 02-16, 067934 06-15
WARD JW 082051 10-03
WARREN RJ 056611 02-15, 056611 02-15
WARRICK G 062510 03-13, 075274 08-13
WASDEN RE 075553 08-04
WASER PG 064408 04-03
WASIK A 072890 08-15, 123373 12-08
WASKOW IE 047832 01-12, 047832 01-12
WATANABE AM 090371 11-13
WATANABE E 118583 12-08
WATANABE H 118583 12-08
WATANABE M 129579 12-09
WATANABE S 100852 12-03
WATERFIELD AA 041974 01-03, 041974 01-03
WATROUS WM 040754 01-03, 040754 01-03
WATSON BCE 045508 01-07, 045508 01-07
WATZMAN N 064259 04-04
WAY EL 069595 07-03
WEATHERALL M 057606 02-05, 057606 02-05
WEDDELL J 077404 09-16
WEIL AT 059290 03-14
WEIL D 072159 07-07
WEIL J 087489 10-10
WEINER M 051121 02-17, 051121 02-17
WEINER N 051126 02-17, 051126 02-17
WEINGARTNER H 052457 02-12, 052457 02-12, 075859 09-12
WEINREICH D 066871 05-04
WEINSHILBOUM R 088376 10-03
WEINTRAUB MI 058534 02-15, 058534 02-15
WEIR RD 070854 07-15
WEIS P 060264 03-17, 060266 03-09, 060267 03-09
WEISCHER M 080144 09-03
WEISE CC 065247 05-10, 065453 05-10, 066709 05-10, 066832 05-10, 075868 09-10
WEISE VK 040126 01-03, 040126 01-03, 040309 01-03, 040309 01-03, 092383 11-03
WEISINGER RS 075915 09-04
WEISS CF 066838 05-14
WEISS G 065176 05-12, 072825 08-14
WEISS JM 090135 11-04
WEISS P 088615 10-05
WEITZMAN P 075846 09-03
WENGER J 083415 10-17
WERDINIUS B 058799 02-03, 058799 02-03
WERRY JS 070975 07-17, 081631 10-14
WEST LJ 071027 07-17
WESTERHUIS R 075881 09-08
WESTON AH 040572 01-03, 040572 01-03
WEYCHERT A 070944 07-09
WHALEN EM 065446 05-10
WHALEN RE 066825 05-04, 067696 06-04, 076086 09-04, 081228 09-04
WHEATLEY D 069057 06-10
WHISHAW IQ 081149 09-04
WHITAKER LH 087470 10-12
WHITE CS 076081 09-04
WHITE JC 072508 08-15
WHITE L 058373 02-07, 058373 02-07, 066852 05-08
WHITE RF 075388 08-10
WHITE RP 064367 04-04
WHITLOCK FA 095443 11-15
WHITMAN RM 069034 06-08
WHITNEY G 046209 01-04, 046209 01-04, 082959 10-05
WHITTINGTON H 067603 06-03
WIBERG GS 064160 04-05, 090032 11-05
WIERZBICKI T 070930 07-08, 072893 08-15
WIESEN RL 067934 06-15
WIKLER A 062940 03-04, 075842 08-03
WILBY WE 071987 07-13
WILCOX AH 081098 09-04
WILDER R 062351 03-15
WILDES JW 092888 11-01
WILKIE F 071336 07-14
WILLARD D 063879 04-14
WILLIAMS F 082172 10-11
WILLIAMS HR 062789 03-07
WILLIAMS JK 066372 05-03
WILLNER JH 079888 09-04
WILSON AB 040639 01-03, 040639 01-03
WILSON DA 075868 09-10
WILSON DE 058989 03-03
WILSON IC 042654 01-09, 042654 01-09, 063588 03-09, 063595 04-10, 075871 09-10
WILSON JE 078378 09-03
WILSON JMO 082732 10-11
WILSON RD 097971 11-07
WILSON WL 075996 09-04
WINGET CN 075321 08-08
WINOKUR A 067687 06-03
WINOKUR G 062350 03-09
WINSLOW WW 068964 06-10
WINSON J 069637 07-04
WINTROB RM 065479 05-08
WISE CD 069311 06-04
WISE DE 082172 10-11
WISECUP P 058454 02-12, 058454 02-12, 064323 04-12
WISEMAN BD 074149 08-04
WITOSLAWSKI JJ 064426 04-04
WITT ED 064170 04-03
WITTENBORN J 046311 01-17, 046311 01-17, 046312 01-04, 046312 01-04, 046313 01-14, 046313 01-14, 046314 01-17, 046314 01-17, 046315 01-11, 046315 01-11, 046316 01-11, 046316 01-11, 115463 12-17, 134057 12-17
WITTERS WL 069610 07-04, 075196 08-04
WITTNER WK 062510 03-13, 075274 08-13
WITTRIG J 063209 03-09, 080634 09-03
WITZTUM J 058455 02-15, 058455 02-15
WOJCIECHOWSKA M 087143 10-11
WOLAK E 072896 08-08
WOLF HH 042837 01-04, 042837 01-04, 064260 04-04, 074146 08-05
WOLF PS 069593 07-04
WOLFF FW 082155 10-09
WOLPERT A 058373 02-07, 058373 02-07, 065314 05-10, 075429 08-08
WOLPERT MK 076576 09-02, 079997 09-03
WONG M 079915 09-15
WOOD MJ 067510 06-15
WOODRUFF DS 079982 09-04
WOODRUFF RA 058455 02-15, 058455 02-15
WOODS AE 080634 09-03
WOODS JH 046207 01-04, 046207 01-04
WOODS SC 075915 09-04
WORTHINGTON AG 082411 10-14
WRIGHT AL 080095 09-14
WRIGHT JA 063927 04-13
WROBLEWSKA-SMOCZYNSKA J 072895 08-11
WRUHS O 080041 09-11
WURTMAN RJ 040246 01-03, 040246 01-03, 063825 04-03, 064161 04-03
WUTTKE W 040758 01-04, 040758 01-04, 071785 07-04
WYATT RJ 070247 07-13
WYCIS HT 071984 07-07
WYSOKI V 087489 10-10
WYSS M 132911 12-12

Y

YABE T 118585 12-09
YAFFE SJ 066838 05-14
YAMADA O 129367 12-07
YAMAMOTO H 040244 01-03, 040244 01-03
YAMANE H 129451 12-08
YAMAUCHI I 129740 12-08
YANG K 060862 03-16
YARDEN PE 089101 10-08
YAREMKO RM 075196 08-04
YARYURA-TOBIAS JA 058373 02-07, 058373 02-07, 064638 05-08, 065314 05-10, 075429 08-08
YEE R 066276 05-10
YEH JA 058571 02-03, 058571 02-03
YEH JZ 064094 04-03, 064261 04-03
YELNOSKY J 058996 03-05
YEN HCY 046143 01-04, 046143 01-04
YERYSKEV O 109724 12-14
YIM GKW 064100 04-03
YOKOO Y 106270 12-03
YOKOYAMA S 129579 12-09
YOO CS 040242 01-03, 040242 01-03
YORK DH 063983 04-03
YOST MA 058951 02-15, 058951 02-15
YOUNG E 066748 05-07
YOUNG GA 075399 08-04
YOUNG P 067602 06-13
YOUNG PA 067601 06-04
YUI T 089788 11-13
YUIZONO T 055586 02-03, 055586 02-03
YUKITAKE A 129753 12-15
YURTCU A 058968 03-08
YUWILER A 042840 01-03, 042840 01-03
YVONNEAU M 094287 11-09

Z

ZABOJNIKOVA M 070948 07-04
ZACCALA M 042756 01-13, 042756 01-13
ZALESKI WA 060268 03-07
ZAMOSTIEN BB 062321 03-10

ZAPLETALEK M 070929 07-08, 070939 07-09, 070946 07-10
ZAPPOLI R 055393 02-11, 055393 02-11
ZAROCHINTSEVA A 111031 12-08
ZAVIDOVSKAYA G 111034 12-08
ZELMAN S 076364 09-15, 090359 11-15
ZERACHIA A 088463 10-03
ZETLER G 055739 02-03, 055739 02-03
ZHURKOV V 102119 12-16
ZIEGLER R 106780 12-03
ZIEM M 088587 10-03, 089041 10-03
ZIGMOND MJ 040246 01-03, 040246 01-03
ZILKHA KJ 043697 01-11, 043697 01-11, 058241 02-11, 058241 C2-11
ZIMMERMANN RL 072144 07-08
ZINBERG NE 059290 03-14
ZIRKLE C 080032 09-02
ZITKOVA L 055398 02-05, 055398 02-05
ZITRIN A 072463 08-04
ZOGLIO MA 046137 01-03, 046137 01-03
ZOLTAN O 126051 12-04, 126053 12-04, 126054 12-04, 126055 12-04, 126056 12-04
ZORNETZER SF 097952 11-04
ZOZULA JK 085453 10-14
ZUCCHI M 093090 11-07
ZUCKER I 076080 09-04, 076239 09-03
ZUMPE D 075829 08-04, 076554 09-03
ZUNG WWK 063592 03-10, 084806 10-14
ZUPKO AG 070899 07-15
ZVERINA E 089036 10-03
ZVOLSKY P 081111 09-03, 089787 11-09, 106776 12-14

# SUBJECT INDEX

[The Subject Index is machine generated. Keywords in the titles of abstracts appear alphabetically in the left hand margin; under each keyword is a list of titles in which the keyword appears. The spelling of words in the titles of abstracts has not been changed; hence, two spellings of the same word may appear in this index -- for example, BEHAVIOR and BEHAVIOUR.]


**A-124**
CLINICAL STUDY ON A NEW PIPERIDYL-PHENOTHIAZINE DERIVATIVE (A-124).
079969 09-07

**ABBREVIATION**
ABBREVIATION OF BEHAVIORAL ESTRUS IN GUINEA-PIGS BY COITAL AND VAGINO-CERVICAL STIMULATION.
065332 05-03

**ABILITY**
LEARNING ABILITY IN EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY UNDER THE INFLUENCE OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126056 12-04

**ABLATION**
EFFECT OF HIPPOCAMPAL AND NEOCORTICAL ABLATION ON SCOPOLAMINE INDUCED ACTIVITY IN THE RAT.
075848 09-04

**ABLATIONS**
EQUIVALENCE OF SIMULTANEOUS AND SUCCESSIVE NEOCORTICAL ABLATIONS IN PRODUCTION OF IMPAIRMENTS OF RETENTION OF BLACK WHITE HABITS IN RATS.
076316 09-04

**ABNORMAL**
ABNORMAL SOCIAL BEHAVIOR IN PHENYLKETONURIC MONKEYS.
060490 03-04

**ABNORMALITIES**
FLUID AND ELECTROLYTE ABNORMALITIES IN ALCOHOLISM.
063591 03-03

SPINAL FLUID CREATINE PHOSPHOKINASE ABNORMALITIES FOLLOWING LSD USAGE.
067213 06-15

CONGENITAL ABNORMALITIES AND ANTICONVULSANT DRUGS.
071949 07-15

**ABRUPT**
SEVERE DELIRIUM AFTER ABRUPT WITHDRAWAL OF THIOTHIXENE IN A CHRONIC SCHIZOPHRENIC INPATIENT: A CASE STUDY.
067221 06-08

**ABSOLUTE**
ABSOLUTE CONFIGURATIONS OF METHOXYLATED AMPHETAMINES.
095700 11-01

**ABSORPTION**
DELAYED ABSORPTION OF PHENYLBUTAZONE CAUSED BY DESMETHYLIMIPRAMINE IN HUMANS.
042756 01-13

ALTERED ABSORPTION OF DRUGS FROM THE RAT SMALL INTESTINE BY CARBONIC ANHYDRASE INHIBITION.
066369 05-03

ABSORPTION AND PHARMACOLOGICAL ACTIVITIES OF A NEW DIAZEPAM PREPARATION.
072586 08-03

IN VIVO EVALUATION OF ABSORPTION AND EXCRETION OF PENTYLENETETRAZOL -10-14C FROM SUSTAINED-RELEASE AND NONSUSTAINED-RELEASE TABLETS.
090427 11-13

STUDIES ON PSYCHOTROPIC DRUGS (SEVENTH REPORT) -- METABOLIC FATE OF APY-606 -- ABSORPTION, DISTRIBUTION, EXCRETION AND METABOLISM OF TRITIATED APY-606.
131059 12-02

**ABSTINENCE**
CONDITIONED NALORPHINE INDUCED ABSTINENCE CHANGES: PERSISTENCE IN POST MORPHINE DEPENDENT MONKEYS.
061632 03-04

PATHOPHYSIOLOGY OF NARCOTIC ADDICTION; POSSIBLE ROLES OF PROTRACTED ABSTINENCE IN RELAPSE (UNPUBLISHED PAPER).
093000 11-13

**ABSTRACT**
ABSTRACT OF THESES FOR DOCTOR OF MEDICAL SCIENCES, THE UNIVERSITY OF TOKYO: MORITA THERAPEUTIC APPROACH TO SCHIZOPHRENIA.
126778 12-17

**ABUSE**
DRUGS: FACTS ON THEIR USE AND ABUSE.
051784 02-13

ABUSE OF AMPHETAMINE AND AMPHETAMINE-LIKE DRUGS.
063753 04-15

DIMYRIL ABUSE IN THE EAST MIDLANDS.
064268 04-15

EMERGENCY TREATMENT OF DRUG ABUSE AND POISON INGESTION.
066395 05-15

AN APPROACH TO THE TREATMENT OF DRUG ABUSE.
067934 06-15

MENTAL DISORDERS CAUSED BY PHENMETRAZINE ABUSE.
072893 08-15

ABUSE OF AND ADDICTION TO DIAZEPAM.
079991 09-15

THE USE AND ABUSE OF PSYCHOTROPIC DRUGS.
083128 10-15

PHARMACOLOGICAL ASPECTS OF DRUG ABUSE.
085613 10-17

THE USE AND ABUSE OF ANTIDEPRESSANTS.
089107 10-17

PSYCHIATRIC DRUG USE AND ABUSE IN THE AGED.
090428 11-17

STATE DRUG ABUSE CONTROL.
105336 12-17

SLEEPING PILLS AND TRANQUILIZER ABUSE.
129237 12-17

PSYCHOPATHOLOGY OF TRANQUILIZER ABUSE.
133935 12-14

**ABUSED**
SYNTHETIC DRUGS USED AND ABUSED.
058070 02-14

**ABUSES**
THE USES AND ABUSES OF LSD AND OTHER HALLUCINOGENIC DRUGS.
087470 10-12

**ACADEMY**
SOMAPSYCHIC RELATIONS IN MEDICINE: SESSION OF HOMAGE OF THE PERUVIAN ACADEMY OF MEDICINE TO PROFESSOR HONORIO DELGADO.
094610 11-14

**ACCELERATE**
USE OF A THYROID HORMONE TO ACCELERATE THE ACTION OF IMIPRAMINE.
063595 04-10

**ACCELERATED**
ACCELERATED ACTION OF PSYCHOTROPIC DRUGS EFFECTED BY PYRITHIOXIN.
079966 09-13

**ACCELERATION**
ACCELERATION OF NORADRENALINE BIOSYNTHESIS IN THE GUINEA-PIG VAS-DEFERENS BY POTASSIUM.
073063 08-06

**ACCIDENTS**
EXTRAPYRAMIDAL ACCIDENTS IN TREATMENT OUTSIDE THE HOSPITAL SETTING.
086443 10-15

**ACCUMULATION**
DAILY RHYTHM IN THE ACCUMULATION OF BRAIN CATECHOLAMINES SYNTHESIZED FROM CIRCULATING H3-TYROSINE.
040246 01-03

L-DOPA INDUCED ACCUMULATION OF METHYLDOPA IN BRAIN AND HEART.
042726 01-03

FURTHER STUDIES ON THE ACCUMULATION AND DISAPPEARANCE OF CATECHOLAMINES FORMED FROM TYROSINE-14C IN MOUSE BRAIN. EFFECT OF SOME PHENOTHIAZINE ANALOGUES.
042727 01-03

ACCUMULATION AND DISAPPEARANCE OF 3H-5-HYDROXYTRYPTAMINE FORMED FROM 3H-TRYPTOPHAN IN MOUSE BRAIN: EFFECT OF LSD-25.
042755 01-03

EFFECT OF ANTIDEPRESSANT DRUGS ON ACCUMULATION AND DISAPPEARANCE OF MONOAMINES FORMED IN VIVO FROM LABELED PRECURSORS IN MOUSE BRAIN.
058798 02-03

INTRANEURONAL AND EXTRANEURONAL ACCUMULATION OF SYMPATHOMIMETIC AMINES IN THE ISOLATED NICTITATING MEMBRANE OF THE CAT.
066363 05-03

CATECHOLAMINE ACCUMULATION IN TISSUES OF THIAMINE-DEFICIENT RATS AFTER INHIBITION OF MONOAMINE OXIDASE.
067243 06-03

**ACCURACY**
SPEED, ACCURACY, AND STRENGTH OF FORELIMB MOVEMENT AFTER UNILATERAL PYRAMIDOTOMY IN RHESUS MONKEYS.
076213 09-04

**ACETIC**
THE EFFECT OF AMINOESTERS OF SUBSTITUTED GLYCOLIC AND ACETIC ACIDS ON THE CONTENT OF NORADRENALINE IN THE BRAIN OF RATS.
073717 08-03

**ACETYLCHOLINE**
EFFECTS OF TWO CHOLINESTERASE INHIBITORS ON ACETYLCHOLINE RELEASE FROM THE GUINEA-PIG ISOLATED ILEUM PREPARATION.
040572 01-03

THE EFFECT OF ANTIADRENALINE COMPOUNDS ON ACETYLCHOLINE RESPONSES OF FROG RECTUS-ABDOMINIS MUSCLE.
041538 01-03
THE EFFECT OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON BRAIN ACETYLCHOLINE LEVELS IN RAT.
041913 01-03
THE EFFECT OF MORPHINE, NALORPHINE, NALOXONE, PENTAZOCINE, CYCLAZOCINE AND OXOTREMORINE ON THE SYNTHESIS AND RELEASE OF ACETYLCHOLINE BY MOUSE CEREBRAL CORTEX SLICES IN VITRO.
058994 03-03
EFFECTS OF MORPHINE AND PENTOBARBITONE ON ACETYLCHOLINE SYNTHESIS BY RAT CEREBRAL CORTEX.
064288 04-03
ACETYLCHOLINE RELEASE FROM CORTICAL BRAIN SLICES OF RATS INJECTED WITH LITHIUM.
066509 05-03
ACTIONS OF RESERPINE AND TYRAMINE ON THE ACETYLCHOLINE CONTENT OF BRAINSTEM, HEART AND BLOOD OF THE RAT.
067461 06-03
QUANTITATION OF THE DEGREE OF ANTAGONISM OF CHLOROQUINE TO HISTAMINE, ACETYLCHOLINE AND SEROTONIN ( PA2 VALUES).
067462 06-03
THE BRAIN ACETYLCHOLINE SYSTEM IN BARBITONE DEPENDENT AND WITHDRAWN RATS.
067604 06-03
COMPLEXES BETWEEN ACETYLCHOLINE AND CATECHOLAMINES AND THEIR TOLERANCE TO MENTAL ILLNESS.
072705 08-01
A NEW WAY OF ACETYLCHOLINE BIOSYNTHESIS IN BRAIN TISSUE.
087303 10-01
INFLUENCE OF IMIPRAMINE, BENACTYZINE AND PROMAZINE ON THE EFFECTS OF INTRAAMYGDALOID INJECTION OF ACETYLCHOLINE AND SEROTONIN.
098024 11-04
EFFECTS OF MORPHINE AND LEVORPHANOL ON BRAIN ACETYLCHOLINE CONTENT IN MICE.
101316 12-03

**ACETYLCHOLINESTERASE**
DEPHOSPHORYLATION IN VIVO OF BRAIN ACETYLCHOLINESTERASE INHIBITED BY ISOPROPYL METHYLPHOSPHONOFLUORIDATE (SARIN).
046188 01-03

**ACETYLENES**
POLYNEURITIS CRANIALIS FOLLOWING POISONING WITH CHLORINATED ACETYLENES WHILE HANDLING VINYLIDINE COPOLYMERS.
051140 02-15

**ACETYLTRANSFERASE**
EFFECTS OF A CHOLINE ACETYLTRANSFERASE INHIBITOR ON SELF-STIMULATORY BEHAVIOR IN THE RAT.
058993 03-04

**ACH**
THE EFFECT OF A PSYCHOTOMIMETIC GLYCOLATE AND ITS ANTIDOTE ESERINE ON THE ACH CONTENT OF THE LOBSTER WALKING LEG NERVE.
069515 06-13

**ACHE**
AN ACHE MASKING DEPRESSION.
064636 05-14
AN ACHE MASKING DEPRESSION.
082422 10-10

**ACHIEVEMENT**
EFFECTS OF MEPROBAMATE ON THE SCHOOL ACHIEVEMENT OF CEREBRAL PALSIED CHILDREN.
083317 10-14

**ACID**
COMPARATIVE EFFECTS OF P-CHLOROPHENYLALANINE, P-CHLOROAMPHETAMINE AND P-CHLORO-N-METHYLAMPHETAMINE ON RAT BRAIN NOREPINEPHRINE, SEROTONIN AND 5-HYDROXYINDOLE-3-ACETIC ACID.
040241 01-03
THE ACTIONS OF GAMMA-AMINOBUTYRIC ACID AND RELATED AMINO ON MAMMALIAN AUTONOMIC GANGLIA.
040752 01-03
INHIBITION OF THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN RATS BY DRUGS WHICH INHIBIT RIBONUCLEIC ACID OR PROTEIN SYNTHESIS.
041570 01-03
EFFECTS OF LYSERGIC ACID DERIVATIVES ON 5-HYDROXYTRYPTAMINE EXCITATION OF BRAINSTEM NEURONES.
041973 01-02
SUBNORMAL SERUM FOLATE DUE TO ANTICONVULSIVE THERAPY: A DOUBLE-BLIND STUDY OF THE EFFECT OF FOLIC ACID TREATMENT IN PATIENTS WITH DRUG INDUCED SUBNORMAL SERUM FOLATES.
042700 01-11
USES AND MISUSES OF LYSERGIC ACID DIETHYLAMIDE.
046736 01-17
CSF HOMOVANILLIC ACID: EFFECTS OF PROBENECID AND ALPHA-METHYLTYROSINE.
047506 01-03
LYSERGIC ACID DIETHYLAMIDE AS A VARIABLE IN THE HOSPITAL TREATMENT OF ALCOHOLISM: A FOLLOW-UP STUDY.
052476 02-11
GABA AS A REPRESSOR OF L-GLUTAMIC ACID DECARBOXYLASE (GAD) IN DEVELOPING CHICK EMBRYO OPTIC LOBES.
058192 02-03
NEUROTROPIC PROPERTIES OF AMINOHYDROXYACETATE AND GAMMA-AMINOHYDROXYBUTYRIC ACID.
058605 02-03
BLOCKADE OF NORADRENALINE UPTAKE AND INHIBITION OF GASTRIC ACID SECRETION BY 2-(P-CHLOROPHENYL-2-(PYRIDYL)HYDROXYMETHYL) IMIDAZOLINE MALEATE (SCH-12650).
058878 02-02
LYSERGIC ACID DIETHYLAMIDE, CHLORPROMAZINE AND MAZE PERFORMANCE.
058997 03-04
DRUGS: ACID REPORT ON ACID.
059318 03-12
PROJECT SUMMARY: ON THE INVESTIGATION OF THE GENETIC EFFECTS OF LYSERGIC ACID DIETHYLAMIDE AND RELATED COMPOUNDS.
060637 03-03
NEUROPHARMACOLOGICAL COMPARISON OF CYSTATHIONINE, CYSTEINE, HOMOSERINE AND ALPHA-KETOBUTYRIC ACID IN CATS.
064367 04-04
MONOAMINES IN THE BRAIN UNDER THE INFLUENCE OF MUSCIMOL AND IBOTENIC ACID, TWO PSYCHOACTIVE PRINCIPLES OF AMANITA-MUSCARIA.
064408 04-03
LYSERGIC ACID DIETHYLAMIDE INTAKE IN PREGNANCY: FETAL DAMAGE IN RATS.
064422 04-05
LYSERGIC ACID DIETHYLAMIDE (LSD-25): XXXIX. THE EFFECT OF HIGH TEMPERATURES ON STABILITY.
064609 04-06
YEAST RIBONUCLEIC ACID: ANALYSIS OF EFFECTS ON POLE-CLIMB AVOIDANCE BEHAVIOR.
065493 05-04
ANTIDIURESIS IN MAN FOLLOWING LYSERGIC ACID DIETHYLAMIDE AND MESCALINE.
066399 05-13
INHIBITION BY P-CHLOROAMPHETAMINE OF THE CONVERSION OF 5-HYDROXYTRYPTAMINE TO 5-HYDROXYINDOLEACETIC ACID IN RAT BRAIN.
066507 05-03
USE OF PANGAMIC ACID (VITAMIN-B15) IN CEREBRAL ARTHEROSCLEROSIS WITH MENTAL DISTURBANCES.
067148 06-10
THE EFFECT OF DISULFIRAM, DIETHYLDITHIOCARBAMATE AND DIMETHYLDITHIOCARBAMATE ON SEROTONIN AND 5-HYDROXYINDOLE-3-ACETIC ACID BRAIN LEVELS IN RATS.
067384 06-03
SOME FACTORS INFLUENCING THE RELEASE OF 5-HYDROXYINDOL-3-YLACETIC ACID IN THE FOREBRAIN.
067598 06-03
EFFECTS OF PSILOCYBIN, DIMETHYLTRYPTAMINE AND VARIOUS LYSERGIC ACID DERIVATIVES ON PHOTICALLY INDUCED EPILEPSY IN THE BABOON (PAPIO-PAPIO).
068163 06-03
NICOTINIC ACID IN THE TREATMENT OF SCHIZOPHRENIAS.
068450 06-08
THE EFFECT OF SOME HALLUCINOGENIC DRUGS ON THE AMINO ACID PRECURSORS OF BRAIN MONOAMINES.
070542 07-03
CHROMOSOME STUDIES ON PATIENTS (IN VIVO) AND CELLS (IN VITRO) TREATED WITH LYSERGIC ACID DIETHYLAMIDE.
071987 07-13
HOSPITAL ADMISSIONS DUE TO LYSERGIC ACID DIETHYLAMIDE.
072149 07-15
FORMATION AND REGIONAL DISTRIBUTION OF GAMMA-HYDROXYBUTYRIC ACID IN MAMMALIAN BRAIN.
074864 08-01
STUDIES ON THE ROLE OF ACID IN THE PATHOGENESIS OF EXPERIMENTAL STRESS ULCERS.
075276 08-03
LYSERGIC ACID DIETHYLAMIDE AND A NOVEL STIMULUS.
075282 08-04
NICOTINIC ACID IN THE PREVENTION AND TREATMENT OF METHIONINE INDUCED EXACERBATION OF PSYCHOPATHOLOGY IN SCHIZOPHRENICS.
075423 08-08
EFFECTS OF LYSERGIC ACID DIETHYLAMIDE ON THE MATERNAL BEHAVIOR OF THE RAT.
075788 08-04
CHILDHOOD SCHIZOPHRENIA: A CASE TREATED WITH NICOTINIC ACID AND NICOTINAMIDE.
075944 09-08
DYNAMIC CONTROL OF ACID BASE EQUILIBRIUM DURING SOME FORMS OF SHOCK THERAPY.
079139 09-13

FOLIC ACID IN FOLATE DEFICIENT PATIENTS WITH EPILEPSY.
080635 09-11

REDUCTION OF LEVEL OF L-GLUTAMIC ACID DECARBOXYLASE BY GAMMA-AMINOBUTYRIC ACID IN MOUSE BRAIN.
083168 10-03

ACTION OF THE SALTS OF OXYGLURIC ACID ON ACUTE ALCOHOL INTOXICATION IN MAN (EXPERIMENTAL STUDY).
086005 10-11

EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND 2-BROM-D-LYSERGIC ACID DIETHYLAMIDE (BOL-148) UPON BEHAVIORAL SLEEP IN RATS.
089045 10-12

EFFECT OF NICOTINIC ACID COMBINED WITH A TRANQUILLIZER (HYDROXYZINE) ON SERUM LIPID LEVELS AND URINARY CATECHOLAMINE EXCRETION IN GERIATRIC PATIENTS.
093689 11-11

STUDY OF AMINO ACID ANALOGS AND BRAIN BIOCHEMISTRY.
094553 11-03

ON THE BIOCHEMICAL MECHANISM OF ACTION OF NICOTINIC ACID, NICOTINAMIDE, METHIONINE, AND D-PENICILLAMINE IN THE TREATMENT OF PSYCHOSES.
094962 11-13

THE EFFECT OF DIETHYLAMIDE OF LYSERGIC ACID (DLA) ON THE CONTENT OF MONOAMINES IN SOME NUCLEI OF THE MIDBRAIN AND HYPOTHALAMUS.
101006 12-03

EFFECT OF A DEFICIENCY OF PANTOTHENIC ACID AND PYRIDOXINE ON THE FUNCTION OF THE CENTRAL NERVOUS SYSTEM AND ITS RESPONSE TO COUMARIN FROM MELILOTUS-OFFICINALIS.
126053 12-04

INFLUENCE OF ISONIAZID ON THE CENTRAL NERVOUS SYSTEM; THE ANTAGONISM BETWEEN ISONIAZID AND PYRIDOXINE, PANTOTHENIC ACID AND COUMARIN IN RATS (MELILOTUS-OFFICINALIS).
126055 12-04

**ACIDOSIS**

THE EFFECTS OF ACIDOSIS ON CHRONOTROPIC RESPONSES, NOREPINEPHRINE STORAGE AND RELEASE IN ISOLATED GUINEA-PIG ATRIA.
040753 01-03

**ACIDS**

EFFECTS OF THALIDOMIDE AND CHLORCYCLIZINE ON THE BIOSYNTHESIS OF NUCLEIC ACIDS AND PROTEINS IN FETAL AND MATERNAL TISSUES OF THE RAT.
040027 01-05

THE EFFECT OF AMINOESTERS OF SUBSTITUTED GLYCOLIC AND ACETIC ACIDS ON THE CONTENT OF NORADRENALINE IN THE BRAIN OF RATS.
073717 08-03

PLASMA FREE FATTY ACIDS BEFORE AND AFTER AN INTRAVENOUS INSULIN INJECTION IN ACUTE SCHIZOPHRENIC MEN.
075212 08-08

HIGH VOLTAGE SLOW WAVE INDUCED BY SHORT-CHAIN FATTY ACIDS WITH SPECIAL REFERENCE TO SLEEP RHYTHM.
088612 10-03

**ACOUSTICALLY**

EFFECTS OF PENTOBARBITONE AND CHLORPROMAZINE ON ACOUSTICALLY EVOKED POTENTIALS IN THE RAT.
074939 08-03

**ACQUIRED**

THE EFFECTS OF CHLORPROMAZINE ON THE EXPRESSION OF AN ACQUIRED PASSIVE AVOIDANCE RESPONSE IN MICE.
097959 11-04

**ACQUISITION**

EFFECT OF AMPHETAMINE, NICOTINE AND HEXAMETHONIUM ON PERFORMANCE OF A CONDITIONED RESPONSE DURING ACQUISITION AND RETENTION TRIALS.
046186 01-04

EFFECTS OF AMOBARBITAL SODIUM ON THE ACQUISITION AND EXTINCTION OF A LEVER-PRESS SPATIAL DISCRIMINATION IN THE RAT.
069075 06-04

EFFECTS OF CHLORDIAZEPOXIDE ON BLACK WHITE DISCRIMINATION ACQUISITION AND REVERSAL IN WHITE RATS.
070083 07-04

EFFECTS OF CHLORDIAZEPOXIDE ON THE ACQUISITION OF SHUTTLE AVOIDANCE IN THE RABBIT.
075235 08-04

THE ROLE OF D-AMPHETAMINE AMOBARBITAL IN SUPPRESSING FREEZING BEHAVIOR DURING AVOIDANCE ACQUISITION AND EXTINCTION.
075882 09-04

EFFECTS OF NEONATAL TESTOSTERONE ON THE ACQUISITION OF AN ACTIVE AVOIDANCE RESPONSE IN GENOTYPICALLY FEMALE RATS.
075890 09-04

FAILURE OF TRICYANOAMINOPROPENE TO FACILITATE ACQUISITION OF DOUBLE ALTERNATION IN RATS.
088471 10-04

**ACRIDAN**

DOUBLE-BLIND STUDY COMPARING THE INTRAMUSCULAR USAGE OF AN ACRIDAN DERIVATIVE, SKF-14336, TO CHLORPROMAZINE.
067513 06-11

**ACTH**

EFFECTS OF ACTH AND ZINC PHOSPHATE VEHICLE ON SHUTTLEBOX CAR.
060756 03-04

THE ALTERATIONS OF PROTEIN METABOLISM OF THE BRAIN CORTEX INDUCED BY ANTICIPATION STRESS AND ACTH.
065434 05-03

THE EFFECT OF DEXAMETHASONE BLOCKADE OF ACTH RELEASE ON AVOIDANCE LEARNING.
067884 06-04

EFFECT OF PITUITARY AND ACTH ON THE MAINTENANCE OF BASAL TYROSINE HYDROXYLASE ACTIVITY IN THE RAT ADRENAL GLAND.
075714 08-03

COMPARISON OF THE EFFECTS OF EXOGENOUS ACTH ON APPROACH AND AVOIDANCE CONDITIONING: IMPLICATIONS FOR THE PHYSIOLOGY OF INCENTIVE MOTIVATION. (PH.D.DISSERTATION).
103354 12-04

**ACTING**

THE EFFECT OF CENTRALLY ACTING DRUGS ON THE CONCENTRATION OF BRAIN ADENOSINE 3PRIME,5PRIME- MONOPHOSPHATE.
043276 01-03

TEMPERATURE RESPONSES AND OTHER EFFECTS OF 5-HYDROXYTRYPTOPHAN AND 5-HYDROXYTRYPTAMINE WHEN ACTING FROM THE LIQUOR SPACE IN UNANESTHETIZED RABBITS.
046404 01-03

THE EFFECTS OF CENTRALLY AND PERIPHERALLY ACTING CHOLINERGIC DRUGS ON THE SHORT-TERM PERFORMANCE GRADIENT FOLLOWING PASSIVE AVOIDANCE TRAINING.
064412 04-04

EFFECTS OF DRUGS ACTING ALONE AND IN COMBINATION ON THE MOTOR ACTIVITY OF INTACT MICE.
090139 11-03

ADRENAL CORTICAL AND MEDULLARY SECRETION AND EVALUATION OF DRUGS ACTING ON THE CENTRAL NERVOUS SYSTEM.
106270 12-03

**ACTINOMYCIN-D**

BRAIN FUNCTION AND MACROMOLECULES: V. THE EFFECT OF CYCLOHEXIMIDE AND ACTINOMYCIN-D ON LEARNING IN THE HEADLESS COCKROACH.
078378 09-03

**ACTION**

BLOCKADE OF THE CARDIAC ACTION OF PHENYLEPHRINE BY BRETYLIUM OR COCAINE.
040242 01-03

ACTION OF PSYCHOTOGENIC DRUGS ON SINGLE MIDBRAIN RAPHE NEURONS.
040418 01-03

THE ROLE OF THE HYPOTHALAMO-PITUITARY SYSTEM IN THE MECHANISM OF ACTION OF RESERPINE AND 5-HYDROXYTRYPTOPHAN ON ANTIBODY PRODUCTION.
040579 01-03

CENTRAL NERVOUS SYSTEM STIMULANT ACTION OF FENFLURAMINE IN RABBITS.
040639 01-03

STUDIES OF DELAYED ACTION MEDICATION: V. PLASMA LEVELS AND URINARY EXCRETION OF FOUR DIFFERENT DOSAGE FORMS OF CHLORPROMAZINE.
041559 01-13

INHIBITION OF THE RE-UPTAKE OF NEURONALLY LIBERATED NORADRENALINE AND ALPHA-RECEPTOR BLOCKING ACTION OF SOME ERGOT ALKALOIDS.
041967 01-03

2,5- DIMETHOXY-4-METHYLAMPHETAMINE – TISSUE DISTRIBUTION AND NEUROCHEMICAL ACTION.
045544 01-03

ACTION OF GUANETHIDINE ON THE PRESSOR EFFECT OF ANGIOTENSIN IN ADRENALECTOMIZED DOGS.
046399 01-03

A POTENTIAL SCREENING TEST FOR MINOR TRANQUILLIZING DRUG ACTION.
051651 02-06

SELECTIVE DEPLETION OF NORADRENALINE: A PROPOSED MECHANISM OF THE ADRENERGIC NEURONE BLOCKING ACTION OF BRETYLIUM.
055323 02-05

WATER STRUCTURE IN ANESTHETIC ACTION: TIME-DEPENDENCE D20 EFFECTS ON NERVE.
055582 02-03

ON THE SITES OF ANTITUSSIVE ACTION OF N-(2-PICOLYL)-N-PHENYL-N-(2-PIPERIDINOETHYL)AMINE (TAT-3).
055586 02-03

PHARMACOLOGICAL STUDIES ON THE ACTION OF SYNTHETIC ALPHA-METHYL-PYRRYL-KETONE ON THE CNS AND ON CIRCULATION.
055740 02-03

THE ROLE OF BRAIN CATECHOLAMINES IN MORPHINE ANALGESIC ACTION IN MORPHINE TOLERANT RATS.
055756 02-03

THE ACTION OF DIAZEPAM IN NEUROLOGICAL DISORDERS WITH EXCESSIVE MOTOR ACTIVITY.
056779 02-11

CLINICAL INVESTIGATIONS OF THE ACTION OF A PHOSPHOLIPID COMPLEX FROM CEREBRAL CORTEX ON CEREBRAL CIRCULATION DISTURBANCES.
058282 02-11

USE OF A THYROID HORMONE TO ACCELERATE THE ACTION OF IMIPRAMINE.
063595 04-10

CHEMICAL CONSTITUTION AND DRUG ACTION OF N-SUBSTITUTED PHENOTHIAZINE IN VENTRICULAR ECTOPIC TACHYCARDIA.
063981 04-03

LSD: NO TERATOGENIC ACTION IN RATS, MICE, AND HAMSTERS.
063993 04-03

PSYCHOPHARMACOLOGICAL ACTION OF NICOTINAMIDE ADENINE DINUCLEOTIDE.
064481 04-04

THE ACTION OF L-DOPA ON SCHIZOPHRENIC PATIENTS (A PRELIMINARY REPORT).
064638 05-08

AMANTADINE DOPAMINE INTERACTION: POSSIBLE MODE OF ACTION IN PARKINSONISM.
066315 05-03

TEGRETAL: THE PROBLEM OF PSYCHOTROPIC ACTION.
067739 06-14

THE DISULFIRAM - LIKE ACTION OF EMBRAN.
067744 06-07

THE STAIRCASE MAZE AND THE SIMPLE STAIRCASE IN THE ANALYSIS OF THE PSYCHOPHARMACOLOGICAL ACTION OF CNS DEPRESSANTS.
068291 06-04

P-CHLOROAMPHETAMINE: IN VIVO INVESTIGATIONS ON THE MECHANISM OF ACTION OF THE SELECTIVE DEPLETION OF CEREBRAL SEROTONIN.
069596 07-03

CENTRAL NERVOUS SYSTEM METABOLISM, DRUG ACTION AND HIGHER FUNCTIONS.
070976 07-17

ACTION OF CODEINE, PETHIDINE AND METHADONE ON THE OPERANT BEHAVIOR OF THE RAT.
071787 07-04

THE ACTION OF CENTRAL DEPRESSANT DRUGS ON THE SPONTANEOUS DISCHARGE OF ACTION POTENTIALS IN THE SUPERIOR CERVICAL SYMPATHETIC TRUNK OF THE CAT.
072034 07-03

DEVELOPMENT OF FIGHTING BEHAVIOR IN STARVED RATS BY CHRONIC ADMINISTRATION OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL AND CANNABIS EXTRACTS: LACK OF ACTION OF OTHER PSYCHOTROPIC DRUGS.
072531 08-04

THE ADRENERGICAL MECHANISMS OF ACTION IN ANTIDEPRESSIVE DRUGS.
073787 08-17

ON THE MODE OF ACTION OF AMANTADINE.
074145 08-04

SITES OF ACTION OF RAM-302 AND NALORPHINE AS MORPHINE ANTAGONISTS.
074934 08-03

ON THE CENTRAL SITES FOR THE ANTINOCICEPTIVE ACTION OF MORPHINE AND FENTANYL.
074936 08-03

THE EFFECTS OF ALTERED BRAIN NOREPINEPHRINE LEVELS ON CONTINUOUS AVOIDANCE RESPONDING AND THE ACTION OF AMPHETAMINES.
074937 08-04

ROLE OF BRAIN AMINES IN THE ANALGESIC ACTION OF MEPERIDINE HYDROCHLORIDE.
075845 09-03

CLINICAL TESTS OF A NEW, PROLONGED ACTION NEUROLEPTIC AGENT, PIMOZIDE.
079863 09-07

ACCELERATED ACTION OF PSYCHOTROPIC DRUGS EFFECTED BY PYRITHIOXIN.
079966 09-13

MECHANISMS OF LITHIUM ACTION: (ENDOGENOUS TISSUE LEVELS, EXCRETION IN EMOTIONAL STATES, AND BEHAVIORAL EFFECTS).
080634 09-03

III. PROLONGED ACTION NEUROLEPTICS: REPORT ON THE PROLONGED ACTION NEUROLEPTICS.
085992 10-11

III. PROLONGED ACTION NEUROLEPTICS: REPORT ON TREATMENT WITH PROLONGED ACTION NEUROLEPTICS IN PSYCHIATRY.
085993 10-11

ACTION OF THE SALTS OF OXYGLURIC ACID ON ACUTE ALCOHOL INTOXICATION IN MAN (EXPERIMENTAL STUDY).
086005 10-11

CONTRIBUTION TO THE STUDY OF THE ACTION OF PROPERICIAZINE ON BEHAVIORAL PROBLEMS OF THE CHILD AND THE ADOLESCENT.
086451 10-11

THE ACTION OF SOME PSYCHOTROPIC DRUGS ON DEFECATION RATE IN THE MOUSE.
089003 10-05

THE USE OF TWO COMBINATIONS OF DRUGS WITH MIXED ACTION, ANTIDEPRESSIVE AND TRANQUILIZING (AMITRYPTILINE - PERPHENAZINE) IN GENERAL AND IN PSYCHOSOMATIC MEDICINE.
089162 10-17

A STUDY OF HEPATIC ALCOHOL DEHYDROGENASE INHIBITION INDUCED BY PYRAZOL: I. IN VIVO ACTION ON ETHANOL AND 2-PHENYLETHANOL.
089548 11-03

POSSIBLE LOCI OF ACTION OF 2-ETHYL-ETHYLAMINO-6-METHOXY-S-TRIAZINE FOR ELECTROENCEPHALOGRAPHIC AND SYMPATHETIC ACTIVATION IN CAT.
089788 11-13

STUDIES ON ADRENERGIC MECHANISMS IN THE ACTION OF DESMETHYLIMIPRAMINE (DMI).
090421 11-04

THE ACTION OF TRYPTAMINE ON THE DOG SPINAL CORD AND ITS RELATIONSHIP TO THE AGONISTIC ACTIONS OF LSD-LIKE PSYCHOTOGENS.
090422 11-03

STUDIES ON THE RECEPTORS INVOLVED IN THE ACTION OF THE VARIOUS AGENTS IN THE PHENYLBENZOQUINONE ANALGESIC ASSAY IN MICE.
090451 11-03

ON THE BIOCHEMICAL MECHANISM OF ACTION OF NICOTINIC ACID, NICOTINAMIDE, METHIONINE, AND D-PENICILLAMINE IN THE TREATMENT OF PSYCHOSES.
094962 11-13

COMPARATIVE STUDY OF NATURAL SLEEP AND THE ACTION OF PHENAMINE AND CHLORPROMAZINE EVALUATION OF THE MEAN EXTREMES FREQUENCY OF ECOG IN CATS.
095655 11-14

ROLE OF BRAIN SEROTONIN IN THE STIMULANT ACTION OF AMPHETAMINE.
098003 11-03

SEROTONINERGIC PROCESSES IN THE ACTION OF PSYCHOTROPIC DRUGS.
098055 11-03

CONCERNING THE EVIDENCE FOR A PROPHYLACTIC ACTION OF LITHIUM.
100082 11-09

ADRENERGIC MECHANISMS IN THE CENTRAL ACTION OF PSYCHOTROPIC DRUGS. (PH.D.DISSERTATION).
102415 12-06

CLINICOELECTROENCEPHALOGRAPHIC EVALUATION OF THE ANTIEPILEPTIC ACTION OF A NEW SERIES OF BENZODIAZEPINIC DERIVATIVES.
105486 12-07

PARTICIPATION OF SEROTONINERGIC PROCESSES IN THE ACTION OF PHENIGAMA.
105620 12-03

CLINICAL CONTROVERSIES AND THEORETICAL MODE OF ACTION OF LITHIUM CARBONATE.
106767 12-13

PROPHYLACTIC ACTION OF LITHIUM SALTS AND THYROID HORMONES ON SYMPTOMS OF MANIC-DEPRESSIVE AND AFFECTIVE PSYCHOSES: CLINICAL AND EXPERIMENTAL RESULTS.
106774 12-09

CENTRAL ACTION OF SOME AUTONOMIC DRUGS IN RESPECT TO EEG AROUSAL REACTION OF THE RABBIT.
107190 12-03

EFFECT OF GANGLIONIC BLOCKING AGENTS ON PRESSOR EFFECTS OF SYMPATHOMIMETIC AMINES OF DIRECT AND INDIRECT ACTION.
110632 12-03

A BIPHASIC ACTION OF PILOCARPINE ON BEHAVIORAL AROUSAL IN THE RAT. (PH.D.DISSERTATION).
110922 12-04

CLINICAL RESULTS ON THE THERAPEUTIC ACTION OF LITHIUM CARBONATE IN DYSTHYMIC PSYCHOSES.
114880 12-09

ON THE EFFICACY AND THE MECHANISM OF ACTION OF LITHIUM SALTS IN MANIC-DEPRESSIVE PSYCHOSES.
130414 12-09

**ACTIONS**

POTENTIATION AND INHIBITION OF SOME CENTRAL ACTIONS OF L(-) DOPA BY DECARBOXYLASE INHIBITORS.
040750 01-03

THE ACTIONS OF GAMMA-AMINOBUTYRIC ACID AND RELATED AMINO ON MAMMALIAN AUTONOMIC GANGLIA.
040752 01-03

THE EFFECT OF HEAT, COLD, AND WORK ON THE CENTRAL ACTIONS OF SCOPOLAMINE.
041562 01-14

POTENTIATION OF THE CENTRAL ACTIONS OF 5-HYDROXYTRYPTOPHAN IN RABBITS BY DL-ALPHA-HYDRAZINO ALPHA-METHYLDOPA.
058879 02-03

BEHAVIORAL AND BRAIN CATECHOLAMINE DEPLETING ACTIONS OF U-14624, AN INHIBITOR OF DOPAMINE BETA-HYDROXYLASE.
058986 03-03

A COMPARATIVE STUDY OF THE PHARMACOLOGIC ACTIONS OF AMPHETAMINE AND FENFLURAMINE.
058996 03-05

CONVULSANT ACTIONS OF TETRAZOLE DERIVATIVES.
064177 04-03

SIMILARITIES BETWEEN BEHAVIORAL AND PHARMACOLOGICAL ACTIONS OF YOHIMBINE AND 5-HYDROXYTRYPTOPHAN IN THE CONSCIOUS DOG.
064253 04-04

MODIFICATION OF THE TOXIC ACTIONS OF L-TRYPTOPHAN BY PARGYLINE AND P-CHLOROPHENYLALANINE.
064277 04-05

A COMPARISON OF THE ANTINOCICEPTIVE ACTIONS OF CHOLINOMIMETIC AND MORPHINE-LIKE DRUGS.
064290 04-03

ACTIONS OF RESERPINE AND TYRAMINE ON THE ACETYLCHOLINE CONTENT OF BRAINSTEM, HEART AND BLOOD OF THE RAT.
067461 06-03

ANTIHEMOLYTIC ACTIONS OF TRICYCLIC TRANQUILIZERS: STRUCTURAL CORRELATIONS.
074862 08-03

ACTIONS OF L-DOPA IN DRUG-INDUCED EXTRAPYRAMIDALISM.
075429 08-08

THE ROLE OF BRAIN DOPAMINE IN BEHAVIORAL REGULATION AND THE ACTIONS OF PSYCHOTROPIC DRUGS.
075869 09-04

THE ACTION OF TRYPTAMINE ON THE DOG SPINAL CORD AND ITS RELATIONSHIP TO THE AGONISTIC ACTIONS OF LSD-LIKE PSYCHOTOGENS.
090422 11-03

A PHARMACOLOGICAL STUDY OF THE ANTIMUSCARINIC ACTIONS OF SEVERAL ANTIDEPRESSANTS. (PH.D.DISSERTATION).
104737 12-03

PHARMACOLOGICAL STUDIES OF OXAZOLAZEPAM, A NEW PSYCHOTROPIC AGENT - I. ACTIONS ON THE CENTRAL NERVOUS SYSTEM, ESPECIALLY ON THE BEHAVIORAL OBSERVATION.
114769 12-02

**ACTIVATION**

PSYCHOTROPIC DRUGS AND THE REGULATION OF BEHAVIORAL ACTIVATION IN PSYCHIATRIC ILLNESS.
070970 07-17

L-DOPA, BEHAVIORAL ACTIVATION AND PSYCHOPATHOLOGY (UNPUBLISHED PAPER).
078542 09-09

ON ACTIVATION OF DREAMS BY THYMOLEPTICS.
079995 09-14

POSSIBLE LOCI OF ACTION OF 2-ETHYL-ETHYLAMINO-6-METHOXY-S-TRIAZINE FOR ELECTROENCEPHALOGRAPHIC AND SYMPATHETIC ACTIVATION IN CAT.
089788 11-13

**ACTIVE**

DOPAMINE CONCENTRATIONS IN THE BRAINSTEM MESENCEPHALON OF ACTIVE RATS AS COMPARED WITH PASSIVE RATS.
060274 03-04

STRAIN DIFFERENCES IN THE EFFECTS OF CHLORPROMAZINE AND CHLORDIAZEPOXIDE UPON ACTIVE AND PASSIVE AVOIDANCE IN MICE.
066828 05-04

PHARMACOLOGY OF THE ACTIVE PRINCIPLE OF BETEL.
067595 06-04

EFFECTS OF NEONATAL TESTOSTERONE ON THE ACQUISITION OF AN ACTIVE AVOIDANCE RESPONSE IN GENOTYPICALLY FEMALE RATS.
075890 09-04

STEREOCHEMICAL ASPECTS OF CENTRALLY ACTIVE COMPOUNDS. (PH.D. DISSERTATION).
137993 12-01

**ACTIVITIES**

RELATIONSHIPS BETWEEN STEREOSTRUCTURE AND PHARMACOLOGICAL ACTIVITIES.
051116 01-17

BIOLOGICAL ACTIVITIES OF SOME 5-SUBSTITUTED N,N DIMETHYLTRYPTAMINES, ALPHA-METHYLTRYPTAMINES, AND GRAMINES.
065494 05-03

EVALUATION OF THE PERIPHERAL AND CENTRAL ANTAGONISTIC ACTIVITIES AGAINST 5-HYDROXYTRYPTAMINE OF SOME NEW AGENTS.
067603 06-03

ABSORPTION AND PHARMACOLOGICAL ACTIVITIES OF A NEW DIAZEPAM PREPARATION.
072586 08-03

EFFECTS OF CHLORIMIPRAMINE ON ELECTRICAL ACTIVITIES OF SUBCORTICAL BRAIN STRUCTURES AND OF SYMPATHETIC NERVES.
079951 09-03

BLOCKADE OF NOREPINEPHRINE UPTAKE AND RELATED ACTIVITIES OF CIS- AND TRANS N,N(PRIME)-BIS-(1-NAPHTHYLMETHYL)-1,4 CYCLOHEXANE BIS-(METHYLAMINE) DIHYDROCHLORIDE.
090136 11-03

**ACTIVITY**

ANALOGS OF ALPHA-METHYLPHENETHYLAMINE (AMPHETAMINE). I. SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF SOME METHOXY AND/OR METHYL ANALOGS.
038488 01-04

EFFECTS OF NICOTINE AND TOBACCO SMOKE ON THE ELECTRICAL ACTIVITY OF THE CEREBRAL CORTEX AND OLFACTORY BULB.
041567 01-03

CLINICAL ANTIDEPRESSANT ACTIVITY OF CYCLAZOCINE -- A NARCOTIC ANTAGONIST.
041568 01-09

CORRELATION BETWEEN THE DURATION OF THE ANTICONVULSANT ACTIVITY OF DIAZEPAM AND ITS PHYSIOLOGICAL DISPOSITION IN MICE.
046402 01-03

TOXICITY OF SOME BENZODIAZEPINE COMPOUNDS WITH CNS ACTIVITY.
046640 01-05

EFFECT OF LITHIUM CARBONATE THERAPY ON ADRENOCORTICAL ACTIVITY.
047954 01-09

4-(BETA-BENZOYLVINYL) ANTIPYRINE DERIVATIVES WITH ANTIPHLOGISTIC AND ANALGESIC ACTIVITY.
055519 02-03

INFLUENCE OF SEROTONIN AND RELATED SUBSTANCES UPON PHOTIC EVOKED POTENTIALS OF RABBIT: EVIDENCE FOR BIOLOGICAL ACTIVITY OF THE ALDEHYDE DERIVATIVE.
055584 02-03

THE ACTION OF DIAZEPAM IN NEUROLOGICAL DISORDERS WITH EXCESSIVE MOTOR ACTIVITY.
056779 02-11

STARTLE RESPONSE CIRCADIAN RHYTHM IN RATS: LACK OF CORRELATION WITH MOTOR ACTIVITY.
058349 02-04

JUMPING ACTIVITY INDUCED BY SODIUM 5-(1,3 DIMETHYLBUTYL)-5 ETHYL BARBITURATE. II. THE EFFECTS OF AGE DIFFERENCE.
058985 03-04

COMPARISON OF PMH AND PEMOLINE ACTIVITY AFTER ELECTROCONVULSIVE SHOCK.
058992 03-04

BIPHASIC EFFECT OF NOREPINEPHRINE IN THE REGULATION OF HEPATIC TYROSINE TRANSAMINASE ACTIVITY.
062327 03-03

THE PRACTICAL USE OF HIGHER NERVOUS ACTIVITY DATA IN THE PHARMACOTHERAPY OF PSYCHOSES.
062664 03-08

EFFECTS OF MORPHINE ON RENSHAW CELL ACTIVITY.
064100 04-03

VALIDITY OF ANTAGONISM OF DIFFERENT EFFECTS OF RESERPINE AS TEST FOR ANTIDEPRESSANT ACTIVITY.
064413 04-03

STRUCTURE-ACTIVITY RELATIONSHIP OF FOUR TETRAHYDROCANNABINOLS AND THE PHARMACOLOGICAL ACTIVITY OF FIVE SEMI-PURIFIED EXTRACTS OF CANNABIS-SATIVA.
064417 04-04

EFFECTS OF DISULFIRAM AND DIETHYLDITHIOCARBAMATE ON SPONTANEOUS LOCOMOTOR ACTIVITY AND BRAIN CATECHOLAMINE LEVELS IN MICE.
064590 04-04

UNIT ACTIVITY IN PREMARIN INDUCED CORTICAL EPILEPTOGENIC FOCI.
066187 05-03

PERINATAL DEVELOPMENT OF DRUG METABOLIZING ENZYME ACTIVITY IN SWINE.
066368 05-03

ELECTRICAL IMPEDANCE CHANGES IN MANY SITES OF BRAIN IN PARADOXICAL SLEEP, ANESTHESIA AND ACTIVITY.
066474 05-03

CORRELATION BETWEEN ACTIVITY AND ELECTRONIC STATE OF HALLUCINOGENIC AMPHETAMINES.
067199 06-06

INVESTIGATIONS ON THE SPECIFICITY OF THE SO-CALLED ANALGESIC ACTIVITY OF NON-NARCOTIC DRUGS.
067254 06-04

THE INFLUENCE OF INDOPAN ON THE HIGHER NERVOUS ACTIVITY OF DOGS.
067299 06-04

EFFECT OF AN ORAL CONTRACEPTIVE ON SPONTANEOUS RUNNING ACTIVITY OF FEMALE RATS.
067716 06-04

EFFECTS OF PRENATAL ADMINISTRATION OF PSYCHOTROPIC DRUGS TO RATS ON BRAIN BUTYRYLCHOLINESTERASE ACTIVITY AT BIRTH.
067980 06-03

STUDIES ON INTERACTIONS INVOLVING ANTIDEPRESSIVE AND OTHER DRUGS WITH TETRABENAZINE AND NORADNAMINE ON LOCOMOTOR

ACTIVITY IN MICE, INCLUDING DETAILS OF THE EXPERIMENTAL DESIGN AND STATISTICAL ANALYSIS.
069077 06-04
THE EFFECT OF VARIOUS NEUROHUMORAL MODULATORS ON THE ACTIVITY OF MORPHINE AND THE NARCOTIC ANTAGONISTS IN THE TAIL-FLICK AND PHENYLQUINONE TESTS.
069594 07-04
EFFECTS OF AGROCLAVINE ON WHEEL TURNING ACTIVITY IN MICE.
069610 07-04
MONOAMINES AND THE REACTIVITY OF RATS WITH DIFFERENT TYPES OF HIGHER NERVOUS ACTIVITY.
070953 07-03
IMPROVEMENT OF LEARNING IN THE AGED BY MODIFICATION OF AUTONOMIC NERVOUS SYSTEM ACTIVITY.
071336 07-14
CENTRAL NEUROTROPIC ACTIVITY OF AMINOPROPYL AND AMINOPROPIONYLIC DERIVATIVES OF IMINOBENZYL AND DIPHENYLAMINE AND ITS RELATION TO IONIZATION CONSTANTS.
072580 08-03
EFFECTS OF 6-HYDROXYDOPAMINE ON CNS CATECHOLAMINES, SPONTANEOUS MOTOR ACTIVITY AND AMPHETAMINE INDUCED HYPERACTIVITY IN RATS.
074053 08-04
THE EFFECT OF ESERINE ON THE EFFERENT NEURONAL ACTIVITY IN THE CERVICAL SYMPATHETIC OF THE RAT.
074133 08-03
THE EFFECT OF ETHANOL AND AMPHETAMINE MIXTURES ON THE ACTIVITY OF RATS IN A Y-MAZE.
074149 08-04
EVALUATION OF THE THERAPEUTIC EFFECT OF NEUROLEPTICS UPON THE HIGHER NERVOUS ACTIVITY IN SCHIZOPHRENIA.
075103 08-14
EFFECTS OF ELYMOCLAVINE ON WHEEL TURNING ACTIVITY IN MICE.
075196 08-04
THE EFFECTS OF NICOTINE ADMINISTRATION IN UTERO UPON ACTIVITY IN THE RAT.
075239 08-04
EFFECT OF PITUITARY AND ACTH ON THE MAINTENANCE OF BASAL TYROSINE HYDROXYLASE ACTIVITY IN THE RAT ADRENAL GLAND.
075714 08-03
EFFECT OF HIPPOCAMPAL AND NEOCORTICAL ABLATION ON SCOPOLAMINE INDUCED ACTIVITY IN THE RAT.
075848 09-04
EFFECTS OF METHYLPHENIDATE ON ACTIVITY AND REACTIONS OF NOVELTY IN RATS.
076066 09-04
MODULATION OF FOOD INTAKE AND LOCOMOTOR ACTIVITY IN FEMALE RATS BY DIENCEPHALIC HORMONE IMPLANTS.
076080 09-04
EATING, DRINKING AND SPONTANEOUS ACTIVITY IN RATS AFTER THE ADMINISTRATION OF CHLORPROMAZINE.
079999 09-04
CLINICAL OBSERVATIONS ON THE THERAPEUTIC ACTIVITY OF FLUPENTHIXOL IN THE TREATMENT OF CHRONIC SCHIZOPHRENIA.
080143 09-08
NEURONAL AND HORMONAL CONTROL OF TYROSINE HYDROXYLASE AND PHENYLETHANOLAMINE N-METHYLTRANSFERASE ACTIVITY.
080352 09-03
FURTHER STUDIES ON THE LONG-LASTING ANTIMETRAZOL ACTIVITY OF DIAZEPAM IN MICE.
081106 09-03
METHYLPHENIDATE AND THIORIDAZINE: LEARNING, REACTION TIME, ACTIVITY, AND CLASSROOM BEHAVIOR IN DISTURBED CHILDREN.
081631 10-14
PHARMACOLOGIC ACTIVITY OF A NEW CLASS OF AGENTS WHICH SELECTIVELY INHIBIT AGGRESSIVE BEHAVIOR IN RATS.
082398 10-04
SOME BEHAVIOURAL EFFECTS OF VARIABLES WHICH INFLUENCE THE GENERAL LEVEL OF ACTIVITY OF RATS.
085204 10-04
EFFECTS OF NEUROLEPTICS ON THE CEREBRAL ELECTRICAL ACTIVITY OF LABORATORY ANIMALS: PRESENTATION OF A MODEL DESIGN FOR NEUROPHARMACOLOGICAL EXPERIMENTS.
085337 10-03
EFFECTS OF DRUGS ON SOMATIC ACTIVITY AND HUMAN RESPONSES.
085757 10-13
MOTOR AND PSYCHOMOTOR ACTIVITY AND STRIATAL MONOAMINES.
086349 10-03
NEURALLY MEDIATED INCREASE IN DOPAMINE-BETA-HYDROXYLASE ACTIVITY (UNPUBLISHED PAPER).
088376 10-03
SUBSTITUTED BENZAMIDES WITH POTENTIAL CNS DEPRESSANT AND HYPOTENSIVE ACTIVITY.
089435 11-02
NEW METHOD FOR ASSAYING ANTIAPOMORPHINE ACTIVITY IN PIGEONS.
089437 11-06
EFFECT OF PHENOTHIAZINES ON MELANOMA TYROSINASE ACTIVITY.
089998 11-05
EFFECTS OF DRUGS ACTING ALONE AND IN COMBINATION ON THE MOTOR ACTIVITY OF INTACT MICE.
090139 11-03
USES AND LIMITATIONS OF PHOTOCELL ACTIVITY CAGES FOR ASSESSING EFFECTS OF DRUGS.
090423 11-06
INHIBITORS OF MONOAMINE OXIDASE VI: EFFECTS OF SUBSTITUTION ON INHIBITORY ACTIVITY OF 6 (OR 8) SUBSTITUTED BETA-CARBOLINES.
090426 11-01
EFFECT OF HYPOPHYSECTOMY ON ADRENAL DOPAMINE-BETA-HYDROXYLASE ACTIVITY IN THE RAT (UNPUBLISHED PAPER).
092383 11-03
INTERACTIONS BETWEEN THE EFFECTS OF CHLORDIAZEPOXIDE AND AMPHETAMINE ON FOOD INTAKE AND SPONTANEOUS MOTOR ACTIVITY IN THE RAT.
092692 11-04
THE SYNTHESIS AND BIOLOGICAL ACTIVITY OF (-)-DELTA9(11)-TRANS TETRAHYDROCANNABINOL; A NEW PROCEDURE FOR THE CLEAVAGE OF PHENYL METHYL ETHERS (UNPUBLISHED PAPER).
092888 11-01
AMNESIA AND BRAIN SEIZURES ACTIVITY IN MICE: EFFECTS OF DIETHYL-ETHER ANESTHESIA PRIOR TO ELECTROSHOCK STIMULATION.
097952 11-04
HABITUATION AND ACTIVITY AS AFFECTED BY CYCLOHEXIMIDE.
097953 11-04
ON THE ROLE OF BRAIN CATECHOLAMINES IN MOTOR ACTIVITY: EXPERIMENTS WITH INHIBITORS OF SYNTHESIS AND OF MONOAMINE OXIDASE.
097960 11-04
THIOTHIXENE: ITS RANGE OF THERAPEUTIC ACTIVITY.
097985 11-11
COMPARATIVE STUDY OF CNS STIMULATORY ACTIVITY AND ANOREXIGENIC POTENCY OF PHENYLETHYLAMINE DERIVATIVES. (PH.D.DISSERTATION).
103710 12-04
DOES KYNURENINE POSSESS ANY NEUROTROPIC ACTIVITY
105621 12-04
EFFECT OF AGENTS INTERACTING WITH CHOLINOREACTIVE AND ADRENOREACTIVE SYSTEMS ON EPILEPTIFORM ACTIVITY IN THE HIPPOCAMPUS OF RABBITS.
110631 12-03
UNCONDITIONED REFLEX ACTIVITY IN THE RAT SUFFERING FROM EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY AND THE THERAPEUTIC EFFECT OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126051 12-04
DECREASE OF SPONTANEOUS MOTILITY IN EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY AND THE PROTECTIVE ACTIVITY OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126052 12-04
EFFECT OF CHLORPROMAZINE ON CONDITIONED REFLEXES AND ANTAGONISTIC ACTIVITY OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126054 12-04

ACUTE
ALTERATIONS OF D-AMPHETAMINE SULFATE LETHALITY AND BODY TEMPERATURE IN MICE DURING ACUTE ALTITUDE EXPOSURE.
040582 01-03
THE EFFECT OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON BRAIN ACETYLCHOLINE LEVELS IN RAT.
041913 01-03
BEHAVIORAL IMPAIRMENT IN ADULT RATS FOLLOWING ACUTE ZINC DEFICIENCY.
045526 01-04
COMBINED ADRENAL AND THYROID DEFICIENCY (SCHMIDTS SYNDROME) PRESENTING AS AN ACUTE PSYCHOSIS.
056350 02-15
ACUTE ORGANIC PSYCHOSIS DUE TO TALWIN (PENTAZOCINE).
058951 02-15
THE EFFECT OF ACUTE ADMINISTRATION OF (META-TRIFLUOROMETHYL-PHENYL)-1-(BENZOYLOXY) ETHYLAMINO-2-PROPANE (780-SE) AND FENFLURAMINE ON HUMAN SLEEP.
063978 04-14
THE USE OF MOLINDONE IN THE TREATMENT OF ACUTE PSYCHOTIC STATES: COMPARISON OF TWO DOSAGE SCHEDULES.
064286 04-08
EFFECT OF IMIPRAMINE AND CHLORIMIPRAMINE ON AN ACUTE INSTRUMENTAL TRACE CONDITIONED REFLEX IN RATS.
064415 04-04
EFFECT OF ACUTE HYPOXIA ON BRAIN SENSITIVITY AND METABOLISM OF BARBITURATES IN MICE.
064480 04-03
ACUTE ETHCHLORVYNOL (PLACIDYL) INTOXICATION.
064623 04-15
THE TREATMENT OF ACUTE ALCOHOL INTOXICATION AND WITHDRAWAL.
065187 05-13
DIAGNOSIS AND THERAPY OF ACUTE WITHDRAWAL FROM ALCOHOL.
065193 05-13

STOOL PORPHYRINS IN ACUTE INTERMITTENT AND HEREDITARY COPROPORPHYRIA: ADVERSE EFFECTS OF TRANQUILIZERS.
066318 05-15

THE EFFECT OF SERUM FROM ACUTE SCHIZOPHRENIC PATIENTS ON RABBIT BRAIN AMINES.
066713 05-03

AN ANALYSIS OF 310 CASES OF ACUTE HIGH-DOSE METHAMPHETAMINE TOXICITY IN HAIGHT-ASHBURY.
067218 06-15

ACUTE TOXICITY OF HEROIN, ALONE AND IN COMBINATION WITH COCAINE OR QUININE.
068167 06-05

LITHIUM NEUROTOXICOLOGIC EFFECTS: 1. ACUTE PHASE (PRELIMINARY OBSERVATIONS).
069312 06-05

INITIAL AND INTERVAL TREATMENT OF ACUTE PSYCHOSES WITH INTRAVENOUS INJECTION OF INOFAL.
073708 08-09

ACUTE CEREBRAL DISORDERS AFTER HIGH DOSES OF OXYQUINOLINE DERIVATIVES.
073900 08-15

PRINCIPAL ELECTROENCEPHALOGRAPHIC CHANGES OBSERVED DURING ACUTE INTOXICATION BY NEUROLEPTICS.
075112 08-13

PLASMA FREE FATTY ACIDS BEFORE AND AFTER AN INTRAVENOUS INSULIN INJECTION IN ACUTE SCHIZOPHRENIC MEN.
075212 08-08

CRISES AND LIFE CHANGES PRECEDING THE ONSET OR RELAPSE OF ACUTE SCHIZOPHRENIA: CLINICAL ASPECTS.
075304 08-08

A CONTROLLED COMPARATIVE STUDY OF FLUPHENAZINE AND FLUPHENAZINE ENANTHATE IN ACUTE AND CHRONIC PSYCHOTIC PATIENTS.
075881 09-08

CLINICAL CONSIDERATIONS ABOUT THE TREATMENT OF VARIOUS ACUTE PSYCHOTIC STATES WITH THIOTHIXENE.
079746 09-11

ACUTE LITHIUM POISONING.
079914 09-15

ACTION OF THE SALTS OF OXYGLURIC ACID ON ACUTE ALCOHOL INTOXICATION IN MAN (EXPERIMENTAL STUDY).
086005 10-11

ACUTE ORAL TOXICITY OF CANNABINOIDS IN VARIOUS SPECIES (UNPUBLISHED PAPER).
088412 10-05

REMARKS ON THE USE OF CLOMIPRAMINE (ANAFRANIL) IN CERTAIN ACUTE DELIRIANT PSYCHOSES (WITHOUT A CLEAR DEPRESSIVE ELEMENT).
088438 10-14

CLINICAL AND EEG APPEARANCES OF ACUTE DRUG INTOXICATION DUE TO CHLORALOSE.
088568 10-15

THE EFFECTS OF ACUTE AND PROLONGED LITHIUM TREATMENT ON THE DISTRIBUTION OF ELECTROLYTES, POTASSIUM AND SODIUM.
088614 10-03

MEASUREMENT OF THE DISTRIBUTION OF HYPNOTICS AND CEREBRAL FUNCTION IN ACUTE INTOXICATIONS BY PH.
089040 10-17

A COMPARATIVE STUDY OF THIOTHIXENE AND TRIFLUOPERAZINE IN THE ACUTE PHASE OF SCHIZOPHRENIA.
089159 10-08

EVALUATING CHANGES IN SYMPTOMS DURING ACUTE ALCOHOL WITHDRAWAL.
094978 11-11

EFFECTS OF AN ACUTE STRESS OF FOREBRAIN 5-HYDROXYTRYPTAMINE (5-HT) METABOLISM IN CNS LESIONED AND DRUG PRETREATED RATS.
095671 11-04

DOUBLE-BLIND STUDY OF CLOPENTHIXOL AND CHLORPROMAZINE IN ACUTE HOSPITALIZED SCHIZOPHRENICS.
098048 11-08

ACUTE POISONING WITH PSYCHOTROPIC DRUGS.
100518 12-15

PREMORBID ADJUSTMENT, PARANOID STATUS, AND PATTERNS OF RESPONSE TO PHENOTHIAZINE IN ACUTE SCHIZOPHRENIA.
103255 12-08

LITHIUMS POSITION AMONG ANTIDEPRESSANTS IN THE TREATMENT OF ACUTE ENDOGENOUS AND INVOLUTIONAL DEPRESSIONS.
106777 12-09

THE SAFETY TEST OF L-DOPA. I. ACUTE AND SUBACUTE TOXICITY OF L-DOPA IN EXPERIMENTAL ANIMALS.
114837 12-05

COMPARISON OF DITRAN INTOXICATION AND ACUTE ALCOHOL PSYCHOSES.
121083 12-14

TWO CASES OF ACUTE P-CHLORONITROBENZENE POISONING SEQUELAE.
129753 12-15

**ACUTELY**

COMPARATIVE EFFICACY OF THIOTHIXENE CAPSULES AND CONCENTRATE IN ACUTELY SCHIZOPHRENIC PATIENTS.
063599 04-08

**ADAMANTYL**

SYNTHESIS OF ADAMANTYL ESTERS.
073265 08-01

**ADAPTATION**

DRUGS AND REALITY IN CAPTIVE SOCIETY. SOME OBSERVATIONS ON CHEMICAL ADAPTATION.
064091 04-17

PSYCHOPHARMACOLOGY AND GENERAL ADAPTATION SYNDROME.
065346 05-17

**ADAPTIVE**

PHARMACOLOGICAL REDUNDANCY AS AN ADAPTIVE MECHANISM IN THE CENTRAL NERVOUS SYSTEM.
056113 02-13

**ADDICT**

USING METHADONE TO TREAT THE HEROIN ADDICT.
062789 03-07

**ADDICTING**

ADDICTING DRUGS.
079256 09-15

**ADDICTION**

IDENTIFICATION OF NARCOTICS AND DIAGNOSIS OF THE ADDICTION. (UNPUBLISHED PAPER).
051207 02-01

PROJECT SUMMARY: LIMBIC SYSTEM LESIONS AND DRUG ADDICTION.
060636 03-03

THIN-LAYER CHROMATOGRAPHIC LABORATORY ANALYSIS IN CASES FROM A DRUG ADDICTION CENTER.
067212 06-06

SUCCESSES AND FAILURES IN METHADONE MAINTENANCE TREATMENT OF HEROIN ADDICTION IN NEW-YORK CITY. (UNPUBLISHED PAPER).
071314 07-17

PSYCHOANALYTIC EVALUATION OF ADDICTION AND HABITATION.
075300 08-13

ADDICTION AND SOCIETY.
079254 09-15

DRUG CONTROLLED ADDICTION.
079990 09-15

ABUSE OF AND ADDICTION TO DIAZEPAM.
079991 09-15

A CASE OF PHENMETRAZINE ADDICTION.
087537 10-15

PATHOPHYSIOLOGY OF NARCOTIC ADDICTION; POSSIBLE ROLES OF PROTRACTED ABSTINENCE IN RELAPSE (UNPUBLISHED PAPER).
093000 11-13

SUBJECTIVE EFFECTS OF NARCOTIC ANTAGONISTS CYCLAZOCINE AND NALORPHINE ON THE ADDICTION RESEARCH CENTER INVENTORY (ARCI).
097961 11-14

**ADDICTIVE**

ADDICTIVE PROPERTIES OF DEXTROMORPHAN DERIVATIVES.
089242 10-17

**ADDICTS**

REACTION TIMES OF METHADONE TREATED EX HEROIN ADDICTS.
062817 03-11

THE USE OF CYCLAZOCINE IN THE TREATMENT OF HEROIN ADDICTS.
068601 06-17

NONADDICTIVE PSYCHOTROPIC MEDICATION FOR IMPRISONED NARCOTIC ADDICTS.
070784 07-13

**ADDITION**

USE OF LEVODOPA MAY BE EXPANDED BY ADDITION OF MK-485 TO DRUG REGIMEN.
097284 11-09

**ADENINE**

PSYCHOPHARMACOLOGICAL ACTION OF NICOTINAMIDE ADENINE DINUCLEOTIDE.
064481 04-04

**ADENOSINE**

THE EFFECT OF CENTRALLY ACTING DRUGS ON THE CONCENTRATION OF BRAIN ADENOSINE 3PRIME,5PRIME- MONOPHOSPHATE.
043276 01-03

THE EFFECTS OF SOME PSYCHOACTIVE DRUGS ON RAT BRAIN ADENOSINE TRIPHOSPHATE LEVELS.
058988 03-03

**ADENYL-CYCLASE**

CYCLIC AMP AND ADENYL-CYCLASE IN THE DEVELOPING RAT BRAIN.
060856 03-03

**ADH**

A STUDY OF HEPATIC ALCOHOL DEHYDROGENASE INHIBITION (ADH) INDUCED BY PYRAZOL: II. THE ROLE OF LIVER ADH IN THE IN VIVO METABOLISM OF HYDROXYL COMPOUNDS.
089547 11-03

**ADJUNCT**
LITHIUM CARBONATE AS AN ADJUNCT IN THE TREATMENT OF SCHIZOPHRENIA.
067364 06-08
DEXEDRINE AS AN ADJUNCT TO APHASIA THERAPY.
101801 12-11

**ADJUNCTIVE**
THE THERAPEUTIC POTENTIAL OF LSD: ITS ADJUNCTIVE USE IN PSYCHOTHERAPY.
073852 08-12

**ADJUSTMENT**
PREMORBID ADJUSTMENT, PARANOID STATUS, AND PATTERNS OF RESPONSE TO PHENOTHIAZINE IN ACUTE SCHIZOPHRENIA.
103255 12-08

**ADJUVANTS**
ADJUVANTS TO L-DOPA FOR PARKINSONISM.
081104 09-14

**ADMINISTERED**
THE ANTAGONISM OF PHENTOLAMINE AGAINST EXOGENOUSLY ADMINISTERED AND ENDOGENOUSLY RELEASED NOREPINEPHRINE IN RABBIT AORTIC STRIPS.
040243 01-03
PERSONALITY DIFFERENCES IN THE RESPONSE TO STIMULANT DRUGS ADMINISTERED DURING A SLEEP DEPRIVED STATE.
052502 02-14
INHIBITION OF CIGARETTE SMOKING BY ORALLY ADMINISTERED NICOTINE.
066277 05-13
THE PHARMACOLOGICAL EFFECTS OF OUABAIN ADMINISTERED INTRACEREBRALLY TO CONSCIOUS MICE.
068165 06-03
MODIFICATION OF CHLORPROMAZINE METABOLISM BY SOME OTHER DRUGS FREQUENTLY ADMINISTERED TO PSYCHIATRIC PATIENTS.
071989 07-13
DELTA1-TETRAHYDROCANNABINOL, SYNHEXYL AND MARIJUANA EXTRACT ADMINISTERED ORALLY IN MAN: CATECHOLAMINE EXCRETION, PLASMA CORTISOL LEVELS AND PLATELET SEROTONIN CONTENT.
075841 08-12
CLINICOELECTROENCEPHALOGRAPHIC EVALUATION OF A NEW BENZODIAZEPINIC DERIVATIVE (RO-5-4023) ADMINISTERED ORALLY IN EPILEPTIC PATIENTS USING A DOUBLE-BLIND METHOD.
100959 12-07

**ADMINISTRATION**
EFFECTS OF CHRONIC ADMINISTRATION OF NICOTINE ON STORAGE AND SYNTHESIS OF NORADRENALINE IN RAT BRAIN.
041552 01-03
THE EFFECT OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON BRAIN ACETYLCHOLINE LEVELS IN RAT.
041913 01-03
EFFECTS OF CHRONIC POSTNATAL DRUG ADMINISTRATION ON ADULT DOMINANCE BEHAVIOR IN TWO GENERA OF MICE.
042837 01-04
INFLUENCE OF MODE AND DURATION OF PHENYLALANINE ADMINISTRATION ON BIOCHEMICAL PARAMETERS IN RATS OF VARIOUS AGES.
042840 01-03
RESPONSE DISRUPTION FOLLOWING AMPHETAMINE SELF-ADMINISTRATION AND PROGRAMMED ADMINISTRATION.
046209 01-04
EFFECTS OF RESERPINE AND DESIPRAMINE ON THE UPTAKE AND SUBCELLULAR DISTRIBUTION OF 5-HYDROXYTRYPTAMINE IN RABBIT BRAINSTEM AFTER INTRAVENOUS ADMINISTRATION OF 5-HYDROXYTRYPTOPHAN.
056610 02-03
HYPERSEXUALITY AND BEHAVIORAL CHANGES IN CATS CAUSED BY ADMINISTRATION OF P-CHLOROPHENYLALANINE.
056934 02-04
EXPERIMENTAL PSYCHOLOGICAL STUDY OF PERFORMANCE CHANGES WITH PERAZINE (TAXILAN) IN MENTALLY DISTURBED AND IN HEALTHY EXPERIMENTAL SUBJECTS FOLLOWING REGIMEN AND SINGLE DOSE ADMINISTRATION.
058235 02-11
A METHOD FOR CHRONIC INTRAVENOUS DRUG ADMINISTRATION IN SQUIRREL MONKEYS.
063725 04-06
THE EFFECT OF ACUTE ADMINISTRATION OF (META-TRIFLUOROMETHYL-PHENYL)-1-(BENZOYLOXY) ETHYLAMINO-2-PROPANE (780-SE) AND FENFLURAMINE ON HUMAN SLEEP.
063978 04-14
THE SENSITIVITY OF THE BRAIN TO BARBITURATE DURING CHRONIC ADMINISTRATION AND WITHDRAWAL OF BARBITONE SODIUM IN THE RAT.
063980 04-03
TRYPTOPHAN HYDROXYLASE CHANGES IN MIDBRAIN OF THE RAT AFTER CHRONIC MORPHINE ADMINISTRATION.
064146 04-03
CHANGES IN THE SERUM CONCENTRATION OF CHOLESTEROL, TRIGLYCERIDES AND PHOSPHOLIPIDS IN THE MOUSE AND RAT AFTER ADMINISTRATION OF EITHER CHLORCYCLIZINE OR PHENOBARBITAL.
064282 04-03
THE EFFECTS OF CHLORPROMAZINE ON ONE-TRIAL PASSIVE AVOIDANCE LEARNING IN MICE: FURTHER EXAMINATION OF PRELEARNING AND POSTLEARNING ADMINISTRATION.
064407 04-04
THE EFFECTIVENESS OF PARENTERAL ADMINISTRATION OF FLUPHENAZINE DECANOATE IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS.
065473 05-07
EFFECT OF MORPHINE ADMINISTRATION ON THE HYDROXYLATION OF STEROID HORMONES BY RAT LIVER MICROSOMES.
066366 05-03
ALDOSTERONE AND SODIUM RESPONSE TO LITHIUM ADMINISTRATION IN MAN.
066493 05-13
EFFECT OF CHRONIC ADMINISTRATION OF P-CHLOROPHENYLALANINE ON SEXUAL RECEPTIVITY OF THE FEMALE RAT.
066825 05-04
ADMINISTRATION OF A PERIPHERAL DECARBOXYLASE INHIBITOR WITH L-DOPA TO DEPRESSED PATIENTS.
067591 06-09
NOREPINEPHRINE TURNOVER AND METABOLISM IN RAT BRAIN AFTER LONG-TERM ADMINISTRATION OF IMIPRAMINE.
067687 06-03
EFFECTS OF PRENATAL ADMINISTRATION OF PSYCHOTROPIC DRUGS TO RATS ON BRAIN BUTYRYLCHOLINESTERASE ACTIVITY AT BIRTH.
067980 06-03
COMBINED ADMINISTRATION OF THIORIDAZINE AND FLUOXYMESTERONE IN THE TREATMENT OF GERIATRIC PATIENTS.
069060 06-11
STRYCHNINE EFFECTS ON DISCRIMINATION LEARNING IN MICE: EFFECTS OF DOSE AND TIME OF ADMINISTRATION.
069066 06-04
OCCURRENCE OF PERIODIC PSYCHOSES DURING PROPHYLACTIC ADMINISTRATION OF LITHIUM.
070950 07-08
SOME EXPERIENCES WITH A PREVENTIVE ADMINISTRATION OF LITHIUM SALTS IN MANIC MELANCHOLIC PSYCHOSIS.
070952 07-09
IMIPRAMINE IN CHILDHOOD ENURESIS: FURTHER STUDIES ON THE RELATIONSHIP OF TIME OF ADMINISTRATION TO EFFECT.
071946 07-11
SEXUAL BEHAVIOR OF MALE CATS AFTER ADMINISTRATION OF P-CHLOROPHENYLALANINE.
072463 08-04
DEVELOPMENT OF FIGHTING BEHAVIOR IN STARVED RATS BY CHRONIC ADMINISTRATION OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL AND CANNABIS EXTRACTS: LACK OF ACTION OF OTHER PSYCHOTROPIC DRUGS.
072531 08-04
EFFECTS OF PRENATAL ADMINISTRATION OF PSYCHOTROPIC DRUGS ON BEHAVIOR OF DEVELOPING RATS.
074830 08-04
CEREBROSPINAL FLUID 5-HYDROXYINDOLES AND BEHAVIOR AFTER L-TRYPTOPHAN AND PYRIDOXINE ADMINISTRATION TO PSYCHIATRIC PATIENTS.
074938 08-14
THE EFFECTS OF NICOTINE ADMINISTRATION IN UTERO UPON ACTIVITY IN THE RAT.
075239 08-04
AMBULATORY BEHAVIOR IN THE RAT AS A FUNCTION OF TWO METHODS OF ALCOHOL ADMINISTRATION.
075316 08-04
PREDICTION OF CHANGES IN SEVERITY OF THE SCHIZOPHRENIC SYNDROME WITH DISCONTINUATION AND ADMINISTRATION OF PHENOTHIAZINES IN CHRONIC SCHIZOPHRENIC PATIENTS: LANGUAGE AS A PREDICTOR AND MEASURE OF CHANGE IN SCHIZOPHRENIA.
075321 08-08
EFFECTS OF INSTRUCTIONS AND DRUG ADMINISTRATION ON TEMPORAL RESOLUTION OF PAIRED FLASHES.
075771 08-14
THE INFLUENCE OF SINGLE AND CHRONIC MORPHINE ADMINISTRATION ON SOME CENTRAL EFFECTS OF AMPHETAMINE AND APOMORPHINE.
075840 08-05
VISUAL THRESHOLD AS A FUNCTION OF TEST AREA AND CAFFEINE ADMINISTRATION.
076016 09-13
FURTHER PSYCHOMETRIC EVALUATION OF OLDER WOMEN – THE EFFECT OF ESTROGEN ADMINISTRATION.
078223 09-14
EATING, DRINKING AND SPONTANEOUS ACTIVITY IN RATS AFTER THE ADMINISTRATION OF CHLORPROMAZINE.
079999 09-04

EFFECTS OF CHRONIC MORPHINE ADMINISTRATION ON THE CATECHOLAMINE DEPLETION INDUCED BY RESERPINE.
081065 09-03

NOREPINEPHRINE TURNOVER IN BRAIN AFTER ADMINISTRATION OF IMIPRAMINE: ENHANCEMENT BY THYROID HORMONE.
090052 11-13

SLEEP IN PATIENTS WITH PARKINSONS DISEASE AND NORMAL SUBJECTS PRIOR TO AND FOLLOWING LEVODOPA ADMINISTRATION.
092974 11-11

INFLUENCE OF CHRONIC ADMINISTRATION OF NICOTINE ON THE TURNOVER AND METABOLISM OF NORADRENALINE IN THE RAT BRAIN.
097958 11-03

CLINICAL TESTING WITH FLUPHENAZINE DEPOT ADMINISTRATION TO SCHIZOPHRENIC PATIENTS.
101034 12-07

ADMINISTRATION OF A NEW BUTYROPHENONE DERIVATIVE, PIMOZIDE, IN THE TREATMENT OF SCHIZOPHRENIA.
123373 12-08

CHANGES OF THE BODY TEMPERATURE OF CODEINE TOLERANT RATS BY THE ADMINISTRATION OF NALORPHINE.
130427 12-03

**ADMINISTRATIONS**
THE MODIFIABILITY OF INFANTILE SHOCK TRAUMATIZATION EFFECTS BY CONTIGUOUS DRUG ADMINISTRATIONS.
060090 03-04

**ADMISSIONS**
HOSPITAL ADMISSIONS DUE TO LYSERGIC ACID DIETHYLAMIDE.
072149 07-15

**ADOLESCENT**
CONTRIBUTION TO THE STUDY OF THE ACTION OF PROPERICIAZINE ON BEHAVIORAL PROBLEMS OF THE CHILD AND THE ADOLESCENT.
086451 10-11

EFFECTS OF ATROPINE AND ESERINE ON THE ELECTROENCEPHALOGRAM, ON BEHAVIOUR AND ON LIGHT INDUCED EPILEPSY IN THE ADOLESCENT BABOON (PAPIO-PAPIO).
090157 11-04

**ADOLESCENTS**
RESULTS OBTAINED WITH PROPERICIAZIN (8-909-RP) IN THE TREATMENT OF BEHAVIOR AND CHARACTER DISTURBANCES IN CHILDREN AND ADOLESCENTS.
078730 09-14

THE USE OF PSYCHOPHARMACOLOGY IN CHILDREN AND ADOLESCENTS.
080096 09-17

MILD INSULIN HYPOGLYCEMIC TREATMENT FOR HOSPITALIZED ADOLESCENTS.
082172 10-11

ANTIAGGRESSIVE EFFECT OF LITHIUM SALTS IN SEVERE MENTALLY RETARDED ADOLESCENTS.
106776 12-14

**ADRENAL**
INHIBITORS OF ADRENAL STEROID BIOSYNTHESIS.
051122 02-17

COMBINED ADRENAL AND THYROID DEFICIENCY (SCHMIDTS SYNDROME) PRESENTING AS AN ACUTE PSYCHOSIS.
056350 02-15

PITUITARY ADRENAL FUNCTION IN THE SQUIRREL MONKEY.
075665 08-03

EFFECT OF PITUITARY AND ACTH ON THE MAINTENANCE OF BASAL TYROSINE HYDROXYLASE ACTIVITY IN THE RAT ADRENAL GLAND.
075714 08-03

PITUITARY ADRENAL ALTERATIONS AND FEAR RESPONDING.
090135 11-04

EFFECT OF HYPOPHYSECTOMY ON ADRENAL DOPAMINE-BETA-HYDROXYLASE ACTIVITY IN THE RAT (UNPUBLISHED PAPER).
092383 11-03

URINARY EXCRETION OF ADRENAL HORMONES IN MAN: EFFECTS OF ETHANOL INGESTION, AND THEIR MODIFICATION BY CHLORMETHIAZOLE.
097974 11-11

HYPOTHALAMIC PITUITARY ADRENAL AXIS.
100532 12-13

ADRENAL CORTICAL AND MEDULLARY SECRETION AND EVALUATION OF DRUGS ACTING ON THE CENTRAL NERVOUS SYSTEM.
106270 12-03

**ADRENALECTOMIZED**
ACTION OF GUANETHIDINE ON THE PRESSOR EFFECT OF ANGIOTENSIN IN ADRENALECTOMIZED DOGS.
046399 01-03

MODIFICATION OF NACL APPETITE IN THE ADRENALECTOMIZED RAT CONSEQUENT TO EXTENSIVE LICL POISONING.
061094 03-04

**ADRENALIN**
ADRENALIN AND AVOIDANCE LEARNING: PARTIAL REPLICATIONS.
075559 08-04

INFLUENCE OF AMINAZIN ON ADRENALIN, NORADRENALINE, DOPAMINE, AND DOPA EXCRETION IN HEALTHY PEOPLE AND IN THE MANIC PHASE OF THE MANIC-DEPRESSIVE PSYCHOSIS.
090355 11-03

**ADRENALINE**
SYNERGISM OF DESMETHYLIMIPRAMINE WITH RESERPINE AND 5-HYDROXYTRYPTOPHAN IN THE FROG: BRAIN SEROTONIN AND ADRENALINE AND BEHAVIOR.
098042 11-03

**ADRENERGIC**
THE ANTAGONISM OF ADRENERGIC NEURONE BLOCKADE BY AMPHETAMINE AND DEXAMPHETAMINE IN THE RAT AND GUINEA-PIG.
055322 02-03

SELECTIVE DEPLETION OF NORADRENALINE: A PROPOSED MECHANISM OF THE ADRENERGIC NEURONE BLOCKING ACTION OF BRETYLIUM.
055323 02-05

CHOLINERGIC MODULATION OF ADRENERGIC AROUSAL IN THE DEVELOPING RAT.
063688 04-04

UPTAKE AND RETENTION OF 3H-NORADRENALINE IN ADRENERGIC NERVE TERMINALS AFTER RESERPINE AND AXOTOMY.
066499 05-03

THE EFFECTS OF ADRENERGIC AND CHOLINERGIC AGENTS UPON EATING AND DRINKING IN DEPRIVED RATS.
076132 09-03

STUDIES ON ADRENERGIC MECHANISMS IN THE ACTION OF DESMETHYLIMIPRAMINE (DMI).
090421 11-04

ADRENERGIC MECHANISMS IN THE CENTRAL ACTION OF PSYCHOTROPIC DRUGS. (PH.D.DISSERTATION).
102415 12-06

ANTISEROTONIN EFFECT OF AGENTS BLOCKING THE ADRENERGIC BETA-RECEPTOR.
108694 12-03

**ADRENERGICAL**
THE ADRENERGICAL MECHANISMS OF ACTION IN ANTIDEPRESSIVE DRUGS.
073787 08-17

**ADRENOCORTICAL**
EFFECT OF LITHIUM CARBONATE THERAPY ON ADRENOCORTICAL ACTIVITY.
047954 01-09

EFFECTS OF DEXAMETHASONE ON THE DEVELOPMENT OF EMOTIONALITY AND ADRENOCORTICAL REACTIVITY.
063605 04-04

THE INFLUENCE OF LITHIUM ION ON THE ADRENOCORTICAL FUNCTION OF RATS.
089787 11-09

**ADRENOREACTIVE**
EFFECT OF AGENTS INTERACTING WITH CHOLINOREACTIVE AND ADRENOREACTIVE SYSTEMS ON EPILEPTIFORM ACTIVITY IN THE HIPPOCAMPUS OF RABBITS.
110631 12-03

**ADULT**
DECARBOXYLATION OF 3,4- DIHYDROXYPHENYLALANINE IN VARIOUS HUMAN ADULT AND FETAL TISSUES.
040105 01-13

EFFECTS OF CHRONIC POSTNATAL DRUG ADMINISTRATION ON ADULT DOMINANCE BEHAVIOR IN TWO GENERA OF MICE.
042837 01-04

BEHAVIORAL IMPAIRMENT IN ADULT RATS FOLLOWING ACUTE ZINC DEFICIENCY.
045526 01-04

EFFECTS OF SYMPATHOMIMETIC AMINES INJECTED INTO THE THIRD CEREBRAL VENTRICLE IN ADULT CHICKENS.
072030 07-03

POST-NEONATAL ANDROGENIZATION AND ADULT AGGRESSIVE BEHAVIOR IN FEMALE MICE.
081233 09-04

**ADULTS**
THE ASSESSMENT OF DRUG EFFECTS IN CHILDREN AS COMPARED TO ADULTS.
072825 08-14

THE EFFECTS OF AN AMPHETAMINE ON MEASURES OF INTELLIGENCE AND LEARNING IN MENTALLY RETARDED ADULTS. (PH.D.DISSERTATION).
103152 12-14

**ADVANTAGE**
AMINOGLUTETHIMIDE: A SIDE-EFFECT TURNED TO THERAPEUTIC ADVANTAGE.
066873 05-15

**ADVANTAGES**
ADVANTAGES AND INDICATIONS FOR MODITEN-RETARD.
088998 10-17

**ADVERSE**
STOOL PORPHYRINS IN ACUTE INTERMITTENT AND HEREDITARY COPROPORPHYRIA: ADVERSE EFFECTS OF TRANQUILIZERS.
066518 05-15

ADVERSE EFFECTS WITH CLOMACRAN.
067174 06-15
ADVERSE MARIJUANA REACTIONS: A CRITICAL EXAMINATION OF THE LITERATURE WITH SELECTED CASE MATERIAL.
069613 07-15
NARCOTIC ANALGESICS -- II. ADVERSE EFFECTS.
071929 07-15
ADVERSE REACTIONS.
100513 11-15

**AFFECTIVE**
LITHIUM CARBONATE FOR AFFECTIVE DISORDERS. I. CLINICAL PHARMACOLOGY AND TOXICOLOGY.
047831 01-09
URINARY CYCLIC AMP IN AFFECTIVE ILLNESS.
059054 03-09
PROPHYLACTIC LITHIUM: A DOUBLE-BLIND TRIAL IN RECURRENT AFFECTIVE DISORDERS.
060263 03-09
METHODOLOGICAL PROBLEMS OF PROPHYLACTIC TRIALS IN RECURRENT AFFECTIVE DISORDERS.
060266 03-09
LITHIUM PROPHYLAXIS IN RECURRENT AFFECTIVE DISORDERS.
060267 03-09
AFFECTIVE DISORDERS: PROGRESS, BUT SOME UNRESOLVED QUESTIONS REMAIN.
061682 03-09
NEUROCHEMICAL STUDIES OF THE AFFECTIVE DISORDERS: THE PHARMACOLOGICAL BRIDGE.
061683 03-09
THE VA-NIMH STUDY OF LITHIUM IN AFFECTIVE DISORDERS.
063607 04-09
LITHIUM CARBONATE IN AFFECTIVE DISORDERS.
064232 04-17
INDIVIDUAL VARIATION IN AFFECTIVE RESPONSES TO TASTE STIMULI.
066710 05-14
AFFECTIVE ILLNESS AND CYCLIC AMP EXCRETION.
071972 07-13
CATECHOLAMINE METABOLISM IN AFFECTIVE DISORDERS -- III. MHPG AND OTHER CATECHOLAMINE METABOLITES IN PATIENTS TREATED WITH LITHIUM CARBONATE.
075410 08-09
PROPHYLACTIC LITHIUM IN RECURRENT AFFECTIVE DISORDERS: A FOUR YEAR STUDY.
081152 09-09
THE USE OF LITHIUM SALTS FOR THE PREVENTION OF AFFECTIVE ATTACKS.
096512 11-09
LONG-TERM DRUG THERAPY IN AFFECTIVE DISORDERS: THEORETICAL AND METHODOLOGICAL ISSUES IN CURRENT RESEARCH ON LITHIUM.
106765 12-09
STUDIES ON THE COURSE OF RECURRENT ENDOGENOUS AFFECTIVE DISORDERS.
106766 12-09
PROPHYLACTIC ACTION OF LITHIUM SALTS AND THYROID HORMONES ON SYMPTOMS OF MANIC-DEPRESSIVE AND AFFECTIVE PSYCHOSES: CLINICAL AND EXPERIMENTAL RESULTS.
106774 12-09
LITHIUM AS A THERAPEUTIC AND PREVENTIVE DRUG IN AFFECTIVE DISORDERS.
109723 12-09
A SUPPLEMENT TO CLINICAL EVALUATION OF THIOTHIXENE WITH SPECIAL REFERENCE TO THE TREATMENT OF AFFECTIVE PSYCHOSES.
129452 12-09

**AGE**
JUMPING ACTIVITY INDUCED BY SODIUM 5-(1,3 DIMETHYLBUTYL)-5 ETHYL BARBITURATE. II. THE EFFECTS OF AGE DIFFERENCE.
058985 03-04
THE EFFECT OF MAGNESIUM PEMOLINE, TRICYANOAMINOPROPENE AND D-AMPHETAMINE ON DISCRIMINATED AVOIDANCE PERFORMANCE IN RATS AS A FUNCTION OF AGE.
076133 09-04
CONTROLLED INVESTIGATION WITH CINNARIZIN IN THE TREATMENT OF DEMENTIA CONDITIONS IN OLD AGE.
089108 10-11
DEPRESSIVE STATES OF OLD AGE AND TREATMENT OF THEM.
111018 12-09

**AGED**
PSEUDO-DEMENTED, CONVULSIVE CURABLE DEPRESSION OF THE AGED.
062347 03-09
BEER SOCIOTHERAPY CAN BENEFIT AGED MENTAL PATIENTS.
064145 04-11
IMPROVEMENT OF LEARNING IN THE AGED BY MODIFICATION OF AUTONOMIC NERVOUS SYSTEM ACTIVITY.
071336 07-14
RESULTS OF THE MEDICAL TREATMENT IN AGED PATIENTS WITH CEREBRAL ORGANIC DISTURBANCES.
087336 10-11
PSYCHIATRIC DRUG USE AND ABUSE IN THE AGED.
090428 11-17
PHARMACOLOGICAL ASSOCIATION OF THIORIDAZINE HYDERGINE IN PSYCHOEMOTIONAL TROUBLES OF THE AGED.
091138 11-14

**AGES**
INFLUENCE OF MODE AND DURATION OF PHENYLALANINE ADMINISTRATION ON BIOCHEMICAL PARAMETERS IN RATS OF VARIOUS AGES.
042840 01-03
TOXICITY, NARCOTIC EFFECT, CONCENTRATION AT END OF ANESTHESIA, ELIMINATION FROM BLOOD AND BIOTRANSFORMATION OF HEXOBARBITAL IN RATS OF VARIOUS AGES FOLLOWING SLEEP INDUCTION WITH BARBITAL AND AFTER.
058987 03-05
A COMPARISON OF SOME EFFECTS OF AMPHETAMINE IN RATS OF DIFFERENT AGES.
088587 10-03

**AGGREGATED**
EFFECT OF DIETHYLDITHIOCARBAMATE ON THE TOXICITY OF AMPHETAMINE IN AGGREGATED MICE.
062937 03-04
AMPHETAMINE TOXICITY AND ENDOGENOUS NORADRENALINE CONCENTRATIONS IN ISOLATED AND AGGREGATED MIC
074146 08-05

**AGGRESSION**
DRUGS AND AGGRESSION.
055628 02-14
STRAIN DIFFERENCES IN MORPHINE WITHDRAWAL INDUCED AGGRESSION IN RATS.
060857 03-03
EFFECT OF LITHIUM ON FOOT SHOCK AGGRESSION IN RATS.
062777 03-04
ALTERATIONS IN BRAIN SENSITIVITY AND BARBITURATE METABOLISM UNRELATED TO AGGRESSION IN SOCIALLY DEPRIVED MICE.
069052 06-03
AROUSAL, ANXIETY, AGGRESSION, AND ATTITUDE CHANGE.
070352 07-14
REDIRECTED AGGRESSION AND GONADAL HORMONES IN CAPTIVE RHESUS MONKEYS (MACACA-MULATTA).
075829 08-04
INCREASED AGGRESSION AMONG GROUPED MALE MICE FED CHLORDIAZEPOXIDE.
081098 09-04

**AGGRESSIVE**
A COMPARISON OF THE EFFECTS OF SOME BENZODIAZEPINES AND OTHER DRUGS ON AGGRESSIVE AND EXPLORATORY BEHAVIOUR IN MICE AND RATS.
040581 01-04
CIRCADIAN RHYTHM FOR EXPERIMENTALLY INDUCED AGGRESSIVE BEHAVIOR IN MICE.
058383 02-03
NEUROCHEMICAL EFFECTS OF IMIPRAMINE AND AMPHETAMINE IN AGGRESSIVE MOUSE KILLING (MURICIDAL) RATS.
064056 04-03
LABORATORY EVALUATION OF AGGRESSIVE BEHAVIOR OF THE GRASSHOPPER MOUSE (ONYCHOMYS).
064260 04-04
AGGRESSIVE BEHAVIOR OF RATS INDUCED BY MESORGYDINE (LYSENYL SPOFA).
070949 07-04
THE EFFECT OF ANTIANDROGENS ON AGGRESSIVE BEHAVIOR IN THE GERBIL.
081159 09-04
POST-NEONATAL ANDROGENIZATION AND ADULT AGGRESSIVE BEHAVIOR IN FEMALE MICE.
081233 09-04
PHARMACOLOGIC ACTIVITY OF A NEW CLASS OF AGENTS WHICH SELECTIVELY INHIBIT AGGRESSIVE BEHAVIOR IN RATS.
082398 10-04
AGGRESSIVE BEHAVIOUR IN CHICKS INDUCED BY TRICYCLIC ANTIDEPRESSANTS.
090420 11-04
LESIONS IN CORPUS-STRIATUM AND CORTEX OF RAT BRAINS AND THE EFFECT ON PHARMACOLOGICALLY INDUCED STEREOTYPED, AGGRESSIVE AND CATALEPTIC BEHAVIOUR.
091127 11-04

**AGING**
THE EFFECT OF A NEW METABOLIC CEREBRAL STIMULANT, CYPRODEMANOL, IN PSYCHIATRIC ASPECTS OF AGING.
089055 10-11

**AGITATED**
RX FOR AGITATED DEPRESSION.
079355 09-03

**AGONISTIC**
THE ACTION OF TRYPTAMINE ON THE DOG SPINAL CORD AND ITS RELATIONSHIP TO THE AGONISTIC ACTIONS OF LSD-LIKE PSYCHOTOGENS.
090422 11-03

**AGRANULOCYTOSIS**
AN UNUSUAL CASE OF CHLORPROMAZINE AGRANULOCYTOSIS.
089443 11-15

**AGROCLAVINE**
EFFECTS OF AGROCLAVINE ON WHEEL TURNING ACTIVITY IN MICE.
069610 07-04

**AHR-1118**
PRECLINICAL EVALUATION OF AHR-1118. A POTENTIAL ANTIDEPRESSANT DRUG.
082051 10-03

**AHR-1900**
A PILOT STUDY OF AHR-1900 IN CHRONIC SCHIZOPHRENIC PATIENTS.
072145 07-08

**AID**
A DOUBLE-BLIND EVALUATION OF CAPURIDE (PACINOX) AS A PRESURGICAL AID TO SLEEP.
058371 02-14

SKIN LESIONS AS A DIAGNOSTIC AID IN BARBITURATE POISONING.
067926 06-15

LSD AS A DIAGNOSTIC AID (UNPUBLISHED PAPER).
085893 10-12

LSD AS A DIAGNOSTIC AID.
138597 12-08

**AIRWAY**
THE INTERACTION OF PSYCHOLOGIC STIMULI AND PHARMACOLOGIC AGENTS ON AIRWAY REACTIVITY IN ASTHMATIC SUBJECTS.
063515 03-13

**AKINESIS**
AKINESIS FOLLOWING STEREOTACTIC SURGERY FOR PARKINSONISM -- THE USE OF L-DOPA.
077404 09-16

**ALARM**
HALLUCINOGENS AND NARCOTICS ALARM PUBLIC.
057978 02-15

**ALBINO**
THE CATECHOLAMINE CONTENT IN THE BRAINSTEM OF ALBINO RATS IN THE DEVELOPMENT OF TOLERANCE TO TRYPHTAZINE.
073681 08-03

A STUDY OF PHARMACODYNAMICS IN PERIODIC CONDITIONAL PROCESSES IN ALBINO RATS.
112003 12-04

**ALCOHOL**
THE EFFECTS OF ALCOHOL ON VISUAL AND SOMATO-SENSORY EVOKED RESPONSES.
056925 02-14

INTERACTIONS BETWEEN ALCOHOL AND DRUGS.
057032 02-04

IMPAIRMENT OF SHOCK AVOIDANCE LEARNING AFTER LONG-TERM ALCOHOL INGESTION IN MICE.
058492 02-04

THE REVERSAL OF DEVELOPED TOLERANCE TO PENTOBARBITAL BY ETHYL ALCOHOL.
058995 03-03

PSYCHOLOGICAL STUDIES OF MARIJUANA AND ALCOHOL IN MAN.
064416 04-12

THE TREATMENT OF ACUTE ALCOHOL INTOXICATION AND WITHDRAWAL.
065187 05-13

DIAGNOSIS AND THERAPY OF ACUTE WITHDRAWAL FROM ALCOHOL.
065193 05-13

STUDIES ON DAMAGE TO THE LIVER BY ALCOHOL.
067130 06-11

INTERACTION BETWEEN INTRAVENOUS ALCOHOL AND SOME SEDATIVES AND TRANQUILLIZERS.
067607 06-03

ALCOHOL DRUG INTERACTIONS.
068412 06-13

ELECTROGRAPHIC AND BEHAVIORAL EFFECTS OF DIAZEPAM DURING ALCOHOL WITHDRAWAL STAGE IN CATS.
072033 07-04

AMBULATORY BEHAVIOR IN THE RAT AS A FUNCTION OF TWO METHODS OF ALCOHOL ADMINISTRATION.
075316 08-04

OPTIMAL THERAPY OF THE ALCOHOL WITHDRAWAL STATE.
078429 09-17

ALCOHOL AND NARCOLEPSY.
078933 09-14

ACTION OF THE SALTS OF OXYGLURIC ACID ON ACUTE ALCOHOL INTOXICATION IN MAN (EXPERIMENTAL STUDY).
086005 10-11

THE EFFECT OF MEDICATIONS ON ALCOHOL METABOLISM.
086788 10-17

THE EFFECT OF MEDICATION ON THE EFFECT OF ALCOHOL.
086844 10-17

A STUDY OF HEPATIC ALCOHOL DEHYDROGENASE INHIBITION (ADH) INDUCED BY PYRAZOL: II. THE ROLE OF LIVER ADH IN THE IN VIVO METABOLISM OF HYDROXYL COMPOUNDS.
089547 11-03

A STUDY OF HEPATIC ALCOHOL DEHYDROGENASE INHIBITION INDUCED BY PYRAZOL: I. IN VIVO ACTION ON ETHANOL AND 2-PHENYLETHANOL.
089548 11-03

EFFECT OF FRUCTOSE ON ALCOHOL CONCENTRATIONS IN THE BLOOD OF MAN.
092004 11-11

ANTIEPILEPTIC DOSING AFTER EXCESSIVE ALCOHOL INTAKE.
093919 11-11

CLINICAL AND PHARMACOLOGICAL CONTRIBUTION TO THE STUDY OF ALCOHOL IMIPRAMINE AND ALCOHOL THIOPROPERAZINE ASSOCIATIONS.
094305 11-11

EVALUATING CHANGES IN SYMPTOMS DURING ACUTE ALCOHOL WITHDRAWAL.
094978 11-11

ALCOHOL AS A DISCRIMINATIVE STIMULUS IN THE CONDITIONED EMOTIONAL RESPONSE. (PH.D.DISSERTATION).
103350 12-04

COMPARISON OF DITRAN INTOXICATION AND ACUTE ALCOHOL PSYCHOSES.
121083 12-14

**ALCOHOLEMIA**
PSYCHOMOTOR REACTIONS TO A SLIGHT ALCOHOLEMIA. A COMPARATIVE STUDY ON DRINKERS AND NORMAL INDIVIDUALS.
085043 10-15

**ALCOHOLIC**
FIELD DEPENDENCE AS A PREDICTOR OF ALCOHOLIC THERAPY DROP-OUTS.
052455 02-11

A COMPARISON OF SHORT-TERM TREATMENT EFFECTS OF INTRAVENOUS SODIUM AMYTAL METHEDRINE AND LSD IN THE ALCOHOLIC.
062934 03-11

TOFRANIL IN THE TREATMENT OF POST ALCOHOLIC DEPRESSIONS.
063588 03-09

HABITUATION TO CHLORDIAZEPOXIDE IN AN ALCOHOLIC POPULATION.
074732 08-11

THE FUNCTION OF MUSIC IN LSD THERAPY FOR ALCOHOLIC PATIENTS.
075191 08-12

SUPPRESSING WITHDRAWAL CONVULSIONS BY DEPAKINE IN ALCOHOLIC DETOXIFICATION CURES.
079858 09-11

**ALCOHOLICS**
PSYCHOTOMIMETIC PROPERTIES AND THERAPEUTIC POTENTIALS OF DEXOXADROL ON CONVALESCING ALCOHOLICS.
058448 02-12

THE INFLUENCE OF CENTROPHENOXINE (LUCIDRIL) ON LEARNING AND MEMORY IN ALCOHOLICS.
062800 03-14

**ALCOHOLISM**
LYSERGIC ACID DIETHYLAMIDE AS A VARIABLE IN THE HOSPITAL TREATMENT OF ALCOHOLISM: A FOLLOW-UP STUDY.
052476 02-11

GROUP TREATMENT OF CHRONIC ALCOHOLISM WITH LSD-25: STUDY II.
057480 02-14

COMBINED USE OF DISULFIRAM AND METRONIDAZOLE IN TREATMENT OF ALCOHOLISM.
058589 02-15

PRELIMINARY CLINICAL OBSERVATIONS CONCERNING THE TREATMENT WITH METRONIDAZOLE IN CHRONIC ALCOHOLISM.
062866 03-11

FLUID AND ELECTROLYTE ABNORMALITIES IN ALCOHOLISM.
063591 03-03

A CONTROLLED STUDY OF LSD TREATMENT IN ALCOHOLISM AND NEUROSIS.
063873 04-12

DRUG THERAPY IN ALCOHOLISM.
065188 05-13

HALLUCINOGENIC DRUGS IN THE TREATMENT OF ALCOHOLISM: A TWO-YEAR FOLLOW-UP.
075290 08-12

THE PHARMACOLOGICAL APPROACH TO ALCOHOLISM -- PART 2.
081072 09-17

TEST OF PEMOLINUM IN COMPLEX TREATMENT OF ALCOHOLISM.
086958 10-11

ELECTROCARDIOGRAPHIC DATA IN CHRONIC ALCOHOLISM BEFORE, DURING AND AFTER TREATMENT WITH TETRAETHYLTHIURAM DISULPHIDE.
092481 11-14

EFFECTS OF PROPRANOLOL (INDERAL) ON PSYCHIATRIC SYMPTOMS IN CHRONIC ALCOHOLISM.
099957 11-11

A LONG-ACTING NEUROLEPTIC IN THE TREATMENT OF CHRONIC ALCOHOLISM IN NEUROTIC AND PSYCHOTIC PATIENTS.
109255 12-11

**ALDEHYDE**
INFLUENCE OF SEROTONIN AND RELATED SUBSTANCES UPON PHOTIC EVOKED POTENTIALS OF RABBIT: EVIDENCE FOR BIOLOGICAL ACTIVITY OF THE ALDEHYDE DERIVATIVE.
055584 02-03

**ALDOSTERONE**
ALDOSTERONE AND SODIUM RESPONSE TO LITHIUM ADMINISTRATION IN MAN.
066493 05-13

**ALKALI**
EXTINCTION OF THE EXCRETORY ALKALI METAL RESPONSE (EAMR) TO STRESS IN A REPTILE.
076068 09-03

**ALKALOIDS**
INHIBITION OF THE RE-UPTAKE OF NEURONALLY LIBERATED NORADRENALINE AND ALPHA-RECEPTOR BLOCKING ACTION OF SOME ERGOT ALKALOIDS.
041967 01-03
COMPLEXES OF ERGOT ALKALOIDS AND DERIVATIVES. II: INTERACTION OF DIHYDROERGOTOXINE WITH CERTAIN XANTHINES.
046137 01-03
DIFFERENTIAL EFFECTS OF NICOTINE AND TOBACCO SMOKE ALKALOIDS ON SWIMMING ENDURANCE IN THE RAT.
069078 06-04
THE EFFECT OF NICOTINE AND TOTAL ALKALOIDS EXTRACTED FROM CIGARETTE SMOKE IN AVOIDANCE BEHAVIOR IN RATS UNDER EXTINCTION PROCEDURE.
069079 06-04
BIOSYNTHESIS OF PHENOLIC TETRAHYDROISOQUINOLINE ALKALOIDS OF PEYOTE.
069804 07-01
CACTUS ALKALOIDS: IX. ISOLATION OF N-METHYL-3-4-DIMETHOXY-BETA-PHENETHYLAMINE AND N-METHYL-4-METHOXY-BETA-PHENETHYLAMINE FROM ARIOCARPUS-RETUSUS.
070751 07-01
INFLUENCE OF HAPLOPHYLLUM ALKALOIDS ON THE BODY TEMPERATURE OF ANIMALS.
105721 12-03

**ALKYL**
PHARMACOLOGY OF ALKYL AND HYDROXYALKYLPYRAZINES.
066497 05-03
THE EFFECT OF ALKYL SUBSTITUTION IN DRUGS.
070779 07-01

**ALL-NIGHT**
HYPNOTICS AND ALTERED SLEEP DREAM PATTERNS: I. ALL-NIGHT EEG STUDIES OF GLUTETHIMIDE, METHYPRYLON, AND PENTOBARBITAL.
066233 05-14
HYPNOTICS AND ALTERED SLEEP DREAM PATTERNS: II. ALL-NIGHT EEG STUDIES OF CHLORAL HYDRATE, FLURAZEPAM, AND METHAQUALONE.
066234 05-14
HYPNOTIC DRUGS AND THEIR EFFECTIVENESS: ALL-NIGHT EEG STUDIES OF INSOMNIAC SUBJECTS.
066235 05-14
THE EFFECT OF CENTROPHENOXINE ON EEG VIGILANCE IN THE COURSE OF SLEEP DEPRIVATION AND ON THE EEG PATTERN OF ALL-NIGHT SLEEP.
070934 07-14

**ALLERGIC**
MENTAL RETARDATION ASSOCIATED WITH PRENATAL INTOXICATION, ALLERGIC REACTIONS, DEFICIENCIES, TRAUMA, AND PHYSICAL AGENTS.
061704 03-15
MENTAL RETARDATION ASSOCIATED WITH POSTNATAL POISONS, TOXINS, ENDOTOXINS, DEFICIENCIES AND ALLERGIC REACTIONS.
061706 03-15

**ALLERGY**
PSYCHOSOMATIC ALLERGY.
063593 03-11

**ALPHA-ADRENERGIC**
ALPHA-ADRENERGIC RECEPTORS IN HYPOTHALAMUS FOR THE SUPPRESSION OF FEEDING BEHAVIOR BY SATIETY.
060801 03-04
RECIPROCAL HUNGER REGULATING CIRCUITS INVOLVING ALPHA-ADRENERGIC AND BETA-ADRENERGIC RECEPTORS LOCATED, RESPECTIVELY, IN THE VENTROMEDIAL AND LATERAL HYPOTHALAMUS.
092166 11-03

**ALPHA-KETOBUTYRIC**
NEUROPHARMACOLOGICAL COMPARISON OF CYSTATHIONINE, CYSTEINE, HOMOSERINE AND ALPHA-KETOBUTYRIC ACID IN CATS.
064367 04-04

**ALPHA-KETOGLUTARATE**
PSYCHOCLINICAL OBSERVATIONS ON THE EFFECT OF THE LOGOS COMPOUND (ASSOCIATION OF PYRITHIOXINE DIHYDROCHLORIDE, TRYPTOPHAN AND CALCIUM ALPHA-KETOGLUTARATE).
109258 12-11

**ALPHA-METHYL-L-TYROSINE**
ANTAGONISM OF D-AMPHETAMINE BY ALPHA-METHYL-L-TYROSINE: BEHAVIORAL EVIDENCE FOR THE PARTICIPATION OF CATECHOLAMINE STORES AND SYNTHESIS IN THE AMPHETAMINE STIMULANT RESPONSE.
064096 04-03

**ALPHA-METHYL-P-TYROSINE**
REVERSIBLE EFFECT OF L-DOPA ON TREMOR AND CATATONIA INDUCED BY ALPHA-METHYL-P-TYROSINE.
040124 01-05
THE EFFECT OF ALPHA-METHYL-P-TYROSINE ON SLEEP AND AROUSAL IN THE RAT.
075891 09-04
ALTERATIONS IN THE BEHAVIORAL EFFECTS OF LSD BY PRETREATMENT WITH P-CHLOROPHENYLALANINE AND ALPHA-METHYL-P-TYROSINE.
097965 11-04

**ALPHA-METHYL-PYRRYL-KETONE**
PHARMACOLOGICAL STUDIES ON THE ACTION OF SYNTHETIC ALPHA-METHYL-PYRRYL-KETONE ON THE CNS AND ON CIRCULATION.
055740 02-03

**ALPHA-METHYLDOPA**
POTENTIATION OF THE CENTRAL ACTIONS OF 5-HYDROXYTRYPTOPHAN IN RABBITS BY DL-ALPHA-HYDRAZINO ALPHA-METHYLDOPA.
058879 02-03
EXCRETION OF VANYLGLYCOL IN HUMAN URINE UNDER DIETARY CONTROL, AND DURING TREATMENT WITH ANTIBIOTICS, DISULFIRAM, A MONOAMINE OXIDASE INHIBITOR, ALPHA-METHYLDOPA, AND RESERPINE.
060272 03-13
THE CENTRAL SYMPATHETIC DEPRESSIVE EFFECT OF RESERPINE, ALPHA-METHYLDOPA AND CLONIDINE.
089046 10-03

**ALPHA-METHYLPHENETHYLAMINE**
ANALOGS OF ALPHA-METHYLPHENETHYLAMINE (AMPHETAMINE). I. SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF SOME METHOXY AND/OR METHYL ANALOGS.
038488 01-04

**ALPHA-METHYLTRYPTAMINES**
BIOLOGICAL ACTIVITIES OF SOME 5-SUBSTITUTED N,N DIMETHYLTRYPTAMINES, ALPHA-METHYLTRYPTAMINES, AND GRAMINES.
065494 05-03

**ALPHA-METHYLTRYPTOPHAN**
A NOVEL METHOD OF REDUCING THE CONCENTRATION OF BRAIN SEROTONIN: USE OF ALPHA-METHYLTRYPTOPHAN.
086350 10-13

**ALPHA-METHYLTYROSINE**
CSF HOMOVANILLIC ACID: EFFECTS OF PROBENECID AND ALPHA-METHYLTYROSINE.
047506 01-03
MODIFICATION OF THE EFFECTS OF ANTIPSYCHOTIC AGENTS ON THE OPEN FIELD PERFORMANCE OF RATS BY TREATMENT WITH ALPHA-METHYLTYROSINE OR P-CHLOROPHENYLALANINE.
064392 04-04

**ALPHA-RECEPTOR**
INHIBITION OF THE RE-UPTAKE OF NEURONALLY LIBERATED NORADRENALINE AND ALPHA-RECEPTOR BLOCKING ACTION OF SOME ERGOT ALKALOIDS.
041967 01-03

**ALPHA-RHYTHM**
CORTISOL EFFECTS ON AVERAGED EVOKED POTENTIAL, ALPHA-RHYTHM, TIME ESTIMATION, AND TWO-FLASH FUSION THRESHOLD.
075274 08-13

**ALTER**
THE SWITCH PROCESS FROM DEPRESSION TO MANIA: RELATIONSHIP TO DRUGS WHICH ALTER BRAIN AMINES.
067585 06-09

**ALTERATION**
THE METABOLIC ALTERATION OF DRUGS.
051117 02-17
TRANQUILIZERS IN THE TREATMENT OF THE CARDIAC NEUROTIC PATIENT AND THE SUBSEQUENT ALTERATION OF COMPLAINTS.
128568 12-14

**ALTERATIONS**
ALTERATIONS OF D-AMPHETAMINE SULFATE LETHALITY AND BODY TEMPERATURE IN MICE DURING ACUTE ALTITUDE EXPOSURE.
040582 01-03
THE ALTERATIONS OF PROTEIN METABOLISM OF THE BRAIN CORTEX INDUCED BY ANTICIPATION STRESS AND ACTH.
065434 05-03
MARIHUANA, ETHANOL, AND DEXTROAMPHETAMINE: MOOD AND MENTAL FUNCTION ALTERATIONS.
066231 05-14
ALTERATIONS IN BRAIN SENSITIVITY AND BARBITURATE METABOLISM UNRELATED TO AGGRESSION IN SOCIALLY DEPRIVED MICE.
069052 06-03

ALTERATIONS IN THE BEHAVIORAL EFFECTS OF LSD BY MIDBRAIN RAPHE LESIONS (UNPUBLISHED PAPER).
082545 10-04

ALTERATIONS IN THE BEHAVIORAL EFFECTS OF LSD BY MIDBRAIN RAPHE LESIONS.
086029 10-12

PITUITARY ADRENAL ALTERATIONS AND FEAR RESPONDING.
090135 11-04

LEVODOPA: ALTERATIONS IN BEHAVIOR.
092975 11-09

ALTERATIONS IN THE BEHAVIORAL EFFECTS OF LSD BY PRETREATMENT WITH P-CHLOROPHENYLALANINE AND ALPHA-METHYL-P-TYROSINE.
097965 11-04

**ALTERED**

HYPNOTICS AND ALTERED SLEEP DREAM PATTERNS: I. ALL-NIGHT EEG STUDIES OF GLUTETHIMIDE, METHYPRYLON, AND PENTOBARBITAL.
066233 05-14

HYPNOTICS AND ALTERED SLEEP DREAM PATTERNS: II. ALL-NIGHT EEG STUDIES OF CHLORAL HYDRATE, FLURAZEPAM, AND METHAQUALONE.
066234 05-14

ALTERED ABSORPTION OF DRUGS FROM THE RAT SMALL INTESTINE BY CARBONIC ANHYDRASE INHIBITION.
066369 05-03

THE EFFECTS OF ALTERED BRAIN NOREPINEPHRINE LEVELS ON CONTINUOUS AVOIDANCE RESPONDING AND THE ACTION OF AMPHETAMINES.
074937 08-04

ALTERED FREE ASSOCIATIONS: SOME COGNITIVE EFFECTS OF DOET (2,5 DIMETHOXY-4-ETHYLAMPHETAMINE).
075859 09-12

**ALTERNATION**

IMPAIRMENT OF ALTERNATION LEARNING IN RATS FOLLOWING MICROINJECTION OF CARBACHOL INTO THE HIPPOCAMPUS.
067522 06-04

EFFECTS OF SCOPOLAMINE ON SPONTANEOUS ALTERNATION FOLLOWING FREE AND FORCED TRIALS.
067882 06-04

FAILURE OF TRICYANOAMINOPROPENE TO FACILITATE ACQUISITION OF DOUBLE ALTERNATION IN RATS.
088471 10-04

**ALTITUDE**

ALTERATIONS OF D-AMPHETAMINE SULFATE LETHALITY AND BODY TEMPERATURE IN MICE DURING ACUTE ALTITUDE EXPOSURE.
040582 01-03

SOME EFFECTS OF D-AMPHETAMINE ON CARBOHYDRATE METABOLISM AT GROUND LEVEL AND ALTITUDE.
069344 06-03

COMBINED EFFECTS OF CHLORPROMAZINE AND ALTITUDE UPON PERFORMANCE IN THE RAT.
071467 07-04

**AMANITA-MUSCARIA**

MONOAMINES IN THE BRAIN UNDER THE INFLUENCE OF MUSCIMOL AND IBOTENIC ACID, TWO PSYCHOACTIVE PRINCIPLES OF AMANITA-MUSCARIA.
064408 04-03

AMANITA-MUSCARIA: PRESENT UNDERSTANDING OF ITS CHEMISTRY.
074074 08-01

**AMANTADINE**

CONTROLLED TRIAL OF AMANTADINE HYDROCHLORIDE IN PARKINSONS DISEASE.
043697 01-11

AMANTADINE IN PARKINSONISM.
058240 02-11

AMANTADINE DOSAGE IN TREATMENT OF PARKINSONS DISEASE.
058241 02-11

AMANTADINE DOPAMINE INTERACTION: POSSIBLE MODE OF ACTION IN PARKINSONISM.
066315 05-03

POTENTIATION BY AMANTADINE HYDROCHLORIDE OF L-DOPA INDUCED EFFECTS IN MICE.
066508 05-03

ON THE MODE OF ACTION OF AMANTADINE.
074145 08-04

THE EFFECT OF AMANTADINE ON THE UPTAKE OF DOPAMINE AND NORADRENALINE BY RAT BRAIN HOMOGENATES.
074148 08-03

EFFECT OF AMANTADINE ON THE EXTRAPYRAMIDAL SYNDROMES INDUCED BY NEUROLEPTICS.
112131 12-09

**AMBIENT**

INTRACRANIAL SELF-STIMULATION AND WAKEFULNESS: EFFECT OF MANIPULATING AMBIENT BRAIN CATECHOLAMINES.
063849 04-04

**AMBULANT**

CLINICAL AND AMBULANT TESTING WITH FLUPHENAZINE DECANOATE LYOGEN DEPOT IN THE LONG-TERM TREATMENT OF PSYCHIATRIC DISEASE.
080040 09-16

**AMBULATORY**

PRIVATE AMBULATORY PATIENTS TREATED WITH FLUPHENAZINE ENANTHATE.
065458 05-07

AMBULATORY BEHAVIOR IN THE RAT AS A FUNCTION OF TWO METHODS OF ALCOHOL ADMINISTRATION.
075316 08-04

COMPARATIVE, DOUBLE-BLIND STUDY OF DOXEPINE AND LIBRIUM IN CASES OF PSYCHONEUROSES WITH ANXIETY AMONG HOSPITALIZED AND AMBULATORY PATIENTS.
087489 10-10

EFFECT OF PYROVALERONE IN THE AMBULATORY TREATMENT OF FATIGUE STATES.
091503 11-11

ON THE PROBLEM OF AMBULATORY TREATMENT OF SCHIZOPHRENIA WITH PSYCHOTROPIC DRUGS.
111034 12-08

**AMENORRHEA**

AMENORRHEA.
100531 12-15

**AMIDES**

SYNTHESIS OF SOME GLYCIDIC HYDRAZIDES AND AMIDES AS POTENTIAL PSYCHOTROPIC AGENTS AND ANTICHOLINERGIC AGENTS.
064258 04-01

**AMINAZIN**

INFLUENCE OF AMINAZIN ON ADRENALIN, NORADRENALINE, DOPAMINE, AND DOPA EXCRETION IN HEALTHY PEOPLE AND IN THE MANIC PHASE OF THE MANIC-DEPRESSIVE PSYCHOSIS.
090355 11-03

**AMINAZINE**

AN ATTEMPT TO ELIMINATE RESISTANCE TO AMINAZINE BY MALARIA THERAPY IN PATIENTS WITH PARANOID SCHIZOPHRENIA.
087312 10-16

**AMINE**

THE EFFECT OF BRETYLIUM ON AMINE RETENTION IN RAT HEART.
040309 01-03

MANNICH BASES FROM 1,2- DIPHENYLINDOLIZINE: EPHEDRINE AND METHAMPHETAMINE AS AMINE COMPONENTS.
055324 02-01

ON THE SITES OF ANTITUSSIVE ACTION OF N-(2-PICOLYL)-N-PHENYL-N-(2-PIPERIDINOETHYL)AMINE (TAT-3).
055586 02-03

IMIPRAMINE AND LITHIUM EFFECTS ON BIOGENIC AMINE TRANSPORT IN DEPRESSED AND MANIC-DEPRESSED PATIENTS.
062326 03-13

IMIPRAMINE AND LITHIUM EFFECTS ON BIOGENIC AMINE TRANSPORT IN DEPRESSED AND MANIC-DEPRESSED PATIENTS.
062366 03-13

FOREBRAIN BIOGENIC AMINE FUNCTION IN HIGH AND LOW FEMALE RATS.
081231 09-04

**AMINES**

AN EVALUATION OF THE VASODILATION PRODUCED BY MEPHENTERMINE AND CERTAIN OTHER SYMPATHOMIMETIC AMINES.
040311 01-03

PHARMACOLOGICAL SIGNIFICANCE OF BIOGENIC AMINES IN THE LUNGS: NORADRENALINE AND DOPAMINE.
041539 01-03

PHARMACOLOGICAL SIGNIFICANCE OF BIOGENIC AMINES IN THE LUNGS: 5-HYDROXYTRYPTAMINE.
041565 01-03

AMINES THAT MANIPULATE THE NEUROTRANSMITTERS.
058963 03-11

INTERACTIONS BETWEEN SYMPATHOMIMETIC AMINES AND A NEW MONOAMINE OXIDASE INHIBITOR.
064406 04-07

INTRANEURONAL AND EXTRANEURONAL ACCUMULATION OF SYMPATHOMIMETIC AMINES IN THE ISOLATED NICTITATING MEMBRANE OF THE CAT.
066363 05-03

THE EFFECT OF SERUM FROM ACUTE SCHIZOPHRENIC PATIENTS ON RABBIT BRAIN AMINES.
066713 05-03

THE SWITCH PROCESS FROM DEPRESSION TO MANIA: RELATIONSHIP TO DRUGS WHICH ALTER BRAIN AMINES.
067585 06-09

PROJECT SUMMARY: ANALYSIS OF URINE AND TISSUE AMINES.
068970 06-03

EFFECTS OF SYMPATHOMIMETIC AMINES INJECTED INTO THE THIRD CEREBRAL VENTRICLE IN ADULT CHICKENS.
072030 07-03

INTRASTRIATAL SPREADING OF BIOGENIC AMINES.
072471 08-03

ROLE OF BRAIN AMINES IN THE ANALGESIC ACTION OF MEPERIDINE HYDROCHLORIDE.
075845 09-03

THE IMPORTANCE OF RESEARCH IN BIOGENIC AMINES FOR THE EXPERIMENTAL PSYCHOPHARMACOLOGY.
081110 09-17

STUDY EXPLORES ROLE OF BIOGENIC AMINES IN DEPRESSION.
087793 10-13
ROLE OF BIOGENIC AMINES IN MORPHINE DEPENDENCE IN THE RAT.
090149 11-03
EFFECT OF GANGLIONIC BLOCKING AGENTS ON PRESSOR EFFECTS OF SYMPATHOMIMETIC AMINES OF DIRECT AND INDIRECT ACTION.
110632 12-03

**AMINO**
THE ACTIONS OF GAMMA-AMINOBUTYRIC ACID AND RELATED AMINO ON MAMMALIAN AUTONOMIC GANGLIA.
040752 01-03
THE EFFECT OF SOME HALLUCINOGENIC DRUGS ON THE AMINO ACID PRECURSORS OF BRAIN MONOAMINES.
070542 07-03
STUDY OF AMINO ACID ANALOGS AND BRAIN BIOCHEMISTRY.
094553 11-03

**AMINOESTERS**
THE EFFECT OF AMINOESTERS OF SUBSTITUTED GLYCOLIC AND ACETIC ACIDS ON THE CONTENT OF NORADRENALINE IN THE BRAIN OF RATS.
073717 08-03

**AMINOGLUTETHIMIDE**
AMINOGLUTETHIMIDE: A SIDE-EFFECT TURNED TO THERAPEUTIC ADVANTAGE.
066873 05-15

**AMINOHYDROXYACETATE**
NEUROTROPIC PROPERTIES OF AMINOHYDROXYACETATE AND GAMMA-AMINOHYDROXYBUTYRIC ACID.
058605 02-03

**AMINOPROPIONYLIC**
CENTRAL NEUROTROPIC ACTIVITY OF AMINOPROPYL AND AMINOPROPIONYLIC DERIVATIVES OF IMINOBENZYL AND DIPHENYLAMINE AND ITS RELATION TO IONIZATION CONSTANTS.
072580 08-03

**AMINOPROPYL**
CENTRAL NEUROTROPIC ACTIVITY OF AMINOPROPYL AND AMINOPROPIONYLIC DERIVATIVES OF IMINOBENZYL AND DIPHENYLAMINE AND ITS RELATION TO IONIZATION CONSTANTS.
072580 08-03

**AMINOTRANSFERASES**
PROJECT SUMMARY: A NEW ASSAY PROCEDURE FOR AMINOTRANSFERASES.
060223 03-03

**AMITRIPTYLINE**
AMITRIPTYLINE IN PSYCHIATRIC THERAPY.
059015 03-09
USE OF AMITRIPTYLINE SYRUP IN THE TREATMENT OF ENURESIS IN CHILDREN.
062407 03-11
COMBINED THERAPY IN ANXIETY DEPRESSIVE SYNDROMES: I. COMPARATIVE EFFECTS OF LIMBITROL (CHLORDIAZEPOXIDE AMITRIPTYLINE) AND PLACEBO.
064312 04-10
A COMPARATIVE STUDY OF FLUPHENAZINE AMITRIPTYLINE COMBINATION AND AMITRIPTYLINE ALONE IN THE TREATMENT OF DEPRESSED PSYCHIATRIC PATIENTS.
064356 04-09
CLINICAL EVALUATION OF DOXEPIN AND AMITRIPTYLINE IN DEPRESSED PATIENTS.
064637 05-09
PERPHENAZINE AMITRIPTYLINE IN NEUROTIC DEPRESSED OUTPATIENTS; A CONTROLLED COLLABORATIVE STUDY.
065247 05-10
AMITRIPTYLINE AND CARDIAC DISEASE: RISK OF SUDDEN DEATH IDENTIFIED BY MONITORING SYSTEM.
070854 07-15
VALUE OF AMITRIPTYLINE SPOFA IN THE PSYCHIATRIC OUTPATIENT AND INPATIENT PRACTICE.
070944 07-09
AMITRIPTYLINE, CHLORPROTHIXENE, PROTHIADENE AND PLACEBO IN THE TREATMENT OF NEUROSES.
070946 07-10
AMITRIPTYLINE IN EMOTIONAL STATES AT THE MENOPAUSE.
071123 07-11
A CONTRIBUTION TO THE DEPRESSIVE DISORDER PHARMACOTHERAPY BY THE COMBINATION OF AMITRIPTYLINE AND PERPHENAZINE.
073707 08-10
AMITRIPTYLINE AND TRIMIPRAMINE IN NEUROTIC DEPRESSED OUTPATIENTS: A COLLABORATIVE STUDY.
075868 09-10
AMITRIPTYLINE IN THE TREATMENT OF ENURESIS.
085453 10-14
A SEVENTH-MONTH DOUBLE-BLIND TRIAL OF AMITRIPTYLINE AND DIAZEPAM IN ECT TREATED DEPRESSED PATIENTS.
097562 11-09
EVALUATION OF AN AMITRIPTYLINE PERPHENAZINE COMBINATION IN CHRONIC SCHIZOPHRENIA.
101681 12-08
EXPERIENCE WITH A COMBINATION OF AMITRIPTYLINE AND THIORIDAZINE FOR THE TREATMENT OF DEPRESSIONS.
105732 12-14

**AMITRYPTILINE**
THE USE OF TWO COMBINATIONS OF DRUGS WITH MIXED ACTION, ANTIDEPRESSIVE AND TRANQUILIZING (AMITRYPTILINE - PERPHENAZINE) IN GENERAL AND IN PSYCHOSOMATIC MEDICINE.
089162 10-17

**AMITRYPTYLINE**
CONTROLLED TRIALS OF AN AMITRYPTYLINE FLUPHENAZINE COMBINATION IN DEPRESSIVE NEUROSES AND PSYCHOSES: A COLLABORATIVE STUDY.
067569 06-11
DRUG TREATMENT IN DEPRESSIVE ILLNESS: AMITRYPTYLINE AND CHLORDIAZEPOXIDE IN TWO NEUROTIC POPULATIONS.
075415 08-10

**AMIZEPINE**
CLINICAL STUDY OF EFFICACY OF AMIZEPINE.
072895 08-11

**AMMONIUM**
DISTRIBUTION, EXCRETION, AND METABOLISM OF 14C-LABELED QUATERNARY AMMONIUM SALT OF MEPAZINE AND PROMETHAZINE IN RATS.
058571 02-03
DISTRIBUTION, EXCRETION, AND METABOLISM OF 14C-LABELED QUATERNARY AMMONIUM SALT OF PERPHENAZINE IN RATS.
064261 04-03

**AMNESIA**
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: III. ANTEROGRADE AMNESIA.
065852 05-14
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: IV. RETROGRADE AMNESIA.
065853 05-14
AMNESIA AND BRAIN SEIZURES ACTIVITY IN MICE: EFFECTS OF DIETHYL-ETHER ANESTHESIA PRIOR TO ELECTROSHOCK STIMULATION.
097952 11-04

**AMNESIC**
A PARALLEL STUDY OF THE AMNESIC EFFECTS OF CYCLOHEXIMIDE AND ECS UNDER DIFFERENT STRENGTHS OF CONDITIONING.
066830 05-04

**AMOBARBITAL**
SODIUM AMOBARBITAL, THE HIPPOCAMPAL THETA RHYTHM, AND THE PARTIAL REINFORCEMENT EXTINCTION EFFECT.
063333 03-03
INTERFERENCE OF BARBITURATES WITH PYRIMIDINE INCORPORATION -- III: STUDIES ON THE MECHANISM OF THE AMOBARBITAL OROTATE RELATIONSHIP.
064045 04-03
OBJECTIVE EFFECTS OF DEXAMPHETAMINE AND AMOBARBITAL AND THEIR RELATIONS TO PSYCHASTHENIC PERSONALITY TRAITS.
064389 04-14
RATE-DEPENDENT EFFECTS OF DRUGS: MODIFICATION BY DISCRIMINATIVE STIMULI OF THE EFFECTS OF AMOBARBITAL ON SCHEDULE CONTROLLED BEHAVIOR.
064749 05-04
EFFECTS OF AMOBARBITAL SODIUM ON THE ACQUISITION AND EXTINCTION OF A LEVER-PRESS SPATIAL DISCRIMINATION IN THE RAT.
069075 06-04
THE ROLE OF D-AMPHETAMINE AMOBARBITAL IN SUPPRESSING FREEZING BEHAVIOR DURING AVOIDANCE ACQUISITION AND EXTINCTION.
075882 09-04
THE SELF-INJECTION OF AMOBARBITAL BY RATS DURING NON-REWARD.
083413 10-04
HYPOTENSIVE EFFECTS OF CHLORDIAZEPOXIDE, AMOBARBITAL AND CHLORPROMAZINE ON BEHAVIORALLY INDUCED ELEVATED ARTERIAL BLOOD PRESSURE IN THE SQUIRREL MONKEY.
089999 11-04

**AMP**
URINARY CYCLIC AMP IN AFFECTIVE ILLNESS.
059054 03-09
CYCLIC AMP AND ADENYL-CYCLASE IN THE DEVELOPING RAT BRAIN.
060856 03-03
AFFECTIVE ILLNESS AND CYCLIC AMP EXCRETION.
071972 07-13
CYCLIC AMP MEDIATION OF NOREPINEPHRINE INHIBITION IN RAT CEREBELLAR CORTEX: A UNIQUE CLASS OF SYNAPTIC RESPONSES (UNPUBLISHED PAPER).
093132 11-03

**AMPHETAMINE**
ANALOGS OF ALPHA-METHYLPHENETHYLAMINE (AMPHETAMINE). I. SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF SOME METHOXY AND/OR METHYL ANALOGS.
038488 01-04
EFFECTS OF AMPHETAMINE DERIVATIVES ON BRAIN DOPAMINE AND NORADRENALINE.
040126 01-03

EFFECTS OF MONOAMINE OXIDASE INHIBITORS AND AMPHETAMINE ON HYPOTHERMIA PRODUCED BY HALOTHANE.
041569 01-03

AMPHETAMINE ANALOGS. II. METHYLATED PHENETHYLAMINES.
041907 01-02

THE EFFECT OF AMPHETAMINE, NICOTINE AND ATROPINE ON PSEUDOCONDITIONED RESPONSES OF RATS.
046142 01-04

EFFECT OF AMPHETAMINE, NICOTINE AND HEXAMETHONIUM ON PERFORMANCE OF A CONDITIONED RESPONSE DURING ACQUISITION AND RETENTION TRIALS.
046186 01-04

COMPARATIVE EFFECTS OF NICOTINE AND AMPHETAMINE ON TIMING BEHAVIOR IN RATS.
046190 01-04

EFFECT OF AMPHETAMINE ANALOGS ON DISRUPTION OF ANIMAL BEHAVIOR AND BARBITURATE SLEEPING TIME.
046196 01-03

RESPONSE DISRUPTION FOLLOWING AMPHETAMINE SELF-ADMINISTRATION AND PROGRAMMED ADMINISTRATION.
046209 01-04

THE ANTAGONISM OF ADRENERGIC NEURONE BLOCKADE BY AMPHETAMINE AND DEXAMPHETAMINE IN THE RAT AND GUINEA-PIG.
055322 02-03

INFRARED IDENTIFICATION OF SOME HALLUCINOGENIC DERIVATIVES OF TRYPTAMINE AND AMPHETAMINE.
058877 02-01

A COMPARATIVE STUDY OF THE PHARMACOLOGIC ACTIONS OF AMPHETAMINE AND FENFLURAMINE.
058996 03-05

ASSOCIATION OF AMPHETAMINE TOXICITY AND TISSUE GLYCOGEN DEPLETION IN MICE AND RATS.
058998 03-05

EFFECTS OF LITHIUM PRETREATMENT ON AMPHETAMINE AND DMI TETRABENAZINE PRODUCED PSYCHOMOTOR BEHAVIOR.
062521 03-04

EFFECT OF DIETHYLDITHIOCARBAMATE ON THE TOXICITY OF AMPHETAMINE IN AGGREGATED MICE.
062937 03-04

BEHAVIOURAL EFFECTS IN RATS OF MORPHINE AND AMPHETAMINE AND OF A COMBINATION OF THE TWO DRUGS.
063019 03-04

THE INTERACTION OF ETHANOL AND AMPHETAMINE METABOLISM.
063062 03-03

ABUSE OF AMPHETAMINE AND AMPHETAMINE-LIKE DRUGS.
063753 04-15

NEUROCHEMICAL EFFECTS OF IMIPRAMINE AND AMPHETAMINE IN AGGRESSIVE MOUSE KILLING (MURICIDAL) RATS.
064056 04-03

ANTAGONISM OF D-AMPHETAMINE BY ALPHA-METHYL-L-TYROSINE: BEHAVIORAL EVIDENCE FOR THE PARTICIPATION OF CATECHOLAMINE STORES AND SYNTHESIS IN THE AMPHETAMINE STIMULANT RESPONSE.
064096 04-03

COLORIMETRIC DETERMINATION OF AMPHETAMINE SALTS IN DOSAGE FORMS.
064159 04-01

THE EFFECTS OF HALOPERIDOL AND CHLORPROMAZINE ON AMPHETAMINE METABOLISM AND AMPHETAMINE STEREOTYPE BEHAVIOR IN THE RAT.
064170 04-03

AMPHETAMINE INTOXICATION WITH COAGULOPATHY, HYPERTHERMIA, AND REVERSIBLE RENAL FAILURE: A SYNDROME RESEMBLING HEATSTROKE.
064236 04-15

PARADOXICAL AMPHETAMINE EFFECT IN HYPERACTIVE RATS IN RELATION TO NOREPINEPHRINE METABOLISM.
064364 04-03

MECHANISMS BY WHICH AMPHETAMINE AND DESIPRAMINE INHIBIT THE METARAMINOL INDUCED RELEASE OF NOREPINEPHRINE FROM SYMPATHETIC NERVE ENDINGS IN RAT HEART.
064427 04-03

THE INFLUENCE OF VARIOUS NEUROLEPTIC DRUGS ON SHOCK AVOIDANCE RESPONDING IN RATS. III. AMPHETAMINE ANTAGONISM IN THE DISCRIMINATED SIDMAN AVOIDANCE PROCEDURE.
064476 04-04

EXPERIMENTAL EFFECTS OF AMPHETAMINE: SUPPLEMENTARY REPORT.
064968 05-04

EFFECTS OF AMPHETAMINE UPON RELEARNING PATTERN AND BLACK WHITE DISCRIMINATIONS FOLLOWING NEOCORTICAL LESIONS IN RATS.
065419 05-04

DIFFERENTIAL EFFECTS OF AMPHETAMINE AND SCOPOLAMINE ON MATCHING PERFORMANCE OF MONKEYS WITH LATERAL FRONTAL LESIONS.
065747 05-04

ON THE COMBINED EFFECTS OF AMPHETAMINE AND FOOD DEPRIVATION: A REPLY TO GOLLUB AND MANN.
066821 05-04

ON THE MECHANISM OF AMPHETAMINE POTENTIATION BY IPRINDOLE.
066955 05-03

RELEASE BY AMPHETAMINE IN MAN OF GROWTH HORMONE AND CORTICOSTEROIDS: THE EFFECTS OF THYMOXAMINE AND PROPRANOLOL.
067602 06-13

THE RELATIONSHIP OF AMPHETAMINE INDUCED ANOREXIA AND FREEZING UNDER A MULTIPLE CRF-EXT OPERANT SCHEDULE.
068288 06-04

THE INHIBITORY EFFECT OF AMPHETAMINE ON EXPLORATION IN MICE.
069080 06-04

AMPHETAMINE: DIFFERENTIATION BY D AND L ISOMERS OF BEHAVIOR INVOLVING BRAIN NOREPINEPHRINE OR DOPAMINE.
070921 07-04

BIOCHEMICAL AND BEHAVIORAL EFFECT OF AMPHETAMINE IN DMI - RO-4-1284 INDUCED HYPERACTIVITY.
070951 07-03

EFFECTS OF 6-HYDROXYDOPAMINE ON CNS CATECHOLAMINES, SPONTANEOUS MOTOR ACTIVITY AND AMPHETAMINE INDUCED HYPERACTIVITY IN RATS.
074053 08-04

AMPHETAMINE TOXICITY AND ENDOGENOUS NORADRENALINE CONCENTRATIONS IN ISOLATED AND AGGREGATED MIC
074146 08-05

THE EFFECT OF ETHANOL AND AMPHETAMINE MIXTURES ON THE ACTIVITY OF RATS IN A Y-MAZE.
074149 08-04

EFFECT OF DESMETHYLIMIPRAMINE, IPRINDOLE AND DL-ERYTHRO-ALPHA-(3,4 DICHLOROPHENYL)-BETA-(T-BUTYLAMINO) PROPANOL HCL ON THE METABOLISM OF AMPHETAMINE.
074866 08-03

COMPARATIVE EFFECTS OF AMPHETAMINE, SCOPOLAMINE, CHLORDIAZEPOXIDE, AND DIPHENYLHYDANTOIN ON OPERANT AND EXTINCTION BEHAVIOR WITH BRAIN STIMULATION AND FOOD REWARD.
074935 08-04

THE INFLUENCE OF SINGLE AND CHRONIC MORPHINE ADMINISTRATION ON SOME CENTRAL EFFECTS OF AMPHETAMINE AND APOMORPHINE.
075840 08-05

MORPHINE AMPHETAMINE INDUCED FIGHTING AND INTERIM SOCIALIZATION.
076131 09-04

PHARMACOLOGICAL IMPLICATIONS OF THE EFFECTS OF AMPHETAMINE AND ITS ANALOGUES ON THE TURNOVER RATE OF TISSUE CATECHOLAMINES (UNPUBLISHED PAPER).
088392 10-03

A COMPARISON OF SOME EFFECTS OF AMPHETAMINE IN RATS OF DIFFERENT AGES.
088587 10-03

THE INFLUENCE OF IMIPRAMINE, DEXPHENMETRAZINE AND AMPHETAMINE SULPHATE ON SYNCHRONOUS AND PARADOXICAL SLEEP IN NARCOLEPSY CATAPLEXY. A POLYGRAPHIC EXAMINATION.
089037 10-14

RELATIONSHIP BETWEEN CENTRAL EFFECTS AND THE CONCENTRATION OF AMPHETAMINE IN LIVER AND BRAIN OF YOUNG AND OLD RATS.
089041 10-03

EFFECT OF AMPHETAMINE ON THE PRESSOR RESPONSE TO TYRAMINE: FORMATION OF P-HYDROXYNOREPHEDRINE FROM AMPHETAMINE IN MAN.
090373 11-03

INTERACTIONS BETWEEN THE EFFECTS OF CHLORDIAZEPOXIDE AND AMPHETAMINE ON FOOD INTAKE AND SPONTANEOUS MOTOR ACTIVITY IN THE RAT.
092692 11-04

EFFECTS OF COCAINE AND AMPHETAMINE ON THE METABOLISM OF TRYPTOPHAN AND 5-HYDROXYTRYPTAMINE IN MOUSE BRAIN IN VIVO.
095440 11-03

INVESTIGATION INTO THE POSSIBLE INFLUENCE OF CHLORINATED AMPHETAMINE DERIVATIVES ON 5-HYDROXYTRYPTAMINE SYNTHESIS IN MAN.
097963 11-13

ROLE OF BRAIN SEROTONIN IN THE STIMULANT ACTION OF AMPHETAMINE.
098003 11-03

THE EFFECTS OF AN AMPHETAMINE ON MEASURES OF INTELLIGENCE AND LEARNING IN MENTALLY RETARDED ADULTS. (PH.D.DISSERTATION).
103152 12-14

**AMPHETAMINE-LIKE**
ABUSE OF AMPHETAMINE AND AMPHETAMINE-LIKE DRUGS.
063753 04-15

**AMPHETAMINES**
FDA WARNS AGAINST USES OF BEHAVIOR AMPHETAMINES.
051373 02-15

CORRELATION BETWEEN ACTIVITY AND ELECTRONIC STATE OF HALLUCINOGENIC AMPHETAMINES.
067199 06-06

THE EFFECTS OF ALTERED BRAIN NOREPINEPHRINE LEVELS ON CONTINUOUS AVOIDANCE RESPONDING AND THE ACTION OF AMPHETAMINES.
074937 08-04
ABSOLUTE CONFIGURATIONS OF METHOXYLATED AMPHETAMINES.
095700 11-01
INTERNATIONAL SYMPOSIUM ON AMPHETAMINES AND RELATED COMPOUNDS.
107549 12-13

**AMYGDALA**
CHANGES IN EMOTIONAL BEHAVIOUR AFTER APPLICATION OF CHOLINESTERASE INHIBITOR IN THE SEPTAL AND AMYGDALA REGION.
040578 01-04
INHIBITORY FUNCTIONS OF THE SEPTUM AND AMYGDALA.
095697 11-03

**AMYLOBARBITONE**
THE KINETICS OF AMYLOBARBITONE METABOLISM IN HEALTHY MEN AND WOMEN.
063800 04-13
PERSISTENT BEHAVIOURAL AND ELECTROENCEPHALOGRAPHIC CHANGES AFTER SINGLE DOSES OF NITRAZEPAM AND AMYLOBARBITONE SODIUM.
068005 06-14
A SEQUENTIAL TRIAL OF AMYLOBARBITONE SODIUM USED AS SEDATION FOR CONFUSED FEMALE PSYCHOGERIATRIC PATIENTS.
082732 10-11

**AMYTAL**
A COMPARISON OF SHORT-TERM TREATMENT EFFECTS OF INTRAVENOUS SODIUM AMYTAL METHEDRINE AND LSD IN THE ALCOHOLIC.
062934 03-11
REINFORCING LIMBIC SYSTEM STIMULATION AND SODIUM AMYTAL.
075553 08-04
ARRESTING OF STATUS-EPILEPTICUS AND SERIAL SEIZURES BY AMYTAL CAFFEINE.
090349 11-11

**ANABOLICS**
RELAXING EFFECT OF VITAMIN-B WITH ANABOLICS.
070778 07-14

**ANAFRANIL**
REMARKS ON THE USE OF CLOMIPRAMINE (ANAFRANIL) IN CERTAIN ACUTE DELIRIANT PSYCHOSES (WITHOUT A CLEAR DEPRESSIVE ELEMENT).
088438 10-14
CLINICAL EXPERIENCE WITH ANAFRANIL.
093091 11-10
CLINICAL CONTRIBUTION OF EXPERIMENTS WITH CHLORIMIPRAMINE (ANAFRANIL).
093443 11-09
THE CLINICAL EFFECT OF CLOMIPRAMINE (ANAFRANIL) AS THE ANTIDEPRESSANT.
118585 12-09

**ANALGESIC**
4-(BETA-BENZOYLVINYL) ANTIPYRINE DERIVATIVES WITH ANTIPHLOGISTIC AND ANALGESIC ACTIVITY.
055519 02-03
THE ROLE OF BRAIN CATECHOLAMINES IN MORPHINE ANALGESIC ACTION IN MORPHINE TOLERANT RATS.
055756 02-03
INVESTIGATIONS ON THE SPECIFICITY OF THE SO-CALLED ANALGESIC ACTIVITY OF NON-NARCOTIC DRUGS.
067254 06-04
ROLE OF BRAIN AMINES IN THE ANALGESIC ACTION OF MEPERIDINE HYDROCHLORIDE.
075845 09-03
COMBINATION TEST ON THE ANALGESIC EFFECT OF DEXTROPROPOXYPHENE AND SOME PSYCHOTROPIC DRUGS IN THE MOUSE.
079961 09-03
REDUCTION OF ANALGESIC EFFECTS BY LITHIUM.
080144 09-03
CLINICAL RESULTS OF THE TESTING FOR ANALGESIC EFFECT OF DEXTROPROPOXYPHENE IN COMBINATION WITH A PSYCHOTROPIC PREPARATION (TROPAX).
081147 09-17
STUDIES ON THE RECEPTORS INVOLVED IN THE ACTION OF THE VARIOUS AGENTS IN THE PHENYLBENZOQUINONE ANALGESIC ASSAY IN MICE.
090451 11-03
ANALGESIC EFFECT OF MORPHINE HYDROCHLORIDE INJECTED DIRECTLY INTO THE VENTRICLE OF MOUSE BRAIN.
130422 12-03

**ANALGESICS**
A METHOD OF IDENTIFYING NARCOTIC ANALGESICS IN HUMAN URINE AFTER THERAPEUTIC DOSES.
057473 02-16
QUANTITATIVE STUDIES ON THE ANTAGONISM BY NALOXONE OF SOME NARCOTIC AND NARCOTIC ANTAGONIST ANALGESICS.
063798 04-03
INTERACTION OF SOME PSYCHOTROPIC DRUGS WITH ANALGESICS.
070948 07-04
NARCOTIC ANALGESICS -- II. ADVERSE EFFECTS.
071929 07-15
CORRELATIONS OF STRUCTURE-ACTIVITY OF MORPHINE-LIKE ANALGESICS USING REGRESSION ANALYSIS.
089042 10-01

**ANALGETIC**
THE TREATMENT OF CHRONIC PAIN SYNDROMES: ANALGETIC EFFECT OF A NEUROLEPTIC SUBSTANCE.
079963 09-11

**ANALOG**
A BENZAZEPINONE: CARBON ANALOG OF DIAZEPAM.
080032 09-02

**ANALOGS**
ANALOGS OF ALPHA-METHYLPHENETHYLAMINE (AMPHETAMINE). I. SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF SOME METHOXY AND/OR METHYL ANALOGS.
038488 01-04
AMPHETAMINE ANALOGS. II. METHYLATED PHENETHYLAMINES.
041907 01-02
EFFECT OF AMPHETAMINE ANALOGS ON DISRUPTION OF ANIMAL BEHAVIOR AND BARBITURATE SLEEPING TIME.
046196 01-03
NEW COMPOUNDS: STRUCTURAL ANALOGS RELATED TO ASARONE AND MESCALINE.
064264 04-01
PROJECT SUMMARY: THIENOPYRIDINE ANALOGS OF SEROTONIN AND TRYPTOPHAN.
066815 05-01
THIENOPYRIDINE ANALOGS OF SEROTONIN AND TRYPTOPHAN.
074844 08-01
STUDY OF AMINO ACID ANALOGS AND BRAIN BIOCHEMISTRY.
094553 11-03

**ANALOGUES**
FURTHER STUDIES ON THE ACCUMULATION AND DISAPPEARANCE OF CATECHOLAMINES FORMED FROM TYROSINE-14C IN MOUSE BRAIN. EFFECT OF SOME PHENOTHIAZINE ANALOGUES.
042727 01-03
PHARMACOLOGICAL IMPLICATIONS OF THE EFFECTS OF AMPHETAMINE AND ITS ANALOGUES ON THE TURNOVER RATE OF TISSUE CATECHOLAMINES (UNPUBLISHED PAPER).
088392 10-03

**ANALYSIS**
STATISTICAL METHOD OF ANALYSIS AND EVALUATION OF PSYCHOTHERAPEUTIC RESULTS: APPLICATION OF A LONG-ACTING NEUROLEPTIC, COMPARED WITH A STANDARD NEUROLEPTIC AND THE SAKEL INSULIN TREATMENT.
042676 01-07
AN ANALYSIS OF PSYCHOLOGICAL DEPENDENCE.
046210 01-04
THE RESPONSE TO MEPROBAMATE -- A PREDICTIVE ANALYSIS.
046311 01-17
A PROCEDURE FOR THE ANALYSIS OF ILLICIT DIAMORPHINE SAMPLES.
046395 01-01
ON THE ANALYSIS OF CARDIAC BETA-RECEPTORS: STUDIES ON THE BASE OF DOSE EFFECT CURVES FOR ISOPRENALINE, PROPRANOLOL, AND KL-255.
055396 02-03
PSYCHOPATHOLOGICAL ANALYSIS OF THE PROCESS OF SEDATION.
059038 03-17
A BEHAVIORAL AND PHARMACOLOGICAL ANALYSIS OF REINFORCEMENT WITHDRAWAL.
062942 03-04
AN ANALYSIS OF METHYLPHENIDATE INDUCED GNAWING IN GUINEA-PIGS.
064414 04-04
YEAST RIBONUCLEIC ACID: ANALYSIS OF EFFECTS ON POLE-CLIMB AVOIDANCE BEHAVIOR.
065493 05-04
ELECTROENCEPHALOGRAPHIC ANALYSIS OF EXPERIMENTAL PSYCHOSIS BROUGHT ON BY DITRAN.
067147 06-13
THIN-LAYER CHROMATOGRAPHIC LABORATORY ANALYSIS IN CASES FROM A DRUG ADDICTION CENTER.
067212 06-06
AN ANALYSIS OF 310 CASES OF ACUTE HIGH-DOSE METHAMPHETAMINE TOXICITY IN HAIGHT-ASHBURY.
067218 06-15
ANALYSIS OF THE LSD FLASHBACK.
067341 06-15
THE STAIRCASE MAZE AND THE SIMPLE STAIRCASE IN THE ANALYSIS OF THE PSYCHOPHARMACOLOGICAL ACTION OF CNS DEPRESSANTS.
068291 06-04
PROJECT SUMMARY: ANALYSIS OF URINE AND TISSUE AMINES.
068970 06-03

STUDIES ON INTERACTIONS INVOLVING ANTIDEPRESSIVE AND OTHER DRUGS WITH TETRABENAZINE AND NORADNAMINE ON LOCOMOTOR ACTIVITY IN MICE, INCLUDING DETAILS OF THE EXPERIMENTAL DESIGN AND STATISTICAL ANALYSIS.
069077 06-04

ANALYSIS OF CHROMOSOMES BEFORE AND AFTER TREATMENT WITH IMURAN.
069082 06-13

AN ANALYSIS OF RECEPTIVE STRUCTURES PARTICIPATING IN THE BEHAVIOR REACTIONS OF CATS INDUCED BY CATECHOLAMINES AND SEROTONIN.
073715 08-03

DOSE RESPONSE ANALYSIS OF CARBACHOL ELICITED DRINKING IN THE RAT LIMBIC SYSTEM.
076081 09-04

CONFIGURATION FREQUENCY ANALYSIS OF SOME LSD EFFECTS.
079956 09-12

CONTRIBUTION TO THE USE OF MULTIVARIATE ANALYSIS IN THERAPEUTIC TESTING.
085343 10-11

ANALYSIS OF RESULTS IN TREATMENT OF PARKINSONISM WITH LEVODOPA.
087660 10-11

CORRELATIONS OF STRUCTURE-ACTIVITY OF MORPHINE-LIKE ANALGESICS USING REGRESSION ANALYSIS.
089042 10-01

PSYCHOTROPIC DRUG USE AND DRIVING RISK: A REVIEW AND ANALYSIS.
093085 11-17

QUANTITATIVE CLINICAL ANALYSIS OF THE EFFECT OF FENETYLLIN (CAPTAGON) ON HYPERKINETIC CHILDREN.
093540 11-11

ON THE ANALYSIS OF 5-HYDROXYTRYPTOPHAN PRODUCED HYPERTHERMIA IN MICE PRETREATED WITH A MONOAMINE OXIDASE INHIBITOR NIAMID.
098035 11-03

ON THE ANALYSIS OF THE EFFECTS OF 5-HYDROXYTRYPTOPHAN.
098064 11-03

AN ANALYSIS OF THE ROLE OF CHOLINERGIC DRUGS IN BEHAVIOR RELATED TO FOOD AND WATER DEPRIVATION. (PH.D.DISSERTATION).
103267 12-04

A TRIAL ON THE VALUE OF SORDINOL IN SCHIZOPHRENIA -- BY SUBJECTIVE METHOD AND PARTLY BY USING SEQUENTIAL ANALYSIS.
129451 12-08

**ANATOMICAL**

CONSIDERATIONS ON THE HYPERKINESIA OF L-DOPA: SIGNIFICANT BIOCHEMICAL AND ANATOMICAL DEFICIENCIES.
078555 09-13

**ANDROGEN**

USE OF AN ANDROGEN DEPLETING HORMONE IN THE TREATMENT OF MALE SEX OFFENDERS.
080178 09-14

**ANDROGENIZATION**

POST-NEONATAL ANDROGENIZATION AND ADULT AGGRESSIVE BEHAVIOR IN FEMALE MICE.
081233 09-04

**ANDROGENIZED**

UPTAKE OF TRITIATED TESTOSTERONE IN BRAIN AND PERIPHERAL TISSUES OF NORMAL AND NEONATALLY ANDROGENIZED FEMALE RATS.
076086 09-04

**ANESTHESIA**

TOXICITY, NARCOTIC EFFECT, CONCENTRATION AT END OF ANESTHESIA, ELIMINATION FROM BLOOD AND BIOTRANSFORMATION OF HEXOBARBITAL IN RATS OF VARIOUS AGES FOLLOWING SLEEP INDUCTION WITH BARBITAL AND AFTER.
058987 03-05

ELECTRICAL IMPEDANCE CHANGES IN MANY SITES OF BRAIN IN PARADOXICAL SLEEP, ANESTHESIA AND ACTIVITY.
066474 05-03

A COMPARISON OF PROPANIDID (EPONTOL) AND THIOPENTONE ANESTHESIA IN ECT.
076276 09-14

AMNESIA AND BRAIN SEIZURES ACTIVITY IN MICE: EFFECTS OF DIETHYL-ETHER ANESTHESIA PRIOR TO ELECTROSHOCK STIMULATION.
097952 11-04

**ANESTHETIC**

ANESTHETIC AGENTS AND THE CHEMICAL SENSITIVITY OF CORTICAL NEURONES.
040580 01-03

WATER STRUCTURE IN ANESTHETIC ACTION: TIME-DEPENDENCE D20 EFFECTS ON NERVE.
055582 02-03

INTERACTIONS BETWEEN CERTAIN DRUGS USED PREOPERATIVELY AND ANESTHETIC AGENTS.
066890 05-15

EVALUATION OF CL-1848C: A NEW DISSOCIATIVE ANESTHETIC IN NORMAL HUMAN VOLUNTEERS.
097971 11-07

**ANESTHETIZED**

ECG CHANGES INDUCED BY PHENOTHIAZINE DRUGS IN THE ANESTHETIZED RAT.
072525 08-03

**ANGER**

A CONTROLLED STUDY OF THE EFFECTS OF DIPHENYLHYDANTOIN ON ANXIETY, IRRITABILITY, AND ANGER IN NEUROTIC OUTPATIENTS.
064478 04-10

**ANGIOTENSIN**

ACTION OF GUANETHIDINE ON THE PRESSOR EFFECT OF ANGIOTENSIN IN ADRENALECTOMIZED DOGS.
046399 01-03

**ANHYDRASE**

THE ROLE OF CARBONIC ANHYDRASE IN ANION SECRETION INTO CEREBROSPINAL FLUID.
040755 01-03

ALTERED ABSORPTION OF DRUGS FROM THE RAT SMALL INTESTINE BY CARBONIC ANHYDRASE INHIBITION.
066369 05-03

TREATMENT AND PROPHYLAXIS OF MANIC STATES WITH A CARBONIC ANHYDRASE INHIBITOR.
105731 12-14

**ANIMAL**

EFFECT OF AMPHETAMINE ANALOGS ON DISRUPTION OF ANIMAL BEHAVIOR AND BARBITURATE SLEEPING TIME.
046196 01-03

LIVER DAMAGE FOLLOWING APPLICATION OF PYRAZINAMIDE IN ANIMAL EXPERIMENTS: 1. CHANGES IN BODY WEIGHT OF RATS UNDER THE INFLUENCE OF PYRAZINAMIDE.
055398 02-05

RETICULAR STIMULATION AND CHLORPROMAZINE: AN ANIMAL MODEL FOR SCHIZOPHRENIC OVERAROUSAL.
058531 02-04

THE CLINICAL EVALUATION OF FOUR PROPOSED ANTIDEPRESSANTS. RELATIONSHIP TO THEIR ANIMAL PHARMACOLOGY.
059040 03-07

MORPHOLOGICAL ASPECTS OF APPLICATION OF NOXIPTILIN (BAY-1521) IN ANIMAL EXPERIMENTS.
079972 09-03

CONTRIBUTION TO THE STUDY OF THE EXTRAPYRAMIDAL SYNDROME WITH ANIMAL EXPERIMENTATION. THE ROLE OF CALCIUM AND O-METHYLENE DERIVATIVES.
086348 10-03

EFFECT OF PHENOBARBITAL ON THE IN VITRO METABOLISM OF DIAZEPAM IN SEVERAL ANIMAL SPECIES.
090134 11-03

LONG-TERM TREATMENT WITH CHLORPROMAZINE IN ANIMAL EXPERIMENTATION.
105619 12-05

**ANIMALS**

OXIDATIVE PHOSPHORYLATION IN HEART MITOCHONDRIA ISOLATED FROM CHLORPROMAZINE TREATED ANIMALS.
041564 01-03

STIMULANT SELF-ADMINISTRATION BY ANIMALS: SOME COMPARISONS WITH OPIATE SELF-ADMINISTRATION.
056237 02-04

PSYCHOLOGICAL APPROACHES TO OPIATE DEPENDENCE AND SELF-ADMINISTRATION BY LABORATORY ANIMALS.
056240 02-04

THE PREDICTIVE VALUE FOR MAN OF TOXICOLOGICAL TESTS OF DRUGS IN LABORATORY ANIMALS.
057607 02-05

UNITED-STATES PROCEDURES FOR SCREENING DRUGS: TESTING FOR DEPENDENCE LIABILITY IN ANIMALS AND MAN.
058971 03-02

THE EFFECT OF LITHIUM ON THE METABOLISM OF EXPERIMENTAL ANIMALS.
081111 09-03

EFFECTS OF NEUROLEPTICS ON THE CEREBRAL ELECTRICAL ACTIVITY OF LABORATORY ANIMALS: PRESENTATION OF A MODEL DESIGN FOR NEUROPHARMACOLOGICAL EXPERIMENTS.
085337 10-03

MAYHEM AMONG THE ANIMALS.
095318 11-04

INFLUENCE OF HAPLOPHYLLUM ALKALOIDS ON THE BODY TEMPERATURE OF ANIMALS.
105721 12-03

THE SAFETY TEST OF L-DOPA -- II. EFFECT OF L-DOPA ON THE DEVELOPMENT OF PRENATAL AND POSTNATAL OFFSPRINGS OF EXPERIMENTAL ANIMALS.
114836 12-02

THE SAFETY TEST OF L-DOPA. I. ACUTE AND SUBACUTE TOXICITY OF L-DOPA IN EXPERIMENTAL ANIMALS.
114837 12-05

**ANION**
THE ROLE OF CARBONIC ANHYDRASE IN ANION SECRETION INTO CEREBROSPINAL FLUID.
040755 01-03

**ANOREXIA**
THE RELATIONSHIP OF AMPHETAMINE INDUCED ANOREXIA AND FREEZING UNDER A MULTIPLE CRF-EXT OPERANT SCHEDULE.
068288 06-04

**ANOREXIA-NERVOSA**
ELECTROSPLANCHNOGRAPHY IN ANOREXIA-NERVOSA AND DEPRESSION -- PRELIMINARY RESULTS.
072154 07-16
CYPROHEPTADINE HYDROCHLORIDE (PERIACTIN) AND ANOREXIA-NERVOSA: A CASE REPORT.
078931 09-07

**ANOREXIGENIC**
COMPARATIVE STUDY OF CNS STIMULATORY ACTIVITY AND ANOREXIGENIC POTENCY OF PHENYLETHYLAMINE DERIVATIVES. (PH.D.DISSERTATION).
103710 12-04

**ANTABUSE**
NEUROTOXIC SIDE-EFFECTS IN DISULFIRAM (ANTABUSE) OVERDOSAGE.
067743 06-15

**ANTAGONISM**
THE ANTAGONISM OF PHENTOLAMINE AGAINST EXOGENOUSLY ADMINISTERED AND ENDOGENOUSLY RELEASED NOREPINEPHRINE IN RABBIT AORTIC STRIPS.
040243 01-03
THE ANTAGONISM OF ADRENERGIC NEURONE BLOCKADE BY AMPHETAMINE AND DEXAMPHETAMINE IN THE RAT AND GUINEA-PIG.
055322 02-03
QUANTITATIVE STUDIES ON THE ANTAGONISM BY NALOXONE OF SOME NARCOTIC AND NARCOTIC ANTAGONIST ANALGESICS.
063798 04-03
ANTAGONISM OF D-AMPHETAMINE BY ALPHA-METHYL-L-TYROSINE: BEHAVIORAL EVIDENCE FOR THE PARTICIPATION OF CATECHOLAMINE STORES AND SYNTHESIS IN THE AMPHETAMINE STIMULANT RESPONSE.
064096 04-03
VALIDITY OF ANTAGONISM OF DIFFERENT EFFECTS OF RESERPINE AS TEST FOR ANTIDEPRESSANT ACTIVITY.
064413 04-03
ANTAGONISM OF THE ANTIAVOIDANCE EFFECTS OF VARIOUS AGENTS BY ANTICHOLINERGIC DRUGS.
064426 04-04
THE INFLUENCE OF VARIOUS NEUROLEPTIC DRUGS ON SHOCK AVOIDANCE RESPONDING IN RATS. III. AMPHETAMINE ANTAGONISM IN THE DISCRIMINATED SIDMAN AVOIDANCE PROCEDURE.
064476 04-04
OBSERVATION OF THE GROOMING BEHAVIOR OF RESERPINIZED WHITE MICE AS A METHOD FOR INVESTIGATING RESERPINE ANTAGONISM AND SYNERGISM.
065442 05-04
QUANTITATION OF THE DEGREE OF ANTAGONISM OF CHLOROQUINE TO HISTAMINE, ACETYLCHOLINE AND SEROTONIN ( PA2 VALUES).
067462 06-03
DRUG ANTAGONISM AND WATER INTAKE.
067703 06-04
ANTAGONISM OF THE BEHAVIORAL EFFECTS OF MORPHINE AND METHADONE BY NARCOTIC ANTAGONISTS IN THE PIGEON.
069593 07-04
DRUG-INDUCED STEREOTYPED BEHAVIOR AND ITS ANTAGONISM IN DOGS.
079888 09-04
ANTAGONISM OF BETA-PHENYLETHYLAMINE DERIVATIVES AND SEROTONIN BLOCKING DRUGS UPON SEROTONIN, TRYPTAMINE AND RESERPINE BEHAVIORAL DEPRESSION IN MICE.
079970 09-04
INFLUENCE OF ISONIAZID ON THE CENTRAL NERVOUS SYSTEM; THE ANTAGONISM BETWEEN ISONIAZID AND PYRIDOXINE, PANTOTHENIC ACID AND COUMARIN IN RATS (MELILOTUS-OFFICINALIS).
126055 12-04

**ANTAGONIST**
CLINICAL ANTIDEPRESSANT ACTIVITY OF CYCLAZOCINE -- A NARCOTIC ANTAGONIST.
041568 01-09
QUANTITATIVE STUDIES ON THE ANTAGONISM BY NALOXONE OF SOME NARCOTIC AND NARCOTIC ANTAGONIST ANALGESICS.
063798 04-03

**ANTAGONISTIC**
ANTAGONISTIC EFFECTS OF DOPA AND PROPRANOLOL ON BRAIN GLYCOGEN.
058800 02-03
EVALUATION OF THE PERIPHERAL AND CENTRAL ANTAGONISTIC ACTIVITIES AGAINST 5-HYDROXYTRYPTAMINE OF SOME NEW AGENTS.
067603 06-03
ANTAGONISTIC INFLUENCE OF BETA-SYMPATHICOLYTICS ON THE METAMPHETAMINE INDUCED CHANGES IN FUNCTION AND METABOLISM OF THE BRAIN.
079954 09-03
EFFECT OF CHLORPROMAZINE ON CONDITIONED REFLEXES AND ANTAGONISTIC ACTIVITY OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126054 12-04

**ANTAGONISTS**
THE EFFECTS OF MORPHINE-LIKE SUBSTANCES AND THEIR ANTAGONISTS ON TRANSMISSION AT THE NEURO EFFECTOR JUNCTION OF THE MYENTERIC PLEXUS LONGITUDINAL MUSCLE PREPARATION OF THE GUINEA-PIG ILEUM.
041974 01-03
NARCOTIC ANTAGONISTS AND THE PROBLEMS OF DRUG DEPENDENCE.
046195 01-13
TREATMENT OF HEROIN DEPENDENCE WITH OPIATE ANTAGONISTS.
065195 05-13
ANTAGONISM OF THE BEHAVIORAL EFFECTS OF MORPHINE AND METHADONE BY NARCOTIC ANTAGONISTS IN THE PIGEON.
069593 07-04
THE EFFECT OF VARIOUS NEUROHUMORAL MODULATORS ON THE ACTIVITY OF MORPHINE AND THE NARCOTIC ANTAGONISTS IN THE TAIL-FLICK AND PHENYLQUINONE TESTS.
069594 07-04
SITES OF ACTION OF RAM-302 AND NALORPHINE AS MORPHINE ANTAGONISTS.
074934 08-03
SUBJECTIVE EFFECTS OF NARCOTIC ANTAGONISTS CYCLAZOCINE AND NALORPHINE ON THE ADDICTION RESEARCH CENTER INVENTORY (ARCI).
097961 11-14

**ANTEROGRADE**
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: III. ANTEROGRADE AMNESIA.
065852 05-14

**ANTIADRENALINE**
THE EFFECT OF ANTIADRENALINE COMPOUNDS ON ACETYLCHOLINE RESPONSES OF FROG RECTUS-ABDOMINIS MUSCLE.
041538 01-03

**ANTIADRENERGIC**
NONANTAGONISM OF ANTIADRENERGIC AGENTS BY A DIBENZOXEPINE: PRELIMINARY REPORT.
089438 11-13

**ANTIAGGRESSIVE**
ANTIAGGRESSIVE EFFECT OF LITHIUM SALTS IN SEVERE MENTALLY RETARDED ADOLESCENTS.
106776 12-14

**ANTIANAPHYLATIC**
EFFECT OF CAPERS ON THE VASCULAR LUMEN OF ISOLATED EXTREMITIES OF SENSITIZED FROGS AND THE ANTIANAPHYLATIC EFFECT OF SUPRASTIN.
105720 12-03

**ANTIANDROGEN**
PSYCHIATRIC CLINICAL EXPERIENCE WITH AN ANTIANDROGEN PREPARATION.
088995 10-14
THE MEDICAL AND SOCIAL INDICATION OF ANTIANDROGEN THERAPY.
105733 12-11

**ANTIANDROGENS**
THE EFFECT OF ANTIANDROGENS ON AGGRESSIVE BEHAVIOR IN THE GERBIL.
081159 09-04

**ANTIANXIETY**
METHODS FOR DETECTING ANTIANXIETY DRUGS USING BABOONS (PAPIO-CYNOCEPHALUS).
041537 01-06
METHODOLOGICAL CONSIDERATIONS IN EVALUATING ANTIANXIETY DRUGS.
046558 01-16
DIPOTASSIUM CHLORAZEPATE: CLINICAL REPORTS ON A NEW ANTIANXIETY AGENT.
055738 02-09
A SURVEY OF ANTIANXIETY AGENTS USED OVER THE PAST 30 YEARS.
063594 03-10
ANTIANXIETY AGENTS.
063923 04-17
THE ANTIANXIETY EFFECTS OF HALOPERIDOL AND TRIFLUOPERAZINE IN AN OUTPATIENT NEUROTIC POPULATION.
089444 11-10

**ANTIAPOMORPHINE**
NEW METHOD FOR ASSAYING ANTIAPOMORPHINE ACTIVITY IN PIGEONS.
089437 11-06

**ANTIARRHYTHMIC**
ANTIARRHYTHMIC AND HEMODYNAMIC EFFECTS OF IMIPRAMINE AND CHLORIMIPRAMINE.
058991 03-05

**ANTIAUTISTIC**
SULPIRIDE, A SINGULAR, ANTIAUTISTIC AND THYMOANALEPTIC NEUROLEPTIC.
089160 10-11

**ANTIAVOIDANCE**
ANTAGONISM OF THE ANTIAVOIDANCE EFFECTS OF VARIOUS AGENTS BY ANTICHOLINERGIC DRUGS.
064426 04-04

**ANTIBIOTICS**
EXCRETION OF VANYLGLYCOL IN HUMAN URINE UNDER DIETARY CONTROL, AND DURING TREATMENT WITH ANTIBIOTICS, DISULFIRAM, A MONOAMINE OXIDASE INHIBITOR, ALPHA-METHYLDOPA, AND RESERPINE.
060272 03-13

**ANTIBODY**
THE ROLE OF THE HYPOTHALAMO-PITUITARY SYSTEM IN THE MECHANISM OF ACTION OF RESERPINE AND 5-HYDROXYTRYPTOPHAN ON ANTIBODY PRODUCTION.
040579 01-03

**ANTICHOLINERGIC**
SYNTHESIS OF SOME GLYCIDIC HYDRAZIDES AND AMIDES AS POTENTIAL PSYCHOTROPIC AGENTS AND ANTICHOLINERGIC AGENTS.
064258 04-01
THE CONCOMITANT EFFECTS OF MILD SLEEP LOSS AND AN ANTICHOLINERGIC DRUG.
064387 04-13
ANTAGONISM OF THE ANTIAVOIDANCE EFFECTS OF VARIOUS AGENTS BY ANTICHOLINERGIC DRUGS.
064426 04-04
CENTRAL AND PERIPHERAL EFFECTS OF ANTICHOLINERGIC COMPOUNDS.
072524 08-04
ANTICHOLINERGIC CENTRAL BLOCKADE OF SALT AROUSED AND DERIVATION INDUCED DRINKING.
081227 09-04
A COMPARATIVE DETERMINATION OF SIDE-EFFECTS ASSOCIATED WITH THE ORAL USE OF THREE ANTICHOLINERGIC PSYCHOTROPIC DRUGS.
126639 12-15

**ANTICHOLINERGICS**
5-HYDROXYTRYPTOPHAN PRODUCED HYPOTHERMIA IN MICE AS A TEST FOR PHARMACOLOGICAL DIFFERENTIATION OF ANTIDEPRESSANTS, ANTICHOLINERGICS AND NEUROLEPTICS: SOME DATA ON THE NATURE OF THIS HYPOTHERMIA.
105622 12-06

**ANTICONVULSANT**
CORRELATION BETWEEN THE DURATION OF THE ANTICONVULSANT ACTIVITY OF DIAZEPAM AND ITS PHYSIOLOGICAL DISPOSITION IN MICE.
046402 01-03
ANTICONVULSANT DRUGS AND SELF-STIMULATION RATES IN RATS.
066871 05-04
CONGENITAL ABNORMALITIES AND ANTICONVULSANT DRUGS.
071949 07-15
ANTICONVULSANT AND MOTOR DEPRESSANT EFFECTS OF DIAZEPAM.
076576 09-02
CLASSICAL HYSTERICAL SEIZURES FACILITATED BY ANTICONVULSANT TOXICITY.
081135 09-15

**ANTICONVULSIVE**
SUBNORMAL SERUM FOLATE DUE TO ANTICONVULSIVE THERAPY: A DOUBLE-BLIND STUDY OF THE EFFECT OF FOLIC ACID TREATMENT IN PATIENTS WITH DRUG INDUCED SUBNORMAL SERUM FOLATES.
042700 01-11
ANTICONVULSIVE PROPERTIES OF SOME BENZODIAZEPINE DERIVATIVES.
058604 02-03
INVESTIGATION ON A NEW ANTICONVULSIVE PRODUCT RO-5-4023.
085454 10-14

**ANTIDEPRESSANT**
CLINICAL ANTIDEPRESSANT ACTIVITY OF CYCLAZOCINE -- A NARCOTIC ANTAGONIST.
041568 01-09
DIMETHACRINE -- A NEW TRICYCLIC ANTIDEPRESSANT: OPEN INVESTIGATIONS IN A CLINIC AND POLYCLINIC.
058281 02-07
TRICYCLIC ANTIDEPRESSANT POISONING.
058333 02-15
EFFECT OF ANTIDEPRESSANT DRUGS ON ACCUMULATION AND DISAPPEARANCE OF MONOAMINES FORMED IN VIVO FROM LABELED PRECURSORS IN MOUSE BRAIN.
058798 02-03
HYDROXYTRYPTAMINE TURNOVER DECREASED BY THE ANTIDEPRESSANT DRUG CHLORIMIPRAMINE.
058799 02-03
USE OF A NEW ANTIDEPRESSANT IN THE FEMALE CLIMACTERIC.
063598 04-09
VALIDITY OF ANTAGONISM OF DIFFERENT EFFECTS OF RESERPINE AS TEST FOR ANTIDEPRESSANT ACTIVITY.
064413 04-03
HYPOTHALAMIC DYSFUNCTION AND ANTIDEPRESSANT DRUGS.
067012 05-14
USE OF ANTIPSYCHOTIC AND ANTIDEPRESSANT DRUGS BY CHRONICALLY ILL PATIENTS.
076351 09-17
A CONTROLLED STUDY OF THE ANTIDEPRESSANT EFFECT OF P-CHLORO-N-METHYLAMPHETAMINE, A COMPOUND WITH A SELECTIVE EFFECT ON THE CENTRAL 5-HYDROXYTRYPTAMINE METABOLISM.
078212 09-10
PRECLINICAL EVALUATION OF AHR-1118. A POTENTIAL ANTIDEPRESSANT DRUG.
082051 10-03
CASE OF SELF-POISONING WITH MULTIPLE ANTIDEPRESSANT DRUGS.
082153 10-15
A THERAPEUTIC AGENT FOR ANTIDEPRESSANT AND TRANQUILIZING CONTROL IN THE POST-TRAUMATIC NEUROSES.
086237 10-07
CHEMISTRY AND PHARMACOLOGY OF A NEW POTENTIAL ANTIDEPRESSANT, N-METHYL-N-(4-CHLOROBENZYL-11-DIHYDRO-5H DIBENZAZEPIN-5-YL) PROPYLAMINE HYDROCHLORIDE) (LEO-640, LOPRAMINE HYDROCHLORIDE).
089786 11-01
THE CLINICAL EFFECT OF CLOMIPRAMINE (ANAFRANIL) AS THE ANTIDEPRESSANT.
118585 12-09
PHARMACOLOGICAL BASIS OF ANTIDEPRESSANT EFFECTS.
118730 12-09

**ANTIDEPRESSANTS**
THE CLINICAL EVALUATION OF FOUR PROPOSED ANTIDEPRESSANTS. RELATIONSHIP TO THEIR ANIMAL PHARMACOLOGY.
059040 03-07
TREATMENT OF PHOBIC STATES WITH ANTIDEPRESSANTS: A RETROSPECTIVE STUDY OF 246 PATIENTS.
063934 04-10
EFFECTS OF A TRANQUILIZER AND TWO ANTIDEPRESSANTS ON LEARNED AND UNLEARNED BEHAVIORS.
064259 04-04
DIFFERENTIAL EFFECTS OF THREE TRICYCLIC ANTIDEPRESSANTS ON SLEEP AND REM SLEEP IN THE RAT.
067919 06-04
INHIBITORY EFFECT OF TWO NEWER ANTIDEPRESSANTS, LU-5-003 AND LU-3-010, ON SEROTONIN UPTAKE IN HUMAN BLOOD PLATELETS IN VITRO.
071791 07-03
MASKED DEPRESSION AND THE USE OF ANTIDEPRESSANTS IN GENERAL PRACTICE.
072219 07-17
THYROID HORMONE AND TRICYCLIC ANTIDEPRESSANTS IN RESISTANT DEPRESSIONS.
075428 08-09
THE USE AND ABUSE OF ANTIDEPRESSANTS.
089107 10-17
AGGRESSIVE BEHAVIOUR IN CHICKS INDUCED BY TRICYCLIC ANTIDEPRESSANTS.
090420 11-04
HYPERTENSIVE CRISIS IN A PATIENT ON MAOI ANTIDEPRESSANTS FOLLOWING A MEAL OF BEEF LIVER.
092211 11-15
DOUBLE-BLIND STUDY WITH ANTIDEPRESSANTS.
098174 11-10
FACTORS AFFECTING THE URINARY EXCRETION OF TRICYCLIC ANTIDEPRESSANTS IN MAN.
100026 11-13
A PHARMACOLOGICAL STUDY OF THE ANTIMUSCARINIC ACTIONS OF SEVERAL ANTIDEPRESSANTS. (PH.D.DISSERTATION).
104737 12-03
5-HYDROXYTRYPTOPHAN PRODUCED HYPOTHERMIA IN MICE AS A TEST FOR PHARMACOLOGICAL DIFFERENTIATION OF ANTIDEPRESSANTS, ANTICHOLINERGICS AND NEUROLEPTICS: SOME DATA ON THE NATURE OF THIS HYPOTHERMIA.
105622 12-06
LITHIUMS POSITION AMONG ANTIDEPRESSANTS IN THE TREATMENT OF ACUTE ENDOGENOUS AND INVOLUTIONAL DEPRESSIONS.
106777 12-09
EFFECT OF ANTIDEPRESSANTS ON CEREBRAL CIRCULATION AND OXYGEN UPTAKE.
110633 12-03
A DOUBLE-BLIND TRIAL OF THREE ANTIDEPRESSANTS (GO-2998, GO-2330 AND IMIPRAMINE HYDROCHLORIDE).
134903 12-09

**ANTIDEPRESSIVE**
PLASMA PROTEIN BINDING OF TRICYCLIC ANTIDEPRESSIVE DRUGS.
040573 01-13
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY. II. ANTIDEPRESSIVE EFFECT.
065851 05-09

STUDIES ON INTERACTIONS INVOLVING ANTIDEPRESSIVE AND OTHER DRUGS WITH TETRABENAZINE AND NORADNAMINE ON LOCOMOTOR ACTIVITY IN MICE, INCLUDING DETAILS OF THE EXPERIMENTAL DESIGN AND STATISTICAL ANALYSIS.
069077 06-04

THE ADRENERGICAL MECHANISMS OF ACTION IN ANTIDEPRESSIVE DRUGS.
073787 08-17

ANTIDEPRESSIVE PHARMACOTHERAPY.
086207 10-17

THE USE OF TWO COMBINATIONS OF DRUGS WITH MIXED ACTION, ANTIDEPRESSIVE AND TRANQUILIZING (AMITRYPTILINE - PERPHENAZINE) IN GENERAL AND IN PSYCHOSOMATIC MEDICINE.
089162 10-17

**ANTIDIURESIS**
ANTIDIURESIS IN MAN FOLLOWING LYSERGIC ACID DIETHYLAMIDE AND MESCALINE.
066399 05-13

**ANTIDOTAL**
ANTIDOTAL THIRST: A RESPONSE TO INTOXICATION.
070821 07-05

**ANTIDOTE**
THE EFFECT OF A PSYCHOTOMIMETIC GLYCOLATE AND ITS ANTIDOTE ESERINE ON THE ACH CONTENT OF THE LOBSTER WALKING LEG NERVE.
069515 06-13

**ANTIEMETIC**
A DOUBLE-BLIND EVALUATION OF THE ANTIEMETIC EFFICACY OF BENZQUINAMIDE, PROCHLORPERAZINE AND TRIMETHOBENZAMIDE IN OFFICE PRACTICE.
063022 03-07

**ANTIEPILEPTIC**
INFLUENCE OF ETHYLPHENACEMIDE ON SERUM LEVELS OF OTHER ANTIEPILEPTIC DRUGS.
066190 05-13

ANTIEPILEPTIC DOSING AFTER EXCESSIVE ALCOHOL INTAKE.
093919 11-11

CLINICOELECTROENCEPHALOGRAPHIC EVALUATION OF THE ANTIEPILEPTIC ACTION OF A NEW SERIES OF BENZODIAZEPINIC DERIVATIVES.
105486 12-07

**ANTIHEMOLYTIC**
ANTIHEMOLYTIC ACTIONS OF TRICYCLIC TRANQUILIZERS: STRUCTURAL CORRELATIONS.
074862 08-03

**ANTIINFLAMMATORY**
NONSTEROID ANTIINFLAMMATORY AGENTS.
051121 02-17

**ANTIMANIC**
CENTRAL ANTISEROTONINERGIC EFFECT OF ANTIMANIC DRUGS.
097988 11-03

**ANTIMETRAZOL**
FURTHER STUDIES ON THE LONG-LASTING ANTIMETRAZOL ACTIVITY OF DIAZEPAM IN MICE.
081106 09-03

**ANTIMUSCARINIC**
A PHARMACOLOGICAL STUDY OF THE ANTIMUSCARINIC ACTIONS OF SEVERAL ANTIDEPRESSANTS. (PH.D.DISSERTATION).
104737 12-03

**ANTINOCICEPTIVE**
A COMPARISON OF THE ANTINOCICEPTIVE ACTIONS OF CHOLINOMIMETIC AND MORPHINE-LIKE DRUGS.
064290 04-03

ON THE CENTRAL SITES FOR THE ANTINOCICEPTIVE ACTION OF MORPHINE AND FENTANYL.
074936 08-03

REDUCTION OF THE ANTINOCICEPTIVE EFFECT OF 5-HYDROXYTRYPTOPHAN IN MORPHINE TOLERANT RATS.
075846 09-03

**ANTIOXIDANTS**
A POSSIBLE PATHWAY FOR ETHANOL INDUCED FATTY LIVER AND MODIFICATION OF LIVER INJURY BY ANTIOXIDANTS.
070906 07-05

**ANTIPARKINSON**
ANTIPARKINSON DRUG OVERUSE.
074217 08-17

EFFICACY OF ANTIPARKINSON AGENTS CAN LEAD TO OVERUSE.
084822 10-15

**ANTIPARKINSONIAN**
A SIMPLE SCREENING METHOD FOR ANTIPARKINSONIAN DRUGS IN MICE.
066415 05-06

EFFECT OF WITHDRAWAL OF ANTIPARKINSONIAN MEDICATION ON CHRONICALLY HOSPITALIZED PSYCHIATRIC PATIENTS.
086445 10-15

**ANTIPARKINSONISM**
CONTROLLED STUDIES OF ANTIPARKINSONISM AGENTS IN THE TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL SYMPTOMS.
063777 04-14

**ANTIPHLOGISTIC**
4-(BETA-BENZOYLVINYL) ANTIPYRINE DERIVATIVES WITH ANTIPHLOGISTIC AND ANALGESIC ACTIVITY.
055519 02-03

**ANTIPOISON**
CONSIDERATIONS OF SOME SIDE-EFFECTS OF DRUGS. (A STUDY BEARING ON 11,410 CALLS RECEIVED BY THE BELGIAN ANTIPOISON CENTER).
042687 01-15

**ANTIPSYCHOTIC**
ANTIPSYCHOTIC PROPERTIES OF LOXAPINE SUCCINATE.
058374 02-07

WITHDRAWAL OF ANTIPSYCHOTIC DRUGS FROM CHRONIC PSYCHIATRIC PATIENTS.
060208 03-08

MODIFICATION OF THE EFFECTS OF ANTIPSYCHOTIC AGENTS ON THE OPEN FIELD PERFORMANCE OF RATS BY TREATMENT WITH ALPHA-METHYLTYROSINE OR P-CHLOROPHENYLALANINE.
064392 04-04

LONG-ACTING, ANTIPSYCHOTIC AGENTS AND EXTRAPYRAMIDAL SIDE-EFFECTS.
065471 05-15

METIAPINE: A NEW ANTIPSYCHOTIC AGENT.
069059 06-07

CHOICE OF ANTIPSYCHOTIC DRUGS.
075872 09-08

USE OF ANTIPSYCHOTIC AND ANTIDEPRESSANT DRUGS BY CHRONICALLY ILL PATIENTS.
076351 09-17

ANTIPSYCHOTIC DRUGS: AN ESSENTIAL TOOL OF COMMUNITY PSYCHIATRY.
080355 09-08

**ANTIPYRINE**
4-(BETA-BENZOYLVINYL) ANTIPYRINE DERIVATIVES WITH ANTIPHLOGISTIC AND ANALGESIC ACTIVITY.
055519 02-03

**ANTISEROTONIN**
ANTISEROTONIN EFFECT OF AGENTS BLOCKING THE ADRENERGIC BETA-RECEPTOR.
108694 12-03

**ANTISEROTONINERGIC**
CENTRAL ANTISEROTONINERGIC EFFECT OF ANTIMANIC DRUGS.
097988 11-03

**ANTITUSSIVE**
PHARMACOLOGICAL STUDIES ON A NEW SPECIFICALLY POTENT ANTITUSSIVE AGENT, 14-HYDROXYDIHYDRO-6-BETA-THEBAINOL-4-METHYLETHER (OXYMETHEBANOL).
055585 02-03

ON THE SITES OF ANTITUSSIVE ACTION OF N-(2-PICOLYL)-N-PHENYL-N-(2-PIPERIDINOETHYL)AMINE (TAT-3).
055586 02-03

**ANXIETY**
TWO TRIALS WITH A NEW PSYCHOTHERAPEUTIC DRUG IN THE TREATMENT OF ANXIETY.
058335 02-10

VERBAL ANXIETY AND THE BETA-ADRENERGIC RECEPTORS: A FACILITATING MECHANISM.
060880 03-13

THE ANXIETY DEPRESSION SYNDROME.
063567 03-10

A CONTROLLED TRIAL OF BENZOCTAMINE (BA-30803) IN NEUROTIC ANXIETY.
064285 04-10

COMBINED THERAPY IN ANXIETY DEPRESSIVE SYNDROMES: I. COMPARATIVE EFFECTS OF LIMBITROL (CHLORDIAZEPOXIDE AMITRIPTYLINE) AND PLACEBO.
064312 04-10

A CONTROLLED STUDY OF THE EFFECTS OF DIPHENYLHYDANTOIN ON ANXIETY, IRRITABILITY, AND ANGER IN NEUROTIC OUTPATIENTS.
064478 04-10

STUDY ON THE EFFECTS OF TABLET COLOUR IN THE TREATMENT OF ANXIETY STATES.
066496 05-10

TRIALS OF RO-5-3350 AND DIAZEPAM FOR ANXIETY SYMPTOMS.
066826 05-07

DOXEPIN (SINEQUAN) AND OTHER DRUGS FOR ANXIETY AND DEPRESSION.
066877 05-17

PSYCHOTROPICS IN ANXIETY AND DEPRESSION -- COMBINATION OR SINGLE AGENT.
068298 06-09

SEROTONIN: A POSSIBLE MEDIATOR OF BEHAVIORAL SUPPRESSION INDUCED BY ANXIETY.
069311 06-04

AROUSAL, ANXIETY, AGGRESSION, AND ATTITUDE CHANGE.
070352 07-14
A COMPARISON OF DOXEPIN AND CHLORDIAZEPOXIDE IN THE THERAPY OF ANXIETY.
072141 07-10
THIOTHIXENE IN THE TREATMENT OF ANXIETY AND DEPRESSION IN OUTPATIENTS.
082052 10-10
COMPARATIVE, DOUBLE-BLIND STUDY OF DOXEPINE AND LIBRIUM IN CASES OF PSYCHONEUROSES WITH ANXIETY AMONG HOSPITALIZED AND AMBULATORY PATIENTS.
087489 10-10
PHARMACOTHERAPY OF TENSION AND ANXIETY.
126180 12-14
USE OF CATTELS IPAT ANXIETY SCALE IN A GROUP OF NEUROTIC PATIENTS BEFORE AND AFTER PSYCHOPHARMACOLOGICAL DRUG AND ELECTRIC SHOCK THERAPY.
128509 12-17

**ANXIOLYTIC**
CLINICAL TESTS OF A NEW ANXIOLYTIC, MEDAZEPAM (NOBRIUM).
079864 09-11
TESTS OF A NEW ANXIOLYTIC: THE USE OF DOXEPINE IN GERIATRIC CASES.
086236 10-07

**ANXIOLYTICS**
ANXIOLYTICS IN THE PRACTICE OF A DISTRICT PHYSICIAN.
086208 10-17

**ANXIOUS**
MOLINDONE IN ANXIOUS NEUROTIC PSYCHIATRIC OUTPATIENTS: A PILOT STUDY.
058969 03-10
HYDROXYZINE AND CHLORDIAZEPOXIDE IN ANXIOUS NEUROTIC OUTPATIENTS: A COLLABORATIVE CONTROLLED STUDY.
062321 03-10
BUTABARBITAL SODIUM AND CHLORDIAZEPOXIDE IN ANXIOUS NEUROTIC OUTPATIENTS: A COLLABORATIVE CONTROLLED STUDY.
066276 05-10
DOXEPIN VERSUS CHLORDIAZEPOXIDE: A DOUBLE-BLIND STUDY ON ANXIOUS OUTPATIENTS.
072143 07-10
THE PREDICTION OF PLACEBO RESPONSE IN ANXIOUS AND DEPRESSED OUTPATIENTS.
092102 11-16
USE OF MELLERIL RETARD IN TREATMENT OF PATIENTS WITH DEPRESSIVE PARANOID AND ANXIOUS DEPRESSIVE SYNDROMES.
109724 12-14

**AOLEPT**
EXPERIENCE WITH PROPERICIAZIN (AOLEPT) IN THE TREATMENT OF CHILDREN WITH DISTURBED PSYCHOMOTOR FUNCTIONS AND RESTLESSNESS.
081144 09-11

**AORTIC**
THE ANTAGONISM OF PHENTOLAMINE AGAINST EXOGENOUSLY ADMINISTERED AND ENDOGENOUSLY RELEASED NOREPINEPHRINE IN RABBIT AORTIC STRIPS.
040243 01-03

**APHAGIA**
APHAGIA, PRODUCED BY DEPOSITION OF DRUGS INTO THE HYPOTHALAMUS OF RATS.
088463 10-03

**APHASIA**
DEXEDRINE AS AN ADJUNCT TO APHASIA THERAPY.
101801 12-11

**APOMORPHINE**
SIMILARITIES BETWEEN NEUROLOGIC EFFECTS OF L-DOPA AND OF APOMORPHINE.
056574 02-11
EFFECT OF APOMORPHINE AND PIMOZIDE ON SYNTHESIS AND TURNOVER OF LABELED CATECHOLAMINES IN MOUSE BRAIN.
066502 05-03
THE INHIBITION OF CATECHOLAMINE BIOSYNTHESIS BY APOMORPHINE.
066854 05-03
THE INFLUENCE OF SINGLE AND CHRONIC MORPHINE ADMINISTRATION ON SOME CENTRAL EFFECTS OF AMPHETAMINE AND APOMORPHINE.
075840 08-05
AUTOMATIC MONITORING OF APOMORPHINE INDUCED PECKING IN PIGEONS.
075922 09-04

**APONEURON**
TESTING THE PERFORMANCE UNDER APONEURON OF OTHERWISE NORMAL SCHOOL CHILDREN WITH A TENDENCY TOWARD REDUCED DRIVE AND EASY TIRING.
080563 09-11

**APPARATUS**
TASTE PREFERENCES: AN APPARATUS FOR RANDOM AND SIMULTANEOUS PRESENTATION OF SEVERAL SOLIDS AND SOLUTIONS.
067892 06-06
AN APPARATUS FOR OBSERVING ATTENTION AND PERSEVERANCE.
086161 10-16

**APPEARANCES**
CLINICAL AND EEG APPEARANCES OF ACUTE DRUG INTOXICATION DUE TO CHLORALOSE.
088568 10-15

**APPETITE**
MODIFICATION OF NACL APPETITE IN THE ADRENALECTOMIZED RAT CONSEQUENT TO EXTENSIVE LICL POISONING.
061094 03-04
CAN WE BRAINWASH THE APPETITE?
064635 05-03

**APPLICATIONS**
POSSIBLE APPLICATIONS OF LONG-ACTING INTRAMUSCULAR MAJOR TRANQUILLIZERS.
100020 11-11

**APPRAISAL**
L-DOPA IN THE TREATMENT OF PARKINSONISM. A PRELIMINARY APPRAISAL.
071985 07-07

**APPROACH**
A NOVEL APPROACH TO THE INVESTIGATION OF NOREPINEPHRINE METABOLISM IN HUMAN SYMPATHETIC NERVE.
064144 04-03
AN APPROACH TO THE TREATMENT OF DRUG ABUSE.
067934 06-15
A DIFFERENTIAL APPROACH TO THE INDICATION OF NEUROLEPTICS.
070924 07-17
THE PHARMACOLOGICAL APPROACH TO ALCOHOLISM -- PART 2.
081072 09-17
THE PHARMACOLOGY OF DISORDERED SLEEP: A LABORATORY APPROACH.
084806 10-14
THE ETHOLOGICAL APPROACH TO SOCIALIZATION.
091173 11-04
COMPARISON OF THE EFFECTS OF EXOGENOUS ACTH ON APPROACH AND AVOIDANCE CONDITIONING: IMPLICATIONS FOR THE PHYSIOLOGY OF INCENTIVE MOTIVATION. (PH.D.DISSERTATION).
103354 12-04
ABSTRACT OF THESES FOR DOCTOR OF MEDICAL SCIENCES, THE UNIVERSITY OF TOKYO: MORITA THERAPEUTIC APPROACH TO SCHIZOPHRENIA.
126778 12-17

**APPROACHES**
PSYCHOLOGICAL APPROACHES TO OPIATE DEPENDENCE AND SELF-ADMINISTRATION BY LABORATORY ANIMALS.
056240 02-04
AN EVALUATION OF THE PHARMACOLOGIC APPROACHES TO LEARNING IMPEDIMENTS.
066838 05-14

**APY-606**
A DOUBLE-BLIND, CROSSOVER COMPARISON OF APY-606 WITH CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIA.
118583 12-08
STUDIES ON PSYCHOTROPIC DRUGS (SIXTH REPORT) - METABOLIC FATE OF APY-606 - EXCRETION AND METABOLISM IN RATS.
131057 12-02
STUDIES ON PSYCHOTROPIC DRUGS (FIFTH REPORT) -- PHARMACOLOGICAL EFFECT OF 8(3-(2-CHLORO-10-PHENOTHIAZINYL)PROPYL)-1 THIADIAZASPIRODECAN-3-ONE HYDROCHLORIDE (APY-606).
131058 12-02
STUDIES ON PSYCHOTROPIC DRUGS (SEVENTH REPORT) -- METABOLIC FATE OF APY-606 -- ABSORPTION, DISTRIBUTION, EXCRETION AND METABOLISM OF TRITIATED APY-606.
131059 12-02

**AQUATICUS**
SENSORY REPRESENTATION IN THE NEOCORTEX OF THE MOLE, SCALOPUS AQUATICUS.
066468 05-03

**ARCI**
SUBJECTIVE EFFECTS OF NARCOTIC ANTAGONISTS CYCLAZOCINE AND NALORPHINE ON THE ADDICTION RESEARCH CENTER INVENTORY (ARCI).
097961 11-14

**ARECOLINE**
BEHAVIORAL EFFECTS OF ARECOLINE IN RATS.
071786 07-04

**ARGININE**
EFFECT OF ARGININE N-ACETYLASPARAGINATE ON DIFFERENT PATTERNS OF DISCRIMINATION.
098049 11-04

**ARIOCARPUS-RETUSUS**
CACTUS ALKALOIDS: IX. ISOLATION OF N-METHYL-3-4-DIMETHOXY-BETA-PHENETHYLAMINE AND N-METHYL-4-METHOXY-BETA-PHENETHYLAMINE FROM ARIOCARPUS-RETUSUS.
070751 07-01

**AROMATIC**
ENCEPHALOPATHY AS A SEQUEL OF CHRONIC INTOXICATION WITH HALOGEN DERIVATIVES OF AROMATIC HYDROCARBONS.
085102 10-15

**AROUSAL**
CHOLINERGIC MODULATION OF ADRENERGIC AROUSAL IN THE DEVELOPING RAT.
063688 04-04
AROUSAL, ANXIETY, AGGRESSION, AND ATTITUDE CHANGE.
070352 07-14
BODY CONSCIOUSNESS IN STATES OF PHARMACOLOGICAL DEPRESSION AND AROUSAL.
072032 07-14
AROUSAL AND SCHIZOPHRENIA.
074625 08-08
DRUG-INDUCED SYMPATHETIC AROUSAL AND NEUROTICISM.
075779 08-13
THE EFFECT OF ALPHA-METHYL-P-TYROSINE ON SLEEP AND AROUSAL IN THE RAT.
075891 09-04
CENTRAL ACTION OF SOME AUTONOMIC DRUGS IN RESPECT TO EEG AROUSAL REACTION OF THE RABBIT.
107190 12-03
A BIPHASIC ACTION OF PILOCARPINE ON BEHAVIORAL AROUSAL IN THE RAT. (PH.D.DISSERTATION).
110922 12-04

**AROUSED**
ANTICHOLINERGIC CENTRAL BLOCKADE OF SALT AROUSED AND DERIVATION INDUCED DRINKING.
081227 09-04

**ARRESTING**
ARRESTING OF STATUS-EPILEPTICUS AND SERIAL SEIZURES BY AMYTAL CAFFEINE.
090349 11-11

**ARRHYTHMIAS**
HYPOKALAEMIA AND ARRHYTHMIAS AS A RESULT OF QUININE POISONING.
071258 07-15
EFFECT OF TWO RECENTLY SYNTHESIZED PHENOTHIAZINE DERIVATIVES UPON EXPERIMENTAL CARDIAC ARRHYTHMIAS.
114978 12-03

**ARTEFACT**
PINK-SPOT - IS IT A DRUG ARTEFACT
068153 06-15

**ARTEMIA-SALINA**
THE EFFECTS OF MORPHINE-LIKE COMPOUNDS ON THE LIGHT RESPONSES OF THE BRINE SHRIMP ARTEMIA-SALINA.
075844 09-04

**ARTERIAL**
HYPOTENSIVE EFFECTS OF CHLORDIAZEPOXIDE, AMOBARBITAL AND CHLORPROMAZINE ON BEHAVIORALLY INDUCED ELEVATED ARTERIAL BLOOD PRESSURE IN THE SQUIRREL MONKEY.
089999 11-04

**ARTERIOSCLEROTIC**
THE EFFECT OF CYCLANDELATE ON MENTAL FUNCTION IN PATIENTS WITH ARTERIOSCLEROTIC BRAIN DISEASE.
061654 03-13
ON BINSWANGERS SUBCORTICAL ARTERIOSCLEROTIC ENCEPHALOPATHY AND THE POSSIBILITY OF ITS CLINICAL RECOGNITION.
078733 09-13

**ARTERY**
CONCERNING A CASE OF THROMBOSIS OF THE MIDDLE CEREBRAL ARTERY IN THE COURSE OF PROGESTINIC TREATMENT.
094467 11-14

**ARTHEROSCLEROSIS**
USE OF PANGAMIC ACID (VITAMIN-B15) IN CEREBRAL ARTHEROSCLEROSIS WITH MENTAL DISTURBANCES.
067148 06-10

**ASARONE**
NEW COMPOUNDS: STRUCTURAL ANALOGS RELATED TO ASARONE AND MESCALINE.
064264 04-01

**ASOCIAL**
RELATIONSHIPS OF THE MECHOLYL TEST, PREMORBID ASOCIAL FUNCTIONING AND LONG-TERM OUTCOME IN SCHIZOPHRENIA.
075227 08-08

**ASPARTATE**
BRAIN DAMAGE IN INFANT MICE FOLLOWING ORAL INTAKE OF GLUTAMATE, ASPARTATE OR CYSTEINE.
094164 11-05

**ASPIRIN**
THE USE AND MISUSE OF ASPIRIN: A CONTEMPORARY PROBLEM.
083415 10-17
GALVESTON COUNTY STUDY SHOWS TRANQUILIZERS SURPASS ASPIRIN AS MEDICINAL POISONING AGENTS.
090070 11-15

**ASSAY**
PROJECT SUMMARY: A NEW ASSAY PROCEDURE FOR AMINOTRANSFERASES.
060223 03-03
MODIFICATION OF AN ENZYME RADIOCHEMICAL ASSAY PROCEDURE FOR NORADRENALINE.
064002 04-06
STUDIES ON THE RECEPTORS INVOLVED IN THE ACTION OF THE VARIOUS AGENTS IN THE PHENYLBENZOQUINONE ANALGESIC ASSAY IN MICE.
090451 11-03

**ASSAYING**
NEW METHOD FOR ASSAYING ANTIAPOMORPHINE ACTIVITY IN PIGEONS.
089437 11-06

**ASSESSING**
USES AND LIMITATIONS OF PHOTOCELL ACTIVITY CAGES FOR ASSESSING EFFECTS OF DRUGS.
090423 11-06

**ASSESSMENT**
SIDE REACTIONS IN NEUROTICS: I. A COMPARISON OF TWO METHODS OF ASSESSMENT.
064287 04-15
THE ASSESSMENT OF DRUG EFFECTS IN CHILDREN AS COMPARED TO ADULTS.
072825 08-14
PSYCHOPHARMACOLOGY IN CHILDREN: PROBLEM AREAS, METHODOLOGICAL CONSIDERATIONS, ASSESSMENT TECHNIQUES.
080350 09-17
FLUPHENAZINE: A RETROSPECTIVE ASSESSMENT IN 130 PATIENTS WITH RESIDUAL SCHIZOPHRENIA.
088951 10-08
INTERPERSONAL UNDERSTANDING, INTERPERSONAL STRESS AND CURRENT STATES: INTERRELATIONSHIPS AND TREATMENT ASSESSMENT. (PH.D. DISSERTATION).
103636 12-14

**ASSISTED**
METHOHEXITONE ASSISTED DESENSITIZATION FOR PHOBIAS.
067074 05-16
METHOHEXITONE ASSISTED DESENSITIZATION IN TREATMENT OF PHOBIAS.
067673 06-11

**ASSOCIATION**
ASSOCIATION OF AMPHETAMINE TOXICITY AND TISSUE GLYCOGEN DEPLETION IN MICE AND RATS.
058998 03-05
ASSOCIATION OF BROMIDE WITH THE SYNAPTOSOMAL FRACTION OF MOUSE BRAIN.
070521 07-01
PHARMACOLOGICAL ASSOCIATION OF THIORIDAZINE HYDERGINE IN PSYCHOEMOTIONAL TROUBLES OF THE AGED.
091138 11-14
PSYCHOCLINICAL OBSERVATIONS ON THE EFFECT OF THE LOGOS COMPOUND (ASSOCIATION OF PYRITHIOXINE DIHYDROCHLORIDE, TRYPTOPHAN AND CALCIUM ALPHA-KETOGLUTARATE).
109258 12-11

**ASSOCIATIONS**
ALTERED FREE ASSOCIATIONS: SOME COGNITIVE EFFECTS OF DOET (2,5 DIMETHOXY-4-ETHYLAMPHETAMINE).
075859 09-12
CLINICAL AND PHARMACOLOGICAL CONTRIBUTION TO THE STUDY OF ALCOHOL IMIPRAMINE AND ALCOHOL THIOPROPERAZINE ASSOCIATIONS.
094305 11-11

**ASTHMATIC**
THE INTERACTION OF PSYCHOLOGIC STIMULI AND PHARMACOLOGIC AGENTS ON AIRWAY REACTIVITY IN ASTHMATIC SUBJECTS.
063515 03-13

**ATPASE**
PHENYTOIN, FOLATES, AND ATPASE.
059055 03-15

**ATRIA**
THE EFFECTS OF ACIDOSIS ON CHRONOTROPIC RESPONSES, NOREPINEPHRINE STORAGE AND RELEASE IN ISOLATED GUINEA-PIG ATRIA.
040753 01-03

**ATROPINE**
THE EFFECT OF AMPHETAMINE, NICOTINE AND ATROPINE ON PSEUDOCONDITIONED RESPONSES OF RATS.
046142 01-04
EFFECTS OF SCOPOLAMINE, ATROPINE, AND D-AMPHETAMINE ON INTERNAL AND EXTERNAL CONTROL OF RESPONDING ON NON-REINFORCED TRIALS.
064410 04-04
CONDITIONAL AUTONOMIC RESPONSES INDUCED IN DOGS BY ATROPINE AND MORPHINE.
066386 05-03
EFFECT OF ATROPINE DOSE LEVEL ON THE SUPPRESSION OF WATER REINFORCED VI RESPONDING.
075870 09-04

INCREASED DURATION OF NEUROPHARMACOLOGICALLY INDUCED BEHAVIORAL EXCITATION BY ATROPINE.
079998 09-04

EFFECTS OF ATROPINE AND ESERINE ON THE ELECTROENCEPHALOGRAM, ON BEHAVIOUR AND ON LIGHT INDUCED EPILEPSY IN THE ADOLESCENT BABOON (PAPIO-PAPIO).
090157 11-04

ELECTROENCEPHALOGRAPHIC EFFECTS OF ATROPINE AND SCOPOLAMINE.
131623 12-03

**ATTACKS**

THE USE OF LITHIUM SALTS FOR THE PREVENTION OF AFFECTIVE ATTACKS.
096512 11-09

**ATTEMPTED**

ATTEMPTED SUICIDE BY DRUG INGESTION.
063277 03-15

CLINICAL STUDY OF A PSYCHOTROPIC DRUG: SULPIRIDE IN ATTEMPTED SUICIDE WITHOUT PSYCHOSIS.
072155 07-14

**ATTENDING**

A SURVEY OF EXTRAPYRAMIDAL MANIFESTATIONS IN PATIENTS ATTENDING AN AFTER CARE CLINIC OF A PSYCHIATRIC HOSPITAL.
070412 07-15

**ATTENTION**

INFLUENCE OF TRIIODOTHYRONINE ON SELECTIVE ATTENTION IN MAN AS MEASURED BY THE VISUAL AVERAGED EVOKED POTENTIAL.
062510 03-13

AN APPARATUS FOR OBSERVING ATTENTION AND PERSEVERANCE.
086161 10-16

**ATTENUATING**

FLUID INTAKE AND PUNISHMENT ATTENUATING DRUGS.
067704 06-04

**ATTENUATION**

THE EFFECTS OF 5-HTP ON P-CHLOROPHENYLALANINE (P-CPA) ATTENUATION OF CONFLICT BEHAVIOR.
047326 01-04

**ATTRITION**

SETTING, PATIENT, AND DOCTOR EFFECTS ON DRUG RESPONSE IN NEUROTIC PATIENTS: I. DIFFERENTIAL ATTRITION, DOSAGE DEVIATION, AND SIDE REACTION RESPONSES TO TREATMENT.
065453 05-10

**AUDITORY**

P-CHLOROPHENYLALANINE AND HABITUATION TO REPETITIVE AUDITORY STARTLE STIMULI IN RATS.
063015 03-03

CARBON MONOXIDE AND PHENOBARBITONE: A COMPARISON OF EFFECTS ON AUDITORY FLUTTER FUSION THRESHOLD AND CRITICAL FLICKER FUSION THRESHOLD.
070303 07-14

**AUTO-INDUCED**

RELATIONSHIP OF BARBITAL DISPOSITION TO AUTO-INDUCED HYPERSUSCEPTIBILITY IN THE RAT.
046144 01-03

**AUTOMATED**

AN AUTOMATED MULTIPLE CHOICE TEST OF SHORT-TERM SPATIAL MEMORY FOR MONKEYS.
075917 09-04

AN AUTOMATED OPEN FIELD METHOD.
081261 09-06

**AUTOMATIC**

AUTOMATIC MONITORING OF APOMORPHINE INDUCED PECKING IN PIGEONS.
075922 09-04

**AUTONOMIC**

THE ACTIONS OF GAMMA-AMINOBUTYRIC ACID AND RELATED AMINO ON MAMMALIAN AUTONOMIC GANGLIA.
040752 01-03

CONDITIONAL AUTONOMIC RESPONSES INDUCED IN DOGS BY ATROPINE AND MORPHINE.
066386 05-03

THE AUTONOMIC NERVOUS SYSTEM.
068952 06-03

IMPROVEMENT OF LEARNING IN THE AGED BY MODIFICATION OF AUTONOMIC NERVOUS SYSTEM ACTIVITY.
071336 07-14

INFLUENCE OF SEVERAL AUTONOMIC DRUGS ON SODIUM NITROPRUSSIDE AND OXOTREMORINE INDUCED HYPOTHERMIA IN IMMATURE AND MATURE MICE.
089436 11-03

AUTONOMIC EFFECTS.
100525 12-15

CENTRAL ACTION OF SOME AUTONOMIC DRUGS IN RESPECT TO EEG AROUSAL REACTION OF THE RABBIT.
107190 12-03

**AUTORADIOGRAPHIC**

(3H)HARMALINE DISTRIBUTION IN MONKEY BRAIN; PHARMACOLOGICAL AND AUTORADIOGRAPHIC STUDY.
067081 05-03

AUTORADIOGRAPHIC STUDIES ON THE DISTRIBUTION OF PSYCHOACTIVE DRUGS IN THE RAT BRAIN: IV. C14-THIORIDAZINE.
073709 08-03

**AVAILABILITY**

MODIFICATION BY DESIPRAMINE (DMI) OF THE AVAILABILITY OF NOREPINEPHRINE RELEASED BY RESERPINE IN THE HYPOTHALAMUS OF THE RAT IN VIVO.
066374 05-03

**AVERAGED**

INFLUENCE OF TRIIODOTHYRONINE ON SELECTIVE ATTENTION IN MAN AS MEASURED BY THE VISUAL AVERAGED EVOKED POTENTIAL.
062510 03-13

CORTISOL EFFECTS ON AVERAGED EVOKED POTENTIAL, ALPHA-RHYTHM, TIME ESTIMATION, AND TWO-FLASH FUSION THRESHOLD.
075274 08-13

**AVERSION**

AVERSION THERAPY WITH SUCCINYLCHOLINE.
067412 06-07

**AVOIDANCE**

MAGNESIUM PEMOLINE: SPECIFICITY OF EFFECTS ON INSTRUMENTAL AVOIDANCE LEARNING.
058430 02-04

IMPAIRMENT OF SHOCK AVOIDANCE LEARNING AFTER LONG-TERM ALCOHOL INGESTION IN MICE.
058492 02-04

EFFECTS OF A MARIHUANA HOMOLOGUE (PYRAHEXYL) ON AVOIDANCE LEARNING IN THE GERBIL.
059032 03-04

EXTINCTION OF AVOIDANCE RESPONDING THROUGH RESPONSE PREVENTION (FLOODING).
063275 03-04

DEPRESSION OF TWO-WAY AVOIDANCE LEARNING AND ENHANCEMENT OF PASSIVE AVOIDANCE LEARNING BY SMALL DOSES OF PHYSOSTIGMINE.
064365 04-04

THE EFFECTS OF CHLORPROMAZINE ON ONE-TRIAL PASSIVE AVOIDANCE LEARNING IN MICE: FURTHER EXAMINATION OF PRELEARNING AND POSTLEARNING ADMINISTRATION.
064407 04-04

THE EFFECTS OF CENTRALLY AND PERIPHERALLY ACTING CHOLINERGIC DRUGS ON THE SHORT-TERM PERFORMANCE GRADIENT FOLLOWING PASSIVE AVOIDANCE TRAINING.
064412 04-04

THE INFLUENCE OF VARIOUS NEUROLEPTIC DRUGS ON SHOCK AVOIDANCE RESPONDING IN RATS. III. AMPHETAMINE ANTAGONISM IN THE DISCRIMINATED SIDMAN AVOIDANCE PROCEDURE.
064476 04-04

COMMENT ON THE INCREASED RESISTANCE TO EXTINCTION OF AN AVOIDANCE RESPONSE INDUCED BY CERTAIN DRUGS.
065070 05-04

DRUG EFFECTS ON A MEASURE OF UNCONDITIONED AVOIDANCE IN THE RAT.
065440 05-04

EFFECTS OF CHLORDIAZEPOXIDE ON DISCRIMINATIVE FEAR CONDITIONING AND SHUTTLE AVOIDANCE PERFORMANCE IN THE RABBIT.
065451 05-04

YEAST RIBONUCLEIC ACID: ANALYSIS OF EFFECTS ON POLE-CLIMB AVOIDANCE BEHAVIOR.
065493 05-04

SCOPOLAMINES EFFECT ON PASSIVE AVOIDANCE.
065876 05-04

STRAIN DIFFERENCES IN THE EFFECTS OF CHLORPROMAZINE AND CHLORDIAZEPOXIDE UPON ACTIVE AND PASSIVE AVOIDANCE IN MICE.
066828 05-04

THE EFFECT OF DEXAMETHASONE BLOCKADE OF ACTH RELEASE ON AVOIDANCE LEARNING.
067884 06-04

THE EFFECT OF NICOTINE AND TOTAL ALKALOIDS EXTRACTED FROM CIGARETTE SMOKE IN AVOIDANCE BEHAVIOR IN RATS UNDER EXTINCTION PROCEDURE.
069079 06-04

THE EFFECTS OF ALTERED BRAIN NOREPINEPHRINE LEVELS ON CONTINUOUS AVOIDANCE RESPONDING AND THE ACTION OF AMPHETAMINES.
074937 08-04

EFFECTS OF CHLORDIAZEPOXIDE ON THE ACQUISITION OF SHUTTLE AVOIDANCE IN THE RABBIT.
075235 08-04

PENTOBARBITAL INDUCED STATE-DEPENDENT LEARNING OF ONE-WAY AVOIDANCE IN MICE.
075288 08-04

AVOIDANCE TRAINING OF HIPPOCAMPAL THETA WAVES IN FLAXEDILIZED DOGS AND ITS RELATION TO SKELETAL MOVEMENT.
075399 08-04

ADRENALIN AND AVOIDANCE LEARNING: PARTIAL REPLICATIONS.
075559 08-04

THE ROLE OF D-AMPHETAMINE AMOBARBITAL IN SUPPRESSING FREEZING BEHAVIOR DURING AVOIDANCE ACQUISITION AND EXTINCTION.
075882 09-04

EFFECTS OF NEONATAL TESTOSTERONE ON THE ACQUISITION OF AN ACTIVE AVOIDANCE RESPONSE IN GENOTYPICALLY FEMALE RATS.
075890 09-04

THE EFFECT OF MAGNESIUM PEMOLINE, TRICYANOAMINOPROPENE AND D-AMPHETAMINE ON DISCRIMINATED AVOIDANCE PERFORMANCE IN RATS AS A FUNCTION OF AGE.
076133 09-04

THE EFFECTS OF DRUGS ON CONTINUOUS AVOIDANCE BEHAVIOR WITH A WARNING STIMULUS.
078402 09-04

THE EFFECT OF PSYCHOSTIMULANTS ON PSYCHOMETRIC TEST PERFORMANCE WITH SPECIAL REFERENCE TO CONFLICT AVOIDANCE BEHAVIOR.
082055 10-04

1-(3,4-DIMETHOXYPHENYL)-2 PROPANOL EFFECT ON CONDITIONED AVOIDANCE RESPONSE IN THE RAT.
089440 11-04

SCOPOLAMINE EFFECTS ON GO-NO-GO AVOIDANCE DISCRIMINATIONS: INFLUENCE OF STIMULUS FACTORS AND PRIMACY OF TRAINING.
090418 11-04

APPLICATION OF ON-LINE COMPUTER PROCEDURES TO EXPERIMENTAL CONTROL AND EVALUATION OF THE EFFECTS OF DRUGS ON OPERANT BEHAVIOR (SIDMAN SHOCK AVOIDANCE RESPONDING BY RATS).
095507 11-06

THE EFFECTS OF CHLORPROMAZINE ON THE EXPRESSION OF AN ACQUIRED PASSIVE AVOIDANCE RESPONSE IN MICE.
097959 11-04

COMPARISON OF THE EFFECTS OF EXOGENOUS ACTH ON APPROACH AND AVOIDANCE CONDITIONING: IMPLICATIONS FOR THE PHYSIOLOGY OF INCENTIVE MOTIVATION. (PH.D.DISSERTATION).
103354 12-04

**AXIS**
HYPOTHALAMIC PITUITARY ADRENAL AXIS.
100532 12-13

**AXON**
EFFECTS OF NARCOTICS ON THE GIANT AXON OF THE SQUID.
090147 11-03

**AXONAL**
AN ELECTRON MICROSCOPIC STUDY OF AXONAL CHANGES IN THE CEREBELLUM OF DIPHENYLHYDANTOIN INTOXICATED RATS: THE FORMATION OF THE SO-CALLED HONEYCOMB STRUCTURE IN THE AXOPLASM.
070334 07-03

**AXOPLASM**
AN ELECTRON MICROSCOPIC STUDY OF AXONAL CHANGES IN THE CEREBELLUM OF DIPHENYLHYDANTOIN INTOXICATED RATS: THE FORMATION OF THE SO-CALLED HONEYCOMB STRUCTURE IN THE AXOPLASM.
070334 07-03

**AXOPLASMIC**
SOME NEUROCHEMICAL CORRELATES OF AXOPLASMIC FLOW.
073327 08-03

**AXOTOMY**
UPTAKE AND RETENTION OF 3H-NORADRENALINE IN ADRENERGIC NERVE TERMINALS AFTER RESERPINE AND AXOTOMY.
066499 05-03

**AZABICYCLO**
AZABICYCLO CHEMISTRY. I. SYNTHESIS OF 1,5-METHANO-7-METHOXY-2,3,4,5-TETRAHYDRO-1H-2- BENZAZEPINES. B-NORBENZOMORPHANS.
038489 01-01

**B-NORBENZOMORPHANS**
AZABICYCLO CHEMISTRY. I. SYNTHESIS OF 1,5-METHANO-7-METHOXY-2,3,4,5-TETRAHYDRO-1H-2- BENZAZEPINES. B-NORBENZOMORPHANS.
038489 01-01

**BA-30803**
A CONTROLLED TRIAL OF BENZOCTAMINE (BA-30803) IN NEUROTIC ANXIETY.
064285 04-10

**BABOON**
EFFECTS OF PSILOCYBIN, DIMETHYLTRYPTAMINE AND VARIOUS LYSERGIC ACID DERIVATIVES ON PHOTICALLY INDUCED EPILEPSY IN THE BABOON (PAPIO-PAPIO).
068163 06-03

EFFECTS OF ATROPINE AND ESERINE ON THE ELECTROENCEPHALOGRAM, ON BEHAVIOUR AND ON LIGHT INDUCED EPILEPSY IN THE ADOLESCENT BABOON (PAPIO-PAPIO).
090157 11-04

**BABOONS**
METHODS FOR DETECTING ANTIANXIETY DRUGS USING BABOONS (PAPIO-CYNOCEPHALUS).
041537 01-06

**BACILLUS-CEREUS**
INTERFERENCE OF BARBITURATES WITH PYRIMIDINE INCORPORATION -- II: STRUCTURAL SPECIFICITY OF THE INHIBITION OF OROTATE UPTAKE IN BACILLUS-CEREUS.
064046 04-03

**BACKGROUND**
ESSENTIALS OF MOLECULAR PHARMACOLOGY: BACKGROUND FOR DRUG DESIGN.
115114 12-17

**BALANCE**
SODIUM BALANCE AND DISTRIBUTION IN LITHIUM CARBONATE THERAPY.
047828 01-09

STUDIES OF MINERAL METABOLISM IN MENTAL DEPRESSION. I. THE EFFECTS OF IMIPRAMINE AND ELECTRIC CONVULSIVE THERAPY ON CALCIUM BALANCE AND KINETICS.
075837 08-11

LITHIUM INDUCED CHANGES IN ELECTROLYTE BALANCE AND TISSUE ELECTROLYTE CONCENTRATION.
090419 11-03

**BARBITAL**
RELATIONSHIP OF BARBITAL DISPOSITION TO AUTO-INDUCED HYPERSUSCEPTIBILITY IN THE RAT.
046144 01-03

TOXICITY, NARCOTIC EFFECT, CONCENTRATION AT END OF ANESTHESIA, ELIMINATION FROM BLOOD AND BIOTRANSFORMATION OF HEXOBARBITAL IN RATS OF VARIOUS AGES FOLLOWING SLEEP INDUCTION WITH BARBITAL AND AFTER.
058987 03-05

**BARBITONE**
THE SENSITIVITY OF THE BRAIN TO BARBITURATE DURING CHRONIC ADMINISTRATION AND WITHDRAWAL OF BARBITONE SODIUM IN THE RAT.
063980 04-03

THE BRAIN ACETYLCHOLINE SYSTEM IN BARBITONE DEPENDENT AND WITHDRAWN RATS.
067604 06-03

**BARBITURATE**
COMPARISON OF LIVER MICROSOME ENZYME SYSTEMS AND BARBITURATE SLEEP TIMES IN RATS CAGED INDIVIDUALLY OR COMMUNALLY.
045545 01-06

EFFECT OF AMPHETAMINE ANALOGS ON DISRUPTION OF ANIMAL BEHAVIOR AND BARBITURATE SLEEPING TIME.
046196 01-03

BARBITURATE DEPENDENCE.
046205 01-15

JUMPING ACTIVITY INDUCED BY SODIUM 5-(1,3 DIMETHYLBUTYL)-5 ETHYL BARBITURATE. II. THE EFFECTS OF AGE DIFFERENCE.
058985 03-04

THE SENSITIVITY OF THE BRAIN TO BARBITURATE DURING CHRONIC ADMINISTRATION AND WITHDRAWAL OF BARBITONE SODIUM IN THE RAT.
063980 04-03

TOXICITY OF ETHANOL BARBITURATE MIXTURES.
064160 04-05

BLISTERS FROM BARBITURATE POISONING.
064634 04-15

EFFECTS OF A CONVULSANT BARBITURATE ON THE SPINAL MONOSYNAPTIC PATHWAY.
066372 05-03

BARBITURATE INDUCED SLEEP IN HYPERTHYROID MICE.
066935 05-05

SKIN LESIONS AS A DIAGNOSTIC AID IN BARBITURATE POISONING.
067926 06-15

RELATIONS BETWEEN BARBITURATE BRAIN LEVELS AND SLEEPING TIME IN VARIOUS EXPERIMENTAL CONDITIONS.
068600 06-03

EFFECT OF METHYLCHLOROFORM INHALATION ON BARBITURATE HYPNOSIS AND HEPATIC DRUG METABOLISM IN MALE MICE.
068978 06-03

ALTERATIONS IN BRAIN SENSITIVITY AND BARBITURATE METABOLISM UNRELATED TO AGGRESSION IN SOCIALLY DEPRIVED MICE.
069052 06-03

NEUROPSYCHIATRIC CLINICAL STUDY OF A BARBITURATE HYPNOTIC: 5-ETHYL 5(1- METHYL-1-BUTENYL) MALONYLUREA.
089173 10-07

REDUCTION OF BARBITURATE DEPENDENCE INDUCED BY REPEATED ELECTROCONVULSIONS.
097548 11-03

**BARBITURATES**
MICELLAR SOLUBILIZATION OF BARBITURATES I: SOLUBILITIES OF CERTAIN BARBITURATES IN POLYSORBATES OF VARYING HYDROPHOBIC CHAIN LENGTH.
046136 01-17

BLOOD AND URINE CONCENTRATIONS OF SUBJECTS RECEIVING BARBITURATES, MEPROBAMATE, GLUTETHIMIDE, OR DIPHENYLHYDANTOIN.
063927 04-13

RELATIONSHIP BETWEEN DIFFERENCE SPECTRA AND METABOLISM: BARBITURATES, DRUG INTERACTION AND SPECIES DIFFERENCE.
064001 04-03

INTERFERENCE OF BARBITURATES WITH PYRIMIDINE INCORPORATION -- III: STUDIES ON THE MECHANISM OF THE AMOBARBITAL OROTATE RELATIONSHIP.
064045 04-03

INTERFERENCE OF BARBITURATES WITH PYRIMIDINE INCORPORATION -- II: STRUCTURAL SPECIFICITY OF THE INHIBITION OF OROTATE UPTAKE IN BACILLUS-CEREUS.
064046 04-03

INTERACTIONS OF DELTA1-TETRAHYDROCANNABINOL WITH BARBITURATES AND METHAMPHETAMINE.
064424 04-04

EFFECT OF ACUTE HYPOXIA ON BRAIN SENSITIVITY AND METABOLISM OF BARBITURATES IN MICE.
064480 04-03

SOME EFFECTS OF ETHANOL ON THE TOXICITY AND DISTRIBUTION OF BARBITURATES IN RATS.
090032 11-05

A STUDY OF THE EXCITATORY EFFECTS OF BARBITURATES.
116471 12-03

**BARRIER**

PERMEABILITY OF THE BLOOD BRAIN BARRIER TO PARENTERAL 5-HYDROXYTRYPTAMINE IN THE NEONATE CHICK.
067253 06-04

**BASAL**

LONG-TERM VARIATION IN BASAL AND PHENOBARBITAL STIMULATED OXIDATIVE DRUG METABOLISM IN THE RAT.
040671 01-03

EFFECT OF PITUITARY AND ACTH ON THE MAINTENANCE OF BASAL TYROSINE HYDROXYLASE ACTIVITY IN THE RAT ADRENAL GLAND.
075714 08-03

**BASE**

ON THE ANALYSIS OF CARDIAC BETA-RECEPTORS: STUDIES ON THE BASE OF DOSE EFFECT CURVES FOR ISOPRENALINE, PROPRANOLOL, AND KL-255.
055396 02-03

DYNAMIC CONTROL OF ACID BASE EQUILIBRIUM DURING SOME FORMS OF SHOCK THERAPY.
079139 09-13

**BASELINE**

RECORDING EVOKED POTENTIALS IN THE CONSCIOUS RAT: THE MAINTENANCE OF A CONSTANT BEHAVIOURAL BASELINE.
067600 06-06

**BAY-1521**

MORPHOLOGICAL ASPECTS OF APPLICATION OF NOXIPTILIN (BAY-1521) IN ANIMAL EXPERIMENTS.
079972 09-03

**BEARING**

CONSIDERATIONS OF SOME SIDE-EFFECTS OF DRUGS. (A STUDY BEARING ON 11,410 CALLS RECEIVED BY THE BELGIAN ANTIPOISON CENTER).
042687 01-15

**BED**

STABILITY OF PSYCHIC FUNCTIONS DURING PROLONGED CONFINEMENT TO BED.
086039 10-14

**BEEF**

HYPERTENSIVE CRISIS IN A PATIENT ON MAOI ANTIDEPRESSANTS FOLLOWING A MEAL OF BEEF LIVER.
092211 11-15

**BEER**

BEER SOCIOTHERAPY CAN BENEFIT AGED MENTAL PATIENTS.
064145 04-11

**BEHAVIOR**

EFFECTS OF SOME BENZODIAZEPINES ON PUNISHED AND UNPUNISHED BEHAVIOR IN THE PIGEON.
040758 01-04

EFFECTS OF CHRONIC POSTNATAL DRUG ADMINISTRATION ON ADULT DOMINANCE BEHAVIOR IN TWO GENERA OF MICE.
042837 01-04

INFLUENCE OF DISPLAY, TASK, AND ORGANISMIC VARIABLES ON INDICES OF MONITORING BEHAVIOR.
043270 01-17

EFFECTS OF SOME PSYCHOACTIVE DRUGS ON EXPERIMENTAL NEUROTIC (CONFLICT INDUCED) BEHAVIOR IN CATS.
046143 01-04

COMPARATIVE EFFECTS OF NICOTINE AND AMPHETAMINE ON TIMING BEHAVIOR IN RATS.
046190 01-04

EFFECT OF AMPHETAMINE ANALOGS ON DISRUPTION OF ANIMAL BEHAVIOR AND BARBITURATE SLEEPING TIME.
046196 01-03

DIFFERENCES IN BRAIN AREA 5-HYDROXYTRYPTAMINE TURNOVER AND REARING BEHAVIOR IN RATS AND MICE OF BOTH SEXES.
047324 01-04

THE EFFECTS OF 5-HTP ON P-CHLOROPHENYLALANINE (P-CPA) ATTENUATION OF CONFLICT BEHAVIOR.
047326 01-04

FDA WARNS AGAINST USES OF BEHAVIOR AMPHETAMINES.
051373 02-15

CIRCADIAN RHYTHM FOR EXPERIMENTALLY INDUCED AGGRESSIVE BEHAVIOR IN MICE.
058383 02-03

FUNCTIONAL RELATIONSHIPS OF BRAIN CIRCUITS IN CONTROL OF DRINKING BEHAVIOR.
058961 03-04

EFFECTS OF A CHOLINE ACETYLTRANSFERASE INHIBITOR ON SELF-STIMULATORY BEHAVIOR IN THE RAT.
058993 03-04

THE EFFECT OF MAGNESIUM PEMOLINE ON DISCRIMINATION LEARNING AND EXPLORATORY BEHAVIOR.
059567 03-04

ABNORMAL SOCIAL BEHAVIOR IN PHENYLKETONURIC MONKEYS.
060490 03-04

ALPHA-ADRENERGIC RECEPTORS IN HYPOTHALAMUS FOR THE SUPPRESSION OF FEEDING BEHAVIOR BY SATIETY.
060801 03-04

THE EFFECTS OF LITHIUM ON ELECTROENCEPHALOGRAM, BEHAVIOR AND SERUM ELECTROLYTES.
060859 03-09

EFFECTS OF LITHIUM PRETREATMENT ON AMPHETAMINE AND DMI TETRABENAZINE PRODUCED PSYCHOMOTOR BEHAVIOR.
062521 03-04

THE EFFECT OF P-CHLOROPHENYLALANINE (PCPA) ON SHOCK INDUCED FIGHTING BEHAVIOR IN RATS.
062853 03-03

EFFECTS OF RESERPINE ON THE COPULATORY BEHAVIOR OF MALE RATS.
063014 03-04

THE EFFECTS OF HALOPERIDOL AND CHLORPROMAZINE ON AMPHETAMINE METABOLISM AND AMPHETAMINE STEREOTYPE BEHAVIOR IN THE RAT.
064170 04-03

LABORATORY EVALUATION OF AGGRESSIVE BEHAVIOR OF THE GRASSHOPPER MOUSE (ONYCHOMYS).
064260 04-04

EFFECTS OF CHLORDIAZEPOXIDE AND PENTOBARBITAL ON CONFLICT BEHAVIOR IN RATS.
064390 04-04

EFFECTS OF MORPHINE ON BEHAVIOR MAINTAINED BY FOUR SIMPLE FOOD REINFORCEMENT SCHEDULES.
064479 04-04

RATE-DEPENDENT EFFECTS OF DRUGS: MODIFICATION BY DISCRIMINATIVE STIMULI OF THE EFFECTS OF AMOBARBITAL ON SCHEDULE CONTROLLED BEHAVIOR.
064749 05-04

OBSERVATION OF THE GROOMING BEHAVIOR OF RESERPINIZED WHITE MICE AS A METHOD FOR INVESTIGATING RESERPINE ANTAGONISM AND SYNERGISM.
065442 05-04

YEAST RIBONUCLEIC ACID: ANALYSIS OF EFFECTS ON POLE-CLIMB AVOIDANCE BEHAVIOR.
065493 05-04

HORMONAL INDUCTION OF MATERNAL BEHAVIOR IN THE OVARIECTOMIZED NULLIPAROUS RAT.
069063 06-04

REDUCTION OF ELECTRICALLY REWARDED BEHAVIOR BY INTERFERENCE WITH MONOAMINE SYNTHESIS.
069065 06-04

THE EFFECT OF NICOTINE AND TOTAL ALKALOIDS EXTRACTED FROM CIGARETTE SMOKE IN AVOIDANCE BEHAVIOR IN RATS UNDER EXTINCTION PROCEDURE.
069079 06-04

EFFECTS OF STAPHYLOCOCCAL ENTEROTOXIN B ON COMPLEX OPERANT BEHAVIOR IN MONKEYS.
069333 06-04

EPINEPHRINE AND NOREPINEPHRINE EFFECTS ON SOCIAL DOMINANCE BEHAVIOR.
069530 07-04

TRYPTAMINERGIC MECHANISMS IN PUNISHED AND NONPUNISHED BEHAVIOR.
069738 07-04

COMPARISON OF THE PAROXYSMAL DYSKINESIAS (NEURODYSLEPSY) INDUCED BY THE NEUROLEPTICS IN MAN AND THE EARLIEST BEHAVIOR PATTERNS OF THE NEW-BORN.
070267 07-13

THE EFFECT OF BROMOTRIFLUOROMETHANE ON OPERANT BEHAVIOR IN MONKEYS.
070732 07-04

AMPHETAMINE: DIFFERENTIATION BY D AND L ISOMERS OF BEHAVIOR INVOLVING BRAIN NOREPINEPHRINE OR DOPAMINE.
070921 07-04
AGGRESSIVE BEHAVIOR OF RATS INDUCED BY MESORGYDINE (LYSENYL SPOFA).
070949 07-04
ACTION OF CODEINE, PETHIDINE AND METHADONE ON THE OPERANT BEHAVIOR OF THE RAT.
071787 07-04
BEHAVIOR AND HISTOPATHOLOGICAL FINDINGS DURING CHRONIC METHEDRINE INTOXICATION.
071993 07-05
SEXUAL BEHAVIOR OF MALE CATS AFTER ADMINISTRATION OF P-CHLOROPHENYLALANINE.
072463 08-04
DEVELOPMENT OF FIGHTING BEHAVIOR IN STARVED RATS BY CHRONIC ADMINISTRATION OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL AND CANNABIS EXTRACTS: LACK OF ACTION OF OTHER PSYCHOTROPIC DRUGS.
072531 08-04
AN ANALYSIS OF RECEPTIVE STRUCTURES PARTICIPATING IN THE BEHAVIOR REACTIONS OF CATS INDUCED BY CATECHOLAMINES AND SEROTONIN.
073715 08-03
EFFECTS OF PRENATAL ADMINISTRATION OF PSYCHOTROPIC DRUGS ON BEHAVIOR OF DEVELOPING RATS.
074830 08-04
COMPARATIVE EFFECTS OF AMPHETAMINE, SCOPOLAMINE, CHLORDIAZEPOXIDE, AND DIPHENYLHYDANTOIN ON OPERANT AND EXTINCTION BEHAVIOR WITH BRAIN STIMULATION AND FOOD REWARD.
074935 08-04
CEREBROSPINAL FLUID 5-HYDROXYINDOLES AND BEHAVIOR AFTER L-TRYPTOPHAN AND PYRIDOXINE ADMINISTRATION TO PSYCHIATRIC PATIENTS.
074938 08-14
AMBULATORY BEHAVIOR IN THE RAT AS A FUNCTION OF TWO METHODS OF ALCOHOL ADMINISTRATION.
075316 08-04
EFFECT OF PRENATAL DRUGS ON THE BEHAVIOR OF THE NEONATE.
075607 08-05
COMMENTS ON AN EFFECT OF YEAST RNA ON BEHAVIOR (MOUNTFORD AND HESLIP).
075720 08-04
EFFECTS OF LYSERGIC ACID DIETHYLAMIDE ON THE MATERNAL BEHAVIOR OF THE RAT.
075788 08-04
THE ROLE OF D-AMPHETAMINE AMOBARBITAL IN SUPPRESSING FREEZING BEHAVIOR DURING AVOIDANCE ACQUISITION AND EXTINCTION.
075882 09-04
HYDROXYZINE AND SHOCK IN OPERANT BEHAVIOR OF RATS.
076164 09-04
THE EFFECTS OF DRUGS ON CONTINUOUS AVOIDANCE BEHAVIOR WITH A WARNING STIMULUS.
078402 09-04
RESULTS OBTAINED WITH PROPERICIAZIN (8-909-RP) IN THE TREATMENT OF BEHAVIOR AND CHARACTER DISTURBANCES IN CHILDREN AND ADOLESCENTS.
078730 09-14
REVIEW OF MEDICINE IN SPECIAL EDUCATION: ANOTHER LOOK AT DRUGS AND BEHAVIOR.
079144 09-17
DRUG-INDUCED STEREOTYPED BEHAVIOR AND ITS ANTAGONISM IN DOGS.
079888 09-04
THE USE OF IMIPRAMINE IN CHILDRENS BEHAVIOR DISORDERS.
080095 09-14
COITAL BEHAVIOR IN DOGS: VI. LONG-TERM EFFECTS OF CASTRATION UPON MATING IN THE MALE.
080606 09-03
THE EFFECT OF ANTIANDROGENS ON AGGRESSIVE BEHAVIOR IN THE GERBIL.
081159 09-04
POST-NEONATAL ANDROGENIZATION AND ADULT AGGRESSIVE BEHAVIOR IN FEMALE MICE.
081233 09-04
METHYLPHENIDATE AND THIORIDAZINE: LEARNING, REACTION TIME, ACTIVITY, AND CLASSROOM BEHAVIOR IN DISTURBED CHILDREN.
081631 10-14
THE EFFECT OF PSYCHOSTIMULANTS ON PSYCHOMETRIC TEST PERFORMANCE WITH SPECIAL REFERENCE TO CONFLICT AVOIDANCE BEHAVIOR.
082055 10-04
PHARMACOLOGIC ACTIVITY OF A NEW CLASS OF AGENTS WHICH SELECTIVELY INHIBIT AGGRESSIVE BEHAVIOR IN RATS.
082398 10-04
MESORIDAZINE IN THE CONTROL OF BEHAVIOR DISORDERS IN CHILDREN.
086780 10-14
EFFECTS OF SELECTED DRUGS ON STIMULUS BOUND EMOTIONAL BEHAVIOR ELICITED BY HYPOTHALAMIC STIMULATION IN THE CAT.
088617 10-04
THE EFFECT OF CHLORDIAZEPOXIDE ON THE BEHAVIOR OF RATS IN A CONFLICT SITUATION.
090424 11-04
LEVODOPA: ALTERATIONS IN BEHAVIOR.
092975 11-09
PHARMACOLOGICAL MANAGEMENT OF CHARACTER TYPE BEHAVIOR DISTURBANCES IN THE INFANT AND CHILD.
093090 11-07
A PSYCHOPHYSIOLOGICAL STUDY OF BREATHING BEHAVIOR.
095020 11-15
APPLICATION OF ON-LINE COMPUTER PROCEDURES TO EXPERIMENTAL CONTROL AND EVALUATION OF THE EFFECTS OF DRUGS ON OPERANT BEHAVIOR (SIDMAN SHOCK AVOIDANCE RESPONDING BY RATS).
095507 11-06
CASUISTIC CONTRIBUTIONS ON THE USE OF A DRUG IN CRIMINOLOGY ON DISSOCIALITY AND ON MINOR IRREGULAR BEHAVIOR.
095719 11-14
THE INFLUENCE OF 5-HYDROXYTRYPTOPHAN ON THE BEHAVIOR AND THE LEVEL OF MONOAMINES IN THE BRAIN OF RATS SENSITIVE TO SOUND.
098040 11-03
SYNERGISM OF DESMETHYLIMIPRAMINE WITH RESERPINE AND 5-HYDROXYTRYPTOPHAN IN THE FROG: BRAIN SEROTONIN AND ADRENALINE AND BEHAVIOR.
098042 11-03
AN ANALYSIS OF THE ROLE OF CHOLINERGIC DRUGS IN BEHAVIOR RELATED TO FOOD AND WATER DEPRIVATION. (PH.D.DISSERTATION).
103267 12-04
BEHAVIORAL TOXICITY. PART 5: GROSS BEHAVIOR PATTERNS.
105560 12-15
PROBLEM BEHAVIOR OF CHILDREN WITH SEVERE MENTAL AND PHYSICAL DISORDERS – EXPERIENCE OF THE USE OF CARBAMAZEPINE.
105790 12-14
THE EFFECTIVENESS OF EXTERNAL AND DRUG PRODUCED INTERNAL STIMULI IN THE DISCRIMINATIVE CONTROL OF OPERANT BEHAVIOR. (PH.D.DISSERTATION).
110682 12-04
INFLUENCES OF POLYPHARMACY ON HALLUCINATORY BEHAVIOR IN A SAMPLE OF FEMALE CHRONIC SCHIZOPHRENIC PATIENTS.
115037 12-08
THIORIDAZINE AND BEHAVIOR DISORDERS (PERSPECTIVES FOR THE USE OF THE DRUG IN CRIMINOLOGY).
124320 12-17

**BEHAVIORAL**

BEHAVIORAL EFFECTS OF HALOTHANE IN PIGEONS.
042719 01-04
EFFECTS OF LITHIUM CARBONATE ON TURNOVER AND METABOLISM OF NOREPINEPHRINE IN THE RAT BRAIN - CORRELATION TO GROSS BEHAVIORAL EFFECTS.
043277 01-03
BEHAVIORAL IMPAIRMENT IN ADULT RATS FOLLOWING ACUTE ZINC DEFICIENCY.
045526 01-04
PHARMACOLOGICAL AND BEHAVIORAL STUDIES OF STP: RELATIONSHIP TO TISSUE DISTRIBUTION.
046198 01-03
BEHAVIORAL EFFECTS OF STP.
046199 01-14
BEHAVIORAL VARIABLES INFLUENCING DRUG SELF-ADMINISTRATION.
046206 01-04
HYPERSEXUALITY AND BEHAVIORAL CHANGES IN CATS CAUSED BY ADMINISTRATION OF P-CHLOROPHENYLALANINE.
056934 02-04
BEHAVIORAL AND BRAIN CATECHOLAMINE DEPLETING ACTIONS OF U-14624, AN INHIBITOR OF DOPAMINE BETA-HYDROXYLASE.
058986 03-03
A BEHAVIORAL AND PHARMACOLOGICAL ANALYSIS OF REINFORCEMENT WITHDRAWAL.
062942 03-04
A CONTROLLED TRIAL OF COMBINED MEDICATIONS ON BEHAVIORAL AND EXTRAPYRAMIDAL EFFECTS.
063774 04-14
ANTAGONISM OF D-AMPHETAMINE BY ALPHA-METHYL-L-TYROSINE: BEHAVIORAL EVIDENCE FOR THE PARTICIPATION OF CATECHOLAMINE STORES AND SYNTHESIS IN THE AMPHETAMINE STIMULANT RESPONSE.
064096 04-03
SIMILARITIES BETWEEN BEHAVIORAL AND PHARMACOLOGICAL ACTIONS OF YOHIMBINE AND 5-HYDROXYTRYPTOPHAN IN THE CONSCIOUS DOG.
064253 04-04

COMPARATIVE BEHAVIORAL AND BIOCHEMICAL EFFECTS OF TRANYLCYPROMINE AND CYSTEINE ON NORMAL CONTROLS AND SCHIZOPHRENIC PATIENTS.
064331 04-08

BEHAVIORAL AND VISCERAL REACTIONS ELICITED BY CHEMICAL STIMULATION OF THE HYPOTHALAMUS AND SEPTUM IN CATS.
064333 04-04

ABBREVIATION OF BEHAVIORAL ESTRUS IN GUINEA-PIGS BY COITAL AND VAGINO-CERVICAL STIMULATION.
065332 05-03

COMPARISONS OF 1,3 BUTANEDIOL AND GLYCEROL ON SEVERAL BEHAVIORAL MEASURES.
066831 05-04

MEASUREMENT OF BEHAVIORAL CHANGES IN PATIENTS ON L-DOPA.
066940 05-14

THE BEHAVIORAL PHARMACOLOGY OF OXYPERTINE.
067175 06-08

PHENOBARBITAL WITHDRAWAL AND BEHAVIORAL DISRUPTION IN THE RAT.
069067 06-04

PIPERACETAZINE (QUIDE) IN THE MANAGEMENT OF BEHAVIORAL DISORDERS IN MILDLY RETARDED INSTITUTIONALIZED BOYS.
069071 06-11

SEROTONIN: A POSSIBLE MEDIATOR OF BEHAVIORAL SUPPRESSION INDUCED BY ANXIETY.
069311 06-04

ANTAGONISM OF THE BEHAVIORAL EFFECTS OF MORPHINE AND METHADONE BY NARCOTIC ANTAGONISTS IN THE PIGEON.
069593 07-04

CRETINISM IN RATS: ENDURING BEHAVIORAL DEFICIT INDUCED BY TRICYANOAMINOPROPENE.
070839 07-02

BIOCHEMICAL AND BEHAVIORAL EFFECT OF AMPHETAMINE IN DMI - RO-4-1284 INDUCED HYPERACTIVITY.
070951 07-03

PSYCHOTROPIC DRUGS AND THE REGULATION OF BEHAVIORAL ACTIVATION IN PSYCHIATRIC ILLNESS.
070970 07-17

BEHAVIORAL EFFECTS OF ARECOLINE IN RATS.
071786 07-04

ELECTROGRAPHIC AND BEHAVIORAL EFFECTS OF DIAZEPAM DURING ALCOHOL WITHDRAWAL STAGE IN CATS.
072033 07-04

BEHAVIORAL CORRELATES OF CHEMICAL STIMULATION IN THE CAT THALAMUS.
075234 08-04

BEHAVIORAL EFFECTS: HIPPOCAMPAL DESTRUCTION AND SCOPOLAMINE.
075280 08-04

DRUGS IN PSYCHOLOGY: A COMMENTARY ON TRAVIS THOMPSON AND CHARLES R. SCHUSTERS BEHAVIORAL PHARMACOLOGY.
075793 08-14

ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL EFFECTS OF HARMALINE IN INTACT CATS AND IN CATS WITH CHRONIC MESENCEPHALIC TRANSECTION.
075847 09-04

THE ROLE OF BRAIN DOPAMINE IN BEHAVIORAL REGULATION AND THE ACTIONS OF PSYCHOTROPIC DRUGS.
075869 09-04

L-DOPA, BEHAVIORAL ACTIVATION AND PSYCHOPATHOLOGY (UNPUBLISHED PAPER).
078542 09-09

ANTAGONISM OF BETA-PHENYLETHYLAMINE DERIVATIVES AND SEROTONIN BLOCKING DRUGS UPON SEROTONIN, TRYPTAMINE AND RESERPINE BEHAVIORAL DEPRESSION IN MICE.
079970 09-04

INCREASED DURATION OF NEUROPHARMACOLOGICALLY INDUCED BEHAVIORAL EXCITATION BY ATROPINE.
079998 09-04

MECHANISMS OF LITHIUM ACTION: (ENDOGENOUS TISSUE LEVELS, EXCRETION IN EMOTIONAL STATES, AND BEHAVIORAL EFFECTS).
080634 09-03

BEHAVIORAL EFFECTS OF P-CHLOROPHENYLALANINE IN RATS: INHIBITION BY LITHIUM.
081112 09-03

ALTERATIONS IN THE BEHAVIORAL EFFECTS OF LSD BY MIDBRAIN RAPHE LESIONS (UNPUBLISHED PAPER).
082545 10-04

BEHAVIORAL CHANGES FOLLOWING REPEATED LOW DOSES OF MONOMETHYLHYDRAZINE.
082959 10-05

ALTERATIONS IN THE BEHAVIORAL EFFECTS OF LSD BY MIDBRAIN RAPHE LESIONS.
086029 10-12

CONTRIBUTION TO THE STUDY OF THE ACTION OF PROPERICIAZINE ON BEHAVIORAL PROBLEMS OF THE CHILD AND THE ADOLESCENT.
086451 10-11

EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND 2-BROM-D-LYSERGIC ACID DIETHYLAMIDE (BOL-148) UPON BEHAVIORAL SLEEP IN RATS.
089045 10-12

NEUROPHYSIOLOGICAL AND BEHAVIORAL CORRELATES OF LITHIUM.
095014 11-03

ALTERATIONS IN THE BEHAVIORAL EFFECTS OF LSD BY PRETREATMENT WITH P-CHLOROPHENYLALANINE AND ALPHA-METHYL-P-TYROSINE.
097965 11-04

BEHAVIORAL TOXICITY. PART 3: PERCEPTUAL COGNITIVE FUNCTIONS AND PART 4: EMOTIONAL (MOOD) STATES.
100523 12-15

BEHAVIORAL TOXICITY. PART 1: DEFINITION AND PART 2: PSYCHOMOTOR FUNCTIONS.
100524 12-15

BEHAVIORAL TOXICITY. PART 5: GROSS BEHAVIOR PATTERNS.
105560 12-15

A BIPHASIC ACTION OF PILOCARPINE ON BEHAVIORAL AROUSAL IN THE RAT. (PH.D.DISSERTATION).
110922 12-04

PHARMACOLOGICAL STUDIES OF OXAZOLAZEPAM, A NEW PSYCHOTROPIC AGENT - I. ACTIONS ON THE CENTRAL NERVOUS SYSTEM, ESPECIALLY ON THE BEHAVIORAL OBSERVATION.
114769 12-02

PREDICTION AND MEASUREMENT OF PERCEPTUAL BEHAVIORAL CHANGE IN DRUG-INDUCED HALLUCINATIONS.
121086 12-12

BEHAVIORAL PHARMACOLOGY OF THE HALLUCINOGENS.
121087 12-14

IMIPRAMINE AS AN EFFECTIVE TOOL IN THE MANAGEMENT OF BEHAVIORAL DISORDERS IN CHILDREN.
134937 12-11

**BEHAVIORALLY**

HYPOTENSIVE EFFECTS OF CHLORDIAZEPOXIDE, AMOBARBITAL AND CHLORPROMAZINE ON BEHAVIORALLY INDUCED ELEVATED ARTERIAL BLOOD PRESSURE IN THE SQUIRREL MONKEY.
089999 11-04

**BEHAVIORS**

EFFECTS OF A TRANQUILIZER AND TWO ANTIDEPRESSANTS ON LEARNED AND UNLEARNED BEHAVIORS.
064259 04-04

EFFECTS OF 6-FLUORO-N-N-DIETHYLTRYPTAMINE (6-FDET) ON SELECTED RAT BEHAVIORS.
075314 08-04

**BEHAVIOUR**

CHANGES IN EMOTIONAL BEHAVIOUR AFTER APPLICATION OF CHOLINESTERASE INHIBITOR IN THE SEPTAL AND AMYGDALA REGION.
040578 01-04

A COMPARISON OF THE EFFECTS OF SOME BENZODIAZEPINES AND OTHER DRUGS ON AGGRESSIVE AND EXPLORATORY BEHAVIOUR IN MICE AND RATS.
040581 01-04

THE EFFECTS OF NORADRENALINE ON RATS BEHAVIOUR.
062941 03-04

A METHOD FOR INVESTIGATING THE EFFECTS OF DRUGS ON THE EXPLORATORY BEHAVIOUR OF MICE.
064289 04-04

DISAPPEARANCE IN RATS WITH SEPTAL LESIONS OF THE STIMULATORY EFFECT OF HYOSCINE ON EXPLORATORY BEHAVIOUR.
067605 06-04

PERSISTENCE OF DOSE RELATED BEHAVIOUR IN MICE.
067606 06-04

URINARY NORADRENALINE AND PLAYROOM BEHAVIOUR IN HYPERACTIVE BOYS.
070024 07-14

STEREOTYPED BEHAVIOUR INDUCED BY (-) EPHEDRINE IN RATS.
074086 08-04

EVALUATION OF TEGRETOL IN THE TREATMENT OF BEHAVIOUR DISORDERS IN CHILDREN: METHODOLOGY AND RESULTS.
080098 09-07

THE EFFECT OF P-CHLOROPHENYLALANINE ON THE BEHAVIOUR OF CATS.
081264 09-04

EFFECTS OF ATROPINE AND ESERINE ON THE ELECTROENCEPHALOGRAM, ON BEHAVIOUR AND ON LIGHT INDUCED EPILEPSY IN THE ADOLESCENT BABOON (PAPIO-PAPIO).
090157 11-04

AGGRESSIVE BEHAVIOUR IN CHICKS INDUCED BY TRICYCLIC ANTIDEPRESSANTS.
090420 11-04

LESIONS IN CORPUS-STRIATUM AND CORTEX OF RAT BRAINS AND THE EFFECT ON PHARMACOLOGICALLY INDUCED STEREOTYPED, AGGRESSIVE AND CATALEPTIC BEHAVIOUR.
091127 11-04

CHANGES IN BEHAVIOUR WITH REPEATED TESTING UNDER THE INFLUENCE OF DRUGS: DRUG EXPERIENCE INTERACTIONS.
091997 11-04

INHIBITION BY DRUGS OF SMOKING BEHAVIOUR IN MONKEYS.
095351 11-03

DRUGS AND HUMAN BEHAVIOUR.
110896 12-14
DRUGS, BRAIN AND BEHAVIOUR: PROCEEDINGS OF SYMPOSIUM ON PSYCHOPHARMACOLOGY IN DURHAM.
129564 12-17

**BEHAVIOURAL**
BEHAVIOURAL EFFECTS IN RATS OF MORPHINE AND AMPHETAMINE AND OF A COMBINATION OF THE TWO DRUGS.
063019 03-04
RECORDING EVOKED POTENTIALS IN THE CONSCIOUS RAT: THE MAINTENANCE OF A CONSTANT BEHAVIOURAL BASELINE.
067600 06-06
PERSISTENT BEHAVIOURAL AND ELECTROENCEPHALOGRAPHIC CHANGES AFTER SINGLE DOSES OF NITRAZEPAM AND AMYLOBARBITONE SODIUM.
068005 06-14
MEASUREMENT OF BEHAVIOURAL CHANGES IN PATIENTS ON L-DOPA.
081039 09-11
SOME BEHAVIOURAL EFFECTS OF VARIABLES WHICH INFLUENCE THE GENERAL LEVEL OF ACTIVITY OF RATS.
085204 10-04

**BELGIAN**
CONSIDERATIONS OF SOME SIDE-EFFECTS OF DRUGS. (A STUDY BEARING ON 11,410 CALLS RECEIVED BY THE BELGIAN ANTIPOISON CENTER).
042687 01-15

**BELIEFS**
LSD, VIOLENCE AND RADICAL RELIGIOUS BELIEFS.
067354 06-12

**BENACTYZINE**
INFLUENCE OF IMIPRAMINE, BENACTYZINE AND PROMAZINE ON THE EFFECTS OF INTRAAMYGDALOID INJECTION OF ACETYLCHOLINE AND SEROTONIN.
098024 11-04

**BENEFIT**
BEER SOCIOTHERAPY CAN BENEFIT AGED MENTAL PATIENTS.
064145 04-11

**BENZAMIDES**
SUBSTITUTED BENZAMIDES WITH POTENTIAL CNS DEPRESSANT AND HYPOTENSIVE ACTIVITY.
089435 11-02

**BENZAZEPINES**
AZABICYCLO CHEMISTRY. I. SYNTHESIS OF 1,5-METHANO-7-METHOXY-2,3,4,5-TETRAHYDRO-1H-2- BENZAZEPINES. B-NORBENZOMORPHANS.
038489 01-01

**BENZAZEPINONE**
A BENZAZEPINONE: CARBON ANALOG OF DIAZEPAM.
080032 09-02

**BENZENE**
A CASE OF PROBABLE HEMATOMYELIA CAUSED BY CHRONIC BENZENE POISONING.
056059 02-15
GOODPASTURE SYNDROME AND THE EFFECTS OF BENZENE.
056060 02-15

**BENZOCTAMINE**
A CONTROLLED TRIAL OF BENZOCTAMINE (BA-30803) IN NEUROTIC ANXIETY.
064285 04-10
EFFECTS OF BENZOCTAMINE (30803-BA, TACITIN), A NEW PSYCHOACTIVE DRUG, ON CATECHOLAMINE METABOLISM.
074861 08-03

**BENZODIAZEPINE**
TOXICITY OF SOME BENZODIAZEPINE COMPOUNDS WITH CNS ACTIVITY.
046640 01-05
PHARMACOLOGICAL, TOXICOLOGICAL, AND TERATOLOGICAL STUDIES ON DIPOTASSIUM 7-CHLORO-3-CARBOXY 1,3-DIHYDRO-2,2-DIHYDROXY-5-PHENYL-2H-1,4 BENZODIAZEPINE CHLORAZEPATE (DIPOTASSIUM CHLORAZEPATE, 4306-CB), A NEW TRANQUILLIZER.
055581 02-03
THE EMPLOYMENT OF A NEW BENZODIAZEPINE, RO-5-4556 IN INTERNAL MEDICINE.
058312 02-11
ANTICONVULSIVE PROPERTIES OF SOME BENZODIAZEPINE DERIVATIVES.
058604 02-03
NOBRIUM, ANOTHER BENZODIAZEPINE DERIVATIVE. 29 MONTHS OF EXPERIENCE.
059037 03-11
THE PHARMACOLOGY OF PRAZEPAM: A NEW BENZODIAZEPINE DERIVATIVE.
064181 04-04
A DOUBLE-BLIND COMPARISON OF S-804 (NEW BENZODIAZEPINE DRUG) WITH CHLORDIAZEPOXIDE AND DIAZEPAM IN THE TREATMENT OF NEUROSIS.
129097 12-10

**BENZODIAZEPINES**
A COMPARISON OF THE EFFECTS OF SOME BENZODIAZEPINES AND OTHER DRUGS ON AGGRESSIVE AND EXPLORATORY BEHAVIOUR IN MICE AND RATS.
040581 01-04
EFFECTS OF SOME BENZODIAZEPINES ON PUNISHED AND UNPUNISHED BEHAVIOR IN THE PIGEON.
040758 01-04

**BENZODIAZEPINIC**
CLINICOELECTROENCEPHALOGRAPHIC EVALUATION OF A NEW BENZODIAZEPINIC DERIVATIVE (RO-5-4023) ADMINISTERED ORALLY IN EPILEPTIC PATIENTS USING A DOUBLE-BLIND METHOD.
100959 12-07
CLINICOELECTROENCEPHALOGRAPHIC EVALUATION OF THE ANTIEPILEPTIC ACTION OF A NEW SERIES OF BENZODIAZEPINIC DERIVATIVES.
105486 12-07

**BENZOXAZINE**
2-ETHYLAMINO-6-CHLORO-4-METHYL-4-PHENYL-4H-3,1 BENZOXAZINE, A NEW PSYCHOTROPIC COMPOUND.
079988 09-02

**BENZOXAZINONES**
A NEW CLASS OF 1,3 BENZOXAZINONES AS POTENTIAL CENTRAL NERVOUS SYSTEM AGENTS.
062322 03-02

**BENZOYLOXY**
THE EFFECT OF ACUTE ADMINISTRATION OF (META-TRIFLUOROMETHYL-PHENYL)-1-(BENZOYLOXY) ETHYLAMINO-2-PROPANE (780-SE) AND FENFLURAMINE ON HUMAN SLEEP.
063978 04-14

**BENZPYRENE**
EFFECTS OF PHENOBARBITAL, PHENYLBUTAZONE, 3,4 BENZPYRENE, OR 3-METHYLCHOLANTHRENE ON ETHANOL METABOLISM IN THE RAT.
066498 05-03

**BENZQUINAMIDE**
A DOUBLE-BLIND EVALUATION OF THE ANTIEMETIC EFFICACY OF BENZQUINAMIDE, PROCHLORPERAZINE AND TRIMETHOBENZAMIDE IN OFFICE PRACTICE.
063022 03-07

**BERNAS**
AN INTERESTING TISSULARY THERAPEUTIC METHOD IN GERIATRICS: BOGOMOLETZ SERUM (BERNAS CYTOTOXIC SERUM).
105551 12-11

**BETA-ADRENERGIC**
CARDIAC CATECHOLAMINE LEVELS AND BLOOD PRESSURE AFTER CHRONIC TREATMENT WITH BETA-ADRENERGIC BLOCKING AGENTS.
055579 02-03
VERBAL ANXIETY AND THE BETA-ADRENERGIC RECEPTORS: A FACILITATING MECHANISM.
060880 03-13
RECIPROCAL HUNGER REGULATING CIRCUITS INVOLVING ALPHA-ADRENERGIC AND BETA-ADRENERGIC RECEPTORS LOCATED, RESPECTIVELY, IN THE VENTROMEDIAL AND LATERAL HYPOTHALAMUS.
092166 11-03

**BETA-ADRENORECEPTOR**
A POTENT BETA-ADRENORECEPTOR BLOCKING DRUG: 4-(2-HYDROXY-3-ISOPROPYLAMINOPROPOXY)INDOLE.
040751 01-03

**BETA-BENZOYLVINYL**
4-(BETA-BENZOYLVINYL) ANTIPYRINE DERIVATIVES WITH ANTIPHLOGISTIC AND ANALGESIC ACTIVITY.
055519 02-03

**BETA-CARBOLINES**
INHIBITORS OF MONOAMINE OXIDASE VI: EFFECTS OF SUBSTITUTION ON INHIBITORY ACTIVITY OF 6 (OR 8) SUBSTITUTED BETA-CARBOLINES.
090426 11-01

**BETA-HYDROXYLASE**
BEHAVIORAL AND BRAIN CATECHOLAMINE DEPLETING ACTIONS OF U-14624, AN INHIBITOR OF DOPAMINE BETA-HYDROXYLASE.
058986 03-03

**BETA-HYDROXYLATION**
BETA-HYDROXYLATION OF N-ACETYL-DIMETHOXYPHENETHYLAMINE AND THE INFLUENCE OF IPRONIAZID ON THE DEMETHYLATION OF THIS COMPOUND IN VIVO IN THE RAT.
064053 04-03

**BETA-PHENETHYLAMINE**
2,3,6 TRIMETHOXYNITROSTYRENE AND ITS BETA-PHENETHYLAMINE.
063606 04-05

**BETA-PHENYLETHYLAMINE**
ANTAGONISM OF BETA-PHENYLETHYLAMINE DERIVATIVES AND SEROTONIN BLOCKING DRUGS UPON SEROTONIN, TRYPTAMINE AND RESERPINE BEHAVIORAL DEPRESSION IN MICE.
079970 09-04

**BETA-RECEPTOR**
ANTISEROTONIN EFFECT OF AGENTS BLOCKING THE ADRENERGIC BETA-RECEPTOR.
108694 12-03

**BETA-RECEPTORS**
OI: THE ANALYSIS OF CARDIAC BETA-RECEPTORS: STUDIES ON THE BASE OF DOSE EFFECT CURVES FOR ISOPRENALINE, PROPRANOLOL, AND KL-255.
055396 02-03

**BETA-SYMPATHICOLYTICS**
ANTAGONISTIC INFLUENCE OF BETA-SYMPATHICOLYTICS ON THE METAMPHETAMINE INDUCED CHANGES IN FUNCTION AND METABOLISM OF THE BRAIN.
079954 09-03

**BETEL**
PHARMACOLOGY OF THE ACTIVE PRINCIPLE OF BETEL.
067595 06-04

**BIBLIOGRAPHY**
THE BROAD RANGE OF USE OF DIPHENYLHYDANTOIN: BIBLIOGRAPHY AND REVIEW.
111961 12-13

**BILE**
THE EFFECT OF ORAL CONTRACEPTIVE STEROIDS ON BILE SECRETION AND BILIRUBIN TM IN RATS.
040125 01-05

**BILIARY**
METABOLISM AND BILIARY EXCRETION OF THE LIPOPHILIC DRUG MOLECULES, IMIPRAMINE AND DESMETHYLIMIPRAMINE IN THE RAT – I. EXPERIMENTS IN VIVO AND WITH ISOLATED PERFUSED LIVERS.
067260 06-03

**BILIRUBIN**
THE EFFECT OF ORAL CONTRACEPTIVE STEROIDS ON BILE SECRETION AND BILIRUBIN TM IN RATS.
040125 01-05

**BINDING**
PLASMA PROTEIN BINDING OF TRICYCLIC ANTIDEPRESSIVE DRUGS.
040573 01-13
PLASMA PROTEIN BINDING OF CHLORPROMAZINE.
046138 01-13
THE ROLE OF PLASMA PROTEIN BINDING IN THE INHIBITORY EFFECT OF NORTRIPTYLINE ON THE NEURONAL UPTAKE OF NOREPINEPHRINE.
066278 05-03
INTERACTION OF CHLORPROMAZINE AND TISSUE BINDING SITES: PRELIMINARY STUDIES.
069367 06-03

**BINSWANGERS**
ON BINSWANGERS SUBCORTICAL ARTERIOSCLEROTIC ENCEPHALOPATHY AND THE POSSIBILITY OF ITS CLINICAL RECOGNITION.
078733 09-13

**BIOCHEMICAL**
INFLUENCE OF MODE AND DURATION OF PHENYLALANINE ADMINISTRATION ON BIOCHEMICAL PARAMETERS IN RATS OF VARIOUS AGES.
042840 01-03
CLINICAL AND BIOCHEMICAL ASPECTS OF DEPRESSION.
063600 04-13
COMPARATIVE BEHAVIORAL AND BIOCHEMICAL EFFECTS OF TRANYLCYPROMINE AND CYSTEINE ON NORMAL CONTROLS AND SCHIZOPHRENIC PATIENTS.
064331 04-08
THE STRUCTURAL AND BIOCHEMICAL BASIS OF MOVEMENT DISORDERS IN TREATMENT WITH NEUROLEPTIC DRUGS AND IN EXTRAPYRAMIDAL DISEASES.
067107 06-13
BIOCHEMICAL AND PHARMACOLOGIC STUDIES OF DYSTONIA.
069852 07-13
TWENTY-FIVE YEARS OF BIOCHEMICAL PSYCHIATRY.
070218 07-02
BIOCHEMICAL AND BEHAVIORAL EFFECT OF AMPHETAMINE IN DMI - RO-4-1284 INDUCED HYPERACTIVITY.
070951 07-03
CONSIDERATIONS ON THE HYPERKINESIA OF L-DOPA: SIGNIFICANT BIOCHEMICAL AND ANATOMICAL DEFICIENCIES.
078555 09-13
BIOCHEMICAL CHANGES DURING LEARNING IN AN INSECT GANGLION.
084758 10-04
BIOCHEMICAL ASPECTS OF LITHIUM PHARMACOLOGY (UNPUBLISHED PAPER).
088356 10-09
ON THE BIOCHEMICAL MECHANISM OF ACTION OF NICOTINIC ACID, NICOTINAMIDE, METHIONINE, AND D-PENICILLAMINE IN THE TREATMENT OF PSYCHOSES.
094962 11-13
LITHIUM IN PSYCHIATRY: CLINICAL AND BIOCHEMICAL ASPECTS.
098018 11-09
PHYSIOLOGICAL AND BIOCHEMICAL MECHANISMS OF THE EFFECT OF LITHIUM SALTS ON THE NERVOUS SYSTEM.
109786 12-13

**BIOCHEMISTRY**
BIOCHEMISTRY AND TREATMENT OF PARKINSONISM.
086351 10-13
STUDY OF AMINO ACID ANALOGS AND BRAIN BIOCHEMISTRY.
094553 11-03

**BIOELECTRIC**
CLINICAL, CLINICO-CHEMICAL AND BRAIN BIOELECTRIC TESTS OF A COMBINATION OF HEXOBENDINE, ETHAMIVAN AND HYDROXYETHYLTHEOPHYLLIN.
072585 08-14

**BIOGENIC**
PHARMACOLOGICAL SIGNIFICANCE OF BIOGENIC AMINES IN THE LUNGS: NORADRENALINE AND DOPAMINE.
041539 01-03
PHARMACOLOGICAL SIGNIFICANCE OF BIOGENIC AMINES IN THE LUNGS: 5-HYDROXYTRYPTAMINE.
041565 01-03
IMIPRAMINE AND LITHIUM EFFECTS ON BIOGENIC AMINE TRANSPORT IN DEPRESSED AND MANIC-DEPRESSED PATIENTS.
062326 03-13
IMIPRAMINE AND LITHIUM EFFECTS ON BIOGENIC AMINE TRANSPORT IN DEPRESSED AND MANIC-DEPRESSED PATIENTS.
062366 03-13
INTRASTRIATAL SPREADING OF BIOGENIC AMINES.
072471 08-03
THE IMPORTANCE OF RESEARCH IN BIOGENIC AMINES FOR THE EXPERIMENTAL PSYCHOPHARMACOLOGY.
081110 09-17
FOREBRAIN BIOGENIC AMINE FUNCTION IN HIGH AND LOW FEMALE RATS.
081231 09-04
STUDY EXPLORES ROLE OF BIOGENIC AMINES IN DEPRESSION.
087793 10-13
ROLE OF BIOGENIC AMINES IN MORPHINE DEPENDENCE IN THE RAT.
090149 11-03

**BIOLOGICAL**
INFLUENCE OF SEROTONIN AND RELATED SUBSTANCES UPON PHOTIC EVOKED POTENTIALS OF RABBIT: EVIDENCE FOR BIOLOGICAL ACTIVITY OF THE ALDEHYDE DERIVATIVE.
055584 02-03
EFFECTS OF PHENOTHIAZINE DERIVATIVES ON BIOLOGICAL MEMBRANES: DRUG-INDUCED CHANGES IN ELECTRON SPIN RESONANCE SPECTRA FROM SPIN-LABELED ERYTHROCYTE GHOST MEMBRANES.
064423 04-03
BIOLOGICAL ACTIVITIES OF SOME 5-SUBSTITUTED N,N DIMETHYLTRYPTAMINES, ALPHA-METHYLTRYPTAMINES, AND GRAMINES.
065494 05-03
CLINICAL AND BIOLOGICAL EFFECTS OF DECANOATE OF FLUPHENAZINE: BASED ON 35 OBSERVATIONS.
085347 10-08
THE SYNTHESIS AND BIOLOGICAL ACTIVITY OF (-)-DELTA9(11)-TRANS TETRAHYDROCANNABINOL; A NEW PROCEDURE FOR THE CLEAVAGE OF PHENYL METHYL ETHERS (UNPUBLISHED PAPER).
092888 11-01
BIOLOGICAL ASPECTS AND NOSOGRAPHY OF THE PSYCHOSES (CRITICAL NOTE).
130417 12-17

**BIOMEDICAL**
A REVIEW OF THE BIOMEDICAL EFFECTS OF MARIHUANA ON MAN IN THE MILITARY ENVIRONMENT.
085756 10-14

**BIOSYNTHESIS**
EFFECTS OF THALIDOMIDE AND CHLORCYCLIZINE ON THE BIOSYNTHESIS OF NUCLEIC ACIDS AND PROTEINS IN FETAL AND MATERNAL TISSUES OF THE RAT.
040027 01-05
INHIBITORS OF ADRENAL STEROID BIOSYNTHESIS.
051122 02-17
REGULATION OF NOREPINEPHRINE BIOSYNTHESIS.
051126 02-17
THE INHIBITION OF CATECHOLAMINE BIOSYNTHESIS BY APOMORPHINE.
066854 05-03
BIOSYNTHESIS OF PHENOLIC TETRAHYDROISOQUINOLINE ALKALOIDS OF PEYOTE.
069804 07-01
ACCELERATION OF NORADRENALINE BIOSYNTHESIS IN THE GUINEA-PIG VAS-DEFERENS BY POTASSIUM.
073063 08-06
A NEW WAY OF ACETYLCHOLINE BIOSYNTHESIS IN BRAIN TISSUE.
087303 10-01

**BIOTELEMETRIC**
MINIATURIZED BIOTELEMETRIC TRANSMITTER.
082706 10-06

**BIOTRANSFORMATION**
TOXICITY, NARCOTIC EFFECT, CONCENTRATION AT END OF ANESTHESIA, ELIMINATION FROM BLOOD AND BIOTRANSFORMATION OF HEXOBARBITAL IN RATS OF VARIOUS AGES FOLLOWING SLEEP INDUCTION WITH BARBITAL AND AFTER.
058987 03-05

**BIPHASIC**
BIPHASIC EFFECT OF NOREPINEPHRINE IN THE REGULATION OF HEPATIC TYROSINE TRANSAMINASE ACTIVITY.
062327 03-03
A BIPHASIC ACTION OF PILOCARPINE ON BEHAVIORAL AROUSAL IN THE RAT. (PH.D.DISSERTATION).
110922 12-04

**BIRTH**
EFFECTS OF PRENATAL ADMINISTRATION OF PSYCHOTROPIC DRUGS TO RATS ON BRAIN BUTYRYLCHOLINESTERASE ACTIVITY AT BIRTH.
067980 06-03

**BLACK**
EFFECTS OF AMPHETAMINE UPON RELEARNING PATTERN AND BLACK WHITE DISCRIMINATIONS FOLLOWING NEOCORTICAL LESIONS IN RATS.
065419 05-04

EFFECTS OF CHLORDIAZEPOXIDE ON BLACK WHITE DISCRIMINATION ACQUISITION AND REVERSAL IN WHITE RATS.
070083 07-04

EQUIVALENCE OF SIMULTANEOUS AND SUCCESSIVE NEOCORTICAL ABLATIONS IN PRODUCTION OF IMPAIRMENTS OF RETENTION OF BLACK WHITE HABITS IN RATS.
076316 09-04

**BLADDERS**
METOCLOPRAMIDE AND THE MUSCULATURE OF ESOPHAGUS, STOMACH, INTESTINE, SPLEEN, TRACHEA, GALL AND URINARY BLADDERS: IN VITRO STUDIES.
055394 02-03

**BLIND**
MARIJUANA: MARY JANE FACES THE IDENTITY CRISIS OR, THREE BLIND MEN STUDY THE ELEPHANT.
082063 10-17

**BLISTERS**
BLISTERS FROM BARBITURATE POISONING.
064634 04-15

**BLOCKADE**
BLOCKADE OF THE CARDIAC ACTION OF PHENYLEPHRINE BY BRETYLIUM OR COCAINE.
040242 01-03

THE ANTAGONISM OF ADRENERGIC NEURONE BLOCKADE BY AMPHETAMINE AND DEXAMPHETAMINE IN THE RAT AND GUINEA-PIG.
055322 02-03

BLOCKADE OF NORADRENALINE UPTAKE AND INHIBITION OF GASTRIC ACID SECRETION BY 2-(P-CHLOROPHENYL-2-(PYRIDYL)HYDROXYMETHYL) IMIDAZOLINE MALEATE (SCH-12650).
058878 02-02

THE EFFECT OF DEXAMETHASONE BLOCKADE OF ACTH RELEASE ON AVOIDANCE LEARNING.
067884 06-04

ANTICHOLINERGIC CENTRAL BLOCKADE OF SALT AROUSED AND DERIVATION INDUCED DRINKING.
081227 09-04

BLOCKADE OF NOREPINEPHRINE UPTAKE AND RELATED ACTIVITIES OF CIS- AND TRANS N,N(PRIME)-BIS-(1-NAPHTHYLMETHYL)-1,4 CYCLOHEXANE BIS-(METHYLAMINE) DIHYDROCHLORIDE.
090136 11-03

**BLOCKING**
A POTENT BETA-ADRENORECEPTOR BLOCKING DRUG: 4-(2-HYDROXY-3-ISOPROPYLAMINOPROPOXY)INDOLE.
040751 01-03

INHIBITION OF THE RE-UPTAKE OF NEURONALLY LIBERATED NORADRENALINE AND ALPHA-RECEPTOR BLOCKING ACTION OF SOME ERGOT ALKALOIDS.
041967 01-03

SELECTIVE DEPLETION OF NORADRENALINE: A PROPOSED MECHANISM OF THE ADRENERGIC NEURONE BLOCKING ACTION OF BRETYLIUM.
055323 02-05

CARDIAC CATECHOLAMINE LEVELS AND BLOOD PRESSURE AFTER CHRONIC TREATMENT WITH BETA-ADRENERGIC BLOCKING AGENTS.
055579 02-03

BLOCKING OF EXPERIMENTAL SPIKE AND WAVE BY A LOCALIZED FOREBRAIN LESION.
066186 05-03

THE INFLUENCE OF THE GANGLIONIC BLOCKING AGENT GANLION ON VISCEROVISCERAL AND VISCEROCEREBRAL REACTIONS OF THE CAT.
071703 07-03

ANTAGONISM OF BETA-PHENYLETHYLAMINE DERIVATIVES AND SEROTONIN BLOCKING DRUGS UPON SEROTONIN, TRYPTAMINE AND RESERPINE BEHAVIORAL DEPRESSION IN MICE.
079970 09-04

FURTHER STUDIES ON THE EFFECTS OF BLOCKING AGENTS ON PROTEIN SYNTHESIS IN GOLDFISH BRAIN.
083170 10-03

ANTISEROTONIN EFFECT OF AGENTS BLOCKING THE ADRENERGIC BETA-RECEPTOR.
108694 12-03

EFFECT OF GANGLIONIC BLOCKING AGENTS ON PRESSOR EFFECTS OF SYMPATHOMIMETIC AMINES OF DIRECT AND INDIRECT ACTION.
110632 12-03

**BLOOD**
CARDIAC CATECHOLAMINE LEVELS AND BLOOD PRESSURE AFTER CHRONIC TREATMENT WITH BETA-ADRENERGIC BLOCKING AGENTS.
055579 02-03

TOXICITY, NARCOTIC EFFECT, CONCENTRATION AT END OF ANESTHESIA, ELIMINATION FROM BLOOD AND BIOTRANSFORMATION OF HEXOBARBITAL IN RATS OF VARIOUS AGES FOLLOWING SLEEP INDUCTION WITH BARBITAL AND AFTER.
058987 03-05

BLOOD AND URINE CONCENTRATIONS OF SUBJECTS RECEIVING BARBITURATES, MEPROBAMATE, GLUTETHIMIDE, OR DIPHENYLHYDANTOIN.
063927 04-13

PERMEABILITY OF THE BLOOD BRAIN BARRIER TO PARENTERAL 5-HYDROXYTRYPTAMINE IN THE NEONATE CHICK.
067253 06-04

ACTIONS OF RESERPINE AND TYRAMINE ON THE ACETYLCHOLINE CONTENT OF BRAINSTEM, HEART AND BLOOD OF THE RAT.
067461 06-03

INHIBITORY EFFECT OF TWO NEWER ANTIDEPRESSANTS, LU-5-003 AND LU-3-010, ON SEROTONIN UPTAKE IN HUMAN BLOOD PLATELETS IN VITRO.
071791 07-03

CORRELATION BETWEEN THE CHANGES OF EEG, PUPILLES AND BLOOD PRESSURE DUE TO INTRAVENOUS INJECTION OF CHLORPROMAZINE: CHLORPROMAZINE TEST.
088611 10-13

HYPOTENSIVE EFFECTS OF CHLORDIAZEPOXIDE, AMOBARBITAL AND CHLORPROMAZINE ON BEHAVIORALLY INDUCED ELEVATED ARTERIAL BLOOD PRESSURE IN THE SQUIRREL MONKEY.
089999 11-04

EFFECT OF L-DOPA ALONE AND IN COMBINATION WITH AN EXTRACEREBRAL DECARBOXYLASE INHIBITOR ON BLOOD PRESSURE AND SOME CARDIOVASCULAR REFLEXES.
090371 11-13

EFFECT OF FRUCTOSE ON ALCOHOL CONCENTRATIONS IN THE BLOOD OF MAN.
092004 11-11

**BODY**
ALTERATIONS OF D-AMPHETAMINE SULFATE LETHALITY AND BODY TEMPERATURE IN MICE DURING ACUTE ALTITUDE EXPOSURE.
040582 01-03

TOTAL BODY KINETICS AND PLACENTAL TRANSFER OF LABELED LSD IN MICE.
046201 01-03

EFFECT OF MOOD AND LITHIUM CARBONATE ON TOTAL BODY POTASSIUM.
047952 01-09

LITHIUM CARBONATE AS A MOOD AND TOTAL BODY WATER STABILIZER.
047953 01-09

LIVER DAMAGE FOLLOWING APPLICATION OF PYRAZINAMIDE IN ANIMAL EXPERIMENTS: 1. CHANGES IN BODY WEIGHT OF RATS UNDER THE INFLUENCE OF PYRAZINAMIDE.
055398 02-05

BODY CONSCIOUSNESS IN STATES OF PHARMACOLOGICAL DEPRESSION AND AROUSAL.
072032 07-14

CENTRAL EFFECTS OF 6-HYDROXYDOPAMINE ON THE BODY TEMPERATURE OF THE RAT.
073069 08-03

SWIM STRESS INDUCED INACTIVITY: RELATION TO BODY TEMPERATURE AND BRAIN NOREPINEPHRINE, AND EFFECTS OF D-AMPHETAMINE.
075275 08-03

PHASE DIFFERENCE IN THE INDUCTION OF TYROSINE HYDROXYLASE IN CELL BODY AND NERVE TERMINALS OF SYMPATHETIC NEURONES.
075715 08-03

DEVELOPMENT OF HORMONAL CONTROL OVER FOOD INTA[illegible]ND BODY WEIGHT IN FEMALE RATS.
076239 09-03

INFLUENCE OF HAPLOPHYLLUM ALKALOIDS ON THE BODY TEMPERATURE OF ANIMALS.
105721 12-03

CHANGES OF THE BODY TEMPERATURE OF CODEINE TOLERANT RATS BY THE ADMINISTRATION OF NALORPHINE.
130427 12-03

**BOGOMOLETZ**
AN INTERESTING TISSULARY THERAPEUTIC METHOD IN GERIATRICS: BOGOMOLETZ SERUM (BERNAS CYTOTOXIC SERUM).
105551 12-11

**BOL-148**
EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND 2-BROM-D-LYSERGIC ACID DIETHYLAMIDE (BOL-148) UPON BEHAVIORAL SLEEP IN RATS.
089045 10-12

**BOUND**
EFFECTS OF SELECTED DRUGS ON STIMULUS BOUND EMOTIONAL BEHAVIOR ELICITED BY HYPOTHALAMIC STIMULATION IN THE CAT.
088617 10-04

**BOYS**

PIPERACETAZINE (QUIDE) IN THE MANAGEMENT OF BEHAVIORAL DISORDERS IN MILDLY RETARDED INSTITUTIONALIZED BOYS.
069071 06-11

URINARY NORADRENALINE AND PLAYROOM BEHAVIOUR IN HYPERACTIVE BOYS.
070024 07-14

**BRADYKININ**

THE EFFECT OF BRADYKININ AND ELEDOISIN INJECTED INTO THE CEREBRAL VENTRICLES OF CONSCIOUS RATS.
047323 01-04

**BRAIN**

EFFECTS OF AMPHETAMINE DERIVATIVES ON BRAIN DOPAMINE AND NORADRENALINE.
040126 01-03

COMPARATIVE EFFECTS OF P-CHLOROPHENYLALANINE, P-CHLOROAMPHETAMINE AND P-CHLORO-N-METHYLAMPHETAMINE ON RAT BRAIN NOREPINEPHRINE, SEROTONIN AND 5-HYDROXYINDOLE-3-ACETIC ACID.
040241 01-03

DAILY RHYTHM IN THE ACCUMULATION OF BRAIN CATECHOLAMINES SYNTHESIZED FROM CIRCULATING H3-TYROSINE.
040246 01-03

EFFECTS OF CHRONIC ADMINISTRATION OF NICOTINE ON STORAGE AND SYNTHESIS OF NORADRENALINE IN RAT BRAIN.
041552 01-03

THE EFFECT OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON BRAIN ACETYLCHOLINE LEVELS IN RAT.
041913 01-03

L-DOPA INDUCED ACCUMULATION OF METHYLDOPA IN BRAIN AND HEART.
042726 01-03

FURTHER STUDIES ON THE ACCUMULATION AND DISAPPEARANCE OF CATECHOLAMINES FORMED FROM TYROSINE-14C IN MOUSE BRAIN. EFFECT OF SOME PHENOTHIAZINE ANALOGUES.
042727 01-03

ACCUMULATION AND DISAPPEARANCE OF 3H-5-HYDROXYTRYPTAMINE FORMED FROM 3H-TRYPTOPHAN IN MOUSE BRAIN: EFFECT OF LSD-25.
042755 01-03

THE EFFECT OF CENTRALLY ACTING DRUGS ON THE CONCENTRATION OF BRAIN ADENOSINE 3PRIME,5PRIME- MONOPHOSPHATE.
043276 01-03

EFFECTS OF LITHIUM CARBONATE ON TURNOVER AND METABOLISM OF NOREPINEPHRINE IN THE RAT BRAIN - CORRELATION TO GROSS BEHAVIORAL EFFECTS.
043277 01-03

DEPHOSPHORYLATION IN VIVO OF BRAIN ACETYLCHOLINESTERASE INHIBITED BY ISOPROPYL METHYLPHOSPHONOFLUORIDATE (SARIN).
046188 01-03

EFFECT OF RESERPINE ON THE INCORPORATION IN VIVO OF RADIOACTIVITY FROM LABELED SEROTONIN AND OTHER 5-HYDROXYINDOLE DERIVATIVES IN MOUSE BRAIN.
046189 01-03

INCREASE IN BRAIN PYRIDOXAL PHOSPHATE BY CHLORPROMAZINE.
046397 01-02

DIFFERENCES IN BRAIN AREA 5-HYDROXYTRYPTAMINE TURNOVER AND REARING BEHAVIOR IN RATS AND MICE OF BOTH SEXES.
047324 01-04

TRANYLCYPROMINE: EFFECTS ON NOREPINEPHRINE METABOLISM IN RAT BRAIN.
052484 02-03

THE ROLE OF BRAIN CATECHOLAMINES IN MORPHINE ANALGESIC ACTION IN MORPHINE TOLERANT RATS.
055756 02-03

A SIMPLE AND INEXPENSIVE CANNULA TECHNIQUE FOR CHEMICAL STIMULATION OF THE BRAIN.
058357 02-06

AN IMPROVED INSTRUMENT FOR IMPLANTING MICROPELLETS IN THE BRAIN.
058358 02-06

EFFECT OF ANTIDEPRESSANT DRUGS ON ACCUMULATION AND DISAPPEARANCE OF MONOAMINES FORMED IN VIVO FROM LABELED PRECURSORS IN MOUSE BRAIN.
058798 02-03

ANTAGONISTIC EFFECTS OF DOPA AND PROPRANOLOL ON BRAIN GLYCOGEN.
058800 02-03

DOPA INDUCED EXCITEMENT IN THE CAT: ITS RELATIONSHIP TO BRAIN NOREPINEPHRINE CONCENTRATIONS.
058840 02-04

DISSOCIATION OF THE EFFECTS OF P-CHLOROPHENYLALANINE ON SELF-STIMULATION AND ON BRAIN SEROTONIN.
058942 02-03

FUNCTIONAL RELATIONSHIPS OF BRAIN CIRCUITS IN CONTROL OF DRINKING BEHAVIOR.
058961 03-04

BEHAVIORAL AND BRAIN CATECHOLAMINE DEPLETING ACTIONS OF U-14624, AN INHIBITOR OF DOPAMINE BETA-HYDROXYLASE.
058986 03-03

THE EFFECTS OF SOME PSYCHOACTIVE DRUGS ON RAT BRAIN ADENOSINE TRIPHOSPHATE LEVELS.
058988 03-03

PROJECT SUMMARY: METHANOL FORMING ENZYME IN MAMMALIAN BRAIN.
060633 03-01

CYCLIC AMP AND ADENYL-CYCLASE IN THE DEVELOPING RAT BRAIN.
060856 03-03

NOREPINEPHRINE AND DOPAMINE IN THE DEVELOPING CHICK BRAIN.
060865 03-03

THE EFFECT OF CYCLANDELATE ON MENTAL FUNCTION IN PATIENTS WITH ARTERIOSCLEROTIC BRAIN DISEASE.
061654 03-13

P-CHLOROAMPHETAMINE: TEMPORAL RELATIONSHIP BETWEEN PSYCHOMOTOR STIMULATION AND METABOLISM OF BRAIN NOREPINEPHRINE.
062805 03-03

ELEVATED CATECHOLAMINES IN THIRTY-DAY-OLD CHICKEN BRAIN AFTER DEPLETION DURING DEVELOPMENT.
063044 03-03

PROJECT SUMMARY: MUCOPOLYSACCHARIDE COMPOSITION OF RAT AND RABBIT BRAIN.
063526 03-01

L-DIHYDROXYPHENYLALANINE: EFFECT ON S-ADENOSYLMETHIONINE IN BRAIN.
063825 04-03

INTRACRANIAL SELF-STIMULATION AND WAKEFULNESS: EFFECT OF MANIPULATING AMBIENT BRAIN CATECHOLAMINES.
063849 04-04

THE SENSITIVITY OF THE BRAIN TO BARBITURATE DURING CHRONIC ADMINISTRATION AND WITHDRAWAL OF BARBITONE SODIUM IN THE RAT.
063980 04-03

SPECIAL APPLICATION OF FLUORESCENCE HISTOCHEMISTRY: STUDIES ON EIGHT MONOAMINE OXIDASE INHIBITORS IN BRAIN NEURONS.
063989 04-06

MONOAMINES IN THE BRAIN UNDER THE INFLUENCE OF MUSCIMOL AND IBOTENIC ACID, TWO PSYCHOACTIVE PRINCIPLES OF AMANITA-MUSCARIA.
064408 04-03

EFFECTS OF DESMETHYLIMIPRAMINE AND COCAINE ON THE UPTAKE, RETENTION AND METABOLISM OF H3-TYRAMINE IN RAT BRAIN SLICES.
064419 04-03

EFFECT OF ACUTE HYPOXIA ON BRAIN SENSITIVITY AND METABOLISM OF BARBITURATES IN MICE.
064480 04-03

EFFECTS OF DISULFIRAM AND DIETHYLDITHIOCARBAMATE ON SPONTANEOUS LOCOMOTOR ACTIVITY AND BRAIN CATECHOLAMINE LEVELS IN MICE.
064590 04-04

THE ALTERATIONS OF PROTEIN METABOLISM OF THE BRAIN CORTEX INDUCED BY ANTICIPATION STRESS AND ACTH.
065434 05-03

THE EFFECT OF PROLONGED LITHIUM TREATMENT ON THE SYNTHESIS RATE AND TURNOVER OF MONOAMINES IN BRAIN REGIONS OF RATS.
066413 05-03

ELECTRICAL IMPEDANCE CHANGES IN MANY SITES OF BRAIN IN PARADOXICAL SLEEP, ANESTHESIA AND ACTIVITY.
066474 05-03

INHIBITION OF CATECHOLAMINE UPTAKE BY 6-HYDROXYDOPAMINE IN RAT BRAIN.
066501 05-03

EFFECT OF APOMORPHINE AND PIMOZIDE ON SYNTHESIS AND TURNOVER OF LABELED CATECHOLAMINES IN MOUSE BRAIN.
066502 05-03

INHIBITION BY P-CHLOROAMPHETAMINE OF THE CONVERSION OF 5-HYDROXYTRYPTAMINE TO 5-HYDROXYINDOLEACETIC ACID IN RAT BRAIN.
066507 05-03

ACETYLCHOLINE RELEASE FROM CORTICAL BRAIN SLICES OF RATS INJECTED WITH LITHIUM.
066509 05-03

THE EFFECT OF SERUM FROM ACUTE SCHIZOPHRENIC PATIENTS ON RABBIT BRAIN AMINES.
066713 05-03

EFFECT OF ETHANOL ON 5-HYDROXYTRYPTAMINE TURNOVER IN RAT BRAIN.
066938 05-03

CONTRACEPTIVES, BRAIN SEROTONIN, AND LIVER TRYPTOPHAN PYRROLASE.
067072 05-03

(3H)HARMALINE DISTRIBUTION IN MONKEY BRAIN; PHARMACOLOGICAL AND AUTORADIOGRAPHIC STUDY.
067081 05-03

UPTAKE OF (14C) PENTYLENETETRAZOL BY DEVELOPING RAT BRAIN.
067120 06-02
PERMEABILITY OF THE BLOOD BRAIN BARRIER TO PARENTERAL 5-HYDROXYTRYPTAMINE IN THE NEONATE CHICK.
067253 06-04
THE EFFECT OF DISULFIRAM, DIETHYLDITHIOCARBAMATE AND DIMETHYLDITHIOCARBAMATE ON SEROTONIN AND 5-HYDROXYINDOLE-3-ACETIC ACID BRAIN LEVELS IN RATS.
067384 06-03
THE SWITCH PROCESS FROM DEPRESSION TO MANIA: RELATIONSHIP TO DRUGS WHICH ALTER BRAIN AMINES.
067585 06-09
THE BRAIN ACETYLCHOLINE SYSTEM IN BARBITONE DEPENDENT AND WITHDRAWN RATS.
067604 06-03
PHYSIOLOGICAL AND DRUG-INDUCED CHANGES IN THE GLYCOGEN CONTENT OF MOUSE BRAIN.
067608 06-03
PENTYLENETETRAZOL AND ETHAMIVAN EFFECTS ON BRAIN SEROTONIN METABOLISM.
067613 06-03
NOREPINEPHRINE TURNOVER AND METABOLISM IN RAT BRAIN AFTER LONG-TERM ADMINISTRATION OF IMIPRAMINE.
067687 06-03
EFFECTS OF PRENATAL ADMINISTRATION OF PSYCHOTROPIC DRUGS TO RATS ON BRAIN BUTYRYLCHOLINESTERASE ACTIVITY AT BIRTH.
067980 06-03
DRUG-INDUCED RELEASE OF 3H-NOREPINEPHRINE AND 3H-SEROTONIN FROM BRAIN SLICES.
068290 06-03
RELATIONS BETWEEN BARBITURATE BRAIN LEVELS AND SLEEPING TIME IN VARIOUS EXPERIMENTAL CONDITIONS.
068600 06-03
ALTERATIONS IN BRAIN SENSITIVITY AND BARBITURATE METABOLISM UNRELATED TO AGGRESSION IN SOCIALLY DEPRIVED MICE.
069052 06-03
THE EFFECT OF LITHIUM UPON BRAIN NEUROAMINES.
069062 06-03
THE EFFECTS OF VARIOUS PRIOR TREATMENTS UPON THE TRANSPORT OF CHLORPROMAZINE AND TRIFLUOPERAZINE INTO RAT BRAIN.
069309 06-02
BRAIN SEROTONIN TURNOVER IN MORPHINE TOLERANT AND DEPENDENT MICE.
069595 07-03
COMPARISON OF DRINKING ELICTED BY ESERINE OR DFP INJECTED INTO PREOPTIC AREA OF RAT BRAIN.
069637 07-04
ASSOCIATION OF BROMIDE WITH THE SYNAPTOSOMAL FRACTION OF MOUSE BRAIN.
070521 07-01
THE EFFECT OF SOME HALLUCINOGENIC DRUGS ON THE AMINO ACID PRECURSORS OF BRAIN MONOAMINES.
070542 07-03
AMPHETAMINE: DIFFERENTIATION BY D AND L ISOMERS OF BEHAVIOR INVOLVING BRAIN NOREPINEPHRINE OR DOPAMINE.
070921 07-04
DRUG RESPONSE FOLLOWING BRAIN DAMAGE.
070977 07-04
HEXOSE AND PENTOSE PHOSPHATES IN BRAIN DURING CONVULSIONS.
072119 07-03
EFFECTS OF 6-HYDROXYDOPAMINE ON CATECHOLAMINE CONTAINING NEURONES IN THE RAT BRAIN.
072120 07-03
EFFECT OF BRAIN ISO-ANTIBODIES ON LEARNING AND MEMORY IN THE RAT.
072516 08-04
CLINICAL, CLINICO-CHEMICAL AND BRAIN BIOELECTRIC TESTS OF A COMBINATION OF HEXOBENDINE, ETHAMIVAN AND HYDROXYETHYLTHEOPHYLLIN.
072585 08-14
AUTORADIOGRAPHIC STUDIES ON THE DISTRIBUTION OF PSYCHOACTIVE DRUGS IN THE RAT BRAIN: IV. C14-THIORIDAZINE.
073709 08-03
THE EFFECT OF AMINOESTERS OF SUBSTITUTED GLYCOLIC AND ACETIC ACIDS ON THE CONTENT OF NORADRENALINE IN THE BRAIN OF RATS.
073717 08-03
FUNCTIONAL CHARACTERISTIC OF THE LINKS OF THE BRAIN CONTROL SYSTEM FOR MENTAL AND MOTOR FUNCTIONS IN MAN.
073770 08-13
THE EFFECT OF AMANTADINE ON THE UPTAKE OF DOPAMINE AND NORADRENALINE BY RAT BRAIN HOMOGENATES.
074148 08-03
FORMATION AND REGIONAL DISTRIBUTION OF GAMMA-HYDROXYBUTYRIC ACID IN MAMMALIAN BRAIN.
074864 08-01
MECHANISM OF THE GAMMA-HYDROXYBUTYRATE INDUCED INCREASE IN BRAIN DOPAMINE AND ITS RELATIONSHIP TO SLEEP.
074865 08-04
COMPARATIVE EFFECTS OF AMPHETAMINE, SCOPOLAMINE, CHLORDIAZEPOXIDE, AND DIPHENYLHYDANTOIN ON OPERANT AND EXTINCTION BEHAVIOR WITH BRAIN STIMULATION AND FOOD REWARD.
074935 08-04
THE EFFECTS OF ALTERED BRAIN NOREPINEPHRINE LEVELS ON CONTINUOUS AVOIDANCE RESPONDING AND THE ACTION OF AMPHETAMINES.
074937 08-04
SWIM STRESS INDUCED INACTIVITY: RELATION TO BODY TEMPERATURE AND BRAIN NOREPINEPHRINE, AND EFFECTS OF D-AMPHETAMINE.
075275 08-03
THE SIGNIFICANCE OF BRAIN DAMAGE IN PERSISTENT ORAL DYSKINESIA.
075416 08-15
ROLE OF BRAIN AMINES IN THE ANALGESIC ACTION OF MEPERIDINE HYDROCHLORIDE.
075845 09-03
THE ROLE OF BRAIN DOPAMINE IN BEHAVIORAL REGULATION AND THE ACTIONS OF PSYCHOTROPIC DRUGS.
075869 09-04
UPTAKE OF TRITIATED TESTOSTERONE IN BRAIN AND PERIPHERAL TISSUES OF NORMAL AND NEONATALLY ANDROGENIZED FEMALE RATS.
076086 09-04
BRAIN FUNCTION AND MACROMOLECULES: V. THE EFFECT OF CYCLOHEXIMIDE AND ACTINOMYCIN-D ON LEARNING IN THE HEADLESS COCKROACH.
078378 09-03
EFFECTS OF CHLORIMIPRAMINE ON ELECTRICAL ACTIVITIES OF SUBCORTICAL BRAIN STRUCTURES AND OF SYMPATHETIC NERVES.
079951 09-03
ANTAGONISTIC INFLUENCE OF BETA-SYMPATHICOLYTICS ON THE METAMPHETAMINE INDUCED CHANGES IN FUNCTION AND METABOLISM OF THE BRAIN.
079954 09-03
PROPOSALS FOR IMPROVING THE TREATMENT OF BRAIN DAMAGED PATIENTS.
080041 09-11
PSYCHOMETRIC TESTS IN EVALUATION OF BRAIN PATHOLOGY, RESPONSE TO DRUGS.
081043 09-14
LATE BRAIN RECOVERY PROCESSES AFTER DRUG OVERDOSE.
082027 10-15
REDUCTION OF LEVEL OF L-GLUTAMIC ACID DECARBOXYLASE BY GAMMA-AMINOBUTYRIC ACID IN MOUSE BRAIN.
083168 10-03
IN VIVO FORMATION AND CATABOLISM OF (14C)HISTAMINE IN MOUSE BRAIN.
083169 10-03
FURTHER STUDIES ON THE EFFECTS OF BLOCKING AGENTS ON PROTEIN SYNTHESIS IN GOLDFISH BRAIN.
083170 10-03
A NOVEL METHOD OF REDUCING THE CONCENTRATION OF BRAIN SEROTONIN: USE OF ALPHA-METHYLTRYPTOPHAN.
086350 10-13
A NEW WAY OF ACETYLCHOLINE BIOSYNTHESIS IN BRAIN TISSUE.
087303 10-01
DIAZEPAM (VALIUM) LEVEL IN THE BRAIN DURING HYPOTHERMIA.
089036 10-03
RELATIONSHIP BETWEEN CENTRAL EFFECTS AND THE CONCENTRATION OF AMPHETAMINE IN LIVER AND BRAIN OF YOUNG AND OLD RATS.
089041 10-03
ON THE UPTAKE OF PHENOTHIAZINE DERIVATIVES BY THE ISOLATED PERFUSED RAT BRAIN.
089043 10-03
PERMEATION CHARACTERISTICS OF MORPHINE-LIKE SUBSTANCES AFTER INJECTION INTO BRAIN TISSUE AND INTO THE VENTRICULAR SYSTEM.
089047 10-03
CLINICAL EXPERIENCE WITH MESORIDAZINE IN THE THERAPY AND REHABILITATION OF TRAUMATIC FRONTAL BRAIN DAMAGE.
089784 11-14
NOREPINEPHRINE TURNOVER IN BRAIN AFTER ADMINISTRATION OF IMIPRAMINE: ENHANCEMENT BY THYROID HORMONE.
090052 11-13
THE EFFECT OF METHIONINE OF THE REGIONAL AND INTRACELLULAR DISPOSITION OF (3H) METHIONINE SULPHOXIMINE IN RAT BRAIN.
090148 11-03
INCREASED INCORPORATION OF 14C-URIDINE INTO RAT BRAIN RNA AS A RESULT OF NOVEL ELECTROSHOCK.
092209 11-01
BRAIN DAMAGE IN INFANT MICE FOLLOWING ORAL INTAKE OF GLUTAMATE, ASPARTATE OR CYSTEINE.
094164 11-05
STUDY OF AMINO ACID ANALOGS AND BRAIN BIOCHEMISTRY.
094553 11-03

EFFECTS OF COCAINE AND AMPHETAMINE ON THE METABOLISM OF TRYPTOPHAN AND 5-HYDROXYTRYPTAMINE IN MOUSE BRAIN IN VIVO.
095440 11-03

AMNESIA AND BRAIN SEIZURES ACTIVITY IN MICE: EFFECTS OF DIETHYL-ETHER ANESTHESIA PRIOR TO ELECTROSHOCK STIMULATION.
097952 11-04

INFLUENCE OF CHRONIC ADMINISTRATION OF NICOTINE ON THE TURNOVER AND METABOLISM OF NORADRENALINE IN THE RAT BRAIN.
097958 11-03

ON THE ROLE OF BRAIN CATECHOLAMINES IN MOTOR ACTIVITY: EXPERIMENTS WITH INHIBITORS OF SYNTHESIS AND OF MONOAMINE OXIDASE.
097960 11-04

ROLE OF BRAIN SEROTONIN IN THE STIMULANT ACTION OF AMPHETAMINE.
098003 11-03

THE INFLUENCE OF 5-HYDROXYTRYPTOPHAN ON THE BEHAVIOR AND THE LEVEL OF MONOAMINES IN THE BRAIN OF RATS SENSITIVE TO SOUND.
098040 11-03

SYNERGISM OF DESMETHYLIMIPRAMINE WITH RESERPINE AND 5-HYDROXYTRYPTOPHAN IN THE FROG: BRAIN SEROTONIN AND ADRENALINE AND BEHAVIOR.
098042 11-03

U-14C TYROSINE METABOLISM OF THE PERFUSED CAT BRAIN WITH HIGH PLASMA PHENYLALANINE OR WITHOUT PLASMA TYROSINE.
100852 12-03

EFFECTS OF MORPHINE AND LEVORPHANOL ON BRAIN ACETYLCHOLINE CONTENT IN MICE.
101316 12-03

STRUCTURAL BASIS OF LITHIUM PSYCHOPHARMACOLOGY: EXTRACELLULAR GROUND SUBSTANCE OF RAT BRAIN.
106783 12-03

EFFECT OF GANGLERONE AND QUATERONE ON CATECHOLAMINE CONTENT IN THE BRAIN.
111767 12-03

MANS TRIPARTITE BRAIN AND PSYCHOSOMATIC MEDICINE.
119884 12-17

DRUGS, BRAIN AND BEHAVIOUR: PROCEEDINGS OF SYMPOSIUM ON PSYCHOPHARMACOLOGY IN DURHAM.
129564 12-17

ANALGESIC EFFECT OF MORPHINE HYDROCHLORIDE INJECTED DIRECTLY INTO THE VENTRICLE OF MOUSE BRAIN.
130422 12-03

**BRAINS**

LESIONS IN CORPUS-STRIATUM AND CORTEX OF RAT BRAINS AND THE EFFECT ON PHARMACOLOGICALLY INDUCED STEREOTYPED, AGGRESSIVE AND CATALEPTIC BEHAVIOUR.
091127 11-04

**BRAINSTEM**

EFFECTS OF LYSERGIC ACID DERIVATIVES ON 5-HYDROXYTRYPTAMINE EXCITATION OF BRAINSTEM NEURONES.
041973 01-02

EFFECTS OF RESERPINE AND DESIPRAMINE ON THE UPTAKE AND SUBCELLULAR DISTRIBUTION OF 5-HYDROXYTRYPTAMINE IN RABBIT BRAINSTEM AFTER INTRAVENOUS ADMINISTRATION OF 5-HYDROXYTRYPTOPHAN.
056610 02-03

DOPAMINE CONCENTRATIONS IN THE BRAINSTEM MESENCEPHALON OF ACTIVE RATS AS COMPARED WITH PASSIVE RATS.
060274 03-04

ACTIONS OF RESERPINE AND TYRAMINE ON THE ACETYLCHOLINE CONTENT OF BRAINSTEM, HEART AND BLOOD OF THE RAT.
067461 06-03

THE CATECHOLAMINE CONTENT IN THE BRAINSTEM OF ALBINO RATS IN THE DEVELOPMENT OF TOLERANCE TO TRYPHTAZINE.
073681 08-03

UPTAKE AND STORAGE MECHANISM OF 5-HYDROXYTRYPTAMINE IN RABBIT BRAINSTEM AND EFFECT OF RESERPINE.
114975 12-03

**BRAINWASH**

CAN WE BRAINWASH THE APPETITE?
064635 05-03

**BREATHING**

A PSYCHOPHYSIOLOGICAL STUDY OF BREATHING BEHAVIOR.
095020 11-15

**BRETYLIUM**

BLOCKADE OF THE CARDIAC ACTION OF PHENYLEPHRINE BY BRETYLIUM OR COCAINE.
040242 01-03

THE EFFECT OF BRETYLIUM ON AMINE RETENTION IN RAT HEART.
040309 01-03

SELECTIVE DEPLETION OF NORADRENALINE: A PROPOSED MECHANISM OF THE ADRENERGIC NEURONE BLOCKING ACTION OF BRETYLIUM.
055323 02-05

**BRIDGE**

NEUROCHEMICAL STUDIES OF THE AFFECTIVE DISORDERS: THE PHARMACOLOGICAL BRIDGE.
061683 03-09

**BRINE**

THE EFFECTS OF MORPHINE-LIKE COMPOUNDS ON THE LIGHT RESPONSES OF THE BRINE SHRIMP ARTEMIA-SALINA.
075844 09-04

**BRITISH**

THE BRITISH DRUG SAFETY SYSTEM.
051782 02-05

**BROMIDE**

RADIOACTIVE BROMIDE IN THE DIAGNOSIS OF CENTRAL NERVOUS SYSTEM DISEASE.
063208 03-16

ASSOCIATION OF BROMIDE WITH THE SYNAPTOSOMAL FRACTION OF MOUSE BRAIN.
070521 07-01

**BROMISM**

A CASE OF BROMISM.
075372 08-15

**BROMOTRIFLUOROMETHANE**

THE EFFECT OF BROMOTRIFLUOROMETHANE ON OPERANT BEHAVIOR IN MONKEYS.
070732 07-04

**BULB**

EFFECTS OF NICOTINE AND TOBACCO SMOKE ON THE ELECTRICAL ACTIVITY OF THE CEREBRAL CORTEX AND OLFACTORY BULB.
041567 01-03

**BURONIL**

CLINICAL INVESTIGATION WITH THE BUTYROPHENONE DERIVATIVE BURONIL.
073706 08-09

CLINICAL EXPERIENCE WITH METHYLPERONE (BURONIL), A NEW BUTYROPHENONE DERIVATIVE.
105730 12-07

**BUTABARBITAL**

BUTABARBITAL SODIUM AND CHLORDIAZEPOXIDE IN ANXIOUS NEUROTIC OUTPATIENTS: A COLLABORATIVE CONTROLLED STUDY.
066276 05-10

**BUTANEDIOL**

COMPARISONS OF 1,3 BUTANEDIOL AND GLYCEROL ON SEVERAL BEHAVIORAL MEASURES.
066831 05-04

**BUTAPERAZINE**

A COMPARATIVE STUDY OF BUTAPERAZINE, CHLORPROMAZINE AND PLACEBO IN CHRONIC SCHIZOPHRENICS.
064431 04-08

BUTAPERAZINE AND HEMOGLOBIN C TRAIT.
067510 06-15

QUANTITATIVE DETERMINATION OF BUTAPERAZINE BY TLC.
090425 11-06

**BUTYROPHENONE**

CI-601, A BUTYROPHENONE DERIVATIVE, IN THE TREATMENT OF CHRONICALLY WITHDRAWN SCHIZOPHRENIC PATIENTS.
072142 07-08

CLINICAL INVESTIGATION WITH THE BUTYROPHENONE DERIVATIVE BURONIL.
073706 08-09

CLINICAL EVALUATION IN 112 PSYCHIATRIC PATIENTS OF A BUTYROPHENONE NEUROLEPTIC, DEHYDROBENZPERIDOL (R-4749).
080142 09-11

CLINICAL EXPERIENCE WITH METHYLPERONE (BURONIL), A NEW BUTYROPHENONE DERIVATIVE.
105730 12-07

ADMINISTRATION OF A NEW BUTYROPHENONE DERIVATIVE, PIMOZIDE, IN THE TREATMENT OF SCHIZOPHRENIA.
123373 12-08

**BUTYRYLCHOLINESTERASE**

EFFECTS OF PRENATAL ADMINISTRATION OF PSYCHOTROPIC DRUGS TO RATS ON BRAIN BUTYRYLCHOLINESTERASE ACTIVITY AT BIRTH.
067980 06-03

**CACTUS**

CACTUS ALKALOIDS: IX. ISOLATION OF N-METHYL-3-4-DIMETHOXY-BETA-PHENETHYLAMINE AND N-METHYL-4-METHOXY-BETA-PHENETHYLAMINE FROM ARIOCARPUS-RETUSUS.
070751 07-01

**CAFFEINE**

EFFECT OF ENVIRONMENTAL TEMPERATURE ON THE TOXICITY OF CAFFEINE AND DEXTROAMPHETAMINE IN MICE.
040028 01-05

RELEASE OF NOREPINEPHRINE IN THE CENTRAL NERVOUS SYSTEM BY THEOPHYLLINE AND CAFFEINE.
066411 05-03

VISUAL THRESHOLD AS A FUNCTION OF TEST AREA AND CAFFEINE ADMINISTRATION.
076016 09-13

ARRESTING OF STATUS-EPILEPTICUS AND SERIAL SEIZURES BY AMYTAL CAFFEINE.
090349 11-11

THE OBJECTIVE EVALUATION OF PSYCHOPHARMACOLOGICAL DRUGS WITH CAFFEINE AND CAFFEINE-FREE COFFEE AS AN EXAMPLE.
098039 11-13

**CAFFEINE-FREE**
THE OBJECTIVE EVALUATION OF PSYCHOPHARMACOLOGICAL DRUGS WITH CAFFEINE AND CAFFEINE-FREE COFFEE AS AN EXAMPLE.
098039 11-13

**CAGED**
COMPARISON OF LIVER MICROSOME ENZYME SYSTEMS AND BARBITURATE SLEEP TIMES IN RATS CAGED INDIVIDUALLY OR COMMUNALLY.
045545 01-06

**CAGES**
USES AND LIMITATIONS OF PHOTOCELL ACTIVITY CAGES FOR ASSESSING EFFECTS OF DRUGS.
090423 11-06

**CALCIUM**
STUDIES OF MINERAL METABOLISM IN MENTAL DEPRESSION. I. THE EFFECTS OF IMIPRAMINE AND ELECTRIC CONVULSIVE THERAPY ON CALCIUM BALANCE AND KINETICS.
075837 08-11

CONTRIBUTION TO THE STUDY OF THE EXTRAPYRAMIDAL SYNDROME WITH ANIMAL EXPERIMENTATION. THE ROLE OF CALCIUM AND O-METHYLENE DERIVATIVES.
086348 10-03

LITHIUM EFFECTS ON CALCIUM METABOLISM IN RATS.
106780 12-03

PSYCHOCLINICAL OBSERVATIONS ON THE EFFECT OF THE LOGOS COMPOUND (ASSOCIATION OF PYRITHIOXINE DIHYDROCHLORIDE, TRYPTOPHAN AND CALCIUM ALPHA-KETOGLUTARATE).
109258 12-11

**CANARY**
STUDIES OF STEREOTYPY FUNCTION IN THE CANARY (SERINUS-CANARIUS).
063634 04-03

**CANNABINOIDS**
ACUTE ORAL TOXICITY OF CANNABINOIDS IN VARIOUS SPECIES (UNPUBLISHED PAPER).
088412 10-05

**CANNABIS**
HUMAN PHARMACOLOGY OF MARIHUANA (CANNABIS).
046202 01-13

IDENTIFICATION OF CANNABIS.
058880 02-06

TWO PSYCHOTIC EPISODES ASSOCIATED WITH CANNABIS.
067692 06-09

DEVELOPMENT OF FIGHTING BEHAVIOR IN STARVED RATS BY CHRONIC ADMINISTRATION OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL AND CANNABIS EXTRACTS: LACK OF ACTION OF OTHER PSYCHOTROPIC DRUGS.
072531 08-04

PRELIMINARY EXPERIMENTS ON THE CHEMISTRY AND PHARMACOLOGY OF CANNABIS.
086405 10-01

CANNABIS: A PSYCHOLOGICAL AND METABOLIC INVESTIGATION.
100014 11-14

THE CINDERELLA OF PSYCHOPHARMACOLOGY (A COMMENTARY ON CANNABIS).
134932 12-13

**CANNABIS-SATIVA**
EFFECTS OF CANNABIS-SATIVA ON LEARNING IN RATS.
064178 04-04

STRUCTURE-ACTIVITY RELATIONSHIP OF FOUR TETRAHYDROCANNABINOLS AND THE PHARMACOLOGICAL ACTIVITY OF FIVE SEMI-PURIFIED EXTRACTS OF CANNABIS-SATIVA.
064417 04-04

EFFECTS OF CANNABIS-SATIVA AND LSD ON PIGEONS IN THREE VISUAL ENVIRONMENTS.
064499 04-04

INDUCTION BY CANNABIS-SATIVA (MARIHUANA) OF RHYTHMIC SPIKE DISCHARGES OVERRIDING REM SLEEP ELECTROCORTICOGRAM IN THE RAT.
069069 06-04

**CANNULA**
A SIMPLE AND INEXPENSIVE CANNULA TECHNIQUE FOR CHEMICAL STIMULATION OF THE BRAIN.
058357 02-06

**CAPACITY**
SCHIZOPHRENIA AND LYMPHOCYTE MITOTIC CAPACITY.
068181 06-15

**CAPERS**
EFFECT OF CAPERS ON THE VASCULAR LUMEN OF ISOLATED EXTREMITIES OF SENSITIZED FROGS AND THE ANTIANAPHYLATIC EFFECT OF SUPRASTIN.
105720 12-03

**CAPSULES**
COMPARATIVE EFFICACY OF THIOTHIXENE CAPSULES AND CONCENTRATE IN ACUTELY SCHIZOPHRENIC PATIENTS.
063599 04-03

**CAPTAGON**
QUANTITATIVE CLINICAL ANALYSIS OF THE EFFECT OF FENETYLLIN (CAPTAGON) ON HYPERKINETIC CHILDREN.
093540 11-11

**CAPTIVE**
DRUGS AND REALITY IN CAPTIVE SOCIETY. SOME OBSERVATIONS ON CHEMICAL ADAPTATION.
064091 04-17

REDIRECTED AGGRESSION AND GONADAL HORMONES IN CAPTIVE RHESUS MONKEYS (MACACA-MULATTA).
075829 08-04

OVARIAN HORMONES AND FEMALE SEXUAL INVITATIONS IN CAPTIVE RHESUS MONKEYS (MACACA-MULATTA).
076554 09-03

**CAPURIDE**
A DOUBLE-BLIND EVALUATION OF CAPURIDE (PACINOX) AS A PRESURGICAL AID TO SLEEP.
058371 02-14

**CAR**
EFFECTS OF ACTH AND ZINC PHOSPHATE VEHICLE ON SHUTTLEBOX CAR.
060756 03-04

**CARBACHOL**
IMPAIRMENT OF ALTERNATION LEARNING IN RATS FOLLOWING MICROINJECTION OF CARBACHOL INTO THE HIPPOCAMPUS.
067522 06-04

DOSE RESPONSE ANALYSIS OF CARBACHOL ELICITED DRINKING IN THE RAT LIMBIC SYSTEM.
076081 09-04

**CARBAMAZEPINE**
PROBLEM BEHAVIOR OF CHILDREN WITH SEVERE MENTAL AND PHYSICAL DISORDERS -- EXPERIENCE OF THE USE OF CARBAMAZEPINE.
105790 12-14

**CARBOHYDRATE**
SOME EFFECTS OF D-AMPHETAMINE ON CARBOHYDRATE METABOLISM AT GROUND LEVEL AND ALTITUDE.
069344 06-03

**CARBON**
CARBON DISULFIDE INTOXICATION FROM OVERDOSAGE OF DISULFIRAM.
065691 05-09

CARBON MONOXIDE AND PHENOBARBITONE: A COMPARISON OF EFFECTS ON AUDITORY FLUTTER FUSION THRESHOLD AND CRITICAL FLICKER FUSION THRESHOLD.
070303 07-14

A BENZAZEPINONE: CARBON ANALOG OF DIAZEPAM.
080032 09-02

**CARBONATE**
EFFECTS OF LITHIUM CARBONATE ON TURNOVER AND METABOLISM OF NOREPINEPHRINE IN THE RAT BRAIN - CORRELATION TO GROSS BEHAVIORAL EFFECTS.
043277 01-03

SODIUM BALANCE AND DISTRIBUTION IN LITHIUM CARBONATE THERAPY.
047828 01-09

LITHIUM CARBONATE FOR AFFECTIVE DISORDERS. I. CLINICAL PHARMACOLOGY AND TOXICOLOGY.
047831 01-09

THE MANY FACES OF MANIA: THERAPEUTIC TRIAL OF LITHIUM CARBONATE.
047919 01-09

EFFECT OF MOOD AND LITHIUM CARBONATE ON TOTAL BODY POTASSIUM.
047952 01-09

LITHIUM CARBONATE AS A MOOD AND TOTAL BODY WATER STABILIZER.
047953 01-09

EFFECT OF LITHIUM CARBONATE THERAPY ON ADRENOCORTICAL ACTIVITY.
047954 01-09

EFFECTIVENESS OF LITHIUM CARBONATE IN THE TREATMENT OF MANIC-DEPRESSIVE ILLNESS.
062348 03-09

A COMPARISON OF LITHIUM CARBONATE AND CHLORPROMAZINE IN MANIA.
062349 03-09

FACTORS ASSOCIATED WITH POOR RESPONSE TO LITHIUM CARBONATE: A CLINICAL STUDY.
062352 03-09

LITHIUM CARBONATE.
064088 04-11

LITHIUM CARBONATE IN AFFECTIVE DISORDERS.
064232 04-17

COMPARISON OF LITHIUM CARBONATE AND IMIPRAMINE (IN PREVENTION OF MANIC-DEPRESSIVE DISEASE).
064317 04-09

LITHIUM CARBONATE IN THERAPY.
065183 05-13

LITHIUM CARBONATE AS AN ADJUNCT IN THE TREATMENT OF SCHIZOPHRENIA.
067364 06-08

SIDE-EFFECTS AND TERATOGENICITY OF LITHIUM CARBONATE TREATMENT.
069580 07-15

TREATMENT WITH LITHIUM CARBONATE: RESULTS IN 35 CASES.
070287 07-09

LEUKOCYTOSIS DURING LITHIUM CARBONATE TREATMENT.
073711 08-15

CATECHOLAMINE METABOLISM IN AFFECTIVE DISORDERS -- III. MHPG AND OTHER CATECHOLAMINE METABOLITES IN PATIENTS TREATED WITH LITHIUM CARBONATE.
075410 08-09

CLINICAL EXPERIENCE WITH LITHIUM CARBONATE.
075424 08-08

LITHIUM CARBONATE TREATMENT IN PSYCHIATRY.
075584 08-11

LITHANE: THE STORY OF LITHIUM CARBONATE.
078106 09-17

LITHIUM CARBONATE IN THERAPY.
078422 09-17

THE TREATMENT OF MANIC RELATED DISEASES WITH LITHIUM CARBONATE.
081516 09-09

TERATOGENIC EFFECT OF LITHIUM CARBONATE IN THE FETAL MOUSE.
089398 10-05

LITHIUM CARBONATE IN PSYCHIATRIC THERAPEUTICS.
094287 11-09

LITHIUM CARBONATE: A DRUG OF LIMITED EFFICACY IN THE PREVENTION OF MANIC-DEPRESSIVE DISEASE.
106764 12-09

CLINICAL CONTROVERSIES AND THEORETICAL MODE OF ACTION OF LITHIUM CARBONATE.
106767 12-13

SUSTAINED-RELEASE LITHIUM CARBONATE.
106768 12-09

TREATMENT OF MOOD DISORDERS WITH LITHIUM CARBONATE.
106773 12-09

CLINICAL RESULTS ON THE THERAPEUTIC ACTION OF LITHIUM CARBONATE IN DYSTHYMIC PSYCHOSES.
114880 12-09

**CARBONIC**

THE ROLE OF CARBONIC ANHYDRASE IN ANION SECRETION INTO CEREBROSPINAL FLUID.
040755 01-03

ALTERED ABSORPTION OF DRUGS FROM THE RAT SMALL INTESTINE BY CARBONIC ANHYDRASE INHIBITION.
066369 05-03

TREATMENT AND PROPHYLAXIS OF MANIC STATES WITH A CARBONIC ANHYDRASE INHIBITOR.
105731 12-14

**CARBRITAL**

A CASE OF SELF-POISONING WITH CARBRITAL.
066903 05-15

**CARDIAC**

BLOCKADE OF THE CARDIAC ACTION OF PHENYLEPHRINE BY BRETYLIUM OR COCAINE.
040242 01-03

ON THE ANALYSIS OF CARDIAC BETA-RECEPTORS: STUDIES ON THE BASE OF DOSE EFFECT CURVES FOR ISOPRENALINE, PROPRANOLOL, AND KL-255.
055396 02-03

CARDIAC CATECHOLAMINE LEVELS AND BLOOD PRESSURE AFTER CHRONIC TREATMENT WITH BETA-ADRENERGIC BLOCKING AGENTS.
055579 02-03

THE PSYCHOPHARMACOLOGICAL TREATMENT OF CARDIAC NEUROTIC PATIENTS WITH DIPOTASSIUM CHLORAZEPATE IN THE DOUBLE-BLIND TEST.
055689 02-10

CARDIAC TOXICITY AND PSYCHOTROPIC DRUGS.
068603 06-15

AMITRIPTYLINE AND CARDIAC DISEASE: RISK OF SUDDEN DEATH IDENTIFIED BY MONITORING SYSTEM.
070854 07-15

CARDIAC CATECHOLAMINE SYNTHESIS, TURNOVER, AND METABOLISM WITH ISOPROTERENOL INDUCED MYOCYTOLYSIS (UNPUBLISHED PAPER).
088374 10-03

EFFECT OF TWO RECENTLY SYNTHESIZED PHENOTHIAZINE DERIVATIVES UPON EXPERIMENTAL CARDIAC ARRHYTHMIAS.
114978 12-03

TRANQUILIZERS IN THE TREATMENT OF THE CARDIAC NEUROTIC PATIENT AND THE SUBSEQUENT ALTERATION OF COMPLAINTS.
128568 12-14

**CARDIOVASCULAR**

DEXAMPHETAMINE: A POSSIBLE ENVIRONMENTAL TRIGGER IN CARDIOVASCULAR MALFORMATIONS.
082039 10-15

EFFECT OF L-DOPA ALONE AND IN COMBINATION WITH AN EXTRACEREBRAL DECARBOXYLASE INHIBITOR ON BLOOD PRESSURE AND SOME CARDIOVASCULAR REFLEXES.
090371 11-13

CARDIOVASCULAR EFFECTS.
100514 12-15

**CARE**

A SURVEY OF EXTRAPYRAMIDAL MANIFESTATIONS IN PATIENTS ATTENDING AN AFTER CARE CLINIC OF A PSYCHIATRIC HOSPITAL.
070412 07-15

NEW IN PSYCHIATRY: MODITEN INJECTABLE THERAPY AND FOLLOW-UP CARE.
072787 08-11

PSYCHIATRIC COMMUNITY CARE SYSTEM: USE OF LONG-ACTING PHENOTHIAZINES.
080007 09-17

ANNIE LEARNS TO CARE.
085860 10-11

**CARPIPRAMINE**

A DOUBLE-BLIND, CONTROLLED STUDY OF THE EFFECTS OF OXYPERTINE AND CARPIPRAMINE ON SCHIZOPHRENIA.
129082 12-08

**CASE**

CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL: CASE 20-1970.
042655 01-15

A CASE OF PROBABLE HEMATOMYELIA CAUSED BY CHRONIC BENZENE POISONING.
056059 02-15

A CASE OF MANIC-DEPRESSIVE ILLNESS WITH LITHIUM TOXICITY.
058213 02-15

LONG-TERM PSYCHOTHERAPY UTILIZING TRIFLUOPERAZINE IN A PSYCHOTIC PRESCHOOL CHILD: (A CASE STUDY).
066806 05-11

A CASE OF SELF-POISONING WITH CARBRITAL.
066903 05-15

LITHIUM IN HAZARDOUS CIRCUMSTANCES WITH ONE CASE OF LITHIUM TOXICITY.
067138 06-15

SEVERE DELIRIUM AFTER ABRUPT WITHDRAWAL OF THIOTHIXENE IN A CHRONIC SCHIZOPHRENIC INPATIENT: A CASE STUDY.
067221 06-08

ADVERSE MARIJUANA REACTIONS: A CRITICAL EXAMINATION OF THE LITERATURE WITH SELECTED CASE MATERIAL.
069613 07-15

A CASE OF BROMISM.
075372 08-15

CHILDHOOD SCHIZOPHRENIA: A CASE TREATED WITH NICOTINIC ACID AND NICOTINAMIDE.
075944 09-08

CYPROHEPTADINE HYDROCHLORIDE (PERIACTIN) AND ANOREXIA-NERVOSA: A CASE REPORT.
078931 09-07

SEVERE PERSISTENT CHOREA WITH PHENOTHIAZINE THERAPY: REPORT OF A CASE.
079915 09-15

CASE OF SELF-POISONING WITH MULTIPLE ANTIDEPRESSANT DRUGS.
082153 10-15

A CASE OF PHENMETRAZINE ADDICTION.
087537 10-15

AN UNUSUAL CASE OF CHLORPROMAZINE AGRANULOCYTOSIS.
089443 11-15

CONCERNING A CASE OF THROMBOSIS OF THE MIDDLE CEREBRAL ARTERY IN THE COURSE OF PROGESTINIC TREATMENT.
094467 11-14

PIGMENTARY RETINOPATHY AND PARANOIC SYNDROME. (PRESENTATION OF ONE CASE).
124309 12-08

**CASTRATION**

COITAL BEHAVIOR IN DOGS: VI. LONG-TERM EFFECTS OF CASTRATION UPON MATING IN THE MALE.
080606 09-03

**CASUISTIC**

CASUISTIC CONTRIBUTIONS ON THE USE OF A DRUG IN CRIMINOLOGY ON DISSOCIALITY AND ON MINOR IRREGULAR BEHAVIOR.
095719 11-14

**CAT**

EFFECTS OF METABOLIC INHIBITORS ON NOREPINEPHRINE RELEASE FROM THE PERFUSED SPLEEN OF THE CAT.
040244 01-03

MONOAMINES AND MONOAMINE OXIDASE IN DENERVATED SYMPATHETIC GANGLIA OF THE CAT.
040756 01-03

DOPA INDUCED EXCITEMENT IN THE CAT: ITS RELATIONSHIP TO BRAIN NOREPINEPHRINE CONCENTRATIONS.
058840 02-04
THE EFFECT OF HEXOBARBITAL ON THE DURATION OF THE RECURRENT IPSP IN CAT MOTONEURONS.
064621 04-03
INTRANEURONAL AND EXTRANEURONAL ACCUMULATION OF SYMPATHOMIMETIC AMINES IN THE ISOLATED NICTITATING MEMBRANE OF THE CAT.
066363 05-03
THE INFLUENCE OF THE GANGLIONIC BLOCKING AGENT GANLION ON VISCEROVISCERAL AND VISCEROCEREBRAL REACTIONS OF THE CAT.
071703 07-03
THE ACTION OF CENTRAL DEPRESSANT DRUGS ON THE SPONTANEOUS DISCHARGE OF ACTION POTENTIALS IN THE SUPERIOR CERVICAL SYMPATHETIC TRUNK OF THE CAT.
072034 07-03
BEHAVIORAL CORRELATES OF CHEMICAL STIMULATION IN THE CAT THALAMUS.
075234 08-04
ON THE MECHANISM OF SUPERSENSITIVITY TO NOREPINEPHRINE IN THE DENERVATED CAT SPLEEN.
080336 09-03
EFFECT OF INTERMITTENT NERVE STIMULATION ON NOREPINEPHRINE SYNTHESIS AND MOBILIZATION IN THE PERFUSED CAT SPLEEN.
080337 09-01
EFFECTS OF SELECTED DRUGS ON STIMULUS BOUND EMOTIONAL BEHAVIOR ELICITED BY HYPOTHALAMIC STIMULATION IN THE CAT.
088617 10-04
POSSIBLE LOCI OF ACTION OF 2-ETHYL-ETHYLAMINO-6-METHOXY-S-TRIAZINE FOR ELECTROENCEPHALOGRAPHIC AND SYMPATHETIC ACTIVATION IN CAT.
089788 11-13
U-14C TYROSINE METABOLISM OF THE PERFUSED CAT BRAIN WITH HIGH PLASMA PHENYLALANINE OR WITHOUT PLASMA TYROSINE.
100852 12-03

**CATABOLISM**
IN VIVO FORMATION AND CATABOLISM OF (14C)HISTAMINE IN MOUSE BRAIN.
083169 10-03

**CATABOLITES**
CEREBROSPINAL FLUID MONOAMINE CATABOLITES IN DRUG-INDUCED EXTRAPYRAMIDAL DISORDERS.
064097 04-13

**CATALEPTIC**
LESIONS IN CORPUS-STRIATUM AND CORTEX OF RAT BRAINS AND THE EFFECT ON PHARMACOLOGICALLY INDUCED STEREOTYPED, AGGRESSIVE AND CATALEPTIC BEHAVIOUR.
091127 11-04

**CATAPLEXY**
THE INFLUENCE OF IMIPRAMINE, DEXPHENMETRAZINE AND AMPHETAMINE SULPHATE ON SYNCHRONOUS AND PARADOXICAL SLEEP IN NARCOLEPSY CATAPLEXY. A POLYGRAPHIC EXAMINATION.
089037 10-14

**CATATONIA**
REVERSIBLE EFFECT OF L-DOPA ON TREMOR AND CATATONIA INDUCED BY ALPHA-METHYL-P-TYROSINE.
040124 01-05

**CATATONIC**
ENCEPHALITIS WITH CATATONIC SCHIZOPHRENIC SYMPTOMS.
069822 07-08

**CATECHOLAMINE**
CARDIAC CATECHOLAMINE LEVELS AND BLOOD PRESSURE AFTER CHRONIC TREATMENT WITH BETA-ADRENERGIC BLOCKING AGENTS.
055579 02-03
BEHAVIORAL AND BRAIN CATECHOLAMINE DEPLETING ACTIONS OF U-14624, AN INHIBITOR OF DOPAMINE BETA-HYDROXYLASE.
058986 03-03
ANTAGONISM OF D-AMPHETAMINE BY ALPHA-METHYL-L-TYROSINE: BEHAVIORAL EVIDENCE FOR THE PARTICIPATION OF CATECHOLAMINE STORES AND SYNTHESIS IN THE AMPHETAMINE STIMULANT RESPONSE.
064096 04-03
EFFECTS OF DISULFIRAM AND DIETHYLDITHIOCARBAMATE ON SPONTANEOUS LOCOMOTOR ACTIVITY AND BRAIN CATECHOLAMINE LEVELS IN MICE.
064590 04-04
INHIBITION OF CATECHOLAMINE UPTAKE BY 6-HYDROXYDOPAMINE IN RAT BRAIN.
066501 05-03
THE INHIBITION OF CATECHOLAMINE BIOSYNTHESIS BY APOMORPHINE.
066854 05-03
CATECHOLAMINE ACCUMULATION IN TISSUES OF THIAMINE-DEFICIENT RATS AFTER INHIBITION OF MONOAMINE OXIDASE.
067243 06-03
THE EFFECT OF INHIBITION OF CATECHOLAMINE SYNTHESIS ON DEXAMPHETAMINE INDUCED CENTRAL STIMULATION.
067259 06-04
CHANGES IN ENZYMES SUBSERVING CATECHOLAMINE METABOLISM IN MORPHINE TOLERANCE AND WITHDRAWAL IN RAT.
067324 06-03
EFFECTS OF 6-HYDROXYDOPAMINE ON CATECHOLAMINE CONTAINING NEURONES IN THE RAT BRAIN.
072120 07-03
THE CATECHOLAMINE CONTENT IN THE BRAINSTEM OF ALBINO RATS IN THE DEVELOPMENT OF TOLERANCE TO TRYPHTAZINE.
073681 08-03
THE EFFECT OF SOME INHIBITORS AND METABOLITES OF CATECHOLAMINE ON THE PROCESSES OF FIXATION AND REPRODUCTION OF MEMORY TRACES.
073716 08-03
A SOURCE OF ERROR IN CATECHOLAMINE TURNOVER STUDIES WITH LABELED DOPA: SLOW DISAPPEARANCE OF THE PRECURSOR.
074818 08-03
EFFECTS OF BENZOCTAMINE (30803-BA, TACITIN), A NEW PSYCHOACTIVE DRUG, ON CATECHOLAMINE METABOLISM.
074861 08-03
CATECHOLAMINE METABOLISM IN AFFECTIVE DISORDERS -- III. MHPG AND OTHER CATECHOLAMINE METABOLITES IN PATIENTS TREATED WITH LITHIUM CARBONATE.
075410 08-09
DELTA1-TETRAHYDROCANNABINOL, SYNHEXYL AND MARIJUANA EXTRACT ADMINISTERED ORALLY IN MAN: CATECHOLAMINE EXCRETION, PLASMA CORTISOL LEVELS AND PLATELET SEROTONIN CONTENT.
075841 08-12
EFFECTS OF CHRONIC MORPHINE ADMINISTRATION ON THE CATECHOLAMINE DEPLETION INDUCED BY RESERPINE.
081065 09-03
CARDIAC CATECHOLAMINE SYNTHESIS, TURNOVER, AND METABOLISM WITH ISOPROTERENOL INDUCED MYOCYTOLYSIS (UNPUBLISHED PAPER).
088374 10-03
EFFECT OF DRUGS ON CATECHOLAMINE SYNTHESIS (UNPUBLISHED PAPER).
092889 11-13
EFFECT OF NICOTINIC ACID COMBINED WITH A TRANQUILLIZER (HYDROXYZINE) ON SERUM LIPID LEVELS AND URINARY CATECHOLAMINE EXCRETION IN GERIATRIC PATIENTS.
093689 11-11
EFFECT OF GANGLERONE AND QUATERONE ON CATECHOLAMINE CONTENT IN THE BRAIN.
111767 12-03

**CATECHOLAMINES**
DAILY RHYTHM IN THE ACCUMULATION OF BRAIN CATECHOLAMINES SYNTHESIZED FROM CIRCULATING H3-TYROSINE.
040246 01-03
FURTHER STUDIES ON THE ACCUMULATION AND DISAPPEARANCE OF CATECHOLAMINES FORMED FROM TYROSINE-14C IN MOUSE BRAIN. EFFECT OF SOME PHENOTHIAZINE ANALOGUES.
042727 01-03
PHOBIA QUESTIONNAIRE RESPONSES AND URINE CATECHOLAMINES.
054890 02-11
INHIBITION OF THE STIMULATING EFFECT OF METHAMPHETAMINE AND MORPHINE ON MOUSE BY INFLUENCING THE ENDOGENOUS CATECHOLAMINES.
055739 02-03
THE ROLE OF BRAIN CATECHOLAMINES IN MORPHINE ANALGESIC ACTION IN MORPHINE TOLERANT RATS.
055756 02-03
ELEVATED CATECHOLAMINES IN THIRTY-DAY-OLD CHICKEN BRAIN AFTER DEPLETION DURING DEVELOPMENT.
063044 03-03
INTRACRANIAL SELF-STIMULATION AND WAKEFULNESS: EFFECT OF MANIPULATING AMBIENT BRAIN CATECHOLAMINES.
063849 04-04
EFFECT OF APOMORPHINE AND PIMOZIDE ON SYNTHESIS AND TURNOVER OF LABELED CATECHOLAMINES IN MOUSE BRAIN.
066502 05-03
COMPLEXES BETWEEN ACETYLCHOLINE AND CATECHOLAMINES AND THEIR TOLERANCE TO MENTAL ILLNESS.
072705 08-01
AN ANALYSIS OF RECEPTIVE STRUCTURES PARTICIPATING IN THE BEHAVIOR REACTIONS OF CATS INDUCED BY CATECHOLAMINES AND SEROTONIN.
073715 08-03
EFFECTS OF 6-HYDROXYDOPAMINE ON CNS CATECHOLAMINES, SPONTANEOUS MOTOR ACTIVITY AND AMPHETAMINE INDUCED HYPERACTIVITY IN RATS.
074053 08-04
PHARMACOLOGICAL IMPLICATIONS OF THE EFFECTS OF AMPHETAMINE AND ITS ANALOGUES ON THE TURNOVER RATE OF TISSUE CATECHOLAMINES (UNPUBLISHED PAPER).
088392 10-03

ON THE ROLE OF BRAIN CATECHOLAMINES IN MOTOR ACTIVITY: EXPERIMENTS WITH INHIBITORS OF SYNTHESIS AND OF MONOAMINE OXIDASE.
097960 11-04

**CATH**
ON THE USE OF CATH (CATHA-EDULIS) AMONG YEMENITE JEWS.
074566 08-15

**CATHA-EDULIS**
ON THE USE OF CATH (CATHA-EDULIS) AMONG YEMENITE JEWS.
074566 08-15

**CATS**
EFFECTS OF PSYCHOTHERAPEUTIC DRUGS ON HYPOTHALAMIC INDUCED HISSING IN CATS.
046139 01-04
EFFECTS OF SOME PSYCHOACTIVE DRUGS ON EXPERIMENTAL NEUROTIC (CONFLICT INDUCED) BEHAVIOR IN CATS.
046143 01-04
HYPERSEXUALITY AND BEHAVIORAL CHANGES IN CATS CAUSED BY ADMINISTRATION OF P-CHLOROPHENYLALANINE.
056934 02-04
CENTRAL NERVOUS SYSTEM CYTOPATHOLOGICAL CHANGES IN CATS WITH CHRONIC METHEDRINE INTOXICATION.
064143 04-05
BEHAVIORAL AND VISCERAL REACTIONS ELICITED BY CHEMICAL STIMULATION OF THE HYPOTHALAMUS AND SEPTUM IN CATS.
064333 04-04
NEUROPHARMACOLOGICAL COMPARISON OF CYSTATHIONINE, CYSTEINE, HOMOSERINE AND ALPHA-KETOBUTYRIC ACID IN CATS.
064367 04-04
EFFECTS OF GENERAL DEPRESSANT DRUGS ON THE ELECTRICAL RESPONSES OF ISOLATED SLABS OF CATS CEREBRAL CORTEX.
066382 05-03
ELECTROGRAPHIC AND BEHAVIORAL EFFECTS OF DIAZEPAM DURING ALCOHOL WITHDRAWAL STAGE IN CATS.
072033 07-04
THE EFFECT OF MEDAZEPAM ON THE THRESHOLDS OF SUBCORTICAL LIMBIC STIMULUS RESPONSES, MEASURED IN UNANESTHETIZED, UNRESTRAINED CATS.
072067 07-03
SEXUAL BEHAVIOR OF MALE CATS AFTER ADMINISTRATION OF P-CHLOROPHENYLALANINE.
072463 08-04
AN ANALYSIS OF RECEPTIVE STRUCTURES PARTICIPATING IN THE BEHAVIOR REACTIONS OF CATS INDUCED BY CATECHOLAMINES AND SEROTONIN.
073715 08-03
THE EFFECT OF INTRAHYPOTHALAMIC MICROINJECTION OF HEMICHOLINIUM (HC-3) ON THE HIPPOCAMPAL THETA RHYTHM OF CATS.
075842 08-03
ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL EFFECTS OF HARMALINE IN INTACT CATS AND IN CATS WITH CHRONIC MESENCEPHALIC TRANSECTION.
075847 09-04
INDUCTION OF RECEPTIVITY IN FEMALE RATS AND CATS WITH ESTROGEN AND TESTOSTERONE.
081228 09-04
THE EFFECT OF P-CHLOROPHENYLALANINE ON THE BEHAVIOUR OF CATS.
081264 09-04
EFFECTS OF GENERAL STIMULANT DRUGS ON THE ELECTRICAL RESPONSES OF ISOLATED SLABS OF CATS CEREBRAL CORTEX.
090189 11-03
COMPARATIVE STUDY OF NATURAL SLEEP AND THE ACTION OF PHENAMINE AND CHLORPROMAZINE EVALUATION OF THE MEAN EXTREMES FREQUENCY OF ECOG IN CATS.
095655 11-14
EFFECT OF LSD-25, CHLORPROMAZINE AND METEDRINE UPON VISUAL EVOKED RESPONSE IN CATS.
098171 11-03

**CATTELS**
USE OF CATTELS IPAT ANXIETY SCALE IN A GROUP OF NEUROTIC PATIENTS BEFORE AND AFTER PSYCHOPHARMACOLOGICAL DRUG AND ELECTRIC SHOCK THERAPY.
128509 12-17

**CAUDATE**
INDUCED CHANGES IN CAUDATE NUCLEUS DOPAMINE AND ELECTROSHOCK THRESHOLD.
079179 09-03

**CELL**
EFFECTS OF MORPHINE ON RENSHAW CELL ACTIVITY.
064100 04-03
PHASE DIFFERENCE IN THE INDUCTION OF TYROSINE HYDROXYLASE IN CELL BODY AND NERVE TERMINALS OF SYMPATHETIC NEURONES.
075715 08-03

**CELLS**
THE NUMBER OF PURKINJE CELLS AFTER DIPHENYLHYDANTOIN INTOXICATION IN MONKEYS.
066189 05-05
CHROMOSOME STUDIES ON PATIENTS (IN VIVO) AND CELLS (IN VITRO) TREATED WITH LYSERGIC ACID DIETHYLAMIDE.
071987 07-13

**CENTER**
CONSIDERATIONS OF SOME SIDE-EFFECTS OF DRUGS. (A STUDY BEARING ON 11,410 CALLS RECEIVED BY THE BELGIAN ANTIPOISON CENTER).
042687 01-15
THIN-LAYER CHROMATOGRAPHIC LABORATORY ANALYSIS IN CASES FROM A DRUG ADDICTION CENTER.
067212 06-06
SUBJECTIVE EFFECTS OF NARCOTIC ANTAGONISTS CYCLAZOCINE AND NALORPHINE ON THE ADDICTION RESEARCH CENTER INVENTORY (ARCI).
097961 11-14

**CENTRAL**
CENTRAL NERVOUS SYSTEM STIMULANT ACTION OF FENFLURAMINE IN RABBITS.
040639 01-03
POTENTIATION AND INHIBITION OF SOME CENTRAL ACTIONS OF L(-) DOPA BY DECARBOXYLASE INHIBITORS.
040750 01-03
THE EFFECT OF HEAT, COLD, AND WORK ON THE CENTRAL ACTIONS OF SCOPOLAMINE.
041562 01-14
PHARMACOLOGICAL REDUNDANCY AS AN ADAPTIVE MECHANISM IN THE CENTRAL NERVOUS SYSTEM.
056113 02-13
POTENTIATION OF THE CENTRAL ACTIONS OF 5-HYDROXYTRYPTOPHAN IN RABBITS BY DL-ALPHA-HYDRAZINO ALPHA-METHYLDOPA.
058879 02-03
PHARMACOLOGICAL PROPERTIES OF SU-19789B, A UNIQUE CENTRAL NERVOUS SYSTEM STIMULANT.
058989 03-03
L-DOPA INDUCED CHANGES IN CENTRAL MONOAMINE NEURONS AFTER PERIPHERAL DECARBOXYLASE INHIBITION.
059033 03-03
A NEW CLASS OF 1,3 BENZOXAZINONES AS POTENTIAL CENTRAL NERVOUS SYSTEM AGENTS.
062322 03-02
RADIOACTIVE BROMIDE IN THE DIAGNOSIS OF CENTRAL NERVOUS SYSTEM DISEASE.
063208 03-16
CENTRAL HYPOTENSIVE EFFECT OF L-DIHYDROXYPHENYLALANINE IN THE RAT.
063888 04-03
CENTRAL NERVOUS SYSTEM CYTOPATHOLOGICAL CHANGES IN CATS WITH CHRONIC METHEDRINE INTOXICATION.
064143 04-05
A COMPARISON OF THE EFFECTS OF COCAINE AND SYNTHETIC CENTRAL STIMULANTS.
064272 04-17
CHLORAL HYDRATE IN CENTRAL NERVOUS SYSTEM DEPRESSION.
064335 04-17
RELEASE OF NOREPINEPHRINE IN THE CENTRAL NERVOUS SYSTEM BY THEOPHYLLINE AND CAFFEINE.
066411 05-03
THE EFFECT OF INHIBITION OF CATECHOLAMINE SYNTHESIS ON DEXAMPHETAMINE INDUCED CENTRAL STIMULATION.
067259 06-04
EVALUATION OF THE PERIPHERAL AND CENTRAL ANTAGONISTIC ACTIVITIES AGAINST 5-HYDROXYTRYPTAMINE OF SOME NEW AGENTS.
067603 06-03
SOME EFFECTS OF NICOTINE ON THE CENTRAL NERVOUS SYSTEM OF CHICKENS.
068166 06-03
PHARMACOLOGY OF THE CENTRAL NERVOUS SYSTEM.
068949 06-03
INDOLEAMINES AND THE CENTRAL NERVOUS SYSTEM: A SOUNDING OF THEIR CLINICAL SIGNIFICANCE.
070881 07-13
CENTRAL NERVOUS SYSTEM METABOLISM, DRUG ACTION AND HIGHER FUNCTIONS.
070976 07-17
THE ACTION OF CENTRAL DEPRESSANT DRUGS ON THE SPONTANEOUS DISCHARGE OF ACTION POTENTIALS IN THE SUPERIOR CERVICAL SYMPATHETIC TRUNK OF THE CAT.
072034 07-03
CENTRAL AND PERIPHERAL EFFECTS OF ANTICHOLINERGIC COMPOUNDS.
072524 08-04
CENTRAL NEUROTROPIC ACTIVITY OF AMINOPROPYL AND AMINOPROPIONYLIC DERIVATIVES OF IMINOBENZYL AND DIPHENYLAMINE AND ITS RELATION TO IONIZATION CONSTANTS.
072580 08-03
CENTRAL EFFECTS OF 6-HYDROXYDOPAMINE ON THE BODY TEMPERATURE OF THE RAT.
073069 08-03
ON THE CENTRAL SITES FOR THE ANTINOCICEPTIVE ACTION OF MORPHINE AND FENTANYL.
074936 08-03

THE INFLUENCE OF SINGLE AND CHRONIC MORPHINE ADMINISTRATION ON SOME CENTRAL EFFECTS OF AMPHETAMINE AND APOMORPHINE. 075840 08-05
A CONTROLLED STUDY OF THE ANTIDEPRESSANT EFFECT OF P-CHLORO-N-METHYLAMPHETAMINE, A COMPOUND WITH A SELECTIVE EFFECT ON THE CENTRAL 5-HYDROXYTRYPTAMINE METABOLISM. 078212 09-10
STUDIES IN MAN ON THE INFLUENCE OF A NEW PSYCHOPHARMACEUTICAL DRUG; 1-((METHYLAMINO) DIBENZOBICYCLOOCTADIENE HYDROCHLORIDE, ON THE CO2 SENSITIVE CENTRAL RESPIRATORY REGULATION. 079971 09-07
CENTRAL MUSCLE RELAXANT EFFECTS OF DIAZEPAM. 079997 09-03
EVIDENCE FOR A CENTRAL NORADRENALINE RECEPTOR: STIMULATION BY CLONIDINE. 081151 09-03
ANTICHOLINERGIC CENTRAL BLOCKADE OF SALT AROUSED AND DERIVATION INDUCED DRINKING. 081227 09-04
RELATIONSHIP BETWEEN CENTRAL EFFECTS AND THE CONCENTRATION OF AMPHETAMINE IN LIVER AND BRAIN OF YOUNG AND OLD RATS. 089041 10-03
INDICATIONS OF CENTRAL NERVOUS EFFECTS OF SMALL AMOUNTS OF MERCURY IN RATS. 089044 10-17
THE CENTRAL SYMPATHETIC DEPRESSIVE EFFECT OF RESERPINE, ALPHA-METHYLDOPA AND CLONIDINE. 089046 10-03
CENTRAL ANTISEROTONINERGIC EFFECT OF ANTIMANIC DRUGS. 097988 11-03
INHIBITION OF CENTRAL SEROTONINERGIC EXCITATION (5-HYDROXYTRYPTOPHAN INDUCED DEAD TWITCHES) IN MICE BY LITHIUM. 097989 11-04
POPULATION DEPENDENT DIFFERENCES OF CENTRAL NERVOUS REACTIVITY TO NEUROLEPTICS. 098022 11-15
ADRENERGIC MECHANISMS IN THE CENTRAL ACTION OF PSYCHOTROPIC DRUGS. (PH.D.DISSERTATION). 102415 12-06
ADRENAL CORTICAL AND MEDULLARY SECRETION AND EVALUATION OF DRUGS ACTING ON THE CENTRAL NERVOUS SYSTEM. 106270 12-03
CENTRAL ACTION OF SOME AUTONOMIC DRUGS IN RESPECT TO EEG AROUSAL REACTION OF THE RABBIT. 107190 12-03
CENTRAL NERVOUS SYSTEM DEPRESSANTS. 110225 12-17
CENTRAL NERVOUS SYSTEM STIMULANTS. 110226 12-17
PHARMACOLOGICAL STUDIES OF OXAZOLAZEPAM, A NEW PSYCHOTROPIC AGENT - I. ACTIONS ON THE CENTRAL NERVOUS SYSTEM, ESPECIALLY ON THE BEHAVIORAL OBSERVATION. 114769 12-02
EFFECT OF A DEFICIENCY OF PANTOTHENIC ACID AND PYRIDOXINE ON THE FUNCTION OF THE CENTRAL NERVOUS SYSTEM AND ITS RESPONSE TO COUMARIN FROM MELILOTUS-OFFICINALIS. 126053 12-04
INFLUENCE OF ISONIAZID ON THE CENTRAL NERVOUS SYSTEM; THE ANTAGONISM BETWEEN ISONIAZID AND PYRIDOXINE, PANTOTHENIC ACID AND COUMARIN IN RATS (MELILOTUS-OFFICINALIS). 126055 12-04

**CENTRALLY**
THE EFFECT OF CENTRALLY ACTING DRUGS ON THE CONCENTRATION OF BRAIN ADENOSINE 3PRIME,5PRIME- MONOPHOSPHATE. 043276 01-03
EVIDENCE FOR A CENTRALLY MEDIATED HYPOTENSIVE EFFECT OF L-DOPA IN THE RAT. 055587 02-03
THE EFFECTS OF CENTRALLY AND PERIPHERALLY ACTING CHOLINERGIC DRUGS ON THE SHORT-TERM PERFORMANCE GRADIENT FOLLOWING PASSIVE AVOIDANCE TRAINING. 064412 04-04
STEREOCHEMICAL ASPECTS OF CENTRALLY ACTIVE COMPOUNDS. (PH.D. DISSERTATION). 137993 12-01

**CENTROPHENOXIN**
INFLUENCE OF CENTROPHENOXIN ON MEMORY DISTURBANCE AFTER ELECTROSHOCK. 079993 09-08

**CENTROPHENOXINE**
THE INFLUENCE OF CENTROPHENOXINE (LUCIDRIL) ON LEARNING AND MEMORY IN ALCOHOLICS. 062800 03-14
THE EFFECT OF CENTROPHENOXINE ON EEG VIGILANCE IN THE COURSE OF SLEEP DEPRIVATION AND ON THE EEG PATTERN OF ALL-NIGHT SLEEP. 070934 07-14

**CEREBELLAR**
CYCLIC AMP MEDIATION OF NOREPINEPHRINE INHIBITION IN RAT CEREBELLAR CORTEX: A UNIQUE CLASS OF SYNAPTIC RESPONSES (UNPUBLISHED PAPER). 093132 11-03

**CEREBELLUM**
AN ELECTRON MICROSCOPIC STUDY OF AXONAL CHANGES IN THE CEREBELLUM OF DIPHENYLHYDANTOIN INTOXICATED RATS: THE FORMATION OF THE SO-CALLED HONEYCOMB STRUCTURE IN THE AXOPLASM. 070334 07-03

**CEREBRAL**
EFFECT OF DRUGS USED IN PSYCHOSES ON CEREBRAL DOPAMINE METABOLISM. 041566 01-03
EFFECTS OF NICOTINE AND TOBACCO SMOKE ON THE ELECTRICAL ACTIVITY OF THE CEREBRAL CORTEX AND OLFACTORY BULB. 041567 01-03
MORPHINE AND THE INCORPORATION OF 32 ORTHOPHOSPHATE IN VIVO INTO PHOSPHOLIPIDS OF THE GUINEA-PIG CEREBRAL CORTEX, LIVER AND SUBCELLULAR FRACTIONS. 046401 01-03
THE EFFECT OF BRADYKININ AND ELEDOISIN INJECTED INTO THE CEREBRAL VENTRICLES OF CONSCIOUS RATS. 047323 01-04
CLINICAL INVESTIGATIONS OF THE ACTION OF A PHOSPHOLIPID COMPLEX FROM CEREBRAL CORTEX ON CEREBRAL CIRCULATION DISTURBANCES. 058282 02-11
THE EFFECT OF MORPHINE, NALORPHINE, NALOXONE, PENTAZOCINE, CYCLAZOCINE AND OXOTREMORINE ON THE SYNTHESIS AND RELEASE OF ACETYLCHOLINE BY MOUSE CEREBRAL CORTEX SLICES IN VITRO. 058994 03-03
IMPROVED CEREBRAL CIRCULATION AND PERFORMANCE IN A PSYCHOLOGICAL EXPERIMENT. 059001 03-11
EFFECTS OF MORPHINE AND PENTOBARBITONE ON ACETYLCHOLINE SYNTHESIS BY RAT CEREBRAL CORTEX. 064288 04-03
EFFECTS OF GENERAL DEPRESSANT DRUGS ON THE ELECTRICAL RESPONSES OF ISOLATED SLABS OF CATS CEREBRAL CORTEX. 066382 05-03
USE OF PANGAMIC ACID (VITAMIN-B15) IN CEREBRAL ARTHEROSCLEROSIS WITH MENTAL DISTURBANCES. 067148 06-10
P-CHLOROAMPHETAMINE: IN VIVO INVESTIGATIONS ON THE MECHANISM OF ACTION OF THE SELECTIVE DEPLETION OF CEREBRAL SEROTONIN. 069596 07-03
EFFECTS OF SYMPATHOMIMETIC AMINES INJECTED INTO THE THIRD CEREBRAL VENTRICLE IN ADULT CHICKENS. 072030 07-03
ACUTE CEREBRAL DISORDERS AFTER HIGH DOSES OF OXYQUINOLINE DERIVATIVES. 073900 08-15
THE PROBLEM OF CEREBRAL EDEMA DURING COMBINED PSYCHOTROPIC DRUG THERAPY. 079992 09-15
EFFECTS OF MEPROBAMATE ON THE SCHOOL ACHIEVEMENT OF CEREBRAL PALSIED CHILDREN. 083317 10-14
EFFECTS OF NEUROLEPTICS ON THE CEREBRAL ELECTRICAL ACTIVITY OF LABORATORY ANIMALS: PRESENTATION OF A MODEL DESIGN FOR NEUROPHARMACOLOGICAL EXPERIMENTS. 085337 10-03
RESULTS OF THE MEDICAL TREATMENT IN AGED PATIENTS WITH CEREBRAL ORGANIC DISTURBANCES. 087336 10-11
MEASUREMENT OF THE DISTRIBUTION OF HYPNOTICS AND CEREBRAL FUNCTION IN ACUTE INTOXICATIONS BY PH. 089040 10-17
THE EFFECT OF A NEW METABOLIC CEREBRAL STIMULANT, CYPRODEMANOL, IN PSYCHIATRIC ASPECTS OF AGING. 089055 10-11
EFFECTS OF GENERAL STIMULANT DRUGS ON THE ELECTRICAL RESPONSES OF ISOLATED SLABS OF CATS CEREBRAL CORTEX. 090189 11-03
CONCERNING A CASE OF THROMBOSIS OF THE MIDDLE CEREBRAL ARTERY IN THE COURSE OF PROGESTINIC TREATMENT. 094467 11-14
THE USE OF THE PYRIMIDINE NUCLEOSIDES (CYTIDINE AND URIDINE) IN THE THERAPY OF CEREBRAL VASCULAR ILLNESS. 094472 11-13
EFFECT OF ANTIDEPRESSANTS ON CEREBRAL CIRCULATION AND OXYGEN UPTAKE. 110633 12-03

**CEREBROSPINAL**

THE ROLE OF CARBONIC ANHYDRASE IN ANION SECRETION INTO CEREBROSPINAL FLUID.
040755 01-03

CEREBROSPINAL FLUID MONOAMINE CATABOLITES IN DRUG-INDUCED EXTRAPYRAMIDAL DISORDERS.
064097 04-13

CEREBROSPINAL FLUID 5-HYDROXYINDOLES AND BEHAVIOR AFTER L-TRYPTOPHAN AND PYRIDOXINE ADMINISTRATION TO PSYCHIATRIC PATIENTS.
074938 08-14

**CERVICAL**

THE ACTION OF CENTRAL DEPRESSANT DRUGS ON THE SPONTANEOUS DISCHARGE OF ACTION POTENTIALS IN THE SUPERIOR CERVICAL SYMPATHETIC TRUNK OF THE CAT.
072034 07-03

THE EFFECT OF ESERINE ON THE EFFERENT NEURONAL ACTIVITY IN THE CERVICAL SYMPATHETIC OF THE RAT.
074133 08-03

**CHAIN**

MICELLAR SOLUBILIZATION OF BARBITURATES I: SOLUBILITIES OF CERTAIN BARBITURATES IN POLYSORBATES OF VARYING HYDROPHOBIC CHAIN LENGTH.
046136 01-17

**CHALLENGES**

CHALLENGES IN DRUG EVALUATION IN MAN.
051133 02-17

**CHAMBER**

TOTAL INTERNAL REFLECTION LIGHT CHAMBER (UNPUBLISHED PAPER).
092999 11-06

**CHANGE**

AROUSAL, ANXIETY, AGGRESSION, AND ATTITUDE CHANGE.
070352 07-14

CHANGE IN SENSITIVITY TO D-AMPHETAMINE IN FRONTAL RATS AS A FUNCTION OF TIME: SHIFTING OF THE DOSE RESPONSE CURVE.
075238 08-04

PREDICTION OF CHANGES IN SEVERITY OF THE SCHIZOPHRENIC SYNDROME WITH DISCONTINUATION AND ADMINISTRATION OF PHENOTHIAZINES IN CHRONIC SCHIZOPHRENIC PATIENTS: LANGUAGE AS A PREDICTOR AND MEASURE OF CHANGE IN SCHIZOPHRENIA.
075321 08-08

DOES NOLUDAR (METHYPRYLON) CHANGE DREAMS?
082173 10-14

PREDICTION AND MEASUREMENT OF PERCEPTUAL BEHAVIORAL CHANGE IN DRUG-INDUCED HALLUCINATIONS.
121086 12-12

**CHANGES**

CHANGES IN EMOTIONAL BEHAVIOUR AFTER APPLICATION OF CHOLINESTERASE INHIBITOR IN THE SEPTAL AND AMYGDALA REGION.
040578 01-04

LIVER DAMAGE FOLLOWING APPLICATION OF PYRAZINAMIDE IN ANIMAL EXPERIMENTS: 1. CHANGES IN BODY WEIGHT OF RATS UNDER THE INFLUENCE OF PYRAZINAMIDE.
055398 02-05

HYPERSEXUALITY AND BEHAVIORAL CHANGES IN CATS CAUSED BY ADMINISTRATION OF P-CHLOROPHENYLALANINE.
056934 02-04

EXPERIMENTAL PSYCHOLOGICAL STUDY OF PERFORMANCE CHANGES WITH PERAZINE (TAXILAN) IN MENTALLY DISTURBED AND IN HEALTHY EXPERIMENTAL SUBJECTS FOLLOWING REGIMEN AND SINGLE DOSE ADMINISTRATION.
058235 02-11

L-DOPA INDUCED CHANGES IN CENTRAL MONOAMINE NEURONS AFTER PERIPHERAL DECARBOXYLASE INHIBITION.
059033 03-03

OCULAR CHANGES OCCURRING WITH PROLONGED HIGH DOSE CHLORPROMAZINE THERAPY. RESULTS FROM A COLLABORATIVE STUDY.
060861 03-15

CONDITIONED NALORPHINE INDUCED ABSTINENCE CHANGES: PERSISTENCE IN POST MORPHINE DEPENDENT MONKEYS.
061632 03-04

HANDWRITING CHANGES AND RESPONSE TO DRUGS – A CONTROLLED STUDY.
063775 04-14

CENTRAL NERVOUS SYSTEM CYTOPATHOLOGICAL CHANGES IN CATS WITH CHRONIC METHEDRINE INTOXICATION.
064143 04-05

TRYPTOPHAN HYDROXYLASE CHANGES IN MIDBRAIN OF THE RAT AFTER CHRONIC MORPHINE ADMINISTRATION.
064146 04-03

CHANGES IN THE SERUM CONCENTRATION OF CHOLESTEROL, TRIGLYCERIDES AND PHOSPHOLIPIDS IN THE MOUSE AND RAT AFTER ADMINISTRATION OF EITHER CHLORCYCLIZINE OR PHENOBARBITAL.
064282 04-03

EFFECTS OF PHENOTHIAZINE DERIVATIVES ON BIOLOGICAL MEMBRANES: DRUG-INDUCED CHANGES IN ELECTRON SPIN RESONANCE SPECTRA FROM SPIN-LABELED ERYTHROCYTE GHOST MEMBRANES.
064423 04-03

ELECTRICAL IMPEDANCE CHANGES IN MANY SITES OF BRAIN IN PARADOXICAL SLEEP, ANESTHESIA AND ACTIVITY.
066474 05-03

ELECTROCARDIOGRAPHIC CHANGES DURING LITHIUM TREATMENT.
066747 05-13

MEASUREMENT OF BEHAVIORAL CHANGES IN PATIENTS ON L-DOPA.
066940 05-14

CHANGES IN ENZYMES SUBSERVING CATECHOLAMINE METABOLISM IN MORPHINE TOLERANCE AND WITHDRAWAL IN RAT.
067324 06-03

MENSTRUATION CHANGES AS UNUSUAL SIDE-EFFECT IN A MOLINDONE TRIAL.
067570 06-15

PHYSIOLOGICAL AND DRUG-INDUCED CHANGES IN THE GLYCOGEN CONTENT OF MOUSE BRAIN.
067608 06-03

CHANGES IN D-AMPHETAMINE REACTIVITY RESULTING FROM SEPTAL FOREBRAIN INJURY.
067695 06-04

PERSISTENT BEHAVIOURAL AND ELECTROENCEPHALOGRAPHIC CHANGES AFTER SINGLE DOSES OF NITRAZEPAM AND AMYLOBARBITONE SODIUM.
068005 06-14

AN ELECTRON MICROSCOPIC STUDY OF AXONAL CHANGES IN THE CEREBELLUM OF DIPHENYLHYDANTOIN INTOXICATED RATS: THE FORMATION OF THE SO-CALLED HONEYCOMB STRUCTURE IN THE AXOPLASM.
070334 07-03

CHLORPROMAZINE AND CNS CHANGES IN MAN.
070968 07-14

ECG CHANGES INDUCED BY PHENOTHIAZINE DRUGS IN THE ANESTHETIZED RAT.
072525 08-03

QUANTITATIVE EEG CHANGES DURING HIGH AND LOW DOSAGE FLUPHENAZINE HYDROCHLORIDE TREATMENT.
073710 08-13

WEIGHT CHANGES WITH SCHIZOPHRENIC PSYCHOSIS AND PSYCHOTROPIC DRUG THERAPY.
074218 08-08

PRINCIPAL ELECTROENCEPHALOGRAPHIC CHANGES OBSERVED DURING ACUTE INTOXICATION BY NEUROLEPTICS.
075112 08-13

CRISES AND LIFE CHANGES PRECEDING THE ONSET OR RELAPSE OF ACUTE SCHIZOPHRENIA: CLINICAL ASPECTS.
075304 08-08

PREDICTION OF CHANGES IN SEVERITY OF THE SCHIZOPHRENIC SYNDROME WITH DISCONTINUATION AND ADMINISTRATION OF PHENOTHIAZINES IN CHRONIC SCHIZOPHRENIC PATIENTS: LANGUAGE AS A PREDICTOR AND MEASURE OF CHANGE IN SCHIZOPHRENIA.
075321 08-08

CHANGES IN PSYCHOLOGICAL SYMPTOMS IN WOMEN TAKING ORAL CONTRACEPTIVES.
075470 08-13

PSYCHOPHYSIOLOGIC CHANGES ACCOMPANYING ORAL CONTRACEPTIVE USE.
075471 08-13

CHANGES IN LIVER DISTURBANCE ASSOCIATED WITH LONG-TERM TRANQUILIZING MEDICATION (A FOLLOW-UP STUDY).
075839 08-15

INDUCED CHANGES IN CAUDATE NUCLEUS DOPAMINE AND ELECTROSHOCK THRESHOLD.
079179 09-03

ANTAGONISTIC INFLUENCE OF BETA-SYMPATHICOLYTICS ON THE METAMPHETAMINE INDUCED CHANGES IN FUNCTION AND METABOLISM OF THE BRAIN.
079954 09-03

MEASUREMENT OF BEHAVIOURAL CHANGES IN PATIENTS ON L-DOPA.
081039 09-11

BEHAVIORAL CHANGES FOLLOWING REPEATED LOW DOSES OF MONOMETHYLHYDRAZINE.
082959 10-05

BIOCHEMICAL CHANGES DURING LEARNING IN AN INSECT GANGLION.
084758 10-04

CORRELATION BETWEEN THE CHANGES OF EEG, PUPILLES AND BLOOD PRESSURE DUE TO INTRAVENOUS INJECTION OF CHLORPROMAZINE: CHLORPROMAZINE TEST.
088611 10-13

THE RELATIONSHIPS BETWEEN CLINICAL AND VISUOMOTOR CHANGES IN A SCHIZOPHRENIC GROUP.
089798 11-08

LITHIUM INDUCED CHANGES IN ELECTROLYTE BALANCE AND TISSUE ELECTROLYTE CONCENTRATION.
090419 11-03

CHANGES IN BEHAVIOUR WITH REPEATED TESTING UNDER THE INFLUENCE OF DRUGS: DRUG EXPERIENCE INTERACTIONS.
091997 11-04
PSYCHIATRIC CHANGES IN PATIENTS TREATED WITH LEVODOPA: I. THE CLINICAL EXPERIMENT.
092917 11-10
EVALUATING CHANGES IN SYMPTOMS DURING ACUTE ALCOHOL WITHDRAWAL.
094978 11-11
OPHTHALMOLOGICAL (PIGMENTARY) CHANGES.
100526 12-15
CHANGES OF THE BODY TEMPERATURE OF CODEINE TOLERANT RATS BY THE ADMINISTRATION OF NALORPHINE.
130427 12-03

**CHANGING**
DIFFERENTIAL RESPONSE TO TREATMENT AS A FUNCTION OF THE CHANGING CHARACTER OF A DEPRESSION.
052574 02-10

**CHARACTER**
DIFFERENTIAL RESPONSE TO TREATMENT AS A FUNCTION OF THE CHANGING CHARACTER OF A DEPRESSION.
052574 02-10
RESULTS OBTAINED WITH PROPERICIAZIN (B-909-RP) IN THE TREATMENT OF BEHAVIOR AND CHARACTER DISTURBANCES IN CHILDREN AND ADOLESCENTS.
078730 09-14
PHARMACOLOGICAL MANAGEMENT OF CHARACTER TYPE BEHAVIOR DISTURBANCES IN THE INFANT AND CHILD.
093090 11-07

**CHARACTERISTIC**
FUNCTIONAL CHARACTERISTIC OF THE LINKS OF THE BRAIN CONTROL SYSTEM FOR MENTAL AND MOTOR FUNCTIONS IN MAN.
073770 08-13

**CHARACTERISTICS**
COMPARATIVE CHARACTERISTICS OF CHLORPROMAZINE AND CHLORACYZINE DISTRIBUTION IN RATS.
072579 08-03
PERMEATION CHARACTERISTICS OF MORPHINE-LIKE SUBSTANCES AFTER INJECTION INTO BRAIN TISSUE AND INTO THE VENTRICULAR SYSTEM.
089047 10-03
ON THE PROBLEM OF TREATMENT AND SOME CLINICAL CHARACTERISTICS OF SCHIZOPHRENIA WITH A GRADUAL PAROXYSMAL LIKE COURSE.
111032 12-08
DYNAMIC CHARACTERISTICS OF THE FUNCTIONAL COMPARTMENT OF DOPAMINE IN DOPAMINERGIC TERMINALS OF THE RAT STRIATUM.
120465 12-03

**CHEMICAL**
ANESTHETIC AGENTS AND THE CHEMICAL SENSITIVITY OF CORTICAL NEURONES.
040580 01-03
A SIMPLE AND INEXPENSIVE CANNULA TECHNIQUE FOR CHEMICAL STIMULATION OF THE BRAIN.
058357 02-06
CHEMICAL CONSTITUTION AND DRUG ACTION OF N-SUBSTITUTED PHENOTHIAZINE IN VENTRICULAR ECTOPIC TACHYCARDIA.
063981 04-03
DRUGS AND REALITY IN CAPTIVE SOCIETY. SOME OBSERVATIONS ON CHEMICAL ADAPTATION.
064091 04-17
BEHAVIORAL AND VISCERAL REACTIONS ELICITED BY CHEMICAL STIMULATION OF THE HYPOTHALAMUS AND SEPTUM IN CATS.
064333 04-04
CHEMICAL INDUCTION OF TRAUMATIC FIGHTING IN RATS.
068765 06-04
BEHAVIORAL CORRELATES OF CHEMICAL STIMULATION IN THE CAT THALAMUS.
075234 08-04
PROJECT SUMMARY: CHEMICAL INDUCTION OF TRAUMATIC FIGHTING IN RATS.
082511 10-04
PROJECT SUMMARY: ELECTRICAL AND CHEMICAL STIMULATION OF THE HYPOTHALAMUS.
085144 10-03
CHEMICAL AND CLINICAL EVALUATION OF THE USE OF GABOB IN SCHIZOPHRENIC PATIENTS.
114885 12-08

**CHEMISTRY**
AZABICYCLO CHEMISTRY. I. SYNTHESIS OF 1,5-METHANO-7-METHOXY-2,3,4,5-TETRAHYDRO-1H-2- BENZAZEPINES. B-NORBENZOMORPHANS.
038489 01-01
THE PROBLEM OF POT: PHARMACOLOGY AND CHEMISTRY.
059622 03-03
CHEMISTRY AND PHARMACOLOGY OF FLUPHENAZINE DECANOATE.
065470 05-03
AMANITA-MUSCARIA: PRESENT UNDERSTANDING OF ITS CHEMISTRY.
074074 08-01
PRELIMINARY EXPERIMENTS ON THE CHEMISTRY AND PHARMACOLOGY OF CANNABIS.
086405 10-01
FLUPHENAZINE ENANTHATE (MODITEN-RETARD N.D.): CHEMISTRY AND PHARMACOLOGY.
088997 10-03
CHEMISTRY AND PHARMACOLOGY OF A NEW POTENTIAL ANTIDEPRESSANT, N-METHYL-N-(4-CHLOROBENZYL-11-DIHYDRO-5H DIBENZAZEPIN-5-YL) PROPYLAMINE HYDROCHLORIDE) (LEO-640, LOPRAMINE HYDROCHLORIDE).
089786 11-01

**CHEMOPSYCHOTHERAPEUTICS**
THE CHEMOPSYCHOTHERAPEUTICS OF GERIATRIC SEDATION.
059380 03-11

**CHEMOTHERAPY**
IS IT FEASIBLE TO TREAT CERTAIN POTENTIALLY DANGEROUS CONDITIONS BY PROLONGED CHEMOTHERAPY.
062406 03-08
CHEMOTHERAPY IN PRIVATE PSYCHIATRIC PRACTICE.
071043 07-09
PULSIONAL ECONOMY AND CHEMOTHERAPY.
086452 10-17

**CHICK**
GABA AS A REPRESSOR OF L-GLUTAMIC ACID DECARBOXYLASE (GAD) IN DEVELOPING CHICK EMBRYO OPTIC LOBES.
058192 02-03
EFFECTS OF DOM (STP) ON THE CHICK EMBRYO.
058974 03-05
NOREPINEPHRINE AND DOPAMINE IN THE DEVELOPING CHICK BRAIN.
060865 03-03
PERMEABILITY OF THE BLOOD BRAIN BARRIER TO PARENTERAL 5-HYDROXYTRYPTAMINE IN THE NEONATE CHICK.
067253 06-04

**CHICKEN**
MECHANISM OF THE RENAL TUBULAR TRANSPORT OF MORPHINE AND MORPHINE ETHEREAL SULFATE IN THE CHICKEN.
040754 01-03
ELEVATED CATECHOLAMINES IN THIRTY-DAY-OLD CHICKEN BRAIN AFTER DEPLETION DURING DEVELOPMENT.
063044 03-03

**CHICKENS**
SOME EFFECTS OF NICOTINE ON THE CENTRAL NERVOUS SYSTEM OF CHICKENS.
068166 06-03
EFFECTS OF SYMPATHOMIMETIC AMINES INJECTED INTO THE THIRD CEREBRAL VENTRICLE IN ADULT CHICKENS.
072030 07-03

**CHICKS**
TRYPTALDEHYDES (INDOLEACETALDEHYDES) IN SEROTONERGIC SLEEP OF NEWLY HATCHED CHICKS.
055583 02-03
AGGRESSIVE BEHAVIOUR IN CHICKS INDUCED BY TRICYCLIC ANTIDEPRESSANTS.
090420 11-04

**CHILD**
LONG-TERM PSYCHOTHERAPY UTILIZING TRIFLUOPERAZINE IN A PSYCHOTIC PRESCHOOL CHILD: (A CASE STUDY).
066806 05-11
TESTING OF SULPIRIDE IN CHILD PSYCHIATRY.
067375 06-07
CHILD NEUROPSYCHIATRY AND NEUROPSYCHOPHARMACOLOGY.
085456 10-14
CONTRIBUTION TO THE STUDY OF THE ACTION OF PROPERICIAZINE ON BEHAVIORAL PROBLEMS OF THE CHILD AND THE ADOLESCENT.
086451 10-11
PHARMACOLOGICAL MANAGEMENT OF CHARACTER TYPE BEHAVIOR DISTURBANCES IN THE INFANT AND CHILD.
093090 11-07

**CHILDHOOD**
AN EVALUATION OF NIACINAMIDE IN THE TREATMENT OF CHILDHOOD SCHIZOPHRENIA.
060240 03-08
THERAPY OF CHILDHOOD SEIZURES.
065175 05-11
IMIPRAMINE IN CHILDHOOD ENURESIS: FURTHER STUDIES ON THE RELATIONSHIP OF TIME OF ADMINISTRATION TO EFFECT.
071946 07-11
CHILDHOOD SCHIZOPHRENIA: A CASE TREATED WITH NICOTINIC ACID AND NICOTINAMIDE.
075944 09-08
THE PSYCHOLYTIC TREATMENT OF A CHILDHOOD SCHIZOPHRENIC GIRL.
080609 09-08

**CHILDREN**
TREATMENT OF CHILDREN OF LITHIUM RESPONDING PARENTS.
058375 02-09
USE OF AMITRIPTYLINE SYRUP IN THE TREATMENT OF ENURESIS IN CHILDREN.
062407 03-11

LYOGEN IN THE TREATMENT OF MENTAL DISEASES IN CHILDREN.
064173 04-07

TREATMENT OF HYPERACTIVITY IN CHILDREN.
065176 05-12

IN DEFENSE OF STIMULANTS FOR HYPERKINETIC CHILDREN.
067059 05-11

DILANTIN EFFECT ON EMOTIONALLY DISTURBED CHILDREN.
070972 07-14

SOME CLINICAL AND LABORATORY STUDIES OF PSYCHOTROPIC DRUGS IN CHILDREN: AN OVERVIEW.
070975 07-17

EPILEPSY THERAPY WITH MENTALLY RETARDED CHILDREN: NEUROPSYCHIATRIC DISORDERS THROUGH DIPHENYLHYDANTOIN.
071241 07-15

THE ASSESSMENT OF DRUG EFFECTS IN CHILDREN AS COMPARED TO ADULTS.
072825 08-14

MEGAVITAMIN THERAPY WITH SEVERELY DISTURBED CHILDREN.
075819 08-11

COMPARISON OF HALOPERIDOL AND FLUPHENAZINE IN DISTURBED CHILDREN.
076233 09-11

RESULTS OBTAINED WITH PROPERICIAZIN (8-909-RP) IN THE TREATMENT OF BEHAVIOR AND CHARACTER DISTURBANCES IN CHILDREN AND ADOLESCENTS.
078730 09-14

THE USE OF PSYCHOPHARMACOLOGY IN CHILDREN AND ADOLESCENTS.
080096 09-17

EVALUATION OF TEGRETOL IN THE TREATMENT OF BEHAVIOUR DISORDERS IN CHILDREN: METHODOLOGY AND RESULTS.
080098 09-07

PSYCHOPHARMACOLOGY IN CHILDREN: PROBLEM AREAS, METHODOLOGICAL CONSIDERATIONS, ASSESSMENT TECHNIQUES.
080350 09-17

TESTING THE PERFORMANCE UNDER APONEURON OF OTHERWISE NORMAL SCHOOL CHILDREN WITH A TENDENCY TOWARD REDUCED DRIVE AND EASY TIRING.
080563 09-11

EXPERIENCE WITH PROPERICIAZIN (AOLEPT) IN THE TREATMENT OF CHILDREN WITH DISTURBED PSYCHOMOTOR FUNCTIONS AND RESTLESSNESS.
081144 09-11

METHYLPHENIDATE AND THIORIDAZINE: LEARNING, REACTION TIME, ACTIVITY, AND CLASSROOM BEHAVIOR IN DISTURBED CHILDREN.
081631 10-14

TREATMENT WITH THIORIDAZINE OF EMOTIONALLY DISTURBED CHILDREN IN A DAY HOSPITAL.
082090 10-14

LETHAL POISONING IN CHILDREN BY MEANS OF THYMOLEPTICS.
082202 10-15

EFFECTS OF MEPROBAMATE ON THE SCHOOL ACHIEVEMENT OF CEREBRAL PALSIED CHILDREN.
083317 10-14

MESORIDAZINE IN THE CONTROL OF BEHAVIOR DISORDERS IN CHILDREN.
086780 10-14

QUANTITATIVE CLINICAL ANALYSIS OF THE EFFECT OF FENETYLLIN (CAPTAGON) ON HYPERKINETIC CHILDREN.
093540 11-11

CLINICAL EXPERIENCE WITH TARASAN AND THIORIDAZINE IN MENTALLY RETARDED CHILDREN -- A COMPARATIVE DOUBLE-BLIND STUDY.
097655 11-14

PSYCHOTROPIC DRUG SIDE-EFFECTS IN CHILDREN.
100517 12-15

STATE-DEPENDENT RECOGNITION WITH METHYLPHENIDATE AND THIORIDAZINE IN RETARDED CHILDREN. (PH.D.DISSERTATION).
103301 12-14

PROBLEM BEHAVIOR OF CHILDREN WITH SEVERE MENTAL AND PHYSICAL DISORDERS -- EXPERIENCE OF THE USE OF CARBAMAZEPINE.
105790 12-14

IMIPRAMINE AS AN EFFECTIVE TOOL IN THE MANAGEMENT OF BEHAVIORAL DISORDERS IN CHILDREN.
134937 12-11

**CHILDRENS**

THE USE OF IMIPRAMINE IN CHILDRENS BEHAVIOR DISORDERS.
080095 09-14

THE CHILDRENS PSYCHOPHARMACOLOGY CLINIC: ITS ROLE WITHIN A TOTAL PROGRAM FOR CHILDRENS PSYCHIATRIC SERVICES.
080097 09-17

**CHLORACYZINE**

COMPARATIVE CHARACTERISTICS OF CHLORPROMAZINE AND CHLORACYZINE DISTRIBUTION IN RATS.
072579 08-03

**CHLORAL**

MANDRAX AS AN HYPNOTIC FOR PSYCHIATRIC INPATIENTS: A COMPARATIVE TRIAL WITH CHLORAL HYDRATE.
061562 03-14

CHLORAL HYDRATE IN CENTRAL NERVOUS SYSTEM DEPRESSION.
064335 04-17

HYPNOTICS AND ALTERED SLEEP DREAM PATTERNS: II. ALL-NIGHT EEG STUDIES OF CHLORAL HYDRATE, FLURAZEPAM, AND METHAQUALONE.
066234 05-14

THE KINETICS OF CHLORAL HYDRATE METABOLISM IN MICE AND THE EFFECT THEREON OF ETHANOL.
066364 05-03

A STUDY OF THE INTERACTION OF THE HYPNOTIC EFFECTS AND OF THE TOXIC EFFECTS OF CHLORAL HYDRATE AND ETHANOL.
066365 05-03

A COMPARATIVE STUDY OF THREE HYPNOTICS: METHYPRYLON, GLUTETHIMIDE AND CHLORAL HYDRATE.
067862 06-14

**CHLORALOSE**

CLINICAL AND EEG APPEARANCES OF ACUTE DRUG INTOXICATION DUE TO CHLORALOSE.
088568 10-15

HUMAN INTOXICATION BY CHLORALOSE.
088618 10-15

**CHLORAZEPATE**

NEUROPHYSIOLOGICAL STUDY OF DIPOTASSIUM CHLORAZEPATE (4306-CB).
055580 02-03

PHARMACOLOGICAL, TOXICOLOGICAL, AND TERATOLOGICAL STUDIES ON DIPOTASSIUM 7-CHLORO-3-CARBOXY 1,3-DIHYDRO-2,2-DIHYDROXY-5-PHENYL-2H-1,4 BENZODIAZEPINE CHLORAZEPATE (DIPOTASSIUM CHLORAZEPATE, 4306-CB), A NEW TRANQUILLIZER.
055581 02-03

THE PSYCHOPHARMACOLOGICAL TREATMENT OF CARDIAC NEUROTIC PATIENTS WITH DIPOTASSIUM CHLORAZEPATE IN THE DOUBLE-BLIND TEST.
055689 02-10

DIPOTASSIUM CHLORAZEPATE: CLINICAL REPORTS ON A NEW ANTIANXIETY AGENT.
055738 02-09

**CHLORCYCLIZINE**

EFFECTS OF THALIDOMIDE AND CHLORCYCLIZINE ON THE BIOSYNTHESIS OF NUCLEIC ACIDS AND PROTEINS IN FETAL AND MATERNAL TISSUES OF THE RAT.
040027 01-05

CHANGES IN THE SERUM CONCENTRATION OF CHOLESTEROL, TRIGLYCERIDES AND PHOSPHOLIPIDS IN THE MOUSE AND RAT AFTER ADMINISTRATION OF EITHER CHLORCYCLIZINE OR PHENOBARBITAL.
064282 04-03

**CHLORDIAZEPOXIDE**

COMPARATIVE EFFECTS OF FLUPHENAZINE, FLUPHENAZINE CHLORDIAZEPOXIDE AND FLUPHENAZINE IMIPRAMINE.
058451 02-15

CHLORPROMAZINE, CHLORDIAZEPOXIDE, AND THE INCENTIVE SHIFT PERFORMANCE IN THE RAT.
060275 03-04

EFFECTS OF D-AMPHETAMINE AND CHLORDIAZEPOXIDE ON SPACED RESPONDING IN PIGEONS.
061597 03-04

HYDROXYZINE AND CHLORDIAZEPOXIDE IN ANXIOUS NEUROTIC OUTPATIENTS: A COLLABORATIVE CONTROLLED STUDY.
062321 03-10

COMBINED THERAPY IN ANXIETY DEPRESSIVE SYNDROMES: I. COMPARATIVE EFFECTS OF LIMBITROL (CHLORDIAZEPOXIDE AMITRIPTYLINE) AND PLACEBO.
064312 04-10

EFFECTS OF CHLORDIAZEPOXIDE AND PENTOBARBITAL ON CONFLICT BEHAVIOR IN RATS.
064390 04-04

EFFECTS OF CHLORDIAZEPOXIDE ON DISCRIMINATIVE FEAR CONDITIONING AND SHUTTLE AVOIDANCE PERFORMANCE IN THE RABBIT.
065451 05-04

BUTABARBITAL SODIUM AND CHLORDIAZEPOXIDE IN ANXIOUS NEUROTIC OUTPATIENTS: A COLLABORATIVE CONTROLLED STUDY.
066276 05-10

STRAIN DIFFERENCES IN THE EFFECTS OF CHLORPROMAZINE AND CHLORDIAZEPOXIDE UPON ACTIVE AND PASSIVE AVOIDANCE IN MICE.
066828 05-04

CHLORDIAZEPOXIDE AND CONDITIONED SUPPRESSION.
066829 05-04

EFFECTS OF CHLORDIAZEPOXIDE ON BLACK WHITE DISCRIMINATION ACQUISITION AND REVERSAL IN WHITE RATS.
070083 07-04

A COMPARATIVE EVALUATION OF DOXEPIN AND CHLORDIAZEPOXIDE IN THE TREATMENT OF PSYCHONEUROTIC OUTPATIENTS.
072140 07-10

A COMPARISON OF DOXEPIN AND CHLORDIAZEPOXIDE IN THE THERAPY OF ANXIETY.
072141 07-10

DOXEPIN VERSUS CHLORDIAZEPOXIDE: A DOUBLE-BLIND STUDY ON ANXIOUS OUTPATIENTS.
072143 07-10

HABITUATION TO CHLORDIAZEPOXIDE IN AN ALCOHOLIC POPULATION.
074732 08-11

COMPARATIVE EFFECTS OF AMPHETAMINE, SCOPOLAMINE, CHLORDIAZEPOXIDE, AND DIPHENYLHYDANTOIN ON OPERANT AND EXTINCTION BEHAVIOR WITH BRAIN STIMULATION AND FOOD REWARD.
074935 08-04

EFFECTS OF CHLORDIAZEPOXIDE ON THE ACQUISITION OF SHUTTLE AVOIDANCE IN THE RABBIT.
075235 08-04

DRUG TREATMENT IN DEPRESSIVE ILLNESS: AMITRYPTYLINE AND CHLORDIAZEPOXIDE IN TWO NEUROTIC POPULATIONS.
075415 08-10

HYPNOTIC PROPERTIES OF NITRAZEPAM (MOGADON) (A COMPARATIVE STUDY OF CHLORDIAZEPOXIDE, DIAZEPAM, NITRAZEPAM, SECOBARBITAL AND PLACEBO IN PSYCHIATRIC PATIENTS).
075884 09-14

INCREASED AGGRESSION AMONG GROUPED MALE MICE FED CHLORDIAZEPOXIDE.
081098 09-04

HYPOTENSIVE EFFECTS OF CHLORDIAZEPOXIDE, AMOBARBITAL AND CHLORPROMAZINE ON BEHAVIORALLY INDUCED ELEVATED ARTERIAL BLOOD PRESSURE IN THE SQUIRREL MONKEY.
089999 11-04

THE EFFECT OF CHLORDIAZEPOXIDE ON THE BEHAVIOR OF RATS IN A CONFLICT SITUATION.
090424 11-04

INTERACTIONS BETWEEN THE EFFECTS OF CHLORDIAZEPOXIDE AND AMPHETAMINE ON FOOD INTAKE AND SPONTANEOUS MOTOR ACTIVITY IN THE RAT.
092692 11-04

A DOUBLE-BLIND COMPARISON OF S-804 (NEW BENZODIAZEPINE DRUG) WITH CHLORDIAZEPOXIDE AND DIAZEPAM IN THE TREATMENT OF NEUROSIS.
129097 12-10

**CHLORIMIPRAMINE**

HYDROXYTRYPTAMINE TURNOVER DECREASED BY THE ANTIDEPRESSANT DRUG CHLORIMIPRAMINE.
058799 02-03

ANTIARRHYTHMIC AND HEMODYNAMIC EFFECTS OF IMIPRAMINE AND CHLORIMIPRAMINE.
058991 03-05

EFFECT OF IMIPRAMINE AND CHLORIMIPRAMINE ON AN ACUTE INSTRUMENTAL TRACE CONDITIONED REFLEX IN RATS.
064415 04-04

CLINICAL EXPERIENCES WITH CHLORIMIPRAMINE IN ENDOGENOUS DEPRESSION.
070942 07-09

EFFECTS OF CHLORIMIPRAMINE ON ELECTRICAL ACTIVITIES OF SUBCORTICAL BRAIN STRUCTURES AND OF SYMPATHETIC NERVES.
079951 09-03

CLINICAL CONSIDERATIONS ON THE TREATMENT OF DEPRESSION WITH CHLORIMIPRAMINE.
081121 09-10

CHLORIMIPRAMINE: THE MAJOR TREATMENT OF DEPRESSIVE STATES.
089157 10-09

CLINICAL CONTRIBUTION OF EXPERIMENTS WITH CHLORIMIPRAMINE (ANAFRANIL).
093443 11-09

**CHLORINATED**

POLYNEURITIS CRANIALIS FOLLOWING POISONING WITH CHLORINATED ACETYLENES WHILE HANDLING VINYLIDINE COPOLYMERS.
051140 02-15

INVESTIGATION INTO THE POSSIBLE INFLUENCE OF CHLORINATED AMPHETAMINE DERIVATIVES ON 5-HYDROXYTRYPTAMINE SYNTHESIS IN MAN.
097963 11-13

**CHLORMETHIAZOLE**

URINARY EXCRETION OF ADRENAL HORMONES IN MAN: EFFECTS OF ETHANOL INGESTION, AND THEIR MODIFICATION BY CHLORMETHIAZOLE.
097974 11-11

**CHLOROQUINE**

QUANTITATION OF THE DEGREE OF ANTAGONISM OF CHLOROQUINE TO HISTAMINE, ACETYLCHOLINE AND SEROTONIN ( PA2 VALUES).
067462 06-03

**CHLORPROMAZINE**

THE DIFFERENTIAL RESPONSE TO PARENTERAL CHLORPROMAZINE AND MESORIDAZINE IN PSYCHOTIC PATIENTS.
040127 01-08

STIMULATION OF DOPA-14C INCORPORATION INTO MELANOMA TISSUE BY CHLORPROMAZINE AND RESERPINE.
040584 01-03

STUDIES OF DELAYED ACTION MEDICATION: V. PLASMA LEVELS AND URINARY EXCRETION OF FOUR DIFFERENT DOSAGE FORMS OF CHLORPROMAZINE.
041559 01-13

OXIDATIVE PHOSPHORYLATION IN HEART MITOCHONDRIA ISOLATED FROM CHLORPROMAZINE TREATED ANIMALS.
041564 01-03

A DOUBLE-BLIND COMPARISON OF CHLORPROMAZINE AND MESORIDAZINE (TPS-23).
045508 01-07

RABBIT AS A MODEL FOR CHLORPROMAZINE INDUCED HYPERPIGMENTATION OF THE SKIN.
045543 01-05

PLASMA PROTEIN BINDING OF CHLORPROMAZINE.
046138 01-13

INCREASE IN BRAIN PYRIDOXAL PHOSPHATE BY CHLORPROMAZINE.
046397 01-02

FACTORS AFFECTING CHLORPROMAZINE PLASMA LEVELS IN PSYCHIATRIC PATIENTS.
047913 01-13

CHLORPROMAZINE PLASMA LEVELS AND EFFECTS.
047951 01-09

RETICULAR STIMULATION AND CHLORPROMAZINE: AN ANIMAL MODEL FOR SCHIZOPHRENIC OVERAROUSAL.
058531 02-04

CHLORPROMAZINE INDUCED GLUCOSE INTOLERANCE IN THE MOUSE.
058984 03-05

LYSERGIC ACID DIETHYLAMIDE, CHLORPROMAZINE AND MAZE PERFORMANCE.
058997 03-04

CHLORPROMAZINE, CHLORDIAZEPOXIDE, AND THE INCENTIVE SHIFT PERFORMANCE IN THE RAT.
060275 03-04

A COMPARISON OF OXYPERTINE AND CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIA.
060659 03-08

OCULAR CHANGES OCCURRING WITH PROLONGED HIGH DOSE CHLORPROMAZINE THERAPY. RESULTS FROM A COLLABORATIVE STUDY.
060861 03-15

A COMPARISON OF LITHIUM CARBONATE AND CHLORPROMAZINE IN MANIA.
062349 03-09

A MECHANISM OF SUDDEN DEATH IN CHLORPROMAZINE THERAPY.
062351 03-15

LITHIUM VERSUS CHLORPROMAZINE FOR MANICS. INITIATIVE AND PRODUCTIVITY VERSUS TRANQUILIZATION HOSPITALIZATION.
063209 03-09

THE EFFECTS OF HALOPERIDOL AND CHLORPROMAZINE ON AMPHETAMINE METABOLISM AND AMPHETAMINE STEREOTYPE BEHAVIOR IN THE RAT.
064170 04-03

SPECTROPHOTOMETRIC DETERMINATION OF CHLORPROMAZINE IN PHARMACEUTICAL DOSAGE FORMS.
064262 04-06

THE EFFECTS OF CHLORPROMAZINE ON ONE-TRIAL PASSIVE AVOIDANCE LEARNING IN MICE: FURTHER EXAMINATION OF PRELEARNING AND POSTLEARNING ADMINISTRATION.
064407 04-04

A COMPARATIVE STUDY OF BUTAPERAZINE, CHLORPROMAZINE AND PLACEBO IN CHRONIC SCHIZOPHRENICS.
064431 04-08

THE RESPONSE OF LYSOSOMES IN CULTURED NEURONS TO CHLORPROMAZINE.
066380 05-03

STRAIN DIFFERENCES IN THE EFFECTS OF CHLORPROMAZINE AND CHLORDIAZEPOXIDE UPON ACTIVE AND PASSIVE AVOIDANCE IN MICE.
066828 05-04

THE PHYSIOLOGICAL DISPOSITION OF CHLORPROMAZINE IN THE RAT AND DOG.
066937 05-03

DOUBLE-BLIND STUDY COMPARING THE INTRAMUSCULAR USAGE OF AN ACRIDAN DERIVATIVE, SKF-14336, TO CHLORPROMAZINE.
067513 06-11

TISSUE DISTRIBUTION OF CHLORPROMAZINE STUDIED BY MICROAUTORADIOGRAPHY.
067961 06-03

THE EFFECTS OF VARIOUS PRIOR TREATMENTS UPON THE TRANSPORT OF CHLORPROMAZINE AND TRIFLUOPERAZINE INTO RAT BRAIN.
069309 06-02

INTERACTION OF CHLORPROMAZINE AND TISSUE BINDING SITES: PRELIMINARY STUDIES.
069367 06-03

A NOTE ON THE EFFECTS OF CHLORPROMAZINE UPON ULCERATION IN THE RAT.
069645 07-03

EFFECTS OF CHLORPROMAZINE ON NEURAL TISSUE IN CULTURE.
070825 07-03

CHLORPROMAZINE AND CNS CHANGES IN MAN.
070968 07-14

COMBINED EFFECTS OF CHLORPROMAZINE AND ALTITUDE UPON PERFORMANCE IN THE RAT.
071467 07-04

MODIFICATION OF CHLORPROMAZINE METABOLISM BY SOME OTHER DRUGS FREQUENTLY ADMINISTERED TO PSYCHIATRIC PATIENTS.
071989 07-13

RETICULAR STIMULATION AND CHLORPROMAZINE.
071997 07-04

COMPARATIVE CHARACTERISTICS OF CHLORPROMAZINE AND CHLORACYZINE DISTRIBUTION IN RATS.
072579 08-03

EFFECTS OF CHLORPROMAZINE ON CONVULSIVE RESPONSES IN DEVELOPING RATS.
074131 08-03

EFFECTS OF PENTOBARBITONE AND CHLORPROMAZINE ON ACOUSTICALLY EVOKED POTENTIALS IN THE RAT.
074939 08-03

A DOUBLE-BLIND COMPARISON OF LITHIUM AND CHLORPROMAZINE IN THE TREATMENT OF MANIC STATES.
075430 08-09

BRIEF SLEEP TREATMENT WITH CHLORPROMAZINE.
075860 09-14

EFFECTS OF CHLORPROMAZINE IN THE PIGEON UNDER A SECOND-ORDER SCHEDULE OF FOOD PRESENTATION.
075906 09-04

EATING, DRINKING AND SPONTANEOUS ACTIVITY IN RATS AFTER THE ADMINISTRATION OF CHLORPROMAZINE.
079999 09-04

EFFECT OF CHLORPROMAZINE ON 5-HYDROXYTRYPTAMINE METABOLISM IN HIPPOCAMPAL STIMULATED RATS.
080338 09-01

CHLORPROMAZINE METABOLISM I: QUANTITATIVE FLUOROMETRIC METHOD FOR 1,1 CHLORPROMAZINE METABOLITES.
080631 09-06

CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIC WOMEN: ITS EFFECT ON THYROID AND LIVER FUNCTION IN RELATION TO SERUM CHOLESTEROL CONCENTRATION.
088221 10-13

SYNTHESIS OF POSSIBLE METABOLITES OF CHLORPROMAZINE: IV. 7-HYDROXY-NOR1-CHLORPROMAZINE AND NOR2-CHLORPROMAZINE SULFOXIDE (UNPUBLISHED PAPER).
088358 10-01

CORRELATION BETWEEN THE CHANGES OF EEG, PUPILLES AND BLOOD PRESSURE DUE TO INTRAVENOUS INJECTION OF CHLORPROMAZINE: CHLORPROMAZINE TEST.
088611 10-13

NEUROENDOCRINOLOGICAL STUDY IN CHLORPROMAZINE TREATED RATS.
089029 10-13

PIPERACETAZINE VS. CHLORPROMAZINE IN THE TREATMENT OF SCHIZOPHRENIA.
089099 10-08

INDICATIONS FOR HIGH DOSE CHLORPROMAZINE THERAPY IN CHRONIC SCHIZOPHRENIA.
089433 10-08

AN UNUSUAL CASE OF CHLORPROMAZINE AGRANULOCYTOSIS.
089443 11-15

HYPOTENSIVE EFFECTS OF CHLORDIAZEPOXIDE, AMOBARBITAL AND CHLORPROMAZINE ON BEHAVIORALLY INDUCED ELEVATED ARTERIAL BLOOD PRESSURE IN THE SQUIRREL MONKEY.
089999 11-04

SYNTHESIS OF POSSIBLE METABOLITES OF CHLORPROMAZINE. III. 7,8 DISUBSTITUTED CHLORPROMAZINE DERIVATIVES.
094623 11-01

COMPARATIVE STUDY OF NATURAL SLEEP AND THE ACTION OF PHENAMINE AND CHLORPROMAZINE EVALUATION OF THE MEAN EXTREMES FREQUENCY OF ECOG IN CATS.
095655 11-14

THE EFFECTS OF CHLORPROMAZINE ON THE EXPRESSION OF AN ACQUIRED PASSIVE AVOIDANCE RESPONSE IN MICE.
097959 11-04

ESTIMATION OF LOW CHLORPROMAZINE CONCENTRATIONS BY SURFACING AND SINKING REACTION OF MINNOWS (GAMBUSIA-AFFINIS).
097964 11-06

DOUBLE-BLIND STUDY OF CLOPENTHIXOL AND CHLORPROMAZINE IN ACUTE HOSPITALIZED SCHIZOPHRENICS.
098048 11-08

EFFECT OF LSD-25, CHLORPROMAZINE AND METEDRINE UPON VISUAL EVOKED RESPONSE IN CATS.
098171 11-03

A PSYCHOLOGICAL STUDY OF THE EFFECTS OF CHLORPROMAZINE (THORAZINE). (PH.D.DISSERTATION).
103273 12-08

LONG-TERM TREATMENT WITH CHLORPROMAZINE IN ANIMAL EXPERIMENTATION.
105619 12-05

A DOUBLE-BLIND, CROSSOVER COMPARISON OF APY-606 WITH CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIA.
118583 12-08

EFFECT OF CHLORPROMAZINE ON CONDITIONED REFLEXES AND ANTAGONISTIC ACTIVITY OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126054 12-04

**CHLORPROTHIXENE**

AMITRIPTYLINE, CHLORPROTHIXENE, PROTHIADENE AND PLACEBO IN THE TREATMENT OF NEUROSES.
070946 07-10

**CHOICE**

A CHOICE TECHNIQUE TO ASSESS THE EFFECTS OF SELECTIVE PUNISHMENT ON FIXED-RATIO PERFORMANCE.
075579 08-04

CHOICE OF ANTIPSYCHOTIC DRUGS.
075872 09-08

AN AUTOMATED MULTIPLE CHOICE TEST OF SHORT-TERM SPATIAL MEMORY FOR MONKEYS.
075917 09-04

**CHOLESTEROL**

CHANGES IN THE SERUM CONCENTRATION OF CHOLESTEROL, TRIGLYCERIDES AND PHOSPHOLIPIDS IN THE MOUSE AND RAT AFTER ADMINISTRATION OF EITHER CHLORCYCLIZINE OR PHENOBARBITAL.
064282 04-03

CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIC WOMEN: ITS EFFECT ON THYROID AND LIVER FUNCTION IN RELATION TO SERUM CHOLESTEROL CONCENTRATION.
088221 10-13

**CHOLINE**

EFFECTS OF A CHOLINE ACETYLTRANSFERASE INHIBITOR ON SELF-STIMULATORY BEHAVIOR IN THE RAT.
058993 03-04

**CHOLINERGIC**

CHOLINERGIC MODULATION OF ADRENERGIC AROUSAL IN THE DEVELOPING RAT.
063688 04-04

THE EFFECTS OF CENTRALLY AND PERIPHERALLY ACTING CHOLINERGIC DRUGS ON THE SHORT-TERM PERFORMANCE GRADIENT FOLLOWING PASSIVE AVOIDANCE TRAINING.
064412 04-04

DRUGS INFLUENCING THE CHOLINERGIC SYSTEM AND THE PROCESS OF LEARNING AND MEMORY IN MAN.
070955 07-14

THE EFFECTS OF ADRENERGIC AND CHOLINERGIC AGENTS UPON EATING AND DRINKING IN DEPRIVED RATS.
076132 09-03

AN ANALYSIS OF THE ROLE OF CHOLINERGIC DRUGS IN BEHAVIOR RELATED TO FOOD AND WATER DEPRIVATION. (PH.D.DISSERTATION).
103267 12-04

**CHOLINESTERASE**

EFFECTS OF TWO CHOLINESTERASE INHIBITORS ON ACETYLCHOLINE RELEASE FROM THE GUINEA-PIG ISOLATED ILEUM PREPARATION.
040572 01-03

CHANGES IN EMOTIONAL BEHAVIOUR AFTER APPLICATION OF CHOLINESTERASE INHIBITOR IN THE SEPTAL AND AMYGDALA REGION.
040578 01-04

PSYCHOPHARMACOLOGIC EFFECTS OF SOME CHOLINESTERASE INHIBITORS IN COMPARISON WITH IMIPRAMINE.
069074 06-04

**CHOLINOCEPTIVE**

LATERAL HYPOTHALAMIC CONTROL OF KILLING: EVIDENCE FOR A CHOLINOCEPTIVE MECHANISM.
058227 02-04

**CHOLINOLYTICS**

SEROTONINERGIC COMPONENT OF THE STIMULANT EFFECT OF CHOLINOLYTICS.
098058 11-03

**CHOLINOMIMETIC**

A COMPARISON OF THE ANTINOCICEPTIVE ACTIONS OF CHOLINOMIMETIC AND MORPHINE-LIKE DRUGS.
064290 04-03

**CHOLINOREACTIVE**

EFFECT OF AGENTS INTERACTING WITH CHOLINOREACTIVE AND ADRENOREACTIVE SYSTEMS ON EPILEPTIFORM ACTIVITY IN THE HIPPOCAMPUS OF RABBITS.
110631 12-03

**CHOREA**

SEVERE PERSISTENT CHOREA WITH PHENOTHIAZINE THERAPY: REPORT OF A CASE.
079915 09-15

**CHOREIFORM**

NEUROPATHOLOGY OF PERSISTENT CHOREIFORM HYPERKINESIAS UNDER LONG-TERM TREATMENT WITH NEUROLEPTICS.
101020 12-15

**CHROMATOGRAPHIC**

THIN-LAYER CHROMATOGRAPHIC LABORATORY ANALYSIS IN CASES FROM A DRUG ADDICTION CENTER.
067212 06-06

QUANTITATIVE THIN-LAYER CHROMATOGRAPHIC ESTIMATION OF LABELED DOPAMINE AND NOREPINEPHRINE, THEIR PRECURSORS AND METABOLITES.
070063 07-06

**CHROMATOGRAPHY**
THE OCCURRENCE OF CYCLOHEXYLAMINE IN URINES STUDIED FOR DRUG USE BY THIN-LAYER CHROMATOGRAPHY.
070576 07-13

**CHROMOSOMAL**
CHROMOSOMAL EFFECTS OF LSD-25, A CONTROVERSY?
058908 02-15

**CHROMOSOME**
CHROMOSOME STUDIES IN PREGNANT RHESUS MACAQUE GIVEN LSD-25.
064315 04-05
CHROMOSOME STUDIES ON PATIENTS (IN VIVO) AND CELLS (IN VITRO) TREATED WITH LYSERGIC ACID DIETHYLAMIDE.
071987 07-13

**CHROMOSOMES**
LSD-25 EFFECTS ON CHROMOSOMES: A REVIEW.
067342 06-15
ANALYSIS OF CHROMOSOMES BEFORE AND AFTER TREATMENT WITH IMURAN.
069082 06-13

**CHRONIC**
EFFECTS OF CHRONIC ADMINISTRATION OF NICOTINE ON STORAGE AND SYNTHESIS OF NORADRENALINE IN RAT BRAIN.
041552 01-03
THE EFFECT OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON BRAIN ACETYLCHOLINE LEVELS IN RAT.
041913 01-03
EFFECTS OF CHRONIC POSTNATAL DRUG ADMINISTRATION ON ADULT DOMINANCE BEHAVIOR IN TWO GENERA OF MICE.
042837 01-04
CARDIAC CATECHOLAMINE LEVELS AND BLOOD PRESSURE AFTER CHRONIC TREATMENT WITH BETA-ADRENERGIC BLOCKING AGENTS.
055579 02-03
A CASE OF PROBABLE HEMATOMYELIA CAUSED BY CHRONIC BENZENE POISONING.
056059 02-15
GROUP TREATMENT OF CHRONIC ALCOHOLISM WITH LSD-25: STUDY II.
057480 02-14
CLOTHIAPIN IN THE TREATMENT OF CHRONIC SCHIZOPHRENIA.
058372 02-08
PROTRIPTYLINE IN THE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS.
058968 03-08
WITHDRAWAL OF ANTIPSYCHOTIC DRUGS FROM CHRONIC PSYCHIATRIC PATIENTS.
060208 03-08
A COMPARISON OF OXYPERTINE AND CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIA.
060659 03-08
PRELIMINARY CLINICAL OBSERVATIONS CONCERNING THE TREATMENT WITH METRONIDAZOLE IN CHRONIC ALCOHOLISM.
062866 03-11
A METHOD FOR CHRONIC INTRAVENOUS DRUG ADMINISTRATION IN SQUIRREL MONKEYS.
063725 04-06
A COMPARATIVE STUDY OF THE EFFECTS OF METHAQUALONE AND GLUTETHIMIDE ON SLEEP IN MALE CHRONIC INSOMNIACS.
063879 04-14
THE SENSITIVITY OF THE BRAIN TO BARBITURATE DURING CHRONIC ADMINISTRATION AND WITHDRAWAL OF BARBITONE SODIUM IN THE RAT.
063980 04-03
CENTRAL NERVOUS SYSTEM CYTOPATHOLOGICAL CHANGES IN CATS WITH CHRONIC METHEDRINE INTOXICATION.
064143 04-05
TRYPTOPHAN HYDROXYLASE CHANGES IN MIDBRAIN OF THE RAT AFTER CHRONIC MORPHINE ADMINISTRATION.
064146 04-03
MAINTENANCE THERAPY OF CHRONIC PSYCHOTIC PATIENTS WITH A WEEKLY ORAL DOSE OF R-16341. A CONTROLLED DOUBLE-BLIND STUDY.
064284 04-09
A COMPARATIVE STUDY OF BUTAPERAZINE, CHLORPROMAZINE AND PLACEBO IN CHRONIC SCHIZOPHRENICS.
064431 04-08
DRUG PLASMA LEVELS IN CHRONIC ILLNESS.
064484 04-17
THE EFFECTIVENESS OF PARENTERAL ADMINISTRATION OF FLUPHENAZINE DECANOATE IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS.
065473 05-07
INSTITUTIONAL MANAGEMENT OF CHRONIC SCHIZOPHRENICS WITH FLUPHENAZINE DECANOATE.
065474 05-07
FLUPHENAZINE HYDROCHLORIDE, ENANTHATE, AND DECANOATE IN THE MANAGEMENT OF CHRONIC PSYCHOSIS.
065476 05-08
FLUPHENAZINE HYDROCHLORIDE AND ENANTHATE IN THE MANAGEMENT OF CHRONIC PSYCHOSIS.
065478 05-08
A COMPARISON OF HALOPERIDOL AND THIORIDAZINE HCL IN CHRONIC TREATMENT RESISTANT SCHIZOPHRENICS.
066398 05-08
A COMPARISON OF HALOPERIDOL AND THIORIDAZINE HCL IN CHRONIC TREATMENT RESISTANT SCHIZOPHRENICS.
066817 05-08
EFFECT OF CHRONIC ADMINISTRATION OF P-CHLOROPHENYLALANINE ON SEXUAL RECEPTIVITY OF THE FEMALE RAT.
066825 05-04
CLINICAL EVALUATION OF MAZINDOL IN CHRONIC SCHIZOPHRENICS.
066852 05-08
USE OF DRUGS IN CONTROL OF CHRONIC PAIN.
066921 05-11
SEVERE DELIRIUM AFTER ABRUPT WITHDRAWAL OF THIOTHIXENE IN A CHRONIC SCHIZOPHRENIC INPATIENT: A CASE STUDY.
067221 06-08
MOLIDONE IN CHRONIC SCHIZOPHRENIA.
067719 06-08
DOUBLE-BLIND COMPARATIVE STUDY OF THE EFFECTS OF THIOTHIXENE AND THIORIDAZINE IN TWENTY CHRONIC SCHIZOPHRENIC PATIENTS.
070880 07-08
BEHAVIOR AND HISTOPATHOLOGICAL FINDINGS DURING CHRONIC METHEDRINE INTOXICATION.
071993 07-05
A PILOT STUDY OF AHR-1900 IN CHRONIC SCHIZOPHRENIC PATIENTS.
072145 07-08
DEVELOPMENT OF FIGHTING BEHAVIOR IN STARVED RATS BY CHRONIC ADMINISTRATION OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL AND CANNABIS EXTRACTS: LACK OF ACTION OF OTHER PSYCHOTROPIC DRUGS.
072531 08-04
CLINICAL RESEARCH INTO CHRONIC INCURABLE SCHIZOPHRENIA.
072891 08-06
OXYPERTINE IN THE TREATMENT OF CHRONIC SCHIZOPHRENIA.
072896 08-08
PREDICTION OF CHANGES IN SEVERITY OF THE SCHIZOPHRENIC SYNDROME WITH DISCONTINUATION AND ADMINISTRATION OF PHENOTHIAZINES IN CHRONIC SCHIZOPHRENIC PATIENTS: LANGUAGE AS A PREDICTOR AND MEASURE OF CHANGE IN SCHIZOPHRENIA.
075321 08-08
THE EFFECT OF SOCIAL FEEDBACK ON CHRONIC SCHIZOPHRENIC PATIENTS.
075362 08-14
THE INFLUENCE OF SINGLE AND CHRONIC MORPHINE ADMINISTRATION ON SOME CENTRAL EFFECTS OF AMPHETAMINE AND APOMORPHINE.
075840 08-05
ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL EFFECTS OF HARMALINE IN INTACT CATS AND IN CATS WITH CHRONIC MESENCEPHALIC TRANSECTION.
075847 09-04
A CONTROLLED COMPARATIVE STUDY OF FLUPHENAZINE AND FLUPHENAZINE ENANTHATE IN ACUTE AND CHRONIC PSYCHOTIC PATIENTS.
075881 09-08
A CLINICAL EXAMINATION OF CHRONIC LSD USE IN THE COMMUNITY.
076254 09-12
A COMPARATIVE DOUBLE-BLIND TRIAL OR PIMOZIDE AND FLUPHENAZINE IN CHRONIC SCHIZOPHRENIA.
078932 09-08
THERAPEUTIC MEDICATION IN CHRONIC DELIRIUM: COMBINATION OF PROCHLORPERAZINE (TEMENTIL) AND LEVOMEPROMAZINE (NOZINAN).
079288 09-11
THE TREATMENT OF CHRONIC PAIN SYNDROMES: ANALGETIC EFFECT OF A NEUROLEPTIC SUBSTANCE.
079963 09-11
CLINICAL OBSERVATIONS ON THE THERAPEUTIC ACTIVITY OF FLUPENTHIXOL IN THE TREATMENT OF CHRONIC SCHIZOPHRENIA.
080143 09-08
EFFECTS OF CHRONIC MORPHINE ADMINISTRATION ON THE CATECHOLAMINE DEPLETION INDUCED BY RESERPINE.
081065 09-03
PIPERACETAZINE (QUIDE): A CONTROLLED EVALUATION OF THE ELIXIR IN CHRONIC SCHIZOPHRENIC PATIENTS.
082053 10-08
CLINICAL TRIAL OF THIOTHIXENE (NAVANE) IN ELDERLY CHRONIC SCHIZOPHRENICS.
082054 10-08
CLINICAL TRIAL OF CLOMACRAN PHOSPHATE (SKF-14336) IN CHRONIC PSYCHOTIC MALE PATIENTS.
082056 10-07

ENCEPHALOPATHY AS A SEQUEL OF CHRONIC INTOXICATION WITH HALOGEN DERIVATIVES OF AROMATIC HYDROCARBONS.
085102 10-15

CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIC WOMEN: ITS EFFECT ON THYROID AND LIVER FUNCTION IN RELATION TO SERUM CHOLESTEROL CONCENTRATION.
088221 10-13

A COMBINED TREATMENT OF CHRONIC SCHIZOPHRENICS WITH OSPOLOT (SULTHIAME) AND STELAZINE (TRIFLUOPERAZINE).
089101 10-08

PROPHYLACTIC LITHIUM THERAPY FOR CHRONIC DEPRESSIVE PSYCHOSIS AND SCHIZO-AFFECTIVE DISORDERS.
089105 10-09

INDICATIONS FOR HIGH DOSE CHLORPROMAZINE THERAPY IN CHRONIC SCHIZOPHRENIA.
089433 10-08

ELECTROCARDIOGRAPHIC DATA IN CHRONIC ALCOHOLISM BEFORE, DURING AND AFTER TREATMENT WITH TETRAETHYLTHIURAM DISULPHIDE.
092481 11-14

INFLUENCE OF CHRONIC ADMINISTRATION OF NICOTINE ON THE TURNOVER AND METABOLISM OF NORADRENALINE IN THE RAT BRAIN.
097958 11-03

EFFECTS OF PROPRANOLOL (INDERAL) ON PSYCHIATRIC SYMPTOMS IN CHRONIC ALCOHOLISM.
099957 11-11

EVALUATION OF AN AMITRIPTYLINE PERPHENAZINE COMBINATION IN CHRONIC SCHIZOPHRENIA.
101681 12-08

A LONG-ACTING NEUROLEPTIC IN THE TREATMENT OF CHRONIC ALCOHOLISM IN NEUROTIC AND PSYCHOTIC PATIENTS.
109255 12-11

INFLUENCES OF POLYPHARMACY ON HALLUCINATORY BEHAVIOR IN A SAMPLE OF FEMALE CHRONIC SCHIZOPHRENIC PATIENTS.
115037 12-08

A DOUBLE-BLIND, CROSSOVER COMPARISON OF APY-606 WITH CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIA.
118583 12-08

THIOTHIXENE IN HOSPITALIZED CHRONIC SCHIZOPHRENIC PATIENTS.
134906 12-08

THE OCCUPATIONAL THERAPY IN A MENTAL HOSPITAL FOR CHRONIC SCHIZOPHRENICS.
139090 12-08

**CHRONICALLY**

CLINICAL STUDY ON OXYPERTINE IN CHRONICALLY PSYCHOTIC PATIENTS.
067597 06-09

CI-601, A BUTYROPHENONE DERIVATIVE, IN THE TREATMENT OF CHRONICALLY WITHDRAWN SCHIZOPHRENIC PATIENTS.
072142 07-08

USE OF ANTIPSYCHOTIC AND ANTIDEPRESSANT DRUGS BY CHRONICALLY ILL PATIENTS.
076351 09-17

EFFECT OF WITHDRAWAL OF ANTIPARKINSONIAN MEDICATION ON CHRONICALLY HOSPITALIZED PSYCHIATRIC PATIENTS.
086445 10-15

**CHRONOTROPIC**

THE EFFECTS OF ACIDOSIS ON CHRONOTROPIC RESPONSES, NOREPINEPHRINE STORAGE AND RELEASE IN ISOLATED GUINEA-PIG ATRIA.
040753 01-03

**CI-601**

CI-601, A BUTYROPHENONE DERIVATIVE, IN THE TREATMENT OF CHRONICALLY WITHDRAWN SCHIZOPHRENIC PATIENTS.
072142 07-08

**CIGARETTE**

SOME EFFECTS OF EXPERIMENTALLY PRODUCED CIGARETTE SMOKE ON THE GROWTH, VITAMIN-C METABOLISM AND ORGAN WEIGHTS OF GUINEA-PIGS.
063061 03-03

INHIBITION OF CIGARETTE SMOKING BY ORALLY ADMINISTERED NICOTINE.
066277 05-13

THE EFFECT OF NICOTINE AND TOTAL ALKALOIDS EXTRACTED FROM CIGARETTE SMOKE IN AVOIDANCE BEHAVIOR IN RATS UNDER EXTINCTION PROCEDURE.
069079 06-04

**CINDERELLA**

THE CINDERELLA OF PSYCHOPHARMACOLOGY (A COMMENTARY ON CANNABIS).
134932 12-13

**CINNARIZIN**

CONTROLLED INVESTIGATION WITH CINNARIZIN IN THE TREATMENT OF DEMENTIA CONDITIONS IN OLD AGE.
089108 10-11

**CIRCADIAN**

STARTLE RESPONSE CIRCADIAN RHYTHM IN RATS: LACK OF CORRELATION WITH MOTOR ACTIVITY.
058349 02-04

CIRCADIAN RHYTHM FOR EXPERIMENTALLY INDUCED AGGRESSIVE BEHAVIOR IN MICE.
058383 02-03

CERTAIN CIRCADIAN RHYTHMS IN MANIC-DEPRESSIVES AND THEIR RESPONSE TO LITHIUM.
106763 12-09

**CIRCUITS**

FUNCTIONAL RELATIONSHIPS OF BRAIN CIRCUITS IN CONTROL OF DRINKING BEHAVIOR.
058961 03-04

RECIPROCAL HUNGER REGULATING CIRCUITS INVOLVING ALPHA-ADRENERGIC AND BETA-ADRENERGIC RECEPTORS LOCATED, RESPECTIVELY, IN THE VENTROMEDIAL AND LATERAL HYPOTHALAMUS.
092166 11-03

**CIRCULATING**

DAILY RHYTHM IN THE ACCUMULATION OF BRAIN CATECHOLAMINES SYNTHESIZED FROM CIRCULATING H3-TYROSINE.
040246 01-03

**CIRCULATION**

PHARMACOLOGICAL STUDIES ON THE ACTION OF SYNTHETIC ALPHA-METHYL-PYRRYL-KETONE ON THE CNS AND ON CIRCULATION.
055740 02-03

CLINICAL INVESTIGATIONS OF THE ACTION OF A PHOSPHOLIPID COMPLEX FROM CEREBRAL CORTEX ON CEREBRAL CIRCULATION DISTURBANCES.
058282 02-11

IMPROVED CEREBRAL CIRCULATION AND PERFORMANCE IN A PSYCHOLOGICAL EXPERIMENT.
059001 03-11

EFFECT OF ANTIDEPRESSANTS ON CEREBRAL CIRCULATION AND OXYGEN UPTAKE.
110633 12-03

**CIRCUMSTANCES**

LITHIUM IN HAZARDOUS CIRCUMSTANCES WITH ONE CASE OF LITHIUM TOXICITY.
067138 06-15

**CL-1848C**

EVALUATION OF CL-1848C: A NEW DISSOCIATIVE ANESTHETIC IN NORMAL HUMAN VOLUNTEERS.
097971 11-07

**CLAIMS**

MEPROBAMATE LOSES SOME LABEL CLAIMS.
070830 07-17

**CLASS**

A NEW CLASS OF 1,3 BENZOXAZINONES AS POTENTIAL CENTRAL NERVOUS SYSTEM AGENTS.
062322 03-02

PHARMACOLOGIC ACTIVITY OF A NEW CLASS OF AGENTS WHICH SELECTIVELY INHIBIT AGGRESSIVE BEHAVIOR IN RATS.
082398 10-04

CYCLIC AMP MEDIATION OF NOREPINEPHRINE INHIBITION IN RAT CEREBELLAR CORTEX: A UNIQUE CLASS OF SYNAPTIC RESPONSES (UNPUBLISHED PAPER).
093132 11-03

**CLASSES**

LABORATORY EXPERIMENTS SUITABLE FOR PRACTICAL CLASSES IN PSYCHOPHARMACOLOGY.
067599 06-06

**CLASSICAL**

THE EFFECT OF PUROMYCIN ON CLASSICAL CONDITIONING IN THE GOLDFISH.
075375 08-04

CLASSICAL HYSTERICAL SEIZURES FACILITATED BY ANTICONVULSANT TOXICITY.
081135 09-15

**CLASSICALLY**

EXPERIMENTAL VARIABLES IN THE EFFECTS OF POSTSESSION INJECTIONS OF STRYCHNINE SULPHATE ON A CLASSICALLY CONDITIONED RESPONSE.
071792 07-04

**CLASSIFICATION**

CLASSIFICATION, NOSOLOGY, AND RATING SCALES OF PSYCHOTROPIC DRUGS.
064090 04-01

SOCIAL MEDICAL CLASSIFICATION OF TOXICOMANIAS.
079257 09-15

CLASSIFICATION OF PSYCHOTROPIC DRUGS.
086202 10-17

**CLASSROOM**

METHYLPHENIDATE AND THIORIDAZINE: LEARNING, REACTION TIME, ACTIVITY, AND CLASSROOM BEHAVIOR IN DISTURBED CHILDREN.
081631 10-14

**CLEAR**
REMARKS ON THE USE OF CLOMIPRAMINE (ANAFRANIL) IN CERTAIN ACUTE DELIRIANT PSYCHOSES (WITHOUT A CLEAR DEPRESSIVE ELEMENT).
088438 10-14

**CLEAVAGE**
THE SYNTHESIS AND BIOLOGICAL ACTIVITY OF (-)-DELTA9(11)-TRANS TETRAHYDROCANNABINOL; A NEW PROCEDURE FOR THE CLEAVAGE OF PHENYL METHYL ETHERS (UNPUBLISHED PAPER).
092888 11-01

**CLIMACTERIC**
USE OF A NEW ANTIDEPRESSANT IN THE FEMALE CLIMACTERIC.
063598 04-09

**CLINIC**
DIMETHACRINE – A NEW TRICYCLIC ANTIDEPRESSANT: OPEN INVESTIGATIONS IN A CLINIC AND POLYCLINIC.
058281 02-07

DEPOT FLUPHENAZINE IN THE TREATMENT OF PSYCHOSIS IN A COMMUNITY MENTAL HEALTH CLINIC.
065475 05-08

A SURVEY OF EXTRAPYRAMIDAL MANIFESTATIONS IN PATIENTS ATTENDING AN AFTER CARE CLINIC OF A PSYCHIATRIC HOSPITAL.
070412 07-15

THE CHILDRENS PSYCHOPHARMACOLOGY CLINIC: ITS ROLE WITHIN A TOTAL PROGRAM FOR CHILDRENS PSYCHIATRIC SERVICES.
080097 09-17

METHODS OF TREATING DELIRIUM-TREMENS AS BASED ON MATERIALS OF THE UNIVERSITY MEDICAL SCHOOLS PSYCHIATRIC CLINIC IN WROCLAW BETWEEN 1958 AND 1968.
087143 10-11

DRUG, DOCTOR WARMTH, AND CLINIC SETTING IN THE SYMPTOMATIC RESPONSE TO MINOR TRANQUILIZERS.
087386 10-10

**CLINICAL**
CLINICAL ANTIDEPRESSANT ACTIVITY OF CYCLAZOCINE – A NARCOTIC ANTAGONIST.
041568 01-09

CLINICAL AND PSYCHOLOGICAL TESTING OF A GERIATRIC DRUG.
042693 01-11

LITHIUM CARBONATE FOR AFFECTIVE DISORDERS. I. CLINICAL PHARMACOLOGY AND TOXICOLOGY.
047831 01-09

2,5 DIMETHOXY-4-METHYLAMPHETAMINE: CLINICAL EVALUATION OF A NEW HALLUCINOGENIC DRUG.
052457 02-12

DIPOTASSIUM CHLORAZEPATE: CLINICAL REPORTS ON A NEW ANTIANXIETY AGENT.
055738 02-09

CLINICAL INVESTIGATIONS OF THE ACTION OF A PHOSPHOLIPID COMPLEX FROM CEREBRAL CORTEX ON CEREBRAL CIRCULATION DISTURBANCES.
058282 02-11

A CLINICAL EVALUATION OF CLOPENTHIXOL.
058373 02-07

THE CLINICAL EVALUATION OF FOUR PROPOSED ANTIDEPRESSANTS. RELATIONSHIP TO THEIR ANIMAL PHARMACOLOGY.
059040 03-07

INDOKLON: CONVULSIVE THERAPY; EXPERIMENTAL CLINICAL STUDIES.
059692 03-07

PHARMACOLOGICAL AND CLINICAL PROBLEMS OF LITHIUM PROPHYLAXIS.
060264 03-17

A CLINICAL EVALUATION OF MESORIDAZINE IN MENTALLY RETARDED PATIENTS.
060268 03-07

FACTORS ASSOCIATED WITH POOR RESPONSE TO LITHIUM CARBONATE: A CLINICAL STUDY.
062352 03-09

PRELIMINARY CLINICAL OBSERVATIONS CONCERNING THE TREATMENT WITH METRONIDAZOLE IN CHRONIC ALCOHOLISM.
062866 03-11

ELECTROENCEPHALOGRAPHIC VARIATIONS INDUCED BY PSYCHOTROPIC DRUGS: CLINICAL ELECTROPHYSIOLOGICAL CORRELATIONS FOR A GUIDED THERAPY.
063200 03-13

CLINICAL AND BIOCHEMICAL ASPECTS OF DEPRESSION.
063600 04-13

A CONTROLLED COMPARISON OF THE TREATMENT OF SCHIZOPHRENIC PATIENTS WHEN TREATED ACCORDING TO THE NEUROLEPTIC THRESHOLD OR BY CLINICAL JUDGMENT.
063776 04-08

METABOLIC STUDIES AND CLINICAL OBSERVATIONS DURING L-DOPA TREATMENT OF PARKINSONS DISEASE.
063822 04-13

CLINICAL EVALUATION OF HALOPERIDOL IN GERIATRIC PATIENTS.
064074 04-14

CLINICAL EVALUATION OF DOXEPIN AND AMITRIPTYLINE IN DEPRESSED PATIENTS.
064637 05-09

A CLINICAL EVALUATION OF FLUPHENAZINE ENANTHATE.
065477 05-08

IS A DOUBLE-BLIND CLINICAL TRIAL REALLY DOUBLE-BLIND: A REPORT OF DOCTORS MEDICATION GUESSES.
065488 05-10

CLINICAL EVALUATION OF MAZINDOL IN CHRONIC SCHIZOPHRENICS.
066852 05-08

CLINICAL STUDY ON OXYPERTINE IN CHRONICALLY PSYCHOTIC PATIENTS.
067597 06-09

INDOLEAMINES AND THE CENTRAL NERVOUS SYSTEM: A SOUNDING OF THEIR CLINICAL SIGNIFICANCE.
070881 07-13

NEW FINDINGS IN THE CLINICAL PHARMACOLOGY OF SLEEP.
070925 07-17

CLINICAL EXPERIENCE WITH OCTOCLOTHEPINE IN MANIC SYNDROMES.
070927 07-09

CLINICAL EXPERIENCE WITH OCTOCLOTHEPINE IN SCHIZOPHRENIC PSYCHOSES.
070929 07-08

CLINICAL EXPERIENCE WITH OCTOCLOTHEPINE.
070930 07-08

CLINICAL EXPERIENCE WITH FLUPHENAZINE DECANOATE.
070931 07-08

CLINICAL EXPERIENCE WITH FLUPHENAZINE DEPOT.
070932 07-08

CLINICAL USE OF THIOPROPAZATE (DARTALAN) IN PATIENTS WITH PSYCHOSIS.
070937 07-09

CLINICAL PILOT STUDY OF DIBENZEPINE TREATMENT OF DEPRESSION.
070939 07-09

THE CLINICAL TESTING OF HYDROTHIADENE IN ENDOGENOUS DEPRESSIONS. INFLUENCE OF DRUGS ON PHOTOMYOCLONIC THRESHOLD.
070940 07-09

CLINICAL EXPERIENCES WITH CHLORIMIPRAMINE IN ENDOGENOUS DEPRESSION.
070942 07-09

CLINICAL EXPERIENCES WITH DESIPRAMINE IN ENDOGENOUS AND INVOLUTIONAL DEPRESSIONS.
070943 07-09

SOME CLINICAL AND LABORATORY STUDIES OF PSYCHOTROPIC DRUGS IN CHILDREN: AN OVERVIEW.
070975 07-17

CLINICAL EXPERIENCE WITH PIPERACETAZINE IN HOSPITALIZED MENTAL PATIENTS: A FOUR YEAR STUDY.
071292 07-07

CLINICAL STUDY OF A PSYCHOTROPIC DRUG: SULPIRIDE IN ATTEMPTED SUICIDE WITHOUT PSYCHOSIS.
072155 07-14

CLINICAL TRIAL OF A NEW MOLECULE SULPIRIDE IN PSYCHIATRIC PRACTICE.
072156 07-15

SULPIRIDE IN PSYCHIATRIC TREATMENT: CLINICAL AND PSYCHOMETRIC STUDY IN 58 PATIENTS.
072158 07-11

CLINICAL EXPERIENCE OF SULPIRIDE IN PSYCHIATRY.
072159 07-07

CLINICAL, CLINICO-CHEMICAL AND BRAIN BIOELECTRIC TESTS OF A COMBINATION OF HEXOBENDINE, ETHAMIVAN AND HYDROXYETHYLTHEOPHYLLIN.
072585 08-14

CLINICAL RESEARCH INTO CHRONIC INCURABLE SCHIZOPHRENIA.
072891 08-08

CLINICAL STUDY OF EFFICACY OF AMIZEPINE.
072895 08-11

CLINICAL INVESTIGATION WITH THE BUTYROPHENONE DERIVATIVE BURONIL.
073706 08-09

HOW CAN CLINICAL TRIALS BE IMPROVED?
075113 08-11

CRISES AND LIFE CHANGES PRECEDING THE ONSET OR RELAPSE OF ACUTE SCHIZOPHRENIA: CLINICAL ASPECTS.
075304 08-08

THE VALUE OF WORSENING RATES IN PSYCHIATRIC CLINICAL TRIALS.
075388 08-10

THE PLACE OF THIOTHIXENE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS. A SYSTEMATIC CLINICAL STUDY.
075422 08-08

CLINICAL EXPERIENCE WITH LITHIUM CARBONATE.
075424 08-08

ENHANCEMENT OF IMIPRAMINE BY THYROID STIMULATING HORMONE; CLINICAL AND THEORETICAL IMPLICATIONS.
075871 09-10

A CLINICAL EVALUATION OF PROLIXIN ENANTHATE.
076003 09-08

A CLINICAL EXAMINATION OF CHRONIC LSD USE IN THE COMMUNITY.
076254 09-12

ON BINSWANGERS SUBCORTICAL ARTERIOSCLEROTIC ENCEPHALOPATHY AND THE POSSIBILITY OF ITS CLINICAL RECOGNITION.
078733 09-13

NEW PSYCHOPHARMACEUTICALS FOR CLINICAL PRACTICE.
079146 09-07

CLINICAL CONSIDERATIONS ABOUT THE TREATMENT OF VARIOUS ACUTE PSYCHOTIC STATES WITH THIOTHIXENE.
079746 09-11

CLINICAL TESTS OF A NEW, PROLONGED ACTION NEUROLEPTIC AGENT, PIMOZIDE.
079863 09-07

CLINICAL TESTS OF A NEW ANXIOLYTIC, MEDAZEPAM (NOBRIUM).
079864 09-11

CLINICAL TREATMENT OF DEPRESSIVE SYNDROMES WITH NOXIPTILIN.
079967 09-10

CLINICAL STUDY ON A NEW PIPERIDYL-PHENOTHIAZINE DERIVATIVE (A-124).
079969 09-07

CLINICAL AND QUANTITATIVE ELECTROENCEPHALOGRAPHICAL EFFECTS OF MK-940.
080031 09-07

CLINICAL AND AMBULANT TESTING WITH FLUPHENAZINE DECANOATE LYOGEN DEPOT IN THE LONG-TERM TREATMENT OF PSYCHIATRIC DISEASE.
080040 09-16

CLINICAL EVALUATION IN 112 PSYCHIATRIC PATIENTS OF A BUTYROPHENONE NEUROLEPTIC, DEHYDROBENZPERIDOL (R-4749).
080142 09-11

CLINICAL OBSERVATIONS ON THE THERAPEUTIC ACTIVITY OF FLUPENTHIXOL IN THE TREATMENT OF CHRONIC SCHIZOPHRENIA.
080143 09-08

CURRENT PROBLEMS OF CLINICAL PSYCHOPHARMACOLOGY.
080394 09-17

CLINICAL CONSIDERATIONS ON THE TREATMENT OF DEPRESSION WITH CHLORIMIPRAMINE.
081121 09-10

CLINICAL RESULTS OF THE TESTING FOR ANALGESIC EFFECT OF DEXTROPROPOXYPHENE IN COMBINATION WITH A PSYCHOTROPIC PREPARATION (TROPAX).
081147 09-17

CLINICAL TRIAL OF THIOTHIXENE (NAVANE) IN ELDERLY CHRONIC SCHIZOPHRENICS.
082054 10-08

CLINICAL TRIAL OF CLOMACRAN PHOSPHATE (SKF-14336) IN CHRONIC PSYCHOTIC MALE PATIENTS.
082056 10-07

EFFECT OF 1035-MD ON CERTAIN CONDITIONS OF MENTAL DEFICIENCY, ESPECIALLY THOSE OF VASCULAR ORIGIN; CLINICAL EEG AND PSYCHOPHARMACOLOGICAL STUDY.
084978 10-08

CURRENT TOXICOMANIAS: CLINICAL AFFECTS OF THE AGENTS USED AND COMMON SEMIOLOGICAL ASPECTS.
085129 10-15

COMPREHENSIVE CLINICAL STUDIES OF PSYCHOACTIVE DRUGS.
085289 10-11

CLINICAL AND BIOLOGICAL EFFECTS OF DECANOATE OF FLUPHENAZINE: BASED ON 35 OBSERVATIONS.
085347 10-08

PERICYAZINE IN CLINICAL PRACTICE.
086453 10-17

CLINICAL STUDY OF MEDAZEPAM (RO-5-4556).
086859 10-11

RELATIONSHIP BETWEEN TASTE THRESHOLD FOR DRUGS AND CLINICAL PROGRESS IN A MIXED GROUP OF PSYCHIATRIC PATIENTS.
087866 10-11

CLINICAL AND EEG APPEARANCES OF ACUTE DRUG INTOXICATION DUE TO CHLORALOSE.
088568 10-15

PSYCHIATRIC CLINICAL EXPERIENCE WITH AN ANTIANDROGEN PREPARATION.
088995 10-14

CLINICAL TOXICOLOGY AND EFFICACY OF PIMOZIDE.
089104 10-09

NEUROPSYCHIATRIC CLINICAL STUDY OF A BARBITURATE HYPNOTIC: 5-ETHYL 5(1- METHYL-1-BUTENYL) MALONYLUREA.
089173 10-07

CLINICAL EXPERIENCE WITH MESORIDAZINE IN THE THERAPY AND REHABILITATION OF TRAUMATIC FRONTAL BRAIN DAMAGE.
089784 11-14

THE RELATIONSHIPS BETWEEN CLINICAL AND VISUOMOTOR CHANGES IN A SCHIZOPHRENIC GROUP.
089798 11-08

CLINICAL TESTS OF PIRIDOXILATE IN PSYCHIATRIC THERAPY.
091500 11-07

CLINICAL TESTS OF THIOTHIXENE, NEUROLEPTIC DISINHIBITER.
091502 11-08

PHARMACOPSYCHOLOGICAL CONTRIBUTION TO THE CLINICAL USE OF A PSYCHOSEDATIVE.
092306 11-11

PSYCHIATRIC CHANGES IN PATIENTS TREATED WITH LEVODOPA: I. THE CLINICAL EXPERIMENT.
092917 11-10

CLINICAL EXPERIENCE WITH ANAFRANIL.
093091 11-10

CLINICAL CONTRIBUTION OF EXPERIMENTS WITH CHLORIMIPRAMINE (ANAFRANIL).
093443 11-09

QUANTITATIVE CLINICAL ANALYSIS OF THE EFFECT OF FENETYLLIN (CAPTAGON) ON HYPERKINETIC CHILDREN.
093540 11-11

CLINICAL AND PHARMACOLOGICAL CONTRIBUTION TO THE STUDY OF ALCOHOL IMIPRAMINE AND ALCOHOL THIOPROPERAZINE ASSOCIATIONS.
094305 11-11

CLINICAL EXPERIMENT WITH A NEW TRANQUILLIZER: TRIOXAZINE.
094423 11-11

CLINICAL PSYCHOPHARMACOLOGY: CONCEPTUAL MODELS OF CURRENT TRENDS.
097621 11-17

CLINICAL EXPERIENCE WITH TARASAN AND THIORIDAZINE IN MENTALLY RETARDED CHILDREN -- A COMPARATIVE DOUBLE-BLIND STUDY.
097655 11-14

CLINICAL EVALUATION OF A NEW PSYCHOTROPIC DRUG -- MOLINDONE.
097997 11-07

LITHIUM IN PSYCHIATRY: CLINICAL AND BIOCHEMICAL ASPECTS.
098018 11-09

CLINICAL EXPERIENCE WITH 10MG RESERPINE INJECTED I.M.IN DEPRESSIVE DISORDERS.
100019 11-09

CLINICAL PROBLEMS IN CONNECTION WITH THE APPLICATION OF LITHIUM.
100076 11-09

PSYCHOPHARMACOLOGY: THE ROLE OF CLINICAL RESEARCH.
100276 11-07

PSYCHOTROPIC DRUG SIDE-EFFECTS: CLINICAL AND THEORETICAL PERSPECTIVES.
100516 12-15

CLINICAL TESTING WITH FLUPHENAZINE DEPOT ADMINISTRATION TO SCHIZOPHRENIC PATIENTS.
101034 12-07

CLINICAL EXPERIENCE WITH METHYLPERONE (BURONIL), A NEW BUTYROPHENONE DERIVATIVE.
105730 12-07

CLINICAL TRIALS AND TREATMENT WITH PSYCHOPHARMACEUTICALS. A SECOND CRITICAL REVIEW: AN IMPRESSION.
105734 12-17

CLINICAL CONTROVERSIES AND THEORETICAL MODE OF ACTION OF LITHIUM CARBONATE.
106767 12-13

PROPHYLACTIC ACTION OF LITHIUM SALTS AND THYROID HORMONES ON SYMPTOMS OF MANIC-DEPRESSIVE AND AFFECTIVE PSYCHOSES: CLINICAL AND EXPERIMENTAL RESULTS.
106774 12-09

ON THE PROBLEM OF TREATMENT AND SOME CLINICAL CHARACTERISTICS OF SCHIZOPHRENIA WITH A GRADUAL PAROXYSMAL LIKE COURSE.
111032 12-08

CLINICAL EVALUATION OF THE USE OF G-32883 IN TRIGEMINAL NEURALGIA.
112130 12-11

CLINICAL RESULTS ON THE THERAPEUTIC ACTION OF LITHIUM CARBONATE IN DYSTHYMIC PSYCHOSES.
114880 12-09

CHEMICAL AND CLINICAL EVALUATION OF THE USE OF GABOB IN SCHIZOPHRENIC PATIENTS.
114885 12-08

THE CLINICAL EFFECT OF CLOMIPRAMINE (ANAFRANIL) AS THE ANTIDEPRESSANT.
118585 12-09

A NEUROPHARMACOLOGICALLY BASED CONCEPT OF HALLUCINATION AND ITS CLINICAL APPLICATION.
121080 12-17

APPLIED CLINICAL PSYCHOPHARMACOLOGY.
121795 12-15

FIRST ORIENTATIONS ON THE USE OF HIGH DOSES OF OXAZEPAM, BASED ON PERSONAL CLINICAL THERAPEUTIC EXPERIENCE.
124308 12-10

CLINICAL STUDY OF THE DRUG MELLERIL.
126631 12-11

THE CLINICAL ASPECTS AND DYNAMICS OF PARANOIAC PSYCHOPATHY WITH MALIGNANT DEVELOPMENT.
126632 12-09

A CLINICAL EXPERIENCE OF OXAZOLAM, A NEW MINOR TRANQUILIZER. 129367 12-07
A SUPPLEMENT TO CLINICAL EVALUATION OF THIOTHIXENE WITH SPECIAL REFERENCE TO THE TREATMENT OF AFFECTIVE PSYCHOSES. 129452 12-09
CLINICAL APPLICATION OF NEW TRANQUILIZER, CS-300, TO SCHIZOPHRENICS. 129879 12-07

**CLINICO-CHEMICAL**
CLINICAL, CLINICO-CHEMICAL AND BRAIN BIOELECTRIC TESTS OF A COMBINATION OF HEXOBENDINE, ETHAMIVAN AND HYDROXYETHYLTHEOPHYLLIN. 072585 08-14

**CLINICOELECTROENCEPHALOGRAPHIC**
CLINICOELECTROENCEPHALOGRAPHIC EVALUATION OF A NEW BENZODIAZEPINIC DERIVATIVE (RO-5-4023) ADMINISTERED ORALLY IN EPILEPTIC PATIENTS USING A DOUBLE-BLIND METHOD. 100959 12-07
CLINICOELECTROENCEPHALOGRAPHIC EVALUATION OF THE ANTIEPILEPTIC ACTION OF A NEW SERIES OF BENZODIAZEPINIC DERIVATIVES. 105486 12-07

**CLINICOPATHOLOGIC**
SUDDEN DEATH IN PHENOTHIAZINE THERAPY: A CLINICOPATHOLOGIC STUDY OF 12 CASES. 062737 03-15

**CLOMACRAN**
ADVERSE EFFECTS WITH CLOMACRAN. 067174 06-15
CLINICAL TRIAL OF CLOMACRAN PHOSPHATE (SKF-14336) IN CHRONIC PSYCHOTIC MALE PATIENTS. 082056 10-07

**CLOMIPRAMINE**
REMARKS ON THE USE OF CLOMIPRAMINE (ANAFRANIL) IN CERTAIN ACUTE DELIRIANT PSYCHOSES (WITHOUT A CLEAR DEPRESSIVE ELEMENT). 088438 10-14
THE CLINICAL EFFECT OF CLOMIPRAMINE (ANAFRANIL) AS THE ANTIDEPRESSANT. 118585 12-09

**CLONIDINE**
EVIDENCE FOR A CENTRAL NORADRENALINE RECEPTOR: STIMULATION BY CLONIDINE. 081151 09-03
THE CENTRAL SYMPATHETIC DEPRESSIVE EFFECT OF RESERPINE, ALPHA-METHYLDOPA AND CLONIDINE. 089046 10-03

**CLOPENTHIXOL**
A CLINICAL EVALUATION OF CLOPENTHIXOL. 058373 02-07
DOUBLE-BLIND STUDY OF CLOPENTHIXOL AND CHLORPROMAZINE IN ACUTE HOSPITALIZED SCHIZOPHRENICS. 098048 11-08

**CLOPTHIAPINE**
INDICATIONS FOR CLOPTHIAPINE IN PSYCHIATRY. 086923 10-09

**CLOSED**
RETENTION RATES OF SCHIZOPHRENIA: A COMPARISON OF SHOCK THERAPY AND PSYCHOPHARMACOLOGICAL ERAS AND OF CLOSED AND OPEN DOOR POLICIES. 069795 07-08

**CLOTHIAPIN**
CLOTHIAPIN IN THE TREATMENT OF CHRONIC SCHIZOPHRENIA. 058372 02-08

**CLOZAPINE**
THE DRUG 100-129-HF-1854 (CLOZAPINE) FOR PSYCHIATRIC TREATMENT. 089100 10-09

**CNS**
TOXICITY OF SOME BENZODIAZEPINE COMPOUNDS WITH CNS ACTIVITY. 046640 01-05
PHARMACOLOGICAL STUDIES ON THE ACTION OF SYNTHETIC ALPHA-METHYL-PYRRYL-KETONE ON THE CNS AND ON CIRCULATION. 055740 02-03
THE STAIRCASE MAZE AND THE SIMPLE STAIRCASE IN THE ANALYSIS OF THE PSYCHOPHARMACOLOGICAL ACTION OF CNS DEPRESSANTS. 068291 06-04
CHLORPROMAZINE AND CNS CHANGES IN MAN. 070968 07-14
EFFECTS OF 6-HYDROXYDOPAMINE ON CNS CATECHOLAMINES, SPONTANEOUS MOTOR ACTIVITY AND AMPHETAMINE INDUCED HYPERACTIVITY IN RATS. 074053 08-04
SUBSTITUTED BENZAMIDES WITH POTENTIAL CNS DEPRESSANT AND HYPOTENSIVE ACTIVITY. 089435 11-02
EFFECTS OF AN ACUTE STRESS OF FOREBRAIN 5-HYDROXYTRYPTAMINE (5-HT) METABOLISM IN CNS LESIONED AND DRUG PRETREATED RATS. 095671 11-04
COMPARATIVE STUDY OF CNS STIMULATORY ACTIVITY AND ANOREXIGENIC POTENCY OF PHENYLETHYLAMINE DERIVATIVES. (PH.D.DISSERTATION). 103710 12-04

**COAGULOPATHY**
AMPHETAMINE INTOXICATION WITH COAGULOPATHY, HYPERTHERMIA, AND REVERSIBLE RENAL FAILURE: A SYNDROME RESEMBLING HEATSTROKE. 064236 04-15

**COBALT**
SYNERGISM BETWEEN COBALT AND ETHANOL ON RAT GROWTH RATE. 088600 10-03

**COCAINE**
BLOCKADE OF THE CARDIAC ACTION OF PHENYLEPHRINE BY BRETYLIUM OR COCAINE. 040242 01-03
ENHANCEMENT BY COCAINE OF INTRACRANIAL SELF-STIMULATION IN THE RAT. 058397 02-13
A COMPARISON OF THE EFFECTS OF COCAINE AND SYNTHETIC CENTRAL STIMULANTS. 064272 04-17
EFFECTS OF DESMETHYLIMIPRAMINE AND COCAINE ON THE UPTAKE, RETENTION AND METABOLISM OF H3-TYRAMINE IN RAT BRAIN SLICES. 064419 04-03
ACUTE TOXICITY OF HEROIN, ALONE AND IN COMBINATION WITH COCAINE OR QUININE. 060167 06-05
EFFECTS OF COCAINE AND AMPHETAMINE ON THE METABOLISM OF TRYPTOPHAN AND 5-HYDROXYTRYPTAMINE IN MOUSE BRAIN IN VIVO. 095440 11-03

**COCKROACH**
BRAIN FUNCTION AND MACROMOLECULES: V. THE EFFECT OF CYCLOHEXIMIDE AND ACTINOMYCIN-D ON LEARNING IN THE HEADLESS COCKROACH. 078378 09-03

**CODEINE**
ACTION OF CODEINE, PETHIDINE AND METHADONE ON THE OPERANT BEHAVIOR OF THE RAT. 071787 07-04
CHANGES OF THE BODY TEMPERATURE OF CODEINE TOLERANT RATS BY THE ADMINISTRATION OF NALORPHINE. 130427 12-03

**COEXISTENCE**
COEXISTENCE OF DIABETES-MELLITUS AND MYXEDEMA IN MENTAL PATIENTS. 116482 12-08

**COFFEE**
THE OBJECTIVE EVALUATION OF PSYCHOPHARMACOLOGICAL DRUGS WITH CAFFEINE AND CAFFEINE-FREE COFFEE AS AN EXAMPLE. 098039 11-13

**COGNITIVE**
ALTERED FREE ASSOCIATIONS: SOME COGNITIVE EFFECTS OF DOET (2,5 DIMETHOXY-4-ETHYLAMPHETAMINE). 075859 09-12
BEHAVIORAL TOXICITY. PART 3: PERCEPTUAL COGNITIVE FUNCTIONS AND PART 4: EMOTIONAL (MOOD) STATES. 100523 12-15

**COINCIDENCES**
COMPLICATIONS OR COINCIDENCES DURING LITHIUM THERAPY: A REVIEW OF SEVERAL CASES. 106775 12-09

**COITAL**
ABBREVIATION OF BEHAVIORAL ESTRUS IN GUINEA-PIGS BY COITAL AND VAGINO-CERVICAL STIMULATION. 065332 05-03
COITAL BEHAVIOR IN DOGS: VI. LONG-TERM EFFECTS OF CASTRATION UPON MATING IN THE MALE. 080606 09-03

**COLD**
THE EFFECT OF HEAT, COLD, AND WORK ON THE CENTRAL ACTIONS OF SCOPOLAMINE. 041562 01-14

**COLLABORATIVE**
OCULAR CHANGES OCCURRING WITH PROLONGED HIGH DOSE CHLORPROMAZINE THERAPY. RESULTS FROM A COLLABORATIVE STUDY. 060861 03-15
HYDROXYZINE AND CHLORDIAZEPOXIDE IN ANXIOUS NEUROTIC OUTPATIENTS: A COLLABORATIVE CONTROLLED STUDY. 062321 03-10
PERPHENAZINE AMITRIPTYLINE IN NEUROTIC DEPRESSED OUTPATIENTS; A CONTROLLED COLLABORATIVE STUDY. 065247 05-10
BUTABARBITAL SODIUM AND CHLORDIAZEPOXIDE IN ANXIOUS NEUROTIC OUTPATIENTS: A COLLABORATIVE CONTROLLED STUDY. 066276 05-10

CONTROLLED TRIALS OF AN AMITRYPTYLINE FLUPHENAZINE COMBINATION IN DEPRESSIVE NEUROSES AND PSYCHOSES: A COLLABORATIVE STUDY.
067569 06-11

AMITRIPTYLINE AND TRIMIPRAMINE IN NEUROTIC DEPRESSED OUTPATIENTS: A COLLABORATIVE STUDY.
075868 09-10

**COLLAGEN**

COLLAGEN DISEASE-LIKE REACTIONS.
100528 12-15

**COLLICULUS**

RELEASE OF 5-HYDROXYTRYPTAMINE FROM SLICES OF SUPERIOR COLLICULUS BY OPTIC TRACT STIMULATION.
064369 04-03

**COLORIMETRIC**

COLORIMETRIC DETERMINATION OF AMPHETAMINE SALTS IN DOSAGE FORMS.
064159 04-01

**COLOUR**

STUDY ON THE EFFECTS OF TABLET COLOUR IN THE TREATMENT OF ANXIETY STATES.
066496 05-10

**COMBINATION**

THERAPY OF PARTIAL EPILEPSY WITH A COMBINATION CONTAINING SULTHIAME.
055393 02-11

BEHAVIOURAL EFFECTS IN RATS OF MORPHINE AND AMPHETAMINE AND OF A COMBINATION OF THE TWO DRUGS.
063019 03-04

A COMPARATIVE STUDY OF FLUPHENAZINE AMITRIPTYLINE COMBINATION AND AMITRIPTYLINE ALONE IN THE TREATMENT OF DEPRESSED PSYCHIATRIC PATIENTS.
064356 04-09

DRUG COMBINATION ALLOWS SMALLER DOSES OF L-DOPA.
066465 05-07

CONTROLLED TRIALS OF AN AMITRYPTYLINE FLUPHENAZINE COMBINATION IN DEPRESSIVE NEUROSES AND PSYCHOSES: A COLLABORATIVE STUDY.
067569 06-11

ACUTE TOXICITY OF HEROIN, ALONE AND IN COMBINATION WITH COCAINE OR QUININE.
068167 06-05

PSYCHOTROPICS IN ANXIETY AND DEPRESSION -- COMBINATION OR SINGLE AGENT.
068298 06-09

CLINICAL, CLINICO-CHEMICAL AND BRAIN BIOELECTRIC TESTS OF A COMBINATION OF HEXOBENDINE, ETHAMIVAN AND HYDROXYETHYLTHEOPHYLLIN.
072585 08-14

A CONTRIBUTION TO THE DEPRESSIVE DISORDER PHARMACOTHERAPY BY THE COMBINATION OF AMITRIPTYLINE AND PERPHENAZINE.
073707 08-10

THERAPEUTIC MEDICATION IN CHRONIC DELIRIUM: COMBINATION OF PROCHLORPERAZINE (TEMENTIL) AND LEVOMEPROMAZINE (NOZINAN).
079288 09-11

COMBINATION TEST ON THE ANALGESIC EFFECT OF DEXTROPROPOXYPHENE AND SOME PSYCHOTROPIC DRUGS IN THE MOUSE.
079961 09-03

CLINICAL RESULTS OF THE TESTING FOR ANALGESIC EFFECT OF DEXTROPROPOXYPHENE IN COMBINATION WITH A PSYCHOTROPIC PREPARATION (TROPAX).
081147 09-17

EFFECTS OF DRUGS ACTING ALONE AND IN COMBINATION ON THE MOTOR ACTIVITY OF INTACT MICE.
090139 11-03

EFFECT OF L-DOPA ALONE AND IN COMBINATION WITH AN EXTRACEREBRAL DECARBOXYLASE INHIBITOR ON BLOOD PRESSURE AND SOME CARDIOVASCULAR REFLEXES.
090371 11-13

THE COMBINATION OF PSYCHOTROPIC DRUGS IN THE TREATMENT OF SCHIZOPHRENIA.
098002 11-08

EVALUATION OF AN AMITRIPTYLINE PERPHENAZINE COMBINATION IN CHRONIC SCHIZOPHRENIA.
101681 12-08

EXPERIENCE WITH A COMBINATION OF AMITRIPTYLINE AND THIORIDAZINE FOR THE TREATMENT OF DEPRESSIONS.
105732 12-14

**COMBINATIONS**

DRUG COMBINATIONS AND INTERACTIONS.
065418 05-13

THE USE OF TWO COMBINATIONS OF DRUGS WITH MIXED ACTION, ANTIDEPRESSIVE AND TRANQUILIZING (AMITRYPTILINE - PERPHENAZINE) IN GENERAL AND IN PSYCHOSOMATIC MEDICINE.
089162 10-17

**COMBINED**

COMBINED ADRENAL AND THYROID DEFICIENCY (SCHMIDTS SYNDROME) PRESENTING AS AN ACUTE PSYCHOSIS.
056350 02-15

COMBINED USE OF DISULFIRAM AND METRONIDAZOLE IN TREATMENT OF ALCOHOLISM.
058589 02-15

A CONTROLLED TRIAL OF COMBINED MEDICATIONS ON BEHAVIORAL AND EXTRAPYRAMIDAL EFFECTS.
063774 04-14

COMBINED THERAPY IN ANXIETY DEPRESSIVE SYNDROMES: I. COMPARATIVE EFFECTS OF LIMBITROL (CHLORDIAZEPOXIDE AMITRIPTYLINE) AND PLACEBO.
064312 04-10

COMBINED EFFECT OF DRUG AND DRIVE ON THE CONSOLIDATION PROCESS.
065452 05-04

MONOAMINE OXIDASE INHIBITORS, COMBINED WITH THYMOLEPTICS: ARE THEY REALLY UNUSABLE FOR HUMAN BEINGS.
066805 05-03

ON THE COMBINED EFFECTS OF AMPHETAMINE AND FOOD DEPRIVATION: A REPLY TO GOLLUB AND MANN.
066821 05-04

COMBINED ADMINISTRATION OF THIORIDAZINE AND FLUOXYMESTERONE IN THE TREATMENT OF GERIATRIC PATIENTS.
069060 06-11

PREVENTION OF PAROXYSMAL TACHYCARDIA OF WOLFF-PARKINSON-WHITE SYNDROME WITH COMBINED PROPRANOLOL AND QUINIDINE THERAPY.
070288 07-10

COMBINED EFFECTS OF CHLORPROMAZINE AND ALTITUDE UPON PERFORMANCE IN THE RAT.
071467 07-04

EFFECT OF A DECARBOXYLASE INHIBITOR (RO-4-4602), COMBINED WITH L-DOPA, ON INHIBITED DEPRESSIVE PATIENTS: II. EXPERIMENTAL PSYCHOLOGICAL STUDIES.
079964 09-14

EFFECT OF A DECARBOXYLASE INHIBITOR (RO-4-4602), COMBINED WITH L-DOPA, ON RETARDED DEPRESSIVE PATIENTS.
079965 09-13

THE PROBLEM OF CEREBRAL EDEMA DURING COMBINED PSYCHOTROPIC DRUG THERAPY.
079992 09-15

A COMBINED TREATMENT OF CHRONIC SCHIZOPHRENICS WITH OSPOLOT (SULTHIAME) AND STELAZINE (TRIFLUOPERAZINE).
089101 10-08

EFFECT OF NICOTINIC ACID COMBINED WITH A TRANQUILLIZER (HYDROXYZINE) ON SERUM LIPID LEVELS AND URINARY CATECHOLAMINE EXCRETION IN GERIATRIC PATIENTS.
093689 11-11

**COMMENTARY**

DRUGS IN PSYCHOLOGY: A COMMENTARY ON TRAVIS THOMPSON AND CHARLES R. SCHUSTERS BEHAVIORAL PHARMACOLOGY.
075793 08-14

THE CINDERELLA OF PSYCHOPHARMACOLOGY (A COMMENTARY ON CANNABIS).
134932 12-13

**COMMUNALLY**

COMPARISON OF LIVER MICROSOME ENZYME SYSTEMS AND BARBITURATE SLEEP TIMES IN RATS CAGED INDIVIDUALLY OR COMMUNALLY.
045545 01-06

**COMMUNITY**

DEPOT FLUPHENAZINE IN THE TREATMENT OF PSYCHOSIS IN A COMMUNITY MENTAL HEALTH CLINIC.
065475 05-08

A CLINICAL EXAMINATION OF CHRONIC LSD USE IN THE COMMUNITY.
076254 09-12

PSYCHIATRIC COMMUNITY CARE SYSTEM: USE OF LONG-ACTING PHENOTHIAZINES.
080007 09-17

ANTIPSYCHOTIC DRUGS: AN ESSENTIAL TOOL OF COMMUNITY PSYCHIATRY.
080355 09-08

EXPERIENCES OF A THERAPEUTIC COMMUNITY.
124312 12-17

**COMPARED**

A NEW STIMULANT, PROLINTANE HYDROCHLORIDE, COMPARED WITH DEXTROAMPHETAMINE IN FATIGUED VOLUNTEERS.
040128 01-14

STATISTICAL METHOD OF ANALYSIS AND EVALUATION OF PSYCHOTHERAPEUTIC RESULTS: APPLICATION OF A LONG-ACTING NEUROLEPTIC, COMPARED WITH A STANDARD NEUROLEPTIC AND THE SAKEL INSULIN TREATMENT.
042676 01-07

DOPAMINE CONCENTRATIONS IN THE BRAINSTEM MESENCEPHALON OF ACTIVE RATS AS COMPARED WITH PASSIVE RATS.
060274 03-04

THE ASSESSMENT OF DRUG EFFECTS IN CHILDREN AS COMPARED TO ADULTS.
072825 08-14

**COMPARING**
DOUBLE-BLIND STUDY COMPARING THE INTRAMUSCULAR USAGE OF AN ACRIDAN DERIVATIVE, SKF-14336, TO CHLORPROMAZINE.
067513 06-11

**COMPARISON**
A COMPARISON OF THE EFFECTS OF SOME BENZODIAZEPINES AND OTHER DRUGS ON AGGRESSIVE AND EXPLORATORY BEHAVIOUR IN MICE AND RATS.
040581 01-04
A DOUBLE-BLIND COMPARISON OF CHLORPROMAZINE AND MESORIDAZINE (TPS-23).
045508 01-07
COMPARISON OF LIVER MICROSOME ENZYME SYSTEMS AND BARBITURATE SLEEP TIMES IN RATS CAGED INDIVIDUALLY OR COMMUNALLY.
045545 01-06
PHARMACOLOGICAL COMPARISON OF R(_), S(-) AND RACEMIC SECOBARBITAL IN MICE.
047325 01-03
COMPARISON OF PMH AND PEMOLINE ACTIVITY AFTER ELECTROCONVULSIVE SHOCK.
058992 03-04
SEQUENTIAL COMPARISON OF L-TRYPTOPHAN WITH ECT IN SEVERE DEPRESSION.
059053 03-09
A COMPARISON OF MARIJUANA USERS AND NON-USERS.
059290 03-14
A COMPARISON OF OXYPERTINE AND CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIA.
060659 03-08
A COMPARISON OF LITHIUM CARBONATE AND CHLORPROMAZINE IN MANIA.
062349 03-09
A COMPARISON OF SHORT-TERM TREATMENT EFFECTS OF INTRAVENOUS SODIUM AMYTAL METHEDRINE AND LSD IN THE ALCOHOLIC.
062934 03-11
A CONTROLLED COMPARISON OF THE TREATMENT OF SCHIZOPHRENIC PATIENTS WHEN TREATED ACCORDING TO THE NEUROLEPTIC THRESHOLD OR BY CLINICAL JUDGMENT.
063776 04-08
A COMPARISON OF THE EFFECTS OF COCAINE AND SYNTHETIC CENTRAL STIMULANTS.
064272 04-17
THE USE OF MOLINDONE IN THE TREATMENT OF ACUTE PSYCHOTIC STATES: COMPARISON OF TWO DOSAGE SCHEDULES.
064286 04-08
SIDE REACTIONS IN NEUROTICS: I. A COMPARISON OF TWO METHODS OF ASSESSMENT.
064287 04-15
A COMPARISON OF THE ANTINOCICEPTIVE ACTIONS OF CHOLINOMIMETIC AND MORPHINE-LIKE DRUGS.
064290 04-03
COMPARISON OF LITHIUM CARBONATE AND IMIPRAMINE (IN PREVENTION OF MANIC-DEPRESSIVE DISEASE).
064317 04-09
NEUROPHARMACOLOGICAL COMPARISON OF CYSTATHIONINE, CYSTEINE, HOMOSERINE AND ALPHA-KETOBUTYRIC ACID IN CATS.
064367 04-04
IMIPRAMINE PAMOATE IN HOSPITALIZED DEPRESSIVES: A DOUBLE-BLIND COMPARISON WITH PLACEBO.
064429 04-10
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: I. SEIZURE AND POST-SEIZURE ELECTROENCEPHALOGRAPHIC PATTERN.
065850 05-11
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY. II. ANTIDEPRESSIVE EFFECT.
065851 05-09
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: III. ANTEROGRADE AMNESIA.
065852 05-14
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: IV. RETROGRADE AMNESIA.
065853 05-14
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: V. CONFUSION AND OTHER SIDE-EFFECTS.
065854 05-15
A COMPARISON OF HALOPERIDOL AND THIORIDAZINE HCL IN CHRONIC TREATMENT RESISTANT SCHIZOPHRENICS.
066398 05-08
A COMPARISON OF HALOPERIDOL AND THIORIDAZINE HCL IN CHRONIC TREATMENT RESISTANT SCHIZOPHRENICS.
066817 05-08
A COMPARISON OF SLEEP PATTERNS IN NATURAL AND MANDRAX AND TUINAL INDUCED SLEEP.
067864 06-14
PSYCHOPHARMACOLOGIC EFFECTS OF SOME CHOLINESTERASE INHIBITORS IN COMPARISON WITH IMIPRAMINE.
069074 06-04
COMPARISON OF DRINKING ELICTED BY ESERINE OR DFP INJECTED INTO PREOPTIC AREA OF RAT BRAIN.
069637 07-04
RETENTION RATES OF SCHIZOPHRENIA: A COMPARISON OF SHOCK THERAPY AND PSYCHOPHARMACOLOGICAL ERAS AND OF CLOSED AND OPEN DOOR POLICIES.
069795 07-08
COMPARISON OF THE PAROXYSMAL DYSKINESIAS (NEURODYSLEPSY) INDUCED BY THE NEUROLEPTICS IN MAN AND THE EARLIEST BEHAVIOR PATTERNS OF THE NEW-BORN.
070267 07-13
CARBON MONOXIDE AND PHENOBARBITONE: A COMPARISON OF EFFECTS ON AUDITORY FLUTTER FUSION THRESHOLD AND CRITICAL FLICKER FUSION THRESHOLD.
070303 07-14
A COMPARISON OF TRIPERIDOL AND PERPHENAZINE IN SCHIZOPHRENIA. EFFECTS ON MYOCLONIC THRESHOLD.
070935 07-08
A COMPARISON OF THE EFFECTS OF METHYLPERIDOL AND PERPHENAZINE IN SCHIZOPHRENIC PSYCHOSIS.
070936 07-08
A COMPARISON OF DOXEPIN AND CHLORDIAZEPOXIDE IN THE THERAPY OF ANXIETY.
072141 07-10
COMPARISON OF METHODS OF RELAXATION USING PHYSIOLOGICAL MEASURES.
074135 08-14
A DOUBLE-BLIND COMPARISON OF LITHIUM AND CHLORPROMAZINE IN THE TREATMENT OF MANIC STATES.
075430 08-09
COMPARISON OF HALOPERIDOL AND FLUPHENAZINE IN DISTURBED CHILDREN.
076233 09-11
A COMPARISON OF PROPANIDID (EPONTOL) AND THIOPENTONE ANESTHESIA IN ECT.
076276 09-14
A COMPARISON OF SOME EFFECTS OF AMPHETAMINE IN RATS OF DIFFERENT AGES.
088587 10-03
COMPARISON OF THE EFFECTS OF EXOGENOUS ACTH ON APPROACH AND AVOIDANCE CONDITIONING: IMPLICATIONS FOR THE PHYSIOLOGY OF INCENTIVE MOTIVATION. (PH.D.DISSERTATION).
103354 12-04
A DOUBLE-BLIND, CROSSOVER COMPARISON OF APY-606 WITH CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIA.
118583 12-08
COMPARISON OF DITRAN INTOXICATION AND ACUTE ALCOHOL PSYCHOSES.
121083 12-14
A DOUBLE-BLIND COMPARISON OF S-804 (NEW BENZODIAZEPINE DRUG) WITH CHLORDIAZEPOXIDE AND DIAZEPAM IN THE TREATMENT OF NEUROSIS.
129097 12-10

**COMPARISONS**
STIMULANT SELF-ADMINISTRATION BY ANIMALS: SOME COMPARISONS WITH OPIATE SELF-ADMINISTRATION.
056237 02-04
COMPARISONS OF 1,3 BUTANEDIOL AND GLYCEROL ON SEVERAL BEHAVIORAL MEASURES.
066831 05-04

**COMPARTMENT**
DYNAMIC CHARACTERISTICS OF THE FUNCTIONAL COMPARTMENT OF DOPAMINE IN DOPAMINERGIC TERMINALS OF THE RAT STRIATUM.
120465 12-03

**COMPENSATORY**
COMPENSATORY SELECTION OF MAGNESIUM SULFATE BY MAGNESIUM DEPLETED LABORATORY RATS.
068287 06-04

**COMPLAINTS**
TRANQUILIZERS IN THE TREATMENT OF THE CARDIAC NEUROTIC PATIENT AND THE SUBSEQUENT ALTERATION OF COMPLAINTS.
128568 12-14

**COMPLEX**
CLINICAL INVESTIGATIONS OF THE ACTION OF A PHOSPHOLIPID COMPLEX FROM CEREBRAL CORTEX ON CEREBRAL CIRCULATION DISTURBANCES.
058282 02-11
EFFECTS OF STAPHYLOCOCCAL ENTEROTOXIN B ON COMPLEX OPERANT BEHAVIOR IN MONKEYS.
069333 06-04
TEST OF PEMOLINUM IN COMPLEX TREATMENT OF ALCOHOLISM.
086958 10-11

**COMPLEXES**
COMPLEXES OF ERGOT ALKALOIDS AND DERIVATIVES. II: INTERACTION OF DIHYDROERGOTOXINE WITH CERTAIN XANTHINES.
046137 01-03
COMPLEXES BETWEEN ACETYLCHOLINE AND CATECHOLAMINES AND THEIR TOLERANCE TO MENTAL ILLNESS.
072705 08-01

**COMPLICATION**
DISORDERS OF CONSCIOUSNESS AS A COMPLICATION IN NIALAMID TREATMENT.
085106 10-15

**COMPLICATIONS**
COMPLICATIONS OR COINCIDENCES DURING LITHIUM THERAPY: A REVIEW OF SEVERAL CASES.
106775 12-09

**COMPOSITION**
A NOTE ON THE COMPOSITION OF ILLICIT DRUGS.
057866 02-01
PROJECT SUMMARY: MUCOPOLYSACCHARIDE COMPOSITION OF RAT AND RABBIT BRAIN.
063526 03-01
HEPATIC COMPOSITION AND METABOLISM AFTER ETHANOL CONSUMPTION IN RATS FED LIQUID PURIFIED DIETS.
088599 10-03

**COMPREHENSIVE**
COMPREHENSIVE CLINICAL STUDIES OF PSYCHOACTIVE DRUGS.
085289 10-11

**COMPUTER**
THE CONCEPT OF THE VISUAL COMPUTER AND ITS EXPLORATION BY THE USE OF DRUGS.
069802 07-13
APPLICATION OF ON-LINE COMPUTER PROCEDURES TO EXPERIMENTAL CONTROL AND EVALUATION OF THE EFFECTS OF DRUGS ON OPERANT BEHAVIOR (SIDMAN SHOCK AVOIDANCE RESPONDING BY RATS).
095507 11-06

**CONCENTRATE**
COMPARATIVE EFFICACY OF THIOTHIXENE CAPSULES AND CONCENTRATE IN ACUTELY SCHIZOPHRENIC PATIENTS.
063599 04-08

**CONCENTRATION**
THE EFFECT OF CENTRALLY ACTING DRUGS ON THE CONCENTRATION OF BRAIN ADENOSINE 3PRIME,5PRIME- MONOPHOSPHATE.
043276 01-03
TOXICITY, NARCOTIC EFFECT, CONCENTRATION AT END OF ANESTHESIA, ELIMINATION FROM BLOOD AND BIOTRANSFORMATION OF HEXOBARBITAL IN RATS OF VARIOUS AGES FOLLOWING SLEEP INDUCTION WITH BARBITAL AND AFTER.
058987 03-05
CHANGES IN THE SERUM CONCENTRATION OF CHOLESTEROL, TRIGLYCERIDES AND PHOSPHOLIPIDS IN THE MOUSE AND RAT AFTER ADMINISTRATION OF EITHER CHLORCYCLIZINE OR PHENOBARBITAL.
064282 04-03
EFFECTS OF SODIUM DIPHENYLHYDANTOINATE AND PEMOLINE UPON CONCENTRATION: A COMPARATIVE STUDY.
070973 07-14
A NOVEL METHOD OF REDUCING THE CONCENTRATION OF BRAIN SEROTONIN: USE OF ALPHA-METHYLTRYPTOPHAN.
086350 10-13
CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIC WOMEN: ITS EFFECT ON THYROID AND LIVER FUNCTION IN RELATION TO SERUM CHOLESTEROL CONCENTRATION.
088221 10-13
RELATIONSHIP BETWEEN CENTRAL EFFECTS AND THE CONCENTRATION OF AMPHETAMINE IN LIVER AND BRAIN OF YOUNG AND OLD RATS.
089041 10-03
LITHIUM INDUCED CHANGES IN ELECTROLYTE BALANCE AND TISSUE ELECTROLYTE CONCENTRATION.
090419 11-03

**CONCENTRATIONS**
DOPA INDUCED EXCITEMENT IN THE CAT: ITS RELATIONSHIP TO BRAIN NOREPINEPHRINE CONCENTRATIONS.
058840 02-04
DOPAMINE CONCENTRATIONS IN THE BRAINSTEM MESENCEPHALON OF ACTIVE RATS AS COMPARED WITH PASSIVE RATS.
060274 03-04
BLOOD AND URINE CONCENTRATIONS OF SUBJECTS RECEIVING BARBITURATES, MEPROBAMATE, GLUTETHIMIDE, OR DIPHENYLHYDANTOIN.
063927 04-13
AMPHETAMINE TOXICITY AND ENDOGENOUS NORADRENALINE CONCENTRATIONS IN ISOLATED AND AGGREGATED MIC
074146 08-05
PLASMA CONCENTRATIONS OF THIORIDAZINE IN PATIENTS WITH DEPRESSION: A PRELIMINARY REPORT.
078213 09-13
CORRELATION OF SUBJECTIVE SIDE-EFFECTS WITH PLASMA CONCENTRATIONS OF NORTRIPTYLINE.
082104 10-15
EFFECT OF FRUCTOSE ON ALCOHOL CONCENTRATIONS IN THE BLOOD OF MAN.
092004 11-11
ESTIMATION OF LOW CHLORPROMAZINE CONCENTRATIONS BY SURFACING AND SINKING REACTION OF MINNOWS (GAMBUSIA-AFFINIS).
097964 11-06

**CONCEPT**
THE CONCEPT OF THE VISUAL COMPUTER AND ITS EXPLORATION BY THE USE OF DRUGS.
069802 07-13
A NEUROPHARMACOLOGICALLY BASED CONCEPT OF HALLUCINATION AND ITS CLINICAL APPLICATION.
121080 12-17

**CONCEPTIONS**
CURRENT CONCEPTIONS ON CERTAIN ASPECTS OF THE PHARMACOLOGY OF NEUROLEPTICS.
074685 08-02

**CONCEPTS**
CONCEPTS, DEFINITIONS, TERMINOLOGY.
079255 09-15

**CONCEPTUAL**
CLINICAL PSYCHOPHARMACOLOGY: CONCEPTUAL MODELS OF CURRENT TRENDS.
097621 11-17

**CONCOMITANTS**
THE MARIHUANA INDUCED SOCIAL HIGH: NEUROLOGICAL AND ELECTROENCEPHALOGRAPHIC CONCOMITANTS.
074782 08-12

**CONDEMNED**
LSD CONDEMNED AS TREATMENT AGENT.
067868 06-15

**CONDENSED**
PROJECT SUMMARY: CONDENSED POLYHETEROCYCLES CONTAINING N,S AND O.
105332 12-01

**CONDITION**
DELIRIUM-ACUTUM, A POTENTIALLY FATAL CONDITION IN THE PSYCHIATRIC HOSPITAL.
075980 09-15

**CONDITIONAL**
CONDITIONAL AUTONOMIC RESPONSES INDUCED IN DOGS BY ATROPINE AND MORPHINE.
066386 05-03
PSYCHOPHARMACOLOGY AND CONDITIONAL REFLEXES.
071705 07-13
A STUDY OF PHARMACODYNAMICS IN PERIODIC CONDITIONAL PROCESSES IN ALBINO RATS.
112003 12-04

**CONDITIONED**
EFFECT OF AMPHETAMINE, NICOTINE AND HEXAMETHONIUM ON PERFORMANCE OF A CONDITIONED RESPONSE DURING ACQUISITION AND RETENTION TRIALS.
046186 01-04
CONDITIONED NALORPHINE INDUCED ABSTINENCE CHANGES: PERSISTENCE IN POST MORPHINE DEPENDENT MONKEYS.
061632 03-04
EFFECT OF IMIPRAMINE AND CHLORIMIPRAMINE ON AN ACUTE INSTRUMENTAL TRACE CONDITIONED REFLEX IN RATS.
064415 04-04
CONDITIONED SUPPRESSION BASED ON POSITIVELY REINFORCING INTRACRANIAL STIMULATION.
064842 05-02
CHLORDIAZEPOXIDE AND CONDITIONED SUPPRESSION.
066829 05-04
SCOPOLAMINE EFFECTS ON CONDITIONED SUPPRESSION: INFLUENCE OF DIURNAL CYCLE AND TRANSITIONS BETWEEN NORMAL AND DRUGGED STATES.
071790 07-03
EXPERIMENTAL VARIABLES IN THE EFFECTS OF POSTSESSION INJECTIONS OF STRYCHNINE SULPHATE ON A CLASSICALLY CONDITIONED RESPONSE.
071792 07-04
RESERPINE AND CONDITIONED SUPPRESSION IN THE FISH TILAPIA H. MACROCEPHALA.
075996 09-04
1-(3,4-DIMETHOXYPHENYL)-2 PROPANOL EFFECT ON CONDITIONED AVOIDANCE RESPONSE IN THE RAT.
089440 11-04
ALCOHOL AS A DISCRIMINATIVE STIMULUS IN THE CONDITIONED EMOTIONAL RESPONSE. (PH.D.DISSERTATION).
103350 12-04
EFFECT OF CHLORPROMAZINE ON CONDITIONED REFLEXES AND ANTAGONISTIC ACTIVITY OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126054 12-04

**CONDITIONING**
RELAPSE TO OPIOID DEPENDENCE: THE ROLE OF CONDITIONING.
046208 01-03

EFFECTS OF CHLORDIAZEPOXIDE ON DISCRIMINATIVE FEAR CONDITIONING AND SHUTTLE AVOIDANCE PERFORMANCE IN THE RABBIT.
065451 05-04
A PARALLEL STUDY OF THE AMNESIC EFFECTS OF CYCLOHEXIMIDE AND ECS UNDER DIFFERENT STRENGTHS OF CONDITIONING.
066830 05-04
PROTECTION OF GSR CONDITIONING BY DEXTROAMPHETAMINE.
075315 08-14
THE EFFECT OF PUROMYCIN ON CLASSICAL CONDITIONING IN THE GOLDFISH.
075375 08-04
THE EFFECT OF EXTRAVERSION AND STIMULANT AND DEPRESSANT DRUGS ON VERBAL CONDITIONING.
078786 09-14
COMPARISON OF THE EFFECTS OF EXOGENOUS ACTH ON APPROACH AND AVOIDANCE CONDITIONING: IMPLICATIONS FOR THE PHYSIOLOGY OF INCENTIVE MOTIVATION. (PH.D.DISSERTATION).
103354 12-04

**CONDITIONS**
IS IT FEASIBLE TO TREAT CERTAIN POTENTIALLY DANGEROUS CONDITIONS BY PROLONGED CHEMOTHERAPY.
062406 03-08
RELATIONS BETWEEN BARBITURATE BRAIN LEVELS AND SLEEPING TIME IN VARIOUS EXPERIMENTAL CONDITIONS.
068600 06-03
SOME USES OF HALOPERIDOL IN THE TREATMENT OF PSYCHIATRIC CONDITIONS.
075879 09-08
EFFECT OF 1035-MD ON CERTAIN CONDITIONS OF MENTAL DEFICIENCY, ESPECIALLY THOSE OF VASCULAR ORIGIN; CLINICAL EEG AND PSYCHOPHARMACOLOGICAL STUDY.
084978 10-08
CONTROLLED INVESTIGATION WITH CINNARIZIN IN THE TREATMENT OF DEMENTIA CONDITIONS IN OLD AGE.
089108 10-11

**CONDUCT**
THE CONDUCT OF INITIAL DRUG STUDIES IN MAN.
051593 02-17

**CONDUCTION**
STUDIES OF THE TOXIC EFFECTS OF DRUGS ON ELECTRICAL CONDUCTION AND FUNCTION OF THE HEART. (PH.D.DISSERTATION).
103004 12-05

**CONFIGURATION**
CONFIGURATION FREQUENCY ANALYSIS OF SOME LSD EFFECTS.
079956 09-12

**CONFIGURATIONS**
ABSOLUTE CONFIGURATIONS OF METHOXYLATED AMPHETAMINES.
095700 11-01

**CONFINEMENT**
STABILITY OF PSYCHIC FUNCTIONS DURING PROLONGED CONFINEMENT TO BED.
086039 10-14

**CONFLICT**
EFFECTS OF SOME PSYCHOACTIVE DRUGS ON EXPERIMENTAL NEUROTIC (CONFLICT INDUCED) BEHAVIOR IN CATS.
046143 01-04
THE EFFECTS OF 5-HTP ON P-CHLOROPHENYLALANINE (P-CPA) ATTENUATION OF CONFLICT BEHAVIOR.
047326 01-04
EFFECTS OF CHLORDIAZEPOXIDE AND PENTOBARBITAL ON CONFLICT BEHAVIOR IN RATS.
064390 04-04
THE EFFECT OF PSYCHOSTIMULANTS ON PSYCHOMETRIC TEST PERFORMANCE WITH SPECIAL REFERENCE TO CONFLICT AVOIDANCE BEHAVIOR.
082055 10-04
THE EFFECT OF CHLORDIAZEPOXIDE ON THE BEHAVIOR OF RATS IN A CONFLICT SITUATION.
090424 11-04

**CONFORMATION**
THE PREFERRED CONFORMATION OF DOPAMINE FROM MOLECULAR ORBITAL THEORY.
090068 11-13

**CONFUSED**
A SEQUENTIAL TRIAL OF AMYLOBARBITONE SODIUM USED AS SEDATION FOR CONFUSED FEMALE PSYCHOGERIATRIC PATIENTS.
082732 10-11

**CONFUSION**
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY; V. CONFUSION AND OTHER SIDE-EFFECTS.
065854 05-15

**CONGENITAL**
CONGENITAL ABNORMALITIES AND ANTICONVULSANT DRUGS.
071949 07-15

**CONSCIOUS**
THE EFFECT OF BRADYKININ AND ELEDOISIN INJECTED INTO THE CEREBRAL VENTRICLES OF CONSCIOUS RATS.
047323 01-04
SIMILARITIES BETWEEN BEHAVIORAL AND PHARMACOLOGICAL ACTIONS OF YOHIMBINE AND 5-HYDROXYTRYPTOPHAN IN THE CONSCIOUS DOG.
064253 04-04
RECORDING EVOKED POTENTIALS IN THE CONSCIOUS RAT: THE MAINTENANCE OF A CONSTANT BEHAVIOURAL BASELINE.
067600 06-06
THE PHARMACOLOGICAL EFFECTS OF OUABAIN ADMINISTERED INTRACEREBRALLY TO CONSCIOUS MICE.
068165 06-03

**CONSCIOUSNESS**
BODY CONSCIOUSNESS IN STATES OF PHARMACOLOGICAL DEPRESSION AND AROUSAL.
072032 07-14
DISORDERS OF CONSCIOUSNESS AS A COMPLICATION IN NIALAMID TREATMENT.
085106 10-15
ON THE QUESTION OF PERSONALITY DEFECTS OF CONSCIOUSNESS IN INITIAL STAGES IN SCHIZOPHRENIA.
090264 11-08

**CONSOLIDATION**
COMBINED EFFECT OF DRUG AND DRIVE ON THE CONSOLIDATION PROCESS.
065452 05-04

**CONSTANCY**
APPARENT MOVEMENT AS A CONSTANCY PHENOMENON.
087679 10-14

**CONSTANT**
RECORDING EVOKED POTENTIALS IN THE CONSCIOUS RAT: THE MAINTENANCE OF A CONSTANT BEHAVIOURAL BASELINE.
067600 06-06

**CONSTANTS**
CENTRAL NEUROTROPIC ACTIVITY OF AMINOPROPYL AND AMINOPROPIONYLIC DERIVATIVES OF IMINOBENZYL AND DIPHENYLAMINE AND ITS RELATION TO IONIZATION CONSTANTS.
072580 08-03

**CONSTITUTION**
CHEMICAL CONSTITUTION AND DRUG ACTION OF N-SUBSTITUTED PHENOTHIAZINE IN VENTRICULAR ECTOPIC TACHYCARDIA.
063981 04-03

**CONSUMPTION**
EFFECTS OF REINFORCEMENT SHIFTS UPON SUBSEQUENT SUCROSE CONSUMPTION.
060871 03-03
HEPATIC COMPOSITION AND METABOLISM AFTER ETHANOL CONSUMPTION IN RATS FED LIQUID PURIFIED DIETS.
088599 10-03

**CONTRACEPTIVE**
THE EFFECT OF ORAL CONTRACEPTIVE STEROIDS ON BILE SECRETION AND BILIRUBIN TM IN RATS.
040125 01-05
PSYCHOENDOCRINE STUDY OF ORAL CONTRACEPTIVE AGENTS.
065118 05-13
EFFECT OF AN ORAL CONTRACEPTIVE ON SPONTANEOUS RUNNING ACTIVITY OF FEMALE RATS.
067716 06-04
PSYCHOPHYSIOLOGIC CHANGES ACCOMPANYING ORAL CONTRACEPTIVE USE.
075471 08-13
THE CONTRACEPTIVE PILL, SIDE-EFFECTS AND PERSONALITY: REPORT OF A CONTROLLED DOUBLE-BLIND TRIAL.
075472 08-15

**CONTRACEPTIVES**
CONTRACEPTIVES, BRAIN SEROTONIN, AND LIVER TRYPTOPHAN PYRROLASE.
067072 05-03
CHANGES IN PSYCHOLOGICAL SYMPTOMS IN WOMEN TAKING ORAL CONTRACEPTIVES.
075470 08-13
ORAL CONTRACEPTIVES: DEPRESSION AND FRIGIDITY.
075968 09-13

**CONTRACTILITY**
EFFECTS OF PSYCHOPHARMACOLOGIC AGENTS ON MYOCARDIAL CONTRACTILITY.
064420 04-15

**CONTRACTION**
14C-5-HYDROXYTRYPTAMINE AND 3H-D-AMPHETAMINE: UPTAKE AND CONTRACTION BY THE RAT STOMACH FUNDUS IN VITRO.
064050 04-03

**CONTROL**
LATERAL HYPOTHALAMIC CONTROL OF KILLING: EVIDENCE FOR A CHOLINOCEPTIVE MECHANISM.
058227 02-04
FUNCTIONAL RELATIONSHIPS OF BRAIN CIRCUITS IN CONTROL OF DRINKING BEHAVIOR.
058961 03-04
EXCRETION OF VANYLGLYCOL IN HUMAN URINE UNDER DIETARY CONTROL, AND DURING TREATMENT WITH ANTIBIOTICS, DISULFIRAM,

A MONOAMINE OXIDASE INHIBITOR, ALPHA-METHYLDOPA, AND RESERPINE.
060272 03-13

EFFECTS OF SCOPOLAMINE, ATROPINE, AND D-AMPHETAMINE ON INTERNAL AND EXTERNAL CONTROL OF RESPONDING ON NON-REINFORCED TRIALS.
064410 04-04

PLACEBO CONTROL EVALUATION OF DESIPRAMINE IN DEPRESSION.
065235 05-10

USE OF DRUGS IN CONTROL OF CHRONIC PAIN.
066921 05-11

FUNCTIONAL CHARACTERISTIC OF THE LINKS OF THE BRAIN CONTROL SYSTEM FOR MENTAL AND MOTOR FUNCTIONS IN MAN.
073770 08-13

DEVELOPMENT OF HORMONAL CONTROL OVER FOOD INTAKE AND BODY WEIGHT IN FEMALE RATS.
076239 09-03

DYNAMIC CONTROL OF ACID BASE EQUILIBRIUM DURING SOME FORMS OF SHOCK THERAPY.
079139 09-13

NEURONAL AND HORMONAL CONTROL OF TYROSINE HYDROXYLASE AND PHENYLETHANOLAMINE N-METHYLTRANSFERASE ACTIVITY.
080352 09-03

A THERAPEUTIC AGENT FOR ANTIDEPRESSANT AND TRANQUILIZING CONTROL IN THE POST-TRAUMATIC NEUROSES.
086237 10-07

MESORIDAZINE IN THE CONTROL OF BEHAVIOR DISORDERS IN CHILDREN.
086780 10-14

APPLICATION OF ON-LINE COMPUTER PROCEDURES TO EXPERIMENTAL CONTROL AND EVALUATION OF THE EFFECTS OF DRUGS ON OPERANT BEHAVIOR (SIDMAN SHOCK AVOIDANCE RESPONDING BY RATS).
095507 11-06

STATE DRUG ABUSE CONTROL.
105336 12-17

DRUGS AND MENTAL CONTROL.
108212 12-17

THE EFFECTIVENESS OF EXTERNAL AND DRUG PRODUCED INTERNAL STIMULI IN THE DISCRIMINATIVE CONTROL OF OPERANT BEHAVIOR. (PH.D.DISSERTATION).
110682 12-04

RESEARCH ON THE DEFECT STATE OF SCHIZOPHRENIC PATIENT UNDER CONTROL OF PSYCHODRUGS.
129273 12-08

**CONTROLLED**

CONTROLLED TRIAL OF AMANTADINE HYDROCHLORIDE IN PARKINSONS DISEASE.
043697 01-11

CONTROLLED STUDIES OF THERAPEUTIC EFFECT.
046315 01-11

CONTROLLED INTERVIEWS USING DRUGS.
047825 01-11

A CONTROLLED STUDY OF NORTRIPTYLINE AND IMIPRAMINE.
052483 02-09

HYDROXYZINE AND CHLORDIAZEPOXIDE IN ANXIOUS NEUROTIC OUTPATIENTS: A COLLABORATIVE CONTROLLED STUDY.
062321 03-10

A CONTROLLED TRIAL OF COMBINED MEDICATIONS ON BEHAVIORAL AND EXTRAPYRAMIDAL EFFECTS.
063774 04-14

HANDWRITING CHANGES AND RESPONSE TO DRUGS -- A CONTROLLED STUDY.
063775 04-14

A CONTROLLED COMPARISON OF THE TREATMENT OF SCHIZOPHRENIC PATIENTS WHEN TREATED ACCORDING TO THE NEUROLEPTIC THRESHOLD OR BY CLINICAL JUDGMENT.
063776 04-08

CONTROLLED STUDIES OF ANTIPARKINSONISM AGENTS IN THE TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL SYMPTOMS.
063777 04-14

A CONTROLLED STUDY OF LSD TREATMENT IN ALCOHOLISM AND NEUROSIS.
063873 04-12

MAINTENANCE THERAPY OF CHRONIC PSYCHOTIC PATIENTS WITH A WEEKLY ORAL DOSE OF R-16341. A CONTROLLED DOUBLE-BLIND STUDY.
064284 04-09

A CONTROLLED TRIAL OF BENZOCTAMINE (BA-30803) IN NEUROTIC ANXIETY.
064285 04-10

A CONTROLLED STUDY OF THE EFFECTS OF DIPHENYLHYDANTOIN ON ANXIETY, IRRITABILITY, AND ANGER IN NEUROTIC OUTPATIENTS.
064478 04-10

RATE-DEPENDENT EFFECTS OF DRUGS: MODIFICATION BY DISCRIMINATIVE STIMULI OF THE EFFECTS OF AMOBARBITAL ON SCHEDULE CONTROLLED BEHAVIOR.
064749 05-04

PERPHENAZINE AMITRIPTYLINE IN NEUROTIC DEPRESSED OUTPATIENTS, A CONTROLLED COLLABORATIVE STUDY.
065247 05-10

BUTABARBITAL SODIUM AND CHLORDIAZEPOXIDE IN ANXIOUS NEUROTIC OUTPATIENTS: A COLLABORATIVE CONTROLLED STUDY.
066276 05-10

CONTROLLED TRIALS OF AN AMITRYPTYLINE FLUPHENAZINE COMBINATION IN DEPRESSIVE NEUROSES AND PSYCHOSES. A COLLABORATIVE STUDY.
067569 06-11

A CONTROLLED STUDY OF THE EFFECT OF THIOTHIXENE AND PERPHENAZINE IN PSYCHOSES AND SCHIZOPHRENIA.
070938 07-08

THE EFFECTS OF D-AMPHETAMINE ON SCHEDULE CONTROLLED WATER LICKING IN THE SQUIRREL MONKEY.
071785 07-04

A CONTROLLED STUDY OF L-DOPA IN PARKINSONS DISEASE.
071974 07-07

CONTROLLED THERAPEUTIC EXPERIMENTATION IN CASES OF PSYCHOGENOUS GASTROENTERIC DISTURBANCE.
072003 07-07

DEPRESSIVE ILLNESS IN A GENERAL PRACTICE. A DEMOGRAPHIC STUDY AND A CONTROLLED TRIAL OF IMIPRAMINE.
072055 07-09

A CONTROLLED STUDY OF THE EFFECTS OF GAMFEXINE IN PHENOTHIAZINE TREATED PATIENTS.
072144 07-08

THE CONTRACEPTIVE PILL, SIDE-EFFECTS AND PERSONALITY: REPORT OF A CONTROLLED DOUBLE-BLIND TRIAL.
075472 08-15

A CONTROLLED COMPARATIVE STUDY OF FLUPHENAZINE AND FLUPHENAZINE ENANTHATE IN ACUTE AND CHRONIC PSYCHOTIC PATIENTS.
075881 09-08

A CONTROLLED STUDY OF THE ANTIDEPRESSANT EFFECT OF P-CHLORO-N-METHYLAMPHETAMINE, A COMPOUND WITH A SELECTIVE EFFECT ON THE CENTRAL 5-HYDROXYTRYPTAMINE METABOLISM.
078212 09-10

DRUG CONTROLLED ADDICTION.
079990 09-15

PIPERACETAZINE (QUIDE): A CONTROLLED EVALUATION OF THE ELIXIR IN CHRONIC SCHIZOPHRENIC PATIENTS.
082053 10-08

CONTROLLED INVESTIGATION WITH CINNARIZIN IN THE TREATMENT OF DEMENTIA CONDITIONS IN OLD AGE.
089108 10-11

CONTROLLED LONG-TERM STUDY ON SENILE HYPERTENSION.
089785 11-15

A DOUBLE-BLIND, CONTROLLED STUDY OF THE EFFECTS OF OXYPERTINE AND CARPIPRAMINE ON SCHIZOPHRENIA.
129082 12-08

**CONTROLS**

COMPARATIVE BEHAVIORAL AND BIOCHEMICAL EFFECTS OF TRANYLCYPROMINE AND CYSTEINE ON NORMAL CONTROLS AND SCHIZOPHRENIC PATIENTS.
064331 04-08

**CONTROVERSIES**

CLINICAL CONTROVERSIES AND THEORETICAL MODE OF ACTION OF LITHIUM CARBONATE.
106767 12-13

**CONTROVERSY**

CHROMOSOMAL EFFECTS OF LSD-25, A CONTROVERSY?
058908 02-15

**CONVALESCING**

PSYCHOTOMIMETIC PROPERTIES AND THERAPEUTIC POTENTIALS OF DEXOXADROL ON CONVALESCING ALCOHOLICS.
058448 02-12

**CONVERSION**

INHIBITION BY P-CHLOROAMPHETAMINE OF THE CONVERSION OF 5-HYDROXYTRYPTAMINE TO 5-HYDROXYINDOLEACETIC ACID IN RAT BRAIN.
066507 05-03

**CONVERSIONS**

METABOLISM OF 14C-IMIPRAMINE: III. CONVERSIONS BY RAT TISSUE.
064409 04-03

**CONVULSANT**

CONVULSANT ACTIONS OF TETRAZOLE DERIVATIVES.
064177 04-03

EFFECTS OF A CONVULSANT BARBITURATE ON THE SPINAL MONOSYNAPTIC PATHWAY.
066372 05-03

INCREASED TRANSMITTER RELEASE INDUCED BY CONVULSANT PHENOLS.
081063 09-03

**CONVULSION**

CONVULSION DURING LITHIUM THERAPY.
067900 06-15

**CONVULSIONS**
HEXOSE AND PENTOSE PHOSPHATES IN BRAIN DURING CONVULSIONS. 072119 07-03
SUPPRESSING WITHDRAWAL CONVULSIONS BY DEPAKINE IN ALCOHOLIC DETOXIFICATION CURES. 079858 09-11

**CONVULSIVE**
INDOKLON: CONVULSIVE THERAPY; EXPERIMENTAL CLINICAL STUDIES. 059692 03-07
PSEUDO-DEMENTED, CONVULSIVE CURABLE DEPRESSION OF THE AGED. 062347 03-09
THE EFFECTS OF IMIPRAMINE AND ELECTRIC CONVULSIVE THERAPY ON THE EXCRETION OF VARIOUS MINERALS IN DEPRESSED PATIENTS. 063939 04-13
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: I. SEIZURE AND POST-SEIZURE ELECTROENCEPHALOGRAPHIC PATTERN. 065850 05-11
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY. II. ANTIDEPRESSIVE EFFECT. 065851 05-09
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: III. ANTEROGRADE AMNESIA. 065852 05-14
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: IV. RETROGRADE AMNESIA. 065853 05-14
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: V. CONFUSION AND OTHER SIDE-EFFECTS. 065854 05-15
FLUROTHYL CONVULSIVE THERAPY: GENERAL DISCUSSION. 065855 05-11
FLUROTHYL CONVULSIVE THERAPY. 065856 05-11
EFFECTS OF CHLORPROMAZINE ON CONVULSIVE RESPONSES IN DEVELOPING RATS. 074131 08-03
STUDIES OF MINERAL METABOLISM IN MENTAL DEPRESSION. I. THE EFFECTS OF IMIPRAMINE AND ELECTRIC CONVULSIVE THERAPY ON CALCIUM BALANCE AND KINETICS. 075837 08-11

**COPOLYMERS**
POLYNEURITIS CRANIALIS FOLLOWING POISONING WITH CHLORINATED ACETYLENES WHILE HANDLING VINYLIDINE COPOLYMERS. 051140 02-15

**COPROPORPHYRIA**
STOOL PORPHYRINS IN ACUTE INTERMITTENT AND HEREDITARY COPROPORPHYRIA: ADVERSE EFFECTS OF TRANQUILIZERS. 066318 05-15

**COPULATORY**
EFFECTS OF RESERPINE ON THE COPULATORY BEHAVIOR OF MALE RATS. 063014 03-04

**CORD**
THE ACTION OF TRYPTAMINE ON THE DOG SPINAL CORD AND ITS RELATIONSHIP TO THE AGONISTIC ACTIONS OF LSD-LIKE PSYCHOTOGENS. 090422 11-03

**CORONARY**
PSYCHOTROPIC AGENTS IN THE CORONARY PATIENT: WHAT AND WHEN. 059728 03-16
DRUGS, DREAMS AND THE CORONARY PATIENT. 066874 05-14
MONOAMINE OXIDASE INHIBITORS AND CORONARY INSUFFICIENCY. 133861 12-13

**CORPUS-STRIATUM**
LESIONS IN CORPUS-STRIATUM AND CORTEX OF RAT BRAINS AND THE EFFECT ON PHARMACOLOGICALLY INDUCED STEREOTYPED, AGGRESSIVE AND CATALEPTIC BEHAVIOUR. 091127 11-04

**CORRELATES**
SOME NEUROCHEMICAL CORRELATES OF AXOPLASMIC FLOW. 073327 08-03
BEHAVIORAL CORRELATES OF CHEMICAL STIMULATION IN THE CAT THALAMUS. 075234 08-04
NEUROPHYSIOLOGICAL AND BEHAVIORAL CORRELATES OF LITHIUM. 095014 11-03

**CORRELATION**
EFFECTS OF LITHIUM CARBONATE ON TURNOVER AND METABOLISM OF NOREPINEPHRINE IN THE RAT BRAIN - CORRELATION TO GROSS BEHAVIORAL EFFECTS. 043277 01-03
CORRELATION BETWEEN THE DURATION OF THE ANTICONVULSANT ACTIVITY OF DIAZEPAM AND ITS PHYSIOLOGICAL DISPOSITION IN MICE. 046402 01-03
STARTLE RESPONSE CIRCADIAN RHYTHM IN RATS: LACK OF CORRELATION WITH MOTOR ACTIVITY. 058349 02-04
CORRELATION BETWEEN ACTIVITY AND ELECTRONIC STATE OF HALLUCINOGENIC AMPHETAMINES. 067199 06-06
CORRELATION OF SUBJECTIVE SIDE-EFFECTS WITH PLASMA CONCENTRATIONS OF NORTRIPTYLINE. 082104 10-15
CORRELATION BETWEEN THE CHANGES OF EEG, PUPILLES AND BLOOD PRESSURE DUE TO INTRAVENOUS INJECTION OF CHLORPROMAZINE: CHLORPROMAZINE TEST. 088611 10-13

**CORRELATIONS**
ELECTROENCEPHALOGRAPHIC VARIATIONS INDUCED BY PSYCHOTROPIC DRUGS: CLINICAL ELECTROPHYSIOLOGICAL CORRELATIONS FOR A GUIDED THERAPY. 063200 03-13
ANTIHEMOLYTIC ACTIONS OF TRICYCLIC TRANQUILIZERS: STRUCTURAL CORRELATIONS. 074862 08-03
CORRELATIONS OF STRUCTURE-ACTIVITY OF MORPHINE-LIKE ANALGESICS USING REGRESSION ANALYSIS. 089042 10-01

**CORTEX**
EFFECTS OF NICOTINE AND TOBACCO SMOKE ON THE ELECTRICAL ACTIVITY OF THE CEREBRAL CORTEX AND OLFACTORY BULB. 041567 01-03
MORPHINE AND THE INCORPORATION OF 32 ORTHOPHOSPHATE IN VIVO INTO PHOSPHOLIPIDS OF THE GUINEA-PIG CEREBRAL CORTEX, LIVER AND SUBCELLULAR FRACTIONS. 046401 01-03
CLINICAL INVESTIGATIONS OF THE ACTION OF A PHOSPHOLIPID COMPLEX FROM CEREBRAL CORTEX ON CEREBRAL CIRCULATION DISTURBANCES. 058282 02-11
THE EFFECT OF MORPHINE, NALORPHINE, NALOXONE, PENTAZOCINE, CYCLAZOCINE AND OXOTREMORINE ON THE SYNTHESIS AND RELEASE OF ACETYLCHOLINE BY MOUSE CEREBRAL CORTEX SLICES IN VITRO. 058994 03-03
EFFECTS OF MORPHINE AND PENTOBARBITONE ON ACETYLCHOLINE SYNTHESIS BY RAT CEREBRAL CORTEX. 064288 04-03
THE ALTERATIONS OF PROTEIN METABOLISM OF THE BRAIN CORTEX INDUCED BY ANTICIPATION STRESS AND ACTH. 065434 05-03
EFFECTS OF GENERAL DEPRESSANT DRUGS ON THE ELECTRICAL RESPONSES OF ISOLATED SLABS OF CATS CEREBRAL CORTEX. 066382 05-03
PENICILLIN INDUCED EPILEPTOGENIC FOCI IN THE RAT CORTEX. 075197 08-04
EFFECTS OF GENERAL STIMULANT DRUGS ON THE ELECTRICAL RESPONSES OF ISOLATED SLABS OF CATS CEREBRAL CORTEX. 090189 11-03
LESIONS IN CORPUS-STRIATUM AND CORTEX OF RAT BRAINS AND THE EFFECT ON PHARMACOLOGICALLY INDUCED STEREOTYPED, AGGRESSIVE AND CATALEPTIC BEHAVIOUR. 091127 11-04
CYCLIC AMP MEDIATION OF NOREPINEPHRINE INHIBITION IN RAT CEREBELLAR CORTEX: A UNIQUE CLASS OF SYNAPTIC RESPONSES (UNPUBLISHED PAPER). 093132 11-03

**CORTICAL**
ANESTHETIC AGENTS AND THE CHEMICAL SENSITIVITY OF CORTICAL NEURONES. 040580 01-03
UNIT ACTIVITY IN PREMARIN INDUCED CORTICAL EPILEPTOGENIC FOCI. 066187 05-03
ACETYLCHOLINE RELEASE FROM CORTICAL BRAIN SLICES OF RATS INJECTED WITH LITHIUM. 066509 05-03
PHARMACOLOGY, LIMBIC REGULATION AND CORTICAL FUNCTION. 070979 07-04
ADRENAL CORTICAL AND MEDULLARY SECRETION AND EVALUATION OF DRUGS ACTING ON THE CENTRAL NERVOUS SYSTEM. 106270 12-03

**CORTICOSTEROIDS**
RELEASE BY AMPHETAMINE IN MAN OF GROWTH HORMONE AND CORTICOSTEROIDS: THE EFFECTS OF THYMOXAMINE AND PROPRANOLOL. 067602 06-13

**CORTISOL**
CORTISOL EFFECTS ON AVERAGED EVOKED POTENTIAL, ALPHA-RHYTHM, TIME ESTIMATION, AND TWO-FLASH FUSION THRESHOLD. 075274 08-13
DELTA1-TETRAHYDROCANNABINOL, SYNHEXYL AND MARIJUANA EXTRACT ADMINISTERED ORALLY IN MAN: CATECHOLAMINE EXCRETION, PLASMA CORTISOL LEVELS AND PLATELET SEROTONIN CONTENT. 075841 08-12

**COUMARIN**
UNCONDITIONED REFLEX ACTIVITY IN THE RAT SUFFERING FROM EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY AND THE THERAPEUTIC EFFECT OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126051 12-04
DECREASE OF SPONTANEOUS MOTILITY IN EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY AND THE PROTECTIVE ACTIVITY OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126052 12-04
EFFECT OF A DEFICIENCY OF PANTOTHENIC ACID AND PYRIDOXINE ON THE FUNCTION OF THE CENTRAL NERVOUS SYSTEM AND ITS RESPONSE TO COUMARIN FROM MELILOTUS-OFFICINALIS.
126053 12-04
EFFECT OF CHLORPROMAZINE ON CONDITIONED REFLEXES AND ANTAGONISTIC ACTIVITY OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126054 12-04
INFLUENCE OF ISONIAZID ON THE CENTRAL NERVOUS SYSTEM; THE ANTAGONISM BETWEEN ISONIAZID AND PYRIDOXINE, PANTOTHENIC ACID AND COUMARIN IN RATS (MELILOTUS-OFFICINALIS).
126055 12-04
LEARNING ABILITY IN EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY UNDER THE INFLUENCE OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126056 12-04

**CO2**
STUDIES IN MAN ON THE INFLUENCE OF A NEW PSYCHOPHARMACEUTICAL DRUG, 1-((METHYLAMINO) DIBENZOBICYCLOOCTADIENE HYDROCHLORIDE, ON THE CO2 SENSITIVE CENTRAL RESPIRATORY REGULATION.
079971 09-07

**CRANIALIS**
POLYNEURITIS CRANIALIS FOLLOWING POISONING WITH CHLORINATED ACETYLENES WHILE HANDLING VINYLIDINE COPOLYMERS.
051140 02-15

**CRASH**
CRASH TREATMENT FOR MELANCHOLIA RESISTANT TO OTHER RECENTLY DEVELOPED METHODS.
058456 02-07

**CREATINE**
SPINAL FLUID CREATINE PHOSPHOKINASE ABNORMALITIES FOLLOWING LSD USAGE.
067213 06-15

**CREATIVE**
ON SIMILAR LINGUISTIC STRUCTURES IN CREATIVE PERFORMANCE AND PSILOCYBIN -NDUCED EXPERIENCE.
065433 05-12

**CREATIVITY**
LITHIUM, CREATIVITY, AND MANIC-DEPRESSIVE ILLNESS: REVIEW AND PROSPECTUS.
063601 04-09

**CRETINISM**
CRETINISM IN RATS: ENDURING BEHAVIORAL DEFICIT INDUCED BY TRICYANOAMINOPROPENE.
070839 07-02

**CRF-EXT**
THE RELATIONSHIP OF AMPHETAMINE INDUCED ANOREXIA AND FREEZING UNDER A MULTIPLE CRF-EXT OPERANT SCHEDULE.
068288 06-04

**CRIMINAL**
PSYCHOPHARMACOLOGICAL AGENTS IN THE TREATMENT OF THE CRIMINAL.
104836 12-17

**CRIMINOLOGY**
CASUISTIC CONTRIBUTIONS ON THE USE OF A DRUG IN CRIMINOLOGY ON DISSOCIALITY AND ON MINOR IRREGULAR BEHAVIOR.
095719 11-14
THIORIDAZINE AND BEHAVIOR DISORDERS (PERSPECTIVES FOR THE USE OF THE DRUG IN CRIMINOLOGY).
124320 12-17

**CRISES**
L-DOPA AND OCULOGYRIC CRISES.
067073 05-15
CRISES AND LIFE CHANGES PRECEDING THE ONSET OR RELAPSE OF ACUTE SCHIZOPHRENIA: CLINICAL ASPECTS.
075304 08-08

**CRISIS**
MARIJUANA: MARY JANE FACES THE IDENTITY CRISIS OR, THREE BLIND MEN STUDY THE ELEPHANT.
082063 10-17
HYPERTENSIVE CRISIS IN A PATIENT ON MAOI ANTIDEPRESSANTS FOLLOWING A MEAL OF BEEF LIVER.
092211 11-15

**CRITIQUE**
CRITIQUE OF STUDIES OF LITHIUM SALTS IN THE TREATMENT OF MANIA.
075867 09-09

**CROSSOVER**
DEXBENZETIMIDE IN NEUROLEPTIC INDUCED PARKINSONISM. A DOUBLE-BLIND CROSSOVER STUDY WITH A 16-WEEK FOLLOW-UP.
067176 06-11
A DOUBLE-BLIND INTENSIVE CROSSOVER DESIGN TRIAL OF METHYSERGIDE IN MANIA.
085327 10-09
A DOUBLE-BLIND, CROSSOVER COMPARISON OF APY-606 WITH CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIA.
118583 12-08
PROTRIPTYLINE: A DOUBLE-BLIND CROSSOVER TRIAL IN DEPRESSIVES.
134940 12-09

**CS-300**
CLINICAL APPLICATION OF NEW TRANQUILIZER, CS-300, TO SCHIZOPHRENICS.
129879 12-07

**CSF**
CSF HOMOVANILLIC ACID: EFFECTS OF PROBENECID AND ALPHA-METHYLTYROSINE.
047506 01-03

**CULTURAL**
DILANTIN TREATMENT OF HOSPITALIZED CULTURAL FAMILIAL RETARDATES.
062175 03-14

**CULTURE**
EFFECTS OF CHLORPROMAZINE ON NEURAL TISSUE IN CULTURE.
070825 07-03
TOXICITY OF HEPATOTOXIC DRUGS ON MOUSE LIVER TISSUE CULTURE.
088615 10-05

**CULTURED**
DELTA8-TETRAHYDROCANNABINOL AND DELTA9-TETRAHYDROCANNABINOL: EFFECTS ON CULTURED HUMAN LEUCOCYTES.
063880 04-15
THE RESPONSE OF LYSOSOMES IN CULTURED NEURONS TO CHLORPROMAZINE.
066380 05-03

**CURABLE**
PSEUDO-DEMENTED, CONVULSIVE CURABLE DEPRESSION OF THE AGED.
062347 03-09

**CURES**
SUPPRESSING WITHDRAWAL CONVULSIONS BY DEPAKINE IN ALCOHOLIC DETOXIFICATION CURES.
079858 09-11

**CURVE**
CHANGE IN SENSITIVITY TO D-AMPHETAMINE IN FRONTAL RATS AS A FUNCTION OF TIME: SHIFTING OF THE DOSE RESPONSE CURVE.
075238 08-04

**CURVES**
ON THE ANALYSIS OF CARDIAC BETA-RECEPTORS: STUDIES ON THE BASE OF DOSE EFFECT CURVES FOR ISOPRENALINE, PROPRANOLOL, AND KL-255.
055396 02-03

**CYBERNETICS**
THE IMPORTANCE OF CYBERNETICS FOR PSYCHOPHARMACOLOGY.
098069 11-16

**CYCLANDELATE**
THE EFFECT OF CYCLANDELATE ON MENTAL FUNCTION IN PATIENTS WITH ARTERIOSCLEROTIC BRAIN DISEASE.
061654 03-13

**CYCLAZOCINE**
CLINICAL ANTIDEPRESSANT ACTIVITY OF CYCLAZOCINE – A NARCOTIC ANTAGONIST.
041568 01-09
THE EFFECT OF MORPHINE, NALORPHINE, NALOXONE, PENTAZOCINE, CYCLAZOCINE AND OXOTREMORINE ON THE SYNTHESIS AND RELEASE OF ACETYLCHOLINE BY MOUSE CEREBRAL CORTEX SLICES IN VITRO.
058994 03-03
THE USE OF CYCLAZOCINE IN THE TREATMENT OF HEROIN ADDICTS.
068601 06-17
A CYCLAZOCINE TYPOLOGY IN OPIATE DEPENDENCE.
075427 08-16
SUBJECTIVE EFFECTS OF NARCOTIC ANTAGONISTS CYCLAZOCINE AND NALORPHINE ON THE ADDICTION RESEARCH CENTER INVENTORY (ARCI).
097961 11-14

**CYCLE**
SCOPOLAMINE EFFECTS ON CONDITIONED SUPPRESSION: INFLUENCE OF DIURNAL CYCLE AND TRANSITIONS BETWEEN NORMAL AND DRUGGED STATES.
071790 07-03

**CYCLIC**
URINARY CYCLIC AMP IN AFFECTIVE ILLNESS.
059054 03-09
CYCLIC AMP AND ADENYL-CYCLASE IN THE DEVELOPING RAT BRAIN.
060856 03-03
AFFECTIVE ILLNESS AND CYCLIC AMP EXCRETION.
071972 07-13

CYCLIC AMP MEDIATION OF NOREPINEPHRINE INHIBITION IN RAT CEREBELLAR CORTEX: A UNIQUE CLASS OF SYNAPTIC RESPONSES (UNPUBLISHED PAPER).
093132 11-03

CYCLIZING
EPINEPHRINE CYCLIZING ENZYME IN SCHIZOPHRENIC SERUM.
075105 08-01

CYCLOHEXANE
BLOCKADE OF NOREPINEPHRINE UPTAKE AND RELATED ACTIVITIES OF CIS- AND TRANS N,N(PRIME)-BIS-(1-NAPHTHYLMETHYL)-1,4 CYCLOHEXANE BIS-(METHYLAMINE) DIHYDROCHLORIDE.
090136 11-03

CYCLOHEXIMIDE
A PARALLEL STUDY OF THE AMNESIC EFFECTS OF CYCLOHEXIMIDE AND ECS UNDER DIFFERENT STRENGTHS OF CONDITIONING.
066830 05-04
BRAIN FUNCTION AND MACROMOLECULES: V. THE EFFECT OF CYCLOHEXIMIDE AND ACTINOMYCIN-D ON LEARNING IN THE HEADLESS COCKROACH.
078378 09-03
HABITUATION AND ACTIVITY AS AFFECTED BY CYCLOHEXIMIDE.
097953 11-04

CYCLOHEXYLAMINE
THE OCCURRENCE OF CYCLOHEXYLAMINE IN URINES STUDIED FOR DRUG USE BY THIN-LAYER CHROMATOGRAPHY.
070576 07-13

CYCLOTHYMIA
THERAPY OF CYCLOTHYMIA.
094963 11-09

CYPRODEMANOL
THE EFFECT OF A NEW METABOLIC CEREBRAL STIMULANT, CYPRODEMANOL, IN PSYCHIATRIC ASPECTS OF AGING.
089055 10-11

CYPROHEPTADINE
CYPROHEPTADINE HYDROCHLORIDE (PERIACTIN) AND ANOREXIA-NERVOSA: A CASE REPORT.
078931 09-07

CYSTATHIONINE
NEUROPHARMACOLOGICAL COMPARISON OF CYSTATHIONINE, CYSTEINE, HOMOSERINE AND ALPHA-KETOBUTYRIC ACID IN CATS.
064367 04-04

CYSTEINE
COMPARATIVE BEHAVIORAL AND BIOCHEMICAL EFFECTS OF TRANYLCYPROMINE AND CYSTEINE ON NORMAL CONTROLS AND SCHIZOPHRENIC PATIENTS.
064331 04-08
NEUROPHARMACOLOGICAL COMPARISON OF CYSTATHIONINE, CYSTEINE, HOMOSERINE AND ALPHA-KETOBUTYRIC ACID IN CATS.
064367 04-04
BRAIN DAMAGE IN INFANT MICE FOLLOWING ORAL INTAKE OF GLUTAMATE, ASPARTATE OR CYSTEINE.
094164 11-05

CYSTOMETRIC
PSYCHOPHARMACOLOGICAL AGENTS AND MICTURITION DISORDERS: CYSTOMETRIC INVESTIGATIONS.
090126 11-15

CYTIDINE
THE USE OF THE PYRIMIDINE NUCLEOSIDES (CYTIDINE AND URIDINE) IN THE THERAPY OF CEREBRAL VASCULAR ILLNESS.
094472 11-13

CYTOPATHOLOGICAL
CENTRAL NERVOUS SYSTEM CYTOPATHOLOGICAL CHANGES IN CATS WITH CHRONIC METHEDRINE INTOXICATION.
064143 04-05

CYTOTOXIC
AN INTERESTING TISSULARY THERAPEUTIC METHOD IN GERIATRICS: BOGOMOLETZ SERUM (BERNAS CYTOTOXIC SERUM).
105551 12-11

CZECHOSLOVAK
OXAZEPAM SPOFA, A NEW CZECHOSLOVAK THERAPEUTIC.
086209 10-17

C14-DIHYDROXYPHENYLALANINE
THE FATE OF C14-DIHYDROXYPHENYLALANINE (C14-DOPA) IN THE WHOLE MOUSE.
064161 04-03

C14-DOPA
THE FATE OF C14-DIHYDROXYPHENYLALANINE (C14-DOPA) IN THE WHOLE MOUSE.
064161 04-03

C14-THIORIDAZINE
AUTORADIOGRAPHIC STUDIES ON THE DISTRIBUTION OF PSYCHOACTIVE DRUGS IN THE RAT BRAIN: IV. C14-THIORIDAZINE.
073709 08-03

C57BL
EFFECTS OF INTRAPERITONEAL INJECTION OF ETHANOL ON ETHANOL INGESTION OF C57BL MICE.
075957 09-02

D-AMPHETAMINE
ALTERATIONS OF D-AMPHETAMINE SULFATE LETHALITY AND BODY TEMPERATURE IN MICE DURING ACUTE ALTITUDE EXPOSURE.
040582 01-03
EFFECTS OF D-AMPHETAMINE AND CHLORDIAZEPOXIDE ON SPACED RESPONDING IN PIGEONS.
061597 03-04
ANTAGONISM OF D-AMPHETAMINE BY ALPHA-METHYL-L-TYROSINE: BEHAVIORAL EVIDENCE FOR THE PARTICIPATION OF CATECHOLAMINE STORES AND SYNTHESIS IN THE AMPHETAMINE STIMULANT RESPONSE.
064096 04-03
EFFECTS OF SCOPOLAMINE, ATROPINE, AND D-AMPHETAMINE ON INTERNAL AND EXTERNAL CONTROL OF RESPONDING ON NON-REINFORCED TRIALS.
064410 04-04
CHANGES IN D-AMPHETAMINE REACTIVITY RESULTING FROM SEPTAL FOREBRAIN INJURY.
067695 06-04
SOME EFFECTS OF D-AMPHETAMINE ON CARBOHYDRATE METABOLISM AT GROUND LEVEL AND ALTITUDE.
069344 06-03
THE EFFECTS OF D-AMPHETAMINE ON SCHEDULE CONTROLLED WATER LICKING IN THE SQUIRREL MONKEY.
071785 07-04
CHANGE IN SENSITIVITY TO D-AMPHETAMINE IN FRONTAL RATS AS A FUNCTION OF TIME: SHIFTING OF THE DOSE RESPONSE CURVE.
075238 08-04
SWIM STRESS INDUCED INACTIVITY: RELATION TO BODY TEMPERATURE AND BRAIN NOREPINEPHRINE, AND EFFECTS OF D-AMPHETAMINE.
075275 08-03
THE ROLE OF D-AMPHETAMINE AMOBARBITAL IN SUPPRESSING FREEZING BEHAVIOR DURING AVOIDANCE ACQUISITION AND EXTINCTION.
075882 09-04
THE EFFECT OF MAGNESIUM PEMOLINE, TRICYANOAMINOPROPENE AND D-AMPHETAMINE ON DISCRIMINATED AVOIDANCE PERFORMANCE IN RATS AS A FUNCTION OF AGE.
076133 09-04

D-CYCLOSERINE
D-CYCLOSERINE THERAPY OF PSYCHOSIS BY SYMPTOM PROVOCATION.
075313 08-08

D-DOPA
METABOLISM OF D-DOPA VS L-DOPA.
056852 02-11

D-LYSERGIC
EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND 2-BROM-D-LYSERGIC ACID DIETHYLAMIDE (BOL-148) UPON BEHAVIORAL SLEEP IN RATS.
089045 10-12

D-PENICILLAMINE
ON THE BIOCHEMICAL MECHANISM OF ACTION OF NICOTINIC ACID, NICOTINAMIDE, METHIONINE, AND D-PENICILLAMINE IN THE TREATMENT OF PSYCHOSES.
094962 11-13

DAILY
DAILY RHYTHM IN THE ACCUMULATION OF BRAIN CATECHOLAMINES SYNTHESIZED FROM CIRCULATING H3-TYROSINE.
040246 01-03

DAMAGE
LIVER DAMAGE FOLLOWING APPLICATION OF PYRAZINAMIDE IN ANIMAL EXPERIMENTS: 1. CHANGES IN BODY WEIGHT OF RATS UNDER THE INFLUENCE OF PYRAZINAMIDE.
055398 02-05
LYSERGIC ACID DIETHYLAMIDE INTAKE IN PREGNANCY: FETAL DAMAGE IN RATS.
064422 04-05
STUDIES ON DAMAGE TO THE LIVER BY ALCOHOL.
067130 06-11
DRUG RESPONSE FOLLOWING BRAIN DAMAGE.
070977 07-04
THE SIGNIFICANCE OF BRAIN DAMAGE IN PERSISTENT ORAL DYSKINESIA.
075416 08-15
CLINICAL EXPERIENCE WITH MESORIDAZINE IN THE THERAPY AND REHABILITATION OF TRAUMATIC FRONTAL BRAIN DAMAGE.
089784 11-14
BRAIN DAMAGE IN INFANT MICE FOLLOWING ORAL INTAKE OF GLUTAMATE, ASPARTATE OR CYSTEINE.
094164 11-05
DRUG-INDUCED DAMAGE OF THE EYE AND THE OPTICAL NERVE.
128389 12-15

DAMAGED
PROPOSALS FOR IMPROVING THE TREATMENT OF BRAIN DAMAGED PATIENTS.
080041 09-11

**DANGEROUS**
IS IT FEASIBLE TO TREAT CERTAIN POTENTIALLY DANGEROUS CONDITIONS BY PROLONGED CHEMOTHERAPY.
062406 03-08

**DANGERS**
THE DANGERS TO THE PATIENT -- AND THE THERAPIST.
046734 01-15
DANGERS OF PREMATURE PSYCHOLOGIC DIAGNOSIS.
067265 06-14

**DARTALAN**
CLINICAL USE OF THIOPROPAZATE (DARTALAN) IN PATIENTS WITH PSYCHOSIS.
070937 07-09

**DATA**
A DATA PROCESSING SYSTEM FOR PSYCHOTROPIC DRUG EVALUATION.
060862 03-16
THE PRACTICAL USE OF HIGHER NERVOUS ACTIVITY DATA IN THE PHARMACOTHERAPY OF PSYCHOSES.
062664 03-08
DRUG EFFECTS UPON DATA PROCESSING AS FUNCTIONS OF STORAGE AND RETRIEVAL PARAMETERS.
065127 05-14
ELECTROCARDIOGRAPHIC DATA IN CHRONIC ALCOHOLISM BEFORE, DURING AND AFTER TREATMENT WITH TETRAETHYLTHIURAM DISULPHIDE.
092481 11-14
5-HYDROXYTRYPTOPHAN PRODUCED HYPOTHERMIA IN MICE AS A TEST FOR PHARMACOLOGICAL DIFFERENTIATION OF ANTIDEPRESSANTS, ANTICHOLINERGICS AND NEUROLEPTICS: SOME DATA ON THE NATURE OF THIS HYPOTHERMIA.
105622 12-06

**DATURA**
DATURA LINN. -- THE FAMOUS NARCOTIC FROM THE EAST -- A REVIEW.
046185 01-17

**DAY**
TREATMENT WITH THIORIDAZINE OF EMOTIONALLY DISTURBED CHILDREN IN A DAY HOSPITAL.
082090 10-14
PRESENT DAY TREATMENT OF DELIRIUM-TREMENS.
089161 10-11

**DEAD**
INHIBITION OF CENTRAL SEROTONINERGIC EXCITATION (5-HYDROXYTRYPTOPHAN INDUCED DEAD TWITCHES) IN MICE BY LITHIUM.
097989 11-04

**DEATH**
WAR WITHOUT DEATH.
046735 01-15
A MECHANISM OF SUDDEN DEATH IN CHLORPROMAZINE THERAPY.
062351 03-15
SUDDEN DEATH IN PHENOTHIAZINE THERAPY: A CLINICOPATHOLOGIC STUDY OF 12 CASES.
062737 03-15
AMITRIPTYLINE AND CARDIAC DISEASE: RISK OF SUDDEN DEATH IDENTIFIED BY MONITORING SYSTEM.
070854 07-15
ELECTRON MICROSCOPY. SUDDEN DEATH IN PATIENTS UNDER PHENOTHIAZINE THERAPY: STUDY OF THREE CASES.
090359 11-15

**DEBRIEFINGS**
DEBRIEFINGS.
046731 01-12

**DECANOATE**
EXPERIENCE OF PSYCHIATRIC MANAGEMENT OF SCHIZOPHRENIA WITH FLUPHENAZINE DECANOATE.
063186 03-08
CHEMISTRY AND PHARMACOLOGY OF FLUPHENAZINE DECANOATE.
065470 05-03
THE EFFECTIVENESS OF PARENTERAL ADMINISTRATION OF FLUPHENAZINE DECANOATE IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS.
065473 05-07
INSTITUTIONAL MANAGEMENT OF CHRONIC SCHIZOPHRENICS WITH FLUPHENAZINE DECANOATE.
065474 05-07
FLUPHENAZINE HYDROCHLORIDE, ENANTHATE, AND DECANOATE IN THE MANAGEMENT OF CHRONIC PSYCHOSIS.
065476 05-08
CLINICAL EXPERIENCE WITH FLUPHENAZINE DECANOATE.
070931 07-08
CLINICAL AND AMBULANT TESTING WITH FLUPHENAZINE DECANOATE LYOGEN DEPOT IN THE LONG-TERM TREATMENT OF PSYCHIATRIC DISEASE.
080040 09-16
CLINICAL AND BIOLOGICAL EFFECTS OF DECANOATE OF FLUPHENAZINE: BASED ON 35 OBSERVATIONS.
085347 10-08

**DECARBOXYLASE**
POTENTIATION AND INHIBITION OF SOME CENTRAL ACTIONS OF L(-) DOPA BY DECARBOXYLASE INHIBITORS.
040750 01-03
GABA AS A REPRESSOR OF L-GLUTAMIC ACID DECARBOXYLASE (GAD) IN DEVELOPING CHICK EMBRYO OPTIC LOBES.
058192 02-03
L-DOPA INDUCED CHANGES IN CENTRAL MONOAMINE NEURONS AFTER PERIPHERAL DECARBOXYLASE INHIBITION.
059033 03-03
L-DOPA PLUS DECARBOXYLASE INHIBITOR IN DEPRESSION.
066322 05-09
ADMINISTRATION OF A PERIPHERAL DECARBOXYLASE INHIBITOR WITH L-DOPA TO DEPRESSED PATIENTS.
067591 06-09
EFFECT OF A DECARBOXYLASE INHIBITOR (RO-4-4602), COMBINED WITH L-DOPA, ON INHIBITED DEPRESSIVE PATIENTS: II. EXPERIMENTAL PSYCHOLOGICAL STUDIES.◉
079964 09-14
EFFECT OF A DECARBOXYLASE INHIBITOR (RO-4-4602), COMBINED WITH L-DOPA, ON RETARDED DEPRESSIVE PATIENTS.
079965 09-13
REDUCTION OF LEVEL OF L-GLUTAMIC ACID DECARBOXYLASE BY GAMMA-AMINOBUTYRIC ACID IN MOUSE BRAIN.
083168 10-03
EFFECT OF L-DOPA ALONE AND IN COMBINATION WITH AN EXTRACEREBRAL DECARBOXYLASE INHIBITOR ON BLOOD PRESSURE AND SOME CARDIOVASCULAR REFLEXES.
090371 11-13

**DECARBOXYLATION**
DECARBOXYLATION OF 3,4- DIHYDROXYPHENYLALANINE IN VARIOUS HUMAN ADULT AND FETAL TISSUES.
040105 01-13

**DECONDITIONING**
PHARMACOLOGICAL DECONDITIONING.
091110 11-10

**DEFECATION**
THE ACTION OF SOME PSYCHOTROPIC DRUGS ON DEFECATION RATE IN THE MOUSE.
089003 10-05

**DEFECT**
RESEARCH ON THE DEFECT STATE OF SCHIZOPHRENIC PATIENT UNDER CONTROL OF PSYCHODRUGS.
129273 12-08

**DEFECTS**
ON THE QUESTION OF PERSONALITY DEFECTS OF CONSCIOUSNESS IN INITIAL STAGES IN SCHIZOPHRENIA.
090264 11-08

**DEFENSE**
IN DEFENSE OF STIMULANTS FOR HYPERKINETIC CHILDREN.
067059 05-11
SUICIDE AND PARANOID DEFENSE (PRELIMINARY REPORT).
113137 12-15

**DEFENSIVENESS**
WORTHINGTON AND PERCEPTUAL DEFENSIVENESS.
082410 10-14
A NOTE ON TRANQUILLIZERS AND PERCEPTUAL DEFENSIVENESS.
082411 10-14

**DEFICIENCIES**
MENTAL RETARDATION ASSOCIATED WITH PRENATAL INTOXICATION, ALLERGIC REACTIONS, DEFICIENCIES, TRAUMA, AND PHYSICAL AGENTS.
061704 03-15
MENTAL RETARDATION ASSOCIATED WITH POSTNATAL POISONS, TOXINS, ENDOTOXINS, DEFICIENCIES AND ALLERGIC REACTIONS.
061706 03-15
CONSIDERATIONS ON THE HYPERKINESIA OF L-DOPA: SIGNIFICANT BIOCHEMICAL AND ANATOMICAL DEFICIENCIES.
078555 09-13

**DEFICIENCY**
BEHAVIORAL IMPAIRMENT IN ADULT RATS FOLLOWING ACUTE ZINC DEFICIENCY.
045526 01-04
COMBINED ADRENAL AND THYROID DEFICIENCY (SCHMIDTS SYNDROME) PRESENTING AS AN ACUTE PSYCHOSIS.
056350 02-15
SPASMOPHILIA CAUSED BY MAGNESIUM DEFICIENCY.
063590 03-17
FOLATE DEFICIENCY IN DEPRESSIVE ILLNESS.
068414 06-13
SODIUM DEFICIENCY AND LATENT LEARNING.
075915 09-04
EFFECT OF 1035-MD ON CERTAIN CONDITIONS OF MENTAL DEFICIENCY, ESPECIALLY THOSE OF VASCULAR ORIGIN; CLINICAL EEG AND PSYCHOPHARMACOLOGICAL STUDY.
084978 10-08

EFFECT OF A DEFICIENCY OF PANTOTHENIC ACID AND PYRIDOXINE ON THE FUNCTION OF THE CENTRAL NERVOUS SYSTEM AND ITS RESPONSE TO COUMARIN FROM MELILOTUS-OFFICINALIS.
126053 12-04

**DEFICIENT**
FOLIC ACID IN FOLATE DEFICIENT PATIENTS WITH EPILEPSY.
080635 09-11

**DEFICIT**
DELAYED LEARNING DEFICIT PRODUCED BY HYDROXYLAMINE.
067713 06-04
TIME-DEPENDENT LEARNING DEFICIT CAUSED BY HYDROXYLAMINE.
068677 06-04
CRETINISM IN RATS: ENDURING BEHAVIORAL DEFICIT INDUCED BY TRICYANOAMINOPROPENE.
070839 07-02

**DEFINED**
THE COURSE OF RECURRENT DEPRESSIVE ILLNESS IN SELECTED PATIENTS FROM A DEFINED POPULATION.
106781 12-09

**DEFINITION**
BEHAVIORAL TOXICITY. PART 1: DEFINITION AND PART 2: PSYCHOMOTOR FUNCTIONS.
100524 12-15

**DEFINITIONS**
CONCEPTS, DEFINITIONS, TERMINOLOGY.
079255 09-15

**DEGRADATION**
THE EFFECT OF PHENELZINE AND TRANYLCYPROMINE ON THE DEGRADATION OF MEPERIDINE.
064421 04-03

**DEGREE**
QUANTITATION OF THE DEGREE OF ANTAGONISM OF CHLOROQUINE TO HISTAMINE, ACETYLCHOLINE AND SEROTONIN ( PA2 VALUES).
067462 06-03

**DEHYDROBENZPERIDOL**
CLINICAL EVALUATION IN 112 PSYCHIATRIC PATIENTS OF A BUTYROPHENONE NEUROLEPTIC, DEHYDROBENZPERIDOL (R-4749).
080142 09-11
A STUDY OF DEHYDROBENZPERIDOL (R-4749) IN THE TREATMENT OF DYSTHYMIC SYNDROMES.
092077 11-09

**DEHYDROGENASE**
A STUDY OF HEPATIC ALCOHOL DEHYDROGENASE INHIBITION (ADH) INDUCED BY PYRAZOL: II. THE ROLE OF LIVER ADH IN THE IN VIVO METABOLISM OF HYDROXYL COMPOUNDS.
089547 11-03
A STUDY OF HEPATIC ALCOHOL DEHYDROGENASE INHIBITION INDUCED BY PYRAZOL: I. IN VIVO ACTION ON ETHANOL AND 2-PHENYLETHANOL.
089548 11-03

**DELAYED**
STUDIES OF DELAYED ACTION MEDICATION: V. PLASMA LEVELS AND URINARY EXCRETION OF FOUR DIFFERENT DOSAGE FORMS OF CHLORPROMAZINE.
041559 01-13
DELAYED ABSORPTION OF PHENYLBUTAZONE CAUSED BY DESMETHYLIMIPRAMINE IN HUMANS.
042756 01-13
DELAYED LEARNING DEFICIT PRODUCED BY HYDROXYLAMINE.
067713 06-04

**DELGADO**
SOMAPSYCHIC RELATIONS IN MEDICINE: SESSION OF HOMAGE OF THE PERUVIAN ACADEMY OF MEDICINE TO PROFESSOR HONORIO DELGADO.
094610 11-14

**DELIRIANT**
REMARKS ON THE USE OF CLOMIPRAMINE (ANAFRANIL) IN CERTAIN ACUTE DELIRIANT PSYCHOSES (WITHOUT A CLEAR DEPRESSIVE ELEMENT).
088438 10-14

**DELIRIUM**
SEVERE DELIRIUM AFTER ABRUPT WITHDRAWAL OF THIOTHIXENE IN A CHRONIC SCHIZOPHRENIC INPATIENT: A CASE STUDY.
067221 06-08
THERAPEUTIC MEDICATION IN CHRONIC DELIRIUM: COMBINATION OF PROCHLORPERAZINE (TEMENTIL) AND LEVOMEPROMAZINE (NOZINAN).
079288 09-11
TREATMENT OF SCOPOLAMINE INDUCED DELIRIUM.
082155 10-09
SOME OBSERVATIONS ON THE DYNAMICS OF THE DESTRUCTURING OF DELIRIUM DURING PHARMACOTHERAPY.
098033 11-17

**DELIRIUM-ACUTUM**
DELIRIUM-ACUTUM, A POTENTIALLY FATAL CONDITION IN THE PSYCHIATRIC HOSPITAL.
075980 09-15

**DELIRIUM-TREMENS**
METHODS OF TREATING DELIRIUM-TREMENS AS BASED ON MATERIALS OF THE UNIVERSITY MEDICAL SCHOOLS PSYCHIATRIC CLINIC IN WROCLAW BETWEEN 1958 AND 1968.
087143 10-11
PRESENT DAY TREATMENT OF DELIRIUM-TREMENS.
089161 10-11

**DELTA1-TETRAHYDROCANNABINOL**
INTERACTIONS OF DELTA1-TETRAHYDROCANNABINOL WITH BARBITURATES AND METHAMPHETAMINE.
064424 04-04
DEPRESSANT EFFECT OF DELTA1-TETRAHYDROCANNABINOL ENHANCED BY INHIBITION OF ITS METABOLISM.
070443 07-03
DELTA1-TETRAHYDROCANNABINOL, SYNHEXYL AND MARIJUANA EXTRACT ADMINISTERED ORALLY IN MAN: CATECHOLAMINE EXCRETION, PLASMA CORTISOL LEVELS AND PLATELET SEROTONIN CONTENT.
075841 08-12

**DELTA8-TETRAHYDROCANNABINOL**
DELTA8-TETRAHYDROCANNABINOL AND DELTA9-TETRAHYDROCANNABINOL: EFFECTS ON CULTURED HUMAN LEUCOCYTES.
063880 04-15

**DELTA9-TETRAHYDROCANNABINOL**
DELTA8-TETRAHYDROCANNABINOL AND DELTA9-TETRAHYDROCANNABINOL: EFFECTS ON CULTURED HUMAN LEUCOCYTES.
063880 04-15
MARIHUANA: STUDIES ON THE DISPOSITION AND METABOLISM OF DELTA9-TETRAHYDROCANNABINOL IN MAN.
069051 06-13

**DELTA9-TRANS-TETRAHYDROCANNABINOL**
DEVELOPMENT OF FIGHTING BEHAVIOR IN STARVED RATS BY CHRONIC ADMINISTRATION OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL AND CANNABIS EXTRACTS: LACK OF ACTION OF OTHER PSYCHOTROPIC DRUGS.
072531 08-04

**DELUSION**
TREATMENT OF DELUSION OF PARASITOSIS.
079994 09-11

**DEMENTIA**
EFFECTS OF L-DOPA IN PATIENTS WITH DEMENTIA.
058403 02-15
L-DOPA IN SENILE DEMENTIA.
059020 03-11
CONTROLLED INVESTIGATION WITH CINNARIZIN IN THE TREATMENT OF DEMENTIA CONDITIONS IN OLD AGE.
089108 10-11

**DEMETHYLATION**
BETA-HYDROXYLATION OF N-ACETYL-DIMETHOXYPHENETHYLAMINE AND THE INFLUENCE OF IPRONIAZID ON THE DEMETHYLATION OF THIS COMPOUND IN VIVO IN THE RAT.
064053 04-03

**DEMOGRAPHIC**
DEPRESSIVE ILLNESS IN A GENERAL PRACTICE. A DEMOGRAPHIC STUDY AND A CONTROLLED TRIAL OF IMIPRAMINE.
072055 07-09
PATIENT PERSONALITY AND DEMOGRAPHIC FACTORS AS PREDICTORS OF EARLY RESPONSE TO PSYCHOTROPIC DRUG TREATMENT.
074130 08-10

**DENERVATED**
MONOAMINES AND MONOAMINE OXIDASE IN DENERVATED SYMPATHETIC GANGLIA OF THE CAT.
040756 01-03
ON THE MECHANISM OF SUPERSENSITIVITY TO NOREPINEPHRINE IN THE DENERVATED CAT SPLEEN.
080336 09-03

**DEPAKINE**
SUPPRESSING WITHDRAWAL CONVULSIONS BY DEPAKINE IN ALCOHOLIC DETOXIFICATION CURES.
079858 09-11

**DEPENDENCE**
DRUG DEPENDENCE.
046194 01-17
NARCOTIC ANTAGONISTS AND THE PROBLEMS OF DRUG DEPENDENCE.
046195 01-13
BARBITURATE DEPENDENCE.
046205 01-15
RELAPSE TO OPIOID DEPENDENCE: THE ROLE OF CONDITIONING.
046208 01-03
AN ANALYSIS OF PSYCHOLOGICAL DEPENDENCE.
046210 01-04
FIELD DEPENDENCE AS A PREDICTOR OF ALCOHOLIC THERAPY DROP-OUTS.
052455 02-11

PSYCHOLOGICAL APPROACHES TO OPIATE DEPENDENCE AND SELF-ADMINISTRATION BY LABORATORY ANIMALS.
056240 02-04
UNITED-STATES PROCEDURES FOR SCREENING DRUGS: TESTING FOR DEPENDENCE LIABILITY IN ANIMALS AND MAN.
058971 03-02
PREFERENCES FOR MORPHINE IN RATS: VALIDATION OF AN EXPERIMENTAL MODEL OF DEPENDENCE.
064475 04-04
TREATMENT OF HEROIN DEPENDENCE WITH OPIATE ANTAGONISTS.
065195 05-13
DRUG DEPENDENCE: SOME RESEARCH ISSUES.
071747 07-16
A CYCLAZOCINE TYPOLOGY IN OPIATE DEPENDENCE.
075427 08-16
EXPERIMENTAL STUDIES ON THE EFFECTIVE PROCEDURE TO INHIBIT THE DEVELOPMENT OF TOLERANCE TO AND DEPENDENCE ON MORPHINE.
089789 11-02
ROLE OF BIOGENIC AMINES IN MORPHINE DEPENDENCE IN THE RAT.
090149 11-03
REDUCTION OF BARBITURATE DEPENDENCE INDUCED BY REPEATED ELECTROCONVULSIONS.
097548 11-03

**DEPENDENT**
DRUG DEPENDENT DIFFERENCES IN THE DEVELOPMENT OF TOLERANCE TO WRITHING IN MICE.
046400 01-03
PERSONALITY TRAIT DEPENDENT PERFORMANCE UNDER PSILOCYBIN (PART II).
058454 02-12
CONDITIONED NALORPHINE INDUCED ABSTINENCE CHANGES: PERSISTENCE IN POST MORPHINE DEPENDENT MONKEYS.
061632 03-04
PERSISTENCE OF RELAPSE TENDENCIES OF RATS PREVIOUSLY MADE PHYSICALLY DEPENDENT ON MORPHINE.
062940 03-04
PERSONALITY TRAIT DEPENDENT PERFORMANCE UNDER PSILOCYBIN.
064323 04-12
THE BRAIN ACETYLCHOLINE SYSTEM IN BARBITONE DEPENDENT AND WITHDRAWN RATS.
067604 06-03
BRAIN SEROTONIN TURNOVER IN MORPHINE TOLERANT AND DEPENDENT MICE.
069595 07-03
POPULATION DEPENDENT DIFFERENCES OF CENTRAL NERVOUS REACTIVITY TO NEUROLEPTICS.
098022 11-15

**DEPERSONALIZATION**
TEMPORAL DISINTEGRATION AND DEPERSONALIZATION DURING MARIHUANA INTOXICATION.
066232 05-14

**DEPHOSPHORYLATION**
DEPHOSPHORYLATION IN VIVO OF BRAIN ACETYLCHOLINESTERASE INHIBITED BY ISOPROPYL METHYLPHOSPHONOFLUORIDATE (SARIN).
046188 01-03

**DEPLETED**
COMPENSATORY SELECTION OF MAGNESIUM SULFATE BY MAGNESIUM DEPLETED LABORATORY RATS.
068287 06-04

**DEPLETING**
BEHAVIORAL AND BRAIN CATECHOLAMINE DEPLETING ACTIONS OF U-14624, AN INHIBITOR OF DOPAMINE BETA-HYDROXYLASE.
058986 03-03
USE OF AN ANDROGEN DEPLETING HORMONE IN THE TREATMENT OF MALE SEX OFFENDERS.
080178 09-14

**DEPLETION**
SELECTIVE DEPLETION OF NORADRENALINE: A PROPOSED MECHANISM OF THE ADRENERGIC NEURONE BLOCKING ACTION OF BRETYLIUM.
055323 02-05
ASSOCIATION OF AMPHETAMINE TOXICITY AND TISSUE GLYCOGEN DEPLETION IN MICE AND RATS.
058998 03-05
ELEVATED CATECHOLAMINES IN THIRTY-DAY-OLD CHICKEN BRAIN AFTER DEPLETION DURING DEVELOPMENT.
063044 03-03
P-CHLOROAMPHETAMINE: IN VIVO INVESTIGATIONS ON THE MECHANISM OF ACTION OF THE SELECTIVE DEPLETION OF CEREBRAL SEROTONIN.
069596 07-03
EFFECTS OF CHRONIC MORPHINE ADMINISTRATION ON THE CATECHOLAMINE DEPLETION INDUCED BY RESERPINE.
081065 09-03

**DEPOSITION**
APHAGIA, PRODUCED BY DEPOSITION OF DRUGS INTO THE HYPOTHALAMUS OF RATS.
088463 10-03

**DEPOT**
DEPOT FLUPHENAZINE IN THE TREATMENT OF PSYCHOSIS IN A COMMUNITY MENTAL HEALTH CLINIC.
065475 05-08
FLUPHENAZINE ENANTHATE IN SESAME-OIL, A DEPOT PREPARATION.
070476 07-11
CLINICAL EXPERIENCE WITH FLUPHENAZINE DEPOT.
070932 07-08
CLINICAL AND AMBULANT TESTING WITH FLUPHENAZINE DECANOATE LYOGEN DEPOT IN THE LONG-TERM TREATMENT OF PSYCHIATRIC DISEASE.
080040 09-16
POSSIBILITIES AND LIMITATIONS OF DEPOT NEUROLEPTIC TREATMENT OF SCHIZOPHRENIC PSYCHOSES.
087066 10-17
CLINICAL TESTING WITH FLUPHENAZINE DEPOT ADMINISTRATION TO SCHIZOPHRENIC PATIENTS.
101034 12-07

**DEPRESSANT**
EFFECTS OF GENERAL DEPRESSANT DRUGS ON THE ELECTRICAL RESPONSES OF ISOLATED SLABS OF CATS CEREBRAL CORTEX.
066382 05-03
DEPRESSANT EFFECT OF DELTA1-TETRAHYDROCANNABINOL ENHANCED BY INHIBITION OF ITS METABOLISM.
070443 07-03
THE ACTION OF CENTRAL DEPRESSANT DRUGS ON THE SPONTANEOUS DISCHARGE OF ACTION POTENTIALS IN THE SUPERIOR CERVICAL SYMPATHETIC TRUNK OF THE CAT.
072034 07-03
ANTICONVULSANT AND MOTOR DEPRESSANT EFFECTS OF DIAZEPAM.
076576 09-02
THE EFFECT OF EXTRAVERSION AND STIMULANT AND DEPRESSANT DRUGS ON VERBAL CONDITIONING.
078786 09-14
SUBSTITUTED BENZAMIDES WITH POTENTIAL CNS DEPRESSANT AND HYPOTENSIVE ACTIVITY.
089435 11-02

**DEPRESSANTS**
THE STAIRCASE MAZE AND THE SIMPLE STAIRCASE IN THE ANALYSIS OF THE PSYCHOPHARMACOLOGICAL ACTION OF CNS DEPRESSANTS.
068291 06-04
CENTRAL NERVOUS SYSTEM DEPRESSANTS.
110225 12-17

**DEPRESSED**
IMIPRAMINE AND LITHIUM EFFECTS ON BIOGENIC AMINE TRANSPORT IN DEPRESSED AND MANIC-DEPRESSED PATIENTS.
062326 03-13
IMIPRAMINE AND LITHIUM EFFECTS ON BIOGENIC AMINE TRANSPORT IN DEPRESSED AND MANIC-DEPRESSED PATIENTS.
062366 03-13
THE EFFECTS OF IMIPRAMINE AND ELECTRIC CONVULSIVE THERAPY ON THE EXCRETION OF VARIOUS MINERALS IN DEPRESSED PATIENTS.
063939 04-13
A COMPARATIVE STUDY OF FLUPHENAZINE AMITRIPTYLINE COMBINATION AND AMITRIPTYLINE ALONE IN THE TREATMENT OF DEPRESSED PSYCHIATRIC PATIENTS.
064356 04-09
CLINICAL EVALUATION OF DOXEPIN AND AMITRIPTYLINE IN DEPRESSED PATIENTS.
064637 05-09
PERPHENAZINE AMITRIPTYLINE IN NEUROTIC DEPRESSED OUTPATIENTS; A CONTROLLED COLLABORATIVE STUDY.
065247 05-10
PEMOLINE AND METHYLPHENIDATE IN MILDLY DEPRESSED OUTPATIENTS.
066709 05-10
ADMINISTRATION OF A PERIPHERAL DECARBOXYLASE INHIBITOR WITH L-DOPA TO DEPRESSED PATIENTS.
067591 06-09
AMITRIPTYLINE AND TRIMIPRAMINE IN NEUROTIC DEPRESSED OUTPATIENTS: A COLLABORATIVE STUDY.
075868 09-10
L-DOPA IN DEPRESSED PATIENTS.
081038 09-09
THE PREDICTION OF PLACEBO RESPONSE IN ANXIOUS AND DEPRESSED OUTPATIENTS.
092102 11-16
A SEVENTH-MONTH DOUBLE-BLIND TRIAL OF AMITRIPTYLINE AND DIAZEPAM IN ECT TREATED DEPRESSED PATIENTS.
097562 11-09

**DEPRESSION**
IMIPRAMINE EFFECTS UPON HOSTILITY IN DEPRESSION.
052456 02-10
DIFFERENTIAL RESPONSE TO TREATMENT AS A FUNCTION OF THE CHANGING CHARACTER OF A DEPRESSION.
052574 02-10
L-TRYPTOPHAN IN DEPRESSION.
058404 02-10

SEQUENTIAL COMPARISON OF L-TRYPTOPHAN WITH ECT IN SEVERE DEPRESSION.
059053 03-09

RECOGNITION AND MANAGEMENT OF DEPRESSION.
060728 03-17

PSEUDO-DEMENTED, CONVULSIVE CURABLE DEPRESSION OF THE AGED.
062347 03-09

DIFFERENTIAL DRUG EFFECTS IN NEUROTIC DEPRESSION.
063207 03-10

THE ANXIETY DEPRESSION SYNDROME.
063567 03-10

CLINICAL AND BIOCHEMICAL ASPECTS OF DEPRESSION.
063600 04-13

TREATMENT OF DEPRESSION BY THE INTERNIST: RESULTS WITH IMIPRAMINE.
064113 04-14

CHLORAL HYDRATE IN CENTRAL NERVOUS SYSTEM DEPRESSION.
064335 04-17

DEPRESSION OF TWO-WAY AVOIDANCE LEARNING AND ENHANCEMENT OF PASSIVE AVOIDANCE LEARNING BY SMALL DOSES OF PHYSOSTIGMINE.
064365 04-04

AN ACHE MASKING DEPRESSION.
064636 05-14

PLACEBO CONTROL EVALUATION OF DESIPRAMINE IN DEPRESSION.
065235 05-10

L-DOPA PLUS DECARBOXYLASE INHIBITOR IN DEPRESSION.
066322 05-09

L-DOPA WITH MK-485 FOR DEPRESSION.
066440 05-10

DOXEPIN (SINEQUAN) AND OTHER DRUGS FOR ANXIETY AND DEPRESSION.
066877 05-17

THE SWITCH PROCESS FROM DEPRESSION TO MANIA: RELATIONSHIP TO DRUGS WHICH ALTER BRAIN AMINES.
067585 06-09

L-TRYPTOPHAN IN DEPRESSION.
067675 06-10

L-TRYPTOPHAN IN DEPRESSION.
067676 06-10

PSYCHOTROPICS IN ANXIETY AND DEPRESSION -- COMBINATION OR SINGLE AGENT.
068298 06-09

COMPARATIVE TRIAL OF A NEW MONOAMINE OXIDASE INHIBITOR IN DEPRESSION.
069057 06-10

TRYPTOPHAN METABOLISM IN DEPRESSION.
069081 06-13

L-DOPA, PARKINSONISM, AND DEPRESSION.
070856 07-09

L-TRYPTOPHAN IN DEPRESSION.
070857 07-09

CLINICAL PILOT STUDY OF DIBENZEPINE TREATMENT OF DEPRESSION.
070939 07-09

CLINICAL EXPERIENCES WITH CHLORIMIPRAMINE IN ENDOGENOUS DEPRESSION.
070942 07-09

DRUGS IN THE MANAGEMENT OF DEPRESSION.
070982 07-17

BODY CONSCIOUSNESS IN STATES OF PHARMACOLOGICAL DEPRESSION AND AROUSAL.
072032 07-14

ELECTROSPLANCHNOGRAPHY IN ANOREXIA-NERVOSA AND DEPRESSION -- PRELIMINARY RESULTS.
072154 07-16

MASKED DEPRESSION AND THE USE OF ANTIDEPRESSANTS IN GENERAL PRACTICE.
072219 07-17

DRUGS IN THE TREATMENT OF DEPRESSION.
074926 08-09

STUDIES OF MINERAL METABOLISM IN MENTAL DEPRESSION. I. THE EFFECTS OF IMIPRAMINE AND ELECTRIC CONVULSIVE THERAPY ON CALCIUM BALANCE AND KINETICS.
075837 08-11

ORAL CONTRACEPTIVES: DEPRESSION AND FRIGIDITY.
075968 09-13

KETIPRAMINE IN THE THERAPY OF DEPRESSION IN OUTPATIENTS.
076347 09-10

PLASMA CONCENTRATIONS OF THIORIDAZINE IN PATIENTS WITH DEPRESSION: A PRELIMINARY REPORT.
078213 09-13

RX FOR AGITATED DEPRESSION.
079355 09-03

ANTAGONISM OF BETA-PHENYLETHYLAMINE DERIVATIVES AND SEROTONIN BLOCKING DRUGS UPON SEROTONIN, TRYPTAMINE AND RESERPINE BEHAVIORAL DEPRESSION IN MICE.
079970 09-04

CLINICAL CONSIDERATIONS ON THE TREATMENT OF DEPRESSION WITH CHLORIMIPRAMINE.
081121 09-10

THIOTHIXENE IN THE TREATMENT OF ANXIETY AND DEPRESSION IN OUTPATIENTS.
082052 10-10

AN ACHE MASKING DEPRESSION.
082422 10-10

THE DRUG TREATMENT OF DEPRESSION.
087632 10-09

STUDY EXPLORES ROLE OF BIOGENIC AMINES IN DEPRESSION.
087793 10-13

L-DOPA WITH MK-485 FOR DEPRESSION.
090188 11-11

MOTIVATIONAL DEPRESSION ASSOCIATED WITH NOREPINEPHRINE INDUCED EATING FROM THE HYPOTHALAMUS: RESEMBLANCE TO THE VENTROMEDIAL HYPERPHAGIC SYNDROME.
090473 11-04

L-DOPA IN DEPRESSION (UNPUBLISHED PAPER).
092688 11-09

EFFECTS OF NORTRIPTYLINE IN THE TREATMENT OF DEPRESSION SYNDROMES.
093133 11-09

THE PROBLEM PATIENT IN PRACTICE: CONTRIBUTION TO A DIFFERENTIAL DIAGNOSTIC PROBLEM OF A TYPE OF DEPRESSION.
094307 11-09

SIGNIFICANCE OF PSYCHOPHARMACOLOGY ON PSYCHOTHERAPY OF DEPRESSION.
094453 11-09

THE EFFECTS OF LITHIUM SALTS IN THE TREATMENT OF DEPRESSION.
129579 12-09

**DEPRESSIONS**

THYROID HORMONE ENHANCEMENT OF IMIPRAMINE IN NONRETARDED DEPRESSIONS.
042654 01-09

TOFRANIL IN THE TREATMENT OF POST ALCOHOLIC DEPRESSIONS.
063588 03-09

THE CLINICAL TESTING OF HYDROTHIADENE IN ENDOGENOUS DEPRESSIONS. INFLUENCE OF DRUGS ON PHOTOMYOCLONIC THRESHOLD.
070940 07-09

TRANYLCYPROMINE IN THE THERAPY OF ENDOGENOUS DEPRESSIONS.
070941 07-09

CLINICAL EXPERIENCES WITH DESIPRAMINE IN ENDOGENOUS AND INVOLUTIONAL DEPRESSIONS.
070943 07-09

ACTUAL PROBLEMS OF ENDOGENOUS AND EXOGENOUS DEPRESSIONS.
070956 07-09

A LONGITUDINAL INVESTIGATION OF LITHIUM AS A PROPHYLACTIC AGENT FOR RECURRENT DEPRESSIONS.
075425 08-10

THYROID HORMONE AND TRICYCLIC ANTIDEPRESSANTS IN RESISTANT DEPRESSIONS.
075428 08-09

TREATMENT OF DEPRESSIONS ACCORDING TO TARGET SYMPTOMS.
078732 09-09

CONTRIBUTION OF NEUROLEPTICS IN CURRENT USE TO THE TREATMENT OF DEPRESSIONS.
086235 10-10

INFLUENCE OF THYMOLEPTIC THERAPY ON THE COURSE OF ENDOGENOUS DEPRESSIONS.
089102 10-17

EXPERIENCE WITH A COMBINATION OF AMITRIPTYLINE AND THIORIDAZINE FOR THE TREATMENT OF DEPRESSIONS.
105732 12-14

LITHIUMS POSITION AMONG ANTIDEPRESSANTS IN THE TREATMENT OF ACUTE ENDOGENOUS AND INVOLUTIONAL DEPRESSIONS.
106777 12-09

**DEPRESSIVE**

COMBINED THERAPY IN ANXIETY DEPRESSIVE SYNDROMES: I. COMPARATIVE EFFECTS OF LIMBITROL (CHLORDIAZEPOXIDE AMITRIPTYLINE) AND PLACEBO.
064312 04-10

DRUGS IN DEPRESSIVE ILLNESS.
067013 05-09

CONTROLLED TRIALS OF AN AMITRYPTYLINE FLUPHENAZINE COMBINATION IN DEPRESSIVE NEUROSES AND PSYCHOSES: A COLLABORATIVE STUDY.
067589 06-11

FOLATE DEFICIENCY IN DEPRESSIVE ILLNESS.
068414 06-13

DEPRESSIVE ILLNESS IN A GENERAL PRACTICE. A DEMOGRAPHIC STUDY AND A CONTROLLED TRIAL OF IMIPRAMINE.
072055 07-09

A CONTRIBUTION TO THE DEPRESSIVE DISORDER PHARMACOTHERAPY BY THE COMBINATION OF AMITRIPTYLINE AND PERPHENAZINE
073707 08-10

DRUG TREATMENT IN DEPRESSIVE ILLNESS: AMITRYPTYLINE AND CHLORDIAZEPOXIDE IN TWO NEUROTIC POPULATIONS.
075415 08-10

THERAPEUTIC INTEREST IN HYDROSARPAN-711 IN DEPRESSIVE STATES AND IN THE PSYCHIATRIC PATHOLOGY OF GERONTOLOGICAL STATES.
079859 09-11

EFFECT OF A DECARBOXYLASE INHIBITOR (RO-4-4602), COMBINED WITH L-DOPA, ON INHIBITED DEPRESSIVE PATIENTS: II. EXPERIMENTAL PSYCHOLOGICAL STUDIES.
079964 09-14

EFFECT OF A DECARBOXYLASE INHIBITOR (RO-4-4602), COMBINED WITH L-DOPA, ON RETARDED DEPRESSIVE PATIENTS.
079965 09-13

CLINICAL TREATMENT OF DEPRESSIVE SYNDROMES WITH NOXIPTILIN.
079967 09-10

REMARKS ON THE USE OF CLOMIPRAMINE (ANAFRANIL) IN CERTAIN ACUTE DELIRIANT PSYCHOSES (WITHOUT A CLEAR DEPRESSIVE ELEMENT).
086438 10-14

THE CENTRAL SYMPATHETIC DEPRESSIVE EFFECT OF RESERPINE, ALPHA-METHYLDOPA AND CLONIDINE.
089046 10-03

PROPHYLACTIC LITHIUM THERAPY FOR CHRONIC DEPRESSIVE PSYCHOSIS AND SCHIZO-AFFECTIVE DISORDERS.
089105 10-09

CHLORIMIPRAMINE: THE MAJOR TREATMENT OF DEPRESSIVE STATES.
089157 10-09

CLINICAL EXPERIENCE WITH 10MG RESERPINE INJECTED I.M.IN DEPRESSIVE DISORDERS.
100019 11-09

THE COURSE OF RECURRENT DEPRESSIVE ILLNESS IN SELECTED PATIENTS FROM A DEFINED POPULATION.
106781 12-09

USE OF MELLERIL RETARD IN TREATMENT OF PATIENTS WITH DEPRESSIVE PARANOID AND ANXIOUS DEPRESSIVE SYNDROMES.
109724 12-14

DEPRESSIVE STATES OF OLD AGE AND TREATMENT OF THEM.
111018 12-09

DEPRESSIVE STATES AS A PHARMACOLOGICAL TARGET.
122378 12-17

DEXAMETHASONE IN DEPRESSIVE SYNDROMES.
134902 12-09

**DEPRESSIVES**

IMIPRAMINE PAMOATE IN HOSPITALIZED DEPRESSIVES: A DOUBLE-BLIND COMPARISON WITH PLACEBO.
064429 04-10

PROTRIPTYLINE: A DOUBLE-BLIND CROSSOVER TRIAL IN DEPRESSIVES.
134940 12-09

**DEPRIVATION**

ON THE COMBINED EFFECTS OF AMPHETAMINE AND FOOD DEPRIVATION: A REPLY TO GOLLUB AND MANN.
066821 05-04

MODIFICATION OF THE SCOPOLAMINE EFFECT BY SLEEP DEPRIVATION.
070933 07-14

THE EFFECT OF CENTROPHENOXINE ON EEG VIGILANCE IN THE COURSE OF SLEEP DEPRIVATION AND ON THE EEG PATTERN OF ALL-NIGHT SLEEP.
070934 07-14

PSYCHOPHYSIOLOGICAL ASPECTS OF EXTENDED EXPOSURE OF MAN TO AN ENVIRONMENT WITH SENSORY DEPRIVATION.
082954 10-14

AN ANALYSIS OF THE ROLE OF CHOLINERGIC DRUGS IN BEHAVIOR RELATED TO FOOD AND WATER DEPRIVATION. (PH.D.DISSERTATION).
103267 12-04

**DEPRIVED**

PERSONALITY DIFFERENCES IN THE RESPONSE TO STIMULANT DRUGS ADMINISTERED DURING A SLEEP DEPRIVED STATE.
052502 02-14

THE EFFECT OF LSD ON SLEEP DEPRIVED MEN.
064388 04-12

ALTERATIONS IN BRAIN SENSITIVITY AND BARBITURATE METABOLISM UNRELATED TO AGGRESSION IN SOCIALLY DEPRIVED MICE.
069052 06-03

THE EFFECTS OF ADRENERGIC AND CHOLINERGIC AGENTS UPON EATING AND DRINKING IN DEPRIVED RATS.
076132 09-03

**DERIVATION**

ANTICHOLINERGIC CENTRAL BLOCKADE OF SALT AROUSED AND DERIVATION INDUCED DRINKING.
081227 09-04

**DERIVATIVE**

INFLUENCE OF SEROTONIN AND RELATED SUBSTANCES UPON PHOTIC EVOKED POTENTIALS OF RABBIT: EVIDENCE FOR BIOLOGICAL ACTIVITY OF THE ALDEHYDE DERIVATIVE.
055584 02-03

NOBRIUM, ANOTHER BENZODIAZEPINE DERIVATIVE. 29 MONTHS OF EXPERIENCE.
059037 03-11

THE PHARMACOLOGY OF PRAZEPAM: A NEW BENZODIAZEPINE DERIVATIVE.
064181 04-04

DOUBLE-BLIND STUDY COMPARING THE INTRAMUSCULAR USAGE OF AN ACRIDAN DERIVATIVE, SKF-14336, TO CHLORPROMAZINE.
067513 06-11

CI-601, A BUTYROPHENONE DERIVATIVE, IN THE TREATMENT OF CHRONICALLY WITHDRAWN SCHIZOPHRENIC PATIENTS.
072142 07-08

CLINICAL INVESTIGATION WITH THE BUTYROPHENONE DERIVATIVE BURONIL.
073706 08-09

CLINICAL STUDY ON A NEW PIPERIDYL-PHENOTHIAZINE DERIVATIVE (A-124).
079969 09-07

CLINICOELECTROENCEPHALOGRAPHIC EVALUATION OF A NEW BENZODIAZEPINIC DERIVATIVE (RO-5-4023) ADMINISTERED ORALLY IN EPILEPTIC PATIENTS USING A DOUBLE-BLIND METHOD.
100959 12-07

CLINICAL EXPERIENCE WITH METHYLPERONE (BURONIL), A NEW BUTYROPHENONE DERIVATIVE.
105730 12-07

ADMINISTRATION OF A NEW BUTYROPHENONE DERIVATIVE, PIMOZIDE, IN THE TREATMENT OF SCHIZOPHRENIA.
123373 12-08

**DERIVATIVES**

EFFECTS OF AMPHETAMINE DERIVATIVES ON BRAIN DOPAMINE AND NORADRENALINE.
040126 01-03

EFFECTS OF LYSERGIC ACID DERIVATIVES ON 5-HYDROXYTRYPTAMINE EXCITATION OF BRAINSTEM NEURONES.
041973 01-02

TEN YEARS OF TREATMENT WITH THIOXANTHENE DERIVATIVES.
042671 01-09

COMPLEXES OF ERGOT ALKALOIDS AND DERIVATIVES. II: INTERACTION OF DIHYDROERGOTOXINE WITH CERTAIN XANTHINES.
046137 01-03

EFFECT OF RESERPINE ON THE INCORPORATION IN VIVO OF RADIOACTIVITY FROM LABELED SEROTONIN AND OTHER 5-HYDROXYINDOLE DERIVATIVES IN MOUSE BRAIN.
046189 01-03

4-(BETA-BENZOYLVINYL) ANTIPYRINE DERIVATIVES WITH ANTIPHLOGISTIC AND ANALGESIC ACTIVITY.
055519 02-03

ANTICONVULSIVE PROPERTIES OF SOME BENZODIAZEPINE DERIVATIVES.
058604 02-03

INFRARED IDENTIFICATION OF SOME HALLUCINOGENIC DERIVATIVES OF TRYPTAMINE AND AMPHETAMINE.
058877 02-01

CONVULSANT ACTIONS OF TETRAZOLE DERIVATIVES.
064177 04-03

EFFECTS OF PHENOTHIAZINE DERIVATIVES ON BIOLOGICAL MEMBRANES: DRUG-INDUCED CHANGES IN ELECTRON SPIN RESONANCE SPECTRA FROM SPIN-LABELED ERYTHROCYTE GHOST MEMBRANES.
064423 04-03

THE METABOLISM OF PSYCHOTROPIC DRUGS (PHENOTHIAZINE AND IMINODIBENZYL DERIVATIVES).
067301 06-17

EFFECTS OF PSILOCYBIN, DIMETHYLTRYPTAMINE AND VARIOUS LYSERGIC ACID DERIVATIVES ON PHOTICALLY INDUCED EPILEPSY IN THE BABOON (PAPIO-PAPIO).
068163 06-03

CENTRAL NEUROTROPIC ACTIVITY OF AMINOPROPYL AND AMINOPROPIONYLIC DERIVATIVES OF IMINOBENZYL AND DIPHENYLAMINE AND ITS RELATION TO IONIZATION CONSTANTS.
072580 08-03

ACUTE CEREBRAL DISORDERS AFTER HIGH DOSES OF OXYQUINOLINE DERIVATIVES.
073900 08-15

ANTAGONISM OF BETA-PHENYLETHYLAMINE DERIVATIVES AND SEROTONIN BLOCKING DRUGS UPON SEROTONIN, TRYPTAMINE AND RESERPINE BEHAVIORAL DEPRESSION IN MICE.
079970 09-04

ENCEPHALOPATHY AS A SEQUEL OF CHRONIC INTOXICATION WITH HALOGEN DERIVATIVES OF AROMATIC HYDROCARBONS.
085102 10-15

CONTRIBUTION TO THE STUDY OF THE EXTRAPYRAMIDAL SYNDROME WITH ANIMAL EXPERIMENTATION. THE ROLE OF CALCIUM AND O-METHYLENE DERIVATIVES.
086348 10-03

ON THE UPTAKE OF PHENOTHIAZINE DERIVATIVES BY THE ISOLATED PERFUSED RAT BRAIN.
089043 10-03

ADDICTIVE PROPERTIES OF DEXTROMORPHAN DERIVATIVES.
089242 10-17

SYNTHESIS OF POSSIBLE METABOLITES OF CHLORPROMAZINE. III. 7,8 DISUBSTITUTED CHLORPROMAZINE DERIVATIVES.
094623 11-01

INVESTIGATION INTO THE POSSIBLE INFLUENCE OF CHLORINATED AMPHETAMINE DERIVATIVES ON 5-HYDROXYTRYPTAMINE SYNTHESIS IN MAN.
097963 11-13
COMPARATIVE STUDY OF CNS STIMULATORY ACTIVITY AND ANOREXIGENIC POTENCY OF PHENYLETHYLAMINE DERIVATIVES. (PH.D.DISSERTATION).
103710 12-04
CLINICOELECTROENCEPHALOGRAPHIC EVALUATION OF THE ANTIEPILEPTIC ACTION OF A NEW SERIES OF BENZODIAZEPINIC DERIVATIVES.
105486 12-07
EFFECT OF TWO RECENTLY SYNTHESIZED PHENOTHIAZINE DERIVATIVES UPON EXPERIMENTAL CARDIAC ARRHYTHMIAS.
114978 12-03

**DERMATOLOGICAL**
DERMATOLOGICAL EFFECTS.
100529 12-15

**DESENSITIZATION**
METHOHEXITONE ASSISTED DESENSITIZATION FOR PHOBIAS.
067074 05-16
METHOHEXITONE ASSISTED DESENSITIZATION IN TREATMENT OF PHOBIAS.
067673 06-11

**DESIGN**
THE DESIGN OF DRUG TRIALS WITH NEUROTIC PATIENTS.
058364 02-16
STUDIES ON INTERACTIONS INVOLVING ANTIDEPRESSIVE AND OTHER DRUGS WITH TETRABENAZINE AND NORADNAMINE ON LOCOMOTOR ACTIVITY IN MICE, INCLUDING DETAILS OF THE EXPERIMENTAL DESIGN AND STATISTICAL ANALYSIS.
069077 06-04
A DOUBLE-BLIND INTENSIVE CROSSOVER DESIGN TRIAL OF METHYSERGIDE IN MANIA.
085327 10-09
EFFECTS OF NEUROLEPTICS ON THE CEREBRAL ELECTRICAL ACTIVITY OF LABORATORY ANIMALS: PRESENTATION OF A MODEL DESIGN FOR NEUROPHARMACOLOGICAL EXPERIMENTS.
085337 10-03
ESSENTIALS OF MOLECULAR PHARMACOLOGY: BACKGROUND FOR DRUG DESIGN.
115114 12-17

**DESIPRAMINE**
EFFECTS OF RESERPINE AND DESIPRAMINE ON THE UPTAKE AND SUBCELLULAR DISTRIBUTION OF 5-HYDROXYTRYPTAMINE IN RABBIT BRAINSTEM AFTER INTRAVENOUS ADMINISTRATION OF 5-HYDROXYTRYPTOPHAN.
056610 02-03
MECHANISMS BY WHICH AMPHETAMINE AND DESIPRAMINE INHIBIT THE METARAMINOL INDUCED RELEASE OF NOREPINEPHRINE FROM SYMPATHETIC NERVE ENDINGS IN RAT HEART.
064427 04-03
PLACEBO CONTROL EVALUATION OF DESIPRAMINE IN DEPRESSION.
065235 05-10
MODIFICATION BY DESIPRAMINE (DMI) OF THE AVAILABILITY OF NOREPINEPHRINE RELEASED BY RESERPINE IN THE HYPOTHALAMUS OF THE RAT IN VIVO.
066374 05-03
CLINICAL EXPERIENCES WITH DESIPRAMINE IN ENDOGENOUS AND INVOLUTIONAL DEPRESSIONS.
070943 07-09
ENHANCEMENT BY DESIPRAMINE OF HYPOTHALAMICALLY EVOKED DISCHARGES IN PREGANGLIONIC SYMPATHETIC NERVES.
097962 11-03

**DESMETHYLIMIPRAMINE**
DELAYED ABSORPTION OF PHENYLBUTAZONE CAUSED BY DESMETHYLIMIPRAMINE IN HUMANS.
042756 01-13
INTERACTION BETWEEN RESERPINE AND DESMETHYLIMIPRAMINE.
064254 04-03
EFFECTS OF DESMETHYLIMIPRAMINE AND COCAINE ON THE UPTAKE, RETENTION AND METABOLISM OF H3-TYRAMINE IN RAT BRAIN SLICES.
064419 04-03
METABOLISM AND BILIARY EXCRETION OF THE LIPOPHILIC DRUG MOLECULES, IMIPRAMINE AND DESMETHYLIMIPRAMINE IN THE RAT -- I. EXPERIMENTS IN VIVO AND WITH ISOLATED PERFUSED LIVERS.
067260 06-03
EFFECT OF DESMETHYLIMIPRAMINE, IPRINDOLE AND DL-ERYTHRO-ALPHA-(3,4 DICHLOROPHENYL)-BETA-(T-BUTYLAMINO) PROPANOL HCL ON THE METABOLISM OF AMPHETAMINE.
074866 08-03
STUDIES ON ADRENERGIC MECHANISMS IN THE ACTION OF DESMETHYLIMIPRAMINE (DMI).
090421 11-04
EXCITATORY EFFECT OF TRYPTOPHAN IN MICE AND RATS AND EFFECT OF IMIPRAMINE AND DESMETHYLIMIPRAMINE UPON IT.
098009 11-03
SYNERGISM OF DESMETHYLIMIPRAMINE WITH RESERPINE AND 5-HYDROXYTRYPTOPHAN IN THE FROG: BRAIN SEROTONIN AND ADRENALINE AND BEHAVIOR.
098042 11-03

**DESTRUCTION**
BEHAVIORAL EFFECTS: HIPPOCAMPAL DESTRUCTION AND SCOPOLAMINE.
075280 08-04

**DESTRUCTURING**
SOME OBSERVATIONS ON THE DYNAMICS OF THE DESTRUCTURING OF DELIRIUM DURING PHARMACOTHERAPY.
098033 11-17

**DETAILS**
STUDIES ON INTERACTIONS INVOLVING ANTIDEPRESSIVE AND OTHER DRUGS WITH TETRABENAZINE AND NORADNAMINE ON LOCOMOTOR ACTIVITY IN MICE, INCLUDING DETAILS OF THE EXPERIMENTAL DESIGN AND STATISTICAL ANALYSIS.
069077 06-04

**DETECTING**
METHODS FOR DETECTING ANTIANXIETY DRUGS USING BABOONS (PAPIO-CYNOCEPHALUS).
041537 01-06

**DETECTION**
DETECTION OF PSYCHOTOMIMETIC N,N DIMETHYLATED INDOLEAMINES IN THE URINE OF FOUR SCHIZOPHRENIC PATIENTS.
080506 09-08

**DETERMINANTS**
DETERMINANTS OF SERUM HALF-LIFE OF GLUTETHIMIDE IN INTOXICATED PATIENTS.
064168 04-15

**DETERMINATION**
COLORIMETRIC DETERMINATION OF AMPHETAMINE SALTS IN DOSAGE FORMS.
064159 04-01
SPECTROPHOTOMETRIC DETERMINATION OF CHLORPROMAZINE IN PHARMACEUTICAL DOSAGE FORMS.
064262 04-06
QUANTITATIVE DETERMINATION OF BUTAPERAZINE BY TLC.
090425 11-06
A COMPARATIVE DETERMINATION OF SIDE-EFFECTS ASSOCIATED WITH THE ORAL USE OF THREE ANTICHOLINERGIC PSYCHOTROPIC DRUGS.
126639 12-15

**DETOXIFICATION**
SUPPRESSING WITHDRAWAL CONVULSIONS BY DEPAKINE IN ALCOHOLIC DETOXIFICATION CURES.
079858 09-11

**DEVELOPED**
CRASH TREATMENT FOR MELANCHOLIA RESISTANT TO OTHER RECENTLY DEVELOPED METHODS.
058456 02-07
THE REVERSAL OF DEVELOPED TOLERANCE TO PENTOBARBITAL BY ETHYL ALCOHOL.
058995 03-03

**DEVELOPING**
GABA AS A REPRESSOR OF L-GLUTAMIC ACID DECARBOXYLASE (GAD) IN DEVELOPING CHICK EMBRYO OPTIC LOBES.
058192 02-03
CYCLIC AMP AND ADENYL-CYCLASE IN THE DEVELOPING RAT BRAIN.
060856 03-03
NOREPINEPHRINE AND DOPAMINE IN THE DEVELOPING CHICK BRAIN.
060865 03-03
CHOLINERGIC MODULATION OF ADRENERGIC AROUSAL IN THE DEVELOPING RAT.
063688 04-04
UPTAKE OF (14C) PENTYLENETETRAZOL BY DEVELOPING RAT BRAIN.
067120 06-02
EFFECTS OF CHLORPROMAZINE ON CONVULSIVE RESPONSES IN DEVELOPING RATS.
074131 08-03
EFFECTS OF PRENATAL ADMINISTRATION OF PSYCHOTROPIC DRUGS ON BEHAVIOR OF DEVELOPING RATS.
074830 08-04

**DEVELOPMENT**
INHIBITION OF THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN RATS BY DRUGS WHICH INHIBIT RIBONUCLEIC ACID OR PROTEIN SYNTHESIS.
041570 01-03
DRUG DEPENDENT DIFFERENCES IN THE DEVELOPMENT OF TOLERANCE TO WRITHING IN MICE.
046400 01-03
POSSIBLE MECHANISMS IN DEVELOPMENT OF TOLERANCE.
056238 02-03
ELEVATED CATECHOLAMINES IN THIRTY-DAY-OLD CHICKEN BRAIN AFTER DEPLETION DURING DEVELOPMENT.
063044 03-03
EFFECTS OF DEXAMETHASONE ON THE DEVELOPMENT OF EMOTIONALITY AND ADRENOCORTICAL REACTIVITY.
063605 04-04
DEVELOPMENT OF TOLERANCE TO PENTOBARBITAL.
064263 04-03

PERINATAL DEVELOPMENT OF DRUG METABOLIZING ENZYME ACTIVITY IN SWINE.
066368 05-03

DEVELOPMENT OF FIGHTING BEHAVIOR IN STARVED RATS BY CHRONIC ADMINISTRATION OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL AND CANNABIS EXTRACTS: LACK OF ACTION OF OTHER PSYCHOTROPIC DRUGS.
072531 08-04

THE CATECHOLAMINE CONTENT IN THE BRAINSTEM OF ALBINO RATS IN THE DEVELOPMENT OF TOLERANCE TO TRYPHTAZINE.
073681 08-03

DEVELOPMENT OF HORMONAL CONTROL OVER FOOD INTAKE AND BODY WEIGHT IN FEMALE RATS.
076239 09-03

EXPERIMENTAL STUDIES ON THE EFFECTIVE PROCEDURE TO INHIBIT THE DEVELOPMENT OF TOLERANCE TO AND DEPENDENCE ON MORPHINE.
089789 11-02

THE SAFETY TEST OF L-DOPA -- II. EFFECT OF L-DOPA ON THE DEVELOPMENT OF PRENATAL AND POSTNATAL OFFSPRINGS OF EXPERIMENTAL ANIMALS.
114836 12-02

THE CLINICAL ASPECTS AND DYNAMICS OF PARANOIAC PSYCHOPATHY WITH MALIGNANT DEVELOPMENT.
126632 12-09

**DEVELOPMENTAL**

DEVELOPMENTAL PHARMACOLOGY.
051125 02-17

**DEVIATION**

SETTING, PATIENT, AND DOCTOR EFFECTS ON DRUG RESPONSE IN NEUROTIC PATIENTS: I. DIFFERENTIAL ATTRITION, DOSAGE DEVIATION, AND SIDE REACTION RESPONSES TO TREATMENT.
065453 05-10

**DEXAMETHASONE**

EFFECTS OF DEXAMETHASONE ON THE DEVELOPMENT OF EMOTIONALITY AND ADRENOCORTICAL REACTIVITY.
063605 04-04

THE EFFECT OF DEXAMETHASONE BLOCKADE OF ACTH RELEASE ON AVOIDANCE LEARNING.
067884 06-04

DEXAMETHASONE SUPPRESSION IN BASIC TRAINEES UNDER STRESS.
086025 10-10

DEXAMETHASONE IN DEPRESSIVE SYNDROMES.
134902 12-09

**DEXAMPHETAMINE**

THE ANTAGONISM OF ADRENERGIC NEURONE BLOCKADE BY AMPHETAMINE AND DEXAMPHETAMINE IN THE RAT AND GUINEA-PIG.
055322 02-03

OBJECTIVE EFFECTS OF DEXAMPHETAMINE AND AMOBARBITAL AND THEIR RELATIONS TO PSYCHASTHENIC PERSONALITY TRAITS.
064389 04-14

THE EFFECT OF INHIBITION OF CATECHOLAMINE SYNTHESIS ON DEXAMPHETAMINE INDUCED CENTRAL STIMULATION.
067259 06-04

INITIAL SUPPRESSION OF THE LOCOMOTOR STIMULANT RESPONSE TO DEXAMPHETAMINE IN RATS EXPOSED TO A NOVEL ENVIRONMENT.
067601 06-04

DEXAMPHETAMINE: A POSSIBLE ENVIRONMENTAL TRIGGER IN CARDIOVASCULAR MALFORMATIONS.
082039 10-15

**DEXBENZETIMIDE**

DEXBENZETIMIDE IN NEUROLEPTIC INDUCED PARKINSONISM. A DOUBLE-BLIND CROSSOVER STUDY WITH A 16-WEEK FOLLOW-UP.
067176 06-11

**DEXCHLORPHENIRAMINE**

DOPA EFFECTS ON MOTILITY IN MICE; POTENTIATION BY MK-485 AND DEXCHLORPHENIRAMINE.
064411 04-03

**DEXEDRINE**

DEXEDRINE AS AN ADJUNCT TO APHASIA THERAPY.
101801 12-11

**DEXOXADROL**

PSYCHOTOMIMETIC PROPERTIES AND THERAPEUTIC POTENTIALS OF DEXOXADROL ON CONVALESCING ALCOHOLICS.
058448 02-12

**DEXPHENMETRAZINE**

THE INFLUENCE OF IMIPRAMINE, DEXPHENMETRAZINE AND AMPHETAMINE SULPHATE ON SYNCHRONOUS AND PARADOXICAL SLEEP IN NARCOLEPSY CATAPLEXY. A POLYGRAPHIC EXAMINATION.
089037 10-14

**DEXTROAMPHETAMINE**

EFFECT OF ENVIRONMENTAL TEMPERATURE ON THE TOXICITY OF CAFFEINE AND DEXTROAMPHETAMINE IN MICE.
040028 01-05

A NEW STIMULANT, PROLINTANE HYDROCHLORIDE, COMPARED WITH DEXTROAMPHETAMINE IN FATIGUED VOLUNTEERS.
040128 01-14

MARIHUANA, ETHANOL, AND DEXTROAMPHETAMINE: MOOD AND MENTAL FUNCTION ALTERATIONS.
066231 05-14

PROTECTION OF GSR CONDITIONING BY DEXTROAMPHETAMINE.
075315 08-14

INHIBITION OF HEPATIC HEXOBARBITAL METABOLISM BY DEXTROAMPHETAMINE.
076186 09-03

**DEXTROMETHORPHAN**

POSSIBLE LETHAL REACTION BETWEEN NARDIL AND DEXTROMETHORPHAN.
063897 04-15

**DEXTROMORPHAN**

ADDICTIVE PROPERTIES OF DEXTROMORPHAN DERIVATIVES.
089242 10-17

**DEXTROPROPOXYPHENE**

COMBINATION TEST ON THE ANALGESIC EFFECT OF DEXTROPROPOXYPHENE AND SOME PSYCHOTROPIC DRUGS IN THE MOUSE.
079961 09-03

CLINICAL RESULTS OF THE TESTING FOR ANALGESIC EFFECT OF DEXTROPROPOXYPHENE IN COMBINATION WITH A PSYCHOTROPIC PREPARATION (TROPAX).
081147 09-17

**DFP**

COMPARISON OF DRINKING ELICTED BY ESERINE OR DFP INJECTED INTO PREOPTIC AREA OF RAT BRAIN.
069637 07-04

**DIABETES-INSIPIDUS**

LITHIUM INDUCED DIABETES-INSIPIDUS LIKE SYNDROME.
075426 08-10

**DIABETES-MELLITUS**

COEXISTENCE OF DIABETES-MELLITUS AND MYXEDEMA IN MENTAL PATIENTS.
116482 12-08

**DIAGNOSE**

DOES PINK-SPOT DIAGNOSE DRUG?
067319 06-08

**DIAGNOSES**

DRUGS, DIAGNOSES, AND OUTCOME OF DRUG TRIALS WITH NEUROTIC PATIENTS: A SURVEY.
075942 09-11

**DIAGNOSIS**

IDENTIFICATION OF NARCOTICS AND DIAGNOSIS OF THE ADDICTION. (UNPUBLISHED PAPER).
051207 02-01

RADIOACTIVE BROMIDE IN THE DIAGNOSIS OF CENTRAL NERVOUS SYSTEM DISEASE.
063208 03-16

DIAGNOSIS AND THERAPY OF ACUTE WITHDRAWAL FROM ALCOHOL.
065193 05-13

DANGERS OF PREMATURE PSYCHOLOGIC DIAGNOSIS.
067265 06-14

IN DIAGNOSIS, TYPE OF REACTION IS MORE IMPORTANT THAN THE DRUG.
067939 06-15

**DIAGNOSTIC**

SKIN LESIONS AS A DIAGNOSTIC AID IN BARBITURATE POISONING.
067926 06-15

LSD AS A DIAGNOSTIC AID (UNPUBLISHED PAPER).
085893 10-12

THE USE OF NARCO-ANALYSIS IN DIAGNOSTIC PSYCHIATRIC TECHNIQUE.
093537 11-14

THE PROBLEM PATIENT IN PRACTICE: CONTRIBUTION TO A DIFFERENTIAL DIAGNOSTIC PROBLEM OF A TYPE OF DEPRESSION.
094307 11-09

LSD AS A DIAGNOSTIC AID.
138597 12-08

**DIAMORPHINE**

A PROCEDURE FOR THE ANALYSIS OF ILLICIT DIAMORPHINE SAMPLES.
046395 01-01

**DIAZEPAM**

CORRELATION BETWEEN THE DURATION OF THE ANTICONVULSANT ACTIVITY OF DIAZEPAM AND ITS PHYSIOLOGICAL DISPOSITION IN MICE.
046402 01-03

THE ACTION OF DIAZEPAM IN NEUROLOGICAL DISORDERS WITH EXCESSIVE MOTOR ACTIVITY.
056779 02-11

DIAZEPAM, NITRAZEPAM AND THE NHS.
058422 02-15

SPECIES DIFFERENCES IN DIAZEPAM METABOLISM -- I. METABOLISM OF DIAZEPAM METABOLITES.
064000 04-03

THE EFFECT OF DIAZEPAM ON THE EEG OF STATUS-EPILEPTICUS.
064610 04-11

TRIALS OF RO-5-3350 AND DIAZEPAM FOR ANXIETY SYMPTOMS.
066826 05-07

EFFECT OF DIAZEPAM ON FATE OF INTRACISTERNALLY INJECTED SEROTONIN-C14.
072031 07-03

ELECTROGRAPHIC AND BEHAVIORAL EFFECTS OF DIAZEPAM DURING ALCOHOL WITHDRAWAL STAGE IN CATS.
072033 07-04
A PILOT STUDY OF INJECTABLE DIAZEPAM IN A GENERAL HOSPITAL SETTING.
072397 07-07
ABSORPTION AND PHARMACOLOGICAL ACTIVITIES OF A NEW DIAZEPAM PREPARATION.
072586 08-03
HYPNOTIC PROPERTIES OF NITRAZEPAM (MOGADON) (A COMPARATIVE STUDY OF CHLORDIAZEPOXIDE, DIAZEPAM, NITRAZEPAM, SECOBARBITAL AND PLACEBO IN PSYCHIATRIC PATIENTS).
075884 09-14
ANTICONVULSANT AND MOTOR DEPRESSANT EFFECTS OF DIAZEPAM.
076576 09-02
ABUSE OF AND ADDICTION TO DIAZEPAM.
079991 09-15
CENTRAL MUSCLE RELAXANT EFFECTS OF DIAZEPAM.
079997 09-03
A BENZAZEPINONE: CARBON ANALOG OF DIAZEPAM.
080032 09-02
FURTHER STUDIES ON THE LONG-LASTING ANTIMETRAZOL ACTIVITY OF DIAZEPAM IN MICE.
081106 09-03
DIAZEPAM IN THE ELECTROENCEPHALOGRAPHIC RECORDINGS OF EPILEPTICS.
087661 10-11
DIAZEPAM (VALIUM) LEVEL IN THE BRAIN DURING HYPOTHERMIA.
089036 10-03
EFFECT OF PHENOBARBITAL ON THE IN VITRO METABOLISM OF DIAZEPAM IN SEVERAL ANIMAL SPECIES.
090134 11-03
A SEVENTH-MONTH DOUBLE-BLIND TRIAL OF AMITRIPTYLINE AND DIAZEPAM IN ECT TREATED DEPRESSED PATIENTS.
097562 11-09
A DOUBLE-BLIND COMPARISON OF S-804 (NEW BENZODIAZEPINE DRUG) WITH CHLORDIAZEPOXIDE AND DIAZEPAM IN THE TREATMENT OF NEUROSIS.
129097 12-10
DOUBLE-BLIND STUDY WITH SINEQUAN (DOXEPIN) VS DIAZEPAM VS PLACEBO IN PSYCHONEUROSIS.
138526 12-10

**DIBENZAZEPIN-5-YL**
CHEMISTRY AND PHARMACOLOGY OF A NEW POTENTIAL ANTIDEPRESSANT, N-METHYL-N-(4-CHLOROBENZYL-11-DIHYDRO-5H DIBENZAZEPIN-5-YL) PROPYLAMINE HYDROCHLORIDE) (LEO-640, LOPRAMINE HYDROCHLORIDE).
089786 11-01

**DIBENZEPINE**
CLINICAL PILOT STUDY OF DIBENZEPINE TREATMENT OF DEPRESSION.
070939 07-09

**DIBENZOBICYCLOOCTADIENE**
STUDIES IN MAN ON THE INFLUENCE OF A NEW PSYCHOPHARMACEUTICAL DRUG, 1-((METHYLAMINO) DIBENZOBICYCLOOCTADIENE HYDROCHLORIDE, ON THE CO2 SENSITIVE CENTRAL RESPIRATORY REGULATION.
079971 09-07

**DIBENZOXAZEPINE**
2-CHLORO-11-(4-METHYLPIPERAZINO) DIBENZOXAZEPINE), (SUM-3170), A NEW NEUROLEPTIC SUBSTANCE: RESULTS OF AN INTERCLINICAL STUDY.
079986 09-07
DIBENZOXAZEPINE IN PSYCHOTIC PATIENTS.
086793 10-09

**DIBENZOXEPINE**
NONANTAGONISM OF ANTIADRENERGIC AGENTS BY A DIBENZOXEPINE: PRELIMINARY REPORT.
089438 11-13

**DICHLOROPHENYL**
EFFECT OF DESMETHYLIMIPRAMINE, IPRINDOLE AND DL-ERYTHRO-ALPHA-(3,4 DICHLOROPHENYL)-BETA-(T-BUTYLAMINO) PROPANOL HCL ON THE METABOLISM OF AMPHETAMINE.
074866 08-03

**DIENCEPHALIC**
MODULATION OF FOOD INTAKE AND LOCOMOTOR ACTIVITY IN FEMALE RATS BY DIENCEPHALIC HORMONE IMPLANTS.
076080 09-04

**DIET**
THE EFFECT OF DIET AND PHENOBARBITONE ON QUININE METABOLISM IN THE RAT AND IN MAN.
046187 01-13

**DIETARY**
EXCRETION OF VANYLGLYCOL IN HUMAN URINE UNDER DIETARY CONTROL, AND DURING TREATMENT WITH ANTIBIOTICS, DISULFIRAM, A MONOAMINE OXIDASE INHIBITOR, ALPHA-METHYLDOPA, AND RESERPINE.
060272 03-13

**DIETETICS**
ADVANCES IN NUTRITION AND DIETETICS.
079912 09-11

**DIETHYL-ETHER**
AMNESIA AND BRAIN SEIZURES ACTIVITY IN MICE: EFFECTS OF DIETHYL-ETHER ANESTHESIA PRIOR TO ELECTROSHOCK STIMULATION.
097952 11-04

**DIETHYLAMIDE**
USES AND MISUSES OF LYSERGIC ACID DIETHYLAMIDE.
046736 01-17
LYSERGIC ACID DIETHYLAMIDE AS A VARIABLE IN THE HOSPITAL TREATMENT OF ALCOHOLISM: A FOLLOW-UP STUDY.
052476 02-11
LYSERGIC ACID DIETHYLAMIDE, CHLORPROMAZINE AND MAZE PERFORMANCE.
058997 03-04
PROJECT SUMMARY: ON THE INVESTIGATION OF THE GENETIC EFFECTS OF LYSERGIC ACID DIETHYLAMIDE AND RELATED COMPOUNDS.
060637 03-03
LYSERGIC ACID DIETHYLAMIDE INTAKE IN PREGNANCY: FETAL DAMAGE IN RATS.
064422 04-05
LYSERGIC ACID DIETHYLAMIDE (LSD-25): XXXIX. THE EFFECT OF HIGH TEMPERATURES ON STABILITY.
064609 04-06
ANTIDIURESIS IN MAN FOLLOWING LYSERGIC ACID DIETHYLAMIDE AND MESCALINE.
066399 05-13
CHROMOSOME STUDIES ON PATIENTS (IN VIVO) AND CELLS (IN VITRO) TREATED WITH LYSERGIC ACID DIETHYLAMIDE.
071987 07-13
HOSPITAL ADMISSIONS DUE TO LYSERGIC ACID DIETHYLAMIDE.
072149 07-15
LYSERGIC ACID DIETHYLAMIDE AND A NOVEL STIMULUS.
075282 08-04
EFFECTS OF LYSERGIC ACID DIETHYLAMIDE ON THE MATERNAL BEHAVIOR OF THE RAT.
075788 08-04
EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND 2-BROM-D-LYSERGIC ACID DIETHYLAMIDE (BOL-148) UPON BEHAVIORAL SLEEP IN RATS.
089045 10-12
THE EFFECT OF DIETHYLAMIDE OF LYSERGIC ACID (DLA) ON THE CONTENT OF MONOAMINES IN SOME NUCLEI OF THE MIDBRAIN AND HYPOTHALAMUS.
101006 12-03

**DIETHYLDITHIOCARBAMATE**
EFFECT OF DIETHYLDITHIOCARBAMATE ON THE TOXICITY OF AMPHETAMINE IN AGGREGATED MICE.
062937 03-04
EFFECTS OF DISULFIRAM AND DIETHYLDITHIOCARBAMATE ON SPONTANEOUS LOCOMOTOR ACTIVITY AND BRAIN CATECHOLAMINE LEVELS IN MICE.
064590 04-04
THE EFFECT OF DISULFIRAM, DIETHYLDITHIOCARBAMATE AND DIMETHYLDITHIOCARBAMATE ON SEROTONIN AND 5-HYDROXYINDOLE-3-ACETIC ACID BRAIN LEVELS IN RATS.
067384 06-03

**DIETHYLPROPION**
DIETHYLPROPION PSYCHOSIS.
080110 09-15
DIETHYLPROPION AND PSYCHOSIS.
095443 11-15

**DIETS**
HEPATIC COMPOSITION AND METABOLISM AFTER ETHANOL CONSUMPTION IN RATS FED LIQUID PURIFIED DIETS.
088599 10-03

**DIFFERENCE**
JUMPING ACTIVITY INDUCED BY SODIUM 5-(1,3 DIMETHYLBUTYL)-5 ETHYL BARBITURATE. II. THE EFFECTS OF AGE DIFFERENCE.
058985 03-04
RELATIONSHIP BETWEEN DIFFERENCE SPECTRA AND METABOLISM: BARBITURATES, DRUG INTERACTION AND SPECIES DIFFERENCE.
064001 04-03
PHASE DIFFERENCE IN THE INDUCTION OF TYROSINE HYDROXYLASE IN CELL BODY AND NERVE TERMINALS OF SYMPATHETIC NEURONES.
075715 08-03

**DIFFERENTIATION**
AMPHETAMINE: DIFFERENTIATION BY D AND L ISOMERS OF BEHAVIOR INVOLVING BRAIN NOREPINEPHRINE OR DOPAMINE.
070921 07-04
5-HYDROXYTRYPTOPHAN PRODUCED HYPOTHERMIA IN MICE AS A TEST FOR PHARMACOLOGICAL DIFFERENTIATION OF ANTIDEPRESSANTS, ANTICHOLINERGICS AND NEUROLEPTICS: SOME DATA ON THE NATURE OF THIS HYPOTHERMIA.
105622 12-06

**DIFFUSION**
THE EFFECT OF FLUROTHYL AND ELECTROSHOCK ON PULMONARY DIFFUSION.
058365 02-15

**DIHYDROCHLORIDE**
BLOCKADE OF NOREPINEPHRINE UPTAKE AND RELATED ACTIVITIES OF CIS- AND TRANS N,N(PRIME)-BIS-(1-NAPHTHYLMETHYL)-1,4 CYCLOHEXANE BIS-(METHYLAMINE) DIHYDROCHLORIDE.
090136 11-03
PSYCHOCLINICAL OBSERVATIONS ON THE EFFECT OF THE LOGOS COMPOUND (ASSOCIATION OF PYRITHIOXINE DIHYDROCHLORIDE, TRYPTOPHAN AND CALCIUM ALPHA-KETOGLUTARATE).
109258 12-11

**DIHYDROERGOTOXINE**
COMPLEXES OF ERGOT ALKALOIDS AND DERIVATIVES. II: INTERACTION OF DIHYDROERGOTOXINE WITH CERTAIN XANTHINES.
046137 01-03

**DIHYDROXYPHENYLALANINE**
DECARBOXYLATION OF 3,4- DIHYDROXYPHENYLALANINE IN VARIOUS HUMAN ADULT AND FETAL TISSUES.
040105 01-13
PHARMACODYNAMICS OF 3,4 DIHYDROXYPHENYLALANINE (DOPA) IN PARKINSONS DISEASE.
063845 04-15

**DILANTIN**
DILANTIN TREATMENT OF HOSPITALIZED CULTURAL FAMILIAL RETARDATES.
062175 03-14
EFFECTS OF DIPHENYLHYDANTOIN (DILANTIN) WITHDRAWAL ON NON-EPILEPTICS: PRELIMINARY REPORT.
067512 06-11
DILANTIN EFFECT ON EMOTIONALLY DISTURBED CHILDREN.
070972 07-14

**DILEMMA**
THE DILEMMA OF DRUG RESEARCH.
068987 06-17

**DIMETHACRINE**
DIMETHACRINE -- A NEW TRICYCLIC ANTIDEPRESSANT: OPEN INVESTIGATIONS IN A CLINIC AND POLYCLINIC.
058281 02-07

**DIMETHOXY-4-ETHYLAMPHETAMINE**
ALTERED FREE ASSOCIATIONS: SOME COGNITIVE EFFECTS OF DOET (2,5 DIMETHOXY-4-ETHYLAMPHETAMINE).
075859 09-12

**DIMETHOXY-4-METHYLAMPHETAMINE**
2,5- DIMETHOXY-4-METHYLAMPHETAMINE -- TISSUE DISTRIBUTION AND NEUROCHEMICAL ACTION.
045544 01-03
PRELIMINARY OBSERVATIONS ON THE METABOLISM OF (3)H-2,5-DIMETHOXY-4-METHYLAMPHETAMINE (STP, DOM).
046197 01-03
2,5 DIMETHOXY-4-METHYLAMPHETAMINE: CLINICAL EVALUATION OF A NEW HALLUCINOGENIC DRUG.
052457 02-12

**DIMETHOXYPHENYLETHYLAMINE**
THE PINK-SPOT, 3,4 DIMETHOXYPHENYLETHYLAMINE, COMMON TEA, AND SCHIZOPHRENIA.
062783 03-13

**DIMETHYLATED**
DETECTION OF PSYCHOTOMIMETIC N,N DIMETHYLATED INDOLEAMINES IN THE URINE OF FOUR SCHIZOPHRENIC PATIENTS.
080506 09-08

**DIMETHYLBUTYL**
JUMPING ACTIVITY INDUCED BY SODIUM 5-(1,3 DIMETHYLBUTYL)-5 ETHYL BARBITURATE. II. THE EFFECTS OF AGE DIFFERENCE.
058985 03-04

**DIMETHYLDITHIOCARBAMATE**
THE EFFECT OF DISULFIRAM, DIETHYLDITHIOCARBAMATE AND DIMETHYLDITHIOCARBAMATE ON SEROTONIN AND 5-HYDROXYINDOLE-3-ACETIC ACID BRAIN LEVELS IN RATS.
067384 06-03

**DIMETHYLTRYPTAMINE**
EFFECTS OF PSILOCYBIN, DIMETHYLTRYPTAMINE AND VARIOUS LYSERGIC ACID DERIVATIVES ON PHOTICALLY INDUCED EPILEPSY IN THE BABOON (PAPIO-PAPIO).
068163 06-03

**DIMETHYLTRYPTAMINES**
BIOLOGICAL ACTIVITIES OF SOME 5-SUBSTITUTED N,N DIMETHYLTRYPTAMINES, ALPHA-METHYLTRYPTAMINES, AND GRAMINES.
065494 05-03

**DIMYRIL**
DIMYRIL ABUSE IN THE EAST MIDLANDS.
064268 04-15

**DINUCLEOTIDE**
PSYCHOPHARMACOLOGICAL ACTION OF NICOTINAMIDE ADENINE DINUCLEOTIDE.
064481 04-04

**DIOXYPHENYLALANINE**
ON THE EFFECT OF DIOXYPHENYLALANINE (L-DOPA) ON EXTRAPYRAMIDAL HYPERKINESIA DUE TO NEUROLEPTIC LONG-TERM MEDICATION.
079950 09-15

**DIPHENYLAMINE**
CENTRAL NEUROTROPIC ACTIVITY OF AMINOPROPYL AND AMINOPROPIONYLIC DERIVATIVES OF IMINOBENZYL AND DIPHENYLAMINE AND ITS RELATION TO IONIZATION CONSTANTS.
072580 08-03

**DIPHENYLHYDANTOIN**
BLOOD AND URINE CONCENTRATIONS OF SUBJECTS RECEIVING BARBITURATES, MEPROBAMATE, GLUTETHIMIDE, OR DIPHENYLHYDANTOIN.
063927 04-13
A CONTROLLED STUDY OF THE EFFECTS OF DIPHENYLHYDANTOIN ON ANXIETY, IRRITABILITY, AND ANGER IN NEUROTIC OUTPATIENTS.
064478 04-10
THE NUMBER OF PURKINJE CELLS AFTER DIPHENYLHYDANTOIN INTOXICATION IN MONKEYS.
066189 05-05
EFFECTS OF DIPHENYLHYDANTOIN (DILANTIN) WITHDRAWAL ON NON-EPILEPTICS: PRELIMINARY REPORT.
067512 06-11
AN ELECTRON MICROSCOPIC STUDY OF AXONAL CHANGES IN THE CEREBELLUM OF DIPHENYLHYDANTOIN INTOXICATED RATS: THE FORMATION OF THE SO-CALLED HONEYCOMB STRUCTURE IN THE AXOPLASM.
070334 07-03
EPILEPSY THERAPY WITH MENTALLY RETARDED CHILDREN: NEUROPSYCHIATRIC DISORDERS THROUGH DIPHENYLHYDANTOIN.
071241 07-15
COMPARATIVE EFFECTS OF AMPHETAMINE, SCOPOLAMINE, CHLORDIAZEPOXIDE, AND DIPHENYLHYDANTOIN ON OPERANT AND EXTINCTION BEHAVIOR WITH BRAIN STIMULATION AND FOOD REWARD.
074935 08-04
THE BROAD RANGE OF USE OF DIPHENYLHYDANTOIN: BIBLIOGRAPHY AND REVIEW.
111961 12-13

**DIPHENYLHYDANTOINATE**
EFFECTS OF SODIUM DIPHENYLHYDANTOINATE AND PEMOLINE UPON CONCENTRATION: A COMPARATIVE STUDY.
070973 07-14

**DIPHENYLINDOLIZINE**
MANNICH BASES FROM 1,2- DIPHENYLINDOLIZINE: EPHEDRINE AND METHAMPHETAMINE AS AMINE COMPONENTS.
055324 02-01

**DIPOTASSIUM**
NEUROPHYSIOLOGICAL STUDY OF DIPOTASSIUM CHLORAZEPATE (4306-CB).
055580 02-03
PHARMACOLOGICAL, TOXICOLOGICAL, AND TERATOLOGICAL STUDIES ON DIPOTASSIUM 7-CHLORO-3-CARBOXY 1,3-DIHYDRO-2,2-DIHYDROXY-5-PHENYL-2H-1,4 BENZODIAZEPINE CHLORAZEPATE (DIPOTASSIUM CHLORAZEPATE, 4306-CB), A NEW TRANQUILLIZER.
055581 02-03
THE PSYCHOPHARMACOLOGICAL TREATMENT OF CARDIAC NEUROTIC PATIENTS WITH DIPOTASSIUM CHLORAZEPATE IN THE DOUBLE-BLIND TEST.
055689 02-10
DIPOTASSIUM CHLORAZEPATE: CLINICAL REPORTS ON A NEW ANTIANXIETY AGENT.
055738 02-09

**DIRECT**
EFFECT OF GANGLIONIC BLOCKING AGENTS ON PRESSOR EFFECTS OF SYMPATHOMIMETIC AMINES OF DIRECT AND INDIRECT ACTION.
110632 12-03

**DISCHARGE**
THE ACTION OF CENTRAL DEPRESSANT DRUGS ON THE SPONTANEOUS DISCHARGE OF ACTION POTENTIALS IN THE SUPERIOR CERVICAL SYMPATHETIC TRUNK OF THE CAT.
072034 07-03

**DISCHARGES**
INDUCTION BY CANNABIS-SATIVA (MARIHUANA) OF RHYTHMIC SPIKE DISCHARGES OVERRIDING REM SLEEP ELECTROCORTICOGRAM IN THE RAT.
069069 06-04
ENHANCEMENT BY DESIPRAMINE OF HYPOTHALAMICALLY EVOKED DISCHARGES IN PREGANGLIONIC SYMPATHETIC NERVES.
097962 11-03

**DISCONTINUATION**
PREDICTION OF CHANGES IN SEVERITY OF THE SCHIZOPHRENIC SYNDROME WITH DISCONTINUATION AND ADMINISTRATION OF PHENOTHIAZINES IN CHRONIC SCHIZOPHRENIC PATIENTS: LANGUAGE AS A PREDICTOR AND MEASURE OF CHANGE IN SCHIZOPHRENIA.
075321 08-08

**DISCONTINUED**
LITHIUM DROP-OUTS: A FOLLOW-UP STUDY OF PATIENTS WHO DISCONTINUED PROPHYLACTIC TREATMENT.
106771 12-09

**DISCRIMINATED**
THE INFLUENCE OF VARIOUS NEUROLEPTIC DRUGS ON SHOCK AVOIDANCE RESPONDING IN RATS. III. AMPHETAMINE ANTAGONISM IN THE DISCRIMINATED SIDMAN AVOIDANCE PROCEDURE.
064476 04-04
THE EFFECT OF MAGNESIUM PEMOLINE, TRICYANOAMINOPROPENE AND D-AMPHETAMINE ON DISCRIMINATED AVOIDANCE PERFORMANCE IN RATS AS A FUNCTION OF AGE.
076133 09-04

**DISCRIMINATION**
THE EFFECT OF MAGNESIUM PEMOLINE ON DISCRIMINATION LEARNING AND EXPLORATORY BEHAVIOR.
059567 03-04
MEMORY ENHANCEMENT OF A PARTLY LEARNED DISCRIMINATION IN PIGEONS BY INTRAMUSCULAR INJECTION OF PHYSOSTIGMINE.
060858 03-04
STRYCHNINE EFFECTS ON DISCRIMINATION LEARNING IN MICE: EFFECTS OF DOSE AND TIME OF ADMINISTRATION.
069066 06-04
EFFECTS OF AMOBARBITAL SODIUM ON THE ACQUISITION AND EXTINCTION OF A LEVER-PRESS SPATIAL DISCRIMINATION IN THE RAT.
069075 06-04
EFFECTS OF CHLORDIAZEPOXIDE ON BLACK WHITE DISCRIMINATION ACQUISITION AND REVERSAL IN WHITE RATS.
070083 07-04
EFFECT OF ARGININE N-ACETYLASPARAGINATE ON DIFFERENT PATTERNS OF DISCRIMINATION.
098049 11-04

**DISCRIMINATIONS**
EFFECTS OF AMPHETAMINE UPON RELEARNING PATTERN AND BLACK WHITE DISCRIMINATIONS FOLLOWING NEOCORTICAL LESIONS IN RATS.
065419 05-04
SCOPOLAMINE EFFECTS ON GO-NO-GO AVOIDANCE DISCRIMINATIONS: INFLUENCE OF STIMULUS FACTORS AND PRIMACY OF TRAINING.
090418 11-04

**DISCRIMINATIVE**
RATE-DEPENDENT EFFECTS OF DRUGS: MODIFICATION BY DISCRIMINATIVE STIMULI OF THE EFFECTS OF AMOBARBITAL ON SCHEDULE CONTROLLED BEHAVIOR.
064749 05-04
EFFECTS OF CHLORDIAZEPOXIDE ON DISCRIMINATIVE FEAR CONDITIONING AND SHUTTLE AVOIDANCE PERFORMANCE IN THE RABBIT.
065451 05-04
THE EFFECT OF EXOGENOUS RNA ON THE RETENTION OF DISCRIMINATIVE LEARNING IN THE RAT.
079982 09-04
ALCOHOL AS A DISCRIMINATIVE STIMULUS IN THE CONDITIONED EMOTIONAL RESPONSE. (PH.D.DISSERTATION).
103350 12-04
THE EFFECTIVENESS OF EXTERNAL AND DRUG PRODUCED INTERNAL STIMULI IN THE DISCRIMINATIVE CONTROL OF OPERANT BEHAVIOR. (PH.D.DISSERTATION).
110682 12-04

**DISEASE**
LEVODOPA, PARKINSONS DISEASE, AND HYPOTENSION.
042521 01-15
CONTROLLED TRIAL OF AMANTADINE HYDROCHLORIDE IN PARKINSONS DISEASE.
043697 01-11
AMANTADINE DOSAGE IN TREATMENT OF PARKINSONS DISEASE.
058241 02-11
TREATMENT OF WILSONS DISEASE WITH L-DOPA AFTER FAILURE WITH PENICILLAMINE.
058243 02-11
PARKINSONS DISEASE: L-DOPA TREATMENT AND HANDWRITING AREA.
058966 03-11
THE EFFECT OF CYCLANDELATE ON MENTAL FUNCTION IN PATIENTS WITH ARTERIOSCLEROTIC BRAIN DISEASE.
061654 03-13
RADIOACTIVE BROMIDE IN THE DIAGNOSIS OF CENTRAL NERVOUS SYSTEM DISEASE.
063208 03-16
METABOLIC STUDIES AND CLINICAL OBSERVATIONS DURING L-DOPA TREATMENT OF PARKINSONS DISEASE.
063822 04-13
PHARMACODYNAMICS OF 3,4 DIHYDROXYPHENYLALANINE (DOPA) IN PARKINSONS DISEASE.
063845 04-15
LIVER DISEASE AND PHENOTHIAZINES; INVOLUNTARY MOVEMENTS.
063854 04-15
L-DOPA THERAPY IN PARKINSONS DISEASE.
064188 04-11
COMPARISON OF LITHIUM CARBONATE AND IMIPRAMINE (IN PREVENTION OF MANIC-DEPRESSIVE DISEASE).
064317 04-09
EFFECTS OF WITHDRAWING DOPA IN PARKINSONS DISEASE.
067623 06-13
THE EFFECT OF L-DOPA ON MONOAMINE METABOLITES IN PARKINSONS DISEASE.
070824 07-13
AMITRIPTYLINE AND CARDIAC DISEASE: RISK OF SUDDEN DEATH IDENTIFIED BY MONITORING SYSTEM.
070854 07-15
A CONTROLLED STUDY OF L-DOPA IN PARKINSONS DISEASE.
071974 07-07
L-DOPA THERAPY OF PARKINSONS DISEASE (A REVIEW OF THE PRELIMINARY EXPERIENCE AT WEST-VIRGINIA UNIVERSITY).
072421 08-07
THE EFFECTS OF L-DOPA THERAPY IN PARKINSONS DISEASE.
072508 08-15
CLINICAL AND AMBULANT TESTING WITH FLUPHENAZINE DECANOATE LYOGEN DEPOT IN THE LONG-TERM TREATMENT OF PSYCHIATRIC DISEASE.
080040 09-16
L-DOPA IN THE TREATMENT OF PARKINSONS DISEASE.
081392 09-17
PSYCHIC SYMPTOMS IN L-DOPA TREATMENT OF PARKINSONS DISEASE.
087659 10-09
L-DOPA IN THE TREATMENT OF FARKINSONS DISEASE.
091715 11-07
SLEEP IN PATIENTS WITH PARKINSONS DISEASE AND NORMAL SUBJECTS PRIOR TO AND FOLLOWING LEVODOPA ADMINISTRATION.
092974 11-11
LITHIUM CARBONATE: A DRUG OF LIMITED EFFICACY IN THE PREVENTION OF MANIC-DEPRESSIVE DISEASE.
106764 12-09

**DISEASE-LIKE**
COLLAGEN DISEASE-LIKE REACTIONS.
100528 12-15

**DISEASES**
LYOGEN IN THE TREATMENT OF MENTAL DISEASES IN CHILDREN.
064173 04-07
THE STRUCTURAL AND BIOCHEMICAL BASIS OF MOVEMENT DISORDERS IN TREATMENT WITH NEUROLEPTIC DRUGS AND IN EXTRAPYRAMIDAL DISEASES.
067107 06-13
THE TREATMENT OF MANIC RELATED DISEASES WITH LITHIUM CARBONATE.
081516 09-09

**DISINHIBITER**
CLINICAL TESTS OF THIOTHIXENE, NEUROLEPTIC DISINHIBITER.
091502 11-08

**DISINTEGRATION**
TEMPORAL DISINTEGRATION AND DEPERSONALIZATION DURING MARIHUANA INTOXICATION.
066232 05-14
MARIHUANA AND TEMPORAL DISINTEGRATION.
071998 07-14

**DISORDER**
A CONTRIBUTION TO THE DEPRESSIVE DISORDER PHARMACOTHERAPY BY THE COMBINATION OF AMITRIPTYLINE AND PERPHENAZINE.
073707 08-10

**DISORDERED**
THE PHARMACOLOGY OF DISORDERED SLEEP: A LABORATORY APPROACH.
084806 10-14

**DISORDERS**
LITHIUM CARBONATE FOR AFFECTIVE DISORDERS. I. CLINICAL PHARMACOLOGY AND TOXICOLOGY.
047831 01-09
THE ACTION OF DIAZEPAM IN NEUROLOGICAL DISORDERS WITH EXCESSIVE MOTOR ACTIVITY.
056779 02-11
PROPHYLACTIC LITHIUM: A DOUBLE-BLIND TRIAL IN RECURRENT AFFECTIVE DISORDERS.
060263 03-09
METHODOLOGICAL PROBLEMS OF PROPHYLACTIC TRIALS IN RECURRENT AFFECTIVE DISORDERS.
060266 03-09
LITHIUM PROPHYLAXIS IN RECURRENT AFFECTIVE DISORDERS.
060267 03-09
AFFECTIVE DISORDERS: PROGRESS, BUT SOME UNRESOLVED QUESTIONS REMAIN.
061682 03-09
NEUROCHEMICAL STUDIES OF THE AFFECTIVE DISORDERS: THE PHARMACOLOGICAL BRIDGE.
061683 03-09
THE VA-NIMH STUDY OF LITHIUM IN AFFECTIVE DISORDERS.
063607 04-09

DRUG-INDUCED EXTRAPYRAMIDAL DISORDERS: A RATING SCALE FOR EXTRAPYRAMIDAL SIDE-EFFECTS.
063773 04-16

CEREBROSPINAL FLUID MONOAMINE CATABOLITES IN DRUG-INDUCED EXTRAPYRAMIDAL DISORDERS.
064097 04-13

LITHIUM CARBONATE IN AFFECTIVE DISORDERS.
064232 04-17

THE USE OF SU-17595A IN THE TREATMENT OF PSYCHIATRIC DISORDERS.
064639 05-07

THIOPENTONE FACILITATED IMPLOSION IN TREATMENT OF PHOBIC DISORDERS.
066907 05-14

THE STRUCTURAL AND BIOCHEMICAL BASIS OF MOVEMENT DISORDERS IN TREATMENT WITH NEUROLEPTIC DRUGS AND IN EXTRAPYRAMIDAL DISEASES.
067107 06-13

A THERAPEUTICAL PATHOMORPHOSIS OF SCHIZOPHRENIA PROCEEDING WITH PARANOID DISORDERS.
067547 06-08

PIPERACETAZINE (QUIDE) IN THE MANAGEMENT OF BEHAVIORAL DISORDERS IN MILDLY RETARDED INSTITUTIONALIZED BOYS.
069071 06-11

EPILEPSY THERAPY WITH MENTALLY RETARDED CHILDREN: NEUROPSYCHIATRIC DISORDERS THROUGH DIPHENYLHYDANTOIN.
071241 07-15

ISONICOTINIC-ACID-HYDRAZIDE (INH) INDUCED MENTAL DISORDERS IN THE COURSE OF LUNG TUBERCULOSIS TREATMENT.
072890 08-15

MENTAL DISORDERS CAUSED BY PHENMETRAZINE ABUSE.
072893 08-15

ACUTE CEREBRAL DISORDERS AFTER HIGH DOSES OF OXYQUINOLINE DERIVATIVES.
073900 08-15

LEVODOPA IN DRUG-INDUCED EXTRAPYRAMIDAL DISORDERS.
074874 08-08

CATECHOLAMINE METABOLISM IN AFFECTIVE DISORDERS -- III. MHPG AND OTHER CATECHOLAMINE METABOLITES IN PATIENTS TREATED WITH LITHIUM CARBONATE.
075410 08-09

THE USE OF IMIPRAMINE IN CHILDRENS BEHAVIOR DISORDERS.
080095 09-14

EVALUATION OF TEGRETOL IN THE TREATMENT OF BEHAVIOUR DISORDERS IN CHILDREN: METHODOLOGY AND RESULTS.
080098 09-07

PROPHYLACTIC LITHIUM IN RECURRENT AFFECTIVE DISORDERS: A FOUR YEAR STUDY.
081152 09-09

DISORDERS OF CONSCIOUSNESS AS A COMPLICATION IN NIALAMID TREATMENT.
085106 10-15

MESORIDAZINE IN THE CONTROL OF BEHAVIOR DISORDERS IN CHILDREN.
086780 10-14

PROPHYLACTIC LITHIUM THERAPY FOR CHRONIC DEPRESSIVE PSYCHOSIS AND SCHIZO-AFFECTIVE DISORDERS.
089105 10-09

UNIVOCAL TREATMENT OF MULTIFORM DISORDERS: DOGMATIL IN PSYCHODIGESTIVE PATHOLOGY.
089174 10-11

PSYCHOSOMATIC FACTORS IN RHEUMATIC DISORDERS AND THEIR RELIEF BY MEDICATION.
089859 11-14

PSYCHOPHARMACOLOGICAL AGENTS AND MICTURITION DISORDERS: CYSTOMETRIC INVESTIGATIONS.
090126 11-15

DRUG-INDUCED EXTRAPYRAMIDAL DISORDERS (UNPUBLISHED PAPER).
093445 11-15

CLINICAL EXPERIENCE WITH 10MG RESERPINE INJECTED I.M.IN DEPRESSIVE DISORDERS.
100019 11-09

EJACULATION DISORDERS.
100533 12-15

PROBLEM BEHAVIOR OF CHILDREN WITH SEVERE MENTAL AND PHYSICAL DISORDERS -- EXPERIENCE OF THE USE OF CARBAMAZEPINE.
105790 12-14

LONG-TERM DRUG THERAPY IN AFFECTIVE DISORDERS: THEORETICAL AND METHODOLOGICAL ISSUES IN CURRENT RESEARCH ON LITHIUM.
106765 12-09

STUDIES ON THE COURSE OF RECURRENT ENDOGENOUS AFFECTIVE DISORDERS.
106766 12-09

TREATMENT OF MOOD DISORDERS WITH LITHIUM CARBONATE.
106773 12-09

LITHIUM AS A THERAPEUTIC AND PREVENTIVE DRUG IN AFFECTIVE DISORDERS.
109723 12-09

THIORIDAZINE AND BEHAVIOR DISORDERS (PERSPECTIVES FOR THE USE OF THE DRUG IN CRIMINOLOGY).
124320 12-17

IMIPRAMINE AS AN EFFECTIVE TOOL IN THE MANAGEMENT OF BEHAVIORAL DISORDERS IN CHILDREN.
134937 12-11

**DISPLAY**

INFLUENCE OF DISPLAY, TASK, AND ORGANISMIC VARIABLES ON INDICES OF MONITORING BEHAVIOR.
043270 01-17

**DISPOSITION**

RELATIONSHIP OF BARBITAL DISPOSITION TO AUTO-INDUCED HYPERSUSCEPTIBILITY IN THE RAT.
046144 01-03

CORRELATION BETWEEN THE DURATION OF THE ANTICONVULSANT ACTIVITY OF DIAZEPAM AND ITS PHYSIOLOGICAL DISPOSITION IN MICE.
046402 01-03

THE PHYSIOLOGICAL DISPOSITION OF CHLORPROMAZINE IN THE RAT AND DOG.
066937 05-03

MARIHUANA: STUDIES ON THE DISPOSITION AND METABOLISM OF DELTA9-TETRAHYDROCANNABINOL IN MAN.
069051 06-13

THE EFFECT OF METHIONINE OF THE REGIONAL AND INTRACELLULAR DISPOSITION OF (3H) METHIONINE SULPHOXIMINE IN RAT BRAIN.
090148 11-03

**DISRUPTION**

EFFECT OF AMPHETAMINE ANALOGS ON DISRUPTION OF ANIMAL BEHAVIOR AND BARBITURATE SLEEPING TIME.
046196 01-03

RESPONSE DISRUPTION FOLLOWING AMPHETAMINE SELF-ADMINISTRATION AND PROGRAMMED ADMINISTRATION.
046209 01-04

PHENOBARBITAL WITHDRAWAL AND BEHAVIORAL DISRUPTION IN THE RAT.
069067 06-04

**DISSOCIALITY**

CASUISTIC CONTRIBUTIONS ON THE USE OF A DRUG IN CRIMINOLOGY ON DISSOCIALITY AND ON MINOR IRREGULAR BEHAVIOR.
095719 11-14

**DISSOCIATION**

DISSOCIATION OF THE EFFECTS OF P-CHLOROPHENYLALANINE ON SELF-STIMULATION AND ON BRAIN SEROTONIN.
058942 02-03

**DISSOCIATIVE**

EVALUATION OF CL-1848C: A NEW DISSOCIATIVE ANESTHETIC IN NORMAL HUMAN VOLUNTEERS.
097971 11-07

**DISTRIBUTION**

2,5- DIMETHOXY-4-METHYLAMPHETAMINE -- TISSUE DISTRIBUTION AND NEUROCHEMICAL ACTION.
045544 01-03

PHARMACOLOGICAL AND BEHAVIORAL STUDIES OF STP: RELATIONSHIP TO TISSUE DISTRIBUTION.
046198 01-03

SODIUM BALANCE AND DISTRIBUTION IN LITHIUM CARBONATE THERAPY.
047828 01-09

EFFECTS OF RESERPINE AND DESIPRAMINE ON THE UPTAKE AND SUBCELLULAR DISTRIBUTION OF 5-HYDROXYTRYPTAMINE IN RABBIT BRAINSTEM AFTER INTRAVENOUS ADMINISTRATION OF 5-HYDROXYTRYPTOPHAN.
056610 02-03

DISTRIBUTION, EXCRETION, AND METABOLISM OF 14C-LABELED QUATERNARY AMMONIUM SALT OF MEPAZINE AND PROMETHAZINE IN RATS.
058571 02-03

DISTRIBUTION, EXCRETION AND METABOLISM OF TRIFLUOPERAZINE METHIODIDE-C14 IN RATS.
064094 04-03

DISTRIBUTION, EXCRETION, AND METABOLISM OF 14C-LABELED QUATERNARY AMMONIUM SALT OF PERPHENAZINE IN RATS.
064261 04-03

(3H)HARMALINE DISTRIBUTION IN MONKEY BRAIN; PHARMACOLOGICAL AND AUTORADIOGRAPHIC STUDY.
067081 05-03

TISSUE DISTRIBUTION OF CHLORPROMAZINE STUDIED BY MICROAUTORADIOGRAPHY.
067961 06-03

COMPARATIVE CHARACTERISTICS OF CHLORPROMAZINE AND CHLORACYZINE DISTRIBUTION IN RATS.
072579 08-03

ON THE DISTRIBUTION AND METABOLISM OF NEUROLEPTIC DRUGS. PART 2: PHARMACOKINETICS OF MOPERONE.
072589 08-03

AUTORADIOGRAPHIC STUDIES ON THE DISTRIBUTION OF PSYCHOACTIVE DRUGS IN THE RAT BRAIN: IV. C14-THIORIDAZINE.
073709 08-03

FORMATION AND REGIONAL DISTRIBUTION OF GAMMA-HYDROXYBUTYRIC ACID IN MAMMALIAN BRAIN.
074864 08-01
DISTRIBUTION AND METABOLISM OF NEUROLEPTIC DRUGS: PART I: PHARMACOKINETICS OF HALOPERIDOL.
079968 09-03
THE EFFECTS OF ACUTE AND PROLONGED LITHIUM TREATMENT ON THE DISTRIBUTION OF ELECTROLYTES, POTASSIUM AND SODIUM.
088614 10-03
MEASUREMENT OF THE DISTRIBUTION OF HYPNOTICS AND CEREBRAL FUNCTION IN ACUTE INTOXICATIONS BY PH.
089040 10-17
SPECIFIC (IN THE SENSE OF INCREASED PREDISPOSITION TO INJURY OF THE SUBDOMINANT HEMISPHERE) DISTRIBUTION OF THE EXTRAPYRAMIDAL SYMPTOMS IN SCHIZOPHRENICS DURING THE COURSE OF HALOPERIDOL TREATMENT.
089106 10-15
SOME EFFECTS OF ETHANOL ON THE TOXICITY AND DISTRIBUTION OF BARBITURATES IN RATS.
090032 11-05
STUDIES ON PSYCHOTROPIC DRUGS (SEVENTH REPORT) -- METABOLIC FATE OF APY-606 -- ABSORPTION, DISTRIBUTION, EXCRETION AND METABOLISM OF TRITIATED APY-606.
131059 12-02

**DISTRICT**
ANXIOLYTICS IN THE PRACTICE OF A DISTRICT PHYSICIAN.
086208 10-17

**DISTURBANCE**
CONTROLLED THERAPEUTIC EXPERIMENTATION IN CASES OF PSYCHOGENOUS GASTROENTERIC DISTURBANCE.
072003 07-07
CHANGES IN LIVER DISTURBANCE ASSOCIATED WITH LONG-TERM TRANQUILIZING MEDICATION (A FOLLOW-UP STUDY).
075839 08-15
INFLUENCE OF CENTROPHENOXIN ON MEMORY DISTURBANCE AFTER ELECTROSHOCK.
079993 09-08

**DISTURBANCES**
CLINICAL INVESTIGATIONS OF THE ACTION OF A PHOSPHOLIPID COMPLEX FROM CEREBRAL CORTEX ON CEREBRAL CIRCULATION DISTURBANCES.
058282 02-11
USE OF PANGAMIC ACID (VITAMIN-B15) IN CEREBRAL ARTHEROSCLEROSIS WITH MENTAL DISTURBANCES.
067148 06-10
TREATMENT OF PSYCHOSOMATIC DISTURBANCES ASSOCIATED WITH PSYCHIC SYMPTOMS IN INTERNAL MEDICINE BY MEANS OF DOXEPIN.
072381 07-09
RESULTS OBTAINED WITH PROPERICIAZIN (8-909-RP) IN THE TREATMENT OF BEHAVIOR AND CHARACTER DISTURBANCES IN CHILDREN AND ADOLESCENTS.
078730 09-14
RESULTS OF THE MEDICAL TREATMENT IN AGED PATIENTS WITH CEREBRAL ORGANIC DISTURBANCES.
087336 10-11
PHARMACOLOGICAL MANAGEMENT OF CHARACTER TYPE BEHAVIOR DISTURBANCES IN THE INFANT AND CHILD.
093090 11-07
DISTURBANCES IN TRYPTAMINE SEROTONIN METABOLISM ASSOCIATED WITH PSYCHOTIC PHENOMENA.
121084 12-13

**DISTURBED**
EXPERIMENTAL PSYCHOLOGICAL STUDY OF PERFORMANCE CHANGES WITH PERAZINE (TAXILAN) IN MENTALLY DISTURBED AND IN HEALTHY EXPERIMENTAL SUBJECTS FOLLOWING REGIMEN AND SINGLE DOSE ADMINISTRATION.
058235 02-11
THE PHARMACOLOGY OF DISTURBED SLEEP.
063592 03-10
DILANTIN EFFECT ON EMOTIONALLY DISTURBED CHILDREN.
070972 07-14
MEGAVITAMIN THERAPY WITH SEVERELY DISTURBED CHILDREN.
075819 08-11
COMPARISON OF HALOPERIDOL AND FLUPHENAZINE IN DISTURBED CHILDREN.
076233 09-11
THE USE OF SULTHIAME WITH DISTURBED MENTALLY SUBNORMAL PATIENTS.
079215 09-11
EXPERIENCE WITH PROPERICIAZIN (AOLEPT) IN THE TREATMENT OF CHILDREN WITH DISTURBED PSYCHOMOTOR FUNCTIONS AND RESTLESSNESS.
081144 09-11
METHYLPHENIDATE AND THIORIDAZINE: LEARNING, REACTION TIME, ACTIVITY, AND CLASSROOM BEHAVIOR IN DISTURBED CHILDREN.
081631 10-14
TREATMENT WITH THIORIDAZINE OF EMOTIONALLY DISTURBED CHILDREN IN A DAY HOSPITAL.
082090 10-14

**DISUBSTITUTED**
SYNTHESIS OF POSSIBLE METABOLITES OF CHLORPROMAZINE. III. 7,8 DISUBSTITUTED CHLORPROMAZINE DERIVATIVES.
094623 11-01

**DISULFIDE**
CARBON DISULFIDE INTOXICATION FROM OVERDOSAGE OF DISULFIRAM.
065691 05-09

**DISULFIRAM**
COMBINED USE OF DISULFIRAM AND METRONIDAZOLE IN TREATMENT OF ALCOHOLISM.
058589 02-15
EXCRETION OF VANYLGLYCOL IN HUMAN URINE UNDER DIETARY CONTROL, AND DURING TREATMENT WITH ANTIBIOTICS, DISULFIRAM, A MONOAMINE OXIDASE INHIBITOR, ALPHA-METHYLDOPA, AND RESERPINE.
060272 03-13
EFFECTS OF DISULFIRAM AND DIETHYLDITHIOCARBAMATE ON SPONTANEOUS LOCOMOTOR ACTIVITY AND BRAIN CATECHOLAMINE LEVELS IN MICE.
064590 04-04
CARBON DISULFIDE INTOXICATION FROM OVERDOSAGE OF DISULFIRAM.
065691 05-09
THE EFFECT OF DISULFIRAM, DIETHYLDITHIOCARBAMATE AND DIMETHYLDITHIOCARBAMATE ON SEROTONIN AND 5-HYDROXYINDOLE-3-ACETIC ACID BRAIN LEVELS IN RATS.
067384 06-03
NEUROTOXIC SIDE-EFFECTS IN DISULFIRAM (ANTABUSE) OVERDOSAGE.
067743 06-15
THE DISULFIRAM - LIKE ACTION OF EMBRAN.
067744 06-07

**DISULPHIDE**
ELECTROCARDIOGRAPHIC DATA IN CHRONIC ALCOHOLISM BEFORE, DURING AND AFTER TREATMENT WITH TETRAETHYLTHIURAM DISULPHIDE.
092481 11-14

**DITRAN**
ELECTROENCEPHALOGRAPHIC ANALYSIS OF EXPERIMENTAL PSYCHOSIS BROUGHT ON BY DITRAN.
067147 06-13
COMPARISON OF DITRAN INTOXICATION AND ACUTE ALCOHOL PSYCHOSES.
121083 12-14

**DIURNAL**
SCOPOLAMINE EFFECTS ON CONDITIONED SUPPRESSION: INFLUENCE OF DIURNAL CYCLE AND TRANSITIONS BETWEEN NORMAL AND DRUGGED STATES.
071790 07-03

**DJAKARTA**
PRELIMINARY EXPERIENCES WITH NOBRIUM IN PRIVATE PSYCHIATRIC PRACTICE IN DJAKARTA.
130714 12-10

**DL-ALPHA-HYDRAZINO**
POTENTIATION OF THE CENTRAL ACTIONS OF 5-HYDROXYTRYPTOPHAN IN RABBITS BY DL-ALPHA-HYDRAZINO ALPHA-METHYLDOPA.
058879 02-03

**DLA**
THE EFFECT OF DIETHYLAMIDE OF LYSERGIC ACID (DLA) ON THE CONTENT OF MONOAMINES IN SOME NUCLEI OF THE MIDBRAIN AND HYPOTHALAMUS.
101006 12-03

**DMI**
EFFECTS OF LITHIUM PRETREATMENT ON AMPHETAMINE AND DMI TETRABENAZINE PRODUCED PSYCHOMOTOR BEHAVIOR.
062521 03-04
MODIFICATION BY DESIPRAMINE (DMI) OF THE AVAILABILITY OF NOREPINEPHRINE RELEASED BY RESERPINE IN THE HYPOTHALAMUS OF THE RAT IN VIVO.
066374 05-03
BIOCHEMICAL AND BEHAVIORAL EFFECT OF AMPHETAMINE IN DMI - RO-4-1284 INDUCED HYPERACTIVITY.
070951 07-03
STUDIES ON ADRENERGIC MECHANISMS IN THE ACTION OF DESMETHYLIMIPRAMINE (DMI).
090421 11-04

**DOCTOR**
SETTING, PATIENT, AND DOCTOR EFFECTS ON DRUG RESPONSE IN NEUROTIC PATIENTS: II. DIFFERENTIAL IMPROVEMENT.
065446 05-10
SETTING, PATIENT, AND DOCTOR EFFECTS ON DRUG RESPONSE IN NEUROTIC PATIENTS: I. DIFFERENTIAL ATTRITION, DOSAGE DEVIATION, AND SIDE REACTION RESPONSES TO TREATMENT.
065453 05-10
DRUG, DOCTOR WARMTH, AND CLINIC SETTING IN THE SYMPTOMATIC RESPONSE TO MINOR TRANQUILIZERS.
087386 10-10
ABSTRACT OF THESES FOR DOCTOR OF MEDICAL SCIENCES, THE UNIVERSITY OF TOKYO: MORITA THERAPEUTIC APPROACH TO SCHIZOPHRENIA.
126778 12-17

**DOCTORS**
IS A DOUBLE-BLIND CLINICAL TRIAL REALLY DOUBLE-BLIND: A REPORT OF DOCTORS MEDICATION GUESSES.
065488 05-10

**DOET**
ALTERED FREE ASSOCIATIONS: SOME COGNITIVE EFFECTS OF DOET (2,5 DIMETHOXY-4-ETHYLAMPHETAMINE).
075859 09-12

**DOG**
SIMILARITIES BETWEEN BEHAVIORAL AND PHARMACOLOGICAL ACTIONS OF YOHIMBINE AND 5-HYDROXYTRYPTOPHAN IN THE CONSCIOUS DOG.
064253 04-04

THE PHYSIOLOGICAL DISPOSITION OF CHLORPROMAZINE IN THE RAT AND DOG.
066937 05-03

PRAZEPAM METABOLITES IN DOG URINE.
071942 07-03

THE ACTION OF TRYPTAMINE ON THE DOG SPINAL CORD AND ITS RELATIONSHIP TO THE AGONISTIC ACTIONS OF LSD-LIKE PSYCHOTOGENS.
090422 11-03

**DOGMATIL**
DOGMATIL: A NEW ILLUMINATION ON THE PSYCHOLOGICAL PROBLEMS OF SENESCENCE.
058313 02-11

UNIVOCAL TREATMENT OF MULTIFORM DISORDERS: DOGMATIL IN PSYCHODIGESTIVE PATHOLOGY.
089174 10-11

**DOGS**
ACTION OF GUANETHIDINE ON THE PRESSOR EFFECT OF ANGIOTENSIN IN ADRENALECTOMIZED DOGS.
046399 01-03

CONDITIONAL AUTONOMIC RESPONSES INDUCED IN DOGS BY ATROPINE AND MORPHINE.
066386 05-03

THE INFLUENCE OF INDOPAN ON THE HIGHER NERVOUS ACTIVITY OF DOGS.
067299 06-04

AVOIDANCE TRAINING OF HIPPOCAMPAL THETA WAVES IN FLAXEDILIZED DOGS AND ITS RELATION TO SKELETAL MOVEMENT.
075399 08-04

DRUG-INDUCED STEREOTYPED BEHAVIOR AND ITS ANTAGONISM IN DOGS.
079888 09-04

COITAL BEHAVIOR IN DOGS: VI. LONG-TERM EFFECTS OF CASTRATION UPON MATING IN THE MALE.
080606 09-03

**DOMESTIC**
THE EXCITATORY AND INHIBITORY INNERVATION OF THE STOMACHS OF THE DOMESTIC FOWL.
074854 08-03

**DOMINANCE**
EFFECTS OF CHRONIC POSTNATAL DRUG ADMINISTRATION ON ADULT DOMINANCE BEHAVIOR IN TWO GENERA OF MICE.
042837 01-04

EPINEPHRINE AND NOREPINEPHRINE EFFECTS ON SOCIAL DOMINANCE BEHAVIOR.
069530 07-04

**DOOR**
RETENTION RATES OF SCHIZOPHRENIA: A COMPARISON OF SHOCK THERAPY AND PSYCHOPHARMACOLOGICAL ERAS AND OF CLOSED AND OPEN DOOR POLICIES.
069795 07-08

**DOPA**
POTENTIATION AND INHIBITION OF SOME CENTRAL ACTIONS OF L(-) DOPA BY DECARBOXYLASE INHIBITORS.
040750 01-03

ANTAGONISTIC EFFECTS OF DOPA AND PROPRANOLOL ON BRAIN GLYCOGEN.
058800 02-03

DOPA INDUCED EXCITEMENT IN THE CAT: ITS RELATIONSHIP TO BRAIN NOREPINEPHRINE CONCENTRATIONS.
058840 02-04

PHARMACODYNAMICS OF 3,4 DIHYDROXYPHENYLALANINE (DOPA) IN PARKINSONS DISEASE.
063845 04-15

DOPA EFFECTS ON MOTILITY IN MICE; POTENTIATION BY MK-485 AND DEXCHLORPHENIRAMINE.
064411 04-03

EFFECTS OF WITHDRAWING DOPA IN PARKINSONS DISEASE.
067623 06-13

A SOURCE OF ERROR IN CATECHOLAMINE TURNOVER STUDIES WITH LABELED DOPA: SLOW DISAPPEARANCE OF THE PRECURSOR.
074818 08-03

INFLUENCE OF AMINAZIN ON ADRENALIN, NORADRENALINE, DOPAMINE, AND DOPA EXCRETION IN HEALTHY PEOPLE AND IN THE MANIC PHASE OF THE MANIC-DEPRESSIVE PSYCHOSIS.
090355 11-03

**DOPA-14C**
STIMULATION OF DOPA-14C INCORPORATION INTO MELANOMA TISSUE BY CHLORPROMAZINE AND RESERPINE.
040584 01-03

**DOPAMINE**
EFFECTS OF AMPHETAMINE DERIVATIVES ON BRAIN DOPAMINE AND NORADRENALINE.
040126 01-03

PHARMACOLOGICAL SIGNIFICANCE OF BIOGENIC AMINES IN THE LUNGS: NORADRENALINE AND DOPAMINE.
041539 01-03

EFFECT OF DRUGS USED IN PSYCHOSES ON CEREBRAL DOPAMINE METABOLISM.
041566 01-03

INCREASED RELEASE OF DOPAMINE FROM STRIATAL DOPAMINERGIC TERMINALS IN THE RAT AFTER TREATMENT WITH A NEUROLEPTIC: THIOPROPERAZINE.
042742 01-03

BEHAVIORAL AND BRAIN CATECHOLAMINE DEPLETING ACTIONS OF U-14624, AN INHIBITOR OF DOPAMINE BETA-HYDROXYLASE.
058986 03-03

DOPAMINE CONCENTRATIONS IN THE BRAINSTEM MESENCEPHALON OF ACTIVE RATS AS COMPARED WITH PASSIVE RATS.
060274 03-04

NOREPINEPHRINE AND DOPAMINE IN THE DEVELOPING CHICK BRAIN.
060865 03-03

AMANTADINE DOPAMINE INTERACTION: POSSIBLE MODE OF ACTION IN PARKINSONISM.
066315 05-03

QUANTITATIVE THIN-LAYER CHROMATOGRAPHIC ESTIMATION OF LABELED DOPAMINE AND NOREPINEPHRINE, THEIR PRECURSORS AND METABOLITES.
070063 07-06

AMPHETAMINE: DIFFERENTIATION BY D AND L ISOMERS OF BEHAVIOR INVOLVING BRAIN NOREPINEPHRINE OR DOPAMINE.
070921 07-04

THE EFFECT OF AMANTADINE ON THE UPTAKE OF DOPAMINE AND NORADRENALINE BY RAT BRAIN HOMOGENATES.
074148 08-03

MECHANISM OF THE GAMMA-HYDROXYBUTYRATE INDUCED INCREASE IN BRAIN DOPAMINE AND ITS RELATIONSHIP TO SLEEP.
074865 08-04

THE ROLE OF BRAIN DOPAMINE IN BEHAVIORAL REGULATION AND THE ACTIONS OF PSYCHOTROPIC DRUGS.
075869 09-04

INDUCED CHANGES IN CAUDATE NUCLEUS DOPAMINE AND ELECTROSHOCK THRESHOLD.
079179 09-03

THE PREFERRED CONFORMATION OF DOPAMINE FROM MOLECULAR ORBITAL THEORY.
090068 11-13

INFLUENCE OF AMINAZIN ON ADRENALIN, NORADRENALINE, DOPAMINE, AND DOPA EXCRETION IN HEALTHY PEOPLE AND IN THE MANIC PHASE OF THE MANIC-DEPRESSIVE PSYCHOSIS.
090355 11-03

DYNAMIC CHARACTERISTICS OF THE FUNCTIONAL COMPARTMENT OF DOPAMINE IN DOPAMINERGIC TERMINALS OF THE RAT STRIATUM.
120465 12-03

**DOPAMINE-BETA-HYDROXYLASE**
NEURALLY MEDIATED INCREASE IN DOPAMINE-BETA-HYDROXYLASE ACTIVITY (UNPUBLISHED PAPER).
088376 10-03

EFFECT OF HYPOPHYSECTOMY ON ADRENAL DOPAMINE-BETA-HYDROXYLASE ACTIVITY IN THE RAT (UNPUBLISHED PAPER).
092383 11-03

**DOPAMINERGIC**
INCREASED RELEASE OF DOPAMINE FROM STRIATAL DOPAMINERGIC TERMINALS IN THE RAT AFTER TREATMENT WITH A NEUROLEPTIC: THIOPROPERAZINE.
042742 01-03

POSSIBLE DOPAMINERGIC PATHWAY FROM SUBSTANTIA-NIGRA TO PUTAMEN.
063983 04-03

DYNAMIC CHARACTERISTICS OF THE FUNCTIONAL COMPARTMENT OF DOPAMINE IN DOPAMINERGIC TERMINALS OF THE RAT STRIATUM.
120465 12-03

**DOPE**
SOME DOPE USERS SPEAK OUT.
070415 07-12

**DOSAGE**
STUDIES OF DELAYED ACTION MEDICATION: V. PLASMA LEVELS AND URINARY EXCRETION OF FOUR DIFFERENT DOSAGE FORMS OF CHLORPROMAZINE.
041559 01-13

AMANTADINE DOSAGE IN TREATMENT OF PARKINSONS DISEASE.
058241 02-11

TREATMENT OF RESISTANT SCHIZOPHRENICS WITH EXTREME HIGH DOSAGE FLUPHENAZINE HYDROCHLORIDE.
063597 04-08

COLORIMETRIC DETERMINATION OF AMPHETAMINE SALTS IN DOSAGE FORMS.
064159 04-01
SPECTROPHOTOMETRIC DETERMINATION OF CHLORPROMAZINE IN PHARMACEUTICAL DOSAGE FORMS.
064262 04-06
THE USE OF MOLINDONE IN THE TREATMENT OF ACUTE PSYCHOTIC STATES: COMPARISON OF TWO DOSAGE SCHEDULES.
064286 04-08
SETTING, PATIENT, AND DOCTOR EFFECTS ON DRUG RESPONSE IN NEUROTIC PATIENTS: I. DIFFERENTIAL ATTRITION, DOSAGE DEVIATION, AND SIDE REACTION RESPONSES TO TREATMENT.
065453 05-10
DOSAGE SCHEDULES IN GENERAL PRACTICE.
068137 06-16
QUANTITATIVE EEG CHANGES DURING HIGH AND LOW DOSAGE FLUPHENAZINE HYDROCHLORIDE TREATMENT.
073710 08-13

**DOSE**
ON THE ANALYSIS OF CARDIAC BETA-RECEPTORS: STUDIES ON THE BASE OF DOSE EFFECT CURVES FOR ISOPRENALINE, PROPRANOLOL, AND KL-255.
055396 02-03
EXPERIMENTAL PSYCHOLOGICAL STUDY OF PERFORMANCE CHANGES WITH PERAZINE (TAXILAN) IN MENTALLY DISTURBED AND IN HEALTHY EXPERIMENTAL SUBJECTS FOLLOWING REGIMEN AND SINGLE DOSE ADMINISTRATION.
058235 02-11
OCULAR CHANGES OCCURRING WITH PROLONGED HIGH DOSE CHLORPROMAZINE THERAPY. RESULTS FROM A COLLABORATIVE STUDY.
060861 03-15
MAINTENANCE THERAPY OF CHRONIC PSYCHOTIC PATIENTS WITH A WEEKLY ORAL DOSE OF R-16341. A CONTROLLED DOUBLE-BLIND STUDY.
064284 04-09
PERSISTENCE OF DOSE RELATED BEHAVIOUR IN MICE.
067606 06-04
STRYCHNINE EFFECTS ON DISCRIMINATION LEARNING IN MICE: EFFECTS OF DOSE AND TIME OF ADMINISTRATION.
069066 06-04
CHANGE IN SENSITIVITY TO D-AMPHETAMINE IN FRONTAL RATS AS A FUNCTION OF TIME: SHIFTING OF THE DOSE RESPONSE CURVE.
075238 08-04
EFFECT OF ATROPINE DOSE LEVEL ON THE SUPPRESSION OF WATER REINFORCED VI RESPONDING.
075870 09-04
DOSE RESPONSE ANALYSIS OF CARBACHOL ELICITED DRINKING IN THE RAT LIMBIC SYSTEM.
076081 09-04
INDICATIONS FOR HIGH DOSE CHLORPROMAZINE THERAPY IN CHRONIC SCHIZOPHRENIA.
089433 10-08

**DOSES**
HIGH DOSES OF TRIFLUOPERAZINE AND TARDIVE DYSKINESIA.
042699 01-15
A METHOD OF IDENTIFYING NARCOTIC ANALGESICS IN HUMAN URINE AFTER THERAPEUTIC DOSES.
057473 02-16
THE USE OF HIGH DOSES OF FLUPHENAZINE IN THE TREATMENT OF PSYCHOTIC PATIENTS.
063589 03-08
ELECTROCORTICAL REACTIONS OF PINEALECTOMIZED AND INTACT RATS TO LETHAL DOSES OF PENTOBARBITAL.
064101 04-03
DEPRESSION OF TWO-WAY AVOIDANCE LEARNING AND ENHANCEMENT OF PASSIVE AVOIDANCE LEARNING BY SMALL DOSES OF PHYSOSTIGMINE.
064365 04-04
DRUG COMBINATION ALLOWS SMALLER DOSES OF L-DOPA.
066465 05-07
PERSISTENT BEHAVIOURAL AND ELECTROENCEPHALOGRAPHIC CHANGES AFTER SINGLE DOSES OF NITRAZEPAM AND AMYLOBARBITONE SODIUM.
068005 06-14
ACUTE CEREBRAL DISORDERS AFTER HIGH DOSES OF OXYQUINOLINE DERIVATIVES.
073900 08-15
BEHAVIORAL CHANGES FOLLOWING REPEATED LOW DOSES OF MONOMETHYLHYDRAZINE.
082959 10-05
FIRST ORIENTATIONS ON THE USE OF HIGH DOSES OF OXAZEPAM, BASED ON PERSONAL CLINICAL THERAPEUTIC EXPERIENCE.
124308 12-10

**DOSING**
ANTIEPILEPTIC DOSING AFTER EXCESSIVE ALCOHOL INTAKE.
093919 11-11

**DOUBLE**
FAILURE OF TRICYANOAMINOPROPENE TO FACILITATE ACQUISITION OF DOUBLE ALTERNATION IN RATS.
088471 10-04

**DOUBLE-BLIND**
SUBNORMAL SERUM FOLATE DUE TO ANTICONVULSIVE THERAPY: A DOUBLE-BLIND STUDY OF THE EFFECT OF FOLIC ACID TREATMENT IN PATIENTS WITH DRUG INDUCED SUBNORMAL SERUM FOLATES.
042700 01-11
A DOUBLE-BLIND COMPARISON OF CHLORPROMAZINE AND MESORIDAZINE (TPS-23).
045508 01-07
THE PSYCHOPHARMACOLOGICAL TREATMENT OF CARDIAC NEUROTIC PATIENTS WITH DIPOTASSIUM CHLORAZEPATE IN THE DOUBLE-BLIND TEST.
055689 02-10
A DOUBLE-BLIND EVALUATION OF CAPURIDE (PACINOX) AS A PRESURGICAL AID TO SLEEP.
058371 02-14
PROPHYLACTIC LITHIUM: A DOUBLE-BLIND TRIAL IN RECURRENT AFFECTIVE DISORDERS.
060263 03-09
A DOUBLE-BLIND EVALUATION OF THE ANTIEMETIC EFFICACY OF BENZQUINAMIDE, PROCHLORPERAZINE AND TRIMETHOBENZAMIDE IN OFFICE PRACTICE.
063022 03-07
MAINTENANCE THERAPY OF CHRONIC PSYCHOTIC PATIENTS WITH A WEEKLY ORAL DOSE OF R-16341. A CONTROLLED DOUBLE-BLIND STUDY.
064284 04-09
IMIPRAMINE PAMOATE IN HOSPITALIZED DEPRESSIVES: A DOUBLE-BLIND COMPARISON WITH PLACEBO.
064429 04-10
IS A DOUBLE-BLIND CLINICAL TRIAL REALLY DOUBLE-BLIND: A REPORT OF DOCTORS MEDICATION GUESSES.
065488 05-10
DEXBENZETIMIDE IN NEUROLEPTIC INDUCED PARKINSONISM. A DOUBLE-BLIND CROSSOVER STUDY WITH A 16-WEEK FOLLOW-UP.
067176 06-11
DOUBLE-BLIND STUDY COMPARING THE INTRAMUSCULAR USAGE OF AN ACRIDAN DERIVATIVE, SKF-14336, TO CHLORPROMAZINE.
067513 06-11
DOUBLE-BLIND COMPARATIVE STUDY OF THE EFFECTS OF THIOTHIXENE AND THIORIDAZINE IN TWENTY CHRONIC SCHIZOPHRENIC PATIENTS.
070880 07-08
DOXEPIN VERSUS CHLORDIAZEPOXIDE: A DOUBLE-BLIND STUDY ON ANXIOUS OUTPATIENTS.
072143 07-10
A DOUBLE-BLIND COMPARISON OF LITHIUM AND CHLORPROMAZINE IN THE TREATMENT OF MANIC STATES.
075430 08-09
THE CONTRACEPTIVE PILL, SIDE-EFFECTS AND PERSONALITY: REPORT OF A CONTROLLED DOUBLE-BLIND TRIAL.
075472 08-15
A COMPARATIVE DOUBLE-BLIND TRIAL OR PIMOZIDE AND FLUPHENAZINE IN CHRONIC SCHIZOPHRENIA.
078932 09-08
A DOUBLE-BLIND INTENSIVE CROSSOVER DESIGN TRIAL OF METHYSERGIDE IN MANIA.
085327 10-09
COMPARATIVE, DOUBLE-BLIND STUDY OF DOXEPINE AND LIBRIUM IN CASES OF PSYCHONEUROSES WITH ANXIETY AMONG HOSPITALIZED AND AMBULATORY PATIENTS.
087489 10-10
THE USEFULNESS OF PLACEBO AND THE DOUBLE-BLIND TECHNIQUE IN THE EVALUATION OF PSYCHOTROPIC DRUGS.
089054 10-17
A SEVENTH-MONTH DOUBLE-BLIND TRIAL OF AMITRIPTYLINE AND DIAZEPAM IN ECT TREATED DEPRESSED PATIENTS.
097562 11-09
CLINICAL EXPERIENCE WITH TARASAN AND THIORIDAZINE IN MENTALLY RETARDED CHILDREN -- A COMPARATIVE DOUBLE-BLIND STUDY.
097655 11-14
DOUBLE-BLIND STUDY OF CLOPENTHIXOL AND CHLORPROMAZINE IN ACUTE HOSPITALIZED SCHIZOPHRENICS.
098048 11-08
DOUBLE-BLIND STUDY WITH ANTIDEPRESSANTS.
098174 11-10
A DOUBLE-BLIND INVESTIGATION WITH FLUPENTHIXOL AND TRIFLUOPERAZINE AT TREATMENT OF SCHIZOPHRENIC PSYCHOSES.
100017 11-08
CLINICOELECTROENCEPHALOGRAPHIC EVALUATION OF A NEW BENZODIAZEPINIC DERIVATIVE (RO-5-4023) ADMINISTERED ORALLY IN EPILEPTIC PATIENTS USING A DOUBLE-BLIND METHOD.
100959 12-07

RESEARCH IN NEW EXPERIMENTAL METHODS FOR PSYCHOTROPIC DRUGS: RESULTS OF A DOUBLE-BLIND STUDY WITH A NEW TRANQUILIZER, NOBRIUM.
112282 12-16

A DOUBLE-BLIND, CROSSOVER COMPARISON OF ABY-606 WITH CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIA.
118583 12-08

A DOUBLE-BLIND, CONTROLLED STUDY OF THE EFFECTS OF OXYPERTINE AND CARPIPRAMINE ON SCHIZOPHRENIA.
129082 12-08

A DOUBLE-BLIND COMPARISON OF S-804 (NEW BENZODIAZEPINE DRUG) WITH CHLORDIAZEPOXIDE AND DIAZEPAM IN THE TREATMENT OF NEUROSIS.
129097 12-10

A DOUBLE-BLIND TRIAL OF THREE ANTIDEPRESSANTS (GO-2998, GO-2330 AND IMIPRAMINE HYDROCHLORIDE).
134903 12-09

PROTRIPTYLINE: A DOUBLE-BLIND CROSSOVER TRIAL IN DEPRESSIVES.
134940 12-09

DOUBLE-BLIND STUDY WITH SINEQUAN (DOXEPIN) VS DIAZEPAM VS PLACEBO IN PSYCHONEUROSIS.
138526 12-10

**DOXEPIN**

CLINICAL EVALUATION OF DOXEPIN AND AMITRIPTYLINE IN DEPRESSED PATIENTS.
064637 05-09

DOXEPIN (SINEQUAN) AND OTHER DRUGS FOR ANXIETY AND DEPRESSION.
066877 05-17

DOXEPIN HCL (SINEQUAN) – CURRENT INFORMATION.
068203 06-13

TRIAL OF A NEW PSYCHOTROPIC DRUG DOXEPIN.
069072 06-07

A COMPARATIVE EVALUATION OF DOXEPIN AND CHLORDIAZEPOXIDE IN THE TREATMENT OF PSYCHONEUROTIC OUTPATIENTS.
072140 07-10

A COMPARISON OF DOXEPIN AND CHLORDIAZEPOXIDE IN THE THERAPY OF ANXIETY.
072141 07-10

DOXEPIN VERSUS CHLORDIAZEPOXIDE: A DOUBLE-BLIND STUDY ON ANXIOUS OUTPATIENTS.
072143 07-10

DOXEPIN IN THE TREATMENT OF PSYCHONEUROTIC PATIENTS.
072146 07-11

TREATMENT OF PSYCHOSOMATIC DISTURBANCES ASSOCIATED WITH PSYCHIC SYMPTOMS IN INTERNAL MEDICINE BY MEANS OF DOXEPIN.
072381 07-09

DOUBLE-BLIND STUDY WITH SINEQUAN (DOXEPIN) VS DIAZEPAM VS PLACEBO IN PSYCHONEUROSIS.
138526 12-10

**DOXEPINE**

TESTS OF A NEW ANXIOLYTIC: THE USE OF DOXEPINE IN GERIATRIC CASES.
086236 10-07

COMPARATIVE, DOUBLE-BLIND STUDY OF DOXEPINE AND LIBRIUM IN CASES OF PSYCHONEUROSES WITH ANXIETY AMONG HOSPITALIZED AND AMBULATORY PATIENTS.
087489 10-10

**DREAM**

HYPNOTICS AND ALTERED SLEEP DREAM PATTERNS: I. ALL-NIGHT EEG STUDIES OF GLUTETHIMIDE, METHYPRYLON, AND PENTOBARBITAL.
066233 05-14

HYPNOTICS AND ALTERED SLEEP DREAM PATTERNS: II. ALL-NIGHT EEG STUDIES OF CHLORAL HYDRATE, FLURAZEPAM, AND METHAQUALONE.
066234 05-14

TO SLEEP, PERCHANCE TO DREAM: NEW DRUG FOR INSOMNIACS DOESNT INTERFERE WITH REM TIME.
068071 06-14

DREAM CONTENT IN MALE SCHIZOPHRENIC PATIENTS.
069034 06-08

**DREAMING**

THE EFFECTS OF 4 HYPNOTIC DRUGS AND PLACEBO ON NORMAL SUBJECTS SLEEPING AND DREAMING AT HOME.
087863 10-06

**DREAMS**

DRUGS, DREAMS AND THE CORONARY PATIENT.
066874 05-14

ON ACTIVATION OF DREAMS BY THYMOLEPTICS.
079995 09-14

DOES NOLUDAR (METHYPRYLON) CHANGE DREAMS?
082173 10-14

FATIGUE, SLEEP AND DREAMS.
133916 12-14

**DRINKERS**

PSYCHOMOTOR REACTIONS TO A SLIGHT ALCOHOLEMIA. A COMPARATIVE STUDY ON DRINKERS AND NORMAL INDIVIDUALS.
085043 10-15

**DRINKING**

FUNCTIONAL RELATIONSHIPS OF BRAIN CIRCUITS IN CONTROL OF DRINKING BEHAVIOR.
058961 03-04

COMPARISON OF DRINKING ELICTED BY ESERINE OR DFP INJECTED INTO PREOPTIC AREA OF RAT BRAIN.
069637 07-04

DOSE RESPONSE ANALYSIS OF CARBACHOL ELICITED DRINKING IN THE RAT LIMBIC SYSTEM.
076081 09-04

THE EFFECTS OF ADRENERGIC AND CHOLINERGIC AGENTS UPON EATING AND DRINKING IN DEPRIVED RATS.
076132 09-03

EATING, DRINKING AND SPONTANEOUS ACTIVITY IN RATS AFTER THE ADMINISTRATION OF CHLORPROMAZINE.
079999 09-04

ANTICHOLINERGIC CENTRAL BLOCKADE OF SALT AROUSED AND DERIVATION INDUCED DRINKING.
081227 09-04

**DRIVE**

COMBINED EFFECT OF DRUG AND DRIVE ON THE CONSOLIDATION PROCESS.
065452 05-04

TESTING THE PERFORMANCE UNDER APONEURON OF OTHERWISE NORMAL SCHOOL CHILDREN WITH A TENDENCY TOWARD REDUCED DRIVE AND EASY TIRING.
080563 09-11

**DRIVING**

PSYCHOTROPIC DRUG USE AND DRIVING RISK: A REVIEW AND ANALYSIS.
093085 11-17

STUDY ON THE EFFECTS OF PSYCHOTROPIC DRUGS UPON THE PHOTICALLY DRIVING THETA RESPONSE OF ELECTROENCEPHALOGRAMS.
129740 12-08

**DROP-OUTS**

FIELD DEPENDENCE AS A PREDICTOR OF ALCOHOLIC THERAPY DROP-OUTS.
052455 02-11

LITHIUM DROP-OUTS: A FOLLOW-UP STUDY OF PATIENTS WHO DISCONTINUED PROPHYLACTIC TREATMENT.
106771 12-09

**DRUG**

LONG-TERM VARIATION IN BASAL AND PHENOBARBITAL STIMULATED OXIDATIVE DRUG METABOLISM IN THE RAT.
040671 01-03

A POTENT BETA-ADRENORECEPTOR BLOCKING DRUG: 4-(2-HYDROXY-3-ISOPROPYLAMINOPROPOXY)INDOLE.
040751 01-03

CLINICAL AND PSYCHOLOGICAL TESTING OF A GERIATRIC DRUG.
042693 01-11

SUBNORMAL SERUM FOLATE DUE TO ANTICONVULSIVE THERAPY: A DOUBLE-BLIND STUDY OF THE EFFECT OF FOLIC ACID TREATMENT IN PATIENTS WITH DRUG INDUCED SUBNORMAL SERUM FOLATES.
042700 01-11

EFFECTS OF CHRONIC POSTNATAL DRUG ADMINISTRATION ON ADULT DOMINANCE BEHAVIOR IN TWO GENERA OF MICE.
042837 01-04

DRUG DEPENDENCE.
046194 01-17

NARCOTIC ANTAGONISTS AND THE PROBLEMS OF DRUG DEPENDENCE.
046195 01-13

BEHAVIORAL VARIABLES INFLUENCING DRUG SELF-ADMINISTRATION.
046206 01-04

REGULATION OF DRUG SELF-ADMINISTRATION.
046207 01-04

DRUG DEPENDENT DIFFERENCES IN THE DEVELOPMENT OF TOLERANCE TO WRITHING IN MICE.
046400 01-03

DRUG PERSONALITY INTERACTION IN INTENSIVE OUTPATIENT TREATMENT.
047836 01-10

SPECIES DIFFERENCES IN DRUG METABOLISM.
051118 02-17

CHALLENGES IN DRUG EVALUATION IN MAN.
051133 02-17

THE CONDUCT OF INITIAL DRUG STUDIES IN MAN.
051593 02-17

A POTENTIAL SCREENING TEST FOR MINOR TRANQUILLIZING DRUG ACTION.
051651 02-06

THE BRITISH DRUG SAFETY SYSTEM.
051782 02-05

2,5 DIMETHOXY-4-METHYLAMPHETAMINE: CLINICAL EVALUATION OF A NEW HALLUCINOGENIC DRUG.
052457 02-12

DRUG MISUSE IN TEENAGERS.
054715 02-12

THE INFLUENCE OF ETHANOL ON DRUG METABOLISM.
057033 02-03

AN INDUSTRIAL VIEW OF CURRENT PRACTICE IN PREDICTING DRUG TOXICITY.
057606 02-05

TWO TRIALS WITH A NEW PSYCHOTHERAPEUTIC DRUG IN THE TREATMENT OF ANXIETY.
058335 02-10

THE DESIGN OF DRUG TRIALS WITH NEUROTIC PATIENTS.
058364 02-16

U-M TEAM ISSUES WARNING ON USE OF DRUG.
058527 02-15

HYDROXYTRYPTAMINE TURNOVER DECREASED BY THE ANTIDEPRESSANT DRUG CHLORIMIPRAMINE.
058799 02-03

THE MODIFIABILITY OF INFANTILE SHOCK TRAUMATIZATION EFFECTS BY CONTIGUOUS DRUG ADMINISTRATIONS.
060090 03-04

PROJECT SUMMARY: LIMBIC SYSTEM LESIONS AND DRUG ADDICTION.
060636 03-03

A DATA PROCESSING SYSTEM FOR PSYCHOTROPIC DRUG EVALUATION.
060862 03-16

DRUG TREATMENT: CRITICAL EVALUATION.
063143 03-11

DRUG TREATMENT: CRITICAL EVALUATION.
063144 03-11

DRUG TREATMENT: CRITICAL EVALUATION.
063145 03-11

DRUG TREATMENT: CRITICAL EVALUATION.
063146 03-11

DRUG TREATMENT IN PSYCHIATRY.
063147 03-11

DIFFERENTIAL DRUG EFFECTS IN NEUROTIC DEPRESSION.
063207 03-10

ATTEMPTED SUICIDE BY DRUG INGESTION.
063277 03-15

ORGANIC INTEGRITY TEST (OIT) IN MONITORING DRUG EFFECTS.
063596 04-08

A METHOD FOR CHRONIC INTRAVENOUS DRUG ADMINISTRATION IN SQUIRREL MONKEYS.
063725 04-06

SERUM VITAMIN-B12 LEVELS IN PSYCHIATRIC PATIENTS ON LONG-TERM PSYCHOTROPIC DRUG THERAPY.
063874 04-13

CHEMICAL CONSTITUTION AND DRUG ACTION OF N-SUBSTITUTED PHENOTHIAZINE IN VENTRICULAR ECTOPIC TACHYCARDIA.
063981 04-03

RELATIONSHIP BETWEEN DIFFERENCE SPECTRA AND METABOLISM: BARBITURATES, DRUG INTERACTION AND SPECIES DIFFERENCE.
064001 04-03

EFFECT OF INHIBITORS AND INDUCERS OF DRUG METABOLISM ON ETHANOL METABOLISM IN VIVO.
064052 04-03

THE CONCOMITANT EFFECTS OF MILD SLEEP LOSS AND AN ANTICHOLINERGIC DRUG.
064387 04-13

DRUG PLASMA LEVELS IN CHRONIC ILLNESS.
064484 04-17

DRUG EFFECTS UPON DATA PROCESSING AS FUNCTIONS OF STORAGE AND RETRIEVAL PARAMETERS.
065127 05-14

DRUG THERAPY IN ALCOHOLISM.
065188 05-13

PHARMACOLOGICAL AND DYNAMIC FACTORS IN PSYCHOTROPIC DRUG THERAPY.
065409 05-15

DRUG COMBINATIONS AND INTERACTIONS.
065418 05-13

SOME EFFECTS OF AN HALLUCINOGENIC DRUG (PHENCYCLIDINE) ON NEUROHUMORAL SUBSTANCES.
065436 05-12

DRUG EFFECTS ON A MEASURE OF UNCONDITIONED AVOIDANCE IN THE RAT.
065440 05-04

SETTING, PATIENT, AND DOCTOR EFFECTS ON DRUG RESPONSE IN NEUROTIC PATIENTS: II. DIFFERENTIAL IMPROVEMENT.
065446 05-10

COMBINED EFFECT OF DRUG AND DRIVE ON THE CONSOLIDATION PROCESS.
065452 05-04

SETTING, PATIENT, AND DOCTOR EFFECTS ON DRUG RESPONSE IN NEUROTIC PATIENTS: I. DIFFERENTIAL ATTRITION, DOSAGE DEVIATION, AND SIDE REACTION RESPONSES TO TREATMENT.
065453 05-10

LONG-ACTING DRUG TREATMENT IN OVERALL PSYCHIATRIC MANAGEMENT.
065472 05-17

DRUG THERAPY. II. TREATMENT OF DRUG MISUSE.
066329 05-15

PERINATAL DEVELOPMENT OF DRUG METABOLIZING ENZYME ACTIVITY IN SWINE.
066368 05-03

EMERGENCY TREATMENT OF DRUG ABUSE AND POISON INGESTION.
066395 05-15

DRUG COMBINATION ALLOWS SMALLER DOSES OF L-DOPA.
066465 05-07

VALIDATION OF THE MACANDREW-ROSEN DRUG THERAPY SCALE.
066741 05-16

THIN-LAYER CHROMATOGRAPHIC LABORATORY ANALYSIS IN CASES FROM A DRUG ADDICTION CENTER.
067212 06-06

METABOLISM AND BILIARY EXCRETION OF THE LIPOPHILIC DRUG MOLECULES, IMIPRAMINE AND DESMETHYLIMIPRAMINE IN THE RAT -- I. EXPERIMENTS IN VIVO AND WITH ISOLATED PERFUSED LIVERS.
067260 06-03

DOES PINK-SPOT DIAGNOSE DRUG?
067319 06-08

A USEFUL DRUG.
067488 06-08

DRUG ANTAGONISM AND WATER INTAKE.
067703 06-04

AN APPROACH TO THE TREATMENT OF DRUG ABUSE.
067934 06-15

IN DIAGNOSIS, TYPE OF REACTION IS MORE IMPORTANT THAN THE DRUG.
067939 06-15

SLEEP AND DRUG OVERDOSE.
068007 06-15

TO SLEEP, PERCHANCE TO DREAM: NEW DRUG FOR INSOMNIACS DOESNT INTERFERE WITH REM TIME.
068021 06-14

PINK-SPOT - IS IT A DRUG ARTEFACT
068153 06-15

ALCOHOL DRUG INTERACTIONS.
068412 06-13

DRUG THERAPY.
068964 06-10

EFFECT OF METHYLCHLOROFORM INHALATION ON BARBITURATE HYPNOSIS AND HEPATIC DRUG METABOLISM IN MALE MICE.
068978 06-03

THE DILEMMA OF DRUG RESEARCH.
068987 06-17

TRIAL OF A NEW PSYCHOTROPIC DRUG DOXEPIN.
069072 06-07

THE OCCURRENCE OF CYCLOHEXYLAMINE IN URINES STUDIED FOR DRUG USE BY THIN-LAYER CHROMATOGRAPHY.
070576 07-13

A PRACTICAL GUIDE TO DRUG INTERACTIONS.
070899 07-15

CENTRAL NERVOUS SYSTEM METABOLISM, DRUG ACTION AND HIGHER FUNCTIONS.
070976 07-17

DRUG RESPONSE FOLLOWING BRAIN DAMAGE.
070977 07-04

DRUG DEPENDENCE: SOME RESEARCH ISSUES.
071747 07-16

CLINICAL STUDY OF A PSYCHOTROPIC DRUG: SULPIRIDE IN ATTEMPTED SUICIDE WITHOUT PSYCHOSIS.
072155 07-14

THE ASSESSMENT OF DRUG EFFECTS IN CHILDREN AS COMPARED TO ADULTS.
072825 08-14

PATIENT PERSONALITY AND DEMOGRAPHIC FACTORS AS PREDICTORS OF EARLY RESPONSE TO PSYCHOTROPIC DRUG TREATMENT.
074130 08-10

ANTIPARKINSON DRUG OVERUSE.
074217 08-17

WEIGHT CHANGES WITH SCHIZOPHRENIC PSYCHOSIS AND PSYCHOTROPIC DRUG THERAPY.
074218 08-08

EFFECTS OF BENZOCTAMINE (30803-BA, TACITIN), A NEW PSYCHOACTIVE DRUG, ON CATECHOLAMINE METABOLISM.
074861 08-03

PUPIL SIZE AND DRUG STATE IN A REACTION TIME TASK.
075161 08-13

DRUG TREATMENT IN DEPRESSIVE ILLNESS: AMITRYPTYLINE AND CHLORDIAZEPOXIDE IN TWO NEUROTIC POPULATIONS.
075415 08-10

EFFECTS OF INSTRUCTIONS AND DRUG ADMINISTRATION ON TEMPORAL RESOLUTION OF PAIRED FLASHES.
075771 08-14

THE PHYSICIAN QUESTIONNAIRE: A USEFUL TOOL IN PSYCHIATRIC DRUG RESEARCH.
075843 09-17

PERSISTENCE OF A DRUG PERSONALITY INTERACTION IN PSYCHIATRIC OUTPATIENTS.
075873 09-14

DRUGS, DIAGNOSES, AND OUTCOME OF DRUG TRIALS WITH NEUROTIC PATIENTS: A SURVEY.
075942 09-11

STUDIES IN MAN ON THE INFLUENCE OF A NEW PSYCHOPHARMACEUTICAL DRUG, 1-(METHYLAMINO) DIBENZOBICYCLOOCTADIENE HYDROCHLORIDE, ON THE CO2 SENSITIVE CENTRAL RESPIRATORY REGULATION.
079971 09-07

A TECHNIQUE TO DEMONSTRATE THE EFFECT OF A PSYCHOPHARMACEUTICAL DRUG IN A PSYCHOPATHOLOGICAL LONGITUDINAL SECTION BY NUMERIC AND GRAPHIC MEANS.
079973 09-06

PSYCHOTROPIC DRUG THERAPY AND THE PHARMACEUTICAL INDUSTRY.
079987 09-17

DRUG CONTROLLED ADDICTION.
079990 09-15

THE PROBLEM OF CEREBRAL EDEMA DURING COMBINED PSYCHOTROPIC DRUG THERAPY.
079992 09-15

LATE BRAIN RECOVERY PROCESSES AFTER DRUG OVERDOSE.
082027 10-15

PRECLINICAL EVALUATION OF AHR-1118. A POTENTIAL ANTIDEPRESSANT DRUG.
082051 10-03

PHARMACOLOGICAL ASPECTS OF DRUG ABUSE.
085613 10-17

THE MECHANISM AND SITE OF DRUG EFFECT.
086206 10-17

DRUG, DOCTOR WARMTH, AND CLINIC SETTING IN THE SYMPTOMATIC RESPONSE TO MINOR TRANQUILIZERS.
087386 10-10

THE DRUG TREATMENT OF DEPRESSION.
087632 10-09

CLINICAL AND EEG APPEARANCES OF ACUTE DRUG INTOXICATION DUE TO CHLORALOSE.
088568 10-15

THE DRUG 100-129-HF-1854 (CLOZAPINE) FOR PSYCHIATRIC TREATMENT.
089100 10-09

USE OF THE DRUG LUVATRENE FOR THE TREATMENT OF OUTPATIENTS.
089109 10-17

EXPERIMENTAL DRUG MAKES RATS SEXY.
090137 11-04

PSYCHIATRIC DRUG USE AND ABUSE IN THE AGED.
090428 11-17

GOVERNMENTAL REGULATION OF THE DRUG INDUSTRY.
091208 11-17

CHANGES IN BEHAVIOUR WITH REPEATED TESTING UNDER THE INFLUENCE OF DRUGS: DRUG EXPERIENCE INTERACTIONS.
091997 11-04

PSYCHOTROPIC DRUG USE AND DRIVING RISK: A REVIEW AND ANALYSIS.
093085 11-17

USE OF HEPATIC MICROSOMES IN THE PREPARATION OF MODEL DRUG METABOLITES.
094789 11-06

EFFECTS OF AN ACUTE STRESS OF FOREBRAIN 5-HYDROXYTRYPTAMINE (5-HT) METABOLISM IN CNS LESIONED AND DRUG PRETREATED RATS.
095671 11-04

CASUISTIC CONTRIBUTIONS ON THE USE OF A DRUG IN CRIMINOLOGY ON DISSOCIALITY AND ON MINOR IRREGULAR BEHAVIOR.
095719 11-14

USE OF LEVODOPA MAY BE EXPANDED BY ADDITION OF MK-485 TO DRUG REGIMEN.
097284 11-09

CLINICAL EVALUATION OF A NEW PSYCHOTROPIC DRUG -- MOLINDONE.
097997 11-07

PSYCHOTROPIC DRUG SIDE-EFFECTS: CLINICAL AND THEORETICAL PERSPECTIVES.
100516 12-15

PSYCHOTROPIC DRUG SIDE-EFFECTS IN CHILDREN.
100517 12-15

STATE DRUG ABUSE CONTROL.
105336 12-17

LITHIUM CARBONATE: A DRUG OF LIMITED EFFICACY IN THE PREVENTION OF MANIC-DEPRESSIVE DISEASE.
106764 12-09

LONG-TERM DRUG THERAPY IN AFFECTIVE DISORDERS: THEORETICAL AND METHODOLOGICAL ISSUES IN CURRENT RESEARCH ON LITHIUM.
106765 12-09

NEUROTOXICITY WITH LITHIUM: DIFFERENTIAL DRUG RESPONSIVENESS.
106769 12-15

LITHIUM AS A THERAPEUTIC AND PREVENTIVE DRUG IN AFFECTIVE DISORDERS.
109723 12-09

THE EFFECTIVENESS OF EXTERNAL AND DRUG PRODUCED INTERNAL STIMULI IN THE DISCRIMINATIVE CONTROL OF OPERANT BEHAVIOR. (PH.D.DISSERTATION).
110682 12-04

MOLECULAR PROPERTIES OF DRUG RECEPTORS.
110897 12-17

ESSENTIALS OF MOLECULAR PHARMACOLOGY: BACKGROUND FOR DRUG DESIGN.
115114 12-17

THIORIDAZINE AND BEHAVIOR DISORDERS (PERSPECTIVES FOR THE USE OF THE DRUG IN CRIMINOLOGY).
124320 12-17

CLINICAL STUDY OF THE DRUG MELLERIL.
126631 12-11

USE OF CATTELS IPAT ANXIETY SCALE IN A GROUP OF NEUROTIC PATIENTS BEFORE AND AFTER PSYCHOPHARMACOLOGICAL DRUG AND ELECTRIC SHOCK THERAPY.
128509 12-17

A DOUBLE-BLIND COMPARISON OF S-804 (NEW BENZODIAZEPINE DRUG) WITH CHLORDIAZEPOXIDE AND DIAZEPAM IN THE TREATMENT OF NEUROSIS.
129097 12-10

**DRUG-INDUCED**

DRUG-INDUCED EXTRAPYRAMIDAL DISORDERS: A RATING SCALE FOR EXTRAPYRAMIDAL SIDE-EFFECTS.
063773 04-16

CONTROLLED STUDIES OF ANTIPARKINSONISM AGENTS IN THE TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL SYMPTOMS.
063777 04-14

HYSTERIA AND DRUG-INDUCED DYSTONIA.
063778 04-15

CEREBROSPINAL FLUID MONOAMINE CATABOLITES IN DRUG-INDUCED EXTRAPYRAMIDAL DISORDERS.
064097 04-13

EFFECTS OF PHENOTHIAZINE DERIVATIVES ON BIOLOGICAL MEMBRANES: DRUG-INDUCED CHANGES IN ELECTRON SPIN RESONANCE SPECTRA FROM SPIN-LABELED ERYTHROCYTE GHOST MEMBRANES.
064423 04-03

PHYSIOLOGICAL AND DRUG-INDUCED CHANGES IN THE GLYCOGEN CONTENT OF MOUSE BRAIN.
067608 06-03

DRUG-INDUCED RELEASE OF 3H-NOREPINEPHRINE AND 3H-SEROTONIN FROM BRAIN SLICES.
068290 06-03

DRUG-INDUCED RELIEF OF EXPERIMENTAL TREMOR IN MONKEYS.
068457 06-04

A POSSIBLE ROLE FOR 5-HYDROXYTRYPTAMINE IN DRUG-INDUCED SEIZURES.
074084 08-03

LEVODOPA IN DRUG-INDUCED EXTRAPYRAMIDAL DISORDERS.
074874 08-08

ACTIONS OF L-DOPA IN DRUG-INDUCED EXTRAPYRAMIDALISM.
075429 08-08

DRUG-INDUCED SYMPATHETIC AROUSAL AND NEUROTICISM.
075779 08-13

DRUG-INDUCED STEREOTYPED BEHAVIOR AND ITS ANTAGONISM IN DOGS.
079888 09-04

DRUG-INDUCED EXTRAPYRAMIDAL DISORDERS (UNPUBLISHED PAPER).
093445 11-15

PREDICTION AND MEASUREMENT OF PERCEPTUAL BEHAVIORAL CHANGE IN DRUG-INDUCED HALLUCINATIONS.
121086 12-12

DRUG-INDUCED DAMAGE OF THE EYE AND THE OPTICAL NERVE.
128389 12-15

**DRUGGED**

SCOPOLAMINE EFFECTS ON CONDITIONED SUPPRESSION: INFLUENCE OF DIURNAL CYCLE AND TRANSITIONS BETWEEN NORMAL AND DRUGGED STATES.
071790 07-03

**DRUGS**

ACTION OF PSYCHOTOGENIC DRUGS ON SINGLE MIDBRAIN RAPHE NEURONS.
040418 01-03

PLASMA PROTEIN BINDING OF TRICYCLIC ANTIDEPRESSIVE DRUGS.
040573 01-13

A COMPARISON OF THE EFFECTS OF SOME BENZODIAZEPINES AND OTHER DRUGS ON AGGRESSIVE AND EXPLORATORY BEHAVIOUR IN MICE AND RATS.
040581 01-04

METHODS FOR DETECTING ANTIANXIETY DRUGS USING BABOONS (PAPIO-CYNOCEPHALUS).
041537 01-06

EFFECT OF DRUGS USED IN PSYCHOSES ON CEREBRAL DOPAMINE METABOLISM.
041566 01-03

INHIBITION OF THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN RATS BY DRUGS WHICH INHIBIT RIBONUCLEIC ACID OR PROTEIN SYNTHESIS.
041570 01-03

CONSIDERATIONS OF SOME SIDE-EFFECTS OF DRUGS. (A STUDY BEARING ON 11,410 CALLS RECEIVED BY THE BELGIAN ANTIPOISON CENTER).
042687 01-15

THE EFFECT OF CENTRALLY ACTING DRUGS ON THE CONCENTRATION OF BRAIN ADENOSINE 3PRIME,5PRIME- MONOPHOSPHATE.
043276 01-03
EFFECTS OF PSYCHOTHERAPEUTIC DRUGS ON HYPOTHALAMIC INDUCED HISSING IN CATS.
046139 01-04
EFFECTS OF SOME PSYCHOACTIVE DRUGS ON EXPERIMENTAL NEUROTIC (CONFLICT INDUCED) BEHAVIOR IN CATS.
046143 01-04
RECENT ADVANCES IN THE PHARMACOLOGY OF MORPHINE-LIKE DRUGS.
046203 01-13
METHODOLOGICAL CONSIDERATIONS IN EVALUATING ANTIANXIETY DRUGS.
046558 01-16
CONTROLLED INTERVIEWS USING DRUGS.
047825 01-11
THE METABOLIC ALTERATION OF DRUGS.
051117 02-17
LETS STOP LYING ABOUT DRUGS.
051530 02-13
DRUGS: FACTS ON THEIR USE AND ABUSE.
051784 02-13
PERSONALITY DIFFERENCES IN THE RESPONSE TO STIMULANT DRUGS ADMINISTERED DURING A SLEEP DEPRIVED STATE.
052502 02-14
DRUGS AND AGGRESSION.
055628 02-14
INTERACTIONS BETWEEN ALCOHOL AND DRUGS.
057032 02-04
TESTING DRUGS FOR TERATOGENICITY AND THEIR EFFECTS ON FERTILITY; THE PRESENT POSITION.
057605 02-05
THE PREDICTIVE VALUE FOR MAN OF TOXICOLOGICAL TESTS OF DRUGS IN LABORATORY ANIMALS.
057607 02-05
THE ROLE OF THE COMMITTEE ON SAFETY OF DRUGS.
057608 02-07
A NOTE ON THE COMPOSITION OF ILLICIT DRUGS.
057866 02-01
SYNTHETIC DRUGS USED AND ABUSED.
058070 02-14
OCULAR (PIGMENTARY) EFFECTS OF PSYCHOTROPIC DRUGS.
058212 02-15
EFFECT OF ANTIDEPRESSANT DRUGS ON ACCUMULATION AND DISAPPEARANCE OF MONOAMINES FORMED IN VIVO FROM LABELED PRECURSORS IN MOUSE BRAIN.
058798 02-03
UNITED-STATES PROCEDURES FOR SCREENING DRUGS: TESTING FOR DEPENDENCE LIABILITY IN ANIMALS AND MAN.
058971 03-02
THE EFFECTS OF SOME PSYCHOACTIVE DRUGS ON RAT BRAIN ADENOSINE TRIPHOSPHATE LEVELS.
058988 03-03
RESPONSE TO DRUGS BY RATS SHOWING LONG OR SHORT HEXOBARBITAL INDUCED SLEEP.
058990 03-03
DRUGS: ACID REPORT ON ACID.
059318 03-12
WITHDRAWAL OF ANTIPSYCHOTIC DRUGS FROM CHRONIC PSYCHIATRIC PATIENTS.
060208 03-08
DRUGS: PERSONALITY::PERSONALITY: DRUGS.
060280 03-14
BEHAVIOURAL EFFECTS IN RATS OF MORPHINE AND AMPHETAMINE AND OF A COMBINATION OF THE TWO DRUGS.
063019 03-04
ELECTROENCEPHALOGRAPHIC VARIATIONS INDUCED BY PSYCHOTROPIC DRUGS: CLINICAL ELECTROPHYSIOLOGICAL CORRELATIONS FOR A GUIDED THERAPY.
063200 03-13
ABUSE OF AMPHETAMINE AND AMPHETAMINE-LIKE DRUGS.
063753 04-15
HANDWRITING CHANGES AND RESPONSE TO DRUGS – A CONTROLLED STUDY.
063775 04-14
EFFECTS OF MORPHINE TREATMENT AND STARVATION ON THE SUBSTRATE INTERACTION WITH P-450 IN THE OXIDATION OF DRUGS BY LIVER MICROSOMES.
063982 04-03
CLASSIFICATION, NOSOLOGY, AND RATING SCALES OF PSYCHOTROPIC DRUGS.
064090 04-01
DRUGS AND REALITY IN CAPTIVE SOCIETY. SOME OBSERVATIONS ON CHEMICAL ADAPTATION.
064091 04-17
A METHOD FOR INVESTIGATING THE EFFECTS OF DRUGS ON THE EXPLORATORY BEHAVIOUR OF MICE.
064289 04-04
A COMPARISON OF THE ANTINOCICEPTIVE ACTIONS OF CHOLINOMIMETIC AND MORPHINE-LIKE DRUGS.
064290 04-03
THE EFFECTS OF CENTRALLY AND PERIPHERALLY ACTING CHOLINERGIC DRUGS ON THE SHORT-TERM PERFORMANCE GRADIENT FOLLOWING PASSIVE AVOIDANCE TRAINING.
064412 04-04
ANTAGONISM OF THE ANTIAVOIDANCE EFFECTS OF VARIOUS AGENTS BY ANTICHOLINERGIC DRUGS.
064426 04-04
PSYCHOACTIVE DRUGS IN THE IMMATURE ORGANISM.
064474 04-13
THE INFLUENCE OF VARIOUS NEUROLEPTIC DRUGS ON SHOCK AVOIDANCE RESPONDING IN RATS. III. AMPHETAMINE ANTAGONISM IN THE DISCRIMINATED SIDMAN AVOIDANCE PROCEDURE.
064476 04-04
INTERACTION OF COMMONLY PRESCRIBED DRUGS AND WARFARIN.
064622 04-15
RATE-DEPENDENT EFFECTS OF DRUGS: MODIFICATION BY DISCRIMINATIVE STIMULI OF THE EFFECTS OF AMOBARBITAL ON SCHEDULE CONTROLLED BEHAVIOR.
064749 05-04
COMMENT ON THE INCREASED RESISTANCE TO EXTINCTION OF AN AVOIDANCE RESPONSE INDUCED BY CERTAIN DRUGS.
065070 05-04
INFLUENCE OF ETHYLPHENACEMIDE ON SERUM LEVELS OF OTHER ANTIEPILEPTIC DRUGS.
066190 05-13
HYPNOTIC DRUGS AND THEIR EFFECTIVENESS: ALL-NIGHT EEG STUDIES OF INSOMNIAC SUBJECTS.
066235 05-14
ALTERED ABSORPTION OF DRUGS FROM THE RAT SMALL INTESTINE BY CARBONIC ANHYDRASE INHIBITION.
066369 05-03
EFFECTS OF GENERAL DEPRESSANT DRUGS ON THE ELECTRICAL RESPONSES OF ISOLATED SLABS OF CATS CEREBRAL CORTEX.
066382 05-03
A SIMPLE SCREENING METHOD FOR ANTIPARKINSONIAN DRUGS IN MICE.
066415 05-06
FLUORESCENT LABELING OF PSYCHOACTIVE DRUGS.
066738 05-06
ANTICONVULSANT DRUGS AND SELF-STIMULATION RATES IN RATS.
066871 05-04
DRUGS, DREAMS AND THE CORONARY PATIENT.
066874 05-14
DOXEPIN (SINEQUAN) AND OTHER DRUGS FOR ANXIETY AND DEPRESSION.
066877 05-17
INTERACTIONS BETWEEN CERTAIN DRUGS USED PREOPERATIVELY AND ANESTHETIC AGENTS.
066890 05-15
USE OF DRUGS IN CONTROL OF CHRONIC PAIN.
066921 05-11
THE PRESENT STATUS OF PSYCHOTROPIC DRUGS.
066950 05-17
HYPOTHALAMIC DYSFUNCTION AND ANTIDEPRESSANT DRUGS.
067012 05-14
DRUGS IN DEPRESSIVE ILLNESS.
067013 05-09
THE STRUCTURAL AND BIOCHEMICAL BASIS OF MOVEMENT DISORDERS IN TREATMENT WITH NEUROLEPTIC DRUGS AND IN EXTRAPYRAMIDAL DISEASES.
067107 06-13
INVESTIGATIONS ON THE SPECIFICITY OF THE SO-CALLED ANALGESIC ACTIVITY OF NON-NARCOTIC DRUGS.
067254 06-04
THE METABOLISM OF PSYCHOTROPIC DRUGS (PHENOTHIAZINE AND IMINODIBENZYL DERIVATIVES).
067301 06-17
THE SWITCH PROCESS FROM DEPRESSION TO MANIA: RELATIONSHIP TO DRUGS WHICH ALTER BRAIN AMINES.
067585 06-09
FLUID INTAKE AND PUNISHMENT ATTENUATING DRUGS.
067704 06-04
EFFECTS OF PRENATAL ADMINISTRATION OF PSYCHOTROPIC DRUGS TO RATS ON BRAIN BUTYRYLCHOLINESTERASE ACTIVITY AT BIRTH.
067980 06-03
CARDIAC TOXICITY AND PSYCHOTROPIC DRUGS.
068603 06-15
THE INFLUENCE OF VARIOUS NEUROLEPTIC DRUGS ON NOISE ESCAPE RESPONSE IN RATS.
069076 06-04
STUDIES ON INTERACTIONS INVOLVING ANTIDEPRESSIVE AND OTHER DRUGS WITH TETRABENAZINE AND NORADNAMINE ON LOCOMOTOR ACTIVITY IN MICE, INCLUDING DETAILS OF THE EXPERIMENTAL DESIGN AND STATISTICAL ANALYSIS.
069077 06-04

THE CONCEPT OF THE VISUAL COMPUTER AND ITS EXPLORATION BY THE USE OF DRUGS.
069802 07-13

THE EFFECT OF SOME HALLUCINOGENIC DRUGS ON THE AMINO ACID PRECURSORS OF BRAIN MONOAMINES.
070542 07-03

THE EFFECT OF ALKYL SUBSTITUTION IN DRUGS.
070779 07-01

HAZARDS IMPLICIT IN PRESCRIBING PSYCHOACTIVE DRUGS.
070897 07-17

THE CLINICAL TESTING OF HYDROTHIADENE IN ENDOGENOUS DEPRESSIONS. INFLUENCE OF DRUGS ON PHOTOMYOCLONIC THRESHOLD.
070940 07-09

INTERACTION OF SOME PSYCHOTROPIC DRUGS WITH ANALGESICS.
070948 07-04

DRUGS INFLUENCING THE CHOLINERGIC SYSTEM AND THE PROCESS OF LEARNING AND MEMORY IN MAN.
070955 07-14

PSYCHOTROPIC DRUGS AND THE REGULATION OF BEHAVIORAL ACTIVATION IN PSYCHIATRIC ILLNESS.
070970 07-17

THE USE OF STIMULANT DRUGS IN ENHANCING PERFORMANCE AND LEARNING.
070971 07-17

SOME CLINICAL AND LABORATORY STUDIES OF PSYCHOTROPIC DRUGS IN CHILDREN: AN OVERVIEW.
070975 07-17

DRUGS IN THE MANAGEMENT OF DEPRESSION.
070982 07-17

METHODOLOGICAL PROBLEMS IN PSYCHOTHERAPY RESEARCH: OBSERVATIONS ON THE KARON-VANDENBOS STUDY OF PSYCHOTHERAPY AND DRUGS IN SCHIZOPHRENIA.
071322 07-08

CONGENITAL ABNORMALITIES AND ANTICONVULSANT DRUGS.
071949 07-15

MODIFICATION OF CHLORPROMAZINE METABOLISM BY SOME OTHER DRUGS FREQUENTLY ADMINISTERED TO PSYCHIATRIC PATIENTS.
071989 07-13

THE ACTION OF CENTRAL DEPRESSANT DRUGS ON THE SPONTANEOUS DISCHARGE OF ACTION POTENTIALS IN THE SUPERIOR CERVICAL SYMPATHETIC TRUNK OF THE CAT.
072034 07-03

ECG CHANGES INDUCED BY PHENOTHIAZINE DRUGS IN THE ANESTHETIZED RAT.
072525 08-03

DEVELOPMENT OF FIGHTING BEHAVIOR IN STARVED RATS BY CHRONIC ADMINISTRATION OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL AND CANNABIS EXTRACTS: LACK OF ACTION OF OTHER PSYCHOTROPIC DRUGS.
072531 08-04

ON THE DISTRIBUTION AND METABOLISM OF NEUROLEPTIC DRUGS. PART 2: PHARMACOKINETICS OF MOPERONE.
072589 08-03

AUTORADIOGRAPHIC STUDIES ON THE DISTRIBUTION OF PSYCHOACTIVE DRUGS IN THE RAT BRAIN: IV. C14-THIORIDAZINE.
073709 08-03

THE ADRENERGICAL MECHANISMS OF ACTION IN ANTIDEPRESSIVE DRUGS.
073787 08-17

EFFECTS OF PRENATAL ADMINISTRATION OF PSYCHOTROPIC DRUGS ON BEHAVIOR OF DEVELOPING RATS.
074830 08-04

DRUGS IN THE TREATMENT OF DEPRESSION.
074926 08-09

HALLUCINOGENIC DRUGS IN THE TREATMENT OF ALCOHOLISM: A TWO-YEAR FOLLOW-UP.
075290 08-12

EFFECT OF PRENATAL DRUGS ON THE BEHAVIOR OF THE NEONATE.
075607 08-05

DRUGS IN PSYCHOLOGY: A COMMENTARY ON TRAVIS THOMPSON AND CHARLES R. SCHUSTERS BEHAVIORAL PHARMACOLOGY.
075793 08-14

THE ROLE OF BRAIN DOPAMINE IN BEHAVIORAL REGULATION AND THE ACTIONS OF PSYCHOTROPIC DRUGS.
075869 09-04

CHOICE OF ANTIPSYCHOTIC DRUGS.
075872 09-08

DRUGS, DIAGNOSES, AND OUTCOME OF DRUG TRIALS WITH NEUROTIC PATIENTS: A SURVEY.
075942 09-11

USE OF ANTIPSYCHOTIC AND ANTIDEPRESSANT DRUGS BY CHRONICALLY ILL PATIENTS.
076351 09-17

THE EFFECTS OF DRUGS ON CONTINUOUS AVOIDANCE BEHAVIOR WITH A WARNING STIMULUS.
076402 09-04

THE RELATION OF PSYCHOPHARMACOLOGICAL DRUGS TO LEARNING AND MEMORY.
078509 09-14

THE EFFECT OF EXTRAVERSION AND STIMULANT AND DEPRESSANT DRUGS ON VERBAL CONDITIONING.
078786 09-14

REVIEW OF MEDICINE IN SPECIAL EDUCATION: ANOTHER LOOK AT DRUGS AND BEHAVIOR.
079144 09-17

ADDICTING DRUGS.
079256 09-15

COMBINATION TEST ON THE ANALGESIC EFFECT OF DEXTROPROPOXYPHENE AND SOME PSYCHOTROPIC DRUGS IN THE MOUSE.
079961 09-03

NEUROPSYCHOTROPIC DRUGS IN THE TREATMENT OF SO-CALLED PAIN SYNDROMES.
079962 09-17

ACCELERATED ACTION OF PSYCHOTROPIC DRUGS EFFECTED BY PYRITHIOXIN.
079966 09-13

DISTRIBUTION AND METABOLISM OF NEUROLEPTIC DRUGS: PART I: PHARMACOKINETICS OF HALOPERIDOL.
079968 09-03

ANTAGONISM OF BETA-PHENYLETHYLAMINE DERIVATIVES AND SEROTONIN BLOCKING DRUGS UPON SEROTONIN, TRYPTAMINE AND RESERPINE BEHAVIORAL DEPRESSION IN MICE.
079970 09-04

THE CURRENT STATUS OF THE HALLUCINOGENIC DRUGS.
080002 09-17

ANTIPSYCHOTIC DRUGS: AN ESSENTIAL TOOL OF COMMUNITY PSYCHIATRY.
080355 09-08

PSYCHOMETRIC TESTS IN EVALUATION OF BRAIN PATHOLOGY, RESPONSE TO DRUGS.
081043 09-14

THE EFFECT OF SOME DRUGS ON GENETIC TREMOR IN THE MOUSE.
081066 09-04

CASE OF SELF-POISONING WITH MULTIPLE ANTIDEPRESSANT DRUGS.
082153 10-15

THE USE AND ABUSE OF PSYCHOTROPIC DRUGS.
083128 10-15

DRUGS AND MODERN TOXICOMANIAS.
085130 10-15

COMPREHENSIVE CLINICAL STUDIES OF PSYCHOACTIVE DRUGS.
085289 10-11

EFFECTS OF DRUGS ON SOMATIC ACTIVITY AND HUMAN RESPONSES.
085757 10-13

CLASSIFICATION OF PSYCHOTROPIC DRUGS.
086202 10-17

RESEARCH ON NEW METHODS OF EXPERIMENTATION WITH PSYCHOTROPIC DRUGS. RESULTS OF A TEST WITH A NEW TRANQUILIZER, NOBRIUM, IN TWO INDEPENDENT INVESTIGATIONS.
086984 10-16

THE USES AND ABUSES OF LSD AND OTHER HALLUCINOGENIC DRUGS.
087470 10-12

THE PSYCHOTHERAPEUTIC USE OF PSYCHODYSLEPTIC DRUGS.
087530 10-12

DRUGS: MORE L-DOPA IN SIGHT.
087724 10-11

THE EFFECTS OF 4 HYPNOTIC DRUGS AND PLACEBO ON NORMAL SUBJECTS SLEEPING AND DREAMING AT HOME.
087863 10-06

RELATIONSHIP BETWEEN TASTE THRESHOLD FOR DRUGS AND CLINICAL PROGRESS IN A MIXED GROUP OF PSYCHIATRIC PATIENTS.
087866 10-11

APHAGIA, PRODUCED BY DEPOSITION OF DRUGS INTO THE HYPOTHALAMUS OF RATS.
088463 10-03

TOXICITY OF HEPATOTOXIC DRUGS ON MOUSE LIVER TISSUE CULTURE.
088615 10-05

EFFECTS OF SELECTED DRUGS ON STIMULUS BOUND EMOTIONAL BEHAVIOR ELICITED BY HYPOTHALAMIC STIMULATION IN THE CAT.
088617 10-04

THE USE AND MISUSE OF PSYCHOTROPIC DRUGS.
088707 10-15

THE ACTION OF SOME PSYCHOTROPIC DRUGS ON DEFECATION RATE IN THE MOUSE.
089003 10-05

THE USEFULNESS OF PLACEBO AND THE DOUBLE-BLIND TECHNIQUE IN THE EVALUATION OF PSYCHOTROPIC DRUGS.
089054 10-17

THE USE OF TWO COMBINATIONS OF DRUGS WITH MIXED ACTION, ANTIDEPRESSIVE AND TRANQUILIZING (AMITRYPTILINE - PERPHENAZINE) IN GENERAL AND IN PSYCHOSOMATIC MEDICINE.
089162 10-17

INFLUENCE OF SEVERAL AUTONOMIC DRUGS ON SODIUM NITROPRUSSIDE AND OXOTREMORINE INDUCED HYPOTHERMIA IN IMMATURE AND MATURE MICE.
089436 11-03

PROBLEMS OF NEW DRUGS.
090078 11-07

EFFECTS OF DRUGS ACTING ALONE AND IN COMBINATION ON THE MOTOR ACTIVITY OF INTACT MICE.
090139 11-03

EFFECTS OF GENERAL STIMULANT DRUGS ON THE ELECTRICAL RESPONSES OF ISOLATED SLABS OF CATS CEREBRAL CORTEX.
090189 11-03

HYPNOTIC DRUGS.
090365 11-17

USES AND LIMITATIONS OF PHOTOCELL ACTIVITY CAGES FOR ASSESSING EFFECTS OF DRUGS.
090423 11-06

CHANGES IN BEHAVIOUR WITH REPEATED TESTING UNDER THE INFLUENCE OF DRUGS: DRUG EXPERIENCE INTERACTIONS.
091997 11-04

MODIFICATION OF LEARNING BY DRUGS; NIMH.
092145 11-04

EFFECT OF DRUGS ON CATECHOLAMINE SYNTHESIS (UNPUBLISHED PAPER).
092889 11-13

INHIBITION BY DRUGS OF SMOKING BEHAVIOUR IN MONKEYS.
095351 11-03

PSYCHIATRIC DRUGS AND TRENDS.
095410 11-15

APPLICATION OF ON-LINE COMPUTER PROCEDURES TO EXPERIMENTAL CONTROL AND EVALUATION OF THE EFFECTS OF DRUGS ON OPERANT BEHAVIOR (SIDMAN SHOCK AVOIDANCE RESPONDING BY RATS).
095507 11-06

CENTRAL ANTISEROTONINERGIC EFFECT OF ANTIMANIC DRUGS.
097988 11-03

THE COMBINATION OF PSYCHOTROPIC DRUGS IN THE TREATMENT OF SCHIZOPHRENIA.
098002 11-08

THE OBJECTIVE EVALUATION OF PSYCHOPHARMACOLOGICAL DRUGS WITH CAFFEINE AND CAFFEINE-FREE COFFEE AS AN EXAMPLE.
098039 11-13

SEROTONINERGIC PROCESSES IN THE ACTION OF PSYCHOTROPIC DRUGS.
098055 11-03

ACUTE POISONING WITH PSYCHOTROPIC DRUGS.
100518 12-15

PREGNANCY AND PSYCHOTROPIC DRUGS.
100519 12-15

ADRENERGIC MECHANISMS IN THE CENTRAL ACTION OF PSYCHOTROPIC DRUGS. (PH.D.DISSERTATION).
102415 12-06

STUDIES OF THE TOXIC EFFECTS OF DRUGS ON ELECTRICAL CONDUCTION AND FUNCTION OF THE HEART. (PH.D.DISSERTATION).
103004 12-05

AN ANALYSIS OF THE ROLE OF CHOLINERGIC DRUGS IN BEHAVIOR RELATED TO FOOD AND WATER DEPRIVATION. (PH.D.DISSERTATION).
103267 12-04

ADRENAL CORTICAL AND MEDULLARY SECRETION AND EVALUATION OF DRUGS ACTING ON THE CENTRAL NERVOUS SYSTEM.
106270 12-03

CENTRAL ACTION OF SOME AUTONOMIC DRUGS IN RESPECT TO EEG AROUSAL REACTION OF THE RABBIT.
107190 12-03

DRUGS AND MENTAL CONTROL.
108212 12-17

DRUGS AND HUMAN BEHAVIOUR.
110896 12-14

ON THE PROBLEM OF AMBULATORY TREATMENT OF SCHIZOPHRENIA WITH PSYCHOTROPIC DRUGS.
111034 12-08

PSYCHEDELICS: THE USES AND IMPLICATIONS OF HALLUCINOGENIC DRUGS.
111933 12-17

RESEARCH IN NEW EXPERIMENTAL METHODS FOR PSYCHOTROPIC DRUGS: RESULTS OF A DOUBLE-BLIND STUDY WITH A NEW TRANQUILIZER, NOBRIUM.
112282 12-16

THE INFLUENCES OF THE STANDARD PREFRONTAL LOBOTOMY OPERATION ON HALLUCINATORY PHENOMENA ASSOCIATED WITH PSYCHOTOMIMETIC DRUGS.
120899 12-13

DRUGS, HALLUCINATIONS AND MEMORY.
121085 12-12

A COMPARATIVE DETERMINATION OF SIDE-EFFECTS ASSOCIATED WITH THE ORAL USE OF THREE ANTICHOLINERGIC PSYCHOTROPIC DRUGS.
126639 12-15

DRUGS, BRAIN AND BEHAVIOUR: PROCEEDINGS OF SYMPOSIUM ON PSYCHOPHARMACOLOGY IN DURHAM.
129564 12-17

STUDY ON THE EFFECTS OF PSYCHOTROPIC DRUGS UPON THE PHOTICALLY DRIVING THETA RESPONSE OF ELECTROENCEPHALOGRAMS.
129740 12-08

STUDIES ON PSYCHOTROPIC DRUGS (SIXTH REPORT) - METABOLIC FATE OF APY-606 - EXCRETION AND METABOLISM IN RATS.
131057 12-02

STUDIES ON PSYCHOTROPIC DRUGS (FIFTH REPORT) -- PHARMACOLOGICAL EFFECT OF 8(3-(2-CHLORO-10-PHENOTHIAZINYL)PROPYL)-1 THIADIAZASPIRODECAN-3-ONE HYDROCHLORIDE (APY-606).
131058 12-02

STUDIES ON PSYCHOTROPIC DRUGS (SEVENTH REPORT) -- METABOLIC FATE OF APY-606 -- ABSORPTION, DISTRIBUTION, EXCRETION AND METABOLISM OF TRITIATED APY-606.
131059 12-02

DRUGS AND PSYCHIATRY.
138145 12-17

**DURATION**

INFLUENCE OF MODE AND DURATION OF PHENYLALANINE ADMINISTRATION ON BIOCHEMICAL PARAMETERS IN RATS OF VARIOUS AGES.
042840 01-03

CORRELATION BETWEEN THE DURATION OF THE ANTICONVULSANT ACTIVITY OF DIAZEPAM AND ITS PHYSIOLOGICAL DISPOSITION IN MICE.
046402 01-03

THE EFFECT OF HEXOBARBITAL ON THE DURATION OF THE RECURRENT IPSP IN CAT MOTONEURONS.
064621 04-03

INCREASED DURATION OF NEUROPHARMACOLOGICALLY INDUCED BEHAVIORAL EXCITATION BY ATROPINE.
079998 09-04

**DURHAM**

DRUGS, BRAIN AND BEHAVIOUR: PROCEEDINGS OF SYMPOSIUM ON PSYCHOPHARMACOLOGY IN DURHAM.
129564 12-17

**DYING**

PSYCHOTHERAPY FOR THE DYING: PRINCIPLES AND ILLUSTRATIVE CASES WITH SPECIAL REFERENCE TO THE USE OF LSD.
062808 03-12

**DYNAMIC**

PHARMACOLOGICAL AND DYNAMIC FACTORS IN PSYCHOTROPIC DRUG THERAPY.
065409 05-15

DYNAMIC CONTROL OF ACID BASE EQUILIBRIUM DURING SOME FORMS OF SHOCK THERAPY.
079139 09-13

DYNAMIC CHARACTERISTICS OF THE FUNCTIONAL COMPARTMENT OF DOPAMINE IN DOPAMINERGIC TERMINALS OF THE RAT STRIATUM.
120465 12-03

**DYNAMICS**

SOME OBSERVATIONS ON THE DYNAMICS OF THE DESTRUCTURING OF DELIRIUM DURING PHARMACOTHERAPY.
098033 11-17

THE CLINICAL ASPECTS AND DYNAMICS OF PARANOIAC PSYCHOPATHY WITH MALIGNANT DEVELOPMENT.
126632 12-09

**DYSFUNCTION**

HYPOTHALAMIC DYSFUNCTION AND ANTIDEPRESSANT DRUGS.
067012 05-14

**DYSKINESIA**

HIGH DOSES OF TRIFLUOPERAZINE AND TARDIVE DYSKINESIA.
042699 01-15

THE SIGNIFICANCE OF BRAIN DAMAGE IN PERSISTENT ORAL DYSKINESIA.
075416 08-15

TREATMENT OF PERSISTENT PHENOTHIAZINE INDUCED ORAL DYSKINESIA.
075417 08-15

TARDIVE DYSKINESIA.
090170 11-15

**DYSKINESIAS**

COMPARISON OF THE PAROXYSMAL DYSKINESIAS (NEURODYSLEPSY) INDUCED BY THE NEUROLEPTICS IN MAN AND THE EARLIEST BEHAVIOR PATTERNS OF THE NEW-BORN.
070267 07-13

PERSISTENT EXTRAPYRAMIDAL ORAL DYSKINESIAS FOLLOWING TREATMENT WITH THYMOLEPTICS.
070945 07-15

ORAL DYSKINESIAS -- OCCURRENCE AND TREATMENT.
083339 10-15

**DYSTHYMIC**

A STUDY OF DEHYDROBENZPERIDOL (R-4749) IN THE TREATMENT OF DYSTHYMIC SYNDROMES.
092077 11-09

CLINICAL RESULTS ON THE THERAPEUTIC ACTION OF LITHIUM CARBONATE IN DYSTHYMIC PSYCHOSES.
114880 12-09

**DYSTONIA**
HYSTERIA AND DRUG-INDUCED DYSTONIA.
063778 04-15
BIOCHEMICAL AND PHARMACOLOGIC STUDIES OF DYSTONIA.
069852 07-13

**D20**
WATER STRUCTURE IN ANESTHETIC ACTION: TIME-DEPENDENCE D20 EFFECTS ON NERVE.
055582 02-03

**EAMR**
EXTINCTION OF THE EXCRETORY ALKALI METAL RESPONSE (EAMR) TO STRESS IN A REPTILE.
076068 09-03

**EAST**
DATURA LINN. – THE FAMOUS NARCOTIC FROM THE EAST – A REVIEW.
046185 01-17
DIMYRIL ABUSE IN THE EAST MIDLANDS.
064268 04-15

**EATING**
THE EFFECTS OF ADRENERGIC AND CHOLINERGIC AGENTS UPON EATING AND DRINKING IN DEPRIVED RATS.
076132 09-03
EATING, DRINKING AND SPONTANEOUS ACTIVITY IN RATS AFTER THE ADMINISTRATION OF CHLORPROMAZINE.
079999 09-04
MOTIVATIONAL DEPRESSION ASSOCIATED WITH NOREPINEPHRINE INDUCED EATING FROM THE HYPOTHALAMUS: RESEMBLANCE TO THE VENTROMEDIAL HYPERPHAGIC SYNDROME.
090473 11-04

**ECG**
ECG CHANGES INDUCED BY PHENOTHIAZINE DRUGS IN THE ANESTHETIZED RAT.
072525 08-03

**ECOG**
COMPARATIVE STUDY OF NATURAL SLEEP AND THE ACTION OF PHENAMINE AND CHLORPROMAZINE EVALUATION OF THE MEAN EXTREMES FREQUENCY OF ECOG IN CATS.
095655 11-14

**ECONOMY**
PULSIONAL ECONOMY AND CHEMOTHERAPY.
086452 10-17

**ECS**
A PARALLEL STUDY OF THE AMNESIC EFFECTS OF CYCLOHEXIMIDE AND ECS UNDER DIFFERENT STRENGTHS OF CONDITIONING.
066830 05-04

**ECT**
SEQUENTIAL COMPARISON OF L-TRYPTOPHAN WITH ECT IN SEVERE DEPRESSION.
059053 03-09
A COMPARISON OF PROPANIDID (EPONTOL) AND THIOPENTONE ANESTHESIA IN ECT.
076276 09-14
A SEVENTH-MONTH DOUBLE-BLIND TRIAL OF AMITRIPTYLINE AND DIAZEPAM IN ECT TREATED DEPRESSED PATIENTS.
097562 11-09

**ECTOPIC**
CHEMICAL CONSTITUTION AND DRUG ACTION OF N-SUBSTITUTED PHENOTHIAZINE IN VENTRICULAR ECTOPIC TACHYCARDIA.
063981 04-03

**EDEMA**
THE PROBLEM OF CEREBRAL EDEMA DURING COMBINED PSYCHOTROPIC DRUG THERAPY.
079992 09-15

**EDUCATION**
REVIEW OF MEDICINE IN SPECIAL EDUCATION: ANOTHER LOOK AT DRUGS AND BEHAVIOR.
079144 09-17

**EEG**
THE EFFECT OF DIAZEPAM ON THE EEG OF STATUS-EPILEPTICUS.
064610 04-11
HYPNOTICS AND ALTERED SLEEP DREAM PATTERNS: I. ALL-NIGHT EEG STUDIES OF GLUTETHIMIDE, METHYPRYLON, AND PENTOBARBITAL.
066233 05-14
HYPNOTICS AND ALTERED SLEEP DREAM PATTERNS: II. ALL-NIGHT EEG STUDIES OF CHLORAL HYDRATE, FLURAZEPAM, AND METHAQUALONE.
066234 05-14
HYPNOTIC DRUGS AND THEIR EFFECTIVENESS: ALL-NIGHT EEG STUDIES OF INSOMNIAC SUBJECTS.
066235 05-14
THE EFFECT OF CENTROPHENOXINE ON EEG VIGILANCE IN THE COURSE OF SLEEP DEPRIVATION AND ON THE EEG PATTERN OF ALL-NIGHT SLEEP.
070934 07-14
QUANTITATIVE EEG CHANGES DURING HIGH AND LOW DOSAGE FLUPHENAZINE HYDROCHLORIDE TREATMENT.
073710 08-13
EFFECT OF 1035-MD ON CERTAIN CONDITIONS OF MENTAL DEFICIENCY, ESPECIALLY THOSE OF VASCULAR ORIGIN; CLINICAL EEG AND PSYCHOPHARMACOLOGICAL STUDY.
084978 10-08
CLINICAL AND EEG APPEARANCES OF ACUTE DRUG INTOXICATION DUE TO CHLORALOSE.
088568 10-15
CORRELATION BETWEEN THE CHANGES OF EEG, PUPILLES AND BLOOD PRESSURE DUE TO INTRAVENOUS INJECTION OF CHLORPROMAZINE: CHLORPROMAZINE TEST.
088611 10-13
CENTRAL ACTION OF SOME AUTONOMIC DRUGS IN RESPECT TO EEG AROUSAL REACTION OF THE RABBIT.
107190 12-03
THE EFFECTS OF LEVOMEPROMAZINE ON THE NOCTURAL SLEEP EEG IN MAN.
129447 12-13

**EFFECTIVENESS**
EFFECTIVENESS OF LITHIUM CARBONATE IN THE TREATMENT OF MANIC-DEPRESSIVE ILLNESS.
062348 03-09
THE EFFECTIVENESS OF PARENTERAL ADMINISTRATION OF FLUPHENAZINE DECANOATE IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS.
065473 05-07
HYPNOTIC DRUGS AND THEIR EFFECTIVENESS: ALL-NIGHT EEG STUDIES OF INSOMNIAC SUBJECTS.
066235 05-14
EFFECTIVENESS AND LIMITATIONS OF LONG-TERM LEVODOPA THERAPY IN PARKINSONISM.
079974 09-11
THE EFFECTIVENESS OF SIMULTANEOUS TREATMENT WITH VITAMIN-B12 AND INSULIN IN SCHIZOPHRENIC PATIENTS, ACCORDING TO THE FREQUENCY OF STABLE REMISSIONS.
096513 11-08
THE EFFECTIVENESS OF EXTERNAL AND DRUG PRODUCED INTERNAL STIMULI IN THE DISCRIMINATIVE CONTROL OF OPERANT BEHAVIOR. (PH.D.DISSERTATION).
110682 12-04

**EFFECTOR**
THE EFFECTS OF MORPHINE-LIKE SUBSTANCES AND THEIR ANTAGONISTS ON TRANSMISSION AT THE NEURO EFFECTOR JUNCTION OF THE MYENTERIC PLEXUS LONGITUDINAL MUSCLE PREPARATION OF THE GUINEA-PIG ILEUM.
041974 01-03

**EFFERENT**
THE EFFECT OF ESERINE ON THE EFFERENT NEURONAL ACTIVITY IN THE CERVICAL SYMPATHETIC OF THE RAT.
074133 08-03

**EFFUSION**
PLEURAL EFFUSION AND FIBROSIS DURING TREATMENT WITH METHYSERGIDE.
067836 06-15

**EIGHT**
SPECIAL APPLICATION OF FLUORESCENCE HISTOCHEMISTRY: STUDIES ON EIGHT MONOAMINE OXIDASE INHIBITORS IN BRAIN NEURONS.
063989 04-06

**EJACULATION**
EJACULATION DISORDERS.
100533 12-15

**EKG**
ELECTROTHERAPY: THE EFFECTS OF METHOHEXITAL ON EKG.
058455 02-15

**ELDERLY**
CLINICAL TRIAL OF THIOTHIXENE (NAVANE) IN ELDERLY CHRONIC SCHIZOPHRENICS.
082054 10-08
PSYCHOPHARMACOLOGY AND THE ELDERLY.
100511 11-15

**ELECTRIC**
THE EFFECTS OF IMIPRAMINE AND ELECTRIC CONVULSIVE THERAPY ON THE EXCRETION OF VARIOUS MINERALS IN DEPRESSED PATIENTS.
063939 04-13
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: I. SEIZURE AND POST-SEIZURE ELECTROENCEPHALOGRAPHIC PATTERN.
065850 05-11
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY. II. ANTIDEPRESSIVE EFFECT.
065851 05-09
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: III. ANTEROGRADE AMNESIA.
065852 05-14
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: IV. RETROGRADE AMNESIA.
065853 05-14
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: V. CONFUSION AND OTHER SIDE-EFFECTS.
065854 05-15

STUDIES OF MINERAL METABOLISM IN MENTAL DEPRESSION. I. THE EFFECTS OF IMIPRAMINE AND ELECTRIC CONVULSIVE THERAPY ON CALCIUM BALANCE AND KINETICS.
075837 08-11

USE OF CATTELS IPAT ANXIETY SCALE IN A GROUP OF NEUROTIC PATIENTS BEFORE AND AFTER PSYCHOPHARMACOLOGICAL DRUG AND ELECTRIC SHOCK THERAPY.
128509 12-17

**ELECTRICAL**

EFFECTS OF NICOTINE AND TOBACCO SMOKE ON THE ELECTRICAL ACTIVITY OF THE CEREBRAL CORTEX AND OLFACTORY BULB.
041567 01-03

EFFECTS OF GENERAL DEPRESSANT DRUGS ON THE ELECTRICAL RESPONSES OF ISOLATED SLABS OF CATS CEREBRAL CORTEX.
066382 05-03

ELECTRICAL IMPEDANCE CHANGES IN MANY SITES OF BRAIN IN PARADOXICAL SLEEP, ANESTHESIA AND ACTIVITY.
066474 05-03

EFFECTS OF CHLORIMIPRAMINE ON ELECTRICAL ACTIVITIES OF SUBCORTICAL BRAIN STRUCTURES AND OF SYMPATHETIC NERVES.
079951 09-03

PROJECT SUMMARY: ELECTRICAL AND CHEMICAL STIMULATION OF THE HYPOTHALAMUS.
085144 10-03

EFFECTS OF NEUROLEPTICS ON THE CEREBRAL ELECTRICAL ACTIVITY OF LABORATORY ANIMALS: PRESENTATION OF A MODEL DESIGN FOR NEUROPHARMACOLOGICAL EXPERIMENTS.
085337 10-03

EFFECTS OF GENERAL STIMULANT DRUGS ON THE ELECTRICAL RESPONSES OF ISOLATED SLABS OF CATS CEREBRAL CORTEX.
090189 11-03

STUDIES OF THE TOXIC EFFECTS OF DRUGS ON ELECTRICAL CONDUCTION AND FUNCTION OF THE HEART. (PH.D.DISSERTATION).
103004 12-05

**ELECTRICALLY**

REDUCTION OF ELECTRICALLY REWARDED BEHAVIOR BY INTERFERENCE WITH MONOAMINE SYNTHESIS.
069065 06-04

**ELECTROCARDIOGRAPHIC**

ELECTROCARDIOGRAPHIC CHANGES DURING LITHIUM TREATMENT.
066747 05-13

ELECTROCARDIOGRAPHIC DATA IN CHRONIC ALCOHOLISM BEFORE, DURING AND AFTER TREATMENT WITH TETRAETHYLTHIURAM DISULPHIDE.
092481 11-14

**ELECTROCLINICAL**

ELECTROCLINICAL RESEARCH ON THE USE OF 1035-MD IN PSYCHIATRY.
087498 10-11

**ELECTROCONVULSIONS**

REDUCTION OF BARBITURATE DEPENDENCE INDUCED BY REPEATED ELECTROCONVULSIONS.
097548 11-03

**ELECTROCONVULSIVE**

COMPARISON OF PMH AND PEMOLINE ACTIVITY AFTER ELECTROCONVULSIVE SHOCK.
058992 03-04

EFFECTS OF INSULIN, METRAZOL, AND ELECTROCONVULSIVE SHOCKS UPON LEARNING TO LEARN 30 SUCCESSIVE REVERSAL PROBLEMS BY RATS.
095188 11-04

STIMULUS PROPERTIES OF ELECTROCONVULSIVE SHOCK IN GOLDFISH. (PH.D.DISSERTATION).
110906 12-04

**ELECTROCORTICAL**

ELECTROCORTICAL REACTIONS OF PINEALECTOMIZED AND INTACT RATS TO LETHAL DOSES OF PENTOBARBITAL.
064101 04-03

**ELECTROCORTICOGRAM**

INDUCTION BY CANNABIS-SATIVA (MARIHUANA) OF RHYTHMIC SPIKE DISCHARGES OVERRIDING REM SLEEP ELECTROCORTICOGRAM IN THE RAT.
069069 06-04

**ELECTROENCEPHALOGRAM**

THE EFFECTS OF LITHIUM ON ELECTROENCEPHALOGRAM, BEHAVIOR AND SERUM ELECTROLYTES.
060859 03-09

EFFECTS OF ATROPINE AND ESERINE ON THE ELECTROENCEPHALOGRAM, ON BEHAVIOUR AND ON LIGHT INDUCED EPILEPSY IN THE ADOLESCENT BABOON (PAPIO-PAPIO).
090157 11-04

**ELECTROENCEPHALOGRAMS**

STUDY ON THE EFFECTS OF PSYCHOTROPIC DRUGS UPON THE PHOTICALLY DRIVING THETA RESPONSE OF ELECTROENCEPHALOGRAMS.
129740 12-08

**ELECTROENCEPHALOGRAPHIC**

ELECTROENCEPHALOGRAPHIC VARIATIONS INDUCED BY PSYCHOTROPIC DRUGS: CLINICAL ELECTROPHYSIOLOGICAL CORRELATIONS FOR A GUIDED THERAPY.
063200 03-13

COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: I. SEIZURE AND POST-SEIZURE ELECTROENCEPHALOGRAPHIC PATTERN.
065850 05-11

ELECTROENCEPHALOGRAPHIC ANALYSIS OF EXPERIMENTAL PSYCHOSIS BROUGHT ON BY DITRAN.
067147 06-13

PERSISTENT BEHAVIOURAL AND ELECTROENCEPHALOGRAPHIC CHANGES AFTER SINGLE DOSES OF NITRAZEPAM AND AMYLOBARBITONE SODIUM.
068005 06-14

THE MARIHUANA INDUCED SOCIAL HIGH: NEUROLOGICAL AND ELECTROENCEPHALOGRAPHIC CONCOMITANTS.
074782 08-12

PRINCIPAL ELECTROENCEPHALOGRAPHIC CHANGES OBSERVED DURING ACUTE INTOXICATION BY NEUROLEPTICS.
075112 08-13

ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL EFFECTS OF HARMALINE IN INTACT CATS AND IN CATS WITH CHRONIC MESENCEPHALIC TRANSECTION.
075847 09-04

DIAZEPAM IN THE ELECTROENCEPHALOGRAPHIC RECORDINGS OF EPILEPTICS.
087661 10-11

POSSIBLE LOCI OF ACTION OF 2-ETHYL-ETHYLAMINO-6-METHOXY-S-TRIAZINE FOR ELECTROENCEPHALOGRAPHIC AND SYMPATHETIC ACTIVATION IN CAT.
089788 11-13

RESULTS OF ELECTROENCEPHALOGRAPHIC STUDIES RELATING TO LITHIUM EFFICACY.
106772 12-13

ELECTROENCEPHALOGRAPHIC EFFECTS OF ATROPINE AND SCOPOLAMINE.
131623 12-03

**ELECTROENCEPHALOGRAPHICAL**

CLINICAL AND QUANTITATIVE ELECTROENCEPHALOGRAPHICAL EFFECTS OF MK-940.
080031 09-07

**ELECTROENCEPHALOGRAPHY**

ELECTROENCEPHALOGRAPHY.
068955 06-11

**ELECTROGASTROGRAM**

RELATIONS BETWEEN THE ELECTROGASTROGRAM AND GASTRIC ULCERATION DURING EXPOSURE TO STRESS.
075438 08-03

**ELECTROGRAPHIC**

ELECTROGRAPHIC AND BEHAVIORAL EFFECTS OF DIAZEPAM DURING ALCOHOL WITHDRAWAL STAGE IN CATS.
072033 07-04

**ELECTROLYTE**

FLUID AND ELECTROLYTE ABNORMALITIES IN ALCOHOLISM.
063591 03-03

LITHIUM INDUCED CHANGES IN ELECTROLYTE BALANCE AND TISSUE ELECTROLYTE CONCENTRATION.
090419 11-03

EFFECTS OF LITHIUM AND OTHER PSYCHOPHARMACA ON RAT ELECTROLYTE METABOLISM.
106778 12-05

**ELECTROLYTES**

THE EFFECTS OF LITHIUM ON ELECTROENCEPHALOGRAM, BEHAVIOR AND SERUM ELECTROLYTES.
060859 03-09

THE EFFECTS OF ACUTE AND PROLONGED LITHIUM TREATMENT ON THE DISTRIBUTION OF ELECTROLYTES, POTASSIUM AND SODIUM.
088614 10-03

**ELECTRON**

EFFECTS OF PHENOTHIAZINE DERIVATIVES ON BIOLOGICAL MEMBRANES: DRUG-INDUCED CHANGES IN ELECTRON SPIN RESONANCE SPECTRA FROM SPIN-LABELED ERYTHROCYTE GHOST MEMBRANES.
064423 04-03

AN ELECTRON MICROSCOPIC STUDY OF AXONAL CHANGES IN THE CEREBELLUM OF DIPHENYLHYDANTOIN INTOXICATED RATS: THE FORMATION OF THE SO-CALLED HONEYCOMB STRUCTURE IN THE AXOPLASM.
070334 07-03

ELECTRON MICROSCOPY. SUDDEN DEATH IN PATIENTS UNDER PHENOTHIAZINE THERAPY: STUDY OF THREE CASES.
090359 11-15

**ELECTRONIC**

CORRELATION BETWEEN ACTIVITY AND ELECTRONIC STATE OF HALLUCINOGENIC AMPHETAMINES.
067199 06-06

**ELECTROPHYSIOLOGICAL**
ELECTROENCEPHALOGRAPHIC VARIATIONS INDUCED BY PSYCHOTROPIC DRUGS: CLINICAL ELECTROPHYSIOLOGICAL CORRELATIONS FOR A GUIDED THERAPY.
063200 03-13

**ELECTROSHOCK**
THE EFFECT OF FLUROTHYL AND ELECTROSHOCK ON PULMONARY DIFFUSION.
058365 02-15

INDUCED CHANGES IN CAUDATE NUCLEUS DOPAMINE AND ELECTROSHOCK THRESHOLD.
079179 09-03

INFLUENCE OF CENTROPHENOXIN ON MEMORY DISTURBANCE AFTER ELECTROSHOCK.
079993 09-08

INCREASED INCORPORATION OF 14C-URIDINE INTO RAT BRAIN RNA AS A RESULT OF NOVEL ELECTROSHOCK.
092209 11-01

AMNESIA AND BRAIN SEIZURES ACTIVITY IN MICE: EFFECTS OF DIETHYL-ETHER ANESTHESIA PRIOR TO ELECTROSHOCK STIMULATION.
097952 11-04

**ELECTROSPLANCHNOGRAPHY**
ELECTROSPLANCHNOGRAPHY IN ANOREXIA-NERVOSA AND DEPRESSION -- PRELIMINARY RESULTS.
072154 07-16

**ELECTROTHERAPY**
ELECTROTHERAPY: THE EFFECTS OF METHOHEXITAL ON EKG.
058455 02-15

**ELEDOISIN**
THE EFFECT OF BRADYKININ AND ELEDOISIN INJECTED INTO THE CEREBRAL VENTRICLES OF CONSCIOUS RATS.
047323 01-04

**ELEMENT**
REMARKS ON THE USE OF CLOMIPRAMINE (ANAFRANIL) IN CERTAIN ACUTE DELIRIANT PSYCHOSES (WITHOUT A CLEAR DEPRESSIVE ELEMENT).
086438 10-14

**ELEPHANT**
MARIJUANA: MARY JANE FACES THE IDENTITY CRISIS OR, THREE BLIND MEN STUDY THE ELEPHANT.
082063 10-17

**ELEVATED**
ELEVATED CATECHOLAMINES IN THIRTY-DAY-OLD CHICKEN BRAIN AFTER DEPLETION DURING DEVELOPMENT.
063044 03-03

HYPOTENSIVE EFFECTS OF CHLORDIAZEPOXIDE, AMOBARBITAL AND CHLORPROMAZINE ON BEHAVIORALLY INDUCED ELEVATED ARTERIAL BLOOD PRESSURE IN THE SQUIRREL MONKEY.
089999 11-04

**ELICTED**
COMPARISON OF DRINKING ELICTED BY ESERINE OR DFP INJECTED INTO PREOPTIC AREA OF RAT BRAIN.
069637 07-04

**ELIMINATE**
AN ATTEMPT TO ELIMINATE RESISTANCE TO AMINAZINE BY MALARIA THERAPY IN PATIENTS WITH PARANOID SCHIZOPHRENIA.
087312 10-16

**ELIMINATION**
TOXICITY, NARCOTIC EFFECT, CONCENTRATION AT END OF ANESTHESIA, ELIMINATION FROM BLOOD AND BIOTRANSFORMATION OF HEXOBARBITAL IN RATS OF VARIOUS AGES FOLLOWING SLEEP INDUCTION WITH BARBITAL AND AFTER.
058987 03-05

**ELIXIR**
PIPERACETAZINE (QUIDE): A CONTROLLED EVALUATION OF THE ELIXIR IN CHRONIC SCHIZOPHRENIC PATIENTS.
082053 10-08

**ELYMOCLAVINE**
EFFECTS OF ELYMOCLAVINE ON WHEEL TURNING ACTIVITY IN MICE.
075196 08-04

**EMBRAN**
THE DISULFIRAM - LIKE ACTION OF EMBRAN.
067744 06-07

**EMBRYO**
GABA AS A REPRESSOR OF L-GLUTAMIC ACID DECARBOXYLASE (GAD) IN DEVELOPING CHICK EMBRYO OPTIC LOBES.
058192 02-03

EFFECTS OF DOM (STP) ON THE CHICK EMBRYO.
058974 03-05

**EMERGENCY**
EMERGENCY TREATMENT OF DRUG ABUSE AND POISON INGESTION.
066395 05-15

**EMOTIONAL**
CHANGES IN EMOTIONAL BEHAVIOUR AFTER APPLICATION OF CHOLINESTERASE INHIBITOR IN THE SEPTAL AND AMYGDALA REGION.
040578 01-04

EFFECTS OF MEPROBAMATE ON EMOTIONAL RESPONSES.
046312 01-04

REVERSIBLE LENTICULAR OPACITIES INDUCED IN RATS BY EMOTIONAL STRESS.
070823 07-03

AMITRIPTYLINE IN EMOTIONAL STATES AT THE MENOPAUSE.
071123 07-11

MECHANISMS OF LITHIUM ACTION: (ENDOGENOUS TISSUE LEVELS, EXCRETION IN EMOTIONAL STATES, AND BEHAVIORAL EFFECTS).
080634 09-03

EFFECTS OF SELECTED DRUGS ON STIMULUS BOUND EMOTIONAL BEHAVIOR ELICITED BY HYPOTHALAMIC STIMULATION IN THE CAT.
088617 10-04

BEHAVIORAL TOXICITY. PART 3: PERCEPTUAL COGNITIVE FUNCTIONS AND PART 4: EMOTIONAL (MOOD) STATES.
100523 12-15

ALCOHOL AS A DISCRIMINATIVE STIMULUS IN THE CONDITIONED EMOTIONAL RESPONSE. (PH.D.DISSERTATION).
103350 12-04

**EMOTIONALITY**
EFFECTS OF DEXAMETHASONE ON THE DEVELOPMENT OF EMOTIONALITY AND ADRENOCORTICAL REACTIVITY.
063605 04-04

**EMOTIONALLY**
DILANTIN EFFECT ON EMOTIONALLY DISTURBED CHILDREN.
070972 07-14

TREATMENT WITH THIORIDAZINE OF EMOTIONALLY DISTURBED CHILDREN IN A DAY HOSPITAL.
082090 10-14

**EMPLOYMENT**
THE EMPLOYMENT OF A NEW BENZODIAZEPINE, RO-5-4556 IN INTERNAL MEDICINE.
058312 02-11

**ENANTHATE**
PRIVATE AMBULATORY PATIENTS TREATED WITH FLUPHENAZINE ENANTHATE.
065458 05-07

FLUPHENAZINE HYDROCHLORIDE, ENANTHATE, AND DECANOATE IN THE MANAGEMENT OF CHRONIC PSYCHOSIS.
065476 05-08

A CLINICAL EVALUATION OF FLUPHENAZINE ENANTHATE.
065477 05-08

FLUPHENAZINE HYDROCHLORIDE AND ENANTHATE IN THE MANAGEMENT OF CHRONIC PSYCHOSIS.
065478 05-08

LONG-ACTING PHENOTHIAZINES AND LONG-TERM PSYCHOTIC PATIENTS: THE ROLE OF FLUPHENAZINE ENANTHATE IN TREATMENT.
065479 05-08

FLUPHENAZINE ENANTHATE GIVEN TO INPATIENTS AND OUTPATIENTS.
065480 05-09

HOSPITAL EXPERIENCE WITH FLUPHENAZINE ENANTHATE.
066748 05-07

FLUPHENAZINE ENANTHATE IN SESAME-OIL, A DEPOT PREPARATION.
070476 07-11

A CONTROLLED COMPARATIVE STUDY OF FLUPHENAZINE AND FLUPHENAZINE ENANTHATE IN ACUTE AND CHRONIC PSYCHOTIC PATIENTS.
075881 09-08

A CLINICAL EVALUATION OF PROLIXIN ENANTHATE.
076003 09-08

FLUPHENAZINE ENANTHATE (MODITEN-RETARD N.D.): CHEMISTRY AND PHARMACOLOGY.
088997 10-03

FLUPHENAZINE ENANTHATE IN THE TREATMENT OF THE POST-HOSPITALIZED PATIENT.
089000 10-17

**ENCEPHALITIS**
ENCEPHALITIS WITH CATATONIC SCHIZOPHRENIC SYMPTOMS.
069822 07-08

**ENCEPHALOPATHY**
ON BINSWANGERS SUBCORTICAL ARTERIOSCLEROTIC ENCEPHALOPATHY AND THE POSSIBILITY OF ITS CLINICAL RECOGNITION.
078733 09-13

ENCEPHALOPATHY AS A SEQUEL OF CHRONIC INTOXICATION WITH HALOGEN DERIVATIVES OF AROMATIC HYDROCARBONS.
085102 10-15

IATROGENIC ENCEPHALOPATHY.
090366 11-15

UNCONDITIONED REFLEX ACTIVITY IN THE RAT SUFFERING FROM EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY AND THE THERAPEUTIC EFFECT OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126051 12-04

DECREASE OF SPONTANEOUS MOTILITY IN EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY AND THE PROTECTIVE ACTIVITY OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126052 12-04

LEARNING ABILITY IN EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY UNDER THE INFLUENCE OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126056 12-04

**END**
TOXICITY, NARCOTIC EFFECT, CONCENTRATION AT END OF ANESTHESIA, ELIMINATION FROM BLOOD AND BIOTRANSFORMATION OF HEXOBARBITAL IN RATS OF VARIOUS AGES FOLLOWING SLEEP INDUCTION WITH BARBITAL AND AFTER.
058987 03-05

**ENDINGS**
MECHANISMS BY WHICH AMPHETAMINE AND DESIPRAMINE INHIBIT THE METARAMINOL INDUCED RELEASE OF NOREPINEPHRINE FROM SYMPATHETIC NERVE ENDINGS IN RAT HEART.
064427 04-03

**ENDOCRINE**
ENDOCRINE HORMONES.
051123 02-17

**ENDOGENOUS**
INHIBITION OF THE STIMULATING EFFECT OF METHAMPHETAMINE AND MORPHINE ON MOUSE BY INFLUENCING THE ENDOGENOUS CATECHOLAMINES.
055739 02-03

THE CLINICAL TESTING OF HYDROTHIADENE IN ENDOGENOUS DEPRESSIONS. INFLUENCE OF DRUGS ON PHOTOMYOCLONIC THRESHOLD.
070940 07-09

TRANYLCYPROMINE IN THE THERAPY OF ENDOGENOUS DEPRESSIONS.
070941 07-09

CLINICAL EXPERIENCES WITH CHLORIMIPRAMINE IN ENDOGENOUS DEPRESSION.
070942 07-09

CLINICAL EXPERIENCES WITH DESIPRAMINE IN ENDOGENOUS AND INVOLUTIONAL DEPRESSIONS.
070943 07-09

ACTUAL PROBLEMS OF ENDOGENOUS AND EXOGENOUS DEPRESSIONS.
070956 07-09

AMPHETAMINE TOXICITY AND ENDOGENOUS NORADRENALINE CONCENTRATIONS IN ISOLATED AND AGGREGATED MIC
074146 08-05

MECHANISMS OF LITHIUM ACTION: (ENDOGENOUS TISSUE LEVELS, EXCRETION IN EMOTIONAL STATES, AND BEHAVIORAL EFFECTS).
080634 09-03

INFLUENCE OF THYMOLEPTIC THERAPY ON THE COURSE OF ENDOGENOUS DEPRESSIONS.
089102 10-17

STUDIES ON THE COURSE OF RECURRENT ENDOGENOUS AFFECTIVE DISORDERS.
106766 12-09

LITHIUMS POSITION AMONG ANTIDEPRESSANTS IN THE TREATMENT OF ACUTE ENDOGENOUS AND INVOLUTIONAL DEPRESSIONS.
106777 12-09

**ENDOGENOUSLY**
THE ANTAGONISM OF PHENTOLAMINE AGAINST EXOGENOUSLY ADMINISTERED AND ENDOGENOUSLY RELEASED NOREPINEPHRINE IN RABBIT AORTIC STRIPS.
040243 01-03

**ENDOTOXINS**
MENTAL RETARDATION ASSOCIATED WITH POSTNATAL POISONS, TOXINS, ENDOTOXINS, DEFICIENCIES AND ALLERGIC REACTIONS.
061706 03-15

**ENDURANCE**
DIFFERENTIAL EFFECTS OF NICOTINE AND TOBACCO SMOKE ALKALOIDS ON SWIMMING ENDURANCE IN THE RAT.
069078 06-04

**ENDURING**
CRETINISM IN RATS: ENDURING BEHAVIORAL DEFICIT INDUCED BY TRICYANOAMINOPROPENE.
070839 07-02

**ENHANCEMENT**
THYROID HORMONE ENHANCEMENT OF IMIPRAMINE IN NONRETARDED DEPRESSIONS.
042654 01-09

ENHANCEMENT BY COCAINE OF INTRACRANIAL SELF-STIMULATION IN THE RAT.
058397 02-13

MEMORY ENHANCEMENT OF A PARTLY LEARNED DISCRIMINATION IN PIGEONS BY INTRAMUSCULAR INJECTION OF PHYSOSTIGMINE.
060858 03-04

DEPRESSION OF TWO-WAY AVOIDANCE LEARNING AND ENHANCEMENT OF PASSIVE AVOIDANCE LEARNING BY SMALL DOSES OF PHYSOSTIGMINE.
064365 04-04

ENHANCEMENT OF IMIPRAMINE BY THYROID STIMULATING HORMONE; CLINICAL AND THEORETICAL IMPLICATIONS.
075871 09-10

NOREPINEPHRINE TURNOVER IN BRAIN AFTER ADMINISTRATION OF IMIPRAMINE: ENHANCEMENT BY THYROID HORMONE.
090052 11-13

ENHANCEMENT BY DESIPRAMINE OF HYPOTHALAMICALLY EVOKED DISCHARGES IN PREGANGLIONIC SYMPATHETIC NERVES.
097962 11-03

**ENHANCING**
THE USE OF STIMULANT DRUGS IN ENHANCING PERFORMANCE AND LEARNING.
070971 07-17

**ENTEROTOXIN**
EFFECTS OF STAPHYLOCOCCAL ENTEROTOXIN B ON COMPLEX OPERANT BEHAVIOR IN MONKEYS.
069333 06-04

**ENURESIS**
USE OF AMITRIPTYLINE SYRUP IN THE TREATMENT OF ENURESIS IN CHILDREN.
062407 03-11

IMIPRAMINE IN CHILDHOOD ENURESIS: FURTHER STUDIES ON THE RELATIONSHIP OF TIME OF ADMINISTRATION TO EFFECT.
071946 07-11

AMITRIPTYLINE IN THE TREATMENT OF ENURESIS.
085453 10-14

**ENVIRONMENT**
INITIAL SUPPRESSION OF THE LOCOMOTOR STIMULANT RESPONSE TO DEXAMPHETAMINE IN RATS EXPOSED TO A NOVEL ENVIRONMENT.
067601 06-04

PSYCHOPHYSIOLOGICAL ASPECTS OF EXTENDED EXPOSURE OF MAN TO AN ENVIRONMENT WITH SENSORY DEPRIVATION.
082954 10-14

A REVIEW OF THE BIOMEDICAL EFFECTS OF MARIHUANA ON MAN IN THE MILITARY ENVIRONMENT.
085756 10-14

SOME PROBLEMS OF ORGANIZING THE PSYCHOTHERAPEUTIC ENVIRONMENT IN A MIXED FEMALE PSYCHIATRIC WARD.
111254 12-17

**ENVIRONMENTAL**
EFFECT OF ENVIRONMENTAL TEMPERATURE ON THE TOXICITY OF CAFFEINE AND DEXTROAMPHETAMINE IN MICE.
040028 01-05

DEXAMPHETAMINE: A POSSIBLE ENVIRONMENTAL TRIGGER IN CARDIOVASCULAR MALFORMATIONS.
082039 10-15

**ENVIRONMENTS**
EFFECTS OF CANNABIS-SATIVA AND LSD ON PIGEONS IN THREE VISUAL ENVIRONMENTS.
064499 04-04

**ENZYME**
COMPARISON OF LIVER MICROSOME ENZYME SYSTEMS AND BARBITURATE SLEEP TIMES IN RATS CAGED INDIVIDUALLY OR COMMUNALLY.
045545 01-06

SPECIFIC IRREVERSIBLE ENZYME INHIBITORS.
051115 01-17

PROJECT SUMMARY: METHANOL FORMING ENZYME IN MAMMALIAN BRAIN.
060633 03-01

MODIFICATION OF AN ENZYME RADIOCHEMICAL ASSAY PROCEDURE FOR NORADRENALINE.
064002 04-06

PERINATAL DEVELOPMENT OF DRUG METABOLIZING ENZYME ACTIVITY IN SWINE.
066368 05-03

HYPOTHALAMIC REGULATION OF HEPATIC HEXOBARBITAL METABOLIZING ENZYME SYSTEM.
067962 06-03

EPINEPHRINE CYCLIZING ENZYME IN SCHIZOPHRENIC SERUM.
075105 08-01

**ENZYMES**
CHANGES IN ENZYMES SUBSERVING CATECHOLAMINE METABOLISM IN MORPHINE TOLERANCE AND WITHDRAWAL IN RAT.
067324 06-03

**EPHEDRINE**
MANNICH BASES FROM 1,2- DIPHENYLINDOLIZINE: EPHEDRINE AND METHAMPHETAMINE AS AMINE COMPONENTS.
055324 02-01

STEREOTYPED BEHAVIOUR INDUCED BY (-) EPHEDRINE IN RATS.
074086 08-04

**EPILEPSY**
THERAPY OF PARTIAL EPILEPSY WITH A COMBINATION CONTAINING SULTHIAME.
055393 02-11

EFFECTS OF PSILOCYBIN, DIMETHYLTRYPTAMINE AND VARIOUS LYSERGIC ACID DERIVATIVES ON PHOTICALLY INDUCED EPILEPSY IN THE BABOON (PAPIO-PAPIO).
068163 06-03

MORFOLEP IN TREATMENT OF SOME FORMS OF EPILEPSY.
069085 06-13

EPILEPSY THERAPY WITH MENTALLY RETARDED CHILDREN: NEUROPSYCHIATRIC DISORDERS THROUGH DIPHENYLHYDANTOIN.
071241 07-15

FOLIC ACID IN FOLATE DEFICIENT PATIENTS WITH EPILEPSY.
080635 09-11

EFFECTS OF ATROPINE AND ESERINE ON THE ELECTROENCEPHALOGRAM, ON BEHAVIOUR AND ON LIGHT INDUCED EPILEPSY IN THE ADOLESCENT BABOON (PAPIO-PAPIO).
090157 11-04

**EPILEPTIC**
CLINICOELECTROENCEPHALOGRAPHIC EVALUATION OF A NEW BENZODIAZEPINIC DERIVATIVE (RO-5-4023) ADMINISTERED ORALLY IN EPILEPTIC PATIENTS USING A DOUBLE-BLIND METHOD.
100959 12-07

**EPILEPTICS**
DIAZEPAM IN THE ELECTROENCEPHALOGRAPHIC RECORDINGS OF EPILEPTICS.
087661 10-11

**EPILEPTIFORM**
EFFECT OF AGENTS INTERACTING WITH CHOLINOREACTIVE AND ADRENOREACTIVE SYSTEMS ON EPILEPTIFORM ACTIVITY IN THE HIPPOCAMPUS OF RABBITS.
110631 12-03

**EPILEPTOGENIC**
UNIT ACTIVITY IN PREMARIN INDUCED CORTICAL EPILEPTOGENIC FOCI.
066187 05-03
PENICILLIN INDUCED EPILEPTOGENIC FOCI IN THE RAT CORTEX.
075197 08-04

**EPINEPHRINE**
EPINEPHRINE AND NOREPINEPHRINE EFFECTS ON SOCIAL DOMINANCE BEHAVIOR.
069530 07-04
EPINEPHRINE CYCLIZING ENZYME IN SCHIZOPHRENIC SERUM.
075105 08-01

**EPISODES**
TWO PSYCHOTIC EPISODES ASSOCIATED WITH CANNABIS.
067692 06-09

**EPONTOL**
A COMPARISON OF PROPANIDID (EPONTOL) AND THIOPENTONE ANESTHESIA IN ECT.
076276 09-14

**EQUILIBRIUM**
DYNAMIC CONTROL OF ACID BASE EQUILIBRIUM DURING SOME FORMS OF SHOCK THERAPY.
079139 09-13

**EQUIVALENCE**
EQUIVALENCE OF SIMULTANEOUS AND SUCCESSIVE NEOCORTICAL ABLATIONS IN PRODUCTION OF IMPAIRMENTS OF RETENTION OF BLACK WHITE HABITS IN RATS.
076316 09-04

**ERAS**
RETENTION RATES OF SCHIZOPHRENIA: A COMPARISON OF SHOCK THERAPY AND PSYCHOPHARMACOLOGICAL ERAS AND OF CLOSED AND OPEN DOOR POLICIES.
069795 07-08

**ERGOT**
INHIBITION OF THE RE-UPTAKE OF NEURONALLY LIBERATED NORADRENALINE AND ALPHA-RECEPTOR BLOCKING ACTION OF SOME ERGOT ALKALOIDS.
041967 01-03
COMPLEXES OF ERGOT ALKALOIDS AND DERIVATIVES. II: INTERACTION OF DIHYDROERGOTOXINE WITH CERTAIN XANTHINES.
046137 01-03

**ERROR**
A SOURCE OF ERROR IN CATECHOLAMINE TURNOVER STUDIES WITH LABELED DOPA: SLOW DISAPPEARANCE OF THE PRECURSOR.
074818 08-03

**ERYTHROCYTE**
EFFECTS OF PHENOTHIAZINE DERIVATIVES ON BIOLOGICAL MEMBRANES: DRUG-INDUCED CHANGES IN ELECTRON SPIN RESONANCE SPECTRA FROM SPIN-LABELED ERYTHROCYTE GHOST MEMBRANES.
064423 04-03

**ESCAPE**
FORGETTING OF AN OPERANT RESPONSE: PHYSOSTIGMINE PRODUCED INCREASES IN ESCAPE LATENCY IN RATS AS A FUNCTION OF TIME OF INJECTION.
061540 03-04
THE INFLUENCE OF VARIOUS NEUROLEPTIC DRUGS ON NOISE ESCAPE RESPONSE IN RATS.
069076 06-04

**ESERINE**
THE EFFECT OF A PSYCHOTOMIMETIC GLYCOLATE AND ITS ANTIDOTE ESERINE ON THE ACH CONTENT OF THE LOBSTER WALKING LEG NERVE.
069515 06-13
COMPARISON OF DRINKING ELICTED BY ESERINE OR DFP INJECTED INTO PREOPTIC AREA OF RAT BRAIN.
069637 07-04
THE EFFECT OF ESERINE ON THE EFFERENT NEURONAL ACTIVITY IN THE CERVICAL SYMPATHETIC OF THE RAT.
074133 08-03

EFFECTS OF ATROPINE AND ESERINE ON THE ELECTROENCEPHALOGRAM, ON BEHAVIOUR AND ON LIGHT INDUCED EPILEPSY IN THE ADOLESCENT BABOON (PAPIO-PAPIO).
090157 11-04

**ESOPHAGUS**
METOCLOPRAMIDE AND THE MUSCULATURE OF ESOPHAGUS, STOMACH, INTESTINE, SPLEEN, TRACHEA, GALL AND URINARY BLADDERS: IN VITRO STUDIES.
055394 02-03

**ESSENTIALS**
ESSENTIALS OF MOLECULAR PHARMACOLOGY: BACKGROUND FOR DRUG DESIGN.
115114 12-17

**ESTERS**
SYNTHESIS OF ADAMANTYL ESTERS.
073265 08-01

**ESTIMATION**
QUANTITATIVE THIN-LAYER CHROMATOGRAPHIC ESTIMATION OF LABELED DOPAMINE AND NOREPINEPHRINE, THEIR PRECURSORS AND METABOLITES.
070063 07-06
CORTISOL EFFECTS ON AVERAGED EVOKED POTENTIAL, ALPHA-RHYTHM, TIME ESTIMATION, AND TWO-FLASH FUSION THRESHOLD.
075274 08-13
ESTIMATION OF LOW CHLORPROMAZINE CONCENTRATIONS BY SURFACING AND SINKING REACTION OF MINNOWS (GAMBUSIA-AFFINIS).
097964 11-06

**ESTRADIOL-17BETA**
INDUCTION OF RECEPTIVITY IN OVARIECTOMIZED FEMALE RATS BY A SINGLE INTRAVENOUS INJECTION OF ESTRADIOL-17BETA.
067696 06-04

**ESTROGEN**
FURTHER PSYCHOMETRIC EVALUATION OF OLDER WOMEN -- THE EFFECT OF ESTROGEN ADMINISTRATION.
078223 09-14
INDUCTION OF RECEPTIVITY IN FEMALE RATS AND CATS WITH ESTROGEN AND TESTOSTERONE.
081228 09-04

**ESTRUS**
ABBREVIATION OF BEHAVIORAL ESTRUS IN GUINEA-PIGS BY COITAL AND VAGINO-CERVICAL STIMULATION.
065332 05-03
FOOD REINFORCED RESPONDING IN RATS DURING ESTRUS.
075645 08-04

**ETHAMIVAN**
PENTYLENETETRAZOL AND ETHAMIVAN EFFECTS ON BRAIN SEROTONIN METABOLISM.
067613 06-03
CLINICAL, CLINICO-CHEMICAL AND BRAIN BIOELECTRIC TESTS OF A COMBINATION OF HEXOBENDINE, ETHAMIVAN AND HYDROXYETHYLTHEOPHYLLIN.
072585 08-14

**ETHANOL**
THE INFLUENCE OF ETHANOL ON DRUG METABOLISM.
057033 02-03
THE INTERACTION OF ETHANOL AND AMPHETAMINE METABOLISM.
063062 03-03
EFFECT OF INHIBITORS AND INDUCERS OF DRUG METABOLISM ON ETHANOL METABOLISM IN VIVO.
064052 04-03
TOXICITY OF ETHANOL BARBITURATE MIXTURES.
064160 04-05
MARIHUANA, ETHANOL, AND DEXTROAMPHETAMINE: MOOD AND MENTAL FUNCTION ALTERATIONS.
066231 05-14
THE KINETICS OF CHLORAL HYDRATE METABOLISM IN MICE AND THE EFFECT THEREON OF ETHANOL.
066364 05-03
A STUDY OF THE INTERACTION OF THE HYPNOTIC EFFECTS AND OF THE TOXIC EFFECTS OF CHLORAL HYDRATE AND ETHANOL.
066365 05-03
EFFECTS OF PHENOBARBITAL, PHENYLBUTAZONE, 3,4 BENZPYRENE, OR 3-METHYLCHOLANTHRENE ON ETHANOL METABOLISM IN THE RAT.
066498 05-03
INHIBITION BY PROPRANOLOL OF ETHANOL INDUCED NARCOSIS.
066510 05-03
EFFECT OF ETHANOL ON 5-HYDROXYTRYPTAMINE TURNOVER IN RAT BRAIN.
066938 05-03
A POSSIBLE PATHWAY FOR ETHANOL INDUCED FATTY LIVER AND MODIFICATION OF LIVER INJURY BY ANTIOXIDANTS.
070906 07-05
THE EFFECT OF ETHANOL AND AMPHETAMINE MIXTURES ON THE ACTIVITY OF RATS IN A Y-MAZE.
074149 08-04

EFFECTS OF INTRAPERITONEAL INJECTION OF ETHANOL ON ETHANOL INGESTION OF C57BL MICE.
075957 09-02

HEPATIC COMPOSITION AND METABOLISM AFTER ETHANOL CONSUMPTION IN RATS FED LIQUID PURIFIED DIETS.
088599 10-03

SYNERGISM BETWEEN COBALT AND ETHANOL ON RAT GROWTH RATE.
088600 10-03

A STUDY OF HEPATIC ALCOHOL DEHYDROGENASE INHIBITION INDUCED BY PYRAZOL: I. IN VIVO ACTION ON ETHANOL AND 2-PHENYLETHANOL.
089548 11-03

SOME EFFECTS OF ETHANOL ON THE TOXICITY AND DISTRIBUTION OF BARBITURATES IN RATS.
090032 11-05

URINARY EXCRETION OF ADRENAL HORMONES IN MAN: EFFECTS OF ETHANOL INGESTION, AND THEIR MODIFICATION BY CHLORMETHIAZOLE.
097974 11-11

**ETHCHLORVYNOL**

ACUTE ETHCHLORVYNOL (PLACIDYL) INTOXICATION.
064623 04-15

**ETHEREAL**

MECHANISM OF THE RENAL TUBULAR TRANSPORT OF MORPHINE AND MORPHINE ETHEREAL SULFATE IN THE CHICKEN.
040754 01-03

**ETHERS**

THE SYNTHESIS AND BIOLOGICAL ACTIVITY OF (-)-DELTA9(11)-TRANS TETRAHYDROCANNABINOL; A NEW PROCEDURE FOR THE CLEAVAGE OF PHENYL METHYL ETHERS (UNPUBLISHED PAPER).
092888 11-01

**ETHOLOGICAL**

THE ETHOLOGICAL APPROACH TO SOCIALIZATION.
091173 11-04

**ETHYL**

JUMPING ACTIVITY INDUCED BY SODIUM 5-(1,3 DIMETHYLBUTYL)-5 ETHYL BARBITURATE. II. THE EFFECTS OF AGE DIFFERENCE.
058985 03-04

THE REVERSAL OF DEVELOPED TOLERANCE TO PENTOBARBITAL BY ETHYL ALCOHOL.
058995 03-03

**ETHYLAMINO-2-PROPANE**

THE EFFECT OF ACUTE ADMINISTRATION OF (META-TRIFLUOROMETHYL-PHENYL)-1-(BENZOYLOXY) ETHYLAMINO-2-PROPANE (780-SE) AND FENFLURAMINE ON HUMAN SLEEP.
063978 04-14

**ETHYLPHENACEMIDE**

INFLUENCE OF ETHYLPHENACEMIDE ON SERUM LEVELS OF OTHER ANTIEPILEPTIC DRUGS.
066190 05-13

**ETIOLOGY**

ETIOLOGY OF LATE HYPERKINESIS IN THE COURSE OF LONG-TERM TREATMENT WITH NEUROLEPTICS.
100997 12-15

**EVALUATE**

PSYCHOLOGICAL METHODS APPLIED TO EVALUATE SYMPTOMATIC GERIATRIC TREATMENT.
064152 04-14

**EVALUATING**

METHODOLOGICAL CONSIDERATIONS IN EVALUATING ANTIANXIETY DRUGS.
046558 01-16

FEASIBILITY OF EVALUATING PSYCHOPHARMACEUTICAL AGENTS IN COOPERATIVE STUDIES IN PRIVATE PRACTICE.
069025 06-10

EVALUATING CHANGES IN SYMPTOMS DURING ACUTE ALCOHOL WITHDRAWAL.
094978 11-11

**EVALUATION**

AN EVALUATION OF THE VASODILATION PRODUCED BY MEPHENTERMINE AND CERTAIN OTHER SYMPATHOMIMETIC AMINES.
040311 01-03

STATISTICAL METHOD OF ANALYSIS AND EVALUATION OF PSYCHOTHERAPEUTIC RESULTS: APPLICATION OF A LONG-ACTING NEUROLEPTIC, COMPARED WITH A STANDARD NEUROLEPTIC AND THE SAKEL INSULIN TREATMENT.
042676 01-07

CHALLENGES IN DRUG EVALUATION IN MAN.
051133 02-17

2,5 DIMETHOXY-4-METHYLAMPHETAMINE: CLINICAL EVALUATION OF A NEW HALLUCINOGENIC DRUG.
052457 02-12

A DOUBLE-BLIND EVALUATION OF CAPURIDE (PACINOX) AS A PRESURGICAL AID TO SLEEP.
058371 02-14

A CLINICAL EVALUATION OF CLOPENTHIXOL.
058373 02-07

THE CLINICAL EVALUATION OF FOUR PROPOSED ANTIDEPRESSANTS. RELATIONSHIP TO THEIR ANIMAL PHARMACOLOGY.
059040 03-

AN EVALUATION OF NIACINAMIDE IN THE TREATMENT OF CHILDHOOD SCHIZOPHRENIA.
060240 03-

A CLINICAL EVALUATION OF MESORIDAZINE IN MENTALLY RETARDED PATIENTS.
060268 03-

A DATA PROCESSING SYSTEM FOR PSYCHOTROPIC DRUG EVALUATION.
060862 03-

A DOUBLE-BLIND EVALUATION OF THE ANTIEMETIC EFFICACY OF BENZQUINAMIDE, PROCHLORPERAZINE AND TRIMETHOBENZAMIDE IN OFFICE PRACTICE.
063022 03-

LITHIUM: CRITICAL EVALUATION.
063139 03-

LITHIUM: CRITICAL EVALUATION.
063140 03-

LITHIUM: CRITICAL EVALUATION.
063141 03-

DRUG TREATMENT: CRITICAL EVALUATION.
063143 03-

DRUG TREATMENT: CRITICAL EVALUATION.
063144 03-

DRUG TREATMENT: CRITICAL EVALUATION.
063145 03-

DRUG TREATMENT: CRITICAL EVALUATION.
063146 03-

TELEVISION TAPE FOR EVALUATION OF TREATMENT RESPONSE.
063568 03-

CLINICAL EVALUATION OF HALOPERIDOL IN GERIATRIC PATIENTS.
064074 04-

LABORATORY EVALUATION OF AGGRESSIVE BEHAVIOR OF THE GRASSHOPPER MOUSE (ONYCHOMYS).
064260 04-

CLINICAL EVALUATION OF DOXEPIN AND AMITRIPTYLINE IN DEPRESSED PATIENTS.
064637 05-

PLACEBO CONTROL EVALUATION OF DESIPRAMINE IN DEPRESSION.
065235 05-

A CLINICAL EVALUATION OF FLUPHENAZINE ENANTHATE.
065477 05-

AN EVALUATION OF THE PHARMACOLOGIC APPROACHES TO LEARNING IMPEDIMENTS.
066838 05-

CLINICAL EVALUATION OF MAZINDOL IN CHRONIC SCHIZOPHRENICS.
066852 05-

EVALUATION OF THE PERIPHERAL AND CENTRAL ANTAGONISTIC ACTIVITIES AGAINST 5-HYDROXYTRYPTAMINE OF SOME NEW AGENTS.
067603 06-

A COMPARATIVE EVALUATION OF DOXEPIN AND CHLORDIAZEPOXIDE IN THE TREATMENT OF PSYCHONEUROTIC OUTPATIENTS.
072140 07-

EVALUATION OF THIOTHIXENE IN THE TREATMENT OF SCHIZOPHRENIA.
072897 08-

EVALUATION OF THE THERAPEUTIC EFFECT OF NEUROLEPTICS UPON THE HIGHER NERVOUS ACTIVITY IN SCHIZOPHRENIA.
075103 08-

PSYCHOANALYTIC EVALUATION OF ADDICTION AND HABITATION.
075300 08-

A CLINICAL EVALUATION OF PROLIXIN ENANTHATE.
076003 09-

FURTHER PSYCHOMETRIC EVALUATION OF OLDER WOMEN -- THE EFFECT OF ESTROGEN ADMINISTRATION.
078223 09-

EVALUATION OF TEGRETOL IN THE TREATMENT OF BEHAVIOUR DISORDERS IN CHILDREN: METHODOLOGY AND RESULTS.
080098 09-

CLINICAL EVALUATION IN 112 PSYCHIATRIC PATIENTS OF A BUTYROPHENONE NEUROLEPTIC, DEHYDROBENZPERIDOL (R-4749).
080142 09-

PSYCHOMETRIC TESTS IN EVALUATION OF BRAIN PATHOLOGY, RESPONSE TO DRUGS.
081043 09-

METRAZOL AND THE EVALUATION OF SEIZURES.
081298 09-

PRECLINICAL EVALUATION OF AHR-1118. A POTENTIAL ANTIDEPRESSANT DRUG.
082051 10-

PIPERACETAZINE (QUIDE): A CONTROLLED EVALUATION OF THE ELIXIR IN CHRONIC SCHIZOPHRENIC PATIENTS.
082053 10-

THE USEFULNESS OF PLACEBO AND THE DOUBLE-BLIND TECHNIQUE IN THE EVALUATION OF PSYCHOTROPIC DRUGS.
089054 10-

IN VIVO EVALUATION OF ABSORPTION AND EXCRETION OF PENTYLENETETRAZOL -10-14C FROM SUSTAINED-RELEASE AND NONSUSTAINED-RELEASE TABLETS.
090427 11-13

APPLICATION OF ON-LINE COMPUTER PROCEDURES TO EXPERIMENTAL CONTROL AND EVALUATION OF THE EFFECTS OF DRUGS ON OPERANT BEHAVIOR (SIDMAN SHOCK AVOIDANCE RESPONDING BY RATS).
095507 11-06

COMPARATIVE STUDY OF NATURAL SLEEP AND THE ACTION OF PHENAMINE AND CHLORPROMAZINE EVALUATION OF THE MEAN EXTREMES FREQUENCY OF ECOG IN CATS.
095655 11-14

EVALUATION OF CL-1848C: A NEW DISSOCIATIVE ANESTHETIC IN NORMAL HUMAN VOLUNTEERS.
097971 11-07

CLINICAL EVALUATION OF A NEW PSYCHOTROPIC DRUG -- MOLINDONE.
097997 11-07

THE OBJECTIVE EVALUATION OF PSYCHOPHARMACOLOGICAL DRUGS WITH CAFFEINE AND CAFFEINE-FREE COFFEE AS AN EXAMPLE.
098039 11-13

CLINICOELECTROENCEPHALOGRAPHIC EVALUATION OF A NEW BENZODIAZEPINIC DERIVATIVE (RO-5-4023) ADMINISTERED ORALLY IN EPILEPTIC PATIENTS USING A DOUBLE-BLIND METHOD.
100959 12-07

EVALUATION OF AN AMITRIPTYLINE PERPHENAZINE COMBINATION IN CHRONIC SCHIZOPHRENIA.
101681 12-08

CLINICOELECTROENCEPHALOGRAPHIC EVALUATION OF THE ANTIEPILEPTIC ACTION OF A NEW SERIES OF BENZODIAZEPINIC DERIVATIVES.
105486 12-07

ADRENAL CORTICAL AND MEDULLARY SECRETION AND EVALUATION OF DRUGS ACTING ON THE CENTRAL NERVOUS SYSTEM.
106270 12-03

CLINICAL EVALUATION OF THE USE OF G-32883 IN TRIGEMINAL NEURALGIA.
112130 12-11

CHEMICAL AND CLINICAL EVALUATION OF THE USE OF GABOB IN SCHIZOPHRENIC PATIENTS.
114885 12-08

A SUPPLEMENT TO CLINICAL EVALUATION OF THIOTHIXENE WITH SPECIAL REFERENCE TO THE TREATMENT OF AFFECTIVE PSYCHOSES.
129452 12-09

**IDENCE**

INFLUENCE OF SEROTONIN AND RELATED SUBSTANCES UPON PHOTIC EVOKED POTENTIALS OF RABBIT: EVIDENCE FOR BIOLOGICAL ACTIVITY OF THE ALDEHYDE DERIVATIVE.
055584 02-03

EVIDENCE FOR A CENTRALLY MEDIATED HYPOTENSIVE EFFECT OF L-DOPA IN THE RAT.
055587 02-03

LATERAL HYPOTHALAMIC CONTROL OF KILLING: EVIDENCE FOR A CHOLINOCEPTIVE MECHANISM.
058227 02-04

ANTAGONISM OF D-AMPHETAMINE BY ALPHA-METHYL-L-TYROSINE: BEHAVIORAL EVIDENCE FOR THE PARTICIPATION OF CATECHOLAMINE STORES AND SYNTHESIS IN THE AMPHETAMINE STIMULANT RESPONSE.
064096 04-03

EVIDENCE FOR A CENTRAL NORADRENALINE RECEPTOR: STIMULATION BY CLONIDINE.
081151 09-03

CONCERNING THE EVIDENCE FOR A PROPHYLACTIC ACTION OF LITHIUM.
100082 11-09

**VOKED**

INFLUENCE OF SEROTONIN AND RELATED SUBSTANCES UPON PHOTIC EVOKED POTENTIALS OF RABBIT: EVIDENCE FOR BIOLOGICAL ACTIVITY OF THE ALDEHYDE DERIVATIVE.
055584 02-03

THE EFFECTS OF ALCOHOL ON VISUAL AND SOMATO-SENSORY EVOKED RESPONSES.
056925 02-14

INFLUENCE OF TRIIODOTHYRONINE ON SELECTIVE ATTENTION IN MAN AS MEASURED BY THE VISUAL AVERAGED EVOKED POTENTIAL.
062510 03-13

RECORDING EVOKED POTENTIALS IN THE CONSCIOUS RAT: THE MAINTENANCE OF A CONSTANT BEHAVIOURAL BASELINE.
067600 06-06

EFFECTS OF PENTOBARBITONE AND CHLORPROMAZINE ON ACOUSTICALLY EVOKED POTENTIALS IN THE RAT.
074939 08-03

CORTISOL EFFECTS ON AVERAGED EVOKED POTENTIAL, ALPHA-RHYTHM, TIME ESTIMATION, AND TWO-FLASH FUSION THRESHOLD.
075274 08-13

ENHANCEMENT BY DESIPRAMINE OF HYPOTHALAMICALLY EVOKED DISCHARGES IN PREGANGLIONIC SYMPATHETIC NERVES.
097962 11-03

EFFECT OF LSD-25, CHLORPROMAZINE AND METEDRINE UPON VISUAL EVOKED RESPONSE IN CATS.
098171 11-03

**EVOKING**

THE INFLUENCE OF A FEAR EVOKING SITUATION ON THE RECTAL TEMPERATURE OF RATS.
082409 10-03

**EXACERBATION**

NICOTINIC ACID IN THE PREVENTION AND TREATMENT OF METHIONINE INDUCED EXACERBATION OF PSYCHOPATHOLOGY IN SCHIZOPHRENICS.
075423 08-08

**EXACERBATIONS**

TRANSIENT EXACERBATIONS, OCCURRING IN THE PROCESS OF NEUROLEPTICAL THERAPY.
081539 10-15

**EXAMINATION**

THE EFFECTS OF CHLORPROMAZINE ON ONE-TRIAL PASSIVE AVOIDANCE LEARNING IN MICE: FURTHER EXAMINATION OF PRELEARNING AND POSTLEARNING ADMINISTRATION.
064407 04-04

ADVERSE MARIJUANA REACTIONS: A CRITICAL EXAMINATION OF THE LITERATURE WITH SELECTED CASE MATERIAL.
069613 07-15

A CLINICAL EXAMINATION OF CHRONIC LSD USE IN THE COMMUNITY.
076254 09-12

THE INFLUENCE OF IMIPRAMINE, DEXPHENMETRAZINE AND AMPHETAMINE SULPHATE ON SYNCHRONOUS AND PARADOXICAL SLEEP IN NARCOLEPSY CATAPLEXY. A POLYGRAPHIC EXAMINATION.
089037 10-14

**EXAMPLE**

THE OBJECTIVE EVALUATION OF PSYCHOPHARMACOLOGICAL DRUGS WITH CAFFEINE AND CAFFEINE-FREE COFFEE AS AN EXAMPLE.
098039 11-13

**EXCESSIVE**

THE ACTION OF DIAZEPAM IN NEUROLOGICAL DISORDERS WITH EXCESSIVE MOTOR ACTIVITY.
056779 02-11

ANTIEPILEPTIC DOSING AFTER EXCESSIVE ALCOHOL INTAKE.
093919 11-11

**EXCITATION**

EFFECTS OF LYSERGIC ACID DERIVATIVES ON 5-HYDROXYTRYPTAMINE EXCITATION OF BRAINSTEM NEURONES.
041973 01-02

INCREASED DURATION OF NEUROPHARMACOLOGICALLY INDUCED BEHAVIORAL EXCITATION BY ATROPINE.
079998 09-04

INHIBITION OF CENTRAL SEROTONINERGIC EXCITATION (5-HYDROXYTRYPTOPHAN INDUCED DEAD TWITCHES) IN MICE BY LITHIUM.
097989 11-04

**EXCITATORY**

THE EXCITATORY AND INHIBITORY INNERVATION OF THE STOMACHS OF THE DOMESTIC FOWL.
074854 08-03

EXCITATORY EFFECT OF TRYPTOPHAN IN MICE AND RATS AND EFFECT OF IMIPRAMINE AND DESMETHYLIMIPRAMINE UPON IT.
098009 11-03

A STUDY OF THE EXCITATORY EFFECTS OF BARBITURATES.
116471 12-03

**EXCITEMENT**

DOPA INDUCED EXCITEMENT IN THE CAT: ITS RELATIONSHIP TO BRAIN NOREPINEPHRINE CONCENTRATIONS.
058840 02-04

**EXCRETION**

STUDIES OF DELAYED ACTION MEDICATION: V. PLASMA LEVELS AND URINARY EXCRETION OF FOUR DIFFERENT DOSAGE FORMS OF CHLORPROMAZINE.
041559 01-13

DISTRIBUTION, EXCRETION, AND METABOLISM OF 14C-LABELED QUATERNARY AMMONIUM SALT OF MEPAZINE AND PROMETHAZINE IN RATS.
058571 02-03

EXCRETION OF VANYLGLYCOL IN HUMAN URINE UNDER DIETARY CONTROL, AND DURING TREATMENT WITH ANTIBIOTICS, DISULFIRAM, A MONOAMINE OXIDASE INHIBITOR, ALPHA-METHYLDOPA, AND RESERPINE.
060272 03-13

THE EFFECTS OF IMIPRAMINE AND ELECTRIC CONVULSIVE THERAPY ON THE EXCRETION OF VARIOUS MINERALS IN DEPRESSED PATIENTS.
063939 04-13

DISTRIBUTION, EXCRETION AND METABOLISM OF TRIFLUOPERAZINE METHIODIDE-C14 IN RATS.
064094 04-03

DISTRIBUTION, EXCRETION, AND METABOLISM OF 14C-LABELED QUATERNARY AMMONIUM SALT OF PERPHENAZINE IN RATS.
064261 04-03

METABOLISM AND BILIARY EXCRETION OF THE LIPOPHILIC DRUG MOLECULES, IMIPRAMINE AND DESMETHYLIMIPRAMINE IN THE RAT -- I. EXPERIMENTS IN VIVO AND WITH ISOLATED PERFUSED LIVERS.
067260 06-03

AFFECTIVE ILLNESS AND CYCLIC AMP EXCRETION.
071972 07-13

DELTA1-TETRAHYDROCANNABINOL, SYNHEXYL AND MARIJUANA EXTRACT ADMINISTERED ORALLY IN MAN: CATECHOLAMINE EXCRETION, PLASMA CORTISOL LEVELS AND PLATELET SEROTONIN CONTENT.
075841 08-12

MECHANISMS OF LITHIUM ACTION: (ENDOGENOUS TISSUE LEVELS, EXCRETION IN EMOTIONAL STATES, AND BEHAVIORAL EFFECTS).
080634 09-03

INFLUENCE OF AMINAZIN ON ADRENALIN, NORADRENALINE, DOPAMINE, AND DOPA EXCRETION IN HEALTHY PEOPLE AND IN THE MANIC PHASE OF THE MANIC-DEPRESSIVE PSYCHOSIS.
090355 11-03

IN VIVO EVALUATION OF ABSORPTION AND EXCRETION OF PENTYLENETETRAZOL -10-14C FROM SUSTAINED-RELEASE AND NONSUSTAINED-RELEASE TABLETS.
090427 11-13

EFFECT OF NICOTINIC ACID COMBINED WITH A TRANQUILLIZER (HYDROXYZINE) ON SERUM LIPID LEVELS AND URINARY CATECHOLAMINE EXCRETION IN GERIATRIC PATIENTS.
093689 11-11

URINARY EXCRETION OF ADRENAL HORMONES IN MAN: EFFECTS OF ETHANOL INGESTION, AND THEIR MODIFICATION BY CHLORMETHIAZOLE.
097974 11-11

FACTORS AFFECTING THE URINARY EXCRETION OF TRICYCLIC ANTIDEPRESSANTS IN MAN.
100026 11-13

STUDIES ON PSYCHOTROPIC DRUGS (SIXTH REPORT) - METABOLIC FATE OF APY-606 - EXCRETION AND METABOLISM IN RATS.
131057 12-02

STUDIES ON PSYCHOTROPIC DRUGS (SEVENTH REPORT) -- METABOLIC FATE OF APY-606 -- ABSORPTION, DISTRIBUTION, EXCRETION AND METABOLISM OF TRITIATED APY-606.
131059 12-02

**EXCRETORY**

EXTINCTION OF THE EXCRETORY ALKALI METAL RESPONSE (EAMR) TO STRESS IN A REPTILE.
076068 09-03

**EXOCRINE**

THE EFFECTS OF PHENOBARBITAL ON EXOCRINE PANCREAS.
064180 04-03

**EXOGENOUS**

FOUR EFFECTS OF EXOGENOUS INSULIN ON FOOD INTAKE.
061572 03-03

ACTUAL PROBLEMS OF ENDOGENOUS AND EXOGENOUS DEPRESSIONS.
070956 07-09

THE EFFECT OF EXOGENOUS RNA ON THE RETENTION OF DISCRIMINATIVE LEARNING IN THE RAT.
079982 09-04

COMPARISON OF THE EFFECTS OF EXOGENOUS ACTH ON APPROACH AND AVOIDANCE CONDITIONING: IMPLICATIONS FOR THE PHYSIOLOGY OF INCENTIVE MOTIVATION. (PH.D.DISSERTATION).
103354 12-04

**EXOGENOUSLY**

THE ANTAGONISM OF PHENTOLAMINE AGAINST EXOGENOUSLY ADMINISTERED AND ENDOGENOUSLY RELEASED NOREPINEPHRINE IN RABBIT AORTIC STRIPS.
040243 01-03

**EXPANDED**

USE OF LEVODOPA MAY BE EXPANDED BY ADDITION OF MK-485 TO DRUG REGIMEN.
097284 11-09

**EXPERIENCE**

NOBRIUM, ANOTHER BENZODIAZEPINE DERIVATIVE. 29 MONTHS OF EXPERIENCE.
059037 03-11

EXPERIENCE OF PSYCHIATRIC MANAGEMENT OF SCHIZOPHRENIA WITH FLUPHENAZINE DECANOATE.
063186 03-08

ON SIMILAR LINGUISTIC STRUCTURES IN CREATIVE PERFORMANCE AND PSILOCYBIN INDUCED EXPERIENCE.
065433 05-12

HOSPITAL EXPERIENCE WITH FLUPHENAZINE ENANTHATE.
066748 05-07

PSYCHEDELIC EXPERIENCE AND THE LANGUAGE PROCESS.
067340 06-12

CLINICAL EXPERIENCE WITH OCTOCLOTHEPINE IN MANIC SYNDROMES.
070927 07-09

CLINICAL EXPERIENCE WITH OCTOCLOTHEPINE IN SCHIZOPHRENIC PSYCHOSES.
070929 07-08

CLINICAL EXPERIENCE WITH OCTOCLOTHEPINE.
070930 07-0

CLINICAL EXPERIENCE WITH FLUPHENAZINE DECANOATE.
070931 07-0

CLINICAL EXPERIENCE WITH FLUPHENAZINE DEPOT.
070932 07-0

CLINICAL EXPERIENCE WITH PIPERACETAZINE IN HOSPITALIZED MENTAL PATIENTS: A FOUR YEAR STUDY.
071292 07-0

CLINICAL EXPERIENCE OF SULPIRIDE IN PSYCHIATRY.
072159 07-0

L-DOPA THERAPY OF PARKINSONS DISEASE (A REVIEW OF THE PRELIMINARY EXPERIENCE AT WEST-VIRGINIA UNIVERSITY).
072421 08-0

OUR EXPERIENCE WITH TOXIC PSYCHOSES.
074575 08-1

MORPHINE INDUCED FIGHTING AND PRIOR SOCIAL EXPERIENCE.
075206 08-0

CLINICAL EXPERIENCE WITH LITHIUM CARBONATE.
075424 08-0

PRELIMINARY EXPERIENCE WITH MEDAZEPAM (NOBRIUM) IN THE MANAGEMENT OF PSYCHOPHYSIOLOGIC REACTIONS.
075878 09-0

EXPERIENCE WITH PROPERICIAZIN (AOLEPT) IN THE TREATMENT OF CHILDREN WITH DISTURBED PSYCHOMOTOR FUNCTIONS AND RESTLESSNESS.
081144 09-11

PSYCHIATRIC CLINICAL EXPERIENCE WITH AN ANTIANDROGEN PREPARATION.
088995 10-14

CLINICAL EXPERIENCE WITH MESORIDAZINE IN THE THERAPY AND REHABILITATION OF TRAUMATIC FRONTAL BRAIN DAMAGE.
089784 11-14

CHANGES IN BEHAVIOUR WITH REPEATED TESTING UNDER THE INFLUENCE OF DRUGS: DRUG EXPERIENCE INTERACTIONS.
091997 11-04

CLINICAL EXPERIENCE WITH ANAFRANIL.
093091 11-10

CLINICAL EXPERIENCE WITH TARASAN AND THIORIDAZINE IN MENTALLY RETARDED CHILDREN -- A COMPARATIVE DOUBLE-BLIND STUDY.
097655 11-14

CLINICAL EXPERIENCE WITH 10MG RESERPINE INJECTED I.M.IN DEPRESSIVE DISORDERS.
100019 11-09

CLINICAL EXPERIENCE WITH METHYLPERONE (BURONIL), A NEW BUTYROPHENONE DERIVATIVE.
105730 12-07

EXPERIENCE WITH A COMBINATION OF AMITRIPTYLINE AND THIORIDAZINE FOR THE TREATMENT OF DEPRESSIONS.
105732 12-14

PROBLEM BEHAVIOR OF CHILDREN WITH SEVERE MENTAL AND PHYSICAL DISORDERS -- EXPERIENCE OF THE USE OF CARBAMAZEPINE.
105790 12-14

FIRST ORIENTATIONS ON THE USE OF HIGH DOSES OF OXAZEPAM, BASED ON PERSONAL CLINICAL THERAPEUTIC EXPERIENCE.
124308 12-10

A CLINICAL EXPERIENCE OF OXAZOLAM, A NEW MINOR TRANQUILIZER.
129367 12-07

**EXPERIENCES**

MARIHUANA INTOXICATION: COMMON EXPERIENCES.
045515 01-17

CLINICAL EXPERIENCES WITH CHLORIMIPRAMINE IN ENDOGENOUS DEPRESSION.
070942 07-09

CLINICAL EXPERIENCES WITH DESIPRAMINE IN ENDOGENOUS AND INVOLUTIONAL DEPRESSIONS.
070943 07-09

SOME EXPERIENCES WITH A PREVENTIVE ADMINISTRATION OF LITHIUM SALTS IN MANIC MELANCHOLIC PSYCHOSIS.
070952 07-09

EXPERIENCES OF A THERAPEUTIC COMMUNITY.
124312 12-17

PRELIMINARY EXPERIENCES WITH NOBRIUM IN PRIVATE PSYCHIATRIC PRACTICE IN DJAKARTA.
130714 12-10

**EXPERIMENT**

IMPROVED CEREBRAL CIRCULATION AND PERFORMANCE IN A PSYCHOLOGICAL EXPERIMENT.
059001 03-11

PSYCHIATRIC CHANGES IN PATIENTS TREATED WITH LEVODOPA: I. THE CLINICAL EXPERIMENT.
092917 11-10

CLINICAL EXPERIMENT WITH A NEW TRANQUILLIZER: TRIOXAZINE.
094423 11-11

**EXPERIMENTAL**

EFFECTS OF SOME PSYCHOACTIVE DRUGS ON EXPERIMENTAL NEUROTIC (CONFLICT INDUCED) BEHAVIOR IN CATS.
046143 01-04

EXPERIMENTAL PSYCHOLOGICAL STUDY OF PERFORMANCE CHANGES WITH PERAZINE (TAXILAN) IN MENTALLY DISTURBED AND IN HEALTHY EXPERIMENTAL SUBJECTS FOLLOWING REGIMEN AND SINGLE DOSE ADMINISTRATION.
058235 02-11

INDOKLON: CONVULSIVE THERAPY; EXPERIMENTAL CLINICAL STUDIES.
059692 03-07

PREFERENCES FOR MORPHINE IN RATS: VALIDATION OF AN EXPERIMENTAL MODEL OF DEPENDENCE.
064475 04-04

EXPERIMENTAL EFFECTS OF AMPHETAMINE: SUPPLEMENTARY REPORT.
064968 05-04

BLOCKING OF EXPERIMENTAL SPIKE AND WAVE BY A LOCALIZED FOREBRAIN LESION.
066186 05-03

ELECTROENCEPHALOGRAPHIC ANALYSIS OF EXPERIMENTAL PSYCHOSIS BROUGHT ON BY DITRAN.
067147 06-13

IMPLICATIONS OF LSD AND EXPERIMENTAL MYSTICISM.
067355 06-12

DRUG-INDUCED RELIEF OF EXPERIMENTAL TREMOR IN MONKEYS.
068457 06-04

RELATIONS BETWEEN BARBITURATE BRAIN LEVELS AND SLEEPING TIME IN VARIOUS EXPERIMENTAL CONDITIONS.
068600 06-03

STUDIES ON INTERACTIONS INVOLVING ANTIDEPRESSIVE AND OTHER DRUGS WITH TETRABENAZINE AND NORADNAMINE ON LOCOMOTOR ACTIVITY IN MICE, INCLUDING DETAILS OF THE EXPERIMENTAL DESIGN AND STATISTICAL ANALYSIS.
069077 06-04

THE INFLUENCE OF LONG-TERM PREMEDICATION WITH TRANYLCYPROMINE ON EXPERIMENTAL PSYCHOSES INDUCED BY LSD.
070954 07-12

EXPERIMENTAL VARIABLES IN THE EFFECTS OF POSTSESSION INJECTIONS OF STRYCHNINE SULPHATE ON A CLASSICALLY CONDITIONED RESPONSE.
071792 07-04

STUDIES ON THE ROLE OF ACID IN THE PATHOGENESIS OF EXPERIMENTAL STRESS ULCERS.
075276 08-03

EFFECT OF A DECARBOXYLASE INHIBITOR (RO-4-4602), COMBINED WITH L-DOPA, ON INHIBITED DEPRESSIVE PATIENTS: II. EXPERIMENTAL PSYCHOLOGICAL STUDIES.
079964 09-14

THE IMPORTANCE OF RESEARCH IN BIOGENIC AMINES FOR THE EXPERIMENTAL PSYCHOPHARMACOLOGY.
081110 09-17

THE EFFECT OF LITHIUM ON THE METABOLISM OF EXPERIMENTAL ANIMALS.
081111 09-03

ACTION OF THE SALTS OF OXYGLURIC ACID ON ACUTE ALCOHOL INTOXICATION IN MAN (EXPERIMENTAL STUDY).
086005 10-11

EXPERIMENTAL STUDIES ON THE EFFECTIVE PROCEDURE TO INHIBIT THE DEVELOPMENT OF TOLERANCE TO AND DEPENDENCE ON MORPHINE.
089789 11-02

EXPERIMENTAL DRUG MAKES RATS SEXY.
090137 11-04

APPLICATION OF ON-LINE COMPUTER PROCEDURES TO EXPERIMENTAL CONTROL AND EVALUATION OF THE EFFECTS OF DRUGS ON OPERANT BEHAVIOR (SIDMAN SHOCK AVOIDANCE RESPONDING BY RATS).
095507 11-06

THE EXPERIMENTAL USE OF PSYCHEDELIC (LSD) PSYCHOTHERAPY.
097286 11-12

LITHIUM INDUCED POLYURIA: EXPERIMENTAL STUDIES IN MAN AND THE RAT.
100083 11-15

PROPHYLACTIC ACTION OF LITHIUM SALTS AND THYROID HORMONES ON SYMPTOMS OF MANIC-DEPRESSIVE AND AFFECTIVE PSYCHOSES: CLINICAL AND EXPERIMENTAL RESULTS.
106774 12-09

EXPERIMENTAL USE OF PREPARATION LUVATREN IN SCHIZOPHRENIC PATIENTS.
111022 12-08

RESEARCH IN NEW EXPERIMENTAL METHODS FOR PSYCHOTROPIC DRUGS: RESULTS OF A DOUBLE-BLIND STUDY WITH A NEW TRANQUILIZER, NOBRIUM.
112282 12-16

THE SAFETY TEST OF L-DOPA -- II. EFFECT OF L-DOPA ON THE DEVELOPMENT OF PRENATAL AND POSTNATAL OFFSPRINGS OF EXPERIMENTAL ANIMALS.
114836 12-02

THE SAFETY TEST OF L-DOPA. I. ACUTE AND SUBACUTE TOXICITY OF L-DOPA IN EXPERIMENTAL ANIMALS.
114837 12-05

EFFECT OF TWO RECENTLY SYNTHESIZED PHENOTHIAZINE DERIVATIVES UPON EXPERIMENTAL CARDIAC ARRHYTHMIAS.
114978 12-03

UNCONDITIONED REFLEX ACTIVITY IN THE RAT SUFFERING FROM EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY AND THE THERAPEUTIC EFFECT OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126051 12-04

DECREASE OF SPONTANEOUS MOTILITY IN EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY AND THE PROTECTIVE ACTIVITY OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126052 12-04

LEARNING ABILITY IN EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY UNDER THE INFLUENCE OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126056 12-04

**EXPERIMENTALLY**

CIRCADIAN RHYTHM FOR EXPERIMENTALLY INDUCED AGGRESSIVE BEHAVIOR IN MICE.
058383 02-03

SOME EFFECTS OF EXPERIMENTALLY PRODUCED CIGARETTE SMOKE ON THE GROWTH, VITAMIN-C METABOLISM AND ORGAN WEIGHTS OF GUINEA-PIGS.
063061 03-03

**EXPERIMENTATION**

CONTROLLED THERAPEUTIC EXPERIMENTATION IN CASES OF PSYCHOGENOUS GASTROENTERIC DISTURBANCE.
072003 07-07

CONTRIBUTION TO THE STUDY OF THE EXTRAPYRAMIDAL SYNDROME WITH ANIMAL EXPERIMENTATION. THE ROLE OF CALCIUM AND O-METHYLENE DERIVATIVES.
086348 10-03

RESEARCH ON NEW METHODS OF EXPERIMENTATION WITH PSYCHOTROPIC DRUGS. RESULTS OF A TEST WITH A NEW TRANQUILIZER, NOBRIUM, IN TWO INDEPENDENT INVESTIGATIONS.
086984 10-16

LONG-TERM TREATMENT WITH CHLORPROMAZINE IN ANIMAL EXPERIMENTATION.
105619 12-05

**EXPERIMENTS**

LIVER DAMAGE FOLLOWING APPLICATION OF PYRAZINAMIDE IN ANIMAL EXPERIMENTS: 1. CHANGES IN BODY WEIGHT OF RATS UNDER THE INFLUENCE OF PYRAZINAMIDE.
055398 02-05

PHYSIOLOGICAL AND SITUATIONAL FACTORS IN PSYCHOPHARMALOGICAL EXPERIMENTS.
058638 02-14

METABOLISM AND BILIARY EXCRETION OF THE LIPOPHILIC DRUG MOLECULES, IMIPRAMINE AND DESMETHYLIMIPRAMINE IN THE RAT -- I. EXPERIMENTS IN VIVO AND WITH ISOLATED PERFUSED LIVERS.
067260 06-03

LABORATORY EXPERIMENTS SUITABLE FOR PRACTICAL CLASSES IN PSYCHOPHARMACOLOGY.
067599 06-06

SLEEP AND HYPNOTICS: FURTHER EXPERIMENTS.
072216 07-14

MORPHOLOGICAL ASPECTS OF APPLICATION OF NOXIPTILIN (BAY-1521) IN ANIMAL EXPERIMENTS.
079972 09-03

EFFECTS OF NEUROLEPTICS ON THE CEREBRAL ELECTRICAL ACTIVITY OF LABORATORY ANIMALS: PRESENTATION OF A MODEL DESIGN FOR NEUROPHARMACOLOGICAL EXPERIMENTS.
085337 10-03

PRELIMINARY EXPERIMENTS ON THE CHEMISTRY AND PHARMACOLOGY OF CANNABIS.
086405 10-01

CLINICAL CONTRIBUTION OF EXPERIMENTS WITH CHLORIMIPRAMINE (ANAFRANIL).
093443 11-09

ON THE ROLE OF BRAIN CATECHOLAMINES IN MOTOR ACTIVITY: EXPERIMENTS WITH INHIBITORS OF SYNTHESIS AND OF MONOAMINE OXIDASE.
097960 11-04

**EXPLORATION**

THE INHIBITORY EFFECT OF AMPHETAMINE ON EXPLORATION IN MICE.
069080 06-04

THE CONCEPT OF THE VISUAL COMPUTER AND ITS EXPLORATION BY THE USE OF DRUGS.
069802 07-13

STRYCHNINE AND SUPPRESSION OF EXPLORATION.
081149 09-04

**EXPLORATORY**

A COMPARISON OF THE EFFECTS OF SOME BENZODIAZEPINES AND OTHER DRUGS ON AGGRESSIVE AND EXPLORATORY BEHAVIOUR IN MICE AND RATS.
040581 01-04

THE EFFECT OF MAGNESIUM PEMOLINE ON DISCRIMINATION LEARNING AND EXPLORATORY BEHAVIOR.
059567 03-04

A METHOD FOR INVESTIGATING THE EFFECTS OF DRUGS ON THE EXPLORATORY BEHAVIOUR OF MICE.
064289 04-04

DISAPPEARANCE IN RATS WITH SEPTAL LESIONS OF THE STIMULATORY EFFECT OF HYOSCINE ON EXPLORATORY BEHAVIOUR.
067605 06-04

**EXPOSED**
INITIAL SUPPRESSION OF THE LOCOMOTOR STIMULANT RESPONSE TO DEXAMPHETAMINE IN RATS EXPOSED TO A NOVEL ENVIRONMENT.
067601 06-04

**EXPOSURE**
ALTERATIONS OF D-AMPHETAMINE SULFATE LETHALITY AND BODY TEMPERATURE IN MICE DURING ACUTE ALTITUDE EXPOSURE.
040582 01-03

LSD EXPOSURE IN UTERO.
056611 02-15

RELATIONS BETWEEN THE ELECTROGASTROGRAM AND GASTRIC ULCERATION DURING EXPOSURE TO STRESS.
075438 08-03

PSYCHOPHYSIOLOGICAL ASPECTS OF EXTENDED EXPOSURE OF MAN TO AN ENVIRONMENT WITH SENSORY DEPRIVATION.
082954 10-14

**EXPRESSION**
THE EFFECTS OF CHLORPROMAZINE ON THE EXPRESSION OF AN ACQUIRED PASSIVE AVOIDANCE RESPONSE IN MICE.
097959 11-04

**EXTENSIVE**
MODIFICATION OF NACL APPETITE IN THE ADRENALECTOMIZED RAT CONSEQUENT TO EXTENSIVE LICL POISONING.
061094 03-04

**EXTERNAL**
EFFECTS OF SCOPOLAMINE, ATROPINE, AND D-AMPHETAMINE ON INTERNAL AND EXTERNAL CONTROL OF RESPONDING ON NON-REINFORCED TRIALS.
064410 04-04

THE EFFECTIVENESS OF EXTERNAL AND DRUG PRODUCED INTERNAL STIMULI IN THE DISCRIMINATIVE CONTROL OF OPERANT BEHAVIOR. (PH.D.DISSERTATION).
110682 12-04

**EXTINCTION**
EXTINCTION OF AVOIDANCE RESPONDING THROUGH RESPONSE PREVENTION (FLOODING).
063275 03-04

SODIUM AMOBARBITAL, THE HIPPOCAMPAL THETA RHYTHM, AND THE PARTIAL REINFORCEMENT EXTINCTION EFFECT.
063333 03-03

THE EFFECTS OF SCOPOLAMINE ON THE EXTINCTION OF A CONTINUOUSLY REINFORCED RESPONSE.
063587 03-04

COMMENT ON THE INCREASED RESISTANCE TO EXTINCTION OF AN AVOIDANCE RESPONSE INDUCED BY CERTAIN DRUGS.
065070 05-04

EFFECTS OF AMOBARBITAL SODIUM ON THE ACQUISITION AND EXTINCTION OF A LEVER-PRESS SPATIAL DISCRIMINATION IN THE RAT.
069075 06-04

THE EFFECT OF NICOTINE AND TOTAL ALKALOIDS EXTRACTED FROM CIGARETTE SMOKE IN AVOIDANCE BEHAVIOR IN RATS UNDER EXTINCTION PROCEDURE.
069079 06-04

COMPARATIVE EFFECTS OF AMPHETAMINE, SCOPOLAMINE, CHLORDIAZEPOXIDE, AND DIPHENYLHYDANTOIN ON OPERANT AND EXTINCTION BEHAVIOR WITH BRAIN STIMULATION AND FOOD REWARD.
074935 08-04

THE ROLE OF D-AMPHETAMINE AMOBARBITAL IN SUPPRESSING FREEZING BEHAVIOR DURING AVOIDANCE ACQUISITION AND EXTINCTION.
075882 09-04

EXTINCTION OF THE EXCRETORY ALKALI METAL RESPONSE (EAMR) TO STRESS IN A REPTILE.
076068 09-03

**EXTRACELLULAR**
STRUCTURAL BASIS OF LITHIUM PSYCHOPHARMACOLOGY: EXTRACELLULAR GROUND SUBSTANCE OF RAT BRAIN.
106783 12-03

**EXTRACEREBRAL**
EFFECT OF L-DOPA ALONE AND IN COMBINATION WITH AN EXTRACEREBRAL DECARBOXYLASE INHIBITOR ON BLOOD PRESSURE AND SOME CARDIOVASCULAR REFLEXES.
090371 11-13

**EXTRACT**
DELTA1-TETRAHYDROCANNABINOL, SYNHEXYL AND MARIJUANA EXTRACT ADMINISTERED ORALLY IN MAN: CATECHOLAMINE EXCRETION, PLASMA CORTISOL LEVELS AND PLATELET SEROTONIN CONTENT.
075841 08-12

**EXTRACTED**
THE EFFECT OF NICOTINE AND TOTAL ALKALOIDS EXTRACTED FROM CIGARETTE SMOKE IN AVOIDANCE BEHAVIOR IN RATS UNDER EXTINCTION PROCEDURE.
069079 06-04

**EXTRACTS**
STRUCTURE-ACTIVITY RELATIONSHIP OF FOUR TETRAHYDROCANNABINOLS AND THE PHARMACOLOGICAL ACTIVITY OF FIVE SEMI-PURIFIED EXTRACTS OF CANNABIS-SATIVA.
064417 04-04

DEVELOPMENT OF FIGHTING BEHAVIOR IN STARVED RATS BY CHRONIC ADMINISTRATION OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL AND CANNABIS EXTRACTS: LACK OF ACTION OF OTHER PSYCHOTROPIC DRUGS.
072531 08-04

**EXTRANEURONAL**
INTRANEURONAL AND EXTRANEURONAL ACCUMULATION OF SYMPATHOMIMETIC AMINES IN THE ISOLATED NICTITATING MEMBRANE OF THE CAT.
066363 05-03

**EXTRAPYRAMIDAL**
DRUG-INDUCED EXTRAPYRAMIDAL DISORDERS: A RATING SCALE FOR EXTRAPYRAMIDAL SIDE-EFFECTS.
063773 04-16

A CONTROLLED TRIAL OF COMBINED MEDICATIONS ON BEHAVIORAL AND EXTRAPYRAMIDAL EFFECTS.
063774 04-14

CONTROLLED STUDIES OF ANTIPARKINSONISM AGENTS IN THE TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL SYMPTOMS.
063777 04-14

CEREBROSPINAL FLUID MONOAMINE CATABOLITES IN DRUG-INDUCED EXTRAPYRAMIDAL DISORDERS.
064097 04-13

LONG-ACTING, ANTIPSYCHOTIC AGENTS AND EXTRAPYRAMIDAL SIDE-EFFECTS.
065471 05-15

THE STRUCTURAL AND BIOCHEMICAL BASIS OF MOVEMENT DISORDERS IN TREATMENT WITH NEUROLEPTIC DRUGS AND IN EXTRAPYRAMIDAL DISEASES.
067107 06-13

A SURVEY OF EXTRAPYRAMIDAL MANIFESTATIONS IN PATIENTS ATTENDING AN AFTER CARE CLINIC OF A PSYCHIATRIC HOSPITAL.
070412 07-15

PERSISTENT EXTRAPYRAMIDAL ORAL DYSKINESIAS FOLLOWING TREATMENT WITH THYMOLEPTICS.
070945 07-15

LEVODOPA IN DRUG-INDUCED EXTRAPYRAMIDAL DISORDERS.
074874 08-08

ON THE EFFECT OF DIOXYPHENYLALANINE (L-DOPA) ON EXTRAPYRAMIDAL HYPERKINESIA DUE TO NEUROLEPTIC LONG-TERM MEDICATION.
079950 09-15

ON PROBLEMS OF LATE EXTRAPYRAMIDAL HYPERKINESIS DUE TO NEUROLEPTIC LONG-TERM THERAPY.
079996 09-15

CONTRIBUTION TO THE STUDY OF THE EXTRAPYRAMIDAL SYNDROME WITH ANIMAL EXPERIMENTATION. THE ROLE OF CALCIUM AND O-METHYLENE DERIVATIVES.
086348 10-03

EXTRAPYRAMIDAL ACCIDENTS IN TREATMENT OUTSIDE THE HOSPITAL SETTING.
086443 10-15

A SURVEY OF EXTRAPYRAMIDAL MANIFESTATIONS IN THE INPATIENT POPULATION OF A PSYCHIATRIC HOSPITAL.
086444 10-15

SPECIFIC (IN THE SENSE OF INCREASED PREDISPOSITION TO INJURY OF THE SUBDOMINANT HEMISPHERE) DISTRIBUTION OF THE EXTRAPYRAMIDAL SYMPTOMS IN SCHIZOPHRENICS DURING THE COURSE OF HALOPERIDOL TREATMENT.
089106 10-15

DRUG-INDUCED EXTRAPYRAMIDAL DISORDERS (UNPUBLISHED PAPER).
093445 11-15

EXTRAPYRAMIDAL EFFECTS.
100527 12-15

EFFECT OF AMANTADINE ON THE EXTRAPYRAMIDAL SYNDROMES INDUCED BY NEUROLEPTICS.
112131 12-09

**EXTRAPYRAMIDALISM**
ACTIONS OF L-DOPA IN DRUG-INDUCED EXTRAPYRAMIDALISM.
075429 08-08

**EXTRAVERSION**
THE PSYCHOPHYSIOLOGICAL BASIS OF INTROVERSION EXTRAVERSION.
064375 04-04

THE EFFECT OF EXTRAVERSION AND STIMULANT AND DEPRESSANT DRUGS ON VERBAL CONDITIONING.
078786 09-14

**EXTREME**
TREATMENT OF RESISTANT SCHIZOPHRENICS WITH EXTREME HIGH DOSAGE FLUPHENAZINE HYDROCHLORIDE.
063597 04-08

**EXTREMES**
COMPARATIVE STUDY OF NATURAL SLEEP AND THE ACTION OF PHENAMINE AND CHLORPROMAZINE EVALUATION OF THE MEAN EXTREMES FREQUENCY OF ECOG IN CATS.
095655 11-14

**EXTREMITIES**
EFFECT OF CAPERS ON THE VASCULAR LUMEN OF ISOLATED EXTREMITIES OF SENSITIZED FROGS AND THE ANTIANAPHYLATIC EFFECT OF SUPRASTIN.
105720 12-03

**EYE**
THE TOXICOLOGY OF NEUROLEPTICS ON THE EYE.
085338 10-15
DRUG-INDUCED DAMAGE OF THE EYE AND THE OPTICAL NERVE.
128389 12-15

**EYES**
SEEING WITH ALL THREE EYES.
046728 01-12

**FACES**
THE MANY FACES OF MANIA: THERAPEUTIC TRIAL OF LITHIUM CARBONATE.
047919 01-09
MARIJUANA: MARY JANE FACES THE IDENTITY CRISIS OR, THREE BLIND MEN STUDY THE ELEPHANT.
082063 10-17

**FACILITATE**
FAILURE OF TRICYANOAMINOPROPENE TO FACILITATE ACQUISITION OF DOUBLE ALTERNATION IN RATS.
088471 10-04

**FACILITATED**
THIOPENTONE FACILITATED IMPLOSION IN TREATMENT OF PHOBIC DISORDERS.
066907 05-14
CLASSICAL HYSTERICAL SEIZURES FACILITATED BY ANTICONVULSANT TOXICITY.
081135 09-15

**FACILITATING**
VERBAL ANXIETY AND THE BETA-ADRENERGIC RECEPTORS: A FACILITATING MECHANISM.
060880 03-13

**FAILURE**
TREATMENT OF WILSONS DISEASE WITH L-DOPA AFTER FAILURE WITH PENICILLAMINE.
058243 02-11
AMPHETAMINE INTOXICATION WITH COAGULOPATHY, HYPERTHERMIA, AND REVERSIBLE RENAL FAILURE: A SYNDROME RESEMBLING HEATSTROKE.
064236 04-15
FAILURE OF TRICYANOAMINOPROPENE TO FACILITATE ACQUISITION OF DOUBLE ALTERNATION IN RATS.
088471 10-04

**FAILURES**
SUCCESSES AND FAILURES IN METHADONE MAINTENANCE TREATMENT OF HEROIN ADDICTION IN NEW-YORK CITY. (UNPUBLISHED PAPER).
071314 07-17

**FAMILIAL**
DILANTIN TREATMENT OF HOSPITALIZED CULTURAL FAMILIAL RETARDATES.
062175 03-14

**FATAL**
DELIRIUM-ACUTUM, A POTENTIALLY FATAL CONDITION IN THE PSYCHIATRIC HOSPITAL.
075980 09-15

**FATALITIES**
HEAT STROKE IN PHENOTHIAZINE TREATED PATIENTS: A REPORT OF THREE FATALITIES.
076364 09-15

**FATE**
THE FATE OF C14-DIHYDROXYPHENYLALANINE (C14-DOPA) IN THE WHOLE MOUSE.
064161 04-03
EFFECT OF SKF-525A ON THE FATE OF THIOPENTONE.
066853 05-03
EFFECT OF DIAZEPAM ON FATE OF INTRACISTERNALLY INJECTED SEROTONIN-C14.
072031 07-03
STUDIES ON PSYCHOTROPIC DRUGS (SIXTH REPORT) - METABOLIC FATE OF APY-606 - EXCRETION AND METABOLISM IN RATS.
131057 12-02
STUDIES ON PSYCHOTROPIC DRUGS (SEVENTH REPORT) -- METABOLIC FATE OF APY-606 -- ABSORPTION, DISTRIBUTION, EXCRETION AND METABOLISM OF TRITIATED APY-606.
131059 12-02

**FATIGUE**
EFFECT OF PYROVALERONE IN THE AMBULATORY TREATMENT OF FATIGUE STATES.
091503 11-11
FATIGUE, SLEEP AND DREAMS.
133916 12-14

**FATIGUED**
A NEW STIMULANT, PROLINTANE HYDROCHLORIDE, COMPARED WITH DEXTROAMPHETAMINE IN FATIGUED VOLUNTEERS.
040128 01-14

**FATTY**
A POSSIBLE PATHWAY FOR ETHANOL INDUCED FATTY LIVER AND MODIFICATION OF LIVER INJURY BY ANTIOXIDANTS.
070906 07-05
PLASMA FREE FATTY ACIDS BEFORE AND AFTER AN INTRAVENOUS INSULIN INJECTION IN ACUTE SCHIZOPHRENIC MEN.
075212 08-08
HIGH VOLTAGE SLOW WAVE INDUCED BY SHORT-CHAIN FATTY ACIDS WITH SPECIAL REFERENCE TO SLEEP RHYTHM.
088612 10-03

**FDA**
FDA WARNS AGAINST USES OF BEHAVIOR AMPHETAMINES.
051373 02-15
FDA APPROVES LITHIUM FOR MANIC-DEPRESSION.
089400 10-17

**FEAR**
EFFECTS OF CHLORDIAZEPOXIDE ON DISCRIMINATIVE FEAR CONDITIONING AND SHUTTLE AVOIDANCE PERFORMANCE IN THE RABBIT.
065451 05-04
THE INFLUENCE OF A FEAR EVOKING SITUATION ON THE RECTAL TEMPERATURE OF RATS.
082409 10-03
PITUITARY ADRENAL ALTERATIONS AND FEAR RESPONDING.
090135 11-04

**FEASIBILITY**
FEASIBILITY OF EVALUATING PSYCHOPHARMACEUTICAL AGENTS IN COOPERATIVE STUDIES IN PRIVATE PRACTICE.
069025 06-10

**FEASIBLE**
IS IT FEASIBLE TO TREAT CERTAIN POTENTIALLY DANGEROUS CONDITIONS BY PROLONGED CHEMOTHERAPY.
062406 03-08

**FEEDBACK**
THE EFFECT OF SOCIAL FEEDBACK ON CHRONIC SCHIZOPHRENIC PATIENTS.
075362 08-14

**FEEDING**
ALPHA-ADRENERGIC RECEPTORS IN HYPOTHALAMUS FOR THE SUPPRESSION OF FEEDING BEHAVIOR BY SATIETY.
060801 03-04

**FEMALE**
USE OF A NEW ANTIDEPRESSANT IN THE FEMALE CLIMACTERIC.
063598 04-09
EFFECT OF CHRONIC ADMINISTRATION OF P-CHLOROPHENYLALANINE ON SEXUAL RECEPTIVITY OF THE FEMALE RAT.
066825 05-04
INDUCTION OF RECEPTIVITY IN OVARIECTOMIZED FEMALE RATS BY A SINGLE INTRAVENOUS INJECTION OF ESTRADIOL-17BETA.
067696 06-04
EFFECT OF AN ORAL CONTRACEPTIVE ON SPONTANEOUS RUNNING ACTIVITY OF FEMALE RATS.
067716 06-04
EFFECTS OF NEONATAL TESTOSTERONE ON THE ACQUISITION OF AN ACTIVE AVOIDANCE RESPONSE IN GENOTYPICALLY FEMALE RATS.
075890 09-04
MODULATION OF FOOD INTAKE AND LOCOMOTOR ACTIVITY IN FEMALE RATS BY DIENCEPHALIC HORMONE IMPLANTS.
076080 09-04
UPTAKE OF TRITIATED TESTOSTERONE IN BRAIN AND PERIPHERAL TISSUES OF NORMAL AND NEONATALLY ANDROGENIZED FEMALE RATS.
076086 09-04
DEVELOPMENT OF HORMONAL CONTROL OVER FOOD INTAKE AND BODY WEIGHT IN FEMALE RATS.
076239 09-03
OVARIAN HORMONES AND FEMALE SEXUAL INVITATIONS IN CAPTIVE RHESUS MONKEYS (MACACA-MULATTA).
076554 09-03
INDUCTION OF RECEPTIVITY IN FEMALE RATS AND CATS WITH ESTROGEN AND TESTOSTERONE.
081228 09-04
FOREBRAIN BIOGENIC AMINE FUNCTION IN HIGH AND LOW FEMALE RATS.
081231 09-04
POST-NEONATAL ANDROGENIZATION AND ADULT AGGRESSIVE BEHAVIOR IN FEMALE MICE.
081233 09-04
A SEQUENTIAL TRIAL OF AMYLOBARBITONE SODIUM USED AS SEDATION FOR CONFUSED FEMALE PSYCHOGERIATRIC PATIENTS.
082732 10-11

SOME PROBLEMS OF ORGANIZING THE PSYCHOTHERAPEUTIC ENVIRONMENT IN A MIXED FEMALE PSYCHIATRIC WARD.
111254 12-17
INFLUENCES OF POLYPHARMACY ON HALLUCINATORY BEHAVIOR IN A SAMPLE OF FEMALE CHRONIC SCHIZOPHRENIC PATIENTS.
115037 12-08

**FENETYLLIN**
QUANTITATIVE CLINICAL ANALYSIS OF THE EFFECT OF FENETYLLIN (CAPTAGON) ON HYPERKINETIC CHILDREN.
093540 11-11

**FENFLURAMINE**
CENTRAL NERVOUS SYSTEM STIMULANT ACTION OF FENFLURAMINE IN RABBITS.
040639 01-03
A COMPARATIVE STUDY OF THE PHARMACOLOGIC ACTIONS OF AMPHETAMINE AND FENFLURAMINE.
058996 03-05
THE EFFECT OF ACUTE ADMINISTRATION OF (META-TRIFLUOROMETHYL-PHENYL)-1-(BENZOYLOXY) ETHYLAMINO-2-PROPANE (780-SE) AND FENFLURAMINE ON HUMAN SLEEP.
063978 04-14

**FENTANYL**
ON THE CENTRAL SITES FOR THE ANTINOCICEPTIVE ACTION OF MORPHINE AND FENTANYL.
074936 08-03

**FERTILITY**
TESTING DRUGS FOR TERATOGENICITY AND THEIR EFFECTS ON FERTILITY; THE PRESENT POSITION.
057605 02-05

**FETAL**
EFFECTS OF THALIDOMIDE AND CHLORCYCLIZINE ON THE BIOSYNTHESIS OF NUCLEIC ACIDS AND PROTEINS IN FETAL AND MATERNAL TISSUES OF THE RAT.
040027 01-05
DECARBOXYLATION OF 3,4- DIHYDROXYPHENYLALANINE IN VARIOUS HUMAN ADULT AND FETAL TISSUES.
040105 01-13
LYSERGIC ACID DIETHYLAMIDE INTAKE IN PREGNANCY: FETAL DAMAGE IN RATS.
064422 04-05
TERATOGENIC EFFECT OF LITHIUM CARBONATE IN THE FETAL MOUSE.
089398 10-05

**FIBROSIS**
PLEURAL EFFUSION AND FIBROSIS DURING TREATMENT WITH METHYSERGIDE.
067836 06-15

**FIGHTING**
THE EFFECT OF P-CHLOROPHENYLALANINE (PCPA) ON SHOCK INDUCED FIGHTING BEHAVIOR IN RATS.
062853 03-03
CHEMICAL INDUCTION OF TRAUMATIC FIGHTING IN RATS.
068765 06-04
DEVELOPMENT OF FIGHTING BEHAVIOR IN STARVED RATS BY CHRONIC ADMINISTRATION OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL AND CANNABIS EXTRACTS: LACK OF ACTION OF OTHER PSYCHOTROPIC DRUGS.
072531 08-04
MORPHINE INDUCED FIGHTING AND PRIOR SOCIAL EXPERIENCE.
075206 08-04
MORPHINE AMPHETAMINE INDUCED FIGHTING AND INTERIM SOCIALIZATION.
076131 09-04
PROJECT SUMMARY: CHEMICAL INDUCTION OF TRAUMATIC FIGHTING IN RATS.
082511 10-04

**FISH**
RESERPINE AND CONDITIONED SUPPRESSION IN THE FISH TILAPIA H. MACROCEPHALA.
075996 09-04

**FIXATION**
THE EFFECT OF SOME INHIBITORS AND METABOLITES OF CATECHOLAMINE ON THE PROCESSES OF FIXATION AND REPRODUCTION OF MEMORY TRACES.
073716 08-03

**FIXED-RATIO**
A CHOICE TECHNIQUE TO ASSESS THE EFFECTS OF SELECTIVE PUNISHMENT ON FIXED-RATIO PERFORMANCE.
075579 08-04

**FLASHBACK**
ANALYSIS OF THE LSD FLASHBACK.
067341 06-15

**FLASHES**
EFFECTS OF INSTRUCTIONS AND DRUG ADMINISTRATION ON TEMPORAL RESOLUTION OF PAIRED FLASHES.
075771 08-14

**FLAXEDILIZED**
AVOIDANCE TRAINING OF HIPPOCAMPAL THETA WAVES IN FLAXEDILIZED DOGS AND ITS RELATION TO SKELETAL MOVEMENT.
075399 08-04

**FLICKER**
CARBON MONOXIDE AND PHENOBARBITONE: A COMPARISON OF EFFECTS ON AUDITORY FLUTTER FUSION THRESHOLD AND CRITICAL FLICKER FUSION THRESHOLD.
070303 07-14

**FLOODING**
EXTINCTION OF AVOIDANCE RESPONDING THROUGH RESPONSE PREVENTION (FLOODING).
063275 03-04

**FLOW**
SOME NEUROCHEMICAL CORRELATES OF AXOPLASMIC FLOW.
073327 08-03

**FLUID**
THE ROLE OF CARBONIC ANHYDRASE IN ANION SECRETION INTO CEREBROSPINAL FLUID.
040755 01-03
FLUID AND ELECTROLYTE ABNORMALITIES IN ALCOHOLISM.
063591 03-03
CEREBROSPINAL FLUID MONOAMINE CATABOLITES IN DRUG-INDUCED EXTRAPYRAMIDAL DISORDERS.
064097 04-13
SPINAL FLUID CREATINE PHOSPHOKINASE ABNORMALITIES FOLLOWING LSD USAGE.
067213 06-15
FLUID INTAKE AND PUNISHMENT ATTENUATING DRUGS.
067704 06-04
CEREBROSPINAL FLUID 5-HYDROXYINDOLES AND BEHAVIOR AFTER L-TRYPTOPHAN AND PYRIDOXINE ADMINISTRATION TO PSYCHIATRIC PATIENTS.
074938 08-14

**FLUORESCENCE**
SPECIAL APPLICATION OF FLUORESCENCE HISTOCHEMISTRY: STUDIES ON EIGHT MONOAMINE OXIDASE INHIBITORS IN BRAIN NEURONS.
063989 04-06

**FLUORESCENT**
FLUORESCENT LABELING OF PSYCHOACTIVE DRUGS.
066738 05-06

**FLUOROMETRIC**
CHLORPROMAZINE METABOLISM I: QUANTITATIVE FLUOROMETRIC METHOD FOR 11 CHLORPROMAZINE METABOLITES.
080631 09-06

**FLUOXYMESTERONE**
COMBINED ADMINISTRATION OF THIORIDAZINE AND FLUOXYMESTERONE IN THE TREATMENT OF GERIATRIC PATIENTS.
069060 06-11

**FLUPENTHIXOL**
CLINICAL OBSERVATIONS ON THE THERAPEUTIC ACTIVITY OF FLUPENTHIXOL IN THE TREATMENT OF CHRONIC SCHIZOPHRENIA.
080143 09-08
A DOUBLE-BLIND INVESTIGATION WITH FLUPENTHIXOL AND TRIFLUOPERAZINE AT TREATMENT OF SCHIZOPHRENIC PSYCHOSES.
100017 11-08

**FLUPHENAZINE**
COMPARATIVE EFFECTS OF FLUPHENAZINE, FLUPHENAZINE CHLORDIAZEPOXIDE AND FLUPHENAZINE IMIPRAMINE.
058451 02-15
EXPERIENCE OF PSYCHIATRIC MANAGEMENT OF SCHIZOPHRENIA WITH FLUPHENAZINE DECANOATE.
063186 03-08
THE USE OF HIGH DOSES OF FLUPHENAZINE IN THE TREATMENT OF PSYCHOTIC PATIENTS.
063589 03-08
TREATMENT OF RESISTANT SCHIZOPHRENICS WITH EXTREME HIGH DOSAGE FLUPHENAZINE HYDROCHLORIDE.
063597 04-08
A COMPARATIVE STUDY OF FLUPHENAZINE AMITRIPTYLINE COMBINATION AND AMITRIPTYLINE ALONE IN THE TREATMENT OF DEPRESSED PSYCHIATRIC PATIENTS.
064356 04-09
PRIVATE AMBULATORY PATIENTS TREATED WITH FLUPHENAZINE ENANTHATE.
065458 05-07
CHEMISTRY AND PHARMACOLOGY OF FLUPHENAZINE DECANOATE.
065470 05-03
THE EFFECTIVENESS OF PARENTERAL ADMINISTRATION OF FLUPHENAZINE DECANOATE IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS.
065473 05-07
INSTITUTIONAL MANAGEMENT OF CHRONIC SCHIZOPHRENICS WITH FLUPHENAZINE DECANOATE.
065474 05-07
DEPOT FLUPHENAZINE IN THE TREATMENT OF PSYCHOSIS IN A COMMUNITY MENTAL HEALTH CLINIC.
065475 05-08

FLUPHENAZINE HYDROCHLORIDE, ENANTHATE, AND DECANOATE IN THE MANAGEMENT OF CHRONIC PSYCHOSIS.
065476 05-08

A CLINICAL EVALUATION OF FLUPHENAZINE ENANTHATE.
065477 05-08

FLUPHENAZINE HYDROCHLORIDE AND ENANTHATE IN THE MANAGEMENT OF CHRONIC PSYCHOSIS.
065478 05-08

LONG-ACTING PHENOTHIAZINES AND LONG-TERM PSYCHOTIC PATIENTS: THE ROLE OF FLUPHENAZINE ENANTHATE IN TREATMENT.
065479 05-08

FLUPHENAZINE ENANTHATE GIVEN TO INPATIENTS AND OUTPATIENTS.
065480 05-09

HOSPITAL EXPERIENCE WITH FLUPHENAZINE ENANTHATE.
066748 05-07

CONTROLLED TRIALS OF AN AMITRYPTYLINE FLUPHENAZINE COMBINATION IN DEPRESSIVE NEUROSES AND PSYCHOSES: A COLLABORATIVE STUDY.
067569 06-11

FLUPHENAZINE ENANTHATE IN SESAME-OIL, A DEPOT PREPARATION.
070476 07-11

CLINICAL EXPERIENCE WITH FLUPHENAZINE DECANOATE.
070931 07-08

CLINICAL EXPERIENCE WITH FLUPHENAZINE DEPOT.
070932 07-08

QUANTITATIVE EEG CHANGES DURING HIGH AND LOW DOSAGE FLUPHENAZINE HYDROCHLORIDE TREATMENT.
073710 08-13

A CONTROLLED COMPARATIVE STUDY OF FLUPHENAZINE AND FLUPHENAZINE ENANTHATE IN ACUTE AND CHRONIC PSYCHOTIC PATIENTS.
075881 09-08

COMPARISON OF HALOPERIDOL AND FLUPHENAZINE IN DISTURBED CHILDREN.
076233 09-11

A COMPARATIVE DOUBLE-BLIND TRIAL OR PIMOZIDE AND FLUPHENAZINE IN CHRONIC SCHIZOPHRENIA.
078932 09-08

CLINICAL AND AMBULANT TESTING WITH FLUPHENAZINE DECANOATE LYOGEN DEPOT IN THE LONG-TERM TREATMENT OF PSYCHIATRIC DISEASE.
080040 09-16

CLINICAL AND BIOLOGICAL EFFECTS OF DECANOATE OF FLUPHENAZINE: BASED ON 35 OBSERVATIONS.
085347 10-08

FLUPHENAZINE: A RETROSPECTIVE ASSESSMENT IN 130 PATIENTS WITH RESIDUAL SCHIZOPHRENIA.
088951 10-08

FLUPHENAZINE ENANTHATE (MODITEN-RETARD N.D.): CHEMISTRY AND PHARMACOLOGY.
088997 10-03

FLUPHENAZINE ENANTHATE IN THE TREATMENT OF THE POST-HOSPITALIZED PATIENT.
089000 10-17

CLINICAL TESTING WITH FLUPHENAZINE DEPOT ADMINISTRATION TO SCHIZOPHRENIC PATIENTS.
101034 12-07

**FLURAZEPAM**

HYPNOTICS AND ALTERED SLEEP DREAM PATTERNS: II. ALL-NIGHT EEG STUDIES OF CHLORAL HYDRATE, FLURAZEPAM, AND METHAQUALONE.
066234 05-14

**FLUROTHYL**

THE EFFECT OF FLUROTHYL AND ELECTROSHOCK ON PULMONARY DIFFUSION.
058365 02-15

COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: I. SEIZURE AND POST-SEIZURE ELECTROENCEPHALOGRAPHIC PATTERN.
065850 05-11

COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY. II. ANTIDEPRESSIVE EFFECT.
065851 05-09

COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: III. ANTEROGRADE AMNESIA.
065852 05-14

COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: IV. RETROGRADE AMNESIA.
065853 05-14

COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: V. CONFUSION AND OTHER SIDE-EFFECTS.
065854 05-15

FLUROTHYL CONVULSIVE THERAPY: GENERAL DISCUSSION.
065855 05-11

FLUROTHYL CONVULSIVE THERAPY.
065856 05-11

EFFECTS OF FLUROTHYL ON MEMORY PROCESSING.
070978 07-04

**FLUTTER**

CARBON MONOXIDE AND PHENOBARBITONE: A COMPARISON OF EFFECTS ON AUDITORY FLUTTER FUSION THRESHOLD AND CRITICAL FLICKER FUSION THRESHOLD.
070303 07-14

**FOCI**

UNIT ACTIVITY IN PREMARIN INDUCED CORTICAL EPILEPTOGENIC FOCI.
066187 05-03

PENICILLIN INDUCED EPILEPTOGENIC FOCI IN THE RAT CORTEX.
075197 08-04

**FOLATE**

SUBNORMAL SERUM FOLATE DUE TO ANTICONVULSIVE THERAPY: A DOUBLE-BLIND STUDY OF THE EFFECT OF FOLIC ACID TREATMENT IN PATIENTS WITH DRUG INDUCED SUBNORMAL SERUM FOLATES.
042700 01-11

FOLATE DEFICIENCY IN DEPRESSIVE ILLNESS.
068414 06-13

FOLIC ACID IN FOLATE DEFICIENT PATIENTS WITH EPILEPSY.
080635 09-11

**FOLATES**

SUBNORMAL SERUM FOLATE DUE TO ANTICONVULSIVE THERAPY: A DOUBLE-BLIND STUDY OF THE EFFECT OF FOLIC ACID TREATMENT IN PATIENTS WITH DRUG INDUCED SUBNORMAL SERUM FOLATES.
042700 01-11

PHENYTOIN, FOLATES, AND ATPASE.
059055 03-15

**FOLIC**

SUBNORMAL SERUM FOLATE DUE TO ANTICONVULSIVE THERAPY: A DOUBLE-BLIND STUDY OF THE EFFECT OF FOLIC ACID TREATMENT IN PATIENTS WITH DRUG INDUCED SUBNORMAL SERUM FOLATES.
042700 01-11

FOLIC ACID IN FOLATE DEFICIENT PATIENTS WITH EPILEPSY.
080635 09-11

**FOLLOW-UP**

LYSERGIC ACID DIETHYLAMIDE AS A VARIABLE IN THE HOSPITAL TREATMENT OF ALCOHOLISM: A FOLLOW-UP STUDY.
052476 02-11

METRAZOL TOLERANCE IN A NORMAL VOLUNTEER POPULATION: A TEN YEAR FOLLOW-UP REPORT.
060649 03-13

DEXBENZETIMIDE IN NEUROLEPTIC INDUCED PARKINSONISM. A DOUBLE-BLIND CROSSOVER STUDY WITH A 16-WEEK FOLLOW-UP.
067176 06-11

NEW IN PSYCHIATRY: MODITEN INJECTABLE THERAPY AND FOLLOW-UP CARE.
072787 08-11

HALLUCINOGENIC DRUGS IN THE TREATMENT OF ALCOHOLISM: A TWO-YEAR FOLLOW-UP.
075290 08-12

CHANGES IN LIVER DISTURBANCE ASSOCIATED WITH LONG-TERM TRANQUILIZING MEDICATION (A FOLLOW-UP STUDY).
075839 08-15

LITHIUM DROP-OUTS: A FOLLOW-UP STUDY OF PATIENTS WHO DISCONTINUED PROPHYLACTIC TREATMENT.
106771 12-09

**FOOD**

FOUR EFFECTS OF EXOGENOUS INSULIN ON FOOD INTAKE.
061572 03-03

EFFECTS OF MORPHINE ON BEHAVIOR MAINTAINED BY FOUR SIMPLE FOOD REINFORCEMENT SCHEDULES.
064479 04-04

ON THE COMBINED EFFECTS OF AMPHETAMINE AND FOOD DEPRIVATION: A REPLY TO GOLLUB AND MANN.
066821 05-04

COMPARATIVE EFFECTS OF AMPHETAMINE, SCOPOLAMINE, CHLORDIAZEPOXIDE, AND DIPHENYLHYDANTOIN ON OPERANT AND EXTINCTION BEHAVIOR WITH BRAIN STIMULATION AND FOOD REWARD.
074935 08-04

FOOD REINFORCED RESPONDING IN RATS DURING ESTRUS.
075645 08-04

EFFECTS OF CHLORPROMAZINE IN THE PIGEON UNDER A SECOND-ORDER SCHEDULE OF FOOD PRESENTATION.
075906 09-04

MODULATION OF FOOD INTAKE AND LOCOMOTOR ACTIVITY IN FEMALE RATS BY DIENCEPHALIC HORMONE IMPLANTS.
076080 09-04

DEVELOPMENT OF HORMONAL CONTROL OVER FOOD INTAKE AND BODY WEIGHT IN FEMALE RATS.
076239 09-03

INTERACTIONS BETWEEN THE EFFECTS OF CHLORDIAZEPOXIDE AND AMPHETAMINE ON FOOD INTAKE AND SPONTANEOUS MOTOR ACTIVITY IN THE RAT.
092692 11-04

AN ANALYSIS OF THE ROLE OF CHOLINERGIC DRUGS IN BEHAVIOR RELATED TO FOOD AND WATER DEPRIVATION. (PH.D.DISSERTATION).
103267 12-04

**FOOT**
EFFECT OF LITHIUM ON FOOT SHOCK AGGRESSION IN RATS.
062777 03-04

**FORCED**
EFFECTS OF SCOPOLAMINE ON SPONTANEOUS ALTERNATION FOLLOWING FREE AND FORCED TRIALS.
067882 06-04

**FOREBRAIN**
BLOCKING OF EXPERIMENTAL SPIKE AND WAVE BY A LOCALIZED FOREBRAIN LESION.
066186 05-03
SOME FACTORS INFLUENCING THE RELEASE OF 5-HYDROXYINDOL-3-YLACETIC ACID IN THE FOREBRAIN.
067598 06-03
CHANGES IN D-AMPHETAMINE REACTIVITY RESULTING FROM SEPTAL FOREBRAIN INJURY.
067695 06-04
FOREBRAIN BIOGENIC AMINE FUNCTION IN HIGH AND LOW FEMALE RATS.
081231 09-04
EFFECTS OF AN ACUTE STRESS OF FOREBRAIN 5-HYDROXYTRYPTAMINE (5-HT) METABOLISM IN CNS LESIONED AND DRUG PRETREATED RATS.
095671 11-04

**FORELIMB**
SPEED, ACCURACY, AND STRENGTH OF FORELIMB MOVEMENT AFTER UNILATERAL PYRAMIDOTOMY IN RHESUS MONKEYS.
076213 09-04

**FORGETTING**
FORGETTING OF AN OPERANT RESPONSE: PHYSOSTIGMINE PRODUCED INCREASES IN ESCAPE LATENCY IN RATS AS A FUNCTION OF TIME OF INJECTION.
061540 03-04

**FORMATION**
AN ELECTRON MICROSCOPIC STUDY OF AXONAL CHANGES IN THE CEREBELLUM OF DIPHENYLHYDANTOIN INTOXICATED RATS: THE FORMATION OF THE SO-CALLED HONEYCOMB STRUCTURE IN THE AXOPLASM.
070334 07-03
FORMATION AND REGIONAL DISTRIBUTION OF GAMMA-HYDROXYBUTYRIC ACID IN MAMMALIAN BRAIN.
074864 08-01
IN VIVO FORMATION AND CATABOLISM OF (14C)HISTAMINE IN MOUSE BRAIN.
083169 10-03
HISTAMINE WHEAL FORMATION AND SCHIZOPHRENIA.
086987 10-13
EFFECT OF AMPHETAMINE ON THE PRESSOR RESPONSE TO TYRAMINE: FORMATION OF P-HYDROXYNOREPHEDRINE FROM AMPHETAMINE IN MAN.
090373 11-03

**FORMED**
FURTHER STUDIES ON THE ACCUMULATION AND DISAPPEARANCE OF CATECHOLAMINES FORMED FROM TYROSINE-14C IN MOUSE BRAIN. EFFECT OF SOME PHENOTHIAZINE ANALOGUES.
042727 01-03
ACCUMULATION AND DISAPPEARANCE OF 3H-5-HYDROXYTRYPTAMINE FORMED FROM 3H-TRYPTOPHAN IN MOUSE BRAIN: EFFECT OF LSD-25.
042755 01-03
EFFECT OF ANTIDEPRESSANT DRUGS ON ACCUMULATION AND DISAPPEARANCE OF MONOAMINES FORMED IN VIVO FROM LABELED PRECURSORS IN MOUSE BRAIN.
058798 02-03

**FORMING**
PROJECT SUMMARY: METHANOL FORMING ENZYME IN MAMMALIAN BRAIN.
060633 03-01

**FOWL**
THE EXCITATORY AND INHIBITORY INNERVATION OF THE STOMACHS OF THE DOMESTIC FOWL.
074854 08-03

**FRACTION**
ASSOCIATION OF BROMIDE WITH THE SYNAPTOSOMAL FRACTION OF MOUSE BRAIN.
070521 07-01

**FRACTIONS**
MORPHINE AND THE INCORPORATION OF 32 ORTHOPHOSPHATE IN VIVO INTO PHOSPHOLIPIDS OF THE GUINEA-PIG CEREBRAL CORTEX, LIVER AND SUBCELLULAR FRACTIONS.
046401 01-03

**FREE**
EFFECTS OF SCOPOLAMINE ON SPONTANEOUS ALTERNATION FOLLOWING FREE AND FORCED TRIALS.
067882 06-04
PLASMA FREE FATTY ACIDS BEFORE AND AFTER AN INTRAVENOUS INSULIN INJECTION IN ACUTE SCHIZOPHRENIC MEN.
075212 08-08
ALTERED FREE ASSOCIATIONS: SOME COGNITIVE EFFECTS OF DOET (2,5 DIMETHOXY-4-ETHYLAMPHETAMINE).
075859 09-12

**FREEZING**
THE RELATIONSHIP OF AMPHETAMINE INDUCED ANOREXIA AND FREEZING UNDER A MULTIPLE CRF-EXT OPERANT SCHEDULE.
068288 06-04
THE ROLE OF D-AMPHETAMINE AMOBARBITAL IN SUPPRESSING FREEZING BEHAVIOR DURING AVOIDANCE ACQUISITION AND EXTINCTION.
075882 09-04

**FREQUENCY**
CONFIGURATION FREQUENCY ANALYSIS OF SOME LSD EFFECTS.
079956 09-12
COMPARATIVE STUDY OF NATURAL SLEEP AND THE ACTION OF PHENAMINE AND CHLORPROMAZINE EVALUATION OF THE MEAN EXTREMES FREQUENCY OF ECOG IN CATS.
095655 11-14
THE EFFECTIVENESS OF SIMULTANEOUS TREATMENT WITH VITAMIN-B12 AND INSULIN IN SCHIZOPHRENIC PATIENTS, ACCORDING TO THE FREQUENCY OF STABLE REMISSIONS.
096513 11-08

**FRIGIDITY**
ORAL CONTRACEPTIVES: DEPRESSION AND FRIGIDITY.
075968 09-13

**FROG**
THE EFFECT OF ANTIADRENALINE COMPOUNDS ON ACETYLCHOLINE RESPONSES OF FROG RECTUS-ABDOMINIS MUSCLE.
041538 01-03
SYNERGISM OF DESMETHYLIMIPRAMINE WITH RESERPINE AND 5-HYDROXYTRYPTOPHAN IN THE FROG: BRAIN SEROTONIN AND ADRENALINE AND BEHAVIOR.
098042 11-03

**FROGS**
EFFECT OF CAPERS ON THE VASCULAR LUMEN OF ISOLATED EXTREMITIES OF SENSITIZED FROGS AND THE ANTIANAPHYLATIC EFFECT OF SUPRASTIN.
105720 12-03

**FRONTAL**
DIFFERENTIAL EFFECTS OF AMPHETAMINE AND SCOPOLAMINE ON MATCHING PERFORMANCE OF MONKEYS WITH LATERAL FRONTAL LESIONS.
065747 05-04
CHANGE IN SENSITIVITY TO D-AMPHETAMINE IN FRONTAL RATS AS A FUNCTION OF TIME: SHIFTING OF THE DOSE RESPONSE CURVE.
075238 08-04
CLINICAL EXPERIENCE WITH MESORIDAZINE IN THE THERAPY AND REHABILITATION OF TRAUMATIC FRONTAL BRAIN DAMAGE.
089784 11-14

**FRUCTOSE**
EFFECT OF FRUCTOSE ON ALCOHOL CONCENTRATIONS IN THE BLOOD OF MAN.
092004 11-11

**FUNCTION**
DIFFERENTIAL RESPONSE TO TREATMENT AS A FUNCTION OF THE CHANGING CHARACTER OF A DEPRESSION.
052574 02-10
FORGETTING OF AN OPERANT RESPONSE: PHYSOSTIGMINE PRODUCED INCREASES IN ESCAPE LATENCY IN RATS AS A FUNCTION OF TIME OF INJECTION.
061540 03-04
THE EFFECT OF CYCLANDELATE ON MENTAL FUNCTION IN PATIENTS WITH ARTERIOSCLEROTIC BRAIN DISEASE.
061654 03-13
STUDIES OF STEREOTYPY FUNCTION IN THE CANARY (SERINUS-CANARIUS).
063634 04-03
EFFECTS OF LITHIUM ON THYROID FUNCTION (A REVIEW).
064316 04-15
MARIHUANA, ETHANOL, AND DEXTROAMPHETAMINE: MOOD AND MENTAL FUNCTION ALTERATIONS.
066231 05-14
PHARMACOLOGY, LIMBIC REGULATION AND CORTICAL FUNCTION.
070979 07-04
THE FUNCTION OF MUSIC IN LSD THERAPY FOR ALCOHOLIC PATIENTS.
075191 08-12
CHANGE IN SENSITIVITY TO D-AMPHETAMINE IN FRONTAL RATS AS A FUNCTION OF TIME: SHIFTING OF THE DOSE RESPONSE CURVE.
075238 08-04
AMBULATORY BEHAVIOR IN THE RAT AS A FUNCTION OF TWO METHODS OF ALCOHOL ADMINISTRATION.
075316 08-04
PITUITARY ADRENAL FUNCTION IN THE SQUIRREL MONKEY.
075665 08-03
VISUAL THRESHOLD AS A FUNCTION OF TEST AREA AND CAFFEINE ADMINISTRATION.
076016 09-13

THE EFFECT OF MAGNESIUM PEMOLINE, TRICYANOAMINOPROPENE AND D-AMPHETAMINE ON DISCRIMINATED AVOIDANCE PERFORMANCE IN RATS AS A FUNCTION OF AGE.
076133 09-04

BRAIN FUNCTION AND MACROMOLECULES: V. THE EFFECT OF CYCLOHEXIMIDE AND ACTINOMYCIN-D ON LEARNING IN THE HEADLESS COCKROACH.
078378 09-03

ANTAGONISTIC INFLUENCE OF BETA-SYMPATHICOLYTICS ON THE METAMPHETAMINE INDUCED CHANGES IN FUNCTION AND METABOLISM OF THE BRAIN.
079954 09-03

FOREBRAIN BIOGENIC AMINE FUNCTION IN HIGH AND LOW FEMALE RATS.
081231 09-04

CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIC WOMEN: ITS EFFECT ON THYROID AND LIVER FUNCTION IN RELATION TO SERUM CHOLESTEROL CONCENTRATION.
088221 10-13

MEASUREMENT OF THE DISTRIBUTION OF HYPNOTICS AND CEREBRAL FUNCTION IN ACUTE INTOXICATIONS BY PH.
089040 10-17

THE INFLUENCE OF LITHIUM ION ON THE ADRENOCORTICAL FUNCTION OF RATS.
089787 11-09

MALE SEXUAL FUNCTION.
100530 12-15

THYROID FUNCTION.
100534 12-15

STUDIES OF THE TOXIC EFFECTS OF DRUGS ON ELECTRICAL CONDUCTION AND FUNCTION OF THE HEART. (PH.D.DISSERTATION).
103004 12-05

EFFECT OF A DEFICIENCY OF PANTOTHENIC ACID AND PYRIDOXINE ON THE FUNCTION OF THE CENTRAL NERVOUS SYSTEM AND ITS RESPONSE TO COUMARIN FROM MELILOTUS-OFFICINALIS.
126053 12-04

**FUNCTIONAL**

FUNCTIONAL RELATIONSHIPS OF BRAIN CIRCUITS IN CONTROL OF DRINKING BEHAVIOR.
058961 03-04

FUNCTIONAL CHARACTERISTIC OF THE LINKS OF THE BRAIN CONTROL SYSTEM FOR MENTAL AND MOTOR FUNCTIONS IN MAN.
073770 08-13

DYNAMIC CHARACTERISTICS OF THE FUNCTIONAL COMPARTMENT OF DOPAMINE IN DOPAMINERGIC TERMINALS OF THE RAT STRIATUM.
120465 12-03

**FUNCTIONING**

RELATIONSHIPS OF THE MECHOLYL TEST, PREMORBID ASOCIAL FUNCTIONING AND LONG-TERM OUTCOME IN SCHIZOPHRENIA.
075227 08-08

**FUNCTIONS**

DRUG EFFECTS UPON DATA PROCESSING AS FUNCTIONS OF STORAGE AND RETRIEVAL PARAMETERS.
065127 05-14

CENTRAL NERVOUS SYSTEM METABOLISM, DRUG ACTION AND HIGHER FUNCTIONS.
070976 07-17

FUNCTIONAL CHARACTERISTIC OF THE LINKS OF THE BRAIN CONTROL SYSTEM FOR MENTAL AND MOTOR FUNCTIONS IN MAN.
073770 08-13

EXPERIENCE WITH PROPERICIAZIN (AOLEPT) IN THE TREATMENT OF CHILDREN WITH DISTURBED PSYCHOMOTOR FUNCTIONS AND RESTLESSNESS.
081144 09-11

STABILITY OF PSYCHIC FUNCTIONS DURING PROLONGED CONFINEMENT TO BED.
086039 10-14

INHIBITORY FUNCTIONS OF THE SEPTUM AND AMYGDALA.
095697 11-03

BEHAVIORAL TOXICITY. PART 3: PERCEPTUAL COGNITIVE FUNCTIONS AND PART 4: EMOTIONAL (MOOD) STATES.
100523 12-15

BEHAVIORAL TOXICITY. PART 1: DEFINITION AND PART 2: PSYCHOMOTOR FUNCTIONS.
100524 12-15

**FUNDUS**

14C-5-HYDROXYTRYPTAMINE AND 3H-D-AMPHETAMINE: UPTAKE AND CONTRACTION BY THE RAT STOMACH FUNDUS IN VITRO.
064050 04-03

**FUSION**

CARBON MONOXIDE AND PHENOBARBITONE: A COMPARISON OF EFFECTS ON AUDITORY FLUTTER FUSION THRESHOLD AND CRITICAL FLICKER FUSION THRESHOLD.
070303 07-14

CORTISOL EFFECTS ON AVERAGED EVOKED POTENTIAL, ALPHA-RHYTHM, TIME ESTIMATION, AND TWO-FLASH FUSION THRESHOLD.
075274 08-13

**G-32883**

CLINICAL EVALUATION OF THE USE OF G-32883 IN TRIGEMINAL NEURALGIA.
112130 12-11

**GABA**

GABA AS A REPRESSOR OF L-GLUTAMIC ACID DECARBOXYLASE (GAD) IN DEVELOPING CHICK EMBRYO OPTIC LOBES.
058192 02-03

**GABOB**

CHEMICAL AND CLINICAL EVALUATION OF THE USE OF GABOB IN SCHIZOPHRENIC PATIENTS.
114885 12-08

**GAD**

GABA AS A REPRESSOR OF L-GLUTAMIC ACID DECARBOXYLASE (GAD) IN DEVELOPING CHICK EMBRYO OPTIC LOBES.
058192 02-03

**GALACTORRHEA**

GALACTORRHEA AND GYNECOMASTIA.
100512 11-15

**GALL**

METOCLOPRAMIDE AND THE MUSCULATURE OF ESOPHAGUS, STOMACH, INTESTINE, SPLEEN, TRACHEA, GALL AND URINARY BLADDERS: IN VITRO STUDIES.
055394 02-03

**GALVESTON**

GALVESTON COUNTY STUDY SHOWS TRANQUILIZERS SURPASS ASPIRIN AS MEDICINAL POISONING AGENTS.
090070 11-15

**GAMBUSIA-AFFINIS**

ESTIMATION OF LOW CHLORPROMAZINE CONCENTRATIONS BY SURFACING AND SINKING REACTION OF MINNOWS (GAMBUSIA-AFFINIS).
097964 11-06

**GAMFEXINE**

A CONTROLLED STUDY OF THE EFFECTS OF GAMFEXINE IN PHENOTHIAZINE TREATED PATIENTS.
072144 07-08

**GAMMA-AMINOBUTYRIC**

THE ACTIONS OF GAMMA-AMINOBUTYRIC ACID AND RELATED AMINO ON MAMMALIAN AUTONOMIC GANGLIA.
040752 01-03

REDUCTION OF LEVEL OF L-GLUTAMIC ACID DECARBOXYLASE BY GAMMA-AMINOBUTYRIC ACID IN MOUSE BRAIN.
083168 10-03

**GAMMA-AMINOHYDROXYBUTYRIC**

NEUROTROPIC PROPERTIES OF AMINOHYDROXYACETATE AND GAMMA-AMINOHYDROXYBUTYRIC ACID.
058605 02-03

**GAMMA-HYDROXYBUTYRATE**

MECHANISM OF THE GAMMA-HYDROXYBUTYRATE INDUCED INCREASE IN BRAIN DOPAMINE AND ITS RELATIONSHIP TO SLEEP.
074865 08-04

**GAMMA-HYDROXYBUTYRIC**

FORMATION AND REGIONAL DISTRIBUTION OF GAMMA-HYDROXYBUTYRIC ACID IN MAMMALIAN BRAIN.
074864 08-01

**GANGLERONE**

EFFECT OF GANGLERONE AND QUATERONE ON CATECHOLAMINE CONTENT IN THE BRAIN.
111767 12-03

**GANGLIA**

THE ACTIONS OF GAMMA-AMINOBUTYRIC ACID AND RELATED AMINO ON MAMMALIAN AUTONOMIC GANGLIA.
040752 01-03

MONOAMINES AND MONOAMINE OXIDASE IN DENERVATED SYMPATHETIC GANGLIA OF THE CAT.
040756 01-03

**GANGLION**

BIOCHEMICAL CHANGES DURING LEARNING IN AN INSECT GANGLION.
084758 10-04

**GANGLIONIC**

THE INFLUENCE OF THE GANGLIONIC BLOCKING AGENT GANLION ON VISCEROVISCERAL AND VISCEROCEREBRAL REACTIONS OF THE CAT.
071703 07-03

EFFECT OF GANGLIONIC BLOCKING AGENTS ON PRESSOR EFFECTS OF SYMPATHOMIMETIC AMINES OF DIRECT AND INDIRECT ACTION.
110632 12-03

**GANLION**

THE INFLUENCE OF THE GANGLIONIC BLOCKING AGENT GANLION ON VISCEROVISCERAL AND VISCEROCEREBRAL REACTIONS OF THE CAT.
071703 07-03

**GASTRIC**

BLOCKADE OF NORADRENALINE UPTAKE AND INHIBITION OF GASTRIC ACID SECRETION BY 2-(P-CHLOROPHENYL-2-(PYRIDYL)HYDROXYMETHYL) IMIDAZOLINE MALEATE (SCH-12650).
058878 02-02

RELATIONS BETWEEN THE ELECTROGASTROGRAM AND GASTRIC ULCERATION DURING EXPOSURE TO STRESS.
075438 08-03

**GASTROENTERIC**
CONTROLLED THERAPEUTIC EXPERIMENTATION IN CASES OF PSYCHOGENOUS GASTROENTERIC DISTURBANCE.
072003 07-07

**GASTROINTESTINAL**
GASTROINTESTINAL EFFECTS.
100520 12-15

**GENETIC**
PROJECT SUMMARY: ON THE INVESTIGATION OF THE GENETIC EFFECTS OF LYSERGIC ACID DIETHYLAMIDE AND RELATED COMPOUNDS.
060637 03-03
THE EFFECT OF SOME DRUGS ON GENETIC TREMOR IN THE MOUSE.
081066 09-04

**GENOTYPICALLY**
EFFECTS OF NEONATAL TESTOSTERONE ON THE ACQUISITION OF AN ACTIVE AVOIDANCE RESPONSE IN GENOTYPICALLY FEMALE RATS.
075890 09-04

**GERBIL**
EFFECTS OF A MARIHUANA HOMOLOGUE (PYRAHEXYL) ON AVOIDANCE LEARNING IN THE GERBIL.
059032 03-04
THE EFFECT OF ANTIANDROGENS ON AGGRESSIVE BEHAVIOR IN THE GERBIL.
081159 09-04

**GERIATRIC**
CLINICAL AND PSYCHOLOGICAL TESTING OF A GERIATRIC DRUG.
042693 01-11
SUSTAINED-RELEASE TRANQUILIZER THERAPY IN HOSPITALIZED GERIATRIC PATIENTS.
059359 03-10
THE CHEMOPSYCHOTHERAPEUTICS OF GERIATRIC SEDATION.
059380 03-11
CLINICAL EVALUATION OF HALOPERIDOL IN GERIATRIC PATIENTS.
064074 04-14
PSYCHOLOGICAL METHODS APPLIED TO EVALUATE SYMPTOMATIC GERIATRIC TREATMENT.
064152 04-14
COMBINED ADMINISTRATION OF THIORIDAZINE AND FLUOXYMESTERONE IN THE TREATMENT OF GERIATRIC PATIENTS.
069060 06-11
TESTS OF A NEW ANXIOLYTIC: THE USE OF DOXEPINE IN GERIATRIC CASES.
086236 10-07
EFFECT OF NICOTINIC ACID COMBINED WITH A TRANQUILLIZER (HYDROXYZINE) ON SERUM LIPID LEVELS AND URINARY CATECHOLAMINE EXCRETION IN GERIATRIC PATIENTS.
093689 11-11

**GERIATRICS**
AN INTERESTING TISSULARY THERAPEUTIC METHOD IN GERIATRICS: BOGOMOLETZ SERUM (BERNAS CYTOTOXIC SERUM).
105551 12-11

**GERONTOLOGICAL**
THERAPEUTIC INTEREST IN HYDROSARPAN-711 IN DEPRESSIVE STATES AND IN THE PSYCHIATRIC PATHOLOGY OF GERONTOLOGICAL STATES.
079859 09-11

**GHOST**
EFFECTS OF PHENOTHIAZINE DERIVATIVES ON BIOLOGICAL MEMBRANES: DRUG-INDUCED CHANGES IN ELECTRC'N SPIN RESONANCE SPECTRA FROM SPIN-LABELED ERYTHROCYTE GHOST MEMBRANES.
064423 04-03

**GIANT**
EFFECTS OF NARCOTICS ON THE GIANT AXON OF THE SQUID.
090147 11-03

**GILLES-DE-LA-TOURETTES**
THE USE OF HALOPERIDOL FOR GILLES-DE-LA-TOURETTES SYNDROME.
067264 06-14
ON GILLES-DE-LA-TOURETTES SYNDROME: SUCCESSFUL TREATMENT WITH HALOPERIDOL IN THREE CASES.
088610 10-11

**GIRL**
THE PSYCHOLYTIC TREATMENT OF A CHILDHOOD SCHIZOPHRENIC GIRL.
080609 09-08

**GLAND**
SCHIZOPHRENIA AND THE PINEAL GLAND.
062935 03-08
EFFECT OF PITUITARY AND ACTH ON THE MAINTENANCE OF BASAL TYROSINE HYDROXYLASE ACTIVITY IN THE RAT ADRENAL GLAND.
075714 08-03

**GLOBAL**
DIFFERENTIAL RELIABILITY IN RATING PSYCHOPATHOLOGY AND GLOBAL IMPROVEMENT.
076292 09-10

**GLUCAGON**
LITHIUM EFFECT ON PLASMA GLUCAGON, LIVER PHOSPHORYLASE-A AND LIVER GLYCOGEN IN RATS.
066822 05-03

**GLUCOSE**
CHLORPROMAZINE INDUCED GLUCOSE INTOLERANCE IN THE MOUSE.
058984 03-05
GLUCOSE METABOLISM.
100515 12-15

**GLUTAMATE**
BRAIN DAMAGE IN INFANT MICE FOLLOWING ORAL INTAKE OF GLUTAMATE, ASPARTATE OR CYSTEINE.
094164 11-05

**GLUTETHIMIDE**
A COMPARATIVE STUDY OF THE EFFECTS OF METHAQUALONE AND GLUTETHIMIDE ON SLEEP IN MALE CHRONIC INSOMNIACS.
063879 04-14
BLOOD AND URINE CONCENTRATIONS OF SUBJECTS RECEIVING BARBITURATES, MEPROBAMATE, GLUTETHIMIDE, OR DIPHENYLHYDANTOIN.
063927 04-13
DETERMINANTS OF SERUM HALF-LIFE OF GLUTETHIMIDE IN INTOXICATED PATIENTS.
064168 04-15
HYPNOTICS AND ALTERED SLEEP DREAM PATTERNS: I. ALL-NIGHT EEG STUDIES OF GLUTETHIMIDE, METHYPRYLON, AND PENTOBARBITAL.
066233 05-14
A COMPARATIVE STUDY OF THREE HYPNOTICS: METHYPRYLON, GLUTETHIMIDE AND CHLORAL HYDRATE.
067862 06-14

**GLYCEROL**
COMPARISONS OF 1,3 BUTANEDIOL AND GLYCEROL ON SEVERAL BEHAVIORAL MEASURES.
066831 05-04

**GLYCIDIC**
SYNTHESIS OF SOME GLYCIDIC HYDRAZIDES AND AMIDES AS POTENTIAL PSYCHOTROPIC AGENTS AND ANTICHOLINERGIC AGENTS.
064258 04-01

**GLYCOGEN**
ANTAGONISTIC EFFECTS OF DOPA AND PROPRANOLOL ON BRAIN GLYCOGEN.
058800 02-03
ASSOCIATION OF AMPHETAMINE TOXICITY AND TISSUE GLYCOGEN DEPLETION IN MICE AND RATS.
058998 03-05
LITHIUM EFFECT ON PLASMA GLUCAGON, LIVER PHOSPHORYLASE-A AND LIVER GLYCOGEN IN RATS.
066822 05-03
PHYSIOLOGICAL AND DRUG-INDUCED CHANGES IN THE GLYCOGEN CONTENT OF MOUSE BRAIN.
067608 06-03

**GLYCOLATE**
THE EFFECT OF A PSYCHOTOMIMETIC GLYCOLATE AND ITS ANTIDOTE ESERINE ON THE ACH CONTENT OF THE LOBSTER WALKING LEG NERVE.
069515 06-13

**GLYCOLIC**
THE EFFECT OF AMINOESTERS OF SUBSTITUTED GLYCOLIC AND ACETIC ACIDS ON THE CONTENT OF NORADRENALINE IN THE BRAIN OF RATS.
073717 08-03

**GNAWING**
AN ANALYSIS OF METHYLPHENIDATE INDUCED GNAWING IN GUINEA-PIGS.
064414 04-04

**GO-NO-GO**
SCOPOLAMINE EFFECTS ON GO-NO-GO AVOIDANCE DISCRIMINATIONS: INFLUENCE OF STIMULUS FACTORS AND PRIMACY OF TRAINING.
090418 11-04

**GO-2330**
A DOUBLE-BLIND TRIAL OF THREE ANTIDEPRESSANTS (GO-2998, GO-2330 AND IMIPRAMINE HYDROCHLORIDE).
134903 12-09

**GO-2998**
A DOUBLE-BLIND TRIAL OF THREE ANTIDEPRESSANTS (GO-2998, GO-2330 AND IMIPRAMINE HYDROCHLORIDE).
134903 12-09

**GOLDFISH**
THE EFFECT OF PUROMYCIN ON RETENTION OF A POSITIVELY REINFORCED RESPONSE IN GOLDFISH.
059616 03-04
THE EFFECT OF PUROMYCIN ON CLASSICAL CONDITIONING IN THE GOLDFISH.
075375 08-04
FURTHER STUDIES ON THE EFFECTS OF BLOCKING AGENTS ON PROTEIN SYNTHESIS IN GOLDFISH BRAIN.
083170 10-03

STIMULUS PROPERTIES OF ELECTROCONVULSIVE SHOCK IN GOLDFISH. (PH.D.DISSERTATION).
110906 12-04

**GOLLUB**
ON THE COMBINED EFFECTS OF AMPHETAMINE AND FOOD DEPRIVATION: A REPLY TO GOLLUB AND MANN.
066821 05-04

**GONADAL**
REDIRECTED AGGRESSION AND GONADAL HORMONES IN CAPTIVE RHESUS MONKEYS (MACACA-MULATTA).
075829 08-04

**GOODPASTURE**
GOODPASTURE SYNDROME AND THE EFFECTS OF BENZENE.
056060 02-15

**GOVERNMENTAL**
GOVERNMENTAL REGULATION OF THE DRUG INDUSTRY.
091208 11-17

**GRADIENT**
THE EFFECTS OF CENTRALLY AND PERIPHERALLY ACTING CHOLINERGIC DRUGS ON THE SHORT-TERM PERFORMANCE GRADIENT FOLLOWING PASSIVE AVOIDANCE TRAINING.
064412 04-04

**GRADUAL**
ON THE PROBLEM OF TREATMENT AND SOME CLINICAL CHARACTERISTICS OF SCHIZOPHRENIA WITH A GRADUAL PAROXYSMAL LIKE COURSE.
111032 12-08

**GRAMINES**
BIOLOGICAL ACTIVITIES OF SOME 5-SUBSTITUTED N,N DIMETHYLTRYPTAMINES, ALPHA-METHYLTRYPTAMINES, AND GRAMINES.
065494 05-03

**GRAPHIC**
A TECHNIQUE TO DEMONSTRATE THE EFFECT OF A PSYCHOPHARMACEUTICAL DRUG IN A PSYCHOPATHOLOGICAL LONGITUDINAL SECTION BY NUMERIC AND GRAPHIC MEANS.
079973 09-06

**GRASSHOPPER**
LABORATORY EVALUATION OF AGGRESSIVE BEHAVIOR OF THE GRASSHOPPER MOUSE (ONYCHOMYS).
064260 04-04

**GROOMING**
OBSERVATION OF THE GROOMING BEHAVIOR OF RESERPINIZED WHITE MICE AS A METHOD FOR INVESTIGATING RESERPINE ANTAGONISM AND SYNERGISM.
065442 05-04

**GROUND**
SOME EFFECTS OF D-AMPHETAMINE ON CARBOHYDRATE METABOLISM AT GROUND LEVEL AND ALTITUDE.
069344 06-03

STRUCTURAL BASIS OF LITHIUM PSYCHOPHARMACOLOGY: EXTRACELLULAR GROUND SUBSTANCE OF RAT BRAIN.
106783 12-03

**GROUP**
GROUP TREATMENT OF CHRONIC ALCOHOLISM WITH LSD-25: STUDY II.
057480 02-14

COMPARATIVE PHARMACOPSYCHOLOGICAL STUDY OF THE EFFECTS PRODUCED BY PSYCHOPHARMACEUTICALS ON VERBAL INTERACTION IN A GROUP OF STUDENTS.
066954 05-14

RELATIONSHIP BETWEEN TASTE THRESHOLD FOR DRUGS AND CLINICAL PROGRESS IN A MIXED GROUP OF PSYCHIATRIC PATIENTS.
087866 10-11

THE RELATIONSHIPS BETWEEN CLINICAL AND VISUOMOTOR CHANGES IN A SCHIZOPHRENIC GROUP.
089798 11-08

USE OF CATTELS IPAT ANXIETY SCALE IN A GROUP OF NEUROTIC PATIENTS BEFORE AND AFTER PSYCHOPHARMACOLOGICAL DRUG AND ELECTRIC SHOCK THERAPY.
128509 12-17

**GROUPED**
INCREASED AGGRESSION AMONG GROUPED MALE MICE FED CHLORDIAZEPOXIDE.
081098 09-04

**GROWTH**
SOME EFFECTS OF EXPERIMENTALLY PRODUCED CIGARETTE SMOKE ON THE GROWTH, VITAMIN-C METABOLISM AND ORGAN WEIGHTS OF GUINEA-PIGS.
063061 03-03

RELEASE BY AMPHETAMINE IN MAN OF GROWTH HORMONE AND CORTICOSTEROIDS: THE EFFECTS OF THYMOXAMINE AND PROPRANOLOL.
067602 06-13

SYNERGISM BETWEEN COBALT AND ETHANOL ON RAT GROWTH RATE.
088600 10-03

**GSR**
PROTECTION OF GSR CONDITIONING BY DEXTROAMPHETAMINE.
075315 08-14

**GUANETHIDINE**
ACTION OF GUANETHIDINE ON THE PRESSOR EFFECT OF ANGIOTENSIN IN ADRENALECTOMIZED DOGS.
046399 01-03

**GUESSES**
IS A DOUBLE-BLIND CLINICAL TRIAL REALLY DOUBLE-BLIND: A REPORT OF DOCTORS MEDICATION GUESSES.
065488 05-10

**GUIDE**
A PRACTICAL GUIDE TO DRUG INTERACTIONS.
070899 07-15

**GUIDED**
ELECTROENCEPHALOGRAPHIC VARIATIONS INDUCED BY PSYCHOTROPIC DRUGS: CLINICAL ELECTROPHYSIOLOGICAL CORRELATIONS FOR A GUIDED THERAPY.
063200 03-13

**GUINEA-PIG**
EFFECTS OF TWO CHOLINESTERASE INHIBITORS ON ACETYLCHOLINE RELEASE FROM THE GUINEA-PIG ISOLATED ILEUM PREPARATION.
040572 01-03

THE EFFECTS OF ACIDOSIS ON CHRONOTROPIC RESPONSES, NOREPINEPHRINE STORAGE AND RELEASE IN ISOLATED GUINEA-PIG ATRIA.
040753 01-03

THE EFFECTS OF MORPHINE-LIKE SUBSTANCES AND THEIR ANTAGONISTS ON TRANSMISSION AT THE NEURO EFFECTOR JUNCTION OF THE MYENTERIC PLEXUS LONGITUDINAL MUSCLE PREPARATION OF THE GUINEA-PIG ILEUM.
041974 01-03

MORPHINE AND THE INCORPORATION OF 32 ORTHOPHOSPHATE IN VIVO INTO PHOSPHOLIPIDS OF THE GUINEA-PIG CEREBRAL CORTEX, LIVER AND SUBCELLULAR FRACTIONS.
046401 01-03

THE ANTAGONISM OF ADRENERGIC NEURONE BLOCKADE BY AMPHETAMINE AND DEXAMPHETAMINE IN THE RAT AND GUINEA-PIG.
055322 02-03

ACCELERATION OF NORADRENALINE BIOSYNTHESIS IN THE GUINEA-PIG VAS-DEFERENS BY POTASSIUM.
073063 08-06

**GUINEA-PIGS**
SOME EFFECTS OF EXPERIMENTALLY PRODUCED CIGARETTE SMOKE ON THE GROWTH, VITAMIN-C METABOLISM AND ORGAN WEIGHTS OF GUINEA-PIGS.
063061 03-03

AN ANALYSIS OF METHYLPHENIDATE INDUCED GNAWING IN GUINEA-PIGS.
064414 04-04

ABBREVIATION OF BEHAVIORAL ESTRUS IN GUINEA-PIGS BY COITAL AND VAGINO-CERVICAL STIMULATION.
065332 05-03

**GYNECOMASTIA**
GALACTORRHEA AND GYNECOMASTIA.
100512 11-15

**HABITATION**
PSYCHOANALYTIC EVALUATION OF ADDICTION AND HABITATION.
075300 08-13

**HABITS**
EQUIVALENCE OF SIMULTANEOUS AND SUCCESSIVE NEOCORTICAL ABLATIONS IN PRODUCTION OF IMPAIRMENTS OF RETENTION OF BLACK WHITE HABITS IN RATS.
076316 09-04

**HABITUATION**
P-CHLOROPHENYLALANINE AND HABITUATION TO REPETITIVE AUDITORY STARTLE STIMULI IN RATS.
063015 03-03

PROTEIN AND RNA INHIBITORS AND PROTOZOAN HABITUATION.
066813 05-04

HABITUATION TO CHLORDIAZEPOXIDE IN AN ALCOHOLIC POPULATION.
074732 08-11

HABITUATION AND ACTIVITY AS AFFECTED BY CYCLOHEXIMIDE.
097953 11-04

**HAIGHT-ASHBURY**
AN ANALYSIS OF 310 CASES OF ACUTE HIGH-DOSE METHAMPHETAMINE TOXICITY IN HAIGHT-ASHBURY.
067218 06-15

**HALF-LIFE**
DETERMINANTS OF SERUM HALF-LIFE OF GLUTETHIMIDE IN INTOXICATED PATIENTS.
064168 04-15

**HALLUCINATION**
A NEUROPHARMACOLOGICALLY BASED CONCEPT OF HALLUCINATION AND ITS CLINICAL APPLICATION.
121080 12-17

**HALLUCINATIONS**
HALLUCINATIONS FOLLOWING PENTAZOCINE.
058442 02-15

DRUGS, HALLUCINATIONS AND MEMORY.
121085 12-12

PREDICTION AND MEASUREMENT OF PERCEPTUAL BEHAVIORAL CHANGE IN DRUGINDUCED HALLUCINATIONS.
121086 12-12

**HALLUCINATORY**
INFLUENCES OF POLYPHARMACY ON HALLUCINATORY BEHAVIOR IN A SAMPLE OF FEMALE CHRONIC SCHIZOPHRENIC PATIENTS.
115037 12-08
THE INFLUENCES OF THE STANDARD PREFRONTAL LOBOTOMY OPERATION ON HALLUCINATORY PHENOMENA ASSOCIATED WITH PSYCHOTOMIMETIC DRUGS.
120899 12-13

**HALLUCINOGEN**
L-DOPA: A HALLUCINOGEN.
075909 09-15

**HALLUCINOGENIC**
2,5 DIMETHOXY-4-METHYLAMPHETAMINE: CLINICAL EVALUATION OF A NEW HALLUCINOGENIC DRUG.
052457 02-12
INFRARED IDENTIFICATION OF SOME HALLUCINOGENIC DERIVATIVES OF TRYPTAMINE AND AMPHETAMINE.
058877 02-01
SOME EFFECTS OF AN HALLUCINOGENIC DRUG (PHENCYCLIDINE) ON NEUROHUMORAL SUBSTANCES.
065436 05-12
CORRELATION BETWEEN ACTIVITY AND ELECTRONIC STATE OF HALLUCINOGENIC AMPHETAMINES.
067199 06-06
THE EFFECT OF SOME HALLUCINOGENIC DRUGS ON THE AMINO ACID PRECURSORS OF BRAIN MONOAMINES.
070542 07-03
HALLUCINOGENIC DRUGS IN THE TREATMENT OF ALCOHOLISM: A TWO-YEAR FOLLOW-UP.
075290 08-12
THE CURRENT STATUS OF THE HALLUCINOGENIC DRUGS.
080002 09-17
THE USES AND ABUSES OF LSD AND OTHER HALLUCINOGENIC DRUGS.
087470 10-12
PSYCHEDELICS: THE USES AND IMPLICATIONS OF HALLUCINOGENIC DRUGS.
111933 12-17
STRUCTURE-ACTIVITY RELATIONSHIP AMONG HALLUCINOGENIC AGENTS.
115027 12-01

**HALLUCINOGENS**
THE INDOLE HALLUCINOGENS.
046200 01-14
HALLUCINOGENS AND NARCOTICS ALARM PUBLIC.
057978 02-15
THE PLANT KINGDOM AND HALLUCINOGENS (PART III).
058973 03-17
HARNESSING POTENT HALLUCINOGENS.
072412 08-01
HALLUCINOGENS.
105266 12-17
BEHAVIORAL PHARMACOLOGY OF THE HALLUCINOGENS.
121087 12-14

**HALOGEN**
ENCEPHALOPATHY AS A SEQUEL OF CHRONIC INTOXICATION WITH HALOGEN DERIVATIVES OF AROMATIC HYDROCARBONS.
085102 10-15

**HALOPERIDOL**
CLINICAL EVALUATION OF HALOPERIDOL IN GERIATRIC PATIENTS.
064074 04-14
THE EFFECTS OF HALOPERIDOL AND CHLORPROMAZINE ON AMPHETAMINE METABOLISM AND AMPHETAMINE STEREOTYPE BEHAVIOR IN THE RAT.
064170 04-03
TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS WITH HALOPERIDOL.
064233 04-10
A COMPARISON OF HALOPERIDOL AND THIORIDAZINE HCL IN CHRONIC TREATMENT RESISTANT SCHIZOPHRENICS.
066398 05-08
A COMPARISON OF HALOPERIDOL AND THIORIDAZINE HCL IN CHRONIC TREATMENT RESISTANT SCHIZOPHRENICS.
066817 05-08
THE USE OF HALOPERIDOL FOR GILLES-DE-LA-TOURETTES SYNDROME.
067264 06-14
SOME USES OF HALOPERIDOL IN THE TREATMENT OF PSYCHIATRIC CONDITIONS.
075879 09-08
COMPARISON OF HALOPERIDOL AND FLUPHENAZINE IN DISTURBED CHILDREN.
076233 09-11
DISTRIBUTION AND METABOLISM OF NEUROLEPTIC DRUGS: PART I: PHARMACOKINETICS OF HALOPERIDOL.
079968 09-03
ON GILLES-DE-LA-TOURETTES SYNDROME: SUCCESSFUL TREATMENT WITH HALOPERIDOL IN THREE CASES.
088610 10-11
SPECIFIC (IN THE SENSE OF INCREASED PREDISPOSITION TO INJURY OF THE SUBDOMINANT HEMISPHERE) DISTRIBUTION OF THE EXTRAPYRAMIDAL SYMPTOMS IN SCHIZOPHRENICS DURING THE COURSE OF HALOPERIDOL TREATMENT.
089106 10-15
THE ANTIANXIETY EFFECTS OF HALOPERIDOL AND TRIFLUOPERAZINE IN AN OUTPATIENT NEUROTIC POPULATION.
089444 11-10
THE USE OF HALOPERIDOL IN RESIDUAL SCHIZOPHRENIA AND IN PARANOID STATES.
093524 11-08

**HALOTHANE**
EFFECTS OF MONOAMINE OXIDASE INHIBITORS AND AMPHETAMINE ON HYPOTHERMIA PRODUCED BY HALOTHANE.
041569 01-03
BEHAVIORAL EFFECTS OF HALOTHANE IN PIGEONS.
042719 01-04

**HAMSTERS**
LSD: NO TERATOGENIC ACTION IN RATS, MICE, AND HAMSTERS.
063993 04-03

**HANDLING**
POLYNEURITIS CRANIALIS FOLLOWING POISONING WITH CHLORINATED ACETYLENES WHILE HANDLING VINYLIDINE COPOLYMERS.
051140 02-15

**HANDWRITING**
PARKINSONS DISEASE: L-DOPA TREATMENT AND HANDWRITING AREA.
058966 03-11
HANDWRITING CHANGES AND RESPONSE TO DRUGS -- A CONTROLLED STUDY.
063775 04-14

**HAPLOPHYLLUM**
INFLUENCE OF HAPLOPHYLLUM ALKALOIDS ON THE BODY TEMPERATURE OF ANIMALS.
105721 12-03

**HARMALINE**
(3H)HARMALINE DISTRIBUTION IN MONKEY BRAIN; PHARMACOLOGICAL AND AUTORADIOGRAPHIC STUDY.
067081 05-03
ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL EFFECTS OF HARMALINE IN INTACT CATS AND IN CATS WITH CHRONIC MESENCEPHALIC TRANSECTION.
075847 09-04

**HARMINE**
URINARY METABOLITES OF HARMINE IN THE RAT AND THEIR INHIBITION OF MONOAMINE OXIDASE.
040417 01-03
A MODEL OF HARMINE METABOLISM IN THE RAT.
064167 04-03

**HARNESSING**
HARNESSING POTENT HALLUCINOGENS.
072412 08-01

**HASHISH**
HASHISH AND ITS EFFECTS.
044134 01-15
HASHISH: A STEREOSPECIFIC SYNTHESIS OF (-)-DELTA 1- AND (-)-DELTA 1(6) TETRAHYDROCANNABINOLS (UNPUBLISHED PAPER).
093550 11-01

**HATCHED**
TRYPTALDEHYDES (INDOLEACETALDEHYDES) IN SEROTONERGIC SLEEP OF NEWLY HATCHED CHICKS.
055583 02-03

**HAZARDOUS**
LITHIUM IN HAZARDOUS CIRCUMSTANCES WITH ONE CASE OF LITHIUM TOXICITY.
067138 06-15

**HAZARDS**
HAZARDS IMPLICIT IN PRESCRIBING PSYCHOACTIVE DRUGS.
070897 07-17

**HC-3**
THE EFFECT OF INTRAHYPOTHALAMIC MICROINJECTION OF HEMICHOLINIUM (HC-3) ON THE HIPPOCAMPAL THETA RHYTHM OF CATS.
075842 08-03

**HEADLESS**
BRAIN FUNCTION AND MACROMOLECULES: V. THE EFFECT OF CYCLOHEXIMIDE AND ACTINOMYCIN-D ON LEARNING IN THE HEADLESS COCKROACH.
078376 09-03

**HEALTH**
DEPOT FLUPHENAZINE IN THE TREATMENT OF PSYCHOSIS IN A COMMUNITY MENTAL HEALTH CLINIC.
065475 05-08

**HEALTHY**
EXPERIMENTAL PSYCHOLOGICAL STUDY OF PERFORMANCE CHANGES WITH PERAZINE (TAXILAN) IN MENTALLY DISTURBED AND IN HEALTHY EXPERIMENTAL SUBJECTS FOLLOWING REGIMEN AND SINGLE DOSE ADMINISTRATION.
058235 02-11

THE KINETICS OF AMYLOBARBITONE METABOLISM IN HEALTHY MEN AND WOMEN.
063800 04-13

INFLUENCE OF AMINAZIN ON ADRENALIN, NORADRENALINE, DOPAMINE, AND DOPA EXCRETION IN HEALTHY PEOPLE AND IN THE MANIC PHASE OF THE MANIC-DEPRESSIVE PSYCHOSIS.
090355 11-03

**HEART**

THE EFFECT OF BRETYLIUM ON AMINE RETENTION IN RAT HEART.
040309 01-03

OXIDATIVE PHOSPHORYLATION IN HEART MITOCHONDRIA ISOLATED FROM CHLORPROMAZINE TREATED ANIMALS.
041564 01-03

L-DOPA INDUCED ACCUMULATION OF METHYLDOPA IN BRAIN AND HEART.
042726 01-03

MECHANISMS BY WHICH AMPHETAMINE AND DESIPRAMINE INHIBIT THE METARAMINOL INDUCED RELEASE OF NOREPINEPHRINE FROM SYMPATHETIC NERVE ENDINGS IN RAT HEART.
064427 04-03

ACTIONS OF RESERPINE AND TYRAMINE ON THE ACETYLCHOLINE CONTENT OF BRAINSTEM, HEART AND BLOOD OF THE RAT.
067461 06-03

STUDIES OF THE TOXIC EFFECTS OF DRUGS ON ELECTRICAL CONDUCTION AND FUNCTION OF THE HEART. (PH.D.DISSERTATION).
103004 12-05

**HEAT**

THE EFFECT OF HEAT, COLD, AND WORK ON THE CENTRAL ACTIONS OF SCOPOLAMINE.
041562 01-14

HEAT STROKE IN PHENOTHIAZINE TREATED PATIENTS: A REPORT OF THREE FATALITIES.
076364 09-15

**HEATSTROKE**

AMPHETAMINE INTOXICATION WITH COAGULOPATHY, HYPERTHERMIA, AND REVERSIBLE RENAL FAILURE: A SYNDROME RESEMBLING HEATSTROKE.
064236 04-15

**HEMATOLOGICAL**

HEMATOLOGICAL EFFECTS.
100522 12-15

**HEMATOMYELIA**

A CASE OF PROBABLE HEMATOMYELIA CAUSED BY CHRONIC BENZENE POISONING.
056059 02-15

**HEMICHOLINIUM**

THE EFFECT OF INTRAHYPOTHALAMIC MICROINJECTION OF HEMICHOLINIUM (HC-3) ON THE HIPPOCAMPAL THETA RHYTHM OF CATS.
075842 08-03

**HEMISPHERE**

SPECIFIC (IN THE SENSE OF INCREASED PREDISPOSITION TO INJURY OF THE SUBDOMINANT HEMISPHERE) DISTRIBUTION OF THE EXTRAPYRAMIDAL SYMPTOMS IN SCHIZOPHRENICS DURING THE COURSE OF HALOPERIDOL TREATMENT.
089106 10-15

**HEMODYNAMIC**

ANTIARRHYTHMIC AND HEMODYNAMIC EFFECTS OF IMIPRAMINE AND CHLORIMIPRAMINE.
058991 03-05

**HEMOGLOBIN**

BUTAPERAZINE AND HEMOGLOBIN C TRAIT.
067510 06-15

**HEPATIC**

BIPHASIC EFFECT OF NOREPINEPHRINE IN THE REGULATION OF HEPATIC TYROSINE TRANSAMINASE ACTIVITY.
062327 03-03

HYPOTHALAMIC REGULATION OF HEPATIC HEXOBARBITAL METABOLIZING ENZYME SYSTEM.
067962 06-03

EFFECT OF METHYLCHLOROFORM INHALATION ON BARBITURATE HYPNOSIS AND HEPATIC DRUG METABOLISM IN MALE MICE.
068978 06-03

INHIBITION OF HEPATIC HEXOBARBITAL METABOLISM BY DEXTROAMPHETAMINE.
076186 09-03

HEPATIC COMPOSITION AND METABOLISM AFTER ETHANOL CONSUMPTION IN RATS FED LIQUID PURIFIED DIETS.
088599 10-03

A STUDY OF HEPATIC ALCOHOL DEHYDROGENASE INHIBITION (ADH) INDUCED BY PYRAZOL: II. THE ROLE OF LIVER ADH IN THE IN VIVO METABOLISM OF HYDROXYL COMPOUNDS.
089547 11-03

A STUDY OF HEPATIC ALCOHOL DEHYDROGENASE INHIBITION INDUCED BY PYRAZOL: I. IN VIVO ACTION ON ETHANOL AND 2-PHENYLETHANOL.
089548 11-03

USE OF HEPATIC MICROSOMES IN THE PREPARATION OF MODEL DRUG METABOLITES.
094789 11-06

HEPATIC EFFECTS.
100521 12-15

**HEPATOTOXIC**

TOXICITY OF HEPATOTOXIC DRUGS ON MOUSE LIVER TISSUE CULTURE.
088615 10-05

**HEREDITARY**

STOOL PORPHYRINS IN ACUTE INTERMITTENT AND HEREDITARY COPROPORPHYRIA: ADVERSE EFFECTS OF TRANQUILIZERS.
066318 05-15

**HEROIN**

USING METHADONE TO TREAT THE HEROIN ADDICT.
062789 03-07

REACTION TIMES OF METHADONE TREATED EX HEROIN ADDICTS.
062817 03-11

TREATMENT OF HEROIN DEPENDENCE WITH OPIATE ANTAGONISTS.
065195 05-13

HEROIN AND HUMAN SLEEP.
067924 06-14

ACUTE TOXICITY OF HEROIN, ALONE AND IN COMBINATION WITH COCAINE OR QUININE.
068167 06-05

THE USE OF CYCLAZOCINE IN THE TREATMENT OF HEROIN ADDICTS.
068601 06-17

SUCCESSES AND FAILURES IN METHADONE MAINTENANCE TREATMENT OF HEROIN ADDICTION IN NEW-YORK CITY. (UNPUBLISHED PAPER).
071314 07-17

**HESLIP**

COMMENTS ON AN EFFECT OF YEAST RNA ON BEHAVIOR (MOUNTFORD AND HESLIP).
075720 08-04

**HEXAMETHONIUM**

EFFECT OF AMPHETAMINE, NICOTINE AND HEXAMETHONIUM ON PERFORMANCE OF A CONDITIONED RESPONSE DURING ACQUISITION AND RETENTION TRIALS.
046186 01-04

**HEXOBARBITAL**

TOXICITY, NARCOTIC EFFECT, CONCENTRATION AT END OF ANESTHESIA, ELIMINATION FROM BLOOD AND BIOTRANSFORMATION OF HEXOBARBITAL IN RATS OF VARIOUS AGES FOLLOWING SLEEP INDUCTION WITH BARBITAL AND AFTER.
058987 03-05

RESPONSE TO DRUGS BY RATS SHOWING LONG OR SHORT HEXOBARBITAL INDUCED SLEEP.
058990 03-03

THE EFFECT OF HEXOBARBITAL ON THE DURATION OF THE RECURRENT IPSP IN CAT MOTONEURONS.
064621 04-03

HYPOTHALAMIC REGULATION OF HEPATIC HEXOBARBITAL METABOLIZING ENZYME SYSTEM.
067962 06-03

INHIBITION OF HEPATIC HEXOBARBITAL METABOLISM BY DEXTROAMPHETAMINE.
076186 09-03

**HEXOBENDINE**

CLINICAL, CLINICO-CHEMICAL AND BRAIN BIOELECTRIC TESTS OF A COMBINATION OF HEXOBENDINE, ETHAMIVAN AND HYDROXYETHYLTHEOPHYLLIN.
072585 08-14

**HEXOSAMINE**

THE ROLE OF METHYLAMPHETAMINE ON PLASMA HEXOSAMINE LEVEL UNDER STRESS.
074855 08-03

**HEXOSE**

HEXOSE AND PENTOSE PHOSPHATES IN BRAIN DURING CONVULSIONS.
072119 07-03

**HIGH-DOSE**

AN ANALYSIS OF 310 CASES OF ACUTE HIGH-DOSE METHAMPHETAMINE TOXICITY IN HAIGHT-ASHBURY.
067218 06-15

**HIPPOCAMPAL**

SODIUM AMOBARBITAL, THE HIPPOCAMPAL THETA RHYTHM, AND THE PARTIAL REINFORCEMENT EXTINCTION EFFECT.
063333 03-03

BEHAVIORAL EFFECTS: HIPPOCAMPAL DESTRUCTION AND SCOPOLAMINE.
075280 08-04

AVOIDANCE TRAINING OF HIPPOCAMPAL THETA WAVES IN FLAXEDILIZED DOGS AND ITS RELATION TO SKELETAL MOVEMENT.
075399 08-04

THE EFFECT OF INTRAHYPOTHALAMIC MICROINJECTION OF HEMICHOLINIUM (HC-3) ON THE HIPPOCAMPAL THETA RHYTHM OF CATS.
075842 08-03

EFFECT OF HIPPOCAMPAL AND NEOCORTICAL ABLATION ON SCOPOLAMINE INDUCED ACTIVITY IN THE RAT.
075848 09-04

EFFECT OF CHLORPROMAZINE ON 5-HYDROXYTRYPTAMINE METABOLISM IN HIPPOCAMPAL STIMULATED RATS.
080338 09-01

**HIPPOCAMPUS**
IMPAIRMENT OF ALTERNATION LEARNING IN RATS FOLLOWING MICROINJECTION OF CARBACHOL INTO THE HIPPOCAMPUS.
067522 06-04
EFFECT OF AGENTS INTERACTING WITH CHOLINOREACTIVE AND ADRENOREACTIVE SYSTEMS ON EPILEPTIFORM ACTIVITY IN THE HIPPOCAMPUS OF RABBITS.
110631 12-03

**HISSING**
EFFECTS OF PSYCHOTHERAPEUTIC DRUGS ON HYPOTHALAMIC INDUCED HISSING IN CATS.
046139 01-04

**HISTAMINE**
QUANTITATION OF THE DEGREE OF ANTAGONISM OF CHLOROQUINE TO HISTAMINE, ACETYLCHOLINE AND SEROTONIN ( PA2 VALUES).
067462 06-03
IN VIVO FORMATION AND CATABOLISM OF (14C)HISTAMINE IN MOUSE BRAIN.
083169 10-03
HISTAMINE WHEAL FORMATION AND SCHIZOPHRENIA.
086987 10-13

**HISTOCHEMISTRY**
SPECIAL APPLICATION OF FLUORESCENCE HISTOCHEMISTRY: STUDIES ON EIGHT MONOAMINE OXIDASE INHIBITORS IN BRAIN NEURONS.
063989 04-06

**HISTOPATHOLOGICAL**
BEHAVIOR AND HISTOPATHOLOGICAL FINDINGS DURING CHRONIC METHEDRINE INTOXICATION.
071993 07-05

**HISTORY**
WHAT WE HAVE FORGOTTEN ABOUT POT -- A PHARMACOLOGISTS HISTORY.
081680 10-17

**HOFMANN**
THE STRANGE TRIP OF DR. HOFMANN.
081694 10-17

**HOMAGE**
SOMAPSYCHIC RELATIONS IN MEDICINE: SESSION OF HOMAGE OF THE PERUVIAN ACADEMY OF MEDICINE TO PROFESSOR HONORIO DELGADO.
094610 11-14

**HOME**
THE EFFECTS OF 4 HYPNOTIC DRUGS AND PLACEBO ON NORMAL SUBJECTS SLEEPING AND DREAMING AT HOME.
087863 10-06

**HOMOGENATES**
THE EFFECT OF AMANTADINE ON THE UPTAKE OF DOPAMINE AND NORADRENALINE BY RAT BRAIN HOMOGENATES.
074148 08-03

**HOMOLOGUE**
EFFECTS OF A MARIHUANA HOMOLOGUE (PYRAHEXYL) ON AVOIDANCE LEARNING IN THE GERBIL.
059032 03-04

**HOMOSERINE**
NEUROPHARMACOLOGICAL COMPARISON OF CYSTATHIONINE, CYSTEINE, HOMOSERINE AND ALPHA-KETOBUTYRIC ACID IN CATS.
064367 04-04

**HOMOVANILLIC**
CSF HOMOVANILLIC ACID: EFFECTS OF PROBENECID AND ALPHA-METHYLTYROSINE.
047506 01-03

**HONEYCOMB**
AN ELECTRON MICROSCOPIC STUDY OF AXONAL CHANGES IN THE CEREBELLUM OF DIPHENYLHYDANTOIN INTOXICATED RATS: THE FORMATION OF THE SO-CALLED HONEYCOMB STRUCTURE IN THE AXOPLASM.
070334 07-03

**HORMONAL**
HORMONAL INDUCTION OF MATERNAL BEHAVIOR IN THE OVARIECTOMIZED NULLIPAROUS RAT.
069063 06-04
DEVELOPMENT OF HORMONAL CONTROL OVER FOOD INTAKE AND BODY WEIGHT IN FEMALE RATS.
076239 09-03
NEURONAL AND HORMONAL CONTROL OF TYROSINE HYDROXYLASE AND PHENYLETHANOLAMINE N-METHYLTRANSFERASE ACTIVITY.
080352 09-03

**HORMONE**
THYROID HORMONE ENHANCEMENT OF IMIPRAMINE IN NONRETARDED DEPRESSIONS.
042654 01-09
USE OF A THYROID HORMONE TO ACCELERATE THE ACTION OF IMIPRAMINE.
063595 04-10
RELEASE BY AMPHETAMINE IN MAN OF GROWTH HORMONE AND CORTICOSTEROIDS: THE EFFECTS OF THYMOXAMINE AND PROPRANOLOL.
067602 06-13
THYROID HORMONE AND TRICYCLIC ANTIDEPRESSANTS IN RESISTANT DEPRESSIONS.
075428 08-09
ENHANCEMENT OF IMIPRAMINE BY THYROID STIMULATING HORMONE: CLINICAL AND THEORETICAL IMPLICATIONS.
075871 09-10
MODULATION OF FOOD INTAKE AND LOCOMOTOR ACTIVITY IN FEMALE RATS BY DIENCEPHALIC HORMONE IMPLANTS.
076080 09-04
USE OF AN ANDROGEN DEPLETING HORMONE IN THE TREATMENT OF MALE SEX OFFENDERS.
080178 09-14
NOREPINEPHRINE TURNOVER IN BRAIN AFTER ADMINISTRATION OF IMIPRAMINE: ENHANCEMENT BY THYROID HORMONE.
090052 11-13

**HORMONES**
ENDOCRINE HORMONES.
051123 02-17
EFFECT OF MORPHINE ADMINISTRATION ON THE HYDROXYLATION OF STEROID HORMONES BY RAT LIVER MICROSOMES.
066366 05-03
REDIRECTED AGGRESSION AND GONADAL HORMONES IN CAPTIVE RHESUS MONKEYS (MACACA-MULATTA).
075829 08-04
OVARIAN HORMONES AND FEMALE SEXUAL INVITATIONS IN CAPTIVE RHESUS MONKEYS (MACACA-MULATTA).
076554 09-03
URINARY EXCRETION OF ADRENAL HORMONES IN MAN: EFFECTS OF ETHANOL INGESTION, AND THEIR MODIFICATION BY CHLORMETHIAZOLE.
097974 11-11
PROPHYLACTIC ACTION OF LITHIUM SALTS AND THYROID HORMONES ON SYMPTOMS OF MANIC-DEPRESSIVE AND AFFECTIVE PSYCHOSES: CLINICAL AND EXPERIMENTAL RESULTS.
106774 12-09

**HOSPITAL**
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL: CASE 20-1970.
042655 01-15
LYSERGIC ACID DIETHYLAMIDE AS A VARIABLE IN THE HOSPITAL TREATMENT OF ALCOHOLISM: A FOLLOW-UP STUDY.
052476 02-11
HOSPITAL EXPERIENCE WITH FLUPHENAZINE ENANTHATE.
066748 05-07
A SURVEY OF EXTRAPYRAMIDAL MANIFESTATIONS IN PATIENTS ATTENDING AN AFTER CARE CLINIC OF A PSYCHIATRIC HOSPITAL.
070412 07-15
HOSPITAL ADMISSIONS DUE TO LYSERGIC ACID DIETHYLAMIDE.
072149 07-15
A PILOT STUDY OF INJECTABLE DIAZEPAM IN A GENERAL HOSPITAL SETTING.
072397 07-07
DELIRIUM-ACUTUM, A POTENTIALLY FATAL CONDITION IN THE PSYCHIATRIC HOSPITAL.
075980 09-15
TREATMENT WITH THIORIDAZINE OF EMOTIONALLY DISTURBED CHILDREN IN A DAY HOSPITAL.
082090 10-14
RELATIONSHIP BETWEEN THE HOSPITAL MILIEU AND THE RESPONSE TO PHENOTHIAZINES IN THE TREATMENT OF SCHIZOPHRENICS.
085237 10-08
EXTRAPYRAMIDAL ACCIDENTS IN TREATMENT OUTSIDE THE HOSPITAL SETTING.
086443 10-15
A SURVEY OF EXTRAPYRAMIDAL MANIFESTATIONS IN THE INPATIENT POPULATION OF A PSYCHIATRIC HOSPITAL.
086444 10-15
TREATMENT MANAGEMENT IN A HOSPITAL SETTING.
089001 10-11
THE OCCUPATIONAL THERAPY IN A MENTAL HOSPITAL FOR CHRONIC SCHIZOPHRENICS.
139090 12-08

**HOSPITALIZATION**
LITHIUM VERSUS CHLORPROMAZINE FOR MANICS. INITIATIVE AND PRODUCTIVITY VERSUS TRANQUILIZATION HOSPITALIZATION.
063209 03-09

**HOSPITALIZED**
SUSTAINED-RELEASE TRANQUILIZER THERAPY IN HOSPITALIZED GERIATRIC PATIENTS.
059359 03-10
DILANTIN TREATMENT OF HOSPITALIZED CULTURAL FAMILIAL RETARDATES.
062175 03-14

IMIPRAMINE PAMOATE IN HOSPITALIZED DEPRESSIVES: A DOUBLE-BLIND COMPARISON WITH PLACEBO.
064429 04-10

CLINICAL EXPERIENCE WITH PIPERACETAZINE IN HOSPITALIZED MENTAL PATIENTS: A FOUR YEAR STUDY.
071292 07-07

MILD INSULIN HYPOGLYCEMIC TREATMENT FOR HOSPITALIZED ADOLESCENTS.
082172 10-11

EFFECT OF WITHDRAWAL OF ANTIPARKINSONIAN MEDICATION ON CHRONICALLY HOSPITALIZED PSYCHIATRIC PATIENTS.
086445 10-15

COMPARATIVE, DOUBLE-BLIND STUDY OF DOXEPINE AND LIBRIUM IN CASES OF PSYCHONEUROSES WITH ANXIETY AMONG HOSPITALIZED AND AMBULATORY PATIENTS.
087489 10-10

DOUBLE-BLIND STUDY OF CLOPENTHIXOL AND CHLORPROMAZINE IN ACUTE HOSPITALIZED SCHIZOPHRENICS.
098048 11-08

THIOTHIXENE IN HOSPITALIZED CHRONIC SCHIZOPHRENIC PATIENTS.
134906 12-08

**HOSTILITY**

IMIPRAMINE EFFECTS UPON HOSTILITY IN DEPRESSION.
052456 02-10

**HUMAN**

DECARBOXYLATION OF 3,4- DIHYDROXYPHENYLALANINE IN VARIOUS HUMAN ADULT AND FETAL TISSUES.
040105 01-13

HUMAN PHARMACOLOGY OF MARIHUANA (CANNABIS).
046202 01-13

A METHOD OF IDENTIFYING NARCOTIC ANALGESICS IN HUMAN URINE AFTER THERAPEUTIC DOSES.
057473 02-16

EXCRETION OF VANYLGLYCOL IN HUMAN URINE UNDER DIETARY CONTROL, AND DURING TREATMENT WITH ANTIBIOTICS, DISULFIRAM, A MONOAMINE OXIDASE INHIBITOR, ALPHA-METHYLDOPA, AND RESERPINE.
060272 03-13

DELTA8-TETRAHYDROCANNABINOL AND DELTA9-TETRAHYDROCANNABINOL: EFFECTS ON CULTURED HUMAN LEUCOCYTES.
063880 04-15

THE EFFECT OF ACUTE ADMINISTRATION OF (META-TRIFLUOROMETHYL-PHENYL)-1-(BENZOYLOXY) ETHYLAMINO-2-PROPANE (780-SE) AND FENFLURAMINE ON HUMAN SLEEP.
063978 04-14

A NOVEL APPROACH TO THE INVESTIGATION OF NOREPINEPHRINE METABOLISM IN HUMAN SYMPATHETIC NERVE.
064144 04-03

MONOAMINE OXIDASE INHIBITORS, COMBINED WITH THYMOLEPTICS: ARE THEY REALLY UNUSABLE FOR HUMAN BEINGS.
066805 05-03

HEROIN AND HUMAN SLEEP.
067924 06-14

COMPARATIVE EFFECTS OF SMOKING MARIHUANA OR PLACEBO ON HUMAN MOTOR AND MENTAL PERFORMANCE.
069579 07-14

INHIBITORY EFFECT OF TWO NEWER ANTIDEPRESSANTS, LU-5-003 AND LU-3-010, ON SEROTONIN UPTAKE IN HUMAN BLOOD PLATELETS IN VITRO.
071791 07-03

EFFECTS OF DRUGS ON SOMATIC ACTIVITY AND HUMAN RESPONSES.
085757 10-13

HUMAN INTOXICATION BY CHLORALOSE.
088618 10-15

EVALUATION OF CL-1848C: A NEW DISSOCIATIVE ANESTHETIC IN NORMAL HUMAN VOLUNTEERS.
097971 11-07

DRUGS AND HUMAN BEHAVIOUR.
110896 12-14

**HUMANS**

DELAYED ABSORPTION OF PHENYLBUTAZONE CAUSED BY DESMETHYLIMIPRAMINE IN HUMANS.
042756 01-13

STATE-DEPENDENT LEARNING IN HUMANS.
058561 02-14

**HUNGER**

RECIPROCAL HUNGER REGULATING CIRCUITS INVOLVING ALPHA-ADRENERGIC AND BETA-ADRENERGIC RECEPTORS LOCATED, RESPECTIVELY, IN THE VENTROMEDIAL AND LATERAL HYPOTHALAMUS.
092166 11-03

**HYDERGINE**

PHARMACOLOGICAL ASSOCIATION OF THIORIDAZINE HYDERGINE IN PSYCHOEMOTIONAL TROUBLES OF THE AGED.
091138 11-14

**HYDRATE**

MANDRAX AS AN HYPNOTIC FOR PSYCHIATRIC INPATIENTS: A COMPARATIVE TRIAL WITH CHLORAL HYDRATE.
061562 03-14

CHLORAL HYDRATE IN CENTRAL NERVOUS SYSTEM DEPRESSION.
064335 04-17

HYPNOTICS AND ALTERED SLEEP DREAM PATTERNS: II. ALL-NIGHT EEG STUDIES OF CHLORAL HYDRATE, FLURAZEPAM, AND METHAQUALONE.
066234 05-14

THE KINETICS OF CHLORAL HYDRATE METABOLISM IN MICE AND THE EFFECT THEREON OF ETHANOL.
066364 05-03

A STUDY OF THE INTERACTION OF THE HYPNOTIC EFFECTS AND OF THE TOXIC EFFECTS OF CHLORAL HYDRATE AND ETHANOL.
066365 05-03

A COMPARATIVE STUDY OF THREE HYPNOTICS: METHYPRYLON, GLUTETHIMIDE AND CHLORAL HYDRATE.
067862 06-14

**HYDRAZIDES**

SYNTHESIS OF SOME GLYCIDIC HYDRAZIDES AND AMIDES AS POTENTIAL PSYCHOTROPIC AGENTS AND ANTICHOLINERGIC AGENTS.
064258 04-01

**HYDROCARBONS**

ENCEPHALOPATHY AS A SEQUEL OF CHRONIC INTOXICATION WITH HALOGEN DERIVATIVES OF AROMATIC HYDROCARBONS.
085102 10-15

**HYDROPHOBIC**

MICELLAR SOLUBILIZATION OF BARBITURATES I: SOLUBILITIES OF CERTAIN BARBITURATES IN POLYSORBATES OF VARYING HYDROPHOBIC CHAIN LENGTH.
046136 01-17

**HYDROSARPAN-711**

THERAPEUTIC INTEREST IN HYDROSARPAN-711 IN DEPRESSIVE STATES AND IN THE PSYCHIATRIC PATHOLOGY OF GERONTOLOGICAL STATES.
079859 09-11

**HYDROTHIADENE**

THE CLINICAL TESTING OF HYDROTHIADENE IN ENDOGENOUS DEPRESSIONS. INFLUENCE OF DRUGS ON PHOTOMYOCLONIC THRESHOLD.
070940 07-09

**HYDROXYALKYLPYRAZINES**

PHARMACOLOGY OF ALKYL AND HYDROXYALKYLPYRAZINES.
066497 05-03

**HYDROXYETHYLTHEOPHYLLIN**

CLINICAL, CLINICO-CHEMICAL AND BRAIN BIOELECTRIC TESTS OF A COMBINATION OF HEXOBENDINE, ETHAMIVAN AND HYDROXYETHYLTHEOPHYLLIN.
072585 08-14

**HYDROXYL**

A STUDY OF HEPATIC ALCOHOL DEHYDROGENASE INHIBITION (ADH) INDUCED BY PYRAZOL: II. THE ROLE OF LIVER ADH IN THE IN VIVO METABOLISM OF HYDROXYL COMPOUNDS.
089547 11-03

**HYDROXYLAMINE**

EFFECT OF HYDROXYLAMINE ON MAZE LEARNING IN MICE.
065933 05-04

DELAYED LEARNING DEFICIT PRODUCED BY HYDROXYLAMINE.
067713 06-04

TIME-DEPENDENT LEARNING DEFICIT CAUSED BY HYDROXYLAMINE.
068677 06-04

**HYDROXYLASE**

TRYPTOPHAN HYDROXYLASE CHANGES IN MIDBRAIN OF THE RAT AFTER CHRONIC MORPHINE ADMINISTRATION.
064146 04-03

EFFECT OF PITUITARY AND ACTH ON THE MAINTENANCE OF BASAL TYROSINE HYDROXYLASE ACTIVITY IN THE RAT ADRENAL GLAND.
075714 08-03

PHASE DIFFERENCE IN THE INDUCTION OF TYROSINE HYDROXYLASE IN CELL BODY AND NERVE TERMINALS OF SYMPATHETIC NEURONES.
075715 08-03

NEURONAL AND HORMONAL CONTROL OF TYROSINE HYDROXYLASE AND PHENYLETHANOLAMINE N-METHYLTRANSFERASE ACTIVITY.
080352 09-03

**HYDROXYLATION**

EFFECT OF MORPHINE ADMINISTRATION ON THE HYDROXYLATION OF STEROID HORMONES BY RAT LIVER MICROSOMES.
066366 05-03

PREPARATION OF 3H-7-HYDROXYCHLORPROMAZINE USING SHEEP LIVER MICROSOMES FOR HYDROXYLATION OF 3H-CHLORPROMAZINE.
097582 11-01

**HYDROXYMETHYL**

BLOCKADE OF NORADRENALINE UPTAKE AND INHIBITION OF GASTRIC ACID SECRETION BY 2-(P-CHLOROPHENYL-2-(PYRIDYL)HYDROXYMETHYL) IMIDAZOLINE MALEATE (SCH-12650).
058878 02-02

**HYDROXYTRYPTAMINE**
HYDROXYTRYPTAMINE TURNOVER DECREASED BY THE ANTIDEPRESSANT DRUG CHLORIMIPRAMINE.
058799 02-03

**HYDROXYZINE**
HYDROXYZINE AND CHLORDIAZEPOXIDE IN ANXIOUS NEUROTIC OUTPATIENTS: A COLLABORATIVE CONTROLLED STUDY.
062321 03-10

HYDROXYZINE AND SHOCK IN OPERANT BEHAVIOR OF RATS.
076164 09-04

EFFECT OF NICOTINIC ACID COMBINED WITH A TRANQUILLIZER (HYDROXYZINE) ON SERUM LIPID LEVELS AND URINARY CATECHOLAMINE EXCRETION IN GERIATRIC PATIENTS.
093689 11-11

**HYOSCINE**
DISAPPEARANCE IN RATS WITH SEPTAL LESIONS OF THE STIMULATORY EFFECT OF HYOSCINE ON EXPLORATORY BEHAVIOUR.
067605 06-04

**HYPERACTIVE**
PARADOXICAL AMPHETAMINE EFFECT IN HYPERACTIVE RATS IN RELATION TO NOREPINEPHRINE METABOLISM.
064364 04-03

URINARY NORADRENALINE AND PLAYROOM BEHAVIOUR IN HYPERACTIVE BOYS.
070024 07-14

**HYPERACTIVITY**
TREATMENT OF HYPERACTIVITY IN CHILDREN.
065176 05-12

BIOCHEMICAL AND BEHAVIORAL EFFECT OF AMPHETAMINE IN DMI - RO-4-1284 INDUCED HYPERACTIVITY.
070951 07-03

EFFECTS OF 6-HYDROXYDOPAMINE ON CNS CATECHOLAMINES, SPONTANEOUS MOTOR ACTIVITY AND AMPHETAMINE INDUCED HYPERACTIVITY IN RATS.
074053 08-04

**HYPERKINESIA**
CONSIDERATIONS ON THE HYPERKINESIA OF L-DOPA: SIGNIFICANT BIOCHEMICAL AND ANATOMICAL DEFICIENCIES.
078555 09-13

ON THE EFFECT OF DIOXYPHENYLALANINE (L-DOPA) ON EXTRAPYRAMIDAL HYPERKINESIA DUE TO NEUROLEPTIC LONG-TERM MEDICATION.
079950 09-15

**HYPERKINESIAS**
NEUROPATHOLOGY OF PERSISTENT CHOREIFORM HYPERKINESIAS UNDER LONG-TERM TREATMENT WITH NEUROLEPTICS.
101020 12-15

**HYPERKINESIS**
ON PROBLEMS OF LATE EXTRAPYRAMIDAL HYPERKINESIS DUE TO NEUROLEPTIC LONG-TERM THERAPY.
079996 09-15

ETIOLOGY OF LATE HYPERKINESIS IN THE COURSE OF LONG-TERM TREATMENT WITH NEUROLEPTICS.
100997 12-15

**HYPERKINETIC**
IN DEFENSE OF STIMULANTS FOR HYPERKINETIC CHILDREN.
067059 05-11

QUANTITATIVE CLINICAL ANALYSIS OF THE EFFECT OF FENETYLLIN (CAPTAGON) ON HYPERKINETIC CHILDREN.
093540 11-11

**HYPERPHAGIC**
MOTIVATIONAL DEPRESSION ASSOCIATED WITH NOREPINEPHRINE INDUCED EATING FROM THE HYPOTHALAMUS: RESEMBLANCE TO THE VENTROMEDIAL HYPERPHAGIC SYNDROME.
090473 11-04

**HYPERPIGMENTATION**
RABBIT AS A MODEL FOR CHLORPROMAZINE INDUCED HYPERPIGMENTATION OF THE SKIN.
045543 01-05

**HYPERSEXUALITY**
HYPERSEXUALITY AND BEHAVIORAL CHANGES IN CATS CAUSED BY ADMINISTRATION OF P-CHLOROPHENYLALANINE.
056934 02-04

**HYPERSUSCEPTIBILITY**
RELATIONSHIP OF BARBITAL DISPOSITION TO AUTO-INDUCED HYPERSUSCEPTIBILITY IN THE RAT.
046144 01-03

**HYPERTENSION**
HYPERTENSION DURING IMIPRAMINE TREATMENT.
071971 07-15

TREATMENT OF LABILE HYPERTENSION.
076346 09-17

CONTROLLED LONG-TERM STUDY ON SENILE HYPERTENSION.
089785 11-15

**HYPERTENSIVE**
HYPERTENSIVE CRISIS IN A PATIENT ON MAOI ANTIDEPRESSANTS FOLLOWING A MEAL OF BEEF LIVER.
092211 11-15

**HYPERTHERMIA**
AMPHETAMINE INTOXICATION WITH COAGULOPATHY, HYPERTHERMIA, AND REVERSIBLE RENAL FAILURE: A SYNDROME RESEMBLING HEATSTROKE.
064236 04-1

ON THE ANALYSIS OF 5-HYDROXYTRYPTOPHAN PRODUCED HYPERTHERMIA IN MICE PRETREATED WITH A MONOAMINE OXIDASE INHIBITOR NIAMID.
098035 11-0

**HYPERTHYROID**
BARBITURATE INDUCED SLEEP IN HYPERTHYROID MICE.
066935 05-0

**HYPNOSIS**
EFFECT OF METHYLCHLOROFORM INHALATION ON BARBITURATE HYPNOSIS AND HEPATIC DRUG METABOLISM IN MALE MICE.
068978 06-0

**HYPNOTIC**
MANDRAX AS AN HYPNOTIC FOR PSYCHIATRIC INPATIENTS: A COMPARATIVE TRIAL WITH CHLORAL HYDRATE.
061562 03-14

HYPNOTIC DRUGS AND THEIR EFFECTIVENESS: ALL-NIGHT EEG STUDIES OF INSOMNIAC SUBJECTS.
066235 05-14

A STUDY OF THE INTERACTION OF THE HYPNOTIC EFFECTS AND OF THE TOXIC EFFECTS OF CHLORAL HYDRATE AND ETHANOL.
066365 05-0

HYPNOTIC PROPERTIES OF NITRAZEPAM (MOGADON) (A COMPARATIVE STUDY OF CHLORDIAZEPOXIDE, DIAZEPAM, NITRAZEPAM, SECOBARBITAL AND PLACEBO IN PSYCHIATRIC PATIENTS).
075884 09-14

THE EFFECTS OF 4 HYPNOTIC DRUGS AND PLACEBO ON NORMAL SUBJECTS SLEEPING AND DREAMING AT HOME.
087863 10-06

NEUROPSYCHIATRIC CLINICAL STUDY OF A BARBITURATE HYPNOTIC: 5-ETHYL 5(1- METHYL-1-BUTENYL) MALONYLUREA.
089173 10-07

HYPNOTIC DRUGS.
090365 11-17

**HYPNOTICS**
HYPNOTICS AND ALTERED SLEEP DREAM PATTERNS: I. ALL-NIGHT EEG STUDIES OF GLUTETHIMIDE, METHYPRYLON, AND PENTOBARBITAL.
066233 05-14

HYPNOTICS AND ALTERED SLEEP DREAM PATTERNS: II. ALL-NIGHT EEG STUDIES OF CHLORAL HYDRATE, FLURAZEPAM, AND METHAQUALONE.
066234 05-14

A COMPARATIVE STUDY OF THREE HYPNOTICS: METHYPRYLON, GLUTETHIMIDE AND CHLORAL HYDRATE.
067862 06-14

SLEEP AND HYPNOTICS: FURTHER EXPERIMENTS.
072216 07-14

MEASUREMENT OF THE DISTRIBUTION OF HYPNOTICS AND CEREBRAL FUNCTION IN ACUTE INTOXICATIONS BY PH.
089040 10-17

**HYPOGLYCEMIC**
MILD INSULIN HYPOGLYCEMIC TREATMENT FOR HOSPITALIZED ADOLESCENTS.
082172 10-11

**HYPOKALAEMIA**
HYPOKALAEMIA AND ARRHYTHMIAS AS A RESULT OF QUININE POISONING.
071258 07-15

**HYPOPHYSECTOMIZED**
STUDY OF THE EFFECTS OF PROGESTERONE THERAPY ON THE STILBOESTROL INDUCED SENSITIVITY OF ISOLATED UTERI OF HYPOPHYSECTOMIZED RATS.
041540 01-03

**HYPOPHYSECTOMY**
EFFECT OF HYPOPHYSECTOMY ON ADRENAL DOPAMINE-BETA-HYDROXYLASE ACTIVITY IN THE RAT (UNPUBLISHED PAPER).
092383 11-03

**HYPOTENSION**
LEVODOPA, PARKINSONS DISEASE, AND HYPOTENSION.
042521 01-15

HYPOTENSION CAUSED BY L-DOPA.
067833 06-03

PREVENTION AND TREATMENT OF HYPOTENSION BY USING PSYCHOPHARMACOLOGY.
091139 11-09

**HYPOTENSIVE**
EVIDENCE FOR A CENTRALLY MEDIATED HYPOTENSIVE EFFECT OF L-DOPA IN THE RAT.
055587 02-03

CENTRAL HYPOTENSIVE EFFECT OF L-DIHYDROXYPHENYLALANINE IN THE RAT.
063888 04-03

SUBSTITUTED BENZAMIDES WITH POTENTIAL CNS DEPRESSANT AND HYPOTENSIVE ACTIVITY.
089435 11-02

HYPOTENSIVE EFFECTS OF CHLORDIAZEPOXIDE, AMOBARBITAL AND CHLORPROMAZINE ON BEHAVIORALLY INDUCED ELEVATED ARTERIAL BLOOD PRESSURE IN THE SQUIRREL MONKEY.
089999 11-04

HYPOTHALAMIC
EFFECTS OF PSYCHOTHERAPEUTIC DRUGS ON HYPOTHALAMIC INDUCED HISSING IN CATS.
046139 01-04
LATERAL HYPOTHALAMIC CONTROL OF KILLING: EVIDENCE FOR A CHOLINOCEPTIVE MECHANISM.
058227 02-04
HYPOTHALAMIC DYSFUNCTION AND ANTIDEPRESSANT DRUGS.
067012 05-14
HYPOTHALAMIC REGULATION OF HEPATIC HEXOBARBITAL METABOLIZING ENZYME SYSTEM.
067962 06-03
EFFECTS OF SELECTED DRUGS ON STIMULUS BOUND EMOTIONAL BEHAVIOR ELICITED BY HYPOTHALAMIC STIMULATION IN THE CAT.
088617 10-04
HYPOTHALAMIC PITUITARY ADRENAL AXIS.
100532 12-13

HYPOTHALAMICALLY
ENHANCEMENT BY DESIPRAMINE OF HYPOTHALAMICALLY EVOKED DISCHARGES IN PREGANGLIONIC SYMPATHETIC NERVES.
097962 11-03

HYPOTHALAMO-PITUITARY
THE ROLE OF THE HYPOTHALAMO-PITUITARY SYSTEM IN THE MECHANISM OF ACTION OF RESERPINE AND 5-HYDROXYTRYPTOPHAN ON ANTIBODY PRODUCTION.
040579 01-03

HYPOTHALAMUS
ALPHA-ADRENERGIC RECEPTORS IN HYPOTHALAMUS FOR THE SUPPRESSION OF FEEDING BEHAVIOR BY SATIETY.
060801 03-04
BEHAVIORAL AND VISCERAL REACTIONS ELICITED BY CHEMICAL STIMULATION OF THE HYPOTHALAMUS AND SEPTUM IN CATS.
064333 04-04
MODIFICATION BY DESIPRAMINE (DMI) OF THE AVAILABILITY OF NOREPINEPHRINE RELEASED BY RESERPINE IN THE HYPOTHALAMUS OF THE RAT IN VIVO.
066374 05-03
PROJECT SUMMARY: ELECTRICAL AND CHEMICAL STIMULATION OF THE HYPOTHALAMUS.
085144 10-03
APHAGIA, PRODUCED BY DEPOSITION OF DRUGS INTO THE HYPOTHALAMUS OF RATS.
088463 10-03
MOTIVATIONAL DEPRESSION ASSOCIATED WITH NOREPINEPHRINE INDUCED EATING FROM THE HYPOTHALAMUS: RESEMBLANCE TO THE VENTROMEDIAL HYPERPHAGIC SYNDROME.
090473 11-04
RECIPROCAL HUNGER REGULATING CIRCUITS INVOLVING ALPHA-ADRENERGIC AND BETA-ADRENERGIC RECEPTORS LOCATED, RESPECTIVELY, IN THE VENTROMEDIAL AND LATERAL HYPOTHALAMUS.
092166 11-03
THE EFFECT OF DIETHYLAMIDE OF LYSERGIC ACID (DLA) ON THE CONTENT OF MONOAMINES IN SOME NUCLEI OF THE MIDBRAIN AND HYPOTHALAMUS.
101006 12-03

HYPOTHERMIA
EFFECTS OF MONOAMINE OXIDASE INHIBITORS AND AMPHETAMINE ON HYPOTHERMIA PRODUCED BY HALOTHANE.
041569 01-03
DIAZEPAM (VALIUM) LEVEL IN THE BRAIN DURING HYPOTHERMIA.
089036 10-03
INFLUENCE OF SEVERAL AUTONOMIC DRUGS ON SODIUM NITROPRUSSIDE AND OXOTREMORINE INDUCED HYPOTHERMIA IN IMMATURE AND MATURE MICE.
089436 11-03
5-HYDROXYTRYPTOPHAN PRODUCED HYPOTHERMIA IN MICE AS A TEST FOR PHARMACOLOGICAL DIFFERENTIATION OF ANTIDEPRESSANTS, ANTICHOLINERGICS AND NEUROLEPTICS: SOME DATA ON THE NATURE OF THIS HYPOTHERMIA.
105622 12-06

HYPOXIA
EFFECT OF ACUTE HYPOXIA ON BRAIN SENSITIVITY AND METABOLISM OF BARBITURATES IN MICE.
064480 04-03

HYSTERIA
HYSTERIA AND DRUG-INDUCED DYSTONIA.
063778 04-15

HYSTERICAL
CLASSICAL HYSTERICAL SEIZURES FACILITATED BY ANTICONVULSANT TOXICITY.
081135 09-15

H3-TYRAMINE
EFFECTS OF DESMETHYLIMIPRAMINE AND COCAINE ON THE UPTAKE, RETENTION AND METABOLISM OF H3-TYRAMINE IN RAT BRAIN SLICES.
064419 04-03

H3-TYROSINE
DAILY RHYTHM IN THE ACCUMULATION OF BRAIN CATECHOLAMINES SYNTHESIZED FROM CIRCULATING H3-TYROSINE.
040246 01-03

IATROGENIC
IATROGENIC ENCEPHALOPATHY.
090366 11-15

IBOTENIC
MONOAMINES IN THE BRAIN UNDER THE INFLUENCE OF MUSCIMOL AND IBOTENIC ACID, TWO PSYCHOACTIVE PRINCIPLES OF AMANITA-MUSCARIA.
064408 04-03

IDENTIFICATION
IDENTIFICATION OF NARCOTICS AND DIAGNOSIS OF THE ADDICTION. (UNPUBLISHED PAPER).
051207 02-01
INFRARED IDENTIFICATION OF SOME HALLUCINOGENIC DERIVATIVES OF TRYPTAMINE AND AMPHETAMINE.
058877 02-01
IDENTIFICATION OF CANNABIS.
058880 02-06
SEPARATION AND IDENTIFICATION OF TRANQUILIZERS AND PSYCHOSTIMULANTS.
131625 12-06

IDENTIFIED
AMITRIPTYLINE AND CARDIAC DISEASE: RISK OF SUDDEN DEATH IDENTIFIED BY MONITORING SYSTEM.
070854 07-15

IDENTIFYING
A METHOD OF IDENTIFYING NARCOTIC ANALGESICS IN HUMAN URINE AFTER THERAPEUTIC DOSES.
057473 02-16

IDENTITY
MARIJUANA: MARY JANE FACES THE IDENTITY CRISIS OR, THREE BLIND MEN STUDY THE ELEPHANT.
082063 10-17

ILEUM
EFFECTS OF TWO CHOLINESTERASE INHIBITORS ON ACETYLCHOLINE RELEASE FROM THE GUINEA-PIG ISOLATED ILEUM PREPARATION.
040572 01-03
THE EFFECTS OF MORPHINE-LIKE SUBSTANCES AND THEIR ANTAGONISTS ON TRANSMISSION AT THE NEURO EFFECTOR JUNCTION OF THE MYENTERIC PLEXUS LONGITUDINAL MUSCLE PREPARATION OF THE GUINEA-PIG ILEUM.
041974 01-03

ILL
USE OF ANTIPSYCHOTIC AND ANTIDEPRESSANT DRUGS BY CHRONICALLY ILL PATIENTS.
076351 09-17

ILLICIT
A PROCEDURE FOR THE ANALYSIS OF ILLICIT DIAMORPHINE SAMPLES.
046395 01-01
A NOTE ON THE COMPOSITION OF ILLICIT DRUGS.
057866 02-01

ILLNESS
A CASE OF MANIC-DEPRESSIVE ILLNESS WITH LITHIUM TOXICITY.
058213 02-15
ARE THERE BENEFITS OF MENTAL ILLNESS?
058431 02-09
URINARY CYCLIC AMP IN AFFECTIVE ILLNESS.
059054 03-09
EFFECTIVENESS OF LITHIUM CARBONATE IN THE TREATMENT OF MANIC-DEPRESSIVE ILLNESS.
062348 03-09
LITHIUM, CREATIVITY, AND MANIC-DEPRESSIVE ILLNESS: REVIEW AND PROSPECTUS.
063601 04-09
DRUG PLASMA LEVELS IN CHRONIC ILLNESS.
064484 04-17
DRUGS IN DEPRESSIVE ILLNESS.
067013 05-09
PSEUDOPREGNANCY, TREATMENT OF PERIODIC PSYCHIATRIC ILLNESS: A PILOT STUDY.
068215 06-09
FOLATE DEFICIENCY IN DEPRESSIVE ILLNESS.
068414 06-13
PSYCHOTROPIC DRUGS AND THE REGULATION OF BEHAVIORAL ACTIVATION IN PSYCHIATRIC ILLNESS.
070970 07-17
AFFECTIVE ILLNESS AND CYCLIC AMP EXCRETION.
071972 07-13

DEPRESSIVE ILLNESS IN A GENERAL PRACTICE. A DEMOGRAPHIC STUDY AND A CONTROLLED TRIAL OF IMIPRAMINE.
072055 07-09
COMPLEXES BETWEEN ACETYLCHOLINE AND CATECHOLAMINES AND THEIR TOLERANCE TO MENTAL ILLNESS.
072705 08-01
DRUG TREATMENT IN DEPRESSIVE ILLNESS: AMITRYPTYLINE AND CHLORDIAZEPOXIDE IN TWO NEUROTIC POPULATIONS.
075415 08-10
THE USE OF THE PYRIMIDINE NUCLEOSIDES (CYTIDINE AND URIDINE) IN THE THERAPY OF CEREBRAL VASCULAR ILLNESS.
094472 11-13
THE COURSE OF RECURRENT DEPRESSIVE ILLNESS IN SELECTED PATIENTS FROM A DEFINED POPULATION.
106781 12-09

**ILLUMINATION**
DOGMATIL: A NEW ILLUMINATION ON THE PSYCHOLOGICAL PROBLEMS OF SENESCENCE.
058313 02-11

**ILLUSTRATIVE**
PSYCHOTHERAPY FOR THE DYING: PRINCIPLES AND ILLUSTRATIVE CASES WITH SPECIAL REFERENCE TO THE USE OF LSD.
062808 03-12

**IMIDAZOLINE**
BLOCKADE OF NORADRENALINE UPTAKE AND INHIBITION OF GASTRIC ACID SECRETION BY 2-(P-CHLOROPHENYL-2-(PYRIDYL)HYDROXYMETHYL) IMIDAZOLINE MALEATE (SCH-12650).
058878 02-02

**IMINOBENZYL**
CENTRAL NEUROTROPIC ACTIVITY OF AMINOPROPYL AND AMINOPROPIONYLIC DERIVATIVES OF IMINOBENZYL AND DIPHENYLAMINE AND ITS RELATION TO IONIZATION CONSTANTS.
072580 08-03

**IMINODIBENZYL**
THE METABOLISM OF PSYCHOTROPIC DRUGS (PHENOTHIAZINE AND IMINODIBENZYL DERIVATIVES).
067301 06-17

**IMIPRAMINE**
THYROID HORMONE ENHANCEMENT OF IMIPRAMINE IN NONRETARDED DEPRESSIONS.
042654 01-09
IMIPRAMINE EFFECTS UPON HOSTILITY IN DEPRESSION.
052456 02-10
A CONTROLLED STUDY OF NORTRIPTYLINE AND IMIPRAMINE.
052483 02-09
COMPARATIVE EFFECTS OF FLUPHENAZINE, FLUPHENAZINE CHLORDIAZEPOXIDE AND FLUPHENAZINE IMIPRAMINE.
058451 02-15
ANTIARRHYTHMIC AND HEMODYNAMIC EFFECTS OF IMIPRAMINE AND CHLORIMIPRAMINE.
058991 03-05
IMIPRAMINE AND LITHIUM EFFECTS ON BIOGENIC AMINE TRANSPORT IN DEPRESSED AND MANIC-DEPRESSED PATIENTS.
062326 03-13
IMIPRAMINE AND LITHIUM EFFECTS ON BIOGENIC AMINE TRANSPORT IN DEPRESSED AND MANIC-DEPRESSED PATIENTS.
062366 03-13
USE OF A THYROID HORMONE TO ACCELERATE THE ACTION OF IMIPRAMINE.
063595 04-10
THE EFFECTS OF IMIPRAMINE AND ELECTRIC CONVULSIVE THERAPY ON THE EXCRETION OF VARIOUS MINERALS IN DEPRESSED PATIENTS.
063939 04-13
NEUROCHEMICAL EFFECTS OF IMIPRAMINE AND AMPHETAMINE IN AGGRESSIVE MOUSE KILLING (MURICIDAL) RATS.
064056 04-03
TREATMENT OF DEPRESSION BY THE INTERNIST: RESULTS WITH IMIPRAMINE.
064113 04-14
COMPARISON OF LITHIUM CARBONATE AND IMIPRAMINE (IN PREVENTION OF MANIC-DEPRESSIVE DISEASE).
064317 04-09
EFFECT OF IMIPRAMINE AND CHLORIMIPRAMINE ON AN ACUTE INSTRUMENTAL TRACE CONDITIONED REFLEX IN RATS.
064415 04-04
IMIPRAMINE PAMOATE IN HOSPITALIZED DEPRESSIVES: A DOUBLE-BLIND COMPARISON WITH PLACEBO.
064429 04-10
METABOLISM AND BILIARY EXCRETION OF THE LIPOPHILIC DRUG MOLECULES, IMIPRAMINE AND DESMETHYLIMIPRAMINE IN THE RAT – I. EXPERIMENTS IN VIVO AND WITH ISOLATED PERFUSED LIVERS.
067260 06-03
NOREPINEPHRINE TURNOVER AND METABOLISM IN RAT BRAIN AFTER LONG-TERM ADMINISTRATION OF IMIPRAMINE.
067687 06-03
PSYCHOPHARMACOLOGIC EFFECTS OF SOME CHOLINESTERASE INHIBITORS IN COMPARISON WITH IMIPRAMINE.
069074 06-04
IMIPRAMINE IN CHILDHOOD ENURESIS: FURTHER STUDIES ON THE RELATIONSHIP OF TIME OF ADMINISTRATION TO EFFECT.
071946 07-11
HYPERTENSION DURING IMIPRAMINE TREATMENT.
071971 07-15
DEPRESSIVE ILLNESS IN A GENERAL PRACTICE. A DEMOGRAPHIC STUDY AND A CONTROLLED TRIAL OF IMIPRAMINE.
072055 07-09
STUDIES OF MINERAL METABOLISM IN MENTAL DEPRESSION. I. THE EFFECTS OF IMIPRAMINE AND ELECTRIC CONVULSIVE THERAPY ON CALCIUM BALANCE AND KINETICS.
075837 08-11
ENHANCEMENT OF IMIPRAMINE BY THYROID STIMULATING HORMONE: CLINICAL AND THEORETICAL IMPLICATIONS.
075871 09-10
THE USE OF IMIPRAMINE IN CHILDRENS BEHAVIOR DISORDERS.
080095 09-14
THE INFLUENCE OF IMIPRAMINE, DEXPHENMETRAZINE AND AMPHETAMINE SULPHATE ON SYNCHRONOUS AND PARADOXICAL SLEEP IN NARCOLEPSY CATAPLEXY. A POLYGRAPHIC EXAMINATION.
089037 10-14
EFFECT OF VEHICLES ON METABOLISM OF SEROTONIN AND IMIPRAMINE.
089439 11-03
NOREPINEPHRINE TURNOVER IN BRAIN AFTER ADMINISTRATION OF IMIPRAMINE: ENHANCEMENT BY THYROID HORMONE.
090052 11-13
CLINICAL AND PHARMACOLOGICAL CONTRIBUTION TO THE STUDY OF ALCOHOL IMIPRAMINE AND ALCOHOL THIOPROPERAZINE ASSOCIATIONS.
094305 11-11
EXCITATORY EFFECT OF TRYPTOPHAN IN MICE AND RATS AND EFFECT OF IMIPRAMINE AND DESMETHYLIMIPRAMINE UPON IT.
098009 11-03
INFLUENCE OF IMIPRAMINE, BENACTYZINE AND PROMAZINE ON THE EFFECTS OF INTRAAMYGDALOID INJECTION OF ACETYLCHOLINE AND SEROTONIN.
098024 11-04
A DOUBLE-BLIND TRIAL OF THREE ANTIDEPRESSANTS (GO-2998, GO-2330 AND IMIPRAMINE HYDROCHLORIDE).
134903 12-09
IMIPRAMINE AS AN EFFECTIVE TOOL IN THE MANAGEMENT OF BEHAVIORAL DISORDERS IN CHILDREN.
134937 12-11

**IMMATURE**
PSYCHOACTIVE DRUGS IN THE IMMATURE ORGANISM.
064474 04-13
INFLUENCE OF SEVERAL AUTONOMIC DRUGS ON SODIUM NITROPRUSSIDE AND OXOTREMORINE INDUCED HYPOTHERMIA IN IMMATURE AND MATURE MICE.
089436 11-03

**IMMEDIATE**
MARIJUANA AND IMMEDIATE MEMORY.
073886 08-14

**IMMUNE**
SECONDARY IMMUNE RESPONSE TO TETANUS TOXOID IN PSYCHIATRIC PATIENTS.
075412 08-13

**IMPACT**
THE IMPACT OF PSYCHOPHARMACOLOGY ON MEDICINE AND PSYCHIATRY.
076508 09-17

**IMPAIRMENT**
BEHAVIORAL IMPAIRMENT IN ADULT RATS FOLLOWING ACUTE ZINC DEFICIENCY.
045526 01-04
IMPAIRMENT OF SHOCK AVOIDANCE LEARNING AFTER LONG-TERM ALCOHOL INGESTION IN MICE.
058492 02-04
IMPAIRMENT OF ALTERNATION LEARNING IN RATS FOLLOWING MICROINJECTION OF CARBACHOL INTO THE HIPPOCAMPUS.
067522 06-04
A LEARNING IMPAIRMENT ASSOCIATED WITH INDUCED PHENYLKETONURIA.
069056 06-04

**IMPAIRMENTS**
EQUIVALENCE OF SIMULTANEOUS AND SUCCESSIVE NEOCORTICAL ABLATIONS IN PRODUCTION OF IMPAIRMENTS OF RETENTION OF BLACK WHITE HABITS IN RATS.
076316 09-04

**IMPEDANCE**
ELECTRICAL IMPEDANCE CHANGES IN MANY SITES OF BRAIN IN PARADOXICAL SLEEP, ANESTHESIA AND ACTIVITY.
066474 05-03

**IMPEDIMENTS**
AN EVALUATION OF THE PHARMACOLOGIC APPROACHES TO LEARNING IMPEDIMENTS.
066838 05-14

**IMPLANTING**
AN IMPROVED INSTRUMENT FOR IMPLANTING MICROPELLETS IN THE BRAIN.
058358 02-06

**IMPLANTS**
MODULATION OF FOOD INTAKE AND LOCOMOTOR ACTIVITY IN FEMALE RATS BY DIENCEPHALIC HORMONE IMPLANTS.
076080 09-04

**IMPLICIT**
HAZARDS IMPLICIT IN PRESCRIBING PSYCHOACTIVE DRUGS.
070897 07-17

**IMPLOSION**
THIOPENTONE FACILITATED IMPLOSION IN TREATMENT OF PHOBIC DISORDERS.
066907 05-14

**IMPORTANT**
IN DIAGNOSIS, TYPE OF REACTION IS MORE IMPORTANT THAN THE DRUG.
067939 06-15

**IMPRESSION**
CLINICAL TRIALS AND TREATMENT WITH PSYCHOPHARMACEUTICALS. A SECOND CRITICAL REVIEW: AN IMPRESSION.
105734 12-17

**IMPRISONED**
NONADDICTIVE PSYCHOTROPIC MEDICATION FOR IMPRISONED NARCOTIC ADDICTS.
070784 07-13

**IMPROVEMENT**
SETTING, PATIENT, AND DOCTOR EFFECTS ON DRUG RESPONSE IN NEUROTIC PATIENTS: II. DIFFERENTIAL IMPROVEMENT.
065446 05-10

PILLS AND IMPROVEMENT: A STUDY OF PLACEBO RESPONSE IN PSYCHONEUROTIC OUTPATIENTS.
066832 05-10

IMPROVEMENT OF LEARNING IN THE AGED BY MODIFICATION OF AUTONOMIC NERVOUS SYSTEM ACTIVITY.
071336 07-14

DIFFERENTIAL RELIABILITY IN RATING PSYCHOPATHOLOGY AND GLOBAL IMPROVEMENT.
076292 09-10

**IMPROVING**
PROPOSALS FOR IMPROVING THE TREATMENT OF BRAIN DAMAGED PATIENTS.
080041 09-11

**IMURAN**
ANALYSIS OF CHROMOSOMES BEFORE AND AFTER TREATMENT WITH IMURAN.
069082 06-13

**INACTIVITY**
SWIM STRESS INDUCED INACTIVITY: RELATION TO BODY TEMPERATURE AND BRAIN NOREPINEPHRINE, AND EFFECTS OF D-AMPHETAMINE.
075275 08-03

**INADEQUATE**
GEORGE: A MAN WITH AN INADEQUATE PERSONALITY.
059100 03-10

**INCENTIVE**
CHLORPROMAZINE, CHLORDIAZEPOXIDE, AND THE INCENTIVE SHIFT PERFORMANCE IN THE RAT.
060275 03-04

COMPARISON OF THE EFFECTS OF EXOGENOUS ACTH ON APPROACH AND AVOIDANCE CONDITIONING: IMPLICATIONS FOR THE PHYSIOLOGY OF INCENTIVE MOTIVATION. (PH.D.DISSERTATION).
103354 12-04

**INCLUDING**
STUDIES ON INTERACTIONS INVOLVING ANTIDEPRESSIVE AND OTHER DRUGS WITH TETRABENAZINE AND NORADNAMINE ON LOCOMOTOR ACTIVITY IN MICE, INCLUDING DETAILS OF THE EXPERIMENTAL DESIGN AND STATISTICAL ANALYSIS.
069077 06-04

**INCONTINENT**
INCONTINENT NOSTALGIA INDUCED BY L-DOPA.
081090 09-15

**INCORPORATION**
STIMULATION OF DOPA-14C INCORPORATION INTO MELANOMA TISSUE BY CHLORPROMAZINE AND RESERPINE.
040584 01-03

EFFECT OF RESERPINE ON THE INCORPORATION IN VIVO OF RADIOACTIVITY FROM LABELED SEROTONIN AND OTHER 5-HYDROXYINDOLE DERIVATIVES IN MOUSE BRAIN.
046189 01-03

MORPHINE AND THE INCORPORATION OF 32 ORTHOPHOSPHATE IN VIVO INTO PHOSPHOLIPIDS OF THE GUINEA-PIG CEREBRAL CORTEX, LIVER AND SUBCELLULAR FRACTIONS.
046401 01-03

INTERFERENCE OF BARBITURATES WITH PYRIMIDINE INCORPORATION -- III: STUDIES ON THE MECHANISM OF THE AMOBARBITAL OROTATE RELATIONSHIP.
064045 04-03

INTERFERENCE OF BARBITURATES WITH PYRIMIDINE INCORPORATION -- II: STRUCTURAL SPECIFICITY OF THE INHIBITION OF OROTATE UPTAKE IN BACILLUS-CEREUS.
064046 04-03

INCREASED INCORPORATION OF 14C-URIDINE INTO RAT BRAIN RNA AS A RESULT OF NOVEL ELECTROSHOCK.
092209 11-01

**INCREASE**
INCREASE IN BRAIN PYRIDOXAL PHOSPHATE BY CHLORPROMAZINE.
046397 01-02

MECHANISM OF THE GAMMA-HYDROXYBUTYRATE INDUCED INCREASE IN BRAIN DOPAMINE AND ITS RELATIONSHIP TO SLEEP.
074865 08-04

NEURALLY MEDIATED INCREASE IN DOPAMINE-BETA-HYDROXYLASE ACTIVITY (UNPUBLISHED PAPER).
088376 10-03

**INCREASES**
FORGETTING OF AN OPERANT RESPONSE: PHYSOSTIGMINE PRODUCED INCREASES IN ESCAPE LATENCY IN RATS AS A FUNCTION OF TIME OF INJECTION.
061540 03-04

TEMPERATURE INCREASES UNDER TREATMENT WITH PSYCHOPHARMACEUTICALS.
097999 11-15

**INCURABLE**
CLINICAL RESEARCH INTO CHRONIC INCURABLE SCHIZOPHRENIA.
072891 08-08

**INDEPENDENT**
RESEARCH ON NEW METHODS OF EXPERIMENTATION WITH PSYCHOTROPIC DRUGS. RESULTS OF A TEST WITH A NEW TRANQUILIZER, NOBRIUM, IN TWO INDEPENDENT INVESTIGATIONS.
086984 10-16

**INDERAL**
EFFECTS OF PROPRANOLOL (INDERAL) ON PSYCHIATRIC SYMPTOMS IN CHRONIC ALCOHOLISM.
099957 11-11

**INDICATION**
A DIFFERENTIAL APPROACH TO THE INDICATION OF NEUROLEPTICS.
070924 07-17

THE MEDICAL AND SOCIAL INDICATION OF ANTIANDROGEN THERAPY.
105733 12-11

**INDICATORS**
USE OF NEUROLEPTICS FOR VITAL INDICATORS IN PATIENTS WITH SEVERE SOMATIC STATES.
111028 12-11

**INDICES**
INFLUENCE OF DISPLAY, TASK, AND ORGANISMIC VARIABLES ON INDICES OF MONITORING BEHAVIOR.
043270 01-17

**INDIRECT**
EFFECT OF GANGLIONIC BLOCKING AGENTS ON PRESSOR EFFECTS OF SYMPATHOMIMETIC AMINES OF DIRECT AND INDIRECT ACTION.
110632 12-03

**INDIVIDUAL**
INDIVIDUAL VARIATION IN AFFECTIVE RESPONSES TO TASTE STIMULI.
066710 05-14

PSYCHOPHARMACOLOGY AND THE INDIVIDUAL PATIENT.
115463 12-17

PSYCHOPHARMACOLOGY AND THE INDIVIDUAL PATIENT.
134057 12-17

**INDIVIDUALLY**
COMPARISON OF LIVER MICROSOME ENZYME SYSTEMS AND BARBITURATE SLEEP TIMES IN RATS CAGED INDIVIDUALLY OR COMMUNALLY.
045545 01-06

**INDIVIDUALS**
PSYCHOMOTOR REACTIONS TO A SLIGHT ALCOHOLEMIA. A COMPARATIVE STUDY ON DRINKERS AND NORMAL INDIVIDUALS.
085043 10-15

**INDOKLON**
INDOKLON: CONVULSIVE THERAPY; EXPERIMENTAL CLINICAL STUDIES.
059692 03-07

**INDOLE**
A POTENT BETA-ADRENORECEPTOR BLOCKING DRUG: 4-(2-HYDROXY-3-ISOPROPYLAMINOPROPOXY)INDOLE.
040751 01-03

THE INDOLE HALLUCINOGENS.
046200 01-14

**INDOLEACETALDEHYDES**
TRYPTALDEHYDES (INDOLEACETALDEHYDES) IN SEROTONERGIC SLEEP OF NEWLY HATCHED CHICKS.
055583 02-03

**INDOLEAMINES**
INDOLEAMINES AND THE CENTRAL NERVOUS SYSTEM: A SOUNDING OF THEIR CLINICAL SIGNIFICANCE.
070881 07-13

DETECTION OF PSYCHOTOMIMETIC N,N DIMETHYLATED INDOLEAMINES IN THE URINE OF FOUR SCHIZOPHRENIC PATIENTS.
080506 09-08

**INDOLES**
SOME RELATIONS BETWEEN INDOLES AND PSYCHIATRY.
068975 06-13

**INDOPAN**
THE INFLUENCE OF INDOPAN ON THE HIGHER NERVOUS ACTIVITY OF DOGS.
067299 06-04

**INDUCED**
REVERSIBLE EFFECT OF L-DOPA ON TREMOR AND CATATONIA INDUCED BY ALPHA-METHYL-P-TYROSINE.
040124 01-05

STUDY OF THE EFFECTS OF PROGESTERONE THERAPY ON THE STILBOESTROL INDUCED SENSITIVITY OF ISOLATED UTERI OF HYPOPHYSECTOMIZED RATS.
041540 01-03

SUBNORMAL SERUM FOLATE DUE TO ANTICONVULSIVE THERAPY: A DOUBLE-BLIND STUDY OF THE EFFECT OF FOLIC ACID TREATMENT IN PATIENTS WITH DRUG INDUCED SUBNORMAL SERUM FOLATES.
042700 01-11

L-DOPA INDUCED ACCUMULATION OF METHYLDOPA IN BRAIN AND HEART.
042726 01-03

RABBIT AS A MODEL FOR CHLORPROMAZINE INDUCED HYPERPIGMENTATION OF THE SKIN.
045543 01-05

EFFECTS OF PSYCHOTHERAPEUTIC DRUGS ON HYPOTHALAMIC INDUCED HISSING IN CATS.
046139 01-04

EFFECTS OF SOME PSYCHOACTIVE DRUGS ON EXPERIMENTAL NEUROTIC (CONFLICT INDUCED) BEHAVIOR IN CATS.
046143 01-04

TRYPTOPHOL, 5-HYDROXYTRYPTOPHOL AND 5-METHOXYTRYPTOPHOL INDUCED SLEEP IN MICE.
058382 02-04

CIRCADIAN RHYTHM FOR EXPERIMENTALLY INDUCED AGGRESSIVE BEHAVIOR IN MICE.
058383 02-03

DOPA INDUCED EXCITEMENT IN THE CAT: ITS RELATIONSHIP TO BRAIN NOREPINEPHRINE CONCENTRATIONS.
058840 02-04

CHLORPROMAZINE INDUCED GLUCOSE INTOLERANCE IN THE MOUSE.
058984 03-05

JUMPING ACTIVITY INDUCED BY SODIUM 5-(1,3 DIMETHYLBUTYL)-5 ETHYL BARBITURATE. II. THE EFFECTS OF AGE DIFFERENCE.
058985 03-04

RESPONSE TO DRUGS BY RATS SHOWING LONG OR SHORT HEXOBARBITAL INDUCED SLEEP.
058990 03-03

L-DOPA INDUCED CHANGES IN CENTRAL MONOAMINE NEURONS AFTER PERIPHERAL DECARBOXYLASE INHIBITION.
059033 03-03

STRAIN DIFFERENCES IN MORPHINE WITHDRAWAL INDUCED AGGRESSION IN RATS.
060857 03-03

CONDITIONED NALORPHINE INDUCED ABSTINENCE CHANGES: PERSISTENCE IN POST MORPHINE DEPENDENT MONKEYS.
061632 03-04

THE EFFECT OF P-CHLOROPHENYLALANINE (PCPA) ON SHOCK INDUCED FIGHTING BEHAVIOR IN RATS.
062853 03-03

ELECTROENCEPHALOGRAPHIC VARIATIONS INDUCED BY PSYCHOTROPIC DRUGS: CLINICAL ELECTROPHYSIOLOGICAL CORRELATIONS FOR A GUIDED THERAPY.
063200 03-13

AN ANALYSIS OF METHYLPHENIDATE INDUCED GNAWING IN GUINEA-PIGS.
064414 04-04

MECHANISMS BY WHICH AMPHETAMINE AND DESIPRAMINE INHIBIT THE METARAMINOL INDUCED RELEASE OF NOREPINEPHRINE FROM SYMPATHETIC NERVE ENDINGS IN RAT HEART.
064427 04-03

COMMENT ON THE INCREASED RESISTANCE TO EXTINCTION OF AN AVOIDANCE RESPONSE INDUCED BY CERTAIN DRUGS.
065070 05-04

ON SIMILAR LINGUISTIC STRUCTURES IN CREATIVE PERFORMANCE AND PSILOCYBIN INDUCED EXPERIENCE.
065433 05-12

THE ALTERATIONS OF PROTEIN METABOLISM OF THE BRAIN CORTEX INDUCED BY ANTICIPATION STRESS AND ACTH.
065434 05-03

UNIT ACTIVITY IN PREMARIN INDUCED CORTICAL EPILEPTOGENIC FOCI.
066187 05-03

CONDITIONAL AUTONOMIC RESPONSES INDUCED IN DOGS BY ATROPINE AND MORPHINE.
066386 05-03

POTENTIATION BY AMANTADINE HYDROCHLORIDE OF L-DOPA INDUCED EFFECTS IN MICE.
066508 05-03

INHIBITION BY PROPRANOLOL OF ETHANOL INDUCED NARCOSIS.
066510 05-03

BARBITURATE INDUCED SLEEP IN HYPERTHYROID MICE.
066935 05-05

DEXBENZETIMIDE IN NEUROLEPTIC INDUCED PARKINSONISM. A DOUBLE-BLIND CROSSOVER STUDY WITH A 16-WEEK FOLLOW-UP.
067176 06-11

THE EFFECT OF INHIBITION OF CATECHOLAMINE SYNTHESIS ON DEXAMPHETAMINE INDUCED CENTRAL STIMULATION.
067259 06-04

A COMPARISON OF SLEEP PATTERNS IN NATURAL AND MANDRAX AND TUINAL INDUCED SLEEP.
067864 06-14

EFFECTS OF PSILOCYBIN, DIMETHYLTRYPTAMINE AND VARIOUS LYSERGIC ACID DERIVATIVES ON PHOTICALLY INDUCED EPILEPSY IN THE BABOON (PAPIO-PAPIO).
068163 06-03

THE RELATIONSHIP OF AMPHETAMINE INDUCED ANOREXIA AND FREEZING UNDER A MULTIPLE CRF-EXT OPERANT SCHEDULE.
068288 06-04

A LEARNING IMPAIRMENT ASSOCIATED WITH INDUCED PHENYLKETONURIA.
069056 06-04

SEROTONIN: A POSSIBLE MEDIATOR OF BEHAVIORAL SUPPRESSION INDUCED BY ANXIETY.
069311 06-04

COMPARISON OF THE PAROXYSMAL DYSKINESIAS (NEURODYSLEPSY) INDUCED BY THE NEUROLEPTICS IN MAN AND THE EARLIEST BEHAVIOR PATTERNS OF THE NEW-BORN.
070267 07-13

REVERSIBLE LENTICULAR OPACITIES INDUCED IN RATS BY EMOTIONAL STRESS.
070823 07-03

CRETINISM IN RATS: ENDURING BEHAVIORAL DEFICIT INDUCED BY TRICYANOAMINOPROPENE.
070839 07-02

A POSSIBLE PATHWAY FOR ETHANOL INDUCED FATTY LIVER AND MODIFICATION OF LIVER INJURY BY ANTIOXIDANTS.
070906 07-05

AGGRESSIVE BEHAVIOR OF RATS INDUCED BY MESORGYDINE (LYSENYL SPOFA).
070949 07-04

BIOCHEMICAL AND BEHAVIORAL EFFECT OF AMPHETAMINE IN DMI - RO-4-1284 INDUCED HYPERACTIVITY.
070951 07-03

THE INFLUENCE OF LONG-TERM PREMEDICATION WITH TRANYLCYPROMINE ON EXPERIMENTAL PSYCHOSES INDUCED BY LSD.
070954 07-12

ECG CHANGES INDUCED BY PHENOTHIAZINE DRUGS IN THE ANESTHETIZED RAT.
072525 08-03

ISONICOTINIC-ACID-HYDRAZIDE (INH) INDUCED MENTAL DISORDERS IN THE COURSE OF LUNG TUBERCULOSIS TREATMENT.
072890 08-15

AN ANALYSIS OF RECEPTIVE STRUCTURES PARTICIPATING IN THE BEHAVIOR REACTIONS OF CATS INDUCED BY CATECHOLAMINES AND SEROTONIN.
073715 08-03

EFFECTS OF 6-HYDROXYDOPAMINE ON CNS CATECHOLAMINES, SPONTANEOUS MOTOR ACTIVITY AND AMPHETAMINE INDUCED HYPERACTIVITY IN RATS.
074053 08-04

STEREOTYPED BEHAVIOUR INDUCED BY (-) EPHEDRINE IN RATS.
074086 08-04

THE MARIHUANA INDUCED SOCIAL HIGH: NEUROLOGICAL AND ELECTROENCEPHALOGRAPHIC CONCOMITANTS.
074782 08-12

MECHANISM OF THE GAMMA-HYDROXYBUTYRATE INDUCED INCREASE IN BRAIN DOPAMINE AND ITS RELATIONSHIP TO SLEEP.
074865 08-04

PENICILLIN INDUCED EPILEPTOGENIC FOCI IN THE RAT CORTEX.
075197 08-04

MORPHINE INDUCED FIGHTING AND PRIOR SOCIAL EXPERIENCE.
075206 08-04

SWIM STRESS INDUCED INACTIVITY: RELATION TO BODY TEMPERATURE AND BRAIN NOREPINEPHRINE, AND EFFECTS OF D-AMPHETAMINE.
075275 08-03

PENTOBARBITAL INDUCED STATE-DEPENDENT LEARNING OF ONE-WAY AVOIDANCE IN MICE.
075288 08-04

TREATMENT OF PERSISTENT PHENOTHIAZINE INDUCED ORAL DYSKINESIA.
075417 08-15

NICOTINIC ACID IN THE PREVENTION AND TREATMENT OF METHIONINE INDUCED EXACERBATION OF PSYCHOPATHOLOGY IN SCHIZOPHRENICS.
075423 08-08

LITHIUM INDUCED DIABETES-INSIPIDUS LIKE SYNDROME.
075426 08-10

EFFECT OF HIPPOCAMPAL AND NEOCORTICAL ABLATION ON SCOPOLAMINE INDUCED ACTIVITY IN THE RAT.
075848 09-04

AUTOMATIC MONITORING OF APOMORPHINE INDUCED PECKING IN PIGEONS.
075922 09-04

MORPHINE AMPHETAMINE INDUCED FIGHTING AND INTERIM SOCIALIZATION.
076131 09-04

INDUCED CHANGES IN CAUDATE NUCLEUS DOPAMINE AND ELECTROSHOCK THRESHOLD.
079179 09-03

ANTAGONISTIC INFLUENCE OF BETA-SYMPATHICOLYTICS ON THE METAMPHETAMINE INDUCED CHANGES IN FUNCTION AND METABOLISM OF THE BRAIN.
079954 09-03

INCREASED DURATION OF NEUROPHARMACOLOGICALLY INDUCED BEHAVIORAL EXCITATION BY ATROPINE.
079998 09-04

INCREASED TRANSMITTER RELEASE INDUCED BY CONVULSANT PHENOLS.
081063 09-03

EFFECTS OF CHRONIC MORPHINE ADMINISTRATION ON THE CATECHOLAMINE DEPLETION INDUCED BY RESERPINE.
081065 09-03

INCONTINENT NOSTALGIA INDUCED BY L-DOPA.
081090 09-15

ANTICHOLINERGIC CENTRAL BLOCKADE OF SALT AROUSED AND DERIVATION INDUCED DRINKING.
081227 09-04

TREATMENT OF SCOPOLAMINE INDUCED DELIRIUM.
082155 10-09

CARDIAC CATECHOLAMINE SYNTHESIS, TURNOVER, AND METABOLISM WITH ISOPROTERENOL INDUCED MYOCYTOLYSIS (UNPUBLISHED PAPER).
088374 10-03

HIGH VOLTAGE SLOW WAVE INDUCED BY SHORT-CHAIN FATTY ACIDS WITH SPECIAL REFERENCE TO SLEEP RHYTHM.
088612 10-03

INFLUENCE OF SEVERAL AUTONOMIC DRUGS ON SODIUM NITROPRUSSIDE AND OXOTREMORINE INDUCED HYPOTHERMIA IN IMMATURE AND MATURE MICE.
089436 11-03

A STUDY OF HEPATIC ALCOHOL DEHYDROGENASE INHIBITION (ADH) INDUCED BY PYRAZOL: II. THE ROLE OF LIVER ADH IN THE IN VIVO METABOLISM OF HYDROXYL COMPOUNDS.
089547 11-03

A STUDY OF HEPATIC ALCOHOL DEHYDROGENASE INHIBITION INDUCED BY PYRAZOL: I. IN VIVO ACTION ON ETHANOL AND 2-PHENYLETHANOL.
089548 11-03

HYPOTENSIVE EFFECTS OF CHLORDIAZEPOXIDE, AMOBARBITAL AND CHLORPROMAZINE ON BEHAVIORALLY INDUCED ELEVATED ARTERIAL BLOOD PRESSURE IN THE SQUIRREL MONKEY.
089999 11-04

EFFECTS OF ATROPINE AND ESERINE ON THE ELECTROENCEPHALOGRAM, ON BEHAVIOUR AND ON LIGHT INDUCED EPILEPSY IN THE ADOLESCENT BABOON (PAPIO-PAPIO).
090157 11-04

LITHIUM INDUCED CHANGES IN ELECTROLYTE BALANCE AND TISSUE ELECTROLYTE CONCENTRATION.
090419 11-03

AGGRESSIVE BEHAVIOUR IN CHICKS INDUCED BY TRICYCLIC ANTIDEPRESSANTS.
090420 11-04

MOTIVATIONAL DEPRESSION ASSOCIATED WITH NOREPINEPHRINE INDUCED EATING FROM THE HYPOTHALAMUS: RESEMBLANCE TO THE VENTROMEDIAL HYPERPHAGIC SYNDROME.
090473 11-04

LESIONS IN CORPUS-STRIATUM AND CORTEX OF RAT BRAINS AND THE EFFECT ON PHARMACOLOGICALLY INDUCED STEREOTYPED, AGGRESSIVE AND CATALEPTIC BEHAVIOUR.
091127 11-04

REDUCTION OF BARBITURATE DEPENDENCE INDUCED BY REPEATED ELECTROCONVULSIONS.
097548 11-03

INHIBITION OF CENTRAL SEROTONINERGIC EXCITATION (5-HYDROXYTRYPTOPHAN INDUCED DEAD TWITCHES) IN MICE BY LITHIUM.
097989 11-04

LITHIUM INDUCED POLYURIA: EXPERIMENTAL STUDIES IN MAN AND THE RAT.
100083 11-15

LITHIUM INDUCED POLYURIA IN RATS.
106779 12-05

EFFECT OF AMANTADINE ON THE EXTRAPYRAMIDAL SYNDROMES INDUCED BY NEUROLEPTICS.
112131 12-09

**INDUCERS**

EFFECT OF INHIBITORS AND INDUCERS OF DRUG METABOLISM ON ETHANOL METABOLISM IN VIVO.
064052 04-03

**INDUCTION**

TOXICITY, NARCOTIC EFFECT, CONCENTRATION AT END OF ANESTHESIA, ELIMINATION FROM BLOOD AND BIOTRANSFORMATION OF HEXOBARBITAL IN RATS OF VARIOUS AGES FOLLOWING SLEEP INDUCTION WITH BARBITAL AND AFTER.
058987 03-05

INDUCTION OF RECEPTIVITY IN OVARIECTOMIZED FEMALE RATS BY A SINGLE INTRAVENOUS INJECTION OF ESTRADIOL-17BETA.
067696 06-04

CHEMICAL INDUCTION OF TRAUMATIC FIGHTING IN RATS.
068765 06-04

HORMONAL INDUCTION OF MATERNAL BEHAVIOR IN THE OVARIECTOMIZED NULLIPAROUS RAT.
069063 06-04

INDUCTION BY CANNABIS-SATIVA (MARIHUANA) OF RHYTHMIC SPIKE DISCHARGES OVERRIDING REM SLEEP ELECTROCORTICOGRAM IN THE RAT.
069069 06-04

THEOPHYLLINE: INDUCTION OF SELF-BITING IN RABBITS.
075236 08-04

PHASE DIFFERENCE IN THE INDUCTION OF TYROSINE HYDROXYLASE IN CELL BODY AND NERVE TERMINALS OF SYMPATHETIC NEURONES.
075715 08-03

INDUCTION OF RECEPTIVITY IN FEMALE RATS AND CATS WITH ESTROGEN AND TESTOSTERONE.
081228 09-04

PROJECT SUMMARY: CHEMICAL INDUCTION OF TRAUMATIC FIGHTING IN RATS.
082511 10-04

**INDUSTRIAL**

AN INDUSTRIAL VIEW OF CURRENT PRACTICE IN PREDICTING DRUG TOXICITY.
057606 02-05

**INDUSTRY**

PSYCHOTROPIC DRUG THERAPY AND THE PHARMACEUTICAL INDUSTRY.
079987 09-17

GOVERNMENTAL REGULATION OF THE DRUG INDUSTRY.
091208 11-17

**INEXPENSIVE**

A SIMPLE AND INEXPENSIVE CANNULA TECHNIQUE FOR CHEMICAL STIMULATION OF THE BRAIN.
058357 02-06

**INFANT**

PHARMACOLOGICAL MANAGEMENT OF CHARACTER TYPE BEHAVIOR DISTURBANCES IN THE INFANT AND CHILD.
093090 11-07

BRAIN DAMAGE IN INFANT MICE FOLLOWING ORAL INTAKE OF GLUTAMATE, ASPARTATE OR CYSTEINE.
094164 11-05

**INFANTILE**

THE MODIFIABILITY OF INFANTILE SHOCK TRAUMATIZATION EFFECTS BY CONTIGUOUS DRUG ADMINISTRATIONS.
060090 03-04

**INFARCTION**

THE VARIABLES OF SILENT MYOCARDIAL INFARCTION IN A PSYCHOTIC POPULATION.
065314 05-10

**INFLUENCE**

INFLUENCE OF MODE AND DURATION OF PHENYLALANINE ADMINISTRATION ON BIOCHEMICAL PARAMETERS IN RATS OF VARIOUS AGES.
042840 01-03

INFLUENCE OF DISPLAY, TASK, AND ORGANISMIC VARIABLES ON INDICES OF MONITORING BEHAVIOR.
043270 01-17

THE INFLUENCE OF MORPHINE ON MAGNESIUM METABOLISM IN RATS.
046191 01-03

LIVER DAMAGE FOLLOWING APPLICATION OF PYRAZINAMIDE IN ANIMAL EXPERIMENTS: 1. CHANGES IN BODY WEIGHT OF RATS UNDER THE INFLUENCE OF PYRAZINAMIDE.
055398 02-05

INFLUENCE OF SEROTONIN AND RELATED SUBSTANCES UPON PHOTIC EVOKED POTENTIALS OF RABBIT: EVIDENCE FOR BIOLOGICAL ACTIVITY OF THE ALDEHYDE DERIVATIVE.
055584 02-03

THE INFLUENCE OF ETHANOL ON DRUG METABOLISM.
057033 02-03

INFLUENCE OF TRIIODOTHYRONINE ON SELECTIVE ATTENTION IN MAN AS MEASURED BY THE VISUAL AVERAGED EVOKED POTENTIAL.
062510 03-13

THE INFLUENCE OF CENTROPHENOXINE (LUCIDRIL) ON LEARNING AND MEMORY IN ALCOHOLICS.
062800 03-14

BETA-HYDROXYLATION OF N-ACETYL-DIMETHOXYPHENETHYLAMINE AND THE INFLUENCE OF IPRONIAZID ON THE DEMETHYLATION OF THIS COMPOUND IN VIVO IN THE RAT.
064053 04-03

MONOAMINES IN THE BRAIN UNDER THE INFLUENCE OF MUSCIMOL AND IBOTENIC ACID, TWO PSYCHOACTIVE PRINCIPLES OF AMANITA-MUSCARIA.
064408 04-03

THE INFLUENCE OF VARIOUS NEUROLEPTIC DRUGS ON SHOCK AVOIDANCE RESPONDING IN RATS. III. AMPHETAMINE ANTAGONISM IN THE DISCRIMINATED SIDMAN AVOIDANCE PROCEDURE.
064476 04-04

INFLUENCE OF ETHYLPHENACEMIDE ON SERUM LEVELS OF OTHER ANTIEPILEPTIC DRUGS.
066190 05-13

THE INFLUENCE OF INDOPAN ON THE HIGHER NERVOUS ACTIVITY OF DOGS.
067299 06-04

THE INFLUENCE OF VARIOUS NEUROLEPTIC DRUGS ON NOISE ESCAPE RESPONSE IN RATS.
069076 06-04

THE CLINICAL TESTING OF HYDROTHIADENE IN ENDOGENOUS DEPRESSIONS. INFLUENCE OF DRUGS ON PHOTOMYOCLONIC THRESHOLD.
070940 07-09

THE INFLUENCE OF LONG-TERM PREMEDICATION WITH TRANYLCYPROMINE ON EXPERIMENTAL PSYCHOSES INDUCED BY LSD.
070954 07-12

THE INFLUENCE OF THE GANGLIONIC BLOCKING AGENT GANLION ON VISCEROVISCERAL AND VISCEROCEREBRAL REACTIONS OF THE CAT.
071703 07-03

SCOPOLAMINE EFFECTS ON CONDITIONED SUPPRESSION: INFLUENCE OF DIURNAL CYCLE AND TRANSITIONS BETWEEN NORMAL AND DRUGGED STATES.
071790 07-03

THE INFLUENCE OF SINGLE AND CHRONIC MORPHINE ADMINISTRATION ON SOME CENTRAL EFFECTS OF AMPHETAMINE AND APOMORPHINE.
075840 08-05

ANTAGONISTIC INFLUENCE OF BETA-SYMPATHICOLYTICS ON THE METAMPHETAMINE INDUCED CHANGES IN FUNCTION AND METABOLISM OF THE BRAIN.
079954 09-03

STUDIES IN MAN ON THE INFLUENCE OF A NEW PSYCHOPHARMACEUTICAL DRUG, 1-((METHYLAMINO) DIBENZOBICYCLOOCTADIENE HYDROCHLORIDE, ON THE CO2 SENSITIVE CENTRAL RESPIRATORY REGULATION.
079971 09-07

INFLUENCE OF CENTROPHENOXIN ON MEMORY DISTURBANCE AFTER ELECTROSHOCK.
079993 09-08

THE INFLUENCE OF A FEAR EVOKING SITUATION ON THE RECTAL TEMPERATURE OF RATS.
082409 10-03

SOME BEHAVIOURAL EFFECTS OF VARIABLES WHICH INFLUENCE THE GENERAL LEVEL OF ACTIVITY OF RATS.
085204 10-04

THE INFLUENCE OF IMIPRAMINE, DEXPHENMETRAZINE AND AMPHETAMINE SULPHATE ON SYNCHRONOUS AND PARADOXICAL SLEEP IN NARCOLEPSY CATAPLEXY. A POLYGRAPHIC EXAMINATION.
089037 10-14

INFLUENCE OF THYMOLEPTIC THERAPY ON THE COURSE OF ENDOGENOUS DEPRESSIONS.
089102 10-17

INFLUENCE OF SEVERAL AUTONOMIC DRUGS ON SODIUM NITROPRUSSIDE AND OXOTREMORINE INDUCED HYPOTHERMIA IN IMMATURE AND MATURE MICE.
089436 11-03

THE INFLUENCE OF LITHIUM ION ON THE ADRENOCORTICAL FUNCTION OF RATS.
089787 11-09

INFLUENCE OF AMINAZIN ON ADRENALIN, NORADRENALINE, DOPAMINE, AND DOPA EXCRETION IN HEALTHY PEOPLE AND IN THE MANIC PHASE OF THE MANIC-DEPRESSIVE PSYCHOSIS.
090355 11-03

SCOPOLAMINE EFFECTS ON GO-NO-GO AVOIDANCE DISCRIMINATIONS: INFLUENCE OF STIMULUS FACTORS AND PRIMACY OF TRAINING.
090418 11-04

CHANGES IN BEHAVIOUR WITH REPEATED TESTING UNDER THE INFLUENCE OF DRUGS: DRUG EXPERIENCE INTERACTIONS.
091997 11-04

INFLUENCE OF CHRONIC ADMINISTRATION OF NICOTINE ON THE TURNOVER AND METABOLISM OF NORADRENALINE IN THE RAT BRAIN.
097958 11-03

INVESTIGATION INTO THE POSSIBLE INFLUENCE OF CHLORINATED AMPHETAMINE DERIVATIVES ON 5-HYDROXYTRYPTAMINE SYNTHESIS IN MAN.
097963 11-13

INFLUENCE OF IMIPRAMINE, BENACTYZINE AND PROMAZINE ON THE EFFECTS OF INTRAAMYGDALOID INJECTION OF ACETYLCHOLINE AND SEROTONIN.
098024 11-04

THE INFLUENCE OF 5-HYDROXYTRYPTOPHAN ON THE BEHAVIOR AND THE LEVEL OF MONOAMINES IN THE BRAIN OF RATS SENSITIVE TO SOUND.
098040 11-03

INFLUENCE OF HAPLOPHYLLUM ALKALOIDS ON THE BODY TEMPERATURE OF ANIMALS.
105721 12-03

INFLUENCE OF ISONIAZID ON THE CENTRAL NERVOUS SYSTEM; THE ANTAGONISM BETWEEN ISONIAZID AND PYRIDOXINE, PANTOTHENIC ACID AND COUMARIN IN RATS (MELILOTUS-OFFICINALIS).
126055 12-04

LEARNING ABILITY IN EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY UNDER THE INFLUENCE OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126056 12-04

**INFLUENCES**

INFLUENCES OF POLYPHARMACY ON HALLUCINATORY BEHAVIOR IN A SAMPLE OF FEMALE CHRONIC SCHIZOPHRENIC PATIENTS.
115037 12-08

THE INFLUENCES OF THE STANDARD PREFRONTAL LOBOTOMY OPERATION ON HALLUCINATORY PHENOMENA ASSOCIATED WITH PSYCHOTOMIMETIC DRUGS.
120899 12-13

**INFLUENCING**

BEHAVIORAL VARIABLES INFLUENCING DRUG SELF-ADMINISTRATION.
046206 01-04

INHIBITION OF THE STIMULATING EFFECT OF METHAMPHETAMINE AND MORPHINE ON MOUSE BY INFLUENCING THE ENDOGENOUS CATECHOLAMINES.
055739 02-03

SOME FACTORS INFLUENCING THE RELEASE OF 5-HYDROXYINDOL-3-YLACETIC ACID IN THE FOREBRAIN.
067598 06-03

DRUGS INFLUENCING THE CHOLINERGIC SYSTEM AND THE PROCESS OF LEARNING AND MEMORY IN MAN.
070955 07-14

**INFORMATION**

DOXEPIN HCL (SINEQUAN) -- CURRENT INFORMATION.
068203 06-13

**INFRARED**

INFRARED IDENTIFICATION OF SOME HALLUCINOGENIC DERIVATIVES OF TRYPTAMINE AND AMPHETAMINE.
058877 02-01

**INFUSED**

EFFECTS OF INFUSED TRYPTAMINE IN MAN.
069053 06-13

**INGESTION**

IMPAIRMENT OF SHOCK AVOIDANCE LEARNING AFTER LONG-TERM ALCOHOL INGESTION IN MICE.
058492 02-04

ATTEMPTED SUICIDE BY DRUG INGESTION.
063277 03-15

EMERGENCY TREATMENT OF DRUG ABUSE AND POISON INGESTION.
066395 05-15

EFFECTS OF INTRAPERITONEAL INJECTION OF ETHANOL ON ETHANOL INGESTION OF C57BL MICE.
075957 09-02

URINARY EXCRETION OF ADRENAL HORMONES IN MAN: EFFECTS OF ETHANOL INGESTION, AND THEIR MODIFICATION BY CHLORMETHIAZOLE.
097974 11-11

**INH**

ISONICOTINIC-ACID-HYDRAZIDE (INH) INDUCED MENTAL DISORDERS IN THE COURSE OF LUNG TUBERCULOSIS TREATMENT.
072890 08-15

**INHALATION**

EFFECT OF METHYLCHLOROFORM INHALATION ON BARBITURATE HYPNOSIS AND HEPATIC DRUG METABOLISM IN MALE MICE.
068978 06-03

**INHIBIT**

INHIBITION OF THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN RATS BY DRUGS WHICH INHIBIT RIBONUCLEIC ACID OR PROTEIN SYNTHESIS.
041570 01-03

MECHANISMS BY WHICH AMPHETAMINE AND DESIPRAMINE INHIBIT THE METARAMINOL INDUCED RELEASE OF NOREPINEPHRINE FROM SYMPATHETIC NERVE ENDINGS IN RAT HEART.
064427 04-03

PHARMACOLOGIC ACTIVITY OF A NEW CLASS OF AGENTS WHICH SELECTIVELY INHIBIT AGGRESSIVE BEHAVIOR IN RATS.
082398 10-04

EXPERIMENTAL STUDIES ON THE EFFECTIVE PROCEDURE TO INHIBIT THE DEVELOPMENT OF TOLERANCE TO AND DEPENDENCE ON MORPHINE.
089789 11-02

**INHIBITED**

DEPHOSPHORYLATION IN VIVO OF BRAIN ACETYLCHOLINESTERASE INHIBITED BY ISOPROPYL METHYLPHOSPHONOFLUORIDATE (SARIN).
046188 01-03

EFFECT OF A DECARBOXYLASE INHIBITOR (RO-4-4602), COMBINED WITH L-DOPA, ON INHIBITED DEPRESSIVE PATIENTS: II. EXPERIMENTAL PSYCHOLOGICAL STUDIES.
079964 09-14

**INHIBITION**

URINARY METABOLITES OF HARMINE IN THE RAT AND THEIR INHIBITION OF MONOAMINE OXIDASE.
040417 01-03

POTENTIATION AND INHIBITION OF SOME CENTRAL ACTIONS OF L(-) DOPA BY DECARBOXYLASE INHIBITORS.
040750 01-03

INHIBITION OF THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN RATS BY DRUGS WHICH INHIBIT RIBONUCLEIC ACID OR PROTEIN SYNTHESIS.
041570 01-03

INHIBITION OF THE RE-UPTAKE OF NEURONALLY LIBERATED NORADRENALINE AND ALPHA-RECEPTOR BLOCKING ACTION OF SOME ERGOT ALKALOIDS.
041967 01-03

INHIBITION OF THE STIMULATING EFFECT OF METHAMPHETAMINE AND MORPHINE ON MOUSE BY INFLUENCING THE ENDOGENOUS CATECHOLAMINES.
055739 02-03

BLOCKADE OF NORADRENALINE UPTAKE AND INHIBITION OF GASTRIC ACID SECRETION BY 2-(P-CHLOROPHENYL-2-(PYRIDYL)HYDROXYMETHYL) IMIDAZOLINE MALEATE (SCH-12650).
058878 02-02

L-DOPA INDUCED CHANGES IN CENTRAL MONOAMINE NEURONS AFTER PERIPHERAL DECARBOXYLASE INHIBITION.
059033 03-03

INTERFERENCE OF BARBITURATES WITH PYRIMIDINE INCORPORATION -- II: STRUCTURAL SPECIFICITY OF THE INHIBITION OF OROTATE UPTAKE IN BACILLUS-CEREUS.
064046 04-03

INHIBITION OF CIGARETTE SMOKING BY ORALLY ADMINISTERED NICOTINE.
066277 05-13

ALTERED ABSORPTION OF DRUGS FROM THE RAT SMALL INTESTINE BY CARBONIC ANHYDRASE INHIBITION.
066369 05-03

INHIBITION OF CATECHOLAMINE UPTAKE BY 6-HYDROXYDOPAMINE IN RAT BRAIN.
066501 05-03

INHIBITION BY P-CHLOROAMPHETAMINE OF THE CONVERSION OF 5-HYDROXYTRYPTAMINE TO 5-HYDROXYINDOLEACETIC ACID IN RAT BRAIN.
066507 05-03

INHIBITION BY PROPRANOLOL OF ETHANOL INDUCED NARCOSIS.
066510 05-03

THE INHIBITION OF CATECHOLAMINE BIOSYNTHESIS BY APOMORPHINE.
066854 05-03

CATECHOLAMINE ACCUMULATION IN TISSUES OF THIAMINE-DEFICIENT RATS AFTER INHIBITION OF MONOAMINE OXIDASE.
067243 06-03

THE EFFECT OF INHIBITION OF CATECHOLAMINE SYNTHESIS ON DEXAMPHETAMINE INDUCED CENTRAL STIMULATION.
067259 06-04

DEPRESSANT EFFECT OF DELTA1-TETRAHYDROCANNABINOL ENHANCED BY INHIBITION OF ITS METABOLISM.
070443 07-03

INHIBITION OF HEPATIC HEXOBARBITAL METABOLISM BY DEXTROAMPHETAMINE.
076186 09-03

BEHAVIORAL EFFECTS OF P-CHLOROPHENYLALANINE IN RATS: INHIBITION BY LITHIUM.
081112 09-03

A STUDY OF HEPATIC ALCOHOL DEHYDROGENASE INHIBITION (ADH) INDUCED BY PYRAZOL: II. THE ROLE OF LIVER ADH IN THE IN VIVO METABOLISM OF HYDROXYL COMPOUNDS.
089547 11-03

A STUDY OF HEPATIC ALCOHOL DEHYDROGENASE INHIBITION INDUCED BY PYRAZOL: I. IN VIVO ACTION ON ETHANOL AND 2-PHENYLETHANOL.
089548 11-03

CYCLIC AMP MEDIATION OF NOREPINEPHRINE INHIBITION IN RAT CEREBELLAR CORTEX: A UNIQUE CLASS OF SYNAPTIC RESPONSES (UNPUBLISHED PAPER).
093132 11-03

INHIBITION BY DRUGS OF SMOKING BEHAVIOUR IN MONKEYS.
095351 11-03

INHIBITION OF CENTRAL SEROTONINERGIC EXCITATION (5-HYDROXYTRYPTOPHAN INDUCED DEAD TWITCHES) IN MICE BY LITHIUM.
097989 11-04

**INHIBITOR**

CHANGES IN EMOTIONAL BEHAVIOUR AFTER APPLICATION OF CHOLINESTERASE INHIBITOR IN THE SEPTAL AND AMYGDALA REGION.
040578 01-04

BEHAVIORAL AND BRAIN CATECHOLAMINE DEPLETING ACTIONS OF U-14624, AN INHIBITOR OF DOPAMINE BETA-HYDROXYLASE.
058986 03-03

EFFECTS OF A CHOLINE ACETYLTRANSFERASE INHIBITOR ON SELF-STIMULATORY BEHAVIOR IN THE RAT.
058993 03-04

EXCRETION OF VANYLGLYCOL IN HUMAN URINE UNDER DIETARY CONTROL, AND DURING TREATMENT WITH ANTIBIOTICS, DISULFIRAM, A MONOAMINE OXIDASE INHIBITOR, ALPHA-METHYLDOPA, AND RESERPINE.
060272 03-13

INTERACTIONS BETWEEN SYMPATHOMIMETIC AMINES AND A NEW MONOAMINE OXIDASE INHIBITOR.
064406 04-07

L-DOPA PLUS DECARBOXYLASE INHIBITOR IN DEPRESSION.
066322 05-09

ADMINISTRATION OF A PERIPHERAL DECARBOXYLASE INHIBITOR WITH L-DOPA TO DEPRESSED PATIENTS.
067591 06-09

COMPARATIVE TRIAL OF A NEW MONOAMINE OXIDASE INHIBITOR IN DEPRESSION.
069057 06-10

EFFECT OF A DECARBOXYLASE INHIBITOR (RO-4-4602), COMBINED WITH L-DOPA, ON INHIBITED DEPRESSIVE PATIENTS: II. EXPERIMENTAL PSYCHOLOGICAL STUDIES.
079964 09-14

EFFECT OF A DECARBOXYLASE INHIBITOR (RO-4-4602), COMBINED WITH L-DOPA, ON RETARDED DEPRESSIVE PATIENTS.
079965 09-13

EFFECT OF L-DOPA ALONE AND IN COMBINATION WITH AN EXTRACEREBRAL DECARBOXYLASE INHIBITOR ON BLOOD PRESSURE AND SOME CARDIOVASCULAR REFLEXES.
090371 11-13

ON THE ANALYSIS OF 5-HYDROXYTRYPTOPHAN PRODUCED HYPERTHERMIA IN MICE PRETREATED WITH A MONOAMINE OXIDASE INHIBITOR NIAMID.
098035 11-03

TREATMENT AND PROPHYLAXIS OF MANIC STATES WITH A CARBONIC ANHYDRASE INHIBITOR.
105731 12-14

**INHIBITORS**

EFFECTS OF METABOLIC INHIBITORS ON NOREPINEPHRINE RELEASE FROM THE PERFUSED SPLEEN OF THE CAT.
040244 01-03

EFFECTS OF TWO CHOLINESTERASE INHIBITORS ON ACETYLCHOLINE RELEASE FROM THE GUINEA-PIG ISOLATED ILEUM PREPARATION.
040572 01-03

POTENTIATION AND INHIBITION OF SOME CENTRAL ACTIONS OF L(-) DOPA BY DECARBOXYLASE INHIBITORS.
040750 01-03

EFFECTS OF MONOAMINE OXIDASE INHIBITORS AND AMPHETAMINE ON HYPOTHERMIA PRODUCED BY HALOTHANE.
041569 01-03

SPECIFIC IRREVERSIBLE ENZYME INHIBITORS.
051115 01-17

INHIBITORS OF ADRENAL STEROID BIOSYNTHESIS.
051122 02-17

TREATMENT OF NARCOLEPSY WITH MONOAMINE OXIDASE INHIBITORS AND SYMPATHOMIMETIC AGENTS.
058327 02-13

SPECIAL APPLICATION OF FLUORESCENCE HISTOCHEMISTRY: STUDIES ON EIGHT MONOAMINE OXIDASE INHIBITORS IN BRAIN NEURONS.
063989 04-06

EFFECT OF INHIBITORS AND INDUCERS OF DRUG METABOLISM ON ETHANOL METABOLISM IN VIVO.
064052 04-03

MONOAMINE OXIDASE INHIBITORS, COMBINED WITH THYMOLEPTICS: ARE THEY REALLY UNUSABLE FOR HUMAN BEINGS.
066805 05-03

PROTEIN AND RNA INHIBITORS AND PROTOZOAN HABITUATION.
066813 05-04

MONOAMINE OXIDASE INHIBITORS AND L-DOPA.
067657 06-15

MONOAMINE OXIDASE INHIBITORS.
068175 06-15

PSYCHOPHARMACOLOGIC EFFECTS OF SOME CHOLINESTERASE INHIBITORS IN COMPARISON WITH IMIPRAMINE.
069074 06-04

THE EFFECT OF SOME INHIBITORS AND METABOLITES OF CATECHOLAMINE ON THE PROCESSES OF FIXATION AND REPRODUCTION OF MEMORY TRACES.
073716 08-03

INHIBITORS OF MONOAMINE OXIDASE VI: EFFECTS OF SUBSTITUTION ON INHIBITORY ACTIVITY OF 6 (OR 8) SUBSTITUTED BETA-CARBOLINES.
090426 11-01

ON THE ROLE OF BRAIN CATECHOLAMINES IN MOTOR ACTIVITY: EXPERIMENTS WITH INHIBITORS OF SYNTHESIS AND OF MONOAMINE OXIDASE.
097960 11-04
MONOAMINE OXIDASE INHIBITORS AND CORONARY INSUFFICIENCY.
133861 12-13

**INHIBITORY**
THE ROLE OF PLASMA PROTEIN BINDING IN THE INHIBITORY EFFECT OF NORTRIPTYLINE ON THE NEURONAL UPTAKE OF NOREPINEPHRINE.
066278 05-03
INHIBITORY EFFECT OF PROPRANOLOL ON THE VASOCONSTRICTOR RESPONSE TO SYMPATHETIC NERVE STIMULATION.
066506 05-03
THE INHIBITORY EFFECT OF AMPHETAMINE ON EXPLORATION IN MICE.
069080 06-04
INHIBITORY EFFECT OF TWO NEWER ANTIDEPRESSANTS, LU-5-003 AND LU-3-010, ON SEROTONIN UPTAKE IN HUMAN BLOOD PLATELETS IN VITRO.
071791 07-03
THE EXCITATORY AND INHIBITORY INNERVATION OF THE STOMACHS OF THE DOMESTIC FOWL.
074854 08-03
INHIBITORS OF MONOAMINE OXIDASE VI: EFFECTS OF SUBSTITUTION ON INHIBITORY ACTIVITY OF 6 (OR 8) SUBSTITUTED BETA-CARBOLINES.
090426 11-01
INDICATIONS FOR INHIBITORY MEDICATIONS.
091076 11-11
INHIBITORY FUNCTIONS OF THE SEPTUM AND AMYGDALA.
095697 11-03

**INITIAL**
THE CONDUCT OF INITIAL DRUG STUDIES IN MAN.
051593 02-17
INITIAL SUPPRESSION OF THE LOCOMOTOR STIMULANT RESPONSE TO DEXAMPHETAMINE IN RATS EXPOSED TO A NOVEL ENVIRONMENT.
067601 06-04
INITIAL AND INTERVAL TREATMENT OF ACUTE PSYCHOSES WITH INTRAVENOUS INJECTION OF INOFAL.
073708 08-09
ON THE QUESTION OF PERSONALITY DEFECTS OF CONSCIOUSNESS IN INITIAL STAGES IN SCHIZOPHRENIA.
090264 11-08
ON THE QUESTION OF THE PROPHYLAXIS OF INITIAL MANIFESTATIONS OF PRESENILE PSYCHOSES.
110105 12-17

**INITIATIVE**
LITHIUM VERSUS CHLORPROMAZINE FOR MANICS. INITIATIVE AND PRODUCTIVITY VERSUS TRANQUILIZATION HOSPITALIZATION.
063209 03-09

**INJECTABLE**
A PILOT STUDY OF INJECTABLE DIAZEPAM IN A GENERAL HOSPITAL SETTING.
072397 07-07
NEW IN PSYCHIATRY: MODITEN INJECTABLE THERAPY AND FOLLOW-UP CARE.
072787 08-11
THE USE OF INJECTABLE MEDAZEPAM (PRELIMINARY NOTE).
086977 10-07

**INJECTED**
THE EFFECT OF BRADYKININ AND ELEDOISIN INJECTED INTO THE CEREBRAL VENTRICLES OF CONSCIOUS RATS.
047323 01-04
ACETYLCHOLINE RELEASE FROM CORTICAL BRAIN SLICES OF RATS INJECTED WITH LITHIUM.
066509 05-03
COMPARISON OF DRINKING ELICTED BY ESERINE OR DFP INJECTED INTO PREOPTIC AREA OF RAT BRAIN.
069637 07-04
EFFECTS OF SYMPATHOMIMETIC AMINES INJECTED INTO THE THIRD CEREBRAL VENTRICLE IN ADULT CHICKENS.
072030 07-03
EFFECT OF DIAZEPAM ON FATE OF INTRACISTERNALLY INJECTED SEROTONIN-C14.
072031 07-03
CLINICAL EXPERIENCE WITH 10MG RESERPINE INJECTED I.M.IN DEPRESSIVE DISORDERS.
100019 11-09
ANALGESIC EFFECT OF MORPHINE HYDROCHLORIDE INJECTED DIRECTLY INTO THE VENTRICLE OF MOUSE BRAIN.
130422 12-03

**INJECTION**
MEMORY ENHANCEMENT OF A PARTLY LEARNED DISCRIMINATION IN PIGEONS BY INTRAMUSCULAR INJECTION OF PHYSOSTIGMINE.
060858 03-04
FORGETTING OF AN OPERANT RESPONSE: PHYSOSTIGMINE PRODUCED INCREASES IN ESCAPE LATENCY IN RATS AS A FUNCTION OF TIME OF INJECTION.
061540 03-04
INDUCTION OF RECEPTIVITY IN OVARIECTOMIZED FEMALE RATS BY A SINGLE INTRAVENOUS INJECTION OF ESTRADIOL-17BETA.
067696 06-04
INITIAL AND INTERVAL TREATMENT OF ACUTE PSYCHOSES WITH INTRAVENOUS INJECTION OF INOFAL.
073708 08-09
PLASMA FREE FATTY ACIDS BEFORE AND AFTER AN INTRAVENOUS INSULIN INJECTION IN ACUTE SCHIZOPHRENIC MEN.
075212 08-08
EFFECTS OF INTRAPERITONEAL INJECTION OF ETHANOL ON ETHANOL INGESTION OF C57BL MICE.
075957 09-02
CORRELATION BETWEEN THE CHANGES OF EEG, PUPILLES AND BLOOD PRESSURE DUE TO INTRAVENOUS INJECTION OF CHLORPROMAZINE: CHLORPROMAZINE TEST.
088611 10-13
PERMEATION CHARACTERISTICS OF MORPHINE-LIKE SUBSTANCES AFTER INJECTION INTO BRAIN TISSUE AND INTO THE VENTRICULAR SYSTEM.
089047 10-03
INFLUENCE OF IMIPRAMINE, BENACTYZINE AND PROMAZINE ON THE EFFECTS OF INTRAAMYGDALOID INJECTION OF ACETYLCHOLINE AND SEROTONIN.
098024 11-04

**INJECTIONS**
EXPERIMENTAL VARIABLES IN THE EFFECTS OF POSTSESSION INJECTIONS OF STRYCHNINE SULPHATE ON A CLASSICALLY CONDITIONED RESPONSE.
071792 07-04

**INJURY**
CHANGES IN D-AMPHETAMINE REACTIVITY RESULTING FROM SEPTAL FOREBRAIN INJURY.
067695 06-04
A POSSIBLE PATHWAY FOR ETHANOL INDUCED FATTY LIVER AND MODIFICATION OF LIVER INJURY BY ANTIOXIDANTS.
070906 07-05
SPECIFIC (IN THE SENSE OF INCREASED PREDISPOSITION TO INJURY OF THE SUBDOMINANT HEMISPHERE) DISTRIBUTION OF THE EXTRAPYRAMIDAL SYMPTOMS IN SCHIZOPHRENICS DURING THE COURSE OF HALOPERIDOL TREATMENT.
089106 10-15

**INNERVATION**
THE EXCITATORY AND INHIBITORY INNERVATION OF THE STOMACHS OF THE DOMESTIC FOWL.
074854 08-03

**INOFAL**
INITIAL AND INTERVAL TREATMENT OF ACUTE PSYCHOSES WITH INTRAVENOUS INJECTION OF INOFAL.
073708 08-09

**INPATIENT**
SEVERE DELIRIUM AFTER ABRUPT WITHDRAWAL OF THIOTHIXENE IN A CHRONIC SCHIZOPHRENIC INPATIENT: A CASE STUDY.
067221 06-08
VALUE OF AMITRIPTYLINE SPOFA IN THE PSYCHIATRIC OUTPATIENT AND INPATIENT PRACTICE.
070944 07-09
A SURVEY OF EXTRAPYRAMIDAL MANIFESTATIONS IN THE INPATIENT POPULATION OF A PSYCHIATRIC HOSPITAL.
086444 10-15

**INPATIENTS**
MANDRAX AS AN HYPNOTIC FOR PSYCHIATRIC INPATIENTS: A COMPARATIVE TRIAL WITH CHLORAL HYDRATE.
061562 03-14
FLUPHENAZINE ENANTHATE GIVEN TO INPATIENTS AND OUTPATIENTS.
065480 05-09

**INSECT**
BIOCHEMICAL CHANGES DURING LEARNING IN AN INSECT GANGLION.
084758 10-04

**INSOMNIAC**
HYPNOTIC DRUGS AND THEIR EFFECTIVENESS: ALL-NIGHT EEG STUDIES OF INSOMNIAC SUBJECTS.
066235 05-14

**INSOMNIACS**
A COMPARATIVE STUDY OF THE EFFECTS OF METHAQUALONE AND GLUTETHIMIDE ON SLEEP IN MALE CHRONIC INSOMNIACS.
063879 04-14
TO SLEEP, PERCHANCE TO DREAM: NEW DRUG FOR INSOMNIACS DOESNT INTERFERE WITH REM TIME.
068021 06-14

**INSTANT**
MODEL PSYCHOSIS OR INSTANT ZEN.
046730 01-12

**INSTITUTIONAL**
INSTITUTIONAL MANAGEMENT OF CHRONIC SCHIZOPHRENICS WITH FLUPHENAZINE DECANOATE.
065474 05-07

**INSTITUTIONALIZED**
PIPERACETAZINE (QUIDE) IN THE MANAGEMENT OF BEHAVIORAL DISORDERS IN MILDLY RETARDED INSTITUTIONALIZED BOYS.
069071 06-11

**INSTRUCTIONS**
EFFECTS OF INSTRUCTIONS AND DRUG ADMINISTRATION ON TEMPORAL RESOLUTION OF PAIRED FLASHES.
075771 08-14

**INSTRUMENT**
AN IMPROVED INSTRUMENT FOR IMPLANTING MICROPELLETS IN THE BRAIN.
058358 02-06

**INSTRUMENTAL**
MAGNESIUM PEMOLINE: SPECIFICITY OF EFFECTS ON INSTRUMENTAL AVOIDANCE LEARNING.
058430 02-04
EFFECT OF IMIPRAMINE AND CHLORIMIPRAMINE ON AN ACUTE INSTRUMENTAL TRACE CONDITIONED REFLEX IN RATS.
064415 04-04

**INSUFFICIENCY**
MONOAMINE OXIDASE INHIBITORS AND CORONARY INSUFFICIENCY.
133861 12-13

**INSULIN**
STATISTICAL METHOD OF ANALYSIS AND EVALUATION OF PSYCHOTHERAPEUTIC RESULTS: APPLICATION OF A LONG-ACTING NEUROLEPTIC, COMPARED WITH A STANDARD NEUROLEPTIC AND THE SAKEL INSULIN TREATMENT.
042676 01-07
FOUR EFFECTS OF EXOGENOUS INSULIN ON FOOD INTAKE.
061572 03-03
PLASMA FREE FATTY ACIDS BEFORE AND AFTER AN INTRAVENOUS INSULIN INJECTION IN ACUTE SCHIZOPHRENIC MEN.
075212 08-08
MILD INSULIN HYPOGLYCEMIC TREATMENT FOR HOSPITALIZED ADOLESCENTS.
082172 10-11
EFFECTS OF INSULIN, METRAZOL, AND ELECTROCONVULSIVE SHOCKS UPON LEARNING TO LEARN 30 SUCCESSIVE REVERSAL PROBLEMS BY RATS.
095188 11-04
THE EFFECTIVENESS OF SIMULTANEOUS TREATMENT WITH VITAMIN-B12 AND INSULIN IN SCHIZOPHRENIC PATIENTS, ACCORDING TO THE FREQUENCY OF STABLE REMISSIONS.
096513 11-08

**INTACT**
ELECTROCORTICAL REACTIONS OF PINEALECTOMIZED AND INTACT RATS TO LETHAL DOSES OF PENTOBARBITAL.
064101 04-03
ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL EFFECTS OF HARMALINE IN INTACT CATS AND IN CATS WITH CHRONIC MESENCEPHALIC TRANSECTION.
075847 09-04
EFFECTS OF DRUGS ACTING ALONE AND IN COMBINATION ON THE MOTOR ACTIVITY OF INTACT MICE.
090139 11-03

**INTAKE**
FOUR EFFECTS OF EXOGENOUS INSULIN ON FOOD INTAKE.
061572 03-03
LYSERGIC ACID DIETHYLAMIDE INTAKE IN PREGNANCY: FETAL DAMAGE IN RATS.
064422 04-05
DRUG ANTAGONISM AND WATER INTAKE.
067703 06-04
FLUID INTAKE AND PUNISHMENT ATTENUATING DRUGS.
067704 06-04
MODULATION OF FOOD INTAKE AND LOCOMOTOR ACTIVITY IN FEMALE RATS BY DIENCEPHALIC HORMONE IMPLANTS.
076080 09-04
DEVELOPMENT OF HORMONAL CONTROL OVER FOOD INTAKE AND BODY WEIGHT IN FEMALE RATS.
076239 09-03
INTERACTIONS BETWEEN THE EFFECTS OF CHLORDIAZEPOXIDE AND AMPHETAMINE ON FOOD INTAKE AND SPONTANEOUS MOTOR ACTIVITY IN THE RAT.
092692 11-04
ANTIEPILEPTIC DOSING AFTER EXCESSIVE ALCOHOL INTAKE.
093919 11-11
BRAIN DAMAGE IN INFANT MICE FOLLOWING ORAL INTAKE OF GLUTAMATE, ASPARTATE OR CYSTEINE.
094164 11-05

**INTEGRITY**
ORGANIC INTEGRITY TEST (OIT) IN MONITORING DRUG EFFECTS.
063596 04-08

**INTELLIGENCE**
THE EFFECTS OF AN AMPHETAMINE ON MEASURES OF INTELLIGENCE AND LEARNING IN MENTALLY RETARDED ADULTS. (PH.D.DISSERTATION).
103152 12-14

**INTENSIVE**
DRUG PERSONALITY INTERACTION IN INTENSIVE OUTPATIENT TREATMENT.
047836 01-10
THE PERFECT SET UP: A STUDY OF INTENSIVE SERVICE.
059275 03-11
A DOUBLE-BLIND INTENSIVE CROSSOVER DESIGN TRIAL OF METHYSERGIDE IN MANIA.
085327 10-09

**INTERACTING**
EFFECT OF AGENTS INTERACTING WITH CHOLINOREACTIVE AND ADRENOREACTIVE SYSTEMS ON EPILEPTIFORM ACTIVITY IN THE HIPPOCAMPUS OF RABBITS.
110631 12-03

**INTERACTION**
THE EFFECT OF P-CHLOROPHENYLALANINE ON SOCIAL INTERACTION OF MALE RATS.
041541 01-04
COMPLEXES OF ERGOT ALKALOIDS AND DERIVATIVES. II: INTERACTION OF DIHYDROERGOTOXINE WITH CERTAIN XANTHINES.
046137 01-03
DRUG PERSONALITY INTERACTION IN INTENSIVE OUTPATIENT TREATMENT.
047836 01-10
THE INTERACTION OF ETHANOL AND AMPHETAMINE METABOLISM.
063062 03-03
THE INTERACTION OF PSYCHOLOGIC STIMULI AND PHARMACOLOGIC AGENTS ON AIRWAY REACTIVITY IN ASTHMATIC SUBJECTS.
063515 03-13
EFFECTS OF MORPHINE TREATMENT AND STARVATION ON THE SUBSTRATE INTERACTION WITH P-450 IN THE OXIDATION OF DRUGS BY LIVER MICROSOMES.
063982 04-03
RELATIONSHIP BETWEEN DIFFERENCE SPECTRA AND METABOLISM: BARBITURATES, DRUG INTERACTION AND SPECIES DIFFERENCE.
064001 04-03
INTERACTION BETWEEN RESERPINE AND DESMETHYLIMIPRAMINE.
064254 04-03
INTERACTION OF COMMONLY PRESCRIBED DRUGS AND WARFARIN.
064622 04-15
AMANTADINE DOPAMINE INTERACTION: POSSIBLE MODE OF ACTION IN PARKINSONISM.
066315 05-03
A STUDY OF THE INTERACTION OF THE HYPNOTIC EFFECTS AND OF THE TOXIC EFFECTS OF CHLORAL HYDRATE AND ETHANOL.
066365 05-03
COMPARATIVE PHARMACOPSYCHOLOGICAL STUDY OF THE EFFECTS PRODUCED BY PSYCHOPHARMACEUTICALS ON VERBAL INTERACTION IN A GROUP OF STUDENTS.
066954 05-14
INTERACTION BETWEEN INTRAVENOUS ALCOHOL AND SOME SEDATIVES AND TRANQUILLIZERS.
067607 06-03
INTERACTION OF CHLORPROMAZINE AND TISSUE BINDING SITES: PRELIMINARY STUDIES.
069367 06-03
INTERACTION OF SOME PSYCHOTROPIC DRUGS WITH ANALGESICS.
070948 07-04
PERSISTENCE OF A DRUG PERSONALITY INTERACTION IN PSYCHIATRIC OUTPATIENTS.
075873 09-14

**INTERACTIONS**
INTERACTIONS BETWEEN ALCOHOL AND DRUGS.
057032 02-04
INTERACTIONS BETWEEN SYMPATHOMIMETIC AMINES AND A NEW MONOAMINE OXIDASE INHIBITOR.
064406 04-07
INTERACTIONS OF DELTA1-TETRAHYDROCANNABINOL WITH BARBITURATES AND METHAMPHETAMINE.
064424 04-04
DRUG COMBINATIONS AND INTERACTIONS.
065418 05-13
INTERACTIONS BETWEEN CERTAIN DRUGS USED PREOPERATIVELY AND ANESTHETIC AGENTS.
066890 05-15
ALCOHOL DRUG INTERACTIONS.
068412 06-13
STUDIES ON INTERACTIONS INVOLVING ANTIDEPRESSIVE AND OTHER DRUGS WITH TETRABENAZINE AND NORADNAMINE ON LOCOMOTOR ACTIVITY IN MICE, INCLUDING DETAILS OF THE EXPERIMENTAL DESIGN AND STATISTICAL ANALYSIS.
069077 06-04
A PRACTICAL GUIDE TO DRUG INTERACTIONS.
070899 07-15
CHANGES IN BEHAVIOUR WITH REPEATED TESTING UNDER THE INFLUENCE OF DRUGS: DRUG EXPERIENCE INTERACTIONS.
091997 11-04

INTERACTIONS BETWEEN THE EFFECTS OF CHLORDIAZEPOXIDE AND AMPHETAMINE ON FOOD INTAKE AND SPONTANEOUS MOTOR ACTIVITY IN THE RAT.
092692 11-04

**INTERCLINICAL**
2-CHLORO-11-(4-METHYLPIPERAZINO) DIBENZOXAZEPINE), (SUM-3170), A NEW NEUROLEPTIC SUBSTANCE: RESULTS OF AN INTERCLINICAL STUDY.
079986 09-07

**INTERDISCIPLINARY**
THE NEUROLEPTICS: AN INTERDISCIPLINARY ATTEMPT OF SYNTHESIS, BASED ON THE NEUROLEPTICS.
075115 08-14

**INTERESTING**
AN INTERESTING TISSULARY THERAPEUTIC METHOD IN GERIATRICS: BOGOMOLETZ SERUM (BERNAS CYTOTOXIC SERUM).
105551 12-11

**INTERFERE**
TO SLEEP, PERCHANCE TO DREAM: NEW DRUG FOR INSOMNIACS DOESNT INTERFERE WITH REM TIME.
068021 06-14

**INTERFERENCE**
INTERFERENCE OF BARBITURATES WITH PYRIMIDINE INCORPORATION -- III: STUDIES ON THE MECHANISM OF THE AMOBARBITAL OROTATE RELATIONSHIP.
064045 04-03

INTERFERENCE OF BARBITURATES WITH PYRIMIDINE INCORPORATION -- II: STRUCTURAL SPECIFICITY OF THE INHIBITION OF OROTATE UPTAKE IN BACILLUS-CEREUS.
064046 04-03

REDUCTION OF ELECTRICALLY REWARDED BEHAVIOR BY INTERFERENCE WITH MONOAMINE SYNTHESIS.
069065 06-04

**INTERMITTENT**
STOOL PORPHYRINS IN ACUTE INTERMITTENT AND HEREDITARY COPROPORPHYRIA: ADVERSE EFFECTS OF TRANQUILIZERS.
066318 05-15

EFFECT OF INTERMITTENT NERVE STIMULATION ON NOREPINEPHRINE SYNTHESIS AND MOBILIZATION IN THE PERFUSED CAT SPLEEN.
080337 09-01

**INTERNAL**
THE EMPLOYMENT OF A NEW BENZODIAZEPINE, RO-5-4556 IN INTERNAL MEDICINE.
058312 02-11

EFFECTS OF SCOPOLAMINE, ATROPINE, AND D-AMPHETAMINE ON INTERNAL AND EXTERNAL CONTROL OF RESPONDING ON NON-REINFORCED TRIALS.
064410 04-04

TREATMENT OF PSYCHOSOMATIC DISTURBANCES ASSOCIATED WITH PSYCHIC SYMPTOMS IN INTERNAL MEDICINE BY MEANS OF DOXEPIN.
072381 07-09

TOTAL INTERNAL REFLECTION LIGHT CHAMBER (UNPUBLISHED PAPER).
092999 11-06

THE EFFECTIVENESS OF EXTERNAL AND DRUG PRODUCED INTERNAL STIMULI IN THE DISCRIMINATIVE CONTROL OF OPERANT BEHAVIOR. (PH.D.DISSERTATION).
110682 12-04

**INTERNATIONAL**
PROBLEMS REGARDING THE INTRODUCTION OF A PSYCHOPHARMACEUTICAL AGENT IN INTERNATIONAL MARKETS.
060729 03-17

INTERNATIONAL SYMPOSIUM ON AMPHETAMINES AND RELATED COMPOUNDS.
107549 12-13

**INTERNIST**
TREATMENT OF DEPRESSION BY THE INTERNIST: RESULTS WITH IMIPRAMINE.
064113 04-14

**INTERPERSONAL**
INTERPERSONAL UNDERSTANDING, INTERPERSONAL STRESS AND CURRENT STATES: INTERRELATIONSHIPS AND TREATMENT ASSESSMENT. (PH.D. DISSERTATION).
103636 12-14

**INTERRELATIONSHIPS**
INTERPERSONAL UNDERSTANDING, INTERPERSONAL STRESS AND CURRENT STATES: INTERRELATIONSHIPS AND TREATMENT ASSESSMENT. (PH.D. DISSERTATION).
103636 12-14

**INTERVAL**
INITIAL AND INTERVAL TREATMENT OF ACUTE PSYCHOSES WITH INTRAVENOUS INJECTION OF INOFAL.
073708 08-09

**INTERVIEWS**
CONTROLLED INTERVIEWS USING DRUGS.
047825 01-11

**INTESTINE**
METOCLOPRAMIDE AND THE MUSCULATURE OF ESOPHAGUS, STOMACH, INTESTINE, SPLEEN, TRACHEA, GALL AND URINARY BLADDERS: IN VITRO STUDIES.
055394 02-03

ALTERED ABSORPTION OF DRUGS FROM THE RAT SMALL INTESTINE BY CARBONIC ANHYDRASE INHIBITION.
066369 05-03

**INTOLERANCE**
CHLORPROMAZINE INDUCED GLUCOSE INTOLERANCE IN THE MOUSE.
058984 03-05

**INTOXICATED**
DETERMINANTS OF SERUM HALF-LIFE OF GLUTETHIMIDE IN INTOXICATED PATIENTS.
064168 04-15

AN ELECTRON MICROSCOPIC STUDY OF AXONAL CHANGES IN THE CEREBELLUM OF DIPHENYLHYDANTOIN INTOXICATED RATS: THE FORMATION OF THE SO-CALLED HONEYCOMB STRUCTURE IN THE AXOPLASM.
070334 07-03

**INTOXICATION**
MARIHUANA INTOXICATION: COMMON EXPERIENCES.
045515 01-17

MENTAL RETARDATION ASSOCIATED WITH PRENATAL INTOXICATION, ALLERGIC REACTIONS, DEFICIENCIES, TRAUMA, AND PHYSICAL AGENTS.
061704 03-15

CENTRAL NERVOUS SYSTEM CYTOPATHOLOGICAL CHANGES IN CATS WITH CHRONIC METHEDRINE INTOXICATION.
064143 04-05

AMPHETAMINE INTOXICATION WITH COAGULOPATHY, HYPERTHERMIA, AND REVERSIBLE RENAL FAILURE: A SYNDROME RESEMBLING HEATSTROKE.
064236 04-15

ACUTE ETHCHLORVYNOL (PLACIDYL) INTOXICATION.
064623 04-15

THE TREATMENT OF ACUTE ALCOHOL INTOXICATION AND WITHDRAWAL.
065187 05-13

CARBON DISULFIDE INTOXICATION FROM OVERDOSAGE OF DISULFIRAM.
065691 05-09

THE NUMBER OF PURKINJE CELLS AFTER DIPHENYLHYDANTOIN INTOXICATION IN MONKEYS.
066189 05-05

TEMPORAL DISINTEGRATION AND DEPERSONALIZATION DURING MARIHUANA INTOXICATION.
066232 05-14

ANTIDOTAL THIRST: A RESPONSE TO INTOXICATION.
070821 07-05

BEHAVIOR AND HISTOPATHOLOGICAL FINDINGS DURING CHRONIC METHEDRINE INTOXICATION.
071993 07-05

PRINCIPAL ELECTROENCEPHALOGRAPHIC CHANGES OBSERVED DURING ACUTE INTOXICATION BY NEUROLEPTICS.
075112 08-13

ENCEPHALOPATHY AS A SEQUEL OF CHRONIC INTOXICATION WITH HALOGEN DERIVATIVES OF AROMATIC HYDROCARBONS.
085102 10-15

ACTION OF THE SALTS OF OXYGLURIC ACID ON ACUTE ALCOHOL INTOXICATION IN MAN (EXPERIMENTAL STUDY).
086005 10-11

CLINICAL AND EEG APPEARANCES OF ACUTE DRUG INTOXICATION DUE TO CHLORALOSE.
088568 10-15

HUMAN INTOXICATION BY CHLORALOSE.
088618 10-15

COMPARISON OF DITRAN INTOXICATION AND ACUTE ALCOHOL PSYCHOSES.
121083 12-14

**INTOXICATIONS**
MEASUREMENT OF THE DISTRIBUTION OF HYPNOTICS AND CEREBRAL FUNCTION IN ACUTE INTOXICATIONS BY PH.
089040 10-17

INTOXICATIONS BY LSD-25: MEDICOLEGAL PROBLEMS.
132911 12-12

**INTRAAMYGDALOID**
INFLUENCE OF IMIPRAMINE, BENACTYZINE AND PROMAZINE ON THE EFFECTS OF INTRAAMYGDALOID INJECTION OF ACETYLCHOLINE AND SEROTONIN.
098024 11-04

**INTRACELLULAR**
THE EFFECT OF METHIONINE OF THE REGIONAL AND INTRACELLULAR DISPOSITION OF (3H) METHIONINE SULPHOXIMINE IN RAT BRAIN.
090148 11-03

**INTRACEREBRALLY**
THE PHARMACOLOGICAL EFFECTS OF OUABAIN ADMINISTERED INTRACEREBRALLY TO CONSCIOUS MICE.
068165 06-03

**INTRACISTERNALLY**
EFFECT OF DIAZEPAM ON FATE OF INTRACISTERNALLY INJECTED SEROTONIN-C14.
072031 07-03

**INTRACRANIAL**
ENHANCEMENT BY COCAINE OF INTRACRANIAL SELF-STIMULATION IN THE RAT.
058397 02-13
INTRACRANIAL SELF-STIMULATION AND WAKEFULNESS: EFFECT OF MANIPULATING AMBIENT BRAIN CATECHOLAMINES.
063849 04-04
CONDITIONED SUPPRESSION BASED ON POSITIVELY REINFORCING INTRACRANIAL STIMULATION.
064842 05-02

**INTRAGASTRIC**
INTRAGASTRIC TELEMETRIC MEASURING OF PH DURING THYMOLEPTIC MEDICATION.
081143 09-13

**INTRAHYPOTHALAMIC**
THE EFFECT OF INTRAHYPOTHALAMIC MICROINJECTION OF HEMICHOLINIUM (HC-3) ON THE HIPPOCAMPAL THETA RHYTHM OF CATS.
075842 08-03

**INTRAMUSCULAR**
MEMORY ENHANCEMENT OF A PARTLY LEARNED DISCRIMINATION IN PIGEONS BY INTRAMUSCULAR INJECTION OF PHYSOSTIGMINE.
060858 03-04
DOUBLE-BLIND STUDY COMPARING THE INTRAMUSCULAR USAGE OF AN ACRIDAN DERIVATIVE, SKF-14336, TO CHLORPROMAZINE.
067513 06-11
POSSIBLE APPLICATIONS OF LONG-ACTING INTRAMUSCULAR MAJOR TRANQUILLIZERS.
100020 11-11

**INTRANEURONAL**
INTRANEURONAL AND EXTRANEURONAL ACCUMULATION OF SYMPATHOMIMETIC AMINES IN THE ISOLATED NICTITATING MEMBRANE OF THE CAT.
066363 05-03

**INTRAPERITONEAL**
EFFECTS OF INTRAPERITONEAL INJECTION OF ETHANOL ON ETHANOL INGESTION OF C57BL MICE.
075957 09-02

**INTRASTRIATAL**
INTRASTRIATAL SPREADING OF BIOGENIC AMINES.
072471 08-03

**INTRAVENOUS**
EFFECTS OF RESERPINE AND DESIPRAMINE ON THE UPTAKE AND SUBCELLULAR DISTRIBUTION OF 5-HYDROXYTRYPTAMINE IN RABBIT BRAINSTEM AFTER INTRAVENOUS ADMINISTRATION OF 5-HYDROXYTRYPTOPHAN.
056610 02-03
A COMPARISON OF SHORT-TERM TREATMENT EFFECTS OF INTRAVENOUS SODIUM AMYTAL METHEDRINE AND LSD IN THE ALCOHOLIC.
062934 03-11
A METHOD FOR CHRONIC INTRAVENOUS DRUG ADMINISTRATION IN SQUIRREL MONKEYS.
063725 04-06
INTERACTION BETWEEN INTRAVENOUS ALCOHOL AND SOME SEDATIVES AND TRANQUILLIZERS.
067607 06-03
INDUCTION OF RECEPTIVITY IN OVARIECTOMIZED FEMALE RATS BY A SINGLE INTRAVENOUS INJECTION OF ESTRADIOL-17BETA.
067696 06-04
INITIAL AND INTERVAL TREATMENT OF ACUTE PSYCHOSES WITH INTRAVENOUS INJECTION OF INOFAL.
073708 08-09
PLASMA FREE FATTY ACIDS BEFORE AND AFTER AN INTRAVENOUS INSULIN INJECTION IN ACUTE SCHIZOPHRENIC MEN.
075212 08-08
CORRELATION BETWEEN THE CHANGES OF EEG, PUPILLES AND BLOOD PRESSURE DUE TO INTRAVENOUS INJECTION OF CHLORPROMAZINE: CHLORPROMAZINE TEST.
088611 10-13

**INTROVERSION**
THE PSYCHOPHYSIOLOGICAL BASIS OF INTROVERSION EXTRAVERSION.
064375 04-04

**INVENTORY**
SUBJECTIVE EFFECTS OF NARCOTIC ANTAGONISTS CYCLAZOCINE AND NALORPHINE ON THE ADDICTION RESEARCH CENTER INVENTORY (ARCI).
097961 11-14

**INVESTIGATING**
A METHOD FOR INVESTIGATING THE EFFECTS OF DRUGS ON THE EXPLORATORY BEHAVIOUR OF MICE.
064289 04-04
OBSERVATION OF THE GROOMING BEHAVIOR OF RESERPINIZED WHITE MICE AS A METHOD FOR INVESTIGATING RESERPINE ANTAGONISM AND SYNERGISM.
065442 05-04

**INVESTIGATION**
PROJECT SUMMARY: ON THE INVESTIGATION OF THE GENETIC EFFECTS OF LYSERGIC ACID DIETHYLAMIDE AND RELATED COMPOUNDS.
060637 03-03
A NOVEL APPROACH TO THE INVESTIGATION OF NOREPINEPHRINE METABOLISM IN HUMAN SYMPATHETIC NERVE.
064144 04-03
CLINICAL INVESTIGATION WITH THE BUTYROPHENONE DERIVATIVE BURONIL.
073706 08-09
A LONGITUDINAL INVESTIGATION OF LITHIUM AS A PROPHYLACTIC AGENT FOR RECURRENT DEPRESSIONS.
075425 08-10
INVESTIGATION ON A NEW ANTICONVULSIVE PRODUCT RO-5-4023.
085454 10-14
CONTROLLED INVESTIGATION WITH CINNARIZIN IN THE TREATMENT OF DEMENTIA CONDITIONS IN OLD AGE.
089108 10-11
INVESTIGATION OF THE PSYCHODYNAMIC REINFORCEMENT OF NEUROLEPTICS WITH 1035-MD.
089111 10-07
INVESTIGATION INTO THE POSSIBLE INFLUENCE OF CHLORINATED AMPHETAMINE DERIVATIVES ON 5-HYDROXYTRYPTAMINE SYNTHESIS IN MAN.
097963 11-13
CANNABIS: A PSYCHOLOGICAL AND METABOLIC INVESTIGATION.
100014 11-14
A DOUBLE-BLIND INVESTIGATION WITH FLUPENTHIXOL AND TRIFLUOPERAZINE AT TREATMENT OF SCHIZOPHRENIC PSYCHOSES.
100017 11-08
CONCERNING THE ARTICLE BY N.N.TIMOFEYEV, V.T.KONDRASHENKO AND N.Y.NEMTSEVA ON OXYMETRIC INVESTIGATION OF PATIENTS WITH SCHIZOPHRENIA AND REACTIVE PSYCHOSIS DURING NEUROLEPTIC TREATMENT.
109788 12-08

**INVESTIGATIONS**
DIMETHACRINE – A NEW TRICYCLIC ANTIDEPRESSANT: OPEN INVESTIGATIONS IN A CLINIC AND POLYCLINIC.
058281 02-07
CLINICAL INVESTIGATIONS OF THE ACTION OF A PHOSPHOLIPID COMPLEX FROM CEREBRAL CORTEX ON CEREBRAL CIRCULATION DISTURBANCES.
058282 02-11
INVESTIGATIONS ON THE SPECIFICITY OF THE SO-CALLED ANALGESIC ACTIVITY OF NON-NARCOTIC DRUGS.
067254 06-04
P-CHLOROAMPHETAMINE: IN VIVO INVESTIGATIONS ON THE MECHANISM OF ACTION OF THE SELECTIVE DEPLETION OF CEREBRAL SEROTONIN.
069596 07-03
INVESTIGATIONS FOR OBJECTIFYING TRANQUILIZER EFFECTS.
079960 09-14
RESEARCH ON NEW METHODS OF EXPERIMENTATION WITH PSYCHOTROPIC DRUGS. RESULTS OF A TEST WITH A NEW TRANQUILIZER, NOBRIUM, IN TWO INDEPENDENT INVESTIGATIONS.
086984 10-16
PSYCHOPHARMACOLOGICAL AGENTS AND MICTURITION DISORDERS: CYSTOMETRIC INVESTIGATIONS.
090126 11-15

**INVITATIONS**
OVARIAN HORMONES AND FEMALE SEXUAL INVITATIONS IN CAPTIVE RHESUS MONKEYS (MACACA-MULATTA).
076554 09-03

**INVOLUNTARY**
LIVER DISEASE AND PHENOTHIAZINES; INVOLUNTARY MOVEMENTS.
063854 04-15

**INVOLUTIONAL**
CLINICAL EXPERIENCES WITH DESIPRAMINE IN ENDOGENOUS AND INVOLUTIONAL DEPRESSIONS.
070943 07-09
LITHIUMS POSITION AMONG ANTIDEPRESSANTS IN THE TREATMENT OF ACUTE ENDOGENOUS AND INVOLUTIONAL DEPRESSIONS.
106777 12-09

**INVOLVED**
STUDIES ON THE RECEPTORS INVOLVED IN THE ACTION OF THE VARIOUS AGENTS IN THE PHENYLBENZOQUINONE ANALGESIC ASSAY IN MICE.
090451 11-03

**INVOLVING**
STUDIES ON INTERACTIONS INVOLVING ANTIDEPRESSIVE AND OTHER DRUGS WITH TETRABENAZINE AND NORADNAMINE ON LOCOMOTOR ACTIVITY IN MICE, INCLUDING DETAILS OF THE EXPERIMENTAL DESIGN AND STATISTICAL ANALYSIS.
069077 06-04
AMPHETAMINE: DIFFERENTIATION BY D AND L ISOMERS OF BEHAVIOR INVOLVING BRAIN NOREPINEPHRINE OR DOPAMINE.
070921 07-04
RECIPROCAL HUNGER REGULATING CIRCUITS INVOLVING ALPHA-ADRENERGIC AND BETA-ADRENERGIC RECEPTORS LOCATED,

RESPECTIVELY, IN THE VENTROMEDIAL AND LATERAL HYPOTHALAMUS.
092166 11-03

**ION**
THE INFLUENCE OF LITHIUM ION ON THE ADRENOCORTICAL FUNCTION OF RATS.
089787 11-09
PSYCHOPHARMACOLOGY OF THE LITHIUM ION (TWENTY YEARS AFTER).
095013 11-09

**IONIZATION**
CENTRAL NEUROTROPIC ACTIVITY OF AMINOPROPYL AND AMINOPROPIONYLIC DERIVATIVES OF IMINOBENZYL AND DIPHENYLAMINE AND ITS RELATION TO IONIZATION CONSTANTS.
072580 08-03

**IPAT**
USE OF CATTELS IPAT ANXIETY SCALE IN A GROUP OF NEUROTIC PATIENTS BEFORE AND AFTER PSYCHOPHARMACOLOGICAL DRUG AND ELECTRIC SHOCK THERAPY.
128509 12-17

**IPRINDOLE**
ON THE MECHANISM OF AMPHETAMINE POTENTIATION BY IPRINDOLE.
066955 05-03
EFFECT OF DESMETHYLIMIPRAMINE, IPRINDOLE AND DL-ERYTHRO-ALPHA-(3,4 DICHLOROPHENYL)-BETA-(T-BUTYLAMINO) PROPANOL HCL ON THE METABOLISM OF AMPHETAMINE.
074866 08-03

**IPRONIAZID**
BETA-HYDROXYLATION OF N-ACETYL-DIMETHOXYPHENETHYLAMINE AND THE INFLUENCE OF IPRONIAZID ON THE DEMETHYLATION OF THIS COMPOUND IN VIVO IN THE RAT.
064053 04-03

**IPSP**
THE EFFECT OF HEXOBARBITAL ON THE DURATION OF THE RECURRENT IPSP IN CAT MOTONEURONS.
064621 04-03

**IRIS**
RELEASE OF NOREPINEPHRINE FROM ISOLATED RAT IRIS BY FIELD STIMULATION.
040245 01-03

**IRREGULAR**
CASUISTIC CONTRIBUTIONS ON THE USE OF A DRUG IN CRIMINOLOGY ON DISSOCIALITY AND ON MINOR IRREGULAR BEHAVIOR.
095719 11-14

**IRREVERSIBLE**
SPECIFIC IRREVERSIBLE ENZYME INHIBITORS.
051115 01-17

**IRRITABILITY**
A CONTROLLED STUDY OF THE EFFECTS OF DIPHENYLHYDANTOIN ON ANXIETY, IRRITABILITY, AND ANGER IN NEUROTIC OUTPATIENTS.
064478 04-10

**ISO-ANTIBODIES**
EFFECT OF BRAIN ISO-ANTIBODIES ON LEARNING AND MEMORY IN THE RAT.
072516 08-04

**ISOLATED**
RELEASE OF NOREPINEPHRINE FROM ISOLATED RAT IRIS BY FIELD STIMULATION.
040245 01-03
EFFECTS OF TWO CHOLINESTERASE INHIBITORS ON ACETYLCHOLINE RELEASE FROM THE GUINEA-PIG ISOLATED ILEUM PREPARATION.
040572 01-03
THE EFFECTS OF ACIDOSIS ON CHRONOTROPIC RESPONSES, NOREPINEPHRINE STORAGE AND RELEASE IN ISOLATED GUINEA-PIG ATRIA.
040753 01-03
STUDY OF THE EFFECTS OF PROGESTERONE THERAPY ON THE STILBOESTROL INDUCED SENSITIVITY OF ISOLATED UTERI OF HYPOPHYSECTOMIZED RATS.
041540 01-03
OXIDATIVE PHOSPHORYLATION IN HEART MITOCHONDRIA ISOLATED FROM CHLORPROMAZINE TREATED ANIMALS.
041564 01-03
INTRANEURONAL AND EXTRANEURONAL ACCUMULATION OF SYMPATHOMIMETIC AMINES IN THE ISOLATED NICTITATING MEMBRANE OF THE CAT.
066363 05-03
EFFECTS OF GENERAL DEPRESSANT DRUGS ON THE ELECTRICAL RESPONSES OF ISOLATED SLABS OF CATS CEREBRAL CORTEX.
066382 05-03
METABOLISM AND BILIARY EXCRETION OF THE LIPOPHILIC DRUG MOLECULES, IMIPRAMINE AND DESMETHYLIMIPRAMINE IN THE RAT -- I. EXPERIMENTS IN VIVO AND WITH ISOLATED PERFUSED LIVERS.
067260 06-03
AMPHETAMINE TOXICITY AND ENDOGENOUS NORADRENALINE CONCENTRATIONS IN ISOLATED AND AGGREGATED MIC
074146 08-05
ON THE UPTAKE OF PHENOTHIAZINE DERIVATIVES BY THE ISOLATED PERFUSED RAT BRAIN.
089043 10-03
EFFECTS OF GENERAL STIMULANT DRUGS ON THE ELECTRICAL RESPONSES OF ISOLATED SLABS OF CATS CEREBRAL CORTEX.
090189 11-03
EFFECT OF CAPERS ON THE VASCULAR LUMEN OF ISOLATED EXTREMITIES OF SENSITIZED FROGS AND THE ANTIANAPHYLATIC EFFECT OF SUPRASTIN.
105720 12-03

**ISOLATION**
CACTUS ALKALOIDS: IX. ISOLATION OF N-METHYL-3-4-DIMETHOXY-BETA-PHENETHYLAMINE AND N-METHYL-4-METHOXY-BETA-PHENETHYLAMINE FROM ARIOCARPUS-RETUSUS.
070751 07-01

**ISOMERS**
AMPHETAMINE: DIFFERENTIATION BY D AND L ISOMERS OF BEHAVIOR INVOLVING BRAIN NOREPINEPHRINE OR DOPAMINE.
070921 07-04

**ISONIAZID**
ISONIAZID SELF-POISONING.
082004 10-15
INFLUENCE OF ISONIAZID ON THE CENTRAL NERVOUS SYSTEM; THE ANTAGONISM BETWEEN ISONIAZID AND PYRIDOXINE, PANTOTHENIC ACID AND COUMARIN IN RATS (MELILOTUS-OFFICINALIS).
126055 12-04

**ISONICOTINIC-ACID-HYDRAZIDE**
ISONICOTINIC-ACID-HYDRAZIDE (INH) INDUCED MENTAL DISORDERS IN THE COURSE OF LUNG TUBERCULOSIS TREATMENT.
072890 08-15

**ISOPRENALINE**
ON THE ANALYSIS OF CARDIAC BETA-RECEPTORS: STUDIES ON THE BASE OF DOSE EFFECT CURVES FOR ISOPRENALINE, PROPRANOLOL, AND KL-255.
055396 02-03

**ISOPROPYL**
DEPHOSPHORYLATION IN VIVO OF BRAIN ACETYLCHOLINESTERASE INHIBITED BY ISOPROPYL METHYLPHOSPHONOFLUORIDATE (SARIN).
046188 01-03

**ISOPROTERENOL**
CARDIAC CATECHOLAMINE SYNTHESIS, TURNOVER, AND METABOLISM WITH ISOPROTERENOL INDUCED MYOCYTOLYSIS (UNPUBLISHED PAPER).
088374 10-03

**ISPROPYLIDENE-PROSCILLARIDIN**
ON THE PHARMACOLOGY OF ISPROPYLIDENE-PROSCILLARIDIN.
055397 02-03

**ITALY**
PROBLEMS PRESENTED BY NEUROLEPTIC THERAPY IN ITALY.
075111 08-14

**JATROSOME**
THERAPY WITH JATROSOME.
133147 12-09

**JEWS**
ON THE USE OF CATH (CATHA-EDULIS) AMONG YEMENITE JEWS.
074566 08-15

**JUDGMENT**
A CONTROLLED COMPARISON OF THE TREATMENT OF SCHIZOPHRENIC PATIENTS WHEN TREATED ACCORDING TO THE NEUROLEPTIC THRESHOLD OR BY CLINICAL JUDGMENT.
063776 04-08

**JUMPING**
JUMPING ACTIVITY INDUCED BY SODIUM 5-(1,3 DIMETHYLBUTYL)-5 ETHYL BARBITURATE. II. THE EFFECTS OF AGE DIFFERENCE.
058985 03-04

**JUNCTION**
THE EFFECTS OF MORPHINE-LIKE SUBSTANCES AND THEIR ANTAGONISTS ON TRANSMISSION AT THE NEURO EFFECTOR JUNCTION OF THE MYENTERIC PLEXUS LONGITUDINAL MUSCLE PREPARATION OF THE GUINEA-PIG ILEUM.
041974 01-03

**KARON-VANDENBOS**
METHODOLOGICAL PROBLEMS IN PSYCHOTHERAPY RESEARCH: OBSERVATIONS ON THE KARON-VANDENBOS STUDY OF PSYCHOTHERAPY AND DRUGS IN SCHIZOPHRENIA.
071322 07-08

**KETIPRAMINE**
KETIPRAMINE IN THE THERAPY OF DEPRESSION IN OUTPATIENTS.
076347 09-10

**KILLING**
LATERAL HYPOTHALAMIC CONTROL OF KILLING: EVIDENCE FOR A CHOLINOCEPTIVE MECHANISM.
058227 03-04
NEUROCHEMICAL EFFECTS OF IMIPRAMINE AND AMPHETAMINE IN AGGRESSIVE MOUSE KILLING (MURICIDAL) RATS.
064056 04-03

**KINETICS**
TOTAL BODY KINETICS AND PLACENTAL TRANSFER OF LABELED LSD IN MICE.
046201 01-03
THE KINETICS OF AMYLOBARBITONE METABOLISM IN HEALTHY MEN AND WOMEN.
063800 04-13
THE KINETICS OF CHLORAL HYDRATE METABOLISM IN MICE AND THE EFFECT THEREON OF ETHANOL.
066364 05-03
STUDIES OF MINERAL METABOLISM IN MENTAL DEPRESSION. I. THE EFFECTS OF IMIPRAMINE AND ELECTRIC CONVULSIVE THERAPY ON CALCIUM BALANCE AND KINETICS.
075837 08-11

**KL-255**
ON THE ANALYSIS OF CARDIAC BETA-RECEPTORS: STUDIES ON THE BASE OF DOSE EFFECT CURVES FOR ISOPRENALINE, PROPRANOLOL, AND KL-255.
055396 02-03

**KNOWS**
THE MIND NOBODY KNOWS.
046729 01-14

**KONDRASHENKO**
CONCERNING THE ARTICLE BY N.N.TIMOFEYEV, V.T.KONDRASHENKO AND N.Y.NEMTSEVA ON OXYMETRIC INVESTIGATION OF PATIENTS WITH SCHIZOPHRENIA AND REACTIVE PSYCHOSIS DURING NEUROLEPTIC TREATMENT.
109788 12-08

**KYNURENINE**
DOES KYNURENINE POSSESS ANY NEUROTROPIC ACTIVITY
105621 12-04

**L-DIHYDROXYPHENYLALANINE**
L-DIHYDROXYPHENYLALANINE: EFFECT ON S-ADENOSYLMETHIONINE IN BRAIN.
063825 04-03
CENTRAL HYPOTENSIVE EFFECT OF L-DIHYDROXYPHENYLALANINE IN THE RAT.
063888 04-03
TREATMENT OF PARKINSONS SYNDROME WITH L-DIHYDROXYPHENYLALANINE (LEVODOPA).
067666 06-07

**L-DOPA**
REVERSIBLE EFFECT OF L-DOPA ON TREMOR AND CATATONIA INDUCED BY ALPHA-METHYL-P-TYROSINE.
040124 01-05
L-DOPA INDUCED ACCUMULATION OF METHYLDOPA IN BRAIN AND HEART.
042726 01-03
EVIDENCE FOR A CENTRALLY MEDIATED HYPOTENSIVE EFFECT OF L-DOPA IN THE RAT.
055587 02-03
SIMILARITIES BETWEEN NEUROLOGIC EFFECTS OF L-DOPA AND OF APOMORPHINE.
056574 02-11
METABOLISM OF D-DOPA VS L-DOPA.
056852 02-11
TREATMENT OF WILSONS DISEASE WITH L-DOPA AFTER FAILURE WITH PENICILLAMINE.
058243 02-11
EFFECTS OF L-DOPA IN PATIENTS WITH DEMENTIA.
058403 02-15
PARKINSONS DISEASE: L-DOPA TREATMENT AND HANDWRITING AREA.
058966 03-11
L-DOPA IN SENILE DEMENTIA.
059020 03-11
L-DOPA INDUCED CHANGES IN CENTRAL MONOAMINE NEURONS AFTER PERIPHERAL DECARBOXYLASE INHIBITION.
059033 03-03
SIDE-EFFECTS OF L-DOPA IN POSTENCEPHALITIC PARKINSONISM.
059057 03-15
METABOLIC STUDIES AND CLINICAL OBSERVATIONS DURING L-DOPA TREATMENT OF PARKINSONS DISEASE.
063822 04-13
L-DOPA THERAPY IN PARKINSONS DISEASE.
064188 04-11
L-DOPA THERAPY: PAST, PRESENT AND FUTURE.
064582 04-07
THE ACTION OF L-DOPA ON SCHIZOPHRENIC PATIENTS (A PRELIMINARY REPORT).
064638 05-08
PRESENT STATUS OF PSYCHOLOGICAL REACTIONS TO L-DOPA.
065165 05-09
L-DOPA PLUS DECARBOXYLASE INHIBITOR IN DEPRESSION.
066322 05-09
MIOSIS DURING L-DOPA THERAPY.
066419 05-13
L-DOPA WITH MK-485 FOR DEPRESSION.
066440 05-10
DRUG COMBINATION ALLOWS SMALLER DOSES OF L-DOPA.
066465 05-07
MENTAL SYMPTOMS IN PARKINSONIAN PATIENTS TREATED WITH L-DOPA.
066490 05-15
POTENTIATION BY AMANTADINE HYDROCHLORIDE OF L-DOPA INDUCED EFFECTS IN MICE.
066508 05-03
L-DOPA IN PARKINSONISM.
066875 05-13
MEASUREMENT OF BEHAVIORAL CHANGES IN PATIENTS ON L-DOPA.
066940 05-14
L-DOPA AND OCULOGYRIC CRISES.
067073 05-15
ADMINISTRATION OF A PERIPHERAL DECARBOXYLASE INHIBITOR WITH L-DOPA TO DEPRESSED PATIENTS.
067591 06-09
MONOAMINE OXIDASE INHIBITORS AND L-DOPA.
067657 06-15
HYPOTENSION CAUSED BY L-DOPA.
067833 06-03
EFFECT OF L-DOPA ON THE SLEEP OF MAN.
070247 07-13
THE EFFECT OF L-DOPA ON MONOAMINE METABOLITES IN PARKINSONS DISEASE.
070824 07-13
L-DOPA, PARKINSONISM, AND DEPRESSION.
070856 07-09
A CONTROLLED STUDY OF L-DOPA IN PARKINSONS DISEASE.
071974 07-07
L-DOPA IN THE TREATMENT OF POST-SURGICAL PARKINSON PATIENTS.
071984 07-07
L-DOPA IN THE TREATMENT OF PARKINSONISM. A PRELIMINARY APPRAISAL.
071985 07-07
L-DOPA THERAPY OF PARKINSONS DISEASE (A REVIEW OF THE PRELIMINARY EXPERIENCE AT WEST-VIRGINIA UNIVERSITY).
072421 08-07
THE EFFECTS OF L-DOPA THERAPY IN PARKINSONS DISEASE.
072508 08-15
ACTIONS OF L-DOPA IN DRUG-INDUCED EXTRAPYRAMIDALISM.
075429 08-08
L-DOPA: A HALLUCINOGEN.
075909 09-15
AKINESIS FOLLOWING STEREOTACTIC SURGERY FOR PARKINSONISM -- THE USE OF L-DOPA.
077404 09-16
L-DOPA, BEHAVIORAL ACTIVATION AND PSYCHOPATHOLOGY (UNPUBLISHED PAPER).
078542 09-09
CONSIDERATIONS ON THE HYPERKINESIA OF L-DOPA: SIGNIFICANT BIOCHEMICAL AND ANATOMICAL DEFICIENCIES.
078555 09-13
ON THE EFFECT OF DIOXYPHENYLALANINE (L-DOPA) ON EXTRAPYRAMIDAL HYPERKINESIA DUE TO NEUROLEPTIC LONG-TERM MEDICATION.
079950 09-15
EFFECT OF A DECARBOXYLASE INHIBITOR (RO-4-4602), COMBINED WITH L-DOPA, ON INHIBITED DEPRESSIVE PATIENTS: II. EXPERIMENTAL PSYCHOLOGICAL STUDIES.
079964 09-14
EFFECT OF A DECARBOXYLASE INHIBITOR (RO-4-4602), COMBINED WITH L-DOPA, ON RETARDED DEPRESSIVE PATIENTS.
079965 09-13
L-DOPA IN DEPRESSED PATIENTS.
081038 09-09
MEASUREMENT OF BEHAVIOURAL CHANGES IN PATIENTS ON L-DOPA.
081039 09-11
MENTAL SYMPTOMS IN PARKINSONIAN PATIENTS TREATED WITH L-DOPA.
081082 09-15
INCONTINENT NOSTALGIA INDUCED BY L-DOPA.
081090 09-15
ADJUVANTS TO L-DOPA FOR PARKINSONISM.
081104 09-14
L-DOPA IN THE TREATMENT OF PARKINSONS DISEASE.
081392 09-17
PSYCHIC SYMPTOMS IN L-DOPA TREATMENT OF PARKINSONS DISEASE.
087659 10-09
DRUGS: MORE L-DOPA IN SIGHT.
087724 10-11
L-DOPA WITH MK-485 FOR DEPRESSION.
090188 11-11
EFFECT OF L-DOPA ALONE AND IN COMBINATION WITH AN EXTRACEREBRAL DECARBOXYLASE INHIBITOR ON BLOOD PRESSURE AND SOME CARDIOVASCULAR REFLEXES.
090371 11-13
L-DOPA IN THE TREATMENT OF PARKINSONS DISEASE.
091715 11-07

L-DOPA IN DEPRESSION (UNPUBLISHED PAPER).
092688 11-09

TREATMENT OF PARKINSONISM WITH L-DOPA.
098172 11-07

THE SAFETY TEST OF L-DOPA – II. EFFECT OF L-DOPA ON THE DEVELOPMENT OF PRENATAL AND POSTNATAL OFFSPRINGS OF EXPERIMENTAL ANIMALS.
114836 12-02

THE SAFETY TEST OF L-DOPA. I. ACUTE AND SUBACUTE TOXICITY OF L-DOPA IN EXPERIMENTAL ANIMALS.
114837 12-05

STUDIES ON GENERAL PHARMACOLOGY OF L-DOPA.
114838 12-02

L-DOPA AND PARKINSONISM.
122098 12-17

**L-GLUTAMIC**

GABA AS A REPRESSOR OF L-GLUTAMIC ACID DECARBOXYLASE (GAD) IN DEVELOPING CHICK EMBRYO OPTIC LOBES.
058192 02-03

REDUCTION OF LEVEL OF L-GLUTAMIC ACID DECARBOXYLASE BY GAMMA-AMINOBUTYRIC ACID IN MOUSE BRAIN.
083168 10-03

**L-TRYPTOPHAN**

L-TRYPTOPHAN IN DEPRESSION.
058404 02-10

SEQUENTIAL COMPARISON OF L-TRYPTOPHAN WITH ECT IN SEVERE DEPRESSION.
059053 03-09

MODIFICATION OF THE TOXIC ACTIONS OF L-TRYPTOPHAN BY PARGYLINE AND P-CHLOROPHENYLALANINE.
064277 04-05

L-TRYPTOPHAN IN DEPRESSION.
067675 06-10

L-TRYPTOPHAN IN DEPRESSION.
067676 06-10

L-TRYPTOPHAN IN DEPRESSION.
070857 07-09

CEREBROSPINAL FLUID 5-HYDROXYINDOLES AND BEHAVIOR AFTER L-TRYPTOPHAN AND PYRIDOXINE ADMINISTRATION TO PSYCHIATRIC PATIENTS.
074938 08-14

**LABEL**

MEPROBAMATE LOSES SOME LABEL CLAIMS.
070830 07-17

**LABELED**

EFFECT OF RESERPINE ON THE INCORPORATION IN VIVO OF RADIOACTIVITY FROM LABELED SEROTONIN AND OTHER 5-HYDROXYINDOLE DERIVATIVES IN MOUSE BRAIN.
046189 01-03

TOTAL BODY KINETICS AND PLACENTAL TRANSFER OF LABELED LSD IN MICE.
046201 01-03

EFFECT OF ANTIDEPRESSANT DRUGS ON ACCUMULATION AND DISAPPEARANCE OF MONOAMINES FORMED IN VIVO FROM LABELED PRECURSORS IN MOUSE BRAIN.
058798 02-03

EFFECT OF APOMORPHINE AND PIMOZIDE ON SYNTHESIS AND TURNOVER OF LABELED CATECHOLAMINES IN MOUSE BRAIN.
066502 05-03

QUANTITATIVE THIN-LAYER CHROMATOGRAPHIC ESTIMATION OF LABELED DOPAMINE AND NOREPINEPHRINE, THEIR PRECURSORS AND METABOLITES.
070063 07-06

A SOURCE OF ERROR IN CATECHOLAMINE TURNOVER STUDIES WITH LABELED DOPA: SLOW DISAPPEARANCE OF THE PRECURSOR.
074818 08-03

**LABELING**

FLUORESCENT LABELING OF PSYCHOACTIVE DRUGS.
066738 05-06

**LABILE**

TREATMENT OF LABILE HYPERTENSION.
076346 09-17

**LABORATORY**

PSYCHOLOGICAL APPROACHES TO OPIATE DEPENDENCE AND SELF-ADMINISTRATION BY LABORATORY ANIMALS.
056240 02-04

THE PREDICTIVE VALUE FOR MAN OF TOXICOLOGICAL TESTS OF DRUGS IN LABORATORY ANIMALS.
057607 02-05

LABORATORY EVALUATION OF AGGRESSIVE BEHAVIOR OF THE GRASSHOPPER MOUSE (ONYCHOMYS).
064260 04-04

THIN-LAYER CHROMATOGRAPHIC LABORATORY ANALYSIS IN CASES FROM A DRUG ADDICTION CENTER.
067212 06-06

LABORATORY EXPERIMENTS SUITABLE FOR PRACTICAL CLASSES IN PSYCHOPHARMACOLOGY.
067599 06-06

COMPENSATORY SELECTION OF MAGNESIUM SULFATE BY MAGNESIUM DEPLETED LABORATORY RATS.
068287 06-04

LONG-TERM TREATMENT WITH OCTOCLOTHEPINE – SIDE-EFFECTS AND LABORATORY FINDINGS.
070928 07-09

SOME CLINICAL AND LABORATORY STUDIES OF PSYCHOTROPIC DRUGS IN CHILDREN: AN OVERVIEW.
070975 07-17

THE PHARMACOLOGY OF DISORDERED SLEEP: A LABORATORY APPROACH.
084806 10-14

EFFECTS OF NEUROLEPTICS ON THE CEREBRAL ELECTRICAL ACTIVITY OF LABORATORY ANIMALS: PRESENTATION OF A MODEL DESIGN FOR NEUROPHARMACOLOGICAL EXPERIMENTS.
085337 10-03

**LANGUAGE**

PSYCHEDELIC EXPERIENCE AND THE LANGUAGE PROCESS.
067340 06-12

PREDICTION OF CHANGES IN SEVERITY OF THE SCHIZOPHRENIC SYNDROME WITH DISCONTINUATION AND ADMINISTRATION OF PHENOTHIAZINES IN CHRONIC SCHIZOPHRENIC PATIENTS: LANGUAGE AS A PREDICTOR AND MEASURE OF CHANGE IN SCHIZOPHRENIA.
075321 08-08

**LATENCY**

FORGETTING OF AN OPERANT RESPONSE: PHYSOSTIGMINE PRODUCED INCREASES IN ESCAPE LATENCY IN RATS AS A FUNCTION OF TIME OF INJECTION.
061540 03-04

**LATENT**

SODIUM DEFICIENCY AND LATENT LEARNING.
075915 09-04

**LATERAL**

LATERAL HYPOTHALAMIC CONTROL OF KILLING: EVIDENCE FOR A CHOLINOCEPTIVE MECHANISM.
058227 02-04

DIFFERENTIAL EFFECTS OF AMPHETAMINE AND SCOPOLAMINE ON MATCHING PERFORMANCE OF MONKEYS WITH LATERAL FRONTAL LESIONS.
065747 05-04

RECIPROCAL HUNGER REGULATING CIRCUITS INVOLVING ALPHA-ADRENERGIC AND BETA-ADRENERGIC RECEPTORS LOCATED, RESPECTIVELY, IN THE VENTROMEDIAL AND LATERAL HYPOTHALAMUS.
092166 11-03

**LEARN**

EFFECTS OF INSULIN, METRAZOL, AND ELECTROCONVULSIVE SHOCKS UPON LEARNING TO LEARN 30 SUCCESSIVE REVERSAL PROBLEMS BY RATS.
095188 11-04

**LEARNED**

MEMORY ENHANCEMENT OF A PARTLY LEARNED DISCRIMINATION IN PIGEONS BY INTRAMUSCULAR INJECTION OF PHYSOSTIGMINE.
060858 03-04

EFFECTS OF A TRANQUILIZER AND TWO ANTIDEPRESSANTS ON LEARNED AND UNLEARNED BEHAVIORS.
064259 04-04

**LEARNING**

MAGNESIUM PEMOLINE: SPECIFICITY OF EFFECTS ON INSTRUMENTAL AVOIDANCE LEARNING.
058430 02-04

IMPAIRMENT OF SHOCK AVOIDANCE LEARNING AFTER LONG-TERM ALCOHOL INGESTION IN MICE.
058492 02-04

STATE-DEPENDENT LEARNING IN HUMANS.
058561 02-14

EFFECTS OF A MARIHUANA HOMOLOGUE (PYRAHEXYL) ON AVOIDANCE LEARNING IN THE GERBIL.
059032 03-04

THE EFFECT OF MAGNESIUM PEMOLINE ON DISCRIMINATION LEARNING AND EXPLORATORY BEHAVIOR.
059567 03-04

THE INFLUENCE OF CENTROPHENOXINE (LUCIDRIL) ON LEARNING AND MEMORY IN ALCOHOLICS.
062800 03-14

EFFECTS OF CANNABIS-SATIVA ON LEARNING IN RATS.
064178 04-04

DEPRESSION OF TWO-WAY AVOIDANCE LEARNING AND ENHANCEMENT OF PASSIVE AVOIDANCE LEARNING BY SMALL DOSES OF PHYSOSTIGMINE.
064365 04-04

THE EFFECTS OF CHLORPROMAZINE ON ONE-TRIAL PASSIVE AVOIDANCE LEARNING IN MICE: FURTHER EXAMINATION OF PRELEARNING AND POSTLEARNING ADMINISTRATION.
064407 04-04

THE PROCESS OF LEARNING IN RATS UNDERGOING PROLONGED TREATMENT WITH PSYCHOTROPIC AGENTS.
065441 05-04

EFFECT OF HYDROXYLAMINE ON MAZE LEARNING IN MICE.
065933 05-04
AN EVALUATION OF THE PHARMACOLOGIC APPROACHES TO LEARNING IMPEDIMENTS.
066838 05-14
IMPAIRMENT OF ALTERNATION LEARNING IN RATS FOLLOWING MICROINJECTION OF CARBACHOL INTO THE HIPPOCAMPUS.
067522 06-04
DELAYED LEARNING DEFICIT PRODUCED BY HYDROXYLAMINE.
067713 06-04
THE EFFECT OF DEXAMETHASONE BLOCKADE OF ACTH RELEASE ON AVOIDANCE LEARNING.
067884 06-04
TIME-DEPENDENT LEARNING DEFICIT CAUSED BY HYDROXYLAMINE.
068677 06-04
A LEARNING IMPAIRMENT ASSOCIATED WITH INDUCED PHENYLKETONURIA.
069056 06-04
STRYCHNINE EFFECTS ON DISCRIMINATION LEARNING IN MICE: EFFECTS OF DOSE AND TIME OF ADMINISTRATION.
069066 06-04
DRUGS INFLUENCING THE CHOLINERGIC SYSTEM AND THE PROCESS OF LEARNING AND MEMORY IN MAN.
070955 07-14
THE USE OF STIMULANT DRUGS IN ENHANCING PERFORMANCE AND LEARNING.
070971 07-17
IMPROVEMENT OF LEARNING IN THE AGED BY MODIFICATION OF AUTONOMIC NERVOUS SYSTEM ACTIVITY.
071336 07-14
EFFECT OF BRAIN ISO-ANTIBODIES ON LEARNING AND MEMORY IN THE RAT.
072516 08-04
LACK OF A LONG-TERM EFFECT OF LSD ON Y-MAZE LEARNING IN MICE.
074422 08-04
PENTOBARBITAL INDUCED STATE-DEPENDENT LEARNING OF ONE-WAY AVOIDANCE IN MICE.
075288 08-04
ADRENALIN AND AVOIDANCE LEARNING: PARTIAL REPLICATIONS.
075559 08-04
THE EFFECTS OF TRICYANOAMINOPROPENE ON LEARNING IN A DIFFERENTIAL REINFORCEMENT OF LOW RATES SITUATION.
075851 09-03
SODIUM DEFICIENCY AND LATENT LEARNING.
075915 09-04
BRAIN FUNCTION AND MACROMOLECULES: V. THE EFFECT OF CYCLOHEXIMIDE AND ACTINOMYCIN-D ON LEARNING IN THE HEADLESS COCKROACH.
078378 09-03
THE RELATION OF PSYCHOPHARMACOLOGICAL DRUGS TO LEARNING AND MEMORY.
078509 09-14
THE EFFECT OF EXOGENOUS RNA ON THE RETENTION OF DISCRIMINATIVE LEARNING IN THE RAT.
079982 09-04
METHYLPHENIDATE AND THIORIDAZINE: LEARNING, REACTION TIME, ACTIVITY, AND CLASSROOM BEHAVIOR IN DISTURBED CHILDREN.
081631 10-14
BIOCHEMICAL CHANGES DURING LEARNING IN AN INSECT GANGLION.
084758 10-04
MODIFICATION OF LEARNING BY DRUGS; NIMH.
092145 11-04
EFFECTS OF INSULIN, METRAZOL, AND ELECTROCONVULSIVE SHOCKS UPON LEARNING TO LEARN 30 SUCCESSIVE REVERSAL PROBLEMS BY RATS.
095188 11-04
THE EFFECTS OF AN AMPHETAMINE ON MEASURES OF INTELLIGENCE AND LEARNING IN MENTALLY RETARDED ADULTS. (PH.D.DISSERTATION).
103152 12-14
LEARNING ABILITY IN EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY UNDER THE INFLUENCE OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126056 12-04

**LEARNS**
ANNIE LEARNS TO CARE.
085860 10-11

**LEG**
THE EFFECT OF A PSYCHOTOMIMETIC GLYCOLATE AND ITS ANTIDOTE ESERINE ON THE ACH CONTENT OF THE LOBSTER WALKING LEG NERVE.
069515 06-13

**LENGTH**
MICELLAR SOLUBILIZATION OF BARBITURATES I: SOLUBILITIES OF CERTAIN BARBITURATES IN POLYSORBATES OF VARYING HYDROPHOBIC CHAIN LENGTH.
046136 01-17

**LENTICULAR**
REVERSIBLE LENTICULAR OPACITIES INDUCED IN RATS BY EMOTIONAL STRESS.
070823 07-03

**LEO-640**
CHEMISTRY AND PHARMACOLOGY OF A NEW POTENTIAL ANTIDEPRESSANT, N-METHYL-N-(4-CHLOROBENZYL-11-DIHYDRO-5H DIBENZAZEPIN-5-YL) PROPYLAMINE HYDROCHLORIDE) (LEO-640, LOPRAMINE HYDROCHLORIDE).
089786 11-01

**LESION**
BLOCKING OF EXPERIMENTAL SPIKE AND WAVE BY A LOCALIZED FOREBRAIN LESION.
066186 05-03

**LESIONED**
REDUCED EFFECT OF MORPHINE IN MIDBRAIN RAPHE LESIONED RATS.
066500 05-03
EFFECTS OF AN ACUTE STRESS OF FOREBRAIN 5-HYDROXYTRYPTAMINE (5-HT) METABOLISM IN CNS LESIONED AND DRUG PRETREATED RATS.
095671 11-04

**LESIONS**
PROJECT SUMMARY: LIMBIC SYSTEM LESIONS AND DRUG ADDICTION.
060636 03-03
EFFECTS OF AMPHETAMINE UPON RELEARNING PATTERN AND BLACK WHITE DISCRIMINATIONS FOLLOWING NEOCORTICAL LESIONS IN RATS.
065419 05-04
DIFFERENTIAL EFFECTS OF AMPHETAMINE AND SCOPOLAMINE ON MATCHING PERFORMANCE OF MONKEYS WITH LATERAL FRONTAL LESIONS.
065747 05-04
DISAPPEARANCE IN RATS WITH SEPTAL LESIONS OF THE STIMULATORY EFFECT OF HYOSCINE ON EXPLORATORY BEHAVIOUR.
067605 06-04
SKIN LESIONS AS A DIAGNOSTIC AID IN BARBITURATE POISONING.
067926 06-15
ALTERATIONS IN THE BEHAVIORAL EFFECTS OF LSD BY MIDBRAIN RAPHE LESIONS (UNPUBLISHED PAPER).
082545 10-04
ALTERATIONS IN THE BEHAVIORAL EFFECTS OF LSD BY MIDBRAIN RAPHE LESIONS.
086029 10-12
LESIONS IN CORPUS-STRIATUM AND CORTEX OF RAT BRAINS AND THE EFFECT ON PHARMACOLOGICALLY INDUCED STEREOTYPED, AGGRESSIVE AND CATALEPTIC BEHAVIOUR.
091127 11-04

**LETHAL**
POSSIBLE LETHAL REACTION BETWEEN NARDIL AND DEXTROMETHORPHAN.
063897 04-15
ELECTROCORTICAL REACTIONS OF PINEALECTOMIZED AND INTACT RATS TO LETHAL DOSES OF PENTOBARBITAL.
064101 04-03
LETHAL POISONING IN CHILDREN BY MEANS OF THYMOLEPTICS.
082202 10-15

**LETHALITY**
ALTERATIONS OF D-AMPHETAMINE SULFATE LETHALITY AND BODY TEMPERATURE IN MICE DURING ACUTE ALTITUDE EXPOSURE.
040582 01-03

**LEUCOCYTES**
DELTA8-TETRAHYDROCANNABINOL AND DELTA9-TETRAHYDROCANNABINOL: EFFECTS ON CULTURED HUMAN LEUCOCYTES.
063880 04-15

**LEUKOCYTOSIS**
LEUKOCYTOSIS DURING LITHIUM CARBONATE TREATMENT.
073711 08-15

**LEVEL**
SOME EFFECTS OF D-AMPHETAMINE ON CARBOHYDRATE METABOLISM AT GROUND LEVEL AND ALTITUDE.
069344 06-03
THE ROLE OF METHYLAMPHETAMINE ON PLASMA HEXOSAMINE LEVEL UNDER STRESS.
074855 08-03
EFFECT OF ATROPINE DOSE LEVEL ON THE SUPPRESSION OF WATER REINFORCED VI RESPONDING.
075870 09-04
REDUCTION OF LEVEL OF L-GLUTAMIC ACID DECARBOXYLASE BY GAMMA-AMINOBUTYRIC ACID IN MOUSE BRAIN.
083168 10-03
SOME BEHAVIOURAL EFFECTS OF VARIABLES WHICH INFLUENCE THE GENERAL LEVEL OF ACTIVITY OF RATS.
085204 10-04
DIAZEPAM (VALIUM) LEVEL IN THE BRAIN DURING HYPOTHERMIA.
089036 10-03
THE INFLUENCE OF 5-HYDROXYTRYPTOPHAN ON THE BEHAVIOR AND THE LEVEL OF MONOAMINES IN THE BRAIN OF RATS SENSITIVE TO SOUND.
098040 11-03

**LEVELS**
STUDIES OF DELAYED ACTION MEDICATION: V. PLASMA LEVELS AND URINARY EXCRETION OF FOUR DIFFERENT DOSAGE FORMS OF CHLORPROMAZINE.
041559 01-13
THE EFFECT OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON BRAIN ACETYLCHOLINE LEVELS IN RAT.
041913 01-03
FACTORS AFFECTING CHLORPROMAZINE PLASMA LEVELS IN PSYCHIATRIC PATIENTS.
047913 01-13
CHLORPROMAZINE PLASMA LEVELS AND EFFECTS.
047951 01-09
CARDIAC CATECHOLAMINE LEVELS AND BLOOD PRESSURE AFTER CHRONIC TREATMENT WITH BETA-ADRENERGIC BLOCKING AGENTS.
055579 02-03
THE EFFECTS OF SOME PSYCHOACTIVE DRUGS ON RAT BRAIN ADENOSINE TRIPHOSPHATE LEVELS.
058988 03-03
SERUM VITAMIN-B12 LEVELS IN PSYCHIATRIC PATIENTS ON LONG-TERM PSYCHOTROPIC DRUG THERAPY.
063874 04-13
DRUG PLASMA LEVELS IN CHRONIC ILLNESS.
064484 04-17
EFFECTS OF DISULFIRAM AND DIETHYLDITHIOCARBAMATE ON SPONTANEOUS LOCOMOTOR ACTIVITY AND BRAIN CATECHOLAMINE LEVELS IN MICE.
064590 04-04
INFLUENCE OF ETHYLPHENACEMIDE ON SERUM LEVELS OF OTHER ANTIEPILEPTIC DRUGS.
066190 05-13
THE EFFECT OF DISULFIRAM, DIETHYLDITHIOCARBAMATE AND DIMETHYLDITHIOCARBAMATE ON SEROTONIN AND 5-HYDROXYINDOLE-3-ACETIC ACID BRAIN LEVELS IN RATS.
067384 06-03
RELATIONS BETWEEN BARBITURATE BRAIN LEVELS AND SLEEPING TIME IN VARIOUS EXPERIMENTAL CONDITIONS.
068600 06-03
THE EFFECTS OF ALTERED BRAIN NOREPINEPHRINE LEVELS ON CONTINUOUS AVOIDANCE RESPONDING AND THE ACTION OF AMPHETAMINES.
074937 08-04
DELTA1-TETRAHYDROCANNABINOL, SYNHEXYL AND MARIJUANA EXTRACT ADMINISTERED ORALLY IN MAN: CATECHOLAMINE EXCRETION, PLASMA CORTISOL LEVELS AND PLATELET SEROTONIN CONTENT.
075841 08-12
MECHANISMS OF LITHIUM ACTION: (ENDOGENOUS TISSUE LEVELS, EXCRETION IN EMOTIONAL STATES, AND BEHAVIORAL EFFECTS).
080634 09-03
EFFECT OF NICOTINIC ACID COMBINED WITH A TRANQUILLIZER (HYDROXYZINE) ON SERUM LIPID LEVELS AND URINARY CATECHOLAMINE EXCRETION IN GERIATRIC PATIENTS.
093689 11-11

**LEVER-PRESS**
EFFECTS OF AMOBARBITAL SODIUM ON THE ACQUISITION AND EXTINCTION OF A LEVER-PRESS SPATIAL DISCRIMINATION IN THE RAT.
069075 06-04

**LEVODOPA**
TREATMENT OF PARKINSONISM WITH LEVODOPA.
042483 01-07
LEVODOPA, PARKINSONS DISEASE, AND HYPOTENSION.
042521 01-15
PUPILLARY EFFECTS OF LEVODOPA THERAPY.
058534 02-15
TREATMENT OF PARKINSONS SYNDROME WITH L-DIHYDROXYPHENYLALANINE (LEVODOPA).
067666 06-07
LEVODOPA IN DRUG-INDUCED EXTRAPYRAMIDAL DISORDERS.
074874 08-08
EFFECTIVENESS AND LIMITATIONS OF LONG-TERM LEVODOPA THERAPY IN PARKINSONISM.
079974 09-11
PSYCHOSIS AND OTHER PSYCHIATRIC MANIFESTATIONS OF LEVODOPA THERAPY.
081150 09-15
A POLYGRAPHIC STUDY OF THE NIGHT SLEEP OF PARKINSONIAN PATIENTS: EFFECTS OF TREATMENT WITH LEVODOPA.
087658 10-14
ANALYSIS OF RESULTS IN TREATMENT OF PARKINSONISM WITH LEVODOPA.
087660 10-11
PSYCHIC EFFECTS IN PATIENTS TREATED WITH LEVODOPA.
091919 11-11
PSYCHIATRIC CHANGES IN PATIENTS TREATED WITH LEVODOPA: I. THE CLINICAL EXPERIMENT.
092917 11-10
SLEEP IN PATIENTS WITH PARKINSONS DISEASE AND NORMAL SUBJECTS PRIOR TO AND FOLLOWING LEVODOPA ADMINISTRATION.
092974 11-11
LEVODOPA: ALTERATIONS IN BEHAVIOR.
092975 11-09
USE OF LEVODOPA MAY BE EXPANDED BY ADDITION OF MK-485 TO DRUG REGIMEN.
097284 11-09

**LEVOMEPROMAZINE**
THERAPEUTIC MEDICATION IN CHRONIC DELIRIUM: COMBINATION OF PROCHLORPERAZINE (TEMENTIL) AND LEVOMEPROMAZINE (NOZINAN).
079288 09-11
THE EFFECTS OF LEVOMEPROMAZINE ON THE NOCTURAL SLEEP EEG IN MAN.
129447 12-13

**LEVORPHANOL**
EFFECTS OF MORPHINE AND LEVORPHANOL ON BRAIN ACETYLCHOLINE CONTENT IN MICE.
101316 12-03

**LIABILITY**
UNITED-STATES PROCEDURES FOR SCREENING DRUGS: TESTING FOR DEPENDENCE LIABILITY IN ANIMALS AND MAN.
058971 03-02

**LIBERATED**
INHIBITION OF THE RE-UPTAKE OF NEURONALLY LIBERATED NORADRENALINE AND ALPHA-RECEPTOR BLOCKING ACTION OF SOME ERGOT ALKALOIDS.
041967 01-03

**LIBRIUM**
COMPARATIVE, DOUBLE-BLIND STUDY OF DOXEPINE AND LIBRIUM IN CASES OF PSYCHONEUROSES WITH ANXIETY AMONG HOSPITALIZED AND AMBULATORY PATIENTS.
087489 10-10

**LICKING**
THE EFFECTS OF D-AMPHETAMINE ON SCHEDULE CONTROLLED WATER LICKING IN THE SQUIRREL MONKEY.
071785 07-04

**LICL**
MODIFICATION OF NACL APPETITE IN THE ADRENALECTOMIZED RAT CONSEQUENT TO EXTENSIVE LICL POISONING.
061094 03-04

**LIFE**
CRISES AND LIFE CHANGES PRECEDING THE ONSET OR RELAPSE OF ACUTE SCHIZOPHRENIA: CLINICAL ASPECTS.
075304 08-08

**LIGHT**
THE EFFECTS OF MORPHINE-LIKE COMPOUNDS ON THE LIGHT RESPONSES OF THE BRINE SHRIMP ARTEMIA-SALINA.
075844 09-04
EFFECTS OF ATROPINE AND ESERINE ON THE ELECTROENCEPHALOGRAM, ON BEHAVIOUR AND ON LIGHT INDUCED EPILEPSY IN THE ADOLESCENT BABOON (PAPIO-PAPIO).
090157 11-04
TOTAL INTERNAL REFLECTION LIGHT CHAMBER (UNPUBLISHED PAPER).
092999 11-06

**LIMBIC**
PROJECT SUMMARY: LIMBIC SYSTEM LESIONS AND DRUG ADDICTION.
060636 03-03
PHARMACOLOGY, LIMBIC REGULATION AND CORTICAL FUNCTION.
070979 07-04
THE EFFECT OF MEDAZEPAM ON THE THRESHOLDS OF SUBCORTICAL LIMBIC STIMULUS RESPONSES, MEASURED IN UNANESTHETIZED, UNRESTRAINED CATS.
072067 07-03
REINFORCING LIMBIC SYSTEM STIMULATION AND SODIUM AMYTAL.
075553 08-04
DOSE RESPONSE ANALYSIS OF CARBACHOL ELICITED DRINKING IN THE RAT LIMBIC SYSTEM.
076081 09-04

**LIMBITROL**
COMBINED THERAPY IN ANXIETY DEPRESSIVE SYNDROMES: 1. COMPARATIVE EFFECTS OF LIMBITROL (CHLORDIAZEPOXIDE AMITRIPTYLINE) AND PLACEBO.
064312 04-10

**LIMITATIONS**
EFFECTIVENESS AND LIMITATIONS OF LONG-TERM LEVODOPA THERAPY IN PARKINSONISM.
079974 09-11
POSSIBILITIES AND LIMITATIONS OF DEPOT NEUROLEPTIC TREATMENT OF SCHIZOPHRENIC PSYCHOSES.
087066 10-17
USES AND LIMITATIONS OF PHOTOCELL ACTIVITY CAGES FOR ASSESSING EFFECTS OF DRUGS.
090423 11-06

**LINGUISTIC**
ON SIMILAR LINGUISTIC STRUCTURES IN CREATIVE PERFORMANCE AND PSILOCYBIN INDUCED EXPERIENCE.
065433 05-12

**LINKS**
FUNCTIONAL CHARACTERISTIC OF THE LINKS OF THE BRAIN CONTROL SYSTEM FOR MENTAL AND MOTOR FUNCTIONS IN MAN.
073770 08-13

**LIPID**
EFFECT OF NICOTINIC ACID COMBINED WITH A TRANQUILLIZER (HYDROXYZINE) ON SERUM LIPID LEVELS AND URINARY CATECHOLAMINE EXCRETION IN GERIATRIC PATIENTS.
093689 11-11

**LIPOPHILIC**
METABOLISM AND BILIARY EXCRETION OF THE LIPOPHILIC DRUG MOLECULES, IMIPRAMINE AND DESMETHYLIMIPRAMINE IN THE RAT -- I. EXPERIMENTS IN VIVO AND WITH ISOLATED PERFUSED LIVERS.
067260 06-03

**LIQUID**
HEPATIC COMPOSITION AND METABOLISM AFTER ETHANOL CONSUMPTION IN RATS FED LIQUID PURIFIED DIETS.
088599 10-03

**LIQUOR**
TEMPERATURE RESPONSES AND OTHER EFFECTS OF 5-HYDROXYTRYPTOPHAN AND 5-HYDROXYTRYPTAMINE WHEN ACTING FROM THE LIQUOR SPACE IN UNANESTHETIZED RABBITS.
046404 01-03

**LITERATURE**
ADVERSE MARIJUANA REACTIONS: A CRITICAL EXAMINATION OF THE LITERATURE WITH SELECTED CASE MATERIAL.
069613 07-15

ON THE MUTAGENIC EFFECT OF MEDICINAL PREPARATIONS USED IN PSYCHIATRY. (REVIEW OF THE LITERATURE).
102119 12-16

**LITHANE**
LITHANE: THE STORY OF LITHIUM CARBONATE.
078106 09-17

**LITHIUM**
EFFECTS OF LITHIUM CARBONATE ON TURNOVER AND METABOLISM OF NOREPINEPHRINE IN THE RAT BRAIN - CORRELATION TO GROSS BEHAVIORAL EFFECTS.
043277 01-03

SODIUM BALANCE AND DISTRIBUTION IN LITHIUM CARBONATE THERAPY.
047828 01-09

LITHIUM CARBONATE FOR AFFECTIVE DISORDERS. I. CLINICAL PHARMACOLOGY AND TOXICOLOGY.
047831 01-09

THE MANY FACES OF MANIA: THERAPEUTIC TRIAL OF LITHIUM CARBONATE.
047919 01-09

EFFECT OF MOOD AND LITHIUM CARBONATE ON TOTAL BODY POTASSIUM.
047952 01-09

LITHIUM CARBONATE AS A MOOD AND TOTAL BODY WATER STABILIZER.
047953 01-09

EFFECT OF LITHIUM CARBONATE THERAPY ON ADRENOCORTICAL ACTIVITY.
047954 01-09

A CASE OF MANIC-DEPRESSIVE ILLNESS WITH LITHIUM TOXICITY.
058213 02-15

TREATMENT OF CHILDREN OF LITHIUM RESPONDING PARENTS.
058375 02-09

LITHIUM IN PREGNANCY.
058405 02-15

PROPHYLACTIC LITHIUM: A DOUBLE-BLIND TRIAL IN RECURRENT AFFECTIVE DISORDERS.
060263 03-09

PHARMACOLOGICAL AND CLINICAL PROBLEMS OF LITHIUM PROPHYLAXIS.
060264 03-17

LITHIUM PROPHYLAXIS IN RECURRENT AFFECTIVE DISORDERS.
060267 03-09

THE EFFECTS OF LITHIUM ON ELECTROENCEPHALOGRAM, BEHAVIOR AND SERUM ELECTROLYTES.
060859 03-09

IMIPRAMINE AND LITHIUM EFFECTS ON BIOGENIC AMINE TRANSPORT IN DEPRESSED AND MANIC-DEPRESSED PATIENTS.
062326 03-13

EFFECTIVENESS OF LITHIUM CARBONATE IN THE TREATMENT OF MANIC-DEPRESSIVE ILLNESS.
062348 03-09

A COMPARISON OF LITHIUM CARBONATE AND CHLORPROMAZINE IN MANIA.
062349 03-09

FACTORS ASSOCIATED WITH POOR RESPONSE TO LITHIUM CARBONATE: A CLINICAL STUDY.
062352 03-09

IMIPRAMINE AND LITHIUM EFFECTS ON BIOGENIC AMINE TRANSPORT IN DEPRESSED AND MANIC-DEPRESSED PATIENTS.
062366 03-13

EFFECTS OF LITHIUM PRETREATMENT ON AMPHETAMINE AND DMI TETRABENAZINE PRODUCED PSYCHOMOTOR BEHAVIOR.
062521 03-04

EFFECT OF LITHIUM ON FOOT SHOCK AGGRESSION IN RATS.
062777 03-04

LITHIUM IN PSYCHIATRY.
063138 03-09

LITHIUM: CRITICAL EVALUATION.
063139 03-09

LITHIUM: CRITICAL EVALUATION.
063140 03-09

LITHIUM: CRITICAL EVALUATION.
063141 03-09

LITHIUM IN PSYCHIATRY.
063142 03-09

LITHIUM VERSUS CHLORPROMAZINE FOR MANICS. INITIATIVE AND PRODUCTIVITY VERSUS TRANQUILIZATION HOSPITALIZATION.
063209 03-09

LITHIUM, CREATIVITY, AND MANIC-DEPRESSIVE ILLNESS: REVIEW AND PROSPECTUS.
063601 04-09

THE VA-NIMH STUDY OF LITHIUM IN AFFECTIVE DISORDERS.
063607 04-09

LITHIUM CARBONATE.
064088 04-11

THE PRESENT STATUS OF LITHIUM THERAPY IN MANIC-DEPRESSIVE PSYCHOSIS.
064089 04-09

LITHIUM CARBONATE IN AFFECTIVE DISORDERS.
064232 04-17

EFFECTS OF LITHIUM ON THYROID FUNCTION (A REVIEW).
064316 04-15

COMPARISON OF LITHIUM CARBONATE AND IMIPRAMINE (IN PREVENTION OF MANIC-DEPRESSIVE DISEASE).
064317 04-09

LITHIUM CARBONATE IN THERAPY.
065183 05-13

THE EFFECT OF PROLONGED LITHIUM TREATMENT ON THE SYNTHESIS RATE AND TURNOVER OF MONOAMINES IN BRAIN REGIONS OF RATS.
066413 05-03

ALDOSTERONE AND SODIUM RESPONSE TO LITHIUM ADMINISTRATION IN MAN.
066493 05-13

ACETYLCHOLINE RELEASE FROM CORTICAL BRAIN SLICES OF RATS INJECTED WITH LITHIUM.
066509 05-03

ELECTROCARDIOGRAPHIC CHANGES DURING LITHIUM TREATMENT.
066747 05-13

LITHIUM EFFECT ON PLASMA GLUCAGON, LIVER PHOSPHORYLASE-A AND LIVER GLYCOGEN IN RATS.
066822 05-03

LITHIUM IN HAZARDOUS CIRCUMSTANCES WITH ONE CASE OF LITHIUM TOXICITY.
067138 06-15

LITHIUM CARBONATE AS AN ADJUNCT IN THE TREATMENT OF SCHIZOPHRENIA.
067364 06-08

CONVULSION DURING LITHIUM THERAPY.
067900 06-15

THE EFFECT OF LITHIUM UPON BRAIN NEUROAMINES.
069062 06-03

LITHIUM NEUROTOXICOLOGIC EFFECTS: 1. ACUTE PHASE (PRELIMINARY OBSERVATIONS).
069312 06-05

SIDE-EFFECTS AND TERATOGENICITY OF LITHIUM CARBONATE TREATMENT.
069580 07-15

TREATMENT WITH LITHIUM CARBONATE: RESULTS IN 35 CASES.
070287 07-09

OCCURRENCE OF PERIODIC PSYCHOSES DURING PROPHYLACTIC ADMINISTRATION OF LITHIUM.
070950 07-08

SOME EXPERIENCES WITH A PREVENTIVE ADMINISTRATION OF LITHIUM SALTS IN MANIC MELANCHOLIC PSYCHOSIS.
070952 07-09

SALT SUPPLEMENTS WITH LITHIUM.
071968 07-15

LITHIUM TOXICITY.
071970 07-15

PROPHYLACTIC LITHIUM.
072429 08-09

LEUKOCYTOSIS DURING LITHIUM CARBONATE TREATMENT.
073711 08-15

LITHIUM IN MANIA.
073734 08-17

CATECHOLAMINE METABOLISM IN AFFECTIVE DISORDERS – III. MHPG AND OTHER CATECHOLAMINE METABOLITES IN PATIENTS TREATED WITH LITHIUM CARBONATE.
075410 08-09

CLINICAL EXPERIENCE WITH LITHIUM CARBONATE.
075424 08-08

A LONGITUDINAL INVESTIGATION OF LITHIUM AS A PROPHYLACTIC AGENT FOR RECURRENT DEPRESSIONS.
075425 08-10

LITHIUM INDUCED DIABETES-INSIPIDUS LIKE SYNDROME.
075426 08-10

A DOUBLE-BLIND COMPARISON OF LITHIUM AND CHLORPROMAZINE IN THE TREATMENT OF MANIC STATES.
075430 08-09

LITHIUM CARBONATE TREATMENT IN PSYCHIATRY.
075584 08-11

CRITIQUE OF STUDIES OF LITHIUM SALTS IN THE TREATMENT OF MANIA.
075867 09-09

LITHANE: THE STORY OF LITHIUM CARBONATE.
078106 09-17

LITHIUM CARBONATE IN THERAPY.
078422 09-17

ACUTE LITHIUM POISONING.
079914 09-15

REDUCTION OF ANALGESIC EFFECTS BY LITHIUM.
080144 09-03

MECHANISMS OF LITHIUM ACTION: (ENDOGENOUS TISSUE LEVELS, EXCRETION IN EMOTIONAL STATES, AND BEHAVIORAL EFFECTS).
080634 09-03

THE EFFECT OF LITHIUM ON THE METABOLISM OF EXPERIMENTAL ANIMALS.
081111 09-03

BEHAVIORAL EFFECTS OF P-CHLOROPHENYLALANINE IN RATS: INHIBITION BY LITHIUM.
081112 09-03

PROPHYLACTIC LITHIUM IN RECURRENT AFFECTIVE DISORDERS: A FOUR YEAR STUDY.
081152 09-09

THE TREATMENT OF MANIC RELATED DISEASES WITH LITHIUM CARBONATE.
081516 09-09

LITHIUM.
082017 10-15

BIOCHEMICAL ASPECTS OF LITHIUM PHARMACOLOGY (UNPUBLISHED PAPER).
088356 10-09

THE EFFECTS OF ACUTE AND PROLONGED LITHIUM TREATMENT ON THE DISTRIBUTION OF ELECTROLYTES, POTASSIUM AND SODIUM.
088614 10-03

PARADOXAL PSYCHIC REACTIONS DURING LITHIUM TREATMENT.
089103 10-15

PROPHYLACTIC LITHIUM THERAPY FOR CHRONIC DEPRESSIVE PSYCHOSIS AND SCHIZO-AFFECTIVE DISORDERS.
089105 10-09

TERATOGENIC EFFECT OF LITHIUM CARBONATE IN THE FETAL MOUSE.
089398 10-05

FDA APPROVES LITHIUM FOR MANIC-DEPRESSION.
089400 10-17

THE INFLUENCE OF LITHIUM ION ON THE ADRENOCORTICAL FUNCTION OF RATS.
089787 11-09

LITHIUM TREATMENT OF THE PSYCHOSES.
090358 11-16

LITHIUM INDUCED CHANGES IN ELECTROLYTE BALANCE AND TISSUE ELECTROLYTE CONCENTRATION.
090419 11-03

LITHIUM CARBONATE IN PSYCHIATRIC THERAPEUTICS.
094287 11-09

PSYCHOPHARMACOLOGY OF THE LITHIUM ION (TWENTY YEARS AFTER).
095013 11-09

NEUROPHYSIOLOGICAL AND BEHAVIORAL CORRELATES OF LITHIUM.
095014 11-03

THE USE OF LITHIUM SALTS FOR THE PREVENTION OF AFFECTIVE ATTACKS.
096512 11-09

INHIBITION OF CENTRAL SEROTONINERGIC EXCITATION (5-HYDROXYTRYPTOPHAN INDUCED DEAD TWITCHES) IN MICE BY LITHIUM.
097989 11-04

LITHIUM IN PSYCHIATRY: CLINICAL AND BIOCHEMICAL ASPECTS.
098018 11-09

CLINICAL PROBLEMS IN CONNECTION WITH THE APPLICATION OF LITHIUM.
100076 11-09

CONCERNING THE EVIDENCE FOR A PROPHYLACTIC ACTION OF LITHIUM.
100082 11-09

LITHIUM INDUCED POLYURIA: EXPERIMENTAL STUDIES IN MAN AND THE RAT.
100083 11-15

PSYCHOSOCIAL PROFILES OF PATIENTS ON LITHIUM TREATMENT.
106762 12-14

CERTAIN CIRCADIAN RHYTHMS IN MANIC-DEPRESSIVES AND THEIR RESPONSE TO LITHIUM.
106763 12-09

LITHIUM CARBONATE: A DRUG OF LIMITED EFFICACY IN THE PREVENTION OF MANIC-DEPRESSIVE DISEASE.
106764 12-09

LONG-TERM DRUG THERAPY IN AFFECTIVE DISORDERS: THEORETICAL AND METHODOLOGICAL ISSUES IN CURRENT RESEARCH ON LITHIUM.
106765 12-09

CLINICAL CONTROVERSIES AND THEORETICAL MODE OF ACTION OF LITHIUM CARBONATE.
106767 12-13

SUSTAINED-RELEASE LITHIUM CARBONATE.
106768 12-09

NEUROTOXICITY WITH LITHIUM: DIFFERENTIAL DRUG RESPONSIVENESS.
106769 12-15

INDICATIONS OF LITHIUM SALTS IN PSYCHOSOMATIC MEDICINE.
106770 12-17

LITHIUM DROP-OUTS: A FOLLOW-UP STUDY OF PATIENTS WHO DISCONTINUED PROPHYLACTIC TREATMENT.
106771 12-09

RESULTS OF ELECTROENCEPHALOGRAPHIC STUDIES RELATING TO LITHIUM EFFICACY.
106772 12-13

TREATMENT OF MOOD DISORDERS WITH LITHIUM CARBONATE.
106773 12-09

PROPHYLACTIC ACTION OF LITHIUM SALTS AND THYROID HORMONES ON SYMPTOMS OF MANIC-DEPRESSIVE AND AFFECTIVE PSYCHOSES: CLINICAL AND EXPERIMENTAL RESULTS.
106774 12-09

COMPLICATIONS OR COINCIDENCES DURING LITHIUM THERAPY: A REVIEW OF SEVERAL CASES.
106775 12-09

ANTIAGGRESSIVE EFFECT OF LITHIUM SALTS IN SEVERE MENTALLY RETARDED ADOLESCENTS.
106776 12-14

EFFECTS OF LITHIUM AND OTHER PSYCHOPHARMACA ON RAT ELECTROLYTE METABOLISM.
106778 12-05

LITHIUM INDUCED POLYURIA IN RATS.
106779 12-05

LITHIUM EFFECTS ON CALCIUM METABOLISM IN RATS.
106780 12-03

LITHIUM: SOME CRITICAL CONSIDERATIONS.
106782 12-17

STRUCTURAL BASIS OF LITHIUM PSYCHOPHARMACOLOGY: EXTRACELLULAR GROUND SUBSTANCE OF RAT BRAIN.
106783 12-03

LITHIUM AS A THERAPEUTIC AND PREVENTIVE DRUG IN AFFECTIVE DISORDERS.
109723 12-09

PHYSIOLOGICAL AND BIOCHEMICAL MECHANISMS OF THE EFFECT OF LITHIUM SALTS ON THE NERVOUS SYSTEM.
109786 12-13

CLINICAL RESULTS ON THE THERAPEUTIC ACTION OF LITHIUM CARBONATE IN DYSTHYMIC PSYCHOSES.
114880 12-09

THE EFFECTS OF LITHIUM SALTS IN THE TREATMENT OF DEPRESSION.
129579 12-09

ON THE EFFICACY AND THE MECHANISM OF ACTION OF LITHIUM SALTS IN MANIC-DEPRESSIVE PSYCHOSES.
130414 12-09

**LITHIUMS**

LITHIUMS POSITION AMONG ANTIDEPRESSANTS IN THE TREATMENT OF ACUTE ENDOGENOUS AND INVOLUTIONAL DEPRESSIONS.
106777 12-09

**LIVER**

COMPARISON OF LIVER MICROSOME ENZYME SYSTEMS AND BARBITURATE SLEEP TIMES IN RATS CAGED INDIVIDUALLY OR COMMUNALLY.
045545 01-06

MORPHINE AND THE INCORPORATION OF 32 ORTHOPHOSPHATE IN VIVO INTO PHOSPHOLIPIDS OF THE GUINEA-PIG CEREBRAL CORTEX, LIVER AND SUBCELLULAR FRACTIONS.
046401 01-03

LIVER DAMAGE FOLLOWING APPLICATION OF PYRAZINAMIDE IN ANIMAL EXPERIMENTS: 1. CHANGES IN BODY WEIGHT OF RATS UNDER THE INFLUENCE OF PYRAZINAMIDE.
055398 02-05

LIVER DISEASE AND PHENOTHIAZINES; INVOLUNTARY MOVEMENTS.
063854 04-15

EFFECTS OF MORPHINE TREATMENT AND STARVATION ON THE SUBSTRATE INTERACTION WITH P-450 IN THE OXIDATION OF DRUGS BY LIVER MICROSOMES.
063982 04-03

EFFECT OF MORPHINE ADMINISTRATION ON THE HYDROXYLATION OF STEROID HORMONES BY RAT LIVER MICROSOMES.
066366 05-03

LITHIUM EFFECT ON PLASMA GLUCAGON, LIVER PHOSPHORYLASE-A AND LIVER GLYCOGEN IN RATS.
066822 05-03

CONTRACEPTIVES, BRAIN SEROTONIN, AND LIVER TRYPTOPHAN PYRROLASE.
067072 05-03

STUDIES ON DAMAGE TO THE LIVER BY ALCOHOL.
067130 06-11

A POSSIBLE PATHWAY FOR ETHANOL INDUCED FATTY LIVER AND MODIFICATION OF LIVER INJURY BY ANTIOXIDANTS.
070906 07-05

CHANGES IN LIVER DISTURBANCE ASSOCIATED WITH LONG-TERM TRANQUILIZING MEDICATION (A FOLLOW-UP STUDY).
075839 08-15

CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIC WOMEN: ITS EFFECT ON THYROID AND LIVER FUNCTION IN RELATION TO SERUM CHOLESTEROL CONCENTRATION.
088221 10-13

TOXICITY OF HEPATOTOXIC DRUGS ON MOUSE LIVER TISSUE CULTURE.
088615 10-05

RELATIONSHIP BETWEEN CENTRAL EFFECTS AND THE CONCENTRATION OF AMPHETAMINE IN LIVER AND BRAIN OF YOUNG AND OLD RATS.
089041 10-03

A STUDY OF HEPATIC ALCOHOL DEHYDROGENASE INHIBITION (ADH) INDUCED BY PYRAZOL: II. THE ROLE OF LIVER ADH IN THE IN VIVO METABOLISM OF HYDROXYL COMPOUNDS.
089547 11-03

HYPERTENSIVE CRISIS IN A PATIENT ON MAOI ANTIDEPRESSANTS FOLLOWING A MEAL OF BEEF LIVER.
092211 11-15

PREPARATION OF 3H-7-HYDROXYCHLORPROMAZINE USING SHEEP LIVER MICROSOMES FOR HYDROXYLATION OF 3H-CHLORPROMAZINE.
097582 11-01

**LIVERS**

METABOLISM AND BILIARY EXCRETION OF THE LIPOPHILIC DRUG MOLECULES, IMIPRAMINE AND DESMETHYLIMIPRAMINE IN THE RAT -- I. EXPERIMENTS IN VIVO AND WITH ISOLATED PERFUSED LIVERS.
067260 06-03

**LOBES**

GABA AS A REPRESSOR OF L-GLUTAMIC ACID DECARBOXYLASE (GAD) IN DEVELOPING CHICK EMBRYO OPTIC LOBES.
058192 02-03

**LOBOTOMY**

THE INFLUENCES OF THE STANDARD PREFRONTAL LOBOTOMY OPERATION ON HALLUCINATORY PHENOMENA ASSOCIATED WITH PSYCHOTOMIMETIC DRUGS.
120899 12-13

**LOBSTER**

THE EFFECT OF A PSYCHOTOMIMETIC GLYCOLATE AND ITS ANTIDOTE ESERINE ON THE ACH CONTENT OF THE LOBSTER WALKING LEG NERVE.
069515 06-13

**LOCALIZED**

BLOCKING OF EXPERIMENTAL SPIKE AND WAVE BY A LOCALIZED FOREBRAIN LESION.
066186 05-03

**LOCATED**

RECIPROCAL HUNGER REGULATING CIRCUITS INVOLVING ALPHA-ADRENERGIC AND BETA-ADRENERGIC RECEPTORS LOCATED, RESPECTIVELY, IN THE VENTROMEDIAL AND LATERAL HYPOTHALAMUS.
092166 11-03

**LOCI**

POSSIBLE LOCI OF ACTION OF 2-ETHYL-ETHYLAMINO-6-METHOXY-S-TRIAZINE FOR ELECTROENCEPHALOGRAPHIC AND SYMPATHETIC ACTIVATION IN CAT.
089788 11-13

**LOCOMOTOR**

EFFECTS OF DISULFIRAM AND DIETHYLDITHIOCARBAMATE ON SPONTANEOUS LOCOMOTOR ACTIVITY AND BRAIN CATECHOLAMINE LEVELS IN MICE.
064590 04-04

INITIAL SUPPRESSION OF THE LOCOMOTOR STIMULANT RESPONSE TO DEXAMPHETAMINE IN RATS EXPOSED TO A NOVEL ENVIRONMENT.
067601 06-04

STUDIES ON INTERACTIONS INVOLVING ANTIDEPRESSIVE AND OTHER DRUGS WITH TETRABENAZINE AND NORADNAMINE ON LOCOMOTOR ACTIVITY IN MICE, INCLUDING DETAILS OF THE EXPERIMENTAL DESIGN AND STATISTICAL ANALYSIS.
069077 06-04

MODULATION OF FOOD INTAKE AND LOCOMOTOR ACTIVITY IN FEMALE RATS BY DIENCEPHALIC HORMONE IMPLANTS.
076080 09-04

**LOGOS**

PSYCHOCLINICAL OBSERVATIONS ON THE EFFECT OF THE LOGOS COMPOUND (ASSOCIATION OF PYRITHIOXINE DIHYDROCHLORIDE, TRYPTOPHAN AND CALCIUM ALPHA-KETOGLUTARATE).
109258 12-11

**LONG**

RESPONSE TO DRUGS BY RATS SHOWING LONG OR SHORT HEXOBARBITAL INDUCED SLEEP.
058990 03-03

**LONG-ACTING**

STATISTICAL METHOD OF ANALYSIS AND EVALUATION OF PSYCHOTHERAPEUTIC RESULTS: APPLICATION OF A LONG-ACTING NEUROLEPTIC, COMPARED WITH A STANDARD NEUROLEPTIC AND THE SAKEL INSULIN TREATMENT.
042676 01-07

THE PHILOSOPHY OF LONG-ACTING MEDICATION IN PSYCHIATRY.
065459 05-17

LONG-ACTING, ANTIPSYCHOTIC AGENTS AND EXTRAPYRAMIDAL SIDE-EFFECTS.
065471 05-15

LONG-ACTING DRUG TREATMENT IN OVERALL PSYCHIATRIC MANAGEMENT.
065472 05-17

LONG-ACTING PHENOTHIAZINES AND LONG-TERM PSYCHOTIC PATIENTS: THE ROLE OF FLUPHENAZINE ENANTHATE IN TREATMENT.
065479 05-08

LONG-ACTING NEUROLEPTICS: III. PILOT STUDY OF PENFLURIDOL (R-16341).
069070 06-07

PSYCHIATRIC COMMUNITY CARE SYSTEM: USE OF LONG-ACTING PHENOTHIAZINES.
080007 09-17

POSSIBLE APPLICATIONS OF LONG-ACTING INTRAMUSCULAR MAJOR TRANQUILLIZERS.
100020 11-11

A LONG-ACTING NEUROLEPTIC IN THE TREATMENT OF CHRONIC ALCOHOLISM IN NEUROTIC AND PSYCHOTIC PATIENTS.
109255 12-11

**LONG-LASTING**

LONG-LASTING EFFECTS OF LSD ON NORMALS.
067343 06-12

FURTHER STUDIES ON THE LONG-LASTING ANTIMETRAZOL ACTIVITY OF DIAZEPAM IN MICE.
081106 09-03

**LONG-TERM**

LONG-TERM VARIATION IN BASAL AND PHENOBARBITAL STIMULATED OXIDATIVE DRUG METABOLISM IN THE RAT.
040671 01-03

IMPAIRMENT OF SHOCK AVOIDANCE LEARNING AFTER LONG-TERM ALCOHOL INGESTION IN MICE.
058492 02-04

SERUM VITAMIN-B12 LEVELS IN PSYCHIATRIC PATIENTS ON LONG-TERM PSYCHOTROPIC DRUG THERAPY.
063874 04-13

LONG-ACTING PHENOTHIAZINES AND LONG-TERM PSYCHOTIC PATIENTS: THE ROLE OF FLUPHENAZINE ENANTHATE IN TREATMENT.
065479 05-08

LONG-TERM PSYCHOTHERAPY UTILIZING TRIFLUOPERAZINE IN A PSYCHOTIC PRESCHOOL CHILD: (A CASE STUDY).
066806 05-11

NOREPINEPHRINE TURNOVER AND METABOLISM IN RAT BRAIN AFTER LONG-TERM ADMINISTRATION OF IMIPRAMINE.
067687 06-03

LONG-TERM TREATMENT WITH OCTOCLOTHEPINE -- SIDE-EFFECTS AND LABORATORY FINDINGS.
070928 07-09

THE INFLUENCE OF LONG-TERM PREMEDICATION WITH TRANYLCYPROMINE ON EXPERIMENTAL PSYCHOSES INDUCED BY LSD.
070954 07-12

LACK OF A LONG-TERM EFFECT OF LSD ON Y-MAZE LEARNING IN MICE.
074422 08-04

RELATIONSHIPS OF THE MECHOLYL TEST, PREMORBID ASOCIAL FUNCTIONING AND LONG-TERM OUTCOME IN SCHIZOPHRENIA.
075227 08-08

CHANGES IN LIVER DISTURBANCE ASSOCIATED WITH LONG-TERM TRANQUILIZING MEDICATION (A FOLLOW-UP STUDY).
075839 08-15

ON THE EFFECT OF DIOXYPHENYLALANINE (L-DOPA) ON EXTRAPYRAMIDAL HYPERKINESIA DUE TO NEUROLEPTIC LONG-TERM MEDICATION.
079950 09-15

EFFECTIVENESS AND LIMITATIONS OF LONG-TERM LEVODOPA THERAPY IN PARKINSONISM.
079974 09-11

ON PROBLEMS OF LATE EXTRAPYRAMIDAL HYPERKINESIS DUE TO NEUROLEPTIC LONG-TERM THERAPY.
079996 09-15

CLINICAL AND AMBULANT TESTING WITH FLUPHENAZINE DECANOATE LYOGEN DEPOT IN THE LONG-TERM TREATMENT OF PSYCHIATRIC DISEASE.
080040 09-16

COITAL BEHAVIOR IN DOGS: VI. LONG-TERM EFFECTS OF CASTRATION UPON MATING IN THE MALE.
080606 09-03

CONTROLLED LONG-TERM STUDY ON SENILE HYPERTENSION.
089785 11-15

ETIOLOGY OF LATE HYPERKINESIS IN THE COURSE OF LONG-TERM TREATMENT WITH NEUROLEPTICS.
100997 12-15

NEUROPATHOLOGY OF PERSISTENT CHOREIFORM HYPERKINESIAS UNDER LONG-TERM TREATMENT WITH NEUROLEPTICS.
101020 12-15

LONG-TERM TREATMENT WITH CHLORPROMAZINE IN ANIMAL EXPERIMENTATION.
105619 12-05

LONG-TERM DRUG THERAPY IN AFFECTIVE DISORDERS: THEORETICAL AND METHODOLOGICAL ISSUES IN CURRENT RESEARCH ON LITHIUM.
106765 12-09

**LONGITUDINAL**

THE EFFECTS OF MORPHINE-LIKE SUBSTANCES AND THEIR ANTAGONISTS ON TRANSMISSION AT THE NEURO EFFECTOR JUNCTION OF THE MYENTERIC PLEXUS LONGITUDINAL MUSCLE PREPARATION OF THE GUINEA-PIG ILEUM.
041974 01-03

A LONGITUDINAL INVESTIGATION OF LITHIUM AS A PROPHYLACTIC AGENT FOR RECURRENT DEPRESSIONS.
075425 08-10

A TECHNIQUE TO DEMONSTRATE THE EFFECT OF A PSYCHOPHARMACEUTICAL DRUG IN A PSYCHOPATHOLOGICAL LONGITUDINAL SECTION BY NUMERIC AND GRAPHIC MEANS.
079973 09-06

**LOPRAMINE**

CHEMISTRY AND PHARMACOLOGY OF A NEW POTENTIAL ANTIDEPRESSANT, N-METHYL-N-(4-CHLOROBENZYL-11-DIHYDRO-5H DIBENZAZEPIN-5-YL) PROPYLAMINE HYDROCHLORIDE) (LEO-640, LOPRAMINE HYDROCHLORIDE).
089786 11-01

**LOSES**

MEPROBAMATE LOSES SOME LABEL CLAIMS.
070830 07-17

**LOSS**

THE CONCOMITANT EFFECTS OF MILD SLEEP LOSS AND AN ANTICHOLINERGIC DRUG.
064387 04-13

**LOXAPINE**

ANTIPSYCHOTIC PROPERTIES OF LOXAPINE SUCCINATE.
058374 02-07

**LSD**

TOTAL BODY KINETICS AND PLACENTAL TRANSFER OF LABELED LSD IN MICE.
046201 01-03

THE BEYOND WITHIN: THE LSD STORY.
046725 01-12

PSYCHOTHERAPY WITH LSD: PRO AND CON.
046733 01-11

LSD EXPOSURE IN UTERO.
056611 02-15

PSYCHOTHERAPY FOR THE DYING: PRINCIPLES AND ILLUSTRATIVE CASES WITH SPECIAL REFERENCE TO THE USE OF LSD.
062808 03-12

A COMPARISON OF SHORT-TERM TREATMENT EFFECTS OF INTRAVENOUS SODIUM AMYTAL METHEDRINE AND LSD IN THE ALCOHOLIC.
062934 03-11

A CONTROLLED STUDY OF LSD TREATMENT IN ALCOHOLISM AND NEUROSIS.
063873 04-12

LSD: NO TERATOGENIC ACTION IN RATS, MICE, AND HAMSTERS.
063993 04-03

THE EFFECT OF LSD ON SLEEP DEPRIVED MEN.
064388 04-12

EFFECTS OF CANNABIS-SATIVA AND LSD ON PIGEONS IN THREE VISUAL ENVIRONMENTS.
064499 04-04

SPINAL FLUID CREATINE PHOSPHOKINASE ABNORMALITIES FOLLOWING LSD USAGE.
067213 06-15

THE USE OF LSD IN PSYCHOTHERAPY.
067339 06-12

ANALYSIS OF THE LSD FLASHBACK.
067341 06-15

LONG-LASTING EFFECTS OF LSD ON NORMALS.
067343 06-12

LSD, VIOLENCE AND RADICAL RELIGIOUS BELIEFS.
067354 06-12

IMPLICATIONS OF LSD AND EXPERIMENTAL MYSTICISM.
067355 06-12

LSD CONDEMNED AS TREATMENT AGENT.
067868 06-15

THE INFLUENCE OF LONG-TERM PREMEDICATION WITH TRANYLCYPROMINE ON EXPERIMENTAL PSYCHOSES INDUCED BY LSD.
070954 07-12

THE THERAPEUTIC POTENTIAL OF LSD: ITS ADJUNCTIVE USE IN PSYCHOTHERAPY.
073852 08-11

LACK OF A LONG-TERM EFFECT OF LSD ON Y-MAZE LEARNING IN MICE.
074422 08-04

TREAD SOFTLY ON MY LSD.
074858 08-12

THE FUNCTION OF MUSIC IN LSD THERAPY FOR ALCOHOLIC PATIENTS.
075191 08-12

A CLINICAL EXAMINATION OF CHRONIC LSD USE IN THE COMMUNITY.
076254 09-12

CONFIGURATION FREQUENCY ANALYSIS OF SOME LSD EFFECTS.
079956 09-12

LSD IN PSYCHIATRY.
082016 10-15

LSD IN PSYCHIATRY.
082018 10-15

ALTERATIONS IN THE BEHAVIORAL EFFECTS OF LSD BY MIDBRAIN RAPHE LESIONS (UNPUBLISHED PAPER).
082545 10-04

LSD AS A DIAGNOSTIC AID (UNPUBLISHED PAPER).
085893 10-12

ALTERATIONS IN THE BEHAVIORAL EFFECTS OF LSD BY MIDBRAIN RAPHE LESIONS.
086029 10-12

THE USES AND ABUSES OF LSD AND OTHER HALLUCINOGENIC DRUGS.
087470 10-12

THE EXPERIMENTAL USE OF PSYCHEDELIC (LSD) PSYCHOTHERAPY.
097286 11-12

ALTERATIONS IN THE BEHAVIORAL EFFECTS OF LSD BY PRETREATMENT WITH P-CHLOROPHENYLALANINE AND ALPHA-METHYL-P-TYROSINE.
097965 11-04

THE PERFORMANCE OF LSD USERS ON CERTAIN NEUROPSYCHOLOGICAL TESTS. (PH.D. DISSERTATION).
135186 12-14

LSD AS A DIAGNOSTIC AID.
138597 12-08

**LSD-LIKE**

THE ACTION OF TRYPTAMINE ON THE DOG SPINAL CORD AND ITS RELATIONSHIP TO THE AGONISTIC ACTIONS OF LSD-LIKE PSYCHOTOGENS.
090422 11-03

**LSD-25**

ACCUMULATION AND DISAPPEARANCE OF 3H-5-HYDROXYTRYPTAMINE FORMED FROM 3H-TRYPTOPHAN IN MOUSE BRAIN: EFFECT OF LSD-25.
042755 01-03

GROUP TREATMENT OF CHRONIC ALCOHOLISM WITH LSD-25: STUDY II.
057480 02-14

CHROMOSOMAL EFFECTS OF LSD-25, A CONTROVERSY?
058908 02-15

CHROMOSOME STUDIES IN PREGNANT RHESUS MACAQUE GIVEN LSD-25.
064315 04-05

LYSERGIC ACID DIETHYLAMIDE (LSD-25): XXXIX. THE EFFECT OF HIGH TEMPERATURES ON STABILITY.
064609 04-06

LSD-25 EFFECTS ON CHROMOSOMES: A REVIEW.
067342 06-13

EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND 2-BROM-D-LYSERGIC ACID DIETHYLAMIDE (BOL-148) UPON BEHAVIORAL SLEEP IN RATS.
089045 10-12

EFFECT OF LSD-25, CHLORPROMAZINE AND METEDRINE UPON VISUAL EVOKED RESPONSE IN CATS.
098171 11-03

INTOXICATIONS BY LSD-25: MEDICOLEGAL PROBLEMS.
132911 12-12

**LU-3-010**

INHIBITORY EFFECT OF TWO NEWER ANTIDEPRESSANTS, LU-5-003 AND LU-3-010, ON SEROTONIN UPTAKE IN HUMAN BLOOD PLATELETS IN VITRO.
071791 07-03

**LU-5-003**

INHIBITORY EFFECT OF TWO NEWER ANTIDEPRESSANTS, LU-5-003 AND LU-3-010, ON SEROTONIN UPTAKE IN HUMAN BLOOD PLATELETS IN VITRO.
071791 07-03

**LUCIDRIL**

THE INFLUENCE OF CENTROPHENOXINE (LUCIDRIL) ON LEARNING AND MEMORY IN ALCOHOLICS.
062800 03-14

**LUMEN**
EFFECT OF CAPERS ON THE VASCULAR LUMEN OF ISOLATED EXTREMITIES OF SENSITIZED FROGS AND THE ANTIANAPHYLATIC EFFECT OF SUPRASTIN.
105720 12-03

**LUNG**
ISONICOTINIC-ACID-HYDRAZIDE (INH) INDUCED MENTAL DISORDERS IN THE COURSE OF LUNG TUBERCULOSIS TREATMENT.
072890 08-15

**LUNGS**
PHARMACOLOGICAL SIGNIFICANCE OF BIOGENIC AMINES IN THE LUNGS: NORADRENALINE AND DOPAMINE.
041539 01-03
PHARMACOLOGICAL SIGNIFICANCE OF BIOGENIC AMINES IN THE LUNGS: 5-HYDROXYTRYPTAMINE.
041565 01-03

**LUVATREN**
EXPERIMENTAL USE OF PREPARATION LUVATREN IN SCHIZOPHRENIC PATIENTS.
111022 12-08

**LUVATRENE**
USE OF THE DRUG LUVATRENE FOR THE TREATMENT OF OUTPATIENTS.
089109 10-17

**LYING**
LETS STOP LYING ABOUT DRUGS.
051530 02-13

**LYMPHOCYTE**
THE EFFECTS OF PHENOTHIAZINE THERAPY ON LYMPHOCYTE TRANSFORMATION IN SCHIZOPHRENIA.
067288 06-15
SCHIZOPHRENIA AND LYMPHOCYTE MITOTIC CAPACITY.
068181 06-15

**LYMPHOGENIC**
UNCONDITIONED REFLEX ACTIVITY IN THE RAT SUFFERING FROM EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY AND THE THERAPEUTIC EFFECT OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126051 12-04
DECREASE OF SPONTANEOUS MOTILITY IN EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY AND THE PROTECTIVE ACTIVITY OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126052 12-04
LEARNING ABILITY IN EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY UNDER THE INFLUENCE OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126056 12-04

**LYOGEN**
LYOGEN IN THE TREATMENT OF MENTAL DISEASES IN CHILDREN.
064173 04-07
CLINICAL AND AMBULANT TESTING WITH FLUPHENAZINE DECANOATE LYOGEN DEPOT IN THE LONG-TERM TREATMENT OF PSYCHIATRIC DISEASE.
080040 09-16

**LYSENYL**
AGGRESSIVE BEHAVIOR OF RATS INDUCED BY MESORGYDINE (LYSENYL SPOFA).
070949 07-04

**LYSERGIC**
EFFECTS OF LYSERGIC ACID DERIVATIVES ON 5-HYDROXYTRYPTAMINE EXCITATION OF BRAINSTEM NEURONES.
041973 01-02
USES AND MISUSES OF LYSERGIC ACID DIETHYLAMIDE.
046736 01-17
LYSERGIC ACID DIETHYLAMIDE AS A VARIABLE IN THE HOSPITAL TREATMENT OF ALCOHOLISM: A FOLLOW-UP STUDY.
052476 02-11
LYSERGIC ACID DIETHYLAMIDE, CHLORPROMAZINE AND MAZE PERFORMANCE.
058997 03-04
PROJECT SUMMARY: ON THE INVESTIGATION OF THE GENETIC EFFECTS OF LYSERGIC ACID DIETHYLAMIDE AND RELATED COMPOUNDS.
060637 03-03
LYSERGIC ACID DIETHYLAMIDE INTAKE IN PREGNANCY: FETAL DAMAGE IN RATS.
064422 04-05
LYSERGIC ACID DIETHYLAMIDE (LSD-25): XXXIX. THE EFFECT OF HIGH TEMPERATURES ON STABILITY.
064609 04-06
ANTIDIURESIS IN MAN FOLLOWING LYSERGIC ACID DIETHYLAMIDE AND MESCALINE.
066399 05-13
EFFECTS OF PSILOCYBIN, DIMETHYLTRYPTAMINE AND VARIOUS LYSERGIC ACID DERIVATIVES ON PHOTICALLY INDUCED EPILEPSY IN THE BABOON (PAPIO-PAPIO).
068163 06-03
CHROMOSOME STUDIES ON PATIENTS (IN VIVO) AND CELLS (IN VITRO) TREATED WITH LYSERGIC ACID DIETHYLAMIDE.
071987 07-13
HOSPITAL ADMISSIONS DUE TO LYSERGIC ACID DIETHYLAMIDE.
072149 07-15
LYSERGIC ACID DIETHYLAMIDE AND A NOVEL STIMULUS.
075282 08-04
EFFECTS OF LYSERGIC ACID DIETHYLAMIDE ON THE MATERNAL BEHAVIOR OF THE RAT.
075788 08-04
THE EFFECT OF DIETHYLAMIDE OF LYSERGIC ACID (DLA) ON THE CONTENT OF MONOAMINES IN SOME NUCLEI OF THE MIDBRAIN AND HYPOTHALAMUS.
101006 12-03

**LYSOSOMES**
THE RESPONSE OF LYSOSOMES IN CULTURED NEURONS TO CHLORPROMAZINE.
066380 05-03

**MACACA-MULATTA**
REDIRECTED AGGRESSION AND GONADAL HORMONES IN CAPTIVE RHESUS MONKEYS (MACACA-MULATTA).
075829 08-04
OVARIAN HORMONES AND FEMALE SEXUAL INVITATIONS IN CAPTIVE RHESUS MONKEYS (MACACA-MULATTA).
076554 09-03

**MACANDREW-ROSEN**
VALIDATION OF THE MACANDREW-ROSEN DRUG THERAPY SCALE.
066741 05-16

**MACAQUE**
CHROMOSOME STUDIES IN PREGNANT RHESUS MACAQUE GIVEN LSD-25.
064315 04-05

**MACROMOLECULES**
BRAIN FUNCTION AND MACROMOLECULES: V. THE EFFECT OF CYCLOHEXIMIDE AND ACTINOMYCIN-D ON LEARNING IN THE HEADLESS COCKROACH.
078378 09-03

**MAGNESIUM**
THE INFLUENCE OF MORPHINE ON MAGNESIUM METABOLISM IN RATS.
046191 01-03
MAGNESIUM PEMOLINE: SPECIFICITY OF EFFECTS ON INSTRUMENTAL AVOIDANCE LEARNING.
058430 02-04
THE EFFECT OF MAGNESIUM PEMOLINE ON DISCRIMINATION LEARNING AND EXPLORATORY BEHAVIOR.
059567 03-04
SPASMOPHILIA CAUSED BY MAGNESIUM DEFICIENCY.
063590 03-17
COMPENSATORY SELECTION OF MAGNESIUM SULFATE BY MAGNESIUM DEPLETED LABORATORY RATS.
068287 06-04
THE EFFECT OF MAGNESIUM PEMOLINE, TRICYANOAMINOPROPENE AND D-AMPHETAMINE ON DISCRIMINATED AVOIDANCE PERFORMANCE IN RATS AS A FUNCTION OF AGE.
076133 09-04

**MAINTAINED**
EFFECTS OF MORPHINE ON BEHAVIOR MAINTAINED BY FOUR SIMPLE FOOD REINFORCEMENT SCHEDULES.
064479 04-04

**MAINTENANCE**
MAINTENANCE THERAPY OF CHRONIC PSYCHOTIC PATIENTS WITH A WEEKLY ORAL DOSE OF R-16341. A CONTROLLED DOUBLE-BLIND STUDY.
064284 04-09
RECORDING EVOKED POTENTIALS IN THE CONSCIOUS RAT: THE MAINTENANCE OF A CONSTANT BEHAVIOURAL BASELINE.
067600 06-06
SUCCESSES AND FAILURES IN METHADONE MAINTENANCE TREATMENT OF HEROIN ADDICTION IN NEW-YORK CITY. (UNPUBLISHED PAPER).
071314 07-17
EFFECT OF PITUITARY AND ACTH ON THE MAINTENANCE OF BASAL TYROSINE HYDROXYLASE ACTIVITY IN THE RAT ADRENAL GLAND.
075714 08-03

**MAJOR**
CHLORIMIPRAMINE: THE MAJOR TREATMENT OF DEPRESSIVE STATES.
089157 10-09
POSSIBLE APPLICATIONS OF LONG-ACTING INTRAMUSCULAR MAJOR TRANQUILLIZERS.
100020 11-11

**MALARIA**
AN ATTEMPT TO ELIMINATE RESISTANCE TO AMINAZINE BY MALARIA THERAPY IN PATIENTS WITH PARANOID SCHIZOPHRENIA.
087312 10-16

**MALE**
THE EFFECT OF P-CHLOROPHENYLALANINE ON SOCIAL INTERACTION OF MALE RATS.
041541 01-04
EFFECTS OF RESERPINE ON THE COPULATORY BEHAVIOR OF MALE RATS.
063014 03-04
A COMPARATIVE STUDY OF THE EFFECTS OF METHAQUALONE AND GLUTETHIMIDE ON SLEEP IN MALE CHRONIC INSOMNIACS.
063879 04-14

EFFECT OF METHYLCHLOROFORM INHALATION ON BARBITURATE HYPNOSIS AND HEPATIC DRUG METABOLISM IN MALE MICE.
068978 06-03

DREAM CONTENT IN MALE SCHIZOPHRENIC PATIENTS.
069034 06-08

SEXUAL BEHAVIOR OF MALE CATS AFTER ADMINISTRATION OF P-CHLOROPHENYLALANINE.
072463 08-04

USE OF AN ANDROGEN DEPLETING HORMONE IN THE TREATMENT OF MALE SEX OFFENDERS.
080178 09-14

COITAL BEHAVIOR IN DOGS: VI. LONG-TERM EFFECTS OF CASTRATION UPON MATING IN THE MALE.
080606 09-03

INCREASED AGGRESSION AMONG GROUPED MALE MICE FED CHLORDIAZEPOXIDE.
081098 09-04

RESPONSES OF MALE RATS TO SEX ODORS.
081226 09-04

CLINICAL TRIAL OF CLOMACRAN PHOSPHATE (SKF-14336) IN CHRONIC PSYCHOTIC MALE PATIENTS.
082056 10-07

MALE SEXUAL FUNCTION.
100530 12-15

**MALEATE**

BLOCKADE OF NORADRENALINE UPTAKE AND INHIBITION OF GASTRIC ACID SECRETION BY 2-(P-CHLOROPHENYL-2-(PYRIDYL)HYDROXYMETHYL) IMIDAZOLINE MALEATE (SCH-12650).
058878 02-02

**MALFORMATIONS**

DEXAMPHETAMINE: A POSSIBLE ENVIRONMENTAL TRIGGER IN CARDIOVASCULAR MALFORMATIONS.
082039 10-15

**MALIGNANT**

THE CLINICAL ASPECTS AND DYNAMICS OF PARANOIAC PSYCHOPATHY WITH MALIGNANT DEVELOPMENT.
126632 12-09

**MALONYLUREA**

NEUROPSYCHIATRIC CLINICAL STUDY OF A BARBITURATE HYPNOTIC: 5-ETHYL 5(1- METHYL-1-BUTENYL) MALONYLUREA.
089173 10-07

**MAMMALIAN**

THE ACTIONS OF GAMMA-AMINOBUTYRIC ACID AND RELATED AMINO ON MAMMALIAN AUTONOMIC GANGLIA.
040752 01-03

PROJECT SUMMARY: METHANOL FORMING ENZYME IN MAMMALIAN BRAIN.
060633 03-01

FORMATION AND REGIONAL DISTRIBUTION OF GAMMA-HYDROXYBUTYRIC ACID IN MAMMALIAN BRAIN.
074864 08-01

**MAN**

THE EFFECT OF DIET AND PHENOBARBITONE ON QUININE METABOLISM IN THE RAT AND IN MAN.
046187 01-13

CHALLENGES IN DRUG EVALUATION IN MAN.
051133 02-17

THE CONDUCT OF INITIAL DRUG STUDIES IN MAN.
051593 02-17

THE PREDICTIVE VALUE FOR MAN OF TOXICOLOGICAL TESTS OF DRUGS IN LABORATORY ANIMALS.
057607 02-05

UNITED-STATES PROCEDURES FOR SCREENING DRUGS: TESTING FOR DEPENDENCE LIABILITY IN ANIMALS AND MAN.
058971 03-02

GEORGE: A MAN WITH AN INADEQUATE PERSONALITY.
059100 03-10

INFLUENCE OF TRIIODOTHYRONINE ON SELECTIVE ATTENTION IN MAN AS MEASURED BY THE VISUAL AVERAGED EVOKED POTENTIAL.
062510 03-13

EFFECTS OF N-ACETYL-DIMETHOXYPHENETHYLAMINE (NADMPEA) IN MAN.
064386 04-14

PSYCHOLOGICAL STUDIES OF MARIJUANA AND ALCOHOL IN MAN.
064416 04-12

ANTIDIURESIS IN MAN FOLLOWING LYSERGIC ACID DIETHYLAMIDE AND MESCALINE.
066399 05-13

ALDOSTERONE AND SODIUM RESPONSE TO LITHIUM ADMINISTRATION IN MAN.
066493 05-13

RELEASE BY AMPHETAMINE IN MAN OF GROWTH HORMONE AND CORTICOSTEROIDS: THE EFFECTS OF THYMOXAMINE AND PROPRANOLOL.
067602 06-13

MARIHUANA: STUDIES ON THE DISPOSITION AND METABOLISM OF DELTA9-TETRAHYDROCANNABINOL IN MAN.
069051 06-13

EFFECTS OF INFUSED TRYPTAMINE IN MAN.
069053 06-13

EFFECT OF L-DOPA ON THE SLEEP OF MAN.
070247 07-13

COMPARISON OF THE PAROXYSMAL DYSKINESIAS (NEURODYSLEPSY) INDUCED BY THE NEUROLEPTICS IN MAN AND THE EARLIEST BEHAVIOR PATTERNS OF THE NEW-BORN.
070267 07-13

DRUGS INFLUENCING THE CHOLINERGIC SYSTEM AND THE PROCESS OF LEARNING AND MEMORY IN MAN.
070955 07-14

CHLORPROMAZINE AND CNS CHANGES IN MAN.
070968 07-14

FUNCTIONAL CHARACTERISTIC OF THE LINKS OF THE BRAIN CONTROL SYSTEM FOR MENTAL AND MOTOR FUNCTIONS IN MAN.
073770 08-13

DELTA1-TETRAHYDROCANNABINOL, SYNHEXYL AND MARIJUANA EXTRACT ADMINISTERED ORALLY IN MAN: CATECHOLAMINE EXCRETION, PLASMA CORTISOL LEVELS AND PLATELET SEROTONIN CONTENT.
075841 08-12

STUDIES IN MAN ON THE INFLUENCE OF A NEW PSYCHOPHARMACEUTICAL DRUG, 1-((METHYLAMINO) DIBENZOBICYCLOOCTADIENE HYDROCHLORIDE, ON THE CO2 SENSITIVE CENTRAL RESPIRATORY REGULATION.
079971 09-07

PSYCHOPHYSIOLOGICAL ASPECTS OF EXTENDED EXPOSURE OF MAN TO AN ENVIRONMENT WITH SENSORY DEPRIVATION.
082954 10-14

A REVIEW OF THE BIOMEDICAL EFFECTS OF MARIHUANA ON MAN IN THE MILITARY ENVIRONMENT.
085756 10-14

ACTION OF THE SALTS OF OXYGLURIC ACID ON ACUTE ALCOHOL INTOXICATION IN MAN (EXPERIMENTAL STUDY).
086005 10-11

EFFECT OF AMPHETAMINE ON THE PRESSOR RESPONSE TO TYRAMINE: FORMATION OF P-HYDROXYNOREPHEDRINE FROM AMPHETAMINE IN MAN.
090373 11-03

EFFECT OF FRUCTOSE ON ALCOHOL CONCENTRATIONS IN THE BLOOD OF MAN.
092004 11-11

INVESTIGATION INTO THE POSSIBLE INFLUENCE OF CHLORINATED AMPHETAMINE DERIVATIVES ON 5-HYDROXYTRYPTAMINE SYNTHESIS IN MAN.
097963 11-13

URINARY EXCRETION OF ADRENAL HORMONES IN MAN: EFFECTS OF ETHANOL INGESTION, AND THEIR MODIFICATION BY CHLORMETHIAZOLE.
097974 11-11

FACTORS AFFECTING THE URINARY EXCRETION OF TRICYCLIC ANTIDEPRESSANTS IN MAN.
100026 11-13

LITHIUM INDUCED POLYURIA: EXPERIMENTAL STUDIES IN MAN AND THE RAT.
100083 11-15

THE EFFECTS OF LEVOMEPROMAZINE ON THE NOCTURAL SLEEP EEG IN MAN.
129447 12-13

**MANAGEMENT**

RECOGNITION AND MANAGEMENT OF DEPRESSION.
060728 03-17

EXPERIENCE OF PSYCHIATRIC MANAGEMENT OF SCHIZOPHRENIA WITH FLUPHENAZINE DECANOATE.
063186 03-08

LONG-ACTING DRUG TREATMENT IN OVERALL PSYCHIATRIC MANAGEMENT.
065472 05-17

INSTITUTIONAL MANAGEMENT OF CHRONIC SCHIZOPHRENICS WITH FLUPHENAZINE DECANOATE.
065474 05-07

FLUPHENAZINE HYDROCHLORIDE, ENANTHATE, AND DECANOATE IN THE MANAGEMENT OF CHRONIC PSYCHOSIS.
065476 05-08

FLUPHENAZINE HYDROCHLORIDE AND ENANTHATE IN THE MANAGEMENT OF CHRONIC PSYCHOSIS.
065478 05-08

PIPERACETAZINE (QUIDE) IN THE MANAGEMENT OF BEHAVIORAL DISORDERS IN MILDLY RETARDED INSTITUTIONALIZED BOYS.
069071 06-11

DRUGS IN THE MANAGEMENT OF DEPRESSION.
070982 07-17

PRELIMINARY EXPERIENCE WITH MEDAZEPAM (NOBRIUM) IN THE MANAGEMENT OF PSYCHOPHYSIOLOGIC REACTIONS.
075878 09-07

TREATMENT MANAGEMENT IN A HOSPITAL SETTING.
089001 10-11

PHARMACOLOGICAL MANAGEMENT OF CHARACTER TYPE BEHAVIOR DISTURBANCES IN THE INFANT AND CHILD.
093090 11-07
IMIPRAMINE AS AN EFFECTIVE TOOL IN THE MANAGEMENT OF BEHAVIORAL DISORDERS IN CHILDREN.
134937 12-11

**MANDRAX**
MANDRAX AS AN HYPNOTIC FOR PSYCHIATRIC INPATIENTS: A COMPARATIVE TRIAL WITH CHLORAL HYDRATE.
061562 03-14
A COMPARISON OF SLEEP PATTERNS IN NATURAL AND MANDRAX AND TUINAL INDUCED SLEEP.
067864 06-14

**MANIA**
THE MANY FACES OF MANIA: THERAPEUTIC TRIAL OF LITHIUM CARBONATE.
047919 01-09
A COMPARISON OF LITHIUM CARBONATE AND CHLORPROMAZINE IN MANIA.
062349 03-09
METHYSERGIDE AS A TREATMENT FOR MANIA.
062350 03-09
THE SWITCH PROCESS FROM DEPRESSION TO MANIA: RELATIONSHIP TO DRUGS WHICH ALTER BRAIN AMINES.
067585 06-09
LITHIUM IN MANIA.
073734 08-17
CRITIQUE OF STUDIES OF LITHIUM SALTS IN THE TREATMENT OF MANIA.
075867 09-09
A DOUBLE-BLIND INTENSIVE CROSSOVER DESIGN TRIAL OF METHYSERGIDE IN MANIA.
085327 10-09

**MANIC**
CLINICAL EXPERIENCE WITH OCTOCLOTHEPINE IN MANIC SYNDROMES.
070927 07-09
SOME EXPERIENCES WITH A PREVENTIVE ADMINISTRATION OF LITHIUM SALTS IN MANIC MELANCHOLIC PSYCHOSIS.
070952 07-09
A DOUBLE-BLIND COMPARISON OF LITHIUM AND CHLORPROMAZINE IN THE TREATMENT OF MANIC STATES.
075430 08-09
THE TREATMENT OF MANIC RELATED DISEASES WITH LITHIUM CARBONATE.
081516 09-09
INFLUENCE OF AMINAZIN ON ADRENALIN, NORADRENALINE, DOPAMINE, AND DOPA EXCRETION IN HEALTHY PEOPLE AND IN THE MANIC PHASE OF THE MANIC-DEPRESSIVE PSYCHOSIS.
090355 11-03
TREATMENT AND PROPHYLAXIS OF MANIC STATES WITH A CARBONIC ANHYDRASE INHIBITOR.
105731 12-14

**MANIC-DEPRESSED**
IMIPRAMINE AND LITHIUM EFFECTS ON BIOGENIC AMINE TRANSPORT IN DEPRESSED AND MANIC-DEPRESSED PATIENTS.
062326 03-13
IMIPRAMINE AND LITHIUM EFFECTS ON BIOGENIC AMINE TRANSPORT IN DEPRESSED AND MANIC-DEPRESSED PATIENTS.
062366 03-13

**MANIC-DEPRESSION**
FDA APPROVES LITHIUM FOR MANIC-DEPRESSION.
089400 10-17

**MANIC-DEPRESSIVE**
A CASE OF MANIC-DEPRESSIVE ILLNESS WITH LITHIUM TOXICITY.
058213 02-15
EFFECTIVENESS OF LITHIUM CARBONATE IN THE TREATMENT OF MANIC-DEPRESSIVE ILLNESS.
062348 03-09
LITHIUM, CREATIVITY, AND MANIC-DEPRESSIVE ILLNESS: REVIEW AND PROSPECTUS.
063601 04-09
THE PRESENT STATUS OF LITHIUM THERAPY IN MANIC-DEPRESSIVE PSYCHOSIS.
064089 04-09
COMPARISON OF LITHIUM CARBONATE AND IMIPRAMINE (IN PREVENTION OF MANIC-DEPRESSIVE DISEASE).
064317 04-09
INFLUENCE OF AMINAZIN ON ADRENALIN, NORADRENALINE, DOPAMINE, AND DOPA EXCRETION IN HEALTHY PEOPLE AND IN THE MANIC PHASE OF THE MANIC-DEPRESSIVE PSYCHOSIS.
090355 11-03
LITHIUM CARBONATE: A DRUG OF LIMITED EFFICACY IN THE PREVENTION OF MANIC-DEPRESSIVE DISEASE.
106764 12-09
PROPHYLACTIC ACTION OF LITHIUM SALTS AND THYROID HORMONES ON SYMPTOMS OF MANIC-DEPRESSIVE AND AFFECTIVE PSYCHOSES: CLINICAL AND EXPERIMENTAL RESULTS.
106774 12-09
ON THE EFFICACY AND THE MECHANISM OF ACTION OF LITHIUM SALTS IN MANIC-DEPRESSIVE PSYCHOSES.
130414 12-09

**MANIC-DEPRESSIVES**
CERTAIN CIRCADIAN RHYTHMS IN MANIC-DEPRESSIVES AND THEIR RESPONSE TO LITHIUM.
106763 12-09

**MANICS**
LITHIUM VERSUS CHLORPROMAZINE FOR MANICS. INITIATIVE AND PRODUCTIVITY VERSUS TRANQUILIZATION HOSPITALIZATION.
063209 03-09

**MANIFESTATIONS**
A SURVEY OF EXTRAPYRAMIDAL MANIFESTATIONS IN PATIENTS ATTENDING AN AFTER CARE CLINIC OF A PSYCHIATRIC HOSPITAL.
070412 07-15
PSYCHOSIS AND OTHER PSYCHIATRIC MANIFESTATIONS OF LEVODOPA THERAPY.
081150 09-15
A SURVEY OF EXTRAPYRAMIDAL MANIFESTATIONS IN THE INPATIENT POPULATION OF A PSYCHIATRIC HOSPITAL.
086444 10-15
ON THE QUESTION OF THE PROPHYLAXIS OF INITIAL MANIFESTATIONS OF PRESENILE PSYCHOSES.
110105 12-17
NEUROPSYCHIATRIC MANIFESTATIONS IN TWO CASES OF PORPHYRIA.
138144 12-11

**MANIPULATE**
AMINES THAT MANIPULATE THE NEUROTRANSMITTERS.
058963 03-11

**MANIPULATING**
INTRACRANIAL SELF-STIMULATION AND WAKEFULNESS: EFFECT OF MANIPULATING AMBIENT BRAIN CATECHOLAMINES.
063849 04-04

**MANN**
ON THE COMBINED EFFECTS OF AMPHETAMINE AND FOOD DEPRIVATION: A REPLY TO GOLLUB AND MANN.
066821 05-04

**MANNICH**
MANNICH BASES FROM 1,2- DIPHENYLINDOLIZINE: EPHEDRINE AND METHAMPHETAMINE AS AMINE COMPONENTS.
055324 02-01

**MANS**
MANS TRIPARTITE BRAIN AND PSYCHOSOMATIC MEDICINE.
119884 12-17

**MAOI**
HYPERTENSIVE CRISIS IN A PATIENT ON MAOI ANTIDEPRESSANTS FOLLOWING A MEAL OF BEEF LIVER.
092211 11-15

**MARIHUANA**
MARIHUANA INTOXICATION: COMMON EXPERIENCES.
045515 01-17
HUMAN PHARMACOLOGY OF MARIHUANA (CANNABIS).
046202 01-13
ON THE PHARMACOLOGY OF MARIHUANA.
058914 02-12
EFFECTS OF A MARIHUANA HOMOLOGUE (PYRAHEXYL) ON AVOIDANCE LEARNING IN THE GERBIL.
059032 03-04
THE PROBLEM OF POT: THE MEDICAL EFFECTS OF MARIHUANA.
059623 03-13
THE PROBLEM OF POT: MARIHUANA, A PSYCHIATRIC POINT OF VIEW.
059624 03-14
MARIHUANA, ETHANOL, AND DEXTROAMPHETAMINE: MOOD AND MENTAL FUNCTION ALTERATIONS.
066231 05-14
TEMPORAL DISINTEGRATION AND DEPERSONALIZATION DURING MARIHUANA INTOXICATION.
066232 05-14
MARIHUANA: STUDIES ON THE DISPOSITION AND METABOLISM OF DELTA9-TETRAHYDROCANNABINOL IN MAN.
069051 06-13
INDUCTION BY CANNABIS-SATIVA (MARIHUANA) OF RHYTHMIC SPIKE DISCHARGES OVERRIDING REM SLEEP ELECTROCORTICOGRAM IN THE RAT.
069069 06-04
COMPARATIVE EFFECTS OF SMOKING MARIHUANA OR PLACEBO ON HUMAN MOTOR AND MENTAL PERFORMANCE.
069579 07-14
MARIHUANA AND TEMPORAL DISINTEGRATION.
071998 07-14
THE MARIHUANA INDUCED SOCIAL HIGH: NEUROLOGICAL AND ELECTROENCEPHALOGRAPHIC CONCOMITANTS.
074782 08-12
A REVIEW OF THE BIOMEDICAL EFFECTS OF MARIHUANA ON MAN IN THE MILITARY ENVIRONMENT.
085756 10-14

**MARIJUANA**
MARIJUANA PROGRAM ADVANCES AT NIMH.
040149 01-14
PHYSIOLOGICAL EFFECTS OF MARIJUANA.
046113 01-13
MARIJUANA.
046430 01-14
A COMPARISON OF MARIJUANA USERS AND NON-USERS.
059290 03-14
PSYCHOLOGICAL STUDIES OF MARIJUANA AND ALCOHOL IN MAN.
064416 04-12
ADVERSE MARIJUANA REACTIONS: A CRITICAL EXAMINATION OF THE LITERATURE WITH SELECTED CASE MATERIAL.
069613 07-15
THE MARIJUANA PROBLEM.
071027 07-17
MARIJUANA AND IMMEDIATE MEMORY.
073886 08-14
DELTA1-TETRAHYDROCANNABINOL, SYNHEXYL AND MARIJUANA EXTRACT ADMINISTERED ORALLY IN MAN: CATECHOLAMINE EXCRETION, PLASMA CORTISOL LEVELS AND PLATELET SEROTONIN CONTENT.
075841 08-12
MARIJUANA: MARY JANE FACES THE IDENTITY CRISIS OR, THREE BLIND MEN STUDY THE ELEPHANT.
082063 10-17

**MARKETS**
PROBLEMS REGARDING THE INTRODUCTION OF A PSYCHOPHARMACEUTICAL AGENT IN INTERNATIONAL MARKETS.
060729 03-17

**MASKED**
MASKED DEPRESSION AND THE USE OF ANTIDEPRESSANTS IN GENERAL PRACTICE.
072219 07-17

**MASKING**
AN ACHE MASKING DEPRESSION.
064636 05-14
AN ACHE MASKING DEPRESSION.
082422 10-10

**MASSACHUSETTS**
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL: CASE 20-1970.
042655 01-15

**MATCHING**
DIFFERENTIAL EFFECTS OF AMPHETAMINE AND SCOPOLAMINE ON MATCHING PERFORMANCE OF MONKEYS WITH LATERAL FRONTAL LESIONS.
065747 05-04

**MATERIALS**
METHODS OF TREATING DELIRIUM-TREMENS AS BASED ON MATERIALS OF THE UNIVERSITY MEDICAL SCHOOLS PSYCHIATRIC CLINIC IN WROCLAW BETWEEN 1958 AND 1968.
087143 10-11

**MATERNAL**
EFFECTS OF THALIDOMIDE AND CHLORCYCLIZINE ON THE BIOSYNTHESIS OF NUCLEIC ACIDS AND PROTEINS IN FETAL AND MATERNAL TISSUES OF THE RAT.
040027 01-05
HORMONAL INDUCTION OF MATERNAL BEHAVIOR IN THE OVARIECTOMIZED NULLIPAROUS RAT.
069063 06-04
EFFECTS OF LYSERGIC ACID DIETHYLAMIDE ON THE MATERNAL BEHAVIOR OF THE RAT.
075788 08-04

**MATING**
COITAL BEHAVIOR IN DOGS: VI. LONG-TERM EFFECTS OF CASTRATION UPON MATING IN THE MALE.
080606 09-03

**MATURE**
INFLUENCE OF SEVERAL AUTONOMIC DRUGS ON SODIUM NITROPRUSSIDE AND OXOTREMORINE INDUCED HYPOTHERMIA IN IMMATURE AND MATURE MICE.
089436 11-03

**MAYHEM**
MAYHEM AMONG THE ANIMALS.
095318 11-04

**MAZE**
LYSERGIC ACID DIETHYLAMIDE, CHLORPROMAZINE AND MAZE PERFORMANCE.
058997 03-04
EFFECT OF HYDROXYLAMINE ON MAZE LEARNING IN MICE.
065933 05-04
THE STAIRCASE MAZE AND THE SIMPLE STAIRCASE IN THE ANALYSIS OF THE PSYCHOPHARMACOLOGICAL ACTION OF CNS DEPRESSANTS.
068291 06-04

**MAZINDOL**
CLINICAL EVALUATION OF MAZINDOL IN CHRONIC SCHIZOPHRENICS.
066852 05-08

**MEAL**
HYPERTENSIVE CRISIS IN A PATIENT ON MAOI ANTIDEPRESSANTS FOLLOWING A MEAL OF BEEF LIVER.
092211 11-15

**MEASURE**
DRUG EFFECTS ON A MEASURE OF UNCONDITIONED AVOIDANCE IN THE RAT.
065440 05-04
PREDICTION OF CHANGES IN SEVERITY OF THE SCHIZOPHRENIC SYNDROME WITH DISCONTINUATION AND ADMINISTRATION OF PHENOTHIAZINES IN CHRONIC SCHIZOPHRENIC PATIENTS: LANGUAGE AS A PREDICTOR AND MEASURE OF CHANGE IN SCHIZOPHRENIA.
075321 08-08

**MEASURED**
INFLUENCE OF TRIIODOTHYRONINE ON SELECTIVE ATTENTION IN MAN AS MEASURED BY THE VISUAL AVERAGED EVOKED POTENTIAL.
062510 03-13
THE EFFECT OF MEDAZEPAM ON THE THRESHOLDS OF SUBCORTICAL LIMBIC STIMULUS RESPONSES, MEASURED IN UNANESTHETIZED, UNRESTRAINED CATS.
072067 07-03

**MEASUREMENT**
MEASUREMENT OF BEHAVIORAL CHANGES IN PATIENTS ON L-DOPA.
066940 05-14
MEASUREMENT OF BEHAVIOURAL CHANGES IN PATIENTS ON L-DOPA.
081039 09-11
MEASUREMENT OF THE DISTRIBUTION OF HYPNOTICS AND CEREBRAL FUNCTION IN ACUTE INTOXICATIONS BY PH.
089040 10-17
PREDICTION AND MEASUREMENT OF PERCEPTUAL BEHAVIORAL CHANGE IN DRUG-INDUCED HALLUCINATIONS.
121086 12-12

**MEASURES**
COMPARISONS OF 1,3 BUTANEDIOL AND GLYCEROL ON SEVERAL BEHAVIORAL MEASURES.
066831 05-04
COMPARISON OF METHODS OF RELAXATION USING PHYSIOLOGICAL MEASURES.
074135 08-14
THE EFFECTS OF AN AMPHETAMINE ON MEASURES OF INTELLIGENCE AND LEARNING IN MENTALLY RETARDED ADULTS. (PH.D.DISSERTATION).
103152 12-14

**MEASURING**
INTRAGASTRIC TELEMETRIC MEASURING OF PH DURING THYMOLEPTIC MEDICATION.
081143 09-13

**MECHANISM**
THE ROLE OF THE HYPOTHALAMO-PITUITARY SYSTEM IN THE MECHANISM OF ACTION OF RESERPINE AND 5-HYDROXYTRYPTOPHAN ON ANTIBODY PRODUCTION.
040579 01-03
MECHANISM OF THE RENAL TUBULAR TRANSPORT OF MORPHINE AND MORPHINE ETHEREAL SULFATE IN THE CHICKEN.
040754 01-03
SELECTIVE DEPLETION OF NORADRENALINE: A PROPOSED MECHANISM OF THE ADRENERGIC NEURONE BLOCKING ACTION OF BRETYLIUM.
055323 02-05
PHARMACOLOGICAL REDUNDANCY AS AN ADAPTIVE MECHANISM IN THE CENTRAL NERVOUS SYSTEM.
056113 02-13
LATERAL HYPOTHALAMIC CONTROL OF KILLING: EVIDENCE FOR A CHOLINOCEPTIVE MECHANISM.
058227 02-04
VERBAL ANXIETY AND THE BETA-ADRENERGIC RECEPTORS: A FACILITATING MECHANISM.
060880 03-13
A MECHANISM OF SUDDEN DEATH IN CHLORPROMAZINE THERAPY.
062351 03-15
INTERFERENCE OF BARBITURATES WITH PYRIMIDINE INCORPORATION -- III: STUDIES ON THE MECHANISM OF THE AMOBARBITAL OROTATE RELATIONSHIP.
064045 04-03
ON THE MECHANISM OF AMPHETAMINE POTENTIATION BY IPRINDOLE.
066955 05-03
P-CHLOROAMPHETAMINE: IN VIVO INVESTIGATIONS ON THE MECHANISM OF ACTION OF THE SELECTIVE DEPLETION OF CEREBRAL SEROTONIN.
069596 07-03
MECHANISM OF THE GAMMA-HYDROXYBUTYRATE INDUCED INCREASE IN BRAIN DOPAMINE AND ITS RELATIONSHIP TO SLEEP.
074865 08-04
ON THE MECHANISM OF SUPERSENSITIVITY TO NOREPINEPHRINE IN THE DENERVATED CAT SPLEEN.
080336 09-03
THE MECHANISM AND SITE OF DRUG EFFECT.
086206 10-17

ON THE BIOCHEMICAL MECHANISM OF ACTION OF NICOTINIC ACID, NICOTINAMIDE, METHIONINE, AND D-PENICILLAMINE IN THE TREATMENT OF PSYCHOSES.
094962 11-13

UPTAKE AND STORAGE MECHANISM OF 5-HYDROXYTRYPTAMINE IN RABBIT BRAINSTEM AND EFFECT OF RESERPINE.
114975 12-03

ON THE EFFICACY AND THE MECHANISM OF ACTION OF LITHIUM SALTS IN MANIC-DEPRESSIVE PSYCHOSES.
130414 12-09

**MECHANISMS**

RECEPTOR MECHANISMS.
051113 01-17

POSSIBLE MECHANISMS IN DEVELOPMENT OF TOLERANCE.
056238 02-03

MECHANISMS BY WHICH AMPHETAMINE AND DESIPRAMINE INHIBIT THE METARAMINOL INDUCED RELEASE OF NOREPINEPHRINE FROM SYMPATHETIC NERVE ENDINGS IN RAT HEART.
064427 04-03

TRYPTAMINERGIC MECHANISMS IN PUNISHED AND NONPUNISHED BEHAVIOR.
069738 07-04

THE ADRENERGICAL MECHANISMS OF ACTION IN ANTIDEPRESSIVE DRUGS.
073787 08-17

MECHANISMS OF LITHIUM ACTION: (ENDOGENOUS TISSUE LEVELS, EXCRETION IN EMOTIONAL STATES, AND BEHAVIORAL EFFECTS).
080634 09-03

STUDIES ON ADRENERGIC MECHANISMS IN THE ACTION OF DESMETHYLIMIPRAMINE (DMI).
090421 11-04

ADRENERGIC MECHANISMS IN THE CENTRAL ACTION OF PSYCHOTROPIC DRUGS. (PH.D.DISSERTATION).
102415 12-06

PHYSIOLOGICAL AND BIOCHEMICAL MECHANISMS OF THE EFFECT OF LITHIUM SALTS ON THE NERVOUS SYSTEM.
109786 12-13

**MECHOLYL**

RELATIONSHIPS OF THE MECHOLYL TEST, PREMORBID ASOCIAL FUNCTIONING AND LONG-TERM OUTCOME IN SCHIZOPHRENIA.
075227 08-08

**MEDAZEPAM**

PHARMACOLOGY OF MEDAZEPAM AND METABOLITES.
063838 04-04

SOME OBSERVATIONS ON THE NEUROPHARMACOLOGY OF MEDAZEPAM HYDROCHLORIDE (RO-5-4556).
063841 04-04

THE EFFECT OF MEDAZEPAM ON THE THRESHOLDS OF SUBCORTICAL LIMBIC STIMULUS RESPONSES, MEASURED IN UNANESTHETIZED, UNRESTRAINED CATS.
072067 07-03

PRELIMINARY EXPERIENCE WITH MEDAZEPAM (NOBRIUM) IN THE MANAGEMENT OF PSYCHOPHYSIOLOGIC REACTIONS.
075878 09-07

CLINICAL TESTS OF A NEW ANXIOLYTIC, MEDAZEPAM (NOBRIUM).
079864 09-11

CLINICAL STUDY OF MEDAZEPAM (RO-5-4556).
086859 10-11

THE USE OF INJECTABLE MEDAZEPAM (PRELIMINARY NOTE).
086977 10-07

**MEDIATED**

EVIDENCE FOR A CENTRALLY MEDIATED HYPOTENSIVE EFFECT OF L-DOPA IN THE RAT.
055587 02-03

NEURALLY MEDIATED INCREASE IN DOPAMINE-BETA-HYDROXYLASE ACTIVITY (UNPUBLISHED PAPER).
088376 10-03

**MEDIATION**

CYCLIC AMP MEDIATION OF NOREPINEPHRINE INHIBITION IN RAT CEREBELLAR CORTEX: A UNIQUE CLASS OF SYNAPTIC RESPONSES (UNPUBLISHED PAPER).
093132 11-03

**MEDIATOR**

SEROTONIN: A POSSIBLE MEDIATOR OF BEHAVIORAL SUPPRESSION INDUCED BY ANXIETY.
069311 06-04

**MEDICAL**

NEWER MEDICAL TREATMENTS IN PARKINSONISM.
059021 03-11

THE PROBLEM OF POT: THE MEDICAL EFFECTS OF MARIHUANA.
059623 03-13

SOCIAL MEDICAL CLASSIFICATION OF TOXICOMANIAS.
079257 09-15

METHODS OF TREATING DELIRIUM-TREMENS AS BASED ON MATERIALS OF THE UNIVERSITY MEDICAL SCHOOLS PSYCHIATRIC CLINIC IN WROCLAW BETWEEN 1958 AND 1968.
087143 10-11

RESULTS OF THE MEDICAL TREATMENT IN AGED PATIENTS WITH CEREBRAL ORGANIC DISTURBANCES.
087336 10-11

THE MEDICAL AND SOCIAL INDICATION OF ANTIANDROGEN THERAPY.
105733 12-11

ABSTRACT OF THESES FOR DOCTOR OF MEDICAL SCIENCES, THE UNIVERSITY OF TOKYO: MORITA THERAPEUTIC APPROACH TO SCHIZOPHRENIA.
126778 12-17

**MEDICATION**

STUDIES OF DELAYED ACTION MEDICATION: V. PLASMA LEVELS AND URINARY EXCRETION OF FOUR DIFFERENT DOSAGE FORMS OF CHLORPROMAZINE.
041559 01-13

THE PHILOSOPHY OF LONG-ACTING MEDICATION IN PSYCHIATRY.
065459 05-17

IS A DOUBLE-BLIND CLINICAL TRIAL REALLY DOUBLE-BLIND: A REPORT OF DOCTORS MEDICATION GUESSES.
065488 05-10

NONADDICTIVE PSYCHOTROPIC MEDICATION FOR IMPRISONED NARCOTIC ADDICTS.
070784 07-13

CHANGES IN LIVER DISTURBANCE ASSOCIATED WITH LONG-TERM TRANQUILIZING MEDICATION (A FOLLOW-UP STUDY).
075839 08-15

THERAPEUTIC MEDICATION IN CHRONIC DELIRIUM: COMBINATION OF PROCHLORPERAZINE (TEMENTIL) AND LEVOMEPROMAZINE (NOZINAN).
079288 09-11

ON THE EFFECT OF DIOXYPHENYLALANINE (L-DOPA) ON EXTRAPYRAMIDAL HYPERKINESIA DUE TO NEUROLEPTIC LONG-TERM MEDICATION.
079950 09-15

INTRAGASTRIC TELEMETRIC MEASURING OF PH DURING THYMOLEPTIC MEDICATION.
081143 09-13

EFFECT OF WITHDRAWAL OF ANTIPARKINSONIAN MEDICATION ON CHRONICALLY HOSPITALIZED PSYCHIATRIC PATIENTS.
086445 10-15

THE EFFECT OF MEDICATION ON THE EFFECT OF ALCOHOL.
086844 10-17

PSYCHOSOMATIC FACTORS IN RHEUMATIC DISORDERS AND THEIR RELIEF BY MEDICATION.
089859 11-14

**MEDICATIONS**

A CONTROLLED TRIAL OF COMBINED MEDICATIONS ON BEHAVIORAL AND EXTRAPYRAMIDAL EFFECTS.
063774 04-14

THE EFFECT OF MEDICATIONS ON ALCOHOL METABOLISM.
086788 10-17

INDICATIONS FOR INHIBITORY MEDICATIONS.
091076 11-11

**MEDICINAL**

GALVESTON COUNTY STUDY SHOWS TRANQUILIZERS SURPASS ASPIRIN AS MEDICINAL POISONING AGENTS.
090070 11-15

ON THE MUTAGENIC EFFECT OF MEDICINAL PREPARATIONS USED IN PSYCHIATRY. (REVIEW OF THE LITERATURE).
102119 12-16

**MEDICINE**

PHARMACOLOGY AND MEDICINE.
051112 01-17

THE EMPLOYMENT OF A NEW BENZODIAZEPINE, RO-5-4556 IN INTERNAL MEDICINE.
058312 02-11

TREATMENT OF PSYCHOSOMATIC DISTURBANCES ASSOCIATED WITH PSYCHIC SYMPTOMS IN INTERNAL MEDICINE BY MEANS OF DOXEPIN.
072381 07-09

THE IMPACT OF PSYCHOPHARMACOLOGY ON MEDICINE AND PSYCHIATRY.
076508 09-17

REVIEW OF MEDICINE IN SPECIAL EDUCATION: ANOTHER LOOK AT DRUGS AND BEHAVIOR.
079144 09-17

THE USE OF TWO COMBINATIONS OF DRUGS WITH MIXED ACTION, ANTIDEPRESSIVE AND TRANQUILIZING (AMITRYPTILINE - PERPHENAZINE) IN GENERAL AND IN PSYCHOSOMATIC MEDICINE.
089162 10-17

SOMAPSYCHIC RELATIONS IN MEDICINE: SESSION OF HOMAGE OF THE PERUVIAN ACADEMY OF MEDICINE TO PROFESSOR HONORIO DELGADO.
094610 11-14

INDICATIONS OF LITHIUM SALTS IN PSYCHOSOMATIC MEDICINE.
106770 12-17

MANS TRIPARTITE BRAIN AND PSYCHOSOMATIC MEDICINE.
119884 12-17

**MEDICOLEGAL**

INTOXICATIONS BY LSD-25: MEDICOLEGAL PROBLEMS.
132911 12-12

**MEDULLARY**
ADRENAL CORTICAL AND MEDULLARY SECRETION AND EVALUATION OF DRUGS ACTING ON THE CENTRAL NERVOUS SYSTEM.
106270 12-03

**MEGAVITAMIN**
ORTHOMOLECULAR PSYCHIATRY: NIACIN AND MEGAVITAMIN THERAPY.
065416 05-08
MEGAVITAMIN THERAPY WITH SEVERELY DISTURBED CHILDREN.
075819 08-11

**MELANCHOLIA**
CRASH TREATMENT FOR MELANCHOLIA RESISTANT TO OTHER RECENTLY DEVELOPED METHODS.
058456 02-07

**MELANCHOLIC**
SOME EXPERIENCES WITH A PREVENTIVE ADMINISTRATION OF LITHIUM SALTS IN MANIC MELANCHOLIC PSYCHOSIS.
070952 07-09

**MELANOMA**
STIMULATION OF DOPA-14C INCORPORATION INTO MELANOMA TISSUE BY CHLORPROMAZINE AND RESERPINE.
040584 01-03
EFFECT OF PHENOTHIAZINES ON MELANOMA TYROSINASE ACTIVITY.
089998 11-05

**MELILOTUS-OFFICINALIS**
UNCONDITIONED REFLEX ACTIVITY IN THE RAT SUFFERING FROM EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY AND THE THERAPEUTIC EFFECT OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126051 12-04
DECREASE OF SPONTANEOUS MOTILITY IN EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY AND THE PROTECTIVE ACTIVITY OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126052 12-04
EFFECT OF A DEFICIENCY OF PANTOTHENIC ACID AND PYRIDOXINE ON THE FUNCTION OF THE CENTRAL NERVOUS SYSTEM AND ITS RESPONSE TO COUMARIN FROM MELILOTUS-OFFICINALIS.
126053 12-04
EFFECT OF CHLORPROMAZINE ON CONDITIONED REFLEXES AND ANTAGONISTIC ACTIVITY OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126054 12-04
INFLUENCE OF ISONIAZID ON THE CENTRAL NERVOUS SYSTEM; THE ANTAGONISM BETWEEN ISONIAZID AND PYRIDOXINE, PANTOTHENIC ACID AND COUMARIN IN RATS (MELILOTUS-OFFICINALIS).
126055 12-04
LEARNING ABILITY IN EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY UNDER THE INFLUENCE OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126056 12-04

**MELLERIL**
USE OF MELLERIL RETARD IN TREATMENT OF PATIENTS WITH DEPRESSIVE PARANOID AND ANXIOUS DEPRESSIVE SYNDROMES.
109724 12-14
CLINICAL STUDY OF THE DRUG MELLERIL.
126631 12-11

**MEMBRANE**
INTRANEURONAL AND EXTRANEURONAL ACCUMULATION OF SYMPATHOMIMETIC AMINES IN THE ISOLATED NICTITATING MEMBRANE OF THE CAT.
066363 05-03

**MEMBRANES**
EFFECTS OF PHENOTHIAZINE DERIVATIVES ON BIOLOGICAL MEMBRANES: DRUG-INDUCED CHANGES IN ELECTRON SPIN RESONANCE SPECTRA FROM SPIN-LABELED ERYTHROCYTE GHOST MEMBRANES.
064423 04-03

**MEMORY**
MEMORY ENHANCEMENT OF A PARTLY LEARNED DISCRIMINATION IN PIGEONS BY INTRAMUSCULAR INJECTION OF PHYSOSTIGMINE.
060858 03-04
THE INFLUENCE OF CENTROPHENOXINE (LUCIDRIL) ON LEARNING AND MEMORY IN ALCOHOLICS.
062800 03-14
DRUGS INFLUENCING THE CHOLINERGIC SYSTEM AND THE PROCESS OF LEARNING AND MEMORY IN MAN.
070955 07-14
EFFECTS OF FLUROTHYL ON MEMORY PROCESSING.
070978 07-04
EFFECT OF BRAIN ISO-ANTIBODIES ON LEARNING AND MEMORY IN THE RAT.
072516 08-04
THE EFFECT OF SOME INHIBITORS AND METABOLITES OF CATECHOLAMINE ON THE PROCESSES OF FIXATION AND REPRODUCTION OF MEMORY TRACES.
073716 08-03
MARIJUANA AND IMMEDIATE MEMORY.
073886 08-14
AN AUTOMATED MULTIPLE CHOICE TEST OF SHORT-TERM SPATIAL MEMORY FOR MONKEYS.
075917 09-04
THE RELATION OF PSYCHOPHARMACOLOGICAL DRUGS TO LEARNING AND MEMORY.
078509 09-14
INFLUENCE OF CENTROPHENOXIN ON MEMORY DISTURBANCE AFTER ELECTROSHOCK.
079993 09-08
DRUGS, HALLUCINATIONS AND MEMORY.
121085 12-12

**MEN**
THE KINETICS OF AMYLOBARBITONE METABOLISM IN HEALTHY MEN AND WOMEN.
063800 04-13
THE EFFECT OF LSD ON SLEEP DEPRIVED MEN.
064388 04-12
PLASMA FREE FATTY ACIDS BEFORE AND AFTER AN INTRAVENOUS INSULIN INJECTION IN ACUTE SCHIZOPHRENIC MEN.
075212 08-08
MARIJUANA: MARY JANE FACES THE IDENTITY CRISIS OR, THREE BLIND MEN STUDY THE ELEPHANT.
082063 10-17

**MENOPAUSE**
AMITRIPTYLINE IN EMOTIONAL STATES AT THE MENOPAUSE.
071123 07-11

**MENSTRUATION**
MENSTRUATION CHANGES AS UNUSUAL SIDE-EFFECT IN A MOLINDONE TRIAL.
067570 06-15

**MENTAL**
ARE THERE BENEFITS OF MENTAL ILLNESS?
058431 02-09
THE EFFECT OF CYCLANDELATE ON MENTAL FUNCTION IN PATIENTS WITH ARTERIOSCLEROTIC BRAIN DISEASE.
061654 03-13
MENTAL RETARDATION ASSOCIATED WITH PRENATAL INTOXICATION, ALLERGIC REACTIONS, DEFICIENCIES, TRAUMA, AND PHYSICAL AGENTS.
061704 03-15
MENTAL RETARDATION ASSOCIATED WITH POSTNATAL POISONS, TOXINS, ENDOTOXINS, DEFICIENCIES AND ALLERGIC REACTIONS.
061706 03-15
BEER SOCIOTHERAPY CAN BENEFIT AGED MENTAL PATIENTS.
064145 04-11
LYOGEN IN THE TREATMENT OF MENTAL DISEASES IN CHILDREN.
064173 04-07
DEPOT FLUPHENAZINE IN THE TREATMENT OF PSYCHOSIS IN A COMMUNITY MENTAL HEALTH CLINIC.
065475 05-08
MARIHUANA, ETHANOL, AND DEXTROAMPHETAMINE: MOOD AND MENTAL FUNCTION ALTERATIONS.
066231 05-14
MENTAL SYMPTOMS IN PARKINSONIAN PATIENTS TREATED WITH L-DOPA.
066490 05-15
USE OF PANGAMIC ACID (VITAMIN-B15) IN CEREBRAL ARTHEROSCLEROSIS WITH MENTAL DISTURBANCES.
067148 06-10
COMPARATIVE EFFECTS OF SMOKING MARIHUANA OR PLACEBO ON HUMAN MOTOR AND MENTAL PERFORMANCE.
069579 07-14
CLINICAL EXPERIENCE WITH PIPERACETAZINE IN HOSPITALIZED MENTAL PATIENTS: A FOUR YEAR STUDY.
071292 07-07
THE EFFECTS OF WITHHOLDING OF NEUROLEPTICS FROM MENTAL PATIENTS.
072406 07-15
COMPLEXES BETWEEN ACETYLCHOLINE AND CATECHOLAMINES AND THEIR TOLERANCE TO MENTAL ILLNESS.
072705 08-01
ISONICOTINIC-ACID-HYDRAZIDE (INH) INDUCED MENTAL DISORDERS IN THE COURSE OF LUNG TUBERCULOSIS TREATMENT.
072890 08-15
MENTAL DISORDERS CAUSED BY PHENMETRAZINE ABUSE.
072893 08-15
FUNCTIONAL CHARACTERISTIC OF THE LINKS OF THE BRAIN CONTROL SYSTEM FOR MENTAL AND MOTOR FUNCTIONS IN MAN.
073770 08-13
STUDIES OF MINERAL METABOLISM IN MENTAL DEPRESSION. I. THE EFFECTS OF IMIPRAMINE AND ELECTRIC CONVULSIVE THERAPY ON CALCIUM BALANCE AND KINETICS.
075837 08-11
MENTAL SYMPTOMS IN PARKINSONIAN PATIENTS TREATED WITH L-DOPA.
081082 09-15
EFFECT OF 1035-MD ON CERTAIN CONDITIONS OF MENTAL DEFICIENCY, ESPECIALLY THOSE OF VASCULAR ORIGIN; CLINICAL EEG AND PSYCHOPHARMACOLOGICAL STUDY.
084978 10-08

PROBLEM BEHAVIOR OF CHILDREN WITH SEVERE MENTAL AND PHYSICAL DISORDERS -- EXPERIENCE OF THE USE OF CARBAMAZEPINE. 105790 12-14

DRUGS AND MENTAL CONTROL. 108212 12-17

COEXISTENCE OF DIABETES-MELLITUS AND MYXEDEMA IN MENTAL PATIENTS. 116482 12-08

THE OCCUPATIONAL THERAPY IN A MENTAL HOSPITAL FOR CHRONIC SCHIZOPHRENICS. 139090 12-08

**MENTALLY**

EXPERIMENTAL PSYCHOLOGICAL STUDY OF PERFORMANCE CHANGES WITH PERAZINE (TAXILAN) IN MENTALLY DISTURBED AND IN HEALTHY EXPERIMENTAL SUBJECTS FOLLOWING REGIMEN AND SINGLE DOSE ADMINISTRATION. 058235 02-11

A CLINICAL EVALUATION OF MESORIDAZINE IN MENTALLY RETARDED PATIENTS. 060268 03-07

EPILEPSY THERAPY WITH MENTALLY RETARDED CHILDREN: NEUROPSYCHIATRIC DISORDERS THROUGH DIPHENYLHYDANTOIN. 071241 07-15

THE USE OF SULTHIAME WITH DISTURBED MENTALLY SUBNORMAL PATIENTS. 079215 09-11

CLINICAL EXPERIENCE WITH TARASAN AND THIORIDAZINE IN MENTALLY RETARDED CHILDREN -- A COMPARATIVE DOUBLE-BLIND STUDY. 097655 11-14

THE EFFECTS OF AN AMPHETAMINE ON MEASURES OF INTELLIGENCE AND LEARNING IN MENTALLY RETARDED ADULTS. (PH.D.DISSERTATION). 103152 12-14

ANTIAGGRESSIVE EFFECT OF LITHIUM SALTS IN SEVERE MENTALLY RETARDED ADOLESCENTS. 106776 12-14

**MEPAZINE**

DISTRIBUTION, EXCRETION, AND METABOLISM OF 14C-LABELED QUATERNARY AMMONIUM SALT OF MEPAZINE AND PROMETHAZINE IN RATS. 058571 02-03

**MEPERIDINE**

THE EFFECT OF PHENELZINE AND TRANYLCYPROMINE ON THE DEGRADATION OF MEPERIDINE. 064421 04-03

ROLE OF BRAIN AMINES IN THE ANALGESIC ACTION OF MEPERIDINE HYDROCHLORIDE. 075845 09-03

**MEPHENTERMINE**

AN EVALUATION OF THE VASODILATION PRODUCED BY MEPHENTERMINE AND CERTAIN OTHER SYMPATHOMIMETIC AMINES. 040311 01-03

**MEPROBAMATE**

THE RESPONSE TO MEPROBAMATE -- A PREDICTIVE ANALYSIS. 046311 01-17

EFFECTS OF MEPROBAMATE ON EMOTIONAL RESPONSES. 046312 01-04

A PRAGMATIC THEORY OF MEPROBAMATE EFFECTS. 046314 01-17

BLOOD AND URINE CONCENTRATIONS OF SUBJECTS RECEIVING BARBITURATES, MEPROBAMATE, GLUTETHIMIDE, OR DIPHENYLHYDANTOIN. 063927 04-13

MEPROBAMATE LOSES SOME LABEL CLAIMS. 070830 07-17

EFFECTS OF MEPROBAMATE ON THE SCHOOL ACHIEVEMENT OF CEREBRAL PALSIED CHILDREN. 083317 10-14

**MERCURY**

INDICATIONS OF CENTRAL NERVOUS EFFECTS OF SMALL AMOUNTS OF MERCURY IN RATS. 089044 10-17

**MESCALINE**

NEW COMPOUNDS: STRUCTURAL ANALOGS RELATED TO ASARONE AND MESCALINE. 064264 04-01

ANTIDIURESIS IN MAN FOLLOWING LYSERGIC ACID DIETHYLAMIDE AND MESCALINE. 066399 05-13

**MESENCEPHALIC**

ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL EFFECTS OF HARMALINE IN INTACT CATS AND IN CATS WITH CHRONIC MESENCEPHALIC TRANSECTION. 075847 09-04

**MESENCEPHALON**

DOPAMINE CONCENTRATIONS IN THE BRAINSTEM MESENCEPHALON OF ACTIVE RATS AS COMPARED WITH PASSIVE RATS. 060274 03-04

**MESORGYDINE**

AGGRESSIVE BEHAVIOR OF RATS INDUCED BY MESORGYDINE (LYSENYL SPOFA). 070949 07-04

**MESORIDAZINE**

THE DIFFERENTIAL RESPONSE TO PARENTERAL CHLORPROMAZINE AND MESORIDAZINE IN PSYCHOTIC PATIENTS. 040127 01-08

A DOUBLE-BLIND COMPARISON OF CHLORPROMAZINE AND MESORIDAZINE (TPS-23). 045508 01-07

A CLINICAL EVALUATION OF MESORIDAZINE IN MENTALLY RETARDED PATIENTS. 060268 03-07

MESORIDAZINE IN THE CONTROL OF BEHAVIOR DISORDERS IN CHILDREN. 086780 10-14

CLINICAL EXPERIENCE WITH MESORIDAZINE IN THE THERAPY AND REHABILITATION OF TRAUMATIC FRONTAL BRAIN DAMAGE. 089784 11-14

**META-TRIFLUOROMETHYL-PHENYL**

THE EFFECT OF ACUTE ADMINISTRATION OF (META-TRIFLUOROMETHYL-PHENYL)-1-(BENZOYLOXY) ETHYLAMINO-2-PROPANE (780-SE) AND FENFLURAMINE ON HUMAN SLEEP. 063978 04-14

**METABOLIC**

EFFECTS OF METABOLIC INHIBITORS ON NOREPINEPHRINE RELEASE FROM THE PERFUSED SPLEEN OF THE CAT. 040244 01-03

THE METABOLIC ALTERATION OF DRUGS. 051117 02-17

METABOLIC STUDIES AND CLINICAL OBSERVATIONS DURING L-DOPA TREATMENT OF PARKINSONS DISEASE. 063822 04-13

METABOLIC STUDIES ON TRIMETHOXYAMPHETAMINES. 071783 07-03

THE EFFECT OF A NEW METABOLIC CEREBRAL STIMULANT, CYPRODEMANOL, IN PSYCHIATRIC ASPECTS OF AGING. 089055 10-11

CANNABIS: A PSYCHOLOGICAL AND METABOLIC INVESTIGATION. 100014 11-14

STUDIES ON PSYCHOTROPIC DRUGS (SIXTH REPORT) - METABOLIC FATE OF APY-606 - EXCRETION AND METABOLISM IN RATS. 131057 12-02

STUDIES ON PSYCHOTROPIC DRUGS (SEVENTH REPORT) -- METABOLIC FATE OF APY-606 -- ABSORPTION, DISTRIBUTION, EXCRETION AND METABOLISM OF TRITIATED APY-606. 131059 12-02

**METABOLISM**

LONG-TERM VARIATION IN BASAL AND PHENOBARBITAL STIMULATED OXIDATIVE DRUG METABOLISM IN THE RAT. 040671 01-03

EFFECT OF DRUGS USED IN PSYCHOSES ON CEREBRAL DOPAMINE METABOLISM. 041566 01-03

EFFECTS OF LITHIUM CARBONATE ON TURNOVER AND METABOLISM OF NOREPINEPHRINE IN THE RAT BRAIN - CORRELATION TO GROSS BEHAVIORAL EFFECTS. 043277 01-03

THE EFFECT OF DIET AND PHENOBARBITONE ON QUININE METABOLISM IN THE RAT AND IN MAN. 046187 01-13

THE INFLUENCE OF MORPHINE ON MAGNESIUM METABOLISM IN RATS. 046191 01-03

PRELIMINARY OBSERVATIONS ON THE METABOLISM OF (3)H-2,5-DIMETHOXY-4-METHYLAMPHETAMINE (STP, DOM). 046197 01-03

SPECIES DIFFERENCES IN DRUG METABOLISM. 051118 02-17

TRANYLCYPROMINE: EFFECTS ON NOREPINEPHRINE METABOLISM IN RAT BRAIN. 052484 02-03

METABOLISM OF D-DOPA VS L-DOPA. 056852 02-11

THE INFLUENCE OF ETHANOL ON DRUG METABOLISM. 057033 02-03

DISTRIBUTION, EXCRETION, AND METABOLISM OF 14C-LABELED QUATERNARY AMMONIUM SALT OF MEPAZINE AND PROMETHAZINE IN RATS. 058571 02-03

P-CHLOROAMPHETAMINE: TEMPORAL RELATIONSHIP BETWEEN PSYCHOMOTOR STIMULATION AND METABOLISM OF BRAIN NOREPINEPHRINE. 062805 03-03

SOME EFFECTS OF EXPERIMENTALLY PRODUCED CIGARETTE SMOKE ON THE GROWTH, VITAMIN-C METABOLISM AND ORGAN WEIGHTS OF GUINEA-PIGS. 063061 03-03

THE INTERACTION OF ETHANOL AND AMPHETAMINE METABOLISM.
063062 03-03

THE KINETICS OF AMYLOBARBITONE METABOLISM IN HEALTHY MEN AND WOMEN.
063800 04-13

SPECIES DIFFERENCES IN DIAZEPAM METABOLISM -- I. METABOLISM OF DIAZEPAM METABOLITES.
064000 04-03

RELATIONSHIP BETWEEN DIFFERENCE SPECTRA AND METABOLISM: BARBITURATES, DRUG INTERACTION AND SPECIES DIFFERENCE.
064001 04-03

EFFECT OF INHIBITORS AND INDUCERS OF DRUG METABOLISM ON ETHANOL METABOLISM IN VIVO.
064052 04-03

DISTRIBUTION, EXCRETION AND METABOLISM OF TRIFLUOPERAZINE METHIODIDE-C14 IN RATS.
064094 04-03

A NOVEL APPROACH TO THE INVESTIGATION OF NOREPINEPHRINE METABOLISM IN HUMAN SYMPATHETIC NERVE.
064144 04-03

A MODEL OF HARMINE METABOLISM IN THE RAT.
064167 04-03

THE EFFECTS OF HALOPERIDOL AND CHLORPROMAZINE ON AMPHETAMINE METABOLISM AND AMPHETAMINE STEREOTYPE BEHAVIOR IN THE RAT.
064170 04-03

DISTRIBUTION, EXCRETION, AND METABOLISM OF 14C-LABELED QUATERNARY AMMONIUM SALT OF PERPHENAZINE IN RATS.
064261 04-03

PARADOXICAL AMPHETAMINE EFFECT IN HYPERACTIVE RATS IN RELATION TO NOREPINEPHRINE METABOLISM.
064364 04-03

METABOLISM OF 14C-IMIPRAMINE: III. CONVERSIONS BY RAT TISSUE.
064409 04-03

EFFECTS OF DESMETHYLIMIPRAMINE AND COCAINE ON THE UPTAKE, RETENTION AND METABOLISM OF H3-TYRAMINE IN RAT BRAIN SLICES.
064419 04-03

EFFECT OF ACUTE HYPOXIA ON BRAIN SENSITIVITY AND METABOLISM OF BARBITURATES IN MICE.
064480 04-03

THE ALTERATIONS OF PROTEIN METABOLISM OF THE BRAIN CORTEX INDUCED BY ANTICIPATION STRESS AND ACTH.
065434 05-03

THE KINETICS OF CHLORAL HYDRATE METABOLISM IN MICE AND THE EFFECT THEREON OF ETHANOL.
066364 05-03

EFFECTS OF PHENOBARBITAL, PHENYLBUTAZONE, 3,4 BENZPYRENE, OR 3-METHYLCHOLANTHRENE ON ETHANOL METABOLISM IN THE RAT.
066498 05-03

METABOLISM AND BILIARY EXCRETION OF THE LIPOPHILIC DRUG MOLECULES, IMIPRAMINE AND DESMETHYLIMIPRAMINE IN THE RAT -- I. EXPERIMENTS IN VIVO AND WITH ISOLATED PERFUSED LIVERS.
067260 06-03

THE METABOLISM OF PSYCHOTROPIC DRUGS (PHENOTHIAZINE AND IMINODIBENZYL DERIVATIVES).
067301 06-17

CHANGES IN ENZYMES SUBSERVING CATECHOLAMINE METABOLISM IN MORPHINE TOLERANCE AND WITHDRAWAL IN RAT.
067324 06-03

PENTYLENETETRAZOL AND ETHAMIVAN EFFECTS ON BRAIN SEROTONIN METABOLISM.
067613 06-03

NOREPINEPHRINE TURNOVER AND METABOLISM IN RAT BRAIN AFTER LONG-TERM ADMINISTRATION OF IMIPRAMINE.
067687 06-03

EFFECT OF METHYLCHLOROFORM INHALATION ON BARBITURATE HYPNOSIS AND HEPATIC DRUG METABOLISM IN MALE MICE.
068978 06-03

MARIHUANA: STUDIES ON THE DISPOSITION AND METABOLISM OF DELTA9-TETRAHYDROCANNABINOL IN MAN.
069051 06-13

ALTERATIONS IN BRAIN SENSITIVITY AND BARBITURATE METABOLISM UNRELATED TO AGGRESSION IN SOCIALLY DEPRIVED MICE.
069052 06-03

TRYPTOPHAN METABOLISM IN DEPRESSION.
069081 06-13

SOME EFFECTS OF D-AMPHETAMINE ON CARBOHYDRATE METABOLISM AT GROUND LEVEL AND ALTITUDE.
069344 06-03

DEPRESSANT EFFECT OF DELTA1-TETRAHYDROCANNABINOL ENHANCED BY INHIBITION OF ITS METABOLISM.
070443 07-03

CENTRAL NERVOUS SYSTEM METABOLISM, DRUG ACTION AND HIGHER FUNCTIONS.
070976 07-17

MODIFICATION OF CHLORPROMAZINE METABOLISM BY SOME OTHER DRUGS FREQUENTLY ADMINISTERED TO PSYCHIATRIC PATIENTS.
071989 07-13

STUDIES ON THE METABOLISM OF 7-CHLORO-1-3-DIHYDRO-3-HYDROXY-5-PHENYL 2H 1-4-BENZODIAZEPIN-2-ONE.
072587 08-13

ON THE DISTRIBUTION AND METABOLISM OF NEUROLEPTIC DRUGS. PART 2: PHARMACOKINETICS OF MOPERONE.
072589 08-03

EFFECTS OF BENZOCTAMINE (30803-BA, TACITIN), A NEW PSYCHOACTIVE DRUG, ON CATECHOLAMINE METABOLISM.
074861 08-03

EFFECT OF DESMETHYLIMIPRAMINE, IPRINDOLE AND DL-FRYTHRO-ALPHA-(3,4 DICHLOROPHENYL)-BETA-(T-BUTYLAMINO) PROPANOL HCL ON THE METABOLISM OF AMPHETAMINE.
074866 08-03

CATECHOLAMINE METABOLISM IN AFFECTIVE DISORDERS -- III. MHPG AND OTHER CATECHOLAMINE METABOLITES IN PATIENTS TREATED WITH LITHIUM CARBONATE.
075410 08-09

STUDIES OF MINERAL METABOLISM IN MENTAL DEPRESSION. I. THE EFFECTS OF IMIPRAMINE AND ELECTRIC CONVULSIVE THERAPY ON CALCIUM BALANCE AND KINETICS.
075837 08-11

INHIBITION OF HEPATIC HEXOBARBITAL METABOLISM BY DEXTROAMPHETAMINE.
076186 09-03

A CONTROLLED STUDY OF THE ANTIDEPRESSANT EFFECT OF P-CHLORO-N-METHYLAMPHETAMINE, A COMPOUND WITH A SELECTIVE EFFECT ON THE CENTRAL 5-HYDROXYTRYPTAMINE METABOLISM.
078212 09-10

ANTAGONISTIC INFLUENCE OF BETA-SYMPATHICOLYTICS ON THE METAMPHETAMINE INDUCED CHANGES IN FUNCTION AND METABOLISM OF THE BRAIN.
079954 09-03

DISTRIBUTION AND METABOLISM OF NEUROLEPTIC DRUGS: PART I: PHARMACOKINETICS OF HALOPERIDOL.
079968 09-03

EFFECT OF CHLORPROMAZINE ON 5-HYDROXYTRYPTAMINE METABOLISM IN HIPPOCAMPAL STIMULATED RATS.
080338 09-01

CHLORPROMAZINE METABOLISM I: QUANTITATIVE FLUOROMETRIC METHOD FOR 11 CHLORPROMAZINE METABOLITES.
080631 09-04

THE EFFECT OF LITHIUM ON THE METABOLISM OF EXPERIMENTAL ANIMALS.
081111 09-03

THE EFFECT OF MEDICATIONS ON ALCOHOL METABOLISM.
086788 10-17

CARDIAC CATECHOLAMINE SYNTHESIS, TURNOVER, AND METABOLISM WITH ISOPROTERENOL INDUCED MYOCYTOLYSIS (UNPUBLISHED PAPER).
088374 10-03

HEPATIC COMPOSITION AND METABOLISM AFTER ETHANOL CONSUMPTION IN RATS FED LIQUID PURIFIED DIETS.
088599 10-03

EFFECT OF VEHICLES ON METABOLISM OF SEROTONIN AND IMIPRAMINE.
089439 11-03

A STUDY OF HEPATIC ALCOHOL DEHYDROGENASE INHIBITION (ADH) INDUCED BY PYRAZOL: II. THE ROLE OF LIVER ADH IN THE IN VIVO METABOLISM OF HYDROXYL COMPOUNDS.
089547 11-03

EFFECT OF PHENOBARBITAL ON THE IN VITRO METABOLISM OF DIAZEPAM IN SEVERAL ANIMAL SPECIES.
090134 11-03

EFFECTS OF COCAINE AND AMPHETAMINE ON THE METABOLISM OF TRYPTOPHAN AND 5-HYDROXYTRYPTAMINE IN MOUSE BRAIN IN VIVO.
095440 11-03

EFFECTS OF AN ACUTE STRESS OF FOREBRAIN 5-HYDROXYTRYPTAMINE (5-HT) METABOLISM IN CNS LESIONED AND DRUG PRETREATED RATS.
095671 11-04

INFLUENCE OF CHRONIC ADMINISTRATION OF NICOTINE ON THE TURNOVER AND METABOLISM OF NORADRENALINE IN THE RAT BRAIN.
097958 11-03

GLUCOSE METABOLISM.
100515 12-15

U-14C TYROSINE METABOLISM OF THE PERFUSED CAT BRAIN WITH HIGH PLASMA PHENYLALANINE OR WITHOUT PLASMA TYROSINE.
100852 12-03

EFFECTS OF LITHIUM AND OTHER PSYCHOPHARMACA ON RAT ELECTROLYTE METABOLISM.
106778 12-05

LITHIUM EFFECTS ON CALCIUM METABOLISM IN RATS.
106780 12-03

DISTURBANCES IN TRYPTAMINE SEROTONIN METABOLISM ASSOCIATED WITH PSYCHOTIC PHENOMENA.
121084 12-13

STUDIES ON PSYCHOTROPIC DRUGS (SIXTH REPORT) - METABOLIC FATE OF APY-606 - EXCRETION AND METABOLISM IN RATS.
131057 12-02

STUDIES ON PSYCHOTROPIC DRUGS (SEVENTH REPORT) -- METABOLIC FATE OF APY-606 -- ABSORPTION, DISTRIBUTION, EXCRETION AND METABOLISM OF TRITIATED APY-606.
131059 12-02

**METABOLITES**

URINARY METABOLITES OF HARMINE IN THE RAT AND THEIR INHIBITION OF MONOAMINE OXIDASE.
040417 01-03

PHARMACOLOGY OF MEDAZEPAM AND METABOLITES.
063838 04-04

SPECIES DIFFERENCES IN DIAZEPAM METABOLISM -- I. METABOLISM OF DIAZEPAM METABOLITES.
064000 04-03

QUANTITATIVE THIN-LAYER CHROMATOGRAPHIC ESTIMATION OF LABELED DOPAMINE AND NOREPINEPHRINE, THEIR PRECURSORS AND METABOLITES.
070063 07-06

THE EFFECT OF L-DOPA ON MONOAMINE METABOLITES IN PARKINSONS DISEASE.
070824 07-13

PRAZEPAM METABOLITES IN DOG URINE.
071942 07-03

THE EFFECT OF SOME INHIBITORS AND METABOLITES OF CATECHOLAMINE ON THE PROCESSES OF FIXATION AND REPRODUCTION OF MEMORY TRACES.
073716 08-03

CATECHOLAMINE METABOLISM IN AFFECTIVE DISORDERS -- III. MHPG AND OTHER CATECHOLAMINE METABOLITES IN PATIENTS TREATED WITH LITHIUM CARBONATE.
075410 08-09

CHLORPROMAZINE METABOLISM I: QUANTITATIVE FLUOROMETRIC METHOD FOR 11 CHLORPROMAZINE METABOLITES.
080631 09-06

SYNTHESIS OF POSSIBLE METABOLITES OF CHLORPROMAZINE: IV. 7-HYDROXY-NOR1-CHLORPROMAZINE AND NOR2-CHLORPROMAZINE SULFOXIDE (UNPUBLISHED PAPER).
088358 10-01

SYNTHESIS OF POSSIBLE METABOLITES OF CHLORPROMAZINE. III. 7,8 DISUBSTITUTED CHLORPROMAZINE DERIVATIVES.
094623 11-01

USE OF HEPATIC MICROSOMES IN THE PREPARATION OF MODEL DRUG METABOLITES.
094789 11-06

**METABOLIZING**

PERINATAL DEVELOPMENT OF DRUG METABOLIZING ENZYME ACTIVITY IN SWINE.
066368 05-03

HYPOTHALAMIC REGULATION OF HEPATIC HEXOBARBITAL METABOLIZING ENZYME SYSTEM.
067962 06-03

**METAL**

EXTINCTION OF THE EXCRETORY ALKALI METAL RESPONSE (EAMR) TO STRESS IN A REPTILE.
076068 09-03

**METAMPHETAMINE**

ANTAGONISTIC INFLUENCE OF BETA-SYMPATHICOLYTICS ON THE METAMPHETAMINE INDUCED CHANGES IN FUNCTION AND METABOLISM OF THE BRAIN.
079954 09-03

**METARAMINOL**

MECHANISMS BY WHICH AMPHETAMINE AND DESIPRAMINE INHIBIT THE METARAMINOL INDUCED RELEASE OF NOREPINEPHRINE FROM SYMPATHETIC NERVE ENDINGS IN RAT HEART.
064427 04-03

**METEDRINE**

EFFECT OF LSD-25, CHLORPROMAZINE AND METEDRINE UPON VISUAL EVOKED RESPONSE IN CATS.
098171 11-03

**METHADONE**

USING METHADONE TO TREAT THE HEROIN ADDICT.
062789 03-07

REACTION TIMES OF METHADONE TREATED EX HEROIN ADDICTS.
062817 03-11

ANTAGONISM OF THE BEHAVIORAL EFFECTS OF MORPHINE AND METHADONE BY NARCOTIC ANTAGONISTS IN THE PIGEON.
069593 07-04

METHADONE PATIENTS ON PROBATION AND PAROLE.
070021 07-13

SUCCESSES AND FAILURES IN METHADONE MAINTENANCE TREATMENT OF HEROIN ADDICTION IN NEW-YORK CITY. (UNPUBLISHED PAPER).
071314 07-17

ACTION OF CODEINE, PETHIDINE AND METHADONE ON THE OPERANT BEHAVIOR OF THE RAT.
071787 07-04

**METHAMPHETAMINE**

MANNICH BASES FROM 1,2- DIPHENYLINDOLIZINE: EPHEDRINE AND METHAMPHETAMINE AS AMINE COMPONENTS.
055324 02-01

INHIBITION OF THE STIMULATING EFFECT OF METHAMPHETAMINE AND MORPHINE ON MOUSE BY INFLUENCING THE ENDOGENOUS CATECHOLAMINES.
055739 02-03

INTERACTIONS OF DELTA1-TETRAHYDROCANNABINOL WITH BARBITURATES AND METHAMPHETAMINE.
064424 04-04

AN ANALYSIS OF 310 CASES OF ACUTE HIGH-DOSE METHAMPHETAMINE TOXICITY IN HAIGHT-ASHBURY.
067218 06-15

**METHANOL**

PROJECT SUMMARY: METHANOL FORMING ENZYME IN MAMMALIAN BRAIN.
060633 03-01

**METHAQUALONE**

A COMPARATIVE STUDY OF THE EFFECTS OF METHAQUALONE AND GLUTETHIMIDE ON SLEEP IN MALE CHRONIC INSOMNIACS.
063879 04-14

HYPNOTICS AND ALTERED SLEEP DREAM PATTERNS: II. ALL-NIGHT EEG STUDIES OF CHLORAL HYDRATE, FLURAZEPAM, AND METHAQUALONE.
066234 05-14

**METHEDRINE**

A COMPARISON OF SHORT-TERM TREATMENT EFFECTS OF INTRAVENOUS SODIUM AMYTAL METHEDRINE AND LSD IN THE ALCOHOLIC.
062934 03-11

CENTRAL NERVOUS SYSTEM CYTOPATHOLOGICAL CHANGES IN CATS WITH CHRONIC METHEDRINE INTOXICATION.
064143 04-05

BEHAVIOR AND HISTOPATHOLOGICAL FINDINGS DURING CHRONIC METHEDRINE INTOXICATION.
071993 07-05

**METHIODIDE-C14**

DISTRIBUTION, EXCRETION AND METABOLISM OF TRIFLUOPERAZINE METHIODIDE-C14 IN RATS.
064094 04-03

**METHIONINE**

NICOTINIC ACID IN THE PREVENTION AND TREATMENT OF METHIONINE INDUCED EXACERBATION OF PSYCHOPATHOLOGY IN SCHIZOPHRENICS.
075423 08-08

THE EFFECT OF METHIONINE OF THE REGIONAL AND INTRACELLULAR DISPOSITION OF (3H) METHIONINE SULPHOXIMINE IN RAT BRAIN.
090148 11-03

ON THE BIOCHEMICAL MECHANISM OF ACTION OF NICOTINIC ACID, NICOTINAMIDE, METHIONINE, AND D-PENICILLAMINE IN THE TREATMENT OF PSYCHOSES.
094962 11-13

**METHOD**

STATISTICAL METHOD OF ANALYSIS AND EVALUATION OF PSYCHOTHERAPEUTIC RESULTS: APPLICATION OF A LONG-ACTING NEUROLEPTIC, COMPARED WITH A STANDARD NEUROLEPTIC AND THE SAKEL INSULIN TREATMENT.
042676 01-07

A METHOD OF IDENTIFYING NARCOTIC ANALGESICS IN HUMAN URINE AFTER THERAPEUTIC DOSES.
057473 02-16

A METHOD FOR CHRONIC INTRAVENOUS DRUG ADMINISTRATION IN SQUIRREL MONKEYS.
063725 04-06

A METHOD FOR INVESTIGATING THE EFFECTS OF DRUGS ON THE EXPLORATORY BEHAVIOUR OF MICE.
064289 04-04

OBSERVATION OF THE GROOMING BEHAVIOR OF RESERPINIZED WHITE MICE AS A METHOD FOR INVESTIGATING RESERPINE ANTAGONISM AND SYNERGISM.
065442 05-04

A SIMPLE SCREENING METHOD FOR ANTIPARKINSONIAN DRUGS IN MICE.
066415 05-06

CHLORPROMAZINE METABOLISM I: QUANTITATIVE FLUOROMETRIC METHOD FOR 11 CHLORPROMAZINE METABOLITES.
080631 09-06

AN AUTOMATED OPEN FIELD METHOD.
081261 09-06

A NOVEL METHOD OF REDUCING THE CONCENTRATION OF BRAIN SEROTONIN: USE OF ALPHA-METHYLTRYPTOPHAN.
086350 10-13

NEW METHOD FOR ASSAYING ANTIAPOMORPHINE ACTIVITY IN PIGEONS.
089437 11-06

CLINICOELECTROENCEPHALOGRAPHIC EVALUATION OF A NEW BENZODIAZEPINIC DERIVATIVE (RO-5-4023) ADMINISTERED ORALLY IN EPILEPTIC PATIENTS USING A DOUBLE-BLIND METHOD.
100959 12-07

AN INTERESTING TISSULARY THERAPEUTIC METHOD IN GERIATRICS: BOGOMOLETZ SERUM (BERNAS CYTOTOXIC SERUM).
105551 12-11

A TRIAL ON THE VALUE OF SORDINOL IN SCHIZOPHRENIA -- BY SUBJECTIVE METHOD AND PARTLY BY USING SEQUENTIAL ANALYSIS.
129451 12-08

**METHODOLOGICAL**

METHODOLOGICAL CONSIDERATIONS IN EVALUATING ANTIANXIETY DRUGS.
046558 01-16

METHODOLOGICAL PROBLEMS OF PROPHYLACTIC TRIALS IN RECURRENT AFFECTIVE DISORDERS.
060266 03-09

METHODOLOGICAL PROBLEMS IN PSYCHOTHERAPY RESEARCH: OBSERVATIONS ON THE KARON-VANDENBOS STUDY OF PSYCHOTHERAPY AND DRUGS IN SCHIZOPHRENIA.
071322 07-08

PSYCHOPHARMACOLOGY IN CHILDREN: PROBLEM AREAS, METHODOLOGICAL CONSIDERATIONS, ASSESSMENT TECHNIQUES.
080350 09-17

LONG-TERM DRUG THERAPY IN AFFECTIVE DISORDERS: THEORETICAL AND METHODOLOGICAL ISSUES IN CURRENT RESEARCH ON LITHIUM.
106765 12-09

**METHODOLOGY**

EVALUATION OF TEGRETOL IN THE TREATMENT OF BEHAVIOUR DISORDERS IN CHILDREN: METHODOLOGY AND RESULTS.
080098 09-07

**METHODS**

METHODS FOR DETECTING ANTIANXIETY DRUGS USING BABOONS (PAPIO-CYNOCEPHALUS).
041537 01-06

CRASH TREATMENT FOR MELANCHOLIA RESISTANT TO OTHER RECENTLY DEVELOPED METHODS.
058456 02-07

PSYCHOLOGICAL METHODS APPLIED TO EVALUATE SYMPTOMATIC GERIATRIC TREATMENT.
064152 04-14

SIDE REACTIONS IN NEUROTICS: I. A COMPARISON OF TWO METHODS OF ASSESSMENT.
064287 04-15

COMPARISON OF METHODS OF RELAXATION USING PHYSIOLOGICAL MEASURES.
074135 08-14

AMBULATORY BEHAVIOR IN THE RAT AS A FUNCTION OF TWO METHODS OF ALCOHOL ADMINISTRATION.
075316 08-04

RESEARCH ON NEW METHODS OF EXPERIMENTATION WITH PSYCHOTROPIC DRUGS. RESULTS OF A TEST WITH A NEW TRANQUILIZER, NOBRIUM, IN TWO INDEPENDENT INVESTIGATIONS.
086984 10-16

METHODS OF TREATING DELIRIUM-TREMENS AS BASED ON MATERIALS OF THE UNIVERSITY MEDICAL SCHOOLS PSYCHIATRIC CLINIC IN WROCLAW BETWEEN 1958 AND 1968.
087143 10-11

RESEARCH IN NEW EXPERIMENTAL METHODS FOR PSYCHOTROPIC DRUGS: RESULTS OF A DOUBLE-BLIND STUDY WITH A NEW TRANQUILIZER, NOBRIUM.
112282 12-16

**METHOHEXITAL**

ELECTROTHERAPY: THE EFFECTS OF METHOHEXITAL ON EKG.
058455 02-15

**METHOHEXITONE**

METHOHEXITONE ASSISTED DESENSITIZATION FOR PHOBIAS.
067074 05-16

METHOHEXITONE ASSISTED DESENSITIZATION IN TREATMENT OF PHOBIAS.
067673 06-11

**METHOXY**

ANALOGS OF ALPHA-METHYLPHENETHYLAMINE (AMPHETAMINE). I. SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF SOME METHOXY AND/OR METHYL ANALOGS.
038488 01-04

**METHOXYLATED**

ABSOLUTE CONFIGURATIONS OF METHOXYLATED AMPHETAMINES.
095700 11-01

**METHYL**

ANALOGS OF ALPHA-METHYLPHENETHYLAMINE (AMPHETAMINE). I. SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF SOME METHOXY AND/OR METHYL ANALOGS.
038488 01-04

THE SYNTHESIS AND BIOLOGICAL ACTIVITY OF (-)-DELTA9(11)-TRANS TETRAHYDROCANNABINOL; A NEW PROCEDURE FOR THE CLEAVAGE OF PHENYL METHYL ETHERS (UNPUBLISHED PAPER).
092888 11-01

**METHYL-1-BUTENYL**

NEUROPSYCHIATRIC CLINICAL STUDY OF A BARBITURATE HYPNOTIC: 5-ETHYL 5(1- METHYL-1-BUTENYL) MALONYLUREA.
089173 10-07

**METHYLAMINE**

BLOCKADE OF NOREPINEPHRINE UPTAKE AND RELATED ACTIVITIES OF CIS- AND TRANS N,N(PRIME)-BIS-(1-NAPHTHYLMETHYL)-1,4 CYCLOHEXANE BIS-(METHYLAMINE) DIHYDROCHLORIDE.
090136 11-03

**METHYLAMINO**

STUDIES IN MAN ON THE INFLUENCE OF A NEW PSYCHOPHARMACEUTICAL DRUG, 1-((METHYLAMINO) DIBENZOBICYCLOOCTADIENE HYDROCHLORIDE, ON THE CO2 SENSITIVE CENTRAL RESPIRATORY REGULATION.
079971 09-07

**METHYLAMPHETAMINE**

THE ROLE OF METHYLAMPHETAMINE ON PLASMA HEXOSAMINE LEVEL UNDER STRESS.
074855 08-03

**METHYLATED**

AMPHETAMINE ANALOGS. II. METHYLATED PHENETHYLAMINES.
041907 01-02

**METHYLCHLOROFORM**

EFFECT OF METHYLCHLOROFORM INHALATION ON BARBITURATE HYPNOSIS AND HEPATIC DRUG METABOLISM IN MALE MICE.
068978 06-03

**METHYLDOPA**

L-DOPA INDUCED ACCUMULATION OF METHYLDOPA IN BRAIN AND HEART.
042726 01-03

**METHYLPERIDOL**

A COMPARISON OF THE EFFECTS OF METHYLPERIDOL AND PERPHENAZINE IN SCHIZOPHRENIC PSYCHOSIS.
070936 07-08

**METHYLPERONE**

CLINICAL EXPERIENCE WITH METHYLPERONE (BURONIL), A NEW BUTYROPHENONE DERIVATIVE.
105730 12-07

**METHYLPHENIDATE**

AN ANALYSIS OF METHYLPHENIDATE INDUCED GNAWING IN GUINEA-PIGS.
064414 04-04

PEMOLINE AND METHYLPHENIDATE IN MILDLY DEPRESSED OUTPATIENTS.
066709 05-10

EFFECTS OF METHYLPHENIDATE ON ACTIVITY AND REACTIONS OF NOVELTY IN RATS.
076066 09-04

METHYLPHENIDATE AND THIORIDAZINE: LEARNING, REACTION TIME, ACTIVITY, AND CLASSROOM BEHAVIOR IN DISTURBED CHILDREN.
081631 10-14

STATE-DEPENDENT RECOGNITION WITH METHYLPHENIDATE AND THIORIDAZINE IN RETARDED CHILDREN. (PH.D.DISSERTATION).
103301 12-14

**METHYLPHOSPHONOFLUORIDATE**

DEPHOSPHORYLATION IN VIVO OF BRAIN ACETYLCHOLINESTERASE INHIBITED BY ISOPROPYL METHYLPHOSPHONOFLUORIDATE (SARIN).
046188 01-03

**METHYPRYLON**

HYPNOTICS AND ALTERED SLEEP DREAM PATTERNS: I. ALL-NIGHT EEG STUDIES OF GLUTETHIMIDE, METHYPRYLON, AND PENTOBARBITAL.
066233 05-14

A COMPARATIVE STUDY OF THREE HYPNOTICS: METHYPRYLON, GLUTETHIMIDE AND CHLORAL HYDRATE.
067862 06-14

DOES NOLUDAR (METHYPRYLON) CHANGE DREAMS?
082173 10-14

**METHYSERGIDE**

METHYSERGIDE AS A TREATMENT FOR MANIA.
062350 03-09

PLEURAL EFFUSION AND FIBROSIS DURING TREATMENT WITH METHYSERGIDE.
067836 06-15

A DOUBLE-BLIND INTENSIVE CROSSOVER DESIGN TRIAL OF METHYSERGIDE IN MANIA.
085327 10-09

**METIAPINE**

METIAPINE: A NEW ANTIPSYCHOTIC AGENT.
069059 06-07

**METOCLOPRAMIDE**

METOCLOPRAMIDE AND THE MUSCULATURE OF ESOPHAGUS, STOMACH, INTESTINE, SPLEEN, TRACHEA, GALL AND URINARY BLADDERS: IN VITRO STUDIES.
055394 02-03

**METRAZOL**

METRAZOL TOLERANCE IN A NORMAL VOLUNTEER POPULATION: A TEN YEAR FOLLOW-UP REPORT.
060649 03-13

METRAZOL AND THE EVALUATION OF SEIZURES.
081298 09-11

EFFECTS OF INSULIN, METRAZOL, AND ELECTROCONVULSIVE SHOCKS UPON LEARNING TO LEARN 30 SUCCESSIVE REVERSAL PROBLEMS BY RATS.
095188 11-04

METRONIDAZOLE

COMBINED USE OF DISULFIRAM AND METRONIDAZOLE IN TREATMENT OF ALCOHOLISM.
058589 02-15

PRELIMINARY CLINICAL OBSERVATIONS CONCERNING THE TREATMENT WITH METRONIDAZOLE IN CHRONIC ALCOHOLISM.
062866 03-11

MHPG

CATECHOLAMINE METABOLISM IN AFFECTIVE DISORDERS – III. MHPG AND OTHER CATECHOLAMINE METABOLITES IN PATIENTS TREATED WITH LITHIUM CARBONATE.
075410 08-09

MICE

EFFECT OF ENVIRONMENTAL TEMPERATURE ON THE TOXICITY OF CAFFEINE AND DEXTROAMPHETAMINE IN MICE.
040028 01-05

A COMPARISON OF THE EFFECTS OF SOME BENZODIAZEPINES AND OTHER DRUGS ON AGGRESSIVE AND EXPLORATORY BEHAVIOUR IN MICE AND RATS.
040581 01-04

ALTERATIONS OF D-AMPHETAMINE SULFATE LETHALITY AND BODY TEMPERATURE IN MICE DURING ACUTE ALTITUDE EXPOSURE.
040582 01-03

EFFECTS OF CHRONIC POSTNATAL DRUG ADMINISTRATION ON ADULT DOMINANCE BEHAVIOR IN TWO GENERA OF MICE.
042837 01-04

TOTAL BODY KINETICS AND PLACENTAL TRANSFER OF LABELED LSD IN MICE.
046201 01-03

DRUG DEPENDENT DIFFERENCES IN THE DEVELOPMENT OF TOLERANCE TO WRITHING IN MICE.
046400 01-03

CORRELATION BETWEEN THE DURATION OF THE ANTICONVULSANT ACTIVITY OF DIAZEPAM AND ITS PHYSIOLOGICAL DISPOSITION IN MICE.
046402 01-03

DIFFERENCES IN BRAIN AREA 5-HYDROXYTRYPTAMINE TURNOVER AND REARING BEHAVIOR IN RATS AND MICE OF BOTH SEXES.
047324 01-04

PHARMACOLOGICAL COMPARISON OF R(..), S(-) AND RACEMIC SECOBARBITAL IN MICE.
047325 01-03

TRYPTOPHOL, 5-HYDROXYTRYPTOPHOL AND 5-METHOXYTRYPTOPHOL INDUCED SLEEP IN MICE.
058382 02-04

CIRCADIAN RHYTHM FOR EXPERIMENTALLY INDUCED AGGRESSIVE BEHAVIOR IN MICE.
058383 02-03

IMPAIRMENT OF SHOCK AVOIDANCE LEARNING AFTER LONG-TERM ALCOHOL INGESTION IN MICE.
058492 02-04

ASSOCIATION OF AMPHETAMINE TOXICITY AND TISSUE GLYCOGEN DEPLETION IN MICE AND RATS.
058998 03-05

EFFECT OF DIETHYLDITHIOCARBAMATE ON THE TOXICITY OF AMPHETAMINE IN AGGREGATED MICE.
062937 03-04

LSD: NO TERATOGENIC ACTION IN RATS, MICE, AND HAMSTERS.
063993 04-03

A METHOD FOR INVESTIGATING THE EFFECTS OF DRUGS ON THE EXPLORATORY BEHAVIOUR OF MICE.
064289 04-04

THE EFFECTS OF CHLORPROMAZINE ON ONE-TRIAL PASSIVE AVOIDANCE LEARNING IN MICE: FURTHER EXAMINATION OF PRELEARNING AND POSTLEARNING ADMINISTRATION.
064407 04-04

DOPA EFFECTS ON MOTILITY IN MICE; POTENTIATION BY MK-485 AND DEXCHLORPHENIRAMINE.
064411 04-03

EFFECT OF ACUTE HYPOXIA ON BRAIN SENSITIVITY AND METABOLISM OF BARBITURATES IN MICE.
064480 04-03

EFFECTS OF DISULFIRAM AND DIETHYLDITHIOCARBAMATE ON SPONTANEOUS LOCOMOTOR ACTIVITY AND BRAIN CATECHOLAMINE LEVELS IN MICE.
064590 04-04

OBSERVATION OF THE GROOMING BEHAVIOR OF RESERPINIZED WHITE MICE AS A METHOD FOR INVESTIGATING RESERPINE ANTAGONISM AND SYNERGISM.
065442 05-04

EFFECT OF HYDROXYLAMINE ON MAZE LEARNING IN MICE.
065933 05-04

THE KINETICS OF CHLORAL HYDRATE METABOLISM IN MICE AND THE EFFECT THEREON OF ETHANOL.
066364 05-03

A SIMPLE SCREENING METHOD FOR ANTIPARKINSONIAN DRUGS IN MICE.
066415 05-06

POTENTIATION BY AMANTADINE HYDROCHLORIDE OF L-DOPA INDUCED EFFECTS IN MICE.
066508 05-03

STRAIN DIFFERENCES IN THE EFFECTS OF CHLORPROMAZINE AND CHLORDIAZEPOXIDE UPON ACTIVE AND PASSIVE AVOIDANCE IN MICE.
066828 05-04

BARBITURATE INDUCED SLEEP IN HYPERTHYROID MICE.
066935 05-05

PERSISTENCE OF DOSE RELATED BEHAVIOUR IN MICE.
067606 06-04

THE PHARMACOLOGICAL EFFECTS OF OUABAIN ADMINISTERED INTRACEREBRALLY TO CONSCIOUS MICE.
068165 06-03

EFFECT OF METHYLCHLOROFORM INHALATION ON BARBITURATE HYPNOSIS AND HEPATIC DRUG METABOLISM IN MALE MICE.
068978 06-03

ALTERATIONS IN BRAIN SENSITIVITY AND BARBITURATE METABOLISM UNRELATED TO AGGRESSION IN SOCIALLY DEPRIVED MICE.
069052 06-03

STRYCHNINE EFFECTS ON DISCRIMINATION LEARNING IN MICE: EFFECTS OF DOSE AND TIME OF ADMINISTRATION.
069066 06-04

STUDIES ON INTERACTIONS INVOLVING ANTIDEPRESSIVE AND OTHER DRUGS WITH TETRABENAZINE AND NORADNAMINE ON LOCOMOTOR ACTIVITY IN MICE, INCLUDING DETAILS OF THE EXPERIMENTAL DESIGN AND STATISTICAL ANALYSIS.
069077 06-04

THE INHIBITORY EFFECT OF AMPHETAMINE ON EXPLORATION IN MICE.
069080 06-04

BRAIN SEROTONIN TURNOVER IN MORPHINE TOLERANT AND DEPENDENT MICE.
069595 07-03

EFFECTS OF AGROCLAVINE ON WHEEL TURNING ACTIVITY IN MICE.
069610 07-04

AMPHETAMINE TOXICITY AND ENDOGENOUS NORADRENALINE CONCENTRATIONS IN ISOLATED AND AGGREGATED MIC
074146 08-05

LACK OF A LONG-TERM EFFECT OF LSD ON Y-MAZE LEARNING IN MICE.
074422 08-04

EFFECTS OF ELYMOCLAVINE ON WHEEL TURNING ACTIVITY IN MICE.
075196 08-04

PENTOBARBITAL INDUCED STATE-DEPENDENT LEARNING OF ONE-WAY AVOIDANCE IN MICE.
075288 08-04

EFFECTS OF INTRAPERITONEAL INJECTION OF ETHANOL ON ETHANOL INGESTION OF C57BL MICE.
075957 09-02

ANTAGONISM OF BETA-PHENYLETHYLAMINE DERIVATIVES AND SEROTONIN BLOCKING DRUGS UPON SEROTONIN, TRYPTAMINE AND RESERPINE BEHAVIORAL DEPRESSION IN MICE.
079970 09-04

INCREASED AGGRESSION AMONG GROUPED MALE MICE FED CHLORDIAZEPOXIDE.
081098 09-04

FURTHER STUDIES ON THE LONG-LASTING ANTIMETRAZOL ACTIVITY OF DIAZEPAM IN MICE.
081106 09-03

POST-NEONATAL ANDROGENIZATION AND ADULT AGGRESSIVE BEHAVIOR IN FEMALE MICE.
081233 09-04

INFLUENCE OF SEVERAL AUTONOMIC DRUGS ON SODIUM NITROPRUSSIDE AND OXOTREMORINE INDUCED HYPOTHERMIA IN IMMATURE AND MATURE MICE.
089436 11-03

EFFECTS OF DRUGS ACTING ALONE AND IN COMBINATION ON THE MOTOR ACTIVITY OF INTACT MICE.
090139 11-03

STUDIES ON THE RECEPTORS INVOLVED IN THE ACTION OF THE VARIOUS AGENTS IN THE PHENYLBENZOQUINONE ANALGESIC ASSAY IN MICE.
090451 11-03

BRAIN DAMAGE IN INFANT MICE FOLLOWING ORAL INTAKE OF GLUTAMATE, ASPARTATE OR CYSTEINE.
094164 11-05

AMNESIA AND BRAIN SEIZURES ACTIVITY IN MICE: EFFECTS OF DIETHYL-ETHER ANESTHESIA PRIOR TO ELECTROSHOCK STIMULATION.
097952 11-04

THE EFFECTS OF CHLORPROMAZINE ON THE EXPRESSION OF AN ACQUIRED PASSIVE AVOIDANCE RESPONSE IN MICE.
097959 11-04

INHIBITION OF CENTRAL SEROTONINERGIC EXCITATION (5-HYDROXYTRYPTOPHAN INDUCED DEAD TWITCHES) IN MICE BY LITHIUM.
097989 11-04

EXCITATORY EFFECT OF TRYPTOPHAN IN MICE AND RATS AND EFFECT OF IMIPRAMINE AND DESMETHYLIMIPRAMINE UPON IT.
098009 11-03

ON THE ANALYSIS OF 5-HYDROXYTRYPTOPHAN PRODUCED HYPERTHERMIA IN MICE PRETREATED WITH A MONOAMINE OXIDASE INHIBITOR NIAMID.
098035 11-03

EFFECTS OF MORPHINE AND LEVORPHANOL ON BRAIN ACETYLCHOLINE CONTENT IN MICE.
101316 12-03

5-HYDROXYTRYPTOPHAN PRODUCED HYPOTHERMIA IN MICE AS A TEST FOR PHARMACOLOGICAL DIFFERENTIATION OF ANTIDEPRESSANTS, ANTICHOLINERGICS AND NEUROLEPTICS: SOME DATA ON THE NATURE OF THIS HYPOTHERMIA.
105622 12-06

**MICELLAR**

MICELLAR SOLUBILIZATION OF BARBITURATES I: SOLUBILITIES OF CERTAIN BARBITURATES IN POLYSORBATES OF VARYING HYDROPHOBIC CHAIN LENGTH.
046136 01-17

**MICROAUTORADIOGRAPHY**

TISSUE DISTRIBUTION OF CHLORPROMAZINE STUDIED BY MICROAUTORADIOGRAPHY.
067961 06-03

**MICROINJECTION**

IMPAIRMENT OF ALTERNATION LEARNING IN RATS FOLLOWING MICROINJECTION OF CARBACHOL INTO THE HIPPOCAMPUS.
067522 06-04

THE EFFECT OF INTRAHYPOTHALAMIC MICROINJECTION OF HEMICHOLINIUM (HC-3) ON THE HIPPOCAMPAL THETA RHYTHM OF CATS.
075842 08-03

**MICROPELLETS**

AN IMPROVED INSTRUMENT FOR IMPLANTING MICROPELLETS IN THE BRAIN.
058358 02-06

**MICROSCOPIC**

AN ELECTRON MICROSCOPIC STUDY OF AXONAL CHANGES IN THE CEREBELLUM OF DIPHENYLHYDANTOIN INTOXICATED RATS: THE FORMATION OF THE SO-CALLED HONEYCOMB STRUCTURE IN THE AXOPLASM.
070334 07-03

**MICROSCOPY**

ELECTRON MICROSCOPY. SUDDEN DEATH IN PATIENTS UNDER PHENOTHIAZINE THERAPY: STUDY OF THREE CASES.
090359 11-15

**MICROSOME**

COMPARISON OF LIVER MICROSOME ENZYME SYSTEMS AND BARBITURATE SLEEP TIMES IN RATS CAGED INDIVIDUALLY OR COMMUNALLY.
045545 01-06

**MICROSOMES**

EFFECTS OF MORPHINE TREATMENT AND STARVATION ON THE SUBSTRATE INTERACTION WITH P-450 IN THE OXIDATION OF DRUGS BY LIVER MICROSOMES.
063982 04-03

EFFECT OF MORPHINE ADMINISTRATION ON THE HYDROXYLATION OF STEROID HORMONES BY RAT LIVER MICROSOMES.
066366 05-03

USE OF HEPATIC MICROSOMES IN THE PREPARATION OF MODEL DRUG METABOLITES.
094789 11-06

PREPARATION OF 3H-7-HYDROXYCHLORPROMAZINE USING SHEEP LIVER MICROSOMES FOR HYDROXYLATION OF 3H-CHLORPROMAZINE.
097582 11-01

**MICTURITION**

PSYCHOPHARMACOLOGICAL AGENTS AND MICTURITION DISORDERS: CYSTOMETRIC INVESTIGATIONS.
090126 11-15

**MIDBRAIN**

ACTION OF PSYCHOTOGENIC DRUGS ON SINGLE MIDBRAIN RAPHE NEURONS.
040418 01-03

TRYPTOPHAN HYDROXYLASE CHANGES IN MIDBRAIN OF THE RAT AFTER CHRONIC MORPHINE ADMINISTRATION.
064146 04-03

REDUCED EFFECT OF MORPHINE IN MIDBRAIN RAPHE LESIONED RATS.
066500 05-03

ALTERATIONS IN THE BEHAVIORAL EFFECTS OF LSD BY MIDBRAIN RAPHE LESIONS (UNPUBLISHED PAPER).
082545 10-04

ALTERATIONS IN THE BEHAVIORAL EFFECTS OF LSD BY MIDBRAIN RAPHE LESIONS.
086029 10-12

THE EFFECT OF DIETHYLAMIDE OF LYSERGIC ACID (DLA) ON THE CONTENT OF MONOAMINES IN SOME NUCLEI OF THE MIDBRAIN AND HYPOTHALAMUS.
101006 12-03

**MIDDLE**

CONCERNING A CASE OF THROMBOSIS OF THE MIDDLE CEREBRAL ARTERY IN THE COURSE OF PROGESTINIC TREATMENT.
094467 11-1

**MIDLANDS**

DIMYRIL ABUSE IN THE EAST MIDLANDS.
064268 04-1

**MILIEU**

RELATIONSHIP BETWEEN THE HOSPITAL MILIEU AND THE RESPONSE TO PHENOTHIAZINES IN THE TREATMENT OF SCHIZOPHRENICS.
085237 10-0

**MILITARY**

A REVIEW OF THE BIOMEDICAL EFFECTS OF MARIHUANA ON MAN IN THE MILITARY ENVIRONMENT.
085756 10-1

**MIND**

THE MIND NOBODY KNOWS.
046729 01-1

**MINERAL**

STUDIES OF MINERAL METABOLISM IN MENTAL DEPRESSION. I. THE EFFECTS OF IMIPRAMINE AND ELECTRIC CONVULSIVE THERAPY ON CALCIUM BALANCE AND KINETICS.
075837 08-1

**MINERALS**

THE EFFECTS OF IMIPRAMINE AND ELECTRIC CONVULSIVE THERAPY ON THE EXCRETION OF VARIOUS MINERALS IN DEPRESSED PATIENTS.
063939 04-1

**MINIATURIZED**

MINIATURIZED BIOTELEMETRIC TRANSMITTER.
082706 10-0

**MINK**

THE MINK AS A PSYCHOPHARMACOLOGICAL MODEL.
088616 10-0

**MINNOWS**

ESTIMATION OF LOW CHLORPROMAZINE CONCENTRATIONS BY SURFACING AND SINKING REACTION OF MINNOWS (GAMBUSIA-AFFINIS).
097964 11-0

**MINOR**

A POTENTIAL SCREENING TEST FOR MINOR TRANQUILLIZING DRUG ACTION.
051651 02-0

DRUG, DOCTOR WARMTH, AND CLINIC SETTING IN THE SYMPTOMATIC RESPONSE TO MINOR TRANQUILIZERS.
087386 10-1

CASUISTIC CONTRIBUTIONS ON THE USE OF A DRUG IN CRIMINOLOGY ON DISSOCIALITY AND ON MINOR IRREGULAR BEHAVIOR.
095719 11-1

A CLINICAL EXPERIENCE OF OXAZOLAM, A NEW MINOR TRANQUILIZER.
129367 12-0

**MIOSIS**

MIOSIS DURING L-DOPA THERAPY.
066419 05-1

**MISUSE**

DRUG MISUSE IN TEENAGERS.
054715 02-1

DRUG THERAPY. II. TREATMENT OF DRUG MISUSE.
066329 05-1

THE USE AND MISUSE OF ASPIRIN: A CONTEMPORARY PROBLEM.
083415 10-1

THE USE AND MISUSE OF PSYCHOTROPIC DRUGS.
088707 10-1

**MISUSES**

USES AND MISUSES OF LYSERGIC ACID DIETHYLAMIDE.
046736 01-1

**MITOCHONDRIA**

OXIDATIVE PHOSPHORYLATION IN HEART MITOCHONDRIA ISOLATED FROM CHLORPROMAZINE TREATED ANIMALS.
041564 01-0

**MITOTIC**

SCHIZOPHRENIA AND LYMPHOCYTE MITOTIC CAPACITY.
068181 06-1

**MIXED**

RELATIONSHIP BETWEEN TASTE THRESHOLD FOR DRUGS AND CLINICAL PROGRESS IN A MIXED GROUP OF PSYCHIATRIC PATIENTS.
087866 10-1

THE USE OF TWO COMBINATIONS OF DRUGS WITH MIXED ACTION, ANTIDEPRESSIVE AND TRANQUILIZING (AMITRYPTILINE - PERPHENAZINE) IN GENERAL AND IN PSYCHOSOMATIC MEDICINE.
089162 10-1

SOME PROBLEMS OF ORGANIZING THE PSYCHOTHERAPEUTIC ENVIRONMENT IN A MIXED FEMALE PSYCHIATRIC WARD.
111254 12-1

**MIXTURES**

TOXICITY OF ETHANOL BARBITURATE MIXTURES.
064160 04-0

THE EFFECT OF ETHANOL AND AMPHETAMINE MIXTURES ON THE ACTIVITY OF RATS IN A Y-MAZE.
074149 08-04

MK-485
DOPA EFFECTS ON MOTILITY IN MICE; POTENTIATION BY MK-485 AND DEXCHLORPHENIRAMINE.
064411 04-03

L-DOPA WITH MK-485 FOR DEPRESSION.
066440 05-10

L-DOPA WITH MK-485 FOR DEPRESSION.
090188 11-11

USE OF LEVODOPA MAY BE EXPANDED BY ADDITION OF MK-485 TO DRUG REGIMEN.
097284 11-09

MK-940
CLINICAL AND QUANTITATIVE ELECTROENCEPHALOGRAPHICAL EFFECTS OF MK-940.
080031 09-07

MOBILIZATION
EFFECT OF INTERMITTENT NERVE STIMULATION ON NOREPINEPHRINE SYNTHESIS AND MOBILIZATION IN THE PERFUSED CAT SPLEEN.
080337 09-01

MODE
INFLUENCE OF MODE AND DURATION OF PHENYLALANINE ADMINISTRATION ON BIOCHEMICAL PARAMETERS IN RATS OF VARIOUS AGES.
042840 01-03

AMANTADINE DOPAMINE INTERACTION: POSSIBLE MODE OF ACTION IN PARKINSONISM.
066315 05-03

ON THE MODE OF ACTION OF AMANTADINE.
074145 08-04

CLINICAL CONTROVERSIES AND THEORETICAL MODE OF ACTION OF LITHIUM CARBONATE.
106767 12-13

MODEL
RABBIT AS A MODEL FOR CHLORPROMAZINE INDUCED HYPERPIGMENTATION OF THE SKIN.
045543 01-05

MODEL PSYCHOSIS OR INSTANT ZEN.
046730 01-12

RETICULAR STIMULATION AND CHLORPROMAZINE: AN ANIMAL MODEL FOR SCHIZOPHRENIC OVERAROUSAL.
058531 02-04

A MODEL OF HARMINE METABOLISM IN THE RAT.
064167 04-03

PREFERENCES FOR MORPHINE IN RATS: VALIDATION OF AN EXPERIMENTAL MODEL OF DEPENDENCE.
064475 04-04

EFFECTS OF NEUROLEPTICS ON THE CEREBRAL ELECTRICAL ACTIVITY OF LABORATORY ANIMALS: PRESENTATION OF A MODEL DESIGN FOR NEUROPHARMACOLOGICAL EXPERIMENTS.
085337 10-03

THE MINK AS A PSYCHOPHARMACOLOGICAL MODEL.
088616 10-06

USE OF HEPATIC MICROSOMES IN THE PREPARATION OF MODEL DRUG METABOLITES.
094789 11-06

MODELS
CLINICAL PSYCHOPHARMACOLOGY: CONCEPTUAL MODELS OF CURRENT TRENDS.
097621 11-17

MODIFIABILITY
THE MODIFIABILITY OF INFANTILE SHOCK TRAUMATIZATION EFFECTS BY CONTIGUOUS DRUG ADMINISTRATIONS.
060090 03-04

MODIFICATION
MODIFICATION OF NACL APPETITE IN THE ADRENALECTOMIZED RAT CONSEQUENT TO EXTENSIVE LICL POISONING.
061094 03-04

MODIFICATION OF AN ENZYME RADIOCHEMICAL ASSAY PROCEDURE FOR NORADRENALINE.
064002 04-06

MODIFICATION OF THE TOXIC ACTIONS OF L-TRYPTOPHAN BY PARGYLINE AND P-CHLOROPHENYLALANINE.
064277 04-05

MODIFICATION OF THE EFFECTS OF ANTIPSYCHOTIC AGENTS ON THE OPEN FIELD PERFORMANCE OF RATS BY TREATMENT WITH ALPHA-METHYLTYROSINE OR P-CHLOROPHENYLALANINE.
064392 04-04

RATE-DEPENDENT EFFECTS OF DRUGS: MODIFICATION BY DISCRIMINATIVE STIMULI OF THE EFFECTS OF AMOBARBITAL ON SCHEDULE CONTROLLED BEHAVIOR.
064749 05-04

MODIFICATION BY DESIPRAMINE (DMI) OF THE AVAILABILITY OF NOREPINEPHRINE RELEASED BY RESERPINE IN THE HYPOTHALAMUS OF THE RAT IN VIVO.
066374 05-03

A POSSIBLE PATHWAY FOR ETHANOL INDUCED FATTY LIVER AND MODIFICATION OF LIVER INJURY BY ANTIOXIDANTS.
070906 07-05

MODIFICATION OF THE SCOPOLAMINE EFFECT BY SLEEP DEPRIVATION.
070933 07-14

IMPROVEMENT OF LEARNING IN THE AGED BY MODIFICATION OF AUTONOMIC NERVOUS SYSTEM ACTIVITY.
071336 07-14

MODIFICATION OF CHLORPROMAZINE METABOLISM BY SOME OTHER DRUGS FREQUENTLY ADMINISTERED TO PSYCHIATRIC PATIENTS.
071989 07-13

MODIFICATION OF LEARNING BY DRUGS; NIMH.
092145 11-04

URINARY EXCRETION OF ADRENAL HORMONES IN MAN: EFFECTS OF ETHANOL INGESTION, AND THEIR MODIFICATION BY CHLORMETHIAZOLE.
097974 11-11

MODITEN
NEW IN PSYCHIATRY: MODITEN INJECTABLE THERAPY AND FOLLOW-UP CARE.
072787 08-11

MODITEN-RETARD
FLUPHENAZINE ENANTHATE (MODITEN-RETARD N.D.): CHEMISTRY AND PHARMACOLOGY.
088997 10-03

ADVANTAGES AND INDICATIONS FOR MODITEN-RETARD.
088998 10-17

THE SIDE-EFFECTS OF MODITEN-RETARD.
088999 10-15

MODULATION
CHOLINERGIC MODULATION OF ADRENERGIC AROUSAL IN THE DEVELOPING RAT.
063688 04-04

MODULATION OF FOOD INTAKE AND LOCOMOTOR ACTIVITY IN FEMALE RATS BY DIENCEPHALIC HORMONE IMPLANTS.
076080 09-04

MODULATORS
THE EFFECT OF VARIOUS NEUROHUMORAL MODULATORS ON THE ACTIVITY OF MORPHINE AND THE NARCOTIC ANTAGONISTS IN THE TAIL-FLICK AND PHENYLQUINONE TESTS.
069594 07-04

MOGADON
HYPNOTIC PROPERTIES OF NITRAZEPAM (MOGADON) (A COMPARATIVE STUDY OF CHLORDIAZEPOXIDE, DIAZEPAM, NITRAZEPAM, SECOBARBITAL AND PLACEBO IN PSYCHIATRIC PATIENTS).
075884 09-14

MOLE
SENSORY REPRESENTATION IN THE NEOCORTEX OF THE MOLE, SCALOPUS AQUATICUS.
066468 05-03

MOLECULAR
THE PREFERRED CONFORMATION OF DOPAMINE FROM MOLECULAR ORBITAL THEORY.
090068 11-13

MOLECULAR PROPERTIES OF DRUG RECEPTORS.
110897 12-17

ESSENTIALS OF MOLECULAR PHARMACOLOGY: BACKGROUND FOR DRUG DESIGN.
115114 12-17

MOLECULE
CLINICAL TRIAL OF A NEW MOLECULE SULPIRIDE IN PSYCHIATRIC PRACTICE.
072156 07-15

MOLECULES
METABOLISM AND BILIARY EXCRETION OF THE LIPOPHILIC DRUG MOLECULES, IMIPRAMINE AND DESMETHYLIMIPRAMINE IN THE RAT -- I. EXPERIMENTS IN VIVO AND WITH ISOLATED PERFUSED LIVERS.
067260 06-03

MOLIDONE
MOLIDONE IN CHRONIC SCHIZOPHRENIA.
067719 06-08

MOLINDONE
A COMPARATIVE STUDY OF MOLINDONE AND TRIFLUOPERAZINE.
056500 02-08

MOLINDONE IN ANXIOUS NEUROTIC PSYCHIATRIC OUTPATIENTS: A PILOT STUDY.
058969 03-10

THE USE OF MOLINDONE IN THE TREATMENT OF ACUTE PSYCHOTIC STATES: COMPARISON OF TWO DOSAGE SCHEDULES.
064286 04-08

MENSTRUATION CHANGES AS UNUSUAL SIDE-EFFECT IN A MOLINDONE TRIAL.
067570 06-15

CLINICAL EVALUATION OF A NEW PSYCHOTROPIC DRUG -- MOLINDONE.
097997 11-07

MONITORING
INFLUENCE OF DISPLAY, TASK, AND ORGANISMIC VARIABLES ON INDICES OF MONITORING BEHAVIOR.
043270 01-17

ORGANIC INTEGRITY TEST (OIT) IN MONITORING DRUG EFFECTS.
063596 04-08

AMITRIPTYLINE AND CARDIAC DISEASE: RISK OF SUDDEN DEATH IDENTIFIED BY MONITORING SYSTEM.
070854 07-15

AUTOMATIC MONITORING OF APOMORPHINE INDUCED PECKING IN PIGEONS.
075922 09-04

**MONKEY**

(3H)HARMALINE DISTRIBUTION IN MONKEY BRAIN, PHARMACOLOGICAL AND AUTORADIOGRAPHIC STUDY.
067081 05-03

THE EFFECTS OF D-AMPHETAMINE ON SCHEDULE CONTROLLED WATER LICKING IN THE SQUIRREL MONKEY.
071785 07-04

PITUITARY ADRENAL FUNCTION IN THE SQUIRREL MONKEY.
075665 08-03

HYPOTENSIVE EFFECTS OF CHLORDIAZEPOXIDE, AMOBARBITAL AND CHLORPROMAZINE ON BEHAVIORALLY INDUCED ELEVATED ARTERIAL BLOOD PRESSURE IN THE SQUIRREL MONKEY.
089999 11-04

**MONKEYS**

ABNORMAL SOCIAL BEHAVIOR IN PHENYLKETONURIC MONKEYS.
060490 03-04

CONDITIONED NALORPHINE INDUCED ABSTINENCE CHANGES: PERSISTENCE IN POST MORPHINE DEPENDENT MONKEYS.
061632 03-04

A METHOD FOR CHRONIC INTRAVENOUS DRUG ADMINISTRATION IN SQUIRREL MONKEYS.
063725 04-06

ROLE OF MONKEYS SPATIAL PREFERENCES IN PERFORMANCE OF A NONSPATIAL TASK.
065420 05-04

DIFFERENTIAL EFFECTS OF AMPHETAMINE AND SCOPOLAMINE ON MATCHING PERFORMANCE OF MONKEYS WITH LATERAL FRONTAL LESIONS.
065747 05-04

THE NUMBER OF PURKINJE CELLS AFTER DIPHENYLHYDANTOIN INTOXICATION IN MONKEYS.
066189 05-05

DRUG-INDUCED RELIEF OF EXPERIMENTAL TREMOR IN MONKEYS.
068457 06-04

EFFECTS OF STAPHYLOCOCCAL ENTEROTOXIN B ON COMPLEX OPERANT BEHAVIOR IN MONKEYS.
069333 06-04

THE EFFECT OF BROMOTRIFLUOROMETHANE ON OPERANT BEHAVIOR IN MONKEYS.
070732 07-04

REDIRECTED AGGRESSION AND GONADAL HORMONES IN CAPTIVE RHESUS MONKEYS (MACACA-MULATTA).
075829 08-04

AN AUTOMATED MULTIPLE CHOICE TEST OF SHORT-TERM SPATIAL MEMORY FOR MONKEYS.
075917 09-04

SPEED, ACCURACY, AND STRENGTH OF FORELIMB MOVEMENT AFTER UNILATERAL PYRAMIDOTOMY IN RHESUS MONKEYS.
076213 09-04

OVARIAN HORMONES AND FEMALE SEXUAL INVITATIONS IN CAPTIVE RHESUS MONKEYS (MACACA-MULATTA).
076554 09-03

INHIBITION BY DRUGS OF SMOKING BEHAVIOUR IN MONKEYS.
095351 11-03

**MONOAMINE**

URINARY METABOLITES OF HARMINE IN THE RAT AND THEIR INHIBITION OF MONOAMINE OXIDASE.
040417 01-03

MONOAMINES AND MONOAMINE OXIDASE IN DENERVATED SYMPATHETIC GANGLIA OF THE CAT.
040756 01-03

EFFECTS OF MONOAMINE OXIDASE INHIBITORS AND AMPHETAMINE ON HYPOTHERMIA PRODUCED BY HALOTHANE.
041569 01-03

TREATMENT OF NARCOLEPSY WITH MONOAMINE OXIDASE INHIBITORS AND SYMPATHOMIMETIC AGENTS.
058327 02-13

L-DOPA INDUCED CHANGES IN CENTRAL MONOAMINE NEURONS AFTER PERIPHERAL DECARBOXYLASE INHIBITION.
059033 03-03

EXCRETION OF VANYLGLYCOL IN HUMAN URINE UNDER DIETARY CONTROL, AND DURING TREATMENT WITH ANTIBIOTICS, DISULFIRAM, A MONOAMINE OXIDASE INHIBITOR, ALPHA-METHYLDOPA, AND RESERPINE.
060272 03-13

SPECIAL APPLICATION OF FLUORESCENCE HISTOCHEMISTRY: STUDIES ON EIGHT MONOAMINE OXIDASE INHIBITORS IN BRAIN NEURONS.
063989 04-06

CEREBROSPINAL FLUID MONOAMINE CATABOLITES IN DRUG-INDUCED EXTRAPYRAMIDAL DISORDERS.
064097 04-13

INTERACTIONS BETWEEN SYMPATHOMIMETIC AMINES AND A NEW MONOAMINE OXIDASE INHIBITOR.
064406 04-0

MONOAMINE OXIDASE INHIBITORS, COMBINED WITH THYMOLEPTICS: ARE THEY REALLY UNUSABLE FOR HUMAN BEINGS.
066805 05-0

CATECHOLAMINE ACCUMULATION IN TISSUES OF THIAMINE-DEFICIENT RATS AFTER INHIBITION OF MONOAMINE OXIDASE.
067243 06-0

MONOAMINE OXIDASE INHIBITORS AND L-DOPA.
067657 06-1

MONOAMINE OXIDASE INHIBITORS.
068175 06-1

COMPARATIVE TRIAL OF A NEW MONOAMINE OXIDASE INHIBITOR IN DEPRESSION.
069057 06-1

REDUCTION OF ELECTRICALLY REWARDED BEHAVIOR BY INTERFERENCE WITH MONOAMINE SYNTHESIS.
069065 06-0

THE EFFECT OF L-DOPA ON MONOAMINE METABOLITES IN PARKINSONS DISEASE.
070824 07-1

INHIBITORS OF MONOAMINE OXIDASE VI: EFFECTS OF SUBSTITUTION ON INHIBITORY ACTIVITY OF 6 (OR 8) SUBSTITUTED BETA-CARBOLINES.
090426 11-0

ON THE ROLE OF BRAIN CATECHOLAMINES IN MOTOR ACTIVITY: EXPERIMENTS WITH INHIBITORS OF SYNTHESIS AND OF MONOAMINE OXIDASE.
097960 11-0

ON THE ANALYSIS OF 5-HYDROXYTRYPTOPHAN PRODUCED HYPERTHERMIA IN MICE PRETREATED WITH A MONOAMINE OXIDASE INHIBITOR NIAMID.
098035 11-0

MONOAMINE OXIDASE INHIBITORS AND CORONARY INSUFFICIENCY.
133861 12-1

**MONOAMINES**

MONOAMINES AND MONOAMINE OXIDASE IN DENERVATED SYMPATHETIC GANGLIA OF THE CAT.
040756 01-0

EFFECT OF ANTIDEPRESSANT DRUGS ON ACCUMULATION AND DISAPPEARANCE OF MONOAMINES FORMED IN VIVO FROM LABELED PRECURSORS IN MOUSE BRAIN.
058798 02-0

MONOAMINES IN THE BRAIN UNDER THE INFLUENCE OF MUSCIMOL AND IBOTENIC ACID, TWO PSYCHOACTIVE PRINCIPLES OF AMANITA-MUSCARIA.
064408 04-0

THE EFFECT OF PROLONGED LITHIUM TREATMENT ON THE SYNTHESIS RATE AND TURNOVER OF MONOAMINES IN BRAIN REGIONS OF RATS.
066413 05-0

THE EFFECT OF SOME HALLUCINOGENIC DRUGS ON THE AMINO ACID PRECURSORS OF BRAIN MONOAMINES.
070542 07-0

MONOAMINES AND THE REACTIVITY OF RATS WITH DIFFERENT TYPES OF HIGHER NERVOUS ACTIVITY.
070953 07-0

MOTOR AND PSYCHOMOTOR ACTIVITY AND STRIATAL MONOAMINES.
086349 10-0

THE INFLUENCE OF 5-HYDROXYTRYPTOPHAN ON THE BEHAVIOR AND THE LEVEL OF MONOAMINES IN THE BRAIN OF RATS SENSITIVE TO SOUND.
098040 11-0

THE EFFECT OF DIETHYLAMIDE OF LYSERGIC ACID (DLA) ON THE CONTENT OF MONOAMINES IN SOME NUCLEI OF THE MIDBRAIN AND HYPOTHALAMUS.
101006 12-0

**MONOMETHYLHYDRAZINE**

BEHAVIORAL CHANGES FOLLOWING REPEATED LOW DOSES OF MONOMETHYLHYDRAZINE.
082959 10-0

**MONOPHOSPHATE**

THE EFFECT OF CENTRALLY ACTING DRUGS ON THE CONCENTRATION OF BRAIN ADENOSINE 3PRIME,5PRIME- MONOPHOSPHATE.
043276 01-0

**MONOSYNAPTIC**

EFFECTS OF A CONVULSANT BARBITURATE ON THE SPINAL MONOSYNAPTIC PATHWAY.
066372 05-0

**MONOXIDE**

CARBON MONOXIDE AND PHENOBARBITONE: A COMPARISON OF EFFECTS ON AUDITORY FLUTTER FUSION THRESHOLD AND CRITICAL FLICKER FUSION THRESHOLD.
070303 07-14

**MOOD**

EFFECT OF MOOD AND LITHIUM CARBONATE ON TOTAL BODY POTASSIUM.
047952 01-0

LITHIUM CARBONATE AS A MOOD AND TOTAL BODY WATER STABILIZER.
047953 01-0

MARIHUANA, ETHANOL, AND DEXTROAMPHETAMINE: MOOD AND MENTAL FUNCTION ALTERATIONS.
066231 05-14

EFFECTS OF TRIMEPRIMINE (SURMONTIL) ON SPERMATOGENESIS AND MOOD IN NORMAL VOLUNTEERS.
072147 07-14

BEHAVIORAL TOXICITY. PART 3: PERCEPTUAL COGNITIVE FUNCTIONS AND PART 4: EMOTIONAL (MOOD) STATES.
100523 12-15

TREATMENT OF MOOD DISORDERS WITH LITHIUM CARBONATE.
106773 12-09

**MOPERONE**

ON THE DISTRIBUTION AND METABOLISM OF NEUROLEPTIC DRUGS. PART 2: PHARMACOKINETICS OF MOPERONE.
072589 08-03

**MORFOLEP**

MORFOLEP IN TREATMENT OF SOME FORMS OF EPILEPSY.
069085 06-13

**MORITA**

ABSTRACT OF THESES FOR DOCTOR OF MEDICAL SCIENCES, THE UNIVERSITY OF TOKYO: MORITA THERAPEUTIC APPROACH TO SCHIZOPHRENIA.
126778 12-17

**MORPHINE**

MECHANISM OF THE RENAL TUBULAR TRANSPORT OF MORPHINE AND MORPHINE ETHEREAL SULFATE IN THE CHICKEN.
040754 01-03

INHIBITION OF THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN RATS BY DRUGS WHICH INHIBIT RIBONUCLEIC ACID OR PROTEIN SYNTHESIS.
041570 01-03

THE EFFECT OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON BRAIN ACETYLCHOLINE LEVELS IN RAT.
041913 01-03

THE INFLUENCE OF MORPHINE ON MAGNESIUM METABOLISM IN RATS.
046191 01-03

MORPHINE AND THE INCORPORATION OF 32 ORTHOPHOSPHATE IN VIVO INTO PHOSPHOLIPIDS OF THE GUINEA-PIG CEREBRAL CORTEX, LIVER AND SUBCELLULAR FRACTIONS.
046401 01-03

INHIBITION OF THE STIMULATING EFFECT OF METHAMPHETAMINE AND MORPHINE ON MOUSE BY INFLUENCING THE ENDOGENOUS CATECHOLAMINES.
055739 02-03

THE ROLE OF BRAIN CATECHOLAMINES IN MORPHINE ANALGESIC ACTION IN MORPHINE TOLERANT RATS.
055756 02-03

THE EFFECT OF MORPHINE, NALORPHINE, NALOXONE, PENTAZOCINE, CYCLAZOCINE AND OXOTREMORINE ON THE SYNTHESIS AND RELEASE OF ACETYLCHOLINE BY MOUSE CEREBRAL CORTEX SLICES IN VITRO.
058994 03-03

STRAIN DIFFERENCES IN MORPHINE WITHDRAWAL INDUCED AGGRESSION IN RATS.
060857 03-03

CONDITIONED NALORPHINE INDUCED ABSTINENCE CHANGES: PERSISTENCE IN POST MORPHINE DEPENDENT MONKEYS.
061632 03-04

PERSISTENCE OF RELAPSE TENDENCIES OF RATS PREVIOUSLY MADE PHYSICALLY DEPENDENT ON MORPHINE.
062940 03-04

BEHAVIOURAL EFFECTS IN RATS OF MORPHINE AND AMPHETAMINE AND OF A COMBINATION OF THE TWO DRUGS.
063019 03-04

MORPHINE: RADIOIMMUNOASSAY.
063848 04-06

EFFECTS OF MORPHINE TREATMENT AND STARVATION ON THE SUBSTRATE INTERACTION WITH P-450 IN THE OXIDATION OF DRUGS BY LIVER MICROSOMES.
063982 04-03

EFFECTS OF MORPHINE ON RENSHAW CELL ACTIVITY.
064100 04-03

TRYPTOPHAN HYDROXYLASE CHANGES IN MIDBRAIN OF THE RAT AFTER CHRONIC MORPHINE ADMINISTRATION.
064146 04-03

EFFECTS OF MORPHINE AND PENTOBARBITONE ON ACETYLCHOLINE SYNTHESIS BY RAT CEREBRAL CORTEX.
064288 04-03

PREFERENCES FOR MORPHINE IN RATS: VALIDATION OF AN EXPERIMENTAL MODEL OF DEPENDENCE.
064475 04-04

EFFECTS OF MORPHINE ON BEHAVIOR MAINTAINED BY FOUR SIMPLE FOOD REINFORCEMENT SCHEDULES.
064479 04-04

EFFECT OF MORPHINE ADMINISTRATION ON THE HYDROXYLATION OF STEROID HORMONES BY RAT LIVER MICROSOMES.
066366 05-03

CONDITIONAL AUTONOMIC RESPONSES INDUCED IN DOGS BY ATROPINE AND MORPHINE.
066386 05-03

REDUCED EFFECT OF MORPHINE IN MIDBRAIN RAPHE LESIONED RATS.
066500 05-03

CHANGES IN ENZYMES SUBSERVING CATECHOLAMINE METABOLISM IN MORPHINE TOLERANCE AND WITHDRAWAL IN RAT.
067324 06-03

ANTAGONISM OF THE BEHAVIORAL EFFECTS OF MORPHINE AND METHADONE BY NARCOTIC ANTAGONISTS IN THE PIGEON.
069593 07-04

THE EFFECT OF VARIOUS NEUROHUMORAL MODULATORS ON THE ACTIVITY OF MORPHINE AND THE NARCOTIC ANTAGONISTS IN THE TAIL-FLICK AND PHENYLQUINONE TESTS.
069594 07-04

BRAIN SEROTONIN TURNOVER IN MORPHINE TOLERANT AND DEPENDENT MICE.
069595 07-03

SITES OF ACTION OF RAM-302 AND NALORPHINE AS MORPHINE ANTAGONISTS.
074934 08-03

ON THE CENTRAL SITES FOR THE ANTINOCICEPTIVE ACTION OF MORPHINE AND FENTANYL.
074936 08-03

MORPHINE INDUCED FIGHTING AND PRIOR SOCIAL EXPERIENCE.
075206 08-04

THE INFLUENCE OF SINGLE AND CHRONIC MORPHINE ADMINISTRATION ON SOME CENTRAL EFFECTS OF AMPHETAMINE AND APOMORPHINE.
075840 08-05

REDUCTION OF THE ANTINOCICEPTIVE EFFECT OF 5-HYDROXYTRYPTOPHAN IN MORPHINE TOLERANT RATS.
075846 09-03

MORPHINE AMPHETAMINE INDUCED FIGHTING AND INTERIM SOCIALIZATION.
076131 09-04

EFFECTS OF CHRONIC MORPHINE ADMINISTRATION ON THE CATECHOLAMINE DEPLETION INDUCED BY RESERPINE.
081065 09-03

EXPERIMENTAL STUDIES ON THE EFFECTIVE PROCEDURE TO INHIBIT THE DEVELOPMENT OF TOLERANCE TO AND DEPENDENCE ON MORPHINE.
089789 11-02

ROLE OF BIOGENIC AMINES IN MORPHINE DEPENDENCE IN THE RAT.
090149 11-03

EFFECTS OF MORPHINE AND LEVORPHANOL ON BRAIN ACETYLCHOLINE CONTENT IN MICE.
101316 12-03

ANALGESIC EFFECT OF MORPHINE HYDROCHLORIDE INJECTED DIRECTLY INTO THE VENTRICLE OF MOUSE BRAIN.
130422 12-03

**MORPHINE-LIKE**

THE EFFECTS OF MORPHINE-LIKE SUBSTANCES AND THEIR ANTAGONISTS ON TRANSMISSION AT THE NEURO EFFECTOR JUNCTION OF THE MYENTERIC PLEXUS LONGITUDINAL MUSCLE PREPARATION OF THE GUINEA-PIG ILEUM.
041974 01-03

RECENT ADVANCES IN THE PHARMACOLOGY OF MORPHINE-LIKE DRUGS.
046203 01-13

A COMPARISON OF THE ANTINOCICEPTIVE ACTIONS OF CHOLINOMIMETIC AND MORPHINE-LIKE DRUGS.
064290 04-03

THE EFFECTS OF MORPHINE-LIKE COMPOUNDS ON THE LIGHT RESPONSES OF THE BRINE SHRIMP ARTEMIA-SALINA.
075844 09-04

CORRELATIONS OF STRUCTURE-ACTIVITY OF MORPHINE-LIKE ANALGESICS USING REGRESSION ANALYSIS.
089042 10-01

PERMEATION CHARACTERISTICS OF MORPHINE-LIKE SUBSTANCES AFTER INJECTION INTO BRAIN TISSUE AND INTO THE VENTRICULAR SYSTEM.
089047 10-03

**MORPHOLOGICAL**

MORPHOLOGICAL ASPECTS OF APPLICATION OF NOXIPTILIN (BAY-1521) IN ANIMAL EXPERIMENTS.
079972 09-03

**MOTILITY**

DOPA EFFECTS ON MOTILITY IN MICE; POTENTIATION BY MK-485 AND DEXCHLORPHENIRAMINE.
064411 04-03

DECREASE OF SPONTANEOUS MOTILITY IN EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY AND THE PROTECTIVE ACTIVITY OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126052 12-04

**MOTIVATION**

COMPARISON OF THE EFFECTS OF EXOGENOUS ACTH ON APPROACH AND AVOIDANCE CONDITIONING: IMPLICATIONS FOR THE PHYSIOLOGY OF INCENTIVE MOTIVATION. (PH.D.DISSERTATION).
103354 12-04

**MOTIVATIONAL**

MOTIVATIONAL DEPRESSION ASSOCIATED WITH NOREPINEPHRINE INDUCED EATING FROM THE HYPOTHALAMUS: RESEMBLANCE TO THE VENTROMEDIAL HYPERPHAGIC SYNDROME.
090473 11-04

**MOTONEURONS**
THE EFFECT OF HEXOBARBITAL ON THE DURATION OF THE RECURRENT IPSP IN CAT MOTONEURONS.
064621 04-03

**MOTOR**
THE ACTION OF DIAZEPAM IN NEUROLOGICAL DISORDERS WITH EXCESSIVE MOTOR ACTIVITY.
056779 02-11

STARTLE RESPONSE CIRCADIAN RHYTHM IN RATS: LACK OF CORRELATION WITH MOTOR ACTIVITY.
058349 02-04

COMPARATIVE EFFECTS OF SMOKING MARIHUANA OR PLACEBO ON HUMAN MOTOR AND MENTAL PERFORMANCE.
069579 07-14

FUNCTIONAL CHARACTERISTIC OF THE LINKS OF THE BRAIN CONTROL SYSTEM FOR MENTAL AND MOTOR FUNCTIONS IN MAN.
073770 08-13

EFFECTS OF 6-HYDROXYDOPAMINE ON CNS CATECHOLAMINES, SPONTANEOUS MOTOR ACTIVITY AND AMPHETAMINE INDUCED HYPERACTIVITY IN RATS.
074053 08-04

ANTICONVULSANT AND MOTOR DEPRESSANT EFFECTS OF DIAZEPAM.
076576 09-02

MOTOR AND PSYCHOMOTOR ACTIVITY AND STRIATAL MONOAMINES.
086349 10-03

EFFECTS OF DRUGS ACTING ALONE AND IN COMBINATION ON THE MOTOR ACTIVITY OF INTACT MICE.
090139 11-03

INTERACTIONS BETWEEN THE EFFECTS OF CHLORDIAZEPOXIDE AND AMPHETAMINE ON FOOD INTAKE AND SPONTANEOUS MOTOR ACTIVITY IN THE RAT.
092692 11-04

ON THE ROLE OF BRAIN CATECHOLAMINES IN MOTOR ACTIVITY: EXPERIMENTS WITH INHIBITORS OF SYNTHESIS AND OF MONOAMINE OXIDASE.
097960 11-04

**MOUNTFORD**
COMMENTS ON AN EFFECT OF YEAST RNA ON BEHAVIOR (MOUNTFORD AND HESLIP).
075720 08-04

**MOUSE**
FURTHER STUDIES ON THE ACCUMULATION AND DISAPPEARANCE OF CATECHOLAMINES FORMED FROM TYROSINE-14C IN MOUSE BRAIN. EFFECT OF SOME PHENOTHIAZINE ANALOGUES.
042727 01-03

ACCUMULATION AND DISAPPEARANCE OF 3H-5-HYDROXYTRYPTAMINE FORMED FROM 3H-TRYPTOPHAN IN MOUSE BRAIN: EFFECT OF LSD-25.
042755 01-03

EFFECT OF RESERPINE ON THE INCORPORATION IN VIVO OF RADIOACTIVITY FROM LABELED SEROTONIN AND OTHER 5-HYDROXYINDOLE DERIVATIVES IN MOUSE BRAIN.
046189 01-03

INHIBITION OF THE STIMULATING EFFECT OF METHAMPHETAMINE AND MORPHINE ON MOUSE BY INFLUENCING THE ENDOGENOUS CATECHOLAMINES.
055739 02-03

EFFECT OF ANTIDEPRESSANT DRUGS ON ACCUMULATION AND DISAPPEARANCE OF MONOAMINES FORMED IN VIVO FROM LABELED PRECURSORS IN MOUSE BRAIN.
058798 02-03

CHLORPROMAZINE INDUCED GLUCOSE INTOLERANCE IN THE MOUSE.
058984 03-05

THE EFFECT OF MORPHINE, NALORPHINE, NALOXONE, PENTAZOCINE, CYCLAZOCINE AND OXOTREMORINE ON THE SYNTHESIS AND RELEASE OF ACETYLCHOLINE BY MOUSE CEREBRAL CORTEX SLICES IN VITRO.
058994 03-03

NEUROCHEMICAL EFFECTS OF IMIPRAMINE AND AMPHETAMINE IN AGGRESSIVE MOUSE KILLING (MURICIDAL) RATS.
064056 04-03

THE FATE OF C14-DIHYDROXYPHENYLALANINE (C14-DOPA) IN THE WHOLE MOUSE.
064161 04-03

LABORATORY EVALUATION OF AGGRESSIVE BEHAVIOR OF THE GRASSHOPPER MOUSE (ONYCHOMYS).
064260 04-04

CHANGES IN THE SERUM CONCENTRATION OF CHOLESTEROL, TRIGLYCERIDES AND PHOSPHOLIPIDS IN THE MOUSE AND RAT AFTER ADMINISTRATION OF EITHER CHLORCYCLIZINE OR PHENOBARBITAL.
064282 04-03

EFFECT OF APOMORPHINE AND PIMOZIDE ON SYNTHESIS AND TURNOVER OF LABELED CATECHOLAMINES IN MOUSE BRAIN.
066502 05-03

PHYSIOLOGICAL AND DRUG-INDUCED CHANGES IN THE GLYCOGEN CONTENT OF MOUSE BRAIN.
067608 06-03

ASSOCIATION OF BROMIDE WITH THE SYNAPTOSOMAL FRACTION OF MOUSE BRAIN.
070521 07-01

COMBINATION TEST ON THE ANALGESIC EFFECT OF DEXTROPROPOXYPHENE AND SOME PSYCHOTROPIC DRUGS IN THE MOUSE.
079961 09-03

THE EFFECT OF SOME DRUGS ON GENETIC TREMOR IN THE MOUSE.
081066 09-04

REDUCTION OF LEVEL OF L-GLUTAMIC ACID DECARBOXYLASE BY GAMMA-AMINOBUTYRIC ACID IN MOUSE BRAIN.
083168 10-03

IN VIVO FORMATION AND CATABOLISM OF (14C)HISTAMINE IN MOUSE BRAIN.
083169 10-03

TOXICITY OF HEPATOTOXIC DRUGS ON MOUSE LIVER TISSUE CULTURE.
088615 10-05

THE ACTION OF SOME PSYCHOTROPIC DRUGS ON DEFECATION RATE IN THE MOUSE.
089003 10-05

TERATOGENIC EFFECT OF LITHIUM CARBONATE IN THE FETAL MOUSE.
089398 10-05

EFFECTS OF COCAINE AND AMPHETAMINE ON THE METABOLISM OF TRYPTOPHAN AND 5-HYDROXYTRYPTAMINE IN MOUSE BRAIN IN VIVO.
095440 11-03

ANALGESIC EFFECT OF MORPHINE HYDROCHLORIDE INJECTED DIRECTLY INTO THE VENTRICLE OF MOUSE BRAIN.
130422 12-03

**MOVEMENT**
THE STRUCTURAL AND BIOCHEMICAL BASIS OF MOVEMENT DISORDERS IN TREATMENT WITH NEUROLEPTIC DRUGS AND IN EXTRAPYRAMIDAL DISEASES.
067107 06-13

AVOIDANCE TRAINING OF HIPPOCAMPAL THETA WAVES IN FLAXEDILIZED DOGS AND ITS RELATION TO SKELETAL MOVEMENT.
075399 08-04

SPEED, ACCURACY, AND STRENGTH OF FORELIMB MOVEMENT AFTER UNILATERAL PYRAMIDOTOMY IN RHESUS MONKEYS.
076213 09-04

APPARENT MOVEMENT AS A CONSTANCY PHENOMENON.
087679 10-14

**MOVEMENTS**
LIVER DISEASE AND PHENOTHIAZINES; INVOLUNTARY MOVEMENTS.
063854 04-15

**MUCOPOLYSACCHARIDE**
PROJECT SUMMARY: MUCOPOLYSACCHARIDE COMPOSITION OF RAT AND RABBIT BRAIN.
063526 03-01

**MULTIFORM**
UNIVOCAL TREATMENT OF MULTIFORM DISORDERS: DOGMATIL IN PSYCHODIGESTIVE PATHOLOGY.
089174 10-11

**MULTIPLE**
THE RELATIONSHIP OF AMPHETAMINE INDUCED ANOREXIA AND FREEZING UNDER A MULTIPLE CRF-EXT OPERANT SCHEDULE.
068288 06-04

AN AUTOMATED MULTIPLE CHOICE TEST OF SHORT-TERM SPATIAL MEMORY FOR MONKEYS.
075917 09-04

CASE OF SELF-POISONING WITH MULTIPLE ANTIDEPRESSANT DRUGS.
082153 10-15

**MULTIVARIATE**
CONTRIBUTION TO THE USE OF MULTIVARIATE ANALYSIS IN THERAPEUTIC TESTING.
085343 10-11

**MURICIDAL**
NEUROCHEMICAL EFFECTS OF IMIPRAMINE AND AMPHETAMINE IN AGGRESSIVE MOUSE KILLING (MURICIDAL) RATS.
064056 04-03

**MUSCIMOL**
MONOAMINES IN THE BRAIN UNDER THE INFLUENCE OF MUSCIMOL AND IBOTENIC ACID, TWO PSYCHOACTIVE PRINCIPLES OF AMANITA-MUSCARIA.
064408 04-03

**MUSCLE**
THE EFFECT OF ANTIADRENALINE COMPOUNDS ON ACETYLCHOLINE RESPONSES OF FROG RECTUS-ABDOMINIS MUSCLE.
041538 01-03

THE EFFECTS OF MORPHINE-LIKE SUBSTANCES AND THEIR ANTAGONISTS ON TRANSMISSION AT THE NEURO EFFECTOR JUNCTION OF THE MYENTERIC PLEXUS LONGITUDINAL MUSCLE PREPARATION OF THE GUINEA-PIG ILEUM.
041974 01-03

CENTRAL MUSCLE RELAXANT EFFECTS OF DIAZEPAM.
079997 09-03

**MUSCULATURE**
METOCLOPRAMIDE AND THE MUSCULATURE OF ESOPHAGUS, STOMACH, INTESTINE, SPLEEN, TRACHEA, GALL AND URINARY BLADDERS: IN VITRO STUDIES.
055394 02-03

**MUSIC**
THE FUNCTION OF MUSIC IN LSD THERAPY FOR ALCOHOLIC PATIENTS.
075191 08-12

**MUTAGENIC**
ON THE MUTAGENIC EFFECT OF MEDICINAL PREPARATIONS USED IN PSYCHIATRY. (REVIEW OF THE LITERATURE).
102119 12-16

**MYENTERIC**
THE EFFECTS OF MORPHINE-LIKE SUBSTANCES AND THEIR ANTAGONISTS ON TRANSMISSION AT THE NEURO EFFECTOR JUNCTION OF THE MYENTERIC PLEXUS LONGITUDINAL MUSCLE PREPARATION OF THE GUINEA-PIG ILEUM.
041974 01-03

**MYOCARDIAL**
EFFECTS OF PSYCHOPHARMACOLOGIC AGENTS ON MYOCARDIAL CONTRACTILITY.
064420 04-15

THE VARIABLES OF SILENT MYOCARDIAL INFARCTION IN A PSYCHOTIC POPULATION.
065314 05-10

**MYOCLONIC**
A COMPARISON OF TRIPERIDOL AND PERPHENAZINE IN SCHIZOPHRENIA. EFFECTS ON MYOCLONIC THRESHOLD.
070935 07-08

**MYOCYTOLYSIS**
CARDIAC CATECHOLAMINE SYNTHESIS, TURNOVER, AND METABOLISM WITH ISOPROTERENOL INDUCED MYOCYTOLYSIS (UNPUBLISHED PAPER).
088374 10-03

**MYSTICISM**
IMPLICATIONS OF LSD AND EXPERIMENTAL MYSTICISM.
067355 06-12

**MYXEDEMA**
COEXISTENCE OF DIABETES-MELLITUS AND MYXEDEMA IN MENTAL PATIENTS.
116482 12-08

**N-ACETYL-DIMETHOXYPHENETHYLAMINE**
BETA-HYDROXYLATION OF N-ACETYL-DIMETHOXYPHENETHYLAMINE AND THE INFLUENCE OF IPRONIAZID ON THE DEMETHYLATION OF THIS COMPOUND IN VIVO IN THE RAT.
064053 04-03

EFFECTS OF N-ACETYL-DIMETHOXYPHENETHYLAMINE (NADMPEA) IN MAN.
064386 04-14

**N-ACETYLASPARAGINATE**
EFFECT OF ARGININE N-ACETYLASPARAGINATE ON DIFFERENT PATTERNS OF DISCRIMINATION.
098049 11-04

**N-METHYL-3-4-DIMETHOXY-BETA-PHENETHYLAMINE**
CACTUS ALKALOIDS: IX. ISOLATION OF N-METHYL-3-4-DIMETHOXY-BETA-PHENETHYLAMINE AND N-METHYL-4-METHOXY-BETA-PHENETHYLAMINE FROM ARIOCARPUS-RETUSUS.
070751 07-01

**N-METHYL-4-METHOXY-BETA-PHENETHYLAMINE**
CACTUS ALKALOIDS: IX. ISOLATION OF N-METHYL-3-4-DIMETHOXY-BETA-PHENETHYLAMINE AND N-METHYL-4-METHOXY-BETA-PHENETHYLAMINE FROM ARIOCARPUS-RETUSUS.
070751 07-01

**N-METHYLTRANSFERASE**
NEURONAL AND HORMONAL CONTROL OF TYROSINE HYDROXYLASE AND PHENYLETHANOLAMINE N-METHYLTRANSFERASE ACTIVITY.
080352 09-03

**N-SUBSTITUTED**
CHEMICAL CONSTITUTION AND DRUG ACTION OF N-SUBSTITUTED PHENOTHIAZINE IN VENTRICULAR ECTOPIC TACHYCARDIA.
063981 04-03

**NACL**
MODIFICATION OF NACL APPETITE IN THE ADRENALECTOMIZED RAT CONSEQUENT TO EXTENSIVE LICL POISONING.
061094 03-04

**NADMPEA**
EFFECTS OF N-ACETYL-DIMETHOXYPHENETHYLAMINE (NADMPEA) IN MAN.
064386 04-14

**NALORPHINE**
THE EFFECT OF MORPHINE, NALORPHINE, NALOXONE, PENTAZOCINE, CYCLAZOCINE AND OXOTREMORINE ON THE SYNTHESIS AND RELEASE OF ACETYLCHOLINE BY MOUSE CEREBRAL CORTEX SLICES IN VITRO.
058994 03-03

CONDITIONED NALORPHINE INDUCED ABSTINENCE CHANGES: PERSISTENCE IN POST MORPHINE DEPENDENT MONKEYS.
061632 03-04

SITES OF ACTION OF RAM-302 AND NALORPHINE AS MORPHINE ANTAGONISTS.
074934 08-03

SUBJECTIVE EFFECTS OF NARCOTIC ANTAGONISTS CYCLAZOCINE AND NALORPHINE ON THE ADDICTION RESEARCH CENTER INVENTORY (ARCI).
097961 11-14

CHANGES OF THE BODY TEMPERATURE OF CODEINE TOLERANT RATS BY THE ADMINISTRATION OF NALORPHINE.
130427 12-03

**NALOXONE**
THE EFFECT OF MORPHINE, NALORPHINE, NALOXONE, PENTAZOCINE, CYCLAZOCINE AND OXOTREMORINE ON THE SYNTHESIS AND RELEASE OF ACETYLCHOLINE BY MOUSE CEREBRAL CORTEX SLICES IN VITRO.
058994 03-03

QUANTITATIVE STUDIES ON THE ANTAGONISM BY NALOXONE OF SOME NARCOTIC AND NARCOTIC ANTAGONIST ANALGESICS.
063798 04-03

**NARCO-ANALYSIS**
THE USE OF NARCO-ANALYSIS IN DIAGNOSTIC PSYCHIATRIC TECHNIQUE.
093537 11-14

**NARCOLEPSY**
TREATMENT OF NARCOLEPSY WITH MONOAMINE OXIDASE INHIBITORS AND SYMPATHOMIMETIC AGENTS.
058327 02-13

ALCOHOL AND NARCOLEPSY.
078933 09-14

THE INFLUENCE OF IMIPRAMINE, DEXPHENMETRAZINE AND AMPHETAMINE SULPHATE ON SYNCHRONOUS AND PARADOXICAL SLEEP IN NARCOLEPSY CATAPLEXY. A POLYGRAPHIC EXAMINATION.
089037 10-14

**NARCOSIS**
INHIBITION BY PROPRANOLOL OF ETHANOL INDUCED NARCOSIS.
066510 05-03

**NARCOTIC**
CLINICAL ANTIDEPRESSANT ACTIVITY OF CYCLAZOCINE -- A NARCOTIC ANTAGONIST.
041568 01-09

DATURA LINN. -- THE FAMOUS NARCOTIC FROM THE EAST -- A REVIEW.
046185 01-17

NARCOTIC ANTAGONISTS AND THE PROBLEMS OF DRUG DEPENDENCE.
046195 01-13

A METHOD OF IDENTIFYING NARCOTIC ANALGESICS IN HUMAN URINE AFTER THERAPEUTIC DOSES.
057473 02-16

TOXICITY, NARCOTIC EFFECT, CONCENTRATION AT END OF ANESTHESIA, ELIMINATION FROM BLOOD AND BIOTRANSFORMATION OF HEXOBARBITAL IN RATS OF VARIOUS AGES FOLLOWING SLEEP INDUCTION WITH BARBITAL AND AFTER.
058987 03-05

QUANTITATIVE STUDIES ON THE ANTAGONISM BY NALOXONE OF SOME NARCOTIC AND NARCOTIC ANTAGONIST ANALGESICS.
063798 04-03

ANTAGONISM OF THE BEHAVIORAL EFFECTS OF MORPHINE AND METHADONE BY NARCOTIC ANTAGONISTS IN THE PIGEON.
069593 07-04

THE EFFECT OF VARIOUS NEUROHUMORAL MODULATORS ON THE ACTIVITY OF MORPHINE AND THE NARCOTIC ANTAGONISTS IN THE TAIL-FLICK AND PHENYLQUINONE TESTS.
069594 07-04

NONADDICTIVE PSYCHOTROPIC MEDICATION FOR IMPRISONED NARCOTIC ADDICTS.
070784 07-13

NARCOTIC ANALGESICS -- II. ADVERSE EFFECTS.
071929 07-15

PATHOPHYSIOLOGY OF NARCOTIC ADDICTION; POSSIBLE ROLES OF PROTRACTED ABSTINENCE IN RELAPSE (UNPUBLISHED PAPER).
093000 11-13

SUBJECTIVE EFFECTS OF NARCOTIC ANTAGONISTS CYCLAZOCINE AND NALORPHINE ON THE ADDICTION RESEARCH CENTER INVENTORY (ARCI).
097961 11-14

**NARCOTICS**
IDENTIFICATION OF NARCOTICS AND DIAGNOSIS OF THE ADDICTION. (UNPUBLISHED PAPER).
051207 02-01

HALLUCINOGENS AND NARCOTICS ALARM PUBLIC.
057978 02-15

EFFECTS OF NARCOTICS ON THE GIANT AXON OF THE SQUID.
090147 11-03

**NARDIL**
POSSIBLE LETHAL REACTION BETWEEN NARDIL AND DEXTROMETHORPHAN.
063897 04-15

**NATURAL**
A COMPARISON OF SLEEP PATTERNS IN NATURAL AND MANDRAX AND TUINAL INDUCED SLEEP.
067864 06-14

COMPARATIVE STUDY OF NATURAL SLEEP AND THE ACTION OF PHENAMINE AND CHLORPROMAZINE EVALUATION OF THE MEAN EXTREMES FREQUENCY OF ECOG IN CATS.
095655 11-14

NATURE
PROJECT SUMMARY: NATURE OF LATE SIDE-EFFECTS OF PHENOTHIAZINE THERAPY.
060222 03-05
5-HYDROXYTRYPTOPHAN PRODUCED HYPOTHERMIA IN MICE AS A TEST FOR PHARMACOLOGICAL DIFFERENTIATION OF ANTIDEPRESSANTS, ANTICHOLINERGICS AND NEUROLEPTICS: SOME DATA ON THE NATURE OF THIS HYPOTHERMIA.
105622 12-06

NAVANE
CLINICAL TRIAL OF THIOTHIXENE (NAVANE) IN ELDERLY CHRONIC SCHIZOPHRENICS.
082054 10-08

NEGATIVE
STUDIES WITH QUALIFIED OR NEGATIVE IMPLICATIONS.
046316 01-11

NEMTSEVA
CONCERNING THE ARTICLE BY N.N.TIMOFEYEV, V.T.KONDRASHENKO AND N.Y.NEMTSEVA ON OXYMETRIC INVESTIGATION OF PATIENTS WITH SCHIZOPHRENIA AND REACTIVE PSYCHOSIS DURING NEUROLEPTIC TREATMENT.
109788 12-08

NEOCORTEX
SENSORY REPRESENTATION IN THE NEOCORTEX OF THE MOLE, SCALOPUS AQUATICUS.
066468 05-03

NEOCORTICAL
EFFECTS OF AMPHETAMINE UPON RELEARNING PATTERN AND BLACK WHITE DISCRIMINATIONS FOLLOWING NEOCORTICAL LESIONS IN RATS.
065419 05-04
EFFECT OF HIPPOCAMPAL AND NEOCORTICAL ABLATION ON SCOPOLAMINE INDUCED ACTIVITY IN THE RAT.
075848 09-04
EQUIVALENCE OF SIMULTANEOUS AND SUCCESSIVE NEOCORTICAL ABLATIONS IN PRODUCTION OF IMPAIRMENTS OF RETENTION OF BLACK WHITE HABITS IN RATS.
076316 09-04

NEONATAL
EFFECTS OF NEONATAL TESTOSTERONE ON THE ACQUISITION OF AN ACTIVE AVOIDANCE RESPONSE IN GENOTYPICALLY FEMALE RATS.
075890 09-04

NEONATALLY
UPTAKE OF TRITIATED TESTOSTERONE IN BRAIN AND PERIPHERAL TISSUES OF NORMAL AND NEONATALLY ANDROGENIZED FEMALE RATS.
076086 09-04

NEONATE
PERMEABILITY OF THE BLOOD BRAIN BARRIER TO PARENTERAL 5-HYDROXYTRYPTAMINE IN THE NEONATE CHICK.
067253 06-04
EFFECT OF PRENATAL DRUGS ON THE BEHAVIOR OF THE NEONATE.
075607 08-05

NERVE
WATER STRUCTURE IN ANESTHETIC ACTION: TIME-DEPENDENCE D20 EFFECTS ON NERVE.
055582 02-03
A NOVEL APPROACH TO THE INVESTIGATION OF NOREPINEPHRINE METABOLISM IN HUMAN SYMPATHETIC NERVE.
064144 04-03
MECHANISMS BY WHICH AMPHETAMINE AND DESIPRAMINE INHIBIT THE METARAMINOL INDUCED RELEASE OF NOREPINEPHRINE FROM SYMPATHETIC NERVE ENDINGS IN RAT HEART.
064427 04-03
UPTAKE AND RETENTION OF 3H-NORADRENALINE IN ADRENERGIC NERVE TERMINALS AFTER RESERPINE AND AXOTOMY.
066499 05-03
INHIBITORY EFFECT OF PROPRANOLOL ON THE VASOCONSTRICTOR RESPONSE TO SYMPATHETIC NERVE STIMULATION.
066506 05-03
THE EFFECT OF A PSYCHOTOMIMETIC GLYCOLATE AND ITS ANTIDOTE ESERINE ON THE ACH CONTENT OF THE LOBSTER WALKING LEG NERVE.
069515 06-13
PHASE DIFFERENCE IN THE INDUCTION OF TYROSINE HYDROXYLASE IN CELL BODY AND NERVE TERMINALS OF SYMPATHETIC NEURONES.
075715 08-03
EFFECT OF INTERMITTENT NERVE STIMULATION ON NOREPINEPHRINE SYNTHESIS AND MOBILIZATION IN THE PERFUSED CAT SPLEEN.
080337 09-01
DRUG-INDUCED DAMAGE OF THE EYE AND THE OPTICAL NERVE.
128389 12-15

NERVES
EFFECTS OF CHLORIMIPRAMINE ON ELECTRICAL ACTIVITIES OF SUBCORTICAL BRAIN STRUCTURES AND OF SYMPATHETIC NERVES.
079951 09-03
ENHANCEMENT BY DESIPRAMINE OF HYPOTHALAMICALLY EVOKED DISCHARGES IN PREGANGLIONIC SYMPATHETIC NERVES.
097962 11-03

NERVOUS
CENTRAL NERVOUS SYSTEM STIMULANT ACTION OF FENFLURAMINE IN RABBITS.
040639 01-03
PHARMACOLOGICAL REDUNDANCY AS AN ADAPTIVE MECHANISM IN THE CENTRAL NERVOUS SYSTEM.
056113 02-13
PHARMACOLOGICAL PROPERTIES OF SU-19789B, A UNIQUE CENTRAL NERVOUS SYSTEM STIMULANT.
058989 03-03
A NEW CLASS OF 1,3 BENZOXAZINONES AS POTENTIAL CENTRAL NERVOUS SYSTEM AGENTS.
062322 03-02
THE PRACTICAL USE OF HIGHER NERVOUS ACTIVITY DATA IN THE PHARMACOTHERAPY OF PSYCHOSES.
062664 03-08
RADIOACTIVE BROMIDE IN THE DIAGNOSIS OF CENTRAL NERVOUS SYSTEM DISEASE.
063208 03-16
CENTRAL NERVOUS SYSTEM CYTOPATHOLOGICAL CHANGES IN CATS WITH CHRONIC METHEDRINE INTOXICATION.
064143 04-05
CHLORAL HYDRATE IN CENTRAL NERVOUS SYSTEM DEPRESSION.
064335 04-17
RELEASE OF NOREPINEPHRINE IN THE CENTRAL NERVOUS SYSTEM BY THEOPHYLLINE AND CAFFEINE.
066411 05-03
THE INFLUENCE OF INDOPAN ON THE HIGHER NERVOUS ACTIVITY OF DOGS.
067299 06-04
SOME EFFECTS OF NICOTINE ON THE CENTRAL NERVOUS SYSTEM OF CHICKENS.
068166 06-03
PHARMACOLOGY OF THE CENTRAL NERVOUS SYSTEM.
068949 06-03
THE AUTONOMIC NERVOUS SYSTEM.
068952 06-03
INDOLEAMINES AND THE CENTRAL NERVOUS SYSTEM: A SOUNDING OF THEIR CLINICAL SIGNIFICANCE.
070881 07-13
MONOAMINES AND THE REACTIVITY OF RATS WITH DIFFERENT TYPES OF HIGHER NERVOUS ACTIVITY.
070953 07-03
CENTRAL NERVOUS SYSTEM METABOLISM, DRUG ACTION AND HIGHER FUNCTIONS.
070976 07-17
IMPROVEMENT OF LEARNING IN THE AGED BY MODIFICATION OF AUTONOMIC NERVOUS SYSTEM ACTIVITY.
071336 07-14
EVALUATION OF THE THERAPEUTIC EFFECT OF NEUROLEPTICS UPON THE HIGHER NERVOUS ACTIVITY IN SCHIZOPHRENIA.
075103 08-14
INDICATIONS OF CENTRAL NERVOUS EFFECTS OF SMALL AMOUNTS OF MERCURY IN RATS.
089044 10-17
POPULATION DEPENDENT DIFFERENCES OF CENTRAL NERVOUS REACTIVITY TO NEUROLEPTICS.
098022 11-15
ADRENAL CORTICAL AND MEDULLARY SECRETION AND EVALUATION OF DRUGS ACTING ON THE CENTRAL NERVOUS SYSTEM.
106270 12-03
PHYSIOLOGICAL AND BIOCHEMICAL MECHANISMS OF THE EFFECT OF LITHIUM SALTS ON THE NERVOUS SYSTEM.
109786 12-13
CENTRAL NERVOUS SYSTEM DEPRESSANTS.
110225 12-17
CENTRAL NERVOUS SYSTEM STIMULANTS.
110226 12-17
PHARMACOLOGICAL STUDIES OF OXAZOLAZEPAM, A NEW PSYCHOTROPIC AGENT - I. ACTIONS ON THE CENTRAL NERVOUS SYSTEM, ESPECIALLY ON THE BEHAVIORAL OBSERVATION.
114769 12-02
EFFECT OF A DEFICIENCY OF PANTOTHENIC ACID AND PYRIDOXINE ON THE FUNCTION OF THE CENTRAL NERVOUS SYSTEM AND ITS RESPONSE TO COUMARIN FROM MELILOTUS-OFFICINALIS.
126053 12-04
INFLUENCE OF ISONIAZID ON THE CENTRAL NERVOUS SYSTEM; THE ANTAGONISM BETWEEN ISONIAZID AND PYRIDOXINE, PANTOTHENIC ACID AND COUMARIN IN RATS (MELILOTUS-OFFICINALIS).
126055 12-04

**NEULEPTIL**
USE OF NEULEPTIL IN TREATMENT OF PATIENTS WITH SCHIZOPHRENIA.
111031 12-08

**NEURAL**
EFFECTS OF CHLORPROMAZINE ON NEURAL TISSUE IN CULTURE.
070825 07-03

**NEURALGIA**
CLINICAL EVALUATION OF THE USE OF G-32883 IN TRIGEMINAL NEURALGIA.
112130 12-11

**NEURALLY**
NEURALLY MEDIATED INCREASE IN DOPAMINE-BETA-HYDROXYLASE ACTIVITY (UNPUBLISHED PAPER).
088376 10-03

**NEURO**
THE EFFECTS OF MORPHINE-LIKE SUBSTANCES AND THEIR ANTAGONISTS ON TRANSMISSION AT THE NEURO EFFECTOR JUNCTION OF THE MYENTERIC PLEXUS LONGITUDINAL MUSCLE PREPARATION OF THE GUINEA-PIG ILEUM.
041974 01-03

**NEUROAMINES**
THE EFFECT OF LITHIUM UPON BRAIN NEUROAMINES.
069062 06-03

**NEUROCHEMICAL**
2,5- DIMETHOXY-4-METHYLAMPHETAMINE – TISSUE DISTRIBUTION AND NEUROCHEMICAL ACTION.
045544 01-03
NEUROCHEMICAL STUDIES OF THE AFFECTIVE DISORDERS: THE PHARMACOLOGICAL BRIDGE.
061683 03-09
NEUROCHEMICAL EFFECTS OF IMIPRAMINE AND AMPHETAMINE IN AGGRESSIVE MOUSE KILLING (MURICIDAL) RATS.
064056 04-03
SOME NEUROCHEMICAL CORRELATES OF AXOPLASMIC FLOW.
073327 08-03

**NEURODYSLEPSY**
COMPARISON OF THE PAROXYSMAL DYSKINESIAS (NEURODYSLEPSY) INDUCED BY THE NEUROLEPTICS IN MAN AND THE EARLIEST BEHAVIOR PATTERNS OF THE NEW-BORN.
070267 07-13

**NEUROENDOCRINOLOGICAL**
NEUROENDOCRINOLOGICAL STUDY IN CHLORPROMAZINE TREATED RATS.
089029 10-13

**NEUROHUMORAL**
SOME EFFECTS OF AN HALLUCINOGENIC DRUG (PHENCYCLIDINE) ON NEUROHUMORAL SUBSTANCES.
065436 05-12
THE EFFECT OF VARIOUS NEUROHUMORAL MODULATORS ON THE ACTIVITY OF MORPHINE AND THE NARCOTIC ANTAGONISTS IN THE TAIL-FLICK AND PHENYLQUINONE TESTS.
069594 07-04

**NEUROLEPTIC**
STATISTICAL METHOD OF ANALYSIS AND EVALUATION OF PSYCHOTHERAPEUTIC RESULTS: APPLICATION OF A LONG-ACTING NEUROLEPTIC, COMPARED WITH A STANDARD NEUROLEPTIC AND THE SAKEL INSULIN TREATMENT.
042676 01-07
INCREASED RELEASE OF DOPAMINE FROM STRIATAL DOPAMINERGIC TERMINALS IN THE RAT AFTER TREATMENT WITH A NEUROLEPTIC: THIOPROPERAZINE.
042742 01-03
A CONTROLLED COMPARISON OF THE TREATMENT OF SCHIZOPHRENIC PATIENTS WHEN TREATED ACCORDING TO THE NEUROLEPTIC THRESHOLD OR BY CLINICAL JUDGMENT.
063776 04-08
THE INFLUENCE OF VARIOUS NEUROLEPTIC DRUGS ON SHOCK AVOIDANCE RESPONDING IN RATS. III. AMPHETAMINE ANTAGONISM IN THE DISCRIMINATED SIDMAN AVOIDANCE PROCEDURE.
064476 04-04
THE STRUCTURAL AND BIOCHEMICAL BASIS OF MOVEMENT DISORDERS IN TREATMENT WITH NEUROLEPTIC DRUGS AND IN EXTRAPYRAMIDAL DISEASES.
067107 06-13
DEXBENZETIMIDE IN NEUROLEPTIC INDUCED PARKINSONISM. A DOUBLE-BLIND CROSSOVER STUDY WITH A 16-WEEK FOLLOW-UP.
067176 06-11
THE INFLUENCE OF VARIOUS NEUROLEPTIC DRUGS ON NOISE ESCAPE RESPONSE IN RATS.
069076 06-04
ON THE DISTRIBUTION AND METABOLISM OF NEUROLEPTIC DRUGS. PART 2: PHARMACOKINETICS OF MOPERONE.
072589 08-03
PROBLEMS PRESENTED BY NEUROLEPTIC THERAPY IN ITALY.
075111 08-14
CLINICAL TESTS OF A NEW, PROLONGED ACTION NEUROLEPTIC AGENT, PIMOZIDE.
079863 09-07
ON THE EFFECT OF DIOXYPHENYLALANINE (L-DOPA) ON EXTRAPYRAMIDAL HYPERKINESIA DUE TO NEUROLEPTIC LONG-TERM MEDICATION.
079950 09-15
THE TREATMENT OF CHRONIC PAIN SYNDROMES: ANALGETIC EFFECT OF A NEUROLEPTIC SUBSTANCE.
079963 09-11
DISTRIBUTION AND METABOLISM OF NEUROLEPTIC DRUGS: PART I: PHARMACOKINETICS OF HALOPERIDOL.
079968 09-03
2-CHLORO-11-(4-METHYLPIPERAZINO) DIBENZOXAZEPINE), (SUM-3170), A NEW NEUROLEPTIC SUBSTANCE: RESULTS OF AN INTERCLINICAL STUDY.
079986 09-07
ON PROBLEMS OF LATE EXTRAPYRAMIDAL HYPERKINESIS DUE TO NEUROLEPTIC LONG-TERM THERAPY.
079996 09-15
CLINICAL EVALUATION IN 112 PSYCHIATRIC PATIENTS OF A BUTYROPHENONE NEUROLEPTIC, DEHYDROBENZPERIDOL (R-4749).
080142 09-11
SOME PROBLEMS OF NEUROLEPTIC THERAPY.
086205 10-15
POSSIBILITIES AND LIMITATIONS OF DEPOT NEUROLEPTIC TREATMENT OF SCHIZOPHRENIC PSYCHOSES.
087066 10-17
SULPIRIDE, A SINGULAR, ANTIAUTISTIC AND THYMOANALEPTIC NEUROLEPTIC.
089160 10-11
OBSERVATIONS ON THE NEUROLEPTIC SYNDROME.
091501 11-08
CLINICAL TESTS OF THIOTHIXENE, NEUROLEPTIC DISINHIBITER.
091502 11-08
A LONG-ACTING NEUROLEPTIC IN THE TREATMENT OF CHRONIC ALCOHOLISM IN NEUROTIC AND PSYCHOTIC PATIENTS.
109255 12-11
CONCERNING THE ARTICLE BY N.N.TIMOFEYEV, V.T.KONDRASHENKO AND N.Y.NEMTSEVA ON OXYMETRIC INVESTIGATION OF PATIENTS WITH SCHIZOPHRENIA AND REACTIVE PSYCHOSIS DURING NEUROLEPTIC TREATMENT.
109788 12-08

**NEUROLEPTICAL**
TRANSIENT EXACERBATIONS, OCCURRING IN THE PROCESS OF NEUROLEPTICAL THERAPY.
081539 10-15

**NEUROLEPTICS**
PSYCHOPHARMACODYNAMICS OF NEUROLEPTICS. ORGANIZATION EFFECTS OF THE PARANOID SYNDROME.
059039 03-17
LONG-ACTING NEUROLEPTICS: III. PILOT STUDY OF PENFLURIDOL (R-16341).
069070 06-07
COMPARISON OF THE PAROXYSMAL DYSKINESIAS (NEURODYSLEPSY) INDUCED BY THE NEUROLEPTICS IN MAN AND THE EARLIEST BEHAVIOR PATTERNS OF THE NEW-BORN.
070267 07-13
A DIFFERENTIAL APPROACH TO THE INDICATION OF NEUROLEPTICS.
070924 07-17
COMPARATIVE PHARMACOLOGICAL STUDY OF NEUROLEPTICS IN RODENTS.
070926 07-02
THE EFFECTS OF WITHHOLDING OF NEUROLEPTICS FROM MENTAL PATIENTS.
072406 07-15
CURRENT CONCEPTIONS ON CERTAIN ASPECTS OF THE PHARMACOLOGY OF NEUROLEPTICS.
074685 08-02
EVALUATION OF THE THERAPEUTIC EFFECT OF NEUROLEPTICS UPON THE HIGHER NERVOUS ACTIVITY IN SCHIZOPHRENIA.
075103 08-14
PRINCIPAL ELECTROENCEPHALOGRAPHIC CHANGES OBSERVED DURING ACUTE INTOXICATION BY NEUROLEPTICS.
075112 08-13
THE NEUROLEPTICS: AN INTERDISCIPLINARY ATTEMPT OF SYNTHESIS, BASED ON THE NEUROLEPTICS.
075115 08-14
EFFECTS OF NEUROLEPTICS ON THE CEREBRAL ELECTRICAL ACTIVITY OF LABORATORY ANIMALS: PRESENTATION OF A MODEL DESIGN FOR NEUROPHARMACOLOGICAL EXPERIMENTS.
085337 10-03
THE TOXICOLOGY OF NEUROLEPTICS ON THE EYE.
085338 10-15
III. PROLONGED ACTION NEUROLEPTICS: REPORT ON THE PROLONGED ACTION NEUROLEPTICS.
085992 10-11
III. PROLONGED ACTION NEUROLEPTICS: REPORT ON TREATMENT WITH PROLONGED ACTION NEUROLEPTICS IN PSYCHIATRY.
085993 10-11

CONTRIBUTION OF NEUROLEPTICS IN CURRENT USE TO THE TREATMENT OF DEPRESSIONS.
086235 10-10
INVESTIGATION OF THE PSYCHODYNAMIC REINFORCEMENT OF NEUROLEPTICS WITH 1035-MD.
089111 10-07
COMPARATIVE STUDY OF THE EFFECT OF TWO NEUROLEPTICS.
089158 10-11
POPULATION DEPENDENT DIFFERENCES OF CENTRAL NERVOUS REACTIVITY TO NEUROLEPTICS.
098022 11-15
ETIOLOGY OF LATE HYPERKINESIS IN THE COURSE OF LONG-TERM TREATMENT WITH NEUROLEPTICS.
100997 12-15
NEUROPATHOLOGY OF PERSISTENT CHOREIFORM HYPERKINESIAS UNDER LONG-TERM TREATMENT WITH NEUROLEPTICS.
101020 12-15
5-HYDROXYTRYPTOPHAN PRODUCED HYPOTHERMIA IN MICE AS A TEST FOR PHARMACOLOGICAL DIFFERENTIATION OF ANTIDEPRESSANTS, ANTICHOLINERGICS AND NEUROLEPTICS: SOME DATA ON THE NATURE OF THIS HYPOTHERMIA.
105622 12-06
PSYCHODYNAMICS OF THE RESPONSE TO PHARMACOLOGIC TREATMENT WITH NEUROLEPTICS IN SCHIZOPHRENICS.
105623 12-08
USE OF NEUROLEPTICS FOR VITAL INDICATORS IN PATIENTS WITH SEVERE SOMATIC STATES.
111028 12-11
EFFECT OF AMANTADINE ON THE EXTRAPYRAMIDAL SYNDROMES INDUCED BY NEUROLEPTICS.
112131 12-09

**NEUROLOGIC**
SIMILARITIES BETWEEN NEUROLOGIC EFFECTS OF L-DOPA AND OF APOMORPHINE.
056574 02-11

**NEUROLOGICAL**
THE ACTION OF DIAZEPAM IN NEUROLOGICAL DISORDERS WITH EXCESSIVE MOTOR ACTIVITY.
056779 02-11
THE MARIHUANA INDUCED SOCIAL HIGH: NEUROLOGICAL AND ELECTROENCEPHALOGRAPHIC CONCOMITANTS.
074782 08-12
PSYCHOPHARMACEUTICALS AND NEUROLOGICAL SIDE-EFFECTS.
128390 12-15

**NEURONAL**
THE ROLE OF PLASMA PROTEIN BINDING IN THE INHIBITORY EFFECT OF NORTRIPTYLINE ON THE NEURONAL UPTAKE OF NOREPINEPHRINE.
066278 05-03
THE EFFECT OF ESERINE ON THE EFFERENT NEURONAL ACTIVITY IN THE CERVICAL SYMPATHETIC OF THE RAT.
074133 08-03
NEURONAL AND HORMONAL CONTROL OF TYROSINE HYDROXYLASE AND PHENYLETHANOLAMINE N-METHYLTRANSFERASE ACTIVITY.
080352 09-03

**NEURONALLY**
INHIBITION OF THE RE-UPTAKE OF NEURONALLY LIBERATED NORADRENALINE AND ALPHA-RECEPTOR BLOCKING ACTION OF SOME ERGOT ALKALOIDS.
041967 01-03

**NEURONE**
THE ANTAGONISM OF ADRENERGIC NEURONE BLOCKADE BY AMPHETAMINE AND DEXAMPHETAMINE IN THE RAT AND GUINEA-PIG.
055322 02-03
SELECTIVE DEPLETION OF NORADRENALINE: A PROPOSED MECHANISM OF THE ADRENERGIC NEURONE BLOCKING ACTION OF BRETYLIUM.
055323 02-05

**NEURONES**
ANESTHETIC AGENTS AND THE CHEMICAL SENSITIVITY OF CORTICAL NEURONES.
040580 01-03
EFFECTS OF LYSERGIC ACID DERIVATIVES ON 5-HYDROXYTRYPTAMINE EXCITATION OF BRAINSTEM NEURONES.
041973 01-02
EFFECTS OF 6-HYDROXYDOPAMINE ON CATECHOLAMINE CONTAINING NEURONES IN THE RAT BRAIN.
072120 07-03
PHASE DIFFERENCE IN THE INDUCTION OF TYROSINE HYDROXYLASE IN CELL BODY AND NERVE TERMINALS OF SYMPATHETIC NEURONES.
075715 08-03

**NEURONS**
ACTION OF PSYCHOTOGENIC DRUGS ON SINGLE MIDBRAIN RAPHE NEURONS.
040418 01-03
L-DOPA INDUCED CHANGES IN CENTRAL MONOAMINE NEURONS AFTER PERIPHERAL DECARBOXYLASE INHIBITION.
059033 03-03
SPECIAL APPLICATION OF FLUORESCENCE HISTOCHEMISTRY: STUDIES ON EIGHT MONOAMINE OXIDASE INHIBITORS IN BRAIN NEURONS.
063989 04-06
THE RESPONSE OF LYSOSOMES IN CULTURED NEURONS TO CHLORPROMAZINE.
066380 05-03

**NEUROPATHOLOGY**
NEUROPATHOLOGY OF PERSISTENT CHOREIFORM HYPERKINESIAS UNDER LONG-TERM TREATMENT WITH NEUROLEPTICS.
101020 12-15

**NEUROPHARMACOLOGICAL**
NEUROPHARMACOLOGICAL COMPARISON OF CYSTATHIONINE, CYSTEINE, HOMOSERINE AND ALPHA-KETOBUTYRIC ACID IN CATS.
064367 04-04
EFFECTS OF NEUROLEPTICS ON THE CEREBRAL ELECTRICAL ACTIVITY OF LABORATORY ANIMALS: PRESENTATION OF A MODEL DESIGN FOR NEUROPHARMACOLOGICAL EXPERIMENTS.
085337 10-03

**NEUROPHARMACOLOGICALLY**
INCREASED DURATION OF NEUROPHARMACOLOGICALLY INDUCED BEHAVIORAL EXCITATION BY ATROPINE.
079998 09-04
A NEUROPHARMACOLOGICALLY BASED CONCEPT OF HALLUCINATION AND ITS CLINICAL APPLICATION.
121080 12-17

**NEUROPHARMACOLOGY**
SOME OBSERVATIONS ON THE NEUROPHARMACOLOGY OF MEDAZEPAM HYDROCHLORIDE (RO-5-4556).
063841 04-04

**NEUROPHYSIOLOGICAL**
NEUROPHYSIOLOGICAL STUDY OF DIPOTASSIUM CHLORAZEPATE (4306-CB).
055580 02-03
NEUROPHYSIOLOGICAL AND BEHAVIORAL CORRELATES OF LITHIUM.
095014 11-03

**NEUROPSYCHIATRIC**
EPILEPSY THERAPY WITH MENTALLY RETARDED CHILDREN: NEUROPSYCHIATRIC DISORDERS THROUGH DIPHENYLHYDANTOIN.
071241 07-15
NEUROPSYCHIATRIC CLINICAL STUDY OF A BARBITURATE HYPNOTIC: 5-ETHYL 5(1- METHYL-1-BUTENYL) MALONYLUREA.
089173 10-07
NEUROPSYCHIATRIC MANIFESTATIONS IN TWO CASES OF PORPHYRIA.
138144 12-11

**NEUROPSYCHIATRY**
CHILD NEUROPSYCHIATRY AND NEUROPSYCHOPHARMACOLOGY.
085456 10-14

**NEUROPSYCHOLOGICAL**
THE PERFORMANCE OF LSD USERS ON CERTAIN NEUROPSYCHOLOGICAL TESTS. (PH.D. DISSERTATION).
135186 12-14

**NEUROPSYCHOPHARMACOLOGY**
CHILD NEUROPSYCHIATRY AND NEUROPSYCHOPHARMACOLOGY.
085456 10-14

**NEUROPSYCHOTROPIC**
NEUROPSYCHOTROPIC DRUGS IN THE TREATMENT OF SO-CALLED PAIN SYNDROMES.
079962 09-17

**NEUROSES**
CONTROLLED TRIALS OF AN AMITRYPTYLINE FLUPHENAZINE COMBINATION IN DEPRESSIVE NEUROSES AND PSYCHOSES: A COLLABORATIVE STUDY.
067569 06-11
AMITRIPTYLINE, CHLORPROTHIXENE, PROTHIADENE AND PLACEBO IN THE TREATMENT OF NEUROSES.
070946 07-10
A THERAPEUTIC AGENT FOR ANTIDEPRESSANT AND TRANQUILIZING CONTROL IN THE POST-TRAUMATIC NEUROSES.
086237 10-07

**NEUROSIS**
A CONTROLLED STUDY OF LSD TREATMENT IN ALCOHOLISM AND NEUROSIS.
063873 04-12
TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS WITH HALOPERIDOL.
064233 04-10
TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS.
067022 05-10
TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS.
067023 05-10
A DOUBLE-BLIND COMPARISON OF S-804 (NEW BENZODIAZEPINE DRUG) WITH CHLORDIAZEPOXIDE AND DIAZEPAM IN THE TREATMENT OF NEUROSIS.
129097 12-10

**NEUROTIC**
EFFECTS OF SOME PSYCHOACTIVE DRUGS ON EXPERIMENTAL NEUROTIC (CONFLICT INDUCED) BEHAVIOR IN CATS.
046143 01-04

THE PSYCHOPHARMACOLOGICAL TREATMENT OF CARDIAC NEUROTIC PATIENTS WITH DIPOTASSIUM CHLORAZEPATE IN THE DOUBLE-BLIND TEST.
055689 02-10

THE DESIGN OF DRUG TRIALS WITH NEUROTIC PATIENTS.
058364 02-16

MOLINDONE IN ANXIOUS NEUROTIC PSYCHIATRIC OUTPATIENTS: A PILOT STUDY.
058969 03-10

HYDROXYZINE AND CHLORDIAZEPOXIDE IN ANXIOUS NEUROTIC OUTPATIENTS: A COLLABORATIVE CONTROLLED STUDY.
062321 03-10

DIFFERENTIAL DRUG EFFECTS IN NEUROTIC DEPRESSION.
063207 03-10

A CONTROLLED TRIAL OF BENZOCTAMINE (BA-30803) IN NEUROTIC ANXIETY.
064285 04-10

A CONTROLLED STUDY OF THE EFFECTS OF DIPHENYLHYDANTOIN ON ANXIETY, IRRITABILITY, AND ANGER IN NEUROTIC OUTPATIENTS.
064478 04-10

PERPHENAZINE AMITRIPTYLINE IN NEUROTIC DEPRESSED OUTPATIENTS; A CONTROLLED COLLABORATIVE STUDY.
065247 05-10

SETTING, PATIENT, AND DOCTOR EFFECTS ON DRUG RESPONSE IN NEUROTIC PATIENTS: II. DIFFERENTIAL IMPROVEMENT.
065446 05-10

SETTING, PATIENT, AND DOCTOR EFFECTS ON DRUG RESPONSE IN NEUROTIC PATIENTS: I. DIFFERENTIAL ATTRITION, DOSAGE DEVIATION, AND SIDE REACTION RESPONSES TO TREATMENT.
065453 05-10

BUTABARBITAL SODIUM AND CHLORDIAZEPOXIDE IN ANXIOUS NEUROTIC OUTPATIENTS: A COLLABORATIVE CONTROLLED STUDY.
066276 05-10

DRUG TREATMENT IN DEPRESSIVE ILLNESS: AMITRYPTYLINE AND CHLORDIAZEPOXIDE IN TWO NEUROTIC POPULATIONS.
075415 08-10

AMITRIPTYLINE AND TRIMIPRAMINE IN NEUROTIC DEPRESSED OUTPATIENTS: A COLLABORATIVE STUDY.
075868 09-10

DRUGS, DIAGNOSES, AND OUTCOME OF DRUG TRIALS WITH NEUROTIC PATIENTS: A SURVEY.
075942 09-11

THE ANTIANXIETY EFFECTS OF HALOPERIDOL AND TRIFLUOPERAZINE IN AN OUTPATIENT NEUROTIC POPULATION.
089444 11-10

A LONG-ACTING NEUROLEPTIC IN THE TREATMENT OF CHRONIC ALCOHOLISM IN NEUROTIC AND PSYCHOTIC PATIENTS.
109255 12-11

USE OF CATTELS IPAT ANXIETY SCALE IN A GROUP OF NEUROTIC PATIENTS BEFORE AND AFTER PSYCHOPHARMACOLOGICAL DRUG AND ELECTRIC SHOCK THERAPY.
128509 12-17

TRANQUILIZERS IN THE TREATMENT OF THE CARDIAC NEUROTIC PATIENT AND THE SUBSEQUENT ALTERATION OF COMPLAINTS.
128568 12-14

**NEUROTICISM**

DRUG-INDUCED SYMPATHETIC AROUSAL AND NEUROTICISM.
075779 08-13

**NEUPOTICS**

SIDE REACTIONS IN NEUROTICS: I. A COMPARISON OF TWO METHODS OF ASSESSMENT.
064287 04-15

**NEUROTOXIC**

NEUROTOXIC SIDE-EFFECTS IN DISULFIRAM (ANTABUSE) OVERDOSAGE.
067743 06-15

**NEUROTOXICITY**

NEUROTOXICITY WITH LITHIUM: DIFFERENTIAL DRUG RESPONSIVENESS.
106769 12-15

**NEUROTOXICOLOGIC**

LITHIUM NEUROTOXICOLOGIC EFFECTS: 1. ACUTE PHASE (PRELIMINARY OBSERVATIONS).
069312 06-05

**NEUROTRANSMITTERS**

AMINES THAT MANIPULATE THE NEUROTRANSMITTERS.
058963 03-11

**NEUROTROPIC**

NEUROTROPIC PROPERTIES OF AMINOHYDROXYACETATE AND GAMMA-AMINOHYDROXYBUTYRIC ACID.
058605 02-03

CENTRAL NEUROTROPIC ACTIVITY OF AMINOPROPYL AND AMINOPROPIONYLIC DERIVATIVES OF IMINOBENZYL AND DIPHENYLAMINE AND ITS RELATION TO IONIZATION CONSTANTS.
072580 08-03

DOES KYNURENINE POSSESS ANY NEUROTROPIC ACTIVITY
105621 12-04

**NEW**

A NEW STIMULANT, PROLINTANE HYDROCHLORIDE, COMPARED WITH DEXTROAMPHETAMINE IN FATIGUED VOLUNTEERS.
040128 01-14

ALL IS AS NEW.
046732 01-12

2,5 DIMETHOXY-4-METHYLAMPHETAMINE: CLINICAL EVALUATION OF A NEW HALLUCINOGENIC DRUG.
052457 02-12

PHARMACOLOGICAL, TOXICOLOGICAL, AND TERATOLOGICAL STUDIES ON DIPOTASSIUM 7-CHLORO-3-CARBOXY 1,3-DIHYDRO-2,2-DIHYDROXY-5-PHENYL-2H-1,4 BENZODIAZEPINE CHLORAZEPATE (DIPOTASSIUM CHLORAZEPATE, 4306-CB), A NEW TRANQUILLIZER.
055581 02-03

PHARMACOLOGICAL STUDIES ON A NEW SPECIFICALLY POTENT ANTITUSSIVE AGENT, 14-HYDROXYDIHYDRO-6-BETA-THEBAINOL-4-METHYLETHER (OXYMETHEBANOL).
055585 02-03

DIPOTASSIUM CHLORAZEPATE: CLINICAL REPORTS ON A NEW ANTIANXIETY AGENT.
055738 02-09

DIMETHACRINE -- A NEW TRICYCLIC ANTIDEPRESSANT: OPEN INVESTIGATIONS IN A CLINIC AND POLYCLINIC.
058281 02-07

THE EMPLOYMENT OF A NEW BENZODIAZEPINE, RO-5-4556 IN INTERNAL MEDICINE.
058312 02-11

DOGMATIL: A NEW ILLUMINATION ON THE PSYCHOLOGICAL PROBLEMS OF SENESCENCE.
058313 02-11

TWO TRIALS WITH A NEW PSYCHOTHERAPEUTIC DRUG IN THE TREATMENT OF ANXIETY.
058335 02-10

PROJECT SUMMARY: A NEW ASSAY PROCEDURE FOR AMINOTRANSFERASES.
060223 03-03

A NEW CLASS OF 1,3 BENZOXAZINONES AS POTENTIAL CENTRAL NERVOUS SYSTEM AGENTS.
062322 03-02

USE OF A NEW ANTIDEPRESSANT IN THE FEMALE CLIMACTERIC.
063598 04-09

THE PHARMACOLOGY OF PRAZEPAM: A NEW BENZODIAZEPINE DERIVATIVE.
064181 04-04

NEW COMPOUNDS: STRUCTURAL ANALOGS RELATED TO ASARONE AND MESCALINE.
064264 04-01

INTERACTIONS BETWEEN SYMPATHOMIMETIC AMINES AND A NEW MONOAMINE OXIDASE INHIBITOR.
064406 04-07

EVALUATION OF THE PERIPHERAL AND CENTRAL ANTAGONISTIC ACTIVITIES AGAINST 5-HYDROXYTRYPTAMINE OF SOME NEW AGENTS.
067603 06-03

TO SLEEP, PERCHANCE TO DREAM: NEW DRUG FOR INSOMNIACS DOESNT INTERFERE WITH REM TIME.
068021 06-14

COMPARATIVE TRIAL OF A NEW MONOAMINE OXIDASE INHIBITOR IN DEPRESSION.
069057 06-10

METIAPINE: A NEW ANTIPSYCHOTIC AGENT.
069059 06-07

TRIAL OF A NEW PSYCHOTROPIC DRUG DOXEPIN.
069072 06-07

NEW FINDINGS IN THE CLINICAL PHARMACOLOGY OF SLEEP.
070925 07-17

CLINICAL TRIAL OF A NEW MOLECULE SULPIRIDE IN PSYCHIATRIC PRACTICE.
072156 07-15

NEW ASPECTS IN THE THERAPY OF PARKINSONISM.
072465 08-11

ABSORPTION AND PHARMACOLOGICAL ACTIVITIES OF A NEW DIAZEPAM PREPARATION.
072586 08-03

NEW IN PSYCHIATRY: MODITEN INJECTABLE THERAPY AND FOLLOW-UP CARE.
072787 08-11

EFFECTS OF BENZOCTAMINE (30803-BA, TACITIN), A NEW PSYCHOACTIVE DRUG, ON CATECHOLAMINE METABOLISM.
074861 08-03

NEW PSYCHOPHARMACEUTICALS FOR CLINICAL PRACTICE.
079146 09-07

CLINICAL TESTS OF A NEW, PROLONGED ACTION NEUROLEPTIC AGENT, PIMOZIDE.
079863 09-07

CLINICAL TESTS OF A NEW ANXIOLYTIC, MEDAZEPAM (NOBRIUM).
079864 09-11

CLINICAL STUDY ON A NEW PIPERIDYL-PHENOTHIAZINE DERIVATIVE (A-124).
079969 09-07

STUDIES IN MAN ON THE INFLUENCE OF A NEW PSYCHOPHARMACEUTICAL DRUG, 1-((METHYLAMINO) DIBENZOBICYCLOOCTADIENE HYDROCHLORIDE, ON THE CO2 SENSITIVE CENTRAL RESPIRATORY REGULATION.
079971 09-07

2-CHLORO-11-(4-METHYLPIPERAZINO) DIBENZOXAZEPINE), (SUM-3170), A NEW NEUROLEPTIC SUBSTANCE: RESULTS OF AN INTERCLINICAL STUDY.
079986 09-07

2-ETHYLAMINO-6-CHLORO-4-METHYL-4-PHENYL-4H-3,1 BENZOXAZINE, A NEW PSYCHOTROPIC COMPOUND.
079988 09-02

PHARMACOLOGIC ACTIVITY OF A NEW CLASS OF AGENTS WHICH SELECTIVELY INHIBIT AGGRESSIVE BEHAVIOR IN RATS.
082398 10-04

INVESTIGATION ON A NEW ANTICONVULSIVE PRODUCT RO-5-4023.
085454 10-14

OXAZEPAM SPOFA, A NEW CZECHOSLOVAK THERAPEUTIC.
086209 10-17

TESTS OF A NEW ANXIOLYTIC: THE USE OF DOXEPINE IN GERIATRIC CASES.
086236 10-07

RESEARCH ON NEW METHODS OF EXPERIMENTATION WITH PSYCHOTROPIC DRUGS. RESULTS OF A TEST WITH A NEW TRANQUILIZER, NOBRIUM, IN TWO INDEPENDENT INVESTIGATIONS.
086984 10-16

A NEW WAY OF ACETYLCHOLINE BIOSYNTHESIS IN BRAIN TISSUE.
087303 10-01

THE EFFECT OF A NEW METABOLIC CEREBRAL STIMULANT, CYPRODEMANOL, IN PSYCHIATRIC ASPECTS OF AGING.
089055 10-11

NEW METHOD FOR ASSAYING ANTIAPOMORPHINE ACTIVITY IN PIGEONS.
089437 11-06

CHEMISTRY AND PHARMACOLOGY OF A NEW POTENTIAL ANTIDEPRESSANT, N-METHYL-N-(4-CHLOROBENZYL-11-DIHYDRO-5H DIBENZAZEPIN-5-YL) PROPYLAMINE HYDROCHLORIDE) (LEO-640, LOPRAMINE HYDROCHLORIDE).
089786 11-01

PROBLEMS OF NEW DRUGS.
090078 11-07

THE SYNTHESIS AND BIOLOGICAL ACTIVITY OF (-)-DELTA9(11)-TRANS TETRAHYDROCANNABINOL; A NEW PROCEDURE FOR THE CLEAVAGE OF PHENYL METHYL ETHERS (UNPUBLISHED PAPER).
092888 11-01

CLINICAL EXPERIMENT WITH A NFW TRANQUILLIZER: TRIOXAZINE.
094423 11-11

EVALUATION OF CL-184BC: A NEW DISSOCIATIVE ANESTHETIC IN NORMAL HUMAN VOLUNTEERS.
097971 11-07

CLINICAL EVALUATION OF A NEW PSYCHOTROPIC DRUG – MOLINDONE.
097997 11-07

CLINICOELECTROENCEPHALOGRAPHIC EVALUATION OF A NEW BENZODIAZEPINIC DERIVATIVE (RO-5-4023) ADMINISTERED ORALLY IN EPILEPTIC PATIENTS USING A DOUBLE-BLIND METHOD.
100959 12-07

CLINICOELECTROENCEPHALOGRAPHIC EVALUATION OF THE ANTIEPILEPTIC ACTION OF A NEW SERIES OF BENZODIAZEPINIC DERIVATIVES.
105486 12-07

CLINICAL EXPERIENCE WITH METHYLPERONE (BURONIL), A NEW BUTYROPHENONE DERIVATIVE.
105730 12-07

RESEARCH IN NEW EXPERIMENTAL METHODS FOR PSYCHOTROPIC DRUGS: RESULTS OF A DOUBLE-BLIND STUDY WITH A NEW TRANQUILIZER, NOBRIUM.
112282 12-16

PHARMACOLOGICAL STUDIES OF OXAZOLAZEPAM, A NEW PSYCHOTROPIC AGENT - I. ACTIONS ON THE CENTRAL NERVOUS SYSTEM, ESPECIALLY ON THE BEHAVIORAL OBSERVATION.
114769 12-02

PHARMACOLOGICAL STUDIES OF OXAZOLAZEPAM, A NEW PSYCHOTROPIC AGENT – II. GENERAL PHARMACOLOGY AND SUBACUTE TOXICITY.
114835 12-07

ADMINISTRATION OF A NEW BUTYROPHENONE DERIVATIVE, PIMOZIDE, IN THE TREATMENT OF SCHIZOPHRENIA.
123373 12-08

A DOUBLE-BLIND COMPARISON OF S-804 (NEW BENZODIAZEPINE DRUG) WITH CHLORDIAZEPOXIDE AND DIAZEPAM IN THE TREATMENT OF NEUROSIS.
129097 12-10

A CLINICAL EXPERIENCE OF OXAZOLAM, A NEW MINOR TRANQUILIZER.
129367 12-07

CLINICAL APPLICATION OF NEW TRANQUILIZER, CS-300, TO SCHIZOPHRENICS.
129879 12-07

**NEW-BORN**

COMPARISON OF THE PAROXYSMAL DYSKINESIAS (NEURODYSLEPSY) INDUCED BY THE NEUROLEPTICS IN MAN AND THE EARLIEST BEHAVIOR PATTERNS OF THE NEW-BORN.
070267 07-13

**NEW-YORK**

SUCCESSES AND FAILURES IN METHADONE MAINTENANCE TREATMENT OF HEROIN ADDICTION IN NEW-YORK CITY. (UNPUBLISHED PAPER).
071314 07-17

**NHS**

DIAZEPAM, NITRAZEPAM AND THE NHS.
058422 02-15

**NIACIN**

NIACIN AND THE SCHIZOPHRENIC PATIENT.
065232 05-15

ORTHOMOLECULAR PSYCHIATRY: NIACIN AND MEGAVITAMIN THERAPY.
065416 05-08

HOW ONE PSYCHIATRIST BEGAN USING NIACIN.
070284 07-17

**NIACINAMIDE**

AN EVALUATION OF NIACINAMIDE IN THE TREATMENT OF CHILDHOOD SCHIZOPHRENIA.
060240 03-08

**NIALAMID**

DISORDERS OF CONSCIOUSNESS AS A COMPLICATION IN NIALAMID TREATMENT.
085106 10-15

**NIAMID**

ON THE ANALYSIS OF 5-HYDROXYTRYPTOPHAN PRODUCED HYPERTHERMIA IN MICE PRETREATED WITH A MONOAMINE OXIDASE INHIBITOR NIAMID.
098035 11-03

**NICOTINAMIDE**

PSYCHOPHARMACOLOGICAL ACTION OF NICOTINAMIDE ADENINE DINUCLEOTIDE.
064481 04-04

CHILDHOOD SCHIZOPHRENIA: A CASE TREATED WITH NICOTINIC ACID AND NICOTINAMIDE.
075944 09-08

ON THE BIOCHEMICAL MECHANISM OF ACTION OF NICOTINIC ACID, NICOTINAMIDE, METHIONINE, AND D-PENICILLAMINE IN THE TREATMENT OF PSYCHOSES.
094962 11-13

**NICOTINE**

EFFECTS OF CHRONIC ADMINISTRATION OF NICOTINE ON STORAGE AND SYNTHESIS OF NORADRENALINE IN RAT BRAIN.
041552 01-03

EFFECTS OF NICOTINE AND TOBACCO SMOKE ON THE ELECTRICAL ACTIVITY OF THE CEREBRAL CORTEX AND OLFACTORY BULB.
041567 01-03

THE EFFECT OF AMPHETAMINE, NICOTINE AND ATROPINE ON PSEUDOCONDITIONED RESPONSES OF RATS.
046142 01-04

EFFECT OF AMPHETAMINE, NICOTINE AND HEXAMETHONIUM ON PERFORMANCE OF A CONDITIONED RESPONSE DURING ACQUISITION AND RETENTION TRIALS.
046186 01-04

COMPARATIVE EFFECTS OF NICOTINE AND AMPHETAMINE ON TIMING BEHAVIOR IN RATS.
046190 01-04

INHIBITION OF CIGARETTE SMOKING BY ORALLY ADMINISTERED NICOTINE.
066277 05-13

SOME EFFECTS OF NICOTINE ON THE CENTRAL NERVOUS SYSTEM OF CHICKENS.
068166 06-03

DIFFERENTIAL EFFECTS OF NICOTINE AND TOBACCO SMOKE ALKALOIDS ON SWIMMING ENDURANCE IN THE RAT.
069078 06-04

THE EFFECT OF NICOTINE AND TOTAL ALKALOIDS EXTRACTED FROM CIGARETTE SMOKE IN AVOIDANCE BEHAVIOR IN RATS UNDER EXTINCTION PROCEDURE.
069079 06-04

THE EFFECTS OF NICOTINE ADMINISTRATION IN UTERO UPON ACTIVITY IN THE RAT.
075239 08-04

INFLUENCE OF CHRONIC ADMINISTRATION OF NICOTINE ON THE TURNOVER AND METABOLISM OF NORADRENALINE IN THE RAT BRAIN.
097958 11-03

**NICOTINIC**

NICOTINIC ACID IN THE TREATMENT OF SCHIZOPHRENIAS.
068450 06-08

NICOTINIC ACID IN THE PREVENTION AND TREATMENT OF METHIONINE INDUCED EXACERBATION OF PSYCHOPATHOLOGY IN SCHIZOPHRENICS.
075423 08-08

CHILDHOOD SCHIZOPHRENIA: A CASE TREATED WITH NICOTINIC ACID AND NICOTINAMIDE.
075944 09-08

EFFECT OF NICOTINIC ACID COMBINED WITH A TRANQUILLIZER (HYDROXYZINE) ON SERUM LIPID LEVELS AND URINARY CATECHOLAMINE EXCRETION IN GERIATRIC PATIENTS.
093689 11-11

ON THE BIOCHEMICAL MECHANISM OF ACTION OF NICOTINIC ACID, NICOTINAMIDE, METHIONINE, AND D-PENICILLAMINE IN THE TREATMENT OF PSYCHOSES.
094962 11-13

**NICTITATING**
INTRANEURONAL AND EXTRANEURONAL ACCUMULATION OF SYMPATHOMIMETIC AMINES IN THE ISOLATED NICTITATING MEMBRANE OF THE CAT.
066363 05-03

**NIGHT**
A POLYGRAPHIC STUDY OF THE NIGHT SLEEP OF PARKINSONIAN PATIENTS: EFFECTS OF TREATMENT WITH LEVODOPA.
087658 10-14

**NIMH**
MARIJUANA PROGRAM ADVANCES AT NIMH.
040149 01-14

MODIFICATION OF LEARNING BY DRUGS; NIMH.
092145 11-04

**NITRAZEPAM**
DIAZEPAM, NITRAZEPAM AND THE NHS.
058422 02-15

STUDIES ON NITRAZEPAM REDUCTION IN VITRO.
064255 04-03

PERSISTENT BEHAVIOURAL AND ELECTROENCEPHALOGRAPHIC CHANGES AFTER SINGLE DOSES OF NITRAZEPAM AND AMYLOBARBITONE SODIUM.
068005 06-14

HYPNOTIC PROPERTIES OF NITRAZEPAM (MOGADON) (A COMPARATIVE STUDY OF CHLORDIAZEPOXIDE, DIAZEPAM, NITRAZEPAM, SECOBARBITAL AND PLACEBO IN PSYCHIATRIC PATIENTS).
075884 09-14

**NITROPRUSSIDE**
INFLUENCE OF SEVERAL AUTONOMIC DRUGS ON SODIUM NITROPRUSSIDE AND OXOTREMORINE INDUCED HYPOTHERMIA IN IMMATURE AND MATURE MICE.
089436 11-03

**NOBODY**
THE MIND NOBODY KNOWS.
046729 01-14

**NOBRIUM**
NOBRIUM, ANOTHER BENZODIAZEPINE DERIVATIVE, 29 MONTHS OF EXPERIENCE.
059037 03-11

PRELIMINARY EXPERIENCE WITH MEDAZEPAM (NOBRIUM) IN THE MANAGEMENT OF PSYCHOPHYSIOLOGIC REACTIONS.
075878 09-07

CLINICAL TESTS OF A NEW ANXIOLYTIC, MEDAZEPAM (NOBRIUM).
079864 09-11

RESEARCH ON NEW METHODS OF EXPERIMENTATION WITH PSYCHOTROPIC DRUGS. RESULTS OF A TEST WITH A NEW TRANQUILIZER, NOBRIUM, IN TWO INDEPENDENT INVESTIGATIONS.
086984 10-16

RESEARCH IN NEW EXPERIMENTAL METHODS FOR PSYCHOTROPIC DRUGS: RESULTS OF A DOUBLE-BLIND STUDY WITH A NEW TRANQUILIZER, NOBRIUM.
112282 12-16

PRELIMINARY EXPERIENCES WITH NOBRIUM IN PRIVATE PSYCHIATRIC PRACTICE IN DJAKARTA.
130714 12-10

**NOCTURAL**
THE EFFECTS OF LEVOMEPROMAZINE ON THE NOCTURAL SLEEP EEG IN MAN.
129447 12-13

**NOISE**
THE INFLUENCE OF VARIOUS NEUROLEPTIC DRUGS ON NOISE ESCAPE RESPONSE IN RATS.
069076 06-04

**NOLUDAR**
DOES NOLUDAR (METHYPRYLON) CHANGE DREAMS?
082173 10-14

**NON-EPILEPTICS**
EFFECTS OF DIPHENYLHYDANTOIN (DILANTIN) WITHDRAWAL ON NON-EPILEPTICS: PRELIMINARY REPORT.
067512 06-11

**NON-NARCOTIC**
INVESTIGATIONS ON THE SPECIFICITY OF THE SO-CALLED ANALGESIC ACTIVITY OF NON-NARCOTIC DRUGS.
067254 06-04

**NON-REINFORCED**
EFFECTS OF SCOPOLAMINE, ATROPINE, AND D-AMPHETAMINE ON INTERNAL AND EXTERNAL CONTROL OF RESPONDING ON NON-REINFORCED TRIALS.
064410 04-04

**NON-REWARD**
THE SELF-INJECTION OF AMOBARBITAL BY RATS DURING NON-REWARD.
083413 10-04

**NON-USERS**
A COMPARISON OF MARIJUANA USERS AND NON-USERS.
059290 03-14

**NONADDICTIVE**
NONADDICTIVE PSYCHOTROPIC MEDICATION FOR IMPRISONED NARCOTIC ADDICTS.
070784 07-13

**NONANTAGONISM**
NONANTAGONISM OF ANTIADRENERGIC AGENTS BY A DIBENZOXEPINE: PRELIMINARY REPORT.
089438 11-13

**NONPUNISHED**
TRYPTAMINERGIC MECHANISMS IN PUNISHED AND NONPUNISHED BEHAVIOR.
069738 07-04

**NONRETARDED**
THYROID HORMONE ENHANCEMENT OF IMIPRAMINE IN NONRETARDED DEPRESSIONS.
042654 01-09

**NONSPATIAL**
ROLE OF MONKEYS SPATIAL PREFERENCES IN PERFORMANCE OF A NONSPATIAL TASK.
065420 05-04

**NONSTEROID**
NONSTEROID ANTIINFLAMMATORY AGENTS.
051121 02-17

**NONSUSTAINED-RELEASE**
IN VIVO EVALUATION OF ABSORPTION AND EXCRETION OF PENTYLENETETRAZOL -10-14C FROM SUSTAINED-RELEASE AND NONSUSTAINED-RELEASE TABLETS.
090427 11-13

**NORADNAMINE**
STUDIES ON INTERACTIONS INVOLVING ANTIDEPRESSIVE AND OTHER DRUGS WITH TETRABENAZINE AND NORADNAMINE ON LOCOMOTOR ACTIVITY IN MICE, INCLUDING DETAILS OF THE EXPERIMENTAL DESIGN AND STATISTICAL ANALYSIS.
069077 06-04

**NORADRENALINE**
EFFECTS OF AMPHETAMINE DERIVATIVES ON BRAIN DOPAMINE AND NORADRENALINE.
040126 01-03

PHARMACOLOGICAL SIGNIFICANCE OF BIOGENIC AMINES IN THE LUNGS: NORADRENALINE AND DOPAMINE.
041539 01-03

EFFECTS OF CHRONIC ADMINISTRATION OF NICOTINE ON STORAGE AND SYNTHESIS OF NORADRENALINE IN RAT BRAIN.
041552 01-03

INHIBITION OF THE RE-UPTAKE OF NEURONALLY LIBERATED NORADRENALINE AND ALPHA-RECEPTOR BLOCKING ACTION OF SOME ERGOT ALKALOIDS.
041967 01-03

SELECTIVE DEPLETION OF NORADRENALINE: A PROPOSED MECHANISM OF THE ADRENERGIC NEURONE BLOCKING ACTION OF BRETYLIUM.
055323 02-05

BLOCKADE OF NORADRENALINE UPTAKE AND INHIBITION OF GASTRIC ACID SECRETION BY 2-(P-CHLOROPHENYL-2-(PYRIDYL)HYDROXYMETHYL) IMIDAZOLINE MALEATE (SCH-12650).
058878 02-02

THE EFFECTS OF NORADRENALINE ON RATS BEHAVIOUR.
062941 03-04

MODIFICATION OF AN ENZYME RADIOCHEMICAL ASSAY PROCEDURE FOR NORADRENALINE.
064002 04-06

URINARY NORADRENALINE AND PLAYROOM BEHAVIOUR IN HYPERACTIVE BOYS.
070024 07-14

ACCELERATION OF NORADRENALINE BIOSYNTHESIS IN THE GUINEA-PIG VAS-DEFERENS BY POTASSIUM.
073063 08-06

THE EFFECT OF AMINOESTERS OF SUBSTITUTED GLYCOLIC AND ACETIC ACIDS ON THE CONTENT OF NORADRENALINE IN THE BRAIN OF RATS.
073717 08-03

AMPHETAMINE TOXICITY AND ENDOGENOUS NORADRENALINE CONCENTRATIONS IN ISOLATED AND AGGREGATED MIC
074146 08-05

THE EFFECT OF AMANTADINE ON THE UPTAKE OF DOPAMINE AND NORADRENALINE BY RAT BRAIN HOMOGENATES.
074148 08-03

EVIDENCE FOR A CENTRAL NORADRENALINE RECEPTOR: STIMULATION BY CLONIDINE.
081151 09-03

INFLUENCE OF AMINAZIN ON ADRENALIN, NORADRENALINE, DOPAMINE, AND DOPA EXCRETION IN HEALTHY PEOPLE AND IN THE MANIC PHASE OF THE MANIC-DEPRESSIVE PSYCHOSIS.
090355 11-03

INFLUENCE OF CHRONIC ADMINISTRATION OF NICOTINE ON THE TURNOVER AND METABOLISM OF NORADRENALINE IN THE RAT BRAIN.
097958 11-03

**NOREPINEPHRINE**

COMPARATIVE EFFECTS OF P-CHLOROPHENYLALANINE, P-CHLOROAMPHETAMINE AND P-CHLORO-N-METHYLAMPHETAMINE ON RAT BRAIN NOREPINEPHRINE, SEROTONIN AND 5-HYDROXYINDOLE-3-ACETIC ACID.
040241 01-03

THE ANTAGONISM OF PHENTOLAMINE AGAINST EXOGENOUSLY ADMINISTERED AND ENDOGENOUSLY RELEASED NOREPINEPHRINE IN RABBIT AORTIC STRIPS.
040243 01-03

EFFECTS OF METABOLIC INHIBITORS ON NOREPINEPHRINE RELEASE FROM THE PERFUSED SPLEEN OF THE CAT.
040244 01-03

RELEASE OF NOREPINEPHRINE FROM ISOLATED RAT IRIS BY FIELD STIMULATION.
040245 01-03

THE EFFECTS OF ACIDOSIS ON CHRONOTROPIC RESPONSES, NOREPINEPHRINE STORAGE AND RELEASE IN ISOLATED GUINEA-PIG ATRIA.
040753 01-03

EFFECTS OF LITHIUM CARBONATE ON TURNOVER AND METABOLISM OF NOREPINEPHRINE IN THE RAT BRAIN - CORRELATION TO GROSS BEHAVIORAL EFFECTS.
043277 01-03

REGULATION OF NOREPINEPHRINE BIOSYNTHESIS.
051126 02-17

TRANYLCYPROMINE: EFFECTS ON NOREPINEPHRINE METABOLISM IN RAT BRAIN.
052484 02-03

DOPA INDUCED EXCITEMENT IN THE CAT: ITS RELATIONSHIP TO BRAIN NOREPINEPHRINE CONCENTRATIONS.
058840 02-04

NOREPINEPHRINE AND DOPAMINE IN THE DEVELOPING CHICK BRAIN.
060865 03-03

BIPHASIC EFFECT OF NOREPINEPHRINE IN THE REGULATION OF HEPATIC TYROSINE TRANSAMINASE ACTIVITY.
062327 03-03

P-CHLOROAMPHETAMINE: TEMPORAL RELATIONSHIP BETWEEN PSYCHOMOTOR STIMULATION AND METABOLISM OF BRAIN NOREPINEPHRINE.
062805 03-03

A NOVEL APPROACH TO THE INVESTIGATION OF NOREPINEPHRINE METABOLISM IN HUMAN SYMPATHETIC NERVE.
064144 04-03

PARADOXICAL AMPHETAMINE EFFECT IN HYPERACTIVE RATS IN RELATION TO NOREPINEPHRINE METABOLISM.
064364 04-03

MECHANISMS BY WHICH AMPHETAMINE AND DESIPRAMINE INHIBIT THE METARAMINOL INDUCED RELEASE OF NOREPINEPHRINE FROM SYMPATHETIC NERVE ENDINGS IN RAT HEART.
064427 04-03

THE ROLE OF PLASMA PROTEIN BINDING IN THE INHIBITORY EFFECT OF NORTRIPTYLINE ON THE NEURONAL UPTAKE OF NOREPINEPHRINE.
066278 05-03

MODIFICATION BY DESIPRAMINE (DMI) OF THE AVAILABILITY OF NOREPINEPHRINE RELEASED BY RESERPINE IN THE HYPOTHALAMUS OF THE RAT IN VIVO.
066374 05-03

RELEASE OF NOREPINEPHRINE IN THE CENTRAL NERVOUS SYSTEM BY THEOPHYLLINE AND CAFFEINE.
066411 05-03

NOREPINEPHRINE TURNOVER AND METABOLISM IN RAT BRAIN AFTER LONG-TERM ADMINISTRATION OF IMIPRAMINE.
067687 06-03

EPINEPHRINE AND NOREPINEPHRINE EFFECTS ON SOCIAL DOMINANCE BEHAVIOR.
069530 07-04

QUANTITATIVE THIN-LAYER CHROMATOGRAPHIC ESTIMATION OF LABELED DOPAMINE AND NOREPINEPHRINE, THEIR PRECURSORS AND METABOLITES.
070063 07-06

AMPHETAMINE: DIFFERENTIATION BY D AND L ISOMERS OF BEHAVIOR INVOLVING BRAIN NOREPINEPHRINE OR DOPAMINE.
070921 07-04

THE EFFECTS OF ALTERED BRAIN NOREPINEPHRINE LEVELS ON CONTINUOUS AVOIDANCE RESPONDING AND THE ACTION OF AMPHETAMINES.
074937 08-04

SWIM STRESS INDUCED INACTIVITY: RELATION TO BODY TEMPERATURE AND BRAIN NOREPINEPHRINE, AND EFFECTS OF D-AMPHETAMINE.
075275 08-03

ON THE MECHANISM OF SUPERSENSITIVITY TO NOREPINEPHRINE IN THE DENERVATED CAT SPLEEN.
080336 09-03

EFFECT OF INTERMITTENT NERVE STIMULATION ON NOREPINEPHRINE SYNTHESIS AND MOBILIZATION IN THE PERFUSED CAT SPLEEN.
080337 09-01

NOREPINEPHRINE TURNOVER IN BRAIN AFTER ADMINISTRATION OF IMIPRAMINE: ENHANCEMENT BY THYROID HORMONE.
090052 11-13

BLOCKADE OF NOREPINEPHRINE UPTAKE AND RELATED ACTIVITIES OF CIS- AND TRANS N,N(PRIME)-BIS-(1-NAPHTHYLMETHYL)-1,4 CYCLOHEXANE BIS-(METHYLAMINE) DIHYDROCHLORIDE.
090136 11-03

MOTIVATIONAL DEPRESSION ASSOCIATED WITH NOREPINEPHRINE INDUCED EATING FROM THE HYPOTHALAMUS: RESEMBLANCE TO THE VENTROMEDIAL HYPERPHAGIC SYNDROME.
090473 11-04

CYCLIC AMP MEDIATION OF NOREPINEPHRINE INHIBITION IN RAT CEREBELLAR CORTEX: A UNIQUE CLASS OF SYNAPTIC RESPONSES (UNPUBLISHED PAPER).
093132 11-03

**NORMAL**

METRAZOL TOLERANCE IN A NORMAL VOLUNTEER POPULATION: A TEN YEAR FOLLOW-UP REPORT.
060649 03-13

COMPARATIVE BEHAVIORAL AND BIOCHEMICAL EFFECTS OF TRANYLCYPROMINE AND CYSTEINE ON NORMAL CONTROLS AND SCHIZOPHRENIC PATIENTS.
064331 04-08

SCOPOLAMINE EFFECTS ON CONDITIONED SUPPRESSION: INFLUENCE OF DIURNAL CYCLE AND TRANSITIONS BETWEEN NORMAL AND DRUGGED STATES.
071790 07-03

EFFECTS OF TRIMEPRIMINE (SURMONTIL) ON SPERMATOGENESIS AND MOOD IN NORMAL VOLUNTEERS.
072147 07-14

UPTAKE OF TRITIATED TESTOSTERONE IN BRAIN AND PERIPHERAL TISSUES OF NORMAL AND NEONATALLY ANDROGENIZED FEMALE RATS.
076086 09-04

TESTING THE PERFORMANCE UNDER APONEURON OF OTHERWISE NORMAL SCHOOL CHILDREN WITH A TENDENCY TOWARD REDUCED DRIVE AND EASY TIRING.
080563 09-11

PSYCHOMOTOR REACTIONS TO A SLIGHT ALCOHOLEMIA. A COMPARATIVE STUDY ON DRINKERS AND NORMAL INDIVIDUALS.
085043 10-15

THE EFFECTS OF 4 HYPNOTIC DRUGS AND PLACEBO ON NORMAL SUBJECTS SLEEPING AND DREAMING AT HOME.
087863 10-06

SLEEP IN PATIENTS WITH PARKINSONS DISEASE AND NORMAL SUBJECTS PRIOR TO AND FOLLOWING LEVODOPA ADMINISTRATION.
092974 11-11

EVALUATION OF CL-1848C: A NEW DISSOCIATIVE ANESTHETIC IN NORMAL HUMAN VOLUNTEERS.
097971 11-07

**NORMALS**

STRESS RESPONSES AMONG NORMALS.
046313 01-14

LONG-LASTING EFFECTS OF LSD ON NORMALS.
067343 06-12

**NORTRIPTYLINE**

A CONTROLLED STUDY OF NORTRIPTYLINE AND IMIPRAMINE.
052483 02-09

THE ROLE OF PLASMA PROTEIN BINDING IN THE INHIBITORY EFFECT OF NORTRIPTYLINE ON THE NEURONAL UPTAKE OF NOREPINEPHRINE.
066278 05-03

CORRELATION OF SUBJECTIVE SIDE-EFFECTS WITH PLASMA CONCENTRATIONS OF NORTRIPTYLINE.
082104 10-15

EFFECTS OF NORTRIPTYLINE IN THE TREATMENT OF DEPRESSION SYNDROMES.
093133 11-09

**NOR2-CHLORPROMAZINE**

SYNTHESIS OF POSSIBLE METABOLITES OF CHLORPROMAZINE: IV. 7-HYDROXY-NOR1-CHLORPROMAZINE AND NOR2-CHLORPROMAZINE SULFOXIDE (UNPUBLISHED PAPER).
088358 10-01

**NOSOGRAPHY**

BIOLOGICAL ASPECTS AND NOSOGRAPHY OF THE PSYCHOSES (CRITICAL NOTE).
130417 12-17

**NOSOLOGY**

CLASSIFICATION, NOSOLOGY, AND RATING SCALES OF PSYCHOTROPIC DRUGS.
064090 04-01

**NOSTALGIA**

INCONTINENT NOSTALGIA INDUCED BY L-DOPA.
081090 09-15

**NOVELTY**
EFFECTS OF METHYLPHENIDATE ON ACTIVITY AND REACTIONS OF NOVELTY IN RATS.
076066 09-04

**NOXIPTILIN**
CLINICAL TREATMENT OF DEPRESSIVE SYNDROMES WITH NOXIPTILIN.
079967 09-10
MORPHOLOGICAL ASPECTS OF APPLICATION OF NOXIPTILIN (BAY-1521) IN ANIMAL EXPERIMENTS.
079972 09-03

**NOZINAN**
THERAPEUTIC MEDICATION IN CHRONIC DELIRIUM: COMBINATION OF PROCHLORPERAZINE (TEMENTIL) AND LEVOMEPROMAZINE (NOZINAN).
079288 09-11

**NUCLEI**
THE EFFECT OF DIETHYLAMIDE OF LYSERGIC ACID (DLA) ON THE CONTENT OF MONOAMINES IN SOME NUCLEI OF THE MIDBRAIN AND HYPOTHALAMUS.
101006 12-03

**NUCLEIC**
EFFECTS OF THALIDOMIDE AND CHLORCYCLIZINE ON THE BIOSYNTHESIS OF NUCLEIC ACIDS AND PROTEINS IN FETAL AND MATERNAL TISSUES OF THE RAT.
040027 01-05

**NUCLEOSIDES**
THE USE OF THE PYRIMIDINE NUCLEOSIDES (CYTIDINE AND URIDINE) IN THE THERAPY OF CEREBRAL VASCULAR ILLNESS.
094472 11-13

**NUCLEUS**
INDUCED CHANGES IN CAUDATE NUCLEUS DOPAMINE AND ELECTROSHOCK THRESHOLD.
079179 09-03

**NULLIPAROUS**
HORMONAL INDUCTION OF MATERNAL BEHAVIOR IN THE OVARIECTOMIZED NULLIPAROUS RAT.
069063 06-04

**NUMERIC**
A TECHNIQUE TO DEMONSTRATE THE EFFECT OF A PSYCHOPHARMACEUTICAL DRUG IN A PSYCHOPATHOLOGICAL LONGITUDINAL SECTION BY NUMERIC AND GRAPHIC MEANS.
079973 09-06

**NURSE**
THE ROLE OF THE PSYCHIATRIC NURSE IN THE REHABILITATION OF THE SCHIZOPHRENIC PATIENT.
062108 03-08

**NUTRITION**
ADVANCES IN NUTRITION AND DIETETICS.
079912 09-11

**O-METHYLENE**
CONTRIBUTION TO THE STUDY OF THE EXTRAPYRAMIDAL SYNDROME WITH ANIMAL EXPERIMENTATION. THE ROLE OF CALCIUM AND O-METHYLENE DERIVATIVES.
086348 10-03

**OBJECTIFYING**
INVESTIGATIONS FOR OBJECTIFYING TRANQUILIZER EFFECTS.
079960 09-14

**OBJECTIVE**
OBJECTIVE EFFECTS OF DEXAMPHETAMINE AND AMOBARBITAL AND THEIR RELATIONS TO PSYCHASTHENIC PERSONALITY TRAITS.
064389 04-14
THE OBJECTIVE EVALUATION OF PSYCHOPHARMACOLOGICAL DRUGS WITH CAFFEINE AND CAFFEINE-FREE COFFEE AS AN EXAMPLE.
098039 11-13

**OBSERVATION**
OBSERVATION OF THE GROOMING BEHAVIOR OF RESERPINIZED WHITE MICE AS A METHOD FOR INVESTIGATING RESERPINE ANTAGONISM AND SYNERGISM.
065442 05-04
PHARMACOLOGICAL STUDIES OF OXAZOLAZEPAM, A NEW PSYCHOTROPIC AGENT - I. ACTIONS ON THE CENTRAL NERVOUS SYSTEM, ESPECIALLY ON THE BEHAVIORAL OBSERVATION.
114769 12-02

**OBSERVATIONS**
PRELIMINARY OBSERVATIONS ON THE METABOLISM OF (3)H-2,5-DIMETHOXY-4-METHYLAMPHETAMINE (STP, DOM).
046197 01-03
PRELIMINARY CLINICAL OBSERVATIONS CONCERNING THE TREATMENT WITH METRONIDAZOLE IN CHRONIC ALCOHOLISM.
062866 03-11
METABOLIC STUDIES AND CLINICAL OBSERVATIONS DURING L-DOPA TREATMENT OF PARKINSONS DISEASE.
063822 04-13
SOME OBSERVATIONS ON THE NEUROPHARMACOLOGY OF MEDAZEPAM HYDROCHLORIDE (RO-5-4556).
063841 04-04
DRUGS AND REALITY IN CAPTIVE SOCIETY. SOME OBSERVATIONS ON CHEMICAL ADAPTATION.
064091 04-17
LITHIUM NEUROTOXICOLOGIC EFFECTS: 1. ACUTE PHASE (PRELIMINARY OBSERVATIONS).
069312 06-05
METHODOLOGICAL PROBLEMS IN PSYCHOTHERAPY RESEARCH: OBSERVATIONS ON THE KARON-VANDENBOS STUDY OF PSYCHOTHERAPY AND DRUGS IN SCHIZOPHRENIA.
071322 07-08
CLINICAL OBSERVATIONS ON THE THERAPEUTIC ACTIVITY OF FLUPENTHIXOL IN THE TREATMENT OF CHRONIC SCHIZOPHRENIA.
080143 09-08
CLINICAL AND BIOLOGICAL EFFECTS OF DECANOATE OF FLUPHENAZINE: BASED ON 35 OBSERVATIONS.
085347 10-08
OBSERVATIONS ON THE NEUROLEPTIC SYNDROME.
091501 11-08
SOME OBSERVATIONS ON THE DYNAMICS OF THE DESTRUCTURING OF DELIRIUM DURING PHARMACOTHERAPY.
098033 11-17
PSYCHOCLINICAL OBSERVATIONS ON THE EFFECT OF THE LOGOS COMPOUND (ASSOCIATION OF PYRITHIOXINE DIHYDROCHLORIDE, TRYPTOPHAN AND CALCIUM ALPHA-KETOGLUTARATE).
109258 12-11

**OBSERVED**
PRINCIPAL ELECTROENCEPHALOGRAPHIC CHANGES OBSERVED DURING ACUTE INTOXICATION BY NEUROLEPTICS.
075112 08-13

**OBSERVING**
AN APPARATUS FOR OBSERVING ATTENTION AND PERSEVERANCE.
086161 10-16

**OBSESSIVE-COMPULSIVE**
TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS WITH HALOPERIDOL.
064233 04-10
TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS.
067022 05-10
TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS.
067023 05-10

**OCCUPATIONAL**
THE OCCUPATIONAL THERAPY IN A MENTAL HOSPITAL FOR CHRONIC SCHIZOPHRENICS.
139090 12-08

**OCTOCLOTHEPINE**
CLINICAL EXPERIENCE WITH OCTOCLOTHEPINE IN MANIC SYNDROMES.
070927 07-09
LONG-TERM TREATMENT WITH OCTOCLOTHEPINE -- SIDE-EFFECTS AND LABORATORY FINDINGS.
070928 07-09
CLINICAL EXPERIENCE WITH OCTOCLOTHEPINE IN SCHIZOPHRENIC PSYCHOSES.
070929 07-08
CLINICAL EXPERIENCE WITH OCTOCLOTHEPINE.
070930 07-08

**OCULAR**
OCULAR (PIGMENTARY) EFFECTS OF PSYCHOTROPIC DRUGS.
058212 02-15
OCULAR CHANGES OCCURRING WITH PROLONGED HIGH DOSE CHLORPROMAZINE THERAPY. RESULTS FROM A COLLABORATIVE STUDY.
060861 03-15

**OCULOGYRIC**
L-DOPA AND OCULOGYRIC CRISES.
067073 05-15

**ODORS**
RESPONSES OF MALE RATS TO SEX ODORS.
081226 09-04

**OFFENDERS**
USE OF AN ANDROGEN DEPLETING HORMONE IN THE TREATMENT OF MALE SEX OFFENDERS.
080178 09-14

**OFFICE**
A DOUBLE-BLIND EVALUATION OF THE ANTIEMETIC EFFICACY OF BENZQUINAMIDE, PROCHLORPERAZINE AND TRIMETHOBENZAMIDE IN OFFICE PRACTICE.
063022 03-07

**OFFSPRINGS**
THE SAFETY TEST OF L-DOPA -- II. EFFECT OF L-DOPA ON THE DEVELOPMENT OF PRENATAL AND POSTNATAL OFFSPRINGS OF EXPERIMENTAL ANIMALS.
114836 12-02

**OLDER**
FURTHER PSYCHOMETRIC EVALUATION OF OLDER WOMEN -- THE EFFECT OF ESTROGEN ADMINISTRATION.
078223 09-14

**OLFACTORY**
EFFECTS OF NICOTINE AND TOBACCO SMOKE ON THE ELECTRICAL ACTIVITY OF THE CEREBRAL CORTEX AND OLFACTORY BULB.
041567 01-03

**ON-LINE**
APPLICATION OF ON-LINE COMPUTER PROCEDURES TO EXPERIMENTAL CONTROL AND EVALUATION OF THE EFFECTS OF DRUGS ON OPERANT BEHAVIOR (SIDMAN SHOCK AVOIDANCE RESPONDING BY RATS).
095507 11-06

**ONE-WAY**
PENTOBARBITAL INDUCED STATE-DEPENDENT LEARNING OF ONE-WAY AVOIDANCE IN MICE.
075288 08-04

**ONYCHOMYS**
LABORATORY EVALUATION OF AGGRESSIVE BEHAVIOR OF THE GRASSHOPPER MOUSE (ONYCHOMYS).
064260 04-04

**OPACITIES**
REVERSIBLE LENTICULAR OPACITIES INDUCED IN RATS BY EMOTIONAL STRESS.
070823 07-03

**OPEN**
DIMETHACRINE – A NEW TRICYCLIC ANTIDEPRESSANT: OPEN INVESTIGATIONS IN A CLINIC AND POLYCLINIC.
058281 02-07
MODIFICATION OF THE EFFECTS OF ANTIPSYCHOTIC AGENTS ON THE OPEN FIELD PERFORMANCE OF RATS BY TREATMENT WITH ALPHA-METHYLTYROSINE OR P-CHLOROPHENYLALANINE.
064392 04-04
RETENTION RATES OF SCHIZOPHRENIA: A COMPARISON OF SHOCK THERAPY AND PSYCHOPHARMACOLOGICAL ERAS AND OF CLOSED AND OPEN DOOR POLICIES.
069795 07-08
AN AUTOMATED OPEN FIELD METHOD.
081261 09-06

**OPERANT**
FORGETTING OF AN OPERANT RESPONSE: PHYSOSTIGMINE PRODUCED INCREASES IN ESCAPE LATENCY IN RATS AS A FUNCTION OF TIME OF INJECTION.
061540 03-04
THE RELATIONSHIP OF AMPHETAMINE INDUCED ANOREXIA AND FREEZING UNDER A MULTIPLE CRF-EXT OPERANT SCHEDULE.
068288 06-04
EFFECTS OF STAPHYLOCOCCAL ENTEROTOXIN B ON COMPLEX OPERANT BEHAVIOR IN MONKEYS.
069333 06-04
THE EFFECT OF BROMOTRIFLUOROMETHANE ON OPERANT BEHAVIOR IN MONKEYS.
070732 07-04
ACTION OF CODEINE, PETHIDINE AND METHADONE ON THE OPERANT BEHAVIOR OF THE RAT.
071787 07-04
COMPARATIVE EFFECTS OF AMPHETAMINE, SCOPOLAMINE, CHLORDIAZEPOXIDE, AND DIPHENYLHYDANTOIN ON OPERANT AND EXTINCTION BEHAVIOR WITH BRAIN STIMULATION AND FOOD REWARD.
074935 08-04
HYDROXYZINE AND SHOCK IN OPERANT BEHAVIOR OF RATS.
076164 09-04
APPLICATION OF ON-LINE COMPUTER PROCEDURES TO EXPERIMENTAL CONTROL AND EVALUATION OF THE EFFECTS OF DRUGS ON OPERANT BEHAVIOR (SIDMAN SHOCK AVOIDANCE RESPONDING BY RATS).
095507 11-06
THE EFFECTIVENESS OF EXTERNAL AND DRUG PRODUCED INTERNAL STIMULI IN THE DISCRIMINATIVE CONTROL OF OPERANT BEHAVIOR. (PH.D.DISSERTATION).
110682 12-04

**OPERATION**
THE INFLUENCES OF THE STANDARD PREFRONTAL LOBOTOMY OPERATION ON HALLUCINATORY PHENOMENA ASSOCIATED WITH PSYCHOTOMIMETIC DRUGS.
120899 12-13

**OPHTHALMOLOGICAL**
OPHTHALMOLOGICAL STUDIES OF PATIENTS RECEIVING PSYCHOTROPIC PREPARATIONS.
073788 08-15
OPHTHALMOLOGICAL (PIGMENTARY) CHANGES.
100526 12-15

**OPIATE**
STIMULANT SELF-ADMINISTRATION BY ANIMALS: SOME COMPARISONS WITH OPIATE SELF-ADMINISTRATION.
056237 02-04
PSYCHOLOGICAL APPROACHES TO OPIATE DEPENDENCE AND SELF-ADMINISTRATION BY LABORATORY ANIMALS.
056240 02-04
TREATMENT OF HEROIN DEPENDENCE WITH OPIATE ANTAGONISTS.
065195 05-13
A CYCLAZOCINE TYPOLOGY IN OPIATE DEPENDENCE.
075427 08-16

**OPIOID**
RELAPSE TO OPIOID DEPENDENCE: THE ROLE OF CONDITIONING.
046208 01-03

**OPTIC**
GABA AS A REPRESSOR OF L-GLUTAMIC ACID DECARBOXYLASE (GAD) IN DEVELOPING CHICK EMBRYO OPTIC LOBES.
058192 02-03
RELEASE OF 5-HYDROXYTRYPTAMINE FROM SLICES OF SUPERIOR COLLICULUS BY OPTIC TRACT STIMULATION.
064369 04-03

**OPTICAL**
DRUG-INDUCED DAMAGE OF THE EYE AND THE OPTICAL NERVE.
128389 12-15

**OPTIMAL**
OPTIMAL THERAPY OF THE ALCOHOL WITHDRAWAL STATE.
078429 09-17

**ORAL**
THE EFFECT OF ORAL CONTRACEPTIVE STEROIDS ON BILE SECRETION AND BILIRUBIN TM IN RATS.
040125 01-05
MAINTENANCE THERAPY OF CHRONIC PSYCHOTIC PATIENTS WITH A WEEKLY ORAL DOSE OF R-16341. A CONTROLLED DOUBLE-BLIND STUDY.
064284 04-09
PSYCHOENDOCRINE STUDY OF ORAL CONTRACEPTIVE AGENTS.
065118 05-13
EFFECT OF AN ORAL CONTRACEPTIVE ON SPONTANEOUS RUNNING ACTIVITY OF FEMALE RATS.
067716 06-04
PERSISTENT EXTRAPYRAMIDAL ORAL DYSKINESIAS FOLLOWING TREATMENT WITH THYMOLEPTICS.
070945 07-15
THE SIGNIFICANCE OF BRAIN DAMAGE IN PERSISTENT ORAL DYSKINESIA.
075416 08-15
TREATMENT OF PERSISTENT PHENOTHIAZINE INDUCED ORAL DYSKINESIA.
075417 08-15
CHANGES IN PSYCHOLOGICAL SYMPTOMS IN WOMEN TAKING ORAL CONTRACEPTIVES.
075470 08-13
PSYCHOPHYSIOLOGIC CHANGES ACCOMPANYING ORAL CONTRACEPTIVE USE.
075471 08-13
ORAL CONTRACEPTIVES: DEPRESSION AND FRIGIDITY.
075968 09-13
ORAL DYSKINESIAS – OCCURRENCE AND TREATMENT.
083339 10-15
ACUTE ORAL TOXICITY OF CANNABINOIDS IN VARIOUS SPECIES (UNPUBLISHED PAPER).
088412 10-05
BRAIN DAMAGE IN INFANT MICE FOLLOWING ORAL INTAKE OF GLUTAMATE, ASPARTATE OR CYSTEINE.
094164 11-05
A COMPARATIVE DETERMINATION OF SIDE-EFFECTS ASSOCIATED WITH THE ORAL USE OF THREE ANTICHOLINERGIC PSYCHOTROPIC DRUGS.
126639 12-15

**ORALLY**
INHIBITION OF CIGARETTE SMOKING BY ORALLY ADMINISTERED NICOTINE.
066277 05-13
DELTA1-TETRAHYDROCANNABINOL, SYNHEXYL AND MARIJUANA EXTRACT ADMINISTERED ORALLY IN MAN: CATECHOLAMINE EXCRETION, PLASMA CORTISOL LEVELS AND PLATELET SEROTONIN CONTENT.
075841 08-12
CLINICOELECTROENCEPHALOGRAPHIC EVALUATION OF A NEW BENZODIAZEPINIC DERIVATIVE (RO-5-4023) ADMINISTERED ORALLY IN EPILEPTIC PATIENTS USING A DOUBLE-BLIND METHOD.
100959 12-07

**ORBITAL**
THE PREFERRED CONFORMATION OF DOPAMINE FROM MOLECULAR ORBITAL THEORY.
090068 11-13

**ORGAN**
SOME EFFECTS OF EXPERIMENTALLY PRODUCED CIGARETTE SMOKE ON THE GROWTH, VITAMIN-C METABOLISM AND ORGAN WEIGHTS OF GUINEA-PIGS.
063061 03-03

**ORGANIC**
ACUTE ORGANIC PSYCHOSIS DUE TO TALWIN (PENTAZOCINE).
058951 02-15
ORGANIC INTEGRITY TEST (OIT) IN MONITORING DRUG EFFECTS.
063596 04-08
RESULTS OF THE MEDICAL TREATMENT IN AGED PATIENTS WITH CEREBRAL ORGANIC DISTURBANCES.
087336 10-11

**ORGANISM**
PSYCHOACTIVE DRUGS IN THE IMMATURE ORGANISM.
064474 04-13

**ORGANISMIC**
INFLUENCE OF DISPLAY, TASK, AND ORGANISMIC VARIABLES ON INDICES OF MONITORING BEHAVIOR.
043270 01-17

**ORGANIZATION**
PSYCHOPHARMACODYNAMICS OF NEUROLEPTICS. ORGANIZATION EFFECTS OF THE PARANOID SYNDROME.
059039 03-17

**ORGANIZING**
SOME PROBLEMS OF ORGANIZING THE PSYCHOTHERAPEUTIC ENVIRONMENT IN A MIXED FEMALE PSYCHIATRIC WARD.
111254 12-17

**ORIENTATIONS**
PSYCHOPHARMACOLOGY TODAY. ORIENTATIONS IN THE TREATMENT OF SCHIZOPHRENIA.
086877 10-17
FIRST ORIENTATIONS ON THE USE OF HIGH DOSES OF OXAZEPAM, BASED ON PERSONAL CLINICAL THERAPEUTIC EXPERIENCE.
124308 12-10

**ORIGIN**
EFFECT OF 1035-MD ON CERTAIN CONDITIONS OF MENTAL DEFICIENCY, ESPECIALLY THOSE OF VASCULAR ORIGIN; CLINICAL EEG AND PSYCHOPHARMACOLOGICAL STUDY.
084978 10-08

**OROTATE**
INTERFERENCE OF BARBITURATES WITH PYRIMIDINE INCORPORATION -- III: STUDIES ON THE MECHANISM OF THE AMOBARBITAL OROTATE RELATIONSHIP.
064045 04-03
INTERFERENCE OF BARBITURATES WITH PYRIMIDINE INCORPORATION -- II: STRUCTURAL SPECIFICITY OF THE INHIBITION OF OROTATE UPTAKE IN BACILLUS-CEREUS.
064046 04-03

**ORTHOMOLECULAR**
ORTHOMOLECULAR PSYCHIATRY: NIACIN AND MEGAVITAMIN THERAPY.
065416 05-08

**ORTHOPHOSPHATE**
MORPHINE AND THE INCORPORATION OF 32 ORTHOPHOSPHATE IN VIVO INTO PHOSPHOLIPIDS OF THE GUINEA-PIG CEREBRAL CORTEX, LIVER AND SUBCELLULAR FRACTIONS.
046401 01-03

**OSPOLOT**
A COMBINED TREATMENT OF CHRONIC SCHIZOPHRENICS WITH OSPOLOT (SULTHIAME) AND STELAZINE (TRIFLUOPERAZINE).
089101 10-08

**OUABAIN**
THE PHARMACOLOGICAL EFFECTS OF OUABAIN ADMINISTERED INTRACEREBRALLY TO CONSCIOUS MICE.
068165 06-03

**OUTCOME**
RELATIONSHIPS OF THE MECHOLYL TEST, PREMORBID ASOCIAL FUNCTIONING AND LONG-TERM OUTCOME IN SCHIZOPHRENIA.
075227 08-08
DRUGS, DIAGNOSES, AND OUTCOME OF DRUG TRIALS WITH NEUROTIC PATIENTS: A SURVEY.
075942 09-11

**OUTPATIENT**
DRUG PERSONALITY INTERACTION IN INTENSIVE OUTPATIENT TREATMENT.
047836 01-10
VALUE OF AMITRIPTYLINE SPOFA IN THE PSYCHIATRIC OUTPATIENT AND INPATIENT PRACTICE.
070944 07-09
THE ANTIANXIETY EFFECTS OF HALOPERIDOL AND TRIFLUOPERAZINE IN AN OUTPATIENT NEUROTIC POPULATION.
089444 11-10

**OUTPATIENTS**
MOLINDONE IN ANXIOUS NEUROTIC PSYCHIATRIC OUTPATIENTS: A PILOT STUDY.
058969 03-10
HYDROXYZINE AND CHLORDIAZEPOXIDE IN ANXIOUS NEUROTIC OUTPATIENTS: A COLLABORATIVE CONTROLLED STUDY.
062321 03-10
A CONTROLLED STUDY OF THE EFFECTS OF DIPHENYLHYDANTOIN ON ANXIETY, IRRITABILITY, AND ANGER IN NEUROTIC OUTPATIENTS.
064478 04-10
PERPHENAZINE AMITRIPTYLINE IN NEUROTIC DEPRESSED OUTPATIENTS; A CONTROLLED COLLABORATIVE STUDY.
065247 05-10
FLUPHENAZINE ENANTHATE GIVEN TO INPATIENTS AND OUTPATIENTS.
065480 05-09
BUTABARBITAL SODIUM AND CHLORDIAZEPOXIDE IN ANXIOUS NEUROTIC OUTPATIENTS: A COLLABORATIVE CONTROLLED STUDY.
066276 05-10
PEMOLINE AND METHYLPHENIDATE IN MILDLY DEPRESSED OUTPATIENTS.
066709 05-10
PILLS AND IMPROVEMENT: A STUDY OF PLACEBO RESPONSE IN PSYCHONEUROTIC OUTPATIENTS.
066832 05-10
A COMPARATIVE EVALUATION OF DOXEPIN AND CHLORDIAZEPOXIDE IN THE TREATMENT OF PSYCHONEUROTIC OUTPATIENTS.
072140 07-10
DOXEPIN VERSUS CHLORDIAZEPOXIDE: A DOUBLE-BLIND STUDY ON ANXIOUS OUTPATIENTS.
072143 07-10
AMITRIPTYLINE AND TRIMIPRAMINE IN NEUROTIC DEPRESSED OUTPATIENTS: A COLLABORATIVE STUDY.
075868 09-10
PERSISTENCE OF A DRUG PERSONALITY INTERACTION IN PSYCHIATRIC OUTPATIENTS.
075873 09-14
KETIPRAMINE IN THE THERAPY OF DEPRESSION IN OUTPATIENTS.
076347 09-10
THIOTHIXENE IN THE TREATMENT OF ANXIETY AND DEPRESSION IN OUTPATIENTS.
082052 10-10
USE OF THE DRUG LUVATRENE FOR THE TREATMENT OF OUTPATIENTS.
089109 10-17
THE PREDICTION OF PLACEBO RESPONSE IN ANXIOUS AND DEPRESSED OUTPATIENTS.
092102 11-16

**OUTSIDE**
EXTRAPYRAMIDAL ACCIDENTS IN TREATMENT OUTSIDE THE HOSPITAL SETTING.
086443 10-15

**OVARIAN**
OVARIAN HORMONES AND FEMALE SEXUAL INVITATIONS IN CAPTIVE RHESUS MONKEYS (MACACA-MULATTA).
076554 09-03

**OVARIECTOMIZED**
INDUCTION OF RECEPTIVITY IN OVARIECTOMIZED FEMALE RATS BY A SINGLE INTRAVENOUS INJECTION OF ESTRADIOL-17BETA.
067696 06-04
HORMONAL INDUCTION OF MATERNAL BEHAVIOR IN THE OVARIECTOMIZED NULLIPAROUS RAT.
069063 06-04

**OVERAROUSAL**
RETICULAR STIMULATION AND CHLORPROMAZINE: AN ANIMAL MODEL FOR SCHIZOPHRENIC OVERAROUSAL.
058531 02-04

**OVERDOSAGE**
CARBON DISULFIDE INTOXICATION FROM OVERDOSAGE OF DISULFIRAM.
065691 05-09
NEUROTOXIC SIDE-EFFECTS IN DISULFIRAM (ANTABUSE) OVERDOSAGE.
067743 06-15

**OVERDOSE**
SLEEP AND DRUG OVERDOSE.
068007 06-15
LATE BRAIN RECOVERY PROCESSES AFTER DRUG OVERDOSE.
082027 10-15

**OVERRIDING**
INDUCTION BY CANNABIS-SATIVA (MARIHUANA) OF RHYTHMIC SPIKE DISCHARGES OVERRIDING REM SLEEP ELECTROCORTICOGRAM IN THE RAT.
069069 06-04

**OVERUSE**
ANTIPARKINSON DRUG OVERUSE.
074217 08-17
EFFICACY OF ANTIPARKINSON AGENTS CAN LEAD TO OVERUSE.
084822 10-15

**OVERVIEW**
SOME CLINICAL AND LABORATORY STUDIES OF PSYCHOTROPIC DRUGS IN CHILDREN. AN OVERVIEW.
070975 07-17

**OXAZEPAM**
OXAZEPAM SPOFA, A NEW CZECHOSLOVAK THERAPEUTIC.
086209 10-17
FIRST ORIENTATIONS ON THE USE OF HIGH DOSES OF OXAZEPAM, BASED ON PERSONAL CLINICAL THERAPEUTIC EXPERIENCE.
124308 12-10

**OXAZOLAM**
A CLINICAL EXPERIENCE OF OXAZOLAM, A NEW MINOR TRANQUILIZER.
129367 12-07

**OXAZOLAZEPAM**
PHARMACOLOGICAL STUDIES OF OXAZOLAZEPAM, A NEW PSYCHOTROPIC AGENT - I. ACTIONS ON THE CENTRAL NERVOUS SYSTEM, ESPECIALLY ON THE BEHAVIORAL OBSERVATION.
114769 12-02
PHARMACOLOGICAL STUDIES OF OXAZOLAZEPAM, A NEW PSYCHOTROPIC AGENT -- II. GENERAL PHARMACOLOGY AND SUBACUTE TOXICITY.
114835 12-07

**OXIDASE**
URINARY METABOLITES OF HARMINE IN THE RAT AND THEIR INHIBITION OF MONOAMINE OXIDASE. 040417 01-03
MONOAMINES AND MONOAMINE OXIDASE IN DENERVATED SYMPATHETIC GANGLIA OF THE CAT. 040756 01-03
EFFECTS OF MONOAMINE OXIDASE INHIBITORS AND AMPHETAMINE ON HYPOTHERMIA PRODUCED BY HALOTHANE. 041569 01-03
TREATMENT OF NARCOLEPSY WITH MONOAMINE OXIDASE INHIBITORS AND SYMPATHOMIMETIC AGENTS. 058327 02-13
EXCRETION OF VANYLGLYCOL IN HUMAN URINE UNDER DIETARY CONTROL, AND DURING TREATMENT WITH ANTIBIOTICS, DISULFIRAM, A MONOAMINE OXIDASE INHIBITOR, ALPHA-METHYLDOPA, AND RESERPINE. 060272 03-13
SPECIAL APPLICATION OF FLUORESCENCE HISTOCHEMISTRY: STUDIES ON EIGHT MONOAMINE OXIDASE INHIBITORS IN BRAIN NEURONS. 063989 04-06
INTERACTIONS BETWEEN SYMPATHOMIMETIC AMINES AND A NEW MONOAMINE OXIDASE INHIBITOR. 064406 04-07
MONOAMINE OXIDASE INHIBITORS, COMBINED WITH THYMOLEPTICS: ARE THEY REALLY UNUSABLE FOR HUMAN BEINGS. 066805 05-03
CATECHOLAMINE ACCUMULATION IN TISSUES OF THIAMINE-DEFICIENT RATS AFTER INHIBITION OF MONOAMINE OXIDASE. 067243 06-03
MONOAMINE OXIDASE INHIBITORS AND L-DOPA. 067657 06-15
MONOAMINE OXIDASE INHIBITORS. 068175 06-15
COMPARATIVE TRIAL OF A NEW MONOAMINE OXIDASE INHIBITOR IN DEPRESSION. 069057 06-10
INHIBITORS OF MONOAMINE OXIDASE VI: EFFECTS OF SUBSTITUTION ON INHIBITORY ACTIVITY OF 6 (OR 8) SUBSTITUTED BETA-CARBOLINES. 090426 11-01
ON THE ROLE OF BRAIN CATECHOLAMINES IN MOTOR ACTIVITY: EXPERIMENTS WITH INHIBITORS OF SYNTHESIS AND OF MONOAMINE OXIDASE. 097960 11-04
ON THE ANALYSIS OF 5-HYDROXYTRYPTOPHAN PRODUCED HYPERTHERMIA IN MICE PRETREATED WITH A MONOAMINE OXIDASE INHIBITOR NIAMID. 098035 11-03
MONOAMINE OXIDASE INHIBITORS AND CORONARY INSUFFICIENCY. 133861 12-13

**OXIDATION**
EFFECTS OF MORPHINE TREATMENT AND STARVATION ON THE SUBSTRATE INTERACTION WITH P-450 IN THE OXIDATION OF DRUGS BY LIVER MICROSOMES. 063982 04-03

**OXIDATIVE**
LONG-TERM VARIATION IN BASAL AND PHENOBARBITAL STIMULATED OXIDATIVE DRUG METABOLISM IN THE RAT. 040671 01-03
OXIDATIVE PHOSPHORYLATION IN HEART MITOCHONDRIA ISOLATED FROM CHLORPROMAZINE TREATED ANIMALS. 041564 01-03

**OXOTREMORINE**
THE EFFECT OF MORPHINE, NALORPHINE, NALOXONE, PENTAZOCINE, CYCLAZOCINE AND OXOTREMORINE ON THE SYNTHESIS AND RELEASE OF ACETYLCHOLINE BY MOUSE CEREBRAL CORTEX SLICES IN VITRO. 058994 03-03
INFLUENCE OF SEVERAL AUTONOMIC DRUGS ON SODIUM NITROPRUSSIDE AND OXOTREMORINE INDUCED HYPOTHERMIA IN IMMATURE AND MATURE MICE. 089436 11-03

**OXYGEN**
EFFECT OF ANTIDEPRESSANTS ON CEREBRAL CIRCULATION AND OXYGEN UPTAKE. 110633 12-03

**OXYGLURIC**
ACTION OF THE SALTS OF OXYGLURIC ACID ON ACUTE ALCOHOL INTOXICATION IN MAN (EXPERIMENTAL STUDY). 086005 10-11

**OXYMETHEBANOL**
PHARMACOLOGICAL STUDIES ON A NEW SPECIFICALLY POTENT ANTITUSSIVE AGENT, 14-HYDROXYDIHYDRO-6-BETA-THEBAINOL-4-METHYLETHER (OXYMETHEBANOL). 055585 02-03

**OXYMETRIC**
CONCERNING THE ARTICLE BY N.N.TIMOFEYEV, V.T.KONDRASHENKO AND N.Y.NEMTSEVA ON OXYMETRIC INVESTIGATION OF PATIENTS WITH SCHIZOPHRENIA AND REACTIVE PSYCHOSIS DURING NEUROLEPTIC TREATMENT. 109788 12-01

**OXYPERTINE**
A COMPARISON OF OXYPERTINE AND CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIA. 060659 03-01
THE BEHAVIORAL PHARMACOLOGY OF OXYPERTINE. 067175 06-01
CLINICAL STUDY ON OXYPERTINE IN CHRONICALLY PSYCHOTIC PATIENTS. 067597 06-01
OXYPERTINE IN THE TREATMENT OF CHRONIC SCHIZOPHRENIA. 072896 08-01
A DOUBLE-BLIND, CONTROLLED STUDY OF THE EFFECTS OF OXYPERTINE AND CARPIPRAMINE ON SCHIZOPHRENIA. 129082 12-01

**OXYQUINOLINE**
ACUTE CEREBRAL DISORDERS AFTER HIGH DOSES OF OXYQUINOLINE DERIVATIVES. 073900 08-11

**P-CHLORO-N-METHYLAMPHETAMINE**
COMPARATIVE EFFECTS OF P-CHLOROPHENYLALANINE, P-CHLOROAMPHETAMINE AND P-CHLORO-N-METHYLAMPHETAMINE ON RAT BRAIN NOREPINEPHRINE, SEROTONIN AND 5-HYDROXYINDOLE-3-ACETIC ACID. 040241 01-03
A CONTROLLED STUDY OF THE ANTIDEPRESSANT EFFECT OF P-CHLORO-N-METHYLAMPHETAMINE, A COMPOUND WITH A SELECTIVE EFFECT ON THE CENTRAL 5-HYDROXYTRYPTAMINE METABOLISM. 078212 09-10

**P-CHLOROAMPHETAMINE**
COMPARATIVE EFFECTS OF P-CHLOROPHENYLALANINE, P-CHLOROAMPHETAMINE AND P-CHLORO-N-METHYLAMPHETAMINE ON RAT BRAIN NOREPINEPHRINE, SEROTONIN AND 5-HYDROXYINDOLE-3-ACETIC ACID. 040241 01-03
P-CHLOROAMPHETAMINE: TEMPORAL RELATIONSHIP BETWEEN PSYCHOMOTOR STIMULATION AND METABOLISM OF BRAIN NOREPINEPHRINE. 062805 03-03
INHIBITION BY P-CHLOROAMPHETAMINE OF THE CONVERSION OF 5-HYDROXYTRYPTAMINE TO 5-HYDROXYINDOLEACETIC ACID IN RAT BRAIN. 066507 05-03
P-CHLOROAMPHETAMINE: IN VIVO INVESTIGATIONS ON THE MECHANISM OF ACTION OF THE SELECTIVE DEPLETION OF CEREBRAL SEROTONIN. 069596 07-03

**P-CHLORONITROBENZENE**
TWO CASES OF ACUTE P-CHLORONITROBENZENE POISONING SEQUELAE. 129753 12-15

**P-CHLOROPHENYLALANINE**
COMPARATIVE EFFECTS OF P-CHLOROPHENYLALANINE, P-CHLOROAMPHETAMINE AND P-CHLORO-N-METHYLAMPHETAMINE ON RAT BRAIN NOREPINEPHRINE, SEROTONIN AND 5-HYDROXYINDOLE-3-ACETIC ACID. 040241 01-03
THE EFFECT OF P-CHLOROPHENYLALANINE ON SOCIAL INTERACTION OF MALE RATS. 041541 01-04
THE EFFECTS OF 5-HTP ON P-CHLOROPHENYLALANINE (P-CPA) ATTENUATION OF CONFLICT BEHAVIOR. 047326 01-04
HYPERSEXUALITY AND BEHAVIORAL CHANGES IN CATS CAUSED BY ADMINISTRATION OF P-CHLOROPHENYLALANINE. 056934 02-04
DISSOCIATION OF THE EFFECTS OF P-CHLOROPHENYLALANINE ON SELF-STIMULATION AND ON BRAIN SEROTONIN. 058942 02-03
THE EFFECT OF P-CHLOROPHENYLALANINE (PCPA) ON SHOCK INDUCED FIGHTING BEHAVIOR IN RATS. 062853 03-03
P-CHLOROPHENYLALANINE AND HABITUATION TO REPETITIVE AUDITORY STARTLE STIMULI IN RATS. 063015 03-03
MODIFICATION OF THE TOXIC ACTIONS OF L-TRYPTOPHAN BY PARGYLINE AND P-CHLOROPHENYLALANINE. 064277 04-05
MODIFICATION OF THE EFFECTS OF ANTIPSYCHOTIC AGENTS ON THE OPEN FIELD PERFORMANCE OF RATS BY TREATMENT WITH ALPHA-METHYLTYROSINE OR P-CHLOROPHENYLALANINE. 064392 04-04
EFFECT OF CHRONIC ADMINISTRATION OF P-CHLOROPHENYLALANINE ON SEXUAL RECEPTIVITY OF THE FEMALE RAT. 066825 05-04

SEXUAL BEHAVIOR OF MALE CATS AFTER ADMINISTRATION OF P-CHLOROPHENYLALANINE.
072463 08-04

BEHAVIORAL EFFECTS OF P-CHLOROPHENYLALANINE IN RATS: INHIBITION BY LITHIUM.
081112 09-03

THE EFFECT OF P-CHLOROPHENYLALANINE ON THE BEHAVIOUR OF CATS.
081264 09-04

ALTERATIONS IN THE BEHAVIORAL EFFECTS OF LSD BY PRETREATMENT WITH P-CHLOROPHENYLALANINE AND ALPHA-METHYL-P-TYROSINE.
097965 11-04

**P-CPA**

THE EFFECTS OF 5-HTP ON P-CHLOROPHENYLALANINE (P-CPA) ATTENUATION OF CONFLICT BEHAVIOR.
047326 01-04

**P-HYDROXYNOREPHEDRINE**

EFFECT OF AMPHETAMINE ON THE PRESSOR RESPONSE TO TYRAMINE: FORMATION OF P-HYDROXYNOREPHEDRINE FROM AMPHETAMINE IN MAN.
090373 11-03

**P-450**

EFFECTS OF MORPHINE TREATMENT AND STARVATION ON THE SUBSTRATE INTERACTION WITH P-450 IN THE OXIDATION OF DRUGS BY LIVER MICROSOMES.
063982 04-03

**PACINOX**

A DOUBLE-BLIND EVALUATION OF CAPURIDE (PACINOX) AS A PRESURGICAL AID TO SLEEP.
058371 02-14

**PAIN**

USE OF DRUGS IN CONTROL OF CHRONIC PAIN.
066921 05-11

NEUROPSYCHOTROPIC DRUGS IN THE TREATMENT OF SO-CALLED PAIN SYNDROMES.
079962 09-17

THE TREATMENT OF CHRONIC PAIN SYNDROMES: ANALGETIC EFFECT OF A NEUROLEPTIC SUBSTANCE.
079963 09-11

**PAIRED**

EFFECTS OF INSTRUCTIONS AND DRUG ADMINISTRATION ON TEMPORAL RESOLUTION OF PAIRED FLASHES.
075771 08-14

**PALSIED**

EFFECTS OF MEPROBAMATE ON THE SCHOOL ACHIEVEMENT OF CEREBRAL PALSIED CHILDREN.
083317 10-14

**PAMOATE**

IMIPRAMINE PAMOATE IN HOSPITALIZED DEPRESSIVES: A DOUBLE-BLIND COMPARISON WITH PLACEBO.
064429 04-10

**PANCREAS**

THE EFFECTS OF PHENOBARBITAL ON EXOCRINE PANCREAS.
064180 04-03

**PANGAMIC**

USE OF PANGAMIC ACID (VITAMIN-B15) IN CEREBRAL ARTHEROSCLEROSIS WITH MENTAL DISTURBANCES.
067148 06-10

**PANTOTHENIC**

EFFECT OF A DEFICIENCY OF PANTOTHENIC ACID AND PYRIDOXINE ON THE FUNCTION OF THE CENTRAL NERVOUS SYSTEM AND ITS RESPONSE TO COUMARIN FROM MELILOTUS-OFFICINALIS.
126053 12-04

INFLUENCE OF ISONIAZID ON THE CENTRAL NERVOUS SYSTEM; THE ANTAGONISM BETWEEN ISONIAZID AND PYRIDOXINE, PANTOTHENIC ACID AND COUMARIN IN RATS (MELILOTUS-OFFICINALIS).
126055 12-04

**PAPIO-CYNOCEPHALUS**

METHODS FOR DETECTING ANTIANXIETY DRUGS USING BABOONS (PAPIO-CYNOCEPHALUS).
041537 01-06

**PAPIO-PAPIO**

EFFECTS OF PSILOCYBIN, DIMETHYLTRYPTAMINE AND VARIOUS LYSERGIC ACID DERIVATIVES ON PHOTICALLY INDUCED EPILEPSY IN THE BABOON (PAPIO-PAPIO).
068163 06-03

EFFECTS OF ATROPINE AND ESERINE ON THE ELECTROENCEPHALOGRAM, ON BEHAVIOUR AND ON LIGHT INDUCED EPILEPSY IN THE ADOLESCENT BABOON (PAPIO-PAPIO).
090157 11-04

**PARADOXAL**

PARADOXAL PSYCHIC REACTIONS DURING LITHIUM TREATMENT.
089103 10-15

**PARADOXICAL**

PARADOXICAL AMPHETAMINE EFFECT IN HYPERACTIVE RATS IN RELATION TO NOREPINEPHRINE METABOLISM.
064364 04-03

ELECTRICAL IMPEDANCE CHANGES IN MANY SITES OF BRAIN IN PARADOXICAL SLEEP, ANESTHESIA AND ACTIVITY.
066474 05-03

THE INFLUENCE OF IMIPRAMINE, DEXPHENMETRAZINE AND AMPHETAMINE SULPHATE ON SYNCHRONOUS AND PARADOXICAL SLEEP IN NARCOLEPSY CATAPLEXY. A POLYGRAPHIC EXAMINATION.
089037 10-14

**PARALLEL**

A PARALLEL STUDY OF THE AMNESIC EFFECTS OF CYCLOHEXIMIDE AND ECS UNDER DIFFERENT STRENGTHS OF CONDITIONING.
066830 05-04

**PARAMETERS**

INFLUENCE OF MODE AND DURATION OF PHENYLALANINE ADMINISTRATION ON BIOCHEMICAL PARAMETERS IN RATS OF VARIOUS AGES.
042840 01-03

DRUG EFFECTS UPON DATA PROCESSING AS FUNCTIONS OF STORAGE AND RETRIEVAL PARAMETERS.
065127 05-14

**PARANOIAC**

THE CLINICAL ASPECTS AND DYNAMICS OF PARANOIAC PSYCHOPATHY WITH MALIGNANT DEVELOPMENT.
126632 12-09

**PARANOIC**

PIGMENTARY RETINOPATHY AND PARANOIC SYNDROME. (PRESENTATION OF ONE CASE).
124309 12-08

**PARANOID**

PSYCHOPHARMACODYNAMICS OF NEUROLEPTICS. ORGANIZATION EFFECTS OF THE PARANOID SYNDROME.
059039 03-17

A THERAPEUTICAL PATHOMORPHOSIS OF SCHIZOPHRENIA PROCEEDING WITH PARANOID DISORDERS.
067547 06-08

AN ATTEMPT TO ELIMINATE RESISTANCE TO AMINAZINE BY MALARIA THERAPY IN PATIENTS WITH PARANOID SCHIZOPHRENIA.
087312 10-16

THE USE OF HALOPERIDOL IN RESIDUAL SCHIZOPHRENIA AND IN PARANOID STATES.
093524 11-08

PREMORBID ADJUSTMENT, PARANOID STATUS, AND PATTERNS OF RESPONSE TO PHENOTHIAZINE IN ACUTE SCHIZOPHRENIA.
103255 12-08

USE OF MELLERIL RETARD IN TREATMENT OF PATIENTS WITH DEPRESSIVE PARANOID AND ANXIOUS DEPRESSIVE SYNDROMES.
109724 12-14

SUICIDE AND PARANOID DEFENSE (PRELIMINARY REPORT).
113137 12-15

**PARASITOSIS**

TREATMENT OF DELUSION OF PARASITOSIS.
079994 09-11

**PARENTERAL**

THE DIFFERENTIAL RESPONSE TO PARENTERAL CHLORPROMAZINE AND MESORIDAZINE IN PSYCHOTIC PATIENTS.
040127 01-08

THE EFFECTIVENESS OF PARENTERAL ADMINISTRATION OF FLUPHENAZINE DECANOATE IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS.
065473 05-07

PERMEABILITY OF THE BLOOD BRAIN BARRIER TO PARENTERAL 5-HYDROXYTRYPTAMINE IN THE NEONATE CHICK.
067253 06-04

THE PARENTERAL USE OF VITAMINS IN THE TREATMENT OF SCHIZOPHRENIA.
068976 06-08

**PARENTS**

TREATMENT OF CHILDREN OF LITHIUM RESPONDING PARENTS.
058375 02-09

**PARGYLINE**

MODIFICATION OF THE TOXIC ACTIONS OF L-TRYPTOPHAN BY PARGYLINE AND P-CHLOROPHENYLALANINE.
064277 04-05

**PARKINSON**

L-DOPA IN THE TREATMENT OF POST-SURGICAL PARKINSON PATIENTS.
071984 07-07

**PARKINSONIAN**

MENTAL SYMPTOMS IN PARKINSONIAN PATIENTS TREATED WITH L-DOPA.
066490 05-15

MENTAL SYMPTOMS IN PARKINSONIAN PATIENTS TREATED WITH L-DOPA.
081082 09-15

A POLYGRAPHIC STUDY OF THE NIGHT SLEEP OF PARKINSONIAN PATIENTS: EFFECTS OF TREATMENT WITH LEVODOPA.
087658 10-14

**PARKINSONISM**

TREATMENT OF PARKINSONISM WITH LEVODOPA.
042483 01-07

AMANTADINE IN PARKINSONISM.
058240 02-11
NEWER MEDICAL TREATMENTS IN PARKINSONISM.
059021 03-11
SIDE-EFFECTS OF L-DOPA IN POSTENCEPHALITIC PARKINSONISM.
059057 03-15
PARKINSONISM.
064524 04-13
AMANTADINE DOPAMINE INTERACTION: POSSIBLE MODE OF ACTION IN PARKINSONISM.
066315 05-03
L-DOPA IN PARKINSONISM.
066875 05-13
DEXBENZETIMIDE IN NEUROLEPTIC INDUCED PARKINSONISM. A DOUBLE-BLIND CROSSOVER STUDY WITH A 16-WEEK FOLLOW-UP.
067176 06-11
L-DOPA, PARKINSONISM, AND DEPRESSION.
070856 07-09
L-DOPA IN THE TREATMENT OF PARKINSONISM. A PRELIMINARY APPRAISAL.
071985 07-07
NEW ASPECTS IN THE THERAPY OF PARKINSONISM.
072465 08-11
AKINESIS FOLLOWING STEREOTACTIC SURGERY FOR PARKINSONISM -- THE USE OF L-DOPA.
077404 09-16
EFFECTIVENESS AND LIMITATIONS OF LONG-TERM LEVODOPA THERAPY IN PARKINSONISM.
079974 09-11
ADJUVANTS TO L-DOPA FOR PARKINSONISM.
081104 09-14
BIOCHEMISTRY AND TREATMENT OF PARKINSONISM.
086351 10-13
ANALYSIS OF RESULTS IN TREATMENT OF PARKINSONISM WITH LEVODOPA.
087660 10-11
TREATMENT OF PARKINSONISM WITH L-DOPA.
098172 11-07
PARKINSONISM: PHYSIOLOGY, PHARMACOLOGY AND TREATMENT.
119840 12-17
L-DOPA AND PARKINSONISM.
122098 12-17

**PARKINSONS**
LEVODOPA, PARKINSONS DISEASE, AND HYPOTENSION.
042521 01-15
CONTROLLED TRIAL OF AMANTADINE HYDROCHLORIDE IN PARKINSONS DISEASE.
043697 01-11
AMANTADINE DOSAGE IN TREATMENT OF PARKINSONS DISEASE.
058241 02-11
PARKINSONS DISEASE: L-DOPA TREATMENT AND HANDWRITING AREA.
058966 03-11
METABOLIC STUDIES AND CLINICAL OBSERVATIONS DURING L-DOPA TREATMENT OF PARKINSONS DISEASE.
063822 04-13
PHARMACODYNAMICS OF 3,4 DIHYDROXYPHENYLALANINE (DOPA) IN PARKINSONS DISEASE.
063845 04-15
L-DOPA THERAPY IN PARKINSONS DISEASE.
064188 04-11
EFFECTS OF WITHDRAWING DOPA IN PARKINSONS DISEASE.
067623 06-13
TREATMENT OF PARKINSONS SYNDROME WITH L-DIHYDROXYPHENYLALANINE (LEVODOPA).
067666 06-07
THE EFFECT OF L-DOPA ON MONOAMINE METABOLITES IN PARKINSONS DISEASE.
070824 07-13
A CONTROLLED STUDY OF L-DOPA IN PARKINSONS DISEASE.
071974 07-07
L-DOPA THERAPY OF PARKINSONS DISEASE (A REVIEW OF THE PRELIMINARY EXPERIENCE AT WEST-VIRGINIA UNIVERSITY).
072421 08-07
THE EFFECTS OF L-DOPA THERAPY IN PARKINSONS DISEASE.
072508 08-15
L-DOPA IN THE TREATMENT OF PARKINSONS DISEASE.
081392 09-17
PSYCHIC SYMPTOMS IN L-DOPA TREATMENT OF PARKINSONS DISEASE.
087659 10-09
L-DOPA IN THE TREATMENT OF PARKINSONS DISEASE.
091715 11-07
SLEEP IN PATIENTS WITH PARKINSONS DISEASE AND NORMAL SUBJECTS PRIOR TO AND FOLLOWING LEVODOPA ADMINISTRATION.
092974 11-11

**PAROLE**
METHADONE PATIENTS ON PROBATION AND PAROLE.
070021 07-13

**PAROXYSMAL**
COMPARISON OF THE PAROXYSMAL DYSKINESIAS (NEURODYSLEPSY) INDUCED BY THE NEUROLEPTICS IN MAN AND THE EARLIEST BEHAVIOR PATTERNS OF THE NEW-BORN.
070267 07-13
PREVENTION OF PAROXYSMAL TACHYCARDIA OF WOLFF-PARKINSON-WHITE SYNDROME WITH COMBINED PROPRANOLOL AND QUINIDINE THERAPY.
070288 07-10
ON THE PROBLEM OF TREATMENT AND SOME CLINICAL CHARACTERISTICS OF SCHIZOPHRENIA WITH A GRADUAL PAROXYSMAL LIKE COURSE.
111032 12-08

**PARTIAL**
THERAPY OF PARTIAL EPILEPSY WITH A COMBINATION CONTAINING SULTHIAME.
055393 02-11
SODIUM AMOBARBITAL, THE HIPPOCAMPAL THETA RHYTHM, AND THE PARTIAL REINFORCEMENT EXTINCTION EFFECT.
063333 03-03
ADRENALIN AND AVOIDANCE LEARNING: PARTIAL REPLICATIONS.
075559 08-04

**PARTICIPATING**
AN ANALYSIS OF RECEPTIVE STRUCTURES PARTICIPATING IN THE BEHAVIOR REACTIONS OF CATS INDUCED BY CATECHOLAMINES AND SEROTONIN.
073715 08-03

**PARTICIPATION**
ANTAGONISM OF D-AMPHETAMINE BY ALPHA-METHYL-L-TYROSINE: BEHAVIORAL EVIDENCE FOR THE PARTICIPATION OF CATECHOLAMINE STORES AND SYNTHESIS IN THE AMPHETAMINE STIMULANT RESPONSE.
064096 04-03
PARTICIPATION OF SEROTONINERGIC PROCESSES IN THE ACTION OF PHENIGAMA.
105620 12-03

**PASSIVE**
DOPAMINE CONCENTRATIONS IN THE BRAINSTEM MESENCEPHALON OF ACTIVE RATS AS COMPARED WITH PASSIVE RATS.
060274 03-04
DEPRESSION OF TWO-WAY AVOIDANCE LEARNING AND ENHANCEMENT OF PASSIVE AVOIDANCE LEARNING BY SMALL DOSES OF PHYSOSTIGMINE.
064365 04-04
THE EFFECTS OF CHLORPROMAZINE ON ONE-TRIAL PASSIVE AVOIDANCE LEARNING IN MICE: FURTHER EXAMINATION OF PRELEARNING AND POSTLEARNING ADMINISTRATION.
064407 04-04
THE EFFECTS OF CENTRALLY AND PERIPHERALLY ACTING CHOLINERGIC DRUGS ON THE SHORT-TERM PERFORMANCE GRADIENT FOLLOWING PASSIVE AVOIDANCE TRAINING.
064412 04-04
SCOPOLAMINES EFFECT ON PASSIVE AVOIDANCE.
065876 05-04
STRAIN DIFFERENCES IN THE EFFECTS OF CHLORPROMAZINE AND CHLORDIAZEPOXIDE UPON ACTIVE AND PASSIVE AVOIDANCE IN MICE.
066828 05-04
THE EFFECTS OF CHLORPROMAZINE ON THE EXPRESSION OF AN ACQUIRED PASSIVE AVOIDANCE RESPONSE IN MICE.
097959 11-04

**PATHOGENESIS**
STUDIES ON THE ROLE OF ACID IN THE PATHOGENESIS OF EXPERIMENTAL STRESS ULCERS.
075276 08-03

**PATHOLOGY**
THERAPEUTIC INTEREST IN HYDROSARPAN-711 IN DEPRESSIVE STATES AND IN THE PSYCHIATRIC PATHOLOGY OF GERONTOLOGICAL STATES.
079859 09-11
PSYCHOMETRIC TESTS IN EVALUATION OF BRAIN PATHOLOGY, RESPONSE TO DRUGS.
081043 09-14
UNIVOCAL TREATMENT OF MULTIFORM DISORDERS: DOGMATIL IN PSYCHODIGESTIVE PATHOLOGY.
089174 10-11

**PATHOMORPHOSIS**
A THERAPEUTICAL PATHOMORPHOSIS OF SCHIZOPHRENIA PROCEEDING WITH PARANOID DISORDERS.
067547 06-08

**PATHOPHYSIOLOGY**
PATHOPHYSIOLOGY OF NARCOTIC ADDICTION; POSSIBLE ROLES OF PROTRACTED ABSTINENCE IN RELAPSE (UNPUBLISHED PAPER).
093000 11-13

**PATHWAY**
POSSIBLE DOPAMINERGIC PATHWAY FROM SUBSTANTIA-NIGRA TO PUTAMEN.
063983 04-03

EFFECTS OF A CONVULSANT BARBITURATE ON THE SPINAL MONOSYNAPTIC PATHWAY.
066372 05-03

A POSSIBLE PATHWAY FOR ETHANOL INDUCED FATTY LIVER AND MODIFICATION OF LIVER INJURY BY ANTIOXIDANTS.
070906 07-05

PATIENT

THE DANGERS TO THE PATIENT – AND THE THERAPIST.
046734 01-15

PSYCHOTROPIC AGENTS IN THE CORONARY PATIENT: WHAT AND WHEN.
059728 03-16

THE ROLE OF THE PSYCHIATRIC NURSE IN THE REHABILITATION OF THE SCHIZOPHRENIC PATIENT.
062108 03-08

NIACIN AND THE SCHIZOPHRENIC PATIENT.
065232 05-15

SETTING, PATIENT, AND DOCTOR EFFECTS ON DRUG RESPONSE IN NEUROTIC PATIENTS: II. DIFFERENTIAL IMPROVEMENT.
065446 05-10

SETTING, PATIENT, AND DOCTOR EFFECTS ON DRUG RESPONSE IN NEUROTIC PATIENTS: I. DIFFERENTIAL ATTRITION, DOSAGE DEVIATION, AND SIDE REACTION RESPONSES TO TREATMENT.
065453 05-10

DRUGS, DREAMS AND THE CORONARY PATIENT.
066874 05-14

PATIENT PERSONALITY AND DEMOGRAPHIC FACTORS AS PREDICTORS OF EARLY RESPONSE TO PSYCHOTROPIC DRUG TREATMENT.
074130 08-10

FLUPHENAZINE ENANTHATE IN THE TREATMENT OF THE POST-HOSPITALIZED PATIENT.
089000 10-17

HYPERTENSIVE CRISIS IN A PATIENT ON MAOI ANTIDEPRESSANTS FOLLOWING A MEAL OF BEEF LIVER.
092211 11-15

THE PROBLEM PATIENT IN PRACTICE: CONTRIBUTION TO A DIFFERENTIAL DIAGNOSTIC PROBLEM OF A TYPE OF DEPRESSION.
094307 11-09

PSYCHOPHARMACOLOGY AND THE INDIVIDUAL PATIENT.
115463 12-17

TRANQUILIZERS IN THE TREATMENT OF THE CARDIAC NEUROTIC PATIENT AND THE SUBSEQUENT ALTERATION OF COMPLAINTS.
128568 12-14

RESEARCH ON THE DEFECT STATE OF SCHIZOPHRENIC PATIENT UNDER CONTROL OF PSYCHODRUGS.
129273 12-08

PSYCHOPHARMACOLOGY AND THE INDIVIDUAL PATIENT.
134057 12-17

PATIENTS

THE DIFFERENTIAL RESPONSE TO PARENTERAL CHLORPROMAZINE AND MESORIDAZINE IN PSYCHOTIC PATIENTS.
040127 01-08

SUBNORMAL SERUM FOLATE DUE TO ANTICONVULSIVE THERAPY: A DOUBLE-BLIND STUDY OF THE EFFECT OF FOLIC ACID TREATMENT IN PATIENTS WITH DRUG INDUCED SUBNORMAL SERUM FOLATES.
042700 01-11

FACTORS AFFECTING CHLORPROMAZINE PLASMA LEVELS IN PSYCHIATRIC PATIENTS.
047913 01-13

THE PSYCHOPHARMACOLOGICAL TREATMENT OF CARDIAC NEUROTIC PATIENTS WITH DIPOTASSIUM CHLORAZEPATE IN THE DOUBLE-BLIND TEST.
055689 02-10

THE DESIGN OF DRUG TRIALS WITH NEUROTIC PATIENTS.
058364 02-16

EFFECTS OF L-DOPA IN PATIENTS WITH DEMENTIA.
058403 02-15

PROTRIPTYLINE IN THE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS.
058968 03-08

SUSTAINED-RELEASE TRANQUILIZER THERAPY IN HOSPITALIZED GERIATRIC PATIENTS.
059359 03-10

WITHDRAWAL OF ANTIPSYCHOTIC DRUGS FROM CHRONIC PSYCHIATRIC PATIENTS.
060208 03-08

A CLINICAL EVALUATION OF MESORIDAZINE IN MENTALLY RETARDED PATIENTS.
060268 03-07

THE EFFECT OF CYCLANDELATE ON MENTAL FUNCTION IN PATIENTS WITH ARTERIOSCLEROTIC BRAIN DISEASE.
061654 03-13

IMIPRAMINE AND LITHIUM EFFECTS ON BIOGENIC AMINE TRANSPORT IN DEPRESSED AND MANIC-DEPRESSED PATIENTS.
062326 03-13

IMIPRAMINE AND LITHIUM EFFECTS ON BIOGENIC AMINE TRANSPORT IN DEPRESSED AND MANIC-DEPRESSED PATIENTS.
062366 03-13

THE USE OF HIGH DOSES OF FLUPHENAZINE IN THE TREATMENT OF PSYCHOTIC PATIENTS.
063589 03-08

COMPARATIVE EFFICACY OF THIOTHIXENE CAPSULES AND CONCENTRATE IN ACUTELY SCHIZOPHRENIC PATIENTS.
063599 04-08

A CONTROLLED COMPARISON OF THE TREATMENT OF SCHIZOPHRENIC PATIENTS WHEN TREATED ACCORDING TO THE NEUROLEPTIC THRESHOLD OR BY CLINICAL JUDGMENT.
063776 04-08

SERUM VITAMIN-B12 LEVELS IN PSYCHIATRIC PATIENTS ON LONG-TERM PSYCHOTROPIC DRUG THERAPY.
063874 04-13

TREATMENT OF PHOBIC STATES WITH ANTIDEPRESSANTS: A RETROSPECTIVE STUDY OF 246 PATIENTS.
063934 04-10

THE EFFECTS OF IMIPRAMINE AND ELECTRIC CONVULSIVE THERAPY ON THE EXCRETION OF VARIOUS MINERALS IN DEPRESSED PATIENTS.
063939 04-13

CLINICAL EVALUATION OF HALOPERIDOL IN GERIATRIC PATIENTS.
064074 04-14

BEER SOCIOTHERAPY CAN BENEFIT AGED MENTAL PATIENTS.
064145 04-11

DETERMINANTS OF SERUM HALF-LIFE OF GLUTETHIMIDE IN INTOXICATED PATIENTS.
064168 04-15

MAINTENANCE THERAPY OF CHRONIC PSYCHOTIC PATIENTS WITH A WEEKLY ORAL DOSE OF R-16341. A CONTROLLED DOUBLE-BLIND STUDY.
064284 04-09

COMPARATIVE BEHAVIORAL AND BIOCHEMICAL EFFECTS OF TRANYLCYPROMINE AND CYSTEINE ON NORMAL CONTROLS AND SCHIZOPHRENIC PATIENTS.
064331 04-08

A COMPARATIVE STUDY OF FLUPHENAZINE AMITRIPTYLINE COMBINATION AND AMITRIPTYLINE ALONE IN THE TREATMENT OF DEPRESSED PSYCHIATRIC PATIENTS.
064356 04-09

CLINICAL EVALUATION OF DOXEPIN AND AMITRIPTYLINE IN DEPRESSED PATIENTS.
064637 05-09

THE ACTION OF L-DOPA ON SCHIZOPHRENIC PATIENTS (A PRELIMINARY REPORT).
064638 05-08

SETTING, PATIENT, AND DOCTOR EFFECTS ON DRUG RESPONSE IN NEUROTIC PATIENTS: II. DIFFERENTIAL IMPROVEMENT.
065446 05-10

SETTING, PATIENT, AND DOCTOR EFFECTS ON DRUG RESPONSE IN NEUROTIC PATIENTS: I. DIFFERENTIAL ATTRITION, DOSAGE DEVIATION, AND SIDE REACTION RESPONSES TO TREATMENT.
065453 05-10

PRIVATE AMBULATORY PATIENTS TREATED WITH FLUPHENAZINE ENANTHATE.
065458 05-07

LONG-ACTING PHENOTHIAZINES AND LONG-TERM PSYCHOTIC PATIENTS: THE ROLE OF FLUPHENAZINE ENANTHATE IN TREATMENT.
065479 05-08

MENTAL SYMPTOMS IN PARKINSONIAN PATIENTS TREATED WITH L-DOPA.
066490 05-15

THE EFFECT OF SERUM FROM ACUTE SCHIZOPHRENIC PATIENTS ON RABBIT BRAIN AMINES.
066713 05-03

MEASUREMENT OF BEHAVIORAL CHANGES IN PATIENTS ON L-DOPA.
066940 05-14

ADMINISTRATION OF A PERIPHERAL DECARBOXYLASE INHIBITOR WITH L-DOPA TO DEPRESSED PATIENTS.
067591 06-09

CLINICAL STUDY ON OXYPERTINE IN CHRONICALLY PSYCHOTIC PATIENTS.
067597 06-09

DREAM CONTENT IN MALE SCHIZOPHRENIC PATIENTS.
069034 06-08

COMBINED ADMINISTRATION OF THIORIDAZINE AND FLUOXYMESTERONE IN THE TREATMENT OF GERIATRIC PATIENTS.
069060 06-11

METHADONE PATIENTS ON PROBATION AND PAROLE.
070021 07-13

A SURVEY OF EXTRAPYRAMIDAL MANIFESTATIONS IN PATIENTS ATTENDING AN AFTER CARE CLINIC OF A PSYCHIATRIC HOSPITAL.
070412 07-15

DOUBLE-BLIND COMPARATIVE STUDY OF THE EFFECTS OF THIOTHIXENE AND THIORIDAZINE IN TWENTY CHRONIC SCHIZOPHRENIC PATIENTS.
070880 07-08

CLINICAL USE OF THIOPROPAZATE (DARTALAN) IN PATIENTS WITH PSYCHOSIS.
070937 07-09

CLINICAL EXPERIENCE WITH PIPERACETAZINE IN HOSPITALIZED MENTAL PATIENTS: A FOUR YEAR STUDY.
071292 07-07
L-DOPA IN THE TREATMENT OF POST-SURGICAL PARKINSON PATIENTS.
071984 07-07
CHROMOSOME STUDIES ON PATIENTS (IN VIVO) AND CELLS (IN VITRO) TREATED WITH LYSERGIC ACID DIETHYLAMIDE.
071987 07-13
MODIFICATION OF CHLORPROMAZINE METABOLISM BY SOME OTHER DRUGS FREQUENTLY ADMINISTERED TO PSYCHIATRIC PATIENTS.
071989 07-13
CI-601, A BUTYROPHENONE DERIVATIVE, IN THE TREATMENT OF CHRONICALLY WITHDRAWN SCHIZOPHRENIC PATIENTS.
072142 07-08
A CONTROLLED STUDY OF THE EFFECTS OF GAMFEXINE IN PHENOTHIAZINE TREATED PATIENTS.
072144 07-08
A PILOT STUDY OF AHR-1900 IN CHRONIC SCHIZOPHRENIC PATIENTS.
072145 07-08
DOXEPIN IN THE TREATMENT OF PSYCHONEUROTIC PATIENTS.
072146 07-11
SULPIRIDE IN PSYCHIATRIC TREATMENT: CLINICAL AND PSYCHOMETRIC STUDY IN 58 PATIENTS.
072158 07-11
THE EFFECTS OF WITHHOLDING OF NEUROLEPTICS FROM MENTAL PATIENTS.
072406 07-15
OPHTHALMOLOGICAL STUDIES OF PATIENTS RECEIVING PSYCHOTROPIC PREPARATIONS.
073788 08-15
CEREBROSPINAL FLUID 5-HYDROXYINDOLES AND BEHAVIOR AFTER L-TRYPTOPHAN AND PYRIDOXINE ADMINISTRATION TO PSYCHIATRIC PATIENTS.
074938 08-14
THE FUNCTION OF MUSIC IN LSD THERAPY FOR ALCOHOLIC PATIENTS.
075191 08-12
PREDICTION OF CHANGES IN SEVERITY OF THE SCHIZOPHRENIC SYNDROME WITH DISCONTINUATION AND ADMINISTRATION OF PHENOTHIAZINES IN CHRONIC SCHIZOPHRENIC PATIENTS: LANGUAGE AS A PREDICTOR AND MEASURE OF CHANGE IN SCHIZOPHRENIA.
075321 08-08
THE EFFECT OF SOCIAL FEEDBACK ON CHRONIC SCHIZOPHRENIC PATIENTS.
075362 08-14
CATECHOLAMINE METABOLISM IN AFFECTIVE DISORDERS -- III. MHPG AND OTHER CATECHOLAMINE METABOLITES IN PATIENTS TREATED WITH LITHIUM CARBONATE.
075410 08-09
SECONDARY IMMUNE RESPONSE TO TETANUS TOXOID IN PSYCHIATRIC PATIENTS.
075412 08-13
THE PLACE OF THIOTHIXENE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS. A SYSTEMATIC CLINICAL STUDY.
075422 08-08
A CONTROLLED COMPARATIVE STUDY OF FLUPHENAZINE AND FLUPHENAZINE ENANTHATE IN ACUTE AND CHRONIC PSYCHOTIC PATIENTS.
075881 09-08
HYPNOTIC PROPERTIES OF NITRAZEPAM (MOGADON) (A COMPARATIVE STUDY OF CHLORDIAZEPOXIDE, DIAZEPAM, NITRAZEPAM, SECOBARBITAL AND PLACEBO IN PSYCHIATRIC PATIENTS).
075884 09-14
DRUGS, DIAGNOSES, AND OUTCOME OF DRUG TRIALS WITH NEUROTIC PATIENTS: A SURVEY.
075942 09-11
USE OF ANTIPSYCHOTIC AND ANTIDEPRESSANT DRUGS BY CHRONICALLY ILL PATIENTS.
076351 09-17
HEAT STROKE IN PHENOTHIAZINE TREATED PATIENTS: A REPORT OF THREE FATALITIES.
076364 09-15
PLASMA CONCENTRATIONS OF THIORIDAZINE IN PATIENTS WITH DEPRESSION: A PRELIMINARY REPORT.
078213 09-13
THE USE OF SULTHIAME WITH DISTURBED MENTALLY SUBNORMAL PATIENTS.
079215 09-11
EFFECT OF A DECARBOXYLASE INHIBITOR (RO-4-4602), COMBINED WITH L-DOPA, ON INHIBITED DEPRESSIVE PATIENTS: II. EXPERIMENTAL PSYCHOLOGICAL STUDIES.
079964 09-14
EFFECT OF A DECARBOXYLASE INHIBITOR (RO-4-4602), COMBINED WITH L-DOPA, ON RETARDED DEPRESSIVE PATIENTS.
079965 09-13
PROPOSALS FOR IMPROVING THE TREATMENT OF BRAIN DAMAGED PATIENTS.
080041 09-11
CLINICAL EVALUATION IN 112 PSYCHIATRIC PATIENTS OF A BUTYROPHENONE NEUROLEPTIC, DEHYDROBENZPERIDOL (R-4749).
080142 09-11
DETECTION OF PSYCHOTOMIMETIC N,N DIMETHYLATED INDOLEAMINES IN THE URINE OF FOUR SCHIZOPHRENIC PATIENTS.
080506 09-08
FOLIC ACID IN FOLATE DEFICIENT PATIENTS WITH EPILEPSY.
080635 09-11
L-DOPA IN DEPRESSED PATIENTS.
081038 09-09
MEASUREMENT OF BEHAVIOURAL CHANGES IN PATIENTS ON L-DOPA.
081039 09-11
MENTAL SYMPTOMS IN PARKINSONIAN PATIENTS TREATED WITH L-DOPA.
081082 09-15
PIPERACETAZINE (QUIDE): A CONTROLLED EVALUATION OF THE ELIXIR IN CHRONIC SCHIZOPHRENIC PATIENTS.
082053 10-08
CLINICAL TRIAL OF CLOMACRAN PHOSPHATE (SKF-14336) IN CHRONIC PSYCHOTIC MALE PATIENTS.
082056 10-07
A SEQUENTIAL TRIAL OF AMYLOBARBITONE SODIUM USED AS SEDATION FOR CONFUSED FEMALE PSYCHOGERIATRIC PATIENTS.
082732 10-11
EFFECT OF WITHDRAWAL OF ANTIPARKINSONIAN MEDICATION ON CHRONICALLY HOSPITALIZED PSYCHIATRIC PATIENTS.
086445 10-15
DIBENZOXAZEPINE IN PSYCHOTIC PATIENTS.
086793 10-09
AN ATTEMPT TO ELIMINATE RESISTANCE TO AMINAZINE BY MALARIA THERAPY IN PATIENTS WITH PARANOID SCHIZOPHRENIA.
087312 10-16
RESULTS OF THE MEDICAL TREATMENT IN AGED PATIENTS WITH CEREBRAL ORGANIC DISTURBANCES.
087336 10-11
COMPARATIVE, DOUBLE-BLIND STUDY OF DOXEPINE AND LIBRIUM IN CASES OF PSYCHONEUROSES WITH ANXIETY AMONG HOSPITALIZED AND AMBULATORY PATIENTS.
087489 10-10
A POLYGRAPHIC STUDY OF THE NIGHT SLEEP OF PARKINSONIAN PATIENTS: EFFECTS OF TREATMENT WITH LEVODOPA.
087658 10-14
RELATIONSHIP BETWEEN TASTE THRESHOLD FOR DRUGS AND CLINICAL PROGRESS IN A MIXED GROUP OF PSYCHIATRIC PATIENTS.
087866 10-11
FLUPHENAZINE: A RETROSPECTIVE ASSESSMENT IN 130 PATIENTS WITH RESIDUAL SCHIZOPHRENIA.
088951 10-08
ELECTRON MICROSCOPY. SUDDEN DEATH IN PATIENTS UNDER PHENOTHIAZINE THERAPY: STUDY OF THREE CASES.
090359 11-15
PSYCHIC EFFECTS IN PATIENTS TREATED WITH LEVODOPA.
091919 11-11
PSYCHIATRIC CHANGES IN PATIENTS TREATED WITH LEVODOPA: I. THE CLINICAL EXPERIMENT.
092917 11-10
SLEEP IN PATIENTS WITH PARKINSONS DISEASE AND NORMAL SUBJECTS PRIOR TO AND FOLLOWING LEVODOPA ADMINISTRATION.
092974 11-11
EFFECT OF NICOTINIC ACID COMBINED WITH A TRANQUILLIZER (HYDROXYZINE) ON SERUM LIPID LEVELS AND URINARY CATECHOLAMINE EXCRETION IN GERIATRIC PATIENTS.
093689 11-11
THE EFFECTIVENESS OF SIMULTANEOUS TREATMENT WITH VITAMIN-B12 AND INSULIN IN SCHIZOPHRENIC PATIENTS, ACCORDING TO THE FREQUENCY OF STABLE REMISSIONS.
096513 11-08
A SEVENTH-MONTH DOUBLE-BLIND TRIAL OF AMITRIPTYLINE AND DIAZEPAM IN ECT TREATED DEPRESSED PATIENTS.
097562 11-09
CLINICOELECTROENCEPHALOGRAPHIC EVALUATION OF A NEW BENZODIAZEPINIC DERIVATIVE (RO-5-4023) ADMINISTERED ORALLY IN EPILEPTIC PATIENTS USING A DOUBLE-BLIND METHOD.
100959 12-07
CLINICAL TESTING WITH FLUPHENAZINE DEPOT ADMINISTRATION TO SCHIZOPHRENIC PATIENTS.
101034 12-07
PSYCHOSOCIAL PROFILES OF PATIENTS ON LITHIUM TREATMENT.
106762 12-14
LITHIUM DROP-OUTS: A FOLLOW-UP STUDY OF PATIENTS WHO DISCONTINUED PROPHYLACTIC TREATMENT.
106771 12-09
THE COURSE OF RECURRENT DEPRESSIVE ILLNESS IN SELECTED PATIENTS FROM A DEFINED POPULATION.
106781 12-09
A LONG-ACTING NEUROLEPTIC IN THE TREATMENT OF CHRONIC ALCOHOLISM IN NEUROTIC AND PSYCHOTIC PATIENTS.
109255 12-11

USE OF MELLERIL RETARD IN TREATMENT OF PATIENTS WITH DEPRESSIVE PARANOID AND ANXIOUS DEPRESSIVE SYNDROMES. 109724 12-14
CONCERNING THE ARTICLE BY N.N.TIMOFEYEV, V.T.KONDRASHENKO AND N.Y.NEMTSEVA ON OXYMETRIC INVESTIGATION OF PATIENTS WITH SCHIZOPHRENIA AND REACTIVE PSYCHOSIS DURING NEUROLEPTIC TREATMENT. 109788 12-08
EXPERIMENTAL USE OF PREPARATION LUVATREN IN SCHIZOPHRENIC PATIENTS. 111022 12-08
USE OF NEUROLEPTICS FOR VITAL INDICATORS IN PATIENTS WITH SEVERE SOMATIC STATES. 111028 12-11
USE OF NEULEPTIL IN TREATMENT OF PATIENTS WITH SCHIZOPHRENIA. 111031 12-08
CHEMICAL AND CLINICAL EVALUATION OF THE USE OF GABOB IN SCHIZOPHRENIC PATIENTS. 114885 12-08
INFLUENCES OF POLYPHARMACY ON HALLUCINATORY BEHAVIOR IN A SAMPLE OF FEMALE CHRONIC SCHIZOPHRENIC PATIENTS. 115037 12-08
COEXISTENCE OF DIABETES-MELLITUS AND MYXEDEMA IN MENTAL PATIENTS. 116482 12-08
USE OF CATTELS IPAT ANXIETY SCALE IN A GROUP OF NEUROTIC PATIENTS BEFORE AND AFTER PSYCHOPHARMACOLOGICAL DRUG AND ELECTRIC SHOCK THERAPY. 128509 12-17
THIOTHIXENE IN HOSPITALIZED CHRONIC SCHIZOPHRENIC PATIENTS. 134906 12-08

**PATTERN**
EFFECTS OF AMPHETAMINE UPON RELEARNING PATTERN AND BLACK WHITE DISCRIMINATIONS FOLLOWING NEOCORTICAL LESIONS IN RATS. 065419 05-04
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: I. SEIZURE AND POST-SEIZURE ELECTROENCEPHALOGRAPHIC PATTERN. 065850 05-11
THE EFFECT OF CENTROPHENOXINE ON EEG VIGILANCE IN THE COURSE OF SLEEP DEPRIVATION AND ON THE EEG PATTERN OF ALL-NIGHT SLEEP. 070934 07-14

**PATTERNS**
HYPNOTICS AND ALTERED SLEEP DREAM PATTERNS: I. ALL-NIGHT EEG STUDIES OF GLUTETHIMIDE, METHYPRYLON, AND PENTOBARBITAL. 066233 05-14
HYPNOTICS AND ALTERED SLEEP DREAM PATTERNS: II. ALL-NIGHT EEG STUDIES OF CHLORAL HYDRATE, FLURAZEPAM, AND METHAQUALONE. 066234 05-14
A COMPARISON OF SLEEP PATTERNS IN NATURAL AND MANDRAX AND TUINAL INDUCED SLEEP. 067864 06-14
COMPARISON OF THE PAROXYSMAL DYSKINESIAS (NEURODYSLEPSY) INDUCED BY THE NEUROLEPTICS IN MAN AND THE EARLIEST BEHAVIOR PATTERNS OF THE NEW-BORN. 070267 07-13
POLYPHARMACY IN PSYCHIATRY: PATTERNS OF DIFFERENTIAL TREATMENT. 075332 08-11
EFFECT OF ARGININE N-ACETYLASPARAGINATE ON DIFFERENT PATTERNS OF DISCRIMINATION. 098049 11-04
PREMORBID ADJUSTMENT, PARANOID STATUS, AND PATTERNS OF RESPONSE TO PHENOTHIAZINE IN ACUTE SCHIZOPHRENIA. 103255 12-08
BEHAVIORAL TOXICITY. PART 5: GROSS BEHAVIOR PATTERNS. 105560 12-15

**PA2**
QUANTITATION OF THE DEGREE OF ANTAGONISM OF CHLOROQUINE TO HISTAMINE, ACETYLCHOLINE AND SEROTONIN ( PA2 VALUES). 067462 06-03

**PCPA**
THE EFFECT OF P-CHLOROPHENYLALANINE (PCPA) ON SHOCK INDUCED FIGHTING BEHAVIOR IN RATS. 062853 03-03

**PECKING**
AUTOMATIC MONITORING OF APOMORPHINE INDUCED PECKING IN PIGEONS. 075922 09-04

**PEDIATRICS**
SULPIRIDE IN PEDIATRICS. 072157 07-07

**PEMOLINE**
MAGNESIUM PEMOLINE: SPECIFICITY OF EFFECTS ON INSTRUMENTAL AVOIDANCE LEARNING. 058430 02-04
COMPARISON OF PMH AND PEMOLINE ACTIVITY AFTER ELECTROCONVULSIVE SHOCK. 058992 03-04
THE EFFECT OF MAGNESIUM PEMOLINE ON DISCRIMINATION LEARNING AND EXPLORATORY BEHAVIOR. 059567 03-04
PEMOLINE AND METHYLPHENIDATE IN MILDLY DEPRESSED OUTPATIENTS. 066709 05-10
EFFECTS OF SODIUM DIPHENYLHYDANTOINATE AND PEMOLINE UPON CONCENTRATION: A COMPARATIVE STUDY. 070973 07-14
THE EFFECT OF MAGNESIUM PEMOLINE, TRICYANOAMINOPROPENE AND D-AMPHETAMINE ON DISCRIMINATED AVOIDANCE PERFORMANCE IN RATS AS A FUNCTION OF AGE. 076133 09-04

**PEMOLINUM**
TEST OF PEMOLINUM IN COMPLEX TREATMENT OF ALCOHOLISM. 086958 10-11

**PENFLURIDOL**
LONG-ACTING NEUROLEPTICS: III. PILOT STUDY OF PENFLURIDOL (R-16341). 069070 06-07

**PENICILLAMINE**
TREATMENT OF WILSONS DISEASE WITH L-DOPA AFTER FAILURE WITH PENICILLAMINE. 058243 02-11

**PENICILLIN**
PENICILLIN INDUCED EPILEPTOGENIC FOCI IN THE RAT CORTEX. 075197 08-04

**PENTAZOCINE**
HALLUCINATIONS FOLLOWING PENTAZOCINE. 058442 02-15
ACUTE ORGANIC PSYCHOSIS DUE TO TALWIN (PENTAZOCINE). 058951 02-15
THE EFFECT OF MORPHINE, NALORPHINE, NALOXONE, PENTAZOCINE, CYCLAZOCINE AND OXOTREMORINE ON THE SYNTHESIS AND RELEASE OF ACETYLCHOLINE BY MOUSE CEREBRAL CORTEX SLICES IN VITRO. 058994 03-03

**PENTOBARBITAL**
PLACENTAL TRANSFER OF PENTOBARBITAL IN THE RAT. 058572 02-05
THE REVERSAL OF DEVELOPED TOLERANCE TO PENTOBARBITAL BY ETHYL ALCOHOL. 058995 03-03
ELECTROCORTICAL REACTIONS OF PINEALECTOMIZED AND INTACT RATS TO LETHAL DOSES OF PENTOBARBITAL. 064101 04-03
DEVELOPMENT OF TOLERANCE TO PENTOBARBITAL. 064263 04-03
EFFECTS OF CHLORDIAZEPOXIDE AND PENTOBARBITAL ON CONFLICT BEHAVIOR IN RATS. 064390 04-04
HYPNOTICS AND ALTERED SLEEP DREAM PATTERNS: I. ALL-NIGHT EEG STUDIES OF GLUTETHIMIDE, METHYPRYLON, AND PENTOBARBITAL. 066233 05-14
PENTOBARBITAL INDUCED STATE-DEPENDENT LEARNING OF ONE-WAY AVOIDANCE IN MICE. 075288 08-04

**PENTOBARBITONE**
EFFECTS OF MORPHINE AND PENTOBARBITONE ON ACETYLCHOLINE SYNTHESIS BY RAT CEREBRAL CORTEX. 064288 04-03
EFFECTS OF PENTOBARBITONE AND CHLORPROMAZINE ON ACOUSTICALLY EVOKED POTENTIALS IN THE RAT. 074939 08-03

**PENTOSE**
HEXOSE AND PENTOSE PHOSPHATES IN BRAIN DURING CONVULSIONS. 072119 07-03

**PENTYLENETETRAZOL**
UPTAKE OF (14C) PENTYLENETETRAZOL BY DEVELOPING RAT BRAIN. 067120 06-02
PENTYLENETETRAZOL AND ETHAMIVAN EFFECTS ON BRAIN SEROTONIN METABOLISM. 067613 06-03
IN VIVO EVALUATION OF ABSORPTION AND EXCRETION OF PENTYLENETETRAZOL -10-14C FROM SUSTAINED-RELEASE AND NONSUSTAINED-RELEASE TABLETS. 090427 11-13

**PEOPLE**
INFLUENCE OF AMINAZIN ON ADRENALIN, NORADRENALINE, DOPAMINE, AND DOPA EXCRETION IN HEALTHY PEOPLE AND IN THE MANIC PHASE OF THE MANIC-DEPRESSIVE PSYCHOSIS. 090355 11-03

**PERAZINE**
EXPERIMENTAL PSYCHOLOGICAL STUDY OF PERFORMANCE CHANGES WITH PERAZINE (TAXILAN) IN MENTALLY DISTURBED AND IN

HEALTHY EXPERIMENTAL SUBJECTS FOLLOWING REGIMEN AND SINGLE DOSE ADMINISTRATION.
058235 02-11

**PERCEPTUAL**
WORTHINGTON AND PERCEPTUAL DEFENSIVENESS.
082410 10-14
A NOTE ON TRANQUILLIZERS AND PERCEPTUAL DEFENSIVENESS.
082411 10-14
BEHAVIORAL TOXICITY. PART 3: PERCEPTUAL COGNITIVE FUNCTIONS AND PART 4: EMOTIONAL (MOOD) STATES.
100523 12-15
PREDICTION AND MEASUREMENT OF PERCEPTUAL BEHAVIORAL CHANGE IN DRUG-INDUCED HALLUCINATIONS.
121086 12-12

**PERCHANCE**
TO SLEEP, PERCHANCE TO DREAM: NEW DRUG FOR INSOMNIACS DOESNT INTERFERE WITH REM TIME.
068021 06-14

**PERFORMANCE**
EFFECT OF AMPHETAMINE, NICOTINE AND HEXAMETHONIUM ON PERFORMANCE OF A CONDITIONED RESPONSE DURING ACQUISITION AND RETENTION TRIALS.
046186 01-04
EXPERIMENTAL PSYCHOLOGICAL STUDY OF PERFORMANCE CHANGES WITH PERAZINE (TAXILAN) IN MENTALLY DISTURBED AND IN HEALTHY EXPERIMENTAL SUBJECTS FOLLOWING REGIMEN AND SINGLE DOSE ADMINISTRATION.
058235 02-11
PERSONALITY TRAIT DEPENDENT PERFORMANCE UNDER PSILOCYBIN (PART II).
058454 02-12
LYSERGIC ACID DIETHYLAMIDE, CHLORPROMAZINE AND MAZE PERFORMANCE.
058997 03-04
IMPROVED CEREBRAL CIRCULATION AND PERFORMANCE IN A PSYCHOLOGICAL EXPERIMENT.
059001 03-11
CHLORPROMAZINE, CHLORDIAZEPOXIDE, AND THE INCENTIVE SHIFT PERFORMANCE IN THE RAT.
060275 03-04
PERSONALITY TRAIT DEPENDENT PERFORMANCE UNDER PSILOCYBIN.
064323 04-12
MODIFICATION OF THE EFFECTS OF ANTIPSYCHOTIC AGENTS ON THE OPEN FIELD PERFORMANCE OF RATS BY TREATMENT WITH ALPHA-METHYLTYROSINE OR P-CHLOROPHENYLALANINE.
064392 04-04
THE EFFECTS OF CENTRALLY AND PERIPHERALLY ACTING CHOLINERGIC DRUGS ON THE SHORT-TERM PERFORMANCE GRADIENT FOLLOWING PASSIVE AVOIDANCE TRAINING.
064412 04-04
ROLE OF MONKEYS SPATIAL PREFERENCES IN PERFORMANCE OF A NONSPATIAL TASK.
065420 05-04
ON SIMILAR LINGUISTIC STRUCTURES IN CREATIVE PERFORMANCE AND PSILOCYBIN INDUCED EXPERIENCE.
065433 05-12
EFFECTS OF CHLORDIAZEPOXIDE ON DISCRIMINATIVE FEAR CONDITIONING AND SHUTTLE AVOIDANCE PERFORMANCE IN THE RABBIT.
065451 05-04
DIFFERENTIAL EFFECTS OF AMPHETAMINE AND SCOPOLAMINE ON MATCHING PERFORMANCE OF MONKEYS WITH LATERAL FRONTAL LESIONS.
065747 05-04
COMPARATIVE EFFECTS OF SMOKING MARIHUANA OR PLACEBO ON HUMAN MOTOR AND MENTAL PERFORMANCE.
069579 07-14
THE USE OF STIMULANT DRUGS IN ENHANCING PERFORMANCE AND LEARNING.
070971 07-17
COMBINED EFFECTS OF CHLORPROMAZINE AND ALTITUDE UPON PERFORMANCE IN THE RAT.
071467 07-04
A CHOICE TECHNIQUE TO ASSESS THE EFFECTS OF SELECTIVE PUNISHMENT ON FIXED-RATIO PERFORMANCE.
075579 08-04
THE EFFECT OF MAGNESIUM PEMOLINE, TRICYANOAMINOPROPENE AND D-AMPHETAMINE ON DISCRIMINATED AVOIDANCE PERFORMANCE IN RATS AS A FUNCTION OF AGE.
076133 09-04
TESTING THE PERFORMANCE UNDER APONEURON OF OTHERWISE NORMAL SCHOOL CHILDREN WITH A TENDENCY TOWARD REDUCED DRIVE AND EASY TIRING.
080563 09-11
THE EFFECT OF PSYCHOSTIMULANTS ON PSYCHOMETRIC TEST PERFORMANCE WITH SPECIAL REFERENCE TO CONFLICT AVOIDANCE BEHAVIOR.
082055 10-04
THE PERFORMANCE OF LSD USERS ON CERTAIN NEUROPSYCHOLOGICAL TESTS. (PH.D. DISSERTATION).
135186 12-14

**PERFUSED**
EFFECTS OF METABOLIC INHIBITORS ON NOREPINEPHRINE RELEASE FROM THE PERFUSED SPLEEN OF THE CAT.
040244 01-03
METABOLISM AND BILIARY EXCRETION OF THE LIPOPHILIC DRUG MOLECULES, IMIPRAMINE AND DESMETHYLIMIPRAMINE IN THE RAT - I. EXPERIMENTS IN VIVO AND WITH ISOLATED PERFUSED LIVERS.
067260 06-03
EFFECT OF INTERMITTENT NERVE STIMULATION ON NOREPINEPHRINE SYNTHESIS AND MOBILIZATION IN THE PERFUSED CAT SPLEEN.
080337 09-01
ON THE UPTAKE OF PHENOTHIAZINE DERIVATIVES BY THE ISOLATED PERFUSED RAT BRAIN.
089043 10-03
U-14C TYROSINE METABOLISM OF THE PERFUSED CAT BRAIN WITH HIGH PLASMA PHENYLALANINE OR WITHOUT PLASMA TYROSINE.
100852 12-03

**PERIACTIN**
CYPROHEPTADINE HYDROCHLORIDE (PERIACTIN) AND ANOREXIA-NERVOSA: A CASE REPORT.
078931 09-07

**PERICYAZINE**
PERICYAZINE IN CLINICAL PRACTICE.
086453 10-17

**PERINATAL**
PERINATAL DEVELOPMENT OF DRUG METABOLIZING ENZYME ACTIVITY IN SWINE.
066368 05-03

**PERIODIC**
PSEUDOPREGNANCY, TREATMENT OF PERIODIC PSYCHIATRIC ILLNESS: A PILOT STUDY.
068215 06-09
OCCURRENCE OF PERIODIC PSYCHOSES DURING PROPHYLACTIC ADMINISTRATION OF LITHIUM.
070950 07-08
A STUDY OF PHARMACODYNAMICS IN PERIODIC CONDITIONAL PROCESSES IN ALBINO RATS.
112003 12-04

**PERIPHERAL**
L-DOPA INDUCED CHANGES IN CENTRAL MONOAMINE NEURONS AFTER PERIPHERAL DECARBOXYLASE INHIBITION.
059033 03-03
ADMINISTRATION OF A PERIPHERAL DECARBOXYLASE INHIBITOR WITH L-DOPA TO DEPRESSED PATIENTS.
067591 06-09
EVALUATION OF THE PERIPHERAL AND CENTRAL ANTAGONISTIC ACTIVITIES AGAINST 5-HYDROXYTRYPTAMINE OF SOME NEW AGENTS.
067603 06-03
CENTRAL AND PERIPHERAL EFFECTS OF ANTICHOLINERGIC COMPOUNDS.
072524 08-04
UPTAKE OF TRITIATED TESTOSTERONE IN BRAIN AND PERIPHERAL TISSUES OF NORMAL AND NEONATALLY ANDROGENIZED FEMALE RATS.
076086 09-04

**PERIPHERALLY**
THE EFFECTS OF CENTRALLY AND PERIPHERALLY ACTING CHOLINERGIC DRUGS ON THE SHORT-TERM PERFORMANCE GRADIENT FOLLOWING PASSIVE AVOIDANCE TRAINING.
064412 04-04

**PERMEABILITY**
PERMEABILITY OF THE BLOOD BRAIN BARRIER TO PARENTERAL 5-HYDROXYTRYPTAMINE IN THE NEONATE CHICK.
067253 06-04

**PERMEATION**
PERMEATION CHARACTERISTICS OF MORPHINE-LIKE SUBSTANCES AFTER INJECTION INTO BRAIN TISSUE AND INTO THE VENTRICULAR SYSTEM.
089047 10-03

**PERPHENAZINE**
DISTRIBUTION, EXCRETION, AND METABOLISM OF 14C-LABELED QUATERNARY AMMONIUM SALT OF PERPHENAZINE IN RATS.
064261 04-03
PERPHENAZINE AMITRIPTYLINE IN NEUROTIC DEPRESSED OUTPATIENTS; A CONTROLLED COLLABORATIVE STUDY.
065247 05-10
A COMPARISON OF TRIPERIDOL AND PERPHENAZINE IN SCHIZOPHRENIA. EFFECTS ON MYOCLONIC THRESHOLD.
070935 07-08
A COMPARISON OF THE EFFECTS OF METHYLPERIDOL AND PERPHENAZINE IN SCHIZOPHRENIC PSYCHOSIS.
070936 07-08
A CONTROLLED STUDY OF THE EFFECT OF THIOTHIXENE AND PERPHENAZINE IN PSYCHOSES AND SCHIZOPHRENIA.
070938 07-08
A CONTRIBUTION TO THE DEPRESSIVE DISORDER PHARMACOTHERAPY BY THE COMBINATION OF AMITRIPTYLINE AND PERPHENAZINE.
073707 08-10

THE USE OF TWO COMBINATIONS OF DRUGS WITH MIXED ACTION, ANTIDEPRESSIVE AND TRANQUILIZING (AMITRYPTILINE - PERPHENAZINE) IN GENERAL AND IN PSYCHOSOMATIC MEDICINE.
089162 10-17

EVALUATION OF AN AMITRIPTYLINE PERPHENAZINE COMBINATION IN CHRONIC SCHIZOPHRENIA.
101681 12-08

**PERSEVERANCE**

AN APPARATUS FOR OBSERVING ATTENTION AND PERSEVERANCE.
086161 10-16

**PERSISTENCE**

CONDITIONED NALORPHINE INDUCED ABSTINENCE CHANGES: PERSISTENCE IN POST MORPHINE DEPENDENT MONKEYS.
061632 03-04

PERSISTENCE OF RELAPSE TENDENCIES OF RATS PREVIOUSLY MADE PHYSICALLY DEPENDENT ON MORPHINE.
062940 03-04

PERSISTENCE OF DOSE RELATED BEHAVIOUR IN MICE.
067606 06-04

PERSISTENCE OF A DRUG PERSONALITY INTERACTION IN PSYCHIATRIC OUTPATIENTS.
075873 09-14

**PERSISTENT**

PERSISTENT BEHAVIOURAL AND ELECTROENCEPHALOGRAPHIC CHANGES AFTER SINGLE DOSES OF NITRAZEPAM AND AMYLOBARBITONE SODIUM.
068005 06-14

PERSISTENT EXTRAPYRAMIDAL ORAL DYSKINESIAS FOLLOWING TREATMENT WITH THYMOLEPTICS.
070945 07-15

THE SIGNIFICANCE OF BRAIN DAMAGE IN PERSISTENT ORAL DYSKINESIA.
075416 08-15

TREATMENT OF PERSISTENT PHENOTHIAZINE INDUCED ORAL DYSKINESIA.
075417 08-15

SEVERE PERSISTENT CHOREA WITH PHENOTHIAZINE THERAPY: REPORT OF A CASE.
079915 09-15

NEUROPATHOLOGY OF PERSISTENT CHOREIFORM HYPERKINESIAS UNDER LONG-TERM TREATMENT WITH NEUROLEPTICS.
101020 12-15

**PERSONAL**

FIRST ORIENTATIONS ON THE USE OF HIGH DOSES OF OXAZEPAM, BASED ON PERSONAL CLINICAL THERAPEUTIC EXPERIENCE.
124308 12-10

**PERSONALITY**

DRUG PERSONALITY INTERACTION IN INTENSIVE OUTPATIENT TREATMENT.
047836 01-10

PERSONALITY DIFFERENCES IN THE RESPONSE TO STIMULANT DRUGS ADMINISTERED DURING A SLEEP DEPRIVED STATE.
052502 02-14

PERSONALITY TRAIT DEPENDENT PERFORMANCE UNDER PSILOCYBIN (PART II).
058454 02-12

GEORGE: A MAN WITH AN INADEQUATE PERSONALITY.
059100 03-10

DRUGS: PERSONALITY::PERSONALITY: DRUGS.
060280 03-14

PERSONALITY TRAIT DEPENDENT PERFORMANCE UNDER PSILOCYBIN.
064323 04-12

OBJECTIVE EFFECTS OF DEXAMPHETAMINE AND AMOBARBITAL AND THEIR RELATIONS TO PSYCHASTHENIC PERSONALITY TRAITS.
064389 04-14

EFFECTS OF DIFFERENT SEDATIVES ON SELF-RATINGS DEPENDING ON SEX AND PERSONALITY.
072588 08-14

PATIENT PERSONALITY AND DEMOGRAPHIC FACTORS AS PREDICTORS OF EARLY RESPONSE TO PSYCHOTROPIC DRUG TREATMENT.
074130 08-10

THE CONTRACEPTIVE PILL, SIDE-EFFECTS AND PERSONALITY: REPORT OF A CONTROLLED DOUBLE-BLIND TRIAL.
075472 08-15

PERSISTENCE OF A DRUG PERSONALITY INTERACTION IN PSYCHIATRIC OUTPATIENTS.
075873 09-14

ON THE QUESTION OF PERSONALITY DEFECTS OF CONSCIOUSNESS IN INITIAL STAGES IN SCHIZOPHRENIA.
090264 11-08

**PERSPECTIVES**

PSYCHOTROPIC DRUG SIDE-EFFECTS: CLINICAL AND THEORETICAL PERSPECTIVES.
100516 12-15

THIORIDAZINE AND BEHAVIOR DISORDERS (PERSPECTIVES FOR THE USE OF THE DRUG IN CRIMINOLOGY).
124320 12-17

**PERUVIAN**

SOMAPSYCHIC RELATIONS IN MEDICINE: SESSION OF HOMAGE OF THE PERUVIAN ACADEMY OF MEDICINE TO PROFESSOR HONORIO DELGADO.
094610 11-14

**PETHIDINE**

ACTION OF CODEINE, PETHIDINE AND METHADONE ON THE OPERANT BEHAVIOR OF THE RAT.
071787 07-04

**PEYOTE**

BIOSYNTHESIS OF PHENOLIC TETRAHYDROISOQUINOLINE ALKALOIDS OF PEYOTE.
069804 07-01

**PHARMACEUTICAL**

SPECTROPHOTOMETRIC DETERMINATION OF CHLORPROMAZINE IN PHARMACEUTICAL DOSAGE FORMS.
064262 04-06

PSYCHOTROPIC DRUG THERAPY AND THE PHARMACEUTICAL INDUSTRY.
079987 09-17

**PHARMACODYNAMICS**

PHARMACODYNAMICS OF 3,4 DIHYDROXYPHENYLALANINE (DOPA) IN PARKINSONS DISEASE.
063845 04-15

A STUDY OF PHARMACODYNAMICS IN PERIODIC CONDITIONAL PROCESSES IN ALBINO RATS.
112003 12-04

**PHARMACOKINETICS**

ON THE DISTRIBUTION AND METABOLISM OF NEUROLEPTIC DRUGS. PART 2: PHARMACOKINETICS OF MOPERONE.
072589 08-03

DISTRIBUTION AND METABOLISM OF NEUROLEPTIC DRUGS: PART I: PHARMACOKINETICS OF HALOPERIDOL.
079968 09-03

**PHARMACOLOGIC**

A COMPARATIVE STUDY OF THE PHARMACOLOGIC ACTIONS OF AMPHETAMINE AND FENFLURAMINE.
058996 03-05

THE INTERACTION OF PSYCHOLOGIC STIMULI AND PHARMACOLOGIC AGENTS ON AIRWAY REACTIVITY IN ASTHMATIC SUBJECTS.
063515 03-13

AN EVALUATION OF THE PHARMACOLOGIC APPROACHES TO LEARNING IMPEDIMENTS.
066838 05-14

BIOCHEMICAL AND PHARMACOLOGIC STUDIES OF DYSTONIA.
069852 07-13

PHARMACOLOGIC ACTIVITY OF A NEW CLASS OF AGENTS WHICH SELECTIVELY INHIBIT AGGRESSIVE BEHAVIOR IN RATS.
082398 10-04

PSYCHODYNAMICS OF THE RESPONSE TO PHARMACOLOGIC TREATMENT WITH NEUROLEPTICS IN SCHIZOPHRENICS.
105623 12-08

**PHARMACOLOGICAL**

ANALOGS OF ALPHA-METHYLPHENETHYLAMINE (AMPHETAMINE). I. SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF SOME METHOXY AND/OR METHYL ANALOGS.
038488 01-04

PHARMACOLOGICAL SIGNIFICANCE OF BIOGENIC AMINES IN THE LUNGS: NORADRENALINE AND DOPAMINE.
041539 01-03

PHARMACOLOGICAL SIGNIFICANCE OF BIOGENIC AMINES IN THE LUNGS: 5-HYDROXYTRYPTAMINE.
041565 01-03

PHARMACOLOGICAL AND BEHAVIORAL STUDIES OF STP: RELATIONSHIP TO TISSUE DISTRIBUTION.
046198 01-03

PHARMACOLOGICAL COMPARISON OF R(-), S(-) AND RACEMIC SECOBARBITAL IN MICE.
047325 01-03

RELATIONSHIPS BETWEEN STEREOSTRUCTURE AND PHARMACOLOGICAL ACTIVITIES.
051116 01-17

PHARMACOLOGICAL, TOXICOLOGICAL, AND TERATOLOGICAL STUDIES ON DIPOTASSIUM 7-CHLORO-3-CARBOXY 1,3-DIHYDRO-2,2-DIHYDROXY-5-PHENYL-2H-1,4 BENZODIAZEPINE CHLORAZEPATE (DIPOTASSIUM CHLORAZEPATE, 4306-CB), A NEW TRANQUILLIZER.
055581 02-03

PHARMACOLOGICAL STUDIES ON A NEW SPECIFICALLY POTENT ANTITUSSIVE AGENT, 14-HYDROXYDIHYDRO-6-BETA-THEBAINOL-4-METHYLETHER (OXYMETHEBANOL).
055585 02-03

PHARMACOLOGICAL STUDIES ON THE ACTION OF SYNTHETIC ALPHA-METHYL-PYRRYL-KETONE ON THE CNS AND ON CIRCULATION.
055740 02-03

PHARMACOLOGICAL REDUNDANCY AS AN ADAPTIVE MECHANISM IN THE CENTRAL NERVOUS SYSTEM.
056113 02-13

PHARMACOLOGICAL PROPERTIES OF SU-19789B, A UNIQUE CENTRAL NERVOUS SYSTEM STIMULANT.
058989 03-03
PHARMACOLOGICAL AND CLINICAL PROBLEMS OF LITHIUM PROPHYLAXIS.
060264 03-17
NEUROCHEMICAL STUDIES OF THE AFFECTIVE DISORDERS: THE PHARMACOLOGICAL BRIDGE.
061683 03-09
A BEHAVIORAL AND PHARMACOLOGICAL ANALYSIS OF REINFORCEMENT WITHDRAWAL.
062942 03-04
SIMILARITIES BETWEEN BEHAVIORAL AND PHARMACOLOGICAL ACTIONS OF YOHIMBINE AND 5-HYDROXYTRYPTOPHAN IN THE CONSCIOUS DOG.
064253 04-04
STRUCTURE-ACTIVITY RELATIONSHIP OF FOUR TETRAHYDROCANNABINOLS AND THE PHARMACOLOGICAL ACTIVITY OF FIVE SEMI-PURIFIED EXTRACTS OF CANNABIS-SATIVA.
064417 04-04
PHARMACOLOGICAL AND DYNAMIC FACTORS IN PSYCHOTROPIC DRUG THERAPY.
065409 05-15
(3H)HARMALINE DISTRIBUTION IN MONKEY BRAIN; PHARMACOLOGICAL AND AUTORADIOGRAPHIC STUDY.
067081 05-03
THE PHARMACOLOGICAL EFFECTS OF OUABAIN ADMINISTERED INTRACEREBRALLY TO CONSCIOUS MICE.
068165 06-03
COMPARATIVE PHARMACOLOGICAL STUDY OF NEUROLEPTICS IN RODENTS.
070926 07-02
BODY CONSCIOUSNESS IN STATES OF PHARMACOLOGICAL DEPRESSION AND AROUSAL.
072032 07-14
ABSORPTION AND PHARMACOLOGICAL ACTIVITIES OF A NEW DIAZEPAM PREPARATION.
072586 08-03
THE PHARMACOLOGICAL APPROACH TO ALCOHOLISM -- PART 2.
081072 09-17
PHARMACOLOGICAL ASPECTS OF DRUG ABUSE.
085613 10-17
PHARMACOLOGICAL IMPLICATIONS OF THE EFFECTS OF AMPHETAMINE AND ITS ANALOGUES ON THE TURNOVER RATE OF TISSUE CATECHOLAMINES (UNPUBLISHED PAPER).
088392 10-03
PHARMACOLOGICAL DECONDITIONING.
091110 11-10
PHARMACOLOGICAL ASSOCIATION OF THIORIDAZINE HYDERGINE IN PSYCHOEMOTIONAL TROUBLES OF THE AGED.
091138 11-14
PHARMACOLOGICAL MANAGEMENT OF CHARACTER TYPE BEHAVIOR DISTURBANCES IN THE INFANT AND CHILD.
093090 11-07
CLINICAL AND PHARMACOLOGICAL CONTRIBUTION TO THE STUDY OF ALCOHOL IMIPRAMINE AND ALCOHOL THIOPROPERAZINE ASSOCIATIONS.
094305 11-11
A PHARMACOLOGICAL STUDY OF THE ANTIMUSCARINIC ACTIONS OF SEVERAL ANTIDEPRESSANTS. (PH.D.DISSERTATION).
104737 12-03
5-HYDROXYTRYPTOPHAN PRODUCED HYPOTHERMIA IN MICE AS A TEST FOR PHARMACOLOGICAL DIFFERENTIATION OF ANTIDEPRESSANTS, ANTICHOLINERGICS AND NEUROLEPTICS: SOME DATA ON THE NATURE OF THIS HYPOTHERMIA.
105622 12-06
PHARMACOLOGICAL STUDIES OF OXAZOLAZEPAM, A NEW PSYCHOTROPIC AGENT - I. ACTIONS ON THE CENTRAL NERVOUS SYSTEM, ESPECIALLY ON THE BEHAVIORAL OBSERVATION.
114769 12-02
PHARMACOLOGICAL STUDIES OF OXAZOLAZEPAM, A NEW PSYCHOTROPIC AGENT -- II. GENERAL PHARMACOLOGY AND SUBACUTE TOXICITY.
114835 12-07
PHARMACOLOGICAL BASIS OF ANTIDEPRESSANT EFFECTS.
118730 12-09
DEPRESSIVE STATES AS A PHARMACOLOGICAL TARGET.
122378 12-17
STUDIES ON PSYCHOTROPIC DRUGS (FIFTH REPORT) -- PHARMACOLOGICAL EFFECT OF 8(3-(2-CHLORO-10-PHENOTHIAZINYL)PROPYL)-1 THIADIAZASPIRODECAN-3-ONE HYDROCHLORIDE (APY-606).
131058 12-02

**PHARMACOLOGICALLY**
LESIONS IN CORPUS-STRIATUM AND CORTEX OF RAT BRAINS AND THE EFFECT ON PHARMACOLOGICALLY INDUCED STEREOTYPED, AGGRESSIVE AND CATALEPTIC BEHAVIOUR.
091127 11-04

**PHARMACOLOGISTS**
WHAT WE HAVE FORGOTTEN ABOUT POT -- A PHARMACOLOGISTS HISTORY.
081680 10-17

**PHARMACOLOGY**
HUMAN PHARMACOLOGY OF MARIHUANA (CANNABIS).
046202 01-13
RECENT ADVANCES IN THE PHARMACOLOGY OF MORPHINE-LIKE DRUGS.
046203 01-13
LITHIUM CARBONATE FOR AFFECTIVE DISORDERS. I. CLINICAL PHARMACOLOGY AND TOXICOLOGY.
047831 01-09
ANNUAL REVIEW OF PHARMACOLOGY.
051111 01-17
PHARMACOLOGY AND MEDICINE.
051112 01-17
PHARMACOLOGY OF VIRUSES.
051120 02-17
DEVELOPMENTAL PHARMACOLOGY.
051125 02-17
ON THE PHARMACOLOGY OF ISPROPYLIDENE-PROSCILLARIDIN.
055397 02-03
ON THE PHARMACOLOGY OF MARIHUANA.
058914 02-12
THE CLINICAL EVALUATION OF FOUR PROPOSED ANTIDEPRESSANTS. RELATIONSHIP TO THEIR ANIMAL PHARMACOLOGY.
059040 03-07
THE PROBLEM OF POT: PHARMACOLOGY AND CHEMISTRY.
059622 03-03
THE PHARMACOLOGY OF DISTURBED SLEEP.
063592 03-10
PHARMACOLOGY OF MEDAZEPAM AND METABOLITES.
063838 04-04
THE PHARMACOLOGY OF PRAZEPAM: A NEW BENZODIAZEPINE DERIVATIVE.
064181 04-04
CHEMISTRY AND PHARMACOLOGY OF FLUPHENAZINE DECANOATE.
065470 05-03
PHARMACOLOGY OF ALKYL AND HYDROXYALKYLPYRAZINES.
066497 05-03
THE BEHAVIORAL PHARMACOLOGY OF OXYPERTINE.
067175 06-08
PHARMACOLOGY OF THE ACTIVE PRINCIPLE OF BETEL.
067595 06-04
PHARMACOLOGY OF THE CENTRAL NERVOUS SYSTEM.
068949 06-03
NEW FINDINGS IN THE CLINICAL PHARMACOLOGY OF SLEEP.
070925 07-17
PHARMACOLOGY, LIMBIC REGULATION AND CORTICAL FUNCTION.
070979 07-04
CURRENT CONCEPTIONS ON CERTAIN ASPECTS OF THE PHARMACOLOGY OF NEUROLEPTICS.
074685 08-02
DRUGS IN PSYCHOLOGY: A COMMENTARY ON TRAVIS THOMPSON AND CHARLES R. SCHUSTERS BEHAVIORAL PHARMACOLOGY.
075793 08-14
THE PHARMACOLOGY OF DISORDERED SLEEP: A LABORATORY APPROACH.
084806 10-14
PRELIMINARY EXPERIMENTS ON THE CHEMISTRY AND PHARMACOLOGY OF CANNABIS.
086405 10-01
BIOCHEMICAL ASPECTS OF LITHIUM PHARMACOLOGY (UNPUBLISHED PAPER).
088356 10-09
FLUPHENAZINE ENANTHATE (MODITEN-RETARD N.D.): CHEMISTRY AND PHARMACOLOGY.
088997 10-03
CHEMISTRY AND PHARMACOLOGY OF A NEW POTENTIAL ANTIDEPRESSANT, N-METHYL-N-(4-CHLOROBENZYL-11-DIHYDRO-5H DIBENZAZEPIN-5-YL) PROPYLAMINE HYDROCHLORIDE) (LEO-640, LOPRAMINE HYDROCHLORIDE).
089786 11-01
PHARMACOLOGICAL STUDIES OF OXAZOLAZEPAM, A NEW PSYCHOTROPIC AGENT -- II. GENERAL PHARMACOLOGY AND SUBACUTE TOXICITY.
114835 12-07
STUDIES ON GENERAL PHARMACOLOGY OF L-DOPA.
114838 12-02
ESSENTIALS OF MOLECULAR PHARMACOLOGY: BACKGROUND FOR DRUG DESIGN.
115114 12-17
PARKINSONISM: PHYSIOLOGY, PHARMACOLOGY AND TREATMENT.
119840 12-17
BEHAVIORAL PHARMACOLOGY OF THE HALLUCINOGENS.
121087 12-14

**PHARMACOPSYCHOLOGICAL**
COMPARATIVE PHARMACOPSYCHOLOGICAL STUDY OF THE EFFECTS PRODUCED BY PSYCHOPHARMACEUTICALS ON VERBAL INTERACTION IN A GROUP OF STUDENTS.
066954 05-14
PHARMACOPSYCHOLOGICAL CONTRIBUTION TO THE CLINICAL USE OF A PSYCHOSEDATIVE.
092306 11-11

**PHARMACOTHERAPY**
THE PRACTICAL USE OF HIGHER NERVOUS ACTIVITY DATA IN THE PHARMACOTHERAPY OF PSYCHOSES.
062664 03-08
A CONTRIBUTION TO THE DEPRESSIVE DISORDER PHARMACOTHERAPY BY THE COMBINATION OF AMITRIPTYLINE AND PERPHENAZINE.
073707 08-10
THE PHARMACOTHERAPY SYSTEM.
075420 08-17
ANTIDEPRESSIVE PHARMACOTHERAPY.
086207 10-17
SOME OBSERVATIONS ON THE DYNAMICS OF THE DESTRUCTURING OF DELIRIUM DURING PHARMACOTHERAPY.
098033 11-17
PHARMACOTHERAPY OF TENSION AND ANXIETY.
126180 12-14

**PHENAMINE**
COMPARATIVE STUDY OF NATURAL SLEEP AND THE ACTION OF PHENAMINE AND CHLORPROMAZINE EVALUATION OF THE MEAN EXTREMES FREQUENCY OF ECOG IN CATS.
095655 11-14

**PHENCYCLIDINE**
SOME EFFECTS OF AN HALLUCINOGENIC DRUG (PHENCYCLIDINE) ON NEUROHUMORAL SUBSTANCES.
065436 05-12

**PHENELZINE**
THE EFFECT OF PHENELZINE AND TRANYLCYPROMINE ON THE DEGRADATION OF MEPERIDINE.
064421 04-03

**PHENETHYLAMINES**
AMPHETAMINE ANALOGS. II. METHYLATED PHENETHYLAMINES.
041907 01-02

**PHENIGAMA**
PARTICIPATION OF SEROTONIKERGIC PROCESSES IN THE ACTION OF PHENIGAMA.
105620 12-03

**PHENMETRAZINE**
MENTAL DISORDERS CAUSED BY PHENMETRAZINE ABUSE.
072893 08-15
A CASE OF PHENMETRAZINE ADDICTION.
087537 10-15

**PHENOBARBITAL**
LONG-TERM VARIATION IN BASAL AND PHENOBARBITAL STIMULATED OXIDATIVE DRUG METABOLISM IN THE RAT.
040671 01-03
THE EFFECTS OF PHENOBARBITAL ON EXOCRINE PANCREAS.
064180 04-03
CHANGES IN THE SERUM CONCENTRATION OF CHOLESTEROL, TRIGLYCERIDES AND PHOSPHOLIPIDS IN THE MOUSE AND RAT AFTER ADMINISTRATION OF EITHER CHLORCYCLIZINE OR PHENOBARBITAL.
064282 04-03
EFFECTS OF PHENOBARBITAL, PHENYLBUTAZONE, 3,4 BENZPYRENE, OR 3-METHYLCHOLANTHRENE ON ETHANOL METABOLISM IN THE RAT.
066498 05-03
PHENOBARBITAL WITHDRAWAL AND BEHAVIORAL DISRUPTION IN THE RAT.
069067 06-04
EFFECT OF PHENOBARBITAL ON THE IN VITRO METABOLISM OF DIAZEPAM IN SEVERAL ANIMAL SPECIES.
090134 11-03

**PHENOBARBITONE**
THE EFFECT OF DIET AND PHENOBARBITONE ON QUININE METABOLISM IN THE RAT AND IN MAN.
046187 01-13
CARBON MONOXIDE AND PHENOBARBITONE: A COMPARISON OF EFFECTS ON AUDITORY FLUTTER FUSION THRESHOLD AND CRITICAL FLICKER FUSION THRESHOLD.
070303 07-14

**PHENOLIC**
BIOSYNTHESIS OF PHENOLIC TETRAHYDROISOQUINOLINE ALKALOIDS OF PEYOTE.
069804 07-01

**PHENOLS**
INCREASED TRANSMITTER RELEASE INDUCED BY CONVULSANT PHENOLS.
081063 09-03

**PHENOMENA**
THE INFLUENCES OF THE STANDARD PREFRONTAL LOBOTOMY OPERATION ON HALLUCINATORY PHENOMENA ASSOCIATED WITH PSYCHOTOMIMETIC DRUGS.
120899 12-13
DISTURBANCES IN TRYPTAMINE SEROTONIN METABOLISM ASSOCIATED WITH PSYCHOTIC PHENOMENA.
121084 12-13
PSYCHOSENSORIAL PHENOMENA DURING TREATMENT WITH TRICYCLIC THYMOANALEPTICS (PRESENTATION OF TWO CASES).
124311 12-15

**PHENOTHIAZINE**
FURTHER STUDIES ON THE ACCUMULATION AND DISAPPEARANCE OF CATECHOLAMINES FORMED FROM TYROSINE-14C IN MOUSE BRAIN. EFFECT OF SOME PHENOTHIAZINE ANALOGUES.
042727 01-03
PHENOTHIAZINE TOXICITY IN POOL SHARK.
059035 03-15
PROJECT SUMMARY: NATURE OF LATE SIDE-EFFECTS OF PHENOTHIAZINE THERAPY.
060222 03-05
SUDDEN DEATH IN PHENOTHIAZINE THERAPY: A CLINICOPATHOLOGIC STUDY OF 12 CASES.
062737 03-15
CHEMICAL CONSTITUTION AND DRUG ACTION OF N-SUBSTITUTED PHENOTHIAZINE IN VENTRICULAR ECTOPIC TACHYCARDIA.
063981 04-03
EFFECTS OF PHENOTHIAZINE DERIVATIVES ON BIOLOGICAL MEMBRANES: DRUG-INDUCED CHANGES IN ELECTRON SPIN RESONANCE SPECTRA FROM SPIN-LABELED ERYTHROCYTE GHOST MEMBRANES.
064423 04-03
THE EFFECTS OF PHENOTHIAZINE THERAPY ON LYMPHOCYTE TRANSFORMATION IN SCHIZOPHRENIA.
067288 06-15
THE METABOLISM OF PSYCHOTROPIC DRUGS (PHENOTHIAZINE AND IMINODIBENZYL DERIVATIVES).
067301 06-17
A CONTROLLED STUDY OF THE EFFECTS OF GAMFEXINE IN PHENOTHIAZINE TREATED PATIENTS.
072144 07-08
ECG CHANGES INDUCED BY PHENOTHIAZINE DRUGS IN THE ANESTHETIZED RAT.
072525 08-03
TREATMENT OF PERSISTENT PHENOTHIAZINE INDUCED ORAL DYSKINESIA.
075417 08-15
HEAT STROKE IN PHENOTHIAZINE TREATED PATIENTS: A REPORT OF THREE FATALITIES.
076364 09-15
SEVERE PERSISTENT CHOREA WITH PHENOTHIAZINE THERAPY: REPORT OF A CASE.
079915 09-15
ON THE UPTAKE OF PHENOTHIAZINE DERIVATIVES BY THE ISOLATED PERFUSED RAT BRAIN.
089043 10-03
ELECTRON MICROSCOPY. SUDDEN DEATH IN PATIENTS UNDER PHENOTHIAZINE THERAPY: STUDY OF THREE CASES.
090359 11-15
PREMORBID ADJUSTMENT, PARANOID STATUS, AND PATTERNS OF RESPONSE TO PHENOTHIAZINE IN ACUTE SCHIZOPHRENIA.
103255 12-08
EFFECT OF TWO RECENTLY SYNTHESIZED PHENOTHIAZINE DERIVATIVES UPON EXPERIMENTAL CARDIAC ARRHYTHMIAS.
114978 12-03

**PHENOTHIAZINES**
LIVER DISEASE AND PHENOTHIAZINES; INVOLUNTARY MOVEMENTS.
063854 04-15
LONG-ACTING PHENOTHIAZINES AND LONG-TERM PSYCHOTIC PATIENTS: THE ROLE OF FLUPHENAZINE ENANTHATE IN TREATMENT.
065479 05-08
PREDICTION OF CHANGES IN SEVERITY OF THE SCHIZOPHRENIC SYNDROME WITH DISCONTINUATION AND ADMINISTRATION OF PHENOTHIAZINES IN CHRONIC SCHIZOPHRENIC PATIENTS: LANGUAGE AS A PREDICTOR AND MEASURE OF CHANGE IN SCHIZOPHRENIA.
075321 08-08
EFFECT OF PHENOTHIAZINES ON REACTION TIME IN SCHIZOPHRENICS.
075413 08-08
PSYCHIATRIC COMMUNITY CARE SYSTEM: USE OF LONG-ACTING PHENOTHIAZINES.
080007 09-17
RELATIONSHIP BETWEEN THE HOSPITAL MILIEU AND THE RESPONSE TO PHENOTHIAZINES IN THE TREATMENT OF SCHIZOPHRENICS.
085237 10-08
EFFECT OF PHENOTHIAZINES ON MELANOMA TYROSINASE ACTIVITY.
089998 11-05
REVIEW OF THE PHENOTHIAZINES (PART I).
096196 11-16

**PHENTOLAMINE**
THE ANTAGONISM OF PHENTOLAMINE AGAINST EXOGENOUSLY ADMINISTERED AND ENDOGENOUSLY RELEASED NOREPINEPHRINE IN RABBIT AORTIC STRIPS.
040243 01-03

**PHENYL**
THE SYNTHESIS AND BIOLOGICAL ACTIVITY OF (-)-DELTA9(11)-TRANS TETRAHYDROCANNABINOL; A NEW PROCEDURE FOR THE CLEAVAGE OF PHENYL METHYL ETHERS (UNPUBLISHED PAPER).
092888 11-01

**PHENYLALANINE**
INFLUENCE OF MODE AND DURATION OF PHENYLALANINE ADMINISTRATION ON BIOCHEMICAL PARAMETERS IN RATS OF VARIOUS AGES.
042840 01-03
U-14C TYROSINE METABOLISM OF THE PERFUSED CAT BRAIN WITH HIGH PLASMA PHENYLALANINE OR WITHOUT PLASMA TYROSINE.
100852 12-03

**PHENYLBENZOQUINONE**
STUDIES ON THE RECEPTORS INVOLVED IN THE ACTION OF THE VARIOUS AGENTS IN THE PHENYLBENZOQUINONE ANALGESIC ASSAY IN MICE.
090451 11-03

**PHENYLBUTAZONE**
DELAYED ABSORPTION OF PHENYLBUTAZONE CAUSED BY DESMETHYLIMIPRAMINE IN HUMANS.
042756 01-13
EFFECTS OF PHENOBARBITAL, PHENYLBUTAZONE, 3,4 BENZPYRENE, OR 3-METHYLCHOLANTHRENE ON ETHANOL METABOLISM IN THE RAT.
066498 05-03

**PHENYLEPHRINE**
BLOCKADE OF THE CARDIAC ACTION OF PHENYLEPHRINE BY BRETYLIUM OR COCAINE.
040242 01-03

**PHENYLETHANOLAMINE**
NEURONAL AND HORMONAL CONTROL OF TYROSINE HYDROXYLASE AND PHENYLETHANOLAMINE N-METHYLTRANSFERASE ACTIVITY.
080352 09-03

**PHENYLETHYLAMINE**
COMPARATIVE STUDY OF CNS STIMULATORY ACTIVITY AND ANOREXIGENIC POTENCY OF PHENYLETHYLAMINE DERIVATIVES. (PH.D.DISSERTATION).
103710 12-04

**PHENYLKETONURIA**
A LEARNING IMPAIRMENT ASSOCIATED WITH INDUCED PHENYLKETONURIA.
069056 06-04

**PHENYLKETONURIC**
ABNORMAL SOCIAL BEHAVIOR IN PHENYLKETONURIC MONKEYS.
060490 03-04

**PHENYLQUINONE**
THE EFFECT OF VARIOUS NEUROHUMORAL MODULATORS ON THE ACTIVITY OF MORPHINE AND THE NARCOTIC ANTAGONISTS IN THE TAIL-FLICK AND PHENYLQUINONE TESTS.
069594 07-04

**PHENYTOIN**
PHENYTOIN, FOLATES, AND ATPASE.
059055 03-15

**PHILOSOPHY**
THE PHILOSOPHY OF LONG-ACTING MEDICATION IN PSYCHIATRY.
065459 05-17

**PHOBIA**
PHOBIA QUESTIONNAIRE RESPONSES AND URINE CATECHOLAMINES.
054890 02-11

**PHOBIAS**
METHOHEXITONE ASSISTED DESENSITIZATION FOR PHOBIAS.
067074 05-16
METHOHEXITONE ASSISTED DESENSITIZATION IN TREATMENT OF PHOBIAS.
067673 06-11

**PHOBIC**
TREATMENT OF PHOBIC STATES WITH ANTIDEPRESSANTS: A RETROSPECTIVE STUDY OF 246 PATIENTS.
063934 04-10
THIOPENTONE FACILITATED IMPLOSION IN TREATMENT OF PHOBIC DISORDERS.
066907 05-14

**PHOSPHATE**
INCREASE IN BRAIN PYRIDOXAL PHOSPHATE BY CHLORPROMAZINE.
046397 01-02
EFFECTS OF ACTH AND ZINC PHOSPHATE VEHICLE ON SHUTTLEBOX CAR.
060756 03-04
CLINICAL TRIAL OF CLOMACRAN PHOSPHATE (SKF-14336) IN CHRONIC PSYCHOTIC MALE PATIENTS.
082056 10-07

**PHOSPHATES**
HEXOSE AND PENTOSE PHOSPHATES IN BRAIN DURING CONVULSIONS.
072119 07-03

**PHOSPHOKINASE**
SPINAL FLUID CREATINE PHOSPHOKINASE ABNORMALITIES FOLLOWING LSD USAGE.
067213 06-15

**PHOSPHOLIPID**
CLINICAL INVESTIGATIONS OF THE ACTION OF A PHOSPHOLIPID COMPLEX FROM CEREBRAL CORTEX ON CEREBRAL CIRCULATION DISTURBANCES.
058282 02-11

**PHOSPHOLIPIDS**
MORPHINE AND THE INCORPORATION OF 32 ORTHOPHOSPHATE IN VIVO INTO PHOSPHOLIPIDS OF THE GUINEA-PIG CEREBRAL CORTEX, LIVER AND SUBCELLULAR FRACTIONS.
046401 01-03
CHANGES IN THE SERUM CONCENTRATION OF CHOLESTEROL, TRIGLYCERIDES AND PHOSPHOLIPIDS IN THE MOUSE AND RAT AFTER ADMINISTRATION OF EITHER CHLORCYCLIZINE OR PHENOBARBITAL.
064282 04-03

**PHOSPHORYLASE-A**
LITHIUM EFFECT ON PLASMA GLUCAGON, LIVER PHOSPHORYLASE-A AND LIVER GLYCOGEN IN RATS.
066822 05-03

**PHOSPHORYLATION**
OXIDATIVE PHOSPHORYLATION IN HEART MITOCHONDRIA ISOLATED FROM CHLORPROMAZINE TREATED ANIMALS.
041564 01-03

**PHOTIC**
INFLUENCE OF SEROTONIN AND RELATED SUBSTANCES UPON PHOTIC EVOKED POTENTIALS OF RABBIT: EVIDENCE FOR BIOLOGICAL ACTIVITY OF THE ALDEHYDE DERIVATIVE.
055584 02-03

**PHOTICALLY**
EFFECTS OF PSILOCYBIN, DIMETHYLTRYPTAMINE AND VARIOUS LYSERGIC ACID DERIVATIVES ON PHOTICALLY INDUCED EPILEPSY IN THE BABOON (PAPIO-PAPIO).
068163 06-03
STUDY ON THE EFFECTS OF PSYCHOTROPIC DRUGS UPON THE PHOTICALLY DRIVING THETA RESPONSE OF ELECTROENCEPHALOGRAMS.
129740 12-08

**PHOTOCELL**
USES AND LIMITATIONS OF PHOTOCELL ACTIVITY CAGES FOR ASSESSING EFFECTS OF DRUGS.
090423 11-06

**PHOTOMYOCLONIC**
THE CLINICAL TESTING OF HYDROTHIADENE IN ENDOGENOUS DEPRESSIONS. INFLUENCE OF DRUGS ON PHOTOMYOCLONIC THRESHOLD.
070940 07-09

**PHYSICAL**
MENTAL RETARDATION ASSOCIATED WITH PRENATAL INTOXICATION, ALLERGIC REACTIONS, DEFICIENCIES, TRAUMA, AND PHYSICAL AGENTS.
061704 03-15
PROBLEM BEHAVIOR OF CHILDREN WITH SEVERE MENTAL AND PHYSICAL DISORDERS -- EXPERIENCE OF THE USE OF CARBAMAZEPINE.
105790 12-14
A COMPARATIVE STUDY OF PHYSICAL TREATMENTS IN SCHIZOPHRENIA.
138362 12-08

**PHYSICALLY**
PERSISTENCE OF RELAPSE TENDENCIES OF RATS PREVIOUSLY MADE PHYSICALLY DEPENDENT ON MORPHINE.
062940 03-04

**PHYSICIAN**
THE PHYSICIAN QUESTIONNAIRE: A USEFUL TOOL IN PSYCHIATRIC DRUG RESEARCH.
075843 09-17
ANXIOLYTICS IN THE PRACTICE OF A DISTRICT PHYSICIAN.
086208 10-17

**PHYSIOLOGICAL**
PHYSIOLOGICAL EFFECTS OF MARIJUANA.
046113 01-13
CORRELATION BETWEEN THE DURATION OF THE ANTICONVULSANT ACTIVITY OF DIAZEPAM AND ITS PHYSIOLOGICAL DISPOSITION IN MICE.
046402 01-03
PHYSIOLOGICAL AND SITUATIONAL FACTORS IN PSYCHOPHARMALOGICAL EXPERIMENTS.
058638 02-14
THE PHYSIOLOGICAL DISPOSITION OF CHLORPROMAZINE IN THE RAT AND DOG.
066937 05-03
PHYSIOLOGICAL AND DRUG-INDUCED CHANGES IN THE GLYCOGEN CONTENT OF MOUSE BRAIN.
067608 06-03
COMPARISON OF METHODS OF RELAXATION USING PHYSIOLOGICAL MEASURES.
074135 08-14
PHYSIOLOGICAL AND BIOCHEMICAL MECHANISMS OF THE EFFECT OF LITHIUM SALTS ON THE NERVOUS SYSTEM.
109786 12-13

**PHYSIOLOGY**
COMPARISON OF THE EFFECTS OF EXOGENOUS ACTH ON APPROACH AND AVOIDANCE CONDITIONING: IMPLICATIONS FOR THE PHYSIOLOGY OF INCENTIVE MOTIVATION. (PH.D.DISSERTATION).
103354 12-04
PARKINSONISM: PHYSIOLOGY, PHARMACOLOGY AND TREATMENT.
119840 12-17

**PHYSOSTIGMINE**
MEMORY ENHANCEMENT OF A PARTLY LEARNED DISCRIMINATION IN PIGEONS BY INTRAMUSCULAR INJECTION OF PHYSOSTIGMINE.
060858 03-04
FORGETTING OF AN OPERANT RESPONSE: PHYSOSTIGMINE PRODUCED INCREASES IN ESCAPE LATENCY IN RATS AS A FUNCTION OF TIME OF INJECTION.
061540 03-04
DEPRESSION OF TWO-WAY AVOIDANCE LEARNING AND ENHANCEMENT OF PASSIVE AVOIDANCE LEARNING BY SMALL DOSES OF PHYSOSTIGMINE.
064365 04-04
PHYSOSTIGMINE: EFFECTS ON RETENTION AT DIFFERENT TIMES AFTER BRIEF TRAINING.
075237 08-04

**PIGEON**
EFFECTS OF SOME BENZODIAZEPINES ON PUNISHED AND UNPUNISHED BEHAVIOR IN THE PIGEON.
040758 01-04
ANTAGONISM OF THE BEHAVIORAL EFFECTS OF MORPHINE AND METHADONE BY NARCOTIC ANTAGONISTS IN THE PIGEON.
069593 07-04
EFFECTS OF CHLORPROMAZINE IN THE PIGEON UNDER A SECOND-ORDER SCHEDULE OF FOOD PRESENTATION.
075906 09-04

**PIGEONS**
BEHAVIORAL EFFECTS OF HALOTHANE IN PIGEONS.
042719 01-04
MEMORY ENHANCEMENT OF A PARTLY LEARNED DISCRIMINATION IN PIGEONS BY INTRAMUSCULAR INJECTION OF PHYSOSTIGMINE.
060858 03-04
EFFECTS OF D-AMPHETAMINE AND CHLORDIAZEPOXIDE ON SPACED RESPONDING IN PIGEONS.
061597 03-04
EFFECTS OF CANNABIS-SATIVA AND LSD ON PIGEONS IN THREE VISUAL ENVIRONMENTS.
064499 04-04
AUTOMATIC MONITORING OF APOMORPHINE INDUCED PECKING IN PIGEONS.
075922 09-04
NEW METHOD FOR ASSAYING ANTIAPOMORPHINE ACTIVITY IN PIGEONS.
089437 11-06

**PIGMENTARY**
OCULAR (PIGMENTARY) EFFECTS OF PSYCHOTROPIC DRUGS.
058212 02-15
OPHTHALMOLOGICAL (PIGMENTARY) CHANGES.
100526 12-15
PIGMENTARY RETINOPATHY AND PARANOIC SYNDROME. (PRESENTATION OF ONE CASE).
124309 12-08

**PILL**
ONE PILL FOR TWO.
057483 02-07
THE CONTRACEPTIVE PILL, SIDE-EFFECTS AND PERSONALITY: REPORT OF A CONTROLLED DOUBLE-BLIND TRIAL.
075472 08-15

**PILLS**
PILLS AND IMPROVEMENT: A STUDY OF PLACEBO RESPONSE IN PSYCHONEUROTIC OUTPATIENTS.
066832 05-10
SLEEPING PILLS.
081087 09-17
SLEEPING PILLS AND TRANQUILIZER ABUSE.
129237 12-17

**PILOCARPINE**
A BIPHASIC ACTION OF PILOCARPINE ON BEHAVIORAL AROUSAL IN THE RAT. (PH.D.DISSERTATION).
110922 12-04

**PILOT**
MOLINDONE IN ANXIOUS NEUROTIC PSYCHIATRIC OUTPATIENTS: A PILOT STUDY.
058969 03-10
PSEUDOPREGNANCY, TREATMENT OF PERIODIC PSYCHIATRIC ILLNESS: A PILOT STUDY.
068215 06-09
LONG-ACTING NEUROLEPTICS: III. PILOT STUDY OF PENFLURIDOL (R-16341).
069070 06-07
CLINICAL PILOT STUDY OF DIBENZEPINE TREATMENT OF DEPRESSION.
070939 07-09
A PILOT STUDY OF AHR-1900 IN CHRONIC SCHIZOPHRENIC PATIENTS.
072145 07-08
A PILOT STUDY OF INJECTABLE DIAZEPAM IN A GENERAL HOSPITAL SETTING.
072397 07-07

**PIMOZIDE**
EFFECT OF APOMORPHINE AND PIMOZIDE ON SYNTHESIS AND TURNOVER OF LABELED CATECHOLAMINES IN MOUSE BRAIN.
066502 05-03
A COMPARATIVE DOUBLE-BLIND TRIAL OR PIMOZIDE AND FLUPHENAZINE IN CHRONIC SCHIZOPHRENIA.
078932 09-08
CLINICAL TESTS OF A NEW, PROLONGED ACTION NEUROLEPTIC AGENT, PIMOZIDE.
079863 09-07
CLINICAL TOXICOLOGY AND EFFICACY OF PIMOZIDE.
089104 10-09
ADMINISTRATION OF A NEW BUTYROPHENONE DERIVATIVE, PIMOZIDE, IN THE TREATMENT OF SCHIZOPHRENIA.
123373 12-08

**PINEAL**
SCHIZOPHRENIA AND THE PINEAL GLAND.
062935 03-08

**PINEALECTOMIZED**
ELECTROCORTICAL REACTIONS OF PINEALECTOMIZED AND INTACT RATS TO LETHAL DOSES OF PENTOBARBITAL.
064101 04-03

**PINK-SPOT**
THE PINK-SPOT, 3,4 DIMETHOXYPHENYLETHYLAMINE, COMMON TEA, AND SCHIZOPHRENIA.
062783 03-13
DOES PINK-SPOT DIAGNOSE DRUG?
067319 06-08
PINK-SPOT - IS IT A DRUG ARTEFACT
068153 06-15

**PIPERACETAZINE**
PIPERACETAZINE (QUIDE) IN THE MANAGEMENT OF BEHAVIORAL DISORDERS IN MILDLY RETARDED INSTITUTIONALIZED BOYS.
069071 06-11
CLINICAL EXPERIENCE WITH PIPERACETAZINE IN HOSPITALIZED MENTAL PATIENTS: A FOUR YEAR STUDY.
071292 07-07
PIPERACETAZINE (QUIDE): A CONTROLLED EVALUATION OF THE ELIXIR IN CHRONIC SCHIZOPHRENIC PATIENTS.
082053 10-08
PIPERACETAZINE VS. CHLORPROMAZINE IN THE TREATMENT OF SCHIZOPHRENIA.
089099 10-08

**PIPERIDYL-PHENOTHIAZINE**
CLINICAL STUDY ON A NEW PIPERIDYL-PHENOTHIAZINE DERIVATIVE (A-124).
079969 09-07

**PIRIDOXILATE**
CLINICAL TESTS OF PIRIDOXILATE IN PSYCHIATRIC THERAPY.
091500 11-07

**PITUITARY**
PITUITARY ADRENAL FUNCTION IN THE SQUIRREL MONKEY.
075665 08-03
EFFECT OF PITUITARY AND ACTH ON THE MAINTENANCE OF BASAL TYROSINE HYDROXYLASE ACTIVITY IN THE RAT ADRENAL GLAND.
075714 08-03
PITUITARY ADRENAL ALTERATIONS AND FEAR RESPONDING.
090135 11-04
HYPOTHALAMIC PITUITARY ADRENAL AXIS.
100532 12-13

**PLACEBO**
COMBINED THERAPY IN ANXIETY DEPRESSIVE SYNDROMES: I. COMPARATIVE EFFECTS OF LIMBITROL (CHLORDIAZEPOXIDE AMITRIPTYLINE) AND PLACEBO.
064312 04-10
IMIPRAMINE PAMOATE IN HOSPITALIZED DEPRESSIVES: A DOUBLE-BLIND COMPARISON WITH PLACEBO.
064429 04-10
A COMPARATIVE STUDY OF BUTAPERAZINE, CHLORPROMAZINE AND PLACEBO IN CHRONIC SCHIZOPHRENICS.
064431 04-08
PLACEBO CONTROL EVALUATION OF DESIPRAMINE IN DEPRESSION.
065235 05-10
PILLS AND IMPROVEMENT: A STUDY OF PLACEBO RESPONSE IN PSYCHONEUROTIC OUTPATIENTS.
066832 05-10
COMPARATIVE EFFECTS OF SMOKING MARIHUANA OR PLACEBO ON HUMAN MOTOR AND MENTAL PERFORMANCE.
069579 07-14
AMITRIPTYLINE, CHLORPROTHIXENE, PROTHIADENE AND PLACEBO IN THE TREATMENT OF NEUROSES.
070946 07-10

HYPNOTIC PROPERTIES OF NITRAZEPAM (MOGADON) (A COMPARATIVE STUDY OF CHLORDIAZEPOXIDE, DIAZEPAM, NITRAZEPAM, SECOBARBITAL AND PLACEBO IN PSYCHIATRIC PATIENTS).
075884 09-14
THE EFFECTS OF 4 HYPNOTIC DRUGS AND PLACEBO ON NORMAL SUBJECTS SLEEPING AND DREAMING AT HOME.
087863 10-06
THE USEFULNESS OF PLACEBO AND THE DOUBLE-BLIND TECHNIQUE IN THE EVALUATION OF PSYCHOTROPIC DRUGS.
089054 10-17
THE PREDICTION OF PLACEBO RESPONSE IN ANXIOUS AND DEPRESSED OUTPATIENTS.
092102 11-16
DOUBLE-BLIND STUDY WITH SINEQUAN (DOXEPIN) VS DIAZEPAM VS PLACEBO IN PSYCHONEUROSIS.
138526 12-10

**PLACENTAL**
TOTAL BODY KINETICS AND PLACENTAL TRANSFER OF LABELED LSD IN MICE.
046201 01-03
PLACENTAL TRANSFER OF PENTOBARBITAL IN THE RAT.
058572 02-05

**PLACIDYL**
ACUTE ETHCHLORVYNOL (PLACIDYL) INTOXICATION.
064623 04-15

**PLANT**
THE PLANT KINGDOM AND HALLUCINOGENS (PART III).
058973 03-17

**PLASMA**
PLASMA PROTEIN BINDING OF TRICYCLIC ANTIDEPRESSIVE DRUGS.
040573 01-13
STUDIES OF DELAYED ACTION MEDICATION: V. PLASMA LEVELS AND URINARY EXCRETION OF FOUR DIFFERENT DOSAGE FORMS OF CHLORPROMAZINE.
041559 01-13
PLASMA PROTEIN BINDING OF CHLORPROMAZINE.
046138 01-13
FACTORS AFFECTING CHLORPROMAZINE PLASMA LEVELS IN PSYCHIATRIC PATIENTS.
047913 01-13
CHLORPROMAZINE PLASMA LEVELS AND EFFECTS.
047951 01-09
DRUG PLASMA LEVELS IN CHRONIC ILLNESS.
064484 04-17
THE ROLE OF PLASMA PROTEIN BINDING IN THE INHIBITORY EFFECT OF NORTRIPTYLINE ON THE NEURONAL UPTAKE OF NOREPINEPHRINE.
066278 05-03
LITHIUM EFFECT ON PLASMA GLUCAGON, LIVER PHOSPHORYLASE-A AND LIVER GLYCOGEN IN RATS.
066822 05-03
THE ROLE OF METHYLAMPHETAMINE ON PLASMA HEXOSAMINE LEVEL UNDER STRESS.
074855 08-03
PLASMA FREE FATTY ACIDS BEFORE AND AFTER AN INTRAVENOUS INSULIN INJECTION IN ACUTE SCHIZOPHRENIC MEN.
075212 08-08
DELTA1-TETRAHYDROCANNABINOL, SYNHEXYL AND MARIJUANA EXTRACT ADMINISTERED ORALLY IN MAN: CATECHOLAMINE EXCRETION, PLASMA CORTISOL LEVELS AND PLATELET SEROTONIN CONTENT.
075841 08-12
PLASMA CONCENTRATIONS OF THIORIDAZINE IN PATIENTS WITH DEPRESSION: A PRELIMINARY REPORT.
078213 09-13
CORRELATION OF SUBJECTIVE SIDE-EFFECTS WITH PLASMA CONCENTRATIONS OF NORTRIPTYLINE.
082104 10-15
U-14C TYROSINE METABOLISM OF THE PERFUSED CAT BRAIN WITH HIGH PLASMA PHENYLALANINE OR WITHOUT PLASMA TYROSINE.
100852 12-03

**PLATELET**
DELTA1-TETRAHYDROCANNABINOL, SYNHEXYL AND MARIJUANA EXTRACT ADMINISTERED ORALLY IN MAN: CATECHOLAMINE EXCRETION, PLASMA CORTISOL LEVELS AND PLATELET SEROTONIN CONTENT.
075841 08-12

**PLATELETS**
INHIBITORY EFFECT OF TWO NEWER ANTIDEPRESSANTS, LU-5-003 AND LU-3-010, ON SEROTONIN UPTAKE IN HUMAN BLOOD PLATELETS IN VITRO.
071791 07-03

**PLAYROOM**
URINARY NORADRENALINE AND PLAYROOM BEHAVIOUR IN HYPERACTIVE BOYS.
070024 07-14

**PLEURAL**
PLEURAL EFFUSION AND FIBROSIS DURING TREATMENT WITH METHYSERGIDE.
067836 06-15

**PLEXUS**
THE EFFECTS OF MORPHINE-LIKE SUBSTANCES AND THEIR ANTAGONISTS ON TRANSMISSION AT THE NEURO EFFECTOR JUNCTION OF THE MYENTERIC PLEXUS LONGITUDINAL MUSCLE PREPARATION OF THE GUINEA-PIG ILEUM.
041974 01-03

**PMH**
COMPARISON OF PMH AND PEMOLINE ACTIVITY AFTER ELECTROCONVULSIVE SHOCK.
058992 03-04

**POISON**
EMERGENCY TREATMENT OF DRUG ABUSE AND POISON INGESTION.
066395 05-15

**POISONING**
POLYNEURITIS CRANIALIS FOLLOWING POISONING WITH CHLORINATED ACETYLENES WHILE HANDLING VINYLIDINE COPOLYMERS.
051140 02-15
A CASE OF PROBABLE HEMATOMYELIA CAUSED BY CHRONIC BENZENE POISONING.
056059 02-15
TRICYCLIC ANTIDEPRESSANT POISONING.
058333 02-15
MODIFICATION OF NACL APPETITE IN THE ADRENALECTOMIZED RAT CONSEQUENT TO EXTENSIVE LICL POISONING.
061094 03-04
BLISTERS FROM BARBITURATE POISONING.
064634 04-15
SKIN LESIONS AS A DIAGNOSTIC AID IN BARBITURATE POISONING.
067926 06-15
HYPOKALAEMIA AND ARRHYTHMIAS AS A RESULT OF QUININE POISONING.
071258 07-15
ACUTE LITHIUM POISONING.
079914 09-15
LETHAL POISONING IN CHILDREN BY MEANS OF THYMOLEPTICS.
082202 10-15
GALVESTON COUNTY STUDY SHOWS TRANQUILIZERS SURPASS ASPIRIN AS MEDICINAL POISONING AGENTS.
090070 11-15
ACUTE POISONING WITH PSYCHOTROPIC DRUGS.
100518 12-15
TWO CASES OF ACUTE P-CHLORONITROBENZENE POISONING SEQUELAE.
129753 12-15

**POISONS**
MENTAL RETARDATION ASSOCIATED WITH POSTNATAL POISONS, TOXINS, ENDOTOXINS, DEFICIENCIES AND ALLERGIC REACTIONS.
061706 03-15

**POLE-CLIMB**
YEAST RIBONUCLEIC ACID: ANALYSIS OF EFFECTS ON POLE-CLIMB AVOIDANCE BEHAVIOR.
065493 05-04

**POLICIES**
RETENTION RATES OF SCHIZOPHRENIA: A COMPARISON OF SHOCK THERAPY AND PSYCHOPHARMACOLOGICAL ERAS AND OF CLOSED AND OPEN DOOR POLICIES.
069795 07-08

**POLYCLINIC**
DIMETHACRINE -- A NEW TRICYCLIC ANTIDEPRESSANT: OPEN INVESTIGATIONS IN A CLINIC AND POLYCLINIC.
058281 02-07

**POLYGRAPHIC**
A POLYGRAPHIC STUDY OF THE NIGHT SLEEP OF PARKINSONIAN PATIENTS: EFFECTS OF TREATMENT WITH LEVODOPA.
087658 10-14
THE INFLUENCE OF IMIPRAMINE, DEXPHENMETRAZINE AND AMPHETAMINE SULPHATE ON SYNCHRONOUS AND PARADOXICAL SLEEP IN NARCOLEPSY CATAPLEXY. A POLYGRAPHIC EXAMINATION.
089037 10-14

**POLYHETEROCYCLES**
PROJECT SUMMARY: CONDENSED POLYHETEROCYCLES CONTAINING N,S AND O.
105332 12-01

**POLYNEURITIS**
POLYNEURITIS CRANIALIS FOLLOWING POISONING WITH CHLORINATED ACETYLENES WHILE HANDLING VINYLIDINE COPOLYMERS.
051140 02-15

**POLYPHARMACY**
POLYPHARMACY IN PSYCHIATRY: PATTERNS OF DIFFERENTIAL TREATMENT.
075332 08-11
INFLUENCES OF POLYPHARMACY ON HALLUCINATORY BEHAVIOR IN A SAMPLE OF FEMALE CHRONIC SCHIZOPHRENIC PATIENTS.
115037 12-08

**POLYSORBATES**
MICELLAR SOLUBILIZATION OF BARBITURATES I: SOLUBILITIES OF CERTAIN BARBITURATES IN POLYSORBATES OF VARYING HYDROPHOBIC CHAIN LENGTH.
046136 01-17

**POLYURIA**
LITHIUM INDUCED POLYURIA: EXPERIMENTAL STUDIES IN MAN AND THE RAT.
100083 11-15
LITHIUM INDUCED POLYURIA IN RATS.
106779 12-05

**POOL**
PHENOTHIAZINE TOXICITY IN POOL SHARK.
059035 03-15

**POOR**
FACTORS ASSOCIATED WITH POOR RESPONSE TO LITHIUM CARBONATE: A CLINICAL STUDY.
062352 03-09

**POPULATION**
METRAZOL TOLERANCE IN A NORMAL VOLUNTEER POPULATION: A TEN YEAR FOLLOW-UP REPORT.
060649 03-13
THE VARIABLES OF SILENT MYOCARDIAL INFARCTION IN A PSYCHOTIC POPULATION.
065314 05-10
HABITUATION TO CHLORDIAZEPOXIDE IN AN ALCOHOLIC POPULATION.
074732 08-11
A SURVEY OF EXTRAPYRAMIDAL MANIFESTATIONS IN THE INPATIENT POPULATION OF A PSYCHIATRIC HOSPITAL.
086444 10-15
THE ANTIANXIETY EFFECTS OF HALOPERIDOL AND TRIFLUOPERAZINE IN AN OUTPATIENT NEUROTIC POPULATION.
089444 11-10
POPULATION DEPENDENT DIFFERENCES OF CENTRAL NERVOUS REACTIVITY TO NEUROLEPTICS.
098022 11-15
THE COURSE OF RECURRENT DEPRESSIVE ILLNESS IN SELECTED PATIENTS FROM A DEFINED POPULATION.
106781 12-09

**POPULATIONS**
DRUG TREATMENT IN DEPRESSIVE ILLNESS: AMITRYPTYLINE AND CHLORDIAZEPOXIDE IN TWO NEUROTIC POPULATIONS.
075415 08-10

**PORPHYRIA**
NEUROPSYCHIATRIC MANIFESTATIONS IN TWO CASES OF PORPHYRIA.
138144 12-11

**PORPHYRINS**
STOOL PORPHYRINS IN ACUTE INTERMITTENT AND HEREDITARY COPROPORPHYRIA: ADVERSE EFFECTS OF TRANQUILIZERS.
066318 05-15

**POSITION**
TESTING DRUGS FOR TERATOGENICITY AND THEIR EFFECTS ON FERTILITY; THE PRESENT POSITION.
057605 02-05
LITHIUMS POSITION AMONG ANTIDEPRESSANTS IN THE TREATMENT OF ACUTE ENDOGENOUS AND INVOLUTIONAL DEPRESSIONS.
106777 12-09

**POSITIVELY**
THE EFFECT OF PUROMYCIN ON RETENTION OF A POSITIVELY REINFORCED RESPONSE IN GOLDFISH.
059616 03-04
CONDITIONED SUPPRESSION BASED ON POSITIVELY REINFORCING INTRACRANIAL STIMULATION.
064842 05-02

**POST**
CONDITIONED NALORPHINE INDUCED ABSTINENCE CHANGES: PERSISTENCE IN POST MORPHINE DEPENDENT MONKEYS.
061632 03-04
TOFRANIL IN THE TREATMENT OF POST ALCOHOLIC DEPRESSIONS.
063588 03-09

**POST-HOSPITALIZED**
FLUPHENAZINE ENANTHATE IN THE TREATMENT OF THE POST-HOSPITALIZED PATIENT.
089000 10-17

**POST-NEONATAL**
POST-NEONATAL ANDROGENIZATION AND ADULT AGGRESSIVE BEHAVIOR IN FEMALE MICE.
081233 09-04

**POST-SEIZURE**
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: I. SEIZURE AND POST-SEIZURE ELECTROENCEPHALOGRAPHIC PATTERN.
065850 05-11

**POST-SURGICAL**
L-DOPA IN THE TREATMENT OF POST-SURGICAL PARKINSON PATIENTS.
071984 07-07

**POST-TRAUMATIC**
A THERAPEUTIC AGENT FOR ANTIDEPRESSANT AND TRANQUILIZING CONTROL IN THE POST-TRAUMATIC NEUROSES.
086237 10-07

**POSTENCEPHALITIC**
SIDE-EFFECTS OF L-DOPA IN POSTENCEPHALITIC PARKINSONISM.
059057 03-15

**POSTLEARNING**
THE EFFECTS OF CHLORPROMAZINE ON ONE-TRIAL PASSIVE AVOIDANCE LEARNING IN MICE: FURTHER EXAMINATION OF PRELEARNING AND POSTLEARNING ADMINISTRATION.
064407 04-04

**POSTNATAL**
EFFECTS OF CHRONIC POSTNATAL DRUG ADMINISTRATION ON ADULT DOMINANCE BEHAVIOR IN TWO GENERA OF MICE.
042837 01-04
MENTAL RETARDATION ASSOCIATED WITH POSTNATAL POISONS, TOXINS, ENDOTOXINS, DEFICIENCIES AND ALLERGIC REACTIONS.
061706 03-15
THE SAFETY TEST OF L-DOPA -- II. EFFECT OF L-DOPA ON THE DEVELOPMENT OF PRENATAL AND POSTNATAL OFFSPRINGS OF EXPERIMENTAL ANIMALS.
114836 12-02

**POSTSESSION**
EXPERIMENTAL VARIABLES IN THE EFFECTS OF POSTSESSION INJECTIONS OF STRYCHNINE SULPHATE ON A CLASSICALLY CONDITIONED RESPONSE.
071792 07-04

**POT**
THE PROBLEM OF POT: PHARMACOLOGY AND CHEMISTRY.
059622 03-03
THE PROBLEM OF POT: THE MEDICAL EFFECTS OF MARIHUANA.
059623 03-13
THE PROBLEM OF POT: MARIHUANA, A PSYCHIATRIC POINT OF VIEW.
059624 03-14
WHAT WE HAVE FORGOTTEN ABOUT POT -- A PHARMACOLOGISTS HISTORY.
081680 10-17

**POTASSIUM**
EFFECT OF MOOD AND LITHIUM CARBONATE ON TOTAL BODY POTASSIUM.
047952 01-09
ACCELERATION OF NORADRENALINE BIOSYNTHESIS IN THE GUINEA-PIG VAS-DEFERENS BY POTASSIUM.
073063 08-06
THE EFFECTS OF ACUTE AND PROLONGED LITHIUM TREATMENT ON THE DISTRIBUTION OF ELECTROLYTES, POTASSIUM AND SODIUM.
088614 10-03

**POTENCY**
COMPARATIVE STUDY OF CNS STIMULATORY ACTIVITY AND ANOREXIGENIC POTENCY OF PHENYLETHYLAMINE DERIVATIVES. (PH.D.DISSERTATION).
103710 12-04

**POTENT**
A POTENT BETA-ADRENORECEPTOR BLOCKING DRUG: 4-(2-HYDROXY-3-ISOPROPYLAMINOPROPOXY)INDOLE.
040751 01-03
PHARMACOLOGICAL STUDIES ON A NEW SPECIFICALLY POTENT ANTITUSSIVE AGENT, 14-HYDROXYDIHYDRO-6-BETA-THEBAINOL-4-METHYLETHER (OXYMETHEBANOL).
055585 02-03
HARNESSING POTENT HALLUCINOGENS.
072412 08-01

**POTENTIAL**
A POTENTIAL SCREENING TEST FOR MINOR TRANQUILLIZING DRUG ACTION.
051651 02-06
A NEW CLASS OF 1,3 BENZOXAZINONES AS POTENTIAL CENTRAL NERVOUS SYSTEM AGENTS.
062322 03-02
PROJECT SUMMARY: SYNTHESIS OF POTENTIAL PSYCHOTROPIC AGENTS.
062435 03-01
INFLUENCE OF TRIIODOTHYRONINE ON SELECTIVE ATTENTION IN MAN AS MEASURED BY THE VISUAL AVERAGED EVOKED POTENTIAL.
062510 03-13
SYNTHESIS OF SOME GLYCIDIC HYDRAZIDES AND AMIDES AS POTENTIAL PSYCHOTROPIC AGENTS AND ANTICHOLINERGIC AGENTS.
064258 04-01
THE THERAPEUTIC POTENTIAL OF LSD: ITS ADJUNCTIVE USE IN PSYCHOTHERAPY.
073852 08-12
CORTISOL EFFECTS ON AVERAGED EVOKED POTENTIAL, ALPHA-RHYTHM, TIME ESTIMATION, AND TWO-FLASH FUSION THRESHOLD.
075274 08-13
PRECLINICAL EVALUATION OF AHR-1118. A POTENTIAL ANTIDEPRESSANT DRUG.
082051 10-03

SUBSTITUTED BENZAMIDES WITH POTENTIAL CNS DEPRESSANT AND HYPOTENSIVE ACTIVITY.
089435 11-02

CHEMISTRY AND PHARMACOLOGY OF A NEW POTENTIAL ANTIDEPRESSANT, N-METHYL-N-(4-CHLOROBENZYL-11-DIHYDRO-5H DIBENZAZEPIN-5-YL) PROPYLAMINE HYDROCHLORIDE) (LEO-640, LOPRAMINE HYDROCHLORIDE).
089786 11-01

**POTENTIALLY**

IS IT FEASIBLE TO TREAT CERTAIN POTENTIALLY DANGEROUS CONDITIONS BY PROLONGED CHEMOTHERAPY.
062406 03-08

DELIRIUM-ACUTUM, A POTENTIALLY FATAL CONDITION IN THE PSYCHIATRIC HOSPITAL.
075980 09-15

**POTENTIALS**

INFLUENCE OF SEROTONIN AND RELATED SUBSTANCES UPON PHOTIC EVOKED POTENTIALS OF RABBIT: EVIDENCE FOR BIOLOGICAL ACTIVITY OF THE ALDEHYDE DERIVATIVE.
055584 02-03

PSYCHOTOMIMETIC PROPERTIES AND THERAPEUTIC POTENTIALS OF DEXOXADROL ON CONVALESCING ALCOHOLICS.
058448 02-12

RECORDING EVOKED POTENTIALS IN THE CONSCIOUS RAT: THE MAINTENANCE OF A CONSTANT BEHAVIOURAL BASELINE.
067600 06-06

THE ACTION OF CENTRAL DEPRESSANT DRUGS ON THE SPONTANEOUS DISCHARGE OF ACTION POTENTIALS IN THE SUPERIOR CERVICAL SYMPATHETIC TRUNK OF THE CAT.
072034 07-03

EFFECTS OF PENTOBARBITONE AND CHLORPROMAZINE ON ACOUSTICALLY EVOKED POTENTIALS IN THE RAT.
074939 08-03

**POTENTIATION**

POTENTIATION AND INHIBITION OF SOME CENTRAL ACTIONS OF L(-) DOPA BY DECARBOXYLASE INHIBITORS.
040750 01-03

POTENTIATION OF THE CENTRAL ACTIONS OF 5-HYDROXYTRYPTOPHAN IN RABBITS BY DL-ALPHA-HYDRAZINO ALPHA-METHYLDOPA.
058879 02-03

DOPA EFFECTS ON MOTILITY IN MICE; POTENTIATION BY MK-485 AND DEXCHLORPHENIRAMINE.
064411 04-03

POTENTIATION BY AMANTADINE HYDROCHLORIDE OF L-DOPA INDUCED EFFECTS IN MICE.
066508 05-03

ON THE MECHANISM OF AMPHETAMINE POTENTIATION BY IPRINDOLE.
066955 05-03

**PRAGMATIC**

A PRAGMATIC THEORY OF MEPROBAMATE EFFECTS.
046314 01-17

**PRAZEPAM**

THE PHARMACOLOGY OF PRAZEPAM: A NEW BENZODIAZEPINE DERIVATIVE.
064181 04-04

PRAZEPAM METABOLITES IN DOG URINE.
071942 07-03

**PRECEDING**

CRISES AND LIFE CHANGES PRECEDING THE ONSET OR RELAPSE OF ACUTE SCHIZOPHRENIA: CLINICAL ASPECTS.
075304 08-08

**PRECLINICAL**

PRECLINICAL EVALUATION OF AHR-1118. A POTENTIAL ANTIDEPRESSANT DRUG.
082051 10-03

**PRECURSOR**

A SOURCE OF ERROR IN CATECHOLAMINE TURNOVER STUDIES WITH LABELED DOPA: SLOW DISAPPEARANCE OF THE PRECURSOR.
074818 08-03

**PRECURSORS**

EFFECT OF ANTIDEPRESSANT DRUGS ON ACCUMULATION AND DISAPPEARANCE OF MONOAMINES FORMED IN VIVO FROM LABELED PRECURSORS IN MOUSE BRAIN.
058798 02-03

QUANTITATIVE THIN-LAYER CHROMATOGRAPHIC ESTIMATION OF LABELED DOPAMINE AND NOREPINEPHRINE, THEIR PRECURSORS AND METABOLITES.
070063 07-06

THE EFFECT OF SOME HALLUCINOGENIC DRUGS ON THE AMINO ACID PRECURSORS OF BRAIN MONOAMINES.
070542 07-03

**PREDICTING**

AN INDUSTRIAL VIEW OF CURRENT PRACTICE IN PREDICTING DRUG TOXICITY.
057606 02-05

**PREDICTION**

PSYCHOMETRIC AND PSYCHOPHYSIOLOGICAL TEST IN THE PREDICTION OF THERAPEUTIC RESPONSIVENESS IN THE SCHIZOPHRENIAS.
062643 03-08

PREDICTION OF CHANGES IN SEVERITY OF THE SCHIZOPHRENIC SYNDROME WITH DISCONTINUATION AND ADMINISTRATION OF PHENOTHIAZINES IN CHRONIC SCHIZOPHRENIC PATIENTS: LANGUAGE AS A PREDICTOR AND MEASURE OF CHANGE IN SCHIZOPHRENIA.
075321 08-08

THE PREDICTION OF PLACEBO RESPONSE IN ANXIOUS AND DEPRESSED OUTPATIENTS.
092102 11-16

PREDICTION AND MEASUREMENT OF PERCEPTUAL BEHAVIORAL CHANGE IN DRUG-INDUCED HALLUCINATIONS.
121086 12-12

**PREDICTIVE**

THE RESPONSE TO MEPROBAMATE – A PREDICTIVE ANALYSIS.
046311 01-17

THE PREDICTIVE VALUE FOR MAN OF TOXICOLOGICAL TESTS OF DRUGS IN LABORATORY ANIMALS.
057607 02-05

**PREDICTOR**

FIELD DEPENDENCE AS A PREDICTOR OF ALCOHOLIC THERAPY DROP-OUTS.
052455 02-11

PREDICTION OF CHANGES IN SEVERITY OF THE SCHIZOPHRENIC SYNDROME WITH DISCONTINUATION AND ADMINISTRATION OF PHENOTHIAZINES IN CHRONIC SCHIZOPHRENIC PATIENTS: LANGUAGE AS A PREDICTOR AND MEASURE OF CHANGE IN SCHIZOPHRENIA.
075321 08-08

**PREDICTORS**

PATIENT PERSONALITY AND DEMOGRAPHIC FACTORS AS PREDICTORS OF EARLY RESPONSE TO PSYCHOTROPIC DRUG TREATMENT.
074130 08-10

**PREDISPOSITION**

SPECIFIC (IN THE SENSE OF INCREASED PREDISPOSITION TO INJURY OF THE SUBDOMINANT HEMISPHERE) DISTRIBUTION OF THE EXTRAPYRAMIDAL SYMPTOMS IN SCHIZOPHRENICS DURING THE COURSE OF HALOPERIDOL TREATMENT.
089106 10-15

**PREFERENCES**

PREFERENCES FOR MORPHINE IN RATS: VALIDATION OF AN EXPERIMENTAL MODEL OF DEPENDENCE.
064475 04-04

ROLE OF MONKEYS SPATIAL PREFERENCES IN PERFORMANCE OF A NONSPATIAL TASK.
065420 05-04

TASTE PREFERENCES: AN APPARATUS FOR RANDOM AND SIMULTANEOUS PRESENTATION OF SEVERAL SOLIDS AND SOLUTIONS.
067892 06-06

**PREFRONTAL**

THE INFLUENCES OF THE STANDARD PREFRONTAL LOBOTOMY OPERATION ON HALLUCINATORY PHENOMENA ASSOCIATED WITH PSYCHOTOMIMETIC DRUGS.
120899 12-13

**PREGANGLIONIC**

ENHANCEMENT BY DESIPRAMINE OF HYPOTHALAMICALLY EVOKED DISCHARGES IN PREGANGLIONIC SYMPATHETIC NERVES.
097962 11-03

**PREGNANCY**

LITHIUM IN PREGNANCY.
058405 02-15

LYSERGIC ACID DIETHYLAMIDE INTAKE IN PREGNANCY: FETAL DAMAGE IN RATS.
064422 04-05

PREGNANCY AND PSYCHOTROPIC DRUGS.
100519 12-15

**PREGNANT**

CHROMOSOME STUDIES IN PREGNANT RHESUS MACAQUE GIVEN LSD-25.
064315 04-05

**PRELEARNING**

THE EFFECTS OF CHLORPROMAZINE ON ONE-TRIAL PASSIVE AVOIDANCE LEARNING IN MICE: FURTHER EXAMINATION OF PRELEARNING AND POSTLEARNING ADMINISTRATION.
064407 04-04

**PREMARIN**

UNIT ACTIVITY IN PREMARIN INDUCED CORTICAL EPILEPTOGENIC FOCI.
066187 05-03

**PREMATURE**

DANGERS OF PREMATURE PSYCHOLOGIC DIAGNOSIS.
067265 06-14

**PREMEDICATION**

THE INFLUENCE OF LONG-TERM PREMEDICATION WITH TRANYLCYPROMINE ON EXPERIMENTAL PSYCHOSES INDUCED BY LSD.
070954 07-12

**PREMORBID**
RELATIONSHIPS OF THE MECHOLYL TEST, PREMORBID ASOCIAL FUNCTIONING AND LONG-TERM OUTCOME IN SCHIZOPHRENIA. 075227 08-08
PREMORBID ADJUSTMENT, PARANOID STATUS, AND PATTERNS OF RESPONSE TO PHENOTHIAZINE IN ACUTE SCHIZOPHRENIA. 103255 12-08

**PRENATAL**
MENTAL RETARDATION ASSOCIATED WITH PRENATAL INTOXICATION, ALLERGIC REACTIONS, DEFICIENCIES, TRAUMA, AND PHYSICAL AGENTS. 061704 03-15
EFFECTS OF PRENATAL ADMINISTRATION OF PSYCHOTROPIC DRUGS TO RATS ON BRAIN BUTYRYLCHOLINESTERASE ACTIVITY AT BIRTH. 067980 06-03
EFFECTS OF PRENATAL ADMINISTRATION OF PSYCHOTROPIC DRUGS ON BEHAVIOR OF DEVELOPING RATS. 074830 08-04
EFFECT OF PRENATAL DRUGS ON THE BEHAVIOR OF THE NEONATE. 075607 08-05
THE SAFETY TEST OF L-DOPA – II. EFFECT OF L-DOPA ON THE DEVELOPMENT OF PRENATAL AND POSTNATAL OFFSPRINGS OF EXPERIMENTAL ANIMALS. 114836 12-02

**PREOPERATIVELY**
INTERACTIONS BETWEEN CERTAIN DRUGS USED PREOPERATIVELY AND ANESTHETIC AGENTS. 066890 05-15

**PREOPTIC**
COMPARISON OF DRINKING ELICTED BY ESERINE OR DFP INJECTED INTO PREOPTIC AREA OF RAT BRAIN. 069637 07-04

**PRESCHOOL**
LONG-TERM PSYCHOTHERAPY UTILIZING TRIFLUOPERAZINE IN A PSYCHOTIC PRESCHOOL CHILD: (A CASE STUDY). 066806 05-11

**PRESCRIBED**
INTERACTION OF COMMONLY PRESCRIBED DRUGS AND WARFARIN. 064622 04-15

**PRESCRIBING**
HAZARDS IMPLICIT IN PRESCRIBING PSYCHOACTIVE DRUGS. 070897 07-17

**PRESENILE**
ON THE QUESTION OF THE PROPHYLAXIS OF INITIAL MANIFESTATIONS OF PRESENILE PSYCHOSES. 110105 12-17

**PRESSOR**
ACTION OF GUANETHIDINE ON THE PRESSOR EFFECT OF ANGIOTENSIN IN ADRENALECTOMIZED DOGS. 046399 01-03
EFFECT OF AMPHETAMINE ON THE PRESSOR RESPONSE TO TYRAMINE: FORMATION OF P-HYDROXYNOREPHEDRINE FROM AMPHETAMINE IN MAN. 090373 11-03
EFFECT OF GANGLIONIC BLOCKING AGENTS ON PRESSOR EFFECTS OF SYMPATHOMIMETIC AMINES OF DIRECT AND INDIRECT ACTION. 110632 12-03

**PRESSURE**
CARDIAC CATECHOLAMINE LEVELS AND BLOOD PRESSURE AFTER CHRONIC TREATMENT WITH BETA-ADRENERGIC BLOCKING AGENTS. 055579 02-03
CORRELATION BETWEEN THE CHANGES OF EEG, PUPILLES AND BLOOD PRESSURE DUE TO INTRAVENOUS INJECTION OF CHLORPROMAZINE: CHLORPROMAZINE TEST. 088611 10-13
HYPOTENSIVE EFFECTS OF CHLORDIAZEPOXIDE, AMOBARBITAL AND CHLORPROMAZINE ON BEHAVIORALLY INDUCED ELEVATED ARTERIAL BLOOD PRESSURE IN THE SQUIRREL MONKEY. 089999 11-04
EFFECT OF L-DOPA ALONE AND IN COMBINATION WITH AN EXTRACEREBRAL DECARBOXYLASE INHIBITOR ON BLOOD PRESSURE AND SOME CARDIOVASCULAR REFLEXES. 090371 11-13

**PRESURGICAL**
A DOUBLE-BLIND EVALUATION OF CAPURIDE (PACINOX) AS A PRESURGICAL AID TO SLEEP. 058371 02-14

**PRETREATED**
EFFECTS OF AN ACUTE STRESS OF FOREBRAIN 5-HYDROXYTRYPTAMINE (5-HT) METABOLISM IN CNS LESIONED AND DRUG PRETREATED RATS. 095671 11-04
ON THE ANALYSIS OF 5-HYDROXYTRYPTOPHAN PRODUCED HYPERTHERMIA IN MICE PRETREATED WITH A MONOAMINE OXIDASE INHIBITOR NIAMID. 098035 11-03

**PRETREATMENT**
EFFECTS OF LITHIUM PRETREATMENT ON AMPHETAMINE AND DMI TETRABENAZINE PRODUCED PSYCHOMOTOR BEHAVIOR. 062521 03-04
ALTERATIONS IN THE BEHAVIORAL EFFECTS OF LSD BY PRETREATMENT WITH P-CHLOROPHENYLALANINE AND ALPHA-METHYL-P-TYROSINE. 097965 11-04

**PREVENTION**
EXTINCTION OF AVOIDANCE RESPONDING THROUGH RESPONSE PREVENTION (FLOODING). 063275 03-04
COMPARISON OF LITHIUM CARBONATE AND IMIPRAMINE (IN PREVENTION OF MANIC-DEPRESSIVE DISEASE). 064317 04-09
PREVENTION OF PAROXYSMAL TACHYCARDIA OF WOLFF-PARKINSON-WHITE SYNDROME WITH COMBINED PROPRANOLOL AND QUINIDINE THERAPY. 070288 07-10
NICOTINIC ACID IN THE PREVENTION AND TREATMENT OF METHIONINE INDUCED EXACERBATION OF PSYCHOPATHOLOGY IN SCHIZOPHRENICS. 075423 08-08
PREVENTION AND TREATMENT OF HYPOTENSION BY USING PSYCHOPHARMACOLOGY. 091139 11-09
THE USE OF LITHIUM SALTS FOR THE PREVENTION OF AFFECTIVE ATTACKS. 096512 11-09
LITHIUM CARBONATE: A DRUG OF LIMITED EFFICACY IN THE PREVENTION OF MANIC-DEPRESSIVE DISEASE. 106764 12-09

**PREVENTIVE**
SOME EXPERIENCES WITH A PREVENTIVE ADMINISTRATION OF LITHIUM SALTS IN MANIC MELANCHOLIC PSYCHOSIS. 070952 07-09
LITHIUM AS A THERAPEUTIC AND PREVENTIVE DRUG IN AFFECTIVE DISORDERS. 109723 12-09

**PRIMACY**
SCOPOLAMINE EFFECTS ON GO-NO-GO AVOIDANCE DISCRIMINATIONS: INFLUENCE OF STIMULUS FACTORS AND PRIMACY OF TRAINING. 090418 11-04

**PRINCIPAL**
PRINCIPAL ELECTROENCEPHALOGRAPHIC CHANGES OBSERVED DURING ACUTE INTOXICATION BY NEUROLEPTICS. 075112 08-13

**PRIVATE**
PRIVATE AMBULATORY PATIENTS TREATED WITH FLUPHENAZINE ENANTHATE. 065458 05-07
FEASIBILITY OF EVALUATING PSYCHOPHARMACEUTICAL AGENTS IN COOPERATIVE STUDIES IN PRIVATE PRACTICE. 069025 06-10
CHEMOTHERAPY IN PRIVATE PSYCHIATRIC PRACTICE. 071043 07-09
PRELIMINARY EXPERIENCES WITH HOBRIUM IN PRIVATE PSYCHIATRIC PRACTICE IN DJAKARTA. 130714 12-10

**PROBATION**
METHADONE PATIENTS ON PROBATION AND PAROLE. 070021 07-13

**PROBENECID**
CSF HOMOVANILLIC ACID: EFFECTS OF PROBENECID AND ALPHA-METHYLTYROSINE. 047506 01-03

**PROBLEM**
THE PROBLEM OF POT: PHARMACOLOGY AND CHEMISTRY. 059622 03-03
THE PROBLEM OF POT: THE MEDICAL EFFECTS OF MARIHUANA. 059623 03-13
THE PROBLEM OF POT: MARIHUANA, A PSYCHIATRIC POINT OF VIEW. 059624 03-14
TEGRETAL: THE PROBLEM OF PSYCHOTROPIC ACTION. 067739 06-14
THE MARIJUANA PROBLEM. 071027 07-17
THE PROBLEM OF CEREBRAL EDEMA DURING COMBINED PSYCHOTROPIC DRUG THERAPY. 079992 09-15
PSYCHOPHARMACOLOGY IN CHILDREN: PROBLEM AREAS, METHODOLOGICAL CONSIDERATIONS, ASSESSMENT TECHNIQUES. 080350 09-17
THE USE AND MISUSE OF ASPIRIN: A CONTEMPORARY PROBLEM. 083415 10-17
THE PROBLEM PATIENT IN PRACTICE: CONTRIBUTION TO A DIFFERENTIAL DIAGNOSTIC PROBLEM OF A TYPE OF DEPRESSION. 094307 11-09

PROBLEM BEHAVIOR OF CHILDREN WITH SEVERE MENTAL AND PHYSICAL DISORDERS -- EXPERIENCE OF THE USE OF CARBAMAZEPINE. 105790 12-14

ON THE PROBLEM OF TREATMENT AND SOME CLINICAL CHARACTERISTICS OF SCHIZOPHRENIA WITH A GRADUAL PAROXYSMAL LIKE COURSE. 111032 12-08

ON THE PROBLEM OF AMBULATORY TREATMENT OF SCHIZOPHRENIA WITH PSYCHOTROPIC DRUGS. 111034 12-08

**PROBLEMS**

NARCOTIC ANTAGONISTS AND THE PROBLEMS OF DRUG DEPENDENCE. 046195 01-13

DOGMATIL: A NEW ILLUMINATION ON THE PSYCHOLOGICAL PROBLEMS OF SENESCENCE. 058313 02-11

PHARMACOLOGICAL AND CLINICAL PROBLEMS OF LITHIUM PROPHYLAXIS. 060264 03-17

METHODOLOGICAL PROBLEMS OF PROPHYLACTIC TRIALS IN RECURRENT AFFECTIVE DISORDERS. 060266 03-09

PROBLEMS REGARDING THE INTRODUCTION OF A PSYCHOPHARMACEUTICAL AGENT IN INTERNATIONAL MARKETS. 060729 03-17

PROBLEMS OF PSYCHOSIS IN SENILITY. 069016 06-11

ACTUAL PROBLEMS OF ENDOGENOUS AND EXOGENOUS DEPRESSIONS. 070956 07-09

METHODOLOGICAL PROBLEMS IN PSYCHOTHERAPY RESEARCH: OBSERVATIONS ON THE KARON-VANDENBOS STUDY OF PSYCHOTHERAPY AND DRUGS IN SCHIZOPHRENIA. 071322 07-08

PROBLEMS PRESENTED BY NEUROLEPTIC THERAPY IN ITALY. 075111 08-14

ON PROBLEMS OF LATE EXTRAPYRAMIDAL HYPERKINESIS DUE TO NEUROLEPTIC LONG-TERM THERAPY. 079996 09-15

CURRENT PROBLEMS OF CLINICAL PSYCHOPHARMACOLOGY. 080394 09-17

SOME PROBLEMS OF NEUROLEPTIC THERAPY. 086205 10-15

CONTRIBUTION TO THE STUDY OF THE ACTION OF PROPERICIAZINE ON BEHAVIORAL PROBLEMS OF THE CHILD AND THE ADOLESCENT. 086451 10-11

PROBLEMS OF NEW DRUGS. 090078 11-07

EFFECTS OF INSULIN, METRAZOL, AND ELECTROCONVULSIVE SHOCKS UPON LEARNING TO LEARN 30 SUCCESSIVE REVERSAL PROBLEMS BY RATS. 095188 11-04

CLINICAL PROBLEMS IN CONNECTION WITH THE APPLICATION OF LITHIUM. 100076 11-09

SOME PROBLEMS OF ORGANIZING THE PSYCHOTHERAPEUTIC ENVIRONMENT IN A MIXED FEMALE PSYCHIATRIC WARD. 111254 12-17

INTOXICATIONS BY LSD-25: MEDICOLEGAL PROBLEMS. 132911 12-12

**PROCEDURE**

A PROCEDURE FOR THE ANALYSIS OF ILLICIT DIAMORPHINE SAMPLES. 046395 01-01

PROJECT SUMMARY: A NEW ASSAY PROCEDURE FOR AMINOTRANSFERASES. 060223 03-03

MODIFICATION OF AN ENZYME RADIOCHEMICAL ASSAY PROCEDURE FOR NORADRENALINE. 064002 04-06

THE INFLUENCE OF VARIOUS NEUROLEPTIC DRUGS ON SHOCK AVOIDANCE RESPONDING IN RATS. III. AMPHETAMINE ANTAGONISM IN THE DISCRIMINATED SIDMAN AVOIDANCE PROCEDURE. 064476 04-04

THE EFFECT OF NICOTINE AND TOTAL ALKALOIDS EXTRACTED FROM CIGARETTE SMOKE IN AVOIDANCE BEHAVIOR IN RATS UNDER EXTINCTION PROCEDURE. 069079 06-04

EXPERIMENTAL STUDIES ON THE EFFECTIVE PROCEDURE TO INHIBIT THE DEVELOPMENT OF TOLERANCE TO AND DEPENDENCE ON MORPHINE. 089789 11-02

THE SYNTHESIS AND BIOLOGICAL ACTIVITY OF (-)-DELTA9(11)-TRANS TETRAHYDROCANNABINOL; A NEW PROCEDURE FOR THE CLEAVAGE OF PHENYL METHYL ETHERS (UNPUBLISHED PAPER). 092888 11-01

**PROCEDURES**

UNITED-STATES PROCEDURES FOR SCREENING DRUGS: TESTING FOR DEPENDENCE LIABILITY IN ANIMALS AND MAN. 058971 03-02

APPLICATION OF ON-LINE COMPUTER PROCEDURES TO EXPERIMENTAL CONTROL AND EVALUATION OF THE EFFECTS OF DRUGS ON OPERANT BEHAVIOR (SIDMAN SHOCK AVOIDANCE RESPONDING BY RATS). 095507 11-06

**PROCEEDING**

A THERAPEUTICAL PATHOMORPHOSIS OF SCHIZOPHRENIA PROCEEDING WITH PARANOID DISORDERS. 067547 06-08

**PROCEEDINGS**

DRUGS, BRAIN AND BEHAVIOUR: PROCEEDINGS OF SYMPOSIUM ON PSYCHOPHARMACOLOGY IN DURHAM. 129564 12-17

**PROCESSING**

A DATA PROCESSING SYSTEM FOR PSYCHOTROPIC DRUG EVALUATION. 060862 03-16

DRUG EFFECTS UPON DATA PROCESSING AS FUNCTIONS OF STORAGE AND RETRIEVAL PARAMETERS. 065127 05-14

EFFECTS OF FLUROTHYL ON MEMORY PROCESSING. 070978 07-04

**PROCHLORPERAZINE**

A DOUBLE-BLIND EVALUATION OF THE ANTIEMETIC EFFICACY OF BENZQUINAMIDE, PROCHLORPERAZINE AND TRIMETHOBENZAMIDE IN OFFICE PRACTICE. 063022 03-07

THERAPEUTIC MEDICATION IN CHRONIC DELIRIUM: COMBINATION OF PROCHLORPERAZINE (TEMENTIL) AND LEVOMEPROMAZINE (NOZINAN). 079288 09-11

**PRODUCTION**

THE ROLE OF THE HYPOTHALAMO-PITUITARY SYSTEM IN THE MECHANISM OF ACTION OF RESERPINE AND 5-HYDROXYTRYPTOPHAN ON ANTIBODY PRODUCTION. 040579 01-03

EQUIVALENCE OF SIMULTANEOUS AND SUCCESSIVE NEOCORTICAL ABLATIONS IN PRODUCTION OF IMPAIRMENTS OF RETENTION OF BLACK WHITE HABITS IN RATS. 076316 09-04

**PRODUCTIVITY**

LITHIUM VERSUS CHLORPROMAZINE FOR MANICS. INITIATIVE AND PRODUCTIVITY VERSUS TRANQUILIZATION HOSPITALIZATION. 063209 03-09

**PROFESSOR**

SOMAPSYCHIC RELATIONS IN MEDICINE: SESSION OF HOMAGE OF THE PERUVIAN ACADEMY OF MEDICINE TO PROFESSOR HONORIO DELGADO. 094610 11-14

**PROFILES**

PSYCHOSOCIAL PROFILES OF PATIENTS ON LITHIUM TREATMENT. 106762 12-14

**PROGESTERONE**

STUDY OF THE EFFECTS OF PROGESTERONE THERAPY ON THE STILBOESTROL INDUCED SENSITIVITY OF ISOLATED UTERI OF HYPOPHYSECTOMIZED RATS. 041540 01-03

**PROGESTINIC**

CONCERNING A CASE OF THROMBOSIS OF THE MIDDLE CEREBRAL ARTERY IN THE COURSE OF PROGESTINIC TREATMENT. 094467 11-14

**PROGRAM**

MARIJUANA PROGRAM ADVANCES AT NIMH. 040149 01-14

THE CHILDRENS PSYCHOPHARMACOLOGY CLINIC: ITS ROLE WITHIN A TOTAL PROGRAM FOR CHILDRENS PSYCHIATRIC SERVICES. 080097 09-17

**PROGRAMMED**

RESPONSE DISRUPTION FOLLOWING AMPHETAMINE SELF-ADMINISTRATION AND PROGRAMMED ADMINISTRATION. 046209 01-04

**PROGRESS**

AFFECTIVE DISORDERS: PROGRESS, BUT SOME UNRESOLVED QUESTIONS REMAIN. 061682 03-09

RELATIONSHIP BETWEEN TASTE THRESHOLD FOR DRUGS AND CLINICAL PROGRESS IN A MIXED GROUP OF PSYCHIATRIC PATIENTS. 087866 10-11

**PROLINTANE**

A NEW STIMULANT, PROLINTANE HYDROCHLORIDE, COMPARED WITH DEXTROAMPHETAMINE IN FATIGUED VOLUNTEERS. 040128 01-14

**PROLIXIN**

A CLINICAL EVALUATION OF PROLIXIN ENANTHATE. 076003 09-08

**PROLONGED**

OCULAR CHANGES OCCURRING WITH PROLONGED HIGH DOSE CHLORPROMAZINE THERAPY. RESULTS FROM A COLLABORATIVE STUDY. 060861 03-15

IS IT FEASIBLE TO TREAT CERTAIN POTENTIALLY DANGEROUS CONDITIONS BY PROLONGED CHEMOTHERAPY.
062406 03-08

THE PROCESS OF LEARNING IN RATS UNDERGOING PROLONGED TREATMENT WITH PSYCHOTROPIC AGENTS.
065441 05-04

THE EFFECT OF PROLONGED LITHIUM TREATMENT ON THE SYNTHESIS RATE AND TURNOVER OF MONOAMINES IN BRAIN REGIONS OF RATS.
066413 05-03

CLINICAL TESTS OF A NEW, PROLONGED ACTION NEUROLEPTIC AGENT, PIMOZIDE.
079863 09-07

III. PROLONGED ACTION NEUROLEPTICS: REPORT ON THE PROLONGED ACTION NEUROLEPTICS.
085992 10-11

III. PROLONGED ACTION NEUROLEPTICS: REPORT ON TREATMENT WITH PROLONGED ACTION NEUROLEPTICS IN PSYCHIATRY.
085993 10-11

STABILITY OF PSYCHIC FUNCTIONS DURING PROLONGED CONFINEMENT TO BED.
086039 10-14

THE EFFECTS OF ACUTE AND PROLONGED LITHIUM TREATMENT ON THE DISTRIBUTION OF ELECTROLYTES, POTASSIUM AND SODIUM.
088614 10-03

**PROMAZINE**

INFLUENCE OF IMIPRAMINE, BENACTYZINE AND PROMAZINE ON THE EFFECTS OF INTRAAMYGDALOID INJECTION OF ACETYLCHOLINE AND SEROTONIN.
098024 11-04

**PROMETHAZINE**

DISTRIBUTION, EXCRETION, AND METABOLISM OF 14C-LABELED QUATERNARY AMMONIUM SALT OF MEPAZINE AND PROMETHAZINE IN RATS.
058571 02-03

**PROPANIDID**

A COMPARISON OF PROPANIDID (EPONTOL) AND THIOPENTONE ANESTHESIA IN ECT.
076276 09-14

**PROPANOL**

EFFECT OF DESMETHYLIMIPRAMINE, IPRINDOLE AND DL-ERYTHRO-ALPHA-(3,4 DICHLOROPHENYL)-BETA-(T-BUTYLAMINO) PROPANOL HCL ON THE METABOLISM OF AMPHETAMINE.
074866 08-03

1-(3,4-DIMETHOXYPHENYL)-2 PROPANOL EFFECT ON CONDITIONED AVOIDANCE RESPONSE IN THE RAT.
089440 11-04

**PROPERICIAZIN**

RESULTS OBTAINED WITH PROPERICIAZIN (8-909-RP) IN THE TREATMENT OF BEHAVIOR AND CHARACTER DISTURBANCES IN CHILDREN AND ADOLESCENTS.
078730 09-14

EXPERIENCE WITH PROPERICIAZIN (AOLEPT) IN THE TREATMENT OF CHILDREN WITH DISTURBED PSYCHOMOTOR FUNCTIONS AND RESTLESSNESS.
081144 09-11

**PROPERICIAZINE**

CONTRIBUTION TO THE STUDY OF THE ACTION OF PROPERICIAZINE ON BEHAVIORAL PROBLEMS OF THE CHILD AND THE ADOLESCENT.
086451 10-11

**PROPHYLACTIC**

PROPHYLACTIC LITHIUM: A DOUBLE-BLIND TRIAL IN RECURRENT AFFECTIVE DISORDERS.
060263 03-09

METHODOLOGICAL PROBLEMS OF PROPHYLACTIC TRIALS IN RECURRENT AFFECTIVE DISORDERS.
060266 03-09

OCCURRENCE OF PERIODIC PSYCHOSES DURING PROPHYLACTIC ADMINISTRATION OF LITHIUM.
070950 07-08

PROPHYLACTIC LITHIUM.
072429 08-09

A LONGITUDINAL INVESTIGATION OF LITHIUM AS A PROPHYLACTIC AGENT FOR RECURRENT DEPRESSIONS.
075425 08-10

PROPHYLACTIC LITHIUM IN RECURRENT AFFECTIVE DISORDERS: A FOUR YEAR STUDY.
081152 09-09

PROPHYLACTIC LITHIUM THERAPY FOR CHRONIC DEPRESSIVE PSYCHOSIS AND SCHIZO-AFFECTIVE DISORDERS.
089105 10-09

CONCERNING THE EVIDENCE FOR A PROPHYLACTIC ACTION OF LITHIUM.
100082 11-09

LITHIUM DROP-OUTS: A FOLLOW-UP STUDY OF PATIENTS WHO DISCONTINUED PROPHYLACTIC TREATMENT.
106771 12-09

PROPHYLACTIC ACTION OF LITHIUM SALTS AND THYROID HORMONES ON SYMPTOMS OF MANIC-DEPRESSIVE AND AFFECTIVE PSYCHOSES: CLINICAL AND EXPERIMENTAL RESULTS.
106774 12-09

**PROPHYLAXIS**

PHARMACOLOGICAL AND CLINICAL PROBLEMS OF LITHIUM PROPHYLAXIS.
060264 03-17

LITHIUM PROPHYLAXIS IN RECURRENT AFFECTIVE DISORDERS.
060267 03-09

TREATMENT AND PROPHYLAXIS OF MANIC STATES WITH A CARBONIC ANHYDRASE INHIBITOR.
105731 12-14

ON THE QUESTION OF THE PROPHYLAXIS OF INITIAL MANIFESTATIONS OF PRESENILE PSYCHOSES.
110105 12-17

**PROPOSALS**

PROPOSALS FOR IMPROVING THE TREATMENT OF BRAIN DAMAGED PATIENTS.
080041 09-11

**PROPRANOLOL**

ON THE ANALYSIS OF CARDIAC BETA-RECEPTORS: STUDIES ON THE BASE OF DOSE EFFECT CURVES FOR ISOPRENALINE, PROPRANOLOL, AND KL-255.
055396 02-03

ANTAGONISTIC EFFECTS OF DOPA AND PROPRANOLOL ON BRAIN GLYCOGEN.
058800 02-03

INHIBITORY EFFECT OF PROPRANOLOL ON THE VASOCONSTRICTOR RESPONSE TO SYMPATHETIC NERVE STIMULATION.
066506 05-03

INHIBITION BY PROPRANOLOL OF ETHANOL INDUCED NARCOSIS.
066510 05-03

RELEASE BY AMPHETAMINE IN MAN OF GROWTH HORMONE AND CORTICOSTEROIDS: THE EFFECTS OF THYMOXAMINE AND PROPRANOLOL.
067602 06-13

PREVENTION OF PAROXYSMAL TACHYCARDIA OF WOLFF-PARKINSON-WHITE SYNDROME WITH COMBINED PROPRANOLOL AND QUINIDINE THERAPY.
070288 07-10

EFFECTS OF PROPRANOLOL (INDERAL) ON PSYCHIATRIC SYMPTOMS IN CHRONIC ALCOHOLISM.
099957 11-11

**PROPYL**

STUDIES ON PSYCHOTROPIC DRUGS (FIFTH REPORT) -- PHARMACOLOGICAL EFFECT OF 8(3-(2-CHLORO-10-PHENOTHIAZINYL)PROPYL)-1 THIADIAZASPIRODECAN-3-ONE HYDROCHLORIDE (APY-606).
131058 12-02

**PROPYLAMINE**

CHEMISTRY AND PHARMACOLOGY OF A NEW POTENTIAL ANTIDEPRESSANT, N-METHYL-N-(4-CHLOROBENZYL-11-DIHYDRO-5H DIBENZAZEPIN-5-YL) PROPYLAMINE HYDROCHLORIDE) (LEO-640, LOPRAMINE HYDROCHLORIDE).
089786 11-01

**PROSPECTUS**

LITHIUM, CREATIVITY, AND MANIC-DEPRESSIVE ILLNESS: REVIEW AND PROSPECTUS.
063601 04-09

**PROTECTION**

PROTECTION OF GSR CONDITIONING BY DEXTROAMPHETAMINE.
075315 08-14

**PROTECTIVE**

DECREASE OF SPONTANEOUS MOTILITY IN EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY AND THE PROTECTIVE ACTIVITY OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126052 12-04

**PROTEIN**

PLASMA PROTEIN BINDING OF TRICYCLIC ANTIDEPRESSIVE DRUGS.
040573 01-13

INHIBITION OF THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN RATS BY DRUGS WHICH INHIBIT RIBONUCLEIC ACID OR PROTEIN SYNTHESIS.
041570 01-03

PLASMA PROTEIN BINDING OF CHLORPROMAZINE.
046138 01-13

THE ALTERATIONS OF PROTEIN METABOLISM OF THE BRAIN CORTEX INDUCED BY ANTICIPATION STRESS AND ACTH.
065434 05-03

THE ROLE OF PLASMA PROTEIN BINDING IN THE INHIBITORY EFFECT OF NORTRIPTYLINE ON THE NEURONAL UPTAKE OF NOREPINEPHRINE.
066278 05-03

PROTEIN AND RNA INHIBITORS AND PROTOZOAN HABITUATION.
066813 05-04

FURTHER STUDIES ON THE EFFECTS OF BLOCKING AGENTS ON PROTEIN SYNTHESIS IN GOLDFISH BRAIN.
083170 10-03

**PROTEINS**
EFFECTS OF THALIDOMIDE AND CHLORCYCLIZINE ON THE BIOSYNTHESIS OF NUCLEIC ACIDS AND PROTEINS IN FETAL AND MATERNAL TISSUES OF THE RAT.
040027 01-05

**PROTHIADENE**
AMITRIPTYLINE, CHLORPROTHIXENE, PROTHIADENE AND PLACEBO IN THE TREATMENT OF NEUROSES.
070946 07-10

**PROTOZOAN**
PROTEIN AND RNA INHIBITORS AND PROTOZOAN HABITUATION.
066813 05-04

**PROTRACTED**
PATHOPHYSIOLOGY OF NARCOTIC ADDICTION; POSSIBLE ROLES OF PROTRACTED ABSTINENCE IN RELAPSE (UNPUBLISHED PAPER).
093000 11-13

**PROTRIPTYLINE**
PROTRIPTYLINE IN THE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS.
058968 03-08
PROTRIPTYLINE: A DOUBLE-BLIND CROSSOVER TRIAL IN DEPRESSIVES.
134940 12-09

**PROVOCATION**
D-CYCLOSERINE THERAPY OF PSYCHOSIS BY SYMPTOM PROVOCATION.
075313 08-08

**PSEUDO-DEMENTED**
PSEUDO-DEMENTED, CONVULSIVE CURABLE DEPRESSION OF THE AGED.
062347 03-09

**PSEUDOCONDITIONED**
THE EFFECT OF AMPHETAMINE, NICOTINE AND ATROPINE ON PSEUDOCONDITIONED RESPONSES OF RATS.
046142 01-04

**PSEUDOPREGNANCY**
PSEUDOPREGNANCY, TREATMENT OF PERIODIC PSYCHIATRIC ILLNESS: A PILOT STUDY.
068215 06-09

**PSILOCYBIN**
PERSONALITY TRAIT DEPENDENT PERFORMANCE UNDER PSILOCYBIN (PART II).
058454 02-12
PERSONALITY TRAIT DEPENDENT PERFORMANCE UNDER PSILOCYBIN.
064323 04-12
ON SIMILAR LINGUISTIC STRUCTURES IN CREATIVE PERFORMANCE AND PSILOCYBIN INDUCED EXPERIENCE.
065433 05-12
EFFECTS OF PSILOCYBIN, DIMETHYLTRYPTAMINE AND VARIOUS LYSERGIC ACID DERIVATIVES ON PHOTICALLY INDUCED EPILEPSY IN THE BABOON (PAPIO-PAPIO).
068163 06-03

**PSYCHASTHENIC**
OBJECTIVE EFFECTS OF DEXAMPHETAMINE AND AMOBARBITAL AND THEIR RELATIONS TO PSYCHASTHENIC PERSONALITY TRAITS.
064389 04-14

**PSYCHEDELIC**
PSYCHEDELIC EXPERIENCE AND THE LANGUAGE PROCESS.
067340 06-12
THE EXPERIMENTAL USE OF PSYCHEDELIC (LSD) PSYCHOTHERAPY.
097286 11-12

**PSYCHEDELICS**
PSYCHEDELICS: THE USES AND IMPLICATIONS OF HALLUCINOGENIC DRUGS.
111933 12-17

**PSYCHIATRIC**
FACTORS AFFECTING CHLORPROMAZINE PLASMA LEVELS IN PSYCHIATRIC PATIENTS.
047913 01-13
MOLINDONE IN ANXIOUS NEUROTIC PSYCHIATRIC OUTPATIENTS: A PILOT STUDY.
058969 03-10
AMITRIPTYLINE IN PSYCHIATRIC THERAPY.
059015 03-09
THE PROBLEM OF POT: MARIHUANA, A PSYCHIATRIC POINT OF VIEW.
059624 03-14
WITHDRAWAL OF ANTIPSYCHOTIC DRUGS FROM CHRONIC PSYCHIATRIC PATIENTS.
060208 03-08
MANDRAX AS AN HYPNOTIC FOR PSYCHIATRIC INPATIENTS: A COMPARATIVE TRIAL WITH CHLORAL HYDRATE.
061562 03-14
THE ROLE OF THE PSYCHIATRIC NURSE IN THE REHABILITATION OF THE SCHIZOPHRENIC PATIENT.
062108 03-08
EXPERIENCE OF PSYCHIATRIC MANAGEMENT OF SCHIZOPHRENIA WITH FLUPHENAZINE DECANOATE.
063186 03-08
SERUM VITAMIN-B12 LEVELS IN PSYCHIATRIC PATIENTS ON LONG-TERM PSYCHOTROPIC DRUG THERAPY.
063874 04-13
A COMPARATIVE STUDY OF FLUPHENAZINE AMITRIPTYLINE COMBINATION AND AMITRIPTYLINE ALONE IN THE TREATMENT OF DEPRESSED PSYCHIATRIC PATIENTS.
064356 04-09
THE USE OF SU-17595A IN THE TREATMENT OF PSYCHIATRIC DISORDERS.
064639 05-07
LONG-ACTING DRUG TREATMENT IN OVERALL PSYCHIATRIC MANAGEMENT.
065472 05-17
PSEUDOPREGNANCY, TREATMENT OF PERIODIC PSYCHIATRIC ILLNESS: A PILOT STUDY.
068215 06-09
A SURVEY OF EXTRAPYRAMIDAL MANIFESTATIONS IN PATIENTS ATTENDING AN AFTER CARE CLINIC OF A PSYCHIATRIC HOSPITAL.
070412 07-15
VALUE OF AMITRIPTYLINE SPOFA IN THE PSYCHIATRIC OUTPATIENT AND INPATIENT PRACTICE.
070944 07-09
PSYCHOTROPIC DRUGS AND THE REGULATION OF BEHAVIORAL ACTIVATION IN PSYCHIATRIC ILLNESS.
070970 07-17
CHEMOTHERAPY IN PRIVATE PSYCHIATRIC PRACTICE.
071043 07-09
MODIFICATION OF CHLORPROMAZINE METABOLISM BY SOME OTHER DRUGS FREQUENTLY ADMINISTERED TO PSYCHIATRIC PATIENTS.
071989 07-13
CLINICAL TRIAL OF A NEW MOLECULE SULPIRIDE IN PSYCHIATRIC PRACTICE.
072156 07-15
SULPIRIDE IN PSYCHIATRIC TREATMENT: CLINICAL AND PSYCHOMETRIC STUDY IN 58 PATIENTS.
072158 07-11
CEREBROSPINAL FLUID 5-HYDROXYINDOLES AND BEHAVIOR AFTER L-TRYPTOPHAN AND PYRIDOXINE ADMINISTRATION TO PSYCHIATRIC PATIENTS.
074938 08-14
THE VALUE OF WORSENING RATES IN PSYCHIATRIC CLINICAL TRIALS.
075388 08-10
SECONDARY IMMUNE RESPONSE TO TETANUS TOXOID IN PSYCHIATRIC PATIENTS.
075412 08-13
THE PHYSICIAN QUESTIONNAIRE: A USEFUL TOOL IN PSYCHIATRIC DRUG RESEARCH.
075843 09-17
PERSISTENCE OF A DRUG PERSONALITY INTERACTION IN PSYCHIATRIC OUTPATIENTS.
075873 09-14
SOME USES OF HALOPERIDOL IN THE TREATMENT OF PSYCHIATRIC CONDITIONS.
075879 09-08
HYPNOTIC PROPERTIES OF NITRAZEPAM (MOGADON) (A COMPARATIVE STUDY OF CHLORDIAZEPOXIDE, DIAZEPAM, NITRAZEPAM, SECOBARBITAL AND PLACEBO IN PSYCHIATRIC PATIENTS).
075884 09-14
DELIRIUM-ACUTUM, A POTENTIALLY FATAL CONDITION IN THE PSYCHIATRIC HOSPITAL.
075980 09-15
THERAPEUTIC INTEREST IN HYDROSARPAN-711 IN DEPRESSIVE STATES AND IN THE PSYCHIATRIC PATHOLOGY OF GERONTOLOGICAL STATES.
079859 09-11
PSYCHIATRIC COMMUNITY CARE SYSTEM: USE OF LONG-ACTING PHENOTHIAZINES.
080007 09-17
CLINICAL AND AMBULANT TESTING WITH FLUPHENAZINE DECANOATE LYOGEN DEPOT IN THE LONG-TERM TREATMENT OF PSYCHIATRIC DISEASE.
080040 09-16
THE CHILDRENS PSYCHOPHARMACOLOGY CLINIC: ITS ROLE WITHIN A TOTAL PROGRAM FOR CHILDRENS PSYCHIATRIC SERVICES.
080097 09-17
CLINICAL EVALUATION IN 112 PSYCHIATRIC PATIENTS OF A BUTYROPHENONE NEUROLEPTIC, DEHYDROBENZPERIDOL (R-4749).
080142 09-11
PSYCHOSIS AND OTHER PSYCHIATRIC MANIFESTATIONS OF LEVODOPA THERAPY.
081150 09-15
A SURVEY OF EXTRAPYRAMIDAL MANIFESTATIONS IN THE INPATIENT POPULATION OF A PSYCHIATRIC HOSPITAL.
086444 10-15
EFFECT OF WITHDRAWAL OF ANTIPARKINSONIAN MEDICATION ON CHRONICALLY HOSPITALIZED PSYCHIATRIC PATIENTS.
086445 10-15
METHODS OF TREATING DELIRIUM-TREMENS AS BASED ON MATERIALS OF THE UNIVERSITY MEDICAL SCHOOLS PSYCHIATRIC CLINIC IN WROCLAW BETWEEN 1958 AND 1968.
087143 10-11

RELATIONSHIP BETWEEN TASTE THRESHOLD FOR DRUGS AND CLINICAL PROGRESS IN A MIXED GROUP OF PSYCHIATRIC PATIENTS.
087866 10-11

PSYCHIATRIC CLINICAL EXPERIENCE WITH AN ANTIANDROGEN PREPARATION.
088995 10-14

THE EFFECT OF A NEW METABOLIC CEREBRAL STIMULANT, CYPRODEMANOL, IN PSYCHIATRIC ASPECTS OF AGING.
089055 10-11

THE DRUG 100-129-HF-1854 (CLOZAPINE) FOR PSYCHIATRIC TREATMENT.
089100 10-09

PSYCHIATRIC DRUG USE AND ABUSE IN THE AGED.
090428 11-17

CLINICAL TESTS OF PIRIDOXILATE IN PSYCHIATRIC THERAPY.
091500 11-07

PSYCHIATRIC CHANGES IN PATIENTS TREATED WITH LEVODOPA: I. THE CLINICAL EXPERIMENT.
092917 11-10

THE USE OF NARCO-ANALYSIS IN DIAGNOSTIC PSYCHIATRIC TECHNIQUE.
093537 11-14

LITHIUM CARBONATE IN PSYCHIATRIC THERAPEUTICS.
094287 11-09

PSYCHIATRIC DRUGS AND TRENDS.
095410 11-15

EFFECTS OF PROPRANOLOL (INDERAL) ON PSYCHIATRIC SYMPTOMS IN CHRONIC ALCOHOLISM.
099957 11-11

SOME PROBLEMS OF ORGANIZING THE PSYCHOTHERAPEUTIC ENVIRONMENT IN A MIXED FEMALE PSYCHIATRIC WARD.
111254 12-17

PRELIMINARY EXPERIENCES WITH NOBRIUM IN PRIVATE PSYCHIATRIC PRACTICE IN DJAKARTA.
130714 12-10

**PSYCHIATRIST**

HOW ONE PSYCHIATRIST BEGAN USING NIACIN.
070284 07-17

**PSYCHIATRY**

LITHIUM IN PSYCHIATRY.
063138 03-09

LITHIUM IN PSYCHIATRY.
063142 03-09

DRUG TREATMENT IN PSYCHIATRY.
063147 03-11

ORTHOMOLECULAR PSYCHIATRY: NIACIN AND MEGAVITAMIN THERAPY.
065416 05-08

THE PHILOSOPHY OF LONG-ACTING MEDICATION IN PSYCHIATRY.
065459 05-17

TESTING OF SULPIRIDE IN CHILD PSYCHIATRY.
067375 06-07

SOME RELATIONS BETWEEN INDOLES AND PSYCHIATRY.
068975 06-13

TWENTY-FIVE YEARS OF BIOCHEMICAL PSYCHIATRY.
070218 07-02

CLINICAL EXPERIENCE OF SULPIRIDE IN PSYCHIATRY.
072159 07-07

NEW IN PSYCHIATRY: MODITEN INJECTABLE THERAPY AND FOLLOW-UP CARE.
072787 08-11

POLYPHARMACY IN PSYCHIATRY: PATTERNS OF DIFFERENTIAL TREATMENT.
075332 08-11

LITHIUM CARBONATE TREATMENT IN PSYCHIATRY.
075584 08-11

THE IMPACT OF PSYCHOPHARMACOLOGY ON MEDICINE AND PSYCHIATRY.
076508 09-17

ANTIPSYCHOTIC DRUGS: AN ESSENTIAL TOOL OF COMMUNITY PSYCHIATRY.
080355 09-08

LSD IN PSYCHIATRY.
082016 10-15

LSD IN PSYCHIATRY.
082018 10-15

III. PROLONGED ACTION NEUROLEPTICS: REPORT ON TREATMENT WITH PROLONGED ACTION NEUROLEPTICS IN PSYCHIATRY.
085993 10-11

INDICATIONS FOR CLOPTHIAPINE IN PSYCHIATRY.
086923 10-09

ELECTROCLINICAL RESEARCH ON THE USE OF 1035-MD IN PSYCHIATRY.
087498 10-11

LITHIUM IN PSYCHIATRY: CLINICAL AND BIOCHEMICAL ASPECTS.
098018 11-09

ON THE MUTAGENIC EFFECT OF MEDICINAL PREPARATIONS USED IN PSYCHIATRY. (REVIEW OF THE LITERATURE).
102119 12-16

DRUGS AND PSYCHIATRY.
138145 12-17

**PSYCHIC**

TREATMENT OF PSYCHOSOMATIC DISTURBANCES ASSOCIATED WITH PSYCHIC SYMPTOMS IN INTERNAL MEDICINE BY MEANS OF DOXEPIN.
072381 07-09

STABILITY OF PSYCHIC FUNCTIONS DURING PROLONGED CONFINEMENT TO BED.
086039 10-14

PSYCHIC SYMPTOMS IN L-DOPA TREATMENT OF PARKINSONS DISEASE.
087659 10-09

PARADOXAL PSYCHIC REACTIONS DURING LITHIUM TREATMENT.
089103 10-15

PSYCHIC EFFECTS IN PATIENTS TREATED WITH LEVODOPA.
091919 11-11

**PSYCHOACTIVE**

EFFECTS OF SOME PSYCHOACTIVE DRUGS ON EXPERIMENTAL NEUROTIC (CONFLICT INDUCED) BEHAVIOR IN CATS.
046143 01-04

THE EFFECTS OF SOME PSYCHOACTIVE DRUGS ON RAT BRAIN ADENOSINE TRIPHOSPHATE LEVELS.
058988 03-03

MONOAMINES IN THE BRAIN UNDER THE INFLUENCE OF MUSCIMOL AND IBOTENIC ACID, TWO PSYCHOACTIVE PRINCIPLES OF AMANITA-MUSCARIA.
064408 04-03

PSYCHOACTIVE DRUGS IN THE IMMATURE ORGANISM.
064474 04-13

FLUORESCENT LABELING OF PSYCHOACTIVE DRUGS.
066738 05-06

HAZARDS IMPLICIT IN PRESCRIBING PSYCHOACTIVE DRUGS.
070897 07-17

AUTORADIOGRAPHIC STUDIES ON THE DISTRIBUTION OF PSYCHOACTIVE DRUGS IN THE RAT BRAIN: IV. C14-THIORIDAZINE.
073709 08-03

EFFECTS OF BENZOCTAMINE (30803-BA, TACITIN), A NEW PSYCHOACTIVE DRUG, ON CATECHOLAMINE METABOLISM.
074861 08-03

COMPREHENSIVE CLINICAL STUDIES OF PSYCHOACTIVE DRUGS.
085289 10-11

**PSYCHOANALYTIC**

PSYCHOANALYTIC EVALUATION OF ADDICTION AND HABITATION.
075300 08-13

**PSYCHOCLINICAL**

PSYCHOCLINICAL OBSERVATIONS ON THE EFFECT OF THE LOGOS COMPOUND (ASSOCIATION OF PYRITHIOXINE DIHYDROCHLORIDE, TRYPTOPHAN AND CALCIUM ALPHA-KETOGLUTARATE).
109258 12-11

**PSYCHODIGESTIVE**

UNIVOCAL TREATMENT OF MULTIFORM DISORDERS: DOGMATIL IN PSYCHODIGESTIVE PATHOLOGY.
089174 10-11

**PSYCHODRUGS**

RESEARCH ON THE DEFECT STATE OF SCHIZOPHRENIC PATIENT UNDER CONTROL OF PSYCHODRUGS.
129273 12-08

**PSYCHODYNAMIC**

INVESTIGATION OF THE PSYCHODYNAMIC REINFORCEMENT OF NEUROLEPTICS WITH 1035-MD.
089111 10-07

**PSYCHODYNAMICS**

PSYCHODYNAMICS OF THE RESPONSE TO PHARMACOLOGIC TREATMENT WITH NEUROLEPTICS IN SCHIZOPHRENICS.
105623 12-08

**PSYCHODYSLEPTIC**

THE PSYCHOTHERAPEUTIC USE OF PSYCHODYSLEPTIC DRUGS.
087530 10-12

**PSYCHOEMOTIONAL**

PHARMACOLOGICAL ASSOCIATION OF THIORIDAZINE HYDERGINE IN PSYCHOEMOTIONAL TROUBLES OF THE AGED.
091138 11-14

**PSYCHOENDOCRINE**

PSYCHOENDOCRINE STUDY OF ORAL CONTRACEPTIVE AGENTS.
065118 05-13

**PSYCHOGENOUS**

CONTROLLED THERAPEUTIC EXPERIMENTATION IN CASES OF PSYCHOGENOUS GASTROENTERIC DISTURBANCE.
072003 07-07

**PSYCHOGERIATRIC**

A SEQUENTIAL TRIAL OF AMYLOBARBITONE SODIUM USED AS SEDATION FOR CONFUSED FEMALE PSYCHOGERIATRIC PATIENTS.
082732 10-11

**PSYCHOLOGIC**

THE INTERACTION OF PSYCHOLOGIC STIMULI AND PHARMACOLOGIC AGENTS ON AIRWAY REACTIVITY IN ASTHMATIC SUBJECTS.
063515 03-13

DANGERS OF PREMATURE PSYCHOLOGIC DIAGNOSIS.
067265 06-14

**PSYCHOLOGICAL**
CLINICAL AND PSYCHOLOGICAL TESTING OF A GERIATRIC DRUG. 042693 01-11
AN ANALYSIS OF PSYCHOLOGICAL DEPENDENCE. 046210 01-04
PSYCHOLOGICAL EFFECTS OF TETRAHYDROCANNABINOL. 047832 01-12
PSYCHOLOGICAL APPROACHES TO OPIATE DEPENDENCE AND SELF-ADMINISTRATION BY LABORATORY ANIMALS. 056240 02-04
EXPERIMENTAL PSYCHOLOGICAL STUDY OF PERFORMANCE CHANGES WITH PERAZINE (TAXILAN) IN MENTALLY DISTURBED AND IN HEALTHY EXPERIMENTAL SUBJECTS FOLLOWING REGIMEN AND SINGLE DOSE ADMINISTRATION. 058235 02-11
DOGMATIL: A NEW ILLUMINATION ON THE PSYCHOLOGICAL PROBLEMS OF SENESCENCE. 058313 02-11
IMPROVED CEREBRAL CIRCULATION AND PERFORMANCE IN A PSYCHOLOGICAL EXPERIMENT. 059001 03-11
PSYCHOLOGICAL METHODS APPLIED TO EVALUATE SYMPTOMATIC GERIATRIC TREATMENT. 064152 04-14
PSYCHOLOGICAL STUDIES OF MARIJUANA AND ALCOHOL IN MAN. 064416 04-12
PRESENT STATUS OF PSYCHOLOGICAL REACTIONS TO L-DOPA. 065165 05-09
CHANGES IN PSYCHOLOGICAL SYMPTOMS IN WOMEN TAKING ORAL CONTRACEPTIVES. 075470 08-13
EFFECT OF A DECARBOXYLASE INHIBITOR (RO-4-4602), COMBINED WITH L-DOPA, ON INHIBITED DEPRESSIVE PATIENTS: II. EXPERIMENTAL PSYCHOLOGICAL STUDIES. 079964 09-14
CANNABIS: A PSYCHOLOGICAL AND METABOLIC INVESTIGATION. 100014 11-14
A PSYCHOLOGICAL STUDY OF THE EFFECTS OF CHLORPROMAZINE (THORAZINE). (PH.D.DISSERTATION). 103273 12-08

**PSYCHOLOGY**
PSYCHOPHARMACOLOGY: INTRODUCTION TO GENERAL PSYCHOLOGY: A SELF-SELECTION TEXTBOOK. 047681 01-17
DRUGS IN PSYCHOLOGY: A COMMENTARY ON TRAVIS THOMPSON AND CHARLES R. SCHUSTERS BEHAVIORAL PHARMACOLOGY. 075793 08-14

**PSYCHOLYTIC**
THE PSYCHOLYTIC TREATMENT OF A CHILDHOOD SCHIZOPHRENIC GIRL. 080609 09-08

**PSYCHOMETRIC**
PSYCHOMETRIC AND PSYCHOPHYSIOLOGICAL TEST IN THE PREDICTION OF THERAPEUTIC RESPONSIVENESS IN THE SCHIZOPHRENIAS. 062643 03-08
SULPIRIDE IN PSYCHIATRIC TREATMENT: CLINICAL AND PSYCHOMETRIC STUDY IN 58 PATIENTS. 072158 07-11
FURTHER PSYCHOMETRIC EVALUATION OF OLDER WOMEN -- THE EFFECT OF ESTROGEN ADMINISTRATION. 078223 09-14
PSYCHOMETRIC TESTS IN EVALUATION OF BRAIN PATHOLOGY, RESPONSE TO DRUGS. 081043 09-14
THE EFFECT OF PSYCHOSTIMULANTS ON PSYCHOMETRIC TEST PERFORMANCE WITH SPECIAL REFERENCE TO CONFLICT AVOIDANCE BEHAVIOR. 082055 10-04

**PSYCHOMOTOR**
EFFECTS OF LITHIUM PRETREATMENT ON AMPHETAMINE AND DMI TETRABENAZINE PRODUCED PSYCHOMOTOR BEHAVIOR. 062521 03-04
P-CHLOROAMPHETAMINE: TEMPORAL RELATIONSHIP BETWEEN PSYCHOMOTOR STIMULATION AND METABOLISM OF BRAIN NOREPINEPHRINE. 062805 03-03
EXPERIENCE WITH PROPERICIAZIN (AOLEPT) IN THE TREATMENT OF CHILDREN WITH DISTURBED PSYCHOMOTOR FUNCTIONS AND RESTLESSNESS. 081144 09-11
PSYCHOMOTOR REACTIONS TO A SLIGHT ALCOHOLEMIA. A COMPARATIVE STUDY ON DRINKERS AND NORMAL INDIVIDUALS. 085043 10-15
MOTOR AND PSYCHOMOTOR ACTIVITY AND STRIATAL MONOAMINES. 086349 10-03
BEHAVIORAL TOXICITY. PART 1: DEFINITION AND PART 2: PSYCHOMOTOR FUNCTIONS. 100524 12-15

**PSYCHONEUROSES**
COMPARATIVE, DOUBLE-BLIND STUDY OF DOXEPINE AND LIBRIUM IN CASES OF PSYCHONEUROSES WITH ANXIETY AMONG HOSPITALIZED AND AMBULATORY PATIENTS. 087489 10-10

**PSYCHONEUROSIS**
DOUBLE-BLIND STUDY WITH SINEQUAN (DOXEPIN) VS DIAZEPAM VS PLACEBO IN PSYCHONEUROSIS. 138526 12-10

**PSYCHONEUROTIC**
PILLS AND IMPROVEMENT: A STUDY OF PLACEBO RESPONSE IN PSYCHONEUROTIC OUTPATIENTS. 066832 05-10
A COMPARATIVE EVALUATION OF DOXEPIN AND CHLORDIAZEPOXIDE IN THE TREATMENT OF PSYCHONEUROTIC OUTPATIENTS. 072140 07-10
DOXEPIN IN THE TREATMENT OF PSYCHONEUROTIC PATIENTS. 072146 07-11

**PSYCHOPATHOLOGICAL**
PSYCHOPATHOLOGICAL ANALYSIS OF THE PROCESS OF SEDATION. 059038 03-17
PSYCHOPATHOLOGICAL SIDE-EFFECTS OF SEDATIVES. 070957 07-15
A TECHNIQUE TO DEMONSTRATE THE EFFECT OF A PSYCHOPHARMACEUTICAL DRUG IN A PSYCHOPATHOLOGICAL LONGITUDINAL SECTION BY NUMERIC AND GRAPHIC MEANS. 079973 09-06

**PSYCHOPATHOLOGY**
NICOTINIC ACID IN THE PREVENTION AND TREATMENT OF METHIONINE INDUCED EXACERBATION OF PSYCHOPATHOLOGY IN SCHIZOPHRENICS. 075423 08-08
DIFFERENTIAL RELIABILITY IN RATING PSYCHOPATHOLOGY AND GLOBAL IMPROVEMENT. 076292 09-10
L-DOPA, BEHAVIORAL ACTIVATION AND PSYCHOPATHOLOGY (UNPUBLISHED PAPER). 078542 09-09
PSYCHOPATHOLOGY OF TRANQUILIZER ABUSE. 133935 12-14

**PSYCHOPATHY**
THE CLINICAL ASPECTS AND DYNAMICS OF PARANOIAC PSYCHOPATHY WITH MALIGNANT DEVELOPMENT. 126632 12-09

**PSYCHOPHARMACA**
EFFECTS OF LITHIUM AND OTHER PSYCHOPHARMACA ON RAT ELECTROLYTE METABOLISM. 106778 12-05

**PSYCHOPHARMACEUTICAL**
PROBLEMS REGARDING THE INTRODUCTION OF A PSYCHOPHARMACEUTICAL AGENT IN INTERNATIONAL MARKETS. 060729 03-17
FEASIBILITY OF EVALUATING PSYCHOPHARMACEUTICAL AGENTS IN COOPERATIVE STUDIES IN PRIVATE PRACTICE. 069025 06-10
STUDIES IN MAN ON THE INFLUENCE OF A NEW PSYCHOPHARMACEUTICAL DRUG, 1-((METHYLAMINO) DIBENZOBICYCLOOCTADIENE HYDROCHLORIDE, ON THE CO2 SENSITIVE CENTRAL RESPIRATORY REGULATION. 079971 09-07
A TECHNIQUE TO DEMONSTRATE THE EFFECT OF A PSYCHOPHARMACEUTICAL DRUG IN A PSYCHOPATHOLOGICAL LONGITUDINAL SECTION BY NUMERIC AND GRAPHIC MEANS. 079973 09-06

**PSYCHOPHARMACEUTICALS**
COMPARATIVE PHARMACOPSYCHOLOGICAL STUDY OF THE EFFECTS PRODUCED BY PSYCHOPHARMACEUTICALS ON VERBAL INTERACTION IN A GROUP OF STUDENTS. 066954 05-14
NEW PSYCHOPHARMACEUTICALS FOR CLINICAL PRACTICE. 079146 09-07
TEMPERATURE INCREASES UNDER TREATMENT WITH PSYCHOPHARMACEUTICALS. 097999 11-15
CLINICAL TRIALS AND TREATMENT WITH PSYCHOPHARMACEUTICALS. A SECOND CRITICAL REVIEW: AN IMPRESSION. 105734 12-17
PSYCHOPHARMACEUTICALS AND NEUROLOGICAL SIDE-EFFECTS. 128390 12-15

**PSYCHOPHARMACODYNAMICS**
PSYCHOPHARMACODYNAMICS OF NEUROLEPTICS. ORGANIZATION EFFECTS OF THE PARANOID SYNDROME. 059039 03-17

**PSYCHOPHARMACOLOGIC**
EFFECTS OF PSYCHOPHARMACOLOGIC AGENTS ON MYOCARDIAL CONTRACTILITY. 064420 04-15

PSYCHOPHARMACOLOGIC EFFECTS OF SOME CHOLINESTERASE INHIBITORS IN COMPARISON WITH IMIPRAMINE.
069074 06-04

**PSYCHOPHARMACOLOGICAL**

THE PSYCHOPHARMACOLOGICAL TREATMENT OF CARDIAC NEUROTIC PATIENTS WITH DIPOTASSIUM CHLORAZEPATE IN THE DOUBLE-BLIND TEST.
055689 02-10

PSYCHOPHARMACOLOGICAL ACTION OF NICOTINAMIDE ADENINE DINUCLEOTIDE.
064481 04-04

THE STAIRCASE MAZE AND THE SIMPLE STAIRCASE IN THE ANALYSIS OF THE PSYCHOPHARMACOLOGICAL ACTION OF CNS DEPRESSANTS.
068291 06-04

RETENTION RATES OF SCHIZOPHRENIA: A COMPARISON OF SHOCK THERAPY AND PSYCHOPHARMACOLOGICAL ERAS AND OF CLOSED AND OPEN DOOR POLICIES.
069795 07-08

THE RELATION OF PSYCHOPHARMACOLOGICAL DRUGS TO LEARNING AND MEMORY.
078509 09-14

EFFECT OF 1035-MD ON CERTAIN CONDITIONS OF MENTAL DEFICIENCY, ESPECIALLY THOSE OF VASCULAR ORIGIN; CLINICAL EEG AND PSYCHOPHARMACOLOGICAL STUDY.
084978 10-08

THE MINK AS A PSYCHOPHARMACOLOGICAL MODEL.
088616 10-06

PSYCHOPHARMACOLOGICAL AGENTS AND MICTURITION DISORDERS: CYSTOMETRIC INVESTIGATIONS.
090126 11-15

THE OBJECTIVE EVALUATION OF PSYCHOPHARMACOLOGICAL DRUGS WITH CAFFEINE AND CAFFEINE-FREE COFFEE AS AN EXAMPLE.
098039 11-13

PSYCHOPHARMACOLOGICAL AGENTS IN THE TREATMENT OF THE CRIMINAL.
104836 12-17

USE OF CATTELS IPAT ANXIETY SCALE IN A GROUP OF NEUROTIC PATIENTS BEFORE AND AFTER PSYCHOPHARMACOLOGICAL DRUG AND ELECTRIC SHOCK THERAPY.
128509 12-17

**PSYCHOPHARMACOLOGY**

PSYCHOPHARMACOLOGY: INTRODUCTION TO GENERAL PSYCHOLOGY: A SELF-SELECTION TEXTBOOK.
047681 01-17

PSYCHOPHARMACOLOGY.
051128 02-17

SOCIAL IMPLICATIONS OF RECENT ADVANCES IN PSYCHOPHARMACOLOGY.
051572 02-17

PSYCHOPHARMACOLOGY.
059072 03-17

PSYCHOPHARMACOLOGY AND GENERAL ADAPTATION SYNDROME.
065346 05-17

LABORATORY EXPERIMENTS SUITABLE FOR PRACTICAL CLASSES IN PSYCHOPHARMACOLOGY.
067599 06-06

PSYCHOPHARMACOLOGY AND CONDITIONAL REFLEXES.
071705 07-13

PSYCHOPHARMACOLOGY: THE PICTURE IS NOT ENTIRELY ROSY.
076327 09-17

THE IMPACT OF PSYCHOPHARMACOLOGY ON MEDICINE AND PSYCHIATRY.
076508 09-17

THE USE OF PSYCHOPHARMACOLOGY IN CHILDREN AND ADOLESCENTS.
080096 09-17

THE CHILDRENS PSYCHOPHARMACOLOGY CLINIC: ITS ROLE WITHIN A TOTAL PROGRAM FOR CHILDRENS PSYCHIATRIC SERVICES.
080097 09-17

PSYCHOPHARMACOLOGY IN CHILDREN: PROBLEM AREAS, METHODOLOGICAL CONSIDERATIONS, ASSESSMENT TECHNIQUES.
080350 09-17

CURRENT PROBLEMS OF CLINICAL PSYCHOPHARMACOLOGY.
080394 09-17

THE IMPORTANCE OF RESEARCH IN BIOGENIC AMINES FOR THE EXPERIMENTAL PSYCHOPHARMACOLOGY.
081110 09-17

PSYCHOPHARMACOLOGY TODAY. ORIENTATIONS IN THE TREATMENT OF SCHIZOPHRENIA.
086877 10-17

PREVENTION AND TREATMENT OF HYPOTENSION BY USING PSYCHOPHARMACOLOGY.
091139 11-09

SIGNIFICANCE OF PSYCHOPHARMACOLOGY ON PSYCHOTHERAPY OF DEPRESSION.
094453 11-09

PSYCHOPHARMACOLOGY OF THE LITHIUM ION (TWENTY YEARS AFTER).
095013 11-09

CLINICAL PSYCHOPHARMACOLOGY: CONCEPTUAL MODELS OF CURRENT TRENDS.
097621 11-17

THE IMPORTANCE OF CYBERNETICS FOR PSYCHOPHARMACOLOGY.
098069 11-16

PSYCHOPHARMACOLOGY: THE ROLE OF CLINICAL RESEARCH.
100276 11-07

PSYCHOPHARMACOLOGY AND THE ELDERLY.
100511 11-15

STRUCTURAL BASIS OF LITHIUM PSYCHOPHARMACOLOGY: EXTRACELLULAR GROUND SUBSTANCE OF RAT BRAIN.
106783 12-03

PSYCHOPHARMACOLOGY AND THE INDIVIDUAL PATIENT.
115463 12-17

APPLIED CLINICAL PSYCHOPHARMACOLOGY.
121795 12-15

DRUGS, BRAIN AND BEHAVIOUR: PROCEEDINGS OF SYMPOSIUM ON PSYCHOPHARMACOLOGY IN DURHAM.
129564 12-17

PSYCHOPHARMACOLOGY AND THE INDIVIDUAL PATIENT.
134057 12-17

THE CINDERELLA OF PSYCHOPHARMACOLOGY (A COMMENTARY ON CANNABIS).
134932 12-13

**PSYCHOPHARMALOGICAL**

PHYSIOLOGICAL AND SITUATIONAL FACTORS IN PSYCHOPHARMALOGICAL EXPERIMENTS.
058638 02-14

**PSYCHOPHYSIOLOGIC**

PSYCHOPHYSIOLOGIC CHANGES ACCOMPANYING ORAL CONTRACEPTIVE USE.
075471 08-13

PRELIMINARY EXPERIENCE WITH MEDAZEPAM (NOBRIUM) IN THE MANAGEMENT OF PSYCHOPHYSIOLOGIC REACTIONS.
075878 09-07

**PSYCHOPHYSIOLOGICAL**

PSYCHOMETRIC AND PSYCHOPHYSIOLOGICAL TEST IN THE PREDICTION OF THERAPEUTIC RESPONSIVENESS IN THE SCHIZOPHRENIAS.
062643 03-08

THE PSYCHOPHYSIOLOGICAL BASIS OF INTROVERSION EXTRAVERSION.
064375 04-04

PSYCHOPHYSIOLOGICAL ASPECTS OF EXTENDED EXPOSURE OF MAN TO AN ENVIRONMENT WITH SENSORY DEPRIVATION.
082954 10-14

A PSYCHOPHYSIOLOGICAL STUDY OF BREATHING BEHAVIOR.
095020 11-15

**PSYCHOSEDATIVE**

PHARMACOPSYCHOLOGICAL CONTRIBUTION TO THE CLINICAL USE OF A PSYCHOSEDATIVE.
092306 11-11

**PSYCHOSENSORIAL**

PSYCHOSENSORIAL PHENOMENA DURING TREATMENT WITH TRICYCLIC THYMOANALEPTICS (PRESENTATION OF TWO CASES).
124311 12-15

**PSYCHOSES**

EFFECT OF DRUGS USED IN PSYCHOSES ON CEREBRAL DOPAMINE METABOLISM.
041566 01-03

THE PRACTICAL USE OF HIGHER NERVOUS ACTIVITY DATA IN THE PHARMACOTHERAPY OF PSYCHOSES.
062664 03-08

CONTROLLED TRIALS OF AN AMITRYPTYLINE FLUPHENAZINE COMBINATION IN DEPRESSIVE NEUROSES AND PSYCHOSES: A COLLABORATIVE STUDY.
067569 06-11

CLINICAL EXPERIENCE WITH OCTOCLOTHEPINE IN SCHIZOPHRENIC PSYCHOSES.
070929 07-08

A CONTROLLED STUDY OF THE EFFECT OF THIOTHIXENE AND PERPHENAZINE IN PSYCHOSES AND SCHIZOPHRENIA.
070938 07-08

OCCURRENCE OF PERIODIC PSYCHOSES DURING PROPHYLACTIC ADMINISTRATION OF LITHIUM.
070950 07-08

THE INFLUENCE OF LONG-TERM PREMEDICATION WITH TRANYLCYPROMINE ON EXPERIMENTAL PSYCHOSES INDUCED BY LSD.
070954 07-12

INITIAL AND INTERVAL TREATMENT OF ACUTE PSYCHOSES WITH INTRAVENOUS INJECTION OF INOFAL.
073708 08-09

OUR EXPERIENCE WITH TOXIC PSYCHOSES.
074575 08-15

POSSIBILITIES AND LIMITATIONS OF DEPOT NEUROLEPTIC TREATMENT OF SCHIZOPHRENIC PSYCHOSES.
087066 10-17

REMARKS ON THE USE OF CLOMIPRAMINE (ANAFRANIL) IN CERTAIN ACUTE DELIRIANT PSYCHOSES (WITHOUT A CLEAR DEPRESSIVE ELEMENT).
088438 10-14

LITHIUM TREATMENT OF THE PSYCHOSES.
090358 11-16

ON THE BIOCHEMICAL MECHANISM OF ACTION OF NICOTINIC ACID, NICOTINAMIDE, METHIONINE, AND D-PENICILLAMINE IN THE TREATMENT OF PSYCHOSES.
094962 11-13

A DOUBLE-BLIND INVESTIGATION WITH FLUPENTHIXOL AND TRIFLUOPERAZINE AT TREATMENT OF SCHIZOPHRENIC PSYCHOSES.
100017 11-08

PROPHYLACTIC ACTION OF LITHIUM SALTS AND THYROID HORMONES ON SYMPTOMS OF MANIC-DEPRESSIVE AND AFFECTIVE PSYCHOSES: CLINICAL AND EXPERIMENTAL RESULTS.
106774 12-09

ON THE QUESTION OF THE PROPHYLAXIS OF INITIAL MANIFESTATIONS OF PRESENILE PSYCHOSES.
110105 12-17

CLINICAL RESULTS ON THE THERAPEUTIC ACTION OF LITHIUM CARBONATE IN DYSTHYMIC PSYCHOSES.
114880 12-09

COMPARISON OF DITRAN INTOXICATION AND ACUTE ALCOHOL PSYCHOSES.
121083 12-14

A SUPPLEMENT TO CLINICAL EVALUATION OF THIOTHIXENE WITH SPECIAL REFERENCE TO THE TREATMENT OF AFFECTIVE PSYCHOSES.
129452 12-09

ON THE EFFICACY AND THE MECHANISM OF ACTION OF LITHIUM SALTS IN MANIC-DEPRESSIVE PSYCHOSES.
130414 12-09

BIOLOGICAL ASPECTS AND NOSOGRAPHY OF THE PSYCHOSES (CRITICAL NOTE).
130417 12-17

**PSYCHOSIS**

MODEL PSYCHOSIS OR INSTANT ZEN.
046730 01-12

COMBINED ADRENAL AND THYROID DEFICIENCY (SCHMIDTS SYNDROME) PRESENTING AS AN ACUTE PSYCHOSIS.
056350 02-15

ACUTE ORGANIC PSYCHOSIS DUE TO TALWIN (PENTAZOCINE).
058951 02-15

THE PRESENT STATUS OF LITHIUM THERAPY IN MANIC-DEPRESSIVE PSYCHOSIS.
064089 04-09

DEPOT FLUPHENAZINE IN THE TREATMENT OF PSYCHOSIS IN A COMMUNITY MENTAL HEALTH CLINIC.
065475 05-08

FLUPHENAZINE HYDROCHLORIDE, ENANTHATE, AND DECANOATE IN THE MANAGEMENT OF CHRONIC PSYCHOSIS.
065476 05-08

FLUPHENAZINE HYDROCHLORIDE AND ENANTHATE IN THE MANAGEMENT OF CHRONIC PSYCHOSIS.
065478 05-08

ELECTROENCEPHALOGRAPHIC ANALYSIS OF EXPERIMENTAL PSYCHOSIS BROUGHT ON BY DITRAN.
067147 06-13

PROBLEMS OF PSYCHOSIS IN SENILITY.
069016 06-11

A COMPARISON OF THE EFFECTS OF METHYLPERIDOL AND PERPHENAZINE IN SCHIZOPHRENIC PSYCHOSIS.
070936 07-08

CLINICAL USE OF THIOPROPAZATE (DARTALAN) IN PATIENTS WITH PSYCHOSIS.
070937 07-09

SOME EXPERIENCES WITH A PREVENTIVE ADMINISTRATION OF LITHIUM SALTS IN MANIC MELANCHOLIC PSYCHOSIS.
070952 07-09

CLINICAL STUDY OF A PSYCHOTROPIC DRUG: SULPIRIDE IN ATTEMPTED SUICIDE WITHOUT PSYCHOSIS.
072155 07-14

WEIGHT CHANGES WITH SCHIZOPHRENIC PSYCHOSIS AND PSYCHOTROPIC DRUG THERAPY.
074218 08-08

D-CYCLOSERINE THERAPY OF PSYCHOSIS BY SYMPTOM PROVOCATION.
075313 08-08

DIETHYLPROPION PSYCHOSIS.
080110 09-15

PSYCHOSIS AND OTHER PSYCHIATRIC MANIFESTATIONS OF LEVODOPA THERAPY.
081150 09-15

PROPHYLACTIC LITHIUM THERAPY FOR CHRONIC DEPRESSIVE PSYCHOSIS AND SCHIZO-AFFECTIVE DISORDERS.
089105 10-09

INFLUENCE OF AMINAZIN ON ADRENALIN, NORADRENALINE, DOPAMINE, AND DOPA EXCRETION IN HEALTHY PEOPLE AND IN THE MANIC PHASE OF THE MANIC-DEPRESSIVE PSYCHOSIS.
090355 11-03

DIETHYLPROPION AND PSYCHOSIS.
095443 11-15

CONCERNING THE ARTICLE BY N.N.TIMOFEYEV, V.T.KONDRASHENKO AND N.Y.NEMTSEVA ON OXYMETRIC INVESTIGATION OF PATIENTS WITH SCHIZOPHRENIA AND REACTIVE PSYCHOSIS DURING NEUROLEPTIC TREATMENT.
109788 12-08

**PSYCHOSOCIAL**

PSYCHOSOCIAL PROFILES OF PATIENTS ON LITHIUM TREATMENT.
106762 12-14

**PSYCHOSOMATIC**

PSYCHOSOMATIC ALLERGY.
063593 03-11

TREATMENT OF PSYCHOSOMATIC DISTURBANCES ASSOCIATED WITH PSYCHIC SYMPTOMS IN INTERNAL MEDICINE BY MEANS OF DOXEPIN.
072381 07-09

THE USE OF TWO COMBINATIONS OF DRUGS WITH MIXED ACTION, ANTIDEPRESSIVE AND TRANQUILIZING (AMITRYPTILINE - PERPHENAZINE) IN GENERAL AND IN PSYCHOSOMATIC MEDICINE.
089162 10-17

PSYCHOSOMATIC FACTORS IN RHEUMATIC DISORDERS AND THEIR RELIEF BY MEDICATION.
089859 11-14

INDICATIONS OF LITHIUM SALTS IN PSYCHOSOMATIC MEDICINE.
106770 12-17

MANS TRIPARTITE BRAIN AND PSYCHOSOMATIC MEDICINE.
119884 12-17

**PSYCHOSTIMULANTS**

THE EFFECT OF PSYCHOSTIMULANTS ON PSYCHOMETRIC TEST PERFORMANCE WITH SPECIAL REFERENCE TO CONFLICT AVOIDANCE BEHAVIOR.
082055 10-04

SEPARATION AND IDENTIFICATION OF TRANQUILIZERS AND PSYCHOSTIMULANTS.
131625 12-06

**PSYCHOTHERAPEUTIC**

STATISTICAL METHOD OF ANALYSIS AND EVALUATION OF PSYCHOTHERAPEUTIC RESULTS: APPLICATION OF A LONG-ACTING NEUROLEPTIC, COMPARED WITH A STANDARD NEUROLEPTIC AND THE SAKEL INSULIN TREATMENT.
042676 01-07

EFFECTS OF PSYCHOTHERAPEUTIC DRUGS ON HYPOTHALAMIC INDUCED HISSING IN CATS.
046139 01-04

TWO TRIALS WITH A NEW PSYCHOTHERAPEUTIC DRUG IN THE TREATMENT OF ANXIETY.
058335 02-10

THE PSYCHOTHERAPEUTIC USE OF PSYCHODYSLEPTIC DRUGS.
087530 10-12

SOME PROBLEMS OF ORGANIZING THE PSYCHOTHERAPEUTIC ENVIRONMENT IN A MIXED FEMALE PSYCHIATRIC WARD.
111254 12-17

**PSYCHOTHERAPY**

PSYCHOTHERAPY WITH LSD: PRO AND CON.
046733 01-11

PSYCHOTHERAPY FOR THE DYING: PRINCIPLES AND ILLUSTRATIVE CASES WITH SPECIAL REFERENCE TO THE USE OF LSD.
062808 03-12

LONG-TERM PSYCHOTHERAPY UTILIZING TRIFLUOPERAZINE IN A PSYCHOTIC PRESCHOOL CHILD: (A CASE STUDY).
066806 05-11

THE USE OF LSD IN PSYCHOTHERAPY.
067339 06-12

METHODOLOGICAL PROBLEMS IN PSYCHOTHERAPY RESEARCH: OBSERVATIONS ON THE KARON-VANDENBOS STUDY OF PSYCHOTHERAPY AND DRUGS IN SCHIZOPHRENIA.
071322 07-08

THE THERAPEUTIC POTENTIAL OF LSD: ITS ADJUNCTIVE USE IN PSYCHOTHERAPY.
073852 08-12

SIGNIFICANCE OF PSYCHOPHARMACOLOGY ON PSYCHOTHERAPY OF DEPRESSION.
094453 11-09

THE EXPERIMENTAL USE OF PSYCHEDELIC (LSD) PSYCHOTHERAPY.
097286 11-12

**PSYCHOTIC**

THE DIFFERENTIAL RESPONSE TO PARENTERAL CHLORPROMAZINE AND MESORIDAZINE IN PSYCHOTIC PATIENTS.
040127 01-08

THE USE OF HIGH DOSES OF FLUPHENAZINE IN THE TREATMENT OF PSYCHOTIC PATIENTS.
063589 03-08

MAINTENANCE THERAPY OF CHRONIC PSYCHOTIC PATIENTS WITH A WEEKLY ORAL DOSE OF R-16341. A CONTROLLED DOUBLE-BLIND STUDY.
064284 04-09

THE USE OF MOLINDONE IN THE TREATMENT OF ACUTE PSYCHOTIC STATES: COMPARISON OF TWO DOSAGE SCHEDULES.
064286 04-08

THE VARIABLES OF SILENT MYOCARDIAL INFARCTION IN A PSYCHOTIC POPULATION.
065314 05-10

LONG-ACTING PHENOTHIAZINES AND LONG-TERM PSYCHOTIC PATIENTS: THE ROLE OF FLUPHENAZINE ENANTHATE IN TREATMENT.
065479 05-08

LONG-TERM PSYCHOTHERAPY UTILIZING TRIFLUOPERAZINE IN A PSYCHOTIC PRESCHOOL CHILD: (A CASE STUDY).
066806 05-11

CLINICAL STUDY ON OXYPERTINE IN CHRONICALLY PSYCHOTIC PATIENTS.
067597 06-09

TWO PSYCHOTIC EPISODES ASSOCIATED WITH CANNABIS.
067692 06-09

A CONTROLLED COMPARATIVE STUDY OF FLUPHENAZINE AND FLUPHENAZINE ENANTHATE IN ACUTE AND CHRONIC PSYCHOTIC PATIENTS.
075881 09-08

CLINICAL CONSIDERATIONS ABOUT THE TREATMENT OF VARIOUS ACUTE PSYCHOTIC STATES WITH THIOTHIXENE.
079746 09-11

CLINICAL TRIAL OF CLOMACRAN PHOSPHATE (SKF-14336) IN CHRONIC PSYCHOTIC MALE PATIENTS.
082056 10-07

DIBENZOXAZEPINE IN PSYCHOTIC PATIENTS.
086793 10-09

A LONG-ACTING NEUROLEPTIC IN THE TREATMENT OF CHRONIC ALCOHOLISM IN NEUROTIC AND PSYCHOTIC PATIENTS.
109255 12-11

DISTURBANCES IN TRYPTAMINE SEROTONIN METABOLISM ASSOCIATED WITH PSYCHOTIC PHENOMENA.
121084 12-13

**PSYCHOTOGENIC**

ACTION OF PSYCHOTOGENIC DRUGS ON SINGLE MIDBRAIN RAPHE NEURONS.
040418 01-03

**PSYCHOTOGENS**

THE ACTION OF TRYPTAMINE ON THE DOG SPINAL CORD AND ITS RELATIONSHIP TO THE AGONISTIC ACTIONS OF LSD-LIKE PSYCHOTOGENS.
090422 11-03

**PSYCHOTOMIMETIC**

PSYCHOTOMIMETIC PROPERTIES AND THERAPEUTIC POTENTIALS OF DEXOXADROL ON CONVALESCING ALCOHOLICS.
058448 02-12

THE EFFECT OF A PSYCHOTOMIMETIC GLYCOLATE AND ITS ANTIDOTE ESERINE ON THE ACH CONTENT OF THE LOBSTER WALKING LEG NERVE.
069515 06-13

EFFECT OF PSYCHOTOMIMETIC AGENTS ON SEX RATIO?
071960 07-15

DETECTION OF PSYCHOTOMIMETIC N,N DIMETHYLATED INDOLEAMINES IN THE URINE OF FOUR SCHIZOPHRENIC PATIENTS.
080506 09-08

THE INFLUENCES OF THE STANDARD PREFRONTAL LOBOTOMY OPERATION ON HALLUCINATORY PHENOMENA ASSOCIATED WITH PSYCHOTOMIMETIC DRUGS.
120899 12-13

**PSYCHOTROPIC**

OCULAR (PIGMENTARY) EFFECTS OF PSYCHOTROPIC DRUGS.
058212 02-15

PSYCHOTROPIC AGENTS IN THE CORONARY PATIENT: WHAT AND WHEN.
059728 03-16

A DATA PROCESSING SYSTEM FOR PSYCHOTROPIC DRUG EVALUATION.
060862 03-16

PROJECT SUMMARY: SYNTHESIS OF POTENTIAL PSYCHOTROPIC AGENTS.
062435 03-01

ELECTROENCEPHALOGRAPHIC VARIATIONS INDUCED BY PSYCHOTROPIC DRUGS: CLINICAL ELECTROPHYSIOLOGICAL CORRELATIONS FOR A GUIDED THERAPY.
063200 03-13

SERUM VITAMIN-B12 LEVELS IN PSYCHIATRIC PATIENTS ON LONG-TERM PSYCHOTROPIC DRUG THERAPY.
063874 04-13

CLASSIFICATION, NOSOLOGY, AND RATING SCALES OF PSYCHOTROPIC DRUGS.
064090 04-01

SYNTHESIS OF SOME GLYCIDIC HYDRAZIDES AND AMIDES AS POTENTIAL PSYCHOTROPIC AGENTS AND ANTICHOLINERGIC AGENTS.
064258 04-01

PHARMACOLOGICAL AND DYNAMIC FACTORS IN PSYCHOTROPIC DRUG THERAPY.
065409 05-15

THE PROCESS OF LEARNING IN RATS UNDERGOING PROLONGED TREATMENT WITH PSYCHOTROPIC AGENTS.
065441 05-04

THE PRESENT STATUS OF PSYCHOTROPIC DRUGS.
066950 05-17

THE METABOLISM OF PSYCHOTROPIC DRUGS (PHENOTHIAZINE AND IMINODIBENZYL DERIVATIVES).
067301 06-17

TEGRETAL: THE PROBLEM OF PSYCHOTROPIC ACTION.
067739 06-14

EFFECTS OF PRENATAL ADMINISTRATION OF PSYCHOTROPIC DRUGS TO RATS ON BRAIN BUTYRYLCHOLINESTERASE ACTIVITY AT BIRTH.
067980 06-03

CARDIAC TOXICITY AND PSYCHOTROPIC DRUGS.
068603 06-15

TRIAL OF A NEW PSYCHOTROPIC DRUG DOXEPIN.
069072 06-07

NONADDICTIVE PSYCHOTROPIC MEDICATION FOR IMPRISONED NARCOTIC ADDICTS.
070784 07-13

INTERACTION OF SOME PSYCHOTROPIC DRUGS WITH ANALGESICS.
070948 07-04

PSYCHOTROPIC DRUGS AND THE REGULATION OF BEHAVIORAL ACTIVATION IN PSYCHIATRIC ILLNESS.
070970 07-17

SOME CLINICAL AND LABORATORY STUDIES OF PSYCHOTROPIC DRUGS IN CHILDREN: AN OVERVIEW.
070975 07-17

CLINICAL STUDY OF A PSYCHOTROPIC DRUG: SULPIRIDE IN ATTEMPTED SUICIDE WITHOUT PSYCHOSIS.
072155 07-14

DEVELOPMENT OF FIGHTING BEHAVIOR IN STARVED RATS BY CHRONIC ADMINISTRATION OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL AND CANNABIS EXTRACTS: LACK OF ACTION OF OTHER PSYCHOTROPIC DRUGS.
072531 08-04

OPHTHALMOLOGICAL STUDIES OF PATIENTS RECEIVING PSYCHOTROPIC PREPARATIONS.
073788 08-15

PATIENT PERSONALITY AND DEMOGRAPHIC FACTORS AS PREDICTORS OF EARLY RESPONSE TO PSYCHOTROPIC DRUG TREATMENT.
074130 08-10

WEIGHT CHANGES WITH SCHIZOPHRENIC PSYCHOSIS AND PSYCHOTROPIC DRUG THERAPY.
074218 08-08

EFFECTS OF PRENATAL ADMINISTRATION OF PSYCHOTROPIC DRUGS ON BEHAVIOR OF DEVELOPING RATS.
074830 08-04

THE ROLE OF BRAIN DOPAMINE IN BEHAVIORAL REGULATION AND THE ACTIONS OF PSYCHOTROPIC DRUGS.
075869 09-04

COMBINATION TEST ON THE ANALGESIC EFFECT OF DEXTROPROPOXYPHENE AND SOME PSYCHOTROPIC DRUGS IN THE MOUSE.
079961 09-03

ACCELERATED ACTION OF PSYCHOTROPIC DRUGS EFFECTED BY PYRITHIOXIN.
079966 09-13

PSYCHOTROPIC DRUG THERAPY AND THE PHARMACEUTICAL INDUSTRY.
079987 09-17

2-ETHYLAMINO-6-CHLORO-4-METHYL-4-PHENYL-4H-3,1 BENZOXAZINE, A NEW PSYCHOTROPIC COMPOUND.
079988 09-02

THE PROBLEM OF CEREBRAL EDEMA DURING COMBINED PSYCHOTROPIC DRUG THERAPY.
079992 09-15

CLINICAL RESULTS OF THE TESTING FOR ANALGESIC EFFECT OF DEXTROPROPOXYPHENE IN COMBINATION WITH A PSYCHOTROPIC PREPARATION (TROPAX).
081147 09-17

THE USE AND ABUSE OF PSYCHOTROPIC DRUGS.
083128 10-15

CLASSIFICATION OF PSYCHOTROPIC DRUGS.
086202 10-17

RESEARCH ON NEW METHODS OF EXPERIMENTATION WITH PSYCHOTROPIC DRUGS. RESULTS OF A TEST WITH A NEW TRANQUILIZER, NOBRIUM, IN TWO INDEPENDENT INVESTIGATIONS.
086984 10-16

THE USE AND MISUSE OF PSYCHOTROPIC DRUGS.
088707 10-15

THE ACTION OF SOME PSYCHOTROPIC DRUGS ON DEFECATION RATE IN THE MOUSE.
089003 10-05

THE USEFULNESS OF PLACEBO AND THE DOUBLE-BLIND TECHNIQUE IN THE EVALUATION OF PSYCHOTROPIC DRUGS.
089054 10-17
PSYCHOTROPIC DRUG USE AND DRIVING RISK: A REVIEW AND ANALYSIS.
093085 11-17
CLINICAL EVALUATION OF A NEW PSYCHOTROPIC DRUG -- MOLINDONE.
097997 11-07
THE COMBINATION OF PSYCHOTROPIC DRUGS IN THE TREATMENT OF SCHIZOPHRENIA.
098002 11-08
SEROTONINERGIC PROCESSES IN THE ACTION OF PSYCHOTROPIC DRUGS.
098055 11-03
PSYCHOTROPIC DRUG SIDE-EFFECTS: CLINICAL AND THEORETICAL PERSPECTIVES.
100516 12-15
PSYCHOTROPIC DRUG SIDE-EFFECTS IN CHILDREN.
100517 12-15
ACUTE POISONING WITH PSYCHOTROPIC DRUGS.
100518 12-15
PREGNANCY AND PSYCHOTROPIC DRUGS.
100519 12-15
ADRENERGIC MECHANISMS IN THE CENTRAL ACTION OF PSYCHOTROPIC DRUGS. (PH.D.DISSERTATION).
102415 12-06
ON THE PROBLEM OF AMBULATORY TREATMENT OF SCHIZOPHRENIA WITH PSYCHOTROPIC DRUGS.
111034 12-08
RESEARCH IN NEW EXPERIMENTAL METHODS FOR PSYCHOTROPIC DRUGS: RESULTS OF A DOUBLE-BLIND STUDY WITH A NEW TRANQUILIZER, NOBRIUM.
112282 12-16
PHARMACOLOGICAL STUDIES OF OXAZOLAZEPAM, A NEW PSYCHOTROPIC AGENT - I. ACTIONS ON THE CENTRAL NERVOUS SYSTEM, ESPECIALLY ON THE BEHAVIORAL OBSERVATION.
114769 12-02
PHARMACOLOGICAL STUDIES OF OXAZOLAZEPAM, A NEW PSYCHOTROPIC AGENT -- II. GENERAL PHARMACOLOGY AND SUBACUTE TOXICITY.
114835 12-07
A COMPARATIVE DETERMINATION OF SIDE-EFFECTS ASSOCIATED WITH THE ORAL USE OF THREE ANTICHOLINERGIC PSYCHOTROPIC DRUGS.
126639 12-15
STUDY ON THE EFFECTS OF PSYCHOTROPIC DRUGS UPON THE PHOTICALLY DRIVING THETA RESPONSE OF ELECTROENCEPHALOGRAMS.
129740 12-08
STUDIES ON PSYCHOTROPIC DRUGS (SIXTH REPORT) - METABOLIC FATE OF APY-606 - EXCRETION AND METABOLISM IN RATS.
131057 12-02
STUDIES ON PSYCHOTROPIC DRUGS (FIFTH REPORT) -- PHARMACOLOGICAL EFFECT OF 8(3-(2-CHLORO-10-PHENOTHIAZINYL)PROPYL)-1 THIADIAZASPIRODECAN-3-ONE HYDROCHLORIDE (APY-606).
131058 12-02
STUDIES ON PSYCHOTROPIC DRUGS (SEVENTH REPORT) -- METABOLIC FATE OF APY-606 -- ABSORPTION, DISTRIBUTION, EXCRETION AND METABOLISM OF TRITIATED APY-606.
131059 12-02

**PSYCHOTROPICS**
PSYCHOTROPICS IN ANXIETY AND DEPRESSION -- COMBINATION OR SINGLE AGENT.
068298 06-09

**PUBLIC**
HALLUCINOGENS AND NARCOTICS ALARM PUBLIC.
057978 02-15

**PULMONARY**
THE EFFECT OF FLUROTHYL AND ELECTROSHOCK ON PULMONARY DIFFUSION.
058365 02-15

**PULSIONAL**
PULSIONAL ECONOMY AND CHEMOTHERAPY.
086452 10-17

**PUNISHED**
EFFECTS OF SOME BENZODIAZEPINES ON PUNISHED AND UNPUNISHED BEHAVIOR IN THE PIGEON.
040758 01-04
TRYPTAMINERGIC MECHANISMS IN PUNISHED AND NONPUNISHED BEHAVIOR.
069738 07-04

**PUNISHMENT**
FLUID INTAKE AND PUNISHMENT ATTENUATING DRUGS.
067704 06-04
A CHOICE TECHNIQUE TO ASSESS THE EFFECTS OF SELECTIVE PUNISHMENT ON FIXED-RATIO PERFORMANCE.
075579 08-04

**PUPIL**
PUPIL SIZE AND DRUG STATE IN A REACTION TIME TASK.
075161 08-13

**PUPILLARY**
PUPILLARY EFFECTS OF LEVODOPA THERAPY.
058534 02-15

**PUPILLES**
CORRELATION BETWEEN THE CHANGES OF EEG, PUPILLES AND BLOOD PRESSURE DUE TO INTRAVENOUS INJECTION OF CHLORPROMAZINE: CHLORPROMAZINE TEST.
088611 10-13

**PURIFIED**
HEPATIC COMPOSITION AND METABOLISM AFTER ETHANOL CONSUMPTION IN RATS FED LIQUID PURIFIED DIETS.
088599 10-03

**PURKINJE**
THE NUMBER OF PURKINJE CELLS AFTER DIPHENYLHYDANTOIN INTOXICATION IN MONKEYS.
066189 05-05

**PUROMYCIN**
THE EFFECT OF PUROMYCIN ON RETENTION OF A POSITIVELY REINFORCED RESPONSE IN GOLDFISH.
059616 03-04
THE EFFECT OF PUROMYCIN ON CLASSICAL CONDITIONING IN THE GOLDFISH.
075375 08-04

**PUTAMEN**
POSSIBLE DOPAMINERGIC PATHWAY FROM SUBSTANTIA-NIGRA TO PUTAMEN.
063983 04-03

**PYRAHEXYL**
EFFECTS OF A MARIHUANA HOMOLOGUE (PYRAHEXYL) ON AVOIDANCE LEARNING IN THE GERBIL.
059032 03-04

**PYRAMIDOTOMY**
SPEED, ACCURACY, AND STRENGTH OF FORELIMB MOVEMENT AFTER UNILATERAL PYRAMIDOTOMY IN RHESUS MONKEYS.
076213 09-04

**PYRAZINAMIDE**
LIVER DAMAGE FOLLOWING APPLICATION OF PYRAZINAMIDE IN ANIMAL EXPERIMENTS: 1. CHANGES IN BODY WEIGHT OF RATS UNDER THE INFLUENCE OF PYRAZINAMIDE.
055398 02-05

**PYRAZOL**
A STUDY OF HEPATIC ALCOHOL DEHYDROGENASE INHIBITION (ADH) INDUCED BY PYRAZOL: II. THE ROLE OF LIVER ADH IN THE IN VIVO METABOLISM OF HYDROXYL COMPOUNDS.
089547 11-03
A STUDY OF HEPATIC ALCOHOL DEHYDROGENASE INHIBITION INDUCED BY PYRAZOL: I. IN VIVO ACTION ON ETHANOL AND 2-PHENYLETHANOL.
089548 11-03

**PYRIDOXAL**
INCREASE IN BRAIN PYRIDOXAL PHOSPHATE BY CHLORPROMAZINE.
046397 01-02

**PYRIDOXINE**
CEREBROSPINAL FLUID 5-HYDROXYINDOLES AND BEHAVIOR AFTER L-TRYPTOPHAN AND PYRIDOXINE ADMINISTRATION TO PSYCHIATRIC PATIENTS.
074938 08-14
EFFECT OF A DEFICIENCY OF PANTOTHENIC ACID AND PYRIDOXINE ON THE FUNCTION OF THE CENTRAL NERVOUS SYSTEM AND ITS RESPONSE TO COUMARIN FROM MELILOTUS-OFFICINALIS.
126053 12-04
INFLUENCE OF ISONIAZID ON THE CENTRAL NERVOUS SYSTEM; THE ANTAGONISM BETWEEN ISONIAZID AND PYRIDOXINE, PANTOTHENIC ACID AND COUMARIN IN RATS (MELILOTUS-OFFICINALIS).
126055 12-04

**PYRIDYL**
BLOCKADE OF NORADRENALINE UPTAKE AND INHIBITION OF GASTRIC ACID SECRETION BY 2-(P-CHLOROPHENYL-2-(PYRIDYL)HYDROXYMETHYL) IMIDAZOLINE MALEATE (SCH-12650).
058878 02-02

**PYRIMIDINE**
INTERFERENCE OF BARBITURATES WITH PYRIMIDINE INCORPORATION -- III: STUDIES ON THE MECHANISM OF THE AMOBARBITAL OROTATE RELATIONSHIP.
064045 04-03
INTERFERENCE OF BARBITURATES WITH PYRIMIDINE INCORPORATION -- II: STRUCTURAL SPECIFICITY OF THE INHIBITION OF OROTATE UPTAKE IN BACILLUS-CEREUS.
064046 04-03
THE USE OF THE PYRIMIDINE NUCLEOSIDES (CYTIDINE AND URIDINE) IN THE THERAPY OF CEREBRAL VASCULAR ILLNESS.
094472 11-13

**PYRITHIOXIN**
ACCELERATED ACTION OF PSYCHOTROPIC DRUGS EFFECTED BY PYRITHIOXIN.
079966 09-13

**PYRITHIOXINE**
PSYCHOCLINICAL OBSERVATIONS ON THE EFFECT OF THE LOGOS COMPOUND (ASSOCIATION OF PYRITHIOXINE DIHYDROCHLORIDE, TRYPTOPHAN AND CALCIUM ALPHA-KETOGLUTARATE).
109258 12-11

**PYROVALERONE**
EFFECT OF PYROVALERONE IN THE AMBULATORY TREATMENT OF FATIGUE STATES.
091503 11-11

**PYRROLASE**
CONTRACEPTIVES, BRAIN SEROTONIN, AND LIVER TRYPTOPHAN PYRROLASE.
067072 05-03

**QUALIFIED**
STUDIES WITH QUALIFIED OR NEGATIVE IMPLICATIONS.
046316 01-11

**QUANTITATION**
QUANTITATION OF THE DEGREE OF ANTAGONISM OF CHLOROQUINE TO HISTAMINE, ACETYLCHOLINE AND SEROTONIN ( PA2 VALUES).
067462 06-03

**QUANTITATIVE**
QUANTITATIVE STUDIES ON THE ANTAGONISM BY NALOXONE OF SOME NARCOTIC AND NARCOTIC ANTAGONIST ANALGESICS.
063798 04-03
QUANTITATIVE THIN-LAYER CHROMATOGRAPHIC ESTIMATION OF LABELED DOPAMINE AND NOREPINEPHRINE, THEIR PRECURSORS AND METABOLITES.
070063 07-06
QUANTITATIVE EEG CHANGES DURING HIGH AND LOW DOSAGE FLUPHENAZINE HYDROCHLORIDE TREATMENT.
073710 08-13
CLINICAL AND QUANTITATIVE ELECTROENCEPHALOGRAPHICAL EFFECTS OF MK-940.
080031 09-07
CHLORPROMAZINE METABOLISM I: QUANTITATIVE FLUOROMETRIC METHOD FOR 11 CHLORPROMAZINE METABOLITES.
080631 09-06
QUANTITATIVE DETERMINATION OF BUTAPERAZINE BY TLC.
090425 11-06
QUANTITATIVE CLINICAL ANALYSIS OF THE EFFECT OF FENETYLLIN (CAPTAGON) ON HYPERKINETIC CHILDREN.
093540 11-11

**QUATERNARY**
DISTRIBUTION, EXCRETION, AND METABOLISM OF 14C-LABELED QUATERNARY AMMONIUM SALT OF MEPAZINE AND PROMETHAZINE IN RATS.
058571 02-03
DISTRIBUTION, EXCRETION, AND METABOLISM OF 14C-LABELED QUATERNARY AMMONIUM SALT OF PERPHENAZINE IN RATS.
064261 04-03

**QUATERONE**
EFFECT OF GANGLERONE AND QUATERONE ON CATECHOLAMINE CONTENT IN THE BRAIN.
111767 12-03

**QUESTION**
ON THE QUESTION OF PERSONALITY DEFECTS OF CONSCIOUSNESS IN INITIAL STAGES IN SCHIZOPHRENIA.
090264 11-08
ON THE QUESTION OF THE PROPHYLAXIS OF INITIAL MANIFESTATIONS OF PRESENILE PSYCHOSES.
110105 12-17

**QUESTIONNAIRE**
PHOBIA QUESTIONNAIRE RESPONSES AND URINE CATECHOLAMINES.
054890 02-11
THE PHYSICIAN QUESTIONNAIRE: A USEFUL TOOL IN PSYCHIATRIC DRUG RESEARCH.
075843 09-17

**QUIDE**
PIPERACETAZINE (QUIDE) IN THE MANAGEMENT OF BEHAVIORAL DISORDERS IN MILDLY RETARDED INSTITUTIONALIZED BOYS.
069071 06-11
PIPERACETAZINE (QUIDE): A CONTROLLED EVALUATION OF THE ELIXIR IN CHRONIC SCHIZOPHRENIC PATIENTS.
082053 10-08

**QUINIDINE**
PREVENTION OF PAROXYSMAL TACHYCARDIA OF WOLFF-PARKINSON-WHITE SYNDROME WITH COMBINED PROPRANOLOL AND QUINIDINE THERAPY.
070288 07-10

**QUININE**
THE EFFECT OF DIET AND PHENOBARBITONE ON QUININE METABOLISM IN THE RAT AND IN MAN.
046187 01-13
ACUTE TOXICITY OF HEROIN, ALONE AND IN COMBINATION WITH COCAINE OR QUININE.
068167 06-05
HYPOKALAEMIA AND ARRHYTHMIAS AS A RESULT OF QUININE POISONING.
071258 07-15

**R-16341**
MAINTENANCE THERAPY OF CHRONIC PSYCHOTIC PATIENTS WITH A WEEKLY ORAL DOSE OF R-16341. A CONTROLLED DOUBLE-BLIND STUDY.
064284 04-09
LONG-ACTING NEUROLEPTICS: III. PILOT STUDY OF PENFLURIDOL (R-16341).
069070 06-07

**R-4749**
CLINICAL EVALUATION IN 112 PSYCHIATRIC PATIENTS OF A BUTYROPHENONE NEUROLEPTIC, DEHYDROBENZPERIDOL (R-4749).
080142 09-11
A STUDY OF DEHYDROBENZPERIDOL (R-4749) IN THE TREATMENT OF DYSTHYMIC SYNDROMES.
092077 11-09

**RABBIT**
THE ANTAGONISM OF PHENTOLAMINE AGAINST EXOGENOUSLY ADMINISTERED AND ENDOGENOUSLY RELEASED NOREPINEPHRINE IN RABBIT AORTIC STRIPS.
040243 01-03
RABBIT AS A MODEL FOR CHLORPROMAZINE INDUCED HYPERPIGMENTATION OF THE SKIN.
045543 01-05
INFLUENCE OF SEROTONIN AND RELATED SUBSTANCES UPON PHOTIC EVOKED POTENTIALS OF RABBIT: EVIDENCE FOR BIOLOGICAL ACTIVITY OF THE ALDEHYDE DERIVATIVE.
055584 02-03
EFFECTS OF RESERPINE AND DESIPRAMINE ON THE UPTAKE AND SUBCELLULAR DISTRIBUTION OF 5-HYDROXYTRYPTAMINE IN RABBIT BRAINSTEM AFTER INTRAVENOUS ADMINISTRATION OF 5-HYDROXYTRYPTOPHAN.
056610 02-03
PROJECT SUMMARY: MUCOPOLYSACCHARIDE COMPOSITION OF RAT AND RABBIT BRAIN.
063526 03-01
EFFECTS OF CHLORDIAZEPOXIDE ON DISCRIMINATIVE FEAR CONDITIONING AND SHUTTLE AVOIDANCE PERFORMANCE IN THE RABBIT.
065451 05-04
THE EFFECT OF SERUM FROM ACUTE SCHIZOPHRENIC PATIENTS ON RABBIT BRAIN AMINES.
066713 05-03
EFFECTS OF CHLORDIAZEPOXIDE ON THE ACQUISITION OF SHUTTLE AVOIDANCE IN THE RABBIT.
075235 08-04
CENTRAL ACTION OF SOME AUTONOMIC DRUGS IN RESPECT TO EEG AROUSAL REACTION OF THE RABBIT.
107190 12-03
UPTAKE AND STORAGE MECHANISM OF 5-HYDROXYTRYPTAMINE IN RABBIT BRAINSTEM AND EFFECT OF RESERPINE.
114975 12-03

**RABBITS**
CENTRAL NERVOUS SYSTEM STIMULANT ACTION OF FENFLURAMINE IN RABBITS.
040639 01-03
TEMPERATURE RESPONSES AND OTHER EFFECTS OF 5-HYDROXYTRYPTOPHAN AND 5-HYDROXYTRYPTAMINE WHEN ACTING FROM THE LIQUOR SPACE IN UNANESTHETIZED RABBITS.
046404 01-03
POTENTIATION OF THE CENTRAL ACTIONS OF 5-HYDROXYTRYPTOPHAN IN RABBITS BY DL-ALPHA-HYDRAZINO ALPHA-METHYLDOPA.
058879 02-03
THEOPHYLLINE: INDUCTION OF SELF-BITING IN RABBITS.
075236 08-04
EFFECT OF AGENTS INTERACTING WITH CHOLINOREACTIVE AND ADRENOREACTIVE SYSTEMS ON EPILEPTIFORM ACTIVITY IN THE HIPPOCAMPUS OF RABBITS.
110631 12-03

**RACEMIC**
PHARMACOLOGICAL COMPARISON OF R(-), S(-) AND RACEMIC SECOBARBITAL IN MICE.
047325 01-03

**RADICAL**
LSD, VIOLENCE AND RADICAL RELIGIOUS BELIEFS.
067354 06-12

**RADIOACTIVE**
RADIOACTIVE BROMIDE IN THE DIAGNOSIS OF CENTRAL NERVOUS SYSTEM DISEASE.
063208 03-16

**RADIOACTIVITY**
EFFECT OF RESERPINE ON THE INCORPORATION IN VIVO OF RADIOACTIVITY FROM LABELED SEROTONIN AND OTHER 5-HYDROXYINDOLE DERIVATIVES IN MOUSE BRAIN.
046189 01-03

**RADIOCHEMICAL**
MODIFICATION OF AN ENZYME RADIOCHEMICAL ASSAY PROCEDURE FOR NORADRENALINE.
064002 04-06

**RADIOIMMUNOASSAY**
MORPHINE: RADIOIMMUNOASSAY.
063848 04-06

**RAM-302**
SITES OF ACTION OF RAM-302 AND NALORPHINE AS MORPHINE ANTAGONISTS.
074934 08-03

**RANDOM**
TASTE PREFERENCES: AN APPARATUS FOR RANDOM AND SIMULTANEOUS PRESENTATION OF SEVERAL SOLIDS AND SOLUTIONS.
067892 06-06

**RANGE**
THIOTHIXENE: ITS RANGE OF THERAPEUTIC ACTIVITY.
097985 11-11
THE BROAD RANGE OF USE OF DIPHENYLHYDANTOIN: BIBLIOGRAPHY AND REVIEW.
111961 12-13

**RAPHE**
ACTION OF PSYCHOTOGENIC DRUGS ON SINGLE MIDBRAIN RAPHE NEURONS.
040418 01-03
REDUCED EFFECT OF MORPHINE IN MIDBRAIN RAPHE LESIONED RATS.
066500 05-03
ALTERATIONS IN THE BEHAVIORAL EFFECTS OF LSD BY MIDBRAIN RAPHE LESIONS (UNPUBLISHED PAPER).
082545 10-04
ALTERATIONS IN THE BEHAVIORAL EFFECTS OF LSD BY MIDBRAIN RAPHE LESIONS.
086029 10-12

**RAT**
EFFECTS OF THALIDOMIDE AND CHLORCYCLIZINE ON THE BIOSYNTHESIS OF NUCLEIC ACIDS AND PROTEINS IN FETAL AND MATERNAL TISSUES OF THE RAT.
040027 01-05
COMPARATIVE EFFECTS OF P-CHLOROPHENYLALANINE, P-CHLOROAMPHETAMINE AND P-CHLORO-N-METHYLAMPHETAMINE ON RAT BRAIN NOREPINEPHRINE, SEROTONIN AND 5-HYDROXYINDOLE-3-ACETIC ACID.
040241 01-03
RELEASE OF NOREPINEPHRINE FROM ISOLATED RAT IRIS BY FIELD STIMULATION.
040245 01-03
THE EFFECT OF BRETYLIUM ON AMINE RETENTION IN RAT HEART.
040309 01-03
URINARY METABOLITES OF HARMINE IN THE RAT AND THEIR INHIBITION OF MONOAMINE OXIDASE.
040417 01-03
LONG-TERM VARIATION IN BASAL AND PHENOBARBITAL STIMULATED OXIDATIVE DRUG METABOLISM IN THE RAT.
040671 01-03
EFFECTS OF CHRONIC ADMINISTRATION OF NICOTINE ON STORAGE AND SYNTHESIS OF NORADRENALINE IN RAT BRAIN.
041552 01-03
THE EFFECT OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON BRAIN ACETYLCHOLINE LEVELS IN RAT.
041913 01-03
INCREASED RELEASE OF DOPAMINE FROM STRIATAL DOPAMINERGIC TERMINALS IN THE RAT AFTER TREATMENT WITH A NEUROLEPTIC: THIOPROPERAZINE.
042742 01-03
EFFECTS OF LITHIUM CARBONATE ON TURNOVER AND METABOLISM OF NOREPINEPHRINE IN THE RAT BRAIN - CORRELATION TO GROSS BEHAVIORAL EFFECTS.
043277 01-03
RELATIONSHIP OF BARBITAL DISPOSITION TO AUTO-INDUCED HYPERSUSCEPTIBILITY IN THE RAT.
046144 01-03
THE EFFECT OF DIET AND PHENOBARBITONE ON QUININE METABOLISM IN THE RAT AND IN MAN.
046187 01-13
TRANYLCYPROMINE: EFFECTS ON NOREPINEPHRINE METABOLISM IN RAT BRAIN.
052484 02-03
THE ANTAGONISM OF ADRENERGIC NEURONE BLOCKADE BY AMPHETAMINE AND DEXAMPHETAMINE IN THE RAT AND GUINEA-PIG.
055322 02-03
EVIDENCE FOR A CENTRALLY MEDIATED HYPOTENSIVE EFFECT OF L-DOPA IN THE RAT.
055587 02-03
ENHANCEMENT BY COCAINE OF INTRACRANIAL SELF-STIMULATION IN THE RAT.
058397 02-13
PLACENTAL TRANSFER OF PENTOBARBITAL IN THE RAT.
058572 02-05
THE EFFECTS OF SOME PSYCHOACTIVE DRUGS ON RAT BRAIN ADENOSINE TRIPHOSPHATE LEVELS.
058988 03-03
EFFECTS OF A CHOLINE ACETYLTRANSFERASE INHIBITOR ON SELF-STIMULATORY BEHAVIOR IN THE RAT.
058993 03-04
CHLORPROMAZINE, CHLORDIAZEPOXIDE, AND THE INCENTIVE SHIFT PERFORMANCE IN THE RAT.
060275 03-04
CYCLIC AMP AND ADENYL-CYCLASE IN THE DEVELOPING RAT BRAIN.
060856 03-03
MODIFICATION OF NACL APPETITE IN THE ADRENALECTOMIZED RAT CONSEQUENT TO EXTENSIVE LICL POISONING.
061094 03-04
PROJECT SUMMARY: MUCOPOLYSACCHARIDE COMPOSITION OF RAT AND RABBIT BRAIN.
063526 03-01
CHOLINERGIC MODULATION OF ADRENERGIC AROUSAL IN THE DEVELOPING RAT.
063688 04-04
CENTRAL HYPOTENSIVE EFFECT OF L-DIHYDROXYPHENYLALANINE IN THE RAT.
063888 04-03
THE SENSITIVITY OF THE BRAIN TO BARBITURATE DURING CHRONIC ADMINISTRATION AND WITHDRAWAL OF BARBITONE SODIUM IN THE RAT.
063980 04-03
14C-5-HYDROXYTRYPTAMINE AND 3H-D-AMPHETAMINE: UPTAKE AND CONTRACTION BY THE RAT STOMACH FUNDUS IN VITRO.
064050 04-03
BETA-HYDROXYLATION OF N-ACETYL-DIMETHOXYPHENETHYLAMINE AND THE INFLUENCE OF IPRONIAZID ON THE DEMETHYLATION OF THIS COMPOUND IN VIVO IN THE RAT.
064053 04-03
TRYPTOPHAN HYDROXYLASE CHANGES IN MIDBRAIN OF THE RAT AFTER CHRONIC MORPHINE ADMINISTRATION.
064146 04-03
A MODEL OF HARMINE METABOLISM IN THE RAT.
064167 04-03
THE EFFECTS OF HALOPERIDOL AND CHLORPROMAZINE ON AMPHETAMINE METABOLISM AND AMPHETAMINE STEREOTYPE BEHAVIOR IN THE RAT.
064170 04-03
CHANGES IN THE SERUM CONCENTRATION OF CHOLESTEROL, TRIGLYCERIDES AND PHOSPHOLIPIDS IN THE MOUSE AND RAT AFTER ADMINISTRATION OF EITHER CHLORCYCLIZINE OR PHENOBARBITAL.
064282 04-03
EFFECTS OF MORPHINE AND PENTOBARBITONE ON ACETYLCHOLINE SYNTHESIS BY RAT CEREBRAL CORTEX.
064288 04-03
METABOLISM OF 14C-IMIPRAMINE: III. CONVERSIONS BY RAT TISSUE.
064409 04-03
EFFECTS OF DESMETHYLIMIPRAMINE AND COCAINE ON THE UPTAKE, RETENTION AND METABOLISM OF H3-TYRAMINE IN RAT BRAIN SLICES.
064419 04-03
MECHANISMS BY WHICH AMPHETAMINE AND DESIPRAMINE INHIBIT THE METARAMINOL INDUCED RELEASE OF NOREPINEPHRINE FROM SYMPATHETIC NERVE ENDINGS IN RAT HEART.
064427 04-03
DRUG EFFECTS ON A MEASURE OF UNCONDITIONED AVOIDANCE IN THE RAT.
065440 05-04
EFFECT OF MORPHINE ADMINISTRATION ON THE HYDROXYLATION OF STEROID HORMONES BY RAT LIVER MICROSOMES.
066366 05-03
ALTERED ABSORPTION OF DRUGS FROM THE RAT SMALL INTESTINE BY CARBONIC ANHYDRASE INHIBITION.
066369 05-03
MODIFICATION BY DESIPRAMINE (DMI) OF THE AVAILABILITY OF NOREPINEPHRINE RELEASED BY RESERPINE IN THE HYPOTHALAMUS OF THE RAT IN VIVO.
066374 05-03
EFFECTS OF PHENOBARBITAL, PHENYLBUTAZONE, 3,4 BENZPYRENE, OR 3-METHYLCHOLANTHRENE ON ETHANOL METABOLISM IN THE RAT.
066498 05-03
INHIBITION OF CATECHOLAMINE UPTAKE BY 6-HYDROXYDOPAMINE IN RAT BRAIN.
066501 05-03
INHIBITION BY P-CHLOROAMPHETAMINE OF THE CONVERSION OF 5-HYDROXYTRYPTAMINE TO 5-HYDROXYINDOLEACETIC ACID IN RAT BRAIN.
066507 05-03

EFFECT OF CHRONIC ADMINISTRATION OF P-CHLOROPHENYLALANINE ON SEXUAL RECEPTIVITY OF THE FEMALE RAT.
066825 05-04

THE PHYSIOLOGICAL DISPOSITION OF CHLORPROMAZINE IN THE RAT AND DOG.
066937 05-03

EFFECT OF ETHANOL ON 5-HYDROXYTRYPTAMINE TURNOVER IN RAT BRAIN.
066938 05-03

UPTAKE OF (14C) PENTYLENETETRAZOL BY DEVELOPING RAT BRAIN.
067120 06-02

METABOLISM AND BILIARY EXCRETION OF THE LIPOPHILIC DRUG MOLECULES, IMIPRAMINE AND DESMETHYLIMIPRAMINE IN THE RAT – I. EXPERIMENTS IN VIVO AND WITH ISOLATED PERFUSED LIVERS.
067260 06-03

CHANGES IN ENZYMES SUBSERVING CATECHOLAMINE METABOLISM IN MORPHINE TOLERANCE AND WITHDRAWAL IN RAT.
067324 06-03

ACTIONS OF RESERPINE AND TYRAMINE ON THE ACETYLCHOLINE CONTENT OF BRAINSTEM, HEART AND BLOOD OF THE RAT.
067461 06-03

RECORDING EVOKED POTENTIALS IN THE CONSCIOUS RAT: THE MAINTENANCE OF A CONSTANT BEHAVIOURAL BASELINE.
067600 06-06

NOREPINEPHRINE TURNOVER AND METABOLISM IN RAT BRAIN AFTER LONG-TERM ADMINISTRATION OF IMIPRAMINE.
067687 06-03

DIFFERENTIAL EFFECTS OF THREE TRICYCLIC ANTIDEPRESSANTS ON SLEEP AND REM SLEEP IN THE RAT.
067919 06-04

HORMONAL INDUCTION OF MATERNAL BEHAVIOR IN THE OVARIECTOMIZED NULLIPAROUS RAT.
069063 06-04

PHENOBARBITAL WITHDRAWAL AND BEHAVIORAL DISRUPTION IN THE RAT.
069067 06-04

INDUCTION BY CANNABIS-SATIVA (MARIHUANA) OF RHYTHMIC SPIKE DISCHARGES OVERRIDING REM SLEEP ELECTROCORTICOGRAM IN THE RAT.
069069 06-04

EFFECTS OF AMOBARBITAL SODIUM ON THE ACQUISITION AND EXTINCTION OF A LEVER-PRESS SPATIAL DISCRIMINATION IN THE RAT.
069075 06-04

DIFFERENTIAL EFFECTS OF NICOTINE AND TOBACCO SMOKE ALKALOIDS ON SWIMMING ENDURANCE IN THE RAT.
069078 06-04

THE EFFECTS OF VARIOUS PRIOR TREATMENTS UPON THE TRANSPORT OF CHLORPROMAZINE AND TRIFLUOPERAZINE INTO RAT BRAIN.
069309 06-02

COMPARISON OF DRINKING ELICTED BY ESERINE OR DFP INJECTED INTO PREOPTIC AREA OF RAT BRAIN.
069637 07-04

A NOTE ON THE EFFECTS OF CHLORPROMAZINE UPON ULCERATION IN THE RAT.
069645 07-03

COMBINED EFFECTS OF CHLORPROMAZINE AND ALTITUDE UPON PERFORMANCE IN THE RAT.
071467 07-04

ACTION OF CODEINE, PETHIDINE AND METHADONE ON THE OPERANT BEHAVIOR OF THE RAT.
071787 07-04

EFFECTS OF 6-HYDROXYDOPAMINE ON CATECHOLAMINE CONTAINING NEURONES IN THE RAT BRAIN.
072120 07-03

EFFECT OF BRAIN ISO-ANTIBODIES ON LEARNING AND MEMORY IN THE RAT.
072516 08-04

ECG CHANGES INDUCED BY PHENOTHIAZINE DRUGS IN THE ANESTHETIZED RAT.
072525 08-03

CENTRAL EFFECTS OF 6-HYDROXYDOPAMINE ON THE BODY TEMPERATURE OF THE RAT.
073069 08-03

AUTORADIOGRAPHIC STUDIES ON THE DISTRIBUTION OF PSYCHOACTIVE DRUGS IN THE RAT BRAIN: IV. C14-THIORIDAZINE.
073709 08-03

THE EFFECT OF ESERINE ON THE EFFERENT NEURONAL ACTIVITY IN THE CERVICAL SYMPATHETIC OF THE RAT.
074133 08-03

THE EFFECT OF AMANTADINE ON THE UPTAKE OF DOPAMINE AND NORADRENALINE BY RAT BRAIN HOMOGENATES.
074148 08-03

EFFECTS OF PENTOBARBITONE AND CHLORPROMAZINE ON ACOUSTICALLY EVOKED POTENTIALS IN THE RAT.
074939 08-03

PENICILLIN INDUCED EPILEPTOGENIC FOCI IN THE RAT CORTEX.
075197 08-04

THE EFFECTS OF NICOTINE ADMINISTRATION IN UTERO UPON ACTIVITY IN THE RAT.
075239 08-04

EFFECTS OF 6-FLUORO-N-N-DIETHYLTRYPTAMINE (6-FDET) ON SELECTED RAT BEHAVIORS.
075314 08-04

AMBULATORY BEHAVIOR IN THE RAT AS A FUNCTION OF TWO METHODS OF ALCOHOL ADMINISTRATION.
075316 08-04

EFFECT OF PITUITARY AND ACTH ON THE MAINTENANCE OF BASAL TYROSINE HYDROXYLASE ACTIVITY IN THE RAT ADRENAL GLAND.
075714 08-03

EFFECTS OF LYSERGIC ACID DIETHYLAMIDE ON THE MATERNAL BEHAVIOR OF THE RAT.
075788 08-04

EFFECT OF HIPPOCAMPAL AND NEOCORTICAL ABLATION ON SCOPOLAMINE INDUCED ACTIVITY IN THE RAT.
075848 09-04

THE EFFECT OF ALPHA-METHYL-P-TYROSINE ON SLEEP AND AROUSAL IN THE RAT.
075891 09-04

DOSE RESPONSE ANALYSIS OF CARBACHOL ELICITED DRINKING IN THE RAT LIMBIC SYSTEM.
076081 09-04

THE EFFECT OF EXOGENOUS RNA ON THE RETENTION OF DISCRIMINATIVE LEARNING IN THE RAT.
079982 09-04

SYNERGISM BETWEEN COBALT AND ETHANOL ON RAT GROWTH RATE.
088600 10-03

ON THE UPTAKE OF PHENOTHIAZINE DERIVATIVES BY THE ISOLATED PERFUSED RAT BRAIN.
089043 10-03

1-(3,4-DIMETHOXYPHENYL)-2 PROPANOL EFFECT ON CONDITIONED AVOIDANCE RESPONSE IN THE RAT.
089440 11-04

THE EFFECT OF METHIONINE OF THE REGIONAL AND INTRACELLULAR DISPOSITION OF (3H) METHIONINE SULPHOXIMINE IN RAT BRAIN.
090148 11-03

ROLE OF BIOGENIC AMINES IN MORPHINE DEPENDENCE IN THE RAT.
090149 11-03

LESIONS IN CORPUS-STRIATUM AND CORTEX OF RAT BRAINS AND THE EFFECT ON PHARMACOLOGICALLY INDUCED STEREOTYPED, AGGRESSIVE AND CATALEPTIC BEHAVIOUR.
091127 11-04

INCREASED INCORPORATION OF 14C-URIDINE INTO RAT BRAIN RNA AS A RESULT OF NOVEL ELECTROSHOCK.
092209 11-01

EFFECT OF HYPOPHYSECTOMY ON ADRENAL DOPAMINE-BETA-HYDROXYLASE ACTIVITY IN THE RAT (UNPUBLISHED PAPER).
092383 11-03

INTERACTIONS BETWEEN THE EFFECTS OF CHLORDIAZEPOXIDE AND AMPHETAMINE ON FOOD INTAKE AND SPONTANEOUS MOTOR ACTIVITY IN THE RAT.
092692 11-04

CYCLIC AMP MEDIATION OF NOREPINEPHRINE INHIBITION IN RAT CEREBELLAR CORTEX: A UNIQUE CLASS OF SYNAPTIC RESPONSES (UNPUBLISHED PAPER).
093132 11-03

INFLUENCE OF CHRONIC ADMINISTRATION OF NICOTINE ON THE TURNOVER AND METABOLISM OF NORADRENALINE IN THE RAT BRAIN.
097958 11-03

LITHIUM INDUCED POLYURIA: EXPERIMENTAL STUDIES IN MAN AND THE RAT.
100083 11-15

EFFECTS OF LITHIUM AND OTHER PSYCHOPHARMACA ON RAT ELECTROLYTE METABOLISM.
106778 12-05

STRUCTURAL BASIS OF LITHIUM PSYCHOPHARMACOLOGY: EXTRACELLULAR GROUND SUBSTANCE OF RAT BRAIN.
106783 12-03

A BIPHASIC ACTION OF PILOCARPINE ON BEHAVIORAL AROUSAL IN THE RAT. (PH.D.DISSERTATION).
110922 12-04

DYNAMIC CHARACTERISTICS OF THE FUNCTIONAL COMPARTMENT OF DOPAMINE IN DOPAMINERGIC TERMINALS OF THE RAT STRIATUM.
120465 12-03

UNCONDITIONED REFLEX ACTIVITY IN THE RAT SUFFERING FROM EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY AND THE THERAPEUTIC EFFECT OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126051 12-04

RATE

THE EFFECT OF PROLONGED LITHIUM TREATMENT ON THE SYNTHESIS RATE AND TURNOVER OF MONOAMINES IN BRAIN REGIONS OF RATS.
066413 05-03

PHARMACOLOGICAL IMPLICATIONS OF THE EFFECTS OF AMPHETAMINE AND ITS ANALOGUES ON THE TURNOVER RATE OF TISSUE CATECHOLAMINES (UNPUBLISHED PAPER).
088392 10-03
SYNERGISM BETWEEN COBALT AND ETHANOL ON RAT GROWTH RATE.
088600 10-03
THE ACTION OF SOME PSYCHOTROPIC DRUGS ON DEFECATION RATE IN THE MOUSE.
089003 10-05

**RATE-DEPENDENT**
RATE-DEPENDENT EFFECTS OF DRUGS: MODIFICATION BY DISCRIMINATIVE STIMULI OF THE EFFECTS OF AMOBARBITAL ON SCHEDULE CONTROLLED BEHAVIOR.
064749 05-04

**RATES**
ANTICONVULSANT DRUGS AND SELF-STIMULATION RATES IN RATS.
066871 05-04
RETENTION RATES OF SCHIZOPHRENIA: A COMPARISON OF SHOCK THERAPY AND PSYCHOPHARMACOLOGICAL ERAS AND OF CLOSED AND OPEN DOOR POLICIES.
069795 07-08
THE VALUE OF WORSENING RATES IN PSYCHIATRIC CLINICAL TRIALS.
075388 08-10
THE EFFECTS OF TRICYANOAMINOPROPENE ON LEARNING IN A DIFFERENTIAL REINFORCEMENT OF LOW RATES SITUATION.
075851 09-03

**RATING**
DRUG-INDUCED EXTRAPYRAMIDAL DISORDERS: A RATING SCALE FOR EXTRAPYRAMIDAL SIDE-EFFECTS.
063773 04-16
CLASSIFICATION, NOSOLOGY, AND RATING SCALES OF PSYCHOTROPIC DRUGS.
064090 04-01
DIFFERENTIAL RELIABILITY IN RATING PSYCHOPATHOLOGY AND GLOBAL IMPROVEMENT.
076292 09-10

**RATIO**
EFFECT OF PSYCHOTOMIMETIC AGENTS ON SEX RATIO?
071960 07-15

**RATS**
THE EFFECT OF ORAL CONTRACEPTIVE STEROIDS ON BILE SECRETION AND BILIRUBIN TM IN RATS.
040125 01-05
A COMPARISON OF THE EFFECTS OF SOME BENZODIAZEPINES AND OTHER DRUGS ON AGGRESSIVE AND EXPLORATORY BEHAVIOUR IN MICE AND RATS.
040581 01-04
STUDY OF THE EFFECTS OF PROGESTERONE THERAPY ON THE STILBOESTROL INDUCED SENSITIVITY OF ISOLATED UTERI OF HYPOPHYSECTOMIZED RATS.
041540 01-03
THE EFFECT OF P-CHLOROPHENYLALANINE ON SOCIAL INTERACTION OF MALE RATS.
041541 01-04
INHIBITION OF THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN RATS BY DRUGS WHICH INHIBIT RIBONUCLEIC ACID OR PROTEIN SYNTHESIS.
041570 01-03
INFLUENCE OF MODE AND DURATION OF PHENYLALANINE ADMINISTRATION ON BIOCHEMICAL PARAMETERS IN RATS OF VARIOUS AGES.
042840 01-03
BEHAVIORAL IMPAIRMENT IN ADULT RATS FOLLOWING ACUTE ZINC DEFICIENCY.
045526 01-04
COMPARISON OF LIVER MICROSOME ENZYME SYSTEMS AND BARBITURATE SLEEP TIMES IN RATS CAGED INDIVIDUALLY OR COMMUNALLY.
045545 01-06
THE EFFECT OF AMPHETAMINE, NICOTINE AND ATROPINE ON PSEUDOCONDITIONED RESPONSES OF RATS.
046142 01-04
COMPARATIVE EFFECTS OF NICOTINE AND AMPHETAMINE ON TIMING BEHAVIOR IN RATS.
046190 01-04
THE INFLUENCE OF MORPHINE ON MAGNESIUM METABOLISM IN RATS.
046191 01-03
THE EFFECT OF BRADYKININ AND ELEDOISIN INJECTED INTO THE CEREBRAL VENTRICLES OF CONSCIOUS RATS.
047323 01-04
DIFFERENCES IN BRAIN AREA 5-HYDROXYTRYPTAMINE TURNOVER AND REARING BEHAVIOR IN RATS AND MICE OF BOTH SEXES.
047324 01-04
LIVER DAMAGE FOLLOWING APPLICATION OF PYRAZINAMIDE IN ANIMAL EXPERIMENTS: 1. CHANGES IN BODY WEIGHT OF RATS UNDER THE INFLUENCE OF PYRAZINAMIDE.
055398 02-05
THE ROLE OF BRAIN CATECHOLAMINES IN MORPHINE ANALGESIC ACTION IN MORPHINE TOLERANT RATS.
055756 02-03
STARTLE RESPONSE CIRCADIAN RHYTHM IN RATS: LACK OF CORRELATION WITH MOTOR ACTIVITY.
058349 02-04
DISTRIBUTION, EXCRETION, AND METABOLISM OF 14C-LABELED QUATERNARY AMMONIUM SALT OF MEPAZINE AND PROMETHAZINE IN RATS.
058571 02-03
TOXICITY, NARCOTIC EFFECT, CONCENTRATION AT END OF ANESTHESIA, ELIMINATION FROM BLOOD AND BIOTRANSFORMATION OF HEXOBARBITAL IN RATS OF VARIOUS AGES FOLLOWING SLEEP INDUCTION WITH BARBITAL AND AFTER.
058987 03-05
RESPONSE TO DRUGS BY RATS SHOWING LONG OR SHORT HEXOBARBITAL INDUCED SLEEP.
058990 03-03
ASSOCIATION OF AMPHETAMINE TOXICITY AND TISSUE GLYCOGEN DEPLETION IN MICE AND RATS.
058998 03-05
DOPAMINE CONCENTRATIONS IN THE BRAINSTEM MESENCEPHALON OF ACTIVE RATS AS COMPARED WITH PASSIVE RATS.
060274 03-04
STRAIN DIFFERENCES IN MORPHINE WITHDRAWAL INDUCED AGGRESSION IN RATS.
060837 03-03
FORGETTING OF AN OPERANT RESPONSE: PHYSOSTIGMINE PRODUCED INCREASES IN ESCAPE LATENCY IN RATS AS A FUNCTION OF TIME OF INJECTION.
061540 03-04
EFFECT OF LITHIUM ON FOOT SHOCK AGGRESSION IN RATS.
062777 03-04
THE EFFECT OF P-CHLOROPHENYLALANINE (PCPA) ON SHOCK INDUCED FIGHTING BEHAVIOR IN RATS.
062853 03-03
PERSISTENCE OF RELAPSE TENDENCIES OF RATS PREVIOUSLY MADE PHYSICALLY DEPENDENT ON MORPHINE.
062940 03-04
THE EFFECTS OF NORADRENALINE ON RATS BEHAVIOUR.
062941 03-04
EFFECTS OF RESERPINE ON THE COPULATORY BEHAVIOR OF MALE RATS.
063014 03-04
P-CHLOROPHENYLALANINE AND HABITUATION TO REPETITIVE AUDITORY STARTLE STIMULI IN RATS.
063015 03-03
BEHAVIOURAL EFFECTS IN RATS OF MORPHINE AND AMPHETAMINE AND OF A COMBINATION OF THE TWO DRUGS.
063019 03-04
LSD: NO TERATOGENIC ACTION IN RATS, MICE, AND HAMSTERS.
063993 04-03
NEUROCHEMICAL EFFECTS OF IMIPRAMINE AND AMPHETAMINE IN AGGRESSIVE MOUSE KILLING (MURICIDAL) RATS.
064056 04-03
DISTRIBUTION, EXCRETION AND METABOLISM OF TRIFLUOPERAZINE METHIODIDE-C14 IN RATS.
064094 04-03
ELECTROCORTICAL REACTIONS OF PINEALECTOMIZED AND INTACT RATS TO LETHAL DOSES OF PENTOBARBITAL.
064101 04-03
EFFECTS OF CANNABIS-SATIVA ON LEARNING IN RATS.
064178 04-04
DISTRIBUTION, EXCRETION, AND METABOLISM OF 14C-LABELED QUATERNARY AMMONIUM SALT OF PERPHENAZINE IN RATS.
064261 04-03
PARADOXICAL AMPHETAMINE EFFECT IN HYPERACTIVE RATS IN RELATION TO NOREPINEPHRINE METABOLISM.
064364 04-03
EFFECTS OF CHLORDIAZEPOXIDE AND PENTOBARBITAL ON CONFLICT BEHAVIOR IN RATS.
064390 04-04
MODIFICATION OF THE EFFECTS OF ANTIPSYCHOTIC AGENTS ON THE OPEN FIELD PERFORMANCE OF RATS BY TREATMENT WITH ALPHA-METHYLTYROSINE OR P-CHLOROPHENYLALANINE.
064392 04-04
EFFECT OF IMIPRAMINE AND CHLORIMIPRAMINE ON AN ACUTE INSTRUMENTAL TRACE CONDITIONED REFLEX IN RATS.
064415 04-04
LYSERGIC ACID DIETHYLAMIDE INTAKE IN PREGNANCY: FETAL DAMAGE IN RATS.
064422 04-05
PREFERENCES FOR MORPHINE IN RATS: VALIDATION OF AN EXPERIMENTAL MODEL OF DEPENDENCE.
064475 04-04
THE INFLUENCE OF VARIOUS NEUROLEPTIC DRUGS ON SHOCK AVOIDANCE RESPONDING IN RATS. III. AMPHETAMINE ANTAGONISM IN THE DISCRIMINATED SIDMAN AVOIDANCE PROCEDURE.
064476 04-04

EFFECTS OF AMPHETAMINE UPON RELEARNING PATTERN AND BLACK WHITE DISCRIMINATIONS FOLLOWING NEOCORTICAL LESIONS IN RATS.
065419 05-04

THE PROCESS OF LEARNING IN RATS UNDERGOING PROLONGED TREATMENT WITH PSYCHOTROPIC AGENTS.
065441 05-04

THE EFFECT OF PROLONGED LITHIUM TREATMENT ON THE SYNTHESIS RATE AND TURNOVER OF MONOAMINES IN BRAIN REGIONS OF RATS.
066413 05-03

REDUCED EFFECT OF MORPHINE IN MIDBRAIN RAPHE LESIONED RATS.
066500 05-03

ACETYLCHOLINE RELEASE FROM CORTICAL BRAIN SLICES OF RATS INJECTED WITH LITHIUM.
066509 05-03

LITHIUM EFFECT ON PLASMA GLUCAGON, LIVER PHOSPHORYLASE-A AND LIVER GLYCOGEN IN RATS.
066822 05-03

ANTICONVULSANT DRUGS AND SELF-STIMULATION RATES IN RATS.
066871 05-04

CATECHOLAMINE ACCUMULATION IN TISSUES OF THIAMINE-DEFICIENT RATS AFTER INHIBITION OF MONOAMINE OXIDASE.
067243 06-03

THE EFFECT OF DISULFIRAM, DIETHYLDITHIOCARBAMATE AND DIMETHYLDITHIOCARBAMATE ON SEROTONIN AND 5-HYDROXYINDOLE-3-ACETIC ACID BRAIN LEVELS IN RATS.
067384 06-03

IMPAIRMENT OF ALTERNATION LEARNING IN RATS FOLLOWING MICROINJECTION OF CARBACHOL INTO THE HIPPOCAMPUS.
067522 06-04

INITIAL SUPPRESSION OF THE LOCOMOTOR STIMULANT RESPONSE TO DEXAMPHETAMINE IN RATS EXPOSED TO A NOVEL ENVIRONMENT.
067601 06-04

THE BRAIN ACETYLCHOLINE SYSTEM IN BARBITONE DEPENDENT AND WITHDRAWN RATS.
067604 06-03

DISAPPEARANCE IN RATS WITH SEPTAL LESIONS OF THE STIMULATORY EFFECT OF HYOSCINE ON EXPLORATORY BEHAVIOUR.
067605 06-04

INDUCTION OF RECEPTIVITY IN OVARIECTOMIZED FEMALE RATS BY A SINGLE INTRAVENOUS INJECTION OF ESTRADIOL-17BETA.
067696 06-04

EFFECT OF AN ORAL CONTRACEPTIVE ON SPONTANEOUS RUNNING ACTIVITY OF FEMALE RATS.
067716 06-04

EFFECTS OF PRENATAL ADMINISTRATION OF PSYCHOTROPIC DRUGS TO RATS ON BRAIN BUTYRYLCHOLINESTERASE ACTIVITY AT BIRTH.
067980 06-03

COMPENSATORY SELECTION OF MAGNESIUM SULFATE BY MAGNESIUM DEPLETED LABORATORY RATS.
068287 06-04

CHEMICAL INDUCTION OF TRAUMATIC FIGHTING IN RATS.
068765 06-04

THE INFLUENCE OF VARIOUS NEUROLEPTIC DRUGS ON NOISE ESCAPE RESPONSE IN RATS.
069076 06-04

THE EFFECT OF NICOTINE AND TOTAL ALKALOIDS EXTRACTED FROM CIGARETTE SMOKE IN AVOIDANCE BEHAVIOR IN RATS UNDER EXTINCTION PROCEDURE.
069079 06-04

EFFECTS OF CHLORDIAZEPOXIDE ON BLACK WHITE DISCRIMINATION ACQUISITION AND REVERSAL IN WHITE RATS.
070083 07-04

AN ELECTRON MICROSCOPIC STUDY OF AXONAL CHANGES IN THE CEREBELLUM OF DIPHENYLHYDANTOIN INTOXICATED RATS: THE FORMATION OF THE SO-CALLED HONEYCOMB STRUCTURE IN THE AXOPLASM.
070334 07-03

REVERSIBLE LENTICULAR OPACITIES INDUCED IN RATS BY EMOTIONAL STRESS.
070823 07-03

CRETINISM IN RATS: ENDURING BEHAVIORAL DEFICIT INDUCED BY TRICYANOAMINOPROPENE.
070839 07-02

AGGRESSIVE BEHAVIOR OF RATS INDUCED BY MESORGYDINE (LYSENYL SPOFA).
070949 07-04

MONOAMINES AND THE REACTIVITY OF RATS WITH DIFFERENT TYPES OF HIGHER NERVOUS ACTIVITY.
070953 07-03

BEHAVIORAL EFFECTS OF ARECOLINE IN RATS.
071786 07-04

DEVELOPMENT OF FIGHTING BEHAVIOR IN STARVED RATS BY CHRONIC ADMINISTRATION OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL AND CANNABIS EXTRACTS: LACK OF ACTION OF OTHER PSYCHOTROPIC DRUGS.
072531 08-04

COMPARATIVE CHARACTERISTICS OF CHLORPROMAZINE AND CHLORACYZINE DISTRIBUTION IN RATS.
072579 08-03

THE CATECHOLAMINE CONTENT IN THE BRAINSTEM OF ALBINO RATS IN THE DEVELOPMENT OF TOLERANCE TO TRYPHTAZINE.
073681 08-03

THE EFFECT OF AMINOESTERS OF SUBSTITUTED GLYCOLIC AND ACETIC ACIDS ON THE CONTENT OF NORADRENALINE IN THE BRAIN OF RATS.
073717 08-03

EFFECTS OF 6-HYDROXYDOPAMINE ON CNS CATECHOLAMINES, SPONTANEOUS MOTOR ACTIVITY AND AMPHETAMINE INDUCED HYPERACTIVITY IN RATS.
074053 08-04

STEREOTYPED BEHAVIOUR INDUCED BY (-) EPHEDRINE IN RATS.
074086 08-04

EFFECTS OF CHLORPROMAZINE ON CONVULSIVE RESPONSES IN DEVELOPING RATS.
074131 08-03

THE EFFECT OF ETHANOL AND AMPHETAMINE MIXTURES ON THE ACTIVITY OF RATS IN A Y-MAZE.
074149 08-04

EFFECTS OF PRENATAL ADMINISTRATION OF PSYCHOTROPIC DRUGS ON BEHAVIOR OF DEVELOPING RATS.
074830 08-04

CHANGE IN SENSITIVITY TO D-AMPHETAMINE IN FRONTAL RATS AS A FUNCTION OF TIME: SHIFTING OF THE DOSE RESPONSE CURVE.
075238 08-04

FOOD REINFORCED RESPONDING IN RATS DURING ESTRUS.
075645 08-04

REDUCTION OF THE ANTINOCICEPTIVE EFFECT OF 5-HYDROXYTRYPTOPHAN IN MORPHINE TOLERANT RATS.
075846 09-03

EFFECTS OF NEONATAL TESTOSTERONE ON THE ACQUISITION OF AN ACTIVE AVOIDANCE RESPONSE IN GENOTYPICALLY FEMALE RATS.
075890 09-04

EFFECTS OF METHYLPHENIDATE ON ACTIVITY AND REACTIONS OF NOVELTY IN RATS.
076066 09-04

MODULATION OF FOOD INTAKE AND LOCOMOTOR ACTIVITY IN FEMALE RATS BY DIENCEPHALIC HORMONE IMPLANTS.
076080 09-04

UPTAKE OF TRITIATED TESTOSTERONE IN BRAIN AND PERIPHERAL TISSUES OF NORMAL AND NEONATALLY ANDROGENIZED FEMALE RATS.
076086 09-04

THE EFFECTS OF ADRENERGIC AND CHOLINERGIC AGENTS UPON EATING AND DRINKING IN DEPRIVED RATS.
076132 09-03

THE EFFECT OF MAGNESIUM PEMOLINE, TRICYANOAMINOPROPENE AND D-AMPHETAMINE ON DISCRIMINATED AVOIDANCE PERFORMANCE IN RATS AS A FUNCTION OF AGE.
076133 09-04

HYDROXYZINE AND SHOCK IN OPERANT BEHAVIOR OF RATS.
076164 09-04

DEVELOPMENT OF HORMONAL CONTROL OVER FOOD INTAKE AND BODY WEIGHT IN FEMALE RATS.
076239 09-03

EQUIVALENCE OF SIMULTANEOUS AND SUCCESSIVE NEOCORTICAL ABLATIONS IN PRODUCTION OF IMPAIRMENTS OF RETENTION OF BLACK WHITE HABITS IN RATS.
076316 09-04

EATING, DRINKING AND SPONTANEOUS ACTIVITY IN RATS AFTER THE ADMINISTRATION OF CHLORPROMAZINE.
079999 09-04

EFFECT OF CHLORPROMAZINE ON 5-HYDROXYTRYPTAMINE METABOLISM IN HIPPOCAMPAL STIMULATED RATS.
080338 09-01

BEHAVIORAL EFFECTS OF P-CHLOROPHENYLALANINE IN RATS: INHIBITION BY LITHIUM.
081112 09-03

RESPONSES OF MALE RATS TO SEX ODORS.
081226 09-04

INDUCTION OF RECEPTIVITY IN FEMALE RATS AND CATS WITH ESTROGEN AND TESTOSTERONE.
081228 09-04

FOREBRAIN BIOGENIC AMINE FUNCTION IN HIGH AND LOW FEMALE RATS.
081231 09-04

PHARMACOLOGIC ACTIVITY OF A NEW CLASS OF AGENTS WHICH SELECTIVELY INHIBIT AGGRESSIVE BEHAVIOR IN RATS.
082398 10-04

THE INFLUENCE OF A FEAR EVOKING SITUATION ON THE RECTAL TEMPERATURE OF RATS.
082409 10-03

PROJECT SUMMARY: CHEMICAL INDUCTION OF TRAUMATIC FIGHTING IN RATS.
082511 10-04

THE SELF-INJECTION OF AMOBARBITAL BY RATS DURING NON-REWARD. 083413 10-04
SOME BEHAVIOURAL EFFECTS OF VARIABLES WHICH INFLUENCE THE GENERAL LEVEL OF ACTIVITY OF RATS. 085204 10-04
APHAGIA, PRODUCED BY DEPOSITION OF DRUGS INTO THE HYPOTHALAMUS OF RATS. 088463 10-03
FAILURE OF TRICYANOAMINOPROPENE TO FACILITATE ACQUISITION OF DOUBLE ALTERNATION IN RATS. 088471 10-04
A COMPARISON OF SOME EFFECTS OF AMPHETAMINE IN RATS OF DIFFERENT AGES. 088587 10-03
HEPATIC COMPOSITION AND METABOLISM AFTER ETHANOL CONSUMPTION IN RATS FED LIQUID PURIFIED DIETS. 088599 10-03
NEUROENDOCRINOLOGICAL STUDY IN CHLORPROMAZINE TREATED RATS. 089029 10-13
RELATIONSHIP BETWEEN CENTRAL EFFECTS AND THE CONCENTRATION OF AMPHETAMINE IN LIVER AND BRAIN OF YOUNG AND OLD RATS. 089041 10-03
INDICATIONS OF CENTRAL NERVOUS EFFECTS OF SMALL AMOUNTS OF MERCURY IN RATS. 089044 10-17
EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND 2-BROM-D-LYSERGIC ACID DIETHYLAMIDE (BOL-148) UPON BEHAVIORAL SLEEP IN RATS. 089045 10-12
THE INFLUENCE OF LITHIUM ION ON THE ADRENOCORTICAL FUNCTION OF RATS. 089787 11-09
SOME EFFECTS OF ETHANOL ON THE TOXICITY AND DISTRIBUTION OF BARBITURATES IN RATS. 090032 11-05
EXPERIMENTAL DRUG MAKES RATS SEXY. 090137 11-04
THE EFFECT OF CHLORDIAZEPOXIDE ON THE BEHAVIOR OF RATS IN A CONFLICT SITUATION. 090424 11-04
EFFECTS OF INSULIN, METRAZOL, AND ELECTROCONVULSIVE SHOCKS UPON LEARNING TO LEARN 30 SUCCESSIVE REVERSAL PROBLEMS BY RATS. 095188 11-04
APPLICATION OF ON-LINE COMPUTER PROCEDURES TO EXPERIMENTAL CONTROL AND EVALUATION OF THE EFFECTS OF DRUGS ON OPERANT BEHAVIOR (SIDMAN SHOCK AVOIDANCE RESPONDING BY RATS). 095507 11-06
EFFECTS OF AN ACUTE STRESS OF FOREBRAIN 5-HYDROXYTRYPTAMINE (5-HT) METABOLISM IN CNS LESIONED AND DRUG PRETREATED RATS. 095671 11-04
EXCITATORY EFFECT OF TRYPTOPHAN IN MICE AND RATS AND EFFECT OF IMIPRAMINE AND DESMETHYLIMIPRAMINE UPON IT. 098009 11-03
THE INFLUENCE OF 5-HYDROXYTRYPTOPHAN ON THE BEHAVIOR AND THE LEVEL OF MONOAMINES IN THE BRAIN OF RATS SENSITIVE TO SOUND. 098040 11-03
LITHIUM INDUCED POLYURIA IN RATS. 106779 12-05
LITHIUM EFFECTS ON CALCIUM METABOLISM IN RATS. 106780 12-03
A STUDY OF PHARMACODYNAMICS IN PERIODIC CONDITIONAL PROCESSES IN ALBINO RATS. 112003 12-04
INFLUENCE OF ISONIAZID ON THE CENTRAL NERVOUS SYSTEM; THE ANTAGONISM BETWEEN ISONIAZID AND PYRIDOXINE, PANTOTHENIC ACID AND COUMARIN IN RATS (MELILOTUS-OFFICINALIS). 126055 12-04
CHANGES OF THE BODY TEMPERATURE OF CODEINE TOLERANT RATS BY THE ADMINISTRATION OF NALORPHINE. 130427 12-03
STUDIES ON PSYCHOTROPIC DRUGS (SIXTH REPORT) - METABOLIC FATE OF APY-606 - EXCRETION AND METABOLISM IN RATS. 131057 12-02

**RE-UPTAKE**
INHIBITION OF THE RE-UPTAKE OF NEURONALLY LIBERATED NORADRENALINE AND ALPHA-RECEPTOR BLOCKING ACTION OF SOME ERGOT ALKALOIDS. 041967 01-03

**REACTION**
REACTION TIMES OF METHADONE TREATED EX HEROIN ADDICTS. 062817 03-11
POSSIBLE LETHAL REACTION BETWEEN NARDIL AND DEXTROMETHORPHAN. 063897 04-15
SETTING, PATIENT, AND DOCTOR EFFECTS ON DRUG RESPONSE IN NEUROTIC PATIENTS: I. DIFFERENTIAL ATTRITION, DOSAGE DEVIATION, AND SIDE REACTION RESPONSES TO TREATMENT. 065453 05-10
IN DIAGNOSIS, TYPE OF REACTION IS MORE IMPORTANT THAN THE DRUG. 067939 06-15
PUPIL SIZE AND DRUG STATE IN A REACTION TIME TASK. 075161 08-13
EFFECT OF PHENOTHIAZINES ON REACTION TIME IN SCHIZOPHRENICS. 075413 08-08
METHYLPHENIDATE AND THIORIDAZINE: LEARNING, REACTION TIME, ACTIVITY, AND CLASSROOM BEHAVIOR IN DISTURBED CHILDREN. 081631 10-14
ESTIMATION OF LOW CHLORPROMAZINE CONCENTRATIONS BY SURFACING AND SINKING REACTION OF MINNOWS (GAMBUSIA-AFFINIS). 097964 11-06
CENTRAL ACTION OF SOME AUTONOMIC DRUGS IN RESPECT TO EEG AROUSAL REACTION OF THE RABBIT. 107190 12-03

**REACTIONS**
MENTAL RETARDATION ASSOCIATED WITH PRENATAL INTOXICATION, ALLERGIC REACTIONS, DEFICIENCIES, TRAUMA, AND PHYSICAL AGENTS. 061704 03-15
MENTAL RETARDATION ASSOCIATED WITH POSTNATAL POISONS, TOXINS, ENDOTOXINS, DEFICIENCIES AND ALLERGIC REACTIONS. 061706 03-15
ELECTROCORTICAL REACTIONS OF PINEALECTOMIZED AND INTACT RATS TO LETHAL DOSES OF PENTOBARBITAL. 064101 04-03
SIDE REACTIONS IN NEUROTICS: I. A COMPARISON OF TWO METHODS OF ASSESSMENT. 064287 04-15
BEHAVIORAL AND VISCERAL REACTIONS ELICITED BY CHEMICAL STIMULATION OF THE HYPOTHALAMUS AND SEPTUM IN CATS. 064333 04-04
PRESENT STATUS OF PSYCHOLOGICAL REACTIONS TO L-DOPA. 065165 05-09
ADVERSE MARIJUANA REACTIONS: A CRITICAL EXAMINATION OF THE LITERATURE WITH SELECTED CASE MATERIAL. 069613 07-15
THE INFLUENCE OF THE GANGLIONIC BLOCKING AGENT GANLION ON VISCEROVISCERAL AND VISCEROCEREBRAL REACTIONS OF THE CAT. 071703 07-03
AN ANALYSIS OF RECEPTIVE STRUCTURES PARTICIPATING IN THE BEHAVIOR REACTIONS OF CATS INDUCED BY CATECHOLAMINES AND SEROTONIN. 073715 08-03
PRELIMINARY EXPERIENCE WITH MEDAZEPAM (NOBRIUM) IN THE MANAGEMENT OF PSYCHOPHYSIOLOGIC REACTIONS. 075878 09-07
EFFECTS OF METHYLPHENIDATE ON ACTIVITY AND REACTIONS OF NOVELTY IN RATS. 076066 09-04
PSYCHOMOTOR REACTIONS TO A SLIGHT ALCOHOLEMIA. A COMPARATIVE STUDY ON DRINKERS AND NORMAL INDIVIDUALS. 085043 10-15
PARADOXAL PSYCHIC REACTIONS DURING LITHIUM TREATMENT. 089103 10-15
ADVERSE REACTIONS. 100513 11-15
COLLAGEN DISEASE-LIKE REACTIONS. 100528 12-15

**REACTIVE**
CONCERNING THE ARTICLE BY N.N.TIMOFEYEV, V.T.KONDRASHENKO AND N.Y.NEMTSEVA ON OXYMETRIC INVESTIGATION OF PATIENTS WITH SCHIZOPHRENIA AND REACTIVE PSYCHOSIS DURING NEUROLEPTIC TREATMENT. 109788 12-08

**REACTIVITY**
THE INTERACTION OF PSYCHOLOGIC STIMULI AND PHARMACOLOGIC AGENTS ON AIRWAY REACTIVITY IN ASTHMATIC SUBJECTS. 063515 03-13
EFFECTS OF DEXAMETHASONE ON THE DEVELOPMENT OF EMOTIONALITY AND ADRENOCORTICAL REACTIVITY. 063605 04-04
CHANGES IN D-AMPHETAMINE REACTIVITY RESULTING FROM SEPTAL FOREBRAIN INJURY. 067695 06-04
MONOAMINES AND THE REACTIVITY OF RATS WITH DIFFERENT TYPES OF HIGHER NERVOUS ACTIVITY. 070953 07-03
POPULATION DEPENDENT DIFFERENCES OF CENTRAL NERVOUS REACTIVITY TO NEUROLEPTICS. 098022 11-15

**REALITY**
DRUGS AND REALITY IN CAPTIVE SOCIETY. SOME OBSERVATIONS ON CHEMICAL ADAPTATION.
064091 04-17

**REARING**
DIFFERENCES IN BRAIN AREA 5-HYDROXYTRYPTAMINE TURNOVER AND REARING BEHAVIOR IN RATS AND MICE OF BOTH SEXES.
047324 01-04

**RECEIVING**
BLOOD AND URINE CONCENTRATIONS OF SUBJECTS RECEIVING BARBITURATES, MEPROBAMATE, GLUTETHIMIDE, OR DIPHENYLHYDANTOIN.
063927 04-13

OPHTHALMOLOGICAL STUDIES OF PATIENTS RECEIVING PSYCHOTROPIC PREPARATIONS.
073788 08-15

**RECEPTIVE**
AN ANALYSIS OF RECEPTIVE STRUCTURES PARTICIPATING IN THE BEHAVIOR REACTIONS OF CATS INDUCED BY CATECHOLAMINES AND SEROTONIN.
073715 08-03

**RECEPTIVITY**
EFFECT OF CHRONIC ADMINISTRATION OF P-CHLOROPHENYLALANINE ON SEXUAL RECEPTIVITY OF THE FEMALE RAT.
066825 05-04

INDUCTION OF RECEPTIVITY IN OVARIECTOMIZED FEMALE RATS BY A SINGLE INTRAVENOUS INJECTION OF ESTRADIOL-17BETA.
067696 06-04

INDUCTION OF RECEPTIVITY IN FEMALE RATS AND CATS WITH ESTROGEN AND TESTOSTERONE.
081228 09-04

**RECEPTOR**
RECEPTOR MECHANISMS.
051113 01-17

EVIDENCE FOR A CENTRAL NORADRENALINE RECEPTOR: STIMULATION BY CLONIDINE.
081151 09-03

**RECEPTORS**
ALPHA-ADRENERGIC RECEPTORS IN HYPOTHALAMUS FOR THE SUPPRESSION OF FEEDING BEHAVIOR BY SATIETY.
060801 03-04

VERBAL ANXIETY AND THE BETA-ADRENERGIC RECEPTORS: A FACILITATING MECHANISM.
060880 03-13

STUDIES ON THE RECEPTORS INVOLVED IN THE ACTION OF THE VARIOUS AGENTS IN THE PHENYLBENZOQUINONE ANALGESIC ASSAY IN MICE.
090451 11-03

RECIPROCAL HUNGER REGULATING CIRCUITS INVOLVING ALPHA-ADRENERGIC AND BETA-ADRENERGIC RECEPTORS LOCATED, RESPECTIVELY, IN THE VENTROMEDIAL AND LATERAL HYPOTHALAMUS.
092166 11-03

MOLECULAR PROPERTIES OF DRUG RECEPTORS.
110897 12-17

**RECIPROCAL**
RECIPROCAL HUNGER REGULATING CIRCUITS INVOLVING ALPHA-ADRENERGIC AND BETA-ADRENERGIC RECEPTORS LOCATED, RESPECTIVELY, IN THE VENTROMEDIAL AND LATERAL HYPOTHALAMUS.
092166 11-03

**RECOGNITION**
RECOGNITION AND MANAGEMENT OF DEPRESSION.
060728 03-17

ON BINSWANGERS SUBCORTICAL ARTERIOSCLEROTIC ENCEPHALOPATHY AND THE POSSIBILITY OF ITS CLINICAL RECOGNITION.
078733 09-13

STATE-DEPENDENT RECOGNITION WITH METHYLPHENIDATE AND THIORIDAZINE IN RETARDED CHILDREN. (PH.D.DISSERTATION).
103301 12-14

**RECORDING**
RECORDING EVOKED POTENTIALS IN THE CONSCIOUS RAT: THE MAINTENANCE OF A CONSTANT BEHAVIOURAL BASELINE.
067600 06-06

**RECORDINGS**
DIAZEPAM IN THE ELECTROENCEPHALOGRAPHIC RECORDINGS OF EPILEPTICS.
087661 10-11

**RECORDS**
CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL: CASE 20-1970.
042655 01-15

**RECOVERY**
LATE BRAIN RECOVERY PROCESSES AFTER DRUG OVERDOSE.
082027 10-15

**RECTAL**
THE INFLUENCE OF A FEAR EVOKING SITUATION ON THE RECTAL TEMPERATURE OF RATS.
082409 10-03

**RECTUS-ABDOMINIS**
THE EFFECT OF ANTIADRENALINE COMPOUNDS ON ACETYLCHOLINE RESPONSES OF FROG RECTUS-ABDOMINIS MUSCLE.
041538 01-03

**RECURRENT**
PROPHYLACTIC LITHIUM: A DOUBLE-BLIND TRIAL IN RECURRENT AFFECTIVE DISORDERS.
060263 03-09

METHODOLOGICAL PROBLEMS OF PROPHYLACTIC TRIALS IN RECURRENT AFFECTIVE DISORDERS.
060266 03-09

LITHIUM PROPHYLAXIS IN RECURRENT AFFECTIVE DISORDERS.
060267 03-09

THE EFFECT OF HEXOBARBITAL ON THE DURATION OF THE RECURRENT IPSP IN CAT MOTONEURONS.
064621 04-03

A LONGITUDINAL INVESTIGATION OF LITHIUM AS A PROPHYLACTIC AGENT FOR RECURRENT DEPRESSIONS.
075425 08-10

PROPHYLACTIC LITHIUM IN RECURRENT AFFECTIVE DISORDERS: A FOUR YEAR STUDY.
081152 09-09

STUDIES ON THE COURSE OF RECURRENT ENDOGENOUS AFFECTIVE DISORDERS.
106766 12-09

THE COURSE OF RECURRENT DEPRESSIVE ILLNESS IN SELECTED PATIENTS FROM A DEFINED POPULATION.
106781 12-09

**REDIRECTED**
REDIRECTED AGGRESSION AND GONADAL HORMONES IN CAPTIVE RHESUS MONKEYS (MACACA-MULATTA).
075829 08-04

**REDUCED**
REDUCED EFFECT OF MORPHINE IN MIDBRAIN RAPHE LESIONED RATS.
066500 05-03

TESTING THE PERFORMANCE UNDER APONEURON OF OTHERWISE NORMAL SCHOOL CHILDREN WITH A TENDENCY TOWARD REDUCED DRIVE AND EASY TIRING.
080563 09-11

**REDUCING**
A NOVEL METHOD OF REDUCING THE CONCENTRATION OF BRAIN SEROTONIN: USE OF ALPHA-METHYLTRYPTOPHAN.
086350 10-13

**REDUCTION**
STUDIES ON NITRAZEPAM REDUCTION IN VITRO.
064255 04-03

REDUCTION OF ELECTRICALLY REWARDED BEHAVIOR BY INTERFERENCE WITH MONOAMINE SYNTHESIS.
069065 06-04

REDUCTION OF THE ANTINOCICEPTIVE EFFECT OF 5-HYDROXYTRYPTOPHAN IN MORPHINE TOLERANT RATS.
075846 09-03

REDUCTION OF ANALGESIC EFFECTS BY LITHIUM.
080144 09-03

REDUCTION OF LEVEL OF L-GLUTAMIC ACID DECARBOXYLASE BY GAMMA-AMINOBUTYRIC ACID IN MOUSE BRAIN.
083168 10-03

REDUCTION OF BARBITURATE DEPENDENCE INDUCED BY REPEATED ELECTROCONVULSIONS.
097548 11-03

**REDUNDANCY**
PHARMACOLOGICAL REDUNDANCY AS AN ADAPTIVE MECHANISM IN THE CENTRAL NERVOUS SYSTEM.
056113 02-13

**REFLECTION**
TOTAL INTERNAL REFLECTION LIGHT CHAMBER (UNPUBLISHED PAPER).
092999 11-06

**REFLEX**
EFFECT OF IMIPRAMINE AND CHLORIMIPRAMINE ON AN ACUTE INSTRUMENTAL TRACE CONDITIONED REFLEX IN RATS.
064415 04-04

UNCONDITIONED REFLEX ACTIVITY IN THE RAT SUFFERING FROM EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY AND THE THERAPEUTIC EFFECT OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126051 12-04

**REFLEXES**
PSYCHOPHARMACOLOGY AND CONDITIONAL REFLEXES.
071705 07-13

EFFECT OF L-DOPA ALONE AND IN COMBINATION WITH AN EXTRACEREBRAL DECARBOXYLASE INHIBITOR ON BLOOD PRESSURE AND SOME CARDIOVASCULAR REFLEXES.
090371 11-13

EFFECT OF CHLORPROMAZINE ON CONDITIONED REFLEXES AND ANTAGONISTIC ACTIVITY OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126054 12-04

**REGIMEN**
EXPERIMENTAL PSYCHOLOGICAL STUDY OF PERFORMANCE CHANGES WITH PERAZINE (TAXILAN) IN MENTALLY DISTURBED AND IN HEALTHY EXPERIMENTAL SUBJECTS FOLLOWING REGIMEN AND SINGLE DOSE ADMINISTRATION.
058235 02-11
USE OF LEVODOPA MAY BE EXPANDED BY ADDITION OF MK-485 TO DRUG REGIMEN.
097284 11-09

**REGION**
CHANGES IN EMOTIONAL BEHAVIOUR AFTER APPLICATION OF CHOLINESTERASE INHIBITOR IN THE SEPTAL AND AMYGDALA REGION.
040578 01-04

**REGRESSION**
CORRELATIONS OF STRUCTURE-ACTIVITY OF MORPHINE-LIKE ANALGESICS USING REGRESSION ANALYSIS.
089042 10-01

**REGULATING**
RECIPROCAL HUNGER REGULATING CIRCUITS INVOLVING ALPHA-ADRENERGIC AND BETA-ADRENERGIC RECEPTORS LOCATED, RESPECTIVELY, IN THE VENTROMEDIAL AND LATERAL HYPOTHALAMUS.
092166 11-03

**REGULATION**
REGULATION OF DRUG SELF-ADMINISTRATION.
046207 01-04
REGULATION OF NOREPINEPHRINE BIOSYNTHESIS.
051126 02-17
BIPHASIC EFFECT OF NOREPINEPHRINE IN THE REGULATION OF HEPATIC TYROSINE TRANSAMINASE ACTIVITY.
062327 03-03
HYPOTHALAMIC REGULATION OF HEPATIC HEXOBARBITAL METABOLIZING ENZYME SYSTEM.
067962 06-03
PSYCHOTROPIC DRUGS AND THE REGULATION OF BEHAVIORAL ACTIVATION IN PSYCHIATRIC ILLNESS.
070970 07-17
PHARMACOLOGY, LIMBIC REGULATION AND CORTICAL FUNCTION.
070979 07-04
THE ROLE OF BRAIN DOPAMINE IN BEHAVIORAL REGULATION AND THE ACTIONS OF PSYCHOTROPIC DRUGS.
075869 09-04
STUDIES IN MAN ON THE INFLUENCE OF A NEW PSYCHOPHARMACEUTICAL DRUG, 1-((METHYLAMINO) DIBENZOBICYCLOOCTADIENE HYDROCHLORIDE, ON THE CO2 SENSITIVE CENTRAL RESPIRATORY REGULATION.
079971 09-07
GOVERNMENTAL REGULATION OF THE DRUG INDUSTRY.
091208 11-17

**REHABILITATION**
THE ROLE OF THE PSYCHIATRIC NURSE IN THE REHABILITATION OF THE SCHIZOPHRENIC PATIENT.
062108 03-08
CLINICAL EXPERIENCE WITH MESORIDAZINE IN THE THERAPY AND REHABILITATION OF TRAUMATIC FRONTAL BRAIN DAMAGE.
089784 11-14

**REINFORCED**
THE EFFECT OF PUROMYCIN ON RETENTION OF A POSITIVELY REINFORCED RESPONSE IN GOLDFISH.
059616 03-04
THE EFFECTS OF SCOPOLAMINE ON THE EXTINCTION OF A CONTINUOUSLY REINFORCED RESPONSE.
063587 03-04
FOOD REINFORCED RESPONDING IN RATS DURING ESTRUS.
075645 08-04
EFFECT OF ATROPINE DOSE LEVEL ON THE SUPPRESSION OF WATER REINFORCED VI RESPONDING.
075870 09-04

**REINFORCEMENT**
EFFECTS OF REINFORCEMENT SHIFTS UPON SUBSEQUENT SUCROSE CONSUMPTION.
060871 03-03
A BEHAVIORAL AND PHARMACOLOGICAL ANALYSIS OF REINFORCEMENT WITHDRAWAL.
062942 03-04
SODIUM AMOBARBITAL, THE HIPPOCAMPAL THETA RHYTHM, AND THE PARTIAL REINFORCEMENT EXTINCTION EFFECT.
063333 03-03
EFFECTS OF MORPHINE ON BEHAVIOR MAINTAINED BY FOUR SIMPLE FOOD REINFORCEMENT SCHEDULES.
064479 04-04
THE EFFECTS OF TRICYANOAMINOPROPENE ON LEARNING IN A DIFFERENTIAL REINFORCEMENT OF LOW RATES SITUATION.
075851 09-03
INVESTIGATION OF THE PSYCHODYNAMIC REINFORCEMENT OF NEUROLEPTICS WITH 1035-MD.
089111 10-07

**REINFORCING**
CONDITIONED SUPPRESSION BASED ON POSITIVELY REINFORCING INTRACRANIAL STIMULATION.
064842 05-02
REINFORCING LIMBIC SYSTEM STIMULATION AND SODIUM AMYTAL.
075553 08-04

**RELAPSE**
RELAPSE TO OPIOID DEPENDENCE: THE ROLE OF CONDITIONING.
046208 01-03
PERSISTENCE OF RELAPSE TENDENCIES OF RATS PREVIOUSLY MADE PHYSICALLY DEPENDENT ON MORPHINE.
062940 03-04
CRISES AND LIFE CHANGES PRECEDING THE ONSET OR RELAPSE OF ACUTE SCHIZOPHRENIA: CLINICAL ASPECTS.
075304 08-08
PATHOPHYSIOLOGY OF NARCOTIC ADDICTION; POSSIBLE ROLES OF PROTRACTED ABSTINENCE IN RELAPSE (UNPUBLISHED PAPER).
093000 11-13

**RELAXANT**
CENTRAL MUSCLE RELAXANT EFFECTS OF DIAZEPAM.
079997 09-03

**RELAXATION**
COMPARISON OF METHODS OF RELAXATION USING PHYSIOLOGICAL MEASURES.
074135 08-14

**RELAXING**
RELAXING EFFECT OF VITAMIN-B WITH ANABOLICS.
070778 07-14

**RELEARNING**
EFFECTS OF AMPHETAMINE UPON RELEARNING PATTERN AND BLACK WHITE DISCRIMINATIONS FOLLOWING NEOCORTICAL LESIONS IN RATS.
065419 05-04

**RELEASE**
EFFECTS OF METABOLIC INHIBITORS ON NOREPINEPHRINE RELEASE FROM THE PERFUSED SPLEEN OF THE CAT.
040244 01-03
RELEASE OF NOREPINEPHRINE FROM ISOLATED RAT IRIS BY FIELD STIMULATION.
040245 01-03
EFFECTS OF TWO CHOLINESTERASE INHIBITORS ON ACETYLCHOLINE RELEASE FROM THE GUINEA-PIG ISOLATED ILEUM PREPARATION.
040572 01-03
THE EFFECTS OF ACIDOSIS ON CHRONOTROPIC RESPONSES, NOREPINEPHRINE STORAGE AND RELEASE IN ISOLATED GUINEA-PIG ATRIA.
040753 01-03
INCREASED RELEASE OF DOPAMINE FROM STRIATAL DOPAMINERGIC TERMINALS IN THE RAT AFTER TREATMENT WITH A NEUROLEPTIC: THIOPROPERAZINE.
042742 01-03
THE EFFECT OF MORPHINE, NALORPHINE, NALOXONE, PENTAZOCINE, CYCLAZOCINE AND OXOTREMORINE ON THE SYNTHESIS AND RELEASE OF ACETYLCHOLINE BY MOUSE CEREBRAL CORTEX SLICES IN VITRO.
058994 03-03
RELEASE OF 5-HYDROXYTRYPTAMINE FROM SLICES OF SUPERIOR COLLICULUS BY OPTIC TRACT STIMULATION.
064369 04-03
MECHANISMS BY WHICH AMPHETAMINE AND DESIPRAMINE INHIBIT THE METARAMINOL INDUCED RELEASE OF NOREPINEPHRINE FROM SYMPATHETIC NERVE ENDINGS IN RAT HEART.
064427 04-03
RELEASE OF NOREPINEPHRINE IN THE CENTRAL NERVOUS SYSTEM BY THEOPHYLLINE AND CAFFEINE.
066411 05-03
ACETYLCHOLINE RELEASE FROM CORTICAL BRAIN SLICES OF RATS INJECTED WITH LITHIUM.
066509 05-03
SOME FACTORS INFLUENCING THE RELEASE OF 5-HYDROXYINDOL-3-YLACETIC ACID IN THE FOREBRAIN.
067598 06-03
RELEASE BY AMPHETAMINE IN MAN OF GROWTH HORMONE AND CORTICOSTEROIDS: THE EFFECTS OF THYMOXAMINE AND PROPRANOLOL.
067602 06-13
THE EFFECT OF DEXAMETHASONE BLOCKADE OF ACTH RELEASE ON AVOIDANCE LEARNING.
067884 06-04
DRUG-INDUCED RELEASE OF 3H-NOREPINEPHRINE AND 3H-SEROTONIN FROM BRAIN SLICES.
068290 06-03
INCREASED TRANSMITTER RELEASE INDUCED BY CONVULSANT PHENOLS.
081063 09-03

**RELEASED**
THE ANTAGONISM OF PHENTOLAMINE AGAINST EXOGENOUSLY ADMINISTERED AND ENDOGENOUSLY RELEASED NOREPINEPHRINE IN RABBIT AORTIC STRIPS.
040243 01-03

MODIFICATION BY DESIPRAMINE (DMI) OF THE AVAILABILITY OF NOREPINEPHRINE RELEASED BY RESERPINE IN THE HYPOTHALAMUS OF THE RAT IN VIVO.
066374 05-03

**RELIABILITY**
DIFFERENTIAL RELIABILITY IN RATING PSYCHOPATHOLOGY AND GLOBAL IMPROVEMENT.
076292 09-10

**RELIEF**
DRUG-INDUCED RELIEF OF EXPERIMENTAL TREMOR IN MONKEYS.
068457 06-04
PSYCHOSOMATIC FACTORS IN RHEUMATIC DISORDERS AND THEIR RELIEF BY MEDICATION.
089859 11-14

**RELIGIOUS**
LSD, VIOLENCE AND RADICAL RELIGIOUS BELIEFS.
067354 06-12

**REM**
DIFFERENTIAL EFFECTS OF THREE TRICYCLIC ANTIDEPRESSANTS ON SLEEP AND REM SLEEP IN THE RAT.
067919 06-04
TO SLEEP, PERCHANCE TO DREAM: NEW DRUG FOR INSOMNIACS DOESNT INTERFERE WITH REM TIME.
068021 06-14
INDUCTION BY CANNABIS-SATIVA (MARIHUANA) OF RHYTHMIC SPIKE DISCHARGES OVERRIDING REM SLEEP ELECTROCORTICOGRAM IN THE RAT.
069069 06-04

**REMAIN**
AFFECTIVE DISORDERS: PROGRESS, BUT SOME UNRESOLVED QUESTIONS REMAIN.
061682 03-09

**REMISSIONS**
THE EFFECTIVENESS OF SIMULTANEOUS TREATMENT WITH VITAMIN-B12 AND INSULIN IN SCHIZOPHRENIC PATIENTS, ACCORDING TO THE FREQUENCY OF STABLE REMISSIONS.
096513 11-08

**RENAL**
MECHANISM OF THE RENAL TUBULAR TRANSPORT OF MORPHINE AND MORPHINE ETHEREAL SULFATE IN THE CHICKEN.
040754 01-03
AMPHETAMINE INTOXICATION WITH COAGULOPATHY, HYPERTHERMIA, AND REVERSIBLE RENAL FAILURE: A SYNDROME RESEMBLING HEATSTROKE.
064236 04-15

**RENSHAW**
EFFECTS OF MORPHINE ON RENSHAW CELL ACTIVITY.
064100 04-03

**REPEATED**
BEHAVIORAL CHANGES FOLLOWING REPEATED LOW DOSES OF MONOMETHYLHYDRAZINE.
082959 10-05
CHANGES IN BEHAVIOUR WITH REPEATED TESTING UNDER THE INFLUENCE OF DRUGS: DRUG EXPERIENCE INTERACTIONS.
091997 11-04
REDUCTION OF BARBITURATE DEPENDENCE INDUCED BY REPEATED ELECTROCONVULSIONS.
097548 11-03

**REPETITIVE**
P-CHLOROPHENYLALANINE AND HABITUATION TO REPETITIVE AUDITORY STARTLE STIMULI IN RATS.
063015 03-03

**REPLICATIONS**
ADRENALIN AND AVOIDANCE LEARNING: PARTIAL REPLICATIONS.
075559 08-04

**REPRESENTATION**
SENSORY REPRESENTATION IN THE NEOCORTEX OF THE MOLE, SCALOPUS AQUATICUS.
066468 05-03

**REPRESSOR**
GABA AS A REPRESSOR OF L-GLUTAMIC ACID DECARBOXYLASE (GAD) IN DEVELOPING CHICK EMBRYO OPTIC LOBES.
058192 02-03

**REPRODUCTION**
THE EFFECT OF SOME INHIBITORS AND METABOLITES OF CATECHOLAMINE ON THE PROCESSES OF FIXATION AND REPRODUCTION OF MEMORY TRACES.
073716 08-03

**REPTILE**
EXTINCTION OF THE EXCRETORY ALKALI METAL RESPONSE (EAMR) TO STRESS IN A REPTILE.
076068 09-03

**RESEARCH**
THE RESEARCH.
046727 01-12
THE DILEMMA OF DRUG RESEARCH.
068987 06-17
METHODOLOGICAL PROBLEMS IN PSYCHOTHERAPY RESEARCH: OBSERVATIONS ON THE KARON-VANDENBOS STUDY OF PSYCHOTHERAPY AND DRUGS IN SCHIZOPHRENIA.
071322 07-08
DRUG DEPENDENCE: SOME RESEARCH ISSUES.
071747 07-16
CLINICAL RESEARCH INTO CHRONIC INCURABLE SCHIZOPHRENIA.
072891 08-08
THE PHYSICIAN QUESTIONNAIRE: A USEFUL TOOL IN PSYCHIATRIC DRUG RESEARCH.
075843 09-17
THE IMPORTANCE OF RESEARCH IN BIOGENIC AMINES FOR THE EXPERIMENTAL PSYCHOPHARMACOLOGY.
081110 09-17
RESEARCH ON NEW METHODS OF EXPERIMENTATION WITH PSYCHOTROPIC DRUGS. RESULTS OF A TEST WITH A NEW TRANQUILIZER, NOBRIUM, IN TWO INDEPENDENT INVESTIGATIONS.
086984 10-16
ELECTROCLINICAL RESEARCH ON THE USE OF 1035-MD IN PSYCHIATRY.
087498 10-11
SUBJECTIVE EFFECTS OF NARCOTIC ANTAGONISTS CYCLAZOCINE AND NALORPHINE ON THE ADDICTION RESEARCH CENTER INVENTORY (ARCI).
097961 11-14
PSYCHOPHARMACOLOGY: THE ROLE OF CLINICAL RESEARCH.
100276 11-07
LONG-TERM DRUG THERAPY IN AFFECTIVE DISORDERS: THEORETICAL AND METHODOLOGICAL ISSUES IN CURRENT RESEARCH ON LITHIUM.
106765 12-09
RESEARCH IN NEW EXPERIMENTAL METHODS FOR PSYCHOTROPIC DRUGS: RESULTS OF A DOUBLE-BLIND STUDY WITH A NEW TRANQUILIZER, NOBRIUM.
112282 12-16
RESEARCH ON THE DEFECT STATE OF SCHIZOPHRENIC PATIENT UNDER CONTROL OF PSYCHODRUGS.
129273 12-08

**RESEMBLANCE**
MOTIVATIONAL DEPRESSION ASSOCIATED WITH NOREPINEPHRINE INDUCED EATING FROM THE HYPOTHALAMUS: RESEMBLANCE TO THE VENTROMEDIAL HYPERPHAGIC SYNDROME.
090473 11-04

**RESEMBLING**
AMPHETAMINE INTOXICATION WITH COAGULOPATHY, HYPERTHERMIA, AND REVERSIBLE RENAL FAILURE: A SYNDROME RESEMBLING HEATSTROKE.
064236 04-15

**RESERPINE**
THE ROLE OF THE HYPOTHALAMO-PITUITARY SYSTEM IN THE MECHANISM OF ACTION OF RESERPINE AND 5-HYDROXYTRYPTOPHAN ON ANTIBODY PRODUCTION.
040579 01-03
STIMULATION OF DOPA-14C INCORPORATION INTO MELANOMA TISSUE BY CHLORPROMAZINE AND RESERPINE.
040584 01-03
EFFECT OF RESERPINE ON THE INCORPORATION IN VIVO OF RADIOACTIVITY FROM LABELED SEROTONIN AND OTHER 5-HYDROXYINDOLE DERIVATIVES IN MOUSE BRAIN.
046189 01-03
EFFECTS OF RESERPINE AND DESIPRAMINE ON THE UPTAKE AND SUBCELLULAR DISTRIBUTION OF 5-HYDROXYTRYPTAMINE IN RABBIT BRAINSTEM AFTER INTRAVENOUS ADMINISTRATION OF 5-HYDROXYTRYPTOPHAN.
056610 02-03
EXCRETION OF VANYLGLYCOL IN HUMAN URINE UNDER DIETARY CONTROL, AND DURING TREATMENT WITH ANTIBIOTICS, DISULFIRAM, A MONOAMINE OXIDASE INHIBITOR, ALPHA-METHYLDOPA, AND RESERPINE.
060272 03-13
EFFECTS OF RESERPINE ON THE COPULATORY BEHAVIOR OF MALE RATS.
063014 03-04
INTERACTION BETWEEN RESERPINE AND DESMETHYLIMIPRAMINE.
064254 04-03
VALIDITY OF ANTAGONISM OF DIFFERENT EFFECTS OF RESERPINE AS TEST FOR ANTIDEPRESSANT ACTIVITY.
064413 04-03
OBSERVATION OF THE GROOMING BEHAVIOR OF RESERPINIZED WHITE MICE AS A METHOD FOR INVESTIGATING RESERPINE ANTAGONISM AND SYNERGISM.
065442 05-04
MODIFICATION BY DESIPRAMINE (DMI) OF THE AVAILABILITY OF NOREPINEPHRINE RELEASED BY RESERPINE IN THE HYPOTHALAMUS OF THE RAT IN VIVO.
066374 05-03
UPTAKE AND RETENTION OF 3H-NORADRENALINE IN ADRENERGIC NERVE TERMINALS AFTER RESERPINE AND AXOTOMY.
066499 05-03

ACTIONS OF RESERPINE AND TYRAMINE ON THE ACETYLCHOLINE CONTENT OF BRAINSTEM, HEART AND BLOOD OF THE RAT.
067461 06-03
RESERPINE AND CONDITIONED SUPPRESSION IN THE FISH TILAPIA H. MACROCEPHALA.
075996 09-04
ANTAGONISM OF BETA-PHENYLETHYLAMINE DERIVATIVES AND SEROTONIN BLOCKING DRUGS UPON SEROTONIN, TRYPTAMINE AND RESERPINE BEHAVIORAL DEPRESSION IN MICE.
079970 09-04
EFFECTS OF CHRONIC MORPHINE ADMINISTRATION ON THE CATECHOLAMINE DEPLETION INDUCED BY RESERPINE.
081065 09-03
THE CENTRAL SYMPATHETIC DEPRESSIVE EFFECT OF RESERPINE, ALPHA-METHYLDOPA AND CLONIDINE.
089046 10-03
SYNERGISM OF DESMETHYLIMIPRAMINE WITH RESERPINE AND 5-HYDROXYTRYPTOPHAN IN THE FROG: BRAIN SEROTONIN AND ADRENALINE AND BEHAVIOR.
098042 11-03
CLINICAL EXPERIENCE WITH 10MG RESERPINE INJECTED I.M.IN DEPRESSIVE DISORDERS.
100019 11-09
UPTAKE AND STORAGE MECHANISM OF 5-HYDROXYTRYPTAMINE IN RABBIT BRAINSTEM AND EFFECT OF RESERPINE.
114975 12-03

**RESERPINIZED**
OBSERVATION OF THE GROOMING BEHAVIOR OF RESERPINIZED WHITE MICE AS A METHOD FOR INVESTIGATING RESERPINE ANTAGONISM AND SYNERGISM.
065442 05-04

**RESIDUAL**
FLUPHENAZINE: A RETROSPECTIVE ASSESSMENT IN 130 PATIENTS WITH RESIDUAL SCHIZOPHRENIA.
088951 10-08
THE USE OF HALOPERIDOL IN RESIDUAL SCHIZOPHRENIA AND IN PARANOID STATES.
093524 11-08

**RESISTANCE**
COMMENT ON THE INCREASED RESISTANCE TO EXTINCTION OF AN AVOIDANCE RESPONSE INDUCED BY CERTAIN DRUGS.
065070 05-04
AN ATTEMPT TO ELIMINATE RESISTANCE TO AMINAZINE BY MALARIA THERAPY IN PATIENTS WITH PARANOID SCHIZOPHRENIA.
087312 10-16

**RESISTANT**
CRASH TREATMENT FOR MELANCHOLIA RESISTANT TO OTHER RECENTLY DEVELOPED METHODS.
058456 02-07
TREATMENT OF RESISTANT SCHIZOPHRENICS WITH EXTREME HIGH DOSAGE FLUPHENAZINE HYDROCHLORIDE.
063597 04-08
A COMPARISON OF HALOPERIDOL AND THIORIDAZINE HCL IN CHRONIC TREATMENT RESISTANT SCHIZOPHRENICS.
066398 05-08
A COMPARISON OF HALOPERIDOL AND THIORIDAZINE HCL IN CHRONIC TREATMENT RESISTANT SCHIZOPHRENICS.
066817 05-08
THYROID HORMONE AND TRICYCLIC ANTIDEPRESSANTS IN RESISTANT DEPRESSIONS.
075428 08-09

**RESONANCE**
EFFECTS OF PHENOTHIAZINE DERIVATIVES ON BIOLOGICAL MEMBRANES: DRUG-INDUCED CHANGES IN ELECTRON SPIN RESONANCE SPECTRA FROM SPIN-LABELED ERYTHROCYTE GHOST MEMBRANES.
064423 04-03

**RESPIRATORY**
STUDIES IN MAN ON THE INFLUENCE OF A NEW PSYCHOPHARMACEUTICAL DRUG, 1-((METHYLAMINO) DIBENZOBICYCLOOCTADIENE HYDROCHLORIDE, ON THE CO2 SENSITIVE CENTRAL RESPIRATORY REGULATION.
079971 09-07

**RESPONSE**
THE DIFFERENTIAL RESPONSE TO PARENTERAL CHLORPROMAZINE AND MESORIDAZINE IN PSYCHOTIC PATIENTS.
040127 01-08
EFFECT OF AMPHETAMINE, NICOTINE AND HEXAMETHONIUM ON PERFORMANCE OF A CONDITIONED RESPONSE DURING ACQUISITION AND RETENTION TRIALS.
046186 01-04
RESPONSE DISRUPTION FOLLOWING AMPHETAMINE SELF-ADMINISTRATION AND PROGRAMMED ADMINISTRATION.
046209 01-04
THE RESPONSE TO MEPROBAMATE – A PREDICTIVE ANALYSIS.
046311 01-17
PERSONALITY DIFFERENCES IN THE RESPONSE TO STIMULANT DRUGS ADMINISTERED DURING A SLEEP DEPRIVED STATE.
052502 02-14
DIFFERENTIAL RESPONSE TO TREATMENT AS A FUNCTION OF THE CHANGING CHARACTER OF A DEPRESSION.
052574 02-10
STARTLE RESPONSE CIRCADIAN RHYTHM IN RATS: LACK OF CORRELATION WITH MOTOR ACTIVITY.
058349 02-04
RESPONSE TO DRUGS BY RATS SHOWING LONG OR SHORT HEXOBARBITAL INDUCED SLEEP.
058990 03-03
THE EFFECT OF PUROMYCIN ON RETENTION OF A POSITIVELY REINFORCED RESPONSE IN GOLDFISH.
059616 03-04
FORGETTING OF AN OPERANT RESPONSE: PHYSOSTIGMINE PRODUCED INCREASES IN ESCAPE LATENCY IN RATS AS A FUNCTION OF TIME OF INJECTION.
061540 03-04
FACTORS ASSOCIATED WITH POOR RESPONSE TO LITHIUM CARBONATE: A CLINICAL STUDY.
062352 03-09
EXTINCTION OF AVOIDANCE RESPONDING THROUGH RESPONSE PREVENTION (FLOODING).
063275 03-04
TELEVISION TAPE FOR EVALUATION OF TREATMENT RESPONSE.
063568 03-17
THE EFFECTS OF SCOPOLAMINE ON THE EXTINCTION OF A CONTINUOUSLY REINFORCED RESPONSE.
063587 03-04
HANDWRITING CHANGES AND RESPONSE TO DRUGS – A CONTROLLED STUDY.
063775 04-14
ANTAGONISM OF D-AMPHETAMINE BY ALPHA-METHYL-L-TYROSINE: BEHAVIORAL EVIDENCE FOR THE PARTICIPATION OF CATECHOLAMINE STORES AND SYNTHESIS IN THE AMPHETAMINE STIMULANT RESPONSE.
064096 04-03
COMMENT ON THE INCREASED RESISTANCE TO EXTINCTION OF AN AVOIDANCE RESPONSE INDUCED BY CERTAIN DRUGS.
065070 05-04
SETTING, PATIENT, AND DOCTOR EFFECTS ON DRUG RESPONSE IN NEUROTIC PATIENTS: II. DIFFERENTIAL IMPROVEMENT.
065446 05-10
SETTING, PATIENT, AND DOCTOR EFFECTS ON DRUG RESPONSE IN NEUROTIC PATIENTS: I. DIFFERENTIAL ATTRITION, DOSAGE DEVIATION, AND SIDE REACTION RESPONSES TO TREATMENT.
065453 05-10
THE RESPONSE OF LYSOSOMES IN CULTURED NEURONS TO CHLORPROMAZINE.
066380 05-03
ALDOSTERONE AND SODIUM RESPONSE TO LITHIUM ADMINISTRATION IN MAN.
066493 05-13
INHIBITORY EFFECT OF PROPRAHOLOL ON THE VASOCONSTRICTOR RESPONSE TO SYMPATHETIC NERVE STIMULATION.
066506 05-03
PILLS AND IMPROVEMENT: A STUDY OF PLACEBO RESPONSE IN PSYCHONEUROTIC OUTPATIENTS.
066832 05-10
INITIAL SUPPRESSION OF THE LOCOMOTOR STIMULANT RESPONSE TO DEXAMPHETAMINE IN RATS EXPOSED TO A NOVEL ENVIRONMENT.
067601 06-04
THE INFLUENCE OF VARIOUS NEUROLEPTIC DRUGS ON NOISE ESCAPE RESPONSE IN RATS.
069076 06-04
ANTIDOTAL THIRST: A RESPONSE TO INTOXICATION.
070821 07-05
DRUG RESPONSE FOLLOWING BRAIN DAMAGE.
070977 07-04
EXPERIMENTAL VARIABLES IN THE EFFECTS OF POSTSESSION INJECTIONS OF STRYCHNINE SULPHATE ON A CLASSICALLY CONDITIONED RESPONSE.
071792 07-04
PATIENT PERSONALITY AND DEMOGRAPHIC FACTORS AS PREDICTORS OF EARLY RESPONSE TO PSYCHOTROPIC DRUG TREATMENT.
074130 08-10
CHANGE IN SENSITIVITY TO D-AMPHETAMINE IN FRONTAL RATS AS A FUNCTION OF TIME: SHIFTING OF THE DOSE RESPONSE CURVE.
075238 08-04
SECONDARY IMMUNE RESPONSE TO TETANUS TOXOID IN PSYCHIATRIC PATIENTS.
075412 08-13
EFFECTS OF NEONATAL TESTOSTERONE ON THE ACQUISITION OF AN ACTIVE AVOIDANCE RESPONSE IN GENOTYPICALLY FEMALE RATS.
075890 09-04
EXTINCTION OF THE EXCRETORY ALKALI METAL RESPONSE (EAMR) TO STRESS IN A REPTILE.
076068 09-03
DOSE RESPONSE ANALYSIS OF CARBACHOL ELICITED DRINKING IN THE RAT LIMBIC SYSTEM.
076081 09-04

PSYCHOMETRIC TESTS IN EVALUATION OF BRAIN PATHOLOGY, RESPONSE TO DRUGS.
081043 09-14
RELATIONSHIP BETWEEN THE HOSPITAL MILIEU AND THE RESPONSE TO PHENOTHIAZINES IN THE TREATMENT OF SCHIZOPHRENICS.
085237 10-08
DRUG, DOCTOR WARMTH, AND CLINIC SETTING IN THE SYMPTOMATIC RESPONSE TO MINOR TRANQUILIZERS.
087386 10-10
1-(3,4-DIMETHOXYPHENYL)-2 PROPANOL EFFECT ON CONDITIONED AVOIDANCE RESPONSE IN THE RAT.
089440 11-04
EFFECT OF AMPHETAMINE ON THE PRESSOR RESPONSE TO TYRAMINE: FORMATION OF P-HYDROXYNOREPHEDRINE FROM AMPHETAMINE IN MAN.
090373 11-03
THE PREDICTION OF PLACEBO RESPONSE IN ANXIOUS AND DEPRESSED OUTPATIENTS.
092102 11-16
THE EFFECTS OF CHLORPROMAZINE ON THE EXPRESSION OF AN ACQUIRED PASSIVE AVOIDANCE RESPONSE IN MICE.
097959 11-04
EFFECT OF LSD-25, CHLORPROMAZINE AND METEDRINE UPON VISUAL EVOKED RESPONSE IN CATS.
098171 11-03
PREMORBID ADJUSTMENT, PARANOID STATUS, AND PATTERNS OF RESPONSE TO PHENOTHIAZINE IN ACUTE SCHIZOPHRENIA.
103255 12-08
ALCOHOL AS A DISCRIMINATIVE STIMULUS IN THE CONDITIONED EMOTIONAL RESPONSE. (PH.D.DISSERTATION).
103350 12-04
PSYCHODYNAMICS OF THE RESPONSE TO PHARMACOLOGIC TREATMENT WITH NEUROLEPTICS IN SCHIZOPHRENICS.
105623 12-08
CERTAIN CIRCADIAN RHYTHMS IN MANIC-DEPRESSIVES AND THEIR RESPONSE TO LITHIUM.
106763 12-09
EFFECT OF A DEFICIENCY OF PANTOTHENIC ACID AND PYRIDOXINE ON THE FUNCTION OF THE CENTRAL NERVOUS SYSTEM AND ITS RESPONSE TO COUMARIN FROM MELILOTUS-OFFICINALIS.
126053 12-04
STUDY ON THE EFFECTS OF PSYCHOTROPIC DRUGS UPON THE PHOTICALLY DRIVING THETA RESPONSE OF ELECTROENCEPHALOGRAMS.
129740 12-08

**RESPONSES**
THE EFFECTS OF ACIDOSIS ON CHRONOTROPIC RESPONSES, NOREPINEPHRINE STORAGE AND RELEASE IN ISOLATED GUINEA-PIG ATRIA.
040753 01-03
THE EFFECT OF ANTIADRENALINE COMPOUNDS ON ACETYLCHOLINE RESPONSES OF FROG RECTUS-ABDOMINIS MUSCLE.
041538 01-03
THE EFFECT OF AMPHETAMINE, NICOTINE AND ATROPINE ON PSEUDOCONDITIONED RESPONSES OF RATS.
046142 01-04
EFFECTS OF MEPROBAMATE ON EMOTIONAL RESPONSES.
046312 01-04
STRESS RESPONSES AMONG NORMALS.
046313 01-14
TEMPERATURE RESPONSES AND OTHER EFFECTS OF 5-HYDROXYTRYPTOPHAN AND 5-HYDROXYTRYPTAMINE WHEN ACTING FROM THE LIQUOR SPACE IN UNANESTHETIZED RABBITS.
046404 01-03
PHOBIA QUESTIONNAIRE RESPONSES AND URINE CATECHOLAMINES.
054890 02-11
THE EFFECTS OF ALCOHOL ON VISUAL AND SOMATO-SENSORY EVOKED RESPONSES.
056925 02-14
SETTING, PATIENT, AND DOCTOR EFFECTS ON DRUG RESPONSE IN NEUROTIC PATIENTS: I. DIFFERENTIAL ATTRITION, DOSAGE DEVIATION, AND SIDE REACTION RESPONSES TO TREATMENT.
065453 05-10
EFFECTS OF GENERAL DEPRESSANT DRUGS ON THE ELECTRICAL RESPONSES OF ISOLATED SLABS OF CATS CEREBRAL CORTEX.
066382 05-03
CONDITIONAL AUTONOMIC RESPONSES INDUCED IN DOGS BY ATROPINE AND MORPHINE.
066386 05-03
INDIVIDUAL VARIATION IN AFFECTIVE RESPONSES TO TASTE STIMULI.
066710 05-14
THE EFFECT OF MEDAZEPAM ON THE THRESHOLDS OF SUBCORTICAL LIMBIC STIMULUS RESPONSES, MEASURED IN UNANESTHETIZED, UNRESTRAINED CATS.
072067 07-03
EFFECTS OF CHLORPROMAZINE ON CONVULSIVE RESPONSES IN DEVELOPING RATS.
074131 08-03
THE EFFECTS OF MORPHINE-LIKE COMPOUNDS ON THE LIGHT RESPONSES OF THE BRINE SHRIMP ARTEMIA-SALINA.
075844 09-04
RESPONSES OF MALE RATS TO SEX ODORS.
081226 09-04
EFFECTS OF DRUGS ON SOMATIC ACTIVITY AND HUMAN RESPONSES.
085757 10-13
EFFECTS OF GENERAL STIMULANT DRUGS ON THE ELECTRICAL RESPONSES OF ISOLATED SLABS OF CATS CEREBRAL CORTEX.
090189 11-03
CYCLIC AMP MEDIATION OF NOREPINEPHRINE INHIBITION IN RAT CEREBELLAR CORTEX: A UNIQUE CLASS OF SYNAPTIC RESPONSES (UNPUBLISHED PAPER).
093132 11-03

**RESPONSIVENESS**
PSYCHOMETRIC AND PSYCHOPHYSIOLOGICAL TEST IN THE PREDICTION OF THERAPEUTIC RESPONSIVENESS IN THE SCHIZOPHRENIAS.
062643 03-08
NEUROTOXICITY WITH LITHIUM: DIFFERENTIAL DRUG RESPONSIVENESS.
106769 12-15

**RESTLESSNESS**
EXPERIENCE WITH PROPERICIAZIN (AOLEPT) IN THE TREATMENT OF CHILDREN WITH DISTURBED PSYCHOMOTOR FUNCTIONS AND RESTLESSNESS.
081144 09-11

**RETARD**
USE OF MELLERIL RETARD IN TREATMENT OF PATIENTS WITH DEPRESSIVE PARANOID AND ANXIOUS DEPRESSIVE SYNDROMES.
109724 12-14

**RETARDATES**
DILANTIN TREATMENT OF HOSPITALIZED CULTURAL FAMILIAL RETARDATES.
062175 03-14

**RETARDATION**
MENTAL RETARDATION ASSOCIATED WITH PRENATAL INTOXICATION, ALLERGIC REACTIONS, DEFICIENCIES, TRAUMA, AND PHYSICAL AGENTS.
061704 03-15
MENTAL RETARDATION ASSOCIATED WITH POSTNATAL POISONS, TOXINS, ENDOTOXINS, DEFICIENCIES AND ALLERGIC REACTIONS.
061706 03-15

**RETARDED**
A CLINICAL EVALUATION OF MESORIDAZINE IN MENTALLY RETARDED PATIENTS.
060268 03-07
PIPERACETAZINE (QUIDE) IN THE MANAGEMENT OF BEHAVIORAL DISORDERS IN MILDLY RETARDED INSTITUTIONALIZED BOYS.
069071 06-11
EPILEPSY THERAPY WITH MENTALLY RETARDED CHILDREN: NEUROPSYCHIATRIC DISORDERS THROUGH DIPHENYLHYDANTOIN.
071241 07-15
EFFECT OF A DECARBOXYLASE INHIBITOR (RO-4-4602), COMBINED WITH L-DOPA, ON RETARDED DEPRESSIVE PATIENTS.
079965 09-13
CLINICAL EXPERIENCE WITH TARASAN AND THIORIDAZINE IN MENTALLY RETARDED CHILDREN -- A COMPARATIVE DOUBLE-BLIND STUDY.
097655 11-14
THE EFFECTS OF AN AMPHETAMINE ON MEASURES OF INTELLIGENCE AND LEARNING IN MENTALLY RETARDED ADULTS. (PH.D.DISSERTATION).
103152 12-14
STATE-DEPENDENT RECOGNITION WITH METHYLPHENIDATE AND THIORIDAZINE IN RETARDED CHILDREN. (PH.D.DISSERTATION).
103301 12-14
ANTIAGGRESSIVE EFFECT OF LITHIUM SALTS IN SEVERE MENTALLY RETARDED ADOLESCENTS.
106776 12-14

**RETENTION**
THE EFFECT OF BRETYLIUM ON AMINE RETENTION IN RAT HEART.
040309 01-03
EFFECT OF AMPHETAMINE, NICOTINE AND HEXAMETHONIUM ON PERFORMANCE OF A CONDITIONED RESPONSE DURING ACQUISITION AND RETENTION TRIALS.
046186 01-04
THE EFFECT OF PUROMYCIN ON RETENTION OF A POSITIVELY REINFORCED RESPONSE IN GOLDFISH.
059616 03-04
EFFECTS OF DESMETHYLIMIPRAMINE AND COCAINE ON THE UPTAKE, RETENTION AND METABOLISM OF H3-TYRAMINE IN RAT BRAIN SLICES.
064419 04-03
UPTAKE AND RETENTION OF 3H-NORADRENALINE IN ADRENERGIC NERVE TERMINALS AFTER RESERPINE AND AXOTOMY.
066499 05-03
RETENTION RATES OF SCHIZOPHRENIA: A COMPARISON OF SHOCK THERAPY AND PSYCHOPHARMACOLOGICAL ERAS AND OF CLOSED AND OPEN DOOR POLICIES.
069795 07-08

PHYSOSTIGMINE: EFFECTS ON RETENTION AT DIFFERENT TIMES AFTER BRIEF TRAINING.
075237 08-04
EQUIVALENCE OF SIMULTANEOUS AND SUCCESSIVE NEOCORTICAL ABLATIONS IN PRODUCTION OF IMPAIRMENTS OF RETENTION OF BLACK WHITE HABITS IN RATS.
076316 09-04
THE EFFECT OF EXOGENOUS RNA ON THE RETENTION OF DISCRIMINATIVE LEARNING IN THE RAT.
079982 09-04

**RETICULAR**
RETICULAR STIMULATION AND CHLORPROMAZINE: AN ANIMAL MODEL FOR SCHIZOPHRENIC OVERAROUSAL.
058531 02-04
RETICULAR STIMULATION AND CHLORPROMAZINE.
071997 07-04

**RETINOPATHY**
RETINOPATHY FOLLOWING THIORIDAZINE TREATMENT.
100016 11-15
PIGMENTARY RETINOPATHY AND PARANOIC SYNDROME. (PRESENTATION OF ONE CASE).
124309 12-08

**RETRIEVAL**
DRUG EFFECTS UPON DATA PROCESSING AS FUNCTIONS OF STORAGE AND RETRIEVAL PARAMETERS.
065127 05-14

**RETROGRADE**
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: IV. RETROGRADE AMNESIA.
065853 05-14

**RETROSPECTIVE**
TREATMENT OF PHOBIC STATES WITH ANTIDEPRESSANTS: A RETROSPECTIVE STUDY OF 246 PATIENTS.
063934 04-10
FLUPHENAZINE: A RETROSPECTIVE ASSESSMENT IN 130 PATIENTS WITH RESIDUAL SCHIZOPHRENIA.
088951 10-08

**REVERSAL**
THE REVERSAL OF DEVELOPED TOLERANCE TO PENTOBARBITAL BY ETHYL ALCOHOL.
058995 03-03
EFFECTS OF CHLORDIAZEPOXIDE ON BLACK WHITE DISCRIMINATION ACQUISITION AND REVERSAL IN WHITE RATS.
070083 07-04
EFFECTS OF INSULIN, METRAZOL, AND ELECTROCONVULSIVE SHOCKS UPON LEARNING TO LEARN 30 SUCCESSIVE REVERSAL PROBLEMS BY RATS.
095188 11-04

**REVERSIBLE**
REVERSIBLE EFFECT OF L-DOPA ON TREMOR AND CATATONIA INDUCED BY ALPHA-METHYL-P-TYROSINE.
040124 01-05
AMPHETAMINE INTOXICATION WITH COAGULOPATHY, HYPERTHERMIA, AND REVERSIBLE RENAL FAILURE: A SYNDROME RESEMBLING HEATSTROKE.
064236 04-15
REVERSIBLE LENTICULAR OPACITIES INDUCED IN RATS BY EMOTIONAL STRESS.
070823 07-03

**REVIEW**
DATURA LINN. -- THE FAMOUS NARCOTIC FROM THE EAST -- A REVIEW.
046185 01-17
ANNUAL REVIEW OF PHARMACOLOGY.
051111 01-17
LITHIUM, CREATIVITY, AND MANIC-DEPRESSIVE ILLNESS: REVIEW AND PROSPECTUS.
063601 04-09
EFFECTS OF LITHIUM ON THYROID FUNCTION (A REVIEW).
064316 04-15
LSD-25 EFFECTS ON CHROMOSOMES: A REVIEW.
067342 06-15
L-DOPA THERAPY OF PARKINSONS DISEASE (A REVIEW OF THE PRELIMINARY EXPERIENCE AT WEST-VIRGINIA UNIVERSITY).
072421 08-07
REVIEW OF MEDICINE IN SPECIAL EDUCATION: ANOTHER LOOK AT DRUGS AND BEHAVIOR.
079144 09-17
A REVIEW OF THE BIOMEDICAL EFFECTS OF MARIHUANA ON MAN IN THE MILITARY ENVIRONMENT.
085756 10-14
PSYCHOTROPIC DRUG USE AND DRIVING RISK: A REVIEW AND ANALYSIS.
093085 11-17
REVIEW OF THE PHENOTHIAZINES (PART I).
096196 11-16
ON THE MUTAGENIC EFFECT OF MEDICINAL PREPARATIONS USED IN PSYCHIATRY. (REVIEW OF THE LITERATURE).
102119 12-16
CLINICAL TRIALS AND TREATMENT WITH PSYCHOPHARMACEUTICALS. A SECOND CRITICAL REVIEW: AN IMPRESSION.
105734 12-17
COMPLICATIONS OR COINCIDENCES DURING LITHIUM THERAPY: A REVIEW OF SEVERAL CASES.
106775 12-09
THE BROAD RANGE OF USE OF DIPHENYLHYDANTOIN: BIBLIOGRAPHY AND REVIEW.
111961 12-13

**REWARD**
COMPARATIVE EFFECTS OF AMPHETAMINE, SCOPOLAMINE, CHLORDIAZEPOXIDE, AND DIPHENYLHYDANTOIN ON OPERANT AND EXTINCTION BEHAVIOR WITH BRAIN STIMULATION AND FOOD REWARD.
074935 08-04

**REWARDED**
REDUCTION OF ELECTRICALLY REWARDED BEHAVIOR BY INTERFERENCE WITH MONOAMINE SYNTHESIS.
069065 06-04

**RHESUS**
CHROMOSOME STUDIES IN PREGNANT RHESUS MACAQUE GIVEN LSD-25.
064315 04-05
REDIRECTED AGGRESSION AND GONADAL HORMONES IN CAPTIVE RHESUS MONKEYS (MACACA-MULATTA).
075829 08-04
SPEED, ACCURACY, AND STRENGTH OF FORELIMB MOVEMENT AFTER UNILATERAL PYRAMIDOTOMY IN RHESUS MONKEYS.
076213 09-04
OVARIAN HORMONES AND FEMALE SEXUAL INVITATIONS IN CAPTIVE RHESUS MONKEYS (MACACA-MULATTA).
076554 09-03

**RHEUMATIC**
PSYCHOSOMATIC FACTORS IN RHEUMATIC DISORDERS AND THEIR RELIEF BY MEDICATION.
089859 11-14

**RHYTHM**
DAILY RHYTHM IN THE ACCUMULATION OF BRAIN CATECHOLAMINES SYNTHESIZED FROM CIRCULATING H3-TYROSINE.
040246 01-03
STARTLE RESPONSE CIRCADIAN RHYTHM IN RATS: LACK OF CORRELATION WITH MOTOR ACTIVITY.
058349 02-04
CIRCADIAN RHYTHM FOR EXPERIMENTALLY INDUCED AGGRESSIVE BEHAVIOR IN MICE.
058383 02-03
SODIUM AMOBARBITAL, THE HIPPOCAMPAL THETA RHYTHM, AND THE PARTIAL REINFORCEMENT EXTINCTION EFFECT.
063333 03-03
THE EFFECT OF INTRAHYPOTHALAMIC MICROINJECTION OF HEMICHOLINIUM (HC-3) ON THE HIPPOCAMPAL THETA RHYTHM OF CATS.
075842 08-03
HIGH VOLTAGE SLOW WAVE INDUCED BY SHORT-CHAIN FATTY ACIDS WITH SPECIAL REFERENCE TO SLEEP RHYTHM.
088612 10-03

**RHYTHMIC**
INDUCTION BY CANNABIS-SATIVA (MARIHUANA) OF RHYTHMIC SPIKE DISCHARGES OVERRIDING REM SLEEP ELECTROCORTICOGRAM IN THE RAT.
069069 06-04

**RHYTHMS**
CERTAIN CIRCADIAN RHYTHMS IN MANIC-DEPRESSIVES AND THEIR RESPONSE TO LITHIUM.
106763 12-09

**RIBONUCLEIC**
INHIBITION OF THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN RATS BY DRUGS WHICH INHIBIT RIBONUCLEIC ACID OR PROTEIN SYNTHESIS.
041570 01-03
YEAST RIBONUCLEIC ACID: ANALYSIS OF EFFECTS ON POLE-CLIMB AVOIDANCE BEHAVIOR.
065493 05-04

**RISK**
AMITRIPTYLINE AND CARDIAC DISEASE: RISK OF SUDDEN DEATH IDENTIFIED BY MONITORING SYSTEM.
070854 07-15
PSYCHOTROPIC DRUG USE AND DRIVING RISK: A REVIEW AND ANALYSIS.
093085 11-17

**RNA**
PROTEIN AND RNA INHIBITORS AND PROTOZOAN HABITUATION.
066813 05-04
COMMENTS ON AN EFFECT OF YEAST RNA ON BEHAVIOR (MOUNTFORD AND HESLIP).
075720 08-04
THE EFFECT OF EXOGENOUS RNA ON THE RETENTION OF DISCRIMINATIVE LEARNING IN THE RAT.
079982 09-04

INCREASED INCORPORATION OF 14C-URIDINE INTO RAT BRAIN RNA AS A RESULT OF NOVEL ELECTROSHOCK.
092209 11-01

**RO-4-1284**
BIOCHEMICAL AND BEHAVIORAL EFFECT OF AMPHETAMINE IN DMI - RO-4-1284 INDUCED HYPERACTIVITY.
070951 07-03

**RO-4-4602**
EFFECT OF A DECARBOXYLASE INHIBITOR (RO-4-4602), COMBINED WITH L-DOPA, ON INHIBITED DEPRESSIVE PATIENTS: II. EXPERIMENTAL PSYCHOLOGICAL STUDIES.
079964 09-14

EFFECT OF A DECARBOXYLASE INHIBITOR (RO-4-4602), COMBINED WITH L-DOPA, ON RETARDED DEPRESSIVE PATIENTS.
079965 09-13

**RO-5-3350**
TRIALS OF RO-5-3350 AND DIAZEPAM FOR ANXIETY SYMPTOMS.
066826 05-07

**RO-5-4023**
INVESTIGATION ON A NEW ANTICONVULSIVE PRODUCT RO-5-4023.
085454 10-14

CLINICOELECTROENCEPHALOGRAPHIC EVALUATION OF A NEW BENZODIAZEPINIC DERIVATIVE (RO-5-4023) ADMINISTERED ORALLY IN EPILEPTIC PATIENTS USING A DOUBLE-BLIND METHOD.
100959 12-07

**RO-5-4556**
THE EMPLOYMENT OF A NEW BENZODIAZEPINE, RO-5-4556 IN INTERNAL MEDICINE.
058312 02-11

SOME OBSERVATIONS ON THE NEUROPHARMACOLOGY OF MEDAZEPAM HYDROCHLORIDE (RO-5-4556).
063841 04-04

CLINICAL STUDY OF MEDAZEPAM (RO-5-4556).
086859 10-11

**RODENTS**
COMPARATIVE PHARMACOLOGICAL STUDY OF NEUROLEPTICS IN RODENTS.
070926 07-02

**ROLE**
THE ROLE OF THE HYPOTHALAMO-PITUITARY SYSTEM IN THE MECHANISM OF ACTION OF RESERPINE AND 5-HYDROXYTRYPTOPHAN ON ANTIBODY PRODUCTION.
040579 01-03

THE ROLE OF CARBONIC ANHYDRASE IN ANION SECRETION INTO CEREBROSPINAL FLUID.
040755 01-03

RELAPSE TO OPIOID DEPENDENCE: THE ROLE OF CONDITIONING.
046208 01-03

THE ROLE OF BRAIN CATECHOLAMINES IN MORPHINE ANALGESIC ACTION IN MORPHINE TOLERANT RATS.
055756 02-03

THE ROLE OF THE COMMITTEE ON SAFETY OF DRUGS.
057608 02-07

THE ROLE OF THE PSYCHIATRIC NURSE IN THE REHABILITATION OF THE SCHIZOPHRENIC PATIENT.
062108 03-08

ROLE OF MONKEYS SPATIAL PREFERENCES IN PERFORMANCE OF A NONSPATIAL TASK.
065420 05-04

LONG-ACTING PHENOTHIAZINES AND LONG-TERM PSYCHOTIC PATIENTS: THE ROLE OF FLUPHENAZINE ENANTHATE IN TREATMENT.
065479 05-08

THE ROLE OF PLASMA PROTEIN BINDING IN THE INHIBITORY EFFECT OF NORTRIPTYLINE ON THE NEURONAL UPTAKE OF NOREPINEPHRINE.
066278 05-03

A POSSIBLE ROLE FOR 5-HYDROXYTRYPTAMINE IN DRUG-INDUCED SEIZURES.
074084 08-03

THE ROLE OF METHYLAMPHETAMINE ON PLASMA HEXOSAMINE LEVEL UNDER STRESS.
074855 08-03

STUDIES ON THE ROLE OF ACID IN THE PATHOGENESIS OF EXPERIMENTAL STRESS ULCERS.
075276 08-03

ROLE OF BRAIN AMINES IN THE ANALGESIC ACTION OF MEPERIDINE HYDROCHLORIDE.
075845 09-03

THE ROLE OF BRAIN DOPAMINE IN BEHAVIORAL REGULATION AND THE ACTIONS OF PSYCHOTROPIC DRUGS.
075869 09-04

THE ROLE OF D-AMPHETAMINE AMOBARBITAL IN SUPPRESSING FREEZING BEHAVIOR DURING AVOIDANCE ACQUISITION AND EXTINCTION.
075882 09-04

THE CHILDRENS PSYCHOPHARMACOLOGY CLINIC: ITS ROLE WITHIN A TOTAL PROGRAM FOR CHILDRENS PSYCHIATRIC SERVICES.
080097 09-17

CONTRIBUTION TO THE STUDY OF THE EXTRAPYRAMIDAL SYNDROME WITH ANIMAL EXPERIMENTATION. THE ROLE OF CALCIUM AND O-METHYLENE DERIVATIVES.
086348 10-03

STUDY EXPLORES ROLE OF BIOGENIC AMINES IN DEPRESSION.
087793 10-13

A STUDY OF HEPATIC ALCOHOL DEHYDROGENASE INHIBITION (ADH) INDUCED BY PYRAZOL: II. THE ROLE OF LIVER ADH IN THE IN VIVO METABOLISM OF HYDROXYL COMPOUNDS.
089547 11-03

ROLE OF BIOGENIC AMINES IN MORPHINE DEPENDENCE IN THE RAT.
090149 11-03

ON THE ROLE OF BRAIN CATECHOLAMINES IN MOTOR ACTIVITY: EXPERIMENTS WITH INHIBITORS OF SYNTHESIS AND OF MONOAMINE OXIDASE.
097960 11-04

ROLE OF BRAIN SEROTONIN IN THE STIMULANT ACTION OF AMPHETAMINE.
098003 11-03

PSYCHOPHARMACOLOGY: THE ROLE OF CLINICAL RESEARCH.
100276 11-07

AN ANALYSIS OF THE ROLE OF CHOLINERGIC DRUGS IN BEHAVIOR RELATED TO FOOD AND WATER DEPRIVATION. (PH.D.DISSERTATION).
103267 12-04

**ROLES**
PATHOPHYSIOLOGY OF NARCOTIC ADDICTION; POSSIBLE ROLES OF PROTRACTED ABSTINENCE IN RELAPSE (UNPUBLISHED PAPER).
093000 11-13

**S-ADENOSYLMETHIONINE**
L-DIHYDROXYPHENYLALANINE: EFFECT ON S-ADENOSYLMETHIONINE IN BRAIN.
063825 04-03

**S-804**
A DOUBLE-BLIND COMPARISON OF S-804 (NEW BENZODIAZEPINE DRUG) WITH CHLORDIAZEPOXIDE AND DIAZEPAM IN THE TREATMENT OF NEUROSIS.
129097 12-10

**SAFETY**
THE BRITISH DRUG SAFETY SYSTEM.
051782 02-05

THE ROLE OF THE COMMITTEE ON SAFETY OF DRUGS.
057608 02-07

THE SAFETY TEST OF L-DOPA - II. EFFECT OF L-DOPA ON THE DEVELOPMENT OF PRENATAL AND POSTNATAL OFFSPRINGS OF EXPERIMENTAL ANIMALS.
114836 12-02

THE SAFETY TEST OF L-DOPA. I. ACUTE AND SUBACUTE TOXICITY OF L-DOPA IN EXPERIMENTAL ANIMALS.
114837 12-05

**SAKEL**
STATISTICAL METHOD OF ANALYSIS AND EVALUATION OF PSYCHOTHERAPEUTIC RESULTS: APPLICATION OF A LONG-ACTING NEUROLEPTIC, COMPARED WITH A STANDARD NEUROLEPTIC AND THE SAKEL INSULIN TREATMENT.
042676 01-07

**SALT**
DISTRIBUTION, EXCRETION, AND METABOLISM OF 14C-LABELED QUATERNARY AMMONIUM SALT OF MEPAZINE AND PROMETHAZINE IN RATS.
058571 02-03

DISTRIBUTION, EXCRETION, AND METABOLISM OF 14C-LABELED QUATERNARY AMMONIUM SALT OF PERPHENAZINE IN RATS.
064261 04-03

SALT SUPPLEMENTS WITH LITHIUM.
071968 07-15

ANTICHOLINERGIC CENTRAL BLOCKADE OF SALT AROUSED AND DERIVATION INDUCED DRINKING.
081227 09-04

**SALTS**
COLORIMETRIC DETERMINATION OF AMPHETAMINE SALTS IN DOSAGE FORMS.
064159 04-01

SOME EXPERIENCES WITH A PREVENTIVE ADMINISTRATION OF LITHIUM SALTS IN MANIC MELANCHOLIC PSYCHOSIS.
070952 07-09

CRITIQUE OF STUDIES OF LITHIUM SALTS IN THE TREATMENT OF MANIA.
075867 09-09

ACTION OF THE SALTS OF OXYGLURIC ACID ON ACUTE ALCOHOL INTOXICATION IN MAN (EXPERIMENTAL STUDY).
086005 10-11

THE USE OF LITHIUM SALTS FOR THE PREVENTION OF AFFECTIVE ATTACKS.
096512 11-09

INDICATIONS OF LITHIUM SALTS IN PSYCHOSOMATIC MEDICINE.
106770 12-17

PROPHYLACTIC ACTION OF LITHIUM SALTS AND THYROID HORMONES ON SYMPTOMS OF MANIC-DEPRESSIVE AND AFFECTIVE PSYCHOSES: CLINICAL AND EXPERIMENTAL RESULTS.
106774 12-09
ANTIAGGRESSIVE EFFECT OF LITHIUM SALTS IN SEVERE MENTALLY RETARDED ADOLESCENTS.
106776 12-14
PHYSIOLOGICAL AND BIOCHEMICAL MECHANISMS OF THE EFFECT OF LITHIUM SALTS ON THE NERVOUS SYSTEM.
109786 12-13
THE EFFECTS OF LITHIUM SALTS IN THE TREATMENT OF DEPRESSION.
129579 12-09
ON THE EFFICACY AND THE MECHANISM OF ACTION OF LITHIUM SALTS IN MANIC-DEPRESSIVE PSYCHOSES.
130414 12-09

**SAMPLE**
INFLUENCES OF POLYPHARMACY ON HALLUCINATORY BEHAVIOR IN A SAMPLE OF FEMALE CHRONIC SCHIZOPHRENIC PATIENTS.
115037 12-08

**SAMPLES**
A PROCEDURE FOR THE ANALYSIS OF ILLICIT DIAMORPHINE SAMPLES.
046395 01-01

**SARIN**
DEPHOSPHORYLATION IN VIVO OF BRAIN ACETYLCHOLINESTERASE INHIBITED BY ISOPROPYL METHYLPHOSPHONOFLUORIDATE (SARIN).
046188 01-03

**SATIETY**
ALPHA-ADRENERGIC RECEPTORS IN HYPOTHALAMUS FOR THE SUPPRESSION OF FEEDING BEHAVIOR BY SATIETY.
060801 03-04

**SCALE**
DRUG-INDUCED EXTRAPYRAMIDAL DISORDERS: A RATING SCALE FOR EXTRAPYRAMIDAL SIDE-EFFECTS.
063773 04-16
VALIDATION OF THE MACANDREW-ROSEN DRUG THERAPY SCALE.
066741 05-16
USE OF CATTELS IPAT ANXIETY SCALE IN A GROUP OF NEUROTIC PATIENTS BEFORE AND AFTER PSYCHOPHARMACOLOGICAL DRUG AND ELECTRIC SHOCK THERAPY.
128509 12-17

**SCALES**
CLASSIFICATION, NOSOLOGY, AND RATING SCALES OF PSYCHOTROPIC DRUGS.
064090 04-01

**SCALOPUS**
SENSORY REPRESENTATION IN THE NEOCORTEX OF THE MOLE, SCALOPUS AQUATICUS.
066468 05-03

**SCH-12650**
BLOCKADE OF NORADRENALINE UPTAKE AND INHIBITION OF GASTRIC ACID SECRETION BY 2-(P-CHLOROPHENYL-2-(PYRIDYL)HYDROXYMETHYL) IMIDAZOLINE MALEATE (SCH-12650).
058878 02-02

**SCHEDULE**
RATE-DEPENDENT EFFECTS OF DRUGS: MODIFICATION BY DISCRIMINATIVE STIMULI OF THE EFFECTS OF AMOBARBITAL ON SCHEDULE CONTROLLED BEHAVIOR.
064749 05-04
THE RELATIONSHIP OF AMPHETAMINE INDUCED ANOREXIA AND FREEZING UNDER A MULTIPLE CRF-EXT OPERANT SCHEDULE.
068288 06-04
THE EFFECTS OF D-AMPHETAMINE ON SCHEDULE CONTROLLED WATER LICKING IN THE SQUIRREL MONKEY.
071785 07-04
EFFECTS OF CHLORPROMAZINE IN THE PIGEON UNDER A SECOND-ORDER SCHEDULE OF FOOD PRESENTATION.
075906 09-04

**SCHEDULES**
THE USE OF MOLINDONE IN THE TREATMENT OF ACUTE PSYCHOTIC STATES: COMPARISON OF TWO DOSAGE SCHEDULES.
064286 04-08
EFFECTS OF MORPHINE ON BEHAVIOR MAINTAINED BY FOUR SIMPLE FOOD REINFORCEMENT SCHEDULES.
064479 04-04
DOSAGE SCHEDULES IN GENERAL PRACTICE.
068137 06-16

**SCHIZO-AFFECTIVE**
PROPHYLACTIC LITHIUM THERAPY FOR CHRONIC DEPRESSIVE PSYCHOSIS AND SCHIZO-AFFECTIVE DISORDERS.
089105 10-09

**SCHIZOPHRENIA**
CLOTHIAPIN IN THE TREATMENT OF CHRONIC SCHIZOPHRENIA.
058372 02-08
SCHIZOPHRENIA.
059102 03-08
AN EVALUATION OF NIACINAMIDE IN THE TREATMENT OF CHILDHOOD SCHIZOPHRENIA.
060240 03-08
A COMPARISON OF OXYPERTINE AND CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIA.
060659 03-08
THE PINK-SPOT, 3,4 DIMETHOXYPHENYLETHYLAMINE, COMMON TEA, AND SCHIZOPHRENIA.
062783 03-13
SCHIZOPHRENIA AND THE PINEAL GLAND.
062935 03-08
EXPERIENCE OF PSYCHIATRIC MANAGEMENT OF SCHIZOPHRENIA WITH FLUPHENAZINE DECANOATE.
063186 03-08
THE EFFECTS OF PHENOTHIAZINE THERAPY ON LYMPHOCYTE TRANSFORMATION IN SCHIZOPHRENIA.
067288 06-15
LITHIUM CARBONATE AS AN ADJUNCT IN THE TREATMENT OF SCHIZOPHRENIA.
067364 06-08
A THERAPEUTICAL PATHOMORPHOSIS OF SCHIZOPHRENIA PROCEEDING WITH PARANOID DISORDERS.
067547 06-08
MOLIDONE IN CHRONIC SCHIZOPHRENIA.
067719 06-08
SCHIZOPHRENIA AND LYMPHOCYTE MITOTIC CAPACITY.
068181 06-15
THE PARENTERAL USE OF VITAMINS IN THE TREATMENT OF SCHIZOPHRENIA.
068976 06-08
RETENTION RATES OF SCHIZOPHRENIA: A COMPARISON OF SHOCK THERAPY AND PSYCHOPHARMACOLOGICAL ERAS AND OF CLOSED AND OPEN DOOR POLICIES.
069795 07-08
A COMPARISON OF TRIPERIDOL AND PERPHENAZINE IN SCHIZOPHRENIA. EFFECTS ON MYOCLONIC THRESHOLD.
070935 07-08
A CONTROLLED STUDY OF THE EFFECT OF THIOTHIXENE AND PERPHENAZINE IN PSYCHOSES AND SCHIZOPHRENIA.
070938 07-08
METHODOLOGICAL PROBLEMS IN PSYCHOTHERAPY RESEARCH: OBSERVATIONS ON THE KARON-VANDENBOS STUDY OF PSYCHOTHERAPY AND DRUGS IN SCHIZOPHRENIA.
071322 07-08
CLINICAL RESEARCH INTO CHRONIC INCURABLE SCHIZOPHRENIA.
072891 08-08
OXYPERTINE IN THE TREATMENT OF CHRONIC SCHIZOPHRENIA.
072896 08-08
EVALUATION OF THIOTHIXENE IN THE TREATMENT OF SCHIZOPHRENIA.
072897 08-08
AROUSAL AND SCHIZOPHRENIA.
074625 08-08
EVALUATION OF THE THERAPEUTIC EFFECT OF NEUROLEPTICS UPON THE HIGHER NERVOUS ACTIVITY IN SCHIZOPHRENIA.
075103 08-14
RELATIONSHIPS OF THE MECHOLYL TEST, PREMORBID ASOCIAL FUNCTIONING AND LONG-TERM OUTCOME IN SCHIZOPHRENIA.
075227 08-08
CRISES AND LIFE CHANGES PRECEDING THE ONSET OR RELAPSE OF ACUTE SCHIZOPHRENIA: CLINICAL ASPECTS.
075304 08-08
PREDICTION OF CHANGES IN SEVERITY OF THE SCHIZOPHRENIC SYNDROME WITH DISCONTINUATION AND ADMINISTRATION OF PHENOTHIAZINES IN CHRONIC SCHIZOPHRENIC PATIENTS: LANGUAGE AS A PREDICTOR AND MEASURE OF CHANGE IN SCHIZOPHRENIA.
075321 08-08
CHILDHOOD SCHIZOPHRENIA: A CASE TREATED WITH NICOTINIC ACID AND NICOTINAMIDE.
075944 09-08
A COMPARATIVE DOUBLE-BLIND TRIAL OR PIMOZIDE AND FLUPHENAZINE IN CHRONIC SCHIZOPHRENIA.
078932 09-08
CLINICAL OBSERVATIONS ON THE THERAPEUTIC ACTIVITY OF FLUPENTHIXOL IN THE TREATMENT OF CHRONIC SCHIZOPHRENIA.
080143 09-08
PSYCHOPHARMACOLOGY TODAY. ORIENTATIONS IN THE TREATMENT OF SCHIZOPHRENIA.
086877 10-17
HISTAMINE WHEAL FORMATION AND SCHIZOPHRENIA.
086987 10-13
AN ATTEMPT TO ELIMINATE RESISTANCE TO AMINAZINE BY MALARIA THERAPY IN PATIENTS WITH PARANOID SCHIZOPHRENIA.
087312 10-16
FLUPHENAZINE: A RETROSPECTIVE ASSESSMENT IN 130 PATIENTS WITH RESIDUAL SCHIZOPHRENIA.
088951 10-08
PIPERACETAZINE VS. CHLORPROMAZINE IN THE TREATMENT OF SCHIZOPHRENIA.
089099 10-08
A COMPARATIVE STUDY OF THIOTHIXENE AND TRIFLUOPERAZINE IN THE ACUTE PHASE OF SCHIZOPHRENIA.
089159 10-08

INDICATIONS FOR HIGH DOSE CHLORPROMAZINE THERAPY IN CHRONIC SCHIZOPHRENIA.
089433 10-08

ON THE QUESTION OF PERSONALITY DEFECTS OF CONSCIOUSNESS IN INITIAL STAGES IN SCHIZOPHRENIA.
090264 11-08

THE USE OF HALOPERIDOL IN RESIDUAL SCHIZOPHRENIA AND IN PARANOID STATES.
093524 11-08

THE COMBINATION OF PSYCHOTROPIC DRUGS IN THE TREATMENT OF SCHIZOPHRENIA.
098002 11-08

EVALUATION OF AN AMITRIPTYLINE PERPHENAZINE COMBINATION IN CHRONIC SCHIZOPHRENIA.
101681 12-08

PREMORBID ADJUSTMENT, PARANOID STATUS, AND PATTERNS OF RESPONSE TO PHENOTHIAZINE IN ACUTE SCHIZOPHRENIA.
103255 12-08

CONCERNING THE ARTICLE BY N.N.TIMOFEYEV, V.T.KONDRASHENKO AND N.Y.NEMTSEVA ON OXYMETRIC INVESTIGATION OF PATIENTS WITH SCHIZOPHRENIA AND REACTIVE PSYCHOSIS DURING NEUROLEPTIC TREATMENT.
109788 12-08

USE OF NEULEPTIL IN TREATMENT OF PATIENTS WITH SCHIZOPHRENIA.
111031 12-08

ON THE PROBLEM OF TREATMENT AND SOME CLINICAL CHARACTERISTICS OF SCHIZOPHRENIA WITH A GRADUAL PAROXYSMAL LIKE COURSE.
111032 12-08

ON THE PROBLEM OF AMBULATORY TREATMENT OF SCHIZOPHRENIA WITH PSYCHOTROPIC DRUGS.
111034 12-08

A DOUBLE-BLIND, CROSSOVER COMPARISON OF APY-606 WITH CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIA.
118583 12-08

ADMINISTRATION OF A NEW BUTYROPHENONE DERIVATIVE, PIMOZIDE, IN THE TREATMENT OF SCHIZOPHRENIA.
123373 12-08

ABSTRACT OF THESES FOR DOCTOR OF MEDICAL SCIENCES, THE UNIVERSITY OF TOKYO: MORITA THERAPEUTIC APPROACH TO SCHIZOPHRENIA.
126778 12-17

A DOUBLE-BLIND, CONTROLLED STUDY OF THE EFFECTS OF OXYPERTINE AND CARPIPRAMINE ON SCHIZOPHRENIA.
129082 12-08

A TRIAL ON THE VALUE OF SORDINOL IN SCHIZOPHRENIA – BY SUBJECTIVE METHOD AND PARTLY BY USING SEQUENTIAL ANALYSIS.
129451 12-08

A COMPARATIVE STUDY OF PHYSICAL TREATMENTS IN SCHIZOPHRENIA.
138362 12-08

SCHIZOPHRENIA.
138967 12-08

**SCHIZOPHRENIAS**

PSYCHOMETRIC AND PSYCHOPHYSIOLOGICAL TEST IN THE PREDICTION OF THERAPEUTIC RESPONSIVENESS IN THE SCHIZOPHRENIAS.
062643 03-08

NICOTINIC ACID IN THE TREATMENT OF SCHIZOPHRENIAS.
068450 06-08

**SCHIZOPHRENIC**

RETICULAR STIMULATION AND CHLORPROMAZINE: AN ANIMAL MODEL FOR SCHIZOPHRENIC OVERAROUSAL.
058531 02-04

PROTRIPTYLINE IN THE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS.
058968 03-08

THE ROLE OF THE PSYCHIATRIC NURSE IN THE REHABILITATION OF THE SCHIZOPHRENIC PATIENT.
062108 03-08

COMPARATIVE EFFICACY OF THIOTHIXENE CAPSULES AND CONCENTRATE IN ACUTELY SCHIZOPHRENIC PATIENTS.
063599 04-08

A CONTROLLED COMPARISON OF THE TREATMENT OF SCHIZOPHRENIC PATIENTS WHEN TREATED ACCORDING TO THE NEUROLEPTIC THRESHOLD OR BY CLINICAL JUDGMENT.
063776 04-08

COMPARATIVE BEHAVIORAL AND BIOCHEMICAL EFFECTS OF TRANYLCYPROMINE AND CYSTEINE ON NORMAL CONTROLS AND SCHIZOPHRENIC PATIENTS.
064331 04-08

THE ACTION OF L-DOPA ON SCHIZOPHRENIC PATIENTS (A PRELIMINARY REPORT).
064638 05-08

NIACIN AND THE SCHIZOPHRENIC PATIENT.
065232 05-15

THE EFFECT OF SERUM FROM ACUTE SCHIZOPHRENIC PATIENTS ON RABBIT BRAIN AMINES.
066713 05-03

SEVERE DELIRIUM AFTER ABRUPT WITHDRAWAL OF THIOTHIXENE IN A CHRONIC SCHIZOPHRENIC INPATIENT: A CASE STUDY.
067221 06-08

DREAM CONTENT IN MALE SCHIZOPHRENIC PATIENTS.
069034 06-08

ENCEPHALITIS WITH CATATONIC SCHIZOPHRENIC SYMPTOMS.
069822 07-08

DOUBLE-BLIND COMPARATIVE STUDY OF THE EFFECTS OF THIOTHIXENE AND THIORIDAZINE IN TWENTY CHRONIC SCHIZOPHRENIC PATIENTS.
070880 07-08

CLINICAL EXPERIENCE WITH OCTOCLOTHEPINE IN SCHIZOPHRENIC PSYCHOSES.
070929 07-08

A COMPARISON OF THE EFFECTS OF METHYLPERIDOL AND PERPHENAZINE IN SCHIZOPHRENIC PSYCHOSIS.
070936 07-08

CI-601, A BUTYROPHENONE DERIVATIVE, IN THE TREATMENT OF CHRONICALLY WITHDRAWN SCHIZOPHRENIC PATIENTS.
072142 07-08

A PILOT STUDY OF AHR-1900 IN CHRONIC SCHIZOPHRENIC PATIENTS.
072145 07-08

WEIGHT CHANGES WITH SCHIZOPHRENIC PSYCHOSIS AND PSYCHOTROPIC DRUG THERAPY.
074218 08-08

EPINEPHRINE CYCLIZING ENZYME IN SCHIZOPHRENIC SERUM.
075105 08-01

PLASMA FREE FATTY ACIDS BEFORE AND AFTER AN INTRAVENOUS INSULIN INJECTION IN ACUTE SCHIZOPHRENIC MEN.
075212 08-08

PREDICTION OF CHANGES IN SEVERITY OF THE SCHIZOPHRENIC SYNDROME WITH DISCONTINUATION AND ADMINISTRATION OF PHENOTHIAZINES IN CHRONIC SCHIZOPHRENIC PATIENTS: LANGUAGE AS A PREDICTOR AND MEASURE OF CHANGE IN SCHIZOPHRENIA.
075321 08-08

THE EFFECT OF SOCIAL FEEDBACK ON CHRONIC SCHIZOPHRENIC PATIENTS.
075362 08-14

THE PLACE OF THIOTHIXENE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS. A SYSTEMATIC CLINICAL STUDY.
075422 08-08

DETECTION OF PSYCHOTOMIMETIC N,N DIMETHYLATED INDOLEAMINES IN THE URINE OF FOUR SCHIZOPHRENIC PATIENTS.
080506 09-08

THE PSYCHOLYTIC TREATMENT OF A CHILDHOOD SCHIZOPHRENIC GIRL.
080609 09-08

PIPERACETAZINE (QUIDE): A CONTROLLED EVALUATION OF THE ELIXIR IN CHRONIC SCHIZOPHRENIC PATIENTS.
082053 10-08

POSSIBILITIES AND LIMITATIONS OF DEPOT NEUROLEPTIC TREATMENT OF SCHIZOPHRENIC PSYCHOSES.
087066 10-17

CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIC WOMEN: ITS EFFECT ON THYROID AND LIVER FUNCTION IN RELATION TO SERUM CHOLESTEROL CONCENTRATION.
088221 10-13

THE RELATIONSHIPS BETWEEN CLINICAL AND VISUOMOTOR CHANGES IN A SCHIZOPHRENIC GROUP.
089798 11-08

THE EFFECTIVENESS OF SIMULTANEOUS TREATMENT WITH VITAMIN-B12 AND INSULIN IN SCHIZOPHRENIC PATIENTS, ACCORDING TO THE FREQUENCY OF STABLE REMISSIONS.
096513 11-08

A DOUBLE-BLIND INVESTIGATION WITH FLUPENTHIXOL AND TRIFLUOPERAZINE AT TREATMENT OF SCHIZOPHRENIC PSYCHOSES.
100017 11-08

CLINICAL TESTING WITH FLUPHENAZINE DEPOT ADMINISTRATION TO SCHIZOPHRENIC PATIENTS.
101034 12-07

EXPERIMENTAL USE OF PREPARATION LUVATREN IN SCHIZOPHRENIC PATIENTS.
111022 12-08

CHEMICAL AND CLINICAL EVALUATION OF THE USE OF GABOB IN SCHIZOPHRENIC PATIENTS.
114885 12-08

INFLUENCES OF POLYPHARMACY ON HALLUCINATORY BEHAVIOR IN A SAMPLE OF FEMALE CHRONIC SCHIZOPHRENIC PATIENTS.
115037 12-08

RESEARCH ON THE DEFECT STATE OF SCHIZOPHRENIC PATIENT UNDER CONTROL OF PSYCHODRUGS.
129273 12-08

THIOTHIXENE IN HOSPITALIZED CHRONIC SCHIZOPHRENIC PATIENTS.
134906 12-08

**SCHIZOPHRENICS**

TREATMENT OF RESISTANT SCHIZOPHRENICS WITH EXTREME HIGH DOSAGE FLUPHENAZINE HYDROCHLORIDE.
063597 04-08

A COMPARATIVE STUDY OF BUTAPERAZINE, CHLORPROMAZINE AND PLACEBO IN CHRONIC SCHIZOPHRENICS.
064431 04-08
THE EFFECTIVENESS OF PARENTERAL ADMINISTRATION OF FLUPHENAZINE DECANOATE IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS.
065473 05-07
INSTITUTIONAL MANAGEMENT OF CHRONIC SCHIZOPHRENICS WITH FLUPHENAZINE DECANOATE.
065474 05-07
A COMPARISON OF HALOPERIDOL AND THIORIDAZINE HCL IN CHRONIC TREATMENT RESISTANT SCHIZOPHRENICS.
066398 05-08
A COMPARISON OF HALOPERIDOL AND THIORIDAZINE HCL IN CHRONIC TREATMENT RESISTANT SCHIZOPHRENICS.
066817 05-08
CLINICAL EVALUATION OF MAZINDOL IN CHRONIC SCHIZOPHRENICS.
066852 05-08
EFFECT OF PHENOTHIAZINES ON REACTION TIME IN SCHIZOPHRENICS.
075413 08-08
NICOTINIC ACID IN THE PREVENTION AND TREATMENT OF METHIONINE INDUCED EXACERBATION OF PSYCHOPATHOLOGY IN SCHIZOPHRENICS.
075423 08-08
CLINICAL TRIAL OF THIOTHIXENE (NAVANE) IN ELDERLY CHRONIC SCHIZOPHRENICS.
082054 10-08
RELATIONSHIP BETWEEN THE HOSPITAL MILIEU AND THE RESPONSE TO PHENOTHIAZINES IN THE TREATMENT OF SCHIZOPHRENICS.
085237 10-08
A COMBINED TREATMENT OF CHRONIC SCHIZOPHRENICS WITH OSPOLOT (SULTHIAME) AND STELAZINE (TRIFLUOPERAZINE).
089101 10-08
SPECIFIC (IN THE SENSE OF INCREASED PREDISPOSITION TO INJURY OF THE SUBDOMINANT HEMISPHERE) DISTRIBUTION OF THE EXTRAPYRAMIDAL SYMPTOMS IN SCHIZOPHRENICS DURING THE COURSE OF HALOPERIDOL TREATMENT.
089106 10-15
DOUBLE-BLIND STUDY OF CLOPENTHIXOL AND CHLORPROMAZINE IN ACUTE HOSPITALIZED SCHIZOPHRENICS.
098048 11-08
PSYCHODYNAMICS OF THE RESPONSE TO PHARMACOLOGIC TREATMENT WITH NEUROLEPTICS IN SCHIZOPHRENICS.
105623 12-08
CLINICAL APPLICATION OF NEW TRANQUILIZER, CS-300, TO SCHIZOPHRENICS.
129879 12-07
THE OCCUPATIONAL THERAPY IN A MENTAL HOSPITAL FOR CHRONIC SCHIZOPHRENICS.
139090 12-08

**SCHMIDTS**
COMBINED ADRENAL AND THYROID DEFICIENCY (SCHMIDTS SYNDROME) PRESENTING AS AN ACUTE PSYCHOSIS.
056350 02-15

**SCHOOL**
TESTING THE PERFORMANCE UNDER APONEURON OF OTHERWISE NORMAL SCHOOL CHILDREN WITH A TENDENCY TOWARD REDUCED DRIVE AND EASY TIRING.
080563 09-11
EFFECTS OF MEPROBAMATE ON THE SCHOOL ACHIEVEMENT OF CEREBRAL PALSIED CHILDREN.
083317 10-14

**SCHOOLS**
METHODS OF TREATING DELIRIUM-TREMENS AS BASED ON MATERIALS OF THE UNIVERSITY MEDICAL SCHOOLS PSYCHIATRIC CLINIC IN WROCLAW BETWEEN 1958 AND 1968.
087143 10-11

**SCHUSTERS**
DRUGS IN PSYCHOLOGY: A COMMENTARY ON TRAVIS THOMPSON AND CHARLES R. SCHUSTERS BEHAVIORAL PHARMACOLOGY.
075793 08-14

**SCIENCES**
ABSTRACT OF THESES FOR DOCTOR OF MEDICAL SCIENCES, THE UNIVERSITY OF TOKYO: MORITA THERAPEUTIC APPROACH TO SCHIZOPHRENIA.
126778 12-17

**SCOPOLAMINE**
THE EFFECT OF HEAT, COLD, AND WORK ON THE CENTRAL ACTIONS OF SCOPOLAMINE.
041562 01-14
THE EFFECTS OF SCOPOLAMINE ON THE EXTINCTION OF A CONTINUOUSLY REINFORCED RESPONSE.
063587 03-04
EFFECTS OF SCOPOLAMINE, ATROPINE, AND D-AMPHETAMINE ON INTERNAL AND EXTERNAL CONTROL OF RESPONDING ON NON-REINFORCED TRIALS.
064410 04-04
DIFFERENTIAL EFFECTS OF AMPHETAMINE AND SCOPOLAMINE ON MATCHING PERFORMANCE OF MONKEYS WITH LATERAL FRONTAL LESIONS.
065747 05-04
EFFECTS OF SCOPOLAMINE ON SPONTANEOUS ALTERNATION FOLLOWING FREE AND FORCED TRIALS.
067882 06-04
MODIFICATION OF THE SCOPOLAMINE EFFECT BY SLEEP DEPRIVATION.
070933 07-14
SCOPOLAMINE EFFECTS ON CONDITIONED SUPPRESSION: INFLUENCE OF DIURNAL CYCLE AND TRANSITIONS BETWEEN NORMAL AND DRUGGED STATES.
071790 07-03
COMPARATIVE EFFECTS OF AMPHETAMINE, SCOPOLAMINE, CHLORDIAZEPOXIDE, AND DIPHENYLHYDANTOIN ON OPERANT AND EXTINCTION BEHAVIOR WITH BRAIN STIMULATION AND FOOD REWARD.
074935 08-04
BEHAVIORAL EFFECTS: HIPPOCAMPAL DESTRUCTION AND SCOPOLAMINE.
075280 08-04
EFFECT OF HIPPOCAMPAL AND NEOCORTICAL ABLATION ON SCOPOLAMINE INDUCED ACTIVITY IN THE RAT.
075848 09-04
TREATMENT OF SCOPOLAMINE INDUCED DELIRIUM.
082155 10-09
SCOPOLAMINE EFFECTS ON GO-NO-GO AVOIDANCE DISCRIMINATIONS: INFLUENCE OF STIMULUS FACTORS AND PRIMACY OF TRAINING.
090418 11-04
ELECTROENCEPHALOGRAPHIC EFFECTS OF ATROPINE AND SCOPOLAMINE.
131623 12-03

**SCOPOLAMINES**
SCOPOLAMINES EFFECT ON PASSIVE AVOIDANCE.
065876 05-04

**SCREENING**
A POTENTIAL SCREENING TEST FOR MINOR TRANQUILLIZING DRUG ACTION.
051651 02-06
UNITED-STATES PROCEDURES FOR SCREENING DRUGS: TESTING FOR DEPENDENCE LIABILITY IN ANIMALS AND MAN.
058971 03-02
A SIMPLE SCREENING METHOD FOR ANTIPARKINSONIAN DRUGS IN MICE.
066415 05-06

**SECOBARBITAL**
PHARMACOLOGICAL COMPARISON OF R(..), S(-) AND RACEMIC SECOBARBITAL IN MICE.
047325 01-03
HYPNOTIC PROPERTIES OF NITRAZEPAM (MOGADON) (A COMPARATIVE STUDY OF CHLORDIAZEPOXIDE, DIAZEPAM, NITRAZEPAM, SECOBARBITAL AND PLACEBO IN PSYCHIATRIC PATIENTS).
075884 09-14

**SECOND-ORDER**
EFFECTS OF CHLORPROMAZINE IN THE PIGEON UNDER A SECOND-ORDER SCHEDULE OF FOOD PRESENTATION.
075906 09-04

**SECONDARY**
SECONDARY IMMUNE RESPONSE TO TETANUS TOXOID IN PSYCHIATRIC PATIENTS.
075412 08-13

**SECRETION**
THE EFFECT OF ORAL CONTRACEPTIVE STEROIDS ON BILE SECRETION AND BILIRUBIN TM IN RATS.
040125 01-05
THE ROLE OF CARBONIC ANHYDRASE IN ANION SECRETION INTO CEREBROSPINAL FLUID.
040755 01-03
BLOCKADE OF NORADRENALINE UPTAKE AND INHIBITION OF GASTRIC ACID SECRETION BY 2-(P-CHLOROPHENYL-2-(PYRIDYL)HYDROXYMETHYL) IMIDAZOLINE MALEATE (SCH-12650).
058878 02-02
ADRENAL CORTICAL AND MEDULLARY SECRETION AND EVALUATION OF DRUGS ACTING ON THE CENTRAL NERVOUS SYSTEM.
106270 12-03

**SECTION**
A TECHNIQUE TO DEMONSTRATE THE EFFECT OF A PSYCHOPHARMACEUTICAL DRUG IN A PSYCHOPATHOLOGICAL LONGITUDINAL SECTION BY NUMERIC AND GRAPHIC MEANS.
079973 09-06

**SEDATION**
PSYCHOPATHOLOGICAL ANALYSIS OF THE PROCESS OF SEDATION.
059038 03-17
THE CHEMOPSYCHOTHERAPEUTICS OF GERIATRIC SEDATION.
059380 03-11
A SEQUENTIAL TRIAL OF AMYLOBARBITONE SODIUM USED AS SEDATION FOR CONFUSED FEMALE PSYCHOGERIATRIC PATIENTS.
082732 10-11

**SEDATIVES**
INTERACTION BETWEEN INTRAVENOUS ALCOHOL AND SOME SEDATIVES AND TRANQUILLIZERS.
067607 06-03
PSYCHOPATHOLOGICAL SIDE-EFFECTS OF SEDATIVES.
070957 07-15
EFFECTS OF DIFFERENT SEDATIVES ON SELF-RATINGS DEPENDING ON SEX AND PERSONALITY.
072588 08-14

**SEEING**
SEEING WITH ALL THREE EYES.
046728 01-12

**SEIZURE**
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: I. SEIZURE AND POST-SEIZURE ELECTROENCEPHALOGRAPHIC PATTERN.
065850 05-11

**SEIZURES**
THERAPY OF CHILDHOOD SEIZURES.
065175 05-11
A POSSIBLE ROLE FOR 5-HYDROXYTRYPTAMINE IN DRUG-INDUCED SEIZURES.
074084 08-03
CLASSICAL HYSTERICAL SEIZURES FACILITATED BY ANTICONVULSANT TOXICITY.
081135 09-15
METRAZOL AND THE EVALUATION OF SEIZURES.
081298 09-11
ARRESTING OF STATUS-EPILEPTICUS AND SERIAL SEIZURES BY AMYTAL CAFFEINE.
090349 11-11
AMNESIA AND BRAIN SEIZURES ACTIVITY IN MICE: EFFECTS OF DIETHYL-ETHER ANESTHESIA PRIOR TO ELECTROSHOCK STIMULATION.
097952 11-04

**SELECTION**
COMPENSATORY SELECTION OF MAGNESIUM SULFATE BY MAGNESIUM DEPLETED LABORATORY RATS.
068287 06-04

**SELECTIVE**
SELECTIVE DEPLETION OF NORADRENALINE: A PROPOSED MECHANISM OF THE ADRENERGIC NEURONE BLOCKING ACTION OF BRETYLIUM.
055323 02-05
INFLUENCE OF TRIIODOTHYRONINE ON SELECTIVE ATTENTION IN MAN AS MEASURED BY THE VISUAL AVERAGED EVOKED POTENTIAL.
062510 03-13
P-CHLOROAMPHETAMINE: IN VIVO INVESTIGATIONS ON THE MECHANISM OF ACTION OF THE SELECTIVE DEPLETION OF CEREBRAL SEROTONIN.
069596 07-03
A CHOICE TECHNIQUE TO ASSESS THE EFFECTS OF SELECTIVE PUNISHMENT ON FIXED-RATIO PERFORMANCE.
075579 08-04
A CONTROLLED STUDY OF THE ANTIDEPRESSANT EFFECT OF P-CHLORO-N-METHYLAMPHETAMINE, A COMPOUND WITH A SELECTIVE EFFECT ON THE CENTRAL 5-HYDROXYTRYPTAMINE METABOLISM.
078212 09-10

**SELECTIVELY**
PHARMACOLOGIC ACTIVITY OF A NEW CLASS OF AGENTS WHICH SELECTIVELY INHIBIT AGGRESSIVE BEHAVIOR IN RATS.
082398 10-04

**SELF-ADMINISTRATION**
BEHAVIORAL VARIABLES INFLUENCING DRUG SELF-ADMINISTRATION.
046206 01-04
REGULATION OF DRUG SELF-ADMINISTRATION.
046207 01-04
RESPONSE DISRUPTION FOLLOWING AMPHETAMINE SELF-ADMINISTRATION AND PROGRAMMED ADMINISTRATION.
046209 01-04
STIMULANT SELF-ADMINISTRATION BY ANIMALS: SOME COMPARISONS WITH OPIATE SELF-ADMINISTRATION.
056237 02-04
PSYCHOLOGICAL APPROACHES TO OPIATE DEPENDENCE AND SELF-ADMINISTRATION BY LABORATORY ANIMALS.
056240 02-04

**SELF-BITING**
THEOPHYLLINE: INDUCTION OF SELF-BITING IN RABBITS.
075236 08-04

**SELF-INJECTION**
THE SELF-INJECTION OF AMOBARBITAL BY RATS DURING NON-REWARD.
083413 10-04

**SELF-POISONING**
A CASE OF SELF-POISONING WITH CARBRITAL.
066903 05-15
ISONIAZID SELF-POISONING.
082004 10-15
CASE OF SELF-POISONING WITH MULTIPLE ANTIDEPRESSANT DRUGS.
082153 10-15

**SELF-RATINGS**
EFFECTS OF DIFFERENT SEDATIVES ON SELF-RATINGS DEPENDING ON SEX AND PERSONALITY.
072588 08-14

**SELF-SELECTION**
PSYCHOPHARMACOLOGY: INTRODUCTION TO GENERAL PSYCHOLOGY: A SELF-SELECTION TEXTBOOK.
047681 01-17

**SELF-STIMULATION**
ENHANCEMENT BY COCAINE OF INTRACRANIAL SELF-STIMULATION IN THE RAT.
058397 02-13
DISSOCIATION OF THE EFFECTS OF P-CHLOROPHENYLALANINE ON SELF-STIMULATION AND ON BRAIN SEROTONIN.
058942 02-03
INTRACRANIAL SELF-STIMULATION AND WAKEFULNESS: EFFECT OF MANIPULATING AMBIENT BRAIN CATECHOLAMINES.
063849 04-04
ANTICONVULSANT DRUGS AND SELF-STIMULATION RATES IN RATS.
066871 05-04

**SELF-STIMULATORY**
EFFECTS OF A CHOLINE ACETYLTRANSFERASE INHIBITOR ON SELF-STIMULATORY BEHAVIOR IN THE RAT.
058993 03-04

**SEMI-PURIFIED**
STRUCTURE-ACTIVITY RELATIONSHIP OF FOUR TETRAHYDROCANNABINOLS AND THE PHARMACOLOGICAL ACTIVITY OF FIVE SEMI-PURIFIED EXTRACTS OF CANNABIS-SATIVA.
064417 04-04

**SEMIOLOGICAL**
CURRENT TOXICOMANIAS: CLINICAL AFFECTS OF THE AGENTS USED AND COMMON SEMIOLOGICAL ASPECTS.
085129 10-15

**SENESCENCE**
DOGMATIL: A NEW ILLUMINATION ON THE PSYCHOLOGICAL PROBLEMS OF SENESCENCE.
058313 02-11

**SENILE**
L-DOPA IN SENILE DEMENTIA.
059020 03-11
CONTROLLED LONG-TERM STUDY ON SENILE HYPERTENSION.
089785 11-15

**SENILITY**
PROBLEMS OF PSYCHOSIS IN SENILITY.
069016 06-11

**SENSITIVE**
STUDIES IN MAN ON THE INFLUENCE OF A NEW PSYCHOPHARMACEUTICAL DRUG, 1-((METHYLAMINO) DIBENZOBICYCLOOCTADIENE HYDROCHLORIDE, ON THE CO2 SENSITIVE CENTRAL RESPIRATORY REGULATION.
079971 09-07
THE INFLUENCE OF 5-HYDROXYTRYPTOPHAN ON THE BEHAVIOR AND THE LEVEL OF MONOAMINES IN THE BRAIN OF RATS SENSITIVE TO SOUND.
098040 11-03

**SENSITIVITY**
ANESTHETIC AGENTS AND THE CHEMICAL SENSITIVITY OF CORTICAL NEURONES.
040580 01-03
STUDY OF THE EFFECTS OF PROGESTERONE THERAPY ON THE STILBOESTROL INDUCED SENSITIVITY OF ISOLATED UTERI OF HYPOPHYSECTOMIZED RATS.
041540 01-03
THE SENSITIVITY OF THE BRAIN TO BARBITURATE DURING CHRONIC ADMINISTRATION AND WITHDRAWAL OF BARBITONE SODIUM IN THE RAT.
063980 04-03
EFFECT OF ACUTE HYPOXIA ON BRAIN SENSITIVITY AND METABOLISM OF BARBITURATES IN MICE.
064480 04-03
ALTERATIONS IN BRAIN SENSITIVITY AND BARBITURATE METABOLISM UNRELATED TO AGGRESSION IN SOCIALLY DEPRIVED MICE.
069052 06-03
CHANGE IN SENSITIVITY TO D-AMPHETAMINE IN FRONTAL RATS AS A FUNCTION OF TIME: SHIFTING OF THE DOSE RESPONSE CURVE.
075238 08-04

**SENSITIZED**
EFFECT OF CAPERS ON THE VASCULAR LUMEN OF ISOLATED EXTREMITIES OF SENSITIZED FROGS AND THE ANTIANAPHYLATIC EFFECT OF SUPRASTIN.
105720 12-03

**SENSORY**
SENSORY REPRESENTATION IN THE NEOCORTEX OF THE MOLE, SCALOPUS AQUATICUS.
066468 05-03
PSYCHOPHYSIOLOGICAL ASPECTS OF EXTENDED EXPOSURE OF MAN TO AN ENVIRONMENT WITH SENSORY DEPRIVATION.
082954 10-14

**SEPARATION**
SEPARATION AND IDENTIFICATION OF TRANQUILIZERS AND PSYCHOSTIMULANTS.
131625 12-06

**SEPTAL**
CHANGES IN EMOTIONAL BEHAVIOUR AFTER APPLICATION OF CHOLINESTERASE INHIBITOR IN THE SEPTAL AND AMYGDALA REGION.
040578 01-04
DISAPPEARANCE IN RATS WITH SEPTAL LESIONS OF THE STIMULATORY EFFECT OF HYOSCINE ON EXPLORATORY BEHAVIOUR.
067605 06-04
CHANGES IN D-AMPHETAMINE REACTIVITY RESULTING FROM SEPTAL FOREBRAIN INJURY.
067695 06-04

**SEPTUM**
BEHAVIORAL AND VISCERAL REACTIONS ELICITED BY CHEMICAL STIMULATION OF THE HYPOTHALAMUS AND SEPTUM IN CATS.
064333 04-04
INHIBITORY FUNCTIONS OF THE SEPTUM AND AMYGDALA.
095697 11-03

**SEQUELAE**
TWO CASES OF ACUTE P-CHLORONITROBENZENE POISONING SEQUELAE.
129753 12-15

**SEQUENTIAL**
SEQUENTIAL COMPARISON OF L-TRYPTOPHAN WITH ECT IN SEVERE DEPRESSION.
059053 03-09
A SEQUENTIAL TRIAL OF AMYLOBARBITONE SODIUM USED AS SEDATION FOR CONFUSED FEMALE PSYCHOGERIATRIC PATIENTS.
082732 10-11
A TRIAL ON THE VALUE OF SORDINOL IN SCHIZOPHRENIA -- BY SUBJECTIVE METHOD AND PARTLY BY USING SEQUENTIAL ANALYSIS.
129451 12-08

**SERIAL**
ARRESTING OF STATUS-EPILEPTICUS AND SERIAL SEIZURES BY AMYTAL CAFFEINE.
090349 11-11

**SERINUS-CANARIUS**
STUDIES OF STEREOTYPY FUNCTION IN THE CANARY (SERINUS-CANARIUS).
063634 04-03

**SEROTONERGIC**
TRYPTALDEHYDES (INDOLEACETALDEHYDES) IN SEROTONERGIC SLEEP OF NEWLY HATCHED CHICKS.
055583 02-03

**SEROTONIN**
COMPARATIVE EFFECTS OF P-CHLOROPHENYLALANINE, P-CHLOROAMPHETAMINE AND P-CHLORO-N-METHYLAMPHETAMINE ON RAT BRAIN NOREPINEPHRINE, SEROTONIN AND 5-HYDROXYINDOLE-3-ACETIC ACID.
040241 01-03
EFFECT OF RESERPINE ON THE INCORPORATION IN VIVO OF RADIOACTIVITY FROM LABELED SEROTONIN AND OTHER 5-HYDROXYINDOLE DERIVATIVES IN MOUSE BRAIN.
046189 01-03
INFLUENCE OF SEROTONIN AND RELATED SUBSTANCES UPON PHOTIC EVOKED POTENTIALS OF RABBIT: EVIDENCE FOR BIOLOGICAL ACTIVITY OF THE ALDEHYDE DERIVATIVE.
055584 02-03
DISSOCIATION OF THE EFFECTS OF P-CHLOROPHENYLALANINE ON SELF-STIMULATION AND ON BRAIN SEROTONIN.
058942 02-03
PROJECT SUMMARY: THIENOPYRIDINE ANALOGS OF SEROTONIN AND TRYPTOPHAN.
066815 05-01
CONTRACEPTIVES, BRAIN SEROTONIN, AND LIVER TRYPTOPHAN PYRROLASE.
067072 05-03
THE EFFECT OF DISULFIRAM, DIETHYLDITHIOCARBAMATE AND DIMETHYLDITHIOCARBAMATE ON SEROTONIN AND 5-HYDROXYINDOLE-3-ACETIC ACID BRAIN LEVELS IN RATS.
067384 06-03
QUANTITATION OF THE DEGREE OF ANTAGONISM OF CHLOROQUINE TO HISTAMINE, ACETYLCHOLINE AND SEROTONIN ( PA2 VALUES).
067462 06-03
PENTYLENETETRAZOL AND ETHAMIVAN EFFECTS ON BRAIN SEROTONIN METABOLISM.
067613 06-03
SEROTONIN: A POSSIBLE MEDIATOR OF BEHAVIORAL SUPPRESSION INDUCED BY ANXIETY.
069311 06-04
BRAIN SEROTONIN TURNOVER IN MORPHINE TOLERANT AND DEPENDENT MICE.
069595 07-03
P-CHLOROAMPHETAMINE: IN VIVO INVESTIGATIONS ON THE MECHANISM OF ACTION OF THE SELECTIVE DEPLETION OF CEREBRAL SEROTONIN.
069596 07-03
INHIBITORY EFFECT OF TWO NEWER ANTIDEPRESSANTS, LU-5-003 AND LU-3-010, ON SEROTONIN UPTAKE IN HUMAN BLOOD PLATELETS IN VITRO.
071791 07-03
AN ANALYSIS OF RECEPTIVE STRUCTURES PARTICIPATING IN THE BEHAVIOR REACTIONS OF CATS INDUCED BY CATECHOLAMINES AND SEROTONIN.
073715 08-03
THIENOPYRIDINE ANALOGS OF SEROTONIN AND TRYPTOPHAN.
074844 08-01
DELTA1-TETRAHYDROCANNABINOL, SYNHEXYL AND MARIJUANA EXTRACT ADMINISTERED ORALLY IN MAN: CATECHOLAMINE EXCRETION, PLASMA CORTISOL LEVELS AND PLATELET SEROTONIN CONTENT.
075841 08-12
ANTAGONISM OF BETA-PHENYLETHYLAMINE DERIVATIVES AND SEROTONIN BLOCKING DRUGS UPON SEROTONIN, TRYPTAMINE AND RESERPINE BEHAVIORAL DEPRESSION IN MICE.
079970 09-04
A NOVEL METHOD OF REDUCING THE CONCENTRATION OF BRAIN SEROTONIN: USE OF ALPHA-METHYLTRYPTOPHAN.
086350 10-13
EFFECT OF VEHICLES ON METABOLISM OF SEROTONIN AND IMIPRAMINE.
089439 11-03
ROLE OF BRAIN SEROTONIN IN THE STIMULANT ACTION OF AMPHETAMINE.
098003 11-03
INFLUENCE OF IMIPRAMINE, BENACTYZINE AND PROMAZINE ON THE EFFECTS OF INTRAAMYGDALOID INJECTION OF ACETYLCHOLINE AND SEROTONIN.
098024 11-04
SYNERGISM OF DESMETHYLIMIPRAMINE WITH RESERPINE AND 5-HYDROXYTRYPTOPHAN IN THE FROG: BRAIN SEROTONIN AND ADRENALINE AND BEHAVIOR.
098042 11-03
DISTURBANCES IN TRYPTAMINE SEROTONIN METABOLISM ASSOCIATED WITH PSYCHOTIC PHENOMENA.
121084 12-13

**SEROTONIN-C14**
EFFECT OF DIAZEPAM ON FATE OF INTRACISTERNALLY INJECTED SEROTONIN-C14.
072031 07-03

**SEROTONINERGIC**
INHIBITION OF CENTRAL SEROTONINERGIC EXCITATION (5-HYDROXYTRYPTOPHAN INDUCED DEAD TWITCHES) IN MICE BY LITHIUM.
097989 11-04
SEROTONINERGIC PROCESSES IN THE ACTION OF PSYCHOTROPIC DRUGS.
098055 11-03
SEROTONINERGIC COMPONENT OF THE STIMULANT EFFECT OF CHOLINOLYTICS.
098058 11-03
PARTICIPATION OF SEROTONINERGIC PROCESSES IN THE ACTION OF PHENIGAMA.
105620 12-03

**SERUM**
SUBNORMAL SERUM FOLATE DUE TO ANTICONVULSIVE THERAPY: A DOUBLE-BLIND STUDY OF THE EFFECT OF FOLIC ACID TREATMENT IN PATIENTS WITH DRUG INDUCED SUBNORMAL SERUM FOLATES.
042700 01-11
THE EFFECTS OF LITHIUM ON ELECTROENCEPHALOGRAM, BEHAVIOR AND SERUM ELECTROLYTES.
060859 03-09
SERUM VITAMIN-B12 LEVELS IN PSYCHIATRIC PATIENTS ON LONG-TERM PSYCHOTROPIC DRUG THERAPY.
063874 04-13
DETERMINANTS OF SERUM HALF-LIFE OF GLUTETHIMIDE IN INTOXICATED PATIENTS.
064168 04-15
CHANGES IN THE SERUM CONCENTRATION OF CHOLESTEROL, TRIGLYCERIDES AND PHOSPHOLIPIDS IN THE MOUSE AND RAT AFTER ADMINISTRATION OF EITHER CHLORCYCLIZINE OR PHENOBARBITAL.
064282 04-03
INFLUENCE OF ETHYLPHENACEMIDE ON SERUM LEVELS OF OTHER ANTIEPILEPTIC DRUGS.
066190 05-13
THE EFFECT OF SERUM FROM ACUTE SCHIZOPHRENIC PATIENTS ON RABBIT BRAIN AMINES.
066713 05-03
EPINEPHRINE CYCLIZING ENZYME IN SCHIZOPHRENIC SERUM.
075105 08-01
CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIC WOMEN: ITS EFFECT ON THYROID AND LIVER FUNCTION IN RELATION TO SERUM CHOLESTEROL CONCENTRATION.
088221 10-13
EFFECT OF NICOTINIC ACID COMBINED WITH A TRANQUILLIZER (HYDROXYZINE) ON SERUM LIPID LEVELS AND URINARY CATECHOLAMINE EXCRETION IN GERIATRIC PATIENTS.
093689 11-11

AN INTERESTING TISSULARY THERAPEUTIC METHOD IN GERIATRICS: BOGOMOLETZ SERUM (BERNAS CYTOTOXIC SERUM).
105551 12-11

**SERVICES**
THE CHILDRENS PSYCHOPHARMACOLOGY CLINIC: ITS ROLE WITHIN A TOTAL PROGRAM FOR CHILDRENS PSYCHIATRIC SERVICES.
080097 09-17

**SESAME-OIL**
FLUPHENAZINE ENANTHATE IN SESAME-OIL, A DEPOT PREPARATION.
070476 07-11

**SEX**
EFFECT OF PSYCHOTOMIMETIC AGENTS ON SEX RATIO?
071960 07-15
EFFECTS OF DIFFERENT SEDATIVES ON SELF-RATINGS DEPENDING ON SEX AND PERSONALITY.
072588 08-14
USE OF AN ANDROGEN DEPLETING HORMONE IN THE TREATMENT OF MALE SEX OFFENDERS.
080178 09-14
RESPONSES OF MALE RATS TO SEX ODORS.
081226 09-04

**SEXES**
DIFFERENCES IN BRAIN AREA 5-HYDROXYTRYPTAMINE TURNOVER AND REARING BEHAVIOR IN RATS AND MICE OF BOTH SEXES.
047324 01-04

**SEXUAL**
EFFECT OF CHRONIC ADMINISTRATION OF P-CHLOROPHENYLALANINE ON SEXUAL RECEPTIVITY OF THE FEMALE RAT.
066825 05-04
SEXUAL BEHAVIOR OF MALE CATS AFTER ADMINISTRATION OF P-CHLOROPHENYLALANINE.
072463 08-04
OVARIAN HORMONES AND FEMALE SEXUAL INVITATIONS IN CAPTIVE RHESUS MONKEYS (MACACA-MULATTA).
076554 09-03
MALE SEXUAL FUNCTION.
100530 12-15

**SEXY**
EXPERIMENTAL DRUG MAKES RATS SEXY.
090137 11-04

**SHARK**
PHENOTHIAZINE TOXICITY IN POOL SHARK.
059035 03-15

**SHEEP**
PREPARATION OF 3H-7-HYDROXYCHLORPROMAZINE USING SHEEP LIVER MICROSOMES FOR HYDROXYLATION OF 3H-CHLORPROMAZINE.
097582 11-01

**SHIFT**
CHLORPROMAZINE, CHLORDIAZEPOXIDE, AND THE INCENTIVE SHIFT PERFORMANCE IN THE RAT.
060275 03-04

**SHIFTING**
CHANGE IN SENSITIVITY TO D-AMPHETAMINE IN FRONTAL RATS AS A FUNCTION OF TIME: SHIFTING OF THE DOSE RESPONSE CURVE.
075238 08-04

**SHIFTS**
EFFECTS OF REINFORCEMENT SHIFTS UPON SUBSEQUENT SUCROSE CONSUMPTION.
060871 03-03

**SHOCK**
IMPAIRMENT OF SHOCK AVOIDANCE LEARNING AFTER LONG-TERM ALCOHOL INGESTION IN MICE.
058492 02-04
COMPARISON OF PMH AND PEMOLINE ACTIVITY AFTER ELECTROCONVULSIVE SHOCK.
058992 03-04
THE MODIFIABILITY OF INFANTILE SHOCK TRAUMATIZATION EFFECTS BY CONTIGUOUS DRUG ADMINISTRATIONS.
060090 03-04
EFFECT OF LITHIUM ON FOOT SHOCK AGGRESSION IN RATS.
062777 03-04
THE EFFECT OF P-CHLOROPHENYLALANINE (PCPA) ON SHOCK INDUCED FIGHTING BEHAVIOR IN RATS.
062853 03-03
THE INFLUENCE OF VARIOUS NEUROLEPTIC DRUGS ON SHOCK AVOIDANCE RESPONDING IN RATS. III. AMPHETAMINE ANTAGONISM IN THE DISCRIMINATED SIDMAN AVOIDANCE PROCEDURE.
064476 04-04
RETENTION RATES OF SCHIZOPHRENIA: A COMPARISON OF SHOCK THERAPY AND PSYCHOPHARMACOLOGICAL ERAS AND OF CLOSED AND OPEN DOOR POLICIES.
069795 07-08
HYDROXYZINE AND SHOCK IN OPERANT BEHAVIOR OF RATS.
076164 09-04
DYNAMIC CONTROL OF ACID BASE EQUILIBRIUM DURING SOME FORMS OF SHOCK THERAPY.
079139 09-13
APPLICATION OF ON-LINE COMPUTER PROCEDURES TO EXPERIMENTAL CONTROL AND EVALUATION OF THE EFFECTS OF DRUGS ON OPERANT BEHAVIOR (SIDMAN SHOCK AVOIDANCE RESPONDING BY RATS).
095507 11-06
STIMULUS PROPERTIES OF ELECTROCONVULSIVE SHOCK IN GOLDFISH. (PH.D.DISSERTATION).
110906 12-04
USE OF CATTELS IPAT ANXIETY SCALE IN A GROUP OF NEUROTIC PATIENTS BEFORE AND AFTER PSYCHOPHARMACOLOGICAL DRUG AND ELECTRIC SHOCK THERAPY.
128509 12-17

**SHOCKS**
EFFECTS OF INSULIN, METRAZOL, AND ELECTROCONVULSIVE SHOCKS UPON LEARNING TO LEARN 30 SUCCESSIVE REVERSAL PROBLEMS BY RATS.
095188 11-04

**SHORT-CHAIN**
HIGH VOLTAGE SLOW WAVE INDUCED BY SHORT-CHAIN FATTY ACIDS WITH SPECIAL REFERENCE TO SLEEP RHYTHM.
088612 10-03

**SHORT-TERM**
A COMPARISON OF SHORT-TERM TREATMENT EFFECTS OF INTRAVENOUS SODIUM AMYTAL METHEDRINE AND LSD IN THE ALCOHOLIC.
062934 03-11
THE EFFECTS OF CENTRALLY AND PERIPHERALLY ACTING CHOLINERGIC DRUGS ON THE SHORT-TERM PERFORMANCE GRADIENT FOLLOWING PASSIVE AVOIDANCE TRAINING.
064412 04-04
AN AUTOMATED MULTIPLE CHOICE TEST OF SHORT-TERM SPATIAL MEMORY FOR MONKEYS.
075917 09-04

**SHOWING**
RESPONSE TO DRUGS BY RATS SHOWING LONG OR SHORT HEXOBARBITAL INDUCED SLEEP.
058990 03-03

**SHRIMP**
THE EFFECTS OF MORPHINE-LIKE COMPOUNDS ON THE LIGHT RESPONSES OF THE BRINE SHRIMP ARTEMIA-SALINA.
075844 09-04

**SHUTTLE**
EFFECTS OF CHLORDIAZEPOXIDE ON DISCRIMINATIVE FEAR CONDITIONING AND SHUTTLE AVOIDANCE PERFORMANCE IN THE RABBIT.
065451 05-04
EFFECTS OF CHLORDIAZEPOXIDE ON THE ACQUISITION OF SHUTTLE AVOIDANCE IN THE RABBIT.
075235 08-04

**SHUTTLEBOX**
EFFECTS OF ACTH AND ZINC PHOSPHATE VEHICLE ON SHUTTLEBOX CAR.
060756 03-04

**SIDE**
SIDE REACTIONS IN NEUROTICS: I. A COMPARISON OF TWO METHODS OF ASSESSMENT.
064287 04-15
SETTING, PATIENT, AND DOCTOR EFFECTS ON DRUG RESPONSE IN NEUROTIC PATIENTS: I. DIFFERENTIAL ATTRITION, DOSAGE DEVIATION, AND SIDE REACTION RESPONSES TO TREATMENT.
065453 05-10

**SIDE-EFFECT**
AMINOGLUTETHIMIDE: A SIDE-EFFECT TURNED TO THERAPEUTIC ADVANTAGE.
066873 05-15
MENSTRUATION CHANGES AS UNUSUAL SIDE-EFFECT IN A MOLINDONE TRIAL.
067570 06-15

**SIDE-EFFECTS**
CONSIDERATIONS OF SOME SIDE-EFFECTS OF DRUGS. (A STUDY BEARING ON 11,410 CALLS RECEIVED BY THE BELGIAN ANTIPOISON CENTER).
042687 01-15
SIDE-EFFECTS OF L-DOPA IN POSTENCEPHALITIC PARKINSONISM.
059057 03-15
PROJECT SUMMARY: NATURE OF LATE SIDE-EFFECTS OF PHENOTHIAZINE THERAPY.
060222 03-05
DRUG-INDUCED EXTRAPYRAMIDAL DISORDERS: A RATING SCALE FOR EXTRAPYRAMIDAL SIDE-EFFECTS.
063773 04-16
LONG-ACTING, ANTIPSYCHOTIC AGENTS AND EXTRAPYRAMIDAL SIDE-EFFECTS.
065471 05-15
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: V. CONFUSION AND OTHER SIDE-EFFECTS.
065854 05-15
NEUROTOXIC SIDE-EFFECTS IN DISULFIRAM (ANTABUSE) OVERDOSAGE.
067743 06-15
SIDE-EFFECTS AND TERATOGENICITY OF LITHIUM CARBONATE TREATMENT.
069580 07-15

LONG-TERM TREATMENT WITH OCTOCLOTHEPINE -- SIDE-EFFECTS AND LABORATORY FINDINGS.
070928 07-09
PSYCHOPATHOLOGICAL SIDE-EFFECTS OF SEDATIVES.
070957 07-15
THE CONTRACEPTIVE PILL, SIDE-EFFECTS AND PERSONALITY: REPORT OF A CONTROLLED DOUBLE-BLIND TRIAL.
075472 08-15
CORRELATION OF SUBJECTIVE SIDE-EFFECTS WITH PLASMA CONCENTRATIONS OF NORTRIPTYLINE.
082104 10-15
THE SIDE-EFFECTS OF MODITEN-RETARD.
088999 10-15
PSYCHOTROPIC DRUG SIDE-EFFECTS: CLINICAL AND THEORETICAL PERSPECTIVES.
100516 12-15
PSYCHOTROPIC DRUG SIDE-EFFECTS IN CHILDREN.
100517 12-15
A COMPARATIVE DETERMINATION OF SIDE-EFFECTS ASSOCIATED WITH THE ORAL USE OF THREE ANTICHOLINERGIC PSYCHOTROPIC DRUGS.
126639 12-15
PSYCHOPHARMACEUTICALS AND NEUROLOGICAL SIDE-EFFECTS.
128390 12-15

**SIDMAN**
THE INFLUENCE OF VARIOUS NEUROLEPTIC DRUGS ON SHOCK AVOIDANCE RESPONDING IN RATS. III. AMPHETAMINE ANTAGONISM IN THE DISCRIMINATED SIDMAN AVOIDANCE PROCEDURE.
064476 04-04
APPLICATION OF ON-LINE COMPUTER PROCEDURES TO EXPERIMENTAL CONTROL AND EVALUATION OF THE EFFECTS OF DRUGS ON OPERANT BEHAVIOR (SIDMAN SHOCK AVOIDANCE RESPONDING BY RATS).
095507 11-06

**SIGHT**
DRUGS: MORE L-DOPA IN SIGHT.
087724 10-11

**SIGNIFICANCE**
PHARMACOLOGICAL SIGNIFICANCE OF BIOGENIC AMINES IN THE LUNGS: NORADRENALINE AND DOPAMINE.
041539 01-03
PHARMACOLOGICAL SIGNIFICANCE OF BIOGENIC AMINES IN THE LUNGS: 5-HYDROXYTRYPTAMINE.
041565 01-03
INDOLEAMINES AND THE CENTRAL NERVOUS SYSTEM: A SOUNDING OF THEIR CLINICAL SIGNIFICANCE.
070881 07-13
THE SIGNIFICANCE OF BRAIN DAMAGE IN PERSISTENT ORAL DYSKINESIA.
075416 08-15
SIGNIFICANCE OF PSYCHOPHARMACOLOGY ON PSYCHOTHERAPY OF DEPRESSION.
094453 11-09

**SIGNIFICANT**
CONSIDERATIONS ON THE HYPERKINESIA OF L-DOPA: SIGNIFICANT BIOCHEMICAL AND ANATOMICAL DEFICIENCIES.
078555 09-13

**SILENT**
THE VARIABLES OF SILENT MYOCARDIAL INFARCTION IN A PSYCHOTIC POPULATION.
065314 05-10

**SIMILARITIES**
SIMILARITIES BETWEEN NEUROLOGIC EFFECTS OF L-DOPA AND OF APOMORPHINE.
056574 02-11
SIMILARITIES BETWEEN BEHAVIORAL AND PHARMACOLOGICAL ACTIONS OF YOHIMBINE AND 5-HYDROXYTRYPTOPHAN IN THE CONSCIOUS DOG.
064253 04-04

**SIMPLE**
A SIMPLE AND INEXPENSIVE CANNULA TECHNIQUE FOR CHEMICAL STIMULATION OF THE BRAIN.
058357 02-06
EFFECTS OF MORPHINE ON BEHAVIOR MAINTAINED BY FOUR SIMPLE FOOD REINFORCEMENT SCHEDULES.
064479 04-04
A SIMPLE SCREENING METHOD FOR ANTIPARKINSONIAN DRUGS IN MICE.
066415 05-06
THE STAIRCASE MAZE AND THE SIMPLE STAIRCASE IN THE ANALYSIS OF THE PSYCHOPHARMACOLOGICAL ACTION OF CNS DEPRESSANTS.
068291 06-04

**SINEQUAN**
DOXEPIN (SINEQUAN) AND OTHER DRUGS FOR ANXIETY AND DEPRESSION.
066877 05-17
DOXEPIN HCL (SINEQUAN) -- CURRENT INFORMATION.
068203 06-13
DOUBLE-BLIND STUDY WITH SINEQUAN (DOXEPIN) VS DIAZEPAM VS PLACEBO IN PSYCHONEUROSIS.
138526 12-10

**SINGLE**
ACTION OF PSYCHOTOGENIC DRUGS ON SINGLE MIDBRAIN RAPHE NEURONS.
040418 01-03
EXPERIMENTAL PSYCHOLOGICAL STUDY OF PERFORMANCE CHANGES WITH PERAZINE (TAXILAN) IN MENTALLY DISTURBED AND IN HEALTHY EXPERIMENTAL SUBJECTS FOLLOWING REGIMEN AND SINGLE DOSE ADMINISTRATION.
058235 02-11
INDUCTION OF RECEPTIVITY IN OVARIECTOMIZED FEMALE RATS BY A SINGLE INTRAVENOUS INJECTION OF ESTRADIOL-17BETA.
067696 06-04
PERSISTENT BEHAVIOURAL AND ELECTROENCEPHALOGRAPHIC CHANGES AFTER SINGLE DOSES OF NITRAZEPAM AND AMYLOBARBITONE SODIUM.
068005 06-14
PSYCHOTROPICS IN ANXIETY AND DEPRESSION -- COMBINATION OR SINGLE AGENT.
068298 06-09
THE INFLUENCE OF SINGLE AND CHRONIC MORPHINE ADMINISTRATION ON SOME CENTRAL EFFECTS OF AMPHETAMINE AND APOMORPHINE.
075840 08-05

**SINGULAR**
SULPIRIDE, A SINGULAR, ANTIAUTISTIC AND THYMOANALEPTIC NEUROLEPTIC.
089160 10-11

**SINKING**
ESTIMATION OF LOW CHLORPROMAZINE CONCENTRATIONS BY SURFACING AND SINKING REACTION OF MINNOWS (GAMBUSIA-AFFINIS).
097964 11-06

**SITES**
ON THE SITES OF ANTITUSSIVE ACTION OF N-(2-PICOLYL)-N-PHENYL-N-(2-PIPERIDINOETHYL)AMINE (TAT-3).
055586 02-03
ELECTRICAL IMPEDANCE CHANGES IN MANY SITES OF BRAIN IN PARADOXICAL SLEEP, ANESTHESIA AND ACTIVITY.
066474 05-03
INTERACTION OF CHLORPROMAZINE AND TISSUE BINDING SITES: PRELIMINARY STUDIES.
069367 06-03
SITES OF ACTION OF RAM-302 AND NALORPHINE AS MORPHINE ANTAGONISTS.
074934 08-03
ON THE CENTRAL SITES FOR THE ANTINOCICEPTIVE ACTION OF MORPHINE AND FENTANYL.
074936 08-03

**SITUATION**
THE EFFECTS OF TRICYANOAMINOPROPENE ON LEARNING IN A DIFFERENTIAL REINFORCEMENT OF LOW RATES SITUATION.
075851 09-03
THE INFLUENCE OF A FEAR EVOKING SITUATION ON THE RECTAL TEMPERATURE OF RATS.
082409 10-03
THE EFFECT OF CHLORDIAZEPOXIDE ON THE BEHAVIOR OF RATS IN A CONFLICT SITUATION.
090424 11-04

**SITUATIONAL**
PHYSIOLOGICAL AND SITUATIONAL FACTORS IN PSYCHOPHARMALOGICAL EXPERIMENTS.
058638 02-14

**SIZE**
PUPIL SIZE AND DRUG STATE IN A REACTION TIME TASK.
075161 08-13

**SKELETAL**
AVOIDANCE TRAINING OF HIPPOCAMPAL THETA WAVES IN FLAXEDILIZED DOGS AND ITS RELATION TO SKELETAL MOVEMENT.
075399 08-04

**SKF-14336**
DOUBLE-BLIND STUDY COMPARING THE INTRAMUSCULAR USAGE OF AN ACRIDAN DERIVATIVE, SKF-14336, TO CHLORPROMAZINE.
067513 06-11
CLINICAL TRIAL OF CLOMACRAN PHOSPHATE (SKF-14336) IN CHRONIC PSYCHOTIC MALE PATIENTS.
082056 10-07

**SKF-525A**
EFFECT OF SKF-525A ON THE FATE OF THIOPENTONE.
066853 05-03

**SKIN**
RABBIT AS A MODEL FOR CHLORPROMAZINE INDUCED HYPERPIGMENTATION OF THE SKIN.
045543 01-05
SKIN LESIONS AS A DIAGNOSTIC AID IN BARBITURATE POISONING.
067926 06-15

**SLABS**
EFFECTS OF GENERAL DEPRESSANT DRUGS ON THE ELECTRICAL RESPONSES OF ISOLATED SLABS OF CATS CEREBRAL CORTEX.
066382 05-03

EFFECTS OF GENERAL STIMULANT DRUGS ON THE ELECTRICAL RESPONSES OF ISOLATED SLABS OF CATS CEREBRAL CORTEX.
090189 11-03

**SLEEP**

COMPARISON OF LIVER MICROSOME ENZYME SYSTEMS AND BARBITURATE SLEEP TIMES IN RATS CAGED INDIVIDUALLY OR COMMUNALLY.
045545 01-06

PERSONALITY DIFFERENCES IN THE RESPONSE TO STIMULANT DRUGS ADMINISTERED DURING A SLEEP DEPRIVED STATE.
052502 02-14

TRYPTALDEHYDES (INDOLEACETALDEHYDES) IN SEROTONERGIC SLEEP OF NEWLY HATCHED CHICKS.
055583 02-03

A DOUBLE-BLIND EVALUATION OF CAPURIDE (PACINOX) AS A PRESURGICAL AID TO SLEEP.
058371 02-14

TRYPTOPHOL, 5-HYDROXYTRYPTOPHOL AND 5-METHOXYTRYPTOPHOL INDUCED SLEEP IN MICE.
058382 02-04

TOXICITY, NARCOTIC EFFECT, CONCENTRATION AT END OF ANESTHESIA, ELIMINATION FROM BLOOD AND BIOTRANSFORMATION OF HEXOBARBITAL IN RATS OF VARIOUS AGES FOLLOWING SLEEP INDUCTION WITH BARBITAL AND AFTER.
058987 03-05

RESPONSE TO DRUGS BY RATS SHOWING LONG OR SHORT HEXOBARBITAL INDUCED SLEEP.
058990 03-03

THE PHARMACOLOGY OF DISTURBED SLEEP.
063592 03-10

A COMPARATIVE STUDY OF THE EFFECTS OF METHAQUALONE AND GLUTETHIMIDE ON SLEEP IN MALE CHRONIC INSOMNIACS.
063879 04-14

THE EFFECT OF ACUTE ADMINISTRATION OF (META-TRIFLUOROMETHYL-PHENYL)-1-(BENZOYLOXY) ETHYLAMINO-2-PROPANE (780-SE) AND FENFLURAMINE ON HUMAN SLEEP.
063978 04-14

THE CONCOMITANT EFFECTS OF MILD SLEEP LOSS AND AN ANTICHOLINERGIC DRUG.
064387 04-13

THE EFFECT OF LSD ON SLEEP DEPRIVED MEN.
064388 04-12

HYPNOTICS AND ALTERED SLEEP DREAM PATTERNS: I. ALL-NIGHT EEG STUDIES OF GLUTETHIMIDE, METHYPRYLON, AND PENTOBARBITAL.
066233 05-14

HYPNOTICS AND ALTERED SLEEP DREAM PATTERNS: II. ALL-NIGHT EEG STUDIES OF CHLORAL HYDRATE, FLURAZEPAM, AND METHAQUALONE.
066234 05-14

ELECTRICAL IMPEDANCE CHANGES IN MANY SITES OF BRAIN IN PARADOXICAL SLEEP, ANESTHESIA AND ACTIVITY.
066474 05-03

BARBITURATE INDUCED SLEEP IN HYPERTHYROID MICE.
066935 05-05

A COMPARISON OF SLEEP PATTERNS IN NATURAL AND MANDRAX AND TUINAL INDUCED SLEEP.
067864 06-14

DIFFERENTIAL EFFECTS OF THREE TRICYCLIC ANTIDEPRESSANTS ON SLEEP AND REM SLEEP IN THE RAT.
067919 06-04

HEROIN AND HUMAN SLEEP.
067924 06-14

SLEEP AND DRUG OVERDOSE.
068007 06-15

TO SLEEP, PERCHANCE TO DREAM: NEW DRUG FOR INSOMNIACS DOESNT INTERFERE WITH REM TIME.
068021 06-14

INDUCTION BY CANNABIS-SATIVA (MARIHUANA) OF RHYTHMIC SPIKE DISCHARGES OVERRIDING REM SLEEP ELECTROCORTICOGRAM IN THE RAT.
069069 06-04

EFFECT OF L-DOPA ON THE SLEEP OF MAN.
070247 07-13

NEW FINDINGS IN THE CLINICAL PHARMACOLOGY OF SLEEP.
070925 07-17

MODIFICATION OF THE SCOPOLAMINE EFFECT BY SLEEP DEPRIVATION.
070933 07-14

THE EFFECT OF CENTROPHENOXINE ON EEG VIGILANCE IN THE COURSE OF SLEEP DEPRIVATION AND ON THE EEG PATTERN OF ALL-NIGHT SLEEP.
070934 07-14

SLEEP AND HYPNOTICS: FURTHER EXPERIMENTS.
072216 07-14

MECHANISM OF THE GAMMA-HYDROXYBUTYRATE INDUCED INCREASE IN BRAIN DOPAMINE AND ITS RELATIONSHIP TO SLEEP.
074865 08-04

BRIEF SLEEP TREATMENT WITH CHLORPROMAZINE.
075860 09-14

THE EFFECT OF ALPHA-METHYL-P-TYROSINE ON SLEEP AND AROUSAL IN THE RAT.
075891 09-04

THE PHARMACOLOGY OF DISORDERED SLEEP: A LABORATORY APPROACH.
084806 10-14

A POLYGRAPHIC STUDY OF THE NIGHT SLEEP OF PARKINSONIAN PATIENTS: EFFECTS OF TREATMENT WITH LEVODOPA.
087658 10-14

HIGH VOLTAGE SLOW WAVE INDUCED BY SHORT-CHAIN FATTY ACIDS WITH SPECIAL REFERENCE TO SLEEP RHYTHM.
088612 10-03

THE INFLUENCE OF IMIPRAMINE, DEXPHENMETRAZINE AND AMPHETAMINE SULPHATE ON SYNCHRONOUS AND PARADOXICAL SLEEP IN NARCOLEPSY CATAPLEXY. A POLYGRAPHIC EXAMINATION.
089037 10-14

EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND 2-BROM-D-LYSERGIC ACID DIETHYLAMIDE (BOL-148) UPON BEHAVIORAL SLEEP IN RATS.
089045 10-12

SLEEP IN PATIENTS WITH PARKINSONS DISEASE AND NORMAL SUBJECTS PRIOR TO AND FOLLOWING LEVODOPA ADMINISTRATION.
092974 11-11

COMPARATIVE STUDY OF NATURAL SLEEP AND THE ACTION OF PHENAMINE AND CHLORPROMAZINE EVALUATION OF THE MEAN EXTREMES FREQUENCY OF ECOG IN CATS.
095655 11-14

THE EFFECTS OF LEVOMEPROMAZINE ON THE NOCTURAL SLEEP EEG IN MAN.
129447 12-13

FATIGUE, SLEEP AND DREAMS.
133916 12-14

**SLEEPING**

EFFECT OF AMPHETAMINE ANALOGS ON DISRUPTION OF ANIMAL BEHAVIOR AND BARBITURATE SLEEPING TIME.
046196 01-03

RELATIONS BETWEEN BARBITURATE BRAIN LEVELS AND SLEEPING TIME IN VARIOUS EXPERIMENTAL CONDITIONS.
068600 06-03

SLEEPING PILLS.
081087 09-17

THE EFFECTS OF 4 HYPNOTIC DRUGS AND PLACEBO ON NORMAL SUBJECTS SLEEPING AND DREAMING AT HOME.
087863 10-06

SLEEPING PILLS AND TRANQUILIZER ABUSE.
129237 12-17

**SLICES**

THE EFFECT OF MORPHINE, NALORPHINE, NALOXONE, PENTAZOCINE, CYCLAZOCINE AND OXOTREMORINE ON THE SYNTHESIS AND RELEASE OF ACETYLCHOLINE BY MOUSE CEREBRAL CORTEX SLICES IN VITRO.
058994 03-03

RELEASE OF 5-HYDROXYTRYPTAMINE FROM SLICES OF SUPERIOR COLLICULUS BY OPTIC TRACT STIMULATION.
064369 04-03

EFFECTS OF DESMETHYLIMIPRAMINE AND COCAINE ON THE UPTAKE, RETENTION AND METABOLISM OF H3-TYRAMINE IN RAT BRAIN SLICES.
064419 04-03

ACETYLCHOLINE RELEASE FROM CORTICAL BRAIN SLICES OF RATS INJECTED WITH LITHIUM.
066509 05-03

DRUG-INDUCED RELEASE OF 3H-NOREPINEPHRINE AND 3H-SEROTONIN FROM BRAIN SLICES.
068290 06-03

**SLIGHT**

PSYCHOMOTOR REACTIONS TO A SLIGHT ALCOHOLEMIA. A COMPARATIVE STUDY ON DRINKERS AND NORMAL INDIVIDUALS.
085043 10-15

**SLOW**

A SOURCE OF ERROR IN CATECHOLAMINE TURNOVER STUDIES WITH LABELED DOPA: SLOW DISAPPEARANCE OF THE PRECURSOR.
074818 08-03

HIGH VOLTAGE SLOW WAVE INDUCED BY SHORT-CHAIN FATTY ACIDS WITH SPECIAL REFERENCE TO SLEEP RHYTHM.
088612 10-03

**SMALLER**

DRUG COMBINATION ALLOWS SMALLER DOSES OF L-DOPA.
066465 05-07

**SMOKE**

EFFECTS OF NICOTINE AND TOBACCO SMOKE ON THE ELECTRICAL ACTIVITY OF THE CEREBRAL CORTEX AND OLFACTORY BULB.
041567 01-03

SOME EFFECTS OF EXPERIMENTALLY PRODUCED CIGARETTE SMOKE ON THE GROWTH, VITAMIN-C METABOLISM AND ORGAN WEIGHTS OF GUINEA-PIGS.
063061 03-03

DIFFERENTIAL EFFECTS OF NICOTINE AND TOBACCO SMOKE ALKALOIDS ON SWIMMING ENDURANCE IN THE RAT.
069078 06-04
THE EFFECT OF NICOTINE AND TOTAL ALKALOIDS EXTRACTED FROM CIGARETTE SMOKE IN AVOIDANCE BEHAVIOR IN RATS UNDER EXTINCTION PROCEDURE.
069079 06-04

**SMOKING**
INHIBITION OF CIGARETTE SMOKING BY ORALLY ADMINISTERED NICOTINE.
066277 05-13
COMPARATIVE EFFECTS OF SMOKING MARIHUANA OR PLACEBO ON HUMAN MOTOR AND MENTAL PERFORMANCE.
069579 07-14
INHIBITION BY DRUGS OF SMOKING BEHAVIOUR IN MONKEYS.
095351 11-03

**SOCIAL**
THE EFFECT OF P-CHLOROPHENYLALANINE ON SOCIAL INTERACTION OF MALE RATS.
041541 01-04
SOCIAL IMPLICATIONS OF RECENT ADVANCES IN PSYCHOPHARMACOLOGY.
051572 02-17
ABNORMAL SOCIAL BEHAVIOR IN PHENYLKETONURIC MONKEYS.
060490 03-04
EPINEPHRINE AND NOREPINEPHRINE EFFECTS ON SOCIAL DOMINANCE BEHAVIOR.
069530 07-04
THE MARIHUANA INDUCED SOCIAL HIGH: NEUROLOGICAL AND ELECTROENCEPHALOGRAPHIC CONCOMITANTS.
074782 08-12
MORPHINE INDUCED FIGHTING AND PRIOR SOCIAL EXPERIENCE.
075206 08-04
THE EFFECT OF SOCIAL FEEDBACK ON CHRONIC SCHIZOPHRENIC PATIENTS.
075362 08-14
SOCIAL MEDICAL CLASSIFICATION OF TOXICOMANIAS.
079257 09-15
THE MEDICAL AND SOCIAL INDICATION OF ANTIANDROGEN THERAPY.
105733 12-11

**SOCIALIZATION**
MORPHINE AMPHETAMINE INDUCED FIGHTING AND INTERIM SOCIALIZATION.
076131 09-04
THE ETHOLOGICAL APPROACH TO SOCIALIZATION.
091173 11-04

**SOCIALLY**
ALTERATIONS IN BRAIN SENSITIVITY AND BARBITURATE METABOLISM UNRELATED TO AGGRESSION IN SOCIALLY DEPRIVED MICE.
069052 06-03

**SOCIETY**
DRUGS AND REALITY IN CAPTIVE SOCIETY. SOME OBSERVATIONS ON CHEMICAL ADAPTATION.
064091 04-17
ADDICTION AND SOCIETY.
079254 09-15

**SOCIOTHERAPY**
BEER SOCIOTHERAPY CAN BENEFIT AGED MENTAL PATIENTS.
064145 04-11

**SODIUM**
SODIUM BALANCE AND DISTRIBUTION IN LITHIUM CARBONATE THERAPY.
047828 01-09
JUMPING ACTIVITY INDUCED BY SODIUM 5-(1,3 DIMETHYLBUTYL)-5 ETHYL BARBITURATE. II. THE EFFECTS OF AGE DIFFERENCE.
058985 03-04
A COMPARISON OF SHORT-TERM TREATMENT EFFECTS OF INTRAVENOUS SODIUM AMYTAL METHEDRINE AND LSD IN THE ALCOHOLIC.
062934 03-11
SODIUM AMOBARBITAL, THE HIPPOCAMPAL THETA RHYTHM, AND THE PARTIAL REINFORCEMENT EXTINCTION EFFECT.
063333 03-03
THE SENSITIVITY OF THE BRAIN TO BARBITURATE DURING CHRONIC ADMINISTRATION AND WITHDRAWAL OF BARBITONE SODIUM IN THE RAT.
063980 04-03
BUTABARBITAL SODIUM AND CHLORDIAZEPOXIDE IN ANXIOUS NEUROTIC OUTPATIENTS: A COLLABORATIVE CONTROLLED STUDY.
066276 05-10
ALDOSTERONE AND SODIUM RESPONSE TO LITHIUM ADMINISTRATION IN MAN.
066493 05-13
PERSISTENT BEHAVIOURAL AND ELECTROENCEPHALOGRAPHIC CHANGES AFTER SINGLE DOSES OF NITRAZEPAM AND AMYLOBARBITONE SODIUM.
068005 06-14
EFFECTS OF AMOBARBITAL SODIUM ON THE ACQUISITION AND EXTINCTION OF A LEVER-PRESS SPATIAL DISCRIMINATION IN THE RAT.
069075 06-04
EFFECTS OF SODIUM DIPHENYLHYDANTOINATE AND PEMOLINE UPON CONCENTRATION: A COMPARATIVE STUDY.
070973 07-14
REINFORCING LIMBIC SYSTEM STIMULATION AND SODIUM AMYTAL.
075553 08-04
SODIUM DEFICIENCY AND LATENT LEARNING.
075915 09-04
A SEQUENTIAL TRIAL OF AMYLOBARBITONE SODIUM USED AS SEDATION FOR CONFUSED FEMALE PSYCHOGERIATRIC PATIENTS.
082732 10-11
THE EFFECTS OF ACUTE AND PROLONGED LITHIUM TREATMENT ON THE DISTRIBUTION OF ELECTROLYTES, POTASSIUM AND SODIUM.
088614 10-03
INFLUENCE OF SEVERAL AUTONOMIC DRUGS ON SODIUM NITROPRUSSIDE AND OXOTREMORINE INDUCED HYPOTHERMIA IN IMMATURE AND MATURE MICE.
089436 11-03

**SOLIDS**
TASTE PREFERENCES: AN APPARATUS FOR RANDOM AND SIMULTANEOUS PRESENTATION OF SEVERAL SOLIDS AND SOLUTIONS.
067892 06-06

**SOLUBILITIES**
MICELLAR SOLUBILIZATION OF BARBITURATES I: SOLUBILITIES OF CERTAIN BARBITURATES IN POLYSORBATES OF VARYING HYDROPHOBIC CHAIN LENGTH.
046136 01-17

**SOLUBILIZATION**
MICELLAR SOLUBILIZATION OF BARBITURATES I: SOLUBILITIES OF CERTAIN BARBITURATES IN POLYSORBATES OF VARYING HYDROPHOBIC CHAIN LENGTH.
046136 01-17

**SOLUTIONS**
TASTE PREFERENCES: AN APPARATUS FOR RANDOM AND SIMULTANEOUS PRESENTATION OF SEVERAL SOLIDS AND SOLUTIONS.
067892 06-06

**SOMAPSYCHIC**
SOMAPSYCHIC RELATIONS IN MEDICINE: SESSION OF HOMAGE OF THE PERUVIAN ACADEMY OF MEDICINE TO PROFESSOR HONORIO DELGADO.
094610 11-14

**SOMATIC**
EFFECTS OF DRUGS ON SOMATIC ACTIVITY AND HUMAN RESPONSES.
085757 10-13
USE OF NEUROLEPTICS FOR VITAL INDICATORS IN PATIENTS WITH SEVERE SOMATIC STATES.
111028 12-11

**SOMATO-SENSORY**
THE EFFECTS OF ALCOHOL ON VISUAL AND SOMATO-SENSORY EVOKED RESPONSES.
056925 02-14

**SORDINOL**
A TRIAL ON THE VALUE OF SORDINOL IN SCHIZOPHRENIA -- BY SUBJECTIVE METHOD AND PARTLY BY USING SEQUENTIAL ANALYSIS.
129451 12-08

**SOUND**
THE INFLUENCE OF 5-HYDROXYTRYPTOPHAN ON THE BEHAVIOR AND THE LEVEL OF MONOAMINES IN THE BRAIN OF RATS SENSITIVE TO SOUND.
098040 11-03

**SOUNDING**
INDOLEAMINES AND THE CENTRAL NERVOUS SYSTEM: A SOUNDING OF THEIR CLINICAL SIGNIFICANCE.
070881 07-13

**SOURCE**
A SOURCE OF ERROR IN CATECHOLAMINE TURNOVER STUDIES WITH LABELED DOPA: SLOW DISAPPEARANCE OF THE PRECURSOR.
074818 08-03

**SPACE**
TEMPERATURE RESPONSES AND OTHER EFFECTS OF 5-HYDROXYTRYPTOPHAN AND 5-HYDROXYTRYPTAMINE WHEN ACTING FROM THE LIQUOR SPACE IN UNANESTHETIZED RABBITS.
046404 01-03

**SPACED**
EFFECTS OF D-AMPHETAMINE AND CHLORDIAZEPOXIDE ON SPACED RESPONDING IN PIGEONS.
061597 03-04

**SPASMOPHILIA**
SPASMOPHILIA CAUSED BY MAGNESIUM DEFICIENCY.
063590 03-17

**SPATIAL**
ROLE OF MONKEYS SPATIAL PREFERENCES IN PERFORMANCE OF A NONSPATIAL TASK.
065420 05-04
EFFECTS OF AMOBARBITAL SODIUM ON THE ACQUISITION AND EXTINCTION OF A LEVER-PRESS SPATIAL DISCRIMINATION IN THE RAT.
069075 06-04

AN AUTOMATED MULTIPLE CHOICE TEST OF SHORT-TERM SPATIAL MEMORY FOR MONKEYS.
075917 09-04

**SPEAK**
SOME DOPE USERS SPEAK OUT.
070415 07-12

**SPECIES**
SPECIES DIFFERENCES IN DRUG METABOLISM.
051118 02-17
SPECIES DIFFERENCES IN DIAZEPAM METABOLISM -- I. METABOLISM OF DIAZEPAM METABOLITES.
064000 04-03
RELATIONSHIP BETWEEN DIFFERENCE SPECTRA AND METABOLISM: BARBITURATES, DRUG INTERACTION AND SPECIES DIFFERENCE.
064001 04-03
ACUTE ORAL TOXICITY OF CANNABINOIDS IN VARIOUS SPECIES (UNPUBLISHED PAPER).
088412 10-05
EFFECT OF PHENOBARBITAL ON THE IN VITRO METABOLISM OF DIAZEPAM IN SEVERAL ANIMAL SPECIES.
090134 11-03

**SPECIFIC**
SPECIFIC IRREVERSIBLE ENZYME INHIBITORS.
051115 01-17
SPECIFIC (IN THE SENSE OF INCREASED PREDISPOSITION TO INJURY OF THE SUBDOMINANT HEMISPHERE) DISTRIBUTION OF THE EXTRAPYRAMIDAL SYMPTOMS IN SCHIZOPHRENICS DURING THE COURSE OF HALOPERIDOL TREATMENT.
089106 10-15

**SPECIFICALLY**
PHARMACOLOGICAL STUDIES ON A NEW SPECIFICALLY POTENT ANTITUSSIVE AGENT, 14-HYDROXYDIHYDRO-6-BETA-THEBAINOL-4-METHYLETHER (OXYMETHEBANOL).
055585 02-03

**SPECIFICITY**
MAGNESIUM PEMOLINE: SPECIFICITY OF EFFECTS ON INSTRUMENTAL AVOIDANCE LEARNING.
058430 02-04
INTERFERENCE OF BARBITURATES WITH PYRIMIDINE INCORPORATION -- II: STRUCTURAL SPECIFICITY OF THE INHIBITION OF OROTATE UPTAKE IN BACILLUS-CEREUS.
064046 04-03
INVESTIGATIONS ON THE SPECIFICITY OF THE SO-CALLED ANALGESIC ACTIVITY OF NON-NARCOTIC DRUGS.
067254 06-04

**SPECTRA**
RELATIONSHIP BETWEEN DIFFERENCE SPECTRA AND METABOLISM: BARBITURATES, DRUG INTERACTION AND SPECIES DIFFERENCE.
064001 04-03
EFFECTS OF PHENOTHIAZINE DERIVATIVES ON BIOLOGICAL MEMBRANES: DRUG-INDUCED CHANGES IN ELECTRON SPIN RESONANCE SPECTRA FROM SPIN-LABELED ERYTHROCYTE GHOST MEMBRANES.
064423 04-03

**SPECTROPHOTOMETRIC**
SPECTROPHOTOMETRIC DETERMINATION OF CHLORPROMAZINE IN PHARMACEUTICAL DOSAGE FORMS.
064262 04-06

**SPEED**
SPEED, ACCURACY, AND STRENGTH OF FORELIMB MOVEMENT AFTER UNILATERAL PYRAMIDOTOMY IN RHESUS MONKEYS.
076213 09-04

**SPERMATOGENESIS**
EFFECTS OF TRIMEPRIMINE (SURMONTIL) ON SPERMATOGENESIS AND MOOD IN NORMAL VOLUNTEERS.
072147 07-14

**SPIKE**
BLOCKING OF EXPERIMENTAL SPIKE AND WAVE BY A LOCALIZED FOREBRAIN LESION.
066186 05-03
INDUCTION BY CANNABIS-SATIVA (MARIHUANA) OF RHYTHMIC SPIKE DISCHARGES OVERRIDING REM SLEEP ELECTROCORTICOGRAM IN THE RAT.
069069 06-04

**SPIN**
EFFECTS OF PHENOTHIAZINE DERIVATIVES ON BIOLOGICAL MEMBRANES: DRUG-INDUCED CHANGES IN ELECTRON SPIN RESONANCE SPECTRA FROM SPIN-LABELED ERYTHROCYTE GHOST MEMBRANES.
064423 04-03

**SPIN-LABELED**
EFFECTS OF PHENOTHIAZINE DERIVATIVES ON BIOLOGICAL MEMBRANES: DRUG-INDUCED CHANGES IN ELECTRON SPIN RESONANCE SPECTRA FROM SPIN-LABELED ERYTHROCYTE GHOST MEMBRANES.
064423 04-03

**SPINAL**
EFFECTS OF A CONVULSANT BARBITURATE ON THE SPINAL MONOSYNAPTIC PATHWAY.
066372 05-03
SPINAL FLUID CREATINE PHOSPHOKINASE ABNORMALITIES FOLLOWING LSD USAGE.
067213 06-15
THE ACTION OF TRYPTAMINE ON THE DOG SPINAL CORD AND ITS RELATIONSHIP TO THE AGONISTIC ACTIONS OF LSD-LIKE PSYCHOTOGENS.
090422 11-03

**SPLEEN**
EFFECTS OF METABOLIC INHIBITORS ON NOREPINEPHRINE RELEASE FROM THE PERFUSED SPLEEN OF THE CAT.
040244 01-03
METOCLOPRAMIDE AND THE MUSCULATURE OF ESOPHAGUS, STOMACH, INTESTINE, SPLEEN, TRACHEA, GALL AND URINARY BLADDERS: IN VITRO STUDIES.
055394 02-03
ON THE MECHANISM OF SUPERSENSITIVITY TO NOREPINEPHRINE IN THE DENERVATED CAT SPLEEN.
080336 09-03
EFFECT OF INTERMITTENT NERVE STIMULATION ON NOREPINEPHRINE SYNTHESIS AND MOBILIZATION IN THE PERFUSED CAT SPLEEN.
080337 09-01

**SPOFA**
VALUE OF AMITRIPTYLINE SPOFA IN THE PSYCHIATRIC OUTPATIENT AND INPATIENT PRACTICE.
070944 07-09
AGGRESSIVE BEHAVIOR OF RATS INDUCED BY MESORGYDINE (LYSENYL SPOFA).
070949 07-04
OXAZEPAM SPOFA, A NEW CZECHOSLOVAK THERAPEUTIC.
086209 10-17

**SPONTANEOUS**
EFFECTS OF DISULFIRAM AND DIETHYLDITHIOCARBAMATE ON SPONTANEOUS LOCOMOTOR ACTIVITY AND BRAIN CATECHOLAMINE LEVELS IN MICE.
064590 04-04
EFFECT OF AN ORAL CONTRACEPTIVE ON SPONTANEOUS RUNNING ACTIVITY OF FEMALE RATS.
067716 06-04
EFFECTS OF SCOPOLAMINE ON SPONTANEOUS ALTERNATION FOLLOWING FREE AND FORCED TRIALS.
067882 06-04
THE ACTION OF CENTRAL DEPRESSANT DRUGS ON THE SPONTANEOUS DISCHARGE OF ACTION POTENTIALS IN THE SUPERIOR CERVICAL SYMPATHETIC TRUNK OF THE CAT.
072034 07-03
EFFECTS OF 6-HYDROXYDOPAMINE ON CNS CATECHOLAMINES, SPONTANEOUS MOTOR ACTIVITY AND AMPHETAMINE INDUCED HYPERACTIVITY IN RATS.
074053 08-04
EATING, DRINKING AND SPONTANEOUS ACTIVITY IN RATS AFTER THE ADMINISTRATION OF CHLORPROMAZINE.
079999 09-04
INTERACTIONS BETWEEN THE EFFECTS OF CHLORDIAZEPOXIDE AND AMPHETAMINE ON FOOD INTAKE AND SPONTANEOUS MOTOR ACTIVITY IN THE RAT.
092692 11-04
DECREASE OF SPONTANEOUS MOTILITY IN EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY AND THE PROTECTIVE ACTIVITY OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126052 12-04

**SPREADING**
INTRASTRIATAL SPREADING OF BIOGENIC AMINES.
072471 08-03

**SQUID**
EFFECTS OF NARCOTICS ON THE GIANT AXON OF THE SQUID.
090147 11-03

**SQUIRREL**
A METHOD FOR CHRONIC INTRAVENOUS DRUG ADMINISTRATION IN SQUIRREL MONKEYS.
063725 04-06
THE EFFECTS OF D-AMPHETAMINE ON SCHEDULE CONTROLLED WATER LICKING IN THE SQUIRREL MONKEY.
071785 07-04
PITUITARY ADRENAL FUNCTION IN THE SQUIRREL MONKEY.
075665 08-03
HYPOTENSIVE EFFECTS OF CHLORDIAZEPOXIDE, AMOBARBITAL AND CHLORPROMAZINE ON BEHAVIORALLY INDUCED ELEVATED ARTERIAL BLOOD PRESSURE IN THE SQUIRREL MONKEY.
089999 11-04

**STABILITY**
LYSERGIC ACID DIETHYLAMIDE (LSD-25): XXXIX. THE EFFECT OF HIGH TEMPERATURES ON STABILITY.
064609 04-06
STABILITY OF PSYCHIC FUNCTIONS DURING PROLONGED CONFINEMENT TO BED.
086039 10-14

**STABILIZER**
LITHIUM CARBONATE AS A MOOD AND TOTAL BODY WATER STABILIZER.
047953 01-09

**STABLE**
THE EFFECTIVENESS OF SIMULTANEOUS TREATMENT WITH VITAMIN-B12 AND INSULIN IN SCHIZOPHRENIC PATIENTS, ACCORDING TO THE FREQUENCY OF STABLE REMISSIONS.
096513 11-08

**STAGE**
ELECTROGRAPHIC AND BEHAVIORAL EFFECTS OF DIAZEPAM DURING ALCOHOL WITHDRAWAL STAGE IN CATS.
072033 07-04

**STAGES**
ON THE QUESTION OF PERSONALITY DEFECTS OF CONSCIOUSNESS IN INITIAL STAGES IN SCHIZOPHRENIA.
090264 11-08

**STAIRCASE**
THE STAIRCASE MAZE AND THE SIMPLE STAIRCASE IN THE ANALYSIS OF THE PSYCHOPHARMACOLOGICAL ACTION OF CNS DEPRESSANTS.
068291 06-04

**STANDARD**
STATISTICAL METHOD OF ANALYSIS AND EVALUATION OF PSYCHOTHERAPEUTIC RESULTS: APPLICATION OF A LONG-ACTING NEUROLEPTIC, COMPARED WITH A STANDARD NEUROLEPTIC AND THE SAKEL INSULIN TREATMENT.
042676 01-07

THE INFLUENCES OF THE STANDARD PREFRONTAL LOBOTOMY OPERATION ON HALLUCINATORY PHENOMENA ASSOCIATED WITH PSYCHOTOMIMETIC DRUGS.
120899 12-13

**STAPHYLOCOCCAL**
EFFECTS OF STAPHYLOCOCCAL ENTEROTOXIN B ON COMPLEX OPERANT BEHAVIOR IN MONKEYS.
069333 06-04

**STARTLE**
STARTLE RESPONSE CIRCADIAN RHYTHM IN RATS: LACK OF CORRELATION WITH MOTOR ACTIVITY.
058349 02-04

P-CHLOROPHENYLALANINE AND HABITUATION TO REPETITIVE AUDITORY STARTLE STIMULI IN RATS.
063015 03-03

**STARVATION**
EFFECTS OF MORPHINE TREATMENT AND STARVATION ON THE SUBSTRATE INTERACTION WITH P-450 IN THE OXIDATION OF DRUGS BY LIVER MICROSOMES.
063982 04-03

**STARVED**
DEVELOPMENT OF FIGHTING BEHAVIOR IN STARVED RATS BY CHRONIC ADMINISTRATION OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL AND CANNABIS EXTRACTS: LACK OF ACTION OF OTHER PSYCHOTROPIC DRUGS.
072531 08-04

**STATE**
PERSONALITY DIFFERENCES IN THE RESPONSE TO STIMULANT DRUGS ADMINISTERED DURING A SLEEP DEPRIVED STATE.
052502 02-14

CORRELATION BETWEEN ACTIVITY AND ELECTRONIC STATE OF HALLUCINOGENIC AMPHETAMINES.
067199 06-06

PUPIL SIZE AND DRUG STATE IN A REACTION TIME TASK.
075161 08-13

OPTIMAL THERAPY OF THE ALCOHOL WITHDRAWAL STATE.
078429 09-17

STATE DRUG ABUSE CONTROL.
105336 12-17

RESEARCH ON THE DEFECT STATE OF SCHIZOPHRENIC PATIENT UNDER CONTROL OF PSYCHODRUGS.
129273 12-08

**STATE-DEPENDENT**
STATE-DEPENDENT LEARNING IN HUMANS.
058561 02-14

PENTOBARBITAL INDUCED STATE-DEPENDENT LEARNING OF ONE-WAY AVOIDANCE IN MICE.
075288 08-04

STATE-DEPENDENT RECOGNITION WITH METHYLPHENIDATE AND THIORIDAZINE IN RETARDED CHILDREN. (PH.D.DISSERTATION).
103301 12-14

**STATISTICAL**
STATISTICAL METHOD OF ANALYSIS AND EVALUATION OF PSYCHOTHERAPEUTIC RESULTS: APPLICATION OF A LONG-ACTING NEUROLEPTIC, COMPARED WITH A STANDARD NEUROLEPTIC AND THE SAKEL INSULIN TREATMENT.
042676 01-07

STUDIES ON INTERACTIONS INVOLVING ANTIDEPRESSIVE AND OTHER DRUGS WITH TETRABENAZINE AND NORADNAMINE ON LOCOMOTOR ACTIVITY IN MICE, INCLUDING DETAILS OF THE EXPERIMENTAL DESIGN AND STATISTICAL ANALYSIS.
069077 06-04

**STATUS-EPILEPTICUS**
THE EFFECT OF DIAZEPAM ON THE EEG OF STATUS-EPILEPTICUS.
064610 04-11

ARRESTING OF STATUS-EPILEPTICUS AND SERIAL SEIZURES BY AMYTAL CAFFEINE.
090349 11-11

**STELAZINE**
A COMBINED TREATMENT OF CHRONIC SCHIZOPHRENICS WITH OSPOLOT (SULTHIAME) AND STELAZINE (TRIFLUOPERAZINE).
089101 10-08

**STEP**
THIOTHIXENE AND TRIFLUOPERAZINE IN A STEP SYSTEM.
075421 08-08

**STEREOCHEMICAL**
STEREOCHEMICAL ASPECTS OF CENTRALLY ACTIVE COMPOUNDS. (PH.D. DISSERTATION).
137993 12-01

**STEREOSPECIFIC**
HASHISH: A STEREOSPECIFIC SYNTHESIS OF (-)-DELTA 1- AND (-)-DELTA 1(6) TETRAHYDROCANNABINOLS (UNPUBLISHED PAPER).
093550 11-01

**STEREOSTRUCTURE**
RELATIONSHIPS BETWEEN STEREOSTRUCTURE AND PHARMACOLOGICAL ACTIVITIES.
051116 01-17

**STEREOTACTIC**
AKINESIS FOLLOWING STEREOTACTIC SURGERY FOR PARKINSONISM – THE USE OF L-DOPA.
077404 09-16

**STEREOTYPE**
THE EFFECTS OF HALOPERIDOL AND CHLORPROMAZINE ON AMPHETAMINE METABOLISM AND AMPHETAMINE STEREOTYPE BEHAVIOR IN THE RAT.
064170 04-03

**STEREOTYPED**
STEREOTYPED BEHAVIOUR INDUCED BY (-) EPHEDRINE IN RATS.
074086 08-04

DRUG-INDUCED STEREOTYPED BEHAVIOR AND ITS ANTAGONISM IN DOGS.
079888 09-04

LESIONS IN CORPUS-STRIATUM AND CORTEX OF RAT BRAINS AND THE EFFECT ON PHARMACOLOGICALLY INDUCED STEREOTYPED, AGGRESSIVE AND CATALEPTIC BEHAVIOUR.
091127 11-04

**STEREOTYPY**
STUDIES OF STEREOTYPY FUNCTION IN THE CANARY (SERINUS-CANARIUS).
063634 04-03

**STEROID**
INHIBITORS OF ADRENAL STEROID BIOSYNTHESIS.
051122 02-17

EFFECT OF MORPHINE ADMINISTRATION ON THE HYDROXYLATION OF STEROID HORMONES BY RAT LIVER MICROSOMES.
066366 05-03

**STEROIDS**
THE EFFECT OF ORAL CONTRACEPTIVE STEROIDS ON BILE SECRETION AND BILIRUBIN TM IN RATS.
040125 01-05

**STILBOESTROL**
STUDY OF THE EFFECTS OF PROGESTERONE THERAPY ON THE STILBOESTROL INDUCED SENSITIVITY OF ISOLATED UTERI OF HYPOPHYSECTOMIZED RATS.
041540 01-03

**STIMULANT**
A NEW STIMULANT, PROLINTANE HYDROCHLORIDE, COMPARED WITH DEXTROAMPHETAMINE IN FATIGUED VOLUNTEERS.
040128 01-14

CENTRAL NERVOUS SYSTEM STIMULANT ACTION OF FENFLURAMINE IN RABBITS.
040639 01-03

PERSONALITY DIFFERENCES IN THE RESPONSE TO STIMULANT DRUGS ADMINISTERED DURING A SLEEP DEPRIVED STATE.
052502 02-14

STIMULANT SELF-ADMINISTRATION BY ANIMALS: SOME COMPARISONS WITH OPIATE SELF-ADMINISTRATION.
056237 02-04

PHARMACOLOGICAL PROPERTIES OF SU-19789F, A UNIQUE CENTRAL NERVOUS SYSTEM STIMULANT.
058989 03-03

ANTAGONISM OF D-AMPHETAMINE BY ALPHA-METHYL-L-TYROSINE: BEHAVIORAL EVIDENCE FOR THE PARTICIPATION OF CATECHOLAMINE STORES AND SYNTHESIS IN THE AMPHETAMINE STIMULANT RESPONSE.
064096 04-03

INITIAL SUPPRESSION OF THE LOCOMOTOR STIMULANT RESPONSE TO DEXAMPHETAMINE IN RATS EXPOSED TO A NOVEL ENVIRONMENT.
067601 06-04

THE USE OF STIMULANT DRUGS IN ENHANCING PERFORMANCE AND LEARNING.
070971 07-17

THE EFFECT OF EXTRAVERSION AND STIMULANT AND DEPRESSANT DRUGS ON VERBAL CONDITIONING.
078786 09-14

THE EFFECT OF A NEW METABOLIC CEREBRAL STIMULANT, CYPRODEMANOL, IN PSYCHIATRIC ASPECTS OF AGING.
089055 10-11

EFFECTS OF GENERAL STIMULANT DRUGS ON THE ELECTRICAL RESPONSES OF ISOLATED SLABS OF CATS CEREBRAL CORTEX.
090189 11-03

ROLE OF BRAIN SEROTONIN IN THE STIMULANT ACTION OF AMPHETAMINE.
098003 11-03

SEROTONINERGIC COMPONENT OF THE STIMULANT EFFECT OF CHOLINOLYTICS.
098058 11-03

**STIMULANTS**

A COMPARISON OF THE EFFECTS OF COCAINE AND SYNTHETIC CENTRAL STIMULANTS.
064272 04-17

IN DEFENSE OF STIMULANTS FOR HYPERKINETIC CHILDREN.
067059 05-11

CENTRAL NERVOUS SYSTEM STIMULANTS.
110226 12-17

**STIMULATED**

LONG-TERM VARIATION IN BASAL AND PHENOBARBITAL STIMULATED OXIDATIVE DRUG METABOLISM IN THE RAT.
040671 01-03

EFFECT OF CHLORPROMAZINE ON 5-HYDROXYTRYPTAMINE METABOLISM IN HIPPOCAMPAL STIMULATED RATS.
080338 09-01

**STIMULATING**

INHIBITION OF THE STIMULATING EFFECT OF METHAMPHETAMINE AND MORPHINE ON MOUSE BY INFLUENCING THE ENDOGENOUS CATECHOLAMINES.
055739 02-03

ENHANCEMENT OF IMIPRAMINE BY THYROID STIMULATING HORMONE; CLINICAL AND THEORETICAL IMPLICATIONS.
075871 09-10

**STIMULATION**

RELEASE OF NOREPINEPHRINE FROM ISOLATED RAT IRIS BY FIELD STIMULATION.
040245 01-03

STIMULATION OF DOPA-14C INCORPORATION INTO MELANOMA TISSUE BY CHLORPROMAZINE AND RESERPINE.
040584 01-03

A SIMPLE AND INEXPENSIVE CANNULA TECHNIQUE FOR CHEMICAL STIMULATION OF THE BRAIN.
058357 02-06

RETICULAR STIMULATION AND CHLORPROMAZINE: AN ANIMAL MODEL FOR SCHIZOPHRENIC OVERAROUSAL.
058531 02-04

P-CHLOROAMPHETAMINE: TEMPORAL RELATIONSHIP BETWEEN PSYCHOMOTOR STIMULATION AND METABOLISM OF BRAIN NOREPINEPHRINE.
062805 03-03

BEHAVIORAL AND VISCERAL REACTIONS ELICITED BY CHEMICAL STIMULATION OF THE HYPOTHALAMUS AND SEPTUM IN CATS.
064333 04-04

RELEASE OF 5-HYDROXYTRYPTAMINE FROM SLICES OF SUPERIOR COLLICULUS BY OPTIC TRACT STIMULATION.
064369 04-03

CONDITIONED SUPPRESSION BASED ON POSITIVELY REINFORCING INTRACRANIAL STIMULATION.
064842 05-02

ABBREVIATION OF BEHAVIORAL ESTRUS IN GUINEA-PIGS BY COITAL AND VAGINO-CERVICAL STIMULATION.
065332 05-03

INHIBITORY EFFECT OF PROPRANOLOL ON THE VASOCONSTRICTOR RESPONSE TO SYMPATHETIC NERVE STIMULATION.
066506 05-03

THE EFFECT OF INHIBITION OF CATECHOLAMINE SYNTHESIS ON DEXAMPHETAMINE INDUCED CENTRAL STIMULATION.
067259 06-04

RETICULAR STIMULATION AND CHLORPROMAZINE.
071997 07-04

COMPARATIVE EFFECTS OF AMPHETAMINE, SCOPOLAMINE, CHLORDIAZEPOXIDE, AND DIPHENYLHYDANTOIN ON OPERANT AND EXTINCTION BEHAVIOR WITH BRAIN STIMULATION AND FOOD REWARD.
074935 08-04

BEHAVIORAL CORRELATES OF CHEMICAL STIMULATION IN THE CAT THALAMUS.
075234 08-04

REINFORCING LIMBIC SYSTEM STIMULATION AND SODIUM AMYTAL.
075553 08-04

EFFECT OF INTERMITTENT NERVE STIMULATION ON NOREPINEPHRINE SYNTHESIS AND MOBILIZATION IN THE PERFUSED CAT SPLEEN.
080337 09-01

EVIDENCE FOR A CENTRAL NORADRENALINE RECEPTOR: STIMULATION BY CLONIDINE.
081151 09-03

PROJECT SUMMARY: ELECTRICAL AND CHEMICAL STIMULATION OF THE HYPOTHALAMUS.
085144 10-03

EFFECTS OF SELECTED DRUGS ON STIMULUS BOUND EMOTIONAL BEHAVIOR ELICITED BY HYPOTHALAMIC STIMULATION IN THE CAT.
088617 10-04

AMNESIA AND BRAIN SEIZURES ACTIVITY IN MICE: EFFECTS OF DIETHYL-ETHER ANESTHESIA PRIOR TO ELECTROSHOCK STIMULATION.
097952 11-04

**STIMULATORY**

DISAPPEARANCE IN RATS WITH SEPTAL LESIONS OF THE STIMULATORY EFFECT OF HYOSCINE ON EXPLORATORY BEHAVIOUR.
067605 06-04

COMPARATIVE STUDY OF CNS STIMULATORY ACTIVITY AND ANOREXIGENIC POTENCY OF PHENYLETHYLAMINE DERIVATIVES. (PH.D.DISSERTATION).
103710 12-04

**STIMULI**

P-CHLOROPHENYLALANINE AND HABITUATION TO REPETITIVE AUDITORY STARTLE STIMULI IN RATS.
063015 03-03

THE INTERACTION OF PSYCHOLOGIC STIMULI AND PHARMACOLOGIC AGENTS ON AIRWAY REACTIVITY IN ASTHMATIC SUBJECTS.
063515 03-13

RATE-DEPENDENT EFFECTS OF DRUGS: MODIFICATION BY DISCRIMINATIVE STIMULI OF THE EFFECTS OF AMOBARBITAL ON SCHEDULE CONTROLLED BEHAVIOR.
064749 05-04

INDIVIDUAL VARIATION IN AFFECTIVE RESPONSES TO TASTE STIMULI.
066710 05-14

THE EFFECTIVENESS OF EXTERNAL AND DRUG PRODUCED INTERNAL STIMULI IN THE DISCRIMINATIVE CONTROL OF OPERANT BEHAVIOR. (PH.D.DISSERTATION).
110682 12-04

**STIMULUS**

THE EFFECT OF MEDAZEPAM ON THE THRESHOLDS OF SUBCORTICAL LIMBIC STIMULUS RESPONSES, MEASURED IN UNANESTHETIZED, UNRESTRAINED CATS.
072067 07-03

LYSERGIC ACID DIETHYLAMIDE AND A NOVEL STIMULUS.
075282 08-04

THE EFFECTS OF DRUGS ON CONTINUOUS AVOIDANCE BEHAVIOR WITH A WARNING STIMULUS.
078402 09-04

EFFECTS OF SELECTED DRUGS ON STIMULUS BOUND EMOTIONAL BEHAVIOR ELICITED BY HYPOTHALAMIC STIMULATION IN THE CAT.
088617 10-04

SCOPOLAMINE EFFECTS ON GO-NO-GO AVOIDANCE DISCRIMINATIONS: INFLUENCE OF STIMULUS FACTORS AND PRIMACY OF TRAINING.
090418 11-04

ALCOHOL AS A DISCRIMINATIVE STIMULUS IN THE CONDITIONED EMOTIONAL RESPONSE. (PH.D.DISSERTATION).
103350 12-04

STIMULUS PROPERTIES OF ELECTROCONVULSIVE SHOCK IN GOLDFISH. (PH.D.DISSERTATION).
110906 12-04

**STOMACH**

METOCLOPRAMIDE AND THE MUSCULATURE OF ESOPHAGUS, STOMACH, INTESTINE, SPLEEN, TRACHEA, GALL AND URINARY BLADDERS: IN VITRO STUDIES.
055394 02-03

14C-5-HYDROXYTRYPTAMINE AND 3H-D-AMPHETAMINE: UPTAKE AND CONTRACTION BY THE RAT STOMACH FUNDUS IN VITRO.
064050 04-03

**STOMACHS**

THE EXCITATORY AND INHIBITORY INNERVATION OF THE STOMACHS OF THE DOMESTIC FOWL.
074854 08-03

**STOOL**

STOOL PORPHYRINS IN ACUTE INTERMITTENT AND HEREDITARY COPROPORPHYRIA: ADVERSE EFFECTS OF TRANQUILIZERS.
066318 05-15

**STOP**

LETS STOP LYING ABOUT DRUGS.
051530 02-13

**STORAGE**
THE EFFECTS OF ACIDOSIS ON CHRONOTROPIC RESPONSES, NOREPINEPHRINE STORAGE AND RELEASE IN ISOLATED GUINEA-PIG ATRIA.
040753 01-03
EFFECTS OF CHRONIC ADMINISTRATION OF NICOTINE ON STORAGE AND SYNTHESIS OF NORADRENALINE IN RAT BRAIN.
041552 01-03
DRUG EFFECTS UPON DATA PROCESSING AS FUNCTIONS OF STORAGE AND RETRIEVAL PARAMETERS.
065127 05-14
UPTAKE AND STORAGE MECHANISM OF 5-HYDROXYTRYPTAMINE IN RABBIT BRAINSTEM AND EFFECT OF RESERPINE.
114975 12-03

**STORES**
ANTAGONISM OF D-AMPHETAMINE BY ALPHA-METHYL-L-TYROSINE: BEHAVIORAL EVIDENCE FOR THE PARTICIPATION OF CATECHOLAMINE STORES AND SYNTHESIS IN THE AMPHETAMINE STIMULANT RESPONSE.
064096 04-03

**STORY**
THE BEYOND WITHIN: THE LSD STORY.
046725 01-12
LITHANE: THE STORY OF LITHIUM CARBONATE.
078106 09-17

**STP**
PRELIMINARY OBSERVATIONS ON THE METABOLISM OF (3)H-2,5-DIMETHOXY-4-METHYLAMPHETAMINE (STP, DOM).
046197 01-03
PHARMACOLOGICAL AND BEHAVIORAL STUDIES OF STP: RELATIONSHIP TO TISSUE DISTRIBUTION.
046198 01-03
BEHAVIORAL EFFECTS OF STP.
046199 01-14
EFFECTS OF DOM (STP) ON THE CHICK EMBRYO.
058974 03-05

**STRAIN**
STRAIN DIFFERENCES IN MORPHINE WITHDRAWAL INDUCED AGGRESSION IN RATS.
060857 03-03
STRAIN DIFFERENCES IN THE EFFECTS OF CHLORPROMAZINE AND CHLORDIAZEPOXIDE UPON ACTIVE AND PASSIVE AVOIDANCE IN MICE.
066828 05-04

**STRANGE**
THE STRANGE TRIP OF DR. HOFMANN.
081694 10-17

**STRENGTH**
SPEED, ACCURACY, AND STRENGTH OF FORELIMB MOVEMENT AFTER UNILATERAL PYRAMIDOTOMY IN RHESUS MONKEYS.
076213 09-04

**STRENGTHS**
A PARALLEL STUDY OF THE AMNESIC EFFECTS OF CYCLOHEXIMIDE AND ECS UNDER DIFFERENT STRENGTHS OF CONDITIONING.
066830 05-04

**STRESS**
STRESS RESPONSES AMONG NORMALS.
046313 01-14
THE ALTERATIONS OF PROTEIN METABOLISM OF THE BRAIN CORTEX INDUCED BY ANTICIPATION STRESS AND ACTH.
065434 05-03
REVERSIBLE LENTICULAR OPACITIES INDUCED IN RATS BY EMOTIONAL STRESS.
070823 07-03
THE ROLE OF METHYLAMPHETAMINE ON PLASMA HEXOSAMINE LEVEL UNDER STRESS.
074855 08-03
SWIM STRESS INDUCED INACTIVITY: RELATION TO BODY TEMPERATURE AND BRAIN NOREPINEPHRINE, AND EFFECTS OF D-AMPHETAMINE.
075275 08-03
STUDIES ON THE ROLE OF ACID IN THE PATHOGENESIS OF EXPERIMENTAL STRESS ULCERS.
075276 08-03
RELATIONS BETWEEN THE ELECTROGASTROGRAM AND GASTRIC ULCERATION DURING EXPOSURE TO STRESS.
075438 08-03
EXTINCTION OF THE EXCRETORY ALKALI METAL RESPONSE (EAMR) TO STRESS IN A REPTILE.
076068 09-03
DEXAMETHASONE SUPPRESSION IN BASIC TRAINEES UNDER STRESS.
086025 10-10
EFFECTS OF AN ACUTE STRESS OF FOREBRAIN 5-HYDROXYTRYPTAMINE (5-HT) METABOLISM IN CNS LESIONED AND DRUG PRETREATED RATS.
095671 11-04
INTERPERSONAL UNDERSTANDING, INTERPERSONAL STRESS AND CURRENT STATES: INTERRELATIONSHIPS AND TREATMENT ASSESSMENT. (PH.D. DISSERTATION).
103636 12-14

**STRIATAL**
INCREASED RELEASE OF DOPAMINE FROM STRIATAL DOPAMINERGIC TERMINALS IN THE RAT AFTER TREATMENT WITH A NEUROLEPTIC: THIOPROPERAZINE.
042742 01-03
MOTOR AND PSYCHOMOTOR ACTIVITY AND STRIATAL MONOAMINES.
086349 10-03

**STRIATUM**
DYNAMIC CHARACTERISTICS OF THE FUNCTIONAL COMPARTMENT OF DOPAMINE IN DOPAMINERGIC TERMINALS OF THE RAT STRIATUM.
120465 12-03

**STRIPS**
THE ANTAGONISM OF PHENTOLAMINE AGAINST EXOGENOUSLY ADMINISTERED AND ENDOGENOUSLY RELEASED NOREPINEPHRINE IN RABBIT AORTIC STRIPS.
040243 01-03

**STROKE**
HEAT STROKE IN PHENOTHIAZINE TREATED PATIENTS: A REPORT OF THREE FATALITIES.
076364 09-15

**STRUCTURAL**
INTERFERENCE OF BARBITURATES WITH PYRIMIDINE INCORPORATION -- II: STRUCTURAL SPECIFICITY OF THE INHIBITION OF OROTATE UPTAKE IN BACILLUS-CEREUS.
064046 04-03
NEW COMPOUNDS: STRUCTURAL ANALOGS RELATED TO ASARONE AND MESCALINE.
064264 04-01
THE STRUCTURAL AND BIOCHEMICAL BASIS OF MOVEMENT DISORDERS IN TREATMENT WITH NEUROLEPTIC DRUGS AND IN EXTRAPYRAMIDAL DISEASES.
067107 06-13
ANTIHEMOLYTIC ACTIONS OF TRICYCLIC TRANQUILIZERS: STRUCTURAL CORRELATIONS.
074862 08-03
STRUCTURAL BASIS OF LITHIUM PSYCHOPHARMACOLOGY: EXTRACELLULAR GROUND SUBSTANCE OF RAT BRAIN.
106783 12-03

**STRUCTURE**
WATER STRUCTURE IN ANESTHETIC ACTION: TIME-DEPENDENCE D20 EFFECTS ON NERVE.
055582 02-03
AN ELECTRON MICROSCOPIC STUDY OF AXONAL CHANGES IN THE CEREBELLUM OF DIPHENYLHYDANTOIN INTOXICATED RATS: THE FORMATION OF THE SO-CALLED HONEYCOMB STRUCTURE IN THE AXOPLASM.
070334 07-03

**STRUCTURE-ACTIVITY**
STRUCTURE-ACTIVITY RELATIONSHIP OF FOUR TETRAHYDROCANNABINOLS AND THE PHARMACOLOGICAL ACTIVITY OF FIVE SEMI-PURIFIED EXTRACTS OF CANNABIS-SATIVA.
064417 04-04
CORRELATIONS OF STRUCTURE-ACTIVITY OF MORPHINE-LIKE ANALGESICS USING REGRESSION ANALYSIS.
089042 10-01
STRUCTURE-ACTIVITY RELATIONSHIP AMONG HALLUCINOGENIC AGENTS.
115027 12-01

**STRUCTURES**
ON SIMILAR LINGUISTIC STRUCTURES IN CREATIVE PERFORMANCE AND PSILOCYBIN INDUCED EXPERIENCE.
065433 05-12
AN ANALYSIS OF RECEPTIVE STRUCTURES PARTICIPATING IN THE BEHAVIOR REACTIONS OF CATS INDUCED BY CATECHOLAMINES AND SEROTONIN.
073715 08-03
EFFECTS OF CHLORIMIPRAMINE ON ELECTRICAL ACTIVITIES OF SUBCORTICAL BRAIN STRUCTURES AND OF SYMPATHETIC NERVES.
079951 09-03

**STRYCHNINE**
STRYCHNINE EFFECTS ON DISCRIMINATION LEARNING IN MICE: EFFECTS OF DOSE AND TIME OF ADMINISTRATION.
069066 06-04
EXPERIMENTAL VARIABLES IN THE EFFECTS OF POSTSESSION INJECTIONS OF STRYCHNINE SULPHATE ON A CLASSICALLY CONDITIONED RESPONSE.
071792 07-04
STRYCHNINE AND SUPPRESSION OF EXPLORATION.
081149 09-04

**STUDENTS**
COMPARATIVE PHARMACOPSYCHOLOGICAL STUDY OF THE EFFECTS PRODUCED BY PSYCHOPHARMACEUTICALS ON VERBAL INTERACTION IN A GROUP OF STUDENTS.
066954 05-14

**SU-17595A**
THE USE OF SU-17595A IN THE TREATMENT OF PSYCHIATRIC DISORDERS.
064639 05-07

**SU-19789B**
PHARMACOLOGICAL PROPERTIES OF SU-19789B, A UNIQUE CENTRAL NERVOUS SYSTEM STIMULANT.
058989 03-03

**SUBACUTE**
PHARMACOLOGICAL STUDIES OF OXAZOLAZEPAM, A NEW PSYCHOTROPIC AGENT -- II. GENERAL PHARMACOLOGY AND SUBACUTE TOXICITY.
114835 12-07

THE SAFETY TEST OF L-DOPA. I. ACUTE AND SUBACUTE TOXICITY OF L-DOPA IN EXPERIMENTAL ANIMALS.
114837 12-05

**SUBCELLULAR**
MORPHINE AND THE INCORPORATION OF 32 ORTHOPHOSPHATE IN VIVO INTO PHOSPHOLIPIDS OF THE GUINEA-PIG CEREBRAL CORTEX, LIVER AND SUBCELLULAR FRACTIONS.
046401 01-03

EFFECTS OF RESERPINE AND DESIPRAMINE ON THE UPTAKE AND SUBCELLULAR DISTRIBUTION OF 5-HYDROXYTRYPTAMINE IN RABBIT BRAINSTEM AFTER INTRAVENOUS ADMINISTRATION OF 5-HYDROXYTRYPTOPHAN.
056610 02-03

**SUBCORTICAL**
THE EFFECT OF MEDAZEPAM ON THE THRESHOLDS OF SUBCORTICAL LIMBIC STIMULUS RESPONSES, MEASURED IN UNANESTHETIZED, UNRESTRAINED CATS.
072067 07-03

ON BINSWANGERS SUBCORTICAL ARTERIOSCLEROTIC ENCEPHALOPATHY AND THE POSSIBILITY OF ITS CLINICAL RECOGNITION.
078733 09-13

EFFECTS OF CHLORIMIPRAMINE ON ELECTRICAL ACTIVITIES OF SUBCORTICAL BRAIN STRUCTURES AND OF SYMPATHETIC NERVES.
079951 09-03

**SUBDOMINANT**
SPECIFIC (IN THE SENSE OF INCREASED PREDISPOSITION TO INJURY OF THE SUBDOMINANT HEMISPHERE) DISTRIBUTION OF THE EXTRAPYRAMIDAL SYMPTOMS IN SCHIZOPHRENICS DURING THE COURSE OF HALOPERIDOL TREATMENT.
089106 10-15

**SUBJECTIVE**
CORRELATION OF SUBJECTIVE SIDE-EFFECTS WITH PLASMA CONCENTRATIONS OF NORTRIPTYLINE.
082104 10-15

SUBJECTIVE EFFECTS OF NARCOTIC ANTAGONISTS CYCLAZOCINE AND NALORPHINE ON THE ADDICTION RESEARCH CENTER INVENTORY (ARCI).
097961 11-14

A TRIAL ON THE VALUE OF SORDINOL IN SCHIZOPHRENIA -- BY SUBJECTIVE METHOD AND PARTLY BY USING SEQUENTIAL ANALYSIS.
129451 12-08

**SUBJECTS**
EXPERIMENTAL PSYCHOLOGICAL STUDY OF PERFORMANCE CHANGES WITH PERAZINE (TAXILAN) IN MENTALLY DISTURBED AND IN HEALTHY EXPERIMENTAL SUBJECTS FOLLOWING REGIMEN AND SINGLE DOSE ADMINISTRATION.
058235 02-11

THE INTERACTION OF PSYCHOLOGIC STIMULI AND PHARMACOLOGIC AGENTS ON AIRWAY REACTIVITY IN ASTHMATIC SUBJECTS.
063515 03-13

BLOOD AND URINE CONCENTRATIONS OF SUBJECTS RECEIVING BARBITURATES, MEPROBAMATE, GLUTETHIMIDE, OR DIPHENYLHYDANTOIN.
063927 04-13

HYPNOTIC DRUGS AND THEIR EFFECTIVENESS: ALL-NIGHT EEG STUDIES OF INSOMNIAC SUBJECTS.
066235 05-14

THE EFFECTS OF 4 HYPNOTIC DRUGS AND PLACEBO ON NORMAL SUBJECTS SLEEPING AND DREAMING AT HOME.
087863 10-06

SLEEP IN PATIENTS WITH PARKINSONS DISEASE AND NORMAL SUBJECTS PRIOR TO AND FOLLOWING LEVODOPA ADMINISTRATION.
092974 11-11

**SUBNORMAL**
SUBNORMAL SERUM FOLATE DUE TO ANTICONVULSIVE THERAPY: A DOUBLE-BLIND STUDY OF THE EFFECT OF FOLIC ACID TREATMENT IN PATIENTS WITH DRUG INDUCED SUBNORMAL SERUM FOLATES.
042700 01-11

THE USE OF SULTHIAME WITH DISTURBED MENTALLY SUBNORMAL PATIENTS.
079215 09-11

**SUBSEQUENT**
EFFECTS OF REINFORCEMENT SHIFTS UPON SUBSEQUENT SUCROSE CONSUMPTION.
060871 03-03

TRANQUILIZERS IN THE TREATMENT OF THE CARDIAC NEUROTIC PATIENT AND THE SUBSEQUENT ALTERATION OF COMPLAINTS.
128568 12-14

**SUBSERVING**
CHANGES IN ENZYMES SUBSERVING CATECHOLAMINE METABOLISM IN MORPHINE TOLERANCE AND WITHDRAWAL IN RAT.
067324 06-03

**SUBSTANCE**
THE TREATMENT OF CHRONIC PAIN SYNDROMES: ANALGETIC EFFECT OF A NEUROLEPTIC SUBSTANCE.
079963 09-11

2-CHLORO-11-(4-METHYLPIPERAZINO) DIBENZOXAZEPINE), (SUM-3170), A NEW NEUROLEPTIC SUBSTANCE: RESULTS OF AN INTERCLINICAL STUDY.
079986 09-07

STRUCTURAL BASIS OF LITHIUM PSYCHOPHARMACOLOGY: EXTRACELLULAR GROUND SUBSTANCE OF RAT BRAIN.
106783 12-03

**SUBSTANTIA-NIGRA**
POSSIBLE DOPAMINERGIC PATHWAY FROM SUBSTANTIA-NIGRA TO PUTAMEN.
063983 04-03

**SUBSTITUTED**
THE EFFECT OF AMINOESTERS OF SUBSTITUTED GLYCOLIC AND ACETIC ACIDS ON THE CONTENT OF NORADRENALINE IN THE BRAIN OF RATS.
073717 08-03

SUBSTITUTED BENZAMIDES WITH POTENTIAL CNS DEPRESSANT AND HYPOTENSIVE ACTIVITY.
089435 11-02

INHIBITORS OF MONOAMINE OXIDASE VI: EFFECTS OF SUBSTITUTION ON INHIBITORY ACTIVITY OF 6 (OR 8) SUBSTITUTED BETA-CARBOLINES.
090426 11-01

**SUBSTITUTION**
THE EFFECT OF ALKYL SUBSTITUTION IN DRUGS.
070779 07-01

INHIBITORS OF MONOAMINE OXIDASE VI: EFFECTS OF SUBSTITUTION ON INHIBITORY ACTIVITY OF 6 (OR 8) SUBSTITUTED BETA-CARBOLINES.
090426 11-01

**SUBSTRATE**
EFFECTS OF MORPHINE TREATMENT AND STARVATION ON THE SUBSTRATE INTERACTION WITH P-450 IN THE OXIDATION OF DRUGS BY LIVER MICROSOMES.
063982 04-03

**SUCCESSES**
SUCCESSES AND FAILURES IN METHADONE MAINTENANCE TREATMENT OF HEROIN ADDICTION IN NEW-YORK CITY. (UNPUBLISHED PAPER).
071314 07-17

**SUCCESSIVE**
EQUIVALENCE OF SIMULTANEOUS AND SUCCESSIVE NEOCORTICAL ABLATIONS IN PRODUCTION OF IMPAIRMENTS OF RETENTION OF BLACK WHITE HABITS IN RATS.
076316 09-04

EFFECTS OF INSULIN, METRAZOL, AND ELECTROCONVULSIVE SHOCKS UPON LEARNING TO LEARN 30 SUCCESSIVE REVERSAL PROBLEMS BY RATS.
095188 11-04

**SUCCINATE**
ANTIPSYCHOTIC PROPERTIES OF LOXAPINE SUCCINATE.
058374 02-07

**SUCCINYLCHOLINE**
AVERSION THERAPY WITH SUCCINYLCHOLINE.
067412 06-07

**SUCROSE**
EFFECTS OF REINFORCEMENT SHIFTS UPON SUBSEQUENT SUCROSE CONSUMPTION.
060871 03-03

**SUDDEN**
A MECHANISM OF SUDDEN DEATH IN CHLORPROMAZINE THERAPY.
062351 03-15

SUDDEN DEATH IN PHENOTHIAZINE THERAPY: A CLINICOPATHOLOGIC STUDY OF 12 CASES.
062737 03-15

AMITRIPTYLINE AND CARDIAC DISEASE: RISK OF SUDDEN DEATH IDENTIFIED BY MONITORING SYSTEM.
070854 07-15

ELECTRON MICROSCOPY. SUDDEN DEATH IN PATIENTS UNDER PHENOTHIAZINE THERAPY: STUDY OF THREE CASES.
090359 11-15

**SUFFERING**
UNCONDITIONED REFLEX ACTIVITY IN THE RAT SUFFERING FROM EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY AND THE THERAPEUTIC EFFECT OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126051 12-04

**SUICIDE**
ATTEMPTED SUICIDE BY DRUG INGESTION.
063277 03-15

CLINICAL STUDY OF A PSYCHOTROPIC DRUG: SULPIRIDE IN ATTEMPTED SUICIDE WITHOUT PSYCHOSIS.
072155 07-14

SUICIDE AND PARANOID DEFENSE (PRELIMINARY REPORT).
113137 12-15

**SUITABLE**
LABORATORY EXPERIMENTS SUITABLE FOR PRACTICAL CLASSES IN PSYCHOPHARMACOLOGY.
067599 06-06

**SULFATE**
ALTERATIONS OF D-AMPHETAMINE SULFATE LETHALITY AND BODY TEMPERATURE IN MICE DURING ACUTE ALTITUDE EXPOSURE.
040582 01-03
MECHANISM OF THE RENAL TUBULAR TRANSPORT OF MORPHINE AND MORPHINE ETHEREAL SULFATE IN THE CHICKEN.
040754 01-03
COMPENSATORY SELECTION OF MAGNESIUM SULFATE BY MAGNESIUM DEPLETED LABORATORY RATS.
068287 06-04

**SULFOXIDE**
SYNTHESIS OF POSSIBLE METABOLITES OF CHLORPROMAZINE: IV. 7-HYDROXY-NOR1-CHLORPROMAZINE AND NOR2-CHLORPROMAZINE SULFOXIDE (UNPUBLISHED PAPER).
088358 10-01

**SULPHATE**
EXPERIMENTAL VARIABLES IN THE EFFECTS OF POSTSESSION INJECTIONS OF STRYCHNINE SULPHATE ON A CLASSICALLY CONDITIONED RESPONSE.
071792 07-04
THE INFLUENCE OF IMIPRAMINE, DEXPHENMETRAZINE AND AMPHETAMINE SULPHATE ON SYNCHRONOUS AND PARADOXICAL SLEEP IN NARCOLEPSY CATAPLEXY. A POLYGRAPHIC EXAMINATION.
089037 10-14

**SULPHOXIMINE**
THE EFFECT OF METHIONINE OF THE REGIONAL AND INTRACELLULAR DISPOSITION OF (3H) METHIONINE SULPHOXIMINE IN RAT BRAIN.
090148 11-03

**SULPIRIDE**
TESTING OF SULPIRIDE IN CHILD PSYCHIATRY.
067375 06-07
CLINICAL STUDY OF A PSYCHOTROPIC DRUG: SULPIRIDE IN ATTEMPTED SUICIDE WITHOUT PSYCHOSIS.
072155 07-14
CLINICAL TRIAL OF A NEW MOLECULE SULPIRIDE IN PSYCHIATRIC PRACTICE.
072156 07-15
SULPIRIDE IN PEDIATRICS.
072157 07-07
SULPIRIDE IN PSYCHIATRIC TREATMENT: CLINICAL AND PSYCHOMETRIC STUDY IN 58 PATIENTS.
072158 07-11
CLINICAL EXPERIENCE OF SULPIRIDE IN PSYCHIATRY.
072159 07-07
SULPIRIDE, A SINGULAR, ANTIAUTISTIC AND THYMOANALEPTIC NEUROLEPTIC.
089160 10-11

**SULTHIAME**
THERAPY OF PARTIAL EPILEPSY WITH A COMBINATION CONTAINING SULTHIAME.
055393 02-11
THE USE OF SULTHIAME WITH DISTURBED MENTALLY SUBNORMAL PATIENTS.
079215 09-11
A COMBINED TREATMENT OF CHRONIC SCHIZOPHRENICS WITH OSPOLOT (SULTHIAME) AND STELAZINE (TRIFLUOPERAZINE).
089101 10-08

**SUM-3170**
2-CHLORO-11-(4-METHYLPIPERAZINO) DIBENZOXAZEPINE), (SUM-3170), A NEW NEUROLEPTIC SUBSTANCE: RESULTS OF AN INTERCLINICAL STUDY.
079986 09-07

**SUPERIOR**
RELEASE OF 5-HYDROXYTRYPTAMINE FROM SLICES OF SUPERIOR COLLICULUS BY OPTIC TRACT STIMULATION.
064369 04-03
THE ACTION OF CENTRAL DEPRESSANT DRUGS ON THE SPONTANEOUS DISCHARGE OF ACTION POTENTIALS IN THE SUPERIOR CERVICAL SYMPATHETIC TRUNK OF THE CAT.
072034 07-03

**SUPERSENSITIVITY**
ON THE MECHANISM OF SUPERSENSITIVITY TO NOREPINEPHRINE IN THE DENERVATED CAT SPLEEN.
080336 09-03

**SUPPLEMENTARY**
EXPERIMENTAL EFFECTS OF AMPHETAMINE: SUPPLEMENTARY REPORT.
064968 05-04

**SUPPLEMENTS**
SALT SUPPLEMENTS WITH LITHIUM.
071968 07-15

**SUPPRESSING**
THE ROLE OF D-AMPHETAMINE AMOBARBITAL IN SUPPRESSING FREEZING BEHAVIOR DURING AVOIDANCE ACQUISITION AND EXTINCTION.
075882 09-04
SUPPRESSING WITHDRAWAL CONVULSIONS BY DEPAKINE IN ALCOHOLIC DETOXIFICATION CURES.
079858 09-11

**SUPPRESSION**
ALPHA-ADRENERGIC RECEPTORS IN HYPOTHALAMUS FOR THE SUPPRESSION OF FEEDING BEHAVIOR BY SATIETY.
060801 03-04
CONDITIONED SUPPRESSION BASED ON POSITIVELY REINFORCING INTRACRANIAL STIMULATION.
064842 05-02
CHLORDIAZEPOXIDE AND CONDITIONED SUPPRESSION.
066829 05-04
INITIAL SUPPRESSION OF THE LOCOMOTOR STIMULANT RESPONSE TO DEXAMPHETAMINE IN RATS EXPOSED TO A NOVEL ENVIRONMENT.
067601 06-04
SEROTONIN: A POSSIBLE MEDIATOR OF BEHAVIORAL SUPPRESSION INDUCED BY ANXIETY.
069311 06-04
SCOPOLAMINE EFFECTS ON CONDITIONED SUPPRESSION: INFLUENCE OF DIURNAL CYCLE AND TRANSITIONS BETWEEN NORMAL AND DRUGGED STATES.
071790 07-03
EFFECT OF ATROPINE DOSE LEVEL ON THE SUPPRESSION OF WATER REINFORCED VI RESPONDING.
075870 09-04
RESERPINE AND CONDITIONED SUPPRESSION IN THE FISH TILAPIA H. MACROCEPHALA.
075996 09-04
STRYCHNINE AND SUPPRESSION OF EXPLORATION.
081149 09-04
DEXAMETHASONE SUPPRESSION IN BASIC TRAINEES UNDER STRESS.
086025 10-10

**SUPRASTIN**
EFFECT OF CAPERS ON THE VASCULAR LUMEN OF ISOLATED EXTREMITIES OF SENSITIZED FROGS AND THE ANTIANAPHYLATIC EFFECT OF SUPRASTIN.
105720 12-03

**SURFACING**
ESTIMATION OF LOW CHLORPROMAZINE CONCENTRATIONS BY SURFACING AND SINKING REACTION OF MINNOWS (GAMBUSIA-AFFINIS).
097964 11-06

**SURGERY**
AKINESIS FOLLOWING STEREOTACTIC SURGERY FOR PARKINSONISM – THE USE OF L-DOPA.
077404 09-16

**SURMONTIL**
EFFECTS OF TRIMEPRIMINE (SURMONTIL) ON SPERMATOGENESIS AND MOOD IN NORMAL VOLUNTEERS.
072147 07-14

**SURPASS**
GALVESTON COUNTY STUDY SHOWS TRANQUILIZERS SURPASS ASPIRIN AS MEDICINAL POISONING AGENTS.
090070 11-15

**SURVEY**
A SURVEY OF ANTIANXIETY AGENTS USED OVER THE PAST 30 YEARS.
063594 03-10
A SURVEY OF EXTRAPYRAMIDAL MANIFESTATIONS IN PATIENTS ATTENDING AN AFTER CARE CLINIC OF A PSYCHIATRIC HOSPITAL.
070412 07-15
DRUGS, DIAGNOSES, AND OUTCOME OF DRUG TRIALS WITH NEUROTIC PATIENTS: A SURVEY.
075942 09-11
A SURVEY OF EXTRAPYRAMIDAL MANIFESTATIONS IN THE INPATIENT POPULATION OF A PSYCHIATRIC HOSPITAL.
086444 10-15

**SUSTAINED-RELEASE**
SUSTAINED-RELEASE TRANQUILIZER THERAPY IN HOSPITALIZED GERIATRIC PATIENTS.
059359 03-10
IN VIVO EVALUATION OF ABSORPTION AND EXCRETION OF PENTYLENETETRAZOL -10-14C FROM SUSTAINED-RELEASE AND NONSUSTAINED-RELEASE TABLETS.
090427 11-13
SUSTAINED-RELEASE LITHIUM CARBONATE.
106768 12-09

**SWIM**
SWIM STRESS INDUCED INACTIVITY: RELATION TO BODY TEMPERATURE AND BRAIN NOREPINEPHRINE, AND EFFECTS OF D-AMPHETAMINE.
075275 08-03

**SWIMMING**
DIFFERENTIAL EFFECTS OF NICOTINE AND TOBACCO SMOKE ALKALOIDS ON SWIMMING ENDURANCE IN THE RAT.
069078 06-04

**SWINE**
PERINATAL DEVELOPMENT OF DRUG METABOLIZING ENZYME ACTIVITY IN SWINE.
066368 05-03

**SWITCH**
THE SWITCH PROCESS FROM DEPRESSION TO MANIA: RELATIONSHIP TO DRUGS WHICH ALTER BRAIN AMINES.
067585 06-09

**SYMPATHETIC**
MONOAMINES AND MONOAMINE OXIDASE IN DENERVATED SYMPATHETIC GANGLIA OF THE CAT.
040756 01-03
A NOVEL APPROACH TO THE INVESTIGATION OF NOREPINEPHRINE METABOLISM IN HUMAN SYMPATHETIC NERVE.
064144 04-03
MECHANISMS BY WHICH AMPHETAMINE AND DESIPRAMINE INHIBIT THE METARAMINOL INDUCED RELEASE OF NOREPINEPHRINE FROM SYMPATHETIC NERVE ENDINGS IN RAT HEART.
064427 04-03
INHIBITORY EFFECT OF PROPRANOLOL ON THE VASOCONSTRICTOR RESPONSE TO SYMPATHETIC NERVE STIMULATION.
066506 05-03
THE ACTION OF CENTRAL DEPRESSANT DRUGS ON THE SPONTANEOUS DISCHARGE OF ACTION POTENTIALS IN THE SUPERIOR CERVICAL SYMPATHETIC TRUNK OF THE CAT.
072034 07-03
THE EFFECT OF ESERINE ON THE EFFERENT NEURONAL ACTIVITY IN THE CERVICAL SYMPATHETIC OF THE RAT.
074133 08-03
PHASE DIFFERENCE IN THE INDUCTION OF TYROSINE HYDROXYLASE IN CELL BODY AND NERVE TERMINALS OF SYMPATHETIC NEURONES.
075715 08-03
DRUG-INDUCED SYMPATHETIC AROUSAL AND NEUROTICISM.
075779 08-13
EFFECTS OF CHLORIMIPRAMINE ON ELECTRICAL ACTIVITIES OF SUBCORTICAL BRAIN STRUCTURES AND OF SYMPATHETIC NERVES.
079951 09-03
THE CENTRAL SYMPATHETIC DEPRESSIVE EFFECT OF RESERPINE, ALPHA-METHYLDOPA AND CLONIDINE.
089046 10-03
POSSIBLE LOCI OF ACTION OF 2-ETHYL-ETHYLAMINO-6-METHOXY-S-TRIAZINE FOR ELECTROENCEPHALOGRAPHIC AND SYMPATHETIC ACTIVATION IN CAT.
089788 11-13
ENHANCEMENT BY DESIPRAMINE OF HYPOTHALAMICALLY EVOKED DISCHARGES IN PREGANGLIONIC SYMPATHETIC NERVES.
097962 11-03

**SYMPATHOMIMETIC**
AN EVALUATION OF THE VASODILATION PRODUCED BY MEPHENTERMINE AND CERTAIN OTHER SYMPATHOMIMETIC AMINES.
040311 01-03
TREATMENT OF NARCOLEPSY WITH MONOAMINE OXIDASE INHIBITORS AND SYMPATHOMIMETIC AGENTS.
058327 02-13
INTERACTIONS BETWEEN SYMPATHOMIMETIC AMINES AND A NEW MONOAMINE OXIDASE INHIBITOR.
064406 04-07
INTRANEURONAL AND EXTRANEURONAL ACCUMULATION OF SYMPATHOMIMETIC AMINES IN THE ISOLATED NICTITATING MEMBRANE OF THE CAT.
066363 05-03
EFFECTS OF SYMPATHOMIMETIC AMINES INJECTED INTO THE THIRD CEREBRAL VENTRICLE IN ADULT CHICKENS.
072030 07-03
EFFECT OF GANGLIONIC BLOCKING AGENTS ON PRESSOR EFFECTS OF SYMPATHOMIMETIC AMINES OF DIRECT AND INDIRECT ACTION.
110632 12-03

**SYMPOSIUM**
INTERNATIONAL SYMPOSIUM ON AMPHETAMINES AND RELATED COMPOUNDS.
107549 12-13
DRUGS, BRAIN AND BEHAVIOUR: PROCEEDINGS OF SYMPOSIUM ON PSYCHOPHARMACOLOGY IN DURHAM.
129564 12-17

**SYMPTOM**
D-CYCLOSERINE THERAPY OF PSYCHOSIS BY SYMPTOM PROVOCATION.
075313 08-08

**SYMPTOMATIC**
PSYCHOLOGICAL METHODS APPLIED TO EVALUATE SYMPTOMATIC GERIATRIC TREATMENT.
064152 04-14
DRUG, DOCTOR WARMTH, AND CLINIC SETTING IN THE SYMPTOMATIC RESPONSE TO MINOR TRANQUILIZERS.
087386 10-10

**SYMPTOMS**
CONTROLLED STUDIES OF ANTIPARKINSONISM AGENTS IN THE TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL SYMPTOMS.
063777 04-14
MENTAL SYMPTOMS IN PARKINSONIAN PATIENTS TREATED WITH L-DOPA.
066490 05-15
TRIALS OF RO-5-3350 AND DIAZEPAM FOR ANXIETY SYMPTOMS.
066826 05-07
ENCEPHALITIS WITH CATATONIC SCHIZOPHRENIC SYMPTOMS.
069822 07-08
TREATMENT OF PSYCHOSOMATIC DISTURBANCES ASSOCIATED WITH PSYCHIC SYMPTOMS IN INTERNAL MEDICINE BY MEANS OF DOXEPIN.
072381 07-09
CHANGES IN PSYCHOLOGICAL SYMPTOMS IN WOMEN TAKING ORAL CONTRACEPTIVES.
075470 08-13
TREATMENT OF DEPRESSIONS ACCORDING TO TARGET SYMPTOMS.
078732 09-09
MENTAL SYMPTOMS IN PARKINSONIAN PATIENTS TREATED WITH L-DOPA.
081082 09-15
PSYCHIC SYMPTOMS IN L-DOPA TREATMENT OF PARKINSONS DISEASE.
087659 10-09
SPECIFIC (IN THE SENSE OF INCREASED PREDISPOSITION TO INJURY OF THE SUBDOMINANT HEMISPHERE) DISTRIBUTION OF THE EXTRAPYRAMIDAL SYMPTOMS IN SCHIZOPHRENICS DURING THE COURSE OF HALOPERIDOL TREATMENT.
089106 10-15
EVALUATING CHANGES IN SYMPTOMS DURING ACUTE ALCOHOL WITHDRAWAL.
094978 11-11
EFFECTS OF PROPRANOLOL (INDERAL) ON PSYCHIATRIC SYMPTOMS IN CHRONIC ALCOHOLISM.
099957 11-11
PROPHYLACTIC ACTION OF LITHIUM SALTS AND THYROID HORMONES ON SYMPTOMS OF MANIC-DEPRESSIVE AND AFFECTIVE PSYCHOSES: CLINICAL AND EXPERIMENTAL RESULTS.
106774 12-09

**SYNAPTIC**
CYCLIC AMP MEDIATION OF NOREPINEPHRINE INHIBITION IN RAT CEREBELLAR CORTEX: A UNIQUE CLASS OF SYNAPTIC RESPONSES (UNPUBLISHED PAPER).
093132 11-03

**SYNAPTOSOMAL**
ASSOCIATION OF BROMIDE WITH THE SYNAPTOSOMAL FRACTION OF MOUSE BRAIN.
070521 07-01

**SYNCHRONOUS**
THE INFLUENCE OF IMIPRAMINE, DEXPHENMETRAZINE AND AMPHETAMINE SULPHATE ON SYNCHRONOUS AND PARADOXICAL SLEEP IN NARCOLEPSY CATAPLEXY. A POLYGRAPHIC EXAMINATION.
089037 10-14

**SYNDROME**
GOODPASTURE SYNDROME AND THE EFFECTS OF BENZENE.
056060 02-15
COMBINED ADRENAL AND THYROID DEFICIENCY (SCHMIDTS SYNDROME) PRESENTING AS AN ACUTE PSYCHOSIS.
056350 02-15
PSYCHOPHARMACODYNAMICS OF NEUROLEPTICS. ORGANIZATION EFFECTS OF THE PARANOID SYNDROME.
059039 03-17
THE ANXIETY DEPRESSION SYNDROME.
063567 03-10
AMPHETAMINE INTOXICATION WITH COAGULOPATHY, HYPERTHERMIA, AND REVERSIBLE RENAL FAILURE: A SYNDROME RESEMBLING HEATSTROKE.
064236 04-15
PSYCHOPHARMACOLOGY AND GENERAL ADAPTATION SYNDROME.
065346 05-17
THE USE OF HALOPERIDOL FOR GILLES-DE-LA-TOURETTES SYNDROME.
067264 06-14
TREATMENT OF PARKINSONS SYNDROME WITH L-DIHYDROXYPHENYLALANINE (LEVODOPA).
067666 06-07
PREVENTION OF PAROXYSMAL TACHYCARDIA OF WOLFF-PARKINSON-WHITE SYNDROME WITH COMBINED PROPRANOLOL AND QUINIDINE THERAPY.
070288 07-10
PREDICTION OF CHANGES IN SEVERITY OF THE SCHIZOPHRENIC SYNDROME WITH DISCONTINUATION AND ADMINISTRATION OF PHENOTHIAZINES IN CHRONIC SCHIZOPHRENIC PATIENTS: LANGUAGE AS A PREDICTOR AND MEASURE OF CHANGE IN SCHIZOPHRENIA.
075321 08-08
LITHIUM INDUCED DIABETES-INSIPIDUS LIKE SYNDROME.
075426 08-10
CONTRIBUTION TO THE STUDY OF THE EXTRAPYRAMIDAL SYNDROME WITH ANIMAL EXPERIMENTATION. THE ROLE OF CALCIUM AND O-METHYLENE DERIVATIVES.
086348 10-03
ON GILLES-DE-LA-TOURETTES SYNDROME: SUCCESSFUL TREATMENT WITH HALOPERIDOL IN THREE CASES.
088610 10-11

MOTIVATIONAL DEPRESSION ASSOCIATED WITH NOREPINEPHRINE INDUCED EATING FROM THE HYPOTHALAMUS: RESEMBLANCE TO THE VENTROMEDIAL HYPERPHAGIC SYNDROME.
090473 11-04

OBSERVATIONS ON THE NEUROLEPTIC SYNDROME.
091501 11-08

PIGMENTARY RETINOPATHY AND PARANOIC SYNDROME. (PRESENTATION OF ONE CASE).
124309 12-08

**SYNDROMES**

COMBINED THERAPY IN ANXIETY DEPRESSIVE SYNDROMES: I. COMPARATIVE EFFECTS OF LIMBITROL (CHLORDIAZEPOXIDE AMITRIPTYLINE) AND PLACEBO.
064312 04-10

CLINICAL EXPERIENCE WITH OCTOCLOTHEPINE IN MANIC SYNDROMES.
070927 07-09

NEUROPSYCHOTROPIC DRUGS IN THE TREATMENT OF SO-CALLED PAIN SYNDROMES.
079962 09-17

THE TREATMENT OF CHRONIC PAIN SYNDROMES: ANALGETIC EFFECT OF A NEUROLEPTIC SUBSTANCE.
079963 09-11

CLINICAL TREATMENT OF DEPRESSIVE SYNDROMES WITH NOXIPTILIN.
079967 09-10

A STUDY OF DEHYDROBENZPERIDOL (R-4749) IN THE TREATMENT OF DYSTHYMIC SYNDROMES.
092077 11-09

EFFECTS OF NORTRIPTYLINE IN THE TREATMENT OF DEPRESSION SYNDROMES.
093133 11-09

USE OF MELLERIL RETARD IN TREATMENT OF PATIENTS WITH DEPRESSIVE PARANOID AND ANXIOUS DEPRESSIVE SYNDROMES.
109724 12-14

EFFECT OF AMANTADINE ON THE EXTRAPYRAMIDAL SYNDROMES INDUCED BY NEUROLEPTICS.
112131 12-09

DEXAMETHASONE IN DEPRESSIVE SYNDROMES.
134902 12-09

**SYNERGISM**

OBSERVATION OF THE GROOMING BEHAVIOR OF RESERPINIZED WHITE MICE AS A METHOD FOR INVESTIGATING RESERPINE ANTAGONISM AND SYNERGISM.
065442 05-04

SYNERGISM BETWEEN COBALT AND ETHANOL ON RAT GROWTH RATE.
088600 10-03

SYNERGISM OF DESMETHYLIMIPRAMINE WITH RESERPINE AND 5-HYDROXYTRYPTOPHAN IN THE FROG: BRAIN SEROTONIN AND ADRENALINE AND BEHAVIOR.
098042 11-03

**SYNHEXYL**

DELTA1-TETRAHYDROCANNABINOL, SYNHEXYL AND MARIJUANA EXTRACT ADMINISTERED ORALLY IN MAN: CATECHOLAMINE EXCRETION, PLASMA CORTISOL LEVELS AND PLATELET SEROTONIN CONTENT.
075841 08-12

**SYNTHESIS**

ANALOGS OF ALPHA-METHYLPHENETHYLAMINE (AMPHETAMINE). I. SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF SOME METHOXY AND/OR METHYL ANALOGS.
038488 01-04

AZABICYCLO CHEMISTRY. I. SYNTHESIS OF 1,5-METHANO-7-METHOXY-2,3,4,5-TETRAHYDRO-1H-2- BENZAZEPINES. B-NORBENZOMORPHANS.
038489 01-01

EFFECTS OF CHRONIC ADMINISTRATION OF NICOTINE ON STORAGE AND SYNTHESIS OF NORADRENALINE IN RAT BRAIN.
041552 01-03

INHIBITION OF THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN RATS BY DRUGS WHICH INHIBIT RIBONUCLEIC ACID OR PROTEIN SYNTHESIS.
041570 01-03

THE EFFECT OF MORPHINE, NALORPHINE, NALOXONE, PENTAZOCINE, CYCLAZOCINE AND OXOTREMORINE ON THE SYNTHESIS AND RELEASE OF ACETYLCHOLINE BY MOUSE CEREBRAL CORTEX SLICES IN VITRO.
058994 03-03

PROJECT SUMMARY: SYNTHESIS OF POTENTIAL PSYCHOTROPIC AGENTS.
062435 03-01

ANTAGONISM OF D-AMPHETAMINE BY ALPHA-METHYL-L-TYROSINE: BEHAVIORAL EVIDENCE FOR THE PARTICIPATION OF CATECHOLAMINE STORES AND SYNTHESIS IN THE AMPHETAMINE STIMULANT RESPONSE.
064096 04-03

SYNTHESIS OF SOME GLYCIDIC HYDRAZIDES AND AMIDES AS POTENTIAL PSYCHOTROPIC AGENTS AND ANTICHOLINERGIC AGENTS.
064258 04-01

EFFECTS OF MORPHINE AND PENTOBARBITONE ON ACETYLCHOLINE SYNTHESIS BY RAT CEREBRAL CORTEX.
064288 04-03

THE EFFECT OF PROLONGED LITHIUM TREATMENT ON THE SYNTHESIS RATE AND TURNOVER OF MONOAMINES IN BRAIN REGIONS OF RATS.
066413 05-03

EFFECT OF APOMORPHINE AND PIMOZIDE ON SYNTHESIS AND TURNOVER OF LABELED CATECHOLAMINES IN MOUSE BRAIN.
066502 05-03

THE EFFECT OF INHIBITION OF CATECHOLAMINE SYNTHESIS ON DEXAMPHETAMINE INDUCED CENTRAL STIMULATION.
067259 06-04

REDUCTION OF ELECTRICALLY REWARDED BEHAVIOR BY INTERFERENCE WITH MONOAMINE SYNTHESIS.
069065 06-04

SYNTHESIS OF ADAMANTYL ESTERS.
073265 08-01

THE NEUROLEPTICS: AN INTERDISCIPLINARY ATTEMPT OF SYNTHESIS, BASED ON THE NEUROLEPTICS.
075115 08-14

EFFECT OF INTERMITTENT NERVE STIMULATION ON NOREPINEPHRINE SYNTHESIS AND MOBILIZATION IN THE PERFUSED CAT SPLEEN.
080337 09-01

FURTHER STUDIES ON THE EFFECTS OF BLOCKING AGENTS ON PROTEIN SYNTHESIS IN GOLDFISH BRAIN.
083170 10-03

SYNTHESIS OF POSSIBLE METABOLITES OF CHLORPROMAZINE: IV. 7-HYDROXY-NOR1-CHLORPROMAZINE AND NOR2-CHLORPROMAZINE SULFOXIDE (UNPUBLISHED PAPER).
088358 10-01

CARDIAC CATECHOLAMINE SYNTHESIS, TURNOVER, AND METABOLISM WITH ISOPROTERENOL INDUCED MYOCYTOLYSIS (UNPUBLISHED PAPER).
088374 10-03

THE SYNTHESIS AND BIOLOGICAL ACTIVITY OF (-)-DELTA9(11)-TRANS TETRAHYDROCANNABINOL; A NEW PROCEDURE FOR THE CLEAVAGE OF PHENYL METHYL ETHERS (UNPUBLISHED PAPER).
092888 11-01

EFFECT OF DRUGS ON CATECHOLAMINE SYNTHESIS (UNPUBLISHED PAPER).
092889 11-13

HASHISH: A STEREOSPECIFIC SYNTHESIS OF (-)-DELTA 1- AND (-)-DELTA 1(6) TETRAHYDROCANNABINOLS (UNPUBLISHED PAPER).
093550 11-01

SYNTHESIS OF POSSIBLE METABOLITES OF CHLORPROMAZINE. III. 7,8 DISUBSTITUTED CHLORPROMAZINE DERIVATIVES.
094623 11-01

ON THE ROLE OF BRAIN CATECHOLAMINES IN MOTOR ACTIVITY: EXPERIMENTS WITH INHIBITORS OF SYNTHESIS AND OF MONOAMINE OXIDASE.
097960 11-04

INVESTIGATION INTO THE POSSIBLE INFLUENCE OF CHLORINATED AMPHETAMINE DERIVATIVES ON 5-HYDROXYTRYPTAMINE SYNTHESIS IN MAN.
097963 11-13

**SYNTHESIZED**

DAILY RHYTHM IN THE ACCUMULATION OF BRAIN CATECHOLAMINES SYNTHESIZED FROM CIRCULATING H3-TYROSINE.
040246 01-03

EFFECT OF TWO RECENTLY SYNTHESIZED PHENOTHIAZINE DERIVATIVES UPON EXPERIMENTAL CARDIAC ARRHYTHMIAS.
114978 12-03

**SYNTHETIC**

PHARMACOLOGICAL STUDIES ON THE ACTION OF SYNTHETIC ALPHA-METHYL-PYRRYL-KETONE ON THE CNS AND ON CIRCULATION.
055740 02-03

SYNTHETIC DRUGS USED AND ABUSED.
058070 02-14

A COMPARISON OF THE EFFECTS OF COCAINE AND SYNTHETIC CENTRAL STIMULANTS.
064272 04-17

**SYRUP**

USE OF AMITRIPTYLINE SYRUP IN THE TREATMENT OF ENURESIS IN CHILDREN.
062407 03-11

**SYSTEMATIC**

THE PLACE OF THIOTHIXENE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS. A SYSTEMATIC CLINICAL STUDY.
075422 08-08

**SYSTEMS**

COMPARISON OF LIVER MICROSOME ENZYME SYSTEMS AND BARBITURATE SLEEP TIMES IN RATS CAGED INDIVIDUALLY OR COMMUNALLY.
045545 01-06

EFFECT OF AGENTS INTERACTING WITH CHOLINOREACTIVE AND ADRENOREACTIVE SYSTEMS ON EPILEPTIFORM ACTIVITY IN THE HIPPOCAMPUS OF RABBITS.
110631 12-03

**T-BUTYLAMINO**
EFFECT OF DESMETHYLIMIPRAMINE, IPRINDOLE AND DL-ERYTHRO-ALPHA-(3,4 DICHLOROPHENYL)-BETA-(T-BUTYLAMINO) PROPANOL HCL ON THE METABOLISM OF AMPHETAMINE.
074866 08-03

**TABLET**
STUDY ON THE EFFECTS OF TABLET COLOUR IN THE TREATMENT OF ANXIETY STATES.
066496 05-10

**TABLETS**
IN VIVO EVALUATION OF ABSORPTION AND EXCRETION OF PENTYLENETETRAZOL -10-14C FROM SUSTAINED-RELEASE AND NONSUSTAINED-RELEASE TABLETS.
090427 11-13

**TACHYCARDIA**
CHEMICAL CONSTITUTION AND DRUG ACTION OF N-SUBSTITUTED PHENOTHIAZINE IN VENTRICULAR ECTOPIC TACHYCARDIA.
063981 04-03
PREVENTION OF PAROXYSMAL TACHYCARDIA OF WOLFF-PARKINSON-WHITE SYNDROME WITH COMBINED PROPRANOLOL AND QUINIDINE THERAPY.
070288 07-10

**TACITIN**
EFFECTS OF BENZOCTAMINE (30803-BA, TACITIN), A NEW PSYCHOACTIVE DRUG, ON CATECHOLAMINE METABOLISM.
074861 08-03

**TAIL-FLICK**
THE EFFECT OF VARIOUS NEUROHUMORAL MODULATORS ON THE ACTIVITY OF MORPHINE AND THE NARCOTIC ANTAGONISTS IN THE TAIL-FLICK AND PHENYLQUINONE TESTS.
069594 07-04

**TALWIN**
ACUTE ORGANIC PSYCHOSIS DUE TO TALWIN (PENTAZOCINE).
058951 02-15

**TAPE**
TELEVISION TAPE FOR EVALUATION OF TREATMENT RESPONSE.
063568 03-17

**TARASAN**
CLINICAL EXPERIENCE WITH TARASAN AND THIORIDAZINE IN MENTALLY RETARDED CHILDREN – A COMPARATIVE DOUBLE-BLIND STUDY.
097655 11-14

**TARDIVE**
HIGH DOSES OF TRIFLUOPERAZINE AND TARDIVE DYSKINESIA.
042699 01-15
TARDIVE DYSKINESIA.
090170 11-15

**TARGET**
TREATMENT OF DEPRESSIONS ACCORDING TO TARGET SYMPTOMS.
078732 09-09
DEPRESSIVE STATES AS A PHARMACOLOGICAL TARGET.
122378 12-17

**TASK**
INFLUENCE OF DISPLAY, TASK, AND ORGANISMIC VARIABLES ON INDICES OF MONITORING BEHAVIOR.
043270 01-17
ROLE OF MONKEYS SPATIAL PREFERENCES IN PERFORMANCE OF A NONSPATIAL TASK.
065420 05-04
PUPIL SIZE AND DRUG STATE IN A REACTION TIME TASK.
075161 08-13

**TASTE**
INDIVIDUAL VARIATION IN AFFECTIVE RESPONSES TO TASTE STIMULI.
066710 05-14
TASTE PREFERENCES: AN APPARATUS FOR RANDOM AND SIMULTANEOUS PRESENTATION OF SEVERAL SOLIDS AND SOLUTIONS.
067892 06-06
RELATIONSHIP BETWEEN TASTE THRESHOLD FOR DRUGS AND CLINICAL PROGRESS IN A MIXED GROUP OF PSYCHIATRIC PATIENTS.
087866 10-11

**TAT-3**
ON THE SITES OF ANTITUSSIVE ACTION OF N-(2-PICOLYL)-N-PHENYL-N-(2-PIPERIDINOETHYL)AMINE (TAT-3).
055586 02-03

**TAXILAN**
EXPERIMENTAL PSYCHOLOGICAL STUDY OF PERFORMANCE CHANGES WITH PERAZINE (TAXILAN) IN MENTALLY DISTURBED AND IN HEALTHY EXPERIMENTAL SUBJECTS FOLLOWING REGIMEN AND SINGLE DOSE ADMINISTRATION.
058235 02-11

**TEA**
THE PINK-SPOT, 3,4 DIMETHOXYPHENYLETHYLAMINE, COMMON TEA, AND SCHIZOPHRENIA.
062783 03-13

**TEAM**
U-M TEAM ISSUES WARNING ON USE OF DRUG.
058527 02-15

**TECHNIQUE**
A SIMPLE AND INEXPENSIVE CANNULA TECHNIQUE FOR CHEMICAL STIMULATION OF THE BRAIN.
058357 02-06
A CHOICE TECHNIQUE TO ASSESS THE EFFECTS OF SELECTIVE PUNISHMENT ON FIXED-RATIO PERFORMANCE.
075579 08-04
A TECHNIQUE TO DEMONSTRATE THE EFFECT OF A PSYCHOPHARMACEUTICAL DRUG IN A PSYCHOPATHOLOGICAL LONGITUDINAL SECTION BY NUMERIC AND GRAPHIC MEANS.
079973 09-06
THE USEFULNESS OF PLACEBO AND THE DOUBLE-BLIND TECHNIQUE IN THE EVALUATION OF PSYCHOTROPIC DRUGS.
089054 10-17
THE USE OF NARCO-ANALYSIS IN DIAGNOSTIC PSYCHIATRIC TECHNIQUE.
093537 11-14

**TECHNIQUES**
PSYCHOPHARMACOLOGY IN CHILDREN: PROBLEM AREAS, METHODOLOGICAL CONSIDERATIONS, ASSESSMENT TECHNIQUES.
080350 09-17

**TEENAGERS**
DRUG MISUSE IN TEENAGERS.
054715 02-12

**TEGRETAL**
TEGRETAL: THE PROBLEM OF PSYCHOTROPIC ACTION.
067739 06-14

**TEGRETOL**
EVALUATION OF TEGRETOL IN THE TREATMENT OF BEHAVIOUR DISORDERS IN CHILDREN: METHODOLOGY AND RESULTS.
080098 09-07

**TELEMETRIC**
INTRAGASTRIC TELEMETRIC MEASURING OF PH DURING THYMOLEPTIC MEDICATION.
081143 09-13

**TELEVISION**
TELEVISION TAPE FOR EVALUATION OF TREATMENT RESPONSE.
063568 03-17

**TEMENTIL**
THERAPEUTIC MEDICATION IN CHRONIC DELIRIUM: COMBINATION OF PROCHLORPERAZINE (TEMENTIL) AND LEVOMEPROMAZINE (NOZINAN).
079288 09-11

**TEMPERATURE**
EFFECT OF ENVIRONMENTAL TEMPERATURE ON THE TOXICITY OF CAFFEINE AND DEXTROAMPHETAMINE IN MICE.
040028 01-05
ALTERATIONS OF D-AMPHETAMINE SULFATE LETHALITY AND BODY TEMPERATURE IN MICE DURING ACUTE ALTITUDE EXPOSURE.
040582 01-03
TEMPERATURE RESPONSES AND OTHER EFFECTS OF 5-HYDROXYTRYPTOPHAN AND 5-HYDROXYTRYPTAMINE WHEN ACTING FROM THE LIQUOR SPACE IN UNANESTHETIZED RABBITS.
046404 01-03
CENTRAL EFFECTS OF 6-HYDROXYDOPAMINE ON THE BODY TEMPERATURE OF THE RAT.
073069 08-03
SWIM STRESS INDUCED INACTIVITY: RELATION TO BODY TEMPERATURE AND BRAIN NOREPINEPHRINE, AND EFFECTS OF D-AMPHETAMINE.
075275 08-03
THE INFLUENCE OF A FEAR EVOKING SITUATION ON THE RECTAL TEMPERATURE OF RATS.
082409 10-03
TEMPERATURE INCREASES UNDER TREATMENT WITH PSYCHOPHARMACEUTICALS.
097999 11-15
INFLUENCE OF HAPLOPHYLLUM ALKALOIDS ON THE BODY TEMPERATURE OF ANIMALS.
105721 12-03
CHANGES OF THE BODY TEMPERATURE OF CODEINE TOLERANT RATS BY THE ADMINISTRATION OF NALORPHINE.
130427 12-03

**TEMPERATURES**
LYSERGIC ACID DIETHYLAMIDE (LSD-25): XXXIX. THE EFFECT OF HIGH TEMPERATURES ON STABILITY.
064609 04-06

**TEMPORAL**
P-CHLOROAMPHETAMINE: TEMPORAL RELATIONSHIP BETWEEN PSYCHOMOTOR STIMULATION AND METABOLISM OF BRAIN NOREPINEPHRINE.
062805 03-03
TEMPORAL DISINTEGRATION AND DEPERSONALIZATION DURING MARIHUANA INTOXICATION.
066232 05-14
MARIHUANA AND TEMPORAL DISINTEGRATION.
071998 07-14
EFFECTS OF INSTRUCTIONS AND DRUG ADMINISTRATION ON TEMPORAL RESOLUTION OF PAIRED FLASHES.
075771 08-14

**TENDENCIES**
PERSISTENCE OF RELAPSE TENDENCIES OF RATS PREVIOUSLY MADE PHYSICALLY DEPENDENT ON MORPHINE.
062940 03-04

**TENDENCY**
TESTING THE PERFORMANCE UNDER APONEURON OF OTHERWISE NORMAL SCHOOL CHILDREN WITH A TENDENCY TOWARD REDUCED DRIVE AND EASY TIRING.
080563 09-11

**TENSION**
PHARMACOTHERAPY OF TENSION AND ANXIETY.
126180 12-14

**TERATOGENIC**
LSD: NO TERATOGENIC ACTION IN RATS, MICE, AND HAMSTERS.
063993 04-03
TERATOGENIC EFFECT OF LITHIUM CARBONATE IN THE FETAL MOUSE.
089398 10-05

**TERATOGENICITY**
TESTING DRUGS FOR TERATOGENICITY AND THEIR EFFECTS ON FERTILITY; THE PRESENT POSITION.
057605 02-05
SIDE-EFFECTS AND TERATOGENICITY OF LITHIUM CARBONATE TREATMENT.
069580 07-15

**TERATOLOGICAL**
PHARMACOLOGICAL, TOXICOLOGICAL, AND TERATOLOGICAL STUDIES ON DIPOTASSIUM 7-CHLORO-3-CARBOXY 1,3-DIHYDRO-2,2-DIHYDROXY-5-PHENYL-2H-1,4 BENZODIAZEPINE CHLORAZEPATE (DIPOTASSIUM CHLORAZEPATE, 4306-CB), A NEW TRANQUILLIZER.
055581 02-03

**TERMINALS**
INCREASED RELEASE OF DOPAMINE FROM STRIATAL DOPAMINERGIC TERMINALS IN THE RAT AFTER TREATMENT WITH A NEUROLEPTIC: THIOPROPERAZINE.
042742 01-03
UPTAKE AND RETENTION OF 3H-NORADRENALINE IN ADRENERGIC NERVE TERMINALS AFTER RESERPINE AND AXOTOMY.
066499 05-03
PHASE DIFFERENCE IN THE INDUCTION OF TYROSINE HYDROXYLASE IN CELL BODY AND NERVE TERMINALS OF SYMPATHETIC NEURONES.
075715 08-03
DYNAMIC CHARACTERISTICS OF THE FUNCTIONAL COMPARTMENT OF DOPAMINE IN DOPAMINERGIC TERMINALS OF THE RAT STRIATUM.
120465 12-03

**TERMINOLOGY**
CONCEPTS, DEFINITIONS, TERMINOLOGY.
079255 09-15

**TEST**
A POTENTIAL SCREENING TEST FOR MINOR TRANQUILLIZING DRUG ACTION.
051651 02-06
THE PSYCHOPHARMACOLOGICAL TREATMENT OF CARDIAC NEUROTIC PATIENTS WITH DIPOTASSIUM CHLORAZEPATE IN THE DOUBLE-BLIND TEST.
055689 02-10
PSYCHOMETRIC AND PSYCHOPHYSIOLOGICAL TEST IN THE PREDICTION OF THERAPEUTIC RESPONSIVENESS IN THE SCHIZOPHRENIAS.
062643 03-08
ORGANIC INTEGRITY TEST (OIT) IN MONITORING DRUG EFFECTS.
063596 04-08
VALIDITY OF ANTAGONISM OF DIFFERENT EFFECTS OF RESERPINE AS TEST FOR ANTIDEPRESSANT ACTIVITY.
064413 04-03
RELATIONSHIPS OF THE MECHOLYL TEST, PREMORBID ASOCIAL FUNCTIONING AND LONG-TERM OUTCOME IN SCHIZOPHRENIA.
075227 08-08
AN AUTOMATED MULTIPLE CHOICE TEST OF SHORT-TERM SPATIAL MEMORY FOR MONKEYS.
075917 09-04
VISUAL THRESHOLD AS A FUNCTION OF TEST AREA AND CAFFEINE ADMINISTRATION.
076016 09-13
COMBINATION TEST ON THE ANALGESIC EFFECT OF DEXTROPROPOXYPHENE AND SOME PSYCHOTROPIC DRUGS IN THE MOUSE.
079961 09-03
THE EFFECT OF PSYCHOSTIMULANTS ON PSYCHOMETRIC TEST PERFORMANCE WITH SPECIAL REFERENCE TO CONFLICT AVOIDANCE BEHAVIOR.
082055 10-04
TEST OF PEMOLINUM IN COMPLEX TREATMENT OF ALCOHOLISM.
086958 10-11
RESEARCH ON NEW METHODS OF EXPERIMENTATION WITH PSYCHOTROPIC DRUGS. RESULTS OF A TEST WITH A NEW TRANQUILIZER, NOBRIUM, IN TWO INDEPENDENT INVESTIGATIONS.
086984 10-16
CORRELATION BETWEEN THE CHANGES OF EEG, PUPILLES AND BLOOD PRESSURE DUE TO INTRAVENOUS INJECTION OF CHLORPROMAZINE: CHLORPROMAZINE TEST.
088611 10-13
5-HYDROXYTRYPTOPHAN PRODUCED HYPOTHERMIA IN MICE AS A TEST FOR PHARMACOLOGICAL DIFFERENTIATION OF ANTIDEPRESSANTS, ANTICHOLINERGICS AND NEUROLEPTICS: SOME DATA ON THE NATURE OF THIS HYPOTHERMIA.
105622 12-06
THE SAFETY TEST OF L-DOPA -- II. EFFECT OF L-DOPA ON THE DEVELOPMENT OF PRENATAL AND POSTNATAL OFFSPRINGS OF EXPERIMENTAL ANIMALS.
114836 12-02
THE SAFETY TEST OF L-DOPA. I. ACUTE AND SUBACUTE TOXICITY OF L-DOPA IN EXPERIMENTAL ANIMALS.
114837 12-05

**TESTING**
CLINICAL AND PSYCHOLOGICAL TESTING OF A GERIATRIC DRUG.
042693 01-11
TESTING DRUGS FOR TERATOGENICITY AND THEIR EFFECTS ON FERTILITY; THE PRESENT POSITION.
057605 02-05
UNITED-STATES PROCEDURES FOR SCREENING DRUGS: TESTING FOR DEPENDENCE LIABILITY IN ANIMALS AND MAN.
058971 03-02
TESTING OF SULPIRIDE IN CHILD PSYCHIATRY.
067375 06-07
THE CLINICAL TESTING OF HYDROTHIADENE IN ENDOGENOUS DEPRESSIONS. INFLUENCE OF DRUGS ON PHOTOMYOCLONIC THRESHOLD.
070940 07-09
CLINICAL AND AMBULANT TESTING WITH FLUPHENAZINE DECANOATE LYOGEN DEPOT IN THE LONG-TERM TREATMENT OF PSYCHIATRIC DISEASE.
080040 09-16
TESTING THE PERFORMANCE UNDER APONEURON OF OTHERWISE NORMAL SCHOOL CHILDREN WITH A TENDENCY TOWARD REDUCED DRIVE AND EASY TIRING.
080563 09-11
CLINICAL RESULTS OF THE TESTING FOR ANALGESIC EFFECT OF DEXTROPROPOXYPHENE IN COMBINATION WITH A PSYCHOTROPIC PREPARATION (TROPAX).
081147 09-17
CONTRIBUTION TO THE USE OF MULTIVARIATE ANALYSIS IN THERAPEUTIC TESTING.
085343 10-11
CHANGES IN BEHAVIOUR WITH REPEATED TESTING UNDER THE INFLUENCE OF DRUGS: DRUG EXPERIENCE INTERACTIONS.
091997 11-04
CLINICAL TESTING WITH FLUPHENAZINE DEPOT ADMINISTRATION TO SCHIZOPHRENIC PATIENTS.
101034 12-07

**TESTOSTERONE**
EFFECTS OF NEONATAL TESTOSTERONE ON THE ACQUISITION OF AN ACTIVE AVOIDANCE RESPONSE IN GENOTYPICALLY FEMALE RATS.
075890 09-04
UPTAKE OF TRITIATED TESTOSTERONE IN BRAIN AND PERIPHERAL TISSUES OF NORMAL AND NEONATALLY ANDROGENIZED FEMALE RATS.
076086 09-04
INDUCTION OF RECEPTIVITY IN FEMALE RATS AND CATS WITH ESTROGEN AND TESTOSTERONE.
081228 09-04

**TESTS**
THE PREDICTIVE VALUE FOR MAN OF TOXICOLOGICAL TESTS OF DRUGS IN LABORATORY ANIMALS.
057607 02-05
THE EFFECT OF VARIOUS NEUROHUMORAL MODULATORS ON THE ACTIVITY OF MORPHINE AND THE NARCOTIC ANTAGONISTS IN THE TAIL-FLICK AND PHENYLQUINONE TESTS.
069594 07-04
CLINICAL, CLINICO-CHEMICAL AND BRAIN BIOELECTRIC TESTS OF A COMBINATION OF HEXOBENDINE, ETHAMIVAN AND HYDROXYETHYLTHEOPHYLLIN.
072585 08-14
CLINICAL TESTS OF A NEW, PROLONGED ACTION NEUROLEPTIC AGENT, PIMOZIDE.
079863 09-07
CLINICAL TESTS OF A NEW ANXIOLYTIC, MEDAZEPAM (NOBRIUM).
079864 09-11
PSYCHOMETRIC TESTS IN EVALUATION OF BRAIN PATHOLOGY, RESPONSE TO DRUGS.
081043 09-14
TESTS OF A NEW ANXIOLYTIC: THE USE OF DOXEPINE IN GERIATRIC CASES.
086236 10-07
CLINICAL TESTS OF PIRIDOXILATE IN PSYCHIATRIC THERAPY.
091500 11-07

CLINICAL TESTS OF THIOTHIXENE, NEUROLEPTIC DISINHIBITER.
091502 11-08
THE PERFORMANCE OF LSD USERS ON CERTAIN NEUROPSYCHOLOGICAL TESTS. (PH.D. DISSERTATION).
135186 12-14

**TETANUS**
SECONDARY IMMUNE RESPONSE TO TETANUS TOXOID IN PSYCHIATRIC PATIENTS.
075412 08-13

**TETRABENAZINE**
EFFECTS OF LITHIUM PRETREATMENT ON AMPHETAMINE AND DMI TETRABENAZINE PRODUCED PSYCHOMOTOR BEHAVIOR.
062521 03-04
STUDIES ON INTERACTIONS INVOLVING ANTIDEPRESSIVE AND OTHER DRUGS WITH TETRABENAZINE AND NORADNAMINE ON LOCOMOTOR ACTIVITY IN MICE, INCLUDING DETAILS OF THE EXPERIMENTAL DESIGN AND STATISTICAL ANALYSIS.
069077 06-04

**TETRAETHYLTHIURAM**
ELECTROCARDIOGRAPHIC DATA IN CHRONIC ALCOHOLISM BEFORE, DURING AND AFTER TREATMENT WITH TETRAETHYLTHIURAM DISULPHIDE.
092481 11-14

**TETRAHYDROCANNABINOL**
PSYCHOLOGICAL EFFECTS OF TETRAHYDROCANNABINOL.
047832 01-12
THE SYNTHESIS AND BIOLOGICAL ACTIVITY OF (-)-DELTA9(11)-TRANS TETRAHYDROCANNABINOL; A NEW PROCEDURE FOR THE CLEAVAGE OF PHENYL METHYL ETHERS (UNPUBLISHED PAPER).
092888 11-01

**TETRAHYDROCANNABINOLS**
STRUCTURE-ACTIVITY RELATIONSHIP OF FOUR TETRAHYDROCANNABINOLS AND THE PHARMACOLOGICAL ACTIVITY OF FIVE SEMI-PURIFIED EXTRACTS OF CANNABIS-SATIVA.
064417 04-04
HASHISH: A STEREOSPECIFIC SYNTHESIS OF (-)-DELTA 1- AND (-)-DELTA 1(6) TETRAHYDROCANNABINOLS (UNPUBLISHED PAPER).
093550 11-01

**TETRAHYDROISOQUINOLINE**
BIOSYNTHESIS OF PHENOLIC TETRAHYDROISOQUINOLINE ALKALOIDS OF PEYOTE.
069804 07-01

**TETRAZOLE**
CONVULSANT ACTIONS OF TETRAZOLE DERIVATIVES.
064177 04-03

**TEXTBOOK**
PSYCHOPHARMACOLOGY: INTRODUCTION TO GENERAL PSYCHOLOGY: A SELF-SELECTION TEXTBOOK.
047681 01-17

**THALAMUS**
BEHAVIORAL CORRELATES OF CHEMICAL STIMULATION IN THE CAT THALAMUS.
075234 08-04

**THALIDOMIDE**
EFFECTS OF THALIDOMIDE AND CHLORCYCLIZINE ON THE BIOSYNTHESIS OF NUCLEIC ACIDS AND PROTEINS IN FETAL AND MATERNAL TISSUES OF THE RAT.
040027 01-05

**THEOPHYLLINE**
RELEASE OF NOREPINEPHRINE IN THE CENTRAL NERVOUS SYSTEM BY THEOPHYLLINE AND CAFFEINE.
066411 05-03
THEOPHYLLINE: INDUCTION OF SELF-BITING IN RABBITS.
075236 08-04

**THEORETICAL**
ENHANCEMENT OF IMIPRAMINE BY THYROID STIMULATING HORMONE; CLINICAL AND THEORETICAL IMPLICATIONS.
075871 09-10
PSYCHOTROPIC DRUG SIDE-EFFECTS: CLINICAL AND THEORETICAL PERSPECTIVES.
100516 12-15
LONG-TERM DRUG THERAPY IN AFFECTIVE DISORDERS: THEORETICAL AND METHODOLOGICAL ISSUES IN CURRENT RESEARCH ON LITHIUM.
106765 12-09
CLINICAL CONTROVERSIES AND THEORETICAL MODE OF ACTION OF LITHIUM CARBONATE.
106767 12-13

**THEORY**
A PRAGMATIC THEORY OF MEPROBAMATE EFFECTS.
046314 01-17
THE PREFERRED CONFORMATION OF DOPAMINE FROM MOLECULAR ORBITAL THEORY.
090068 11-13

**THERAPEUTIC**
CONTROLLED STUDIES OF THERAPEUTIC EFFECT.
046315 01-11
THE MANY FACES OF MANIA: THERAPEUTIC TRIAL OF LITHIUM CARBONATE.
047919 01-09
A METHOD OF IDENTIFYING NARCOTIC ANALGESICS IN HUMAN URINE AFTER THERAPEUTIC DOSES.
057473 02-16
PSYCHOTOMIMETIC PROPERTIES AND THERAPEUTIC POTENTIALS OF DEXOXADROL ON CONVALESCING ALCOHOLICS.
058448 02-12
PSYCHOMETRIC AND PSYCHOPHYSIOLOGICAL TEST IN THE PREDICTION OF THERAPEUTIC RESPONSIVENESS IN THE SCHIZOPHRENIAS.
062643 03-08
AMINOGLUTETHIMIDE: A SIDE-EFFECT TURNED TO THERAPEUTIC ADVANTAGE.
066873 05-15
CONTROLLED THERAPEUTIC EXPERIMENTATION IN CASES OF PSYCHOGENOUS GASTROENTERIC DISTURBANCE.
072003 07-07
THE THERAPEUTIC POTENTIAL OF LSD: ITS ADJUNCTIVE USE IN PSYCHOTHERAPY.
073852 08-12
EVALUATION OF THE THERAPEUTIC EFFECT OF NEUROLEPTICS UPON THE HIGHER NERVOUS ACTIVITY IN SCHIZOPHRENIA.
075103 08-14
THERAPEUTIC MEDICATION IN CHRONIC DELIRIUM: COMBINATION OF PROCHLORPERAZINE (TEMENTIL) AND LEVOMEPROMAZINE (NOZINAN).
079288 09-11
THERAPEUTIC INTEREST IN HYDROSARPAN-711 IN DEPRESSIVE STATES AND IN THE PSYCHIATRIC PATHOLOGY OF GERONTOLOGICAL STATES.
079859 09-11
CLINICAL OBSERVATIONS ON THE THERAPEUTIC ACTIVITY OF FLUPENTHIXOL IN THE TREATMENT OF CHRONIC SCHIZOPHRENIA.
080143 09-08
CONTRIBUTION TO THE USE OF MULTIVARIATE ANALYSIS IN THERAPEUTIC TESTING.
085343 10-11
OXAZEPAM SPOFA, A NEW CZECHOSLOVAK THERAPEUTIC.
086209 10-17
A THERAPEUTIC AGENT FOR ANTIDEPRESSANT AND TRANQUILIZING CONTROL IN THE POST-TRAUMATIC NEUROSES.
086237 10-07
THIOTHIXENE: ITS RANGE OF THERAPEUTIC ACTIVITY.
097985 11-11
AN INTERESTING TISSULARY THERAPEUTIC METHOD IN GERIATRICS: BOGOMOLETZ SERUM (BERNAS CYTOTOXIC SERUM).
105551 12-11
LITHIUM AS A THERAPEUTIC AND PREVENTIVE DRUG IN AFFECTIVE DISORDERS.
109723 12-09
CLINICAL RESULTS ON THE THERAPEUTIC ACTION OF LITHIUM CARBONATE IN DYSTHYMIC PSYCHOSES.
114880 12-09
FIRST ORIENTATIONS ON THE USE OF HIGH DOSES OF OXAZEPAM, BASED ON PERSONAL CLINICAL THERAPEUTIC EXPERIENCE.
124308 12-10
EXPERIENCES OF A THERAPEUTIC COMMUNITY.
124312 12-17
UNCONDITIONED REFLEX ACTIVITY IN THE RAT SUFFERING FROM EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY AND THE THERAPEUTIC EFFECT OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126051 12-04
ABSTRACT OF THESES FOR DOCTOR OF MEDICAL SCIENCES, THE UNIVERSITY OF TOKYO: MORITA THERAPEUTIC APPROACH TO SCHIZOPHRENIA.
126778 12-17

**THERAPEUTICAL**
A THERAPEUTICAL PATHOMORPHOSIS OF SCHIZOPHRENIA PROCEEDING WITH PARANOID DISORDERS.
067547 06-08

**THERAPEUTICS**
LITHIUM CARBONATE IN PSYCHIATRIC THERAPEUTICS.
094287 11-09

**THERAPIST**
THE DANGERS TO THE PATIENT -- AND THE THERAPIST.
046734 01-15

**THERAPY**
STUDY OF THE EFFECTS OF PROGESTERONE THERAPY ON THE STILBOESTROL INDUCED SENSITIVITY OF ISOLATED UTERI OF HYPOPHYSECTOMIZED RATS.
041540 01-03
SUBNORMAL SERUM FOLATE DUE TO ANTICONVULSIVE THERAPY: A DOUBLE-BLIND STUDY OF THE EFFECT OF FOLIC ACID TREATMENT IN PATIENTS WITH DRUG INDUCED SUBNORMAL SERUM FOLATES.
042700 01-11
SODIUM BALANCE AND DISTRIBUTION IN LITHIUM CARBONATE THERAPY.
047828 01-09
EFFECT OF LITHIUM CARBONATE THERAPY ON ADRENOCORTICAL ACTIVITY.
047954 01-09

FIELD DEPENDENCE AS A PREDICTOR OF ALCOHOLIC THERAPY DROP-OUTS.
052455 02-11
THERAPY OF PARTIAL EPILEPSY WITH A COMBINATION CONTAINING SULTHIAME.
055393 02-11
PUPILLARY EFFECTS OF LEVODOPA THERAPY.
058534 02-15
AMITRIPTYLINE IN PSYCHIATRIC THERAPY.
059015 03-09
SUSTAINED-RELEASE TRANQUILIZER THERAPY IN HOSPITALIZED GERIATRIC PATIENTS.
059359 03-10
INDOKLON: CONVULSIVE THERAPY; EXPERIMENTAL CLINICAL STUDIES.
059692 03-07
PROJECT SUMMARY: NATURE OF LATE SIDE-EFFECTS OF PHENOTHIAZINE THERAPY.
060222 03-05
OCULAR CHANGES OCCURRING WITH PROLONGED HIGH DOSE CHLORPROMAZINE THERAPY. RESULTS FROM A COLLABORATIVE STUDY.
060861 03-15
A MECHANISM OF SUDDEN DEATH IN CHLORPROMAZINE THERAPY.
062351 03-15
SUDDEN DEATH IN PHENOTHIAZINE THERAPY: A CLINICOPATHOLOGIC STUDY OF 12 CASES.
062737 03-15
ELECTROENCEPHALOGRAPHIC VARIATIONS INDUCED BY PSYCHOTROPIC DRUGS: CLINICAL ELECTROPHYSIOLOGICAL CORRELATIONS FOR A GUIDED THERAPY.
063200 03-13
SERUM VITAMIN-B12 LEVELS IN PSYCHIATRIC PATIENTS ON LONG-TERM PSYCHOTROPIC DRUG THERAPY.
063874 04-13
THE EFFECTS OF IMIPRAMINE AND ELECTRIC CONVULSIVE THERAPY ON THE EXCRETION OF VARIOUS MINERALS IN DEPRESSED PATIENTS.
063939 04-13
THE PRESENT STATUS OF LITHIUM THERAPY IN MANIC-DEPRESSIVE PSYCHOSIS.
064089 04-09
L-DOPA THERAPY IN PARKINSONS DISEASE.
064188 04-11
MAINTENANCE THERAPY OF CHRONIC PSYCHOTIC PATIENTS WITH A WEEKLY ORAL DOSE OF R-16341. A CONTROLLED DOUBLE-BLIND STUDY.
064284 04-09
COMBINED THERAPY IN ANXIETY DEPRESSIVE SYNDROMES: I. COMPARATIVE EFFECTS OF LIMBITROL (CHLORDIAZEPOXIDE AMITRIPTYLINE) AND PLACEBO.
064312 04-10
L-DOPA THERAPY: PAST, PRESENT AND FUTURE.
064582 04-07
THERAPY OF CHILDHOOD SEIZURES.
065175 05-11
LITHIUM CARBONATE IN THERAPY.
065183 05-13
DRUG THERAPY IN ALCOHOLISM.
065188 05-13
DIAGNOSIS AND THERAPY OF ACUTE WITHDRAWAL FROM ALCOHOL.
065193 05-13
PHARMACOLOGICAL AND DYNAMIC FACTORS IN PSYCHOTROPIC DRUG THERAPY.
065409 05-15
ORTHOMOLECULAR PSYCHIATRY: NIACIN AND MEGAVITAMIN THERAPY.
065416 05-08
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: I. SEIZURE AND POST-SEIZURE ELECTROENCEPHALOGRAPHIC PATTERN.
065850 05-11
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY. II. ANTIDEPRESSIVE EFFECT.
065851 05-09
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: III. ANTEROGRADE AMNESIA.
065852 05-14
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: IV. RETROGRADE AMNESIA.
065853 05-14
COMPARISON OF ELECTRIC AND FLUROTHYL CONVULSIVE THERAPY: V. CONFUSION AND OTHER SIDE-EFFECTS.
065854 05-15
FLUROTHYL CONVULSIVE THERAPY: GENERAL DISCUSSION.
065855 05-11
FLUROTHYL CONVULSIVE THERAPY.
065856 05-11
DRUG THERAPY. II. TREATMENT OF DRUG MISUSE.
066329 05-15
MIOSIS DURING L-DOPA THERAPY.
066419 05-13
VALIDATION OF THE MACANDREW-ROSEN DRUG THERAPY SCALE.
066741 05-16
THE EFFECTS OF PHENOTHIAZINE THERAPY ON LYMPHOCYTE TRANSFORMATION IN SCHIZOPHRENIA.
067288 06-15
AVERSION THERAPY WITH SUCCINYLCHOLINE.
067412 06-07
CONVULSION DURING LITHIUM THERAPY.
067900 06-15
DRUG THERAPY.
068964 06-10
RETENTION RATES OF SCHIZOPHRENIA: A COMPARISON OF SHOCK THERAPY AND PSYCHOPHARMACOLOGICAL ERAS AND OF CLOSED AND OPEN DOOR POLICIES.
069795 07-08
PREVENTION OF PAROXYSMAL TACHYCARDIA OF WOLFF-PARKINSON-WHITE SYNDROME WITH COMBINED PROPRANOLOL AND QUINIDINE THERAPY.
070288 07-10
TRANYLCYPROMINE IN THE THERAPY OF ENDOGENOUS DEPRESSIONS.
070941 07-09
EPILEPSY THERAPY WITH MENTALLY RETARDED CHILDREN: NEUROPSYCHIATRIC DISORDERS THROUGH DIPHENYLHYDANTOIN.
071241 07-15
A COMPARISON OF DOXEPIN AND CHLORDIAZEPOXIDE IN THE THERAPY OF ANXIETY.
072141 07-10
L-DOPA THERAPY OF PARKINSONS DISEASE (A REVIEW OF THE PRELIMINARY EXPERIENCE AT WEST-VIRGINIA UNIVERSITY).
072421 08-07
NEW ASPECTS IN THE THERAPY OF PARKINSONISM.
072465 08-11
THE EFFECTS OF L-DOPA THERAPY IN PARKINSONS DISEASE.
072508 08-15
NEW IN PSYCHIATRY: MODITEN INJECTABLE THERAPY AND FOLLOW-UP CARE.
072787 08-11
WEIGHT CHANGES WITH SCHIZOPHRENIC PSYCHOSIS AND PSYCHOTROPIC DRUG THERAPY.
074218 08-08
PROBLEMS PRESENTED BY NEUROLEPTIC THERAPY IN ITALY.
075111 08-14
THE FUNCTION OF MUSIC IN LSD THERAPY FOR ALCOHOLIC PATIENTS.
075191 08-12
D-CYCLOSERINE THERAPY OF PSYCHOSIS BY SYMPTOM PROVOCATION.
075313 08-08
MEGAVITAMIN THERAPY WITH SEVERELY DISTURBED CHILDREN.
075819 08-11
STUDIES OF MINERAL METABOLISM IN MENTAL DEPRESSION. I. THE EFFECTS OF IMIPRAMINE AND ELECTRIC CONVULSIVE THERAPY ON CALCIUM BALANCE AND KINETICS.
075837 08-11
KETIPRAMINE IN THE THERAPY OF DEPRESSION IN OUTPATIENTS.
076347 09-10
LITHIUM CARBONATE IN THERAPY.
078422 09-17
OPTIMAL THERAPY OF THE ALCOHOL WITHDRAWAL STATE.
078429 09-17
DYNAMIC CONTROL OF ACID BASE EQUILIBRIUM DURING SOME FORMS OF SHOCK THERAPY.
079139 09-13
SEVERE PERSISTENT CHOREA WITH PHENOTHIAZINE THERAPY: REPORT OF A CASE.
079915 09-15
EFFECTIVENESS AND LIMITATIONS OF LONG-TERM LEVODOPA THERAPY IN PARKINSONISM.
079974 09-11
PSYCHOTROPIC DRUG THERAPY AND THE PHARMACEUTICAL INDUSTRY.
079987 09-17
THE PROBLEM OF CEREBRAL EDEMA DURING COMBINED PSYCHOTROPIC DRUG THERAPY.
079992 09-15
ON PROBLEMS OF LATE EXTRAPYRAMIDAL HYPERKINESIS DUE TO NEUROLEPTIC LONG-TERM THERAPY.
079996 09-15
PSYCHOSIS AND OTHER PSYCHIATRIC MANIFESTATIONS OF LEVODOPA THERAPY.
081150 09-15
TRANSIENT EXACERBATIONS, OCCURRING IN THE PROCESS OF NEUROLEPTICAL THERAPY.
081539 10-15
SOME PROBLEMS OF NEUROLEPTIC THERAPY.
086205 10-15
AN ATTEMPT TO ELIMINATE RESISTANCE TO AMINAZINE BY MALARIA THERAPY IN PATIENTS WITH PARANOID SCHIZOPHRENIA.
087312 10-16
INFLUENCE OF THYMOLEPTIC THERAPY ON THE COURSE OF ENDOGENOUS DEPRESSIONS.
089102 10-17

PROPHYLACTIC LITHIUM THERAPY FOR CHRONIC DEPRESSIVE PSYCHOSIS AND SCHIZO-AFFECTIVE DISORDERS.
089105 10-09

INDICATIONS FOR HIGH DOSE CHLORPROMAZINE THERAPY IN CHRONIC SCHIZOPHRENIA.
089433 10-08

CLINICAL EXPERIENCE WITH MESORIDAZINE IN THE THERAPY AND REHABILITATION OF TRAUMATIC FRONTAL BRAIN DAMAGE.
089784 11-14

ELECTRON MICROSCOPY. SUDDEN DEATH IN PATIENTS UNDER PHENOTHIAZINE THERAPY: STUDY OF THREE CASES.
090359 11-15

CLINICAL TESTS OF PIRIDOXILATE IN PSYCHIATRIC THERAPY.
091500 11-07

THE USE OF THE PYRIMIDINE NUCLEOSIDES (CYTIDINE AND URIDINE) IN THE THERAPY OF CEREBRAL VASCULAR ILLNESS.
094472 11-13

THERAPY OF CYCLOTHYMIA.
094963 11-09

DEXEDRINE AS AN ADJUNCT TO APHASIA THERAPY.
101801 12-11

THE MEDICAL AND SOCIAL INDICATION OF ANTIANDROGEN THERAPY.
105733 12-11

LONG-TERM DRUG THERAPY IN AFFECTIVE DISORDERS: THEORETICAL AND METHODOLOGICAL ISSUES IN CURRENT RESEARCH ON LITHIUM.
106765 12-09

COMPLICATIONS OR COINCIDENCES DURING LITHIUM THERAPY: A REVIEW OF SEVERAL CASES.
106775 12-09

USE OF CATTELS IPAT ANXIETY SCALE IN A GROUP OF NEUROTIC PATIENTS BEFORE AND AFTER PSYCHOPHARMACOLOGICAL DRUG AND ELECTRIC SHOCK THERAPY.
128509 12-17

THERAPY WITH JATROSOME.
133147 12-09

THE OCCUPATIONAL THERAPY IN A MENTAL HOSPITAL FOR CHRONIC SCHIZOPHRENICS.
139090 12-08

**THETA**

SODIUM AMOBARBITAL, THE HIPPOCAMPAL THETA RHYTHM, AND THE PARTIAL REINFORCEMENT EXTINCTION EFFECT.
063333 03-03

AVOIDANCE TRAINING OF HIPPOCAMPAL THETA WAVES IN FLAXEDILIZED DOGS AND ITS RELATION TO SKELETAL MOVEMENT.
075399 08-04

THE EFFECT OF INTRAHYPOTHALAMIC MICROINJECTION OF HEMICHOLINIUM (HC-3) ON THE HIPPOCAMPAL THETA RHYTHM OF CATS.
075842 08-03

STUDY ON THE EFFECTS OF PSYCHOTROPIC DRUGS UPON THE PHOTICALLY DRIVING THETA RESPONSE OF ELECTROENCEPHALOGRAMS.
129740 12-08

**THIADIAZASPIRODECAN-3-ONE**

STUDIES ON PSYCHOTROPIC DRUGS (FIFTH REPORT) -- PHARMACOLOGICAL EFFECT OF 8(3-(2-CHLORO-10-PHENOTHIAZINYL)PROPYL)-1 THIADIAZASPIRODECAN-3-ONE HYDROCHLORIDE (APY-606).
131058 12-02

**THIAMINE-DEFICIENT**

CATECHOLAMINE ACCUMULATION IN TISSUES OF THIAMINE-DEFICIENT RATS AFTER INHIBITION OF MONOAMINE OXIDASE.
067243 06-03

**THIENOPYRIDINE**

PROJECT SUMMARY: THIENOPYRIDINE ANALOGS OF SEROTONIN AND TRYPTOPHAN.
066815 05-01

THIENOPYRIDINE ANALOGS OF SEROTONIN AND TRYPTOPHAN.
074844 08-01

**THIN-LAYER**

THIN-LAYER CHROMATOGRAPHIC LABORATORY ANALYSIS IN CASES FROM A DRUG ADDICTION CENTER.
067212 06-06

QUANTITATIVE THIN-LAYER CHROMATOGRAPHIC ESTIMATION OF LABELED DOPAMINE AND NOREPINEPHRINE, THEIR PRECURSORS AND METABOLITES.
070063 07-06

THE OCCURRENCE OF CYCLOHEXYLAMINE IN URINES STUDIED FOR DRUG USE BY THIN-LAYER CHROMATOGRAPHY.
070576 07-13

**THIOPENTONE**

EFFECT OF SKF-525A ON THE FATE OF THIOPENTONE.
066853 05-03

THIOPENTONE FACILITATED IMPLOSION IN TREATMENT OF PHOBIC DISORDERS.
066907 05-14

A COMPARISON OF PROPANIDID (EPONTOL) AND THIOPENTONE ANESTHESIA IN ECT.
076276 09-14

**THIOPROPAZATE**

CLINICAL USE OF THIOPROPAZATE (DARTALAN) IN PATIENTS WITH PSYCHOSIS.
070937 07-09

**THIOPROPERAZINE**

INCREASED RELEASE OF DOPAMINE FROM STRIATAL DOPAMINERGIC TERMINALS IN THE RAT AFTER TREATMENT WITH A NEUROLEPTIC: THIOPROPERAZINE.
042742 01-03

CLINICAL AND PHARMACOLOGICAL CONTRIBUTION TO THE STUDY OF ALCOHOL IMIPRAMINE AND ALCOHOL THIOPROPERAZINE ASSOCIATIONS.
094305 11-11

**THIORIDAZINE**

A COMPARISON OF HALOPERIDOL AND THIORIDAZINE HCL IN CHRONIC TREATMENT RESISTANT SCHIZOPHRENICS.
066398 05-08

A COMPARISON OF HALOPERIDOL AND THIORIDAZINE HCL IN CHRONIC TREATMENT RESISTANT SCHIZOPHRENICS.
066817 05-08

COMBINED ADMINISTRATION OF THIORIDAZINE AND FLUOXYMESTERONE IN THE TREATMENT OF GERIATRIC PATIENTS.
069060 06-11

DOUBLE-BLIND COMPARATIVE STUDY OF THE EFFECTS OF THIOTHIXENE AND THIORIDAZINE IN TWENTY CHRONIC SCHIZOPHRENIC PATIENTS.
070880 07-08

PLASMA CONCENTRATIONS OF THIORIDAZINE IN PATIENTS WITH DEPRESSION: A PRELIMINARY REPORT.
078213 09-13

METHYLPHENIDATE AND THIORIDAZINE: LEARNING, REACTION TIME, ACTIVITY, AND CLASSROOM BEHAVIOR IN DISTURBED CHILDREN.
081631 10-14

TREATMENT WITH THIORIDAZINE OF EMOTIONALLY DISTURBED CHILDREN IN A DAY HOSPITAL.
082090 10-14

PHARMACOLOGICAL ASSOCIATION OF THIORIDAZINE HYDERGINE IN PSYCHOEMOTIONAL TROUBLES OF THE AGED.
091138 11-14

CLINICAL EXPERIENCE WITH TARASAN AND THIORIDAZINE IN MENTALLY RETARDED CHILDREN -- A COMPARATIVE DOUBLE-BLIND STUDY.
097655 11-14

RETINOPATHY FOLLOWING THIORIDAZINE TREATMENT.
100016 11-15

STATE-DEPENDENT RECOGNITION WITH METHYLPHENIDATE AND THIORIDAZINE IN RETARDED CHILDREN. (PH.D.DISSERTATION).
103301 12-14

EXPERIENCE WITH A COMBINATION OF AMITRIPTYLINE AND THIORIDAZINE FOR THE TREATMENT OF DEPRESSIONS.
105732 12-14

THIORIDAZINE AND BEHAVIOR DISORDERS (PERSPECTIVES FOR THE USE OF THE DRUG IN CRIMINOLOGY).
124320 12-17

**THIOTHIXENE**

COMPARATIVE EFFICACY OF THIOTHIXENE CAPSULES AND CONCENTRATE IN ACUTELY SCHIZOPHRENIC PATIENTS.
063599 04-08

SEVERE DELIRIUM AFTER ABRUPT WITHDRAWAL OF THIOTHIXENE IN A CHRONIC SCHIZOPHRENIC INPATIENT: A CASE STUDY.
067221 06-08

DOUBLE-BLIND COMPARATIVE STUDY OF THE EFFECTS OF THIOTHIXENE AND THIORIDAZINE IN TWENTY CHRONIC SCHIZOPHRENIC PATIENTS.
070880 07-08

A CONTROLLED STUDY OF THE EFFECT OF THIOTHIXENE AND PERPHENAZINE IN PSYCHOSES AND SCHIZOPHRENIA.
070938 07-08

EVALUATION OF THIOTHIXENE IN THE TREATMENT OF SCHIZOPHRENIA.
072897 08-08

THIOTHIXENE AND TRIFLUOPERAZINE IN A STEP SYSTEM.
075421 08-08

THE PLACE OF THIOTHIXENE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS. A SYSTEMATIC CLINICAL STUDY.
075422 08-08

CLINICAL CONSIDERATIONS ABOUT THE TREATMENT OF VARIOUS ACUTE PSYCHOTIC STATES WITH THIOTHIXENE.
079746 09-11

THIOTHIXENE IN THE TREATMENT OF ANXIETY AND DEPRESSION IN OUTPATIENTS.
082052 10-10

CLINICAL TRIAL OF THIOTHIXENE (NAVANE) IN ELDERLY CHRONIC SCHIZOPHRENICS.
082054 10-08

A COMPARATIVE STUDY OF THIOTHIXENE AND TRIFLUOPERAZINE IN THE ACUTE PHASE OF SCHIZOPHRENIA.
089159 10-08

CLINICAL TESTS OF THIOTHIXENE, NEUROLEPTIC DISINHIBITER.
091502 11-08

THIOTHIXENE: ITS RANGE OF THERAPEUTIC ACTIVITY.
097985 11-11

A SUPPLEMENT TO CLINICAL EVALUATION OF THIOTHIXENE WITH SPECIAL REFERENCE TO THE TREATMENT OF AFFECTIVE PSYCHOSES. 129452 12-09
THIOTHIXENE IN HOSPITALIZED CHRONIC SCHIZOPHRENIC PATIENTS. 134906 12-08

**THIOXANTHENE**
TEN YEARS OF TREATMENT WITH THIOXANTHENE DERIVATIVES. 042671 01-09

**THIRST**
ANTIDOTAL THIRST: A RESPONSE TO INTOXICATION. 070821 07-05

**THOMPSON**
DRUGS IN PSYCHOLOGY: A COMMENTARY ON TRAVIS THOMPSON AND CHARLES R. SCHUSTERS BEHAVIORAL PHARMACOLOGY. 075793 08-14

**THORAZINE**
A PSYCHOLOGICAL STUDY OF THE EFFECTS OF CHLORPROMAZINE (THORAZINE). (PH.D.DISSERTATION). 103273 12-08

**THRESHOLD**
A CONTROLLED COMPARISON OF THE TREATMENT OF SCHIZOPHRENIC PATIENTS WHEN TREATED ACCORDING TO THE NEUROLEPTIC THRESHOLD OR BY CLINICAL JUDGMENT. 063776 04-08
CARBON MONOXIDE AND PHENOBARBITONE: A COMPARISON OF EFFECTS ON AUDITORY FLUTTER FUSION THRESHOLD AND CRITICAL FLICKER FUSION THRESHOLD. 070303 07-14
A COMPARISON OF TRIPERIDOL AND PERPHENAZINE IN SCHIZOPHRENIA. EFFECTS ON MYOCLONIC THRESHOLD. 070935 07-08
THE CLINICAL TESTING OF HYDROTHIADENE IN ENDOGENOUS DEPRESSIONS. INFLUENCE OF DRUGS ON PHOTOMYOCLONIC THRESHOLD. 070940 07-09
CORTISOL EFFECTS ON AVERAGED EVOKED POTENTIAL, ALPHA-RHYTHM, TIME ESTIMATION, AND TWO-FLASH FUSION THRESHOLD. 075274 08-13
VISUAL THRESHOLD AS A FUNCTION OF TEST AREA AND CAFFEINE ADMINISTRATION. 076016 09-13
INDUCED CHANGES IN CAUDATE NUCLEUS DOPAMINE AND ELECTROSHOCK THRESHOLD. 079179 09-03
RELATIONSHIP BETWEEN TASTE THRESHOLD FOR DRUGS AND CLINICAL PROGRESS IN A MIXED GROUP OF PSYCHIATRIC PATIENTS. 087866 10-11

**THRESHOLDS**
THE EFFECT OF MEDAZEPAM ON THE THRESHOLDS OF SUBCORTICAL LIMBIC STIMULUS RESPONSES, MEASURED IN UNANESTHETIZED, UNRESTRAINED CATS. 072067 07-03

**THROMBOSIS**
CONCERNING A CASE OF THROMBOSIS OF THE MIDDLE CEREBRAL ARTERY IN THE COURSE OF PROGESTINIC TREATMENT. 094467 11-14

**THYMOANALEPTIC**
SULPIRIDE, A SINGULAR, ANTIAUTISTIC AND THYMOANALEPTIC NEUROLEPTIC. 089160 10-11

**THYMOANALEPTICS**
PSYCHOSENSORIAL PHENOMENA DURING TREATMENT WITH TRICYCLIC THYMOANALEPTICS (PRESENTATION OF TWO CASES). 124311 12-15

**THYMOLEPTIC**
INTRAGASTRIC TELEMETRIC MEASURING OF PH DURING THYMOLEPTIC MEDICATION. 081143 09-13
INFLUENCE OF THYMOLEPTIC THERAPY ON THE COURSE OF ENDOGENOUS DEPRESSIONS. 089102 10-17

**THYMOLEPTICS**
MONOAMINE OXIDASE INHIBITORS, COMBINED WITH THYMOLEPTICS: ARE THEY REALLY UNUSABLE FOR HUMAN BEINGS. 066805 05-03
PERSISTENT EXTRAPYRAMIDAL ORAL DYSKINESIAS FOLLOWING TREATMENT WITH THYMOLEPTICS. 070945 07-15
ON ACTIVATION OF DREAMS BY THYMOLEPTICS. 079995 09-14
LETHAL POISONING IN CHILDREN BY MEANS OF THYMOLEPTICS. 082202 10-15

**THYMOXAMINE**
RELEASE BY AMPHETAMINE IN MAN OF GROWTH HORMONE AND CORTICOSTEROIDS: THE EFFECTS OF THYMOXAMINE AND PROPRANOLOL. 067602 06-13

**THYROID**
THYROID HORMONE ENHANCEMENT OF IMIPRAMINE IN NONRETARDED DEPRESSIONS. 042654 01-09
COMBINED ADRENAL AND THYROID DEFICIENCY (SCHMIDTS SYNDROME) PRESENTING AS AN ACUTE PSYCHOSIS. 056350 02-15
USE OF A THYROID HORMONE TO ACCELERATE THE ACTION OF IMIPRAMINE. 063595 04-10
EFFECTS OF LITHIUM ON THYROID FUNCTION (A REVIEW). 064316 04-15
THYROID HORMONE AND TRICYCLIC ANTIDEPRESSANTS IN RESISTANT DEPRESSIONS. 075428 08-09
ENHANCEMENT OF IMIPRAMINE BY THYROID STIMULATING HORMONE; CLINICAL AND THEORETICAL IMPLICATIONS. 075871 09-10
CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIC WOMEN: ITS EFFECT ON THYROID AND LIVER FUNCTION IN RELATION TO SERUM CHOLESTEROL CONCENTRATION. 088221 10-13
NOREPINEPHRINE TURNOVER IN BRAIN AFTER ADMINISTRATION OF IMIPRAMINE: ENHANCEMENT BY THYROID HORMONE. 090052 11-13
THYROID FUNCTION. 100534 12-15
PROPHYLACTIC ACTION OF LITHIUM SALTS AND THYROID HORMONES ON SYMPTOMS OF MANIC-DEPRESSIVE AND AFFECTIVE PSYCHOSES: CLINICAL AND EXPERIMENTAL RESULTS. 106774 12-09

**TIME**
EFFECT OF AMPHETAMINE ANALOGS ON DISRUPTION OF ANIMAL BEHAVIOR AND BARBITURATE SLEEPING TIME. 046196 01-03
FORGETTING OF AN OPERANT RESPONSE: PHYSOSTIGMINE PRODUCED INCREASES IN ESCAPE LATENCY IN RATS AS A FUNCTION OF TIME OF INJECTION. 061540 03-04
TO SLEEP, PERCHANCE TO DREAM: NEW DRUG FOR INSOMNIACS DOESNT INTERFERE WITH REM TIME. 068021 06-14
RELATIONS BETWEEN BARBITURATE BRAIN LEVELS AND SLEEPING TIME IN VARIOUS EXPERIMENTAL CONDITIONS. 068600 06-03
STRYCHNINE EFFECTS ON DISCRIMINATION LEARNING IN MICE: EFFECTS OF DOSE AND TIME OF ADMINISTRATION. 069066 06-04
IMIPRAMINE IN CHILDHOOD ENURESIS: FURTHER STUDIES ON THE RELATIONSHIP OF TIME OF ADMINISTRATION TO EFFECT. 071946 07-11
PUPIL SIZE AND DRUG STATE IN A REACTION TIME TASK. 075161 08-13
CHANGE IN SENSITIVITY TO D-AMPHETAMINE IN FRONTAL RATS AS A FUNCTION OF TIME: SHIFTING OF THE DOSE RESPONSE CURVE. 075238 08-04
CORTISOL EFFECTS ON AVERAGED EVOKED POTENTIAL, ALPHA-RHYTHM, TIME ESTIMATION, AND TWO-FLASH FUSION THRESHOLD. 075274 08-13
EFFECT OF PHENOTHIAZINES ON REACTION TIME IN SCHIZOPHRENICS. 075413 08-08
METHYLPHENIDATE AND THIORIDAZINE: LEARNING, REACTION TIME, ACTIVITY, AND CLASSROOM BEHAVIOR IN DISTURBED CHILDREN. 081631 10-14

**TIME-DEPENDENCE**
WATER STRUCTURE IN ANESTHETIC ACTION: TIME-DEPENDENCE D20 EFFECTS ON NERVE. 055582 02-03

**TIME-DEPENDENT**
TIME-DEPENDENT LEARNING DEFICIT CAUSED BY HYDROXYLAMINE. 068677 06-04

**TIMES**
COMPARISON OF LIVER MICROSOME ENZYME SYSTEMS AND BARBITURATE SLEEP TIMES IN RATS CAGED INDIVIDUALLY OR COMMUNALLY. 045545 01-06
REACTION TIMES OF METHADONE TREATED EX HEROIN ADDICTS. 062817 03-11
PHYSOSTIGMINE: EFFECTS ON RETENTION AT DIFFERENT TIMES AFTER BRIEF TRAINING. 075237 08-04

**TIMING**
COMPARATIVE EFFECTS OF NICOTINE AND AMPHETAMINE ON TIMING BEHAVIOR IN RATS. 046190 01-04

**TIMOFEYEV**
CONCERNING THE ARTICLE BY N.N.TIMOFEYEV, V.T.KONDRASHENKO AND N.Y.NEMTSEVA ON OXYMETRIC INVESTIGATION OF PATIENTS WITH SCHIZOPHRENIA AND REACTIVE PSYCHOSIS DURING NEUROLEPTIC TREATMENT.
109788 12-08

**TIRING**
TESTING THE PERFORMANCE UNDER APONEURON OF OTHERWISE NORMAL SCHOOL CHILDREN WITH A TENDENCY TOWARD REDUCED DRIVE AND EASY TIRING.
080563 09-11

**TISSUE**
STIMULATION OF DOPA-14C INCORPORATION INTO MELANOMA TISSUE BY CHLORPROMAZINE AND RESERPINE.
040584 01-03
2,5- DIMETHOXY-4-METHYLAMPHETAMINE -- TISSUE DISTRIBUTION AND NEUROCHEMICAL ACTION.
045544 01-03
PHARMACOLOGICAL AND BEHAVIORAL STUDIES OF STP: RELATIONSHIP TO TISSUE DISTRIBUTION.
046198 01-03
ASSOCIATION OF AMPHETAMINE TOXICITY AND TISSUE GLYCOGEN DEPLETION IN MICE AND RATS.
058998 03-05
METABOLISM OF 14C-IMIPRAMINE: III. CONVERSIONS BY RAT TISSUE.
064409 04-03
TISSUE DISTRIBUTION OF CHLORPROMAZINE STUDIED BY MICROAUTORADIOGRAPHY.
067961 06-03
PROJECT SUMMARY: ANALYSIS OF URINE AND TISSUE AMINES.
068970 06-03
INTERACTION OF CHLORPROMAZINE AND TISSUE BINDING SITES: PRELIMINARY STUDIES.
069367 06-03
EFFECTS OF CHLORPROMAZINE ON NEURAL TISSUE IN CULTURE.
070825 07-03
MECHANISMS OF LITHIUM ACTION: (ENDOGENOUS TISSUE LEVELS, EXCRETION IN EMOTIONAL STATES, AND BEHAVIORAL EFFECTS).
080634 09-03
A NEW WAY OF ACETYLCHOLINE BIOSYNTHESIS IN BRAIN TISSUE.
087303 10-01
PHARMACOLOGICAL IMPLICATIONS OF THE EFFECTS OF AMPHETAMINE AND ITS ANALOGUES ON THE TURNOVER RATE OF TISSUE CATECHOLAMINES (UNPUBLISHED PAPER).
088392 10-03
TOXICITY OF HEPATOTOXIC DRUGS ON MOUSE LIVER TISSUE CULTURE.
088615 10-05
PERMEATION CHARACTERISTICS OF MORPHINE-LIKE SUBSTANCES AFTER INJECTION INTO BRAIN TISSUE AND INTO THE VENTRICULAR SYSTEM.
089047 10-03
LITHIUM INDUCED CHANGES IN ELECTROLYTE BALANCE AND TISSUE ELECTROLYTE CONCENTRATION.
090419 11-03

**TISSUES**
EFFECTS OF THALIDOMIDE AND CHLORCYCLIZINE ON THE BIOSYNTHESIS OF NUCLEIC ACIDS AND PROTEINS IN FETAL AND MATERNAL TISSUES OF THE RAT.
040027 01-05
DECARBOXYLATION OF 3,4- DIHYDROXYPHENYLALANINE IN VARIOUS HUMAN ADULT AND FETAL TISSUES.
040105 01-13
CATECHOLAMINE ACCUMULATION IN TISSUES OF THIAMINE-DEFICIENT RATS AFTER INHIBITION OF MONOAMINE OXIDASE.
067243 06-03
UPTAKE OF TRITIATED TESTOSTERONE IN BRAIN AND PERIPHERAL TISSUES OF NORMAL AND NEONATALLY ANDROGENIZED FEMALE RATS.
076086 09-04

**TISSULARY**
AN INTERESTING TISSULARY THERAPEUTIC METHOD IN GERIATRICS: BOGOMOLETZ SERUM (BERNAS CYTOTOXIC SERUM).
105551 12-11

**TLC**
QUANTITATIVE DETERMINATION OF BUTAPERAZINE BY TLC.
090425 11-06

**TOBACCO**
EFFECTS OF NICOTINE AND TOBACCO SMOKE ON THE ELECTRICAL ACTIVITY OF THE CEREBRAL CORTEX AND OLFACTORY BULB.
041567 01-03
DIFFERENTIAL EFFECTS OF NICOTINE AND TOBACCO SMOKE ALKALOIDS ON SWIMMING ENDURANCE IN THE RAT.
069078 06-04

**TOFRANIL**
TOFRANIL IN THE TREATMENT OF POST ALCOHOLIC DEPRESSIONS.
063588 03-09

**TOKYO**
ABSTRACT OF THESES FOR DOCTOR OF MEDICAL SCIENCES, THE UNIVERSITY OF TOKYO: MORITA THERAPEUTIC APPROACH TO SCHIZOPHRENIA.
126778 12-17

**TOLERANCE**
INHIBITION OF THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN RATS BY DRUGS WHICH INHIBIT RIBONUCLEIC ACID OR PROTEIN SYNTHESIS.
041570 01-03
DRUG DEPENDENT DIFFERENCES IN THE DEVELOPMENT OF TOLERANCE TO WRITHING IN MICE.
046400 01-03
POSSIBLE MECHANISMS IN DEVELOPMENT OF TOLERANCE.
056238 02-03
THE REVERSAL OF DEVELOPED TOLERANCE TO PENTOBARBITAL BY ETHYL ALCOHOL.
058995 03-03
METRAZOL TOLERANCE IN A NORMAL VOLUNTEER POPULATION: A TEN YEAR FOLLOW-UP REPORT.
060649 03-13
DEVELOPMENT OF TOLERANCE TO PENTOBARBITAL.
064263 04-03
CHANGES IN ENZYMES SUBSERVING CATECHOLAMINE METABOLISM IN MORPHINE TOLERANCE AND WITHDRAWAL IN RAT.
067324 06-03
COMPLEXES BETWEEN ACETYLCHOLINE AND CATECHOLAMINES AND THEIR TOLERANCE TO MENTAL ILLNESS.
072705 08-01
THE CATECHOLAMINE CONTENT IN THE BRAINSTEM OF ALBINO RATS IN THE DEVELOPMENT OF TOLERANCE TO TRYPHTAZINE.
073681 08-03
EXPERIMENTAL STUDIES ON THE EFFECTIVE PROCEDURE TO INHIBIT THE DEVELOPMENT OF TOLERANCE TO AND DEPENDENCE ON MORPHINE.
089789 11-02

**TOLERANT**
THE ROLE OF BRAIN CATECHOLAMINES IN MORPHINE ANALGESIC ACTION IN MORPHINE TOLERANT RATS.
055756 02-03
BRAIN SEROTONIN TURNOVER IN MORPHINE TOLERANT AND DEPENDENT MICE.
069595 07-03
REDUCTION OF THE ANTINOCICEPTIVE EFFECT OF 5-HYDROXYTRYPTOPHAN IN MORPHINE TOLERANT RATS.
075846 09-03
CHANGES OF THE BODY TEMPERATURE OF CODEINE TOLERANT RATS BY THE ADMINISTRATION OF NALORPHINE.
130427 12-03

**TOOL**
THE PHYSICIAN QUESTIONNAIRE: A USEFUL TOOL IN PSYCHIATRIC DRUG RESEARCH.
075843 09-17
ANTIPSYCHOTIC DRUGS: AN ESSENTIAL TOOL OF COMMUNITY PSYCHIATRY.
080355 09-08
IMIPRAMINE AS AN EFFECTIVE TOOL IN THE MANAGEMENT OF BEHAVIORAL DISORDERS IN CHILDREN.
134937 12-11

**TOXIC**
MODIFICATION OF THE TOXIC ACTIONS OF L-TRYPTOPHAN BY PARGYLINE AND P-CHLOROPHENYLALANINE.
064277 04-05
A STUDY OF THE INTERACTION OF THE HYPNOTIC EFFECTS AND OF THE TOXIC EFFECTS OF CHLORAL HYDRATE AND ETHANOL.
066365 05-03
OUR EXPERIENCE WITH TOXIC PSYCHOSES.
074575 08-15
STUDIES OF THE TOXIC EFFECTS OF DRUGS ON ELECTRICAL CONDUCTION AND FUNCTION OF THE HEART. (PH.D.DISSERTATION).
103004 12-05

**TOXICITY**
EFFECT OF ENVIRONMENTAL TEMPERATURE ON THE TOXICITY OF CAFFEINE AND DEXTROAMPHETAMINE IN MICE.
040028 01-05
TOXICITY OF SOME BENZODIAZEPINE COMPOUNDS WITH CNS ACTIVITY.
046640 01-05
AN INDUSTRIAL VIEW OF CURRENT PRACTICE IN PREDICTING DRUG TOXICITY.
057606 02-05
A CASE OF MANIC-DEPRESSIVE ILLNESS WITH LITHIUM TOXICITY.
058213 02-15
TOXICITY, NARCOTIC EFFECT, CONCENTRATION AT END OF ANESTHESIA, ELIMINATION FROM BLOOD AND BIOTRANSFORMATION OF HEXOBARBITAL IN RATS OF VARIOUS AGES FOLLOWING SLEEP INDUCTION WITH BARBITAL AND AFTER.
058987 03-05

ASSOCIATION OF AMPHETAMINE TOXICITY AND TISSUE GLYCOGEN DEPLETION IN MICE AND RATS.
058998 03-05
PHENOTHIAZINE TOXICITY IN POOL SHARK.
059035 03-15
EFFECT OF DIETHYLDITHIOCARBAMATE ON THE TOXICITY OF AMPHETAMINE IN AGGREGATED MICE.
062937 03-04
TOXICITY OF ETHANOL BARBITURATE MIXTURES.
064160 04-05
LITHIUM IN HAZARDOUS CIRCUMSTANCES WITH ONE CASE OF LITHIUM TOXICITY.
067138 06-15
AN ANALYSIS OF 310 CASES OF ACUTE HIGH-DOSE METHAMPHETAMINE TOXICITY IN HAIGHT-ASHBURY.
067218 06-15
ACUTE TOXICITY OF HEROIN, ALONE AND IN COMBINATION WITH COCAINE OR QUININE.
068167 06-05
CARDIAC TOXICITY AND PSYCHOTROPIC DRUGS.
068603 06-15
LITHIUM TOXICITY.
071970 07-15
AMPHETAMINE TOXICITY AND ENDOGENOUS NORADRENALINE CONCENTRATIONS IN ISOLATED AND AGGREGATED MIC
074146 08-05
CLASSICAL HYSTERICAL SEIZURES FACILITATED BY ANTICONVULSANT TOXICITY.
081135 09-15
ACUTE ORAL TOXICITY OF CANNABINOIDS IN VARIOUS SPECIES (UNPUBLISHED PAPER).
088412 10-05
TOXICITY OF HEPATOTOXIC DRUGS ON MOUSE LIVER TISSUE CULTURE.
088615 10-05
SOME EFFECTS OF ETHANOL ON THE TOXICITY AND DISTRIBUTION OF BARBITURATES IN RATS.
090032 11-05
BEHAVIORAL TOXICITY. PART 3: PERCEPTUAL COGNITIVE FUNCTIONS AND PART 4: EMOTIONAL (MOOD) STATES.
100523 12-15
BEHAVIORAL TOXICITY. PART 1: DEFINITION AND PART 2: PSYCHOMOTOR FUNCTIONS.
100524 12-15
BEHAVIORAL TOXICITY. PART 5: GROSS BEHAVIOR PATTERNS.
105560 12-15
PHARMACOLOGICAL STUDIES OF OXAZOLAZEPAM, A NEW PSYCHOTROPIC AGENT -- II. GENERAL PHARMACOLOGY AND SUBACUTE TOXICITY.
114835 12-07
THE SAFETY TEST OF L-DOPA. I. ACUTE AND SUBACUTE TOXICITY OF L-DOPA IN EXPERIMENTAL ANIMALS.
114837 12-05

**TOXICOLOGICAL**
PHARMACOLOGICAL, TOXICOLOGICAL, AND TERATOLOGICAL STUDIES ON DIPOTASSIUM 7-CHLORO-3-CARBOXY 1,3-DIHYDRO-2,2-DIHYDROXY-5-PHENYL-2H-1,4 BENZODIAZEPINE CHLORAZEPATE (DIPOTASSIUM CHLORAZEPATE, 4306-CB), A NEW TRANQUILLIZER.
055581 02-03
THE PREDICTIVE VALUE FOR MAN OF TOXICOLOGICAL TESTS OF DRUGS IN LABORATORY ANIMALS.
057607 02-05

**TOXICOLOGY**
LITHIUM CARBONATE FOR AFFECTIVE DISORDERS. I. CLINICAL PHARMACOLOGY AND TOXICOLOGY.
047831 01-09
THE TOXICOLOGY OF NEUROLEPTICS ON THE EYE.
085338 10-15
CLINICAL TOXICOLOGY AND EFFICACY OF PIMOZIDE.
089104 10-09

**TOXICOMANIAS**
SOCIAL MEDICAL CLASSIFICATION OF TOXICOMANIAS.
079257 09-15
CURRENT TOXICOMANIAS: CLINICAL AFFECTS OF THE AGENTS USED AND COMMON SEMIOLOGICAL ASPECTS.
085129 10-15
DRUGS AND MODERN TOXICOMANIAS.
085130 10-15

**TOXINS**
MENTAL RETARDATION ASSOCIATED WITH POSTNATAL POISONS, TOXINS, ENDOTOXINS, DEFICIENCIES AND ALLERGIC REACTIONS.
061706 03-15

**TOXOID**
SECONDARY IMMUNE RESPONSE TO TETANUS TOXOID IN PSYCHIATRIC PATIENTS.
075412 08-13

**TPS-23**
A DOUBLE-BLIND COMPARISON OF CHLORPROMAZINE AND MESORIDAZINE (TPS-23).
045508 01-07

**TRACE**
EFFECT OF IMIPRAMINE AND CHLORIMIPRAMINE ON AN ACUTE INSTRUMENTAL TRACE CONDITIONED REFLEX IN RATS.
064415 04-04

**TRACES**
THE EFFECT OF SOME INHIBITORS AND METABOLITES OF CATECHOLAMINE ON THE PROCESSES OF FIXATION AND REPRODUCTION OF MEMORY TRACES.
073716 08-03

**TRACHEA**
METOCLOPRAMIDE AND THE MUSCULATURE OF ESOPHAGUS, STOMACH, INTESTINE, SPLEEN, TRACHEA, GALL AND URINARY BLADDERS: IN VITRO STUDIES.
055394 02-03

**TRACT**
RELEASE OF 5-HYDROXYTRYPTAMINE FROM SLICES OF SUPERIOR COLLICULUS BY OPTIC TRACT STIMULATION.
064369 04-03

**TRAINEES**
DEXAMETHASONE SUPPRESSION IN BASIC TRAINEES UNDER STRESS.
086025 10-10

**TRAINING**
THE EFFECTS OF CENTRALLY AND PERIPHERALLY ACTING CHOLINERGIC DRUGS ON THE SHORT-TERM PERFORMANCE GRADIENT FOLLOWING PASSIVE AVOIDANCE TRAINING.
064412 04-04
PHYSOSTIGMINE: EFFECTS ON RETENTION AT DIFFERENT TIMES AFTER BRIEF TRAINING.
075237 08-04
AVOIDANCE TRAINING OF HIPPOCAMPAL THETA WAVES IN FLAXEDILIZED DOGS AND ITS RELATION TO SKELETAL MOVEMENT.
075399 08-04
SCOPOLAMINE EFFECTS ON GO-NO-GO AVOIDANCE DISCRIMINATIONS: INFLUENCE OF STIMULUS FACTORS AND PRIMACY OF TRAINING.
090418 11-04

**TRAIT**
PERSONALITY TRAIT DEPENDENT PERFORMANCE UNDER PSILOCYBIN (PART II).
058454 02-12
PERSONALITY TRAIT DEPENDENT PERFORMANCE UNDER PSILOCYBIN.
064323 04-12
BUTAPERAZINE AND HEMOGLOBIN C TRAIT.
067510 06-15

**TRAITS**
OBJECTIVE EFFECTS OF DEXAMPHETAMINE AND AMOBARBITAL AND THEIR RELATIONS TO PSYCHASTHENIC PERSONALITY TRAITS.
064389 04-14

**TRANQUILIZATION**
LITHIUM VERSUS CHLORPROMAZINE FOR MANICS. INITIATIVE AND PRODUCTIVITY VERSUS TRANQUILIZATION HOSPITALIZATION.
063209 03-09

**TRANQUILIZER**
SUSTAINED-RELEASE TRANQUILIZER THERAPY IN HOSPITALIZED GERIATRIC PATIENTS.
059359 03-10
EFFECTS OF A TRANQUILIZER AND TWO ANTIDEPRESSANTS ON LEARNED AND UNLEARNED BEHAVIORS.
064259 04-04
INVESTIGATIONS FOR OBJECTIFYING TRANQUILIZER EFFECTS.
079960 09-14
RESEARCH ON NEW METHODS OF EXPERIMENTATION WITH PSYCHOTROPIC DRUGS. RESULTS OF A TEST WITH A NEW TRANQUILIZER, NOBRIUM, IN TWO INDEPENDENT INVESTIGATIONS.
086984 10-16
RESEARCH IN NEW EXPERIMENTAL METHODS FOR PSYCHOTROPIC DRUGS: RESULTS OF A DOUBLE-BLIND STUDY WITH A NEW TRANQUILIZER, NOBRIUM.
112282 12-16
SLEEPING PILLS AND TRANQUILIZER ABUSE.
129237 12-17
A CLINICAL EXPERIENCE OF OXAZOLAM, A NEW MINOR TRANQUILIZER.
129367 12-07
CLINICAL APPLICATION OF NEW TRANQUILIZER, CS-300, TO SCHIZOPHRENICS.
129879 12-07
PSYCHOPATHOLOGY OF TRANQUILIZER ABUSE.
133935 12-14

**TRANQUILIZERS**
STOOL PORPHYRINS IN ACUTE INTERMITTENT AND HEREDITARY COPROPORPHYRIA: ADVERSE EFFECTS OF TRANQUILIZERS.
066318 05-15
ANTIHEMOLYTIC ACTIONS OF TRICYCLIC TRANQUILIZERS: STRUCTURAL CORRELATIONS.
074862 08-03

DRUG, DOCTOR WARMTH, AND CLINIC SETTING IN THE SYMPTOMATIC RESPONSE TO MINOR TRANQUILIZERS.
087386 10-10

GALVESTON COUNTY STUDY SHOWS TRANQUILIZERS SURPASS ASPIRIN AS MEDICINAL POISONING AGENTS.
090070 11-15

TRANQUILIZERS IN THE TREATMENT OF THE CARDIAC NEUROTIC PATIENT AND THE SUBSEQUENT ALTERATION OF COMPLAINTS.
128568 12-14

SEPARATION AND IDENTIFICATION OF TRANQUILIZERS AND PSYCHOSTIMULANTS.
131625 12-06

**TRANQUILIZING**

CHANGES IN LIVER DISTURBANCE ASSOCIATED WITH LONG-TERM TRANQUILIZING MEDICATION (A FOLLOW-UP STUDY).
075839 08-15

A THERAPEUTIC AGENT FOR ANTIDEPRESSANT AND TRANQUILIZING CONTROL IN THE POST-TRAUMATIC NEUROSES.
086237 10-07

THE USE OF TWO COMBINATIONS OF DRUGS WITH MIXED ACTION, ANTIDEPRESSIVE AND TRANQUILIZING (AMITRYPTILINE _ PERPHENAZINE) IN GENERAL AND IN PSYCHOSOMATIC MEDICINE.
089162 10-17

**TRANQUILLIZER**

PHARMACOLOGICAL, TOXICOLOGICAL, AND TERATOLOGICAL STUDIES ON DIPOTASSIUM 7-CHLORO-3-CARBOXY 1,3-DIHYDRO-2,2-DIHYDROXY-5-PHENYL-2H-1,4 BENZODIAZEPINE CHLORAZEPATE (DIPOTASSIUM CHLORAZEPATE, 4306-CB), A NEW TRANQUILLIZER.
055581 02-03

EFFECT OF NICOTINIC ACID COMBINED WITH A TRANQUILLIZER (HYDROXYZINE) ON SERUM LIPID LEVELS AND URINARY CATECHOLAMINE EXCRETION IN GERIATRIC PATIENTS.
093689 11-11

CLINICAL EXPERIMENT WITH A NEW TRANQUILLIZER: TRIOXAZINE.
094423 11-11

**TRANQUILLIZERS**

INTERACTION BETWEEN INTRAVENOUS ALCOHOL AND SOME SEDATIVES AND TRANQUILLIZERS.
067607 06-03

A NOTE ON TRANQUILLIZERS AND PERCEPTUAL DEFENSIVENESS.
082411 10-14

POSSIBLE APPLICATIONS OF LONG-ACTING INTRAMUSCULAR MAJOR TRANQUILLIZERS.
100020 11-11

**TRANQUILLIZING**

A POTENTIAL SCREENING TEST FOR MINOR TRANQUILLIZING DRUG ACTION.
051651 02-06

**TRANSAMINASE**

BIPHASIC EFFECT OF NOREPINEPHRINE IN THE REGULATION OF HEPATIC TYROSINE TRANSAMINASE ACTIVITY.
062327 03-03

**TRANSECTION**

ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL EFFECTS OF HARMALINE IN INTACT CATS AND IN CATS WITH CHRONIC MESENCEPHALIC TRANSECTION.
075847 09-04

**TRANSFER**

TOTAL BODY KINETICS AND PLACENTAL TRANSFER OF LABELED LSD IN MICE.
046201 01-03

PLACENTAL TRANSFER OF PENTOBARBITAL IN THE RAT.
058572 02-05

**TRANSFORMATION**

THE EFFECTS OF PHENOTHIAZINE THERAPY ON LYMPHOCYTE TRANSFORMATION IN SCHIZOPHRENIA.
067288 06-15

**TRANSIENT**

TRANSIENT EXACERBATIONS, OCCURRING IN THE PROCESS OF NEUROLEPTICAL THERAPY.
081539 10-15

**TRANSITIONS**

SCOPOLAMINE EFFECTS ON CONDITIONED SUPPRESSION: INFLUENCE OF DIURNAL CYCLE AND TRANSITIONS BETWEEN NORMAL AND DRUGGED STATES.
071790 07-03

**TRANSMISSION**

THE EFFECTS OF MORPHINE-LIKE SUBSTANCES AND THEIR ANTAGONISTS ON TRANSMISSION AT THE NEURO EFFECTOR JUNCTION OF THE MYENTERIC PLEXUS LONGITUDINAL MUSCLE PREPARATION OF THE GUINEA-PIG ILEUM.
041974 01-03

**TRANSMITTER**

INCREASED TRANSMITTER RELEASE INDUCED BY CONVULSANT PHENOLS.
081063 09-03

MINIATURIZED BIOTELEMETRIC TRANSMITTER.
082706 10-06

**TRANSPORT**

MECHANISM OF THE RENAL TUBULAR TRANSPORT OF MORPHINE AND MORPHINE ETHEREAL SULFATE IN THE CHICKEN.
040754 01-03

IMIPRAMINE AND LITHIUM EFFECTS ON BIOGENIC AMINE TRANSPORT IN DEPRESSED AND MANIC-DEPRESSED PATIENTS.
062326 03-13

IMIPRAMINE AND LITHIUM EFFECTS ON BIOGENIC AMINE TRANSPORT IN DEPRESSED AND MANIC-DEPRESSED PATIENTS.
062366 03-13

THE EFFECTS OF VARIOUS PRIOR TREATMENTS UPON THE TRANSPORT OF CHLORPROMAZINE AND TRIFLUOPERAZINE INTO RAT BRAIN.
069309 06-02

**TRANYLCYPROMINE**

TRANYLCYPROMINE: EFFECTS ON NOREPINEPHRINE METABOLISM IN RAT BRAIN.
052484 02-03

COMPARATIVE BEHAVIORAL AND BIOCHEMICAL EFFECTS OF TRANYLCYPROMINE AND CYSTEINE ON NORMAL CONTROLS AND SCHIZOPHRENIC PATIENTS.
064331 04-08

THE EFFECT OF PHENELZINE AND TRANYLCYPROMINE ON THE DEGRADATION OF MEPERIDINE.
064421 04-03

TRANYLCYPROMINE IN THE THERAPY OF ENDOGENOUS DEPRESSIONS.
070941 07-09

THE INFLUENCE OF LONG-TERM PREMEDICATION WITH TRANYLCYPROMINE ON EXPERIMENTAL PSYCHOSES INDUCED BY LSD.
070954 07-12

**TRAUMA**

MENTAL RETARDATION ASSOCIATED WITH PRENATAL INTOXICATION, ALLERGIC REACTIONS, DEFICIENCIES, TRAUMA, AND PHYSICAL AGENTS.
061704 03-15

**TRAUMATIC**

CHEMICAL INDUCTION OF TRAUMATIC FIGHTING IN RATS.
068765 06-04

PROJECT SUMMARY: CHEMICAL INDUCTION OF TRAUMATIC FIGHTING IN RATS.
082511 10-04

CLINICAL EXPERIENCE WITH MESORIDAZINE IN THE THERAPY AND REHABILITATION OF TRAUMATIC FRONTAL BRAIN DAMAGE.
089784 11-14

**TRAUMATIZATION**

THE MODIFIABILITY OF INFANTILE SHOCK TRAUMATIZATION EFFECTS BY CONTIGUOUS DRUG ADMINISTRATIONS.
060090 03-04

**TREAT**

IS IT FEASIBLE TO TREAT CERTAIN POTENTIALLY DANGEROUS CONDITIONS BY PROLONGED CHEMOTHERAPY.
062406 03-08

USING METHADONE TO TREAT THE HEROIN ADDICT.
062789 03-07

**TREATED**

OXIDATIVE PHOSPHORYLATION IN HEART MITOCHONDRIA ISOLATED FROM CHLORPROMAZINE TREATED ANIMALS.
041564 01-03

REACTION TIMES OF METHADONE TREATED EX HEROIN ADDICTS.
062817 03-11

A CONTROLLED COMPARISON OF THE TREATMENT OF SCHIZOPHRENIC PATIENTS WHEN TREATED ACCORDING TO THE NEUROLEPTIC THRESHOLD OR BY CLINICAL JUDGMENT.
063776 04-08

PRIVATE AMBULATORY PATIENTS TREATED WITH FLUPHENAZINE ENANTHATE.
065458 05-07

MENTAL SYMPTOMS IN PARKINSONIAN PATIENTS TREATED WITH L-DOPA.
066490 05-15

CHROMOSOME STUDIES ON PATIENTS (IN VIVO) AND CELLS (IN VITRO) TREATED WITH LYSERGIC ACID DIETHYLAMIDE.
071987 07-13

A CONTROLLED STUDY OF THE EFFECTS OF GAMFEXINE IN PHENOTHIAZINE TREATED PATIENTS.
072144 07-08

CATECHOLAMINE METABOLISM IN AFFECTIVE DISORDERS -- III. MHPG AND OTHER CATECHOLAMINE METABOLITES IN PATIENTS TREATED WITH LITHIUM CARBONATE.
075410 08-09

CHILDHOOD SCHIZOPHRENIA: A CASE TREATED WITH NICOTINIC ACID AND NICOTINAMIDE.
075944 09-08

HEAT STROKE IN PHENOTHIAZINE TREATED PATIENTS: A REPORT OF THREE FATALITIES.
076364 09-15

MENTAL SYMPTOMS IN PARKINSONIAN PATIENTS TREATED WITH L-DOPA.
081082 09-15

NEUROENDOCRINOLOGICAL STUDY IN CHLORPROMAZINE TREATED RATS. 089029 10-13
PSYCHIC EFFECTS IN PATIENTS TREATED WITH LEVODOPA. 091919 11-11
PSYCHIATRIC CHANGES IN PATIENTS TREATED WITH LEVODOPA: I. THE CLINICAL EXPERIMENT. 092917 11-10
A SEVENTH-MONTH DOUBLE-BLIND TRIAL OF AMITRIPTYLINE AND DIAZEPAM IN ECT TREATED DEPRESSED PATIENTS. 097562 11-09

TREATING
METHODS OF TREATING DELIRIUM-TREMENS AS BASED ON MATERIALS OF THE UNIVERSITY MEDICAL SCHOOLS PSYCHIATRIC CLINIC IN WROCLAW BETWEEN 1958 AND 1968. 087143 10-11

TREATMENT
TREATMENT OF PARKINSONISM WITH LEVODOPA. 042483 01-07
TEN YEARS OF TREATMENT WITH THIOXANTHENE DERIVATIVES. 042671 01-09
STATISTICAL METHOD OF ANALYSIS AND EVALUATION OF PSYCHOTHERAPEUTIC RESULTS: APPLICATION OF A LONG-ACTING NEUROLEPTIC, COMPARED WITH A STANDARD NEUROLEPTIC AND THE SAKEL INSULIN TREATMENT. 042676 01-07
SUBNORMAL SERUM FOLATE DUE TO ANTICONVULSIVE THERAPY: A DOUBLE-BLIND STUDY OF THE EFFECT OF FOLIC ACID TREATMENT IN PATIENTS WITH DRUG INDUCED SUBNORMAL SERUM FOLATES. 042700 01-11
INCREASED RELEASE OF DOPAMINE FROM STRIATAL DOPAMINERGIC TERMINALS IN THE RAT AFTER TREATMENT WITH A NEUROLEPTIC: THIOPROPERAZINE. 042742 01-03
DRUG PERSONALITY INTERACTION IN INTENSIVE OUTPATIENT TREATMENT. 047836 01-10
LYSERGIC ACID DIETHYLAMIDE AS A VARIABLE IN THE HOSPITAL TREATMENT OF ALCOHOLISM: A FOLLOW-UP STUDY. 052476 02-11
DIFFERENTIAL RESPONSE TO TREATMENT AS A FUNCTION OF THE CHANGING CHARACTER OF A DEPRESSION. 052574 02-10
CARDIAC CATECHOLAMINE LEVELS AND BLOOD PRESSURE AFTER CHRONIC TREATMENT WITH BETA-ADRENERGIC BLOCKING AGENTS. 055579 02-03
THE PSYCHOPHARMACOLOGICAL TREATMENT OF CARDIAC NEUROTIC PATIENTS WITH DIPOTASSIUM CHLORAZEPATE IN THE DOUBLE-BLIND TEST. 055689 02-10
GROUP TREATMENT OF CHRONIC ALCOHOLISM WITH LSD-25: STUDY II. 057480 02-14
AMANTADINE DOSAGE IN TREATMENT OF PARKINSONS DISEASE. 058241 02-11
TREATMENT OF WILSONS DISEASE WITH L-DOPA AFTER FAILURE WITH PENICILLAMINE. 058243 02-11
TREATMENT OF NARCOLEPSY WITH MONOAMINE OXIDASE INHIBITORS AND SYMPATHOMIMETIC AGENTS. 058327 02-13
TWO TRIALS WITH A NEW PSYCHOTHERAPEUTIC DRUG IN THE TREATMENT OF ANXIETY. 058335 02-10
CLOTHIAPIN IN THE TREATMENT OF CHRONIC SCHIZOPHRENIA. 058372 02-08
TREATMENT OF CHILDREN OF LITHIUM RESPONDING PARENTS. 058375 02-09
CRASH TREATMENT FOR MELANCHOLIA RESISTANT TO OTHER RECENTLY DEVELOPED METHODS. 058456 02-07
COMBINED USE OF DISULFIRAM AND METRONIDAZOLE IN TREATMENT OF ALCOHOLISM. 058589 02-15
PARKINSONS DISEASE: L-DOPA TREATMENT AND HANDWRITING AREA. 058966 03-11
PROTRIPTYLINE IN THE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS. 058968 03-08
AN EVALUATION OF NIACINAMIDE IN THE TREATMENT OF CHILDHOOD SCHIZOPHRENIA. 060240 03-08
EXCRETION OF VANYLGLYCOL IN HUMAN URINE UNDER DIETARY CONTROL, AND DURING TREATMENT WITH ANTIBIOTICS, DISULFIRAM, A MONOAMINE OXIDASE INHIBITOR, ALPHA-METHYLDOPA, AND RESERPINE. 060272 03-13
DILANTIN TREATMENT OF HOSPITALIZED CULTURAL FAMILIAL RETARDATES. 062175 03-14
EFFECTIVENESS OF LITHIUM CARBONATE IN THE TREATMENT OF MANIC-DEPRESSIVE ILLNESS. 062348 03-09
METHYSERGIDE AS A TREATMENT FOR MANIA. 062350 03-09
USE OF AMITRIPTYLINE SYRUP IN THE TREATMENT OF ENURESIS IN CHILDREN. 062407 03-11
PRELIMINARY CLINICAL OBSERVATIONS CONCERNING THE TREATMENT WITH METRONIDAZOLE IN CHRONIC ALCOHOLISM. 062866 03-11
A COMPARISON OF SHORT-TERM TREATMENT EFFECTS OF INTRAVENOUS SODIUM AMYTAL METHEDRINE AND LSD IN THE ALCOHOLIC. 062934 03-11
DRUG TREATMENT: CRITICAL EVALUATION. 063143 03-11
DRUG TREATMENT: CRITICAL EVALUATION. 063144 03-11
DRUG TREATMENT: CRITICAL EVALUATION. 063145 03-11
DRUG TREATMENT: CRITICAL EVALUATION. 063146 03-11
DRUG TREATMENT IN PSYCHIATRY. 063147 03-11
TELEVISION TAPE FOR EVALUATION OF TREATMENT RESPONSE. 063568 03-17
TOFRANIL IN THE TREATMENT OF POST ALCOHOLIC DEPRESSIONS. 063588 03-09
THE USE OF HIGH DOSES OF FLUPHENAZINE IN THE TREATMENT OF PSYCHOTIC PATIENTS. 063589 03-08
TREATMENT OF RESISTANT SCHIZOPHRENICS WITH EXTREME HIGH DOSAGE FLUPHENAZINE HYDROCHLORIDE. 063597 04-08
A CONTROLLED COMPARISON OF THE TREATMENT OF SCHIZOPHRENIC PATIENTS WHEN TREATED ACCORDING TO THE NEUROLEPTIC THRESHOLD OR BY CLINICAL JUDGMENT. 063776 04-08
CONTROLLED STUDIES OF ANTIPARKINSONISM AGENTS IN THE TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL SYMPTOMS. 063777 04-14
METABOLIC STUDIES AND CLINICAL OBSERVATIONS DURING L-DOPA TREATMENT OF PARKINSONS DISEASE. 063822 04-13
A CONTROLLED STUDY OF LSD TREATMENT IN ALCOHOLISM AND NEUROSIS. 063873 04-12
TREATMENT OF PHOBIC STATES WITH ANTIDEPRESSANTS: A RETROSPECTIVE STUDY OF 246 PATIENTS. 063934 04-10
EFFECTS OF MORPHINE TREATMENT AND STARVATION ON THE SUBSTRATE INTERACTION WITH P-450 IN THE OXIDATION OF DRUGS BY LIVER MICROSOMES. 063982 04-03
TREATMENT OF DEPRESSION BY THE INTERNIST: RESULTS WITH IMIPRAMINE. 064113 04-14
PSYCHOLOGICAL METHODS APPLIED TO EVALUATE SYMPTOMATIC GERIATRIC TREATMENT. 064152 04-14
LYOGEN IN THE TREATMENT OF MENTAL DISEASES IN CHILDREN. 064173 04-07
TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS WITH HALOPERIDOL. 064233 04-10
THE USE OF MOLINDONE IN THE TREATMENT OF ACUTE PSYCHOTIC STATES: COMPARISON OF TWO DOSAGE SCHEDULES. 064266 04-08
A COMPARATIVE STUDY OF FLUPHENAZINE AMITRIPTYLINE COMBINATION AND AMITRIPTYLINE ALONE IN THE TREATMENT OF DEPRESSED PSYCHIATRIC PATIENTS. 064356 04-09
MODIFICATION OF THE EFFECTS OF ANTIPSYCHOTIC AGENTS ON THE OPEN FIELD PERFORMANCE OF RATS BY TREATMENT WITH ALPHA-METHYLTYROSINE OR P-CHLOROPHENYLALANINE. 064392 04-04
THE USE OF SU-17595A IN THE TREATMENT OF PSYCHIATRIC DISORDERS. 064639 05-07
TREATMENT OF HYPERACTIVITY IN CHILDREN. 065176 05-12
THE TREATMENT OF ACUTE ALCOHOL INTOXICATION AND WITHDRAWAL. 065187 05-13
TREATMENT OF HEROIN DEPENDENCE WITH OPIATE ANTAGONISTS. 065195 05-13
THE PROCESS OF LEARNING IN RATS UNDERGOING PROLONGED TREATMENT WITH PSYCHOTROPIC AGENTS. 065441 05-04

SETTING, PATIENT, AND DOCTOR EFFECTS ON DRUG RESPONSE IN NEUROTIC PATIENTS: I. DIFFERENTIAL ATTRITION, DOSAGE DEVIATION, AND SIDE REACTION RESPONSES TO TREATMENT.
065453 05-10

LONG-ACTING DRUG TREATMENT IN OVERALL PSYCHIATRIC MANAGEMENT.
065472 05-17

THE EFFECTIVENESS OF PARENTERAL ADMINISTRATION OF FLUPHENAZINE DECANOATE IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS.
065473 05-07

DEPOT FLUPHENAZINE IN THE TREATMENT OF PSYCHOSIS IN A COMMUNITY MENTAL HEALTH CLINIC.
065475 05-08

LONG-ACTING PHENOTHIAZINES AND LONG-TERM PSYCHOTIC PATIENTS: THE ROLE OF FLUPHENAZINE ENANTHATE IN TREATMENT.
065479 05-08

DRUG THERAPY. II. TREATMENT OF DRUG MISUSE.
066329 05-15

EMERGENCY TREATMENT OF DRUG ABUSE AND POISON INGESTION.
066395 05-15

A COMPARISON OF HALOPERIDOL AND THIORIDAZINE HCL IN CHRONIC TREATMENT RESISTANT SCHIZOPHRENICS.
066398 05-08

THE EFFECT OF PROLONGED LITHIUM TREATMENT ON THE SYNTHESIS RATE AND TURNOVER OF MONOAMINES IN BRAIN REGIONS OF RATS.
066413 05-03

STUDY ON THE EFFECTS OF TABLET COLOUR IN THE TREATMENT OF ANXIETY STATES.
066496 05-10

ELECTROCARDIOGRAPHIC CHANGES DURING LITHIUM TREATMENT.
066747 05-13

A COMPARISON OF HALOPERIDOL AND THIORIDAZINE HCL IN CHRONIC TREATMENT RESISTANT SCHIZOPHRENICS.
066817 05-08

THIOPENTONE FACILITATED IMPLOSION IN TREATMENT OF PHOBIC DISORDERS.
066907 05-14

TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS.
067022 05-10

TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS.
067023 05-10

THE STRUCTURAL AND BIOCHEMICAL BASIS OF MOVEMENT DISORDERS IN TREATMENT WITH NEUROLEPTIC DRUGS AND IN EXTRAPYRAMIDAL DISEASES.
067107 06-13

LITHIUM CARBONATE AS AN ADJUNCT IN THE TREATMENT OF SCHIZOPHRENIA.
067364 06-08

TREATMENT OF PARKINSONS SYNDROME WITH L-DIHYDROXYPHENYLALANINE (LEVODOPA).
067666 06-07

METHOHEXITONE ASSISTED DESENSITIZATION IN TREATMENT OF PHOBIAS.
067673 06-11

PLEURAL EFFUSION AND FIBROSIS DURING TREATMENT WITH METHYSERGIDE.
067836 06-15

LSD CONDEMNED AS TREATMENT AGENT.
067868 06-15

AN APPROACH TO THE TREATMENT OF DRUG ABUSE.
067934 06-15

PSEUDOPREGNANCY, TREATMENT OF PERIODIC PSYCHIATRIC ILLNESS: A PILOT STUDY.
068215 06-09

NICOTINIC ACID IN THE TREATMENT OF SCHIZOPHRENIAS.
068450 06-08

THE USE OF CYCLAZOCINE IN THE TREATMENT OF HEROIN ADDICTS.
068601 06-17

THE PARENTERAL USE OF VITAMINS IN THE TREATMENT OF SCHIZOPHRENIA.
068976 06-08

COMBINED ADMINISTRATION OF THIORIDAZINE AND FLUOXYMESTERONE IN THE TREATMENT OF GERIATRIC PATIENTS.
069060 06-11

ANALYSIS OF CHROMOSOMES BEFORE AND AFTER TREATMENT WITH IMURAN.
069082 06-13

MORFOLEP IN TREATMENT OF SOME FORMS OF EPILEPSY.
069085 06-13

SIDE-EFFECTS AND TERATOGENICITY OF LITHIUM CARBONATE TREATMENT.
069580 07-15

TREATMENT WITH LITHIUM CARBONATE: RESULTS IN 35 CASES.
070287 07-09

LONG-TERM TREATMENT WITH OCTOCLOTHEPINE -- SIDE-EFFECTS AND LABORATORY FINDINGS.
070928 07-09

CLINICAL PILOT STUDY OF DIBENZEPINE TREATMENT OF DEPRESSION.
070939 07-09

PERSISTENT EXTRAPYRAMIDAL ORAL DYSKINESIAS FOLLOWING TREATMENT WITH THYMOLEPTICS.
070945 07-15

AMITRIPTYLINE, CHLORPROTHIXENE, PROTHIADENE AND PLACEBO IN THE TREATMENT OF NEUROSES.
070946 07-10

SUCCESSES AND FAILURES IN METHADONE MAINTENANCE TREATMENT OF HEROIN ADDICTION IN NEW-YORK CITY. (UNPUBLISHED PAPER).
071314 07-17

HYPERTENSION DURING IMIPRAMINE TREATMENT.
071971 07-15

L-DOPA IN THE TREATMENT OF POST-SURGICAL PARKINSON PATIENTS.
071984 07-07

L-DOPA IN THE TREATMENT OF PARKINSONISM. A PRELIMINARY APPRAISAL.
071985 07-07

A COMPARATIVE EVALUATION OF DOXEPIN AND CHLORDIAZEPOXIDE IN THE TREATMENT OF PSYCHONEUROTIC OUTPATIENTS.
072140 07-10

CI-601, A BUTYROPHENONE DERIVATIVE, IN THE TREATMENT OF CHRONICALLY WITHDRAWN SCHIZOPHRENIC PATIENTS.
072142 07-08

DOXEPIN IN THE TREATMENT OF PSYCHONEUROTIC PATIENTS.
072146 07-11

SULPIRIDE IN PSYCHIATRIC TREATMENT: CLINICAL AND PSYCHOMETRIC STUDY IN 58 PATIENTS.
072158 07-11

TREATMENT OF PSYCHOSOMATIC DISTURBANCES ASSOCIATED WITH PSYCHIC SYMPTOMS IN INTERNAL MEDICINE BY MEANS OF DOXEPIN.
072381 07-09

ISONICOTINIC-ACID-HYDRAZIDE (INH) INDUCED MENTAL DISORDERS IN THE COURSE OF LUNG TUBERCULOSIS TREATMENT.
072890 08-15

OXYPERTINE IN THE TREATMENT OF CHRONIC SCHIZOPHRENIA.
072896 08-08

EVALUATION OF THIOTHIXENE IN THE TREATMENT OF SCHIZOPHRENIA.
072897 08-08

INITIAL AND INTERVAL TREATMENT OF ACUTE PSYCHOSES WITH INTRAVENOUS INJECTION OF INOFAL.
073708 08-09

QUANTITATIVE EEG CHANGES DURING HIGH AND LOW DOSAGE FLUPHENAZINE HYDROCHLORIDE TREATMENT.
073710 08-13

LEUKOCYTOSIS DURING LITHIUM CARBONATE TREATMENT.
073711 08-15

PATIENT PERSONALITY AND DEMOGRAPHIC FACTORS AS PREDICTORS OF EARLY RESPONSE TO PSYCHOTROPIC DRUG TREATMENT.
074130 08-10

DRUGS IN THE TREATMENT OF DEPRESSION.
074926 08-09

HALLUCINOGENIC DRUGS IN THE TREATMENT OF ALCOHOLISM: A TWO-YEAR FOLLOW-UP.
075290 08-12

POLYPHARMACY IN PSYCHIATRY: PATTERNS OF DIFFERENTIAL TREATMENT.
075332 08-11

DRUG TREATMENT IN DEPRESSIVE ILLNESS: AMITRYPTYLINE AND CHLORDIAZEPOXIDE IN TWO NEUROTIC POPULATIONS.
075415 08-10

TREATMENT OF PERSISTENT PHENOTHIAZINE INDUCED ORAL DYSKINESIA.
075417 08-15

THE PLACE OF THIOTHIXENE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS. A SYSTEMATIC CLINICAL STUDY.
075422 08-08

NICOTINIC ACID IN THE PREVENTION AND TREATMENT OF METHIONINE INDUCED EXACERBATION OF PSYCHOPATHOLOGY IN SCHIZOPHRENICS.
075423 08-08

A DOUBLE-BLIND COMPARISON OF LITHIUM AND CHLORPROMAZINE IN THE TREATMENT OF MANIC STATES.
075430 08-09

LITHIUM CARBONATE TREATMENT IN PSYCHIATRY.
075584 08-11

BRIEF SLEEP TREATMENT WITH CHLORPROMAZINE.
075860 09-14

CRITIQUE OF STUDIES OF LITHIUM SALTS IN THE TREATMENT OF MANIA.
075867 09-09

SOME USES OF HALOPERIDOL IN THE TREATMENT OF PSYCHIATRIC CONDITIONS.
075879 09-08

TREATMENT OF LABILE HYPERTENSION.
076346 09-17

RESULTS OBTAINED WITH PROPERICIAZIN (8-909-RP) IN THE TREATMENT OF BEHAVIOR AND CHARACTER DISTURBANCES IN CHILDREN AND ADOLESCENTS.
078730 09-14

TREATMENT OF DEPRESSIONS ACCORDING TO TARGET SYMPTOMS.
078732 09-09
CLINICAL CONSIDERATIONS ABOUT THE TREATMENT OF VARIOUS ACUTE PSYCHOTIC STATES WITH THIOTHIXENE.
079746 09-11
NEUROPSYCHOTROPIC DRUGS IN THE TREATMENT OF SO-CALLED PAIN SYNDROMES.
079962 09-17
THE TREATMENT OF CHRONIC PAIN SYNDROMES: ANALGETIC EFFECT OF A NEUROLEPTIC SUBSTANCE.
079963 09-11
CLINICAL TREATMENT OF DEPRESSIVE SYNDROMES WITH NOXIPTILIN.
079967 09-10
TREATMENT OF DELUSION OF PARASITOSIS.
079994 09-11
CLINICAL AND AMBULANT TESTING WITH FLUPHENAZINE DECANOATE LYOGEN DEPOT IN THE LONG-TERM TREATMENT OF PSYCHIATRIC DISEASE.
080040 09-16
PROPOSALS FOR IMPROVING THE TREATMENT OF BRAIN DAMAGED PATIENTS.
080041 09-11
EVALUATION OF TEGRETOL IN THE TREATMENT OF BEHAVIOUR DISORDERS IN CHILDREN: METHODOLOGY AND RESULTS.
080098 09-07
CLINICAL OBSERVATIONS ON THE THERAPEUTIC ACTIVITY OF FLUPENTHIXOL IN THE TREATMENT OF CHRONIC SCHIZOPHRENIA.
080143 09-08
USE OF AN ANDROGEN DEPLETING HORMONE IN THE TREATMENT OF MALE SEX OFFENDERS.
080178 09-14
THE PSYCHOLYTIC TREATMENT OF A CHILDHOOD SCHIZOPHRENIC GIRL.
080609 09-08
CLINICAL CONSIDERATIONS ON THE TREATMENT OF DEPRESSION WITH CHLORIMIPRAMINE.
081121 09-10
EXPERIENCE WITH PROPERICIAZIN (AOLEPT) IN THE TREATMENT OF CHILDREN WITH DISTURBED PSYCHOMOTOR FUNCTIONS AND RESTLESSNESS.
081144 09-11
L-DOPA IN THE TREATMENT OF PARKINSONS DISEASE.
081392 09-17
THE TREATMENT OF MANIC RELATED DISEASES WITH LITHIUM CARBONATE.
081516 09-09
THIOTHIXENE IN THE TREATMENT OF ANXIETY AND DEPRESSION IN OUTPATIENTS.
082052 10-10
TREATMENT WITH THIORIDAZINE OF EMOTIONALLY DISTURBED CHILDREN IN A DAY HOSPITAL.
082090 10-14
TREATMENT OF SCOPOLAMINE INDUCED DELIRIUM.
082155 10-09
MILD INSULIN HYPOGLYCEMIC TREATMENT FOR HOSPITALIZED ADOLESCENTS.
082172 10-11
ORAL DYSKINESIAS -- OCCURRENCE AND TREATMENT.
083339 10-15
DISORDERS OF CONSCIOUSNESS AS A COMPLICATION IN NIALAMID TREATMENT.
085106 10-15
RELATIONSHIP BETWEEN THE HOSPITAL MILIEU AND THE RESPONSE TO PHENOTHIAZINES IN THE TREATMENT OF SCHIZOPHRENICS.
085237 10-08
AMITRIPTYLINE IN THE TREATMENT OF ENURESIS.
085453 10-14
III. PROLONGED ACTION NEUROLEPTICS: REPORT ON TREATMENT WITH PROLONGED ACTION NEUROLEPTICS IN PSYCHIATRY.
085993 10-11
CONTRIBUTION OF NEUROLEPTICS IN CURRENT USE TO THE TREATMENT OF DEPRESSIONS.
086235 10-10
BIOCHEMISTRY AND TREATMENT OF PARKINSONISM.
086351 10-13
EXTRAPYRAMIDAL ACCIDENTS IN TREATMENT OUTSIDE THE HOSPITAL SETTING.
086443 10-15
PSYCHOPHARMACOLOGY TODAY. ORIENTATIONS IN THE TREATMENT OF SCHIZOPHRENIA.
086877 10-17
TEST OF PEMOLINUM IN COMPLEX TREATMENT OF ALCOHOLISM.
086958 10-11
POSSIBILITIES AND LIMITATIONS OF DEPOT NEUROLEPTIC TREATMENT OF SCHIZOPHRENIC PSYCHOSES.
087066 10-17
RESULTS OF THE MEDICAL TREATMENT IN AGED PATIENTS WITH CEREBRAL ORGANIC DISTURBANCES.
087336 10-11
THE DRUG TREATMENT OF DEPRESSION.
087632 10-09
A POLYGRAPHIC STUDY OF THE NIGHT SLEEP OF PARKINSONIAN PATIENTS: EFFECTS OF TREATMENT WITH LEVODOPA.
087658 10-14
PSYCHIC SYMPTOMS IN L-DOPA TREATMENT OF PARKINSONS DISEASE.
087659 10-09
ANALYSIS OF RESULTS IN TREATMENT OF PARKINSONISM WITH LEVODOPA.
087660 10-11
ON GILLES-DE-LA-TOURETTES SYNDROME: SUCCESSFUL TREATMENT WITH HALOPERIDOL IN THREE CASES.
088610 10-11
THE EFFECTS OF ACUTE AND PROLONGED LITHIUM TREATMENT ON THE DISTRIBUTION OF ELECTROLYTES, POTASSIUM AND SODIUM.
088614 10-03
FLUPHENAZINE ENANTHATE IN THE TREATMENT OF THE POST-HOSPITALIZED PATIENT.
089000 10-17
TREATMENT MANAGEMENT IN A HOSPITAL SETTING.
089001 10-11
PIPERACETAZINE VS. CHLORPROMAZINE IN THE TREATMENT OF SCHIZOPHRENIA.
089099 10-08
THE DRUG 100-129-HF-1854 (CLOZAPINE) FOR PSYCHIATRIC TREATMENT.
089100 10-09
A COMBINED TREATMENT OF CHRONIC SCHIZOPHRENICS WITH OSPOLOT (SULTHIAME) AND STELAZINE (TRIFLUOPERAZINE).
089101 10-08
PARADOXAL PSYCHIC REACTIONS DURING LITHIUM TREATMENT.
089103 10-15
SPECIFIC (IN THE SENSE OF INCREASED PREDISPOSITION TO INJURY OF THE SUBDOMINANT HEMISPHERE) DISTRIBUTION OF THE EXTRAPYRAMIDAL SYMPTOMS IN SCHIZOPHRENICS DURING THE COURSE OF HALOPERIDOL TREATMENT.
089106 10-15
CONTROLLED INVESTIGATION WITH CINNARIZIN IN THE TREATMENT OF DEMENTIA CONDITIONS IN OLD AGE.
089108 10-11
USE OF THE DRUG LUVATRENE FOR THE TREATMENT OF OUTPATIENTS.
089109 10-17
CHLORIMIPRAMINE: THE MAJOR TREATMENT OF DEPRESSIVE STATES.
089157 10-09
PRESENT DAY TREATMENT OF DELIRIUM-TREMENS.
089161 10-11
UNIVOCAL TREATMENT OF MULTIFORM DISORDERS: DOGMATIL IN PSYCHODIGESTIVE PATHOLOGY.
089174 10-11
LITHIUM TREATMENT OF THE PSYCHOSES.
090358 11-16
PREVENTION AND TREATMENT OF HYPOTENSION BY USING PSYCHOPHARMACOLOGY.
091139 11-09
EFFECT OF PYROVALERONE IN THE AMBULATORY TREATMENT OF FATIGUE STATES.
091503 11-11
L-DOPA IN THE TREATMENT OF PARKINSONS DISEASE.
091715 11-07
A STUDY OF DEHYDROBENZPERIDOL (R-4749) IN THE TREATMENT OF DYSTHYMIC SYNDROMES.
092077 11-09
ELECTROCARDIOGRAPHIC DATA IN CHRONIC ALCOHOLISM BEFORE, DURING AND AFTER TREATMENT WITH TETRAETHYLTHIURAM DISULPHIDE.
092481 11-14
EFFECTS OF NORTRIPTYLINE IN THE TREATMENT OF DEPRESSION SYNDROMES.
093133 11-09
CONCERNING A CASE OF THROMBOSIS OF THE MIDDLE CEREBRAL ARTERY IN THE COURSE OF PROGESTINIC TREATMENT.
094467 11-14
ON THE BIOCHEMICAL MECHANISM OF ACTION OF NICOTINIC ACID, NICOTINAMIDE, METHIONINE, AND D-PENICILLAMINE IN THE TREATMENT OF PSYCHOSES.
094962 11-13
THE EFFECTIVENESS OF SIMULTANEOUS TREATMENT WITH VITAMIN-B12 AND INSULIN IN SCHIZOPHRENIC PATIENTS, ACCORDING TO THE FREQUENCY OF STABLE REMISSIONS.
096513 11-08
TEMPERATURE INCREASES UNDER TREATMENT WITH PSYCHOPHARMACEUTICALS.
097999 11-15
THE COMBINATION OF PSYCHOTROPIC DRUGS IN THE TREATMENT OF SCHIZOPHRENIA.
098002 11-08
TREATMENT OF PARKINSONISM WITH L-DOPA.
098172 11-07

RETINOPATHY FOLLOWING THIORIDAZINE TREATMENT.
100016 11-15

A DOUBLE-BLIND INVESTIGATION WITH FLUPENTHIXOL AND TRIFLUOPERAZINE AT TREATMENT OF SCHIZOPHRENIC PSYCHOSES.
100017 11-08

ETIOLOGY OF LATE HYPERKINESIS IN THE COURSE OF LONG-TERM TREATMENT WITH NEUROLEPTICS.
100997 12-15

NEUROPATHOLOGY OF PERSISTENT CHOREIFORM HYPERKINESIAS UNDER LONG-TERM TREATMENT WITH NEUROLEPTICS.
101020 12-15

INTERPERSONAL UNDERSTANDING, INTERPERSONAL STRESS AND CURRENT STATES: INTERRELATIONSHIPS AND TREATMENT ASSESSMENT. (PH.D. DISSERTATION).
103636 12-14

PSYCHOPHARMACOLOGICAL AGENTS IN THE TREATMENT OF THE CRIMINAL.
104836 12-17

LONG-TERM TREATMENT WITH CHLORPROMAZINE IN ANIMAL EXPERIMENTATION.
105619 12-05

PSYCHODYNAMICS OF THE RESPONSE TO PHARMACOLOGIC TREATMENT WITH NEUROLEPTICS IN SCHIZOPHRENICS.
105623 12-08

TREATMENT AND PROPHYLAXIS OF MANIC STATES WITH A CARBONIC ANHYDRASE INHIBITOR.
105731 12-14

EXPERIENCE WITH A COMBINATION OF AMITRIPTYLINE AND THIORIDAZINE FOR THE TREATMENT OF DEPRESSIONS.
105732 12-14

CLINICAL TRIALS AND TREATMENT WITH PSYCHOPHARMACEUTICALS. A SECOND CRITICAL REVIEW: AN IMPRESSION.
105734 12-17

PSYCHOSOCIAL PROFILES OF PATIENTS ON LITHIUM TREATMENT.
106762 12-14

LITHIUM DROP-OUTS: A FOLLOW-UP STUDY OF PATIENTS WHO DISCONTINUED PROPHYLACTIC TREATMENT.
106771 12-09

TREATMENT OF MOOD DISORDERS WITH LITHIUM CARBONATE.
106773 12-09

LITHIUMS POSITION AMONG ANTIDEPRESSANTS IN THE TREATMENT OF ACUTE ENDOGENOUS AND INVOLUTIONAL DEPRESSIONS.
106777 12-09

A LONG-ACTING NEUROLEPTIC IN THE TREATMENT OF CHRONIC ALCOHOLISM IN NEUROTIC AND PSYCHOTIC PATIENTS.
109255 12-11

USE OF MELLERIL RETARD IN TREATMENT OF PATIENTS WITH DEPRESSIVE PARANOID AND ANXIOUS DEPRESSIVE SYNDROMES.
109724 12-14

CONCERNING THE ARTICLE BY N.N.TIMOFEYEV, V.T.KONDRASHENKO AND N.Y.NEMTSEVA ON OXYMETRIC INVESTIGATION OF PATIENTS WITH SCHIZOPHRENIA AND REACTIVE PSYCHOSIS DURING NEUROLEPTIC TREATMENT.
109788 12-08

DEPRESSIVE STATES OF OLD AGE AND TREATMENT OF THEM.
111018 12-09

USE OF NEULEPTIL IN TREATMENT OF PATIENTS WITH SCHIZOPHRENIA.
111031 12-08

ON THE PROBLEM OF TREATMENT AND SOME CLINICAL CHARACTERISTICS OF SCHIZOPHRENIA WITH A GRADUAL PAROXYSMAL LIKE COURSE.
111032 12-08

ON THE PROBLEM OF AMBULATORY TREATMENT OF SCHIZOPHRENIA WITH PSYCHOTROPIC DRUGS.
111034 12-08

PARKINSONISM: PHYSIOLOGY, PHARMACOLOGY AND TREATMENT.
119840 12-17

ADMINISTRATION OF A NEW BUTYROPHENONE DERIVATIVE, PIMOZIDE, IN THE TREATMENT OF SCHIZOPHRENIA.
123373 12-08

PSYCHOSENSORIAL PHENOMENA DURING TREATMENT WITH TRICYCLIC THYMOANALEPTICS (PRESENTATION OF TWO CASES).
124311 12-15

TRANQUILIZERS IN THE TREATMENT OF THE CARDIAC NEUROTIC PATIENT AND THE SUBSEQUENT ALTERATION OF COMPLAINTS.
128568 12-14

A DOUBLE-BLIND COMPARISON OF S-804 (NEW BENZODIAZEPINE DRUG) WITH CHLORDIAZEPOXIDE AND DIAZEPAM IN THE TREATMENT OF NEUROSIS.
129097 12-10

A SUPPLEMENT TO CLINICAL EVALUATION OF THIOTHIXENE WITH SPECIAL REFERENCE TO THE TREATMENT OF AFFECTIVE PSYCHOSES.
129452 12-09

THE EFFECTS OF LITHIUM SALTS IN THE TREATMENT OF DEPRESSION.
129579 12-09

**TREATMENTS**

NEWER MEDICAL TREATMENTS IN PARKINSONISM.
059021 03-11

THE EFFECTS OF VARIOUS PRIOR TREATMENTS UPON THE TRANSPORT OF CHLORPROMAZINE AND TRIFLUOPERAZINE INTO RAT BRAIN.
069309 06-02

A COMPARATIVE STUDY OF PHYSICAL TREATMENTS IN SCHIZOPHRENIA.
138362 12-08

**TREMOR**

REVERSIBLE EFFECT OF L-DOPA ON TREMOR AND CATATONIA INDUCED BY ALPHA-METHYL-P-TYROSINE.
040124 01-05

DRUG-INDUCED RELIEF OF EXPERIMENTAL TREMOR IN MONKEYS.
068457 06-04

THE EFFECT OF SOME DRUGS ON GENETIC TREMOR IN THE MOUSE.
081066 09-04

**TRENDS**

PSYCHIATRIC DRUGS AND TRENDS.
095410 11-15

CLINICAL PSYCHOPHARMACOLOGY: CONCEPTUAL MODELS OF CURRENT TRENDS.
097621 11-17

**TRICYANOAMINOPROPENE**

CRETINISM IN RATS: ENDURING BEHAVIORAL DEFICIT INDUCED BY TRICYANOAMINOPROPENE.
070839 07-02

THE EFFECTS OF TRICYANOAMINOPROPENE ON LEARNING IN A DIFFERENTIAL REINFORCEMENT OF LOW RATES SITUATION.
075851 09-03

THE EFFECT OF MAGNESIUM PEMOLINE, TRICYANOAMINOPROPENE AND D-AMPHETAMINE ON DISCRIMINATED AVOIDANCE PERFORMANCE IN RATS AS A FUNCTION OF AGE.
076133 09-04

FAILURE OF TRICYANOAMINOPROPENE TO FACILITATE ACQUISITION OF DOUBLE ALTERNATION IN RATS.
088471 10-04

**TRICYCLIC**

PLASMA PROTEIN BINDING OF TRICYCLIC ANTIDEPRESSIVE DRUGS.
040573 01-13

DIMETHACRINE – A NEW TRICYCLIC ANTIDEPRESSANT: OPEN INVESTIGATIONS IN A CLINIC AND POLYCLINIC.
058281 02-07

TRICYCLIC ANTIDEPRESSANT POISONING.
058333 02-15

DIFFERENTIAL EFFECTS OF THREE TRICYCLIC ANTIDEPRESSANTS ON SLEEP AND REM SLEEP IN THE RAT.
067919 06-04

ANTIHEMOLYTIC ACTIONS OF TRICYCLIC TRANQUILIZERS: STRUCTURAL CORRELATIONS.
074862 08-03

THYROID HORMONE AND TRICYCLIC ANTIDEPRESSANTS IN RESISTANT DEPRESSIONS.
075428 08-09

AGGRESSIVE BEHAVIOUR IN CHICKS INDUCED BY TRICYCLIC ANTIDEPRESSANTS.
090420 11-04

FACTORS AFFECTING THE URINARY EXCRETION OF TRICYCLIC ANTIDEPRESSANTS IN MAN.
100026 11-13

PSYCHOSENSORIAL PHENOMENA DURING TREATMENT WITH TRICYCLIC THYMOANALEPTICS (PRESENTATION OF TWO CASES).
124311 12-15

**TRIFLUOPERAZINE**

HIGH DOSES OF TRIFLUOPERAZINE AND TARDIVE DYSKINESIA.
042699 01-15

A COMPARATIVE STUDY OF MOLINDONE AND TRIFLUOPERAZINE.
056500 02-08

DISTRIBUTION, EXCRETION AND METABOLISM OF TRIFLUOPERAZINE METHIODIDE-C14 IN RATS.
064094 04-03

LONG-TERM PSYCHOTHERAPY UTILIZING TRIFLUOPERAZINE IN A PSYCHOTIC PRESCHOOL CHILD: (A CASE STUDY).
066806 05-11

THE EFFECTS OF VARIOUS PRIOR TREATMENTS UPON THE TRANSPORT OF CHLORPROMAZINE AND TRIFLUOPERAZINE INTO RAT BRAIN.
069309 06-02

THIOTHIXENE AND TRIFLUOPERAZINE IN A STEP SYSTEM.
075421 08-08

A COMBINED TREATMENT OF CHRONIC SCHIZOPHRENICS WITH OSPOLOT (SULTHIAME) AND STELAZINE (TRIFLUOPERAZINE).
089101 10-08

A COMPARATIVE STUDY OF THIOTHIXENE AND TRIFLUOPERAZINE IN THE ACUTE PHASE OF SCHIZOPHRENIA.
089159 10-08

THE ANTIANXIETY EFFECTS OF HALOPERIDOL AND TRIFLUOPERAZINE IN AN OUTPATIENT NEUROTIC POPULATION.
089444 11-10

A DOUBLE-BLIND INVESTIGATION WITH FLUPENTHIXOL AND TRIFLUOPERAZINE AT TREATMENT OF SCHIZOPHRENIC PSYCHOSES.
100017 11-08

**TRIGEMINAL**
CLINICAL EVALUATION OF THE USE OF G-32883 IN TRIGEMINAL NEURALGIA.
112130 12-11

**TRIGGER**
DEXAMPHETAMINE: A POSSIBLE ENVIRONMENTAL TRIGGER IN CARDIOVASCULAR MALFORMATIONS.
082039 10-15

**TRIGLYCERIDES**
CHANGES IN THE SERUM CONCENTRATION OF CHOLESTEROL, TRIGLYCERIDES AND PHOSPHOLIPIDS IN THE MOUSE AND RAT AFTER ADMINISTRATION OF EITHER CHLORCYCLIZINE OR PHENOBARBITAL.
064282 04-03

**TRIIODOTHYRONINE**
INFLUENCE OF TRIIODOTHYRONINE ON SELECTIVE ATTENTION IN MAN AS MEASURED BY THE VISUAL AVERAGED EVOKED POTENTIAL.
062510 03-13

**TRIMEPRIMINE**
EFFECTS OF TRIMEPRIMINE (SURMONTIL) ON SPERMATOGENESIS AND MOOD IN NORMAL VOLUNTEERS.
072147 07-14

**TRIMETHOBENZAMIDE**
A DOUBLE-BLIND EVALUATION OF THE ANTIEMETIC EFFICACY OF BENZQUINAMIDE, PROCHLORPERAZINE AND TRIMETHOBENZAMIDE IN OFFICE PRACTICE.
063022 03-07

**TRIMETHOXYAMPHETAMINES**
METABOLIC STUDIES ON TRIMETHOXYAMPHETAMINES.
071783 07-03

**TRIMETHOXYNITROSTYRENE**
2,3,6 TRIMETHOXYNITROSTYRENE AND ITS BETA-PHENETHYLAMINE.
063606 04-05

**TRIMIPRAMINE**
AMITRIPTYLINE AND TRIMIPRAMINE IN NEUROTIC DEPRESSED OUTPATIENTS: A COLLABORATIVE STUDY.
075868 09-10

**TRIOXAZINE**
CLINICAL EXPERIMENT WITH A NEW TRANQUILLIZER: TRIOXAZINE.
094423 11-11

**TRIP**
THE STRANGE TRIP OF DR. HOFMANN.
081694 10-17

**TRIPARTITE**
MANS TRIPARTITE BRAIN AND PSYCHOSOMATIC MEDICINE.
119884 12-17

**TRIPERIDOL**
A COMPARISON OF TRIPERIDOL AND PERPHENAZINE IN SCHIZOPHRENIA. EFFECTS ON MYOCLONIC THRESHOLD.
070935 07-08

**TRIPHOSPHATE**
THE EFFECTS OF SOME PSYCHOACTIVE DRUGS ON RAT BRAIN ADENOSINE TRIPHOSPHATE LEVELS.
058988 03-03

**TRITIATED**
UPTAKE OF TRITIATED TESTOSTERONE IN BRAIN AND PERIPHERAL TISSUES OF NORMAL AND NEONATALLY ANDROGENIZED FEMALE RATS.
076086 09-04
STUDIES ON PSYCHOTROPIC DRUGS (SEVENTH REPORT) – METABOLIC FATE OF APY-606 – ABSORPTION, DISTRIBUTION, EXCRETION AND METABOLISM OF TRITIATED APY-606.
131059 12-02

**TROPAX**
CLINICAL RESULTS OF THE TESTING FOR ANALGESIC EFFECT OF DEXTROPROPOXYPHENE IN COMBINATION WITH A PSYCHOTROPIC PREPARATION (TROPAX).
081147 09-17

**TROUBLES**
PHARMACOLOGICAL ASSOCIATION OF THIORIDAZINE HYDERGINE IN PSYCHOEMOTIONAL TROUBLES OF THE AGED.
091138 11-14

**TRUNK**
THE ACTION OF CENTRAL DEPRESSANT DRUGS ON THE SPONTANEOUS DISCHARGE OF ACTION POTENTIALS IN THE SUPERIOR CERVICAL SYMPATHETIC TRUNK OF THE CAT.
072034 07-03

**TRYPHTAZINE**
THE CATECHOLAMINE CONTENT IN THE BRAINSTEM OF ALBINO RATS IN THE DEVELOPMENT OF TOLERANCE TO TRYPHTAZINE.
073681 08-03

**TRYPTALDEHYDES**
TRYPTALDEHYDES (INDOLEACETALDEHYDES) IN SEROTONERGIC SLEEP OF NEWLY HATCHED CHICKS.
055583 02-03

**TRYPTAMINE**
INFRARED IDENTIFICATION OF SOME HALLUCINOGENIC DERIVATIVES OF TRYPTAMINE AND AMPHETAMINE.
058877 02-01
EFFECTS OF INFUSED TRYPTAMINE IN MAN.
069053 06-13
ANTAGONISM OF BETA-PHENYLETHYLAMINE DERIVATIVES AND SEROTONIN BLOCKING DRUGS UPON SEROTONIN, TRYPTAMINE AND RESERPINE BEHAVIORAL DEPRESSION IN MICE.
079970 09-04
THE ACTION OF TRYPTAMINE ON THE DOG SPINAL CORD AND ITS RELATIONSHIP TO THE AGONISTIC ACTIONS OF LSD-LIKE PSYCHOTOGENS.
090422 11-03
DISTURBANCES IN TRYPTAMINE SEROTONIN METABOLISM ASSOCIATED WITH PSYCHOTIC PHENOMENA.
121084 12-13

**TRYPTAMINERGIC**
TRYPTAMINERGIC MECHANISMS IN PUNISHED AND NONPUNISHED BEHAVIOR.
069738 07-04

**TRYPTOPHAN**
TRYPTOPHAN HYDROXYLASE CHANGES IN MIDBRAIN OF THE RAT AFTER CHRONIC MORPHINE ADMINISTRATION.
064146 04-03
PROJECT SUMMARY: THIENOPYRIDINE ANALOGS OF SEROTONIN AND TRYPTOPHAN.
066815 05-01
CONTRACEPTIVES, BRAIN SEROTONIN, AND LIVER TRYPTOPHAN PYRROLASE.
067072 05-03
TRYPTOPHAN METABOLISM IN DEPRESSION.
069081 06-13
THIENOPYRIDINE ANALOGS OF SEROTONIN AND TRYPTOPHAN.
074844 08-01
EFFECTS OF COCAINE AND AMPHETAMINE ON THE METABOLISM OF TRYPTOPHAN AND 5-HYDROXYTRYPTAMINE IN MOUSE BRAIN IN VIVO.
095440 11-03
EXCITATORY EFFECT OF TRYPTOPHAN IN MICE AND RATS AND EFFECT OF IMIPRAMINE AND DESMETHYLIMIPRAMINE UPON IT.
098009 11-03
PSYCHOCLINICAL OBSERVATIONS ON THE EFFECT OF THE LOGOS COMPOUND (ASSOCIATION OF PYRITHIOXINE DIHYDROCHLORIDE, TRYPTOPHAN AND CALCIUM ALPHA-KETOGLUTARATE).
109258 12-11

**TRYPTOPHOL**
TRYPTOPHOL, 5-HYDROXYTRYPTOPHOL AND 5-METHOXYTRYPTOPHOL INDUCED SLEEP IN MICE.
058382 02-04

**TUBERCULOSIS**
ISONICOTINIC-ACID-HYDRAZIDE (INH) INDUCED MENTAL DISORDERS IN THE COURSE OF LUNG TUBERCULOSIS TREATMENT.
072890 08-15

**TUBULAR**
MECHANISM OF THE RENAL TUBULAR TRANSPORT OF MORPHINE AND MORPHINE ETHEREAL SULFATE IN THE CHICKEN.
040754 01-03

**TUINAL**
A COMPARISON OF SLEEP PATTERNS IN NATURAL AND MANDRAX AND TUINAL INDUCED SLEEP.
067864 06-14

**TWITCHES**
INHIBITION OF CENTRAL SEROTONINERGIC EXCITATION (5-HYDROXYTRYPTOPHAN INDUCED DEAD TWITCHES) IN MICE BY LITHIUM.
097989 11-04

**TWO-FLASH**
CORTISOL EFFECTS ON AVERAGED EVOKED POTENTIAL, ALPHA-RHYTHM, TIME ESTIMATION, AND TWO-FLASH FUSION THRESHOLD.
075274 08-13

**TWO-WAY**
DEPRESSION OF TWO-WAY AVOIDANCE LEARNING AND ENHANCEMENT OF PASSIVE AVOIDANCE LEARNING BY SMALL DOSES OF PHYSOSTIGMINE.
064365 04-04

**TYPOLOGY**
A CYCLAZOCINE TYPOLOGY IN OPIATE DEPENDENCE.
075427 08-16

**TYRAMINE**
ACTIONS OF RESERPINE AND TYRAMINE ON THE ACETYLCHOLINE CONTENT OF BRAINSTEM, HEART AND BLOOD OF THE RAT.
067461 06-03
EFFECT OF AMPHETAMINE ON THE PRESSOR RESPONSE TO TYRAMINE: FORMATION OF P-HYDROXYNOREPHEDRINE FROM AMPHETAMINE IN MAN.
090373 11-03

**TYROSINASE**
EFFECT OF PHENOTHIAZINES ON MELANOMA TYROSINASE ACTIVITY.
089998 11-05

**TYROSINE**
BIPHASIC EFFECT OF NOREPINEPHRINE IN THE REGULATION OF HEPATIC TYROSINE TRANSAMINASE ACTIVITY.
062327 03-03
EFFECT OF PITUITARY AND ACTH ON THE MAINTENANCE OF BASAL TYROSINE HYDROXYLASE ACTIVITY IN THE RAT ADRENAL GLAND.
075714 08-03
PHASE DIFFERENCE IN THE INDUCTION OF TYROSINE HYDROXYLASE IN CELL BODY AND NERVE TERMINALS OF SYMPATHETIC NEURONES.
075715 08-03
NEURONAL AND HORMONAL CONTROL OF TYROSINE HYDROXYLASE AND PHENYLETHANOLAMINE N-METHYLTRANSFERASE ACTIVITY.
080352 09-03
U-14C TYROSINE METABOLISM OF THE PERFUSED CAT BRAIN WITH HIGH PLASMA PHENYLALANINE OR WITHOUT PLASMA TYROSINE.
100852 12-03

**TYROSINE-14C**
FURTHER STUDIES ON THE ACCUMULATION AND DISAPPEARANCE OF CATECHOLAMINES FORMED FROM TYROSINE-14C IN MOUSE BRAIN. EFFECT OF SOME PHENOTHIAZINE ANALOGUES.
042727 01-03

**U-M**
U-M TEAM ISSUES WARNING ON USE OF DRUG.
058527 02-15

**U-14624**
BEHAVIORAL AND BRAIN CATECHOLAMINE DEPLETING ACTIONS OF U-14624, AN INHIBITOR OF DOPAMINE BETA-HYDROXYLASE.
058986 03-03

**ULCERATION**
A NOTE ON THE EFFECTS OF CHLORPROMAZINE UPON ULCERATION IN THE RAT.
069645 07-03
RELATIONS BETWEEN THE ELECTROGASTROGRAM AND GASTRIC ULCERATION DURING EXPOSURE TO STRESS.
075438 08-03

**ULCERS**
STUDIES ON THE ROLE OF ACID IN THE PATHOGENESIS OF EXPERIMENTAL STRESS ULCERS.
075276 08-03

**UNANESTHETIZED**
TEMPERATURE RESPONSES AND OTHER EFFECTS OF 5-HYDROXYTRYPTOPHAN AND 5-HYDROXYTRYPTAMINE WHEN ACTING FROM THE LIQUOR SPACE IN UNANESTHETIZED RABBITS.
046404 01-03
THE EFFECT OF MEDAZEPAM ON THE THRESHOLDS OF SUBCORTICAL LIMBIC STIMULUS RESPONSES, MEASURED IN UNANESTHETIZED, UNRESTRAINED CATS.
072067 07-03

**UNCONDITIONED**
DRUG EFFECTS ON A MEASURE OF UNCONDITIONED AVOIDANCE IN THE RAT.
065440 05-04
UNCONDITIONED REFLEX ACTIVITY IN THE RAT SUFFERING FROM EXPERIMENTAL LYMPHOGENIC ENCEPHALOPATHY AND THE THERAPEUTIC EFFECT OF COUMARIN FROM MELILOTUS-OFFICINALIS.
126051 12-04

**UNDERSTANDING**
AMANITA-MUSCARIA: PRESENT UNDERSTANDING OF ITS CHEMISTRY.
074074 08-01
INTERPERSONAL UNDERSTANDING, INTERPERSONAL STRESS AND CURRENT STATES: INTERRELATIONSHIPS AND TREATMENT ASSESSMENT. (PH.D. DISSERTATION).
103636 12-14

**UNILATERAL**
SPEED, ACCURACY, AND STRENGTH OF FORELIMB MOVEMENT AFTER UNILATERAL PYRAMIDOTOMY IN RHESUS MONKEYS.
076213 09-04

**UNIT**
UNIT ACTIVITY IN PREMARIN INDUCED CORTICAL EPILEPTOGENIC FOCI.
066187 05-03

**UNITED-STATES**
UNITED-STATES PROCEDURES FOR SCREENING DRUGS: TESTING FOR DEPENDENCE LIABILITY IN ANIMALS AND MAN.
058971 03-02

**UNIVERSITY**
L-DOPA THERAPY OF PARKINSONS DISEASE (A REVIEW OF THE PRELIMINARY EXPERIENCE AT WEST-VIRGINIA UNIVERSITY).
073421 08-07
METHODS OF TREATING DELIRIUM-TREMENS AS BASED ON MATERIALS OF THE UNIVERSITY MEDICAL SCHOOLS PSYCHIATRIC CLINIC IN WROCLAW BETWEEN 1958 AND 1968.
087143 10-11
ABSTRACT OF THESES FOR DOCTOR OF MEDICAL SCIENCES, THE UNIVERSITY OF TOKYO: MORITA THERAPEUTIC APPROACH TO SCHIZOPHRENIA.
126778 12-17

**UNIVOCAL**
UNIVOCAL TREATMENT OF MULTIFORM DISORDERS: DOGMATIL IN PSYCHODIGESTIVE PATHOLOGY.
089174 10-11

**UNLEARNED**
EFFECTS OF A TRANQUILIZER AND TWO ANTIDEPRESSANTS ON LEARNED AND UNLEARNED BEHAVIORS.
064259 04-04

**UNPUNISHED**
EFFECTS OF SOME BENZODIAZEPINES ON PUNISHED AND UNPUNISHED BEHAVIOR IN THE PIGEON.
040758 01-04

**UNRELATED**
ALTERATIONS IN BRAIN SENSITIVITY AND BARBITURATE METABOLISM UNRELATED TO AGGRESSION IN SOCIALLY DEPRIVED MICE.
069052 06-03

**UNRESOLVED**
AFFECTIVE DISORDERS: PROGRESS, BUT SOME UNRESOLVED QUESTIONS REMAIN.
061682 03-09

**UNRESTRAINED**
THE EFFECT OF MEDAZEPAM ON THE THRESHOLDS OF SUBCORTICAL LIMBIC STIMULUS RESPONSES, MEASURED IN UNANESTHETIZED, UNRESTRAINED CATS.
072067 07-03

**UNUSABLE**
MONOAMINE OXIDASE INHIBITORS, COMBINED WITH THYMOLEPTICS: ARE THEY REALLY UNUSABLE FOR HUMAN BEINGS.
066805 05-03

**UPTAKE**
EFFECTS OF RESERPINE AND DESIPRAMINE ON THE UPTAKE AND SUBCELLULAR DISTRIBUTION OF 5-HYDROXYTRYPTAMINE IN RABBIT BRAINSTEM AFTER INTRAVENOUS ADMINISTRATION OF 5-HYDROXYTRYPTOPHAN.
056610 02-03
BLOCKADE OF NORADRENALINE UPTAKE AND INHIBITION OF GASTRIC ACID SECRETION BY 2-(P-CHLOROPHENYL-2-(PYRIDYL)HYDROXYMETHYL) IMIDAZOLINE MALEATE (SCH-12650).
058878 02-02
INTERFERENCE OF BARBITURATES WITH PYRIMIDINE INCORPORATION -- II: STRUCTURAL SPECIFICITY OF THE INHIBITION OF OROTATE UPTAKE IN BACILLUS-CEREUS.
064046 04-03
14C-5-HYDROXYTRYPTAMINE AND 3H-D-AMPHETAMINE: UPTAKE AND CONTRACTION BY THE RAT STOMACH FUNDUS IN VITRO.
064050 04-03
EFFECTS OF DESMETHYLIMIPRAMINE AND COCAINE ON THE UPTAKE, RETENTION AND METABOLISM OF H3-TYRAMINE IN RAT BRAIN SLICES.
064419 04-03
THE ROLE OF PLASMA PROTEIN BINDING IN THE INHIBITORY EFFECT OF NORTRIPTYLINE ON THE NEURONAL UPTAKE OF NOREPINEPHRINE.
066278 05-03
UPTAKE AND RETENTION OF 3H-NORADRENALINE IN ADRENERGIC NERVE TERMINALS AFTER RESERPINE AND AXOTOMY.
066499 05-03
INHIBITION OF CATECHOLAMINE UPTAKE BY 6-HYDROXYDOPAMINE IN RAT BRAIN.
066501 05-03
UPTAKE OF (14C) PENTYLENETETRAZOL BY DEVELOPING RAT BRAIN.
067120 06-02
INHIBITORY EFFECT OF TWO NEWER ANTIDEPRESSANTS, LU-5-003 AND LU-3-010, ON SEROTONIN UPTAKE IN HUMAN BLOOD PLATELETS IN VITRO.
071791 07-03
THE EFFECT OF AMANTADINE ON THE UPTAKE OF DOPAMINE AND NORADRENALINE BY RAT BRAIN HOMOGENATES.
074148 08-03
UPTAKE OF TRITIATED TESTOSTERONE IN BRAIN AND PERIPHERAL TISSUES OF NORMAL AND NEONATALLY ANDROGENIZED FEMALE RATS.
076086 09-04
ON THE UPTAKE OF PHENOTHIAZINE DERIVATIVES BY THE ISOLATED PERFUSED RAT BRAIN.
089043 10-03
BLOCKADE OF NOREPINEPHRINE UPTAKE AND RELATED ACTIVITIES OF CIS- AND TRANS N,N(PRIME)-BIS-(1-NAPHTHYLMETHYL)-1,4 CYCLOHEXANE BIS-(METHYLAMINE) DIHYDROCHLORIDE.
090136 11-03
EFFECT OF ANTIDEPRESSANTS ON CEREBRAL CIRCULATION AND OXYGEN UPTAKE.
110633 12-03
UPTAKE AND STORAGE MECHANISM OF 5-HYDROXYTRYPTAMINE IN RABBIT BRAINSTEM AND EFFECT OF RESERPINE.
114975 12-03

**URIDINE**
THE USE OF THE PYRIMIDINE NUCLEOSIDES (CYTIDINE AND URIDINE) IN THE THERAPY OF CEREBRAL VASCULAR ILLNESS.
094472 11-13

**URINARY**
URINARY METABOLITES OF HARMINE IN THE RAT AND THEIR INHIBITION OF MONOAMINE OXIDASE.
040417 01-03
STUDIES OF DELAYED ACTION MEDICATION: V. PLASMA LEVELS AND URINARY EXCRETION OF FOUR DIFFERENT DOSAGE FORMS OF CHLORPROMAZINE.
041559 01-13
METOCLOPRAMIDE AND THE MUSCULATURE OF ESOPHAGUS, STOMACH, INTESTINE, SPLEEN, TRACHEA, GALL AND URINARY BLADDERS: IN VITRO STUDIES.
055394 02-03
URINARY CYCLIC AMP IN AFFECTIVE ILLNESS.
059054 03-09
URINARY NORADRENALINE AND PLAYROOM BEHAVIOUR IN HYPERACTIVE BOYS.
070024 07-14
EFFECT OF NICOTINIC ACID COMBINED WITH A TRANQUILLIZER (HYDROXYZINE) ON SERUM LIPID LEVELS AND URINARY CATECHOLAMINE EXCRETION IN GERIATRIC PATIENTS.
093689 11-11
URINARY EXCRETION OF ADRENAL HORMONES IN MAN: EFFECTS OF ETHANOL INGESTION, AND THEIR MODIFICATION BY CHLORMETHIAZOLE.
097974 11-11
FACTORS AFFECTING THE URINARY EXCRETION OF TRICYCLIC ANTIDEPRESSANTS IN MAN.
100026 11-13

**URINE**
PHOBIA QUESTIONNAIRE RESPONSES AND URINE CATECHOLAMINES.
054890 02-11
A METHOD OF IDENTIFYING NARCOTIC ANALGESICS IN HUMAN URINE AFTER THERAPEUTIC DOSES.
057473 02-16
EXCRETION OF VANYLGLYCOL IN HUMAN URINE UNDER DIETARY CONTROL, AND DURING TREATMENT WITH ANTIBIOTICS, DISULFIRAM, A MONOAMINE OXIDASE INHIBITOR, ALPHA-METHYLDOPA, AND RESERPINE.
060272 03-13
BLOOD AND URINE CONCENTRATIONS OF SUBJECTS RECEIVING BARBITURATES, MEPROBAMATE, GLUTETHIMIDE, OR DIPHENYLHYDANTOIN.
063927 04-13
PROJECT SUMMARY: ANALYSIS OF URINE AND TISSUE AMINES.
068970 06-03
PRAZEPAM METABOLITES IN DOG URINE.
071942 07-03
DETECTION OF PSYCHOTOMIMETIC N,N DIMETHYLATED INDOLEAMINES IN THE URINE OF FOUR SCHIZOPHRENIC PATIENTS.
080506 09-08

**URINES**
THE OCCURRENCE OF CYCLOHEXYLAMINE IN URINES STUDIED FOR DRUG USE BY THIN-LAYER CHROMATOGRAPHY.
070576 07-13

**USAGE**
SPINAL FLUID CREATINE PHOSPHOKINASE ABNORMALITIES FOLLOWING LSD USAGE.
067213 06-15
DOUBLE-BLIND STUDY COMPARING THE INTRAMUSCULAR USAGE OF AN ACRIDAN DERIVATIVE, SKF-14336, TO CHLORPROMAZINE.
067513 06-11

**USERS**
A COMPARISON OF MARIJUANA USERS AND NON-USERS.
059290 03-14
SOME DOPE USERS SPEAK OUT.
070415 07-12
THE PERFORMANCE OF LSD USERS ON CERTAIN NEUROPSYCHOLOGICAL TESTS. (PH.D. DISSERTATION).
135186 12-14

**UTERI**
STUDY OF THE EFFECTS OF PROGESTERONE THERAPY ON THE STILBOESTROL INDUCED SENSITIVITY OF ISOLATED UTERI OF HYPOPHYSECTOMIZED RATS.
041540 01-03

**UTERO**
LSD EXPOSURE IN UTERO.
056611 02-15
THE EFFECTS OF NICOTINE ADMINISTRATION IN UTERO UPON ACTIVITY IN THE RAT.
075239 08-04

**UTILIZING**
LONG-TERM PSYCHOTHERAPY UTILIZING TRIFLUOPERAZINE IN A PSYCHOTIC PRESCHOOL CHILD: (A CASE STUDY).
066806 05-11

**VA-NIMH**
THE VA-NIMH STUDY OF LITHIUM IN AFFECTIVE DISORDERS.
063607 04-09

**VAGINO-CERVICAL**
ABBREVIATION OF BEHAVIORAL ESTRUS IN GUINEA-PIGS BY COITAL AND VAGINO-CERVICAL STIMULATION.
065332 05-03

**VALIDATION**
PREFERENCES FOR MORPHINE IN RATS: VALIDATION OF AN EXPERIMENTAL MODEL OF DEPENDENCE.
064475 04-04
VALIDATION OF THE MACANDREW-ROSEN DRUG THERAPY SCALE.
066741 05-16

**VALIDITY**
VALIDITY OF ANTAGONISM OF DIFFERENT EFFECTS OF RESERPINE AS TEST FOR ANTIDEPRESSANT ACTIVITY.
064413 04-03

**VALIUM**
DIAZEPAM (VALIUM) LEVEL IN THE BRAIN DURING HYPOTHERMIA.
089036 10-03

**VALUE**
THE PREDICTIVE VALUE FOR MAN OF TOXICOLOGICAL TESTS OF DRUGS IN LABORATORY ANIMALS.
057607 02-05
VALUE OF AMITRIPTYLINE SPOFA IN THE PSYCHIATRIC OUTPATIENT AND INPATIENT PRACTICE.
070944 07-09
THE VALUE OF WORSENING RATES IN PSYCHIATRIC CLINICAL TRIALS.
075388 08-10
A TRIAL ON THE VALUE OF SORDINOL IN SCHIZOPHRENIA -- BY SUBJECTIVE METHOD AND PARTLY BY USING SEQUENTIAL ANALYSIS.
129451 12-08

**VALUES**
QUANTITATION OF THE DEGREE OF ANTAGONISM OF CHLOROQUINE TO HISTAMINE, ACETYLCHOLINE AND SEROTONIN ( PA2 VALUES).
067462 06-03

**VANYLGLYCOL**
EXCRETION OF VANYLGLYCOL IN HUMAN URINE UNDER DIETARY CONTROL, AND DURING TREATMENT WITH ANTIBIOTICS, DISULFIRAM, A MONOAMINE OXIDASE INHIBITOR, ALPHA-METHYLDOPA, AND RESERPINE.
060272 03-13

**VARIABLE**
LYSERGIC ACID DIETHYLAMIDE AS A VARIABLE IN THE HOSPITAL TREATMENT OF ALCOHOLISM: A FOLLOW-UP STUDY.
052476 02-11

**VARIABLES**
INFLUENCE OF DISPLAY, TASK, AND ORGANISMIC VARIABLES ON INDICES OF MONITORING BEHAVIOR.
043270 01-17
BEHAVIORAL VARIABLES INFLUENCING DRUG SELF-ADMINISTRATION.
046206 01-04
THE VARIABLES OF SILENT MYOCARDIAL INFARCTION IN A PSYCHOTIC POPULATION.
065314 05-10
EXPERIMENTAL VARIABLES IN THE EFFECTS OF POSTSESSION INJECTIONS OF STRYCHNINE SULPHATE ON A CLASSICALLY CONDITIONED RESPONSE.
071792 07-04
SOME BEHAVIOURAL EFFECTS OF VARIABLES WHICH INFLUENCE THE GENERAL LEVEL OF ACTIVITY OF RATS.
085204 10-04

**VARIATION**
LONG-TERM VARIATION IN BASAL AND PHENOBARBITAL STIMULATED OXIDATIVE DRUG METABOLISM IN THE RAT.
040671 01-03
INDIVIDUAL VARIATION IN AFFECTIVE RESPONSES TO TASTE STIMULI.
066710 05-14

**VARIATIONS**
ELECTROENCEPHALOGRAPHIC VARIATIONS INDUCED BY PSYCHOTROPIC DRUGS: CLINICAL ELECTROPHYSIOLOGICAL CORRELATIONS FOR A GUIDED THERAPY.
063200 03-13

**VAS-DEFERENS**
ACCELERATION OF NORADRENALINE BIOSYNTHESIS IN THE GUINEA-PIG VAS-DEFERENS BY POTASSIUM.
073063 08-06

**VASCULAR**
EFFECT OF 1035-MD ON CERTAIN CONDITIONS OF MENTAL DEFICIENCY, ESPECIALLY THOSE OF VASCULAR ORIGIN; CLINICAL EEG AND PSYCHOPHARMACOLOGICAL STUDY.
084978 10-08
THE USE OF THE PYRIMIDINE NUCLEOSIDES (CYTIDINE AND URIDINE) IN THE THERAPY OF CEREBRAL VASCULAR ILLNESS.
094472 11-13
EFFECT OF CAPERS ON THE VASCULAR LUMEN OF ISOLATED EXTREMITIES OF SENSITIZED FROGS AND THE ANTIANAPHYLATIC EFFECT OF SUPRASTIN.
105720 12-03

**VASOCONSTRICTOR**
INHIBITORY EFFECT OF PROPRANOLOL ON THE VASOCONSTRICTOR RESPONSE TO SYMPATHETIC NERVE STIMULATION.
066506 05-03

**VASODILATION**
AN EVALUATION OF THE VASODILATION PRODUCED BY MEPHENTERMINE AND CERTAIN OTHER SYMPATHOMIMETIC AMINES.
040311 01-03

**VEHICLE**
EFFECTS OF ACTH AND ZINC PHOSPHATE VEHICLE ON SHUTTLEBOX CAR.
060756 03-04

**VEHICLES**
EFFECT OF VEHICLES ON METABOLISM OF SEROTONIN AND IMIPRAMINE.
089439 11-03

**VENTRICLE**
EFFECTS OF SYMPATHOMIMETIC AMINES INJECTED INTO THE THIRD CEREBRAL VENTRICLE IN ADULT CHICKENS.
072030 07-03
ANALGESIC EFFECT OF MORPHINE HYDROCHLORIDE INJECTED DIRECTLY INTO THE VENTRICLE OF MOUSE BRAIN.
130422 12-03

**VENTRICLES**
THE EFFECT OF BRADYKININ AND ELEDOISIN INJECTED INTO THE CEREBRAL VENTRICLES OF CONSCIOUS RATS.
047323 01-04

**VENTRICULAR**
CHEMICAL CONSTITUTION AND DRUG ACTION OF N-SUBSTITUTED PHENOTHIAZINE IN VENTRICULAR ECTOPIC TACHYCARDIA.
063981 04-03
PERMEATION CHARACTERISTICS OF MORPHINE-LIKE SUBSTANCES AFTER INJECTION INTO BRAIN TISSUE AND INTO THE VENTRICULAR SYSTEM.
089047 10-03

**VENTROMEDIAL**
MOTIVATIONAL DEPRESSION ASSOCIATED WITH NOREPINEPHRINE INDUCED EATING FROM THE HYPOTHALAMUS: RESEMBLANCE TO THE VENTROMEDIAL HYPERPHAGIC SYNDROME.
090473 11-04
RECIPROCAL HUNGER REGULATING CIRCUITS INVOLVING ALPHA-ADRENERGIC AND BETA-ADRENERGIC RECEPTORS LOCATED, RESPECTIVELY, IN THE VENTROMEDIAL AND LATERAL HYPOTHALAMUS.
092166 11-03

**VERBAL**
VERBAL ANXIETY AND THE BETA-ADRENERGIC RECEPTORS: A FACILITATING MECHANISM.
060880 03-13
COMPARATIVE PHARMACOPSYCHOLOGICAL STUDY OF THE EFFECTS PRODUCED BY PSYCHOPHARMACEUTICALS ON VERBAL INTERACTION IN A GROUP OF STUDENTS.
066954 05-14
THE EFFECT OF EXTRAVERSION AND STIMULANT AND DEPRESSANT DRUGS ON VERBAL CONDITIONING.
078786 09-14

**VIGILANCE**
THE EFFECT OF CENTROPHENOXINE ON EEG VIGILANCE IN THE COURSE OF SLEEP DEPRIVATION AND ON THE EEG PATTERN OF ALL-NIGHT SLEEP.
070934 07-14

**VINYLIDINE**
POLYNEURITIS CRANIALIS FOLLOWING POISONING WITH CHLORINATED ACETYLENES WHILE HANDLING VINYLIDINE COPOLYMERS.
051140 02-15

**VIOLENCE**
LSD, VIOLENCE AND RADICAL RELIGIOUS BELIEFS.
067354 06-12

**VIRUSES**
PHARMACOLOGY OF VIRUSES.
051120 02-17

**VISCERAL**
BEHAVIORAL AND VISCERAL REACTIONS ELICITED BY CHEMICAL STIMULATION OF THE HYPOTHALAMUS AND SEPTUM IN CATS.
064333 04-04

**VISCEROCEREBRAL**
THE INFLUENCE OF THE GANGLIONIC BLOCKING AGENT GANLION ON VISCEROVISCERAL AND VISCEROCEREBRAL REACTIONS OF THE CAT.
071703 07-03

**VISCEROVISCERAL**
THE INFLUENCE OF THE GANGLIONIC BLOCKING AGENT GANLION ON VISCEROVISCERAL AND VISCEROCEREBRAL REACTIONS OF THE CAT.
071703 07-03

**VISUAL**
THE EFFECTS OF ALCOHOL ON VISUAL AND SOMATO-SENSORY EVOKED RESPONSES.
056925 02-14
INFLUENCE OF TRIIODOTHYRONINE ON SELECTIVE ATTENTION IN MAN AS MEASURED BY THE VISUAL AVERAGED EVOKED POTENTIAL.
062510 03-13
EFFECTS OF CANNABIS-SATIVA AND LSD ON PIGEONS IN THREE VISUAL ENVIRONMENTS.
064499 04-04
THE CONCEPT OF THE VISUAL COMPUTER AND ITS EXPLORATION BY THE USE OF DRUGS.
069802 07-13
VISUAL THRESHOLD AS A FUNCTION OF TEST AREA AND CAFFEINE ADMINISTRATION.
076016 09-13
EFFECT OF LSD-25, CHLORPROMAZINE AND METEDRINE UPON VISUAL EVOKED RESPONSE IN CATS.
098171 11-03

**VISUOMOTOR**
THE RELATIONSHIPS BETWEEN CLINICAL AND VISUOMOTOR CHANGES IN A SCHIZOPHRENIC GROUP.
089798 11-08

**VITAL**
USE OF NEUROLEPTICS FOR VITAL INDICATORS IN PATIENTS WITH SEVERE SOMATIC STATES.
111028 12-11

**VITAMIN-B**
RELAXING EFFECT OF VITAMIN-B WITH ANABOLICS.
070778 07-14

**VITAMIN-B12**
SERUM VITAMIN-B12 LEVELS IN PSYCHIATRIC PATIENTS ON LONG-TERM PSYCHOTROPIC DRUG THERAPY.
063874 04-13
THE EFFECTIVENESS OF SIMULTANEOUS TREATMENT WITH VITAMIN-B12 AND INSULIN IN SCHIZOPHRENIC PATIENTS, ACCORDING TO THE FREQUENCY OF STABLE REMISSIONS.
096513 11-08

**VITAMIN-B15**
USE OF PANGAMIC ACID (VITAMIN-B15) IN CEREBRAL ARTHEROSCLEROSIS WITH MENTAL DISTURBANCES.
067148 06-10

**VITAMIN-C**
SOME EFFECTS OF EXPERIMENTALLY PRODUCED CIGARETTE SMOKE ON THE GROWTH, VITAMIN-C METABOLISM AND ORGAN WEIGHTS OF GUINEA-PIGS.
063061 03-03

**VITAMINS**
THE PARENTERAL USE OF VITAMINS IN THE TREATMENT OF SCHIZOPHRENIA.
068976 06-08

**VOLTAGE**
HIGH VOLTAGE SLOW WAVE INDUCED BY SHORT-CHAIN FATTY ACIDS WITH SPECIAL REFERENCE TO SLEEP RHYTHM.
088612 10-03

**VOLUNTEER**
METRAZOL TOLERANCE IN A NORMAL VOLUNTEER POPULATION: A TEN YEAR FOLLOW-UP REPORT.
060649 03-13

**VOLUNTEERS**
A NEW STIMULANT, PROLINTANE HYDROCHLORIDE, COMPARED WITH DEXTROAMPHETAMINE IN FATIGUED VOLUNTEERS.
040128 01-14
EFFECTS OF TRIMEPRIMINE (SURMONTIL) ON SPERMATOGENESIS AND MOOD IN NORMAL VOLUNTEERS.
072147 07-14
EVALUATION OF CL-1848C: A NEW DISSOCIATIVE ANESTHETIC IN NORMAL HUMAN VOLUNTEERS.
097971 11-07

**WAKEFULNESS**
INTRACRANIAL SELF-STIMULATION AND WAKEFULNESS: EFFECT OF MANIPULATING AMBIENT BRAIN CATECHOLAMINES.
063849 04-04

**WALKING**
THE EFFECT OF A PSYCHOTOMIMETIC GLYCOLATE AND ITS ANTIDOTE ESERINE ON THE ACH CONTENT OF THE LOBSTER WALKING LEG NERVE.
069515 06-13

**WAR**
WAR WITHOUT DEATH.
046735 01-15

**WARD**
SOME PROBLEMS OF ORGANIZING THE PSYCHOTHERAPEUTIC ENVIRONMENT IN A MIXED FEMALE PSYCHIATRIC WARD.
111254 12-17

**WARFARIN**
INTERACTION OF COMMONLY PRESCRIBED DRUGS AND WARFARIN.
064622 04-15

**WARMTH**
DRUG, DOCTOR WARMTH, AND CLINIC SETTING IN THE SYMPTOMATIC RESPONSE TO MINOR TRANQUILIZERS.
087386 10-10

**WARNING**
U-M TEAM ISSUES WARNING ON USE OF DRUG.
058527 02-15

THE EFFECTS OF DRUGS ON CONTINUOUS AVOIDANCE BEHAVIOR WITH A WARNING STIMULUS.
078402 09-04

**WARNS**
FDA WARNS AGAINST USES OF BEHAVIOR AMPHETAMINES.
051373 02-15

**WATER**
LITHIUM CARBONATE AS A MOOD AND TOTAL BODY WATER STABILIZER.
047953 01-09

WATER STRUCTURE IN ANESTHETIC ACTION: TIME-DEPENDENCE D20 EFFECTS ON NERVE.
055582 02-03

DRUG ANTAGONISM AND WATER INTAKE.
067703 06-04

THE EFFECTS OF D-AMPHETAMINE ON SCHEDULE CONTROLLED WATER LICKING IN THE SQUIRREL MONKEY.
071785 07-04

EFFECT OF ATROPINE DOSE LEVEL ON THE SUPPRESSION OF WATER REINFORCED VI RESPONDING.
075870 09-04

AN ANALYSIS OF THE ROLE OF CHOLINERGIC DRUGS IN BEHAVIOR RELATED TO FOOD AND WATER DEPRIVATION. (PH.D.DISSERTATION).
103267 12-04

**WAVE**
BLOCKING OF EXPERIMENTAL SPIKE AND WAVE BY A LOCALIZED FOREBRAIN LESION.
066186 05-03

HIGH VOLTAGE SLOW WAVE INDUCED BY SHORT-CHAIN FATTY ACIDS WITH SPECIAL REFERENCE TO SLEEP RHYTHM.
088612 10-03

**WAVES**
AVOIDANCE TRAINING OF HIPPOCAMPAL THETA WAVES IN FLAXEDILIZED DOGS AND ITS RELATION TO SKELETAL MOVEMENT.
075399 08-04

**WEIGHT**
LIVER DAMAGE FOLLOWING APPLICATION OF PYRAZINAMIDE IN ANIMAL EXPERIMENTS: 1. CHANGES IN BODY WEIGHT OF RATS UNDER THE INFLUENCE OF PYRAZINAMIDE.
055398 02-05

WEIGHT CHANGES WITH SCHIZOPHRENIC PSYCHOSIS AND PSYCHOTROPIC DRUG THERAPY.
074218 08-08

DEVELOPMENT OF HORMONAL CONTROL OVER FOOD INTAKE AND BODY WEIGHT IN FEMALE RATS.
076239 09-03

**WEIGHTS**
SOME EFFECTS OF EXPERIMENTALLY PRODUCED CIGARETTE SMOKE ON THE GROWTH, VITAMIN-C METABOLISM AND ORGAN WEIGHTS OF GUINEA-PIGS.
063061 03-03

**WEST-VIRGINIA**
L-DOPA THERAPY OF PARKINSONS DISEASE (A REVIEW OF THE PRELIMINARY EXPERIENCE AT WEST-VIRGINIA UNIVERSITY).
072421 08-07

**WHEAL**
HISTAMINE WHEAL FORMATION AND SCHIZOPHRENIA.
086987 10-13

**WHEEL**
EFFECTS OF AGROCLAVINE ON WHEEL TURNING ACTIVITY IN MICE.
069610 07-04

EFFECTS OF ELYMOCLAVINE ON WHEEL TURNING ACTIVITY IN MICE.
075196 08-04

**WHOLE**
THE FATE OF C14-DIHYDROXYPHENYLALANINE (C14-DOPA) IN THE WHOLE MOUSE.
064161 04-03

**WILSONS**
TREATMENT OF WILSONS DISEASE WITH L-DOPA AFTER FAILURE WITH PENICILLAMINE.
058243 02-11

**WITHDRAWAL**
WITHDRAWAL OF ANTIPSYCHOTIC DRUGS FROM CHRONIC PSYCHIATRIC PATIENTS.
060208 03-08

STRAIN DIFFERENCES IN MORPHINE WITHDRAWAL INDUCED AGGRESSION IN RATS.
060857 03-03

A BEHAVIORAL AND PHARMACOLOGICAL ANALYSIS OF REINFORCEMENT WITHDRAWAL.
062942 03-04

THE SENSITIVITY OF THE BRAIN TO BARBITURATE DURING CHRONIC ADMINISTRATION AND WITHDRAWAL OF BARBITONE SODIUM IN THE RAT.
063980 04-03

THE TREATMENT OF ACUTE ALCOHOL INTOXICATION AND WITHDRAWAL.
065187 05-13

DIAGNOSIS AND THERAPY OF ACUTE WITHDRAWAL FROM ALCOHOL.
065193 05-13

SEVERE DELIRIUM AFTER ABRUPT WITHDRAWAL OF THIOTHIXENE IN A CHRONIC SCHIZOPHRENIC INPATIENT: A CASE STUDY.
067221 06-08

CHANGES IN ENZYMES SUBSERVING CATECHOLAMINE METABOLISM IN MORPHINE TOLERANCE AND WITHDRAWAL IN RAT.
067324 06-03

EFFECTS OF DIPHENYLHYDANTOIN (DILANTIN) WITHDRAWAL ON NON-EPILEPTICS: PRELIMINARY REPORT.
067512 06-11

PHENOBARBITAL WITHDRAWAL AND BEHAVIORAL DISRUPTION IN THE RAT.
069067 06-04

ELECTROGRAPHIC AND BEHAVIORAL EFFECTS OF DIAZEPAM DURING ALCOHOL WITHDRAWAL STAGE IN CATS.
072033 07-04

OPTIMAL THERAPY OF THE ALCOHOL WITHDRAWAL STATE.
078429 09-17

SUPPRESSING WITHDRAWAL CONVULSIONS BY DEPAKINE IN ALCOHOLIC DETOXIFICATION CURES.
079858 09-11

EFFECT OF WITHDRAWAL OF ANTIPARKINSONIAN MEDICATION ON CHRONICALLY HOSPITALIZED PSYCHIATRIC PATIENTS.
086445 10-15

EVALUATING CHANGES IN SYMPTOMS DURING ACUTE ALCOHOL WITHDRAWAL.
094978 11-11

**WITHDRAWING**
EFFECTS OF WITHDRAWING DOPA IN PARKINSONS DISEASE.
067623 06-13

**WITHDRAWN**
THE BRAIN ACETYLCHOLINE SYSTEM IN BARBITONE DEPENDENT AND WITHDRAWN RATS.
067604 06-03

CI-601, A BUTYROPHENONE DERIVATIVE, IN THE TREATMENT OF CHRONICALLY WITHDRAWN SCHIZOPHRENIC PATIENTS.
072142 07-08

**WITHHOLDING**
THE EFFECTS OF WITHHOLDING OF NEUROLEPTICS FROM MENTAL PATIENTS.
072406 07-15

**WOLFF-PARKINSON-WHITE**
PREVENTION OF PAROXYSMAL TACHYCARDIA OF WOLFF-PARKINSON-WHITE SYNDROME WITH COMBINED PROPRANOLOL AND QUINIDINE THERAPY.
070288 07-10

**WOMEN**
THE KINETICS OF AMYLOBARBITONE METABOLISM IN HEALTHY MEN AND WOMEN.
063800 04-13

CHANGES IN PSYCHOLOGICAL SYMPTOMS IN WOMEN TAKING ORAL CONTRACEPTIVES.
075470 08-13

FURTHER PSYCHOMETRIC EVALUATION OF OLDER WOMEN -- THE EFFECT OF ESTROGEN ADMINISTRATION.
078223 09-14

CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIC WOMEN: ITS EFFECT ON THYROID AND LIVER FUNCTION IN RELATION TO SERUM CHOLESTEROL CONCENTRATION.
088221 10-13

**WORK**
THE EFFECT OF HEAT, COLD, AND WORK ON THE CENTRAL ACTIONS OF SCOPOLAMINE.
041562 01-14

**WORSENING**
THE VALUE OF WORSENING RATES IN PSYCHIATRIC CLINICAL TRIALS.
075388 08-10

**WORTHINGTON**
WORTHINGTON AND PERCEPTUAL DEFENSIVENESS.
082410 10-14

**WRITHING**
DRUG DEPENDENT DIFFERENCES IN THE DEVELOPMENT OF TOLERANCE TO WRITHING IN MICE.
046400 01-03

**WROCLAW**
METHODS OF TREATING DELIRIUM-TREMENS AS BASED ON MATERIALS OF THE UNIVERSITY MEDICAL SCHOOLS PSYCHIATRIC CLINIC IN WROCLAW BETWEEN 1958 AND 1968.
087143 10-11

**XANTHINES**
COMPLEXES OF ERGOT ALKALOIDS AND DERIVATIVES. II: INTERACTION OF DIHYDROERGOTOXINE WITH CERTAIN XANTHINES.
046137 01-03

**Y-MAZE**
THE EFFECT OF ETHANOL AND AMPHETAMINE MIXTURES ON THE ACTIVITY OF RATS IN A Y-MAZE.
074149 08-04

LACK OF A LONG-TERM EFFECT OF LSD ON Y-MAZE LEARNING IN MICE.
074422 08-04

**YEAST**
YEAST RIBONUCLEIC ACID: ANALYSIS OF EFFECTS ON POLE-CLIMB AVOIDANCE BEHAVIOR.
065493 05-04
COMMENTS ON AN EFFECT OF YEAST RNA ON BEHAVIOR (MOUNTFORD AND HESLIP).
075720 08-04

**YEMENITE**
ON THE USE OF CATH (CATHA-EDULIS) AMONG YEMENITE JEWS.
074566 08-15

**YOHIMBINE**
SIMILARITIES BETWEEN BEHAVIORAL AND PHARMACOLOGICAL ACTIONS OF YOHIMBINE AND 5-HYDROXYTRYPTOPHAN IN THE CONSCIOUS DOG.
064253 04-04

**YOUNG**
RELATIONSHIP BETWEEN CENTRAL EFFECTS AND THE CONCENTRATION OF AMPHETAMINE IN LIVER AND BRAIN OF YOUNG AND OLD RATS.
089041 10-03

**ZEN**
MODEL PSYCHOSIS OR INSTANT ZEN.
046730 01-12

**ZINC**
BEHAVIORAL IMPAIRMENT IN ADULT RATS FOLLOWING ACUTE ZINC DEFICIENCY.
045526 01-04
EFFECTS OF ACTH AND ZINC PHOSPHATE VEHICLE ON SHUTTLEBOX CAR.
060756 03-04

**1-NAPHTHYLMETHYL**
BLOCKADE OF NOREPINEPHRINE UPTAKE AND RELATED ACTIVITIES OF CIS- AND TRANS N,N(PRIME)-BIS-(1-NAPHTHYLMETHYL)-1,4 CYCLOHEXANE BIS-(METHYLAMINE) DIHYDROCHLORIDE.
090136 11-03

**1-4-BENZODIAZEPIN-2-ONE**
STUDIES ON THE METABOLISM OF 7-CHLORO-1-3-DIHYDRO-3-HYDROXY-5-PHENYL 2H 1-4-BENZODIAZEPIN-2-ONE.
072587 08-13

**100-129-HF-1854**
THE DRUG 100-129-HF-1854 (CLOZAPINE) FOR PSYCHIATRIC TREATMENT.
089100 10-09

**1035-MD**
EFFECT OF 1035-MD ON CERTAIN CONDITIONS OF MENTAL DEFICIENCY, ESPECIALLY THOSE OF VASCULAR ORIGIN; CLINICAL EEG AND PSYCHOPHARMACOLOGICAL STUDY.
084978 10-08
ELECTROCLINICAL RESEARCH ON THE USE OF 1035-MD IN PSYCHIATRY.
087498 10-11
INVESTIGATION OF THE PSYCHODYNAMIC REINFORCEMENT OF NEUROLEPTICS WITH 1035-MD.
089111 10-07

**14-HYDROXYDIHYDRO-6-BETA-THEBAINOL-4-METHYLETHER**
PHARMACOLOGICAL STUDIES ON A NEW SPECIFICALLY POTENT ANTITUSSIVE AGENT, 14-HYDROXYDIHYDRO-6-BETA-THEBAINOL-4-METHYLETHER (OXYMETHEBANOL).
055585 02-03

**14C-IMIPRAMINE**
METABOLISM OF 14C-IMIPRAMINE: III. CONVERSIONS BY RAT TISSUE.
064409 04-03

**14C-LABELED**
DISTRIBUTION, EXCRETION, AND METABOLISM OF 14C-LABELED QUATERNARY AMMONIUM SALT OF MEPAZINE AND PROMETHAZINE IN RATS.
058571 02-03
DISTRIBUTION, EXCRETION, AND METABOLISM OF 14C-LABELED QUATERNARY AMMONIUM SALT OF PERPHENAZINE IN RATS.
064261 04-03

**14C-URIDINE**
INCREASED INCORPORATION OF 14C-URIDINE INTO RAT BRAIN RNA AS A RESULT OF NOVEL ELECTROSHOCK.
092209 11-01

**14C-5-HYDROXYTRYPTAMINE**
14C-5-HYDROXYTRYPTAMINE AND 3H-D-AMPHETAMINE: UPTAKE AND CONTRACTION BY THE RAT STOMACH FUNDUS IN VITRO.
064050 04-03

**2-BROM-D-LYSERGIC**
EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND 2-BROM-D-LYSERGIC ACID DIETHYLAMIDE (BOL-148) UPON BEHAVIORAL SLEEP IN RATS.
089045 10-12

**2-CHLORO-10-PHENOTHIAZINYL**
STUDIES ON PSYCHOTROPIC DRUGS (FIFTH REPORT) -- PHARMACOLOGICAL EFFECT OF 8(3-(2-CHLORO-10-PHENOTHIAZINYL)PROPYL)-1 THIADIAZASPIRODECAN-3-ONE HYDROCHLORIDE (APY-606).
131058 12-02

**2-ETHYL-ETHYLAMINO-6-METHOXY-S-TRIAZINE**
POSSIBLE LOCI OF ACTION OF 2-ETHYL-ETHYLAMINO-6-METHOXY-S-TRIAZINE FOR ELECTROENCEPHALOGRAPHIC AND SYMPATHETIC ACTIVATION IN CAT.
089788 11-13

**2-HYDROXY-3-ISOPROPYLAMINOPROPOXY**
A POTENT BETA-ADRENORECEPTOR BLOCKING DRUG: 4-(2-HYDROXY-3-ISOPROPYLAMINOPROPOXY)INDOLE.
040751 01-03

**2-PHENYLETHANOL**
A STUDY OF HEPATIC ALCOHOL DEHYDROGENASE INHIBITION INDUCED BY PYRAZOL: I. IN VIVO ACTION ON ETHANOL AND 2-PHENYLETHANOL.
089548 11-03

**3-METHYLCHOLANTHRENE**
EFFECTS OF PHENOBARBITAL, PHENYLBUTAZONE, 3,4 BENZPYRENE, OR 3-METHYLCHOLANTHRENE ON ETHANOL METABOLISM IN THE RAT.
066498 05-03

**3H-CHLORPROMAZINE**
PREPARATION OF 3H-7-HYDROXYCHLORPROMAZINE USING SHEEP LIVER MICROSOMES FOR HYDROXYLATION OF 3H-CHLORPROMAZINE.
097582 11-01

**3H-D-AMPHETAMINE**
14C-5-HYDROXYTRYPTAMINE AND 3H-D-AMPHETAMINE: UPTAKE AND CONTRACTION BY THE RAT STOMACH FUNDUS IN VITRO.
064050 04-03

**3H-NORADRENALINE**
UPTAKE AND RETENTION OF 3H-NORADRENALINE IN ADRENERGIC NERVE TERMINALS AFTER RESERPINE AND AXOTOMY.
066499 05-03

**3H-NOREPINEPHRINE**
DRUG-INDUCED RELEASE OF 3H-NOREPINEPHRINE AND 3H-SEROTONIN FROM BRAIN SLICES.
068290 06-03

**3H-SEROTONIN**
DRUG-INDUCED RELEASE OF 3H-NOREPINEPHRINE AND 3H-SEROTONIN FROM BRAIN SLICES.
068290 06-03

**3H-TRYPTOPHAN**
ACCUMULATION AND DISAPPEARANCE OF 3H-5-HYDROXYTRYPTAMINE FORMED FROM 3H-TRYPTOPHAN IN MOUSE BRAIN: EFFECT OF LSD-25.
042755 01-03

**3H-5-HYDROXYTRYPTAMINE**
ACCUMULATION AND DISAPPEARANCE OF 3H-5-HYDROXYTRYPTAMINE FORMED FROM 3H-TRYPTOPHAN IN MOUSE BRAIN: EFFECT OF LSD-25.
042755 01-03

**3H-7-HYDROXYCHLORPROMAZINE**
PREPARATION OF 3H-7-HYDROXYCHLORPROMAZINE USING SHEEP LIVER MICROSOMES FOR HYDROXYLATION OF 3H-CHLORPROMAZINE.
097582 11-01

**30803-BA**
EFFECTS OF BENZOCTAMINE (30803-BA, TACITIN), A NEW PSYCHOACTIVE DRUG, ON CATECHOLAMINE METABOLISM.
074861 08-03

**4306-CB**
NEUROPHYSIOLOGICAL STUDY OF DIPOTASSIUM CHLORAZEPATE (4306-CB).
055580 02-03
PHARMACOLOGICAL, TOXICOLOGICAL, AND TERATOLOGICAL STUDIES ON DIPOTASSIUM 7-CHLORO-3-CARBOXY 1,3-DIHYDRO-2,2-DIHYDROXY-5-PHENYL-2H-1,4 BENZODIAZEPINE CHLORAZEPATE (DIPOTASSIUM CHLORAZEPATE, 4306-CB), A NEW TRANQUILLIZER.
055581 02-03

**5-HT**
EFFECTS OF AN ACUTE STRESS OF FOREBRAIN 5-HYDROXYTRYPTAMINE (5-HT) METABOLISM IN CNS LESIONED AND DRUG PRETREATED RATS.
095671 11-04

**5-HTP**
THE EFFECTS OF 5-HTP ON P-CHLOROPHENYLALANINE (P-CPA) ATTENUATION OF CONFLICT BEHAVIOR.
047326 01-04

**5-HYDROXYINDOL-3-YLACETIC**
SOME FACTORS INFLUENCING THE RELEASE OF 5-HYDROXYINDOL-3-YLACETIC ACID IN THE FOREBRAIN.
067598 06-03

**5-HYDROXYINDOLE**
EFFECT OF RESERPINE ON THE INCORPORATION IN VIVO OF RADIOACTIVITY FROM LABELED SEROTONIN AND OTHER 5-HYDROXYINDOLE DERIVATIVES IN MOUSE BRAIN.
046189 01-03

**5-HYDROXYINDOLE-3-ACETIC**
COMPARATIVE EFFECTS OF P-CHLOROPHENYLALANINE, P-CHLOROAMPHETAMINE AND P-CHLORO-N-METHYLAMPHETAMINE ON RAT BRAIN NOREPINEPHRINE, SEROTONIN AND 5-HYDROXYINDOLE-3-ACETIC ACID.
040241 01-03

THE EFFECT OF DISULFIRAM, DIETHYLDITHIOCARBAMATE AND DIMETHYLDITHIOCARBAMATE ON SEROTONIN AND 5-HYDROXYINDOLE-3aACETIC ACID BRAIN LEVELS IN RATS.
067384 06-03

**5-HYDROXYINDOLEACETIC**
INHIBITION BY P-CHLOROAMPHETAMINE OF THE CONVERSION OF 5-HYDROXYTRYPTAMINE TO 5-HYDROXYINDOLEACETIC ACID IN RAT BRAIN.
066507 05-03

**5-HYDROXYINDOLES**
CEREBROSPINAL FLUID 5-HYDROXYINDOLES AND BEHAVIOR AFTER L-TRYPTOPHAN AND PYRIDOXINE ADMINISTRATION TO PSYCHIATRIC PATIENTS.
074938 08-14

**5-HYDROXYTRYPTAMINE**
PHARMACOLOGICAL SIGNIFICANCE OF BIOGENIC AMINES IN THE LUNGS: 5-HYDROXYTRYPTAMINE.
041565 01-03

EFFECTS OF LYSERGIC ACID DERIVATIVES ON 5-HYDROXYTRYPTAMINE EXCITATION OF BRAINSTEM NEURONES.
041973 01-02

TEMPERATURE RESPONSES AND OTHER EFFECTS OF 5-HYDROXYTRYPTOPHAN AND 5-HYDROXYTRYPTAMINE WHEN ACTING FROM THE LIQUOR SPACE IN UNANESTHETIZED RABBITS.
046404 01-03

DIFFERENCES IN BRAIN AREA 5-HYDROXYTRYPTAMINE TURNOVER AND REARING BEHAVIOR IN RATS AND MICE OF BOTH SEXES.
047324 01-04

EFFECTS OF RESERPINE AND DESIPRAMINE ON THE UPTAKE AND SUBCELLULAR DISTRIBUTION OF 5-HYDROXYTRYPTAMINE IN RABBIT BRAINSTEM AFTER INTRAVENOUS ADMINISTRATION OF 5-HYDROXYTRYPTOPHAN.
056610 02-03

RELEASE OF 5-HYDROXYTRYPTAMINE FROM SLICES OF SUPERIOR COLLICULUS BY OPTIC TRACT STIMULATION.
064369 04-03

INHIBITION BY P-CHLOROAMPHETAMINE OF THE CONVERSION OF 5-HYDROXYTRYPTAMINE TO 5-HYDROXYINDOLEACETIC ACID IN RAT BRAIN.
066507 05-03

EFFECT OF ETHANOL ON 5-HYDROXYTRYPTAMINE TURNOVER IN RAT BRAIN.
066938 05-03

PERMEABILITY OF THE BLOOD BRAIN BARRIER TO PARENTERAL 5-HYDROXYTRYPTAMINE IN THE NEONATE CHICK.
067253 06-04

EVALUATION OF THE PERIPHERAL AND CENTRAL ANTAGONISTIC ACTIVITIES AGAINST 5-HYDROXYTRYPTAMINE OF SOME NEW AGENTS.
067603 06-03

A POSSIBLE ROLE FOR 5-HYDROXYTRYPTAMINE IN DRUG-INDUCED SEIZURES.
074084 08-03

A CONTROLLED STUDY OF THE ANTIDEPRESSANT EFFECT OF P-CHLORO-N-METHYLAMPHETAMINE, A COMPOUND WITH A SELECTIVE EFFECT ON THE CENTRAL 5-HYDROXYTRYPTAMINE METABOLISM.
078212 09-10

EFFECT OF CHLORPROMAZINE ON 5-HYDROXYTRYPTAMINE METABOLISM IN HIPPOCAMPAL STIMULATED RATS.
080338 09-01

EFFECTS OF COCAINE AND AMPHETAMINE ON THE METABOLISM OF TRYPTOPHAN AND 5-HYDROXYTRYPTAMINE IN MOUSE BRAIN IN VIVO.
095440 11-03

EFFECTS OF AN ACUTE STRESS OF FOREBRAIN 5-HYDROXYTRYPTAMINE (5-HT) METABOLISM IN CNS LESIONED AND DRUG PRETREATED RATS.
095671 11-04

INVESTIGATION INTO THE POSSIBLE INFLUENCE OF CHLORINATED AMPHETAMINE DERIVATIVES ON 5-HYDROXYTRYPTAMINE SYNTHESIS IN MAN.
097963 11-13

UPTAKE AND STORAGE MECHANISM OF 5-HYDROXYTRYPTAMINE IN RABBIT BRAINSTEM AND EFFECT OF RESERPINE.
114975 12-03

**5-HYDROXYTRYPTOPHAN**
THE ROLE OF THE HYPOTHALAMO-PITUITARY SYSTEM IN THE MECHANISM OF ACTION OF RESERPINE AND 5-HYDROXYTRYPTOPHAN ON ANTIBODY PRODUCTION.
040579 01-03

TEMPERATURE RESPONSES AND OTHER EFFECTS OF 5-HYDROXYTRYPTOPHAN AND 5-HYDROXYTRYPTAMINE WHEN ACTING FROM THE LIQUOR SPACE IN UNANESTHETIZED RABBITS.
046404 01-03

EFFECTS OF RESERPINE AND DESIPRAMINE ON THE UPTAKE AND SUBCELLULAR DISTRIBUTION OF 5-HYDROXYTRYPTAMINE IN RABBIT BRAINSTEM AFTER INTRAVENOUS ADMINISTRATION OF 5-HYDROXYTRYPTOPHAN.
056610 02-03

POTENTIATION OF THE CENTRAL ACTIONS OF 5-HYDROXYTRYPTOPHAN IN RABBITS BY DL-ALPHA-HYDRAZINO ALPHA-METHYLDOPA.
058879 02-03

SIMILARITIES BETWEEN BEHAVIORAL AND PHARMACOLOGICAL ACTIONS OF YOHIMBINE AND 5-HYDROXYTRYPTOPHAN IN THE CONSCIOUS DOG.
064253 04-04

REDUCTION OF THE ANTINOCICEPTIVE EFFECT OF 5-HYDROXYTRYPTOPHAN IN MORPHINE TOLERANT RATS.
075846 09-03

INHIBITION OF CENTRAL SEROTONINERGIC EXCITATION (5-HYDROXYTRYPTOPHAN INDUCED DEAD TWITCHES) IN MICE BY LITHIUM.
097989 11-04

ON THE ANALYSIS OF 5-HYDROXYTRYPTOPHAN PRODUCED HYPERTHERMIA IN MICE PRETREATED WITH A MONOAMINE OXIDASE INHIBITOR NIAMID.
098035 11-03

THE INFLUENCE OF 5-HYDROXYTRYPTOPHAN ON THE BEHAVIOR AND THE LEVEL OF MONOAMINES IN THE BRAIN OF RATS SENSITIVE TO SOUND.
098040 11-03

SYNERGISM OF DESMETHYLIMIPRAMINE WITH RESERPINE AND 5-HYDROXYTRYPTOPHAN IN THE FROG: BRAIN SEROTONIN AND ADRENALINE AND BEHAVIOR.
098042 11-03

ON THE ANALYSIS OF THE EFFECTS OF 5-HYDROXYTRYPTOPHAN.
098064 11-03

5-HYDROXYTRYPTOPHAN PRODUCED HYPOTHERMIA IN MICE AS A TEST FOR PHARMACOLOGICAL DIFFERENTIATION OF ANTIDEPRESSANTS, ANTICHOLINERGICS AND NEUROLEPTICS: SOME DATA ON THE NATURE OF THIS HYPOTHERMIA.
105622 12-06

**5-HYDROXYTRYPTOPHOL**
TRYPTOPHOL, 5-HYDROXYTRYPTOPHOL AND 5-METHOXYTRYPTOPHOL INDUCED SLEEP IN MICE.
058382 02-04

**5-METHOXYTRYPTOPHOL**
TRYPTOPHOL, 5-HYDROXYTRYPTOPHOL AND 5-METHOXYTRYPTOPHOL INDUCED SLEEP IN MICE.
058382 02-04

**6-FDET**
EFFECTS OF 6-FLUORO-N-N-DIETHYLTRYPTAMINE (6-FDET) ON SELECTED RAT BEHAVIORS.
075314 08-04

**6-FLUORO-N-N-DIETHYLTRYPTAMINE**
EFFECTS OF 6-FLUORO-N-N-DIETHYLTRYPTAMINE (6-FDET) ON SELECTED RAT BEHAVIORS.
075314 08-04

**6-HYDROXYDOPAMINE**
INHIBITION OF CATECHOLAMINE UPTAKE BY 6-HYDROXYDOPAMINE IN RAT BRAIN.
066501 05-03

EFFECTS OF 6-HYDROXYDOPAMINE ON CATECHOLAMINE CONTAINING NEURONES IN THE RAT BRAIN.
072120 07-03

CENTRAL EFFECTS OF 6-HYDROXYDOPAMINE ON THE BODY TEMPERATURE OF THE RAT.
073069 08-03

EFFECTS OF 6-HYDROXYDOPAMINE ON CNS CATECHOLAMINES, SPONTANEOUS MOTOR ACTIVITY AND AMPHETAMINE INDUCED HYPERACTIVITY IN RATS.
074053 08-04

**7-CHLORO-1-3-DIHYDRO-3-HYDROXY-5-PHENYL**
STUDIES ON THE METABOLISM OF 7-CHLORO-1-3-DIHYDRO-3-HYDROXY-5-PHENYL 2H 1-4-BENZODIAZEPIN-2-ONE.
072587 08-13

**7-CHLORO-3-CARBOXY**
PHARMACOLOGICAL, TOXICOLOGICAL, AND TERATOLOGICAL STUDIES ON DIPOTASSIUM 7-CHLORO-3-CARBOXY 1,3-DIHYDRO-2,2-DIHYDROXY-5-PHENYL-2H-1,4 BENZODIAZEPINE CHLORAZEPATE (DIPOTASSIUM CHLORAZEPATE, 4306-CB), A NEW TRANQUILLIZER.
055581 02-03

**7-HYDROXY-NOR1-CHLORPROMAZINE**
SYNTHESIS OF POSSIBLE METABOLITES OF CHLORPROMAZINE: IV. 7-HYDROXY-NOR1-CHLORPROMAZINE AND NOR2-CHLORPROMAZINE SULFOXIDE (UNPUBLISHED PAPER).
088358 10-01

**780-SE**
THE EFFECT OF ACUTE ADMINISTRATION OF (META-TRIFLUOROMETHYL-PHENYL)-1-(BENZOYLOXY) ETHYLAMINO-2-PROPANE (780-SE) AND FENFLURAMINE ON HUMAN SLEEP.
063978 04-14

**8-909-RP**
RESULTS OBTAINED WITH PROPERICIAZIN (8-909-RP) IN THE TREATMENT OF BEHAVIOR AND CHARACTER DISTURBANCES IN CHILDREN AND ADOLESCENTS.
078730 09-14



☆ U.S. GOVERNMENT PRINTING OFFICE : 1974 731-526/146

cts
AN
2-03
ONS
4-04
9-03
1-04
ASE
1-03
THE
UND.
1-03
1-03
1-03
EST
URE
2-06
2-04
2-04
D
8-04
D
8-04
N
5-03
7-03
8-03
8-04
Y-5-
8-13
2-03
0-01
L-
4-14
ENT
-14